[{"header": {"dataset": "BioASQ", "split": "dev"}}]
{"context": "The Philadelphia chromosome translocation (t(9;22)) results in the molecular juxtaposition of two genes, BCR and ABL, to form an aberrant BCR-ABL gene on chromosome 22. BCR-ABL is critical to the pathogenesis of chronic myelogenous leukemia and a subset of acute leukemias. The chimeric Bcr-Abl protein has constitutively elevated tyrosine phosphokinase activity. This abnormal enzymatic activation is critical to the oncogenic potential of Bcr-Abl. Initially, protein kinases were thought to be poor therapeutic targets because of their ubiquitous nature and crucial role in many normal physiologic processes. However, the advent of imatinib mesylate (Gleevec, Novartis Pharmaceuticals, Basel, Switzerland), formerly known as STI571 and CGP57148B, demonstrated that designer kinase inhibitors could be specific. This agent has shown striking activity in chronic myelogenous leukemia. It also inhibits phosphorylation of Kit (stem-cell factor receptor) and platelet-derived growth factor receptor. In addition, it has shown similar impressive responses, with little host toxicity, in gastrointestinal stromal tumors, which harbor activating Kit mutations, and in tumors with activated platelet-derived growth factor receptor. The studies of imatinib mesylate provide proof-of-principle for using aberrant kinases as a therapeutic target and are a model for the promise of molecular therapeutics. This paper reviews the current knowledge on the function of Bcr-Abl and its normal counterparts (Bcr and Abl), as well as the impact of this knowledge on the development of a remarkably successful targeted therapy approach.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "ec447381a9274cb2925d3a6a913cd81a", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[33, 35], [76, 78], [54, 56], [249, 251], [25, 27]], "char_spans": [[169, 175], [441, 447], [287, 293], [1456, 1462], [138, 144]]}]}], "context_tokens": [["The", 0], ["Philadelphia", 4], ["chromosome", 17], ["translocation", 28], ["(", 42], ["t(9;22", 43], [")", 49], [")", 50], ["results", 52], ["in", 60], ["the", 63], ["molecular", 67], ["juxtaposition", 77], ["of", 91], ["two", 94], ["genes", 98], [",", 103], ["BCR", 105], ["and", 109], ["ABL", 113], [",", 116], ["to", 118], ["form", 121], ["an", 126], ["aberrant", 129], ["BCR", 138], ["-", 141], ["ABL", 142], ["gene", 146], ["on", 151], ["chromosome", 154], ["22", 165], [".", 167], ["BCR", 169], ["-", 172], ["ABL", 173], ["is", 177], ["critical", 180], ["to", 189], ["the", 192], ["pathogenesis", 196], ["of", 209], ["chronic", 212], ["myelogenous", 220], ["leukemia", 232], ["and", 241], ["a", 245], ["subset", 247], ["of", 254], ["acute", 257], ["leukemias", 263], [".", 272], ["The", 274], ["chimeric", 278], ["Bcr", 287], ["-", 290], ["Abl", 291], ["protein", 295], ["has", 303], ["constitutively", 307], ["elevated", 322], ["tyrosine", 331], ["phosphokinase", 340], ["activity", 354], [".", 362], ["This", 364], ["abnormal", 369], ["enzymatic", 378], ["activation", 388], ["is", 399], ["critical", 402], ["to", 411], ["the", 414], ["oncogenic", 418], ["potential", 428], ["of", 438], ["Bcr", 441], ["-", 444], ["Abl", 445], [".", 448], ["Initially", 450], [",", 459], ["protein", 461], ["kinases", 469], ["were", 477], ["thought", 482], ["to", 490], ["be", 493], ["poor", 496], ["therapeutic", 501], ["targets", 513], ["because", 521], ["of", 529], ["their", 532], ["ubiquitous", 538], ["nature", 549], ["and", 556], ["crucial", 560], ["role", 568], ["in", 573], ["many", 576], ["normal", 581], ["physiologic", 588], ["processes", 600], [".", 609], ["However", 611], [",", 618], ["the", 620], ["advent", 624], ["of", 631], ["imatinib", 634], ["mesylate", 643], ["(", 652], ["Gleevec", 653], [",", 660], ["Novartis", 662], ["Pharmaceuticals", 671], [",", 686], ["Basel", 688], [",", 693], ["Switzerland", 695], [")", 706], [",", 707], ["formerly", 709], ["known", 718], ["as", 724], ["STI571", 727], ["and", 734], ["CGP57148B", 738], [",", 747], ["demonstrated", 749], ["that", 762], ["designer", 767], ["kinase", 776], ["inhibitors", 783], ["could", 794], ["be", 800], ["specific", 803], [".", 811], ["This", 813], ["agent", 818], ["has", 824], ["shown", 828], ["striking", 834], ["activity", 843], ["in", 852], ["chronic", 855], ["myelogenous", 863], ["leukemia", 875], [".", 883], ["It", 885], ["also", 888], ["inhibits", 893], ["phosphorylation", 902], ["of", 918], ["Kit", 921], ["(", 925], ["stem", 926], ["-", 930], ["cell", 931], ["factor", 936], ["receptor", 943], [")", 951], ["and", 953], ["platelet", 957], ["-", 965], ["derived", 966], ["growth", 974], ["factor", 981], ["receptor", 988], [".", 996], ["In", 998], ["addition", 1001], [",", 1009], ["it", 1011], ["has", 1014], ["shown", 1018], ["similar", 1024], ["impressive", 1032], ["responses", 1043], [",", 1052], ["with", 1054], ["little", 1059], ["host", 1066], ["toxicity", 1071], [",", 1079], ["in", 1081], ["gastrointestinal", 1084], ["stromal", 1101], ["tumors", 1109], [",", 1115], ["which", 1117], ["harbor", 1123], ["activating", 1130], ["Kit", 1141], ["mutations", 1145], [",", 1154], ["and", 1156], ["in", 1160], ["tumors", 1163], ["with", 1170], ["activated", 1175], ["platelet", 1185], ["-", 1193], ["derived", 1194], ["growth", 1202], ["factor", 1209], ["receptor", 1216], [".", 1224], ["The", 1226], ["studies", 1230], ["of", 1238], ["imatinib", 1241], ["mesylate", 1250], ["provide", 1259], ["proof", 1267], ["-", 1272], ["of", 1273], ["-", 1275], ["principle", 1276], ["for", 1286], ["using", 1290], ["aberrant", 1296], ["kinases", 1305], ["as", 1313], ["a", 1316], ["therapeutic", 1318], ["target", 1330], ["and", 1337], ["are", 1341], ["a", 1345], ["model", 1347], ["for", 1353], ["the", 1357], ["promise", 1361], ["of", 1369], ["molecular", 1372], ["therapeutics", 1382], [".", 1394], ["This", 1396], ["paper", 1401], ["reviews", 1407], ["the", 1415], ["current", 1419], ["knowledge", 1427], ["on", 1437], ["the", 1440], ["function", 1444], ["of", 1453], ["Bcr", 1456], ["-", 1459], ["Abl", 1460], ["and", 1464], ["its", 1468], ["normal", 1472], ["counterparts", 1479], ["(", 1492], ["Bcr", 1493], ["and", 1497], ["Abl", 1501], [")", 1504], [",", 1505], ["as", 1507], ["well", 1510], ["as", 1515], ["the", 1518], ["impact", 1522], ["of", 1529], ["this", 1532], ["knowledge", 1537], ["on", 1547], ["the", 1550], ["development", 1554], ["of", 1566], ["a", 1569], ["remarkably", 1571], ["successful", 1582], ["targeted", 1593], ["therapy", 1602], ["approach", 1610], [".", 1618]]}
{"context": "Reported prevalence of restless legs syndrome (RLS), also known as Willis-Ekbom disease (WED), varies from country to country, and methodologic inconsistencies limit comparison of data. Impact of RLS on quality of life and health has been studied primarily in industrialized countries, particularly Europe and the United States. Many studies have relied exclusively on self-report of symptoms or have assessed only medical populations. Recently, interest has emerged on the impact of WED in rural, underserved populations globally. In a population-based survey conducted in rural Ecuador, we assessed the relationship of psychological distress to WED, evaluated with the Depression Anxiety Stress Scales-21. WED was diagnosed through a 2-phase method in which all residents were screened with the International Restless Legs Syndrome Study Group (IRLSSG) questionnaire and all suspected cases were subsequently confirmed through expert medical examination. WED severity was assessed with the IRLSSG rating scale. Of 665 persons (mean [SD] age, 59.5 [12.6] years; women, 386 [58%]), 76 had depression, 93 had anxiety, and 60 reported stress. Forty persons (6%) had WED, with 15 (38%) having severe disease. In a regression model adjusted for age and sex, the prevalence of depression, anxiety, and stress was about 3 times greater among persons with WED than the general population. Although cross-sectional data cannot establish causation, this study shows the large behavioral health burden associated with WED in an untreated, rural population.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "5dc7b7888b6a4035ae95f669a8d8cfff", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[139, 141], [3, 5]], "char_spans": [[811, 832], [23, 44]]}]}], "context_tokens": [["Reported", 0], ["prevalence", 9], ["of", 20], ["restless", 23], ["legs", 32], ["syndrome", 37], ["(", 46], ["RLS", 47], [")", 50], [",", 51], ["also", 53], ["known", 58], ["as", 64], ["Willis", 67], ["-", 73], ["Ekbom", 74], ["disease", 80], ["(", 88], ["WED", 89], [")", 92], [",", 93], ["varies", 95], ["from", 102], ["country", 107], ["to", 115], ["country", 118], [",", 125], ["and", 127], ["methodologic", 131], ["inconsistencies", 144], ["limit", 160], ["comparison", 166], ["of", 177], ["data", 180], [".", 184], ["Impact", 186], ["of", 193], ["RLS", 196], ["on", 200], ["quality", 203], ["of", 211], ["life", 214], ["and", 219], ["health", 223], ["has", 230], ["been", 234], ["studied", 239], ["primarily", 247], ["in", 257], ["industrialized", 260], ["countries", 275], [",", 284], ["particularly", 286], ["Europe", 299], ["and", 306], ["the", 310], ["United", 314], ["States", 321], [".", 327], ["Many", 329], ["studies", 334], ["have", 342], ["relied", 347], ["exclusively", 354], ["on", 366], ["self", 369], ["-", 373], ["report", 374], ["of", 381], ["symptoms", 384], ["or", 393], ["have", 396], ["assessed", 401], ["only", 410], ["medical", 415], ["populations", 423], [".", 434], ["Recently", 436], [",", 444], ["interest", 446], ["has", 455], ["emerged", 459], ["on", 467], ["the", 470], ["impact", 474], ["of", 481], ["WED", 484], ["in", 488], ["rural", 491], [",", 496], ["underserved", 498], ["populations", 510], ["globally", 522], [".", 530], ["In", 532], ["a", 535], ["population", 537], ["-", 547], ["based", 548], ["survey", 554], ["conducted", 561], ["in", 571], ["rural", 574], ["Ecuador", 580], [",", 587], ["we", 589], ["assessed", 592], ["the", 601], ["relationship", 605], ["of", 618], ["psychological", 621], ["distress", 635], ["to", 644], ["WED", 647], [",", 650], ["evaluated", 652], ["with", 662], ["the", 667], ["Depression", 671], ["Anxiety", 682], ["Stress", 690], ["Scales-21", 697], [".", 706], ["WED", 708], ["was", 712], ["diagnosed", 716], ["through", 726], ["a", 734], ["2-phase", 736], ["method", 744], ["in", 751], ["which", 754], ["all", 760], ["residents", 764], ["were", 774], ["screened", 779], ["with", 788], ["the", 793], ["International", 797], ["Restless", 811], ["Legs", 820], ["Syndrome", 825], ["Study", 834], ["Group", 840], ["(", 846], ["IRLSSG", 847], [")", 853], ["questionnaire", 855], ["and", 869], ["all", 873], ["suspected", 877], ["cases", 887], ["were", 893], ["subsequently", 898], ["confirmed", 911], ["through", 921], ["expert", 929], ["medical", 936], ["examination", 944], [".", 955], ["WED", 957], ["severity", 961], ["was", 970], ["assessed", 974], ["with", 983], ["the", 988], ["IRLSSG", 992], ["rating", 999], ["scale", 1006], [".", 1011], ["Of", 1013], ["665", 1016], ["persons", 1020], ["(", 1028], ["mean", 1029], ["[", 1034], ["SD", 1035], ["]", 1037], ["age", 1039], [",", 1042], ["59.5", 1044], ["[", 1049], ["12.6", 1050], ["]", 1054], ["years", 1056], [";", 1061], ["women", 1063], [",", 1068], ["386", 1070], ["[", 1074], ["58", 1075], ["%", 1077], ["]", 1078], [")", 1079], [",", 1080], ["76", 1082], ["had", 1085], ["depression", 1089], [",", 1099], ["93", 1101], ["had", 1104], ["anxiety", 1108], [",", 1115], ["and", 1117], ["60", 1121], ["reported", 1124], ["stress", 1133], [".", 1139], ["Forty", 1141], ["persons", 1147], ["(", 1155], ["6", 1156], ["%", 1157], [")", 1158], ["had", 1160], ["WED", 1164], [",", 1167], ["with", 1169], ["15", 1174], ["(", 1177], ["38", 1178], ["%", 1180], [")", 1181], ["having", 1183], ["severe", 1190], ["disease", 1197], [".", 1204], ["In", 1206], ["a", 1209], ["regression", 1211], ["model", 1222], ["adjusted", 1228], ["for", 1237], ["age", 1241], ["and", 1245], ["sex", 1249], [",", 1252], ["the", 1254], ["prevalence", 1258], ["of", 1269], ["depression", 1272], [",", 1282], ["anxiety", 1284], [",", 1291], ["and", 1293], ["stress", 1297], ["was", 1304], ["about", 1308], ["3", 1314], ["times", 1316], ["greater", 1322], ["among", 1330], ["persons", 1336], ["with", 1344], ["WED", 1349], ["than", 1353], ["the", 1358], ["general", 1362], ["population", 1370], [".", 1380], ["Although", 1382], ["cross", 1391], ["-", 1396], ["sectional", 1397], ["data", 1407], ["can", 1412], ["not", 1415], ["establish", 1419], ["causation", 1429], [",", 1438], ["this", 1440], ["study", 1445], ["shows", 1451], ["the", 1457], ["large", 1461], ["behavioral", 1467], ["health", 1478], ["burden", 1485], ["associated", 1492], ["with", 1503], ["WED", 1508], ["in", 1512], ["an", 1515], ["untreated", 1518], [",", 1527], ["rural", 1529], ["population", 1535], [".", 1545]]}
{"context": "The light-harvesting chlorophyll a/b-protein complex of photosystem II (LHCII) is the most abundant membrane protein in green plants, and its degradation is a crucial process for the acclimation to high light conditions and for the recovery of nitrogen (N) and carbon (C) during senescence. However, the molecular mechanism of LHCII degradation is largely unknown. Here, we report that chlorophyll b reductase, which catalyzes the first step of chlorophyll b degradation, plays a central role in LHCII degradation. When the genes for chlorophyll b reductases NOL and NYC1 were disrupted in Arabidopsis thaliana, chlorophyll b and LHCII were not degraded during senescence, whereas other pigment complexes completely disappeared. When purified trimeric LHCII was incubated with recombinant chlorophyll b reductase (NOL), expressed in Escherichia coli, the chlorophyll b in LHCII was converted to 7-hydroxymethyl chlorophyll a. Accompanying this conversion, chlorophylls were released from LHCII apoproteins until all the chlorophyll molecules in LHCII dissociated from the complexes. Chlorophyll-depleted LHCII apoproteins did not dissociate into monomeric forms but remained in the trimeric form. Based on these results, we propose the novel hypothesis that chlorophyll b reductase catalyzes the initial step of LHCII degradation, and that trimeric LHCII is a substrate of LHCII degradation.", "qas": [{"question": "Which is the most abundant membrane protein on Earth?", "answers": ["Light-harvesting pigment-protein complex of Photosystem II", "LHCII"], "qid": "e65867b72b4e4b6cab1e8ae033a60312", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["most", 13], ["abundant", 18], ["membrane", 27], ["protein", 36], ["on", 44], ["Earth", 47], ["?", 52]], "detected_answers": [{"text": "LHCII", "token_spans": [[64, 64], [226, 226], [133, 133], [154, 154], [177, 177], [186, 186], [116, 116], [220, 220], [169, 169], [231, 231], [94, 94], [15, 15]], "char_spans": [[327, 331], [1349, 1353], [752, 756], [872, 876], [1045, 1049], [1104, 1108], [630, 634], [1312, 1316], [988, 992], [1373, 1377], [496, 500], [72, 76]]}]}], "context_tokens": [["The", 0], ["light", 4], ["-", 9], ["harvesting", 10], ["chlorophyll", 21], ["a", 33], ["/", 34], ["b", 35], ["-", 36], ["protein", 37], ["complex", 45], ["of", 53], ["photosystem", 56], ["II", 68], ["(", 71], ["LHCII", 72], [")", 77], ["is", 79], ["the", 82], ["most", 86], ["abundant", 91], ["membrane", 100], ["protein", 109], ["in", 117], ["green", 120], ["plants", 126], [",", 132], ["and", 134], ["its", 138], ["degradation", 142], ["is", 154], ["a", 157], ["crucial", 159], ["process", 167], ["for", 175], ["the", 179], ["acclimation", 183], ["to", 195], ["high", 198], ["light", 203], ["conditions", 209], ["and", 220], ["for", 224], ["the", 228], ["recovery", 232], ["of", 241], ["nitrogen", 244], ["(", 253], ["N", 254], [")", 255], ["and", 257], ["carbon", 261], ["(", 268], ["C", 269], [")", 270], ["during", 272], ["senescence", 279], [".", 289], ["However", 291], [",", 298], ["the", 300], ["molecular", 304], ["mechanism", 314], ["of", 324], ["LHCII", 327], ["degradation", 333], ["is", 345], ["largely", 348], ["unknown", 356], [".", 363], ["Here", 365], [",", 369], ["we", 371], ["report", 374], ["that", 381], ["chlorophyll", 386], ["b", 398], ["reductase", 400], [",", 409], ["which", 411], ["catalyzes", 417], ["the", 427], ["first", 431], ["step", 437], ["of", 442], ["chlorophyll", 445], ["b", 457], ["degradation", 459], [",", 470], ["plays", 472], ["a", 478], ["central", 480], ["role", 488], ["in", 493], ["LHCII", 496], ["degradation", 502], [".", 513], ["When", 515], ["the", 520], ["genes", 524], ["for", 530], ["chlorophyll", 534], ["b", 546], ["reductases", 548], ["NOL", 559], ["and", 563], ["NYC1", 567], ["were", 572], ["disrupted", 577], ["in", 587], ["Arabidopsis", 590], ["thaliana", 602], [",", 610], ["chlorophyll", 612], ["b", 624], ["and", 626], ["LHCII", 630], ["were", 636], ["not", 641], ["degraded", 645], ["during", 654], ["senescence", 661], [",", 671], ["whereas", 673], ["other", 681], ["pigment", 687], ["complexes", 695], ["completely", 705], ["disappeared", 716], [".", 727], ["When", 729], ["purified", 734], ["trimeric", 743], ["LHCII", 752], ["was", 758], ["incubated", 762], ["with", 772], ["recombinant", 777], ["chlorophyll", 789], ["b", 801], ["reductase", 803], ["(", 813], ["NOL", 814], [")", 817], [",", 818], ["expressed", 820], ["in", 830], ["Escherichia", 833], ["coli", 845], [",", 849], ["the", 851], ["chlorophyll", 855], ["b", 867], ["in", 869], ["LHCII", 872], ["was", 878], ["converted", 882], ["to", 892], ["7-hydroxymethyl", 895], ["chlorophyll", 911], ["a.", 923], ["Accompanying", 926], ["this", 939], ["conversion", 944], [",", 954], ["chlorophylls", 956], ["were", 969], ["released", 974], ["from", 983], ["LHCII", 988], ["apoproteins", 994], ["until", 1006], ["all", 1012], ["the", 1016], ["chlorophyll", 1020], ["molecules", 1032], ["in", 1042], ["LHCII", 1045], ["dissociated", 1051], ["from", 1063], ["the", 1068], ["complexes", 1072], [".", 1081], ["Chlorophyll", 1083], ["-", 1094], ["depleted", 1095], ["LHCII", 1104], ["apoproteins", 1110], ["did", 1122], ["not", 1126], ["dissociate", 1130], ["into", 1141], ["monomeric", 1146], ["forms", 1156], ["but", 1162], ["remained", 1166], ["in", 1175], ["the", 1178], ["trimeric", 1182], ["form", 1191], [".", 1195], ["Based", 1197], ["on", 1203], ["these", 1206], ["results", 1212], [",", 1219], ["we", 1221], ["propose", 1224], ["the", 1232], ["novel", 1236], ["hypothesis", 1242], ["that", 1253], ["chlorophyll", 1258], ["b", 1270], ["reductase", 1272], ["catalyzes", 1282], ["the", 1292], ["initial", 1296], ["step", 1304], ["of", 1309], ["LHCII", 1312], ["degradation", 1318], [",", 1329], ["and", 1331], ["that", 1335], ["trimeric", 1340], ["LHCII", 1349], ["is", 1355], ["a", 1358], ["substrate", 1360], ["of", 1370], ["LHCII", 1373], ["degradation", 1379], [".", 1390]]}
{"context": "Lewy bodies, neuropathological hallmarks of Parkinson's disease and dementia with Lewy bodies, comprise alpha-synuclein filaments and other less defined proteins. Characterization of Lewy body proteins that interact with alpha-synuclein may provide insight into the mechanism of Lewy body formation. Double immunofluorescence labeling and confocal microscopy revealed approximately 80% of cortical Lewy bodies contained microtubule-associated protein 1B (MAP-1B) that overlapped with alpha-synuclein. Lewy bodies were isolated using an immunomagnetic technique from brain tissue of patients dying with dementia with Lewy bodies. Lewy body proteins were resolved by polyacrylamide gel electrophoresis. Immunoblotting confirmed the presence of MAP-1B and alpha-synuclein in purified Lewy bodies. Direct binding studies revealed a high affinity interaction (IC(50) approximately 20 nm) between MAP-1B and alpha-synuclein. The MAP-1B-binding sites were mapped to the last 45 amino acids of the alpha-synuclein C terminus. MAP-1B also bound in vitro assembled alpha-synuclein fibrils. Thus, MAP-1B may be involved in the pathogenesis of Lewy bodies via its interaction with monomeric and fibrillar alpha-synuclein.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "61399ac72d9a4c4397aa7b80ee902d25", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[172, 174], [196, 198], [141, 143], [74, 76], [16, 18], [160, 162], [34, 36], [115, 117]], "char_spans": [[1055, 1069], [1193, 1207], [902, 916], [484, 498], [104, 118], [990, 1004], [221, 235], [753, 767]]}]}], "context_tokens": [["Lewy", 0], ["bodies", 5], [",", 11], ["neuropathological", 13], ["hallmarks", 31], ["of", 41], ["Parkinson", 44], ["'s", 53], ["disease", 56], ["and", 64], ["dementia", 68], ["with", 77], ["Lewy", 82], ["bodies", 87], [",", 93], ["comprise", 95], ["alpha", 104], ["-", 109], ["synuclein", 110], ["filaments", 120], ["and", 130], ["other", 134], ["less", 140], ["defined", 145], ["proteins", 153], [".", 161], ["Characterization", 163], ["of", 180], ["Lewy", 183], ["body", 188], ["proteins", 193], ["that", 202], ["interact", 207], ["with", 216], ["alpha", 221], ["-", 226], ["synuclein", 227], ["may", 237], ["provide", 241], ["insight", 249], ["into", 257], ["the", 262], ["mechanism", 266], ["of", 276], ["Lewy", 279], ["body", 284], ["formation", 289], [".", 298], ["Double", 300], ["immunofluorescence", 307], ["labeling", 326], ["and", 335], ["confocal", 339], ["microscopy", 348], ["revealed", 359], ["approximately", 368], ["80", 382], ["%", 384], ["of", 386], ["cortical", 389], ["Lewy", 398], ["bodies", 403], ["contained", 410], ["microtubule", 420], ["-", 431], ["associated", 432], ["protein", 443], ["1B", 451], ["(", 454], ["MAP-1B", 455], [")", 461], ["that", 463], ["overlapped", 468], ["with", 479], ["alpha", 484], ["-", 489], ["synuclein", 490], [".", 499], ["Lewy", 501], ["bodies", 506], ["were", 513], ["isolated", 518], ["using", 527], ["an", 533], ["immunomagnetic", 536], ["technique", 551], ["from", 561], ["brain", 566], ["tissue", 572], ["of", 579], ["patients", 582], ["dying", 591], ["with", 597], ["dementia", 602], ["with", 611], ["Lewy", 616], ["bodies", 621], [".", 627], ["Lewy", 629], ["body", 634], ["proteins", 639], ["were", 648], ["resolved", 653], ["by", 662], ["polyacrylamide", 665], ["gel", 680], ["electrophoresis", 684], [".", 699], ["Immunoblotting", 701], ["confirmed", 716], ["the", 726], ["presence", 730], ["of", 739], ["MAP-1B", 742], ["and", 749], ["alpha", 753], ["-", 758], ["synuclein", 759], ["in", 769], ["purified", 772], ["Lewy", 781], ["bodies", 786], [".", 792], ["Direct", 794], ["binding", 801], ["studies", 809], ["revealed", 817], ["a", 826], ["high", 828], ["affinity", 833], ["interaction", 842], ["(", 854], ["IC(50", 855], [")", 860], ["approximately", 862], ["20", 876], ["nm", 879], [")", 881], ["between", 883], ["MAP-1B", 891], ["and", 898], ["alpha", 902], ["-", 907], ["synuclein", 908], [".", 917], ["The", 919], ["MAP-1B", 923], ["-", 929], ["binding", 930], ["sites", 938], ["were", 944], ["mapped", 949], ["to", 956], ["the", 959], ["last", 963], ["45", 968], ["amino", 971], ["acids", 977], ["of", 983], ["the", 986], ["alpha", 990], ["-", 995], ["synuclein", 996], ["C", 1006], ["terminus", 1008], [".", 1016], ["MAP-1B", 1018], ["also", 1025], ["bound", 1030], ["in", 1036], ["vitro", 1039], ["assembled", 1045], ["alpha", 1055], ["-", 1060], ["synuclein", 1061], ["fibrils", 1071], [".", 1078], ["Thus", 1080], [",", 1084], ["MAP-1B", 1086], ["may", 1093], ["be", 1097], ["involved", 1100], ["in", 1109], ["the", 1112], ["pathogenesis", 1116], ["of", 1129], ["Lewy", 1132], ["bodies", 1137], ["via", 1144], ["its", 1148], ["interaction", 1152], ["with", 1164], ["monomeric", 1169], ["and", 1179], ["fibrillar", 1183], ["alpha", 1193], ["-", 1198], ["synuclein", 1199], [".", 1208]]}
{"context": "A proteomic study predicted that about one hundred kinds of proteins constitute a basic structure of the centrosome. Most of the core centrosomal proteins contain extensive coiled-coil domains, suggesting that the protein-protein interaction is a critical force for the core centrosome configuration. In the present study, we investigated a novel interaction between CEP135 and C-NAP1, two core centriolar proteins. Depletion of CEP135 caused a premature centrosome splitting. Reduction of the centrosomal C-NAP1 level was accompanied in a specific manner. Ectopic expression of the CEP135 mutant proteins also caused centrosome splitting in association with the reduction of the centrosomal C-NAP1 levels. Based on these results, we propose that CEP135 acts as a platform protein for C-NAP1 at the centriole.", "qas": [{"question": "Where in the cell do we find the protein Cep135?", "answers": ["centrosome"], "qid": "ed3f5c3a0167499384a5f2031c714e92", "question_tokens": [["Where", 0], ["in", 6], ["the", 9], ["cell", 13], ["do", 18], ["we", 21], ["find", 24], ["the", 29], ["protein", 33], ["Cep135", 41], ["?", 47]], "detected_answers": [{"text": "centrosome", "token_spans": [[104, 104], [17, 17], [77, 77], [46, 46]], "char_spans": [[618, 627], [105, 114], [455, 464], [275, 284]]}]}], "context_tokens": [["A", 0], ["proteomic", 2], ["study", 12], ["predicted", 18], ["that", 28], ["about", 33], ["one", 39], ["hundred", 43], ["kinds", 51], ["of", 57], ["proteins", 60], ["constitute", 69], ["a", 80], ["basic", 82], ["structure", 88], ["of", 98], ["the", 101], ["centrosome", 105], [".", 115], ["Most", 117], ["of", 122], ["the", 125], ["core", 129], ["centrosomal", 134], ["proteins", 146], ["contain", 155], ["extensive", 163], ["coiled", 173], ["-", 179], ["coil", 180], ["domains", 185], [",", 192], ["suggesting", 194], ["that", 205], ["the", 210], ["protein", 214], ["-", 221], ["protein", 222], ["interaction", 230], ["is", 242], ["a", 245], ["critical", 247], ["force", 256], ["for", 262], ["the", 266], ["core", 270], ["centrosome", 275], ["configuration", 286], [".", 299], ["In", 301], ["the", 304], ["present", 308], ["study", 316], [",", 321], ["we", 323], ["investigated", 326], ["a", 339], ["novel", 341], ["interaction", 347], ["between", 359], ["CEP135", 367], ["and", 374], ["C", 378], ["-", 379], ["NAP1", 380], [",", 384], ["two", 386], ["core", 390], ["centriolar", 395], ["proteins", 406], [".", 414], ["Depletion", 416], ["of", 426], ["CEP135", 429], ["caused", 436], ["a", 443], ["premature", 445], ["centrosome", 455], ["splitting", 466], [".", 475], ["Reduction", 477], ["of", 487], ["the", 490], ["centrosomal", 494], ["C", 506], ["-", 507], ["NAP1", 508], ["level", 513], ["was", 519], ["accompanied", 523], ["in", 535], ["a", 538], ["specific", 540], ["manner", 549], [".", 555], ["Ectopic", 557], ["expression", 565], ["of", 576], ["the", 579], ["CEP135", 583], ["mutant", 590], ["proteins", 597], ["also", 606], ["caused", 611], ["centrosome", 618], ["splitting", 629], ["in", 639], ["association", 642], ["with", 654], ["the", 659], ["reduction", 663], ["of", 673], ["the", 676], ["centrosomal", 680], ["C", 692], ["-", 693], ["NAP1", 694], ["levels", 699], [".", 705], ["Based", 707], ["on", 713], ["these", 716], ["results", 722], [",", 729], ["we", 731], ["propose", 734], ["that", 742], ["CEP135", 747], ["acts", 754], ["as", 759], ["a", 762], ["platform", 764], ["protein", 773], ["for", 781], ["C", 785], ["-", 786], ["NAP1", 787], ["at", 792], ["the", 795], ["centriole", 799], [".", 808]]}
{"context": "Neural stem/progenitor cell (NSP) biology and neurogenesis in adult central nervous system (CNS) are important both towards potential future therapeutic applications for CNS repair, and for the fundamental function of the CNS. In the present study, we report the characterization of NSP population from subventricular zone (SVZ) of neonatal piglet brain using in vivo and in vitro systems. We show that the nestin and vimentin-positive neural progenitor cells are present in the SVZ of the lateral ventricles of neonatal piglet brain. In vitro, piglet NSPs proliferated as neurospheres, expressed the typical protein of neural progenitors, nestin and a range of well-established neurodevelopmental markers. Upon dissociation and subculture, piglet NSPs differentiated into neurons and glial cells. Clonal analysis demonstrates that piglet NSPs are multipotent and retain the capacity to generate both glia and neurons. These cells expressed VEGF, VEGFR1, VEGFR2 and Neuropilin-1 and -2 mRNAs. Real time PCR revealed that SVZ NSPs from newborn piglet expressed total VEGF and all VEGF splice variants. These findings show that piglet NSPs may be helpful to more effectively design growth factor based strategies to enhance endogenous precursor cells for cell transplantation studies potentially leading to the application of this strategy in the nervous system disease and injury.", "qas": [{"question": "Which intermediate filament (IF) protein can be used as a non-specific marker of the neuronal precursor cells of the subventricular zone?", "answers": ["Nestin"], "qid": "93550bd7ff2742e5be0946f9e56d9da7", "question_tokens": [["Which", 0], ["intermediate", 6], ["filament", 19], ["(", 28], ["IF", 29], [")", 31], ["protein", 33], ["can", 41], ["be", 45], ["used", 48], ["as", 53], ["a", 56], ["non", 58], ["-", 61], ["specific", 62], ["marker", 71], ["of", 78], ["the", 81], ["neuronal", 85], ["precursor", 94], ["cells", 104], ["of", 110], ["the", 113], ["subventricular", 117], ["zone", 132], ["?", 136]], "detected_answers": [{"text": "Nestin", "token_spans": [[113, 113], [74, 74]], "char_spans": [[640, 645], [407, 412]]}]}], "context_tokens": [["Neural", 0], ["stem", 7], ["/", 11], ["progenitor", 12], ["cell", 23], ["(", 28], ["NSP", 29], [")", 32], ["biology", 34], ["and", 42], ["neurogenesis", 46], ["in", 59], ["adult", 62], ["central", 68], ["nervous", 76], ["system", 84], ["(", 91], ["CNS", 92], [")", 95], ["are", 97], ["important", 101], ["both", 111], ["towards", 116], ["potential", 124], ["future", 134], ["therapeutic", 141], ["applications", 153], ["for", 166], ["CNS", 170], ["repair", 174], [",", 180], ["and", 182], ["for", 186], ["the", 190], ["fundamental", 194], ["function", 206], ["of", 215], ["the", 218], ["CNS", 222], [".", 225], ["In", 227], ["the", 230], ["present", 234], ["study", 242], [",", 247], ["we", 249], ["report", 252], ["the", 259], ["characterization", 263], ["of", 280], ["NSP", 283], ["population", 287], ["from", 298], ["subventricular", 303], ["zone", 318], ["(", 323], ["SVZ", 324], [")", 327], ["of", 329], ["neonatal", 332], ["piglet", 341], ["brain", 348], ["using", 354], ["in", 360], ["vivo", 363], ["and", 368], ["in", 372], ["vitro", 375], ["systems", 381], [".", 388], ["We", 390], ["show", 393], ["that", 398], ["the", 403], ["nestin", 407], ["and", 414], ["vimentin", 418], ["-", 426], ["positive", 427], ["neural", 436], ["progenitor", 443], ["cells", 454], ["are", 460], ["present", 464], ["in", 472], ["the", 475], ["SVZ", 479], ["of", 483], ["the", 486], ["lateral", 490], ["ventricles", 498], ["of", 509], ["neonatal", 512], ["piglet", 521], ["brain", 528], [".", 533], ["In", 535], ["vitro", 538], [",", 543], ["piglet", 545], ["NSPs", 552], ["proliferated", 557], ["as", 570], ["neurospheres", 573], [",", 585], ["expressed", 587], ["the", 597], ["typical", 601], ["protein", 609], ["of", 617], ["neural", 620], ["progenitors", 627], [",", 638], ["nestin", 640], ["and", 647], ["a", 651], ["range", 653], ["of", 659], ["well", 662], ["-", 666], ["established", 667], ["neurodevelopmental", 679], ["markers", 698], [".", 705], ["Upon", 707], ["dissociation", 712], ["and", 725], ["subculture", 729], [",", 739], ["piglet", 741], ["NSPs", 748], ["differentiated", 753], ["into", 768], ["neurons", 773], ["and", 781], ["glial", 785], ["cells", 791], [".", 796], ["Clonal", 798], ["analysis", 805], ["demonstrates", 814], ["that", 827], ["piglet", 832], ["NSPs", 839], ["are", 844], ["multipotent", 848], ["and", 860], ["retain", 864], ["the", 871], ["capacity", 875], ["to", 884], ["generate", 887], ["both", 896], ["glia", 901], ["and", 906], ["neurons", 910], [".", 917], ["These", 919], ["cells", 925], ["expressed", 931], ["VEGF", 941], [",", 945], ["VEGFR1", 947], [",", 953], ["VEGFR2", 955], ["and", 962], ["Neuropilin-1", 966], ["and", 979], ["-2", 983], ["mRNAs", 986], [".", 991], ["Real", 993], ["time", 998], ["PCR", 1003], ["revealed", 1007], ["that", 1016], ["SVZ", 1021], ["NSPs", 1025], ["from", 1030], ["newborn", 1035], ["piglet", 1043], ["expressed", 1050], ["total", 1060], ["VEGF", 1066], ["and", 1071], ["all", 1075], ["VEGF", 1079], ["splice", 1084], ["variants", 1091], [".", 1099], ["These", 1101], ["findings", 1107], ["show", 1116], ["that", 1121], ["piglet", 1126], ["NSPs", 1133], ["may", 1138], ["be", 1142], ["helpful", 1145], ["to", 1153], ["more", 1156], ["effectively", 1161], ["design", 1173], ["growth", 1180], ["factor", 1187], ["based", 1194], ["strategies", 1200], ["to", 1211], ["enhance", 1214], ["endogenous", 1222], ["precursor", 1233], ["cells", 1243], ["for", 1249], ["cell", 1253], ["transplantation", 1258], ["studies", 1274], ["potentially", 1282], ["leading", 1294], ["to", 1302], ["the", 1305], ["application", 1309], ["of", 1321], ["this", 1324], ["strategy", 1329], ["in", 1338], ["the", 1341], ["nervous", 1345], ["system", 1353], ["disease", 1360], ["and", 1368], ["injury", 1372], [".", 1378]]}
{"context": "Tardive dyskinesia (TD) is a movement disorder characterized by abnormal involuntary facial movements induced by chronic therapy with classical antipsychotic medications. Currently, there is no satisfactory pharmacotherapy for TD, which represents a major limitation to therapy with classical antipsychotics. In order to develop or optimize therapies for TD, and to develop new APDs with lower indices of motor side effects, the pathology underlying TD must first be understood. The use of animal models has been used to further this objective. Here, we review different preparations that have been used to model TD and discuss the contribution of neuroimaging studies conducted in these models. Studies in animal models have lead to several hypotheses of TD pathology, although none has yet emerged as the ultimate underlying cause of this syndrome. We discuss alterations in functional indices, neuron and synapse morphology and changes in specific neurotransmitter systems that have been described in animal models of TD, and outline how these findings have contributed to our understanding of antipsychotic-induced dyskinesias. We conclude that several non-mutually exclusive theories of TD are supported by animal studies, including increases in oxidative stress leading to structural and functional changes in specific neurotransmitter systems. Elucidating the mechanisms underlying TD neuropathology partly through the use of animal models will lead to the development of APDs with superior side effect profiles or more effective therapies for TD.", "qas": [{"question": "What is the cause of Tardive dyskinesia?", "answers": ["Tardive dyskinesia (TD) is a movement disorder characterized by abnormal involuntary facial movements induced by chronic therapy with classical antipsychotic medications."], "qid": "b0f3562cb2574620ba46ae33c88d65b3", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["cause", 12], ["of", 18], ["Tardive", 21], ["dyskinesia", 29], ["?", 39]], "detected_answers": [{"text": "Tardive dyskinesia (TD) is a movement disorder characterized by abnormal involuntary facial movements induced by chronic therapy with classical antipsychotic medications.", "token_spans": [[0, 22]], "char_spans": [[0, 168]]}]}], "context_tokens": [["Tardive", 0], ["dyskinesia", 8], ["(", 19], ["TD", 20], [")", 22], ["is", 24], ["a", 27], ["movement", 29], ["disorder", 38], ["characterized", 47], ["by", 61], ["abnormal", 64], ["involuntary", 73], ["facial", 85], ["movements", 92], ["induced", 102], ["by", 110], ["chronic", 113], ["therapy", 121], ["with", 129], ["classical", 134], ["antipsychotic", 144], ["medications", 158], [".", 169], ["Currently", 171], [",", 180], ["there", 182], ["is", 188], ["no", 191], ["satisfactory", 194], ["pharmacotherapy", 207], ["for", 223], ["TD", 227], [",", 229], ["which", 231], ["represents", 237], ["a", 248], ["major", 250], ["limitation", 256], ["to", 267], ["therapy", 270], ["with", 278], ["classical", 283], ["antipsychotics", 293], [".", 307], ["In", 309], ["order", 312], ["to", 318], ["develop", 321], ["or", 329], ["optimize", 332], ["therapies", 341], ["for", 351], ["TD", 355], [",", 357], ["and", 359], ["to", 363], ["develop", 366], ["new", 374], ["APDs", 378], ["with", 383], ["lower", 388], ["indices", 394], ["of", 402], ["motor", 405], ["side", 411], ["effects", 416], [",", 423], ["the", 425], ["pathology", 429], ["underlying", 439], ["TD", 450], ["must", 453], ["first", 458], ["be", 464], ["understood", 467], [".", 477], ["The", 479], ["use", 483], ["of", 487], ["animal", 490], ["models", 497], ["has", 504], ["been", 508], ["used", 513], ["to", 518], ["further", 521], ["this", 529], ["objective", 534], [".", 543], ["Here", 545], [",", 549], ["we", 551], ["review", 554], ["different", 561], ["preparations", 571], ["that", 584], ["have", 589], ["been", 594], ["used", 599], ["to", 604], ["model", 607], ["TD", 613], ["and", 616], ["discuss", 620], ["the", 628], ["contribution", 632], ["of", 645], ["neuroimaging", 648], ["studies", 661], ["conducted", 669], ["in", 679], ["these", 682], ["models", 688], [".", 694], ["Studies", 696], ["in", 704], ["animal", 707], ["models", 714], ["have", 721], ["lead", 726], ["to", 731], ["several", 734], ["hypotheses", 742], ["of", 753], ["TD", 756], ["pathology", 759], [",", 768], ["although", 770], ["none", 779], ["has", 784], ["yet", 788], ["emerged", 792], ["as", 800], ["the", 803], ["ultimate", 807], ["underlying", 816], ["cause", 827], ["of", 833], ["this", 836], ["syndrome", 841], [".", 849], ["We", 851], ["discuss", 854], ["alterations", 862], ["in", 874], ["functional", 877], ["indices", 888], [",", 895], ["neuron", 897], ["and", 904], ["synapse", 908], ["morphology", 916], ["and", 927], ["changes", 931], ["in", 939], ["specific", 942], ["neurotransmitter", 951], ["systems", 968], ["that", 976], ["have", 981], ["been", 986], ["described", 991], ["in", 1001], ["animal", 1004], ["models", 1011], ["of", 1018], ["TD", 1021], [",", 1023], ["and", 1025], ["outline", 1029], ["how", 1037], ["these", 1041], ["findings", 1047], ["have", 1056], ["contributed", 1061], ["to", 1073], ["our", 1076], ["understanding", 1080], ["of", 1094], ["antipsychotic", 1097], ["-", 1110], ["induced", 1111], ["dyskinesias", 1119], [".", 1130], ["We", 1132], ["conclude", 1135], ["that", 1144], ["several", 1149], ["non", 1157], ["-", 1160], ["mutually", 1161], ["exclusive", 1170], ["theories", 1180], ["of", 1189], ["TD", 1192], ["are", 1195], ["supported", 1199], ["by", 1209], ["animal", 1212], ["studies", 1219], [",", 1226], ["including", 1228], ["increases", 1238], ["in", 1248], ["oxidative", 1251], ["stress", 1261], ["leading", 1268], ["to", 1276], ["structural", 1279], ["and", 1290], ["functional", 1294], ["changes", 1305], ["in", 1313], ["specific", 1316], ["neurotransmitter", 1325], ["systems", 1342], [".", 1349], ["Elucidating", 1351], ["the", 1363], ["mechanisms", 1367], ["underlying", 1378], ["TD", 1389], ["neuropathology", 1392], ["partly", 1407], ["through", 1414], ["the", 1422], ["use", 1426], ["of", 1430], ["animal", 1433], ["models", 1440], ["will", 1447], ["lead", 1452], ["to", 1457], ["the", 1460], ["development", 1464], ["of", 1476], ["APDs", 1479], ["with", 1484], ["superior", 1489], ["side", 1498], ["effect", 1503], ["profiles", 1510], ["or", 1519], ["more", 1522], ["effective", 1527], ["therapies", 1537], ["for", 1547], ["TD", 1551], [".", 1553]]}
{"context": "Chaperone-mediated autophagy is one of several lysosomal pathways of proteolysis. This pathway is activated by physiological stresses such as prolonged starvation. Cytosolic proteins with particular peptide sequence motifs are recognized by a complex of molecular chaperones and delivered to lysosomes. No vesicular traffic is required for this protein degradation pathway, so it differs from microautophagy and macroautophagy. Protein substrates bind to a receptor in the lysosomal membrane, the lysosome-associated membrane protein (lamp) type 2a. Levels of lamp2a in the lysosomal membrane are controlled by alterations in the lamp2a half-life as well as by the dynamic distribution of the protein between the lysosomal membrane and the lumen. Substrate proteins are unfolded before transport into the lysosome lumen, and the transport of substrate proteins requires a molecular chaperone within the lysosomal lumen. The exact roles of this lysosomal chaperone remain to be defined. The mechanisms of chaperone-mediated autophagy are similar to mechanisms of protein import into mitochondria, chloroplasts, and the endoplasmic reticulum.", "qas": [{"question": "Which is the receptor for substrates of Chaperone Mediated Autophagy?", "answers": ["LAMP2A", "Lysosome-associated membrane protein 2 isoform A"], "qid": "2af13c4b405e44c8820036a07143c462", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["receptor", 13], ["for", 22], ["substrates", 26], ["of", 37], ["Chaperone", 40], ["Mediated", 50], ["Autophagy", 59], ["?", 68]], "detected_answers": [{"text": "LAMP2A", "token_spans": [[100, 100], [89, 89]], "char_spans": [[630, 635], [560, 565]]}]}], "context_tokens": [["Chaperone", 0], ["-", 9], ["mediated", 10], ["autophagy", 19], ["is", 29], ["one", 32], ["of", 36], ["several", 39], ["lysosomal", 47], ["pathways", 57], ["of", 66], ["proteolysis", 69], [".", 80], ["This", 82], ["pathway", 87], ["is", 95], ["activated", 98], ["by", 108], ["physiological", 111], ["stresses", 125], ["such", 134], ["as", 139], ["prolonged", 142], ["starvation", 152], [".", 162], ["Cytosolic", 164], ["proteins", 174], ["with", 183], ["particular", 188], ["peptide", 199], ["sequence", 207], ["motifs", 216], ["are", 223], ["recognized", 227], ["by", 238], ["a", 241], ["complex", 243], ["of", 251], ["molecular", 254], ["chaperones", 264], ["and", 275], ["delivered", 279], ["to", 289], ["lysosomes", 292], [".", 301], ["No", 303], ["vesicular", 306], ["traffic", 316], ["is", 324], ["required", 327], ["for", 336], ["this", 340], ["protein", 345], ["degradation", 353], ["pathway", 365], [",", 372], ["so", 374], ["it", 377], ["differs", 380], ["from", 388], ["microautophagy", 393], ["and", 408], ["macroautophagy", 412], [".", 426], ["Protein", 428], ["substrates", 436], ["bind", 447], ["to", 452], ["a", 455], ["receptor", 457], ["in", 466], ["the", 469], ["lysosomal", 473], ["membrane", 483], [",", 491], ["the", 493], ["lysosome", 497], ["-", 505], ["associated", 506], ["membrane", 517], ["protein", 526], ["(", 534], ["lamp", 535], [")", 539], ["type", 541], ["2a", 546], [".", 548], ["Levels", 550], ["of", 557], ["lamp2a", 560], ["in", 567], ["the", 570], ["lysosomal", 574], ["membrane", 584], ["are", 593], ["controlled", 597], ["by", 608], ["alterations", 611], ["in", 623], ["the", 626], ["lamp2a", 630], ["half", 637], ["-", 641], ["life", 642], ["as", 647], ["well", 650], ["as", 655], ["by", 658], ["the", 661], ["dynamic", 665], ["distribution", 673], ["of", 686], ["the", 689], ["protein", 693], ["between", 701], ["the", 709], ["lysosomal", 713], ["membrane", 723], ["and", 732], ["the", 736], ["lumen", 740], [".", 745], ["Substrate", 747], ["proteins", 757], ["are", 766], ["unfolded", 770], ["before", 779], ["transport", 786], ["into", 796], ["the", 801], ["lysosome", 805], ["lumen", 814], [",", 819], ["and", 821], ["the", 825], ["transport", 829], ["of", 839], ["substrate", 842], ["proteins", 852], ["requires", 861], ["a", 870], ["molecular", 872], ["chaperone", 882], ["within", 892], ["the", 899], ["lysosomal", 903], ["lumen", 913], [".", 918], ["The", 920], ["exact", 924], ["roles", 930], ["of", 936], ["this", 939], ["lysosomal", 944], ["chaperone", 954], ["remain", 964], ["to", 971], ["be", 974], ["defined", 977], [".", 984], ["The", 986], ["mechanisms", 990], ["of", 1001], ["chaperone", 1004], ["-", 1013], ["mediated", 1014], ["autophagy", 1023], ["are", 1033], ["similar", 1037], ["to", 1045], ["mechanisms", 1048], ["of", 1059], ["protein", 1062], ["import", 1070], ["into", 1077], ["mitochondria", 1082], [",", 1094], ["chloroplasts", 1096], [",", 1108], ["and", 1110], ["the", 1114], ["endoplasmic", 1118], ["reticulum", 1130], [".", 1139]]}
{"context": "The Web site for the Anxiety Disorders Association of America (ADAA) receives more than 5 million visits per month and thus represents a unique medium for the study of anxiety disorders. ADAA Web site users from October 2002 to January 2003 were invited to complete a survey oriented toward trauma history and psychiatric sequelae. A diagnostic approximation of posttraumatic stress disorder (PTSD) was based on responses to the Trauma Questionnaire, the Davidson Trauma Scale, and questions about impairment. The Connor-Davidson Resilience Scale was also used. Variables were tested for their association with PTSD. Among 1558 participants, 87% had a history of trauma, and 38% had current PTSD. The population was comprised predominantly of white middle-class women, half of whom were married. More than 90% were first-time users of the site. Factors associated with PTSD included death of, or harm to, a loved one; personal history of incest, rape, or physical abuse; lower age; lower income; unemployment; missed work; increased medical care; dissatisfaction with psychotropic medication; depressive symptoms; and lower resilience. In this selective convenience sample, there were high rates of traumatization and PTSD. The demographics of this group are similar to those seen in previously studied populations that had contacted the ADAA. Furthermore, the factors associated with PTSD were like those in many community surveys. The ADAA Web site has the opportunity to benefit large numbers of highly distressed individuals.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "7b813fb8fbe444c2b8ed096bcfc51ca6", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "PTSD", "token_spans": [[123, 123], [251, 251], [104, 104], [159, 159], [66, 66], [223, 223]], "char_spans": [[691, 694], [1385, 1388], [611, 614], [869, 872], [393, 396], [1218, 1221]]}]}], "context_tokens": [["The", 0], ["Web", 4], ["site", 8], ["for", 13], ["the", 17], ["Anxiety", 21], ["Disorders", 29], ["Association", 39], ["of", 51], ["America", 54], ["(", 62], ["ADAA", 63], [")", 67], ["receives", 69], ["more", 78], ["than", 83], ["5", 88], ["million", 90], ["visits", 98], ["per", 105], ["month", 109], ["and", 115], ["thus", 119], ["represents", 124], ["a", 135], ["unique", 137], ["medium", 144], ["for", 151], ["the", 155], ["study", 159], ["of", 165], ["anxiety", 168], ["disorders", 176], [".", 185], ["ADAA", 187], ["Web", 192], ["site", 196], ["users", 201], ["from", 207], ["October", 212], ["2002", 220], ["to", 225], ["January", 228], ["2003", 236], ["were", 241], ["invited", 246], ["to", 254], ["complete", 257], ["a", 266], ["survey", 268], ["oriented", 275], ["toward", 284], ["trauma", 291], ["history", 298], ["and", 306], ["psychiatric", 310], ["sequelae", 322], [".", 330], ["A", 332], ["diagnostic", 334], ["approximation", 345], ["of", 359], ["posttraumatic", 362], ["stress", 376], ["disorder", 383], ["(", 392], ["PTSD", 393], [")", 397], ["was", 399], ["based", 403], ["on", 409], ["responses", 412], ["to", 422], ["the", 425], ["Trauma", 429], ["Questionnaire", 436], [",", 449], ["the", 451], ["Davidson", 455], ["Trauma", 464], ["Scale", 471], [",", 476], ["and", 478], ["questions", 482], ["about", 492], ["impairment", 498], [".", 508], ["The", 510], ["Connor", 514], ["-", 520], ["Davidson", 521], ["Resilience", 530], ["Scale", 541], ["was", 547], ["also", 551], ["used", 556], [".", 560], ["Variables", 562], ["were", 572], ["tested", 577], ["for", 584], ["their", 588], ["association", 594], ["with", 606], ["PTSD", 611], [".", 615], ["Among", 617], ["1558", 623], ["participants", 628], [",", 640], ["87", 642], ["%", 644], ["had", 646], ["a", 650], ["history", 652], ["of", 660], ["trauma", 663], [",", 669], ["and", 671], ["38", 675], ["%", 677], ["had", 679], ["current", 683], ["PTSD", 691], [".", 695], ["The", 697], ["population", 701], ["was", 712], ["comprised", 716], ["predominantly", 726], ["of", 740], ["white", 743], ["middle", 749], ["-", 755], ["class", 756], ["women", 762], [",", 767], ["half", 769], ["of", 774], ["whom", 777], ["were", 782], ["married", 787], [".", 794], ["More", 796], ["than", 801], ["90", 806], ["%", 808], ["were", 810], ["first", 815], ["-", 820], ["time", 821], ["users", 826], ["of", 832], ["the", 835], ["site", 839], [".", 843], ["Factors", 845], ["associated", 853], ["with", 864], ["PTSD", 869], ["included", 874], ["death", 883], ["of", 889], [",", 891], ["or", 893], ["harm", 896], ["to", 901], [",", 903], ["a", 905], ["loved", 907], ["one", 913], [";", 916], ["personal", 918], ["history", 927], ["of", 935], ["incest", 938], [",", 944], ["rape", 946], [",", 950], ["or", 952], ["physical", 955], ["abuse", 964], [";", 969], ["lower", 971], ["age", 977], [";", 980], ["lower", 982], ["income", 988], [";", 994], ["unemployment", 996], [";", 1008], ["missed", 1010], ["work", 1017], [";", 1021], ["increased", 1023], ["medical", 1033], ["care", 1041], [";", 1045], ["dissatisfaction", 1047], ["with", 1063], ["psychotropic", 1068], ["medication", 1081], [";", 1091], ["depressive", 1093], ["symptoms", 1104], [";", 1112], ["and", 1114], ["lower", 1118], ["resilience", 1124], [".", 1134], ["In", 1136], ["this", 1139], ["selective", 1144], ["convenience", 1154], ["sample", 1166], [",", 1172], ["there", 1174], ["were", 1180], ["high", 1185], ["rates", 1190], ["of", 1196], ["traumatization", 1199], ["and", 1214], ["PTSD", 1218], [".", 1222], ["The", 1224], ["demographics", 1228], ["of", 1241], ["this", 1244], ["group", 1249], ["are", 1255], ["similar", 1259], ["to", 1267], ["those", 1270], ["seen", 1276], ["in", 1281], ["previously", 1284], ["studied", 1295], ["populations", 1303], ["that", 1315], ["had", 1320], ["contacted", 1324], ["the", 1334], ["ADAA", 1338], [".", 1342], ["Furthermore", 1344], [",", 1355], ["the", 1357], ["factors", 1361], ["associated", 1369], ["with", 1380], ["PTSD", 1385], ["were", 1390], ["like", 1395], ["those", 1400], ["in", 1406], ["many", 1409], ["community", 1414], ["surveys", 1424], [".", 1431], ["The", 1433], ["ADAA", 1437], ["Web", 1442], ["site", 1446], ["has", 1451], ["the", 1455], ["opportunity", 1459], ["to", 1471], ["benefit", 1474], ["large", 1482], ["numbers", 1488], ["of", 1496], ["highly", 1499], ["distressed", 1506], ["individuals", 1517], [".", 1528]]}
{"context": "Chronic myeloid leukemia (CML) is the first human malignancy for which the promise of targeted therapy has come true. CML is invariably associated with a specific genetic lesion--the t(9;22) chromosomal translocation. As a consequence of this translocation, a BCR-ABL fusion gene is formed on the 22q- derivative (traditionally known as the Philadelphia chromosome) and the deregulated tyrosine kinase activity of the protein encoded by this gene has been shown to be both necessary and sufficient for initiation and maintenance of the disease. Imatinib mesylate, an orally available tyrosine kinase inhibitor that targets Bcr-Abl, entered clinical evaluation in 1998. Its efficacy surpassed almost everyone's predictions, and the observation of high response rates and favorable toxicity profile associated with imatinib therapy led to its approval as first-line treatment for all newly diagnosed CML patients over an exceptionally short period of time. The 6-year results of the Phase III trial have recently been reported and confirm durability of responses and declining incidence of adverse events over time, although, at present, occurrence of unexpected side effects in the long term cannot be excluded. Although imatinib does not 'cure' CML and has to be administered chronically to patients, it has revolutionized both outcome and quality of life of CML patients.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "b84adc8ad62e42e3b5cd84477d1d0750", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[46, 48], [106, 108]], "char_spans": [[260, 266], [623, 629]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukemia", 16], ["(", 25], ["CML", 26], [")", 29], ["is", 31], ["the", 34], ["first", 38], ["human", 44], ["malignancy", 50], ["for", 61], ["which", 65], ["the", 71], ["promise", 75], ["of", 83], ["targeted", 86], ["therapy", 95], ["has", 103], ["come", 107], ["true", 112], [".", 116], ["CML", 118], ["is", 122], ["invariably", 125], ["associated", 136], ["with", 147], ["a", 152], ["specific", 154], ["genetic", 163], ["lesion", 171], ["--", 177], ["the", 179], ["t(9;22", 183], [")", 189], ["chromosomal", 191], ["translocation", 203], [".", 216], ["As", 218], ["a", 221], ["consequence", 223], ["of", 235], ["this", 238], ["translocation", 243], [",", 256], ["a", 258], ["BCR", 260], ["-", 263], ["ABL", 264], ["fusion", 268], ["gene", 275], ["is", 280], ["formed", 283], ["on", 290], ["the", 293], ["22q-", 297], ["derivative", 302], ["(", 313], ["traditionally", 314], ["known", 328], ["as", 334], ["the", 337], ["Philadelphia", 341], ["chromosome", 354], [")", 364], ["and", 366], ["the", 370], ["deregulated", 374], ["tyrosine", 386], ["kinase", 395], ["activity", 402], ["of", 411], ["the", 414], ["protein", 418], ["encoded", 426], ["by", 434], ["this", 437], ["gene", 442], ["has", 447], ["been", 451], ["shown", 456], ["to", 462], ["be", 465], ["both", 468], ["necessary", 473], ["and", 483], ["sufficient", 487], ["for", 498], ["initiation", 502], ["and", 513], ["maintenance", 517], ["of", 529], ["the", 532], ["disease", 536], [".", 543], ["Imatinib", 545], ["mesylate", 554], [",", 562], ["an", 564], ["orally", 567], ["available", 574], ["tyrosine", 584], ["kinase", 593], ["inhibitor", 600], ["that", 610], ["targets", 615], ["Bcr", 623], ["-", 626], ["Abl", 627], [",", 630], ["entered", 632], ["clinical", 640], ["evaluation", 649], ["in", 660], ["1998", 663], [".", 667], ["Its", 669], ["efficacy", 673], ["surpassed", 682], ["almost", 692], ["everyone", 699], ["'s", 707], ["predictions", 710], [",", 721], ["and", 723], ["the", 727], ["observation", 731], ["of", 743], ["high", 746], ["response", 751], ["rates", 760], ["and", 766], ["favorable", 770], ["toxicity", 780], ["profile", 789], ["associated", 797], ["with", 808], ["imatinib", 813], ["therapy", 822], ["led", 830], ["to", 834], ["its", 837], ["approval", 841], ["as", 850], ["first", 853], ["-", 858], ["line", 859], ["treatment", 864], ["for", 874], ["all", 878], ["newly", 882], ["diagnosed", 888], ["CML", 898], ["patients", 902], ["over", 911], ["an", 916], ["exceptionally", 919], ["short", 933], ["period", 939], ["of", 946], ["time", 949], [".", 953], ["The", 955], ["6-year", 959], ["results", 966], ["of", 974], ["the", 977], ["Phase", 981], ["III", 987], ["trial", 991], ["have", 997], ["recently", 1002], ["been", 1011], ["reported", 1016], ["and", 1025], ["confirm", 1029], ["durability", 1037], ["of", 1048], ["responses", 1051], ["and", 1061], ["declining", 1065], ["incidence", 1075], ["of", 1085], ["adverse", 1088], ["events", 1096], ["over", 1103], ["time", 1108], [",", 1112], ["although", 1114], [",", 1122], ["at", 1124], ["present", 1127], [",", 1134], ["occurrence", 1136], ["of", 1147], ["unexpected", 1150], ["side", 1161], ["effects", 1166], ["in", 1174], ["the", 1177], ["long", 1181], ["term", 1186], ["can", 1191], ["not", 1194], ["be", 1198], ["excluded", 1201], [".", 1209], ["Although", 1211], ["imatinib", 1220], ["does", 1229], ["not", 1234], ["'", 1238], ["cure", 1239], ["'", 1243], ["CML", 1245], ["and", 1249], ["has", 1253], ["to", 1257], ["be", 1260], ["administered", 1263], ["chronically", 1276], ["to", 1288], ["patients", 1291], [",", 1299], ["it", 1301], ["has", 1304], ["revolutionized", 1308], ["both", 1323], ["outcome", 1328], ["and", 1336], ["quality", 1340], ["of", 1348], ["life", 1351], ["of", 1356], ["CML", 1359], ["patients", 1363], [".", 1371]]}
{"context": "The Ehlers-Danlos syndromes (EDS) comprise a heterogenous group of heritable disorders of connective tissue, characterized by joint hypermobility, skin hyperextensibility and tissue fragility. Most EDS types are caused by mutations in genes encoding different types of collagen or enzymes, essential for normal processing of collagen. Oral health was assessed in 31 subjects with EDS (16 with hypermobility EDS, nine with classical EDS and six with vascular EDS), including signs and symptoms of temporomandibular disorders (TMD), alterations of dental hard tissues, oral mucosa and periodontium, and was compared with matched controls. All EDS subjects were symptomatic for TMD and reported recurrent temporomandibular joint (TMJ) dislocations. Abnormal pulp shape (13%) and pulp calcification (78%) were observed in subjects affected with classical EDS. Caries experience was higher in EDS compared with controls and was related to poor oral hygiene, influenced by increased mucosal fragility and restraint of (wrist) joint mobility. The overall periodontal status in EDS was poor, with 62% of EDS subjects presenting high periodontal treatment needs (community periodontal index for treatment need, CPITN = II). Oral health may be severely compromised in EDS as a result of specific alterations of collagen in orofacial structures. When considering dental treatment in EDS, a number of tissue responses (mucosa, periodontium, pulp) and precautions (TMJ dislocation) should be anticipated.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "e43d93e0fc3b425690165278b7db59e3", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[16, 17]], "char_spans": [[90, 106]]}]}], "context_tokens": [["The", 0], ["Ehlers", 4], ["-", 10], ["Danlos", 11], ["syndromes", 18], ["(", 28], ["EDS", 29], [")", 32], ["comprise", 34], ["a", 43], ["heterogenous", 45], ["group", 58], ["of", 64], ["heritable", 67], ["disorders", 77], ["of", 87], ["connective", 90], ["tissue", 101], [",", 107], ["characterized", 109], ["by", 123], ["joint", 126], ["hypermobility", 132], [",", 145], ["skin", 147], ["hyperextensibility", 152], ["and", 171], ["tissue", 175], ["fragility", 182], [".", 191], ["Most", 193], ["EDS", 198], ["types", 202], ["are", 208], ["caused", 212], ["by", 219], ["mutations", 222], ["in", 232], ["genes", 235], ["encoding", 241], ["different", 250], ["types", 260], ["of", 266], ["collagen", 269], ["or", 278], ["enzymes", 281], [",", 288], ["essential", 290], ["for", 300], ["normal", 304], ["processing", 311], ["of", 322], ["collagen", 325], [".", 333], ["Oral", 335], ["health", 340], ["was", 347], ["assessed", 351], ["in", 360], ["31", 363], ["subjects", 366], ["with", 375], ["EDS", 380], ["(", 384], ["16", 385], ["with", 388], ["hypermobility", 393], ["EDS", 407], [",", 410], ["nine", 412], ["with", 417], ["classical", 422], ["EDS", 432], ["and", 436], ["six", 440], ["with", 444], ["vascular", 449], ["EDS", 458], [")", 461], [",", 462], ["including", 464], ["signs", 474], ["and", 480], ["symptoms", 484], ["of", 493], ["temporomandibular", 496], ["disorders", 514], ["(", 524], ["TMD", 525], [")", 528], [",", 529], ["alterations", 531], ["of", 543], ["dental", 546], ["hard", 553], ["tissues", 558], [",", 565], ["oral", 567], ["mucosa", 572], ["and", 579], ["periodontium", 583], [",", 595], ["and", 597], ["was", 601], ["compared", 605], ["with", 614], ["matched", 619], ["controls", 627], [".", 635], ["All", 637], ["EDS", 641], ["subjects", 645], ["were", 654], ["symptomatic", 659], ["for", 671], ["TMD", 675], ["and", 679], ["reported", 683], ["recurrent", 692], ["temporomandibular", 702], ["joint", 720], ["(", 726], ["TMJ", 727], [")", 730], ["dislocations", 732], [".", 744], ["Abnormal", 746], ["pulp", 755], ["shape", 760], ["(", 766], ["13", 767], ["%", 769], [")", 770], ["and", 772], ["pulp", 776], ["calcification", 781], ["(", 795], ["78", 796], ["%", 798], [")", 799], ["were", 801], ["observed", 806], ["in", 815], ["subjects", 818], ["affected", 827], ["with", 836], ["classical", 841], ["EDS", 851], [".", 854], ["Caries", 856], ["experience", 863], ["was", 874], ["higher", 878], ["in", 885], ["EDS", 888], ["compared", 892], ["with", 901], ["controls", 906], ["and", 915], ["was", 919], ["related", 923], ["to", 931], ["poor", 934], ["oral", 939], ["hygiene", 944], [",", 951], ["influenced", 953], ["by", 964], ["increased", 967], ["mucosal", 977], ["fragility", 985], ["and", 995], ["restraint", 999], ["of", 1009], ["(", 1012], ["wrist", 1013], [")", 1018], ["joint", 1020], ["mobility", 1026], [".", 1034], ["The", 1036], ["overall", 1040], ["periodontal", 1048], ["status", 1060], ["in", 1067], ["EDS", 1070], ["was", 1074], ["poor", 1078], [",", 1082], ["with", 1084], ["62", 1089], ["%", 1091], ["of", 1093], ["EDS", 1096], ["subjects", 1100], ["presenting", 1109], ["high", 1120], ["periodontal", 1125], ["treatment", 1137], ["needs", 1147], ["(", 1153], ["community", 1154], ["periodontal", 1164], ["index", 1176], ["for", 1182], ["treatment", 1186], ["need", 1196], [",", 1200], ["CPITN", 1202], ["=", 1208], ["II", 1210], [")", 1212], [".", 1213], ["Oral", 1215], ["health", 1220], ["may", 1227], ["be", 1231], ["severely", 1234], ["compromised", 1243], ["in", 1255], ["EDS", 1258], ["as", 1262], ["a", 1265], ["result", 1267], ["of", 1274], ["specific", 1277], ["alterations", 1286], ["of", 1298], ["collagen", 1301], ["in", 1310], ["orofacial", 1313], ["structures", 1323], [".", 1333], ["When", 1335], ["considering", 1340], ["dental", 1352], ["treatment", 1359], ["in", 1369], ["EDS", 1372], [",", 1375], ["a", 1377], ["number", 1379], ["of", 1386], ["tissue", 1389], ["responses", 1396], ["(", 1406], ["mucosa", 1407], [",", 1413], ["periodontium", 1415], [",", 1427], ["pulp", 1429], [")", 1433], ["and", 1435], ["precautions", 1439], ["(", 1451], ["TMJ", 1452], ["dislocation", 1456], [")", 1467], ["should", 1469], ["be", 1476], ["anticipated", 1479], [".", 1490]]}
{"context": "Cells respond to stresses such as osmotic shock and heat shock by activating stress-activated protein kinases (SAPKs), including c-Jun N-terminal kinase (JNK) [1]. Activation of JNK requires phosphorylation of threonine and tyrosine residues in the TPY activation loop motif [2, 3] and can be reversed by the removal of either phosphate group. Numerous JNK phosphatases including dual-specificity phosphatases [4, 5], have been identified. Many stimuli activate JNK by increasing its rate of phosphorylation; however, JNK dephosphorylation is inhibited in cells after heat shock [6], suggesting that a JNK phosphatase(s) is inactivated. M3/6 is a dual-specificity phosphatase selective for JNK [7, 8]. We have previously expressed M3/6 in the mouse bone marrow cell line BAF3 in order to show that JNK activation by IL-3 is necessary for cell survival and proliferation [9]. Here we report that M3/6 dissociates from JNK and appears in an insoluble fraction after heat shock. These data identify M3/6 as a JNK phosphatase that is inactivated by heat shock and provide a molecular mechanism for the activation of JNK by heat shock.", "qas": [{"question": "Which protein is affected by dusp8 activation?", "answers": ["JNK"], "qid": "902996f009de41b18ed94ad607438522", "question_tokens": [["Which", 0], ["protein", 6], ["is", 14], ["affected", 17], ["by", 26], ["dusp8", 29], ["activation", 35], ["?", 45]], "detected_answers": [{"text": "JNK", "token_spans": [[37, 37], [69, 69], [99, 99], [115, 115], [173, 173], [89, 89], [153, 153], [190, 190], [130, 130], [31, 31], [207, 207]], "char_spans": [[178, 180], [353, 355], [518, 520], [602, 604], [917, 919], [462, 464], [798, 800], [1006, 1008], [690, 692], [154, 156], [1112, 1114]]}]}], "context_tokens": [["Cells", 0], ["respond", 6], ["to", 14], ["stresses", 17], ["such", 26], ["as", 31], ["osmotic", 34], ["shock", 42], ["and", 48], ["heat", 52], ["shock", 57], ["by", 63], ["activating", 66], ["stress", 77], ["-", 83], ["activated", 84], ["protein", 94], ["kinases", 102], ["(", 110], ["SAPKs", 111], [")", 116], [",", 117], ["including", 119], ["c", 129], ["-", 130], ["Jun", 131], ["N", 135], ["-", 136], ["terminal", 137], ["kinase", 146], ["(", 153], ["JNK", 154], [")", 157], ["[", 159], ["1].", 160], ["Activation", 164], ["of", 175], ["JNK", 178], ["requires", 182], ["phosphorylation", 191], ["of", 207], ["threonine", 210], ["and", 220], ["tyrosine", 224], ["residues", 233], ["in", 242], ["the", 245], ["TPY", 249], ["activation", 253], ["loop", 264], ["motif", 269], ["[", 275], ["2", 276], [",", 277], ["3", 279], ["]", 280], ["and", 282], ["can", 286], ["be", 290], ["reversed", 293], ["by", 302], ["the", 305], ["removal", 309], ["of", 317], ["either", 320], ["phosphate", 327], ["group", 337], [".", 342], ["Numerous", 344], ["JNK", 353], ["phosphatases", 357], ["including", 370], ["dual", 380], ["-", 384], ["specificity", 385], ["phosphatases", 397], ["[", 410], ["4", 411], [",", 412], ["5", 414], ["]", 415], [",", 416], ["have", 418], ["been", 423], ["identified", 428], [".", 438], ["Many", 440], ["stimuli", 445], ["activate", 453], ["JNK", 462], ["by", 466], ["increasing", 469], ["its", 480], ["rate", 484], ["of", 489], ["phosphorylation", 492], [";", 507], ["however", 509], [",", 516], ["JNK", 518], ["dephosphorylation", 522], ["is", 540], ["inhibited", 543], ["in", 553], ["cells", 556], ["after", 562], ["heat", 568], ["shock", 573], ["[", 579], ["6", 580], ["]", 581], [",", 582], ["suggesting", 584], ["that", 595], ["a", 600], ["JNK", 602], ["phosphatase(s", 606], [")", 619], ["is", 621], ["inactivated", 624], [".", 635], ["M3/6", 637], ["is", 642], ["a", 645], ["dual", 647], ["-", 651], ["specificity", 652], ["phosphatase", 664], ["selective", 676], ["for", 686], ["JNK", 690], ["[", 694], ["7", 695], [",", 696], ["8].", 698], ["We", 702], ["have", 705], ["previously", 710], ["expressed", 721], ["M3/6", 731], ["in", 736], ["the", 739], ["mouse", 743], ["bone", 749], ["marrow", 754], ["cell", 761], ["line", 766], ["BAF3", 771], ["in", 776], ["order", 779], ["to", 785], ["show", 788], ["that", 793], ["JNK", 798], ["activation", 802], ["by", 813], ["IL-3", 816], ["is", 821], ["necessary", 824], ["for", 834], ["cell", 838], ["survival", 843], ["and", 852], ["proliferation", 856], ["[", 870], ["9].", 871], ["Here", 875], ["we", 880], ["report", 883], ["that", 890], ["M3/6", 895], ["dissociates", 900], ["from", 912], ["JNK", 917], ["and", 921], ["appears", 925], ["in", 933], ["an", 936], ["insoluble", 939], ["fraction", 949], ["after", 958], ["heat", 964], ["shock", 969], [".", 974], ["These", 976], ["data", 982], ["identify", 987], ["M3/6", 996], ["as", 1001], ["a", 1004], ["JNK", 1006], ["phosphatase", 1010], ["that", 1022], ["is", 1027], ["inactivated", 1030], ["by", 1042], ["heat", 1045], ["shock", 1050], ["and", 1056], ["provide", 1060], ["a", 1068], ["molecular", 1070], ["mechanism", 1080], ["for", 1090], ["the", 1094], ["activation", 1098], ["of", 1109], ["JNK", 1112], ["by", 1116], ["heat", 1119], ["shock", 1124], [".", 1129]]}
{"context": "Lung cancer is the leading cause of death worldwide. Adenocarcinomas, the most common histologic subtype of non-small cell lung cancer (NSCLC), are frequently associated with activating mutations in the epidermal growth factor receptor (EGFR) gene. Although these patients often respond clinically to the EGFR tyrosine kinase inhibitors erlotinib and gefitinib, relapse inevitably occurs, suggesting the development of escape mechanisms that promote cell survival. Using a loss-of-function, whole genome short hairpin RNA (shRNA) screen, we identified that the canonical Wnt pathway contributes to the maintenance of NSCLC cells during EGFR inhibition, particularly the poly-ADP-ribosylating enzymes tankyrase 1 and 2 that positively regulate canonical Wnt signaling. Inhibition of tankyrase and various other components of the Wnt pathway with shRNAs or small molecules significantly increased the efficacy of EGFR inhibitors both in vitro and in vivo. Our findings therefore reveal a critical role for tankyrase and the canonical Wnt pathway in maintaining lung cancer cells during EGFR inhibition. Targeting the Wnt-tankyrase-\u03b2-catenin pathway together with EGFR inhibition may improve clinical outcome in patients with NSCLC.", "qas": [{"question": "Mutations in which gene determine response to both erlotinib and gefitinib?", "answers": ["epidermal growth factor receptor (EGFR) gene"], "qid": "5cfd33dc4aa142d6ae71e5954d750d83", "question_tokens": [["Mutations", 0], ["in", 10], ["which", 13], ["gene", 19], ["determine", 24], ["response", 34], ["to", 43], ["both", 46], ["erlotinib", 51], ["and", 61], ["gefitinib", 65], ["?", 74]], "detected_answers": [{"text": "epidermal growth factor receptor (EGFR) gene", "token_spans": [[36, 43]], "char_spans": [[203, 246]]}]}], "context_tokens": [["Lung", 0], ["cancer", 5], ["is", 12], ["the", 15], ["leading", 19], ["cause", 27], ["of", 33], ["death", 36], ["worldwide", 42], [".", 51], ["Adenocarcinomas", 53], [",", 68], ["the", 70], ["most", 74], ["common", 79], ["histologic", 86], ["subtype", 97], ["of", 105], ["non", 108], ["-", 111], ["small", 112], ["cell", 118], ["lung", 123], ["cancer", 128], ["(", 135], ["NSCLC", 136], [")", 141], [",", 142], ["are", 144], ["frequently", 148], ["associated", 159], ["with", 170], ["activating", 175], ["mutations", 186], ["in", 196], ["the", 199], ["epidermal", 203], ["growth", 213], ["factor", 220], ["receptor", 227], ["(", 236], ["EGFR", 237], [")", 241], ["gene", 243], [".", 247], ["Although", 249], ["these", 258], ["patients", 264], ["often", 273], ["respond", 279], ["clinically", 287], ["to", 298], ["the", 301], ["EGFR", 305], ["tyrosine", 310], ["kinase", 319], ["inhibitors", 326], ["erlotinib", 337], ["and", 347], ["gefitinib", 351], [",", 360], ["relapse", 362], ["inevitably", 370], ["occurs", 381], [",", 387], ["suggesting", 389], ["the", 400], ["development", 404], ["of", 416], ["escape", 419], ["mechanisms", 426], ["that", 437], ["promote", 442], ["cell", 450], ["survival", 455], [".", 463], ["Using", 465], ["a", 471], ["loss", 473], ["-", 477], ["of", 478], ["-", 480], ["function", 481], [",", 489], ["whole", 491], ["genome", 497], ["short", 504], ["hairpin", 510], ["RNA", 518], ["(", 522], ["shRNA", 523], [")", 528], ["screen", 530], [",", 536], ["we", 538], ["identified", 541], ["that", 552], ["the", 557], ["canonical", 561], ["Wnt", 571], ["pathway", 575], ["contributes", 583], ["to", 595], ["the", 598], ["maintenance", 602], ["of", 614], ["NSCLC", 617], ["cells", 623], ["during", 629], ["EGFR", 636], ["inhibition", 641], [",", 651], ["particularly", 653], ["the", 666], ["poly", 670], ["-", 674], ["ADP", 675], ["-", 678], ["ribosylating", 679], ["enzymes", 692], ["tankyrase", 700], ["1", 710], ["and", 712], ["2", 716], ["that", 718], ["positively", 723], ["regulate", 734], ["canonical", 743], ["Wnt", 753], ["signaling", 757], [".", 766], ["Inhibition", 768], ["of", 779], ["tankyrase", 782], ["and", 792], ["various", 796], ["other", 804], ["components", 810], ["of", 821], ["the", 824], ["Wnt", 828], ["pathway", 832], ["with", 840], ["shRNAs", 845], ["or", 852], ["small", 855], ["molecules", 861], ["significantly", 871], ["increased", 885], ["the", 895], ["efficacy", 899], ["of", 908], ["EGFR", 911], ["inhibitors", 916], ["both", 927], ["in", 932], ["vitro", 935], ["and", 941], ["in", 945], ["vivo", 948], [".", 952], ["Our", 954], ["findings", 958], ["therefore", 967], ["reveal", 977], ["a", 984], ["critical", 986], ["role", 995], ["for", 1000], ["tankyrase", 1004], ["and", 1014], ["the", 1018], ["canonical", 1022], ["Wnt", 1032], ["pathway", 1036], ["in", 1044], ["maintaining", 1047], ["lung", 1059], ["cancer", 1064], ["cells", 1071], ["during", 1077], ["EGFR", 1084], ["inhibition", 1089], [".", 1099], ["Targeting", 1101], ["the", 1111], ["Wnt", 1115], ["-", 1118], ["tankyrase", 1119], ["-", 1128], ["\u03b2", 1129], ["-", 1130], ["catenin", 1131], ["pathway", 1139], ["together", 1147], ["with", 1156], ["EGFR", 1161], ["inhibition", 1166], ["may", 1177], ["improve", 1181], ["clinical", 1189], ["outcome", 1198], ["in", 1206], ["patients", 1209], ["with", 1218], ["NSCLC", 1223], [".", 1228]]}
{"context": "Mgm1 is a member of the dynamin family of GTP-binding proteins. Mgm1 was first identified in yeast, where it affects mitochondrial morphology. The human homologue of Mgm1 is called OPA1. Mutations in the OPA1 gene are the prevailing cause of dominant optic atrophy, a hereditary disease in which progressive degeneration of the optic nerve can lead to blindness. Here we investigate the properties of the Mgm1/OPA1 protein in mammalian cells. We find that Mgm1/OPA1 is localized to the mitochondrial intermembrane space, where it is tightly bound to the outer surface of the inner membrane. Overexpression of wild type or mutant forms of the Mgm1/OPA1 protein cause mitochondria to fragment and, in some cases, cluster near the nucleus, whereas the loss of protein caused by small interfering RNA (siRNA) leads to dispersal of mitochondrial fragments throughout the cytosol. The cristae of these fragmented mitochondria are disorganized. At early time points after transfection with Mgm1/OPA1 siRNA, the mitochondria are not yet fragmented. Instead, the mitochondria swell and stretch, after which they form localized constrictions similar to the mitochondrial abnormalities observed during the early stages of apoptosis. These abnormalities might be the earliest effects of losing Mgm1/OPA1 protein.", "qas": [{"question": "Which is the cellular localization of the protein Opa1?", "answers": ["mitochondrial intermembrane space"], "qid": "da99a2b47daf44bb94a87ccf477bf308", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["cellular", 13], ["localization", 22], ["of", 35], ["the", 38], ["protein", 42], ["Opa1", 50], ["?", 54]], "detected_answers": [{"text": "mitochondrial intermembrane space", "token_spans": [[87, 89]], "char_spans": [[486, 518]]}]}], "context_tokens": [["Mgm1", 0], ["is", 5], ["a", 8], ["member", 10], ["of", 17], ["the", 20], ["dynamin", 24], ["family", 32], ["of", 39], ["GTP", 42], ["-", 45], ["binding", 46], ["proteins", 54], [".", 62], ["Mgm1", 64], ["was", 69], ["first", 73], ["identified", 79], ["in", 90], ["yeast", 93], [",", 98], ["where", 100], ["it", 106], ["affects", 109], ["mitochondrial", 117], ["morphology", 131], [".", 141], ["The", 143], ["human", 147], ["homologue", 153], ["of", 163], ["Mgm1", 166], ["is", 171], ["called", 174], ["OPA1", 181], [".", 185], ["Mutations", 187], ["in", 197], ["the", 200], ["OPA1", 204], ["gene", 209], ["are", 214], ["the", 218], ["prevailing", 222], ["cause", 233], ["of", 239], ["dominant", 242], ["optic", 251], ["atrophy", 257], [",", 264], ["a", 266], ["hereditary", 268], ["disease", 279], ["in", 287], ["which", 290], ["progressive", 296], ["degeneration", 308], ["of", 321], ["the", 324], ["optic", 328], ["nerve", 334], ["can", 340], ["lead", 344], ["to", 349], ["blindness", 352], [".", 361], ["Here", 363], ["we", 368], ["investigate", 371], ["the", 383], ["properties", 387], ["of", 398], ["the", 401], ["Mgm1/OPA1", 405], ["protein", 415], ["in", 423], ["mammalian", 426], ["cells", 436], [".", 441], ["We", 443], ["find", 446], ["that", 451], ["Mgm1/OPA1", 456], ["is", 466], ["localized", 469], ["to", 479], ["the", 482], ["mitochondrial", 486], ["intermembrane", 500], ["space", 514], [",", 519], ["where", 521], ["it", 527], ["is", 530], ["tightly", 533], ["bound", 541], ["to", 547], ["the", 550], ["outer", 554], ["surface", 560], ["of", 568], ["the", 571], ["inner", 575], ["membrane", 581], [".", 589], ["Overexpression", 591], ["of", 606], ["wild", 609], ["type", 614], ["or", 619], ["mutant", 622], ["forms", 629], ["of", 635], ["the", 638], ["Mgm1/OPA1", 642], ["protein", 652], ["cause", 660], ["mitochondria", 666], ["to", 679], ["fragment", 682], ["and", 691], [",", 694], ["in", 696], ["some", 699], ["cases", 704], [",", 709], ["cluster", 711], ["near", 719], ["the", 724], ["nucleus", 728], [",", 735], ["whereas", 737], ["the", 745], ["loss", 749], ["of", 754], ["protein", 757], ["caused", 765], ["by", 772], ["small", 775], ["interfering", 781], ["RNA", 793], ["(", 797], ["siRNA", 798], [")", 803], ["leads", 805], ["to", 811], ["dispersal", 814], ["of", 824], ["mitochondrial", 827], ["fragments", 841], ["throughout", 851], ["the", 862], ["cytosol", 866], [".", 873], ["The", 875], ["cristae", 879], ["of", 887], ["these", 890], ["fragmented", 896], ["mitochondria", 907], ["are", 920], ["disorganized", 924], [".", 936], ["At", 938], ["early", 941], ["time", 947], ["points", 952], ["after", 959], ["transfection", 965], ["with", 978], ["Mgm1/OPA1", 983], ["siRNA", 993], [",", 998], ["the", 1000], ["mitochondria", 1004], ["are", 1017], ["not", 1021], ["yet", 1025], ["fragmented", 1029], [".", 1039], ["Instead", 1041], [",", 1048], ["the", 1050], ["mitochondria", 1054], ["swell", 1067], ["and", 1073], ["stretch", 1077], [",", 1084], ["after", 1086], ["which", 1092], ["they", 1098], ["form", 1103], ["localized", 1108], ["constrictions", 1118], ["similar", 1132], ["to", 1140], ["the", 1143], ["mitochondrial", 1147], ["abnormalities", 1161], ["observed", 1175], ["during", 1184], ["the", 1191], ["early", 1195], ["stages", 1201], ["of", 1208], ["apoptosis", 1211], [".", 1220], ["These", 1222], ["abnormalities", 1228], ["might", 1242], ["be", 1248], ["the", 1251], ["earliest", 1255], ["effects", 1264], ["of", 1272], ["losing", 1275], ["Mgm1/OPA1", 1282], ["protein", 1292], [".", 1299]]}
{"context": "Objective. A study to determine if addition of palatal petechiae to Centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children. Hypothesis. In children, Centor Criteria does not cover all the symptoms and signs of acute strep pharyngitis. We hypothesize that addition of palatal petechiae to Centor Criteria will increase the possibility of clinical diagnosis of group A streptococcal pharyngitis in children. Methods. One hundred patients with a complaint of sore throat were enrolled in the study. All the patients were examined clinically using the Centor Criteria. They were also examined for other signs and symptoms like petechial lesions over the palate, abdominal pain, and skin rash. All the patients were given rapid strep tests, and throat cultures were sent. No antibiotics were given until culture results were obtained. Results. The sample size was 100 patients. All 100 had fever, sore throat, and erythema of tonsils. Twenty of the 100 patients had tonsillar exudates, 85/100 had tender anterior cervical lymph nodes, and 86/100 had no cough. In total, 9 out of the 100 patients had positive throat cultures. We observed that petechiae over the palate, a very significant sign, is not included in the Centor Criteria. Palatal petechiae were present in 8 out of the 100 patients. Six out of these 8 with palatal petechiae had positive throat culture for strep (75%). Only 7 out of 20 with exudates had positive strep culture. Sixteen out of the 100 patients had rapid strep test positive. Those 84/100 who had negative rapid strep also had negative throat culture. Statistics. We used Fisher's exact test, comparing throat culture positive and negative versus presence of exudates and palatal hemorrhages with positive and negative throat cultures and the resultant P value <.0001. Conclusion. Our study concludes that addition of petechiae over the palate to Centor Criteria will increase the possibility of diagnosing acute group A streptococcal pharyngitis in children.", "qas": [{"question": "Centor criteria are used for which disease?", "answers": ["streptococcal pharyngitis"], "qid": "345cc6f39eb0472ebb37229e6f4e34b1", "question_tokens": [["Centor", 0], ["criteria", 7], ["are", 16], ["used", 20], ["for", 25], ["which", 29], ["disease", 35], ["?", 42]], "detected_answers": [{"text": "streptococcal pharyngitis", "token_spans": [[356, 357], [67, 68]], "char_spans": [[1984, 2008], [406, 430]]}]}], "context_tokens": [["Objective", 0], [".", 9], ["A", 11], ["study", 13], ["to", 19], ["determine", 22], ["if", 32], ["addition", 35], ["of", 44], ["palatal", 47], ["petechiae", 55], ["to", 65], ["Centor", 68], ["criteria", 75], ["adds", 84], ["more", 89], ["value", 94], ["for", 100], ["clinical", 104], ["diagnosis", 113], ["of", 123], ["acute", 126], ["strep", 132], ["pharyngitis", 138], ["in", 150], ["children", 153], [".", 161], ["Hypothesis", 163], [".", 173], ["In", 175], ["children", 178], [",", 186], ["Centor", 188], ["Criteria", 195], ["does", 204], ["not", 209], ["cover", 213], ["all", 219], ["the", 223], ["symptoms", 227], ["and", 236], ["signs", 240], ["of", 246], ["acute", 249], ["strep", 255], ["pharyngitis", 261], [".", 272], ["We", 274], ["hypothesize", 277], ["that", 289], ["addition", 294], ["of", 303], ["palatal", 306], ["petechiae", 314], ["to", 324], ["Centor", 327], ["Criteria", 334], ["will", 343], ["increase", 348], ["the", 357], ["possibility", 361], ["of", 373], ["clinical", 376], ["diagnosis", 385], ["of", 395], ["group", 398], ["A", 404], ["streptococcal", 406], ["pharyngitis", 420], ["in", 432], ["children", 435], [".", 443], ["Methods", 445], [".", 452], ["One", 454], ["hundred", 458], ["patients", 466], ["with", 475], ["a", 480], ["complaint", 482], ["of", 492], ["sore", 495], ["throat", 500], ["were", 507], ["enrolled", 512], ["in", 521], ["the", 524], ["study", 528], [".", 533], ["All", 535], ["the", 539], ["patients", 543], ["were", 552], ["examined", 557], ["clinically", 566], ["using", 577], ["the", 583], ["Centor", 587], ["Criteria", 594], [".", 602], ["They", 604], ["were", 609], ["also", 614], ["examined", 619], ["for", 628], ["other", 632], ["signs", 638], ["and", 644], ["symptoms", 648], ["like", 657], ["petechial", 662], ["lesions", 672], ["over", 680], ["the", 685], ["palate", 689], [",", 695], ["abdominal", 697], ["pain", 707], [",", 711], ["and", 713], ["skin", 717], ["rash", 722], [".", 726], ["All", 728], ["the", 732], ["patients", 736], ["were", 745], ["given", 750], ["rapid", 756], ["strep", 762], ["tests", 768], [",", 773], ["and", 775], ["throat", 779], ["cultures", 786], ["were", 795], ["sent", 800], [".", 804], ["No", 806], ["antibiotics", 809], ["were", 821], ["given", 826], ["until", 832], ["culture", 838], ["results", 846], ["were", 854], ["obtained", 859], [".", 867], ["Results", 869], [".", 876], ["The", 878], ["sample", 882], ["size", 889], ["was", 894], ["100", 898], ["patients", 902], [".", 910], ["All", 912], ["100", 916], ["had", 920], ["fever", 924], [",", 929], ["sore", 931], ["throat", 936], [",", 942], ["and", 944], ["erythema", 948], ["of", 957], ["tonsils", 960], [".", 967], ["Twenty", 969], ["of", 976], ["the", 979], ["100", 983], ["patients", 987], ["had", 996], ["tonsillar", 1000], ["exudates", 1010], [",", 1018], ["85/100", 1020], ["had", 1027], ["tender", 1031], ["anterior", 1038], ["cervical", 1047], ["lymph", 1056], ["nodes", 1062], [",", 1067], ["and", 1069], ["86/100", 1073], ["had", 1080], ["no", 1084], ["cough", 1087], [".", 1092], ["In", 1094], ["total", 1097], [",", 1102], ["9", 1104], ["out", 1106], ["of", 1110], ["the", 1113], ["100", 1117], ["patients", 1121], ["had", 1130], ["positive", 1134], ["throat", 1143], ["cultures", 1150], [".", 1158], ["We", 1160], ["observed", 1163], ["that", 1172], ["petechiae", 1177], ["over", 1187], ["the", 1192], ["palate", 1196], [",", 1202], ["a", 1204], ["very", 1206], ["significant", 1211], ["sign", 1223], [",", 1227], ["is", 1229], ["not", 1232], ["included", 1236], ["in", 1245], ["the", 1248], ["Centor", 1252], ["Criteria", 1259], [".", 1267], ["Palatal", 1269], ["petechiae", 1277], ["were", 1287], ["present", 1292], ["in", 1300], ["8", 1303], ["out", 1305], ["of", 1309], ["the", 1312], ["100", 1316], ["patients", 1320], [".", 1328], ["Six", 1330], ["out", 1334], ["of", 1338], ["these", 1341], ["8", 1347], ["with", 1349], ["palatal", 1354], ["petechiae", 1362], ["had", 1372], ["positive", 1376], ["throat", 1385], ["culture", 1392], ["for", 1400], ["strep", 1404], ["(", 1410], ["75", 1411], ["%", 1413], [")", 1414], [".", 1415], ["Only", 1417], ["7", 1422], ["out", 1424], ["of", 1428], ["20", 1431], ["with", 1434], ["exudates", 1439], ["had", 1448], ["positive", 1452], ["strep", 1461], ["culture", 1467], [".", 1474], ["Sixteen", 1476], ["out", 1484], ["of", 1488], ["the", 1491], ["100", 1495], ["patients", 1499], ["had", 1508], ["rapid", 1512], ["strep", 1518], ["test", 1524], ["positive", 1529], [".", 1537], ["Those", 1539], ["84/100", 1545], ["who", 1552], ["had", 1556], ["negative", 1560], ["rapid", 1569], ["strep", 1575], ["also", 1581], ["had", 1586], ["negative", 1590], ["throat", 1599], ["culture", 1606], [".", 1613], ["Statistics", 1615], [".", 1625], ["We", 1627], ["used", 1630], ["Fisher", 1635], ["'s", 1641], ["exact", 1644], ["test", 1650], [",", 1654], ["comparing", 1656], ["throat", 1666], ["culture", 1673], ["positive", 1681], ["and", 1690], ["negative", 1694], ["versus", 1703], ["presence", 1710], ["of", 1719], ["exudates", 1722], ["and", 1731], ["palatal", 1735], ["hemorrhages", 1743], ["with", 1755], ["positive", 1760], ["and", 1769], ["negative", 1773], ["throat", 1782], ["cultures", 1789], ["and", 1798], ["the", 1802], ["resultant", 1806], ["P", 1816], ["value", 1818], ["<", 1824], [".0001", 1825], [".", 1830], ["Conclusion", 1832], [".", 1842], ["Our", 1844], ["study", 1848], ["concludes", 1854], ["that", 1864], ["addition", 1869], ["of", 1878], ["petechiae", 1881], ["over", 1891], ["the", 1896], ["palate", 1900], ["to", 1907], ["Centor", 1910], ["Criteria", 1917], ["will", 1926], ["increase", 1931], ["the", 1940], ["possibility", 1944], ["of", 1956], ["diagnosing", 1959], ["acute", 1970], ["group", 1976], ["A", 1982], ["streptococcal", 1984], ["pharyngitis", 1998], ["in", 2010], ["children", 2013], [".", 2021]]}
{"context": "The aim of this study was to evaluate the efficacy and tolerability of tiagabine in adult patients with post-traumatic stress disorder (PTSD). This 12-week, multicenter, double-blind study randomized patients to receive either tiagabine or placebo. Tiagabine (administered in divided doses) was initiated at 4 mg/d (2 mg BID) and individually titrated of up to 4 mg/d weekly to a maximum dose of 16 mg/d. Assessments included the Clinician-Administered PTSD Scale, Clinical Global Impressions of Change, Treatment Outcome PTSD Scale, Davidson Trauma Scale, Connor-Davidson Resilience Scale, Sheehan Disability Scale, Massachusetts General Hospital Sexual Functioning Questionnaire, and Montgomery-Asberg Depression Rating Scale. A total of 232 patients (tiagabine, n = 116; placebo, n = 116) were randomized. There were no significant differences in change from baseline in the Clinician-Administered PTSD Scale total score at final visit for tiagabine compared with placebo (P = 0.85). Similarly, no significant differences were observed with tiagabine on the other efficacy outcome measures (described above) compared with placebo. Tiagabine was generally well tolerated and not associated with weight gain, changes in sexual function, or worsening of depressive symptoms. Tiagabine was not significantly different from placebo in the treatment of symptoms of PTSD. Additional studies are needed to assess the role of drugs that target the gamma-aminobutyric acid system in the treatment of PTSD.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "b5c03080f08845128cbb48af0b93fc6d", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "post-traumatic stress disorder", "token_spans": [[18, 22]], "char_spans": [[104, 133]]}, {"text": "PTSD", "token_spans": [[91, 91], [246, 246], [102, 102], [169, 169], [24, 24], [270, 270]], "char_spans": [[453, 456], [1362, 1365], [522, 525], [901, 904], [136, 139], [1493, 1496]]}]}], "context_tokens": [["The", 0], ["aim", 4], ["of", 8], ["this", 11], ["study", 16], ["was", 22], ["to", 26], ["evaluate", 29], ["the", 38], ["efficacy", 42], ["and", 51], ["tolerability", 55], ["of", 68], ["tiagabine", 71], ["in", 81], ["adult", 84], ["patients", 90], ["with", 99], ["post", 104], ["-", 108], ["traumatic", 109], ["stress", 119], ["disorder", 126], ["(", 135], ["PTSD", 136], [")", 140], [".", 141], ["This", 143], ["12-week", 148], [",", 155], ["multicenter", 157], [",", 168], ["double", 170], ["-", 176], ["blind", 177], ["study", 183], ["randomized", 189], ["patients", 200], ["to", 209], ["receive", 212], ["either", 220], ["tiagabine", 227], ["or", 237], ["placebo", 240], [".", 247], ["Tiagabine", 249], ["(", 259], ["administered", 260], ["in", 273], ["divided", 276], ["doses", 284], [")", 289], ["was", 291], ["initiated", 295], ["at", 305], ["4", 308], ["mg", 310], ["/", 312], ["d", 313], ["(", 315], ["2", 316], ["mg", 318], ["BID", 321], [")", 324], ["and", 326], ["individually", 330], ["titrated", 343], ["of", 352], ["up", 355], ["to", 358], ["4", 361], ["mg", 363], ["/", 365], ["d", 366], ["weekly", 368], ["to", 375], ["a", 378], ["maximum", 380], ["dose", 388], ["of", 393], ["16", 396], ["mg", 399], ["/", 401], ["d", 402], [".", 403], ["Assessments", 405], ["included", 417], ["the", 426], ["Clinician", 430], ["-", 439], ["Administered", 440], ["PTSD", 453], ["Scale", 458], [",", 463], ["Clinical", 465], ["Global", 474], ["Impressions", 481], ["of", 493], ["Change", 496], [",", 502], ["Treatment", 504], ["Outcome", 514], ["PTSD", 522], ["Scale", 527], [",", 532], ["Davidson", 534], ["Trauma", 543], ["Scale", 550], [",", 555], ["Connor", 557], ["-", 563], ["Davidson", 564], ["Resilience", 573], ["Scale", 584], [",", 589], ["Sheehan", 591], ["Disability", 599], ["Scale", 610], [",", 615], ["Massachusetts", 617], ["General", 631], ["Hospital", 639], ["Sexual", 648], ["Functioning", 655], ["Questionnaire", 667], [",", 680], ["and", 682], ["Montgomery", 686], ["-", 696], ["Asberg", 697], ["Depression", 704], ["Rating", 715], ["Scale", 722], [".", 727], ["A", 729], ["total", 731], ["of", 737], ["232", 740], ["patients", 744], ["(", 753], ["tiagabine", 754], [",", 763], ["n", 765], ["=", 767], ["116", 769], [";", 772], ["placebo", 774], [",", 781], ["n", 783], ["=", 785], ["116", 787], [")", 790], ["were", 792], ["randomized", 797], [".", 807], ["There", 809], ["were", 815], ["no", 820], ["significant", 823], ["differences", 835], ["in", 847], ["change", 850], ["from", 857], ["baseline", 862], ["in", 871], ["the", 874], ["Clinician", 878], ["-", 887], ["Administered", 888], ["PTSD", 901], ["Scale", 906], ["total", 912], ["score", 918], ["at", 924], ["final", 927], ["visit", 933], ["for", 939], ["tiagabine", 943], ["compared", 953], ["with", 962], ["placebo", 967], ["(", 975], ["P", 976], ["=", 978], ["0.85", 980], [")", 984], [".", 985], ["Similarly", 987], [",", 996], ["no", 998], ["significant", 1001], ["differences", 1013], ["were", 1025], ["observed", 1030], ["with", 1039], ["tiagabine", 1044], ["on", 1054], ["the", 1057], ["other", 1061], ["efficacy", 1067], ["outcome", 1076], ["measures", 1084], ["(", 1093], ["described", 1094], ["above", 1104], [")", 1109], ["compared", 1111], ["with", 1120], ["placebo", 1125], [".", 1132], ["Tiagabine", 1134], ["was", 1144], ["generally", 1148], ["well", 1158], ["tolerated", 1163], ["and", 1173], ["not", 1177], ["associated", 1181], ["with", 1192], ["weight", 1197], ["gain", 1204], [",", 1208], ["changes", 1210], ["in", 1218], ["sexual", 1221], ["function", 1228], [",", 1236], ["or", 1238], ["worsening", 1241], ["of", 1251], ["depressive", 1254], ["symptoms", 1265], [".", 1273], ["Tiagabine", 1275], ["was", 1285], ["not", 1289], ["significantly", 1293], ["different", 1307], ["from", 1317], ["placebo", 1322], ["in", 1330], ["the", 1333], ["treatment", 1337], ["of", 1347], ["symptoms", 1350], ["of", 1359], ["PTSD", 1362], [".", 1366], ["Additional", 1368], ["studies", 1379], ["are", 1387], ["needed", 1391], ["to", 1398], ["assess", 1401], ["the", 1408], ["role", 1412], ["of", 1417], ["drugs", 1420], ["that", 1426], ["target", 1431], ["the", 1438], ["gamma", 1442], ["-", 1447], ["aminobutyric", 1448], ["acid", 1461], ["system", 1466], ["in", 1473], ["the", 1476], ["treatment", 1480], ["of", 1490], ["PTSD", 1493], [".", 1497]]}
{"context": "During mitosis, Promyelocytic leukemia nuclear bodies (PML NBs) change dramatically in morphology and composition, but little is known about function of PML in mitosis. Here, we show that PML is phosphorylated at T409 (PML p409) in a mitosis-specific manner. More importantly, PML p409 contributes to maintain the duration of pro-metaphase and regulates spindle checkpoint. Deficient PML p409 caused a shortening of pro-metaphase and challenged the nocodazole-triggered mitotic arrest. T409A mutation led to a higher frequency of misaligned chromosomes on metaphase plate, and subsequently death in late mitosis. In addition, inhibition of PML p409 repressed growth of tumor cells, suggesting that PML p409 is a potential target for cancer therapy. Collectively, our study demonstrated an important phosphorylated site of PML, which contributed to explore the role of PML in mitosis.", "qas": [{"question": "What is the effect of nocodazole cell treatment?", "answers": ["Mitotic arrest"], "qid": "fb1932c2568743f8a7e02da6141a50f9", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["effect", 12], ["of", 19], ["nocodazole", 22], ["cell", 33], ["treatment", 38], ["?", 47]], "detected_answers": [{"text": "Mitotic arrest", "token_spans": [[85, 86]], "char_spans": [[470, 483]]}]}], "context_tokens": [["During", 0], ["mitosis", 7], [",", 14], ["Promyelocytic", 16], ["leukemia", 30], ["nuclear", 39], ["bodies", 47], ["(", 54], ["PML", 55], ["NBs", 59], [")", 62], ["change", 64], ["dramatically", 71], ["in", 84], ["morphology", 87], ["and", 98], ["composition", 102], [",", 113], ["but", 115], ["little", 119], ["is", 126], ["known", 129], ["about", 135], ["function", 141], ["of", 150], ["PML", 153], ["in", 157], ["mitosis", 160], [".", 167], ["Here", 169], [",", 173], ["we", 175], ["show", 178], ["that", 183], ["PML", 188], ["is", 192], ["phosphorylated", 195], ["at", 210], ["T409", 213], ["(", 218], ["PML", 219], ["p409", 223], [")", 227], ["in", 229], ["a", 232], ["mitosis", 234], ["-", 241], ["specific", 242], ["manner", 251], [".", 257], ["More", 259], ["importantly", 264], [",", 275], ["PML", 277], ["p409", 281], ["contributes", 286], ["to", 298], ["maintain", 301], ["the", 310], ["duration", 314], ["of", 323], ["pro", 326], ["-", 329], ["metaphase", 330], ["and", 340], ["regulates", 344], ["spindle", 354], ["checkpoint", 362], [".", 372], ["Deficient", 374], ["PML", 384], ["p409", 388], ["caused", 393], ["a", 400], ["shortening", 402], ["of", 413], ["pro", 416], ["-", 419], ["metaphase", 420], ["and", 430], ["challenged", 434], ["the", 445], ["nocodazole", 449], ["-", 459], ["triggered", 460], ["mitotic", 470], ["arrest", 478], [".", 484], ["T409A", 486], ["mutation", 492], ["led", 501], ["to", 505], ["a", 508], ["higher", 510], ["frequency", 517], ["of", 527], ["misaligned", 530], ["chromosomes", 541], ["on", 553], ["metaphase", 556], ["plate", 566], [",", 571], ["and", 573], ["subsequently", 577], ["death", 590], ["in", 596], ["late", 599], ["mitosis", 604], [".", 611], ["In", 613], ["addition", 616], [",", 624], ["inhibition", 626], ["of", 637], ["PML", 640], ["p409", 644], ["repressed", 649], ["growth", 659], ["of", 666], ["tumor", 669], ["cells", 675], [",", 680], ["suggesting", 682], ["that", 693], ["PML", 698], ["p409", 702], ["is", 707], ["a", 710], ["potential", 712], ["target", 722], ["for", 729], ["cancer", 733], ["therapy", 740], [".", 747], ["Collectively", 749], [",", 761], ["our", 763], ["study", 767], ["demonstrated", 773], ["an", 786], ["important", 789], ["phosphorylated", 799], ["site", 814], ["of", 819], ["PML", 822], [",", 825], ["which", 827], ["contributed", 833], ["to", 845], ["explore", 848], ["the", 856], ["role", 860], ["of", 865], ["PML", 868], ["in", 872], ["mitosis", 875], [".", 882]]}
{"context": "Ehlers-Danlos syndrome denotes a group of inherited connective tissue diseases comprising nine types. Type IV Ehlers-Danlos syndrome is the most life-threatening form. It is characterized by a type III collagen deficiency resulting in arterial fragility and death from vascular rupture or bowel perforation. This disease involves a col 3A1 gene mutation. We report the case of a 44 year-old woman with type IV Ehlers-Danlos syndrome. The medical history of our patient included bowel necrosis and two vascular ruptures. We indicate data required to establish Ehlers-Danlos syndrome diagnosis and guidelines for patient management.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "549476d728754e0e979168d1b056eae7", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[9, 10]], "char_spans": [[52, 68]]}]}], "context_tokens": [["Ehlers", 0], ["-", 6], ["Danlos", 7], ["syndrome", 14], ["denotes", 23], ["a", 31], ["group", 33], ["of", 39], ["inherited", 42], ["connective", 52], ["tissue", 63], ["diseases", 70], ["comprising", 79], ["nine", 90], ["types", 95], [".", 100], ["Type", 102], ["IV", 107], ["Ehlers", 110], ["-", 116], ["Danlos", 117], ["syndrome", 124], ["is", 133], ["the", 136], ["most", 140], ["life", 145], ["-", 149], ["threatening", 150], ["form", 162], [".", 166], ["It", 168], ["is", 171], ["characterized", 174], ["by", 188], ["a", 191], ["type", 193], ["III", 198], ["collagen", 202], ["deficiency", 211], ["resulting", 222], ["in", 232], ["arterial", 235], ["fragility", 244], ["and", 254], ["death", 258], ["from", 264], ["vascular", 269], ["rupture", 278], ["or", 286], ["bowel", 289], ["perforation", 295], [".", 306], ["This", 308], ["disease", 313], ["involves", 321], ["a", 330], ["col", 332], ["3A1", 336], ["gene", 340], ["mutation", 345], [".", 353], ["We", 355], ["report", 358], ["the", 365], ["case", 369], ["of", 374], ["a", 377], ["44", 379], ["year", 382], ["-", 386], ["old", 387], ["woman", 391], ["with", 397], ["type", 402], ["IV", 407], ["Ehlers", 410], ["-", 416], ["Danlos", 417], ["syndrome", 424], [".", 432], ["The", 434], ["medical", 438], ["history", 446], ["of", 454], ["our", 457], ["patient", 461], ["included", 469], ["bowel", 478], ["necrosis", 484], ["and", 493], ["two", 497], ["vascular", 501], ["ruptures", 510], [".", 518], ["We", 520], ["indicate", 523], ["data", 532], ["required", 537], ["to", 546], ["establish", 549], ["Ehlers", 559], ["-", 565], ["Danlos", 566], ["syndrome", 573], ["diagnosis", 582], ["and", 592], ["guidelines", 596], ["for", 607], ["patient", 611], ["management", 619], [".", 629]]}
{"context": "Hereditary long QT syndrome (LQTS) is a genetically heterogeneous disease characterized by prolonged QT intervals and an increased risk for ventricular arrhythmias and sudden cardiac death. Mutations in the voltage-gated potassium channel subunit KCNQ1 induce the most common form of LQTS. KCNQ1 is associated with two different entities of LQTS, the autosomal-dominant Romano-Ward syndrome (RWS), and the autosomal-recessive Jervell and Lange-Nielsen syndrome (JLNS) characterized by bilateral deafness in addition to cardiac arrhythmias. In this study, we investigate and discuss dominant-negative I(Ks) current reduction by a KCNQ1 deletion mutation identified in a RWS family. Single-strand conformation polymorphism analysis and direct sequencing were used to screen LQTS genes for mutations. Mutant KCNQ1 channels were heterologously expressed in Xenopus oocytes, and potassium currents were recorded using the two-microelectrode voltage clamp technique. A heterozygous deletion of three nucleotides (CTT) identified in the KCNQ1 gene caused the loss of a single phenylalanine residue at position 339 (KCNQ1-deltaF339). Electrophysiological measurements in the presence and absence of the regulatory beta-subunit KCNE1 revealed that mutant and wild type forms of an N-terminal truncated KCNQ1 subunit (isoform 2) caused much stronger dominant-negative current reduction than the mutant form of the full-length KCNQ1 subunit (isoform 1). This study highlights the functional relevance of the truncated KCNQ1 splice variant (isoform 2) in establishment and mode of inheritance in long QT syndrome. In the RWS family presented here, the autosomal-dominant trait is caused by multiple dominant-negative effects provoked by heteromultimeric channels formed by wild type and mutant KCNQ1-isoforms in combination with KCNE1.", "qas": [{"question": "What is the mode of inheritance of Romano Ward long QT syndrome?", "answers": ["autosomal-dominant", "autosomal dominant"], "qid": "3c809ea1a7604eca9f5319c8cf28554b", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Romano", 35], ["Ward", 42], ["long", 47], ["QT", 52], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[282, 284], [58, 60]], "char_spans": [[1640, 1657], [351, 368]]}]}], "context_tokens": [["Hereditary", 0], ["long", 11], ["QT", 16], ["syndrome", 19], ["(", 28], ["LQTS", 29], [")", 33], ["is", 35], ["a", 38], ["genetically", 40], ["heterogeneous", 52], ["disease", 66], ["characterized", 74], ["by", 88], ["prolonged", 91], ["QT", 101], ["intervals", 104], ["and", 114], ["an", 118], ["increased", 121], ["risk", 131], ["for", 136], ["ventricular", 140], ["arrhythmias", 152], ["and", 164], ["sudden", 168], ["cardiac", 175], ["death", 183], [".", 188], ["Mutations", 190], ["in", 200], ["the", 203], ["voltage", 207], ["-", 214], ["gated", 215], ["potassium", 221], ["channel", 231], ["subunit", 239], ["KCNQ1", 247], ["induce", 253], ["the", 260], ["most", 264], ["common", 269], ["form", 276], ["of", 281], ["LQTS", 284], [".", 288], ["KCNQ1", 290], ["is", 296], ["associated", 299], ["with", 310], ["two", 315], ["different", 319], ["entities", 329], ["of", 338], ["LQTS", 341], [",", 345], ["the", 347], ["autosomal", 351], ["-", 360], ["dominant", 361], ["Romano", 370], ["-", 376], ["Ward", 377], ["syndrome", 382], ["(", 391], ["RWS", 392], [")", 395], [",", 396], ["and", 398], ["the", 402], ["autosomal", 406], ["-", 415], ["recessive", 416], ["Jervell", 426], ["and", 434], ["Lange", 438], ["-", 443], ["Nielsen", 444], ["syndrome", 452], ["(", 461], ["JLNS", 462], [")", 466], ["characterized", 468], ["by", 482], ["bilateral", 485], ["deafness", 495], ["in", 504], ["addition", 507], ["to", 516], ["cardiac", 519], ["arrhythmias", 527], [".", 538], ["In", 540], ["this", 543], ["study", 548], [",", 553], ["we", 555], ["investigate", 558], ["and", 570], ["discuss", 574], ["dominant", 582], ["-", 590], ["negative", 591], ["I(Ks", 600], [")", 604], ["current", 606], ["reduction", 614], ["by", 624], ["a", 627], ["KCNQ1", 629], ["deletion", 635], ["mutation", 644], ["identified", 653], ["in", 664], ["a", 667], ["RWS", 669], ["family", 673], [".", 679], ["Single", 681], ["-", 687], ["strand", 688], ["conformation", 695], ["polymorphism", 708], ["analysis", 721], ["and", 730], ["direct", 734], ["sequencing", 741], ["were", 752], ["used", 757], ["to", 762], ["screen", 765], ["LQTS", 772], ["genes", 777], ["for", 783], ["mutations", 787], [".", 796], ["Mutant", 798], ["KCNQ1", 805], ["channels", 811], ["were", 820], ["heterologously", 825], ["expressed", 840], ["in", 850], ["Xenopus", 853], ["oocytes", 861], [",", 868], ["and", 870], ["potassium", 874], ["currents", 884], ["were", 893], ["recorded", 898], ["using", 907], ["the", 913], ["two", 917], ["-", 920], ["microelectrode", 921], ["voltage", 936], ["clamp", 944], ["technique", 950], [".", 959], ["A", 961], ["heterozygous", 963], ["deletion", 976], ["of", 985], ["three", 988], ["nucleotides", 994], ["(", 1006], ["CTT", 1007], [")", 1010], ["identified", 1012], ["in", 1023], ["the", 1026], ["KCNQ1", 1030], ["gene", 1036], ["caused", 1041], ["the", 1048], ["loss", 1052], ["of", 1057], ["a", 1060], ["single", 1062], ["phenylalanine", 1069], ["residue", 1083], ["at", 1091], ["position", 1094], ["339", 1103], ["(", 1107], ["KCNQ1-deltaF339", 1108], [")", 1123], [".", 1124], ["Electrophysiological", 1126], ["measurements", 1147], ["in", 1160], ["the", 1163], ["presence", 1167], ["and", 1176], ["absence", 1180], ["of", 1188], ["the", 1191], ["regulatory", 1195], ["beta", 1206], ["-", 1210], ["subunit", 1211], ["KCNE1", 1219], ["revealed", 1225], ["that", 1234], ["mutant", 1239], ["and", 1246], ["wild", 1250], ["type", 1255], ["forms", 1260], ["of", 1266], ["an", 1269], ["N", 1272], ["-", 1273], ["terminal", 1274], ["truncated", 1283], ["KCNQ1", 1293], ["subunit", 1299], ["(", 1307], ["isoform", 1308], ["2", 1316], [")", 1317], ["caused", 1319], ["much", 1326], ["stronger", 1331], ["dominant", 1340], ["-", 1348], ["negative", 1349], ["current", 1358], ["reduction", 1366], ["than", 1376], ["the", 1381], ["mutant", 1385], ["form", 1392], ["of", 1397], ["the", 1400], ["full", 1404], ["-", 1408], ["length", 1409], ["KCNQ1", 1416], ["subunit", 1422], ["(", 1430], ["isoform", 1431], ["1", 1439], [")", 1440], [".", 1441], ["This", 1443], ["study", 1448], ["highlights", 1454], ["the", 1465], ["functional", 1469], ["relevance", 1480], ["of", 1490], ["the", 1493], ["truncated", 1497], ["KCNQ1", 1507], ["splice", 1513], ["variant", 1520], ["(", 1528], ["isoform", 1529], ["2", 1537], [")", 1538], ["in", 1540], ["establishment", 1543], ["and", 1557], ["mode", 1561], ["of", 1566], ["inheritance", 1569], ["in", 1581], ["long", 1584], ["QT", 1589], ["syndrome", 1592], [".", 1600], ["In", 1602], ["the", 1605], ["RWS", 1609], ["family", 1613], ["presented", 1620], ["here", 1630], [",", 1634], ["the", 1636], ["autosomal", 1640], ["-", 1649], ["dominant", 1650], ["trait", 1659], ["is", 1665], ["caused", 1668], ["by", 1675], ["multiple", 1678], ["dominant", 1687], ["-", 1695], ["negative", 1696], ["effects", 1705], ["provoked", 1713], ["by", 1722], ["heteromultimeric", 1725], ["channels", 1742], ["formed", 1751], ["by", 1758], ["wild", 1761], ["type", 1766], ["and", 1771], ["mutant", 1775], ["KCNQ1-isoforms", 1782], ["in", 1797], ["combination", 1800], ["with", 1812], ["KCNE1", 1817], [".", 1822]]}
{"context": "Members of the signal transducer and activator of transcription (STAT) family of transcription factors are potential targets for the treatment and prevention of cancers including non-small-cell lung cancer. STAT proteins can be phosphorylated and activated by diverse upstream kinases including cytokine receptors and tyrosine kinases. We examined STAT protein activation in lung cancer cell lines including those with activating mutations in the EGFR and examined upstream kinases responsible for STAT3 phosphorylation and activation using small molecules, antibodies, and RNA interference. We found more pronounced STAT3 activation in cells with activating EGFR mutations, yet inhibition of EGFR activity had no effect on STAT3 activation. Inhibition of JAK1 with small molecules or RNA interference resulted in loss of STAT3 tyrosine phosphorylation and inhibition of cell growth. An interleukin-6 neutralizing antibody, siltuximab (CNTO 328) could inhibit STAT3 tyrosine phosphorylation in a cell-dependent manner. Siltuximab could completely inhibit STAT3 tyrosine phosphorylation in H1650 cells, and this resulted in inhibition of lung cancer cell growth in vivo. Combined EGFR inhibition with erlotinib and siltuximab resulted in dual inhibition of both tyrosine and serine STAT3 phosphorylation, more pronounced inhibition of STAT3 transcriptional activity, and translated into combined effects on lung cancer growth in a mouse model. Our results suggest that JAK1 is responsible for STAT3 activation in lung cancer cells and that indirect attacks on JAK1-STAT3 using an IL-6 neutralizing antibody with or without EGFR inhibition can inhibit lung cancer growth in lung cancer subsets.", "qas": [{"question": "Which interleukin is blocked by Siltuximab?", "answers": ["interleukin-6"], "qid": "fc6f88c8ca2e451284d7c33fa8b5071a", "question_tokens": [["Which", 0], ["interleukin", 6], ["is", 18], ["blocked", 21], ["by", 29], ["Siltuximab", 32], ["?", 42]], "detected_answers": [{"text": "interleukin-6", "token_spans": [[139, 139]], "char_spans": [[887, 899]]}]}], "context_tokens": [["Members", 0], ["of", 8], ["the", 11], ["signal", 15], ["transducer", 22], ["and", 33], ["activator", 37], ["of", 47], ["transcription", 50], ["(", 64], ["STAT", 65], [")", 69], ["family", 71], ["of", 78], ["transcription", 81], ["factors", 95], ["are", 103], ["potential", 107], ["targets", 117], ["for", 125], ["the", 129], ["treatment", 133], ["and", 143], ["prevention", 147], ["of", 158], ["cancers", 161], ["including", 169], ["non", 179], ["-", 182], ["small", 183], ["-", 188], ["cell", 189], ["lung", 194], ["cancer", 199], [".", 205], ["STAT", 207], ["proteins", 212], ["can", 221], ["be", 225], ["phosphorylated", 228], ["and", 243], ["activated", 247], ["by", 257], ["diverse", 260], ["upstream", 268], ["kinases", 277], ["including", 285], ["cytokine", 295], ["receptors", 304], ["and", 314], ["tyrosine", 318], ["kinases", 327], [".", 334], ["We", 336], ["examined", 339], ["STAT", 348], ["protein", 353], ["activation", 361], ["in", 372], ["lung", 375], ["cancer", 380], ["cell", 387], ["lines", 392], ["including", 398], ["those", 408], ["with", 414], ["activating", 419], ["mutations", 430], ["in", 440], ["the", 443], ["EGFR", 447], ["and", 452], ["examined", 456], ["upstream", 465], ["kinases", 474], ["responsible", 482], ["for", 494], ["STAT3", 498], ["phosphorylation", 504], ["and", 520], ["activation", 524], ["using", 535], ["small", 541], ["molecules", 547], [",", 556], ["antibodies", 558], [",", 568], ["and", 570], ["RNA", 574], ["interference", 578], [".", 590], ["We", 592], ["found", 595], ["more", 601], ["pronounced", 606], ["STAT3", 617], ["activation", 623], ["in", 634], ["cells", 637], ["with", 643], ["activating", 648], ["EGFR", 659], ["mutations", 664], [",", 673], ["yet", 675], ["inhibition", 679], ["of", 690], ["EGFR", 693], ["activity", 698], ["had", 707], ["no", 711], ["effect", 714], ["on", 721], ["STAT3", 724], ["activation", 730], [".", 740], ["Inhibition", 742], ["of", 753], ["JAK1", 756], ["with", 761], ["small", 766], ["molecules", 772], ["or", 782], ["RNA", 785], ["interference", 789], ["resulted", 802], ["in", 811], ["loss", 814], ["of", 819], ["STAT3", 822], ["tyrosine", 828], ["phosphorylation", 837], ["and", 853], ["inhibition", 857], ["of", 868], ["cell", 871], ["growth", 876], [".", 882], ["An", 884], ["interleukin-6", 887], ["neutralizing", 901], ["antibody", 914], [",", 922], ["siltuximab", 924], ["(", 935], ["CNTO", 936], ["328", 941], [")", 944], ["could", 946], ["inhibit", 952], ["STAT3", 960], ["tyrosine", 966], ["phosphorylation", 975], ["in", 991], ["a", 994], ["cell", 996], ["-", 1000], ["dependent", 1001], ["manner", 1011], [".", 1017], ["Siltuximab", 1019], ["could", 1030], ["completely", 1036], ["inhibit", 1047], ["STAT3", 1055], ["tyrosine", 1061], ["phosphorylation", 1070], ["in", 1086], ["H1650", 1089], ["cells", 1095], [",", 1100], ["and", 1102], ["this", 1106], ["resulted", 1111], ["in", 1120], ["inhibition", 1123], ["of", 1134], ["lung", 1137], ["cancer", 1142], ["cell", 1149], ["growth", 1154], ["in", 1161], ["vivo", 1164], [".", 1168], ["Combined", 1170], ["EGFR", 1179], ["inhibition", 1184], ["with", 1195], ["erlotinib", 1200], ["and", 1210], ["siltuximab", 1214], ["resulted", 1225], ["in", 1234], ["dual", 1237], ["inhibition", 1242], ["of", 1253], ["both", 1256], ["tyrosine", 1261], ["and", 1270], ["serine", 1274], ["STAT3", 1281], ["phosphorylation", 1287], [",", 1302], ["more", 1304], ["pronounced", 1309], ["inhibition", 1320], ["of", 1331], ["STAT3", 1334], ["transcriptional", 1340], ["activity", 1356], [",", 1364], ["and", 1366], ["translated", 1370], ["into", 1381], ["combined", 1386], ["effects", 1395], ["on", 1403], ["lung", 1406], ["cancer", 1411], ["growth", 1418], ["in", 1425], ["a", 1428], ["mouse", 1430], ["model", 1436], [".", 1441], ["Our", 1443], ["results", 1447], ["suggest", 1455], ["that", 1463], ["JAK1", 1468], ["is", 1473], ["responsible", 1476], ["for", 1488], ["STAT3", 1492], ["activation", 1498], ["in", 1509], ["lung", 1512], ["cancer", 1517], ["cells", 1524], ["and", 1530], ["that", 1534], ["indirect", 1539], ["attacks", 1548], ["on", 1556], ["JAK1-STAT3", 1559], ["using", 1570], ["an", 1576], ["IL-6", 1579], ["neutralizing", 1584], ["antibody", 1597], ["with", 1606], ["or", 1611], ["without", 1614], ["EGFR", 1622], ["inhibition", 1627], ["can", 1638], ["inhibit", 1642], ["lung", 1650], ["cancer", 1655], ["growth", 1662], ["in", 1669], ["lung", 1672], ["cancer", 1677], ["subsets", 1684], [".", 1691]]}
{"context": "Ataxin-3 is a ubiquitously expressed deubiqutinating enzyme with important functions in the proteasomal protein degradation pathway and regulation of transcription. The C-terminus of the ataxin-3 protein contains a polyglutamine (PolyQ) region that, when mutationally expanded to over 52 glutamines, causes the neurodegenerative disease spinocerebellar ataxia 3 (SCA3). In spite of extensive research, the molecular mechanisms underlying the cellular toxicity resulting from mutant ataxin-3 remain elusive and no preventive treatment is currently available. It has become clear over the last decade that the hallmark intracellular ataxin-3 aggregates are likely not the main toxic entity in SCA3. Instead, the soluble PolyQ containing fragments arising from proteolytic cleavage of ataxin-3 by caspases and calpains are now regarded to be of greater influence in pathogenesis. In addition, recent evidence suggests potential involvement of a RNA toxicity component in SCA3 and other PolyQ expansion disorders, increasing the pathogenic complexity. Herein, we review the functioning of ataxin-3 and the involvement of known protein and RNA toxicity mechanisms of mutant ataxin-3 that have been discovered, as well as future opportunities for therapeutic intervention.", "qas": [{"question": "Which is the protein implicated in Spinocerebellar ataxia type 3?", "answers": ["Ataxin-3"], "qid": "5196d6a345bb4a5db1019bc0c286be72", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["protein", 13], ["implicated", 21], ["in", 32], ["Spinocerebellar", 35], ["ataxia", 51], ["type", 58], ["3", 63], ["?", 64]], "detected_answers": [{"text": "Ataxin-3", "token_spans": [[0, 0], [96, 96], [27, 27], [182, 182], [73, 73], [169, 169], [120, 120]], "char_spans": [[0, 7], [631, 638], [187, 194], [1169, 1176], [482, 489], [1085, 1092], [782, 789]]}]}], "context_tokens": [["Ataxin-3", 0], ["is", 9], ["a", 12], ["ubiquitously", 14], ["expressed", 27], ["deubiqutinating", 37], ["enzyme", 53], ["with", 60], ["important", 65], ["functions", 75], ["in", 85], ["the", 88], ["proteasomal", 92], ["protein", 104], ["degradation", 112], ["pathway", 124], ["and", 132], ["regulation", 136], ["of", 147], ["transcription", 150], [".", 163], ["The", 165], ["C", 169], ["-", 170], ["terminus", 171], ["of", 180], ["the", 183], ["ataxin-3", 187], ["protein", 196], ["contains", 204], ["a", 213], ["polyglutamine", 215], ["(", 229], ["PolyQ", 230], [")", 235], ["region", 237], ["that", 244], [",", 248], ["when", 250], ["mutationally", 255], ["expanded", 268], ["to", 277], ["over", 280], ["52", 285], ["glutamines", 288], [",", 298], ["causes", 300], ["the", 307], ["neurodegenerative", 311], ["disease", 329], ["spinocerebellar", 337], ["ataxia", 353], ["3", 360], ["(", 362], ["SCA3", 363], [")", 367], [".", 368], ["In", 370], ["spite", 373], ["of", 379], ["extensive", 382], ["research", 392], [",", 400], ["the", 402], ["molecular", 406], ["mechanisms", 416], ["underlying", 427], ["the", 438], ["cellular", 442], ["toxicity", 451], ["resulting", 460], ["from", 470], ["mutant", 475], ["ataxin-3", 482], ["remain", 491], ["elusive", 498], ["and", 506], ["no", 510], ["preventive", 513], ["treatment", 524], ["is", 534], ["currently", 537], ["available", 547], [".", 556], ["It", 558], ["has", 561], ["become", 565], ["clear", 572], ["over", 578], ["the", 583], ["last", 587], ["decade", 592], ["that", 599], ["the", 604], ["hallmark", 608], ["intracellular", 617], ["ataxin-3", 631], ["aggregates", 640], ["are", 651], ["likely", 655], ["not", 662], ["the", 666], ["main", 670], ["toxic", 675], ["entity", 681], ["in", 688], ["SCA3", 691], [".", 695], ["Instead", 697], [",", 704], ["the", 706], ["soluble", 710], ["PolyQ", 718], ["containing", 724], ["fragments", 735], ["arising", 745], ["from", 753], ["proteolytic", 758], ["cleavage", 770], ["of", 779], ["ataxin-3", 782], ["by", 791], ["caspases", 794], ["and", 803], ["calpains", 807], ["are", 816], ["now", 820], ["regarded", 824], ["to", 833], ["be", 836], ["of", 839], ["greater", 842], ["influence", 850], ["in", 860], ["pathogenesis", 863], [".", 875], ["In", 877], ["addition", 880], [",", 888], ["recent", 890], ["evidence", 897], ["suggests", 906], ["potential", 915], ["involvement", 925], ["of", 937], ["a", 940], ["RNA", 942], ["toxicity", 946], ["component", 955], ["in", 965], ["SCA3", 968], ["and", 973], ["other", 977], ["PolyQ", 983], ["expansion", 989], ["disorders", 999], [",", 1008], ["increasing", 1010], ["the", 1021], ["pathogenic", 1025], ["complexity", 1036], [".", 1046], ["Herein", 1048], [",", 1054], ["we", 1056], ["review", 1059], ["the", 1066], ["functioning", 1070], ["of", 1082], ["ataxin-3", 1085], ["and", 1094], ["the", 1098], ["involvement", 1102], ["of", 1114], ["known", 1117], ["protein", 1123], ["and", 1131], ["RNA", 1135], ["toxicity", 1139], ["mechanisms", 1148], ["of", 1159], ["mutant", 1162], ["ataxin-3", 1169], ["that", 1178], ["have", 1183], ["been", 1188], ["discovered", 1193], [",", 1203], ["as", 1205], ["well", 1208], ["as", 1213], ["future", 1216], ["opportunities", 1223], ["for", 1237], ["therapeutic", 1241], ["intervention", 1253], [".", 1265]]}
{"context": "A specialized nucleotide excision repair pathway known as transcription-coupled repair (TCR) counteracts the toxic effects of DNA damage in transcriptionally active genes. The clustering of active genes into gene-rich chromosomal domains predicts that the sites of TCR are unevenly distributed through the genome. To elucidate the genomic organization and chromosomal localization of TCR, we isolated DNA fragments encompassing TCR-mediated repair sites from UV-C irradiated xeroderma pigmentosum group C cells, which can only repair the transcribed strand of active genes. This DNA was used as a molecular probe to visualize TCR in normal metaphase spreads by reverse fluorescence in situ hybridization. Whereas DNA repair sites in normal human cells are evenly distributed through the genome, TCR is highly localized at specific chromosomal domains. Particularly, clusters of TCR sites were identified at early-replicating gene-rich bands and telomeric regions of several chromosomes. High gene-density chromosomes such as chromosome 19 and the GC-rich domains of several chromosomes (T bands) are preferential locations of TCR. Our results demonstrate that the intragenomic localization of TCR resembles the uneven distribution of the human transcriptome, CpG islands, and hyperacetylated histones, enforcing the basic link between DNA repair, transcription, and nuclear organization in a complex genome.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "a279fbb04c944d8dbfb90dbe26a570cd", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[88, 89]], "char_spans": [[538, 555]]}]}], "context_tokens": [["A", 0], ["specialized", 2], ["nucleotide", 14], ["excision", 25], ["repair", 34], ["pathway", 41], ["known", 49], ["as", 55], ["transcription", 58], ["-", 71], ["coupled", 72], ["repair", 80], ["(", 87], ["TCR", 88], [")", 91], ["counteracts", 93], ["the", 105], ["toxic", 109], ["effects", 115], ["of", 123], ["DNA", 126], ["damage", 130], ["in", 137], ["transcriptionally", 140], ["active", 158], ["genes", 165], [".", 170], ["The", 172], ["clustering", 176], ["of", 187], ["active", 190], ["genes", 197], ["into", 203], ["gene", 208], ["-", 212], ["rich", 213], ["chromosomal", 218], ["domains", 230], ["predicts", 238], ["that", 247], ["the", 252], ["sites", 256], ["of", 262], ["TCR", 265], ["are", 269], ["unevenly", 273], ["distributed", 282], ["through", 294], ["the", 302], ["genome", 306], [".", 312], ["To", 314], ["elucidate", 317], ["the", 327], ["genomic", 331], ["organization", 339], ["and", 352], ["chromosomal", 356], ["localization", 368], ["of", 381], ["TCR", 384], [",", 387], ["we", 389], ["isolated", 392], ["DNA", 401], ["fragments", 405], ["encompassing", 415], ["TCR", 428], ["-", 431], ["mediated", 432], ["repair", 441], ["sites", 448], ["from", 454], ["UV", 459], ["-", 461], ["C", 462], ["irradiated", 464], ["xeroderma", 475], ["pigmentosum", 485], ["group", 497], ["C", 503], ["cells", 505], [",", 510], ["which", 512], ["can", 518], ["only", 522], ["repair", 527], ["the", 534], ["transcribed", 538], ["strand", 550], ["of", 557], ["active", 560], ["genes", 567], [".", 572], ["This", 574], ["DNA", 579], ["was", 583], ["used", 587], ["as", 592], ["a", 595], ["molecular", 597], ["probe", 607], ["to", 613], ["visualize", 616], ["TCR", 626], ["in", 630], ["normal", 633], ["metaphase", 640], ["spreads", 650], ["by", 658], ["reverse", 661], ["fluorescence", 669], ["in", 682], ["situ", 685], ["hybridization", 690], [".", 703], ["Whereas", 705], ["DNA", 713], ["repair", 717], ["sites", 724], ["in", 730], ["normal", 733], ["human", 740], ["cells", 746], ["are", 752], ["evenly", 756], ["distributed", 763], ["through", 775], ["the", 783], ["genome", 787], [",", 793], ["TCR", 795], ["is", 799], ["highly", 802], ["localized", 809], ["at", 819], ["specific", 822], ["chromosomal", 831], ["domains", 843], [".", 850], ["Particularly", 852], [",", 864], ["clusters", 866], ["of", 875], ["TCR", 878], ["sites", 882], ["were", 888], ["identified", 893], ["at", 904], ["early", 907], ["-", 912], ["replicating", 913], ["gene", 925], ["-", 929], ["rich", 930], ["bands", 935], ["and", 941], ["telomeric", 945], ["regions", 955], ["of", 963], ["several", 966], ["chromosomes", 974], [".", 985], ["High", 987], ["gene", 992], ["-", 996], ["density", 997], ["chromosomes", 1005], ["such", 1017], ["as", 1022], ["chromosome", 1025], ["19", 1036], ["and", 1039], ["the", 1043], ["GC", 1047], ["-", 1049], ["rich", 1050], ["domains", 1055], ["of", 1063], ["several", 1066], ["chromosomes", 1074], ["(", 1086], ["T", 1087], ["bands", 1089], [")", 1094], ["are", 1096], ["preferential", 1100], ["locations", 1113], ["of", 1123], ["TCR", 1126], [".", 1129], ["Our", 1131], ["results", 1135], ["demonstrate", 1143], ["that", 1155], ["the", 1160], ["intragenomic", 1164], ["localization", 1177], ["of", 1190], ["TCR", 1193], ["resembles", 1197], ["the", 1207], ["uneven", 1211], ["distribution", 1218], ["of", 1231], ["the", 1234], ["human", 1238], ["transcriptome", 1244], [",", 1257], ["CpG", 1259], ["islands", 1263], [",", 1270], ["and", 1272], ["hyperacetylated", 1276], ["histones", 1292], [",", 1300], ["enforcing", 1302], ["the", 1312], ["basic", 1316], ["link", 1322], ["between", 1327], ["DNA", 1335], ["repair", 1339], [",", 1345], ["transcription", 1347], [",", 1360], ["and", 1362], ["nuclear", 1366], ["organization", 1374], ["in", 1387], ["a", 1390], ["complex", 1392], ["genome", 1400], [".", 1406]]}
{"context": "Viliuisk encephalomyelitis (VE) is an endemic neurological disease in Northeast Siberia and generally considered to be a chronic encephalomyelitis of unknown origin actually spreading in the Sakha (Yakutian) Republic. In search for the pathophysiology and causative agent of VE, we performed a cross-sectional study on clinical, serological and neuroimaging data on chronic VE patients during two medical expeditions to three villages within the Viliuiski river basin in the Republic of Sakha in 2000 and to the capital Yakutsk in 2006. The severity of the core clinical picture with predominant sensory ataxia, gait apraxia, lower limb spasticity, cognitive impairment and bladder dysfunction correlated with the degree of MRI findings showing enlargement of inner ventricular spaces as in communicating hydrocephalus. Laboratory studies revealed transient eosinophilia during the preceding acute meningitis-like phase, but no ongoing inflammatory process in the CSF. We found immune reactions against Toxocara canis in the majority of chronic VE patients but rarely in controls (P = 0.025; Fisher's exact test). Histological analysis of subacute to subchronic VE brain samples showed eosinophilic infiltrations with no signs of persistent Toxocara canis infection. Our data showed that pressure by the communicating hydrocephalus as a mechanical factor is the major pathogenic mechanism in chronic VE, most likely triggered by eosinophilic meningitis. There are no signs for an ongoing inflammatory process in chronic VE. The past eosinophilic reaction in VE might be caused by Toxocara ssp. infection and might therefore represent the first hint for an initial cause leading to the development of chronic VE. Our data provide a framework for future studies and potential therapeutic interventions for this enigmatic epidemic neurological disease potentially spreading in Sakha Republic.", "qas": [{"question": "Viliuisk encephalomyelitis is diagnosed in which geographical area?", "answers": ["Northeast Siberia"], "qid": "15bd193287ec4c43b761c54699d4ca55", "question_tokens": [["Viliuisk", 0], ["encephalomyelitis", 9], ["is", 27], ["diagnosed", 30], ["in", 40], ["which", 43], ["geographical", 49], ["area", 62], ["?", 66]], "detected_answers": [{"text": "Northeast Siberia", "token_spans": [[11, 12]], "char_spans": [[70, 86]]}]}], "context_tokens": [["Viliuisk", 0], ["encephalomyelitis", 9], ["(", 27], ["VE", 28], [")", 30], ["is", 32], ["an", 35], ["endemic", 38], ["neurological", 46], ["disease", 59], ["in", 67], ["Northeast", 70], ["Siberia", 80], ["and", 88], ["generally", 92], ["considered", 102], ["to", 113], ["be", 116], ["a", 119], ["chronic", 121], ["encephalomyelitis", 129], ["of", 147], ["unknown", 150], ["origin", 158], ["actually", 165], ["spreading", 174], ["in", 184], ["the", 187], ["Sakha", 191], ["(", 197], ["Yakutian", 198], [")", 206], ["Republic", 208], [".", 216], ["In", 218], ["search", 221], ["for", 228], ["the", 232], ["pathophysiology", 236], ["and", 252], ["causative", 256], ["agent", 266], ["of", 272], ["VE", 275], [",", 277], ["we", 279], ["performed", 282], ["a", 292], ["cross", 294], ["-", 299], ["sectional", 300], ["study", 310], ["on", 316], ["clinical", 319], [",", 327], ["serological", 329], ["and", 341], ["neuroimaging", 345], ["data", 358], ["on", 363], ["chronic", 366], ["VE", 374], ["patients", 377], ["during", 386], ["two", 393], ["medical", 397], ["expeditions", 405], ["to", 417], ["three", 420], ["villages", 426], ["within", 435], ["the", 442], ["Viliuiski", 446], ["river", 456], ["basin", 462], ["in", 468], ["the", 471], ["Republic", 475], ["of", 484], ["Sakha", 487], ["in", 493], ["2000", 496], ["and", 501], ["to", 505], ["the", 508], ["capital", 512], ["Yakutsk", 520], ["in", 528], ["2006", 531], [".", 535], ["The", 537], ["severity", 541], ["of", 550], ["the", 553], ["core", 557], ["clinical", 562], ["picture", 571], ["with", 579], ["predominant", 584], ["sensory", 596], ["ataxia", 604], [",", 610], ["gait", 612], ["apraxia", 617], [",", 624], ["lower", 626], ["limb", 632], ["spasticity", 637], [",", 647], ["cognitive", 649], ["impairment", 659], ["and", 670], ["bladder", 674], ["dysfunction", 682], ["correlated", 694], ["with", 705], ["the", 710], ["degree", 714], ["of", 721], ["MRI", 724], ["findings", 728], ["showing", 737], ["enlargement", 745], ["of", 757], ["inner", 760], ["ventricular", 766], ["spaces", 778], ["as", 785], ["in", 788], ["communicating", 791], ["hydrocephalus", 805], [".", 818], ["Laboratory", 820], ["studies", 831], ["revealed", 839], ["transient", 848], ["eosinophilia", 858], ["during", 871], ["the", 878], ["preceding", 882], ["acute", 892], ["meningitis", 898], ["-", 908], ["like", 909], ["phase", 914], [",", 919], ["but", 921], ["no", 925], ["ongoing", 928], ["inflammatory", 936], ["process", 949], ["in", 957], ["the", 960], ["CSF", 964], [".", 967], ["We", 969], ["found", 972], ["immune", 978], ["reactions", 985], ["against", 995], ["Toxocara", 1003], ["canis", 1012], ["in", 1018], ["the", 1021], ["majority", 1025], ["of", 1034], ["chronic", 1037], ["VE", 1045], ["patients", 1048], ["but", 1057], ["rarely", 1061], ["in", 1068], ["controls", 1071], ["(", 1080], ["P", 1081], ["=", 1083], ["0.025", 1085], [";", 1090], ["Fisher", 1092], ["'s", 1098], ["exact", 1101], ["test", 1107], [")", 1111], [".", 1112], ["Histological", 1114], ["analysis", 1127], ["of", 1136], ["subacute", 1139], ["to", 1148], ["subchronic", 1151], ["VE", 1162], ["brain", 1165], ["samples", 1171], ["showed", 1179], ["eosinophilic", 1186], ["infiltrations", 1199], ["with", 1213], ["no", 1218], ["signs", 1221], ["of", 1227], ["persistent", 1230], ["Toxocara", 1241], ["canis", 1250], ["infection", 1256], [".", 1265], ["Our", 1267], ["data", 1271], ["showed", 1276], ["that", 1283], ["pressure", 1288], ["by", 1297], ["the", 1300], ["communicating", 1304], ["hydrocephalus", 1318], ["as", 1332], ["a", 1335], ["mechanical", 1337], ["factor", 1348], ["is", 1355], ["the", 1358], ["major", 1362], ["pathogenic", 1368], ["mechanism", 1379], ["in", 1389], ["chronic", 1392], ["VE", 1400], [",", 1402], ["most", 1404], ["likely", 1409], ["triggered", 1416], ["by", 1426], ["eosinophilic", 1429], ["meningitis", 1442], [".", 1452], ["There", 1454], ["are", 1460], ["no", 1464], ["signs", 1467], ["for", 1473], ["an", 1477], ["ongoing", 1480], ["inflammatory", 1488], ["process", 1501], ["in", 1509], ["chronic", 1512], ["VE", 1520], [".", 1522], ["The", 1524], ["past", 1528], ["eosinophilic", 1533], ["reaction", 1546], ["in", 1555], ["VE", 1558], ["might", 1561], ["be", 1567], ["caused", 1570], ["by", 1577], ["Toxocara", 1580], ["ssp", 1589], [".", 1592], ["infection", 1594], ["and", 1604], ["might", 1608], ["therefore", 1614], ["represent", 1624], ["the", 1634], ["first", 1638], ["hint", 1644], ["for", 1649], ["an", 1653], ["initial", 1656], ["cause", 1664], ["leading", 1670], ["to", 1678], ["the", 1681], ["development", 1685], ["of", 1697], ["chronic", 1700], ["VE", 1708], [".", 1710], ["Our", 1712], ["data", 1716], ["provide", 1721], ["a", 1729], ["framework", 1731], ["for", 1741], ["future", 1745], ["studies", 1752], ["and", 1760], ["potential", 1764], ["therapeutic", 1774], ["interventions", 1786], ["for", 1800], ["this", 1804], ["enigmatic", 1809], ["epidemic", 1819], ["neurological", 1828], ["disease", 1841], ["potentially", 1849], ["spreading", 1861], ["in", 1871], ["Sakha", 1874], ["Republic", 1880], [".", 1888]]}
{"context": "Tanezumab, a monoclonal antibody, inhibits nerve growth factor and reduces chronic pain. This randomised, double-blind, controlled multicentre study was conducted to evaluate the efficacy and safety of tanezumab added to oral diclofenac sustained release (DSR) in patients with hip or knee osteoarthritis (OA) pain. Patients (N=604) with moderate to severe knee or hip OA tolerating stable DSR were randomised and treated with DSR 75\u2005mg twice daily combined with intravenous tanezumab 10, 5 or 2.5\u2005mg or placebo at weeks 0, 8 and 16. Co-primary efficacy endpoints (Western Ontario and McMaster Universities OA Index (WOMAC) Pain and Physical Function subscales and patient's global assessment of OA) were assessed at week 16. All co-primary endpoints were significantly improved for all tanezumab+DSR groups versus placebo+DSR (p\u22640.039). The incidence of adverse events of abnormal peripheral sensation was lower than in previous tanezumab trials. No new safety signals emerged. Overall incidence of adverse events was higher with tanezumab+DSR (45.2%-49.7%) than with placebo+DSR (34.9%); serious adverse event rates were similar across treatments (5.3%-7.6%). Osteonecrosis was reported in six of 452 patients with tanezumab+DSR (1.3%), but an external adjudication committee did not confirm osteonecrosis in any patient. Addition of tanezumab to DSR resulted in significant improvements in pain, function and global assessments in patients with OA. Although no new safety signals were observed, the higher incidence of adverse events in the tanezumab+diclofenac group suggests that combination therapy is unfavourable. Further investigations of tanezumab monotherapy for OA pain treatment are required. NCT00864097.", "qas": [{"question": "What is the target of tanezumab?", "answers": ["nerve growth factor", "NGF"], "qid": "24a13e3726da44deb5ad15627d9c04f8", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["target", 12], ["of", 19], ["tanezumab", 22], ["?", 31]], "detected_answers": [{"text": "nerve growth factor", "token_spans": [[7, 9]], "char_spans": [[43, 61]]}]}], "context_tokens": [["Tanezumab", 0], [",", 9], ["a", 11], ["monoclonal", 13], ["antibody", 24], [",", 32], ["inhibits", 34], ["nerve", 43], ["growth", 49], ["factor", 56], ["and", 63], ["reduces", 67], ["chronic", 75], ["pain", 83], [".", 87], ["This", 89], ["randomised", 94], [",", 104], ["double", 106], ["-", 112], ["blind", 113], [",", 118], ["controlled", 120], ["multicentre", 131], ["study", 143], ["was", 149], ["conducted", 153], ["to", 163], ["evaluate", 166], ["the", 175], ["efficacy", 179], ["and", 188], ["safety", 192], ["of", 199], ["tanezumab", 202], ["added", 212], ["to", 218], ["oral", 221], ["diclofenac", 226], ["sustained", 237], ["release", 247], ["(", 255], ["DSR", 256], [")", 259], ["in", 261], ["patients", 264], ["with", 273], ["hip", 278], ["or", 282], ["knee", 285], ["osteoarthritis", 290], ["(", 305], ["OA", 306], [")", 308], ["pain", 310], [".", 314], ["Patients", 316], ["(", 325], ["N=604", 326], [")", 331], ["with", 333], ["moderate", 338], ["to", 347], ["severe", 350], ["knee", 357], ["or", 362], ["hip", 365], ["OA", 369], ["tolerating", 372], ["stable", 383], ["DSR", 390], ["were", 394], ["randomised", 399], ["and", 410], ["treated", 414], ["with", 422], ["DSR", 427], ["75", 431], ["mg", 434], ["twice", 437], ["daily", 443], ["combined", 449], ["with", 458], ["intravenous", 463], ["tanezumab", 475], ["10", 485], [",", 487], ["5", 489], ["or", 491], ["2.5", 494], ["mg", 498], ["or", 501], ["placebo", 504], ["at", 512], ["weeks", 515], ["0", 521], [",", 522], ["8", 524], ["and", 526], ["16", 530], [".", 532], ["Co", 534], ["-", 536], ["primary", 537], ["efficacy", 545], ["endpoints", 554], ["(", 564], ["Western", 565], ["Ontario", 573], ["and", 581], ["McMaster", 585], ["Universities", 594], ["OA", 607], ["Index", 610], ["(", 616], ["WOMAC", 617], [")", 622], ["Pain", 624], ["and", 629], ["Physical", 633], ["Function", 642], ["subscales", 651], ["and", 661], ["patient", 665], ["'s", 672], ["global", 675], ["assessment", 682], ["of", 693], ["OA", 696], [")", 698], ["were", 700], ["assessed", 705], ["at", 714], ["week", 717], ["16", 722], [".", 724], ["All", 726], ["co", 730], ["-", 732], ["primary", 733], ["endpoints", 741], ["were", 751], ["significantly", 756], ["improved", 770], ["for", 779], ["all", 783], ["tanezumab+DSR", 787], ["groups", 801], ["versus", 808], ["placebo+DSR", 815], ["(", 827], ["p\u22640.039", 828], [")", 835], [".", 836], ["The", 838], ["incidence", 842], ["of", 852], ["adverse", 855], ["events", 863], ["of", 870], ["abnormal", 873], ["peripheral", 882], ["sensation", 893], ["was", 903], ["lower", 907], ["than", 913], ["in", 918], ["previous", 921], ["tanezumab", 930], ["trials", 940], [".", 946], ["No", 948], ["new", 951], ["safety", 955], ["signals", 962], ["emerged", 970], [".", 977], ["Overall", 979], ["incidence", 987], ["of", 997], ["adverse", 1000], ["events", 1008], ["was", 1015], ["higher", 1019], ["with", 1026], ["tanezumab+DSR", 1031], ["(", 1045], ["45.2%-49.7", 1046], ["%", 1056], [")", 1057], ["than", 1059], ["with", 1064], ["placebo+DSR", 1069], ["(", 1081], ["34.9", 1082], ["%", 1086], [")", 1087], [";", 1088], ["serious", 1090], ["adverse", 1098], ["event", 1106], ["rates", 1112], ["were", 1118], ["similar", 1123], ["across", 1131], ["treatments", 1138], ["(", 1149], ["5.3%-7.6", 1150], ["%", 1158], [")", 1159], [".", 1160], ["Osteonecrosis", 1162], ["was", 1176], ["reported", 1180], ["in", 1189], ["six", 1192], ["of", 1196], ["452", 1199], ["patients", 1203], ["with", 1212], ["tanezumab+DSR", 1217], ["(", 1231], ["1.3", 1232], ["%", 1235], [")", 1236], [",", 1237], ["but", 1239], ["an", 1243], ["external", 1246], ["adjudication", 1255], ["committee", 1268], ["did", 1278], ["not", 1282], ["confirm", 1286], ["osteonecrosis", 1294], ["in", 1308], ["any", 1311], ["patient", 1315], [".", 1322], ["Addition", 1324], ["of", 1333], ["tanezumab", 1336], ["to", 1346], ["DSR", 1349], ["resulted", 1353], ["in", 1362], ["significant", 1365], ["improvements", 1377], ["in", 1390], ["pain", 1393], [",", 1397], ["function", 1399], ["and", 1408], ["global", 1412], ["assessments", 1419], ["in", 1431], ["patients", 1434], ["with", 1443], ["OA", 1448], [".", 1450], ["Although", 1452], ["no", 1461], ["new", 1464], ["safety", 1468], ["signals", 1475], ["were", 1483], ["observed", 1488], [",", 1496], ["the", 1498], ["higher", 1502], ["incidence", 1509], ["of", 1519], ["adverse", 1522], ["events", 1530], ["in", 1537], ["the", 1540], ["tanezumab+diclofenac", 1544], ["group", 1565], ["suggests", 1571], ["that", 1580], ["combination", 1585], ["therapy", 1597], ["is", 1605], ["unfavourable", 1608], [".", 1620], ["Further", 1622], ["investigations", 1630], ["of", 1645], ["tanezumab", 1648], ["monotherapy", 1658], ["for", 1670], ["OA", 1674], ["pain", 1677], ["treatment", 1682], ["are", 1692], ["required", 1696], [".", 1704], ["NCT00864097", 1706], [".", 1717]]}
{"context": "Transgenic mice over-expressing a mutated form of the human amyloid precursor protein (APP, 695 isoform) bearing a mutation associated with Alzheimer's disease (V642I, so-called London mutation, hereafter APPLd2) and wild-type controls were studied at age periods (3 and 10 months) prior to the overt development of neuritic amyloid plaques. Both 3- and 10-month-old APPLd2 mice had reflex eyelid responses like those of controls, but only younger mice were able to acquire a classical conditioning of eyelid responses in a trace paradigm. In vitro studies on hippocampal slices showed that 10-month-old APPLd2 mice also presented deficits in paired-pulse facilitation and long-term potentiation, but presented a normal synaptic activation of CA1 pyramidal cells by the stimulation of Schaffer collaterals. It is proposed that definite functional changes may appear well in advance of noticeable structural alterations in this animal model of Alzheimer's disease, and that specific learning tasks could have a relevant diagnostic value.", "qas": [{"question": "Which disease the London mutation involved in?", "answers": ["Alzheimer's Disease", "AD"], "qid": "b8293e4bcc944de3949762790d040d05", "question_tokens": [["Which", 0], ["disease", 6], ["the", 14], ["London", 18], ["mutation", 25], ["involved", 34], ["in", 43], ["?", 45]], "detected_answers": [{"text": "Alzheimer's Disease", "token_spans": [[25, 27], [167, 169]], "char_spans": [[140, 158], [943, 961]]}]}], "context_tokens": [["Transgenic", 0], ["mice", 11], ["over", 16], ["-", 20], ["expressing", 21], ["a", 32], ["mutated", 34], ["form", 42], ["of", 47], ["the", 50], ["human", 54], ["amyloid", 60], ["precursor", 68], ["protein", 78], ["(", 86], ["APP", 87], [",", 90], ["695", 92], ["isoform", 96], [")", 103], ["bearing", 105], ["a", 113], ["mutation", 115], ["associated", 124], ["with", 135], ["Alzheimer", 140], ["'s", 149], ["disease", 152], ["(", 160], ["V642I", 161], [",", 166], ["so", 168], ["-", 170], ["called", 171], ["London", 178], ["mutation", 185], [",", 193], ["hereafter", 195], ["APPLd2", 205], [")", 211], ["and", 213], ["wild", 217], ["-", 221], ["type", 222], ["controls", 227], ["were", 236], ["studied", 241], ["at", 249], ["age", 252], ["periods", 256], ["(", 264], ["3", 265], ["and", 267], ["10", 271], ["months", 274], [")", 280], ["prior", 282], ["to", 288], ["the", 291], ["overt", 295], ["development", 301], ["of", 313], ["neuritic", 316], ["amyloid", 325], ["plaques", 333], [".", 340], ["Both", 342], ["3-", 347], ["and", 350], ["10-month", 354], ["-", 362], ["old", 363], ["APPLd2", 367], ["mice", 374], ["had", 379], ["reflex", 383], ["eyelid", 390], ["responses", 397], ["like", 407], ["those", 412], ["of", 418], ["controls", 421], [",", 429], ["but", 431], ["only", 435], ["younger", 440], ["mice", 448], ["were", 453], ["able", 458], ["to", 463], ["acquire", 466], ["a", 474], ["classical", 476], ["conditioning", 486], ["of", 499], ["eyelid", 502], ["responses", 509], ["in", 519], ["a", 522], ["trace", 524], ["paradigm", 530], [".", 538], ["In", 540], ["vitro", 543], ["studies", 549], ["on", 557], ["hippocampal", 560], ["slices", 572], ["showed", 579], ["that", 586], ["10-month", 591], ["-", 599], ["old", 600], ["APPLd2", 604], ["mice", 611], ["also", 616], ["presented", 621], ["deficits", 631], ["in", 640], ["paired", 643], ["-", 649], ["pulse", 650], ["facilitation", 656], ["and", 669], ["long", 673], ["-", 677], ["term", 678], ["potentiation", 683], [",", 695], ["but", 697], ["presented", 701], ["a", 711], ["normal", 713], ["synaptic", 720], ["activation", 729], ["of", 740], ["CA1", 743], ["pyramidal", 747], ["cells", 757], ["by", 763], ["the", 766], ["stimulation", 770], ["of", 782], ["Schaffer", 785], ["collaterals", 794], [".", 805], ["It", 807], ["is", 810], ["proposed", 813], ["that", 822], ["definite", 827], ["functional", 836], ["changes", 847], ["may", 855], ["appear", 859], ["well", 866], ["in", 871], ["advance", 874], ["of", 882], ["noticeable", 885], ["structural", 896], ["alterations", 907], ["in", 919], ["this", 922], ["animal", 927], ["model", 934], ["of", 940], ["Alzheimer", 943], ["'s", 952], ["disease", 955], [",", 962], ["and", 964], ["that", 968], ["specific", 973], ["learning", 982], ["tasks", 991], ["could", 997], ["have", 1003], ["a", 1008], ["relevant", 1010], ["diagnostic", 1019], ["value", 1030], [".", 1035]]}
{"context": "Epigenetic modifications of histones regulate gene expression and chromatin structure. Here we show that Meisetz (meiosis-induced factor containing a PR/SET domain and zinc-finger motif) is a histone methyltransferase that is important for the progression of early meiotic prophase. Meisetz transcripts are detected only in germ cells entering meiotic prophase in female fetal gonads and in postnatal testis. Notably, Meisetz has catalytic activity for trimethylation, but not mono- or dimethylation, of lysine 4 of histone H3, and a transactivation activity that depends on its methylation activity. Mice in which the Meisetz gene is disrupted show sterility in both sexes due to severe impairment of the double-stranded break repair pathway, deficient pairing of homologous chromosomes and impaired sex body formation. In Meisetz-deficient testis, trimethylation of lysine 4 of histone H3 is attenuated and meiotic gene transcription is altered. These findings indicate that meiosis-specific epigenetic events in mammals are crucial for proper meiotic progression.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "549167c35b584704bfc6c93fb4bb55e9", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[25, 26]], "char_spans": [[153, 162]]}]}], "context_tokens": [["Epigenetic", 0], ["modifications", 11], ["of", 25], ["histones", 28], ["regulate", 37], ["gene", 46], ["expression", 51], ["and", 62], ["chromatin", 66], ["structure", 76], [".", 85], ["Here", 87], ["we", 92], ["show", 95], ["that", 100], ["Meisetz", 105], ["(", 113], ["meiosis", 114], ["-", 121], ["induced", 122], ["factor", 130], ["containing", 137], ["a", 148], ["PR", 150], ["/", 152], ["SET", 153], ["domain", 157], ["and", 164], ["zinc", 168], ["-", 172], ["finger", 173], ["motif", 180], [")", 185], ["is", 187], ["a", 190], ["histone", 192], ["methyltransferase", 200], ["that", 218], ["is", 223], ["important", 226], ["for", 236], ["the", 240], ["progression", 244], ["of", 256], ["early", 259], ["meiotic", 265], ["prophase", 273], [".", 281], ["Meisetz", 283], ["transcripts", 291], ["are", 303], ["detected", 307], ["only", 316], ["in", 321], ["germ", 324], ["cells", 329], ["entering", 335], ["meiotic", 344], ["prophase", 352], ["in", 361], ["female", 364], ["fetal", 371], ["gonads", 377], ["and", 384], ["in", 388], ["postnatal", 391], ["testis", 401], [".", 407], ["Notably", 409], [",", 416], ["Meisetz", 418], ["has", 426], ["catalytic", 430], ["activity", 440], ["for", 449], ["trimethylation", 453], [",", 467], ["but", 469], ["not", 473], ["mono-", 477], ["or", 483], ["dimethylation", 486], [",", 499], ["of", 501], ["lysine", 504], ["4", 511], ["of", 513], ["histone", 516], ["H3", 524], [",", 526], ["and", 528], ["a", 532], ["transactivation", 534], ["activity", 550], ["that", 559], ["depends", 564], ["on", 572], ["its", 575], ["methylation", 579], ["activity", 591], [".", 599], ["Mice", 601], ["in", 606], ["which", 609], ["the", 615], ["Meisetz", 619], ["gene", 627], ["is", 632], ["disrupted", 635], ["show", 645], ["sterility", 650], ["in", 660], ["both", 663], ["sexes", 668], ["due", 674], ["to", 678], ["severe", 681], ["impairment", 688], ["of", 699], ["the", 702], ["double", 706], ["-", 712], ["stranded", 713], ["break", 722], ["repair", 728], ["pathway", 735], [",", 742], ["deficient", 744], ["pairing", 754], ["of", 762], ["homologous", 765], ["chromosomes", 776], ["and", 788], ["impaired", 792], ["sex", 801], ["body", 805], ["formation", 810], [".", 819], ["In", 821], ["Meisetz", 824], ["-", 831], ["deficient", 832], ["testis", 842], [",", 848], ["trimethylation", 850], ["of", 865], ["lysine", 868], ["4", 875], ["of", 877], ["histone", 880], ["H3", 888], ["is", 891], ["attenuated", 894], ["and", 905], ["meiotic", 909], ["gene", 917], ["transcription", 922], ["is", 936], ["altered", 939], [".", 946], ["These", 948], ["findings", 954], ["indicate", 963], ["that", 972], ["meiosis", 977], ["-", 984], ["specific", 985], ["epigenetic", 994], ["events", 1005], ["in", 1012], ["mammals", 1015], ["are", 1023], ["crucial", 1027], ["for", 1035], ["proper", 1039], ["meiotic", 1046], ["progression", 1054], [".", 1065]]}
{"context": "Allelic polymorphism of the apolipoprotein E (ApoE) gene (ApoE \u03b52, ApoE \u03b53 and ApoE \u03b54 alleles) gives rise to three protein isoforms (ApoE2, ApoE3 and ApoE4) that differ by 1 or 2 amino acids. Inheritance of the ApoE \u03b54 allele is a risk factor for developing Alzheimer's disease (AD). The potential diagnostic value of ApoE protein levels in biological fluids (i.e. cerebrospinal fluid, plasma and serum) for distinguishing between AD patients and healthy elderly subjects is subject to great controversy. Although a recent study reported subnormal total ApoE and ApoE4 levels in the plasma of AD patients, other studies have found normal or even elevated protein levels (versus controls). Because all previously reported assays were based on immunoenzymatic techniques, we decided to develop an orthogonal assay based on targeted mass spectrometry by tracking (i) a proteotypic peptide common to all ApoE isoforms and (ii) a peptide that is specific for the \u03b54 allele. After trypsin digestion, the ApoE4-specific peptide contains an oxidation-prone methionine residue. The endogenous methionine oxidation level was evaluated in a small cohort (n=68) of heterozygous \u03b53\u03b54 carriers containing both healthy controls and AD patients. As expected, the proportion of oxidized residues varied from 0 to 10%, with an average of 5%. We therefore developed a standardized strategy for the unbiased, absolute quantification of ApoE4, based on performic acid oxidization of methionine. Once the sample workflow had been thoroughly validated, it was applied to the concomitant quantification of total ApoE and ApoE4 isoform in a large case-control study (n=669). The final measurements were consistent with most previously reported ApoE concentration values and confirm the influence of the different alleles on the protein expression level. Our results illustrate (i) the reliability of selected reaction monitoring-based assays and (ii) the value of the oxidization step for unbiased monitoring of methionine-containing proteotypic peptides. Furthermore, a statistical analysis indicated that neither total ApoE and ApoE4 levels nor the ApoE/ApoE4 ratio correlated with the diagnosis of AD. These findings reinforce the conclusions of previous studies in which plasma ApoE levels had no obvious clinical significance.", "qas": [{"question": "Which ApoE isoform is associated with atherosclerosis and Alzheimer's disease?", "answers": ["ApoE4 isoform", "Apolipoprotein E4 isoform"], "qid": "2594b3b5c34d4b7f830baf5eb3094b4c", "question_tokens": [["Which", 0], ["ApoE", 6], ["isoform", 11], ["is", 19], ["associated", 22], ["with", 33], ["atherosclerosis", 38], ["and", 54], ["Alzheimer", 58], ["'s", 67], ["disease", 70], ["?", 77]], "detected_answers": [{"text": "ApoE4 isoform", "token_spans": [[286, 287]], "char_spans": [[1598, 1610]]}]}], "context_tokens": [["Allelic", 0], ["polymorphism", 8], ["of", 21], ["the", 24], ["apolipoprotein", 28], ["E", 43], ["(", 45], ["ApoE", 46], [")", 50], ["gene", 52], ["(", 57], ["ApoE", 58], ["\u03b52", 63], [",", 65], ["ApoE", 67], ["\u03b53", 72], ["and", 75], ["ApoE", 79], ["\u03b54", 84], ["alleles", 87], [")", 94], ["gives", 96], ["rise", 102], ["to", 107], ["three", 110], ["protein", 116], ["isoforms", 124], ["(", 133], ["ApoE2", 134], [",", 139], ["ApoE3", 141], ["and", 147], ["ApoE4", 151], [")", 156], ["that", 158], ["differ", 163], ["by", 170], ["1", 173], ["or", 175], ["2", 178], ["amino", 180], ["acids", 186], [".", 191], ["Inheritance", 193], ["of", 205], ["the", 208], ["ApoE", 212], ["\u03b54", 217], ["allele", 220], ["is", 227], ["a", 230], ["risk", 232], ["factor", 237], ["for", 244], ["developing", 248], ["Alzheimer", 259], ["'s", 268], ["disease", 271], ["(", 279], ["AD", 280], [")", 282], [".", 283], ["The", 285], ["potential", 289], ["diagnostic", 299], ["value", 310], ["of", 316], ["ApoE", 319], ["protein", 324], ["levels", 332], ["in", 339], ["biological", 342], ["fluids", 353], ["(", 360], ["i.e.", 361], ["cerebrospinal", 366], ["fluid", 380], [",", 385], ["plasma", 387], ["and", 394], ["serum", 398], [")", 403], ["for", 405], ["distinguishing", 409], ["between", 424], ["AD", 432], ["patients", 435], ["and", 444], ["healthy", 448], ["elderly", 456], ["subjects", 464], ["is", 473], ["subject", 476], ["to", 484], ["great", 487], ["controversy", 493], [".", 504], ["Although", 506], ["a", 515], ["recent", 517], ["study", 524], ["reported", 530], ["subnormal", 539], ["total", 549], ["ApoE", 555], ["and", 560], ["ApoE4", 564], ["levels", 570], ["in", 577], ["the", 580], ["plasma", 584], ["of", 591], ["AD", 594], ["patients", 597], [",", 605], ["other", 607], ["studies", 613], ["have", 621], ["found", 626], ["normal", 632], ["or", 639], ["even", 642], ["elevated", 647], ["protein", 656], ["levels", 664], ["(", 671], ["versus", 672], ["controls", 679], [")", 687], [".", 688], ["Because", 690], ["all", 698], ["previously", 702], ["reported", 713], ["assays", 722], ["were", 729], ["based", 734], ["on", 740], ["immunoenzymatic", 743], ["techniques", 759], [",", 769], ["we", 771], ["decided", 774], ["to", 782], ["develop", 785], ["an", 793], ["orthogonal", 796], ["assay", 807], ["based", 813], ["on", 819], ["targeted", 822], ["mass", 831], ["spectrometry", 836], ["by", 849], ["tracking", 852], ["(", 861], ["i", 862], [")", 863], ["a", 865], ["proteotypic", 867], ["peptide", 879], ["common", 887], ["to", 894], ["all", 897], ["ApoE", 901], ["isoforms", 906], ["and", 915], ["(", 919], ["ii", 920], [")", 922], ["a", 924], ["peptide", 926], ["that", 934], ["is", 939], ["specific", 942], ["for", 951], ["the", 955], ["\u03b54", 959], ["allele", 962], [".", 968], ["After", 970], ["trypsin", 976], ["digestion", 984], [",", 993], ["the", 995], ["ApoE4-specific", 999], ["peptide", 1014], ["contains", 1022], ["an", 1031], ["oxidation", 1034], ["-", 1043], ["prone", 1044], ["methionine", 1050], ["residue", 1061], [".", 1068], ["The", 1070], ["endogenous", 1074], ["methionine", 1085], ["oxidation", 1096], ["level", 1106], ["was", 1112], ["evaluated", 1116], ["in", 1126], ["a", 1129], ["small", 1131], ["cohort", 1137], ["(", 1144], ["n=68", 1145], [")", 1149], ["of", 1151], ["heterozygous", 1154], ["\u03b53\u03b54", 1167], ["carriers", 1172], ["containing", 1181], ["both", 1192], ["healthy", 1197], ["controls", 1205], ["and", 1214], ["AD", 1218], ["patients", 1221], [".", 1229], ["As", 1231], ["expected", 1234], [",", 1242], ["the", 1244], ["proportion", 1248], ["of", 1259], ["oxidized", 1262], ["residues", 1271], ["varied", 1280], ["from", 1287], ["0", 1292], ["to", 1294], ["10", 1297], ["%", 1299], [",", 1300], ["with", 1302], ["an", 1307], ["average", 1310], ["of", 1318], ["5", 1321], ["%", 1322], [".", 1323], ["We", 1325], ["therefore", 1328], ["developed", 1338], ["a", 1348], ["standardized", 1350], ["strategy", 1363], ["for", 1372], ["the", 1376], ["unbiased", 1380], [",", 1388], ["absolute", 1390], ["quantification", 1399], ["of", 1414], ["ApoE4", 1417], [",", 1422], ["based", 1424], ["on", 1430], ["performic", 1433], ["acid", 1443], ["oxidization", 1448], ["of", 1460], ["methionine", 1463], [".", 1473], ["Once", 1475], ["the", 1480], ["sample", 1484], ["workflow", 1491], ["had", 1500], ["been", 1504], ["thoroughly", 1509], ["validated", 1520], [",", 1529], ["it", 1531], ["was", 1534], ["applied", 1538], ["to", 1546], ["the", 1549], ["concomitant", 1553], ["quantification", 1565], ["of", 1580], ["total", 1583], ["ApoE", 1589], ["and", 1594], ["ApoE4", 1598], ["isoform", 1604], ["in", 1612], ["a", 1615], ["large", 1617], ["case", 1623], ["-", 1627], ["control", 1628], ["study", 1636], ["(", 1642], ["n=669", 1643], [")", 1648], [".", 1649], ["The", 1651], ["final", 1655], ["measurements", 1661], ["were", 1674], ["consistent", 1679], ["with", 1690], ["most", 1695], ["previously", 1700], ["reported", 1711], ["ApoE", 1720], ["concentration", 1725], ["values", 1739], ["and", 1746], ["confirm", 1750], ["the", 1758], ["influence", 1762], ["of", 1772], ["the", 1775], ["different", 1779], ["alleles", 1789], ["on", 1797], ["the", 1800], ["protein", 1804], ["expression", 1812], ["level", 1823], [".", 1828], ["Our", 1830], ["results", 1834], ["illustrate", 1842], ["(", 1853], ["i", 1854], [")", 1855], ["the", 1857], ["reliability", 1861], ["of", 1873], ["selected", 1876], ["reaction", 1885], ["monitoring", 1894], ["-", 1904], ["based", 1905], ["assays", 1911], ["and", 1918], ["(", 1922], ["ii", 1923], [")", 1925], ["the", 1927], ["value", 1931], ["of", 1937], ["the", 1940], ["oxidization", 1944], ["step", 1956], ["for", 1961], ["unbiased", 1965], ["monitoring", 1974], ["of", 1985], ["methionine", 1988], ["-", 1998], ["containing", 1999], ["proteotypic", 2010], ["peptides", 2022], [".", 2030], ["Furthermore", 2032], [",", 2043], ["a", 2045], ["statistical", 2047], ["analysis", 2059], ["indicated", 2068], ["that", 2078], ["neither", 2083], ["total", 2091], ["ApoE", 2097], ["and", 2102], ["ApoE4", 2106], ["levels", 2112], ["nor", 2119], ["the", 2123], ["ApoE", 2127], ["/", 2131], ["ApoE4", 2132], ["ratio", 2138], ["correlated", 2144], ["with", 2155], ["the", 2160], ["diagnosis", 2164], ["of", 2174], ["AD", 2177], [".", 2179], ["These", 2181], ["findings", 2187], ["reinforce", 2196], ["the", 2206], ["conclusions", 2210], ["of", 2222], ["previous", 2225], ["studies", 2234], ["in", 2242], ["which", 2245], ["plasma", 2251], ["ApoE", 2258], ["levels", 2263], ["had", 2270], ["no", 2274], ["obvious", 2277], ["clinical", 2285], ["significance", 2294], [".", 2306]]}
{"context": "The generation of reactive oxygen species (ROS) is required for proper cell signaling, but must be tightly regulated to minimize deleterious oxidizing effects. Activation of the NADPH oxidases (Nox) triggers ROS production and, thus, regulatory mechanisms exist to properly control Nox activity. In this study, we report a novel mechanism in which Nox1 activity is regulated through the proteasomal degradation of Nox organizer 1 (NoxO1). We found that through the interaction between NoxO1 and growth receptor-bound protein 2 (Grb2), the Casitas B-lineage lymphoma (Cbl) E3 ligase was recruited, leading to decreased NoxO1 stability and a subsequent reduction in ROS generation upon epidermal growth factor (EGF) stimulation. Additionally, we show that EGF-mediated phosphorylation of NoxO1 induced its release from Grb2 and facilitated its association with Nox activator 1 (NoxA1) to stimulate ROS production. Consistently, overexpression of Grb2 resulted in decreased Nox1 activity, whereas knockdown of Grb2 led to increased Nox1 activity in response to EGF. CRISPR/Cas9-mediated NoxO1 knockout in human colon cancer cells abrogated anchorage-independent growth on soft agar and tumor-forming ability in athymic nude mice. Moreover, the expression and stability of NoxO1 were significantly increased in human colon cancer tissues compared with normal colon. Taken together, these results support a model whereby Nox1 activity and ROS generation are regulated by Grb2/Cbl-mediated proteolysis of NoxO1 in response to EGF, providing new insight into the processes by which excessive ROS production may promote oncogenic signaling to drive colorectal tumorigenesis.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "9017897d71c2434d90f474f17544eebd", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NOX1", "token_spans": [[172, 172], [247, 247], [182, 182], [62, 62]], "char_spans": [[971, 974], [1416, 1419], [1029, 1032], [348, 351]]}]}], "context_tokens": [["The", 0], ["generation", 4], ["of", 15], ["reactive", 18], ["oxygen", 27], ["species", 34], ["(", 42], ["ROS", 43], [")", 46], ["is", 48], ["required", 51], ["for", 60], ["proper", 64], ["cell", 71], ["signaling", 76], [",", 85], ["but", 87], ["must", 91], ["be", 96], ["tightly", 99], ["regulated", 107], ["to", 117], ["minimize", 120], ["deleterious", 129], ["oxidizing", 141], ["effects", 151], [".", 158], ["Activation", 160], ["of", 171], ["the", 174], ["NADPH", 178], ["oxidases", 184], ["(", 193], ["Nox", 194], [")", 197], ["triggers", 199], ["ROS", 208], ["production", 212], ["and", 223], [",", 226], ["thus", 228], [",", 232], ["regulatory", 234], ["mechanisms", 245], ["exist", 256], ["to", 262], ["properly", 265], ["control", 274], ["Nox", 282], ["activity", 286], [".", 294], ["In", 296], ["this", 299], ["study", 304], [",", 309], ["we", 311], ["report", 314], ["a", 321], ["novel", 323], ["mechanism", 329], ["in", 339], ["which", 342], ["Nox1", 348], ["activity", 353], ["is", 362], ["regulated", 365], ["through", 375], ["the", 383], ["proteasomal", 387], ["degradation", 399], ["of", 411], ["Nox", 414], ["organizer", 418], ["1", 428], ["(", 430], ["NoxO1", 431], [")", 436], [".", 437], ["We", 439], ["found", 442], ["that", 448], ["through", 453], ["the", 461], ["interaction", 465], ["between", 477], ["NoxO1", 485], ["and", 491], ["growth", 495], ["receptor", 502], ["-", 510], ["bound", 511], ["protein", 517], ["2", 525], ["(", 527], ["Grb2", 528], [")", 532], [",", 533], ["the", 535], ["Casitas", 539], ["B", 547], ["-", 548], ["lineage", 549], ["lymphoma", 557], ["(", 566], ["Cbl", 567], [")", 570], ["E3", 572], ["ligase", 575], ["was", 582], ["recruited", 586], [",", 595], ["leading", 597], ["to", 605], ["decreased", 608], ["NoxO1", 618], ["stability", 624], ["and", 634], ["a", 638], ["subsequent", 640], ["reduction", 651], ["in", 661], ["ROS", 664], ["generation", 668], ["upon", 679], ["epidermal", 684], ["growth", 694], ["factor", 701], ["(", 708], ["EGF", 709], [")", 712], ["stimulation", 714], [".", 725], ["Additionally", 727], [",", 739], ["we", 741], ["show", 744], ["that", 749], ["EGF", 754], ["-", 757], ["mediated", 758], ["phosphorylation", 767], ["of", 783], ["NoxO1", 786], ["induced", 792], ["its", 800], ["release", 804], ["from", 812], ["Grb2", 817], ["and", 822], ["facilitated", 826], ["its", 838], ["association", 842], ["with", 854], ["Nox", 859], ["activator", 863], ["1", 873], ["(", 875], ["NoxA1", 876], [")", 881], ["to", 883], ["stimulate", 886], ["ROS", 896], ["production", 900], [".", 910], ["Consistently", 912], [",", 924], ["overexpression", 926], ["of", 941], ["Grb2", 944], ["resulted", 949], ["in", 958], ["decreased", 961], ["Nox1", 971], ["activity", 976], [",", 984], ["whereas", 986], ["knockdown", 994], ["of", 1004], ["Grb2", 1007], ["led", 1012], ["to", 1016], ["increased", 1019], ["Nox1", 1029], ["activity", 1034], ["in", 1043], ["response", 1046], ["to", 1055], ["EGF", 1058], [".", 1061], ["CRISPR", 1063], ["/", 1069], ["Cas9-mediated", 1070], ["NoxO1", 1084], ["knockout", 1090], ["in", 1099], ["human", 1102], ["colon", 1108], ["cancer", 1114], ["cells", 1121], ["abrogated", 1127], ["anchorage", 1137], ["-", 1146], ["independent", 1147], ["growth", 1159], ["on", 1166], ["soft", 1169], ["agar", 1174], ["and", 1179], ["tumor", 1183], ["-", 1188], ["forming", 1189], ["ability", 1197], ["in", 1205], ["athymic", 1208], ["nude", 1216], ["mice", 1221], [".", 1225], ["Moreover", 1227], [",", 1235], ["the", 1237], ["expression", 1241], ["and", 1252], ["stability", 1256], ["of", 1266], ["NoxO1", 1269], ["were", 1275], ["significantly", 1280], ["increased", 1294], ["in", 1304], ["human", 1307], ["colon", 1313], ["cancer", 1319], ["tissues", 1326], ["compared", 1334], ["with", 1343], ["normal", 1348], ["colon", 1355], [".", 1360], ["Taken", 1362], ["together", 1368], [",", 1376], ["these", 1378], ["results", 1384], ["support", 1392], ["a", 1400], ["model", 1402], ["whereby", 1408], ["Nox1", 1416], ["activity", 1421], ["and", 1430], ["ROS", 1434], ["generation", 1438], ["are", 1449], ["regulated", 1453], ["by", 1463], ["Grb2/Cbl", 1466], ["-", 1474], ["mediated", 1475], ["proteolysis", 1484], ["of", 1496], ["NoxO1", 1499], ["in", 1505], ["response", 1508], ["to", 1517], ["EGF", 1520], [",", 1523], ["providing", 1525], ["new", 1535], ["insight", 1539], ["into", 1547], ["the", 1552], ["processes", 1556], ["by", 1566], ["which", 1569], ["excessive", 1575], ["ROS", 1585], ["production", 1589], ["may", 1600], ["promote", 1604], ["oncogenic", 1612], ["signaling", 1622], ["to", 1632], ["drive", 1635], ["colorectal", 1641], ["tumorigenesis", 1652], [".", 1665]]}
{"context": "Methylation of lysine residues in the N-terminal tails of histones is thought to represent an important component of the mechanism that regulates chromatin structure. The evolutionarily conserved SET domain occurs in most proteins known to possess histone lysine methyltransferase activity. We present here the crystal structure of a large fragment of human SET7/9 that contains a N-terminal beta-sheet domain as well as the conserved SET domain. Mutagenesis identifies two residues in the C terminus of the protein that appear essential for catalytic activity toward lysine-4 of histone H3. Furthermore, we show how the cofactor AdoMet binds to this domain and present biochemical data supporting the role of invariant residues in catalysis, binding of AdoMet, and interactions with the peptide substrate.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "3f7b340bb0f840e98a015f2346104288", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[72, 73], [30, 31]], "char_spans": [[435, 444], [196, 205]]}]}], "context_tokens": [["Methylation", 0], ["of", 12], ["lysine", 15], ["residues", 22], ["in", 31], ["the", 34], ["N", 38], ["-", 39], ["terminal", 40], ["tails", 49], ["of", 55], ["histones", 58], ["is", 67], ["thought", 70], ["to", 78], ["represent", 81], ["an", 91], ["important", 94], ["component", 104], ["of", 114], ["the", 117], ["mechanism", 121], ["that", 131], ["regulates", 136], ["chromatin", 146], ["structure", 156], [".", 165], ["The", 167], ["evolutionarily", 171], ["conserved", 186], ["SET", 196], ["domain", 200], ["occurs", 207], ["in", 214], ["most", 217], ["proteins", 222], ["known", 231], ["to", 237], ["possess", 240], ["histone", 248], ["lysine", 256], ["methyltransferase", 263], ["activity", 281], [".", 289], ["We", 291], ["present", 294], ["here", 302], ["the", 307], ["crystal", 311], ["structure", 319], ["of", 329], ["a", 332], ["large", 334], ["fragment", 340], ["of", 349], ["human", 352], ["SET7/9", 358], ["that", 365], ["contains", 370], ["a", 379], ["N", 381], ["-", 382], ["terminal", 383], ["beta", 392], ["-", 396], ["sheet", 397], ["domain", 403], ["as", 410], ["well", 413], ["as", 418], ["the", 421], ["conserved", 425], ["SET", 435], ["domain", 439], [".", 445], ["Mutagenesis", 447], ["identifies", 459], ["two", 470], ["residues", 474], ["in", 483], ["the", 486], ["C", 490], ["terminus", 492], ["of", 501], ["the", 504], ["protein", 508], ["that", 516], ["appear", 521], ["essential", 528], ["for", 538], ["catalytic", 542], ["activity", 552], ["toward", 561], ["lysine-4", 568], ["of", 577], ["histone", 580], ["H3", 588], [".", 590], ["Furthermore", 592], [",", 603], ["we", 605], ["show", 608], ["how", 613], ["the", 617], ["cofactor", 621], ["AdoMet", 630], ["binds", 637], ["to", 643], ["this", 646], ["domain", 651], ["and", 658], ["present", 662], ["biochemical", 670], ["data", 682], ["supporting", 687], ["the", 698], ["role", 702], ["of", 707], ["invariant", 710], ["residues", 720], ["in", 729], ["catalysis", 732], [",", 741], ["binding", 743], ["of", 751], ["AdoMet", 754], [",", 760], ["and", 762], ["interactions", 766], ["with", 779], ["the", 784], ["peptide", 788], ["substrate", 796], [".", 805]]}
{"context": "We have determined sequences of PCR-amplified B1 elements from hamster and rat (Myomorpha), chipmunk (Sciuromorpha), and guinea pig (Caviomorpha). Between three and six B1 subfamilies were found in these species. In the phylogenetic analysis B1 sequences of hamster, mouse, and rat clustered separately from those of chipmunk and those of guinea pig. This is consistent with an independent evolution of B1 elements in separate rodent lineages. We exclude the possibility of convergent mutations to explain certain diagnostic characters within the modern B1 quasi-dimers and view these elements as mosaic structures assembling preexisting mutations. Furthermore, the presence of Alu-like structural motifs supports the hypothesis of the monophyletic origin of Alu and B1 repeats, i.e., from a common 7SL RNA-derived retroposing monomeric element.", "qas": [{"question": "From which sequence does the Alu repeat originate from?", "answers": ["7SL RNA"], "qid": "e4f9aab09e074c42b56d239bd1ea6bf9", "question_tokens": [["From", 0], ["which", 5], ["sequence", 11], ["does", 20], ["the", 25], ["Alu", 29], ["repeat", 33], ["originate", 40], ["from", 50], ["?", 54]], "detected_answers": [{"text": "7SL RNA", "token_spans": [[140, 141]], "char_spans": [[799, 805]]}]}], "context_tokens": [["We", 0], ["have", 3], ["determined", 8], ["sequences", 19], ["of", 29], ["PCR", 32], ["-", 35], ["amplified", 36], ["B1", 46], ["elements", 49], ["from", 58], ["hamster", 63], ["and", 71], ["rat", 75], ["(", 79], ["Myomorpha", 80], [")", 89], [",", 90], ["chipmunk", 92], ["(", 101], ["Sciuromorpha", 102], [")", 114], [",", 115], ["and", 117], ["guinea", 121], ["pig", 128], ["(", 132], ["Caviomorpha", 133], [")", 144], [".", 145], ["Between", 147], ["three", 155], ["and", 161], ["six", 165], ["B1", 169], ["subfamilies", 172], ["were", 184], ["found", 189], ["in", 195], ["these", 198], ["species", 204], [".", 211], ["In", 213], ["the", 216], ["phylogenetic", 220], ["analysis", 233], ["B1", 242], ["sequences", 245], ["of", 255], ["hamster", 258], [",", 265], ["mouse", 267], [",", 272], ["and", 274], ["rat", 278], ["clustered", 282], ["separately", 292], ["from", 303], ["those", 308], ["of", 314], ["chipmunk", 317], ["and", 326], ["those", 330], ["of", 336], ["guinea", 339], ["pig", 346], [".", 349], ["This", 351], ["is", 356], ["consistent", 359], ["with", 370], ["an", 375], ["independent", 378], ["evolution", 390], ["of", 400], ["B1", 403], ["elements", 406], ["in", 415], ["separate", 418], ["rodent", 427], ["lineages", 434], [".", 442], ["We", 444], ["exclude", 447], ["the", 455], ["possibility", 459], ["of", 471], ["convergent", 474], ["mutations", 485], ["to", 495], ["explain", 498], ["certain", 506], ["diagnostic", 514], ["characters", 525], ["within", 536], ["the", 543], ["modern", 547], ["B1", 554], ["quasi", 557], ["-", 562], ["dimers", 563], ["and", 570], ["view", 574], ["these", 579], ["elements", 585], ["as", 594], ["mosaic", 597], ["structures", 604], ["assembling", 615], ["preexisting", 626], ["mutations", 638], [".", 647], ["Furthermore", 649], [",", 660], ["the", 662], ["presence", 666], ["of", 675], ["Alu", 678], ["-", 681], ["like", 682], ["structural", 687], ["motifs", 698], ["supports", 705], ["the", 714], ["hypothesis", 718], ["of", 729], ["the", 732], ["monophyletic", 736], ["origin", 749], ["of", 756], ["Alu", 759], ["and", 763], ["B1", 767], ["repeats", 770], [",", 777], ["i.e.", 779], [",", 783], ["from", 785], ["a", 790], ["common", 792], ["7SL", 799], ["RNA", 803], ["-", 806], ["derived", 807], ["retroposing", 815], ["monomeric", 827], ["element", 837], [".", 844]]}
{"context": "Fluorescence in situ hybridization (FISH) technique has been successfully used to detect the BCR-ABL gene fusion in chronic myeloid leukemia (CML) with the classic form of the Philadelphia chromosome (Ph). We applied FISH to study three CML patients showing variant Ph chromosome (either complex or simple type). The results demonstrate that the use of a yeast artificial chromosome (YAC)-derived probe (D107F9) and a cosmid probe (cos-abl 8), specific for BCR and ABL genes respectively, allows also the detection of the BCR-ABL fusion in CML patients with variant Ph.", "qas": [{"question": "Which gene fusion is the result of the \"philadelphia translocation\" or the \"philadelphia chromosome\" mutation?", "answers": ["The BCR/ABL gene fusion", "ABL/BCR fusion"], "qid": "97cb4d97afcb4eb2952fd63b3de90dbf", "question_tokens": [["Which", 0], ["gene", 6], ["fusion", 11], ["is", 18], ["the", 21], ["result", 25], ["of", 32], ["the", 35], ["\"", 39], ["philadelphia", 40], ["translocation", 53], ["\"", 66], ["or", 68], ["the", 71], ["\"", 75], ["philadelphia", 76], ["chromosome", 89], ["\"", 99], ["mutation", 101], ["?", 109]], "detected_answers": [{"text": "The BCR/ABL gene fusion", "token_spans": [[15, 19]], "char_spans": [[93, 111]]}]}], "context_tokens": [["Fluorescence", 0], ["in", 13], ["situ", 16], ["hybridization", 21], ["(", 35], ["FISH", 36], [")", 40], ["technique", 42], ["has", 52], ["been", 56], ["successfully", 61], ["used", 74], ["to", 79], ["detect", 82], ["the", 89], ["BCR", 93], ["-", 96], ["ABL", 97], ["gene", 101], ["fusion", 106], ["in", 113], ["chronic", 116], ["myeloid", 124], ["leukemia", 132], ["(", 141], ["CML", 142], [")", 145], ["with", 147], ["the", 152], ["classic", 156], ["form", 164], ["of", 169], ["the", 172], ["Philadelphia", 176], ["chromosome", 189], ["(", 200], ["Ph", 201], [")", 203], [".", 204], ["We", 206], ["applied", 209], ["FISH", 217], ["to", 222], ["study", 225], ["three", 231], ["CML", 237], ["patients", 241], ["showing", 250], ["variant", 258], ["Ph", 266], ["chromosome", 269], ["(", 280], ["either", 281], ["complex", 288], ["or", 296], ["simple", 299], ["type", 306], [")", 310], [".", 311], ["The", 313], ["results", 317], ["demonstrate", 325], ["that", 337], ["the", 342], ["use", 346], ["of", 350], ["a", 353], ["yeast", 355], ["artificial", 361], ["chromosome", 372], ["(", 383], ["YAC)-derived", 384], ["probe", 397], ["(", 403], ["D107F9", 404], [")", 410], ["and", 412], ["a", 416], ["cosmid", 418], ["probe", 425], ["(", 431], ["cos", 432], ["-", 435], ["abl", 436], ["8)", 440], [",", 442], ["specific", 444], ["for", 453], ["BCR", 457], ["and", 461], ["ABL", 465], ["genes", 469], ["respectively", 475], [",", 487], ["allows", 489], ["also", 496], ["the", 501], ["detection", 505], ["of", 515], ["the", 518], ["BCR", 522], ["-", 525], ["ABL", 526], ["fusion", 530], ["in", 537], ["CML", 540], ["patients", 544], ["with", 553], ["variant", 558], ["Ph", 566], [".", 568]]}
{"context": "The Malaria Policy Advisory Committee to the World Health Organization met in Geneva, Switzerland from 13 to 15 March, 2013. This article provides a summary of the discussions, conclusions and recommendations from that meeting.Meeting sessions included: a review of the efficacy of artemisinin-based combination therapy in Guyana and Suriname; the outcomes from a consultation on non-malaria febrile illness; the outcomes from the second meeting of the Evidence Review Group on malaria burden estimation; an update on the review of the WHO Guidelines for the Treatment of Malaria; an update regarding progress on the constitution of the vector control Technical Expert Group; updates on the RTS, S/AS01 vaccine and the malaria vaccine technology roadmap; financing and resource allocation for malaria control; malaria surveillance and the need for a surveillance, monitoring and evaluation Technical Expert Group; criteria and classification related to malaria elimination; the next meeting of the Evidence Review Group on Intermittent Preventive Treatment in pregnancy; an update on the soon-to-be launched Elimination Scenario Planning Tool; and an update on the process for the Global Technical Strategy for Malaria Control and Elimination (2016-2025).Policy statements, position statements, and guidelines that arise from the MPAC meeting conclusions and recommendations will be formally issued and disseminated to World Health Organization Member States by the World Health Organization Global Malaria Programme.", "qas": [{"question": "RTS S AS01 vaccine was developed to prevent which disease?", "answers": ["malaria"], "qid": "08c2300228d848599dbb36a771fdc904", "question_tokens": [["RTS", 0], ["S", 4], ["AS01", 6], ["vaccine", 11], ["was", 19], ["developed", 23], ["to", 33], ["prevent", 36], ["which", 44], ["disease", 50], ["?", 57]], "detected_answers": [{"text": "malaria", "token_spans": [[128, 128], [83, 83], [67, 67], [138, 138], [141, 141], [100, 100], [249, 249], [162, 162], [1, 1], [207, 207]], "char_spans": [[719, 725], [478, 484], [384, 390], [793, 799], [810, 816], [572, 578], [1499, 1505], [953, 959], [4, 10], [1211, 1217]]}]}], "context_tokens": [["The", 0], ["Malaria", 4], ["Policy", 12], ["Advisory", 19], ["Committee", 28], ["to", 38], ["the", 41], ["World", 45], ["Health", 51], ["Organization", 58], ["met", 71], ["in", 75], ["Geneva", 78], [",", 84], ["Switzerland", 86], ["from", 98], ["13", 103], ["to", 106], ["15", 109], ["March", 112], [",", 117], ["2013", 119], [".", 123], ["This", 125], ["article", 130], ["provides", 138], ["a", 147], ["summary", 149], ["of", 157], ["the", 160], ["discussions", 164], [",", 175], ["conclusions", 177], ["and", 189], ["recommendations", 193], ["from", 209], ["that", 214], ["meeting", 219], [".", 226], ["Meeting", 227], ["sessions", 235], ["included", 244], [":", 252], ["a", 254], ["review", 256], ["of", 263], ["the", 266], ["efficacy", 270], ["of", 279], ["artemisinin", 282], ["-", 293], ["based", 294], ["combination", 300], ["therapy", 312], ["in", 320], ["Guyana", 323], ["and", 330], ["Suriname", 334], [";", 342], ["the", 344], ["outcomes", 348], ["from", 357], ["a", 362], ["consultation", 364], ["on", 377], ["non", 380], ["-", 383], ["malaria", 384], ["febrile", 392], ["illness", 400], [";", 407], ["the", 409], ["outcomes", 413], ["from", 422], ["the", 427], ["second", 431], ["meeting", 438], ["of", 446], ["the", 449], ["Evidence", 453], ["Review", 462], ["Group", 469], ["on", 475], ["malaria", 478], ["burden", 486], ["estimation", 493], [";", 503], ["an", 505], ["update", 508], ["on", 515], ["the", 518], ["review", 522], ["of", 529], ["the", 532], ["WHO", 536], ["Guidelines", 540], ["for", 551], ["the", 555], ["Treatment", 559], ["of", 569], ["Malaria", 572], [";", 579], ["an", 581], ["update", 584], ["regarding", 591], ["progress", 601], ["on", 610], ["the", 613], ["constitution", 617], ["of", 630], ["the", 633], ["vector", 637], ["control", 644], ["Technical", 652], ["Expert", 662], ["Group", 669], [";", 674], ["updates", 676], ["on", 684], ["the", 687], ["RTS", 691], [",", 694], ["S", 696], ["/", 697], ["AS01", 698], ["vaccine", 703], ["and", 711], ["the", 715], ["malaria", 719], ["vaccine", 727], ["technology", 735], ["roadmap", 746], [";", 753], ["financing", 755], ["and", 765], ["resource", 769], ["allocation", 778], ["for", 789], ["malaria", 793], ["control", 801], [";", 808], ["malaria", 810], ["surveillance", 818], ["and", 831], ["the", 835], ["need", 839], ["for", 844], ["a", 848], ["surveillance", 850], [",", 862], ["monitoring", 864], ["and", 875], ["evaluation", 879], ["Technical", 890], ["Expert", 900], ["Group", 907], [";", 912], ["criteria", 914], ["and", 923], ["classification", 927], ["related", 942], ["to", 950], ["malaria", 953], ["elimination", 961], [";", 972], ["the", 974], ["next", 978], ["meeting", 983], ["of", 991], ["the", 994], ["Evidence", 998], ["Review", 1007], ["Group", 1014], ["on", 1020], ["Intermittent", 1023], ["Preventive", 1036], ["Treatment", 1047], ["in", 1057], ["pregnancy", 1060], [";", 1069], ["an", 1071], ["update", 1074], ["on", 1081], ["the", 1084], ["soon", 1088], ["-", 1092], ["to", 1093], ["-", 1095], ["be", 1096], ["launched", 1099], ["Elimination", 1108], ["Scenario", 1120], ["Planning", 1129], ["Tool", 1138], [";", 1142], ["and", 1144], ["an", 1148], ["update", 1151], ["on", 1158], ["the", 1161], ["process", 1165], ["for", 1173], ["the", 1177], ["Global", 1181], ["Technical", 1188], ["Strategy", 1198], ["for", 1207], ["Malaria", 1211], ["Control", 1219], ["and", 1227], ["Elimination", 1231], ["(", 1243], ["2016", 1244], ["-", 1248], ["2025).Policy", 1249], ["statements", 1262], [",", 1272], ["position", 1274], ["statements", 1283], [",", 1293], ["and", 1295], ["guidelines", 1299], ["that", 1310], ["arise", 1315], ["from", 1321], ["the", 1326], ["MPAC", 1330], ["meeting", 1335], ["conclusions", 1343], ["and", 1355], ["recommendations", 1359], ["will", 1375], ["be", 1380], ["formally", 1383], ["issued", 1392], ["and", 1399], ["disseminated", 1403], ["to", 1416], ["World", 1419], ["Health", 1425], ["Organization", 1432], ["Member", 1445], ["States", 1452], ["by", 1459], ["the", 1462], ["World", 1466], ["Health", 1472], ["Organization", 1479], ["Global", 1492], ["Malaria", 1499], ["Programme", 1507], [".", 1516]]}
{"context": "The organization of chromatin into higher-order structures influences chromosome function and epigenetic gene regulation. Higher-order chromatin has been proposed to be nucleated by the covalent modification of histone tails and the subsequent establishment of chromosomal subdomains by non-histone modifier factors. Here we show that human SUV39H1 and murine Suv39h1--mammalian homologues of Drosophila Su(var)3-9 and of Schizosaccharomyces pombe clr4--encode histone H3-specific methyltransferases that selectively methylate lysine 9 of the amino terminus of histone H3 in vitro. We mapped the catalytic motif to the evolutionarily conserved SET domain, which requires adjacent cysteine-rich regions to confer histone methyltransferase activity. Methylation of lysine 9 interferes with phosphorylation of serine 10, but is also influenced by pre-existing modifications in the amino terminus of H3. In vivo, deregulated SUV39H1 or disrupted Suv39h activity modulate H3 serine 10 phosphorylation in native chromatin and induce aberrant mitotic divisions. Our data reveal a functional interdependence of site-specific H3 tail modifications and suggest a dynamic mechanism for the regulation of higher-order chromatin.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "d2b96659e02a4db4a080036e2a0c4128", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[99, 100]], "char_spans": [[644, 653]]}]}], "context_tokens": [["The", 0], ["organization", 4], ["of", 17], ["chromatin", 20], ["into", 30], ["higher", 35], ["-", 41], ["order", 42], ["structures", 48], ["influences", 59], ["chromosome", 70], ["function", 81], ["and", 90], ["epigenetic", 94], ["gene", 105], ["regulation", 110], [".", 120], ["Higher", 122], ["-", 128], ["order", 129], ["chromatin", 135], ["has", 145], ["been", 149], ["proposed", 154], ["to", 163], ["be", 166], ["nucleated", 169], ["by", 179], ["the", 182], ["covalent", 186], ["modification", 195], ["of", 208], ["histone", 211], ["tails", 219], ["and", 225], ["the", 229], ["subsequent", 233], ["establishment", 244], ["of", 258], ["chromosomal", 261], ["subdomains", 273], ["by", 284], ["non", 287], ["-", 290], ["histone", 291], ["modifier", 299], ["factors", 308], [".", 315], ["Here", 317], ["we", 322], ["show", 325], ["that", 330], ["human", 335], ["SUV39H1", 341], ["and", 349], ["murine", 353], ["Suv39h1", 360], ["-", 367], ["-mammalian", 368], ["homologues", 379], ["of", 390], ["Drosophila", 393], ["Su(var)3", 404], ["-", 412], ["9", 413], ["and", 415], ["of", 419], ["Schizosaccharomyces", 422], ["pombe", 442], ["clr4", 448], ["-", 452], ["-encode", 453], ["histone", 461], ["H3-specific", 469], ["methyltransferases", 481], ["that", 500], ["selectively", 505], ["methylate", 517], ["lysine", 527], ["9", 534], ["of", 536], ["the", 539], ["amino", 543], ["terminus", 549], ["of", 558], ["histone", 561], ["H3", 569], ["in", 572], ["vitro", 575], [".", 580], ["We", 582], ["mapped", 585], ["the", 592], ["catalytic", 596], ["motif", 606], ["to", 612], ["the", 615], ["evolutionarily", 619], ["conserved", 634], ["SET", 644], ["domain", 648], [",", 654], ["which", 656], ["requires", 662], ["adjacent", 671], ["cysteine", 680], ["-", 688], ["rich", 689], ["regions", 694], ["to", 702], ["confer", 705], ["histone", 712], ["methyltransferase", 720], ["activity", 738], [".", 746], ["Methylation", 748], ["of", 760], ["lysine", 763], ["9", 770], ["interferes", 772], ["with", 783], ["phosphorylation", 788], ["of", 804], ["serine", 807], ["10", 814], [",", 816], ["but", 818], ["is", 822], ["also", 825], ["influenced", 830], ["by", 841], ["pre", 844], ["-", 847], ["existing", 848], ["modifications", 857], ["in", 871], ["the", 874], ["amino", 878], ["terminus", 884], ["of", 893], ["H3", 896], [".", 898], ["In", 900], ["vivo", 903], [",", 907], ["deregulated", 909], ["SUV39H1", 921], ["or", 929], ["disrupted", 932], ["Suv39h", 942], ["activity", 949], ["modulate", 958], ["H3", 967], ["serine", 970], ["10", 977], ["phosphorylation", 980], ["in", 996], ["native", 999], ["chromatin", 1006], ["and", 1016], ["induce", 1020], ["aberrant", 1027], ["mitotic", 1036], ["divisions", 1044], [".", 1053], ["Our", 1055], ["data", 1059], ["reveal", 1064], ["a", 1071], ["functional", 1073], ["interdependence", 1084], ["of", 1100], ["site", 1103], ["-", 1107], ["specific", 1108], ["H3", 1117], ["tail", 1120], ["modifications", 1125], ["and", 1139], ["suggest", 1143], ["a", 1151], ["dynamic", 1153], ["mechanism", 1161], ["for", 1171], ["the", 1175], ["regulation", 1179], ["of", 1190], ["higher", 1193], ["-", 1199], ["order", 1200], ["chromatin", 1206], [".", 1215]]}
{"context": "Haploinsufficiency of the NSD1 gene due to 5q35 microdeletions or intragenic mutations is the major cause of Sotos syndrome characterized by generalized overgrowth, large hands and feet with advanced bone age, craniofacial dysmorphic features, learning disability, and possible susceptibility to tumors. Here, we report on a 14-month-old boy with a reverse phenotype of Sotos syndrome due to the reciprocal duplication of the 5q35.3 region, including the NSD1 gene, detected by array CGH. The phenotype includes delayed bone age, microcephaly, seizures, and failure to thrive. Our case suggests that the gene dosage effect of the NSD1 gene is the likely cause for the reversed phenotype of Sotos syndrome in this patient.", "qas": [{"question": "Which gene is responsible for the development of Sotos syndrome?", "answers": ["NSD1 gene"], "qid": "4dacfcd587cf4e6f8eed4e508e7a454e", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["Sotos", 49], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "NSD1 gene", "token_spans": [[109, 110], [75, 76], [3, 4]], "char_spans": [[630, 638], [455, 463], [26, 34]]}]}], "context_tokens": [["Haploinsufficiency", 0], ["of", 19], ["the", 22], ["NSD1", 26], ["gene", 31], ["due", 36], ["to", 40], ["5q35", 43], ["microdeletions", 48], ["or", 63], ["intragenic", 66], ["mutations", 77], ["is", 87], ["the", 90], ["major", 94], ["cause", 100], ["of", 106], ["Sotos", 109], ["syndrome", 115], ["characterized", 124], ["by", 138], ["generalized", 141], ["overgrowth", 153], [",", 163], ["large", 165], ["hands", 171], ["and", 177], ["feet", 181], ["with", 186], ["advanced", 191], ["bone", 200], ["age", 205], [",", 208], ["craniofacial", 210], ["dysmorphic", 223], ["features", 234], [",", 242], ["learning", 244], ["disability", 253], [",", 263], ["and", 265], ["possible", 269], ["susceptibility", 278], ["to", 293], ["tumors", 296], [".", 302], ["Here", 304], [",", 308], ["we", 310], ["report", 313], ["on", 320], ["a", 323], ["14-month", 325], ["-", 333], ["old", 334], ["boy", 338], ["with", 342], ["a", 347], ["reverse", 349], ["phenotype", 357], ["of", 367], ["Sotos", 370], ["syndrome", 376], ["due", 385], ["to", 389], ["the", 392], ["reciprocal", 396], ["duplication", 407], ["of", 419], ["the", 422], ["5q35.3", 426], ["region", 433], [",", 439], ["including", 441], ["the", 451], ["NSD1", 455], ["gene", 460], [",", 464], ["detected", 466], ["by", 475], ["array", 478], ["CGH", 484], [".", 487], ["The", 489], ["phenotype", 493], ["includes", 503], ["delayed", 512], ["bone", 520], ["age", 525], [",", 528], ["microcephaly", 530], [",", 542], ["seizures", 544], [",", 552], ["and", 554], ["failure", 558], ["to", 566], ["thrive", 569], [".", 575], ["Our", 577], ["case", 581], ["suggests", 586], ["that", 595], ["the", 600], ["gene", 604], ["dosage", 609], ["effect", 616], ["of", 623], ["the", 626], ["NSD1", 630], ["gene", 635], ["is", 640], ["the", 643], ["likely", 647], ["cause", 654], ["for", 660], ["the", 664], ["reversed", 668], ["phenotype", 677], ["of", 687], ["Sotos", 690], ["syndrome", 696], ["in", 705], ["this", 708], ["patient", 713], [".", 720]]}
{"context": "Romano-Ward syndrome is an autosomal dominant long-QT syndrome (LQTS) that predisposes affected individuals to sudden death from tachyarrhythmias. We investigated the molecular basis of LQTS in a Taiwanese kindred. Clinical and genetic analyses revealed that a mutation was linked to the human ether-a-go-go-related gene (HERG). The coding sequences and exon-intron borders of HERG were amplified by means of polymerase chain reaction and subjected to single-strand conformation polymorphism (SSCP) analysis. An exon with an aberrant SSCP pattern was cloned and sequenced to study the molecular lesion. A C-->T transition in codon 614, leading to substitution of a valine for an alanine residue in the pore region of the HERG protein, was identified. Analysis with Bsp12861 endonuclease digestion showed the mutation to be present in all affected family members. Given that an unaffected paternal uncle had inherited the same allele from the grandfather as the proband's father, a de novo mutation had apparently occurred in the father and was transmitted to his offspring. In addition to offering presymptomatic genetic diagnosis, identification of the disease-causing mutation may suggest new therapeutic approaches for treatment and prevention of this cardiovascular disease.", "qas": [{"question": "What is the mode of inheritance of Romano Ward long QT syndrome?", "answers": ["autosomal dominant"], "qid": "d838cda896684309ac3a07c8d28d403e", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Romano", 35], ["Ward", 42], ["long", 47], ["QT", 52], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[6, 7]], "char_spans": [[27, 44]]}]}], "context_tokens": [["Romano", 0], ["-", 6], ["Ward", 7], ["syndrome", 12], ["is", 21], ["an", 24], ["autosomal", 27], ["dominant", 37], ["long", 46], ["-", 50], ["QT", 51], ["syndrome", 54], ["(", 63], ["LQTS", 64], [")", 68], ["that", 70], ["predisposes", 75], ["affected", 87], ["individuals", 96], ["to", 108], ["sudden", 111], ["death", 118], ["from", 124], ["tachyarrhythmias", 129], [".", 145], ["We", 147], ["investigated", 150], ["the", 163], ["molecular", 167], ["basis", 177], ["of", 183], ["LQTS", 186], ["in", 191], ["a", 194], ["Taiwanese", 196], ["kindred", 206], [".", 213], ["Clinical", 215], ["and", 224], ["genetic", 228], ["analyses", 236], ["revealed", 245], ["that", 254], ["a", 259], ["mutation", 261], ["was", 270], ["linked", 274], ["to", 281], ["the", 284], ["human", 288], ["ether", 294], ["-", 299], ["a", 300], ["-", 301], ["go", 302], ["-", 304], ["go", 305], ["-", 307], ["related", 308], ["gene", 316], ["(", 321], ["HERG", 322], [")", 326], [".", 327], ["The", 329], ["coding", 333], ["sequences", 340], ["and", 350], ["exon", 354], ["-", 358], ["intron", 359], ["borders", 366], ["of", 374], ["HERG", 377], ["were", 382], ["amplified", 387], ["by", 397], ["means", 400], ["of", 406], ["polymerase", 409], ["chain", 420], ["reaction", 426], ["and", 435], ["subjected", 439], ["to", 449], ["single", 452], ["-", 458], ["strand", 459], ["conformation", 466], ["polymorphism", 479], ["(", 492], ["SSCP", 493], [")", 497], ["analysis", 499], [".", 507], ["An", 509], ["exon", 512], ["with", 517], ["an", 522], ["aberrant", 525], ["SSCP", 534], ["pattern", 539], ["was", 547], ["cloned", 551], ["and", 558], ["sequenced", 562], ["to", 572], ["study", 575], ["the", 581], ["molecular", 585], ["lesion", 595], [".", 601], ["A", 603], ["C-->T", 605], ["transition", 611], ["in", 622], ["codon", 625], ["614", 631], [",", 634], ["leading", 636], ["to", 644], ["substitution", 647], ["of", 660], ["a", 663], ["valine", 665], ["for", 672], ["an", 676], ["alanine", 679], ["residue", 687], ["in", 695], ["the", 698], ["pore", 702], ["region", 707], ["of", 714], ["the", 717], ["HERG", 721], ["protein", 726], [",", 733], ["was", 735], ["identified", 739], [".", 749], ["Analysis", 751], ["with", 760], ["Bsp12861", 765], ["endonuclease", 774], ["digestion", 787], ["showed", 797], ["the", 804], ["mutation", 808], ["to", 817], ["be", 820], ["present", 823], ["in", 831], ["all", 834], ["affected", 838], ["family", 847], ["members", 854], [".", 861], ["Given", 863], ["that", 869], ["an", 874], ["unaffected", 877], ["paternal", 888], ["uncle", 897], ["had", 903], ["inherited", 907], ["the", 917], ["same", 921], ["allele", 926], ["from", 933], ["the", 938], ["grandfather", 942], ["as", 954], ["the", 957], ["proband", 961], ["'s", 968], ["father", 971], [",", 977], ["a", 979], ["de", 981], ["novo", 984], ["mutation", 989], ["had", 998], ["apparently", 1002], ["occurred", 1013], ["in", 1022], ["the", 1025], ["father", 1029], ["and", 1036], ["was", 1040], ["transmitted", 1044], ["to", 1056], ["his", 1059], ["offspring", 1063], [".", 1072], ["In", 1074], ["addition", 1077], ["to", 1086], ["offering", 1089], ["presymptomatic", 1098], ["genetic", 1113], ["diagnosis", 1121], [",", 1130], ["identification", 1132], ["of", 1147], ["the", 1150], ["disease", 1154], ["-", 1161], ["causing", 1162], ["mutation", 1170], ["may", 1179], ["suggest", 1183], ["new", 1191], ["therapeutic", 1195], ["approaches", 1207], ["for", 1218], ["treatment", 1222], ["and", 1232], ["prevention", 1236], ["of", 1247], ["this", 1250], ["cardiovascular", 1255], ["disease", 1270], [".", 1277]]}
{"context": "Facioscapulohumeral dystrophy (FSHD) is an autosomal-dominant disorder characterized by weakness of the face, upper arm, shoulder, and lower limb musculature, with an onset between the first and third decades. Coats disease is a congenital disorder of retinal vascular development characterized by unilateral peripheral retinal telangiectasia and progressive subretinal and intraretinal exudation. This condition has a predilection for children and is usually isolated. Retinal vascular changes similar to those seen in Coats disease have been demonstrated by fluorescein angiography in 40% to 75% of patients with FSHD. Most patients have asymptomatic retinal telangiectasia found at ocular screening in adulthood after diagnosis of FSHD. We report a 7-month-old infant with bilateral Coats-like retinopathy in which the eye disease was discovered before findings of FSHD were clinically evident. To our knowledge, this patient represents the youngest reported case of preclinical FSHD with ocular disease.", "qas": [{"question": "What is the mode of inheritance of Facioscapulohumeral muscular dystrophy (FSHD)?", "answers": ["autosomal-dominant", "autosomal dominant"], "qid": "a40ec3c2b8dd4fa4a955eb489be36aa0", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Facioscapulohumeral", 35], ["muscular", 55], ["dystrophy", 64], ["(", 74], ["FSHD", 75], [")", 79], ["?", 80]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[7, 9]], "char_spans": [[43, 60]]}]}], "context_tokens": [["Facioscapulohumeral", 0], ["dystrophy", 20], ["(", 30], ["FSHD", 31], [")", 35], ["is", 37], ["an", 40], ["autosomal", 43], ["-", 52], ["dominant", 53], ["disorder", 62], ["characterized", 71], ["by", 85], ["weakness", 88], ["of", 97], ["the", 100], ["face", 104], [",", 108], ["upper", 110], ["arm", 116], [",", 119], ["shoulder", 121], [",", 129], ["and", 131], ["lower", 135], ["limb", 141], ["musculature", 146], [",", 157], ["with", 159], ["an", 164], ["onset", 167], ["between", 173], ["the", 181], ["first", 185], ["and", 191], ["third", 195], ["decades", 201], [".", 208], ["Coats", 210], ["disease", 216], ["is", 224], ["a", 227], ["congenital", 229], ["disorder", 240], ["of", 249], ["retinal", 252], ["vascular", 260], ["development", 269], ["characterized", 281], ["by", 295], ["unilateral", 298], ["peripheral", 309], ["retinal", 320], ["telangiectasia", 328], ["and", 343], ["progressive", 347], ["subretinal", 359], ["and", 370], ["intraretinal", 374], ["exudation", 387], [".", 396], ["This", 398], ["condition", 403], ["has", 413], ["a", 417], ["predilection", 419], ["for", 432], ["children", 436], ["and", 445], ["is", 449], ["usually", 452], ["isolated", 460], [".", 468], ["Retinal", 470], ["vascular", 478], ["changes", 487], ["similar", 495], ["to", 503], ["those", 506], ["seen", 512], ["in", 517], ["Coats", 520], ["disease", 526], ["have", 534], ["been", 539], ["demonstrated", 544], ["by", 557], ["fluorescein", 560], ["angiography", 572], ["in", 584], ["40", 587], ["%", 589], ["to", 591], ["75", 594], ["%", 596], ["of", 598], ["patients", 601], ["with", 610], ["FSHD", 615], [".", 619], ["Most", 621], ["patients", 626], ["have", 635], ["asymptomatic", 640], ["retinal", 653], ["telangiectasia", 661], ["found", 676], ["at", 682], ["ocular", 685], ["screening", 692], ["in", 702], ["adulthood", 705], ["after", 715], ["diagnosis", 721], ["of", 731], ["FSHD", 734], [".", 738], ["We", 740], ["report", 743], ["a", 750], ["7-month", 752], ["-", 759], ["old", 760], ["infant", 764], ["with", 771], ["bilateral", 776], ["Coats", 786], ["-", 791], ["like", 792], ["retinopathy", 797], ["in", 809], ["which", 812], ["the", 818], ["eye", 822], ["disease", 826], ["was", 834], ["discovered", 838], ["before", 849], ["findings", 856], ["of", 865], ["FSHD", 868], ["were", 873], ["clinically", 878], ["evident", 889], [".", 896], ["To", 898], ["our", 901], ["knowledge", 905], [",", 914], ["this", 916], ["patient", 921], ["represents", 929], ["the", 940], ["youngest", 944], ["reported", 953], ["case", 962], ["of", 967], ["preclinical", 970], ["FSHD", 982], ["with", 987], ["ocular", 992], ["disease", 999], [".", 1006]]}
{"context": "To investigate whether gender is an independent factor associated with disease expression in early rheumatoid arthritis (RA) patients. 438 patients with early RA (disease duration less than one year) were studied. They all were patients with early RA who presented at the Rheumatology Clinic of the University Hospital of Ioannina during the period 1991-2000. All patients fulfilled the American College of Rheumatology criteria for RA. The demographic, clinical, laboratory, radiological and therapeutic characteristics of the disease at diagnosis, and at the last follow-up were analyzed according to gender. We studied 312 women and 126 men with early RA. The female to male ratio was 2.5:1 and the mean age at diagnosis was 49.4 +/- 14.9 years for women and 55.3 +/-15.6 years for men (P < 0.0003). Women had a longer duration of follow-up (P < 0.0003). There were no differences between genders in the general symptoms or the simmetricity of joint involvement at at disease onset. However at disease onset women had a higher erythrocyte sedimentation rate (ESR) (> 30 mm/1st hour), although there were no significant differences between the two groups concerninig the rest of the clinical, laboratory and radiological findings. At the last follow-up women still had a higher ESR (>30 min/1st hour), but no significant differences were found between the two groups concerning the rest of the parameters investigated independently of the follow-up duration. Finally, women and men showed the same degree of radiological changes and functional ability and were treated similarly except for the more frequent use of hydroxychloroquine in women. It seems that gender does not signficantly influence the expression of RA.", "qas": [{"question": "Is Rheumatoid Arthritis more common in men or women?", "answers": ["Women"], "qid": "b3aff0ff72834de8bbd3a3ca13a60532", "question_tokens": [["Is", 0], ["Rheumatoid", 3], ["Arthritis", 14], ["more", 24], ["common", 29], ["in", 36], ["men", 39], ["or", 43], ["women", 46], ["?", 51]], "detected_answers": [{"text": "Women", "token_spans": [[235, 235], [275, 275], [150, 150], [301, 301], [108, 108], [136, 136], [190, 190]], "char_spans": [[1255, 1259], [1470, 1474], [803, 807], [1639, 1643], [626, 630], [752, 756], [1011, 1015]]}]}], "context_tokens": [["To", 0], ["investigate", 3], ["whether", 15], ["gender", 23], ["is", 30], ["an", 33], ["independent", 36], ["factor", 48], ["associated", 55], ["with", 66], ["disease", 71], ["expression", 79], ["in", 90], ["early", 93], ["rheumatoid", 99], ["arthritis", 110], ["(", 120], ["RA", 121], [")", 123], ["patients", 125], [".", 133], ["438", 135], ["patients", 139], ["with", 148], ["early", 153], ["RA", 159], ["(", 162], ["disease", 163], ["duration", 171], ["less", 180], ["than", 185], ["one", 190], ["year", 194], [")", 198], ["were", 200], ["studied", 205], [".", 212], ["They", 214], ["all", 219], ["were", 223], ["patients", 228], ["with", 237], ["early", 242], ["RA", 248], ["who", 251], ["presented", 255], ["at", 265], ["the", 268], ["Rheumatology", 272], ["Clinic", 285], ["of", 292], ["the", 295], ["University", 299], ["Hospital", 310], ["of", 319], ["Ioannina", 322], ["during", 331], ["the", 338], ["period", 342], ["1991", 349], ["-", 353], ["2000", 354], [".", 358], ["All", 360], ["patients", 364], ["fulfilled", 373], ["the", 383], ["American", 387], ["College", 396], ["of", 404], ["Rheumatology", 407], ["criteria", 420], ["for", 429], ["RA", 433], [".", 435], ["The", 437], ["demographic", 441], [",", 452], ["clinical", 454], [",", 462], ["laboratory", 464], [",", 474], ["radiological", 476], ["and", 489], ["therapeutic", 493], ["characteristics", 505], ["of", 521], ["the", 524], ["disease", 528], ["at", 536], ["diagnosis", 539], [",", 548], ["and", 550], ["at", 554], ["the", 557], ["last", 561], ["follow", 566], ["-", 572], ["up", 573], ["were", 576], ["analyzed", 581], ["according", 590], ["to", 600], ["gender", 603], [".", 609], ["We", 611], ["studied", 614], ["312", 622], ["women", 626], ["and", 632], ["126", 636], ["men", 640], ["with", 644], ["early", 649], ["RA", 655], [".", 657], ["The", 659], ["female", 663], ["to", 670], ["male", 673], ["ratio", 678], ["was", 684], ["2.5:1", 688], ["and", 694], ["the", 698], ["mean", 702], ["age", 707], ["at", 711], ["diagnosis", 714], ["was", 724], ["49.4", 728], ["+", 733], ["/-", 734], ["14.9", 737], ["years", 742], ["for", 748], ["women", 752], ["and", 758], ["55.3", 762], ["+", 767], ["/-15.6", 768], ["years", 775], ["for", 781], ["men", 785], ["(", 789], ["P", 790], ["<", 792], ["0.0003", 794], [")", 800], [".", 801], ["Women", 803], ["had", 809], ["a", 813], ["longer", 815], ["duration", 822], ["of", 831], ["follow", 834], ["-", 840], ["up", 841], ["(", 844], ["P", 845], ["<", 847], ["0.0003", 849], [")", 855], [".", 856], ["There", 858], ["were", 864], ["no", 869], ["differences", 872], ["between", 884], ["genders", 892], ["in", 900], ["the", 903], ["general", 907], ["symptoms", 915], ["or", 924], ["the", 927], ["simmetricity", 931], ["of", 944], ["joint", 947], ["involvement", 953], ["at", 965], ["at", 968], ["disease", 971], ["onset", 979], [".", 984], ["However", 986], ["at", 994], ["disease", 997], ["onset", 1005], ["women", 1011], ["had", 1017], ["a", 1021], ["higher", 1023], ["erythrocyte", 1030], ["sedimentation", 1042], ["rate", 1056], ["(", 1061], ["ESR", 1062], [")", 1065], ["(", 1067], [">", 1068], ["30", 1070], ["mm/1st", 1073], ["hour", 1080], [")", 1084], [",", 1085], ["although", 1087], ["there", 1096], ["were", 1102], ["no", 1107], ["significant", 1110], ["differences", 1122], ["between", 1134], ["the", 1142], ["two", 1146], ["groups", 1150], ["concerninig", 1157], ["the", 1169], ["rest", 1173], ["of", 1178], ["the", 1181], ["clinical", 1185], [",", 1193], ["laboratory", 1195], ["and", 1206], ["radiological", 1210], ["findings", 1223], [".", 1231], ["At", 1233], ["the", 1236], ["last", 1240], ["follow", 1245], ["-", 1251], ["up", 1252], ["women", 1255], ["still", 1261], ["had", 1267], ["a", 1271], ["higher", 1273], ["ESR", 1280], ["(", 1284], [">", 1285], ["30", 1286], ["min/1st", 1289], ["hour", 1297], [")", 1301], [",", 1302], ["but", 1304], ["no", 1308], ["significant", 1311], ["differences", 1323], ["were", 1335], ["found", 1340], ["between", 1346], ["the", 1354], ["two", 1358], ["groups", 1362], ["concerning", 1369], ["the", 1380], ["rest", 1384], ["of", 1389], ["the", 1392], ["parameters", 1396], ["investigated", 1407], ["independently", 1420], ["of", 1434], ["the", 1437], ["follow", 1441], ["-", 1447], ["up", 1448], ["duration", 1451], [".", 1459], ["Finally", 1461], [",", 1468], ["women", 1470], ["and", 1476], ["men", 1480], ["showed", 1484], ["the", 1491], ["same", 1495], ["degree", 1500], ["of", 1507], ["radiological", 1510], ["changes", 1523], ["and", 1531], ["functional", 1535], ["ability", 1546], ["and", 1554], ["were", 1558], ["treated", 1563], ["similarly", 1571], ["except", 1581], ["for", 1588], ["the", 1592], ["more", 1596], ["frequent", 1601], ["use", 1610], ["of", 1614], ["hydroxychloroquine", 1617], ["in", 1636], ["women", 1639], [".", 1644], ["It", 1646], ["seems", 1649], ["that", 1655], ["gender", 1660], ["does", 1667], ["not", 1672], ["signficantly", 1676], ["influence", 1689], ["the", 1699], ["expression", 1703], ["of", 1714], ["RA", 1717], [".", 1719]]}
{"context": "Sleep disorders are frequent comorbidities in neurologic patients. This review focuses on clinical aspects and prognosis of 3 neurologic sleep disorders: narcolepsy, restless legs syndrome/Willis-Ekbom disease (RLS/WED), and REM sleep behavior disorder (RBD). Narcolepsy causes pervasive, enduring excessive daytime sleepiness, adversely affecting patients' daily functioning. RLS/WED is characterized by an uncomfortable urge to move the legs before sleep, often evolving toward augmentation and resulting in daylong bothersome symptoms. RBD causes potentially injurious dream enactment behaviors that often signify future evolution of overt synucleinopathy neurodegeneration in as many as 81% of patients. Timely recognition, referral for polysomnography, and longitudinal follow-up of narcolepsy, RLS/WED, and RBD patients are imperatives for neurologists in providing quality comprehensive patient care.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "2e85dc045cba4859af5eff8296aecc96", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[25, 27]], "char_spans": [[166, 187]]}]}], "context_tokens": [["Sleep", 0], ["disorders", 6], ["are", 16], ["frequent", 20], ["comorbidities", 29], ["in", 43], ["neurologic", 46], ["patients", 57], [".", 65], ["This", 67], ["review", 72], ["focuses", 79], ["on", 87], ["clinical", 90], ["aspects", 99], ["and", 107], ["prognosis", 111], ["of", 121], ["3", 124], ["neurologic", 126], ["sleep", 137], ["disorders", 143], [":", 152], ["narcolepsy", 154], [",", 164], ["restless", 166], ["legs", 175], ["syndrome", 180], ["/", 188], ["Willis", 189], ["-", 195], ["Ekbom", 196], ["disease", 202], ["(", 210], ["RLS", 211], ["/", 214], ["WED", 215], [")", 218], [",", 219], ["and", 221], ["REM", 225], ["sleep", 229], ["behavior", 235], ["disorder", 244], ["(", 253], ["RBD", 254], [")", 257], [".", 258], ["Narcolepsy", 260], ["causes", 271], ["pervasive", 278], [",", 287], ["enduring", 289], ["excessive", 298], ["daytime", 308], ["sleepiness", 316], [",", 326], ["adversely", 328], ["affecting", 338], ["patients", 348], ["'", 356], ["daily", 358], ["functioning", 364], [".", 375], ["RLS", 377], ["/", 380], ["WED", 381], ["is", 385], ["characterized", 388], ["by", 402], ["an", 405], ["uncomfortable", 408], ["urge", 422], ["to", 427], ["move", 430], ["the", 435], ["legs", 439], ["before", 444], ["sleep", 451], [",", 456], ["often", 458], ["evolving", 464], ["toward", 473], ["augmentation", 480], ["and", 493], ["resulting", 497], ["in", 507], ["daylong", 510], ["bothersome", 518], ["symptoms", 529], [".", 537], ["RBD", 539], ["causes", 543], ["potentially", 550], ["injurious", 562], ["dream", 572], ["enactment", 578], ["behaviors", 588], ["that", 598], ["often", 603], ["signify", 609], ["future", 617], ["evolution", 624], ["of", 634], ["overt", 637], ["synucleinopathy", 643], ["neurodegeneration", 659], ["in", 677], ["as", 680], ["many", 683], ["as", 688], ["81", 691], ["%", 693], ["of", 695], ["patients", 698], [".", 706], ["Timely", 708], ["recognition", 715], [",", 726], ["referral", 728], ["for", 737], ["polysomnography", 741], [",", 756], ["and", 758], ["longitudinal", 762], ["follow", 775], ["-", 781], ["up", 782], ["of", 785], ["narcolepsy", 788], [",", 798], ["RLS", 800], ["/", 803], ["WED", 804], [",", 807], ["and", 809], ["RBD", 813], ["patients", 817], ["are", 826], ["imperatives", 830], ["for", 842], ["neurologists", 846], ["in", 859], ["providing", 862], ["quality", 872], ["comprehensive", 880], ["patient", 894], ["care", 902], [".", 906]]}
{"context": "The amino acid selenocysteine is encoded by UGA, usually a stop codon, thus requiring a specialized machinery to enable its incorporation into selenoproteins. The machinery comprises the tRNA(Sec), a 3'-UTR mRNA stem-loop termed SElenoCysteine Insertion Sequence (SECIS), which is mandatory for recoding UGA as a Sec codon, the SECIS Binding Protein 2 (SBP2), and other proteins. Little is known about the molecular mechanism and, in particular, when, where, and how the SECIS and SBP2 contact the ribosome. Previous work by others used the isolated SECIS RNA to address this question. Here, we developed a novel approach using instead engineered minimal selenoprotein mRNAs containing SECIS elements derivatized with photoreactive groups. By cross-linking experiments in rabbit reticulocyte lysate, new information could be gained about the SBP2 and SECIS contacts with components of the translation machinery at various translation steps. In particular, we found that SBP2 was bound only to the SECIS in 48S pre-initiation and 80S pretranslocation complexes. In the complex where the Sec-tRNA(Sec) was accommodated to the A site but transpeptidation was blocked, SBP2 bound the ribosome and possibly the SECIS element as well, and the SECIS had flexible contacts with the 60S ribosomal subunit involving several ribosomal proteins. Altogether, our findings led to broadening our understanding about the unique mechanism of selenocysteine incorporation in mammals.", "qas": [{"question": "What is the name of the stem loop present in the 3' end of genes encoding for selenoproteins?", "answers": ["SECIS"], "qid": "00475180d274498e9dad745b5ff8c048", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["stem", 24], ["loop", 29], ["present", 34], ["in", 42], ["the", 45], ["3", 49], ["'", 50], ["end", 52], ["of", 56], ["genes", 59], ["encoding", 65], ["for", 74], ["selenoproteins", 78], ["?", 92]], "detected_answers": [{"text": "SECIS", "token_spans": [[176, 176], [59, 59], [125, 125], [90, 90], [214, 214], [221, 221], [44, 44], [151, 151], [104, 104]], "char_spans": [[997, 1001], [328, 332], [686, 690], [471, 475], [1206, 1210], [1237, 1241], [264, 268], [851, 855], [550, 554]]}]}], "context_tokens": [["The", 0], ["amino", 4], ["acid", 10], ["selenocysteine", 15], ["is", 30], ["encoded", 33], ["by", 41], ["UGA", 44], [",", 47], ["usually", 49], ["a", 57], ["stop", 59], ["codon", 64], [",", 69], ["thus", 71], ["requiring", 76], ["a", 86], ["specialized", 88], ["machinery", 100], ["to", 110], ["enable", 113], ["its", 120], ["incorporation", 124], ["into", 138], ["selenoproteins", 143], [".", 157], ["The", 159], ["machinery", 163], ["comprises", 173], ["the", 183], ["tRNA(Sec", 187], [")", 195], [",", 196], ["a", 198], ["3'-UTR", 200], ["mRNA", 207], ["stem", 212], ["-", 216], ["loop", 217], ["termed", 222], ["SElenoCysteine", 229], ["Insertion", 244], ["Sequence", 254], ["(", 263], ["SECIS", 264], [")", 269], [",", 270], ["which", 272], ["is", 278], ["mandatory", 281], ["for", 291], ["recoding", 295], ["UGA", 304], ["as", 308], ["a", 311], ["Sec", 313], ["codon", 317], [",", 322], ["the", 324], ["SECIS", 328], ["Binding", 334], ["Protein", 342], ["2", 350], ["(", 352], ["SBP2", 353], [")", 357], [",", 358], ["and", 360], ["other", 364], ["proteins", 370], [".", 378], ["Little", 380], ["is", 387], ["known", 390], ["about", 396], ["the", 402], ["molecular", 406], ["mechanism", 416], ["and", 426], [",", 429], ["in", 431], ["particular", 434], [",", 444], ["when", 446], [",", 450], ["where", 452], [",", 457], ["and", 459], ["how", 463], ["the", 467], ["SECIS", 471], ["and", 477], ["SBP2", 481], ["contact", 486], ["the", 494], ["ribosome", 498], [".", 506], ["Previous", 508], ["work", 517], ["by", 522], ["others", 525], ["used", 532], ["the", 537], ["isolated", 541], ["SECIS", 550], ["RNA", 556], ["to", 560], ["address", 563], ["this", 571], ["question", 576], [".", 584], ["Here", 586], [",", 590], ["we", 592], ["developed", 595], ["a", 605], ["novel", 607], ["approach", 613], ["using", 622], ["instead", 628], ["engineered", 636], ["minimal", 647], ["selenoprotein", 655], ["mRNAs", 669], ["containing", 675], ["SECIS", 686], ["elements", 692], ["derivatized", 701], ["with", 713], ["photoreactive", 718], ["groups", 732], [".", 738], ["By", 740], ["cross", 743], ["-", 748], ["linking", 749], ["experiments", 757], ["in", 769], ["rabbit", 772], ["reticulocyte", 779], ["lysate", 792], [",", 798], ["new", 800], ["information", 804], ["could", 816], ["be", 822], ["gained", 825], ["about", 832], ["the", 838], ["SBP2", 842], ["and", 847], ["SECIS", 851], ["contacts", 857], ["with", 866], ["components", 871], ["of", 882], ["the", 885], ["translation", 889], ["machinery", 901], ["at", 911], ["various", 914], ["translation", 922], ["steps", 934], [".", 939], ["In", 941], ["particular", 944], [",", 954], ["we", 956], ["found", 959], ["that", 965], ["SBP2", 970], ["was", 975], ["bound", 979], ["only", 985], ["to", 990], ["the", 993], ["SECIS", 997], ["in", 1003], ["48S", 1006], ["pre", 1010], ["-", 1013], ["initiation", 1014], ["and", 1025], ["80S", 1029], ["pretranslocation", 1033], ["complexes", 1050], [".", 1059], ["In", 1061], ["the", 1064], ["complex", 1068], ["where", 1076], ["the", 1082], ["Sec", 1086], ["-", 1089], ["tRNA(Sec", 1090], [")", 1098], ["was", 1100], ["accommodated", 1104], ["to", 1117], ["the", 1120], ["A", 1124], ["site", 1126], ["but", 1131], ["transpeptidation", 1135], ["was", 1152], ["blocked", 1156], [",", 1163], ["SBP2", 1165], ["bound", 1170], ["the", 1176], ["ribosome", 1180], ["and", 1189], ["possibly", 1193], ["the", 1202], ["SECIS", 1206], ["element", 1212], ["as", 1220], ["well", 1223], [",", 1227], ["and", 1229], ["the", 1233], ["SECIS", 1237], ["had", 1243], ["flexible", 1247], ["contacts", 1256], ["with", 1265], ["the", 1270], ["60S", 1274], ["ribosomal", 1278], ["subunit", 1288], ["involving", 1296], ["several", 1306], ["ribosomal", 1314], ["proteins", 1324], [".", 1332], ["Altogether", 1334], [",", 1344], ["our", 1346], ["findings", 1350], ["led", 1359], ["to", 1363], ["broadening", 1366], ["our", 1377], ["understanding", 1381], ["about", 1395], ["the", 1401], ["unique", 1405], ["mechanism", 1412], ["of", 1422], ["selenocysteine", 1425], ["incorporation", 1440], ["in", 1454], ["mammals", 1457], [".", 1464]]}
{"context": "The mixed-lineage leukemia protein MLL1 is a transcriptional regulator with an essential role in early development and hematopoiesis. The biological function of MLL1 is mediated by the histone H3K4 methyltransferase activity of the carboxyl-terminal SET domain. We have determined the crystal structure of the MLL1 SET domain in complex with cofactor product AdoHcy and a histone H3 peptide. This structure indicates that, in order to form a well-ordered active site, a highly variable but essential component of the SET domain must be repositioned. To test this idea, we compared the effect of the addition of MLL complex members on methyltransferase activity and show that both RbBP5 and Ash2L but not Wdr5 stimulate activity. Additionally, we have determined the effect of posttranslational modifications on histone H3 residues downstream and upstream from the target lysine and provide a structural explanation for why H3T3 phosphorylation and H3K9 acetylation regulate activity.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "f7e5563396b64495a72b3ad4feedde3e", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[89, 90], [39, 40], [51, 52]], "char_spans": [[517, 526], [250, 259], [315, 324]]}]}], "context_tokens": [["The", 0], ["mixed", 4], ["-", 9], ["lineage", 10], ["leukemia", 18], ["protein", 27], ["MLL1", 35], ["is", 40], ["a", 43], ["transcriptional", 45], ["regulator", 61], ["with", 71], ["an", 76], ["essential", 79], ["role", 89], ["in", 94], ["early", 97], ["development", 103], ["and", 115], ["hematopoiesis", 119], [".", 132], ["The", 134], ["biological", 138], ["function", 149], ["of", 158], ["MLL1", 161], ["is", 166], ["mediated", 169], ["by", 178], ["the", 181], ["histone", 185], ["H3K4", 193], ["methyltransferase", 198], ["activity", 216], ["of", 225], ["the", 228], ["carboxyl", 232], ["-", 240], ["terminal", 241], ["SET", 250], ["domain", 254], [".", 260], ["We", 262], ["have", 265], ["determined", 270], ["the", 281], ["crystal", 285], ["structure", 293], ["of", 303], ["the", 306], ["MLL1", 310], ["SET", 315], ["domain", 319], ["in", 326], ["complex", 329], ["with", 337], ["cofactor", 342], ["product", 351], ["AdoHcy", 359], ["and", 366], ["a", 370], ["histone", 372], ["H3", 380], ["peptide", 383], [".", 390], ["This", 392], ["structure", 397], ["indicates", 407], ["that", 417], [",", 421], ["in", 423], ["order", 426], ["to", 432], ["form", 435], ["a", 440], ["well", 442], ["-", 446], ["ordered", 447], ["active", 455], ["site", 462], [",", 466], ["a", 468], ["highly", 470], ["variable", 477], ["but", 486], ["essential", 490], ["component", 500], ["of", 510], ["the", 513], ["SET", 517], ["domain", 521], ["must", 528], ["be", 533], ["repositioned", 536], [".", 548], ["To", 550], ["test", 553], ["this", 558], ["idea", 563], [",", 567], ["we", 569], ["compared", 572], ["the", 581], ["effect", 585], ["of", 592], ["the", 595], ["addition", 599], ["of", 608], ["MLL", 611], ["complex", 615], ["members", 623], ["on", 631], ["methyltransferase", 634], ["activity", 652], ["and", 661], ["show", 665], ["that", 670], ["both", 675], ["RbBP5", 680], ["and", 686], ["Ash2L", 690], ["but", 696], ["not", 700], ["Wdr5", 704], ["stimulate", 709], ["activity", 719], [".", 727], ["Additionally", 729], [",", 741], ["we", 743], ["have", 746], ["determined", 751], ["the", 762], ["effect", 766], ["of", 773], ["posttranslational", 776], ["modifications", 794], ["on", 808], ["histone", 811], ["H3", 819], ["residues", 822], ["downstream", 831], ["and", 842], ["upstream", 846], ["from", 855], ["the", 860], ["target", 864], ["lysine", 871], ["and", 878], ["provide", 882], ["a", 890], ["structural", 892], ["explanation", 903], ["for", 915], ["why", 919], ["H3T3", 923], ["phosphorylation", 928], ["and", 944], ["H3K9", 948], ["acetylation", 953], ["regulate", 965], ["activity", 974], [".", 982]]}
{"context": "The nationwide prevalence of latent tuberculosis infection (LTBI) in Italian patients with psoriasis has never been investigated. To estimate the nationwide prevalence of LTBI in Italian patients with psoriasis who are candidates for systemic treatment. Data were obtained from the Psocare Registry on those patients (n\u00a0=\u00a04946) with age >\u00a018\u00a0years, systemic treatment at entry specified and tuberculin skin test (TST) performed according to the Mantoux method. LTBI diagnosis was based on a positive TST result in the absence of any clinical, radiological or microbiological evidence of active tuberculosis. Latent tuberculosis infection was diagnosed in 8\u00b73% of patients with psoriasis (409 of 4946). The prevalence of LTBI was lower in patients on biologics than in those on conventional systemic treatments, ranging from 4\u00b73% (19 of 444) of patients on adalimumab to 31% (eight of 26) of those on psoralen-ultraviolet A (P\u00a0<\u00a00\u00b705). Independent factors associated with LTBI were male sex [odds ratio (OR) 1\u00b730, 95% confidence interval (CI) 1\u00b704-1\u00b762; P\u00a0=\u00a00\u00b702], age over 55\u00a0years (OR 2\u00b793, 95% CI 2\u00b718-3\u00b793; P\u00a0<\u00a00\u00b7001) and being entered into a conventional treatment (OR 3\u00b783, 95% CI 3\u00b710-4\u00b774; P\u00a0<\u00a00\u00b7001). Positive history of tuberculosis was seen in 1% of patients (n\u00a0=\u00a049). The nationwide prevalence of LTBI in Italian patients with psoriasis candidate to systemic treatment is high, and screening is recommended prior to biological treatment.", "qas": [{"question": "The Mantoux test detects what latent infection/disease?", "answers": ["tuberculosis"], "qid": "4edb95a363144efdb21977cc7f1912a8", "question_tokens": [["The", 0], ["Mantoux", 4], ["test", 12], ["detects", 17], ["what", 25], ["latent", 30], ["infection", 37], ["/", 46], ["disease", 47], ["?", 54]], "detected_answers": [{"text": "tuberculosis", "token_spans": [[104, 104], [5, 5], [101, 101], [250, 250]], "char_spans": [[615, 626], [36, 47], [594, 605], [1229, 1240]]}]}], "context_tokens": [["The", 0], ["nationwide", 4], ["prevalence", 15], ["of", 26], ["latent", 29], ["tuberculosis", 36], ["infection", 49], ["(", 59], ["LTBI", 60], [")", 64], ["in", 66], ["Italian", 69], ["patients", 77], ["with", 86], ["psoriasis", 91], ["has", 101], ["never", 105], ["been", 111], ["investigated", 116], [".", 128], ["To", 130], ["estimate", 133], ["the", 142], ["nationwide", 146], ["prevalence", 157], ["of", 168], ["LTBI", 171], ["in", 176], ["Italian", 179], ["patients", 187], ["with", 196], ["psoriasis", 201], ["who", 211], ["are", 215], ["candidates", 219], ["for", 230], ["systemic", 234], ["treatment", 243], [".", 252], ["Data", 254], ["were", 259], ["obtained", 264], ["from", 273], ["the", 278], ["Psocare", 282], ["Registry", 290], ["on", 299], ["those", 302], ["patients", 308], ["(", 317], ["n", 318], ["=", 320], ["4946", 322], [")", 326], ["with", 328], ["age", 333], [">", 337], ["18", 339], ["years", 342], [",", 347], ["systemic", 349], ["treatment", 358], ["at", 368], ["entry", 371], ["specified", 377], ["and", 387], ["tuberculin", 391], ["skin", 402], ["test", 407], ["(", 412], ["TST", 413], [")", 416], ["performed", 418], ["according", 428], ["to", 438], ["the", 441], ["Mantoux", 445], ["method", 453], [".", 459], ["LTBI", 461], ["diagnosis", 466], ["was", 476], ["based", 480], ["on", 486], ["a", 489], ["positive", 491], ["TST", 500], ["result", 504], ["in", 511], ["the", 514], ["absence", 518], ["of", 526], ["any", 529], ["clinical", 533], [",", 541], ["radiological", 543], ["or", 556], ["microbiological", 559], ["evidence", 575], ["of", 584], ["active", 587], ["tuberculosis", 594], [".", 606], ["Latent", 608], ["tuberculosis", 615], ["infection", 628], ["was", 638], ["diagnosed", 642], ["in", 652], ["8\u00b73", 655], ["%", 658], ["of", 660], ["patients", 663], ["with", 672], ["psoriasis", 677], ["(", 687], ["409", 688], ["of", 692], ["4946", 695], [")", 699], [".", 700], ["The", 702], ["prevalence", 706], ["of", 717], ["LTBI", 720], ["was", 725], ["lower", 729], ["in", 735], ["patients", 738], ["on", 747], ["biologics", 750], ["than", 760], ["in", 765], ["those", 768], ["on", 774], ["conventional", 777], ["systemic", 790], ["treatments", 799], [",", 809], ["ranging", 811], ["from", 819], ["4\u00b73", 824], ["%", 827], ["(", 829], ["19", 830], ["of", 833], ["444", 836], [")", 839], ["of", 841], ["patients", 844], ["on", 853], ["adalimumab", 856], ["to", 867], ["31", 870], ["%", 872], ["(", 874], ["eight", 875], ["of", 881], ["26", 884], [")", 886], ["of", 888], ["those", 891], ["on", 897], ["psoralen", 900], ["-", 908], ["ultraviolet", 909], ["A", 921], ["(", 923], ["P", 924], ["<", 926], ["0\u00b705", 928], [")", 932], [".", 933], ["Independent", 935], ["factors", 947], ["associated", 955], ["with", 966], ["LTBI", 971], ["were", 976], ["male", 981], ["sex", 986], ["[", 990], ["odds", 991], ["ratio", 996], ["(", 1002], ["OR", 1003], [")", 1005], ["1\u00b730", 1007], [",", 1011], ["95", 1013], ["%", 1015], ["confidence", 1017], ["interval", 1028], ["(", 1037], ["CI", 1038], [")", 1040], ["1\u00b704", 1042], ["-", 1046], ["1\u00b762", 1047], [";", 1051], ["P", 1053], ["=", 1055], ["0\u00b702", 1057], ["]", 1061], [",", 1062], ["age", 1064], ["over", 1068], ["55", 1073], ["years", 1076], ["(", 1082], ["OR", 1083], ["2\u00b793", 1086], [",", 1090], ["95", 1092], ["%", 1094], ["CI", 1096], ["2\u00b718", 1099], ["-", 1103], ["3\u00b793", 1104], [";", 1108], ["P", 1110], ["<", 1112], ["0\u00b7001", 1114], [")", 1119], ["and", 1121], ["being", 1125], ["entered", 1131], ["into", 1139], ["a", 1144], ["conventional", 1146], ["treatment", 1159], ["(", 1169], ["OR", 1170], ["3\u00b783", 1173], [",", 1177], ["95", 1179], ["%", 1181], ["CI", 1183], ["3\u00b710", 1186], ["-", 1190], ["4\u00b774", 1191], [";", 1195], ["P", 1197], ["<", 1199], ["0\u00b7001", 1201], [")", 1206], [".", 1207], ["Positive", 1209], ["history", 1218], ["of", 1226], ["tuberculosis", 1229], ["was", 1242], ["seen", 1246], ["in", 1251], ["1", 1254], ["%", 1255], ["of", 1257], ["patients", 1260], ["(", 1269], ["n", 1270], ["=", 1272], ["49", 1274], [")", 1276], [".", 1277], ["The", 1279], ["nationwide", 1283], ["prevalence", 1294], ["of", 1305], ["LTBI", 1308], ["in", 1313], ["Italian", 1316], ["patients", 1324], ["with", 1333], ["psoriasis", 1338], ["candidate", 1348], ["to", 1358], ["systemic", 1361], ["treatment", 1370], ["is", 1380], ["high", 1383], [",", 1387], ["and", 1389], ["screening", 1393], ["is", 1403], ["recommended", 1406], ["prior", 1418], ["to", 1424], ["biological", 1427], ["treatment", 1438], [".", 1447]]}
{"context": "The McLeod syndrome is a rare X-linked recessive disorder characterized by blood group, neuromuscular and haematopoietic abnormalities. It is caused by XK gene defects and may include large deletions in the Xp21 region. Analysis of three unrelated McLeod patients for the presence of the XK, DMD, CYBB, ETX1, RPGR and OTC loci, as well as for the DXS709 marker, revealed deletions from the 39th exon of DMD to the ETX1 locus (patient Be), from the XK to RPGR loci (patient Bi) and from the XK to CYBB loci (patient Lh). All three patients normally expressed the Lutheran (Lu) red cell antigens, thus excluding the interval between the RPGR and DMD genes as site of the XS locus, previously mapped to the Xp21.2-Xq21.1 region and thought to regulate the expression of the LU blood group gene on chromosome 19.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "e6169de72a8e46a8bfd4b79a1daa5dc7", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[100, 100], [89, 89], [25, 25], [49, 49]], "char_spans": [[490, 491], [448, 449], [152, 153], [288, 289]]}]}], "context_tokens": [["The", 0], ["McLeod", 4], ["syndrome", 11], ["is", 20], ["a", 23], ["rare", 25], ["X", 30], ["-", 31], ["linked", 32], ["recessive", 39], ["disorder", 49], ["characterized", 58], ["by", 72], ["blood", 75], ["group", 81], [",", 86], ["neuromuscular", 88], ["and", 102], ["haematopoietic", 106], ["abnormalities", 121], [".", 134], ["It", 136], ["is", 139], ["caused", 142], ["by", 149], ["XK", 152], ["gene", 155], ["defects", 160], ["and", 168], ["may", 172], ["include", 176], ["large", 184], ["deletions", 190], ["in", 200], ["the", 203], ["Xp21", 207], ["region", 212], [".", 218], ["Analysis", 220], ["of", 229], ["three", 232], ["unrelated", 238], ["McLeod", 248], ["patients", 255], ["for", 264], ["the", 268], ["presence", 272], ["of", 281], ["the", 284], ["XK", 288], [",", 290], ["DMD", 292], [",", 295], ["CYBB", 297], [",", 301], ["ETX1", 303], [",", 307], ["RPGR", 309], ["and", 314], ["OTC", 318], ["loci", 322], [",", 326], ["as", 328], ["well", 331], ["as", 336], ["for", 339], ["the", 343], ["DXS709", 347], ["marker", 354], [",", 360], ["revealed", 362], ["deletions", 371], ["from", 381], ["the", 386], ["39th", 390], ["exon", 395], ["of", 400], ["DMD", 403], ["to", 407], ["the", 410], ["ETX1", 414], ["locus", 419], ["(", 425], ["patient", 426], ["Be", 434], [")", 436], [",", 437], ["from", 439], ["the", 444], ["XK", 448], ["to", 451], ["RPGR", 454], ["loci", 459], ["(", 464], ["patient", 465], ["Bi", 473], [")", 475], ["and", 477], ["from", 481], ["the", 486], ["XK", 490], ["to", 493], ["CYBB", 496], ["loci", 501], ["(", 506], ["patient", 507], ["Lh", 515], [")", 517], [".", 518], ["All", 520], ["three", 524], ["patients", 530], ["normally", 539], ["expressed", 548], ["the", 558], ["Lutheran", 562], ["(", 571], ["Lu", 572], [")", 574], ["red", 576], ["cell", 580], ["antigens", 585], [",", 593], ["thus", 595], ["excluding", 600], ["the", 610], ["interval", 614], ["between", 623], ["the", 631], ["RPGR", 635], ["and", 640], ["DMD", 644], ["genes", 648], ["as", 654], ["site", 657], ["of", 662], ["the", 665], ["XS", 669], ["locus", 672], [",", 677], ["previously", 679], ["mapped", 690], ["to", 697], ["the", 700], ["Xp21.2-Xq21.1", 704], ["region", 718], ["and", 725], ["thought", 729], ["to", 737], ["regulate", 740], ["the", 749], ["expression", 753], ["of", 764], ["the", 767], ["LU", 771], ["blood", 774], ["group", 780], ["gene", 786], ["on", 791], ["chromosome", 794], ["19", 805], [".", 807]]}
{"context": "To determine the change in prevalence of posttraumatic stress disorder (PTSD) symptoms in victims of the March 11 attacks and their relatives, 1 and 6 months after the attacks. Evaluation of PTSD symptoms using the Davidson Trauma Scale (DTS) and General Health Questionnaire (GHQ) in a sample of 56 patients admitted to an emergency room of a general hospital, and assessment of PTSD symptoms in relatives of the patients. At Month 1, 41.1% of patients (31.3% of males and 54.2% of females) presented with PTSD. At Month 6, this figure was 40.9% (30.4% of males and 52.4% of females). There was a significant improvement in perception of health among females between Month 1 and Month 6. Relatives presented similar DTS scores at baseline and at 6 months. We verified that rates of PTSD did not vary substantively between the two evaluations. PTSD symptoms positively correlated with psychological health involvement. This correlation points out that both PTSD symptoms and subjective general health involvement are part of the psychological response to trauma. The prevalence of PTSD symptoms was high and remained stable between Month 1 and Month 6, while subjective perception of health improved significantly.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "c35f27d4167846e1adc3aadd2981e4dc", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "PTSD", "token_spans": [[35, 35], [11, 11], [202, 202], [100, 100], [71, 71], [183, 183], [168, 168], [158, 158]], "char_spans": [[191, 194], [72, 75], [1081, 1084], [507, 510], [380, 383], [957, 960], [844, 847], [783, 786]]}]}], "context_tokens": [["To", 0], ["determine", 3], ["the", 13], ["change", 17], ["in", 24], ["prevalence", 27], ["of", 38], ["posttraumatic", 41], ["stress", 55], ["disorder", 62], ["(", 71], ["PTSD", 72], [")", 76], ["symptoms", 78], ["in", 87], ["victims", 90], ["of", 98], ["the", 101], ["March", 105], ["11", 111], ["attacks", 114], ["and", 122], ["their", 126], ["relatives", 132], [",", 141], ["1", 143], ["and", 145], ["6", 149], ["months", 151], ["after", 158], ["the", 164], ["attacks", 168], [".", 175], ["Evaluation", 177], ["of", 188], ["PTSD", 191], ["symptoms", 196], ["using", 205], ["the", 211], ["Davidson", 215], ["Trauma", 224], ["Scale", 231], ["(", 237], ["DTS", 238], [")", 241], ["and", 243], ["General", 247], ["Health", 255], ["Questionnaire", 262], ["(", 276], ["GHQ", 277], [")", 280], ["in", 282], ["a", 285], ["sample", 287], ["of", 294], ["56", 297], ["patients", 300], ["admitted", 309], ["to", 318], ["an", 321], ["emergency", 324], ["room", 334], ["of", 339], ["a", 342], ["general", 344], ["hospital", 352], [",", 360], ["and", 362], ["assessment", 366], ["of", 377], ["PTSD", 380], ["symptoms", 385], ["in", 394], ["relatives", 397], ["of", 407], ["the", 410], ["patients", 414], [".", 422], ["At", 424], ["Month", 427], ["1", 433], [",", 434], ["41.1", 436], ["%", 440], ["of", 442], ["patients", 445], ["(", 454], ["31.3", 455], ["%", 459], ["of", 461], ["males", 464], ["and", 470], ["54.2", 474], ["%", 478], ["of", 480], ["females", 483], [")", 490], ["presented", 492], ["with", 502], ["PTSD", 507], [".", 511], ["At", 513], ["Month", 516], ["6", 522], [",", 523], ["this", 525], ["figure", 530], ["was", 537], ["40.9", 541], ["%", 545], ["(", 547], ["30.4", 548], ["%", 552], ["of", 554], ["males", 557], ["and", 563], ["52.4", 567], ["%", 571], ["of", 573], ["females", 576], [")", 583], [".", 584], ["There", 586], ["was", 592], ["a", 596], ["significant", 598], ["improvement", 610], ["in", 622], ["perception", 625], ["of", 636], ["health", 639], ["among", 646], ["females", 652], ["between", 660], ["Month", 668], ["1", 674], ["and", 676], ["Month", 680], ["6", 686], [".", 687], ["Relatives", 689], ["presented", 699], ["similar", 709], ["DTS", 717], ["scores", 721], ["at", 728], ["baseline", 731], ["and", 740], ["at", 744], ["6", 747], ["months", 749], [".", 755], ["We", 757], ["verified", 760], ["that", 769], ["rates", 774], ["of", 780], ["PTSD", 783], ["did", 788], ["not", 792], ["vary", 796], ["substantively", 801], ["between", 815], ["the", 823], ["two", 827], ["evaluations", 831], [".", 842], ["PTSD", 844], ["symptoms", 849], ["positively", 858], ["correlated", 869], ["with", 880], ["psychological", 885], ["health", 899], ["involvement", 906], [".", 917], ["This", 919], ["correlation", 924], ["points", 936], ["out", 943], ["that", 947], ["both", 952], ["PTSD", 957], ["symptoms", 962], ["and", 971], ["subjective", 975], ["general", 986], ["health", 994], ["involvement", 1001], ["are", 1013], ["part", 1017], ["of", 1022], ["the", 1025], ["psychological", 1029], ["response", 1043], ["to", 1052], ["trauma", 1055], [".", 1061], ["The", 1063], ["prevalence", 1067], ["of", 1078], ["PTSD", 1081], ["symptoms", 1086], ["was", 1095], ["high", 1099], ["and", 1104], ["remained", 1108], ["stable", 1117], ["between", 1124], ["Month", 1132], ["1", 1138], ["and", 1140], ["Month", 1144], ["6", 1150], [",", 1151], ["while", 1153], ["subjective", 1159], ["perception", 1170], ["of", 1181], ["health", 1184], ["improved", 1191], ["significantly", 1200], [".", 1213]]}
{"context": "With the recent introduction of inhibitors of mammalian target of rapamycin (mTOR) in oncology, distinct cutaneous and oral adverse events have been identified. In fact, stomatitis and rash are documented as the most frequent and potentially dose-limiting side effects. Clinically, mTOR inhibitor-associated stomatitis (mIAS) more closely resembles aphthous stomatitis than oral mucositis due to conventional anticancer therapies. While most cases of mIAS are mild to moderate and self-limiting, more severe and persistent mIAS can become a dose-limiting toxicity. Small ulcerations may cause significant pain and mucosal sensitivity may occur in the absence of clinical changes. Use of clinical assessment tools that are primarily driven by ulceration size may underestimate mIAS, and assessment should include patient-reported outcomes. This article provides an up-to-date review of the clinical presentation, terminology, pathogenesis, assessment and management of mIAS and other mTOR inhibitor-associated oral adverse events. In addition, areas of future research are considered.", "qas": [{"question": "What does mTOR stands for?", "answers": ["mammalian target of rapamycin"], "qid": "51c0f6328c564f34adfee63c41eda084", "question_tokens": [["What", 0], ["does", 5], ["mTOR", 10], ["stands", 15], ["for", 22], ["?", 25]], "detected_answers": [{"text": "mammalian target of rapamycin", "token_spans": [[7, 10]], "char_spans": [[46, 74]]}]}], "context_tokens": [["With", 0], ["the", 5], ["recent", 9], ["introduction", 16], ["of", 29], ["inhibitors", 32], ["of", 43], ["mammalian", 46], ["target", 56], ["of", 63], ["rapamycin", 66], ["(", 76], ["mTOR", 77], [")", 81], ["in", 83], ["oncology", 86], [",", 94], ["distinct", 96], ["cutaneous", 105], ["and", 115], ["oral", 119], ["adverse", 124], ["events", 132], ["have", 139], ["been", 144], ["identified", 149], [".", 159], ["In", 161], ["fact", 164], [",", 168], ["stomatitis", 170], ["and", 181], ["rash", 185], ["are", 190], ["documented", 194], ["as", 205], ["the", 208], ["most", 212], ["frequent", 217], ["and", 226], ["potentially", 230], ["dose", 242], ["-", 246], ["limiting", 247], ["side", 256], ["effects", 261], [".", 268], ["Clinically", 270], [",", 280], ["mTOR", 282], ["inhibitor", 287], ["-", 296], ["associated", 297], ["stomatitis", 308], ["(", 319], ["mIAS", 320], [")", 324], ["more", 326], ["closely", 331], ["resembles", 339], ["aphthous", 349], ["stomatitis", 358], ["than", 369], ["oral", 374], ["mucositis", 379], ["due", 389], ["to", 393], ["conventional", 396], ["anticancer", 409], ["therapies", 420], [".", 429], ["While", 431], ["most", 437], ["cases", 442], ["of", 448], ["mIAS", 451], ["are", 456], ["mild", 460], ["to", 465], ["moderate", 468], ["and", 477], ["self", 481], ["-", 485], ["limiting", 486], [",", 494], ["more", 496], ["severe", 501], ["and", 508], ["persistent", 512], ["mIAS", 523], ["can", 528], ["become", 532], ["a", 539], ["dose", 541], ["-", 545], ["limiting", 546], ["toxicity", 555], [".", 563], ["Small", 565], ["ulcerations", 571], ["may", 583], ["cause", 587], ["significant", 593], ["pain", 605], ["and", 610], ["mucosal", 614], ["sensitivity", 622], ["may", 634], ["occur", 638], ["in", 644], ["the", 647], ["absence", 651], ["of", 659], ["clinical", 662], ["changes", 671], [".", 678], ["Use", 680], ["of", 684], ["clinical", 687], ["assessment", 696], ["tools", 707], ["that", 713], ["are", 718], ["primarily", 722], ["driven", 732], ["by", 739], ["ulceration", 742], ["size", 753], ["may", 758], ["underestimate", 762], ["mIAS", 776], [",", 780], ["and", 782], ["assessment", 786], ["should", 797], ["include", 804], ["patient", 812], ["-", 819], ["reported", 820], ["outcomes", 829], [".", 837], ["This", 839], ["article", 844], ["provides", 852], ["an", 861], ["up", 864], ["-", 866], ["to", 867], ["-", 869], ["date", 870], ["review", 875], ["of", 882], ["the", 885], ["clinical", 889], ["presentation", 898], [",", 910], ["terminology", 912], [",", 923], ["pathogenesis", 925], [",", 937], ["assessment", 939], ["and", 950], ["management", 954], ["of", 965], ["mIAS", 968], ["and", 973], ["other", 977], ["mTOR", 983], ["inhibitor", 988], ["-", 997], ["associated", 998], ["oral", 1009], ["adverse", 1014], ["events", 1022], [".", 1028], ["In", 1030], ["addition", 1033], [",", 1041], ["areas", 1043], ["of", 1049], ["future", 1052], ["research", 1059], ["are", 1068], ["considered", 1072], [".", 1082]]}
{"context": "Parkinson's disease (PD) and dementia with Lewy bodies (DLB) are characterized by abnormal deposition of \u03b1-synuclein aggregates in many regions of the central and peripheral nervous systems. Accumulating evidence suggests that the \u03b1-synuclein pathology initiates in a few discrete regions and spreads to larger areas in the nervous system. Recent pathological studies of PD patients have raised the possibility that the enteric nervous system is one of the initial sites of \u03b1-synuclein aggregation and propagation. Here, we evaluated the induction and propagation of \u03b1-synuclein aggregates in the enteric nervous system of the A53T \u03b1-synuclein transgenic mice after injection of human brain tissue extracts into the gastric walls of the mice. Western analysis of the brain extracts showed that the DLB extract contained detergent-stable \u03b1-synuclein aggregates, but the normal brain extract did not. Injection of the DLB extract resulted in an increased deposition of \u03b1-synuclein in the myenteric neurons, in which \u03b1-synuclein formed punctate aggregates over time up to 4 months. In these mice, inflammatory responses were increased transiently at early time points. None of these changes were observed in the A53T mice injected with saline or the normal brain extract, nor were these found in the wild type mice injected with the DLB extract. These results demonstrate that pathological \u03b1-synuclein aggregates present in the brain of DLB patient can induce the aggregation of endogenous \u03b1-synuclein in the myenteric neurons in A53T mice, suggesting the transmission of synucleinopathy lesions in the enteric nervous system.", "qas": [{"question": "Which disease of the central nervous system is characterized by the presence of Lewy bodies?", "answers": ["Parkinson's disease (PD)"], "qid": "9a225d6aa2034d27a58fc2dea42dbe40", "question_tokens": [["Which", 0], ["disease", 6], ["of", 14], ["the", 17], ["central", 21], ["nervous", 29], ["system", 37], ["is", 44], ["characterized", 47], ["by", 61], ["the", 64], ["presence", 68], ["of", 77], ["Lewy", 80], ["bodies", 85], ["?", 91]], "detected_answers": [{"text": "Parkinson's disease (PD)", "token_spans": [[0, 4]], "char_spans": [[0, 22]]}]}], "context_tokens": [["Parkinson", 0], ["'s", 9], ["disease", 12], ["(", 20], ["PD", 21], [")", 23], ["and", 25], ["dementia", 29], ["with", 38], ["Lewy", 43], ["bodies", 48], ["(", 55], ["DLB", 56], [")", 59], ["are", 61], ["characterized", 65], ["by", 79], ["abnormal", 82], ["deposition", 91], ["of", 102], ["\u03b1", 105], ["-", 106], ["synuclein", 107], ["aggregates", 117], ["in", 128], ["many", 131], ["regions", 136], ["of", 144], ["the", 147], ["central", 151], ["and", 159], ["peripheral", 163], ["nervous", 174], ["systems", 182], [".", 189], ["Accumulating", 191], ["evidence", 204], ["suggests", 213], ["that", 222], ["the", 227], ["\u03b1", 231], ["-", 232], ["synuclein", 233], ["pathology", 243], ["initiates", 253], ["in", 263], ["a", 266], ["few", 268], ["discrete", 272], ["regions", 281], ["and", 289], ["spreads", 293], ["to", 301], ["larger", 304], ["areas", 311], ["in", 317], ["the", 320], ["nervous", 324], ["system", 332], [".", 338], ["Recent", 340], ["pathological", 347], ["studies", 360], ["of", 368], ["PD", 371], ["patients", 374], ["have", 383], ["raised", 388], ["the", 395], ["possibility", 399], ["that", 411], ["the", 416], ["enteric", 420], ["nervous", 428], ["system", 436], ["is", 443], ["one", 446], ["of", 450], ["the", 453], ["initial", 457], ["sites", 465], ["of", 471], ["\u03b1", 474], ["-", 475], ["synuclein", 476], ["aggregation", 486], ["and", 498], ["propagation", 502], [".", 513], ["Here", 515], [",", 519], ["we", 521], ["evaluated", 524], ["the", 534], ["induction", 538], ["and", 548], ["propagation", 552], ["of", 564], ["\u03b1", 567], ["-", 568], ["synuclein", 569], ["aggregates", 579], ["in", 590], ["the", 593], ["enteric", 597], ["nervous", 605], ["system", 613], ["of", 620], ["the", 623], ["A53", 627], ["T", 630], ["\u03b1", 632], ["-", 633], ["synuclein", 634], ["transgenic", 644], ["mice", 655], ["after", 660], ["injection", 666], ["of", 676], ["human", 679], ["brain", 685], ["tissue", 691], ["extracts", 698], ["into", 707], ["the", 712], ["gastric", 716], ["walls", 724], ["of", 730], ["the", 733], ["mice", 737], [".", 741], ["Western", 743], ["analysis", 751], ["of", 760], ["the", 763], ["brain", 767], ["extracts", 773], ["showed", 782], ["that", 789], ["the", 794], ["DLB", 798], ["extract", 802], ["contained", 810], ["detergent", 820], ["-", 829], ["stable", 830], ["\u03b1", 837], ["-", 838], ["synuclein", 839], ["aggregates", 849], [",", 859], ["but", 861], ["the", 865], ["normal", 869], ["brain", 876], ["extract", 882], ["did", 890], ["not", 894], [".", 897], ["Injection", 899], ["of", 909], ["the", 912], ["DLB", 916], ["extract", 920], ["resulted", 928], ["in", 937], ["an", 940], ["increased", 943], ["deposition", 953], ["of", 964], ["\u03b1", 967], ["-", 968], ["synuclein", 969], ["in", 979], ["the", 982], ["myenteric", 986], ["neurons", 996], [",", 1003], ["in", 1005], ["which", 1008], ["\u03b1", 1014], ["-", 1015], ["synuclein", 1016], ["formed", 1026], ["punctate", 1033], ["aggregates", 1042], ["over", 1053], ["time", 1058], ["up", 1063], ["to", 1066], ["4", 1069], ["months", 1071], [".", 1077], ["In", 1079], ["these", 1082], ["mice", 1088], [",", 1092], ["inflammatory", 1094], ["responses", 1107], ["were", 1117], ["increased", 1122], ["transiently", 1132], ["at", 1144], ["early", 1147], ["time", 1153], ["points", 1158], [".", 1164], ["None", 1166], ["of", 1171], ["these", 1174], ["changes", 1180], ["were", 1188], ["observed", 1193], ["in", 1202], ["the", 1205], ["A53", 1209], ["T", 1212], ["mice", 1214], ["injected", 1219], ["with", 1228], ["saline", 1233], ["or", 1240], ["the", 1243], ["normal", 1247], ["brain", 1254], ["extract", 1260], [",", 1267], ["nor", 1269], ["were", 1273], ["these", 1278], ["found", 1284], ["in", 1290], ["the", 1293], ["wild", 1297], ["type", 1302], ["mice", 1307], ["injected", 1312], ["with", 1321], ["the", 1326], ["DLB", 1330], ["extract", 1334], [".", 1341], ["These", 1343], ["results", 1349], ["demonstrate", 1357], ["that", 1369], ["pathological", 1374], ["\u03b1", 1387], ["-", 1388], ["synuclein", 1389], ["aggregates", 1399], ["present", 1410], ["in", 1418], ["the", 1421], ["brain", 1425], ["of", 1431], ["DLB", 1434], ["patient", 1438], ["can", 1446], ["induce", 1450], ["the", 1457], ["aggregation", 1461], ["of", 1473], ["endogenous", 1476], ["\u03b1", 1487], ["-", 1488], ["synuclein", 1489], ["in", 1499], ["the", 1502], ["myenteric", 1506], ["neurons", 1516], ["in", 1524], ["A53", 1527], ["T", 1530], ["mice", 1532], [",", 1536], ["suggesting", 1538], ["the", 1549], ["transmission", 1553], ["of", 1566], ["synucleinopathy", 1569], ["lesions", 1585], ["in", 1593], ["the", 1596], ["enteric", 1600], ["nervous", 1608], ["system", 1616], [".", 1622]]}
{"context": "Amyloid precursor protein (APP) is strongly related to the onset of Alzheimer's disease. It possesses cleavage sites for beta- and gamma-secretases, and the resulting cleaved products (amyloid-beta peptides) are capable of causing neurotoxicity. Such cleavage is promoted by the Swedish and London mutations (APPSwe/Lon) inside the APP gene. Here, we characterized APPSL transgenic mice (APPSL-Tg) to determine the effects of this mutation. We observed that both the amount of insoluble amyloid-beta and the ratio of amyloid-beta 42/40 increased promptly in the brain during 6-16 months of age. Amyloid-beta plaques were observed in whole brain sections at 12 months. In contrast, the spatial memory assessed by the Morris water maze task was already impaired at 3 months, which suggested that the APPSL-Tg mice may represent an early-onset model of familial Alzheimer's disease. Furthermore, the levels of LAMP-1, a marker protein of lysosome, increased in the brain at 28 months. Such LAMP-1 protein was detected around the amyloid-beta plaques at the hippocampal regions of the APPSL-Tg mice. Our results suggested that the increase in LAMP-1 was enhanced by the accumulation of amyloid-beta occurring during aging. Our findings coincided with the pathological hallmarks of Alzheimer's disease.", "qas": [{"question": "Which disease the London mutation involved in?", "answers": ["Alzheimer's Disease", "AD"], "qid": "d8237f9d763b42d483bb971b70dd1706", "question_tokens": [["Which", 0], ["disease", 6], ["the", 14], ["London", 18], ["mutation", 25], ["involved", 34], ["in", 43], ["?", 45]], "detected_answers": [{"text": "Alzheimer's Disease", "token_spans": [[13, 15], [244, 246], [168, 170]], "char_spans": [[68, 86], [1277, 1295], [859, 877]]}]}], "context_tokens": [["Amyloid", 0], ["precursor", 8], ["protein", 18], ["(", 26], ["APP", 27], [")", 30], ["is", 32], ["strongly", 35], ["related", 44], ["to", 52], ["the", 55], ["onset", 59], ["of", 65], ["Alzheimer", 68], ["'s", 77], ["disease", 80], [".", 87], ["It", 89], ["possesses", 92], ["cleavage", 102], ["sites", 111], ["for", 117], ["beta-", 121], ["and", 127], ["gamma", 131], ["-", 136], ["secretases", 137], [",", 147], ["and", 149], ["the", 153], ["resulting", 157], ["cleaved", 167], ["products", 175], ["(", 184], ["amyloid", 185], ["-", 192], ["beta", 193], ["peptides", 198], [")", 206], ["are", 208], ["capable", 212], ["of", 220], ["causing", 223], ["neurotoxicity", 231], [".", 244], ["Such", 246], ["cleavage", 251], ["is", 260], ["promoted", 263], ["by", 272], ["the", 275], ["Swedish", 279], ["and", 287], ["London", 291], ["mutations", 298], ["(", 308], ["APPSwe", 309], ["/", 315], ["Lon", 316], [")", 319], ["inside", 321], ["the", 328], ["APP", 332], ["gene", 336], [".", 340], ["Here", 342], [",", 346], ["we", 348], ["characterized", 351], ["APPSL", 365], ["transgenic", 371], ["mice", 382], ["(", 387], ["APPSL", 388], ["-", 393], ["Tg", 394], [")", 396], ["to", 398], ["determine", 401], ["the", 411], ["effects", 415], ["of", 423], ["this", 426], ["mutation", 431], [".", 439], ["We", 441], ["observed", 444], ["that", 453], ["both", 458], ["the", 463], ["amount", 467], ["of", 474], ["insoluble", 477], ["amyloid", 487], ["-", 494], ["beta", 495], ["and", 500], ["the", 504], ["ratio", 508], ["of", 514], ["amyloid", 517], ["-", 524], ["beta", 525], ["42/40", 530], ["increased", 536], ["promptly", 546], ["in", 555], ["the", 558], ["brain", 562], ["during", 568], ["6", 575], ["-", 576], ["16", 577], ["months", 580], ["of", 587], ["age", 590], [".", 593], ["Amyloid", 595], ["-", 602], ["beta", 603], ["plaques", 608], ["were", 616], ["observed", 621], ["in", 630], ["whole", 633], ["brain", 639], ["sections", 645], ["at", 654], ["12", 657], ["months", 660], [".", 666], ["In", 668], ["contrast", 671], [",", 679], ["the", 681], ["spatial", 685], ["memory", 693], ["assessed", 700], ["by", 709], ["the", 712], ["Morris", 716], ["water", 723], ["maze", 729], ["task", 734], ["was", 739], ["already", 743], ["impaired", 751], ["at", 760], ["3", 763], ["months", 765], [",", 771], ["which", 773], ["suggested", 779], ["that", 789], ["the", 794], ["APPSL", 798], ["-", 803], ["Tg", 804], ["mice", 807], ["may", 812], ["represent", 816], ["an", 826], ["early", 829], ["-", 834], ["onset", 835], ["model", 841], ["of", 847], ["familial", 850], ["Alzheimer", 859], ["'s", 868], ["disease", 871], [".", 878], ["Furthermore", 880], [",", 891], ["the", 893], ["levels", 897], ["of", 904], ["LAMP-1", 907], [",", 913], ["a", 915], ["marker", 917], ["protein", 924], ["of", 932], ["lysosome", 935], [",", 943], ["increased", 945], ["in", 955], ["the", 958], ["brain", 962], ["at", 968], ["28", 971], ["months", 974], [".", 980], ["Such", 982], ["LAMP-1", 987], ["protein", 994], ["was", 1002], ["detected", 1006], ["around", 1015], ["the", 1022], ["amyloid", 1026], ["-", 1033], ["beta", 1034], ["plaques", 1039], ["at", 1047], ["the", 1050], ["hippocampal", 1054], ["regions", 1066], ["of", 1074], ["the", 1077], ["APPSL", 1081], ["-", 1086], ["Tg", 1087], ["mice", 1090], [".", 1094], ["Our", 1096], ["results", 1100], ["suggested", 1108], ["that", 1118], ["the", 1123], ["increase", 1127], ["in", 1136], ["LAMP-1", 1139], ["was", 1146], ["enhanced", 1150], ["by", 1159], ["the", 1162], ["accumulation", 1166], ["of", 1179], ["amyloid", 1182], ["-", 1189], ["beta", 1190], ["occurring", 1195], ["during", 1205], ["aging", 1212], [".", 1217], ["Our", 1219], ["findings", 1223], ["coincided", 1232], ["with", 1242], ["the", 1247], ["pathological", 1251], ["hallmarks", 1264], ["of", 1274], ["Alzheimer", 1277], ["'s", 1286], ["disease", 1289], [".", 1296]]}
{"context": "\u03b1-Synuclein (\u03b1Syn), which forms amyloid fibrils, is linked to the neuronal pathology of Parkinson's disease, as it is the major fibrillar component of Lewy bodies, the inclusions that are characteristic of the disease. Oligomeric structures, common to many neurodegenerative disease-related proteins, may in fact be the primary toxic species, while the amyloid fibrils exist either as a less toxic dead-end species or even as a beneficial mechanism for clearing damaged proteins. To alter the progression of the aggregation and gain insights into the prefibrillar structures, we determined the effect of heme on \u03b1Syn oligomerization by several different techniques, including native (nondenaturing) polyacrylamide gel electrophoresis, thioflavin T fluorescence, transmission electron microscopy, atomic force microscopy, circular dichroism, and membrane permeation using a calcein release assay. During aggregation, heme is able to bind the \u03b1Syn in a specific fashion, stabilizing distinct oligomeric conformations and promoting the formation of \u03b1Syn into annular structures, thereby delaying and/or inhibiting the fibrillation process. These results indicate that heme may play a regulatory role in the progression of Parkinson's disease; in addition, they provide insights into how the aggregation process may be altered, which may be applicable to the understanding of many neurodegenerative diseases.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "bbcdadd974b7443eae14570e28207e80", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "\u03b1-synuclein", "token_spans": [[0, 2]], "char_spans": [[0, 10]]}, {"text": "\u03b1Syn", "token_spans": [[175, 175], [4, 4], [160, 160], [111, 111]], "char_spans": [[1046, 1049], [13, 16], [941, 944], [612, 615]]}]}], "context_tokens": [["\u03b1", 0], ["-", 1], ["Synuclein", 2], ["(", 12], ["\u03b1Syn", 13], [")", 17], [",", 18], ["which", 20], ["forms", 26], ["amyloid", 32], ["fibrils", 40], [",", 47], ["is", 49], ["linked", 52], ["to", 59], ["the", 62], ["neuronal", 66], ["pathology", 75], ["of", 85], ["Parkinson", 88], ["'s", 97], ["disease", 100], [",", 107], ["as", 109], ["it", 112], ["is", 115], ["the", 118], ["major", 122], ["fibrillar", 128], ["component", 138], ["of", 148], ["Lewy", 151], ["bodies", 156], [",", 162], ["the", 164], ["inclusions", 168], ["that", 179], ["are", 184], ["characteristic", 188], ["of", 203], ["the", 206], ["disease", 210], [".", 217], ["Oligomeric", 219], ["structures", 230], [",", 240], ["common", 242], ["to", 249], ["many", 252], ["neurodegenerative", 257], ["disease", 275], ["-", 282], ["related", 283], ["proteins", 291], [",", 299], ["may", 301], ["in", 305], ["fact", 308], ["be", 313], ["the", 316], ["primary", 320], ["toxic", 328], ["species", 334], [",", 341], ["while", 343], ["the", 349], ["amyloid", 353], ["fibrils", 361], ["exist", 369], ["either", 375], ["as", 382], ["a", 385], ["less", 387], ["toxic", 392], ["dead", 398], ["-", 402], ["end", 403], ["species", 407], ["or", 415], ["even", 418], ["as", 423], ["a", 426], ["beneficial", 428], ["mechanism", 439], ["for", 449], ["clearing", 453], ["damaged", 462], ["proteins", 470], [".", 478], ["To", 480], ["alter", 483], ["the", 489], ["progression", 493], ["of", 505], ["the", 508], ["aggregation", 512], ["and", 524], ["gain", 528], ["insights", 533], ["into", 542], ["the", 547], ["prefibrillar", 551], ["structures", 564], [",", 574], ["we", 576], ["determined", 579], ["the", 590], ["effect", 594], ["of", 601], ["heme", 604], ["on", 609], ["\u03b1Syn", 612], ["oligomerization", 617], ["by", 633], ["several", 636], ["different", 644], ["techniques", 654], [",", 664], ["including", 666], ["native", 676], ["(", 683], ["nondenaturing", 684], [")", 697], ["polyacrylamide", 699], ["gel", 714], ["electrophoresis", 718], [",", 733], ["thioflavin", 735], ["T", 746], ["fluorescence", 748], [",", 760], ["transmission", 762], ["electron", 775], ["microscopy", 784], [",", 794], ["atomic", 796], ["force", 803], ["microscopy", 809], [",", 819], ["circular", 821], ["dichroism", 830], [",", 839], ["and", 841], ["membrane", 845], ["permeation", 854], ["using", 865], ["a", 871], ["calcein", 873], ["release", 881], ["assay", 889], [".", 894], ["During", 896], ["aggregation", 903], [",", 914], ["heme", 916], ["is", 921], ["able", 924], ["to", 929], ["bind", 932], ["the", 937], ["\u03b1Syn", 941], ["in", 946], ["a", 949], ["specific", 951], ["fashion", 960], [",", 967], ["stabilizing", 969], ["distinct", 981], ["oligomeric", 990], ["conformations", 1001], ["and", 1015], ["promoting", 1019], ["the", 1029], ["formation", 1033], ["of", 1043], ["\u03b1Syn", 1046], ["into", 1051], ["annular", 1056], ["structures", 1064], [",", 1074], ["thereby", 1076], ["delaying", 1084], ["and/or", 1093], ["inhibiting", 1100], ["the", 1111], ["fibrillation", 1115], ["process", 1128], [".", 1135], ["These", 1137], ["results", 1143], ["indicate", 1151], ["that", 1160], ["heme", 1165], ["may", 1170], ["play", 1174], ["a", 1179], ["regulatory", 1181], ["role", 1192], ["in", 1197], ["the", 1200], ["progression", 1204], ["of", 1216], ["Parkinson", 1219], ["'s", 1228], ["disease", 1231], [";", 1238], ["in", 1240], ["addition", 1243], [",", 1251], ["they", 1253], ["provide", 1258], ["insights", 1266], ["into", 1275], ["how", 1280], ["the", 1284], ["aggregation", 1288], ["process", 1300], ["may", 1308], ["be", 1312], ["altered", 1315], [",", 1322], ["which", 1324], ["may", 1330], ["be", 1334], ["applicable", 1337], ["to", 1348], ["the", 1351], ["understanding", 1355], ["of", 1369], ["many", 1372], ["neurodegenerative", 1377], ["diseases", 1395], [".", 1403]]}
{"context": "Low back pain with or without radiculopathy is an important cause of disability and economic expenditure. However, many patients are not meeting optimal pain control through existing treatments. Recent studies have linked nerve growth factor (NGF) and the pathophysiology of persistent pain. Anti-NGF could be an alternative drug treatment for low back pain. Systematically review the efficacy and safety of anti-NGF in the treatment of low back pain. A systematic review of the literature with no language, date or publication status restriction, using Medline, EMBASE, Cochrane Library, and the clinicaltrials.gov database. Additional literature was retrieved by conferring with experts in the field or reviewing bibliographies and annals of meetings and congresses. Search terms included \"monoclonal antibodies,\" \"nerve growth factor,\" \"anti-ngf,\" \"fulranumab,\" \"tanezumab,\" \"sciatica,\" \"back pain,\" and \"spine.\" Inclusion criteria were observational studies with safety as an outcome and randomized or nonrandomized controlled trials studying the efficacy and/or the safety of anti-NGF drugs on low back pain. Exclusion criteria included patients with autoimmune conditions or osteoporosis. Studies were assessed independently by 2 authors regarding inclusion/exclusion criteria, risk of bias, clinical relevance, and quality of evidence (GRADE approach). 1,168 studies were retrieved. After excluding duplicates and applying the inclusion/exclusion criteria, 4 RCTs remained (n = 2,109): 2 for tanezumab, one for REGN475, and one for fulranumab. Only the tanezumab studies showed any significant difference over placebo (n = 1,563) for both pain relief and functional improvement. There is very low evidence that systemically administered anti-NGF therapy has a small positive effect compared to placebo for both pain relief (standarized mean difference [SMD] = -0.29, 95% confidence interval [CI] -0.58 to 0.00) and functional improvement (SMD = -0.21, 95%CI -0.37 to -0.05 ) of low back pain. There was low evidence of adverse effects (AEs) compared to placebo and low evidence of neurological AEs than placebo (relative risk = 1.93, 95%CI 1.41 to 2.64).Tanezumab, as a specific anti-NGF treatment, showed low evidence of a small to moderate effect for pain relief of low back pain (SMD = -0.44, 95%CI -0.81 to -0.07); and low evidence of a small effect for functional improvement (SMD = -0.26, 95%CI -0.40 to -0.12) with systemic administration, although not clinically significant. Tanezumab and anti-NGFs overall had, respectively, moderate and low evidence of overall AEs and serious AEs and a higher risk of developing neurological AEs when compared with placebo. Although anti-NGF, specifically tanezumab, showed a low-to-moderate effect on pain relief and functional improvement, it cannot be recommended for low back pain treatment. Without more research on the pathophysiology of anti-NGFs and adverse effects, its use is not safe in the overall population. However, as corroborated by the US Food and Drug Administration, this meta-analysis underscores a role for greater insight into anti-NGF therapy for painful conditions that are refractory to current drugs, such as oncologic pain, chronic pancreatitis, and phantom-limb pain. Given the pathophysiology of axial pain involving inflammatory mediators and the adverse effects of systemic anti-NGF use, consideration of local therapies may warrant further exploration.", "qas": [{"question": "What is the target of tanezumab?", "answers": ["nerve growth factor", "NGF"], "qid": "2ab00371c0644e0ca45158c35d6dbf8e", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["target", 12], ["of", 19], ["tanezumab", 22], ["?", 31]], "detected_answers": [{"text": "nerve growth factor", "token_spans": [[139, 141], [35, 37]], "char_spans": [[817, 835], [222, 240]]}, {"text": "NGF", "token_spans": [[147, 147], [197, 197], [314, 314], [499, 499], [579, 579], [404, 404], [39, 39], [71, 71], [50, 50], [622, 622]], "char_spans": [[845, 847], [1086, 1088], [1749, 1751], [2690, 2692], [3107, 3109], [2191, 2193], [243, 245], [413, 415], [297, 299], [3363, 3365]]}]}], "context_tokens": [["Low", 0], ["back", 4], ["pain", 9], ["with", 14], ["or", 19], ["without", 22], ["radiculopathy", 30], ["is", 44], ["an", 47], ["important", 50], ["cause", 60], ["of", 66], ["disability", 69], ["and", 80], ["economic", 84], ["expenditure", 93], [".", 104], ["However", 106], [",", 113], ["many", 115], ["patients", 120], ["are", 129], ["not", 133], ["meeting", 137], ["optimal", 145], ["pain", 153], ["control", 158], ["through", 166], ["existing", 174], ["treatments", 183], [".", 193], ["Recent", 195], ["studies", 202], ["have", 210], ["linked", 215], ["nerve", 222], ["growth", 228], ["factor", 235], ["(", 242], ["NGF", 243], [")", 246], ["and", 248], ["the", 252], ["pathophysiology", 256], ["of", 272], ["persistent", 275], ["pain", 286], [".", 290], ["Anti", 292], ["-", 296], ["NGF", 297], ["could", 301], ["be", 307], ["an", 310], ["alternative", 313], ["drug", 325], ["treatment", 330], ["for", 340], ["low", 344], ["back", 348], ["pain", 353], [".", 357], ["Systematically", 359], ["review", 374], ["the", 381], ["efficacy", 385], ["and", 394], ["safety", 398], ["of", 405], ["anti", 408], ["-", 412], ["NGF", 413], ["in", 417], ["the", 420], ["treatment", 424], ["of", 434], ["low", 437], ["back", 441], ["pain", 446], [".", 450], ["A", 452], ["systematic", 454], ["review", 465], ["of", 472], ["the", 475], ["literature", 479], ["with", 490], ["no", 495], ["language", 498], [",", 506], ["date", 508], ["or", 513], ["publication", 516], ["status", 528], ["restriction", 535], [",", 546], ["using", 548], ["Medline", 554], [",", 561], ["EMBASE", 563], [",", 569], ["Cochrane", 571], ["Library", 580], [",", 587], ["and", 589], ["the", 593], ["clinicaltrials.gov", 597], ["database", 616], [".", 624], ["Additional", 626], ["literature", 637], ["was", 648], ["retrieved", 652], ["by", 662], ["conferring", 665], ["with", 676], ["experts", 681], ["in", 689], ["the", 692], ["field", 696], ["or", 702], ["reviewing", 705], ["bibliographies", 715], ["and", 730], ["annals", 734], ["of", 741], ["meetings", 744], ["and", 753], ["congresses", 757], [".", 767], ["Search", 769], ["terms", 776], ["included", 782], ["\"", 791], ["monoclonal", 792], ["antibodies", 803], [",", 813], ["\"", 814], ["\"", 816], ["nerve", 817], ["growth", 823], ["factor", 830], [",", 836], ["\"", 837], ["\"", 839], ["anti", 840], ["-", 844], ["ngf", 845], [",", 848], ["\"", 849], ["\"", 851], ["fulranumab", 852], [",", 862], ["\"", 863], ["\"", 865], ["tanezumab", 866], [",", 875], ["\"", 876], ["\"", 878], ["sciatica", 879], [",", 887], ["\"", 888], ["\"", 890], ["back", 891], ["pain", 896], [",", 900], ["\"", 901], ["and", 903], ["\"", 907], ["spine", 908], [".", 913], ["\"", 914], ["Inclusion", 916], ["criteria", 926], ["were", 935], ["observational", 940], ["studies", 954], ["with", 962], ["safety", 967], ["as", 974], ["an", 977], ["outcome", 980], ["and", 988], ["randomized", 992], ["or", 1003], ["nonrandomized", 1006], ["controlled", 1020], ["trials", 1031], ["studying", 1038], ["the", 1047], ["efficacy", 1051], ["and/or", 1060], ["the", 1067], ["safety", 1071], ["of", 1078], ["anti", 1081], ["-", 1085], ["NGF", 1086], ["drugs", 1090], ["on", 1096], ["low", 1099], ["back", 1103], ["pain", 1108], [".", 1112], ["Exclusion", 1114], ["criteria", 1124], ["included", 1133], ["patients", 1142], ["with", 1151], ["autoimmune", 1156], ["conditions", 1167], ["or", 1178], ["osteoporosis", 1181], [".", 1193], ["Studies", 1195], ["were", 1203], ["assessed", 1208], ["independently", 1217], ["by", 1231], ["2", 1234], ["authors", 1236], ["regarding", 1244], ["inclusion", 1254], ["/", 1263], ["exclusion", 1264], ["criteria", 1274], [",", 1282], ["risk", 1284], ["of", 1289], ["bias", 1292], [",", 1296], ["clinical", 1298], ["relevance", 1307], [",", 1316], ["and", 1318], ["quality", 1322], ["of", 1330], ["evidence", 1333], ["(", 1342], ["GRADE", 1343], ["approach", 1349], [")", 1357], [".", 1358], ["1,168", 1360], ["studies", 1366], ["were", 1374], ["retrieved", 1379], [".", 1388], ["After", 1390], ["excluding", 1396], ["duplicates", 1406], ["and", 1417], ["applying", 1421], ["the", 1430], ["inclusion", 1434], ["/", 1443], ["exclusion", 1444], ["criteria", 1454], [",", 1462], ["4", 1464], ["RCTs", 1466], ["remained", 1471], ["(", 1480], ["n", 1481], ["=", 1483], ["2,109", 1485], [")", 1490], [":", 1491], ["2", 1493], ["for", 1495], ["tanezumab", 1499], [",", 1508], ["one", 1510], ["for", 1514], ["REGN475", 1518], [",", 1525], ["and", 1527], ["one", 1531], ["for", 1535], ["fulranumab", 1539], [".", 1549], ["Only", 1551], ["the", 1556], ["tanezumab", 1560], ["studies", 1570], ["showed", 1578], ["any", 1585], ["significant", 1589], ["difference", 1601], ["over", 1612], ["placebo", 1617], ["(", 1625], ["n", 1626], ["=", 1628], ["1,563", 1630], [")", 1635], ["for", 1637], ["both", 1641], ["pain", 1646], ["relief", 1651], ["and", 1658], ["functional", 1662], ["improvement", 1673], [".", 1684], ["There", 1686], ["is", 1692], ["very", 1695], ["low", 1700], ["evidence", 1704], ["that", 1713], ["systemically", 1718], ["administered", 1731], ["anti", 1744], ["-", 1748], ["NGF", 1749], ["therapy", 1753], ["has", 1761], ["a", 1765], ["small", 1767], ["positive", 1773], ["effect", 1782], ["compared", 1789], ["to", 1798], ["placebo", 1801], ["for", 1809], ["both", 1813], ["pain", 1818], ["relief", 1823], ["(", 1830], ["standarized", 1831], ["mean", 1843], ["difference", 1848], ["[", 1859], ["SMD", 1860], ["]", 1863], ["=", 1865], ["-0.29", 1867], [",", 1872], ["95", 1874], ["%", 1876], ["confidence", 1878], ["interval", 1889], ["[", 1898], ["CI", 1899], ["]", 1901], ["-0.58", 1903], ["to", 1909], ["0.00", 1912], [")", 1916], ["and", 1918], ["functional", 1922], ["improvement", 1933], ["(", 1945], ["SMD", 1946], ["=", 1950], ["-0.21", 1952], [",", 1957], ["95%CI", 1959], ["-0.37", 1965], ["to", 1971], ["-0.05", 1974], [")", 1980], ["of", 1982], ["low", 1985], ["back", 1989], ["pain", 1994], [".", 1998], ["There", 2000], ["was", 2006], ["low", 2010], ["evidence", 2014], ["of", 2023], ["adverse", 2026], ["effects", 2034], ["(", 2042], ["AEs", 2043], [")", 2046], ["compared", 2048], ["to", 2057], ["placebo", 2060], ["and", 2068], ["low", 2072], ["evidence", 2076], ["of", 2085], ["neurological", 2088], ["AEs", 2101], ["than", 2105], ["placebo", 2110], ["(", 2118], ["relative", 2119], ["risk", 2128], ["=", 2133], ["1.93", 2135], [",", 2139], ["95%CI", 2141], ["1.41", 2147], ["to", 2152], ["2.64).Tanezumab", 2155], [",", 2170], ["as", 2172], ["a", 2175], ["specific", 2177], ["anti", 2186], ["-", 2190], ["NGF", 2191], ["treatment", 2195], [",", 2204], ["showed", 2206], ["low", 2213], ["evidence", 2217], ["of", 2226], ["a", 2229], ["small", 2231], ["to", 2237], ["moderate", 2240], ["effect", 2249], ["for", 2256], ["pain", 2260], ["relief", 2265], ["of", 2272], ["low", 2275], ["back", 2279], ["pain", 2284], ["(", 2289], ["SMD", 2290], ["=", 2294], ["-0.44", 2296], [",", 2301], ["95%CI", 2303], ["-0.81", 2309], ["to", 2315], ["-0.07", 2318], [")", 2323], [";", 2324], ["and", 2326], ["low", 2330], ["evidence", 2334], ["of", 2343], ["a", 2346], ["small", 2348], ["effect", 2354], ["for", 2361], ["functional", 2365], ["improvement", 2376], ["(", 2388], ["SMD", 2389], ["=", 2393], ["-0.26", 2395], [",", 2400], ["95%CI", 2402], ["-0.40", 2408], ["to", 2414], ["-0.12", 2417], [")", 2422], ["with", 2424], ["systemic", 2429], ["administration", 2438], [",", 2452], ["although", 2454], ["not", 2463], ["clinically", 2467], ["significant", 2478], [".", 2489], ["Tanezumab", 2491], ["and", 2501], ["anti", 2505], ["-", 2509], ["NGFs", 2510], ["overall", 2515], ["had", 2523], [",", 2526], ["respectively", 2528], [",", 2540], ["moderate", 2542], ["and", 2551], ["low", 2555], ["evidence", 2559], ["of", 2568], ["overall", 2571], ["AEs", 2579], ["and", 2583], ["serious", 2587], ["AEs", 2595], ["and", 2599], ["a", 2603], ["higher", 2605], ["risk", 2612], ["of", 2617], ["developing", 2620], ["neurological", 2631], ["AEs", 2644], ["when", 2648], ["compared", 2653], ["with", 2662], ["placebo", 2667], [".", 2674], ["Although", 2676], ["anti", 2685], ["-", 2689], ["NGF", 2690], [",", 2693], ["specifically", 2695], ["tanezumab", 2708], [",", 2717], ["showed", 2719], ["a", 2726], ["low", 2728], ["-", 2731], ["to", 2732], ["-", 2734], ["moderate", 2735], ["effect", 2744], ["on", 2751], ["pain", 2754], ["relief", 2759], ["and", 2766], ["functional", 2770], ["improvement", 2781], [",", 2792], ["it", 2794], ["can", 2797], ["not", 2800], ["be", 2804], ["recommended", 2807], ["for", 2819], ["low", 2823], ["back", 2827], ["pain", 2832], ["treatment", 2837], [".", 2846], ["Without", 2848], ["more", 2856], ["research", 2861], ["on", 2870], ["the", 2873], ["pathophysiology", 2877], ["of", 2893], ["anti", 2896], ["-", 2900], ["NGFs", 2901], ["and", 2906], ["adverse", 2910], ["effects", 2918], [",", 2925], ["its", 2927], ["use", 2931], ["is", 2935], ["not", 2938], ["safe", 2942], ["in", 2947], ["the", 2950], ["overall", 2954], ["population", 2962], [".", 2972], ["However", 2974], [",", 2981], ["as", 2983], ["corroborated", 2986], ["by", 2999], ["the", 3002], ["US", 3006], ["Food", 3009], ["and", 3014], ["Drug", 3018], ["Administration", 3023], [",", 3037], ["this", 3039], ["meta", 3044], ["-", 3048], ["analysis", 3049], ["underscores", 3058], ["a", 3070], ["role", 3072], ["for", 3077], ["greater", 3081], ["insight", 3089], ["into", 3097], ["anti", 3102], ["-", 3106], ["NGF", 3107], ["therapy", 3111], ["for", 3119], ["painful", 3123], ["conditions", 3131], ["that", 3142], ["are", 3147], ["refractory", 3151], ["to", 3162], ["current", 3165], ["drugs", 3173], [",", 3178], ["such", 3180], ["as", 3185], ["oncologic", 3188], ["pain", 3198], [",", 3202], ["chronic", 3204], ["pancreatitis", 3212], [",", 3224], ["and", 3226], ["phantom", 3230], ["-", 3237], ["limb", 3238], ["pain", 3243], [".", 3247], ["Given", 3249], ["the", 3255], ["pathophysiology", 3259], ["of", 3275], ["axial", 3278], ["pain", 3284], ["involving", 3289], ["inflammatory", 3299], ["mediators", 3312], ["and", 3322], ["the", 3326], ["adverse", 3330], ["effects", 3338], ["of", 3346], ["systemic", 3349], ["anti", 3358], ["-", 3362], ["NGF", 3363], ["use", 3367], [",", 3370], ["consideration", 3372], ["of", 3386], ["local", 3389], ["therapies", 3395], ["may", 3405], ["warrant", 3409], ["further", 3417], ["exploration", 3425], [".", 3436]]}
{"context": "Direct oral anticoagulants (DOACs) offer noninferior efficacy and improved safety compared to vitamin K antagonists (VKAs) for the prevention and treatment of venous thromboembolism and for the prevention of stroke and systemic embolism in nonvalvular atrial fibrillation. Unlike VKAs, DOACs do not require routine laboratory monitoring of anticoagulant effect and dose adjustment. In certain situations, however, laboratory assessment of anticoagulant effect may be desirable. Here we review the utility of currently available assays for assessment of DOAC effect and recommend an optimal assessment strategy for each drug, including calibrated dilute thrombin time or ecarin-based assays for dabigatran and calibrated anti-Xa activity assays for the factor Xa inhibitors. We also discuss reversal strategies, both specific and nonspecific, for each drug, including the preferential use of idarucizumab for the reversal of dabigatran and two agents, andexanet and ciraparantag, currently under development for the reversal of rivaroxaban, apixaban, and edoxaban.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "e6ccf71d79284970a5d7adfff0807ec8", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[148, 148], [109, 109]], "char_spans": [[924, 933], [694, 703]]}]}], "context_tokens": [["Direct", 0], ["oral", 7], ["anticoagulants", 12], ["(", 27], ["DOACs", 28], [")", 33], ["offer", 35], ["noninferior", 41], ["efficacy", 53], ["and", 62], ["improved", 66], ["safety", 75], ["compared", 82], ["to", 91], ["vitamin", 94], ["K", 102], ["antagonists", 104], ["(", 116], ["VKAs", 117], [")", 121], ["for", 123], ["the", 127], ["prevention", 131], ["and", 142], ["treatment", 146], ["of", 156], ["venous", 159], ["thromboembolism", 166], ["and", 182], ["for", 186], ["the", 190], ["prevention", 194], ["of", 205], ["stroke", 208], ["and", 215], ["systemic", 219], ["embolism", 228], ["in", 237], ["nonvalvular", 240], ["atrial", 252], ["fibrillation", 259], [".", 271], ["Unlike", 273], ["VKAs", 280], [",", 284], ["DOACs", 286], ["do", 292], ["not", 295], ["require", 299], ["routine", 307], ["laboratory", 315], ["monitoring", 326], ["of", 337], ["anticoagulant", 340], ["effect", 354], ["and", 361], ["dose", 365], ["adjustment", 370], [".", 380], ["In", 382], ["certain", 385], ["situations", 393], [",", 403], ["however", 405], [",", 412], ["laboratory", 414], ["assessment", 425], ["of", 436], ["anticoagulant", 439], ["effect", 453], ["may", 460], ["be", 464], ["desirable", 467], [".", 476], ["Here", 478], ["we", 483], ["review", 486], ["the", 493], ["utility", 497], ["of", 505], ["currently", 508], ["available", 518], ["assays", 528], ["for", 535], ["assessment", 539], ["of", 550], ["DOAC", 553], ["effect", 558], ["and", 565], ["recommend", 569], ["an", 579], ["optimal", 582], ["assessment", 590], ["strategy", 601], ["for", 610], ["each", 614], ["drug", 619], [",", 623], ["including", 625], ["calibrated", 635], ["dilute", 646], ["thrombin", 653], ["time", 662], ["or", 667], ["ecarin", 670], ["-", 676], ["based", 677], ["assays", 683], ["for", 690], ["dabigatran", 694], ["and", 705], ["calibrated", 709], ["anti", 720], ["-", 724], ["Xa", 725], ["activity", 728], ["assays", 737], ["for", 744], ["the", 748], ["factor", 752], ["Xa", 759], ["inhibitors", 762], [".", 772], ["We", 774], ["also", 777], ["discuss", 782], ["reversal", 790], ["strategies", 799], [",", 809], ["both", 811], ["specific", 816], ["and", 825], ["nonspecific", 829], [",", 840], ["for", 842], ["each", 846], ["drug", 851], [",", 855], ["including", 857], ["the", 867], ["preferential", 871], ["use", 884], ["of", 888], ["idarucizumab", 891], ["for", 904], ["the", 908], ["reversal", 912], ["of", 921], ["dabigatran", 924], ["and", 935], ["two", 939], ["agents", 943], [",", 949], ["andexanet", 951], ["and", 961], ["ciraparantag", 965], [",", 977], ["currently", 979], ["under", 989], ["development", 995], ["for", 1007], ["the", 1011], ["reversal", 1015], ["of", 1024], ["rivaroxaban", 1027], [",", 1038], ["apixaban", 1040], [",", 1048], ["and", 1050], ["edoxaban", 1054], [".", 1062]]}
{"context": "A novel approach to design selective spleen tyrosine kinase (Syk) inhibitors is described. Inhibition of spleen tyrosine kinase has attracted much attention as a mechanism for the treatment of autoimmune diseases such as asthma, rheumatoid arthritis, and SLE. Fostamatinib, a Syk inhibitor that successfully completed phase II clinical trials, also exhibits some undesirable side effects. More selective Syk inhibitors could offer safer, alternative treatments. Through a systematic evaluation of the kinome, we identified Pro455 and Asn457 in the Syk ATP binding site as a rare combination among sequence aligned kinases and hypothesized that optimizing the interaction between them and a Syk inhibitor molecule would impart high selectivity for Syk over other kinases. We report the structure-guided identification of three series of selective spleen tyrosine kinase inhibitors that support our hypothesis and offer useful guidance to other researchers in the field.", "qas": [{"question": "Which enzyme is inhibited by a drug fostamatinib?", "answers": ["spleen tyrosine kinase"], "qid": "a684e2797a984c48b274c3513981d491", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["a", 29], ["drug", 31], ["fostamatinib", 36], ["?", 48]], "detected_answers": [{"text": "spleen tyrosine kinase", "token_spans": [[137, 139], [18, 20], [6, 8]], "char_spans": [[846, 867], [105, 126], [37, 58]]}]}], "context_tokens": [["A", 0], ["novel", 2], ["approach", 8], ["to", 17], ["design", 20], ["selective", 27], ["spleen", 37], ["tyrosine", 44], ["kinase", 53], ["(", 60], ["Syk", 61], [")", 64], ["inhibitors", 66], ["is", 77], ["described", 80], [".", 89], ["Inhibition", 91], ["of", 102], ["spleen", 105], ["tyrosine", 112], ["kinase", 121], ["has", 128], ["attracted", 132], ["much", 142], ["attention", 147], ["as", 157], ["a", 160], ["mechanism", 162], ["for", 172], ["the", 176], ["treatment", 180], ["of", 190], ["autoimmune", 193], ["diseases", 204], ["such", 213], ["as", 218], ["asthma", 221], [",", 227], ["rheumatoid", 229], ["arthritis", 240], [",", 249], ["and", 251], ["SLE", 255], [".", 258], ["Fostamatinib", 260], [",", 272], ["a", 274], ["Syk", 276], ["inhibitor", 280], ["that", 290], ["successfully", 295], ["completed", 308], ["phase", 318], ["II", 324], ["clinical", 327], ["trials", 336], [",", 342], ["also", 344], ["exhibits", 349], ["some", 358], ["undesirable", 363], ["side", 375], ["effects", 380], [".", 387], ["More", 389], ["selective", 394], ["Syk", 404], ["inhibitors", 408], ["could", 419], ["offer", 425], ["safer", 431], [",", 436], ["alternative", 438], ["treatments", 450], [".", 460], ["Through", 462], ["a", 470], ["systematic", 472], ["evaluation", 483], ["of", 494], ["the", 497], ["kinome", 501], [",", 507], ["we", 509], ["identified", 512], ["Pro455", 523], ["and", 530], ["Asn457", 534], ["in", 541], ["the", 544], ["Syk", 548], ["ATP", 552], ["binding", 556], ["site", 564], ["as", 569], ["a", 572], ["rare", 574], ["combination", 579], ["among", 591], ["sequence", 597], ["aligned", 606], ["kinases", 614], ["and", 622], ["hypothesized", 626], ["that", 639], ["optimizing", 644], ["the", 655], ["interaction", 659], ["between", 671], ["them", 679], ["and", 684], ["a", 688], ["Syk", 690], ["inhibitor", 694], ["molecule", 704], ["would", 713], ["impart", 719], ["high", 726], ["selectivity", 731], ["for", 743], ["Syk", 747], ["over", 751], ["other", 756], ["kinases", 762], [".", 769], ["We", 771], ["report", 774], ["the", 781], ["structure", 785], ["-", 794], ["guided", 795], ["identification", 802], ["of", 817], ["three", 820], ["series", 826], ["of", 833], ["selective", 836], ["spleen", 846], ["tyrosine", 853], ["kinase", 862], ["inhibitors", 869], ["that", 880], ["support", 885], ["our", 893], ["hypothesis", 897], ["and", 908], ["offer", 912], ["useful", 918], ["guidance", 925], ["to", 934], ["other", 937], ["researchers", 943], ["in", 955], ["the", 958], ["field", 962], [".", 967]]}
{"context": "In chronic myelogenous leukemia (CML), the development of chromosomal abnormalities in addition to the Philadelphia chromosome (clonal evolution) is considered by many to be a feature of accelerated phase (AP). Imatinib mesylate (STI571), a selective inhibitor of the Bcr-Abl tyrosine kinase, has significant activity in AP CML. As clonal evolution could allow Bcr-Abl independent proliferation, we analyzed its impact on the outcome of 71 AP patients treated with 600 mg of imatinib mesylate. Fifteen patients had clonal evolution alone (AP-CE), 32 had AP features but no evidence of clonal evolution (HEM-AP), and 24 had AP features plus clonal evolution (HEM-AP + CE). Of the AP-CE patients, 73% had a major cytogenetic response, compared with 31% of the HEM-AP patients (P =.043) and 12.5% of the HEM-AP + CE patients (P =.007). Complete cytogenetic responses were seen in 60% of AP-CE patients, compared with 31% of HEM-AP patients (P =.19) and 8% of HEM-AP + CE patients (P <.001). With mean follow-up of 11.2 months, 35% of all patients failed treatment. The lowest estimated rate of treatment failure at 1 year, 0%, was seen in AP-CE patients, compared with rates of 31% for HEM-AP patients and 69% for HEM-AP + CE patients (P =.0004). After 1 year, 100% of AP-CE patients were still alive, compared with 85% of HEM-AP patients and 67.5% of HEM-AP + CE patients (P =.01). In conclusion, in patients with clonal evolution as the sole criterion of disease acceleration, good responses to imatinib are still possible. Once patients have other signs of acceleration, clonal evolution predicts lower response rates and a shorter time to treatment failure.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "3cc897405a194e8f95127a9560586a7a", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[49, 51], [67, 69]], "char_spans": [[268, 274], [361, 367]]}]}], "context_tokens": [["In", 0], ["chronic", 3], ["myelogenous", 11], ["leukemia", 23], ["(", 32], ["CML", 33], [")", 36], [",", 37], ["the", 39], ["development", 43], ["of", 55], ["chromosomal", 58], ["abnormalities", 70], ["in", 84], ["addition", 87], ["to", 96], ["the", 99], ["Philadelphia", 103], ["chromosome", 116], ["(", 127], ["clonal", 128], ["evolution", 135], [")", 144], ["is", 146], ["considered", 149], ["by", 160], ["many", 163], ["to", 168], ["be", 171], ["a", 174], ["feature", 176], ["of", 184], ["accelerated", 187], ["phase", 199], ["(", 205], ["AP", 206], [")", 208], [".", 209], ["Imatinib", 211], ["mesylate", 220], ["(", 229], ["STI571", 230], [")", 236], [",", 237], ["a", 239], ["selective", 241], ["inhibitor", 251], ["of", 261], ["the", 264], ["Bcr", 268], ["-", 271], ["Abl", 272], ["tyrosine", 276], ["kinase", 285], [",", 291], ["has", 293], ["significant", 297], ["activity", 309], ["in", 318], ["AP", 321], ["CML", 324], [".", 327], ["As", 329], ["clonal", 332], ["evolution", 339], ["could", 349], ["allow", 355], ["Bcr", 361], ["-", 364], ["Abl", 365], ["independent", 369], ["proliferation", 381], [",", 394], ["we", 396], ["analyzed", 399], ["its", 408], ["impact", 412], ["on", 419], ["the", 422], ["outcome", 426], ["of", 434], ["71", 437], ["AP", 440], ["patients", 443], ["treated", 452], ["with", 460], ["600", 465], ["mg", 469], ["of", 472], ["imatinib", 475], ["mesylate", 484], [".", 492], ["Fifteen", 494], ["patients", 502], ["had", 511], ["clonal", 515], ["evolution", 522], ["alone", 532], ["(", 538], ["AP", 539], ["-", 541], ["CE", 542], [")", 544], [",", 545], ["32", 547], ["had", 550], ["AP", 554], ["features", 557], ["but", 566], ["no", 570], ["evidence", 573], ["of", 582], ["clonal", 585], ["evolution", 592], ["(", 602], ["HEM", 603], ["-", 606], ["AP", 607], [")", 609], [",", 610], ["and", 612], ["24", 616], ["had", 619], ["AP", 623], ["features", 626], ["plus", 635], ["clonal", 640], ["evolution", 647], ["(", 657], ["HEM", 658], ["-", 661], ["AP", 662], ["+", 665], ["CE", 667], [")", 669], [".", 670], ["Of", 672], ["the", 675], ["AP", 679], ["-", 681], ["CE", 682], ["patients", 685], [",", 693], ["73", 695], ["%", 697], ["had", 699], ["a", 703], ["major", 705], ["cytogenetic", 711], ["response", 723], [",", 731], ["compared", 733], ["with", 742], ["31", 747], ["%", 749], ["of", 751], ["the", 754], ["HEM", 758], ["-", 761], ["AP", 762], ["patients", 765], ["(", 774], ["P", 775], ["=", 777], [".043", 778], [")", 782], ["and", 784], ["12.5", 788], ["%", 792], ["of", 794], ["the", 797], ["HEM", 801], ["-", 804], ["AP", 805], ["+", 808], ["CE", 810], ["patients", 813], ["(", 822], ["P", 823], ["=", 825], [".007", 826], [")", 830], [".", 831], ["Complete", 833], ["cytogenetic", 842], ["responses", 854], ["were", 864], ["seen", 869], ["in", 874], ["60", 877], ["%", 879], ["of", 881], ["AP", 884], ["-", 886], ["CE", 887], ["patients", 890], [",", 898], ["compared", 900], ["with", 909], ["31", 914], ["%", 916], ["of", 918], ["HEM", 921], ["-", 924], ["AP", 925], ["patients", 928], ["(", 937], ["P", 938], ["=", 940], [".19", 941], [")", 944], ["and", 946], ["8", 950], ["%", 951], ["of", 953], ["HEM", 956], ["-", 959], ["AP", 960], ["+", 963], ["CE", 965], ["patients", 968], ["(", 977], ["P", 978], ["<", 980], [".001", 981], [")", 985], [".", 986], ["With", 988], ["mean", 993], ["follow", 998], ["-", 1004], ["up", 1005], ["of", 1008], ["11.2", 1011], ["months", 1016], [",", 1022], ["35", 1024], ["%", 1026], ["of", 1028], ["all", 1031], ["patients", 1035], ["failed", 1044], ["treatment", 1051], [".", 1060], ["The", 1062], ["lowest", 1066], ["estimated", 1073], ["rate", 1083], ["of", 1088], ["treatment", 1091], ["failure", 1101], ["at", 1109], ["1", 1112], ["year", 1114], [",", 1118], ["0", 1120], ["%", 1121], [",", 1122], ["was", 1124], ["seen", 1128], ["in", 1133], ["AP", 1136], ["-", 1138], ["CE", 1139], ["patients", 1142], [",", 1150], ["compared", 1152], ["with", 1161], ["rates", 1166], ["of", 1172], ["31", 1175], ["%", 1177], ["for", 1179], ["HEM", 1183], ["-", 1186], ["AP", 1187], ["patients", 1190], ["and", 1199], ["69", 1203], ["%", 1205], ["for", 1207], ["HEM", 1211], ["-", 1214], ["AP", 1215], ["+", 1218], ["CE", 1220], ["patients", 1223], ["(", 1232], ["P", 1233], ["=", 1235], [".0004", 1236], [")", 1241], [".", 1242], ["After", 1244], ["1", 1250], ["year", 1252], [",", 1256], ["100", 1258], ["%", 1261], ["of", 1263], ["AP", 1266], ["-", 1268], ["CE", 1269], ["patients", 1272], ["were", 1281], ["still", 1286], ["alive", 1292], [",", 1297], ["compared", 1299], ["with", 1308], ["85", 1313], ["%", 1315], ["of", 1317], ["HEM", 1320], ["-", 1323], ["AP", 1324], ["patients", 1327], ["and", 1336], ["67.5", 1340], ["%", 1344], ["of", 1346], ["HEM", 1349], ["-", 1352], ["AP", 1353], ["+", 1356], ["CE", 1358], ["patients", 1361], ["(", 1370], ["P", 1371], ["=", 1373], [".01", 1374], [")", 1377], [".", 1378], ["In", 1380], ["conclusion", 1383], [",", 1393], ["in", 1395], ["patients", 1398], ["with", 1407], ["clonal", 1412], ["evolution", 1419], ["as", 1429], ["the", 1432], ["sole", 1436], ["criterion", 1441], ["of", 1451], ["disease", 1454], ["acceleration", 1462], [",", 1474], ["good", 1476], ["responses", 1481], ["to", 1491], ["imatinib", 1494], ["are", 1503], ["still", 1507], ["possible", 1513], [".", 1521], ["Once", 1523], ["patients", 1528], ["have", 1537], ["other", 1542], ["signs", 1548], ["of", 1554], ["acceleration", 1557], [",", 1569], ["clonal", 1571], ["evolution", 1578], ["predicts", 1588], ["lower", 1597], ["response", 1603], ["rates", 1612], ["and", 1618], ["a", 1622], ["shorter", 1624], ["time", 1632], ["to", 1637], ["treatment", 1640], ["failure", 1650], [".", 1657]]}
{"context": "Allele-specific gene silencing by RNA interference (RNAi) is therapeutically useful for specifically suppressing the expression of alleles associated with disease. To realize such allele-specific RNAi (ASPRNAi), the design and assessment of small interfering RNA (siRNA) duplexes conferring ASP-RNAi is vital, but is also difficult. Here, we show ASP-RNAi against the Swedish- and London-type amyloid precursor protein (APP) variants related to familial Alzheimer's disease using two reporter alleles encoding the Photinus and Renilla luciferase genes and carrying mutant and wild-type allelic sequences in their 3'-untranslated regions. We examined the effects of siRNA duplexes against the mutant alleles in allele-specific gene silencing and off-target silencing against the wild-type allele under heterozygous conditions, which were generated by cotransfecting the reporter alleles and siRNA duplexes into cultured human cells. Consistently, the siRNA duplexes determined to confer ASP-RNAi also inhibited the expression of the bona fide mutant APP and the production of either amyloid beta 40- or 42-peptide in Cos-7 cells expressing both the full-length Swedish- and wild-type APP alleles. The present data suggest that the system with reporter alleles may permit the preclinical assessment of siRNA duplexes conferring ASP-RNAi, and thus contribute to the design and selection of the most suitable of such siRNA duplexes.", "qas": [{"question": "Which disease the London mutation involved in?", "answers": ["Alzheimer's Disease", "AD"], "qid": "32973e8f67554664bd82736f4b992923", "question_tokens": [["Which", 0], ["disease", 6], ["the", 14], ["London", 18], ["mutation", 25], ["involved", 34], ["in", 43], ["?", 45]], "detected_answers": [{"text": "Alzheimer's Disease", "token_spans": [[84, 86]], "char_spans": [[454, 472]]}]}], "context_tokens": [["Allele", 0], ["-", 6], ["specific", 7], ["gene", 16], ["silencing", 21], ["by", 31], ["RNA", 34], ["interference", 38], ["(", 51], ["RNAi", 52], [")", 56], ["is", 58], ["therapeutically", 61], ["useful", 77], ["for", 84], ["specifically", 88], ["suppressing", 101], ["the", 113], ["expression", 117], ["of", 128], ["alleles", 131], ["associated", 139], ["with", 150], ["disease", 155], [".", 162], ["To", 164], ["realize", 167], ["such", 175], ["allele", 180], ["-", 186], ["specific", 187], ["RNAi", 196], ["(", 201], ["ASPRNAi", 202], [")", 209], [",", 210], ["the", 212], ["design", 216], ["and", 223], ["assessment", 227], ["of", 238], ["small", 241], ["interfering", 247], ["RNA", 259], ["(", 263], ["siRNA", 264], [")", 269], ["duplexes", 271], ["conferring", 280], ["ASP", 291], ["-", 294], ["RNAi", 295], ["is", 300], ["vital", 303], [",", 308], ["but", 310], ["is", 314], ["also", 317], ["difficult", 322], [".", 331], ["Here", 333], [",", 337], ["we", 339], ["show", 342], ["ASP", 347], ["-", 350], ["RNAi", 351], ["against", 356], ["the", 364], ["Swedish-", 368], ["and", 377], ["London", 381], ["-", 387], ["type", 388], ["amyloid", 393], ["precursor", 401], ["protein", 411], ["(", 419], ["APP", 420], [")", 423], ["variants", 425], ["related", 434], ["to", 442], ["familial", 445], ["Alzheimer", 454], ["'s", 463], ["disease", 466], ["using", 474], ["two", 480], ["reporter", 484], ["alleles", 493], ["encoding", 501], ["the", 510], ["Photinus", 514], ["and", 523], ["Renilla", 527], ["luciferase", 535], ["genes", 546], ["and", 552], ["carrying", 556], ["mutant", 565], ["and", 572], ["wild", 576], ["-", 580], ["type", 581], ["allelic", 586], ["sequences", 594], ["in", 604], ["their", 607], ["3'-untranslated", 613], ["regions", 629], [".", 636], ["We", 638], ["examined", 641], ["the", 650], ["effects", 654], ["of", 662], ["siRNA", 665], ["duplexes", 671], ["against", 680], ["the", 688], ["mutant", 692], ["alleles", 699], ["in", 707], ["allele", 710], ["-", 716], ["specific", 717], ["gene", 726], ["silencing", 731], ["and", 741], ["off", 745], ["-", 748], ["target", 749], ["silencing", 756], ["against", 766], ["the", 774], ["wild", 778], ["-", 782], ["type", 783], ["allele", 788], ["under", 795], ["heterozygous", 801], ["conditions", 814], [",", 824], ["which", 826], ["were", 832], ["generated", 837], ["by", 847], ["cotransfecting", 850], ["the", 865], ["reporter", 869], ["alleles", 878], ["and", 886], ["siRNA", 890], ["duplexes", 896], ["into", 905], ["cultured", 910], ["human", 919], ["cells", 925], [".", 930], ["Consistently", 932], [",", 944], ["the", 946], ["siRNA", 950], ["duplexes", 956], ["determined", 965], ["to", 976], ["confer", 979], ["ASP", 986], ["-", 989], ["RNAi", 990], ["also", 995], ["inhibited", 1000], ["the", 1010], ["expression", 1014], ["of", 1025], ["the", 1028], ["bona", 1032], ["fide", 1037], ["mutant", 1042], ["APP", 1049], ["and", 1053], ["the", 1057], ["production", 1061], ["of", 1072], ["either", 1075], ["amyloid", 1082], ["beta", 1090], ["40-", 1095], ["or", 1099], ["42-peptide", 1102], ["in", 1113], ["Cos-7", 1116], ["cells", 1122], ["expressing", 1128], ["both", 1139], ["the", 1144], ["full", 1148], ["-", 1152], ["length", 1153], ["Swedish-", 1160], ["and", 1169], ["wild", 1173], ["-", 1177], ["type", 1178], ["APP", 1183], ["alleles", 1187], [".", 1194], ["The", 1196], ["present", 1200], ["data", 1208], ["suggest", 1213], ["that", 1221], ["the", 1226], ["system", 1230], ["with", 1237], ["reporter", 1242], ["alleles", 1251], ["may", 1259], ["permit", 1263], ["the", 1270], ["preclinical", 1274], ["assessment", 1286], ["of", 1297], ["siRNA", 1300], ["duplexes", 1306], ["conferring", 1315], ["ASP", 1326], ["-", 1329], ["RNAi", 1330], [",", 1334], ["and", 1336], ["thus", 1340], ["contribute", 1345], ["to", 1356], ["the", 1359], ["design", 1363], ["and", 1370], ["selection", 1374], ["of", 1384], ["the", 1387], ["most", 1391], ["suitable", 1396], ["of", 1405], ["such", 1408], ["siRNA", 1413], ["duplexes", 1419], [".", 1427]]}
{"context": "NADPH oxidase 1 (Nox1) is a multicomponent enzyme consisting of p22(phox), Nox organizer 1 (NOXO1), Nox1 activator 1, and Rac1. Interleukin-1beta, flagellin, interferon-gamma, and tumor necrosis factor alpha (TNF-alpha) similarly induced Nox1 in a colon cancer cell line (T84), whereas only TNF-alpha fully induced NOXO1 and upregulated superoxide-producing activity by ninefold. This upregulation was canceled by knockdown of NOXO1 with small interfering RNAs. TNF-alpha rapidly phosphorylated p38 mitogen-activated protein kinase and c-Jun N-terminal kinase 1/2, followed by phosphorylation of c-Jun and c-Fos and appearance of an AP-1 binding activity within 30 min. We cloned the 5' flank of the human NOXO1 gene (-3888 to +263 bp), and found that the region between -585 and -452 bp, which contains consensus elements of YY-1, AP-1, and Ets, and the GC-rich region encoding three putative binding sites for SP-1, was crucial for TNF-alpha-dependent promoter activity. Serial mutation analysis of the elements identified an AP-1 binding site (from -561 to -551 bp, agtAAGtcatg) as a crucial element for TNF-alpha-stimulated transcription of the human NOXO1 gene, which was also confirmed by the AP-1 decoy experiments. Thus, TNF-alpha acts as a potent activator of Nox1-based oxidase in colon epithelial cells, suggesting a potential role of this oxidase in inflammation of the colon.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "6779bef390824d269a423840772240f6", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NADPH oxidase 1", "token_spans": [[0, 2]], "char_spans": [[0, 14]]}, {"text": "NOX1", "token_spans": [[4, 4], [49, 49], [22, 22]], "char_spans": [[17, 20], [238, 241], [100, 103]]}]}], "context_tokens": [["NADPH", 0], ["oxidase", 6], ["1", 14], ["(", 16], ["Nox1", 17], [")", 21], ["is", 23], ["a", 26], ["multicomponent", 28], ["enzyme", 43], ["consisting", 50], ["of", 61], ["p22(phox", 64], [")", 72], [",", 73], ["Nox", 75], ["organizer", 79], ["1", 89], ["(", 91], ["NOXO1", 92], [")", 97], [",", 98], ["Nox1", 100], ["activator", 105], ["1", 115], [",", 116], ["and", 118], ["Rac1", 122], [".", 126], ["Interleukin-1beta", 128], [",", 145], ["flagellin", 147], [",", 156], ["interferon", 158], ["-", 168], ["gamma", 169], [",", 174], ["and", 176], ["tumor", 180], ["necrosis", 186], ["factor", 195], ["alpha", 202], ["(", 208], ["TNF", 209], ["-", 212], ["alpha", 213], [")", 218], ["similarly", 220], ["induced", 230], ["Nox1", 238], ["in", 243], ["a", 246], ["colon", 248], ["cancer", 254], ["cell", 261], ["line", 266], ["(", 271], ["T84", 272], [")", 275], [",", 276], ["whereas", 278], ["only", 286], ["TNF", 291], ["-", 294], ["alpha", 295], ["fully", 301], ["induced", 307], ["NOXO1", 315], ["and", 321], ["upregulated", 325], ["superoxide", 337], ["-", 347], ["producing", 348], ["activity", 358], ["by", 367], ["ninefold", 370], [".", 378], ["This", 380], ["upregulation", 385], ["was", 398], ["canceled", 402], ["by", 411], ["knockdown", 414], ["of", 424], ["NOXO1", 427], ["with", 433], ["small", 438], ["interfering", 444], ["RNAs", 456], [".", 460], ["TNF", 462], ["-", 465], ["alpha", 466], ["rapidly", 472], ["phosphorylated", 480], ["p38", 495], ["mitogen", 499], ["-", 506], ["activated", 507], ["protein", 517], ["kinase", 525], ["and", 532], ["c", 536], ["-", 537], ["Jun", 538], ["N", 542], ["-", 543], ["terminal", 544], ["kinase", 553], ["1/2", 560], [",", 563], ["followed", 565], ["by", 574], ["phosphorylation", 577], ["of", 593], ["c", 596], ["-", 597], ["Jun", 598], ["and", 602], ["c", 606], ["-", 607], ["Fos", 608], ["and", 612], ["appearance", 616], ["of", 627], ["an", 630], ["AP-1", 633], ["binding", 638], ["activity", 646], ["within", 655], ["30", 662], ["min", 665], [".", 668], ["We", 670], ["cloned", 673], ["the", 680], ["5", 684], ["'", 685], ["flank", 687], ["of", 693], ["the", 696], ["human", 700], ["NOXO1", 706], ["gene", 712], ["(", 717], ["-3888", 718], ["to", 724], ["+263", 727], ["bp", 732], [")", 734], [",", 735], ["and", 737], ["found", 741], ["that", 747], ["the", 752], ["region", 756], ["between", 763], ["-585", 771], ["and", 776], ["-452", 780], ["bp", 785], [",", 787], ["which", 789], ["contains", 795], ["consensus", 804], ["elements", 814], ["of", 823], ["YY-1", 826], [",", 830], ["AP-1", 832], [",", 836], ["and", 838], ["Ets", 842], [",", 845], ["and", 847], ["the", 851], ["GC", 855], ["-", 857], ["rich", 858], ["region", 863], ["encoding", 870], ["three", 879], ["putative", 885], ["binding", 894], ["sites", 902], ["for", 908], ["SP-1", 912], [",", 916], ["was", 918], ["crucial", 922], ["for", 930], ["TNF", 934], ["-", 937], ["alpha", 938], ["-", 943], ["dependent", 944], ["promoter", 954], ["activity", 963], [".", 971], ["Serial", 973], ["mutation", 980], ["analysis", 989], ["of", 998], ["the", 1001], ["elements", 1005], ["identified", 1014], ["an", 1025], ["AP-1", 1028], ["binding", 1033], ["site", 1041], ["(", 1046], ["from", 1047], ["-561", 1052], ["to", 1057], ["-551", 1060], ["bp", 1065], [",", 1067], ["agtAAGtcatg", 1069], [")", 1080], ["as", 1082], ["a", 1085], ["crucial", 1087], ["element", 1095], ["for", 1103], ["TNF", 1107], ["-", 1110], ["alpha", 1111], ["-", 1116], ["stimulated", 1117], ["transcription", 1128], ["of", 1142], ["the", 1145], ["human", 1149], ["NOXO1", 1155], ["gene", 1161], [",", 1165], ["which", 1167], ["was", 1173], ["also", 1177], ["confirmed", 1182], ["by", 1192], ["the", 1195], ["AP-1", 1199], ["decoy", 1204], ["experiments", 1210], [".", 1221], ["Thus", 1223], [",", 1227], ["TNF", 1229], ["-", 1232], ["alpha", 1233], ["acts", 1239], ["as", 1244], ["a", 1247], ["potent", 1249], ["activator", 1256], ["of", 1266], ["Nox1-based", 1269], ["oxidase", 1280], ["in", 1288], ["colon", 1291], ["epithelial", 1297], ["cells", 1308], [",", 1313], ["suggesting", 1315], ["a", 1326], ["potential", 1328], ["role", 1338], ["of", 1343], ["this", 1346], ["oxidase", 1351], ["in", 1359], ["inflammation", 1362], ["of", 1375], ["the", 1378], ["colon", 1382], [".", 1387]]}
{"context": "Machado-Joseph disease (MJD), also called spinocerebellar ataxia type 3, is caused by mutant ataxin-3 with a polyglutamine expansion. Although there is no treatment available at present to cure or delay the onset of MJD, mouse models have been generated to facilitate the development of a therapy. In this review, the published reports on mouse models of MJD and other polyglutamine spinocerebellar ataxias are compared. Based on these studies, the following approaches will be discussed as candidate treatments for MJD: 1) interfering with the formation of the mutant ataxin-3 cleavage fragment and possibly aggregate or inclusions, 2) reducing the disease protein nuclear localization, and 3) decreasing mutant ataxin-3 expression in neurons.", "qas": [{"question": "Which is the protein implicated in Spinocerebellar ataxia type 3?", "answers": ["Ataxin-3"], "qid": "e0187e9fdece45e5bba46192786ac6b4", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["protein", 13], ["implicated", 21], ["in", 32], ["Spinocerebellar", 35], ["ataxia", 51], ["type", 58], ["3", 63], ["?", 64]], "detected_answers": [{"text": "Ataxin-3", "token_spans": [[124, 124], [19, 19], [101, 101]], "char_spans": [[713, 720], [93, 100], [569, 576]]}]}], "context_tokens": [["Machado", 0], ["-", 7], ["Joseph", 8], ["disease", 15], ["(", 23], ["MJD", 24], [")", 27], [",", 28], ["also", 30], ["called", 35], ["spinocerebellar", 42], ["ataxia", 58], ["type", 65], ["3", 70], [",", 71], ["is", 73], ["caused", 76], ["by", 83], ["mutant", 86], ["ataxin-3", 93], ["with", 102], ["a", 107], ["polyglutamine", 109], ["expansion", 123], [".", 132], ["Although", 134], ["there", 143], ["is", 149], ["no", 152], ["treatment", 155], ["available", 165], ["at", 175], ["present", 178], ["to", 186], ["cure", 189], ["or", 194], ["delay", 197], ["the", 203], ["onset", 207], ["of", 213], ["MJD", 216], [",", 219], ["mouse", 221], ["models", 227], ["have", 234], ["been", 239], ["generated", 244], ["to", 254], ["facilitate", 257], ["the", 268], ["development", 272], ["of", 284], ["a", 287], ["therapy", 289], [".", 296], ["In", 298], ["this", 301], ["review", 306], [",", 312], ["the", 314], ["published", 318], ["reports", 328], ["on", 336], ["mouse", 339], ["models", 345], ["of", 352], ["MJD", 355], ["and", 359], ["other", 363], ["polyglutamine", 369], ["spinocerebellar", 383], ["ataxias", 399], ["are", 407], ["compared", 411], [".", 419], ["Based", 421], ["on", 427], ["these", 430], ["studies", 436], [",", 443], ["the", 445], ["following", 449], ["approaches", 459], ["will", 470], ["be", 475], ["discussed", 478], ["as", 488], ["candidate", 491], ["treatments", 501], ["for", 512], ["MJD", 516], [":", 519], ["1", 521], [")", 522], ["interfering", 524], ["with", 536], ["the", 541], ["formation", 545], ["of", 555], ["the", 558], ["mutant", 562], ["ataxin-3", 569], ["cleavage", 578], ["fragment", 587], ["and", 596], ["possibly", 600], ["aggregate", 609], ["or", 619], ["inclusions", 622], [",", 632], ["2", 634], [")", 635], ["reducing", 637], ["the", 646], ["disease", 650], ["protein", 658], ["nuclear", 666], ["localization", 674], [",", 686], ["and", 688], ["3", 692], [")", 693], ["decreasing", 695], ["mutant", 706], ["ataxin-3", 713], ["expression", 722], ["in", 733], ["neurons", 736], [".", 743]]}
{"context": "The acromelic dysplasia group includes three rare disorders: Weill-Marchesani syndrome (WMS), Geleophysic dysplasia (GD) and Acromicric dysplasia (AD) all characterized by short stature, short hands and stiff joints. The clinical overlap between the three disorders is striking. Indeed, in addition to the diagnostic criteria, they all share common features including delayed bone age, cone shaped epiphyses, thick skin and heart disease. In contrast, a microspherophakic lens seems to be a characteristic feature of WMS whereas hepatomegaly and a severe outcome are encountered only in the most severe forms of GD. Finally, WMS is transmitted either by an autosomal dominant or an autosomal recessive (AR) mode of inheritance, GD by an autosomal recessive mode of inheritance and AD by an autosomal dominant mode of inheritance. Using genetic approaches, we have identified the molecular basis of WMS and GD which both involved the same superfamily of proteins, the ADAMTS [A Disintegrin-like And Metalloproteinase domain (reprolysin type) with ThromboSpondin type 1 repeats (TSR)]. We have found ADAMTS10 mutations in the recessive form of WMS and Fibrillin 1 mutations in the dominant form of WMS. More recently, we have identified ADAMTSL2 mutations in GD. The function of ADAMTS1 0 and AD AMTSL 2 are unknown. But the findings of FBN1 and ADAMTS10 mutations in WMS suggest a direct link between the two proteins. Using a yeast double hybrid screen, we have identified LTBP1 (Latent TGFbeta Binding protein 1) as a partner of ADAMTSL2. The combination of these findings suggests that ADAMTS10 and ADAMTSL2 are both involved in the microfibrillar network.", "qas": [{"question": "What is the mode of inheritance of Acromicric dysplasia?", "answers": ["autosomal dominant"], "qid": "30fd38ce62fe459b88937446ee06bcbb", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Acromicric", 35], ["dysplasia", 46], ["?", 55]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[143, 144], [118, 119]], "char_spans": [[790, 807], [657, 674]]}]}], "context_tokens": [["The", 0], ["acromelic", 4], ["dysplasia", 14], ["group", 24], ["includes", 30], ["three", 39], ["rare", 45], ["disorders", 50], [":", 59], ["Weill", 61], ["-", 66], ["Marchesani", 67], ["syndrome", 78], ["(", 87], ["WMS", 88], [")", 91], [",", 92], ["Geleophysic", 94], ["dysplasia", 106], ["(", 116], ["GD", 117], [")", 119], ["and", 121], ["Acromicric", 125], ["dysplasia", 136], ["(", 146], ["AD", 147], [")", 149], ["all", 151], ["characterized", 155], ["by", 169], ["short", 172], ["stature", 178], [",", 185], ["short", 187], ["hands", 193], ["and", 199], ["stiff", 203], ["joints", 209], [".", 215], ["The", 217], ["clinical", 221], ["overlap", 230], ["between", 238], ["the", 246], ["three", 250], ["disorders", 256], ["is", 266], ["striking", 269], [".", 277], ["Indeed", 279], [",", 285], ["in", 287], ["addition", 290], ["to", 299], ["the", 302], ["diagnostic", 306], ["criteria", 317], [",", 325], ["they", 327], ["all", 332], ["share", 336], ["common", 342], ["features", 349], ["including", 358], ["delayed", 368], ["bone", 376], ["age", 381], [",", 384], ["cone", 386], ["shaped", 391], ["epiphyses", 398], [",", 407], ["thick", 409], ["skin", 415], ["and", 420], ["heart", 424], ["disease", 430], [".", 437], ["In", 439], ["contrast", 442], [",", 450], ["a", 452], ["microspherophakic", 454], ["lens", 472], ["seems", 477], ["to", 483], ["be", 486], ["a", 489], ["characteristic", 491], ["feature", 506], ["of", 514], ["WMS", 517], ["whereas", 521], ["hepatomegaly", 529], ["and", 542], ["a", 546], ["severe", 548], ["outcome", 555], ["are", 563], ["encountered", 567], ["only", 579], ["in", 584], ["the", 587], ["most", 591], ["severe", 596], ["forms", 603], ["of", 609], ["GD", 612], [".", 614], ["Finally", 616], [",", 623], ["WMS", 625], ["is", 629], ["transmitted", 632], ["either", 644], ["by", 651], ["an", 654], ["autosomal", 657], ["dominant", 667], ["or", 676], ["an", 679], ["autosomal", 682], ["recessive", 692], ["(", 702], ["AR", 703], [")", 705], ["mode", 707], ["of", 712], ["inheritance", 715], [",", 726], ["GD", 728], ["by", 731], ["an", 734], ["autosomal", 737], ["recessive", 747], ["mode", 757], ["of", 762], ["inheritance", 765], ["and", 777], ["AD", 781], ["by", 784], ["an", 787], ["autosomal", 790], ["dominant", 800], ["mode", 809], ["of", 814], ["inheritance", 817], [".", 828], ["Using", 830], ["genetic", 836], ["approaches", 844], [",", 854], ["we", 856], ["have", 859], ["identified", 864], ["the", 875], ["molecular", 879], ["basis", 889], ["of", 895], ["WMS", 898], ["and", 902], ["GD", 906], ["which", 909], ["both", 915], ["involved", 920], ["the", 929], ["same", 933], ["superfamily", 938], ["of", 950], ["proteins", 953], [",", 961], ["the", 963], ["ADAMTS", 967], ["[", 974], ["A", 975], ["Disintegrin", 977], ["-", 988], ["like", 989], ["And", 994], ["Metalloproteinase", 998], ["domain", 1016], ["(", 1023], ["reprolysin", 1024], ["type", 1035], [")", 1039], ["with", 1041], ["ThromboSpondin", 1046], ["type", 1061], ["1", 1066], ["repeats", 1068], ["(", 1076], ["TSR)].", 1077], ["We", 1084], ["have", 1087], ["found", 1092], ["ADAMTS10", 1098], ["mutations", 1107], ["in", 1117], ["the", 1120], ["recessive", 1124], ["form", 1134], ["of", 1139], ["WMS", 1142], ["and", 1146], ["Fibrillin", 1150], ["1", 1160], ["mutations", 1162], ["in", 1172], ["the", 1175], ["dominant", 1179], ["form", 1188], ["of", 1193], ["WMS", 1196], [".", 1199], ["More", 1201], ["recently", 1206], [",", 1214], ["we", 1216], ["have", 1219], ["identified", 1224], ["ADAMTSL2", 1235], ["mutations", 1244], ["in", 1254], ["GD", 1257], [".", 1259], ["The", 1261], ["function", 1265], ["of", 1274], ["ADAMTS1", 1277], ["0", 1285], ["and", 1287], ["AD", 1291], ["AMTSL", 1294], ["2", 1300], ["are", 1302], ["unknown", 1306], [".", 1313], ["But", 1315], ["the", 1319], ["findings", 1323], ["of", 1332], ["FBN1", 1335], ["and", 1340], ["ADAMTS10", 1344], ["mutations", 1353], ["in", 1363], ["WMS", 1366], ["suggest", 1370], ["a", 1378], ["direct", 1380], ["link", 1387], ["between", 1392], ["the", 1400], ["two", 1404], ["proteins", 1408], [".", 1416], ["Using", 1418], ["a", 1424], ["yeast", 1426], ["double", 1432], ["hybrid", 1439], ["screen", 1446], [",", 1452], ["we", 1454], ["have", 1457], ["identified", 1462], ["LTBP1", 1473], ["(", 1479], ["Latent", 1480], ["TGFbeta", 1487], ["Binding", 1495], ["protein", 1503], ["1", 1511], [")", 1512], ["as", 1514], ["a", 1517], ["partner", 1519], ["of", 1527], ["ADAMTSL2", 1530], [".", 1538], ["The", 1540], ["combination", 1544], ["of", 1556], ["these", 1559], ["findings", 1565], ["suggests", 1574], ["that", 1583], ["ADAMTS10", 1588], ["and", 1597], ["ADAMTSL2", 1601], ["are", 1610], ["both", 1614], ["involved", 1619], ["in", 1628], ["the", 1631], ["microfibrillar", 1635], ["network", 1650], [".", 1657]]}
{"context": "Mutations in the SLC9A6 gene cause Christianson syndrome in boys. This X-linked syndrome is characterized by profound mental retardation with autistic behavior, microcephaly, epilepsy, ophthalmoplegia, and ataxia. Progressive cerebellar atrophy with motor regression is a remarkable feature in some patients. We report on a 22year-old male patient with Christianson syndrome carrying the novel p.Gln306X mutation. The infantile phenotype suggested pervasive developmental disorder, then profound mental retardation ensued. In later childhood, progressive cerebellar atrophy was diagnosed on serial brain MRIs and motor regression occurred. Furthermore, ophthalmological evaluations showed a retinitis pigmentosum previously unreported in this condition. We conclude that the natural history of the disease in this patient tends to confirm the degenerative nature of Christianson syndrome, and that retinal degeneration may be part of the condition. Before the onset of degeneration, the syndromic association of severe mental retardation, autistic behavior, external ophthalmoplegia, and facial dysmorphism in male patients is a clue to the diagnosis.", "qas": [{"question": "Mutation of which gene is implicated in the Christianson syndrome?", "answers": ["SLC9A6"], "qid": "1c8d376fd6a5424aa7f69d6d2222e256", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["implicated", 26], ["in", 37], ["the", 40], ["Christianson", 44], ["syndrome", 57], ["?", 65]], "detected_answers": [{"text": "SLC9A6", "token_spans": [[3, 3]], "char_spans": [[17, 22]]}]}], "context_tokens": [["Mutations", 0], ["in", 10], ["the", 13], ["SLC9A6", 17], ["gene", 24], ["cause", 29], ["Christianson", 35], ["syndrome", 48], ["in", 57], ["boys", 60], [".", 64], ["This", 66], ["X", 71], ["-", 72], ["linked", 73], ["syndrome", 80], ["is", 89], ["characterized", 92], ["by", 106], ["profound", 109], ["mental", 118], ["retardation", 125], ["with", 137], ["autistic", 142], ["behavior", 151], [",", 159], ["microcephaly", 161], [",", 173], ["epilepsy", 175], [",", 183], ["ophthalmoplegia", 185], [",", 200], ["and", 202], ["ataxia", 206], [".", 212], ["Progressive", 214], ["cerebellar", 226], ["atrophy", 237], ["with", 245], ["motor", 250], ["regression", 256], ["is", 267], ["a", 270], ["remarkable", 272], ["feature", 283], ["in", 291], ["some", 294], ["patients", 299], [".", 307], ["We", 309], ["report", 312], ["on", 319], ["a", 322], ["22year", 324], ["-", 330], ["old", 331], ["male", 335], ["patient", 340], ["with", 348], ["Christianson", 353], ["syndrome", 366], ["carrying", 375], ["the", 384], ["novel", 388], ["p", 394], [".", 395], ["Gln306X", 396], ["mutation", 404], [".", 412], ["The", 414], ["infantile", 418], ["phenotype", 428], ["suggested", 438], ["pervasive", 448], ["developmental", 458], ["disorder", 472], [",", 480], ["then", 482], ["profound", 487], ["mental", 496], ["retardation", 503], ["ensued", 515], [".", 521], ["In", 523], ["later", 526], ["childhood", 532], [",", 541], ["progressive", 543], ["cerebellar", 555], ["atrophy", 566], ["was", 574], ["diagnosed", 578], ["on", 588], ["serial", 591], ["brain", 598], ["MRIs", 604], ["and", 609], ["motor", 613], ["regression", 619], ["occurred", 630], [".", 638], ["Furthermore", 640], [",", 651], ["ophthalmological", 653], ["evaluations", 670], ["showed", 682], ["a", 689], ["retinitis", 691], ["pigmentosum", 701], ["previously", 713], ["unreported", 724], ["in", 735], ["this", 738], ["condition", 743], [".", 752], ["We", 754], ["conclude", 757], ["that", 766], ["the", 771], ["natural", 775], ["history", 783], ["of", 791], ["the", 794], ["disease", 798], ["in", 806], ["this", 809], ["patient", 814], ["tends", 822], ["to", 828], ["confirm", 831], ["the", 839], ["degenerative", 843], ["nature", 856], ["of", 863], ["Christianson", 866], ["syndrome", 879], [",", 887], ["and", 889], ["that", 893], ["retinal", 898], ["degeneration", 906], ["may", 919], ["be", 923], ["part", 926], ["of", 931], ["the", 934], ["condition", 938], [".", 947], ["Before", 949], ["the", 956], ["onset", 960], ["of", 966], ["degeneration", 969], [",", 981], ["the", 983], ["syndromic", 987], ["association", 997], ["of", 1009], ["severe", 1012], ["mental", 1019], ["retardation", 1026], [",", 1037], ["autistic", 1039], ["behavior", 1048], [",", 1056], ["external", 1058], ["ophthalmoplegia", 1067], [",", 1082], ["and", 1084], ["facial", 1088], ["dysmorphism", 1095], ["in", 1107], ["male", 1110], ["patients", 1115], ["is", 1124], ["a", 1127], ["clue", 1129], ["to", 1134], ["the", 1137], ["diagnosis", 1141], [".", 1150]]}
{"context": "Erythrasma is a superficial infection caused by Corynebacterium minutissimum and affects the major skin folds and the interdigital regions of the feet. It is characterized by erythematous, brown, scaly patches and maceration, and exhibits coral-red fluorescence under Wood light. The aim of this study was to determine the frequency of erythrasma in patients with interdigital lesions. An open, prospective, longitudinal, observational study was performed in a hospital in Mexico City between March and December, 2006. All patients with interdigital lesions were examined with a Wood lamp and direct examination was performed with 20 % potassium hydroxide. Cultures were done in Sabouraud dextrose agar and brain heart infusion agar, and smears were analyzed. General characteristics and concomitant diseases were recorded. We examined 73 patients, of whom 24 (32.8 %) were diagnosed with erythrasma based on coral-red fluorescence under Wood light and identification of corynebacteria by Gram staining. The disease was more common in women (83.33 %) and the mean age of the patients was 43.5 years. The main clinical findings were scaling and maceration, and the fourth interdigital web was the most commonly affected. Corynebacterium could not be isolated in any of the cases. Mycology was positive in 15 cases (62.5 %) and the following microorganisms were isolated: Candida (16.6 %), dermatophytes (12.5 %), and Trichosporon (4.1 %). Interdigital erythrasma is a common condition and can be easily confused with interdigital tinea. It persists if not treated appropriately. Rapid diagnosis is easily obtained by examination with a Wood lamp, while culture is difficult and unnecessary for diagnosis. The coexistence of erythrasma with dermatophytes and Candida should be considered when the interdigital webs are affected.", "qas": [{"question": "Which bacteria causes erythrasma?", "answers": ["Corynebacterium minutissimum"], "qid": "c5a3515ce38440f0bf803e4cbe2c9b10", "question_tokens": [["Which", 0], ["bacteria", 6], ["causes", 15], ["erythrasma", 22], ["?", 32]], "detected_answers": [{"text": "Corynebacterium minutissimum", "token_spans": [[7, 8]], "char_spans": [[48, 75]]}]}], "context_tokens": [["Erythrasma", 0], ["is", 11], ["a", 14], ["superficial", 16], ["infection", 28], ["caused", 38], ["by", 45], ["Corynebacterium", 48], ["minutissimum", 64], ["and", 77], ["affects", 81], ["the", 89], ["major", 93], ["skin", 99], ["folds", 104], ["and", 110], ["the", 114], ["interdigital", 118], ["regions", 131], ["of", 139], ["the", 142], ["feet", 146], [".", 150], ["It", 152], ["is", 155], ["characterized", 158], ["by", 172], ["erythematous", 175], [",", 187], ["brown", 189], [",", 194], ["scaly", 196], ["patches", 202], ["and", 210], ["maceration", 214], [",", 224], ["and", 226], ["exhibits", 230], ["coral", 239], ["-", 244], ["red", 245], ["fluorescence", 249], ["under", 262], ["Wood", 268], ["light", 273], [".", 278], ["The", 280], ["aim", 284], ["of", 288], ["this", 291], ["study", 296], ["was", 302], ["to", 306], ["determine", 309], ["the", 319], ["frequency", 323], ["of", 333], ["erythrasma", 336], ["in", 347], ["patients", 350], ["with", 359], ["interdigital", 364], ["lesions", 377], [".", 384], ["An", 386], ["open", 389], [",", 393], ["prospective", 395], [",", 406], ["longitudinal", 408], [",", 420], ["observational", 422], ["study", 436], ["was", 442], ["performed", 446], ["in", 456], ["a", 459], ["hospital", 461], ["in", 470], ["Mexico", 473], ["City", 480], ["between", 485], ["March", 493], ["and", 499], ["December", 503], [",", 511], ["2006", 513], [".", 517], ["All", 519], ["patients", 523], ["with", 532], ["interdigital", 537], ["lesions", 550], ["were", 558], ["examined", 563], ["with", 572], ["a", 577], ["Wood", 579], ["lamp", 584], ["and", 589], ["direct", 593], ["examination", 600], ["was", 612], ["performed", 616], ["with", 626], ["20", 631], ["%", 634], ["potassium", 636], ["hydroxide", 646], [".", 655], ["Cultures", 657], ["were", 666], ["done", 671], ["in", 676], ["Sabouraud", 679], ["dextrose", 689], ["agar", 698], ["and", 703], ["brain", 707], ["heart", 713], ["infusion", 719], ["agar", 728], [",", 732], ["and", 734], ["smears", 738], ["were", 745], ["analyzed", 750], [".", 758], ["General", 760], ["characteristics", 768], ["and", 784], ["concomitant", 788], ["diseases", 800], ["were", 809], ["recorded", 814], [".", 822], ["We", 824], ["examined", 827], ["73", 836], ["patients", 839], [",", 847], ["of", 849], ["whom", 852], ["24", 857], ["(", 860], ["32.8", 861], ["%", 866], [")", 867], ["were", 869], ["diagnosed", 874], ["with", 884], ["erythrasma", 889], ["based", 900], ["on", 906], ["coral", 909], ["-", 914], ["red", 915], ["fluorescence", 919], ["under", 932], ["Wood", 938], ["light", 943], ["and", 949], ["identification", 953], ["of", 968], ["corynebacteria", 971], ["by", 986], ["Gram", 989], ["staining", 994], [".", 1002], ["The", 1004], ["disease", 1008], ["was", 1016], ["more", 1020], ["common", 1025], ["in", 1032], ["women", 1035], ["(", 1041], ["83.33", 1042], ["%", 1048], [")", 1049], ["and", 1051], ["the", 1055], ["mean", 1059], ["age", 1064], ["of", 1068], ["the", 1071], ["patients", 1075], ["was", 1084], ["43.5", 1088], ["years", 1093], [".", 1098], ["The", 1100], ["main", 1104], ["clinical", 1109], ["findings", 1118], ["were", 1127], ["scaling", 1132], ["and", 1140], ["maceration", 1144], [",", 1154], ["and", 1156], ["the", 1160], ["fourth", 1164], ["interdigital", 1171], ["web", 1184], ["was", 1188], ["the", 1192], ["most", 1196], ["commonly", 1201], ["affected", 1210], [".", 1218], ["Corynebacterium", 1220], ["could", 1236], ["not", 1242], ["be", 1246], ["isolated", 1249], ["in", 1258], ["any", 1261], ["of", 1265], ["the", 1268], ["cases", 1272], [".", 1277], ["Mycology", 1279], ["was", 1288], ["positive", 1292], ["in", 1301], ["15", 1304], ["cases", 1307], ["(", 1313], ["62.5", 1314], ["%", 1319], [")", 1320], ["and", 1322], ["the", 1326], ["following", 1330], ["microorganisms", 1340], ["were", 1355], ["isolated", 1360], [":", 1368], ["Candida", 1370], ["(", 1378], ["16.6", 1379], ["%", 1384], [")", 1385], [",", 1386], ["dermatophytes", 1388], ["(", 1402], ["12.5", 1403], ["%", 1408], [")", 1409], [",", 1410], ["and", 1412], ["Trichosporon", 1416], ["(", 1429], ["4.1", 1430], ["%", 1434], [")", 1435], [".", 1436], ["Interdigital", 1438], ["erythrasma", 1451], ["is", 1462], ["a", 1465], ["common", 1467], ["condition", 1474], ["and", 1484], ["can", 1488], ["be", 1492], ["easily", 1495], ["confused", 1502], ["with", 1511], ["interdigital", 1516], ["tinea", 1529], [".", 1534], ["It", 1536], ["persists", 1539], ["if", 1548], ["not", 1551], ["treated", 1555], ["appropriately", 1563], [".", 1576], ["Rapid", 1578], ["diagnosis", 1584], ["is", 1594], ["easily", 1597], ["obtained", 1604], ["by", 1613], ["examination", 1616], ["with", 1628], ["a", 1633], ["Wood", 1635], ["lamp", 1640], [",", 1644], ["while", 1646], ["culture", 1652], ["is", 1660], ["difficult", 1663], ["and", 1673], ["unnecessary", 1677], ["for", 1689], ["diagnosis", 1693], [".", 1702], ["The", 1704], ["coexistence", 1708], ["of", 1720], ["erythrasma", 1723], ["with", 1734], ["dermatophytes", 1739], ["and", 1753], ["Candida", 1757], ["should", 1765], ["be", 1772], ["considered", 1775], ["when", 1786], ["the", 1791], ["interdigital", 1795], ["webs", 1808], ["are", 1813], ["affected", 1817], [".", 1825]]}
{"context": "Empirical data have challenged chronic posttraumatic stress disorder (PTSD) consisting of three dimensions. In the present study we aimed to determine the factor structure of acute posttraumatic symptoms in two recently traumatized samples. In sample 1, 203 civilian trauma survivors were administered the Davidson Trauma Scale (DTS) approximately 1 week posttrauma. In sample 2, 182 civilian treatment seeking trauma survivors completed the DTS at an average of 41.4 days posttrauma. Our confirmatory factor analyses indicated that a 4-factor intercorrelated model provided the best representation of the data in both samples. The four factors are best described as reexperiencing, active avoidance, dysphoria, and hyperarousal. For acute posttraumatic symptoms, the empirical data suggest to split the avoidance cluster into 'Active avoidance' and 'Dysphoria'-confirming findings in studies on chronic PTSD. In future revisions of the DSM, the diagnostic criteria for PTSD may need to be adapted to fit the research findings.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "154d75312f834698b4172f50c831682d", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "PTSD", "token_spans": [[145, 145], [9, 9], [158, 158]], "char_spans": [[904, 907], [70, 73], [970, 973]]}]}], "context_tokens": [["Empirical", 0], ["data", 10], ["have", 15], ["challenged", 20], ["chronic", 31], ["posttraumatic", 39], ["stress", 53], ["disorder", 60], ["(", 69], ["PTSD", 70], [")", 74], ["consisting", 76], ["of", 87], ["three", 90], ["dimensions", 96], [".", 106], ["In", 108], ["the", 111], ["present", 115], ["study", 123], ["we", 129], ["aimed", 132], ["to", 138], ["determine", 141], ["the", 151], ["factor", 155], ["structure", 162], ["of", 172], ["acute", 175], ["posttraumatic", 181], ["symptoms", 195], ["in", 204], ["two", 207], ["recently", 211], ["traumatized", 220], ["samples", 232], [".", 239], ["In", 241], ["sample", 244], ["1", 251], [",", 252], ["203", 254], ["civilian", 258], ["trauma", 267], ["survivors", 274], ["were", 284], ["administered", 289], ["the", 302], ["Davidson", 306], ["Trauma", 315], ["Scale", 322], ["(", 328], ["DTS", 329], [")", 332], ["approximately", 334], ["1", 348], ["week", 350], ["posttrauma", 355], [".", 365], ["In", 367], ["sample", 370], ["2", 377], [",", 378], ["182", 380], ["civilian", 384], ["treatment", 393], ["seeking", 403], ["trauma", 411], ["survivors", 418], ["completed", 428], ["the", 438], ["DTS", 442], ["at", 446], ["an", 449], ["average", 452], ["of", 460], ["41.4", 463], ["days", 468], ["posttrauma", 473], [".", 483], ["Our", 485], ["confirmatory", 489], ["factor", 502], ["analyses", 509], ["indicated", 518], ["that", 528], ["a", 533], ["4-factor", 535], ["intercorrelated", 544], ["model", 560], ["provided", 566], ["the", 575], ["best", 579], ["representation", 584], ["of", 599], ["the", 602], ["data", 606], ["in", 611], ["both", 614], ["samples", 619], [".", 626], ["The", 628], ["four", 632], ["factors", 637], ["are", 645], ["best", 649], ["described", 654], ["as", 664], ["reexperiencing", 667], [",", 681], ["active", 683], ["avoidance", 690], [",", 699], ["dysphoria", 701], [",", 710], ["and", 712], ["hyperarousal", 716], [".", 728], ["For", 730], ["acute", 734], ["posttraumatic", 740], ["symptoms", 754], [",", 762], ["the", 764], ["empirical", 768], ["data", 778], ["suggest", 783], ["to", 791], ["split", 794], ["the", 800], ["avoidance", 804], ["cluster", 814], ["into", 822], ["'", 827], ["Active", 828], ["avoidance", 835], ["'", 844], ["and", 846], ["'", 850], ["Dysphoria'-confirming", 851], ["findings", 873], ["in", 882], ["studies", 885], ["on", 893], ["chronic", 896], ["PTSD", 904], [".", 908], ["In", 910], ["future", 913], ["revisions", 920], ["of", 930], ["the", 933], ["DSM", 937], [",", 940], ["the", 942], ["diagnostic", 946], ["criteria", 957], ["for", 966], ["PTSD", 970], ["may", 975], ["need", 979], ["to", 984], ["be", 987], ["adapted", 990], ["to", 998], ["fit", 1001], ["the", 1005], ["research", 1009], ["findings", 1018], [".", 1026]]}
{"context": "Non-vitamin K anticoagulants (NOAC) such as dabigatran have become important therapeutic options for the prevention of stroke. Until recently, there were only nonspecific agents to reverse their anticoagulant effects in a case of emergency. Idarucizumab, an antibody fragment targeting dabigatran, is the first specific antidote for a NOAC to be approved, but real-world experience is limited. We report two cases of patients on dabigatran with acute intracerebral hemorrhage who received idarucizumab. In both cases, idarucizumab promptly reversed the anticoagulant effect of dabigatran and there was no hematoma expansion in follow-up imaging. In addition to clinical and preclinical studies, our cases add to the experience regarding the safety and efficacy of idarucizumab. They show that idarucizumab may be an important safety option for patients on dabigatran in emergency situations.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "0f0142c6d85345b6ad31f47e1f7b98d4", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[144, 144], [96, 96], [10, 10], [76, 76], [47, 47]], "char_spans": [[856, 865], [577, 586], [44, 53], [429, 438], [286, 295]]}]}], "context_tokens": [["Non", 0], ["-", 3], ["vitamin", 4], ["K", 12], ["anticoagulants", 14], ["(", 29], ["NOAC", 30], [")", 34], ["such", 36], ["as", 41], ["dabigatran", 44], ["have", 55], ["become", 60], ["important", 67], ["therapeutic", 77], ["options", 89], ["for", 97], ["the", 101], ["prevention", 105], ["of", 116], ["stroke", 119], [".", 125], ["Until", 127], ["recently", 133], [",", 141], ["there", 143], ["were", 149], ["only", 154], ["nonspecific", 159], ["agents", 171], ["to", 178], ["reverse", 181], ["their", 189], ["anticoagulant", 195], ["effects", 209], ["in", 217], ["a", 220], ["case", 222], ["of", 227], ["emergency", 230], [".", 239], ["Idarucizumab", 241], [",", 253], ["an", 255], ["antibody", 258], ["fragment", 267], ["targeting", 276], ["dabigatran", 286], [",", 296], ["is", 298], ["the", 301], ["first", 305], ["specific", 311], ["antidote", 320], ["for", 329], ["a", 333], ["NOAC", 335], ["to", 340], ["be", 343], ["approved", 346], [",", 354], ["but", 356], ["real", 360], ["-", 364], ["world", 365], ["experience", 371], ["is", 382], ["limited", 385], [".", 392], ["We", 394], ["report", 397], ["two", 404], ["cases", 408], ["of", 414], ["patients", 417], ["on", 426], ["dabigatran", 429], ["with", 440], ["acute", 445], ["intracerebral", 451], ["hemorrhage", 465], ["who", 476], ["received", 480], ["idarucizumab", 489], [".", 501], ["In", 503], ["both", 506], ["cases", 511], [",", 516], ["idarucizumab", 518], ["promptly", 531], ["reversed", 540], ["the", 549], ["anticoagulant", 553], ["effect", 567], ["of", 574], ["dabigatran", 577], ["and", 588], ["there", 592], ["was", 598], ["no", 602], ["hematoma", 605], ["expansion", 614], ["in", 624], ["follow", 627], ["-", 633], ["up", 634], ["imaging", 637], [".", 644], ["In", 646], ["addition", 649], ["to", 658], ["clinical", 661], ["and", 670], ["preclinical", 674], ["studies", 686], [",", 693], ["our", 695], ["cases", 699], ["add", 705], ["to", 709], ["the", 712], ["experience", 716], ["regarding", 727], ["the", 737], ["safety", 741], ["and", 748], ["efficacy", 752], ["of", 761], ["idarucizumab", 764], [".", 776], ["They", 778], ["show", 783], ["that", 788], ["idarucizumab", 793], ["may", 806], ["be", 810], ["an", 813], ["important", 816], ["safety", 826], ["option", 833], ["for", 840], ["patients", 844], ["on", 853], ["dabigatran", 856], ["in", 867], ["emergency", 870], ["situations", 880], [".", 890]]}
{"context": "Facioscapulohumeral muscular dystrophy (FSHD) is a common form of muscular dystrophy characterized by an asymmetric progressive weakness and wasting of the facial, shoulder and upper arm muscles, frequently accompanied by hearing loss and retinal vasculopathy. FSHD is an autosomal dominant disease linked to chromosome 4q35, but the causative gene remains controversial. DUX4 is a leading candidate gene as causative of FSHD. However, DUX4 expression is extremely low in FSHD muscle, and there is no DUX4 animal model that mirrors the pathology in human FSHD. Here, we show that the misexpression of very low levels of human DUX4 in zebrafish development recapitulates the phenotypes seen in human FSHD patients. Microinjection of small amounts of human full-length DUX4 (DUX4-fl) mRNA into fertilized zebrafish eggs caused asymmetric abnormalities such as less pigmentation of the eyes, altered morphology of ears, developmental abnormality of fin muscle, disorganization of facial musculature and/or degeneration of trunk muscle later in development. Moreover, DUX4-fl expression caused aberrant localization of myogenic cells marked with \u03b1-actin promoter-driven enhanced green fluorescent protein outside somite boundary, especially in head region. These abnormalities were rescued by coinjection of the short form of DUX4 (DUX4-s). Our results suggest that the misexpression of DUX4-fl, even at extremely low level, can recapitulate the phenotype observed in FSHD patients in a vertebrate model. These results strongly support the current hypothesis for a role of DUX4 in FSHD pathogenesis. We also propose that DUX4 expression during development is important for the pathogenesis of FSHD.", "qas": [{"question": "Which disease is associated with the ectopic expression of the protein encoded by the gene DUX4?", "answers": ["Facioscapulohumeral dystrophy", "FSHD"], "qid": "69c2179d41c04582949a39853d960dbb", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["associated", 17], ["with", 28], ["the", 33], ["ectopic", 37], ["expression", 45], ["of", 56], ["the", 59], ["protein", 63], ["encoded", 71], ["by", 79], ["the", 82], ["gene", 86], ["DUX4", 91], ["?", 95]], "detected_answers": [{"text": "FSHD", "token_spans": [[93, 93], [67, 67], [77, 77], [118, 118], [262, 262], [4, 4], [279, 279], [40, 40], [242, 242]], "char_spans": [[555, 558], [421, 424], [472, 475], [699, 702], [1577, 1580], [40, 43], [1689, 1692], [261, 264], [1464, 1467]]}]}], "context_tokens": [["Facioscapulohumeral", 0], ["muscular", 20], ["dystrophy", 29], ["(", 39], ["FSHD", 40], [")", 44], ["is", 46], ["a", 49], ["common", 51], ["form", 58], ["of", 63], ["muscular", 66], ["dystrophy", 75], ["characterized", 85], ["by", 99], ["an", 102], ["asymmetric", 105], ["progressive", 116], ["weakness", 128], ["and", 137], ["wasting", 141], ["of", 149], ["the", 152], ["facial", 156], [",", 162], ["shoulder", 164], ["and", 173], ["upper", 177], ["arm", 183], ["muscles", 187], [",", 194], ["frequently", 196], ["accompanied", 207], ["by", 219], ["hearing", 222], ["loss", 230], ["and", 235], ["retinal", 239], ["vasculopathy", 247], [".", 259], ["FSHD", 261], ["is", 266], ["an", 269], ["autosomal", 272], ["dominant", 282], ["disease", 291], ["linked", 299], ["to", 306], ["chromosome", 309], ["4q35", 320], [",", 324], ["but", 326], ["the", 330], ["causative", 334], ["gene", 344], ["remains", 349], ["controversial", 357], [".", 370], ["DUX4", 372], ["is", 377], ["a", 380], ["leading", 382], ["candidate", 390], ["gene", 400], ["as", 405], ["causative", 408], ["of", 418], ["FSHD", 421], [".", 425], ["However", 427], [",", 434], ["DUX4", 436], ["expression", 441], ["is", 452], ["extremely", 455], ["low", 465], ["in", 469], ["FSHD", 472], ["muscle", 477], [",", 483], ["and", 485], ["there", 489], ["is", 495], ["no", 498], ["DUX4", 501], ["animal", 506], ["model", 513], ["that", 519], ["mirrors", 524], ["the", 532], ["pathology", 536], ["in", 546], ["human", 549], ["FSHD", 555], [".", 559], ["Here", 561], [",", 565], ["we", 567], ["show", 570], ["that", 575], ["the", 580], ["misexpression", 584], ["of", 598], ["very", 601], ["low", 606], ["levels", 610], ["of", 617], ["human", 620], ["DUX4", 626], ["in", 631], ["zebrafish", 634], ["development", 644], ["recapitulates", 656], ["the", 670], ["phenotypes", 674], ["seen", 685], ["in", 690], ["human", 693], ["FSHD", 699], ["patients", 704], [".", 712], ["Microinjection", 714], ["of", 729], ["small", 732], ["amounts", 738], ["of", 746], ["human", 749], ["full", 755], ["-", 759], ["length", 760], ["DUX4", 767], ["(", 772], ["DUX4-fl", 773], [")", 780], ["mRNA", 782], ["into", 787], ["fertilized", 792], ["zebrafish", 803], ["eggs", 813], ["caused", 818], ["asymmetric", 825], ["abnormalities", 836], ["such", 850], ["as", 855], ["less", 858], ["pigmentation", 863], ["of", 876], ["the", 879], ["eyes", 883], [",", 887], ["altered", 889], ["morphology", 897], ["of", 908], ["ears", 911], [",", 915], ["developmental", 917], ["abnormality", 931], ["of", 943], ["fin", 946], ["muscle", 950], [",", 956], ["disorganization", 958], ["of", 974], ["facial", 977], ["musculature", 984], ["and/or", 996], ["degeneration", 1003], ["of", 1016], ["trunk", 1019], ["muscle", 1025], ["later", 1032], ["in", 1038], ["development", 1041], [".", 1052], ["Moreover", 1054], [",", 1062], ["DUX4-fl", 1064], ["expression", 1072], ["caused", 1083], ["aberrant", 1090], ["localization", 1099], ["of", 1112], ["myogenic", 1115], ["cells", 1124], ["marked", 1130], ["with", 1137], ["\u03b1", 1142], ["-", 1143], ["actin", 1144], ["promoter", 1150], ["-", 1158], ["driven", 1159], ["enhanced", 1166], ["green", 1175], ["fluorescent", 1181], ["protein", 1193], ["outside", 1201], ["somite", 1209], ["boundary", 1216], [",", 1224], ["especially", 1226], ["in", 1237], ["head", 1240], ["region", 1245], [".", 1251], ["These", 1253], ["abnormalities", 1259], ["were", 1273], ["rescued", 1278], ["by", 1286], ["coinjection", 1289], ["of", 1301], ["the", 1304], ["short", 1308], ["form", 1314], ["of", 1319], ["DUX4", 1322], ["(", 1327], ["DUX4-s", 1328], [")", 1334], [".", 1335], ["Our", 1337], ["results", 1341], ["suggest", 1349], ["that", 1357], ["the", 1362], ["misexpression", 1366], ["of", 1380], ["DUX4-fl", 1383], [",", 1390], ["even", 1392], ["at", 1397], ["extremely", 1400], ["low", 1410], ["level", 1414], [",", 1419], ["can", 1421], ["recapitulate", 1425], ["the", 1438], ["phenotype", 1442], ["observed", 1452], ["in", 1461], ["FSHD", 1464], ["patients", 1469], ["in", 1478], ["a", 1481], ["vertebrate", 1483], ["model", 1494], [".", 1499], ["These", 1501], ["results", 1507], ["strongly", 1515], ["support", 1524], ["the", 1532], ["current", 1536], ["hypothesis", 1544], ["for", 1555], ["a", 1559], ["role", 1561], ["of", 1566], ["DUX4", 1569], ["in", 1574], ["FSHD", 1577], ["pathogenesis", 1582], [".", 1594], ["We", 1596], ["also", 1599], ["propose", 1604], ["that", 1612], ["DUX4", 1617], ["expression", 1622], ["during", 1633], ["development", 1640], ["is", 1652], ["important", 1655], ["for", 1665], ["the", 1669], ["pathogenesis", 1673], ["of", 1686], ["FSHD", 1689], [".", 1693]]}
{"context": "To compare tumor control rates after surgical resection or stereotactic radiosurgery for patients with small- to medium-size intracranial meningiomas. Between 1990 and 1997, 198 adult meningioma patients treated at our center underwent either surgical resection (n = 136) or radiosurgery (n = 62) as primary management for benign meningiomas <35 mm in average diameter. Tumor recurrence or progression rates were calculated by the Kaplan-Meier method according to an independent radiographic review. The mean follow-up was 64 months. The tumor resections were Simpson Grade 1 in 57 (42%), Grade 2 in 57 (42%), and Grade 3-4 in 22 (16%). The mean margin and maximal radiation dose at radiosurgery was 17.7 Gy and 34.9 Gy, respectively. Tumor recurrence/progression was more frequent in the surgical resection group (12%) than in the radiosurgical group (2%; p = 0.04). No statistically significant difference was detected in the 3- and 7-year actuarial progression-free survival (PFS) rate between patients with Simpson Grade 1 resections (100% and 96%, respectively) and patients who underwent radiosurgery (100% and 95%, respectively; p = 0.94). Radiosurgery provided a higher PFS rate compared with patients with Simpson Grade 2 (3- and 7-year PFS rate, 91% and 82%, respectively; p <0.05) and Grade 3-4 (3- and 7-year PFS rate, 68% and 34%, respectively; p <0.001) resections. Subsequent tumor treatments were more common after surgical resection (15% vs. 3%, p = 0.02). Complications occurred in 10% of patients after radiosurgery compared with 22% of patients after surgical resection (p = 0.06). The PFS rate after radiosurgery was equivalent to that after resection of a Simpson Grade 1 tumor and was superior to Grade 2 and 3-4 resections in our study. If long-term follow-up confirms the high tumor control rate and low morbidity of radiosurgery, this technique will likely become the preferred treatment for most patients with small- to moderate-size meningiomas without symptomatic mass effect.", "qas": [{"question": "Simpson grading is used to describe resection of which brain tumor?", "answers": ["meningioma"], "qid": "df74d144994648f89a2af1ac7f36e432", "question_tokens": [["Simpson", 0], ["grading", 8], ["is", 16], ["used", 19], ["to", 24], ["describe", 27], ["resection", 36], ["of", 46], ["which", 49], ["brain", 55], ["tumor", 61], ["?", 66]], "detected_answers": [{"text": "meningioma", "token_spans": [[29, 29]], "char_spans": [[184, 193]]}]}], "context_tokens": [["To", 0], ["compare", 3], ["tumor", 11], ["control", 17], ["rates", 25], ["after", 31], ["surgical", 37], ["resection", 46], ["or", 56], ["stereotactic", 59], ["radiosurgery", 72], ["for", 85], ["patients", 89], ["with", 98], ["small-", 103], ["to", 110], ["medium", 113], ["-", 119], ["size", 120], ["intracranial", 125], ["meningiomas", 138], [".", 149], ["Between", 151], ["1990", 159], ["and", 164], ["1997", 168], [",", 172], ["198", 174], ["adult", 178], ["meningioma", 184], ["patients", 195], ["treated", 204], ["at", 212], ["our", 215], ["center", 219], ["underwent", 226], ["either", 236], ["surgical", 243], ["resection", 252], ["(", 262], ["n", 263], ["=", 265], ["136", 267], [")", 270], ["or", 272], ["radiosurgery", 275], ["(", 288], ["n", 289], ["=", 291], ["62", 293], [")", 295], ["as", 297], ["primary", 300], ["management", 308], ["for", 319], ["benign", 323], ["meningiomas", 330], ["<", 342], ["35", 343], ["mm", 346], ["in", 349], ["average", 352], ["diameter", 360], [".", 368], ["Tumor", 370], ["recurrence", 376], ["or", 387], ["progression", 390], ["rates", 402], ["were", 408], ["calculated", 413], ["by", 424], ["the", 427], ["Kaplan", 431], ["-", 437], ["Meier", 438], ["method", 444], ["according", 451], ["to", 461], ["an", 464], ["independent", 467], ["radiographic", 479], ["review", 492], [".", 498], ["The", 500], ["mean", 504], ["follow", 509], ["-", 515], ["up", 516], ["was", 519], ["64", 523], ["months", 526], [".", 532], ["The", 534], ["tumor", 538], ["resections", 544], ["were", 555], ["Simpson", 560], ["Grade", 568], ["1", 574], ["in", 576], ["57", 579], ["(", 582], ["42", 583], ["%", 585], [")", 586], [",", 587], ["Grade", 589], ["2", 595], ["in", 597], ["57", 600], ["(", 603], ["42", 604], ["%", 606], [")", 607], [",", 608], ["and", 610], ["Grade", 614], ["3", 620], ["-", 621], ["4", 622], ["in", 624], ["22", 627], ["(", 630], ["16", 631], ["%", 633], [")", 634], [".", 635], ["The", 637], ["mean", 641], ["margin", 646], ["and", 653], ["maximal", 657], ["radiation", 665], ["dose", 675], ["at", 680], ["radiosurgery", 683], ["was", 696], ["17.7", 700], ["Gy", 705], ["and", 708], ["34.9", 712], ["Gy", 717], [",", 719], ["respectively", 721], [".", 733], ["Tumor", 735], ["recurrence", 741], ["/", 751], ["progression", 752], ["was", 764], ["more", 768], ["frequent", 773], ["in", 782], ["the", 785], ["surgical", 789], ["resection", 798], ["group", 808], ["(", 814], ["12", 815], ["%", 817], [")", 818], ["than", 820], ["in", 825], ["the", 828], ["radiosurgical", 832], ["group", 846], ["(", 852], ["2", 853], ["%", 854], [";", 855], ["p", 857], ["=", 859], ["0.04", 861], [")", 865], [".", 866], ["No", 868], ["statistically", 871], ["significant", 885], ["difference", 897], ["was", 908], ["detected", 912], ["in", 921], ["the", 924], ["3-", 928], ["and", 931], ["7-year", 935], ["actuarial", 942], ["progression", 952], ["-", 963], ["free", 964], ["survival", 969], ["(", 978], ["PFS", 979], [")", 982], ["rate", 984], ["between", 989], ["patients", 997], ["with", 1006], ["Simpson", 1011], ["Grade", 1019], ["1", 1025], ["resections", 1027], ["(", 1038], ["100", 1039], ["%", 1042], ["and", 1044], ["96", 1048], ["%", 1050], [",", 1051], ["respectively", 1053], [")", 1065], ["and", 1067], ["patients", 1071], ["who", 1080], ["underwent", 1084], ["radiosurgery", 1094], ["(", 1107], ["100", 1108], ["%", 1111], ["and", 1113], ["95", 1117], ["%", 1119], [",", 1120], ["respectively", 1122], [";", 1134], ["p", 1136], ["=", 1138], ["0.94", 1140], [")", 1144], [".", 1145], ["Radiosurgery", 1147], ["provided", 1160], ["a", 1169], ["higher", 1171], ["PFS", 1178], ["rate", 1182], ["compared", 1187], ["with", 1196], ["patients", 1201], ["with", 1210], ["Simpson", 1215], ["Grade", 1223], ["2", 1229], ["(", 1231], ["3-", 1232], ["and", 1235], ["7-year", 1239], ["PFS", 1246], ["rate", 1250], [",", 1254], ["91", 1256], ["%", 1258], ["and", 1260], ["82", 1264], ["%", 1266], [",", 1267], ["respectively", 1269], [";", 1281], ["p", 1283], ["<", 1285], ["0.05", 1286], [")", 1290], ["and", 1292], ["Grade", 1296], ["3", 1302], ["-", 1303], ["4", 1304], ["(", 1306], ["3-", 1307], ["and", 1310], ["7-year", 1314], ["PFS", 1321], ["rate", 1325], [",", 1329], ["68", 1331], ["%", 1333], ["and", 1335], ["34", 1339], ["%", 1341], [",", 1342], ["respectively", 1344], [";", 1356], ["p", 1358], ["<", 1360], ["0.001", 1361], [")", 1366], ["resections", 1368], [".", 1378], ["Subsequent", 1380], ["tumor", 1391], ["treatments", 1397], ["were", 1408], ["more", 1413], ["common", 1418], ["after", 1425], ["surgical", 1431], ["resection", 1440], ["(", 1450], ["15", 1451], ["%", 1453], ["vs.", 1455], ["3", 1459], ["%", 1460], [",", 1461], ["p", 1463], ["=", 1465], ["0.02", 1467], [")", 1471], [".", 1472], ["Complications", 1474], ["occurred", 1488], ["in", 1497], ["10", 1500], ["%", 1502], ["of", 1504], ["patients", 1507], ["after", 1516], ["radiosurgery", 1522], ["compared", 1535], ["with", 1544], ["22", 1549], ["%", 1551], ["of", 1553], ["patients", 1556], ["after", 1565], ["surgical", 1571], ["resection", 1580], ["(", 1590], ["p", 1591], ["=", 1593], ["0.06", 1595], [")", 1599], [".", 1600], ["The", 1602], ["PFS", 1606], ["rate", 1610], ["after", 1615], ["radiosurgery", 1621], ["was", 1634], ["equivalent", 1638], ["to", 1649], ["that", 1652], ["after", 1657], ["resection", 1663], ["of", 1673], ["a", 1676], ["Simpson", 1678], ["Grade", 1686], ["1", 1692], ["tumor", 1694], ["and", 1700], ["was", 1704], ["superior", 1708], ["to", 1717], ["Grade", 1720], ["2", 1726], ["and", 1728], ["3", 1732], ["-", 1733], ["4", 1734], ["resections", 1736], ["in", 1747], ["our", 1750], ["study", 1754], [".", 1759], ["If", 1761], ["long", 1764], ["-", 1768], ["term", 1769], ["follow", 1774], ["-", 1780], ["up", 1781], ["confirms", 1784], ["the", 1793], ["high", 1797], ["tumor", 1802], ["control", 1808], ["rate", 1816], ["and", 1821], ["low", 1825], ["morbidity", 1829], ["of", 1839], ["radiosurgery", 1842], [",", 1854], ["this", 1856], ["technique", 1861], ["will", 1871], ["likely", 1876], ["become", 1883], ["the", 1890], ["preferred", 1894], ["treatment", 1904], ["for", 1914], ["most", 1918], ["patients", 1923], ["with", 1932], ["small-", 1937], ["to", 1944], ["moderate", 1947], ["-", 1955], ["size", 1956], ["meningiomas", 1961], ["without", 1973], ["symptomatic", 1981], ["mass", 1993], ["effect", 1998], [".", 2004]]}
{"context": "Selenoprotein P (Sepp1) is a secreted protein that is made up of 2 domains. The larger N-terminal domain contains 1 selenocysteine residue in a redox motif and the smaller C-terminal domain contains the other 9 selenocysteines. Sepp1 isoforms of varying lengths occur but quantitation of them has not been achieved. Hepatic synthesis of Sepp1 affects whole-body selenium content and the liver is the source of most plasma Sepp1. ApoER2, a member of the lipoprotein receptor family, binds Sepp1 and facilitates its uptake into the testis and retention of its selenium by the brain. Megalin, another lipoprotein receptor, facilitates uptake of filtered Sepp1 into proximal tubule cells of the kidney. Thus, Sepp1 serves in homeostasis and distribution of selenium. Mice with deletion of Sepp1 suffer greater morbidity and mortality from infection with Trypanosoma congolense than do wild-type mice. Mice that express only the N-terminal domain of Sepp1 have the same severity of illness as wild-type mice, indicating that the protective function of Sepp1 against the infection resides in the N-terminal (redox) domain. Thus, Sepp1 has several functions. In addition, plasma Sepp1 concentration falls in selenium deficiency and, therefore, it can be used as an index of selenium nutritional status.", "qas": [{"question": "Which is the human selenoprotein that contains several Se-Cys residues?", "answers": ["Selenoprotein P"], "qid": "109aecf700c048eb8d16d5d20b654c22", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["human", 13], ["selenoprotein", 19], ["that", 33], ["contains", 38], ["several", 47], ["Se", 55], ["-", 57], ["Cys", 58], ["residues", 62], ["?", 70]], "detected_answers": [{"text": "Selenoprotein P", "token_spans": [[0, 1]], "char_spans": [[0, 14]]}]}], "context_tokens": [["Selenoprotein", 0], ["P", 14], ["(", 16], ["Sepp1", 17], [")", 22], ["is", 24], ["a", 27], ["secreted", 29], ["protein", 38], ["that", 46], ["is", 51], ["made", 54], ["up", 59], ["of", 62], ["2", 65], ["domains", 67], [".", 74], ["The", 76], ["larger", 80], ["N", 87], ["-", 88], ["terminal", 89], ["domain", 98], ["contains", 105], ["1", 114], ["selenocysteine", 116], ["residue", 131], ["in", 139], ["a", 142], ["redox", 144], ["motif", 150], ["and", 156], ["the", 160], ["smaller", 164], ["C", 172], ["-", 173], ["terminal", 174], ["domain", 183], ["contains", 190], ["the", 199], ["other", 203], ["9", 209], ["selenocysteines", 211], [".", 226], ["Sepp1", 228], ["isoforms", 234], ["of", 243], ["varying", 246], ["lengths", 254], ["occur", 262], ["but", 268], ["quantitation", 272], ["of", 285], ["them", 288], ["has", 293], ["not", 297], ["been", 301], ["achieved", 306], [".", 314], ["Hepatic", 316], ["synthesis", 324], ["of", 334], ["Sepp1", 337], ["affects", 343], ["whole", 351], ["-", 356], ["body", 357], ["selenium", 362], ["content", 371], ["and", 379], ["the", 383], ["liver", 387], ["is", 393], ["the", 396], ["source", 400], ["of", 407], ["most", 410], ["plasma", 415], ["Sepp1", 422], [".", 427], ["ApoER2", 429], [",", 435], ["a", 437], ["member", 439], ["of", 446], ["the", 449], ["lipoprotein", 453], ["receptor", 465], ["family", 474], [",", 480], ["binds", 482], ["Sepp1", 488], ["and", 494], ["facilitates", 498], ["its", 510], ["uptake", 514], ["into", 521], ["the", 526], ["testis", 530], ["and", 537], ["retention", 541], ["of", 551], ["its", 554], ["selenium", 558], ["by", 567], ["the", 570], ["brain", 574], [".", 579], ["Megalin", 581], [",", 588], ["another", 590], ["lipoprotein", 598], ["receptor", 610], [",", 618], ["facilitates", 620], ["uptake", 632], ["of", 639], ["filtered", 642], ["Sepp1", 651], ["into", 657], ["proximal", 662], ["tubule", 671], ["cells", 678], ["of", 684], ["the", 687], ["kidney", 691], [".", 697], ["Thus", 699], [",", 703], ["Sepp1", 705], ["serves", 711], ["in", 718], ["homeostasis", 721], ["and", 733], ["distribution", 737], ["of", 750], ["selenium", 753], [".", 761], ["Mice", 763], ["with", 768], ["deletion", 773], ["of", 782], ["Sepp1", 785], ["suffer", 791], ["greater", 798], ["morbidity", 806], ["and", 816], ["mortality", 820], ["from", 830], ["infection", 835], ["with", 845], ["Trypanosoma", 850], ["congolense", 862], ["than", 873], ["do", 878], ["wild", 881], ["-", 885], ["type", 886], ["mice", 891], [".", 895], ["Mice", 897], ["that", 902], ["express", 907], ["only", 915], ["the", 920], ["N", 924], ["-", 925], ["terminal", 926], ["domain", 935], ["of", 942], ["Sepp1", 945], ["have", 951], ["the", 956], ["same", 960], ["severity", 965], ["of", 974], ["illness", 977], ["as", 985], ["wild", 988], ["-", 992], ["type", 993], ["mice", 998], [",", 1002], ["indicating", 1004], ["that", 1015], ["the", 1020], ["protective", 1024], ["function", 1035], ["of", 1044], ["Sepp1", 1047], ["against", 1053], ["the", 1061], ["infection", 1065], ["resides", 1075], ["in", 1083], ["the", 1086], ["N", 1090], ["-", 1091], ["terminal", 1092], ["(", 1101], ["redox", 1102], [")", 1107], ["domain", 1109], [".", 1115], ["Thus", 1117], [",", 1121], ["Sepp1", 1123], ["has", 1129], ["several", 1133], ["functions", 1141], [".", 1150], ["In", 1152], ["addition", 1155], [",", 1163], ["plasma", 1165], ["Sepp1", 1172], ["concentration", 1178], ["falls", 1192], ["in", 1198], ["selenium", 1201], ["deficiency", 1210], ["and", 1221], [",", 1224], ["therefore", 1226], [",", 1235], ["it", 1237], ["can", 1240], ["be", 1244], ["used", 1247], ["as", 1252], ["an", 1255], ["index", 1258], ["of", 1264], ["selenium", 1267], ["nutritional", 1276], ["status", 1288], [".", 1294]]}
{"context": "The McLeod syndrome is an X-linked neuroacanthocytosis manifesting with myopathy and progressive chorea. It is caused by mutations of the XK gene encoding the XK protein, a putative membrane transport protein of yet unknown function. In erythroid tissues, XK forms a functional complex with the Kell glycoprotein. Here, we present an immunohistochemical study in skeletal muscle of normal controls and a McLeod patient with a XK gene point mutation (C977T) using affinity-purified antibodies against XK and Kell proteins. Histological examination of the affected muscle revealed the typical pattern of McLeod myopathy including type 2 fiber atrophy. In control muscles, Kell immunohistochemistry stained sarcoplasmic membranes. XK immunohistochemistry resulted in a type 2 fiber-specific intracellular staining that was most probably confined to the sarcoplasmic reticulum. In contrast, there was only a weak background signal without a specific staining pattern for XK and Kell in the McLeod muscle. Our results demonstrate that the lack of physiological XK expression correlates to the type 2 fiber atrophy in McLeod myopathy, and suggest that the XK protein represents a crucial factor for the maintenance of normal muscle structure and function.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "f252703de7194f1983547f4bf860ba40", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[192, 192], [27, 27], [44, 44], [87, 87], [23, 23], [73, 73], [121, 121], [175, 175], [159, 159]], "char_spans": [[1150, 1151], [159, 160], [256, 257], [500, 501], [138, 139], [426, 427], [728, 729], [1056, 1057], [967, 968]]}]}], "context_tokens": [["The", 0], ["McLeod", 4], ["syndrome", 11], ["is", 20], ["an", 23], ["X", 26], ["-", 27], ["linked", 28], ["neuroacanthocytosis", 35], ["manifesting", 55], ["with", 67], ["myopathy", 72], ["and", 81], ["progressive", 85], ["chorea", 97], [".", 103], ["It", 105], ["is", 108], ["caused", 111], ["by", 118], ["mutations", 121], ["of", 131], ["the", 134], ["XK", 138], ["gene", 141], ["encoding", 146], ["the", 155], ["XK", 159], ["protein", 162], [",", 169], ["a", 171], ["putative", 173], ["membrane", 182], ["transport", 191], ["protein", 201], ["of", 209], ["yet", 212], ["unknown", 216], ["function", 224], [".", 232], ["In", 234], ["erythroid", 237], ["tissues", 247], [",", 254], ["XK", 256], ["forms", 259], ["a", 265], ["functional", 267], ["complex", 278], ["with", 286], ["the", 291], ["Kell", 295], ["glycoprotein", 300], [".", 312], ["Here", 314], [",", 318], ["we", 320], ["present", 323], ["an", 331], ["immunohistochemical", 334], ["study", 354], ["in", 360], ["skeletal", 363], ["muscle", 372], ["of", 379], ["normal", 382], ["controls", 389], ["and", 398], ["a", 402], ["McLeod", 404], ["patient", 411], ["with", 419], ["a", 424], ["XK", 426], ["gene", 429], ["point", 434], ["mutation", 440], ["(", 449], ["C977", 450], ["T", 454], [")", 455], ["using", 457], ["affinity", 463], ["-", 471], ["purified", 472], ["antibodies", 481], ["against", 492], ["XK", 500], ["and", 503], ["Kell", 507], ["proteins", 512], [".", 520], ["Histological", 522], ["examination", 535], ["of", 547], ["the", 550], ["affected", 554], ["muscle", 563], ["revealed", 570], ["the", 579], ["typical", 583], ["pattern", 591], ["of", 599], ["McLeod", 602], ["myopathy", 609], ["including", 618], ["type", 628], ["2", 633], ["fiber", 635], ["atrophy", 641], [".", 648], ["In", 650], ["control", 653], ["muscles", 661], [",", 668], ["Kell", 670], ["immunohistochemistry", 675], ["stained", 696], ["sarcoplasmic", 704], ["membranes", 717], [".", 726], ["XK", 728], ["immunohistochemistry", 731], ["resulted", 752], ["in", 761], ["a", 764], ["type", 766], ["2", 771], ["fiber", 773], ["-", 778], ["specific", 779], ["intracellular", 788], ["staining", 802], ["that", 811], ["was", 816], ["most", 820], ["probably", 825], ["confined", 834], ["to", 843], ["the", 846], ["sarcoplasmic", 850], ["reticulum", 863], [".", 872], ["In", 874], ["contrast", 877], [",", 885], ["there", 887], ["was", 893], ["only", 897], ["a", 902], ["weak", 904], ["background", 909], ["signal", 920], ["without", 927], ["a", 935], ["specific", 937], ["staining", 946], ["pattern", 955], ["for", 963], ["XK", 967], ["and", 970], ["Kell", 974], ["in", 979], ["the", 982], ["McLeod", 986], ["muscle", 993], [".", 999], ["Our", 1001], ["results", 1005], ["demonstrate", 1013], ["that", 1025], ["the", 1030], ["lack", 1034], ["of", 1039], ["physiological", 1042], ["XK", 1056], ["expression", 1059], ["correlates", 1070], ["to", 1081], ["the", 1084], ["type", 1088], ["2", 1093], ["fiber", 1095], ["atrophy", 1101], ["in", 1109], ["McLeod", 1112], ["myopathy", 1119], [",", 1127], ["and", 1129], ["suggest", 1133], ["that", 1141], ["the", 1146], ["XK", 1150], ["protein", 1153], ["represents", 1161], ["a", 1172], ["crucial", 1174], ["factor", 1182], ["for", 1189], ["the", 1193], ["maintenance", 1197], ["of", 1209], ["normal", 1212], ["muscle", 1219], ["structure", 1226], ["and", 1236], ["function", 1240], [".", 1248]]}
{"context": "Gefitinib, the specific inhibitor of the epidermal growth factor receptor (EGFR), may cause growth delay in cancer cell lines. Thorough understanding of the downstream cellular signaling of gefitinib will facilitate the discovery of biomarkers for predicting outcomes and monitoring anti-EGFR therapies, and provide information for key targets for therapeutic intervention. In this study, we investigated the role of transducer of erbB2.1 (TOB1) in gefitinib therapy. Using the lung carcinoma cell lines A549 and NCI-H1975, the results suggested that gefitinib might mediate cell cycle arrest in lung cancer cells at least by targeting TOB1 expression. Gefitinib treatment caused cell cycle arrest predominantly at the G1 phase, which is associated with TOB1 nuclear translocation and its interaction with cyclin D1. We also showed that knockdown of TOB1 expression by RNAi rescued lung cancer cells from gefitinib-induced cell-proliferative arrest. These results suggest that TOB1 interaction with cyclin D1 and nuclear translocation is directly involved in the gefitinib-induced anti-proliferative cell cycle arrest.", "qas": [{"question": "Which is the cellular target of gefitinib?", "answers": ["Epidermal growth factor receptor (EGFR)"], "qid": "69bb73c08e1848e080576cacd9b2c307", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["cellular", 13], ["target", 22], ["of", 29], ["gefitinib", 32], ["?", 41]], "detected_answers": [{"text": "Epidermal growth factor receptor (EGFR)", "token_spans": [[7, 12]], "char_spans": [[41, 78]]}]}], "context_tokens": [["Gefitinib", 0], [",", 9], ["the", 11], ["specific", 15], ["inhibitor", 24], ["of", 34], ["the", 37], ["epidermal", 41], ["growth", 51], ["factor", 58], ["receptor", 65], ["(", 74], ["EGFR", 75], [")", 79], [",", 80], ["may", 82], ["cause", 86], ["growth", 92], ["delay", 99], ["in", 105], ["cancer", 108], ["cell", 115], ["lines", 120], [".", 125], ["Thorough", 127], ["understanding", 136], ["of", 150], ["the", 153], ["downstream", 157], ["cellular", 168], ["signaling", 177], ["of", 187], ["gefitinib", 190], ["will", 200], ["facilitate", 205], ["the", 216], ["discovery", 220], ["of", 230], ["biomarkers", 233], ["for", 244], ["predicting", 248], ["outcomes", 259], ["and", 268], ["monitoring", 272], ["anti", 283], ["-", 287], ["EGFR", 288], ["therapies", 293], [",", 302], ["and", 304], ["provide", 308], ["information", 316], ["for", 328], ["key", 332], ["targets", 336], ["for", 344], ["therapeutic", 348], ["intervention", 360], [".", 372], ["In", 374], ["this", 377], ["study", 382], [",", 387], ["we", 389], ["investigated", 392], ["the", 405], ["role", 409], ["of", 414], ["transducer", 417], ["of", 428], ["erbB2.1", 431], ["(", 439], ["TOB1", 440], [")", 444], ["in", 446], ["gefitinib", 449], ["therapy", 459], [".", 466], ["Using", 468], ["the", 474], ["lung", 478], ["carcinoma", 483], ["cell", 493], ["lines", 498], ["A549", 504], ["and", 509], ["NCI", 513], ["-", 516], ["H1975", 517], [",", 522], ["the", 524], ["results", 528], ["suggested", 536], ["that", 546], ["gefitinib", 551], ["might", 561], ["mediate", 567], ["cell", 575], ["cycle", 580], ["arrest", 586], ["in", 593], ["lung", 596], ["cancer", 601], ["cells", 608], ["at", 614], ["least", 617], ["by", 623], ["targeting", 626], ["TOB1", 636], ["expression", 641], [".", 651], ["Gefitinib", 653], ["treatment", 663], ["caused", 673], ["cell", 680], ["cycle", 685], ["arrest", 691], ["predominantly", 698], ["at", 712], ["the", 715], ["G1", 719], ["phase", 722], [",", 727], ["which", 729], ["is", 735], ["associated", 738], ["with", 749], ["TOB1", 754], ["nuclear", 759], ["translocation", 767], ["and", 781], ["its", 785], ["interaction", 789], ["with", 801], ["cyclin", 806], ["D1", 813], [".", 815], ["We", 817], ["also", 820], ["showed", 825], ["that", 832], ["knockdown", 837], ["of", 847], ["TOB1", 850], ["expression", 855], ["by", 866], ["RNAi", 869], ["rescued", 874], ["lung", 882], ["cancer", 887], ["cells", 894], ["from", 900], ["gefitinib", 905], ["-", 914], ["induced", 915], ["cell", 923], ["-", 927], ["proliferative", 928], ["arrest", 942], [".", 948], ["These", 950], ["results", 956], ["suggest", 964], ["that", 972], ["TOB1", 977], ["interaction", 982], ["with", 994], ["cyclin", 999], ["D1", 1006], ["and", 1009], ["nuclear", 1013], ["translocation", 1021], ["is", 1035], ["directly", 1038], ["involved", 1047], ["in", 1056], ["the", 1059], ["gefitinib", 1063], ["-", 1072], ["induced", 1073], ["anti", 1081], ["-", 1085], ["proliferative", 1086], ["cell", 1100], ["cycle", 1105], ["arrest", 1111], [".", 1117]]}
{"context": "Mutations of the alpha-synuclein gene have shown to be relevant in some rare families with autosomal dominant Parkinson's disease (PD). Furthermore, alpha-synuclein protein is a major component of the Lewy bodies also in sporadic PD patients. Increased levels of wildtype alpha-synuclein in the cell leads to increased intracellular hydrogen peroxide levels and causes death of dopaminergic neurons in rat primary culture. Subsequently, oxidative stress has been directly linked with alpha-synuclein aggregation in vitro. This raises the question whether increased alpha-synuclein expression might be linked to higher susceptibility to PD and whether alpha-synuclein promoter polymorphisms are associated with PD. Here, two polymorphisms (-116C>G and -668T>C) of the alpha-synuclein promoter defining four haplotypes have been characterized in 315 German PD patients. The influence of the four haplotypes on gene expression was studied by CAT reporter gene assays in neuronal SK-N-AS cells. The -668C/-116G haplotype revealed significant higher CAT expression than the -668T/-116G or the -668T/-116C haplotype, respectively. Although the -668C/-116G haplotype was more common in PD patients, this difference was not significant.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "25ed7d746b414134b9454c0b72df2885", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[3, 5], [28, 30], [110, 112], [96, 98], [135, 137], [50, 52], [83, 85]], "char_spans": [[17, 31], [149, 163], [651, 665], [565, 579], [767, 781], [272, 286], [484, 498]]}]}], "context_tokens": [["Mutations", 0], ["of", 10], ["the", 13], ["alpha", 17], ["-", 22], ["synuclein", 23], ["gene", 33], ["have", 38], ["shown", 43], ["to", 49], ["be", 52], ["relevant", 55], ["in", 64], ["some", 67], ["rare", 72], ["families", 77], ["with", 86], ["autosomal", 91], ["dominant", 101], ["Parkinson", 110], ["'s", 119], ["disease", 122], ["(", 130], ["PD", 131], [")", 133], [".", 134], ["Furthermore", 136], [",", 147], ["alpha", 149], ["-", 154], ["synuclein", 155], ["protein", 165], ["is", 173], ["a", 176], ["major", 178], ["component", 184], ["of", 194], ["the", 197], ["Lewy", 201], ["bodies", 206], ["also", 213], ["in", 218], ["sporadic", 221], ["PD", 230], ["patients", 233], [".", 241], ["Increased", 243], ["levels", 253], ["of", 260], ["wildtype", 263], ["alpha", 272], ["-", 277], ["synuclein", 278], ["in", 288], ["the", 291], ["cell", 295], ["leads", 300], ["to", 306], ["increased", 309], ["intracellular", 319], ["hydrogen", 333], ["peroxide", 342], ["levels", 351], ["and", 358], ["causes", 362], ["death", 369], ["of", 375], ["dopaminergic", 378], ["neurons", 391], ["in", 399], ["rat", 402], ["primary", 406], ["culture", 414], [".", 421], ["Subsequently", 423], [",", 435], ["oxidative", 437], ["stress", 447], ["has", 454], ["been", 458], ["directly", 463], ["linked", 472], ["with", 479], ["alpha", 484], ["-", 489], ["synuclein", 490], ["aggregation", 500], ["in", 512], ["vitro", 515], [".", 520], ["This", 522], ["raises", 527], ["the", 534], ["question", 538], ["whether", 547], ["increased", 555], ["alpha", 565], ["-", 570], ["synuclein", 571], ["expression", 581], ["might", 592], ["be", 598], ["linked", 601], ["to", 608], ["higher", 611], ["susceptibility", 618], ["to", 633], ["PD", 636], ["and", 639], ["whether", 643], ["alpha", 651], ["-", 656], ["synuclein", 657], ["promoter", 667], ["polymorphisms", 676], ["are", 690], ["associated", 694], ["with", 705], ["PD", 710], [".", 712], ["Here", 714], [",", 718], ["two", 720], ["polymorphisms", 724], ["(", 738], ["-116C", 739], [">", 744], ["G", 745], ["and", 747], ["-668T", 751], [">", 756], ["C", 757], [")", 758], ["of", 760], ["the", 763], ["alpha", 767], ["-", 772], ["synuclein", 773], ["promoter", 783], ["defining", 792], ["four", 801], ["haplotypes", 806], ["have", 817], ["been", 822], ["characterized", 827], ["in", 841], ["315", 844], ["German", 848], ["PD", 855], ["patients", 858], [".", 866], ["The", 868], ["influence", 872], ["of", 882], ["the", 885], ["four", 889], ["haplotypes", 894], ["on", 905], ["gene", 908], ["expression", 913], ["was", 924], ["studied", 928], ["by", 936], ["CAT", 939], ["reporter", 943], ["gene", 952], ["assays", 957], ["in", 964], ["neuronal", 967], ["SK", 976], ["-", 978], ["N", 979], ["-", 980], ["AS", 981], ["cells", 984], [".", 989], ["The", 991], ["-668C/-116", 995], ["G", 1005], ["haplotype", 1007], ["revealed", 1017], ["significant", 1026], ["higher", 1038], ["CAT", 1045], ["expression", 1049], ["than", 1060], ["the", 1065], ["-668T/-116", 1069], ["G", 1079], ["or", 1081], ["the", 1084], ["-668T/-116C", 1088], ["haplotype", 1100], [",", 1109], ["respectively", 1111], [".", 1123], ["Although", 1125], ["the", 1134], ["-668C/-116", 1138], ["G", 1148], ["haplotype", 1150], ["was", 1160], ["more", 1164], ["common", 1169], ["in", 1176], ["PD", 1179], ["patients", 1182], [",", 1190], ["this", 1192], ["difference", 1197], ["was", 1208], ["not", 1212], ["significant", 1216], [".", 1227]]}
{"context": "Primary sinonasal intestinal-type adenocarcinomas (ITAC) are defined on the basis of their morphological similarities to colorectal adenocarcinomas (CRA). Thus, differential diagnosis with sinonasal metastasis of CRA could be a real challenge. Neuroendocrine differentiation has been variably described in several types of adenocarcinomas and notably in ITACs and CRAs. In a series of 25 ITACs and 25 lymph node metastasis of CRAs (nmCRA), we analysed neuroendocrine differentiation by immunohistochemistry with anti-chromogranin A and synaptophysin antibodies. Neuroendocrine differentiation (chromogranin A and/or synaptophysin positivity) was significantly different (p=0.0002) in ITACs (72%) and in nmCRAs (20%). In conclusion, presence of neuroendocrine cells seems more in favour of a sinonasal intestinal-type adenocarcinoma, than metastatic CRA. This immunohistochemical study could be useful in difficult cases and should be an interesting complement in a clinical discussion.", "qas": [{"question": "Which cell type has the protein Chromogranin A as marker?", "answers": ["neuroendocrine cells"], "qid": "ec272621cd3149a5b39e759406ab8844", "question_tokens": [["Which", 0], ["cell", 6], ["type", 11], ["has", 16], ["the", 20], ["protein", 24], ["Chromogranin", 32], ["A", 45], ["as", 47], ["marker", 50], ["?", 56]], "detected_answers": [{"text": "neuroendocrine cells", "token_spans": [[124, 125]], "char_spans": [[744, 763]]}]}], "context_tokens": [["Primary", 0], ["sinonasal", 8], ["intestinal", 18], ["-", 28], ["type", 29], ["adenocarcinomas", 34], ["(", 50], ["ITAC", 51], [")", 55], ["are", 57], ["defined", 61], ["on", 69], ["the", 72], ["basis", 76], ["of", 82], ["their", 85], ["morphological", 91], ["similarities", 105], ["to", 118], ["colorectal", 121], ["adenocarcinomas", 132], ["(", 148], ["CRA", 149], [")", 152], [".", 153], ["Thus", 155], [",", 159], ["differential", 161], ["diagnosis", 174], ["with", 184], ["sinonasal", 189], ["metastasis", 199], ["of", 210], ["CRA", 213], ["could", 217], ["be", 223], ["a", 226], ["real", 228], ["challenge", 233], [".", 242], ["Neuroendocrine", 244], ["differentiation", 259], ["has", 275], ["been", 279], ["variably", 284], ["described", 293], ["in", 303], ["several", 306], ["types", 314], ["of", 320], ["adenocarcinomas", 323], ["and", 339], ["notably", 343], ["in", 351], ["ITACs", 354], ["and", 360], ["CRAs", 364], [".", 368], ["In", 370], ["a", 373], ["series", 375], ["of", 382], ["25", 385], ["ITACs", 388], ["and", 394], ["25", 398], ["lymph", 401], ["node", 407], ["metastasis", 412], ["of", 423], ["CRAs", 426], ["(", 431], ["nmCRA", 432], [")", 437], [",", 438], ["we", 440], ["analysed", 443], ["neuroendocrine", 452], ["differentiation", 467], ["by", 483], ["immunohistochemistry", 486], ["with", 507], ["anti", 512], ["-", 516], ["chromogranin", 517], ["A", 530], ["and", 532], ["synaptophysin", 536], ["antibodies", 550], [".", 560], ["Neuroendocrine", 562], ["differentiation", 577], ["(", 593], ["chromogranin", 594], ["A", 607], ["and/or", 609], ["synaptophysin", 616], ["positivity", 630], [")", 640], ["was", 642], ["significantly", 646], ["different", 660], ["(", 670], ["p=0.0002", 671], [")", 679], ["in", 681], ["ITACs", 684], ["(", 690], ["72", 691], ["%", 693], [")", 694], ["and", 696], ["in", 700], ["nmCRAs", 703], ["(", 710], ["20", 711], ["%", 713], [")", 714], [".", 715], ["In", 717], ["conclusion", 720], [",", 730], ["presence", 732], ["of", 741], ["neuroendocrine", 744], ["cells", 759], ["seems", 765], ["more", 771], ["in", 776], ["favour", 779], ["of", 786], ["a", 789], ["sinonasal", 791], ["intestinal", 801], ["-", 811], ["type", 812], ["adenocarcinoma", 817], [",", 831], ["than", 833], ["metastatic", 838], ["CRA", 849], [".", 852], ["This", 854], ["immunohistochemical", 859], ["study", 879], ["could", 885], ["be", 891], ["useful", 894], ["in", 901], ["difficult", 904], ["cases", 914], ["and", 920], ["should", 924], ["be", 931], ["an", 934], ["interesting", 937], ["complement", 949], ["in", 960], ["a", 963], ["clinical", 965], ["discussion", 974], [".", 984]]}
{"context": "Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers worldwide. Despite significant progresses in the last decades, the origin of this cancer remains unclear and no efficient therapy exists. PDAC does not arise de novo: three remarkable different types of pancreatic lesions can evolve towards pancreatic cancer. These precursor lesions include: Pancreatic intraepithelial neoplasia (PanIN) that are microscopic lesions of the pancreas, Intraductal Papillary Mucinous Neoplasms (IPMN) and Mucinous Cystic Neoplasms (MCN) that are both macroscopic lesions. However, the cellular origin of these lesions is still a matter of debate. Classically, neoplasm initiation or progression is driven by several genetic and epigenetic alterations. The aim of this review is to assemble the current information on genetic mutations and epigenetic disorders that affect genes during pancreatic carcinogenesis. We will further discuss the interest of the genetic and epigenetic alterations for the diagnosis and prognosis of PDAC. Large genetic alterations (chromosomal deletion/amplification) and single point mutations are well described for carcinogenesis inducers. Mutations classically occur within key regions of the genome. Consequences are various and include activation of mitogenic pathways or silencing of apoptotic processes. Alterations of K-RAS, P16 and DPC4 genes are frequently observed in PDAC samples and have been described to arise gradually during carcinogenesis. DNA methylation is an epigenetic process involved in imprinting and X chromosome inactivation. Alteration of DNA methylation patterns leads to deregulation of gene expression, in the absence of mutation. Both genetic and epigenetic events influence genes and non-coding RNA expression, with dramatic effects on proliferation, survival and invasion. Besides improvement in our fundamental understanding of PDAC development, highlighting the molecular alterations that occur in pancreatic carcinogenesis could provide new clinical tools for early diagnosis of PDAC and the molecular basis for the development of new effective therapies.", "qas": [{"question": "Which is the molecular mechanism underlying K-ras alterations in carcinomas?", "answers": ["Point mutations"], "qid": "2729af5d87194532a74ffb452dcb9886", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["molecular", 13], ["mechanism", 23], ["underlying", 33], ["K", 44], ["-", 45], ["ras", 46], ["alterations", 50], ["in", 62], ["carcinomas", 65], ["?", 75]], "detected_answers": [{"text": "Point mutations", "token_spans": [[180, 181]], "char_spans": [[1111, 1125]]}]}], "context_tokens": [["Pancreatic", 0], ["ductal", 11], ["adenocarcinoma", 18], ["(", 33], ["PDAC", 34], [")", 38], ["is", 40], ["one", 43], ["of", 47], ["the", 50], ["most", 54], ["lethal", 59], ["cancers", 66], ["worldwide", 74], [".", 83], ["Despite", 85], ["significant", 93], ["progresses", 105], ["in", 116], ["the", 119], ["last", 123], ["decades", 128], [",", 135], ["the", 137], ["origin", 141], ["of", 148], ["this", 151], ["cancer", 156], ["remains", 163], ["unclear", 171], ["and", 179], ["no", 183], ["efficient", 186], ["therapy", 196], ["exists", 204], [".", 210], ["PDAC", 212], ["does", 217], ["not", 222], ["arise", 226], ["de", 232], ["novo", 235], [":", 239], ["three", 241], ["remarkable", 247], ["different", 258], ["types", 268], ["of", 274], ["pancreatic", 277], ["lesions", 288], ["can", 296], ["evolve", 300], ["towards", 307], ["pancreatic", 315], ["cancer", 326], [".", 332], ["These", 334], ["precursor", 340], ["lesions", 350], ["include", 358], [":", 365], ["Pancreatic", 367], ["intraepithelial", 378], ["neoplasia", 394], ["(", 404], ["PanIN", 405], [")", 410], ["that", 412], ["are", 417], ["microscopic", 421], ["lesions", 433], ["of", 441], ["the", 444], ["pancreas", 448], [",", 456], ["Intraductal", 458], ["Papillary", 470], ["Mucinous", 480], ["Neoplasms", 489], ["(", 499], ["IPMN", 500], [")", 504], ["and", 506], ["Mucinous", 510], ["Cystic", 519], ["Neoplasms", 526], ["(", 536], ["MCN", 537], [")", 540], ["that", 542], ["are", 547], ["both", 551], ["macroscopic", 556], ["lesions", 568], [".", 575], ["However", 577], [",", 584], ["the", 586], ["cellular", 590], ["origin", 599], ["of", 606], ["these", 609], ["lesions", 615], ["is", 623], ["still", 626], ["a", 632], ["matter", 634], ["of", 641], ["debate", 644], [".", 650], ["Classically", 652], [",", 663], ["neoplasm", 665], ["initiation", 674], ["or", 685], ["progression", 688], ["is", 700], ["driven", 703], ["by", 710], ["several", 713], ["genetic", 721], ["and", 729], ["epigenetic", 733], ["alterations", 744], [".", 755], ["The", 757], ["aim", 761], ["of", 765], ["this", 768], ["review", 773], ["is", 780], ["to", 783], ["assemble", 786], ["the", 795], ["current", 799], ["information", 807], ["on", 819], ["genetic", 822], ["mutations", 830], ["and", 840], ["epigenetic", 844], ["disorders", 855], ["that", 865], ["affect", 870], ["genes", 877], ["during", 883], ["pancreatic", 890], ["carcinogenesis", 901], [".", 915], ["We", 917], ["will", 920], ["further", 925], ["discuss", 933], ["the", 941], ["interest", 945], ["of", 954], ["the", 957], ["genetic", 961], ["and", 969], ["epigenetic", 973], ["alterations", 984], ["for", 996], ["the", 1000], ["diagnosis", 1004], ["and", 1014], ["prognosis", 1018], ["of", 1028], ["PDAC", 1031], [".", 1035], ["Large", 1037], ["genetic", 1043], ["alterations", 1051], ["(", 1063], ["chromosomal", 1064], ["deletion", 1076], ["/", 1084], ["amplification", 1085], [")", 1098], ["and", 1100], ["single", 1104], ["point", 1111], ["mutations", 1117], ["are", 1127], ["well", 1131], ["described", 1136], ["for", 1146], ["carcinogenesis", 1150], ["inducers", 1165], [".", 1173], ["Mutations", 1175], ["classically", 1185], ["occur", 1197], ["within", 1203], ["key", 1210], ["regions", 1214], ["of", 1222], ["the", 1225], ["genome", 1229], [".", 1235], ["Consequences", 1237], ["are", 1250], ["various", 1254], ["and", 1262], ["include", 1266], ["activation", 1274], ["of", 1285], ["mitogenic", 1288], ["pathways", 1298], ["or", 1307], ["silencing", 1310], ["of", 1320], ["apoptotic", 1323], ["processes", 1333], [".", 1342], ["Alterations", 1344], ["of", 1356], ["K", 1359], ["-", 1360], ["RAS", 1361], [",", 1364], ["P16", 1366], ["and", 1370], ["DPC4", 1374], ["genes", 1379], ["are", 1385], ["frequently", 1389], ["observed", 1400], ["in", 1409], ["PDAC", 1412], ["samples", 1417], ["and", 1425], ["have", 1429], ["been", 1434], ["described", 1439], ["to", 1449], ["arise", 1452], ["gradually", 1458], ["during", 1468], ["carcinogenesis", 1475], [".", 1489], ["DNA", 1491], ["methylation", 1495], ["is", 1507], ["an", 1510], ["epigenetic", 1513], ["process", 1524], ["involved", 1532], ["in", 1541], ["imprinting", 1544], ["and", 1555], ["X", 1559], ["chromosome", 1561], ["inactivation", 1572], [".", 1584], ["Alteration", 1586], ["of", 1597], ["DNA", 1600], ["methylation", 1604], ["patterns", 1616], ["leads", 1625], ["to", 1631], ["deregulation", 1634], ["of", 1647], ["gene", 1650], ["expression", 1655], [",", 1665], ["in", 1667], ["the", 1670], ["absence", 1674], ["of", 1682], ["mutation", 1685], [".", 1693], ["Both", 1695], ["genetic", 1700], ["and", 1708], ["epigenetic", 1712], ["events", 1723], ["influence", 1730], ["genes", 1740], ["and", 1746], ["non", 1750], ["-", 1753], ["coding", 1754], ["RNA", 1761], ["expression", 1765], [",", 1775], ["with", 1777], ["dramatic", 1782], ["effects", 1791], ["on", 1799], ["proliferation", 1802], [",", 1815], ["survival", 1817], ["and", 1826], ["invasion", 1830], [".", 1838], ["Besides", 1840], ["improvement", 1848], ["in", 1860], ["our", 1863], ["fundamental", 1867], ["understanding", 1879], ["of", 1893], ["PDAC", 1896], ["development", 1901], [",", 1912], ["highlighting", 1914], ["the", 1927], ["molecular", 1931], ["alterations", 1941], ["that", 1953], ["occur", 1958], ["in", 1964], ["pancreatic", 1967], ["carcinogenesis", 1978], ["could", 1993], ["provide", 1999], ["new", 2007], ["clinical", 2011], ["tools", 2020], ["for", 2026], ["early", 2030], ["diagnosis", 2036], ["of", 2046], ["PDAC", 2049], ["and", 2054], ["the", 2058], ["molecular", 2062], ["basis", 2072], ["for", 2078], ["the", 2082], ["development", 2086], ["of", 2098], ["new", 2101], ["effective", 2105], ["therapies", 2115], [".", 2124]]}
{"context": "Women in sub-Saharan Africa are a priority population for evaluation of new biomedical HIV-1 prevention strategies. Antiretroviral pre-exposure prophylaxis is a promising prevention approach; however, clinical trials among young women using daily or coitally-dependent products have found low adherence. Antiretroviral-containing vaginal microbicide rings, which release medication over a month or longer, may reduce these adherence challenges. ASPIRE (A Study to Prevent Infection with a Ring for Extended Use) is a phase III, randomized, double-blind, placebo-controlled trial testing the safety and effectiveness of a vaginal ring containing the non-nucleoside reverse transcriptase inhibitor dapivirine for prevention of HIV-1 infection. We describe the baseline characteristics of African women enrolled in the ASPIRE trial. Between August 2012 and June 2014, 5516 women were screened and 2629 HIV-1 seronegative women between 18-45 years of age were enrolled from 15 research sites in Malawi, South Africa, Uganda, and Zimbabwe. The median age was 26 years (IQR 22-31) and the majority (59%) were unmarried. Nearly 100% of participants reported having a primary sex partner in the prior three months but 43% did not know the HIV-1 status of their primary partner; 17% reported additional concurrent partners. Nearly two-thirds (64%) reported having disclosed to primary partners about planned vaginal ring use in the trial. Sexually transmitted infections were prevalent: 12% had Chlamydia trachomatis, 7% Trichomonas vaginalis, 4% Neisseria gonorrhoeae, and 1% syphilis. African HIV-1 seronegative women at risk of HIV -1 infection were successfully enrolled into a phase III trial of dapivirine vaginal ring for HIV-1 prevention.", "qas": [{"question": "Which infection can be prevented with Dapivirine?", "answers": ["HIV"], "qid": "5c077ce1a2b84aa199040b93309cc5b6", "question_tokens": [["Which", 0], ["infection", 6], ["can", 16], ["be", 20], ["prevented", 23], ["with", 33], ["Dapivirine", 38], ["?", 48]], "detected_answers": [{"text": "HIV", "token_spans": [[294, 294]], "char_spans": [[1622, 1624]]}]}], "context_tokens": [["Women", 0], ["in", 6], ["sub", 9], ["-", 12], ["Saharan", 13], ["Africa", 21], ["are", 28], ["a", 32], ["priority", 34], ["population", 43], ["for", 54], ["evaluation", 58], ["of", 69], ["new", 72], ["biomedical", 76], ["HIV-1", 87], ["prevention", 93], ["strategies", 104], [".", 114], ["Antiretroviral", 116], ["pre", 131], ["-", 134], ["exposure", 135], ["prophylaxis", 144], ["is", 156], ["a", 159], ["promising", 161], ["prevention", 171], ["approach", 182], [";", 190], ["however", 192], [",", 199], ["clinical", 201], ["trials", 210], ["among", 217], ["young", 223], ["women", 229], ["using", 235], ["daily", 241], ["or", 247], ["coitally", 250], ["-", 258], ["dependent", 259], ["products", 269], ["have", 278], ["found", 283], ["low", 289], ["adherence", 293], [".", 302], ["Antiretroviral", 304], ["-", 318], ["containing", 319], ["vaginal", 330], ["microbicide", 338], ["rings", 350], [",", 355], ["which", 357], ["release", 363], ["medication", 371], ["over", 382], ["a", 387], ["month", 389], ["or", 395], ["longer", 398], [",", 404], ["may", 406], ["reduce", 410], ["these", 417], ["adherence", 423], ["challenges", 433], [".", 443], ["ASPIRE", 445], ["(", 452], ["A", 453], ["Study", 455], ["to", 461], ["Prevent", 464], ["Infection", 472], ["with", 482], ["a", 487], ["Ring", 489], ["for", 494], ["Extended", 498], ["Use", 507], [")", 510], ["is", 512], ["a", 515], ["phase", 517], ["III", 523], [",", 526], ["randomized", 528], [",", 538], ["double", 540], ["-", 546], ["blind", 547], [",", 552], ["placebo", 554], ["-", 561], ["controlled", 562], ["trial", 573], ["testing", 579], ["the", 587], ["safety", 591], ["and", 598], ["effectiveness", 602], ["of", 616], ["a", 619], ["vaginal", 621], ["ring", 629], ["containing", 634], ["the", 645], ["non", 649], ["-", 652], ["nucleoside", 653], ["reverse", 664], ["transcriptase", 672], ["inhibitor", 686], ["dapivirine", 696], ["for", 707], ["prevention", 711], ["of", 722], ["HIV-1", 725], ["infection", 731], [".", 740], ["We", 742], ["describe", 745], ["the", 754], ["baseline", 758], ["characteristics", 767], ["of", 783], ["African", 786], ["women", 794], ["enrolled", 800], ["in", 809], ["the", 812], ["ASPIRE", 816], ["trial", 823], [".", 828], ["Between", 830], ["August", 838], ["2012", 845], ["and", 850], ["June", 854], ["2014", 859], [",", 863], ["5516", 865], ["women", 870], ["were", 876], ["screened", 881], ["and", 890], ["2629", 894], ["HIV-1", 899], ["seronegative", 905], ["women", 918], ["between", 924], ["18", 932], ["-", 934], ["45", 935], ["years", 938], ["of", 944], ["age", 947], ["were", 951], ["enrolled", 956], ["from", 965], ["15", 970], ["research", 973], ["sites", 982], ["in", 988], ["Malawi", 991], [",", 997], ["South", 999], ["Africa", 1005], [",", 1011], ["Uganda", 1013], [",", 1019], ["and", 1021], ["Zimbabwe", 1025], [".", 1033], ["The", 1035], ["median", 1039], ["age", 1046], ["was", 1050], ["26", 1054], ["years", 1057], ["(", 1063], ["IQR", 1064], ["22", 1068], ["-", 1070], ["31", 1071], [")", 1073], ["and", 1075], ["the", 1079], ["majority", 1083], ["(", 1092], ["59", 1093], ["%", 1095], [")", 1096], ["were", 1098], ["unmarried", 1103], [".", 1112], ["Nearly", 1114], ["100", 1121], ["%", 1124], ["of", 1126], ["participants", 1129], ["reported", 1142], ["having", 1151], ["a", 1158], ["primary", 1160], ["sex", 1168], ["partner", 1172], ["in", 1180], ["the", 1183], ["prior", 1187], ["three", 1193], ["months", 1199], ["but", 1206], ["43", 1210], ["%", 1212], ["did", 1214], ["not", 1218], ["know", 1222], ["the", 1227], ["HIV-1", 1231], ["status", 1237], ["of", 1244], ["their", 1247], ["primary", 1253], ["partner", 1261], [";", 1268], ["17", 1270], ["%", 1272], ["reported", 1274], ["additional", 1283], ["concurrent", 1294], ["partners", 1305], [".", 1313], ["Nearly", 1315], ["two", 1322], ["-", 1325], ["thirds", 1326], ["(", 1333], ["64", 1334], ["%", 1336], [")", 1337], ["reported", 1339], ["having", 1348], ["disclosed", 1355], ["to", 1365], ["primary", 1368], ["partners", 1376], ["about", 1385], ["planned", 1391], ["vaginal", 1399], ["ring", 1407], ["use", 1412], ["in", 1416], ["the", 1419], ["trial", 1423], [".", 1428], ["Sexually", 1430], ["transmitted", 1439], ["infections", 1451], ["were", 1462], ["prevalent", 1467], [":", 1476], ["12", 1478], ["%", 1480], ["had", 1482], ["Chlamydia", 1486], ["trachomatis", 1496], [",", 1507], ["7", 1509], ["%", 1510], ["Trichomonas", 1512], ["vaginalis", 1524], [",", 1533], ["4", 1535], ["%", 1536], ["Neisseria", 1538], ["gonorrhoeae", 1548], [",", 1559], ["and", 1561], ["1", 1565], ["%", 1566], ["syphilis", 1568], [".", 1576], ["African", 1578], ["HIV-1", 1586], ["seronegative", 1592], ["women", 1605], ["at", 1611], ["risk", 1614], ["of", 1619], ["HIV", 1622], ["-1", 1626], ["infection", 1629], ["were", 1639], ["successfully", 1644], ["enrolled", 1657], ["into", 1666], ["a", 1671], ["phase", 1673], ["III", 1679], ["trial", 1683], ["of", 1689], ["dapivirine", 1692], ["vaginal", 1703], ["ring", 1711], ["for", 1716], ["HIV-1", 1720], ["prevention", 1726], [".", 1736]]}
{"context": "Facio-scapulo-humeral dystrophy (FSHD) results from deletions in the subtelomeric macrosatellite D4Z4 array on the 4q35 region. Upregulation of the DUX4 retrogene from the last D4Z4 repeated unit is thought to underlie FSHD pathophysiology. However, no one knows what triggers muscle defect and when alteration arises. To gain further insights into the molecular mechanisms of the disease, we evaluated at the molecular level, the perturbation linked to the FSHD genotype with no a priori on disease onset, severity or penetrance and prior to any infiltration by fibrotic or adipose tissue in biopsies from fetuses carrying a short pathogenic D4Z4 array (n = 6) compared with fetuses with a non-pathogenic D4Z4 array (n = 21). By measuring expression of several muscle-specific markers and 4q35 genes including the DUX4 retrogene by an RT-PCR and western blotting, we observed a global dysregulation of genes involved in myogenesis including MYOD1 in samples with <11 D4Z4. The DUX4-fl pathogenic transcript was detected in FSHD biopsies but also in controls. Importantly, in FSHD fetuses, we mainly detected the non-spliced DUX4-fl isoform. In addition, several other genes clustered at the 4q35 locus are upregulated in FSHD fetuses. Our study is the first to examine fetuses carrying an FSHD-linked genotype and reveals an extensive dysregulation of several muscle-specific and 4q35 genes at early development stage at a distance from any muscle defect. Overall, our work suggests that even if FSHD is an adult-onset muscular dystrophy, the disease might also involve early molecular defects arising during myogenesis or early differentiation.", "qas": [{"question": "Which disease is associated with the ectopic expression of the protein encoded by the gene DUX4?", "answers": ["Facioscapulohumeral dystrophy", "FSHD"], "qid": "4fc29c2642a542c698f2e6a566dc9c37", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["associated", 17], ["with", 28], ["the", 33], ["ectopic", 37], ["expression", 45], ["of", 56], ["the", 59], ["protein", 63], ["encoded", 71], ["by", 79], ["the", 82], ["gene", 86], ["DUX4", 91], ["?", 95]], "detected_answers": [{"text": "FSHD", "token_spans": [[221, 221], [38, 38], [234, 234], [7, 7], [184, 184], [194, 194], [79, 79], [271, 271]], "char_spans": [[1222, 1225], [219, 222], [1290, 1293], [33, 36], [1024, 1027], [1076, 1079], [458, 461], [1497, 1500]]}]}], "context_tokens": [["Facio", 0], ["-", 5], ["scapulo", 6], ["-", 13], ["humeral", 14], ["dystrophy", 22], ["(", 32], ["FSHD", 33], [")", 37], ["results", 39], ["from", 47], ["deletions", 52], ["in", 62], ["the", 65], ["subtelomeric", 69], ["macrosatellite", 82], ["D4Z4", 97], ["array", 102], ["on", 108], ["the", 111], ["4q35", 115], ["region", 120], [".", 126], ["Upregulation", 128], ["of", 141], ["the", 144], ["DUX4", 148], ["retrogene", 153], ["from", 163], ["the", 168], ["last", 172], ["D4Z4", 177], ["repeated", 182], ["unit", 191], ["is", 196], ["thought", 199], ["to", 207], ["underlie", 210], ["FSHD", 219], ["pathophysiology", 224], [".", 239], ["However", 241], [",", 248], ["no", 250], ["one", 253], ["knows", 257], ["what", 263], ["triggers", 268], ["muscle", 277], ["defect", 284], ["and", 291], ["when", 295], ["alteration", 300], ["arises", 311], [".", 317], ["To", 319], ["gain", 322], ["further", 327], ["insights", 335], ["into", 344], ["the", 349], ["molecular", 353], ["mechanisms", 363], ["of", 374], ["the", 377], ["disease", 381], [",", 388], ["we", 390], ["evaluated", 393], ["at", 403], ["the", 406], ["molecular", 410], ["level", 420], [",", 425], ["the", 427], ["perturbation", 431], ["linked", 444], ["to", 451], ["the", 454], ["FSHD", 458], ["genotype", 463], ["with", 472], ["no", 477], ["a", 480], ["priori", 482], ["on", 489], ["disease", 492], ["onset", 500], [",", 505], ["severity", 507], ["or", 516], ["penetrance", 519], ["and", 530], ["prior", 534], ["to", 540], ["any", 543], ["infiltration", 547], ["by", 560], ["fibrotic", 563], ["or", 572], ["adipose", 575], ["tissue", 583], ["in", 590], ["biopsies", 593], ["from", 602], ["fetuses", 607], ["carrying", 615], ["a", 624], ["short", 626], ["pathogenic", 632], ["D4Z4", 643], ["array", 648], ["(", 654], ["n", 655], ["=", 657], ["6", 659], [")", 660], ["compared", 662], ["with", 671], ["fetuses", 676], ["with", 684], ["a", 689], ["non", 691], ["-", 694], ["pathogenic", 695], ["D4Z4", 706], ["array", 711], ["(", 717], ["n", 718], ["=", 720], ["21", 722], [")", 724], [".", 725], ["By", 727], ["measuring", 730], ["expression", 740], ["of", 751], ["several", 754], ["muscle", 762], ["-", 768], ["specific", 769], ["markers", 778], ["and", 786], ["4q35", 790], ["genes", 795], ["including", 801], ["the", 811], ["DUX4", 815], ["retrogene", 820], ["by", 830], ["an", 833], ["RT", 836], ["-", 838], ["PCR", 839], ["and", 843], ["western", 847], ["blotting", 855], [",", 863], ["we", 865], ["observed", 868], ["a", 877], ["global", 879], ["dysregulation", 886], ["of", 900], ["genes", 903], ["involved", 909], ["in", 918], ["myogenesis", 921], ["including", 932], ["MYOD1", 942], ["in", 948], ["samples", 951], ["with", 959], ["<", 964], ["11", 965], ["D4Z4", 968], [".", 972], ["The", 974], ["DUX4-fl", 978], ["pathogenic", 986], ["transcript", 997], ["was", 1008], ["detected", 1012], ["in", 1021], ["FSHD", 1024], ["biopsies", 1029], ["but", 1038], ["also", 1042], ["in", 1047], ["controls", 1050], [".", 1058], ["Importantly", 1060], [",", 1071], ["in", 1073], ["FSHD", 1076], ["fetuses", 1081], [",", 1088], ["we", 1090], ["mainly", 1093], ["detected", 1100], ["the", 1109], ["non", 1113], ["-", 1116], ["spliced", 1117], ["DUX4-fl", 1125], ["isoform", 1133], [".", 1140], ["In", 1142], ["addition", 1145], [",", 1153], ["several", 1155], ["other", 1163], ["genes", 1169], ["clustered", 1175], ["at", 1185], ["the", 1188], ["4q35", 1192], ["locus", 1197], ["are", 1203], ["upregulated", 1207], ["in", 1219], ["FSHD", 1222], ["fetuses", 1227], [".", 1234], ["Our", 1236], ["study", 1240], ["is", 1246], ["the", 1249], ["first", 1253], ["to", 1259], ["examine", 1262], ["fetuses", 1270], ["carrying", 1278], ["an", 1287], ["FSHD", 1290], ["-", 1294], ["linked", 1295], ["genotype", 1302], ["and", 1311], ["reveals", 1315], ["an", 1323], ["extensive", 1326], ["dysregulation", 1336], ["of", 1350], ["several", 1353], ["muscle", 1361], ["-", 1367], ["specific", 1368], ["and", 1377], ["4q35", 1381], ["genes", 1386], ["at", 1392], ["early", 1395], ["development", 1401], ["stage", 1413], ["at", 1419], ["a", 1422], ["distance", 1424], ["from", 1433], ["any", 1438], ["muscle", 1442], ["defect", 1449], [".", 1455], ["Overall", 1457], [",", 1464], ["our", 1466], ["work", 1470], ["suggests", 1475], ["that", 1484], ["even", 1489], ["if", 1494], ["FSHD", 1497], ["is", 1502], ["an", 1505], ["adult", 1508], ["-", 1513], ["onset", 1514], ["muscular", 1520], ["dystrophy", 1529], [",", 1538], ["the", 1540], ["disease", 1544], ["might", 1552], ["also", 1558], ["involve", 1563], ["early", 1571], ["molecular", 1577], ["defects", 1587], ["arising", 1595], ["during", 1603], ["myogenesis", 1610], ["or", 1621], ["early", 1624], ["differentiation", 1630], [".", 1645]]}
{"context": "Restless legs syndrome, now called Willis-Ekbom Disease (RLS/WED), is a sensorimotor-related sleep disorder. Little is known of the effect of RLS/WED on motor function. The current study investigated upper limb function in RLS/WED patients. We hypothesised that RLS/WED patients exhibit subtle changes in tremor amplitude but normal dexterity and movement speed and rhythmicity compared to healthy controls. RLS/WED patients (n=17, 59 \u00b1 7 years) with moderate disease and healthy controls (n=17, 58 \u00b1 6 years) completed screening tests and five tasks including object manipulation, maximal pinch grip, flexion and extension of the index finger (tremor assessment), maximal finger tapping (movement speed and rhythmicity assessment), and the grooved pegboard test. Force, acceleration, and/or first dorsal interosseus EMG were recorded during four of the tasks. Task performance did not differ between groups. Learning was evident on tasks with repeated trials and the magnitude of learning did not differ between groups. Hand function, tremor, and task learning were unaffected in RLS/WED patients. Patients manipulated objects in a normal manner and exhibited normal movement speed, rhythmicity, and tremor. Further research is needed to assess other types of movement in RLS/WED patients to gain insight into the motor circuitry affected and the underlying pathophysiology.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "3e5986f118e1472abdf00781a69c02a0", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[0, 2]], "char_spans": [[0, 21]]}]}], "context_tokens": [["Restless", 0], ["legs", 9], ["syndrome", 14], [",", 22], ["now", 24], ["called", 28], ["Willis", 35], ["-", 41], ["Ekbom", 42], ["Disease", 48], ["(", 56], ["RLS", 57], ["/", 60], ["WED", 61], [")", 64], [",", 65], ["is", 67], ["a", 70], ["sensorimotor", 72], ["-", 84], ["related", 85], ["sleep", 93], ["disorder", 99], [".", 107], ["Little", 109], ["is", 116], ["known", 119], ["of", 125], ["the", 128], ["effect", 132], ["of", 139], ["RLS", 142], ["/", 145], ["WED", 146], ["on", 150], ["motor", 153], ["function", 159], [".", 167], ["The", 169], ["current", 173], ["study", 181], ["investigated", 187], ["upper", 200], ["limb", 206], ["function", 211], ["in", 220], ["RLS", 223], ["/", 226], ["WED", 227], ["patients", 231], [".", 239], ["We", 241], ["hypothesised", 244], ["that", 257], ["RLS", 262], ["/", 265], ["WED", 266], ["patients", 270], ["exhibit", 279], ["subtle", 287], ["changes", 294], ["in", 302], ["tremor", 305], ["amplitude", 312], ["but", 322], ["normal", 326], ["dexterity", 333], ["and", 343], ["movement", 347], ["speed", 356], ["and", 362], ["rhythmicity", 366], ["compared", 378], ["to", 387], ["healthy", 390], ["controls", 398], [".", 406], ["RLS", 408], ["/", 411], ["WED", 412], ["patients", 416], ["(", 425], ["n=17", 426], [",", 430], ["59", 432], ["\u00b1", 435], ["7", 437], ["years", 439], [")", 444], ["with", 446], ["moderate", 451], ["disease", 460], ["and", 468], ["healthy", 472], ["controls", 480], ["(", 489], ["n=17", 490], [",", 494], ["58", 496], ["\u00b1", 499], ["6", 501], ["years", 503], [")", 508], ["completed", 510], ["screening", 520], ["tests", 530], ["and", 536], ["five", 540], ["tasks", 545], ["including", 551], ["object", 561], ["manipulation", 568], [",", 580], ["maximal", 582], ["pinch", 590], ["grip", 596], [",", 600], ["flexion", 602], ["and", 610], ["extension", 614], ["of", 624], ["the", 627], ["index", 631], ["finger", 637], ["(", 644], ["tremor", 645], ["assessment", 652], [")", 662], [",", 663], ["maximal", 665], ["finger", 673], ["tapping", 680], ["(", 688], ["movement", 689], ["speed", 698], ["and", 704], ["rhythmicity", 708], ["assessment", 720], [")", 730], [",", 731], ["and", 733], ["the", 737], ["grooved", 741], ["pegboard", 749], ["test", 758], [".", 762], ["Force", 764], [",", 769], ["acceleration", 771], [",", 783], ["and/or", 785], ["first", 792], ["dorsal", 798], ["interosseus", 805], ["EMG", 817], ["were", 821], ["recorded", 826], ["during", 835], ["four", 842], ["of", 847], ["the", 850], ["tasks", 854], [".", 859], ["Task", 861], ["performance", 866], ["did", 878], ["not", 882], ["differ", 886], ["between", 893], ["groups", 901], [".", 907], ["Learning", 909], ["was", 918], ["evident", 922], ["on", 930], ["tasks", 933], ["with", 939], ["repeated", 944], ["trials", 953], ["and", 960], ["the", 964], ["magnitude", 968], ["of", 978], ["learning", 981], ["did", 990], ["not", 994], ["differ", 998], ["between", 1005], ["groups", 1013], [".", 1019], ["Hand", 1021], ["function", 1026], [",", 1034], ["tremor", 1036], [",", 1042], ["and", 1044], ["task", 1048], ["learning", 1053], ["were", 1062], ["unaffected", 1067], ["in", 1078], ["RLS", 1081], ["/", 1084], ["WED", 1085], ["patients", 1089], [".", 1097], ["Patients", 1099], ["manipulated", 1108], ["objects", 1120], ["in", 1128], ["a", 1131], ["normal", 1133], ["manner", 1140], ["and", 1147], ["exhibited", 1151], ["normal", 1161], ["movement", 1168], ["speed", 1177], [",", 1182], ["rhythmicity", 1184], [",", 1195], ["and", 1197], ["tremor", 1201], [".", 1207], ["Further", 1209], ["research", 1217], ["is", 1226], ["needed", 1229], ["to", 1236], ["assess", 1239], ["other", 1246], ["types", 1252], ["of", 1258], ["movement", 1261], ["in", 1270], ["RLS", 1273], ["/", 1276], ["WED", 1277], ["patients", 1281], ["to", 1290], ["gain", 1293], ["insight", 1298], ["into", 1306], ["the", 1311], ["motor", 1315], ["circuitry", 1321], ["affected", 1331], ["and", 1340], ["the", 1344], ["underlying", 1348], ["pathophysiology", 1359], [".", 1374]]}
{"context": "Several gene products are involved in co-translational insertion of selenocysteine by the tRNA(Sec). In addition, a stem-loop structure in the mRNAs coding for selenoproteins is essential to mediate the selection of the proper selenocysteine UGA codon. Interestingly, in eukaryotic selenoprotein mRNAs, this stem-loop structure, the selenocysteine insertion sequence (SECIS) element, resides in the 3'-untranslated region, far downstream of the UGA codon. In view of unravelling the underlying complex mechanism, we have attempted to detect RNA-binding proteins with specificity for the SECIS element. Using mobility shift assays, we could show that a protein, present in different types of mammalian cell extracts, possesses the capacity of binding the SECIS element of the selenoprotein glutathione peroxidase (GPx) mRNA. We have termed this protein SBP, for Secis Binding Protein. Competition experiments attested that the binding is highly specific and UV cross-linking indicated that the protein has an apparent molecular weight in the range of 60-65 kDa. Finally, some data suggest that the SECIS elements in the mRNAs of GPx and another selenoprotein, type I iodothyronine 5' deiodinase, recognize the same SBP protein. This constitutes the first report of the existence of a 3' UTR binding protein possibly involved in the eukaryotic selenocysteine insertion mechanism.", "qas": [{"question": "What is the name of the stem loop present in the 3' end of genes encoding for selenoproteins?", "answers": ["SECIS"], "qid": "22db25e825ff4bcfb783e89d2d7a8162", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["stem", 24], ["loop", 29], ["present", 34], ["in", 42], ["the", 45], ["3", 49], ["'", 50], ["end", 52], ["of", 56], ["genes", 59], ["encoding", 65], ["for", 74], ["selenoproteins", 78], ["?", 92]], "detected_answers": [{"text": "SECIS", "token_spans": [[131, 131], [101, 101], [151, 151], [62, 62], [194, 194]], "char_spans": [[754, 758], [587, 591], [861, 865], [368, 372], [1097, 1101]]}]}], "context_tokens": [["Several", 0], ["gene", 8], ["products", 13], ["are", 22], ["involved", 26], ["in", 35], ["co", 38], ["-", 40], ["translational", 41], ["insertion", 55], ["of", 65], ["selenocysteine", 68], ["by", 83], ["the", 86], ["tRNA(Sec", 90], [")", 98], [".", 99], ["In", 101], ["addition", 104], [",", 112], ["a", 114], ["stem", 116], ["-", 120], ["loop", 121], ["structure", 126], ["in", 136], ["the", 139], ["mRNAs", 143], ["coding", 149], ["for", 156], ["selenoproteins", 160], ["is", 175], ["essential", 178], ["to", 188], ["mediate", 191], ["the", 199], ["selection", 203], ["of", 213], ["the", 216], ["proper", 220], ["selenocysteine", 227], ["UGA", 242], ["codon", 246], [".", 251], ["Interestingly", 253], [",", 266], ["in", 268], ["eukaryotic", 271], ["selenoprotein", 282], ["mRNAs", 296], [",", 301], ["this", 303], ["stem", 308], ["-", 312], ["loop", 313], ["structure", 318], [",", 327], ["the", 329], ["selenocysteine", 333], ["insertion", 348], ["sequence", 358], ["(", 367], ["SECIS", 368], [")", 373], ["element", 375], [",", 382], ["resides", 384], ["in", 392], ["the", 395], ["3'-untranslated", 399], ["region", 415], [",", 421], ["far", 423], ["downstream", 427], ["of", 438], ["the", 441], ["UGA", 445], ["codon", 449], [".", 454], ["In", 456], ["view", 459], ["of", 464], ["unravelling", 467], ["the", 479], ["underlying", 483], ["complex", 494], ["mechanism", 502], [",", 511], ["we", 513], ["have", 516], ["attempted", 521], ["to", 531], ["detect", 534], ["RNA", 541], ["-", 544], ["binding", 545], ["proteins", 553], ["with", 562], ["specificity", 567], ["for", 579], ["the", 583], ["SECIS", 587], ["element", 593], [".", 600], ["Using", 602], ["mobility", 608], ["shift", 617], ["assays", 623], [",", 629], ["we", 631], ["could", 634], ["show", 640], ["that", 645], ["a", 650], ["protein", 652], [",", 659], ["present", 661], ["in", 669], ["different", 672], ["types", 682], ["of", 688], ["mammalian", 691], ["cell", 701], ["extracts", 706], [",", 714], ["possesses", 716], ["the", 726], ["capacity", 730], ["of", 739], ["binding", 742], ["the", 750], ["SECIS", 754], ["element", 760], ["of", 768], ["the", 771], ["selenoprotein", 775], ["glutathione", 789], ["peroxidase", 801], ["(", 812], ["GPx", 813], [")", 816], ["mRNA", 818], [".", 822], ["We", 824], ["have", 827], ["termed", 832], ["this", 839], ["protein", 844], ["SBP", 852], [",", 855], ["for", 857], ["Secis", 861], ["Binding", 867], ["Protein", 875], [".", 882], ["Competition", 884], ["experiments", 896], ["attested", 908], ["that", 917], ["the", 922], ["binding", 926], ["is", 934], ["highly", 937], ["specific", 944], ["and", 953], ["UV", 957], ["cross", 960], ["-", 965], ["linking", 966], ["indicated", 974], ["that", 984], ["the", 989], ["protein", 993], ["has", 1001], ["an", 1005], ["apparent", 1008], ["molecular", 1017], ["weight", 1027], ["in", 1034], ["the", 1037], ["range", 1041], ["of", 1047], ["60", 1050], ["-", 1052], ["65", 1053], ["kDa", 1056], [".", 1059], ["Finally", 1061], [",", 1068], ["some", 1070], ["data", 1075], ["suggest", 1080], ["that", 1088], ["the", 1093], ["SECIS", 1097], ["elements", 1103], ["in", 1112], ["the", 1115], ["mRNAs", 1119], ["of", 1125], ["GPx", 1128], ["and", 1132], ["another", 1136], ["selenoprotein", 1144], [",", 1157], ["type", 1159], ["I", 1164], ["iodothyronine", 1166], ["5", 1180], ["'", 1181], ["deiodinase", 1183], [",", 1193], ["recognize", 1195], ["the", 1205], ["same", 1209], ["SBP", 1214], ["protein", 1218], [".", 1225], ["This", 1227], ["constitutes", 1232], ["the", 1244], ["first", 1248], ["report", 1254], ["of", 1261], ["the", 1264], ["existence", 1268], ["of", 1278], ["a", 1281], ["3", 1283], ["'", 1284], ["UTR", 1286], ["binding", 1290], ["protein", 1298], ["possibly", 1306], ["involved", 1315], ["in", 1324], ["the", 1327], ["eukaryotic", 1331], ["selenocysteine", 1342], ["insertion", 1357], ["mechanism", 1367], [".", 1376]]}
{"context": "alpha-Synuclein and ubiquitin are two Lewy body protein components that may play antagonistic roles in the pathogenesis of Lewy bodies. We examined the relationship between alpha-synuclein, ubiquitin, and lipids in Lewy bodies of fixed brain sections or isolated from cortical tissues of dementia with Lewy bodies. Lewy bodies exhibited a range of labeling patterns for alpha-synuclein and ubiquitin, from a homogeneous pattern in which alpha-synuclein and ubiquitin were evenly distributed and overlapped across the inclusion body to a concentric pattern in which alpha-synuclein and ubiquitin were partially segregated, with alpha-synuclein labeling concentrated in the peripheral domain and ubiquitin in the central domain of the Lewy body. Lipids represented a significant component in both homogeneous and concentric Lewy bodies. These results suggest that Lewy bodies are heterogeneous in their subregional composition. The segregation of alpha-synuclein to Lewy body peripheral domain is consistent with the hypothesis that alpha-synuclein is continually deposited onto Lewy bodies.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "84268ced61744024a40b6f8d2316d275", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[63, 65], [28, 30], [154, 156], [168, 170], [95, 97], [105, 107], [0, 2], [75, 77]], "char_spans": [[370, 384], [173, 187], [945, 959], [1031, 1045], [565, 579], [627, 641], [0, 14], [437, 451]]}]}], "context_tokens": [["alpha", 0], ["-", 5], ["Synuclein", 6], ["and", 16], ["ubiquitin", 20], ["are", 30], ["two", 34], ["Lewy", 38], ["body", 43], ["protein", 48], ["components", 56], ["that", 67], ["may", 72], ["play", 76], ["antagonistic", 81], ["roles", 94], ["in", 100], ["the", 103], ["pathogenesis", 107], ["of", 120], ["Lewy", 123], ["bodies", 128], [".", 134], ["We", 136], ["examined", 139], ["the", 148], ["relationship", 152], ["between", 165], ["alpha", 173], ["-", 178], ["synuclein", 179], [",", 188], ["ubiquitin", 190], [",", 199], ["and", 201], ["lipids", 205], ["in", 212], ["Lewy", 215], ["bodies", 220], ["of", 227], ["fixed", 230], ["brain", 236], ["sections", 242], ["or", 251], ["isolated", 254], ["from", 263], ["cortical", 268], ["tissues", 277], ["of", 285], ["dementia", 288], ["with", 297], ["Lewy", 302], ["bodies", 307], [".", 313], ["Lewy", 315], ["bodies", 320], ["exhibited", 327], ["a", 337], ["range", 339], ["of", 345], ["labeling", 348], ["patterns", 357], ["for", 366], ["alpha", 370], ["-", 375], ["synuclein", 376], ["and", 386], ["ubiquitin", 390], [",", 399], ["from", 401], ["a", 406], ["homogeneous", 408], ["pattern", 420], ["in", 428], ["which", 431], ["alpha", 437], ["-", 442], ["synuclein", 443], ["and", 453], ["ubiquitin", 457], ["were", 467], ["evenly", 472], ["distributed", 479], ["and", 491], ["overlapped", 495], ["across", 506], ["the", 513], ["inclusion", 517], ["body", 527], ["to", 532], ["a", 535], ["concentric", 537], ["pattern", 548], ["in", 556], ["which", 559], ["alpha", 565], ["-", 570], ["synuclein", 571], ["and", 581], ["ubiquitin", 585], ["were", 595], ["partially", 600], ["segregated", 610], [",", 620], ["with", 622], ["alpha", 627], ["-", 632], ["synuclein", 633], ["labeling", 643], ["concentrated", 652], ["in", 665], ["the", 668], ["peripheral", 672], ["domain", 683], ["and", 690], ["ubiquitin", 694], ["in", 704], ["the", 707], ["central", 711], ["domain", 719], ["of", 726], ["the", 729], ["Lewy", 733], ["body", 738], [".", 742], ["Lipids", 744], ["represented", 751], ["a", 763], ["significant", 765], ["component", 777], ["in", 787], ["both", 790], ["homogeneous", 795], ["and", 807], ["concentric", 811], ["Lewy", 822], ["bodies", 827], [".", 833], ["These", 835], ["results", 841], ["suggest", 849], ["that", 857], ["Lewy", 862], ["bodies", 867], ["are", 874], ["heterogeneous", 878], ["in", 892], ["their", 895], ["subregional", 901], ["composition", 913], [".", 924], ["The", 926], ["segregation", 930], ["of", 942], ["alpha", 945], ["-", 950], ["synuclein", 951], ["to", 961], ["Lewy", 964], ["body", 969], ["peripheral", 974], ["domain", 985], ["is", 992], ["consistent", 995], ["with", 1006], ["the", 1011], ["hypothesis", 1015], ["that", 1026], ["alpha", 1031], ["-", 1036], ["synuclein", 1037], ["is", 1047], ["continually", 1050], ["deposited", 1062], ["onto", 1072], ["Lewy", 1077], ["bodies", 1082], [".", 1088]]}
{"context": "Research during the last 15 years has conclusively shown that viroids are not only fundamentally different from viruses at the molecular level, but that they are most likely not directly related to viruses in an evolutionary sense. Today, viroids are among the most thoroughly studied biological macromolecules. Their molecular structures have been elucidated to a large extent, but much needs to be learned regarding the correlation between molecular structure and biological function. The availability of the tools of recombinant DNA technology in viroid research promises rapid progress in these areas of inquiry.", "qas": [{"question": "Which are the smallest known subviral pathogens of plants?", "answers": ["Viroids"], "qid": "e33fefebc3a946c4b17c7aaf7f33de2e", "question_tokens": [["Which", 0], ["are", 6], ["the", 10], ["smallest", 14], ["known", 23], ["subviral", 29], ["pathogens", 38], ["of", 48], ["plants", 51], ["?", 57]], "detected_answers": [{"text": "Viroids", "token_spans": [[41, 41], [10, 10]], "char_spans": [[239, 245], [62, 68]]}]}], "context_tokens": [["Research", 0], ["during", 9], ["the", 16], ["last", 20], ["15", 25], ["years", 28], ["has", 34], ["conclusively", 38], ["shown", 51], ["that", 57], ["viroids", 62], ["are", 70], ["not", 74], ["only", 78], ["fundamentally", 83], ["different", 97], ["from", 107], ["viruses", 112], ["at", 120], ["the", 123], ["molecular", 127], ["level", 137], [",", 142], ["but", 144], ["that", 148], ["they", 153], ["are", 158], ["most", 162], ["likely", 167], ["not", 174], ["directly", 178], ["related", 187], ["to", 195], ["viruses", 198], ["in", 206], ["an", 209], ["evolutionary", 212], ["sense", 225], [".", 230], ["Today", 232], [",", 237], ["viroids", 239], ["are", 247], ["among", 251], ["the", 257], ["most", 261], ["thoroughly", 266], ["studied", 277], ["biological", 285], ["macromolecules", 296], [".", 310], ["Their", 312], ["molecular", 318], ["structures", 328], ["have", 339], ["been", 344], ["elucidated", 349], ["to", 360], ["a", 363], ["large", 365], ["extent", 371], [",", 377], ["but", 379], ["much", 383], ["needs", 388], ["to", 394], ["be", 397], ["learned", 400], ["regarding", 408], ["the", 418], ["correlation", 422], ["between", 434], ["molecular", 442], ["structure", 452], ["and", 462], ["biological", 466], ["function", 477], [".", 485], ["The", 487], ["availability", 491], ["of", 504], ["the", 507], ["tools", 511], ["of", 517], ["recombinant", 520], ["DNA", 532], ["technology", 536], ["in", 547], ["viroid", 550], ["research", 557], ["promises", 566], ["rapid", 575], ["progress", 581], ["in", 590], ["these", 593], ["areas", 599], ["of", 605], ["inquiry", 608], [".", 615]]}
{"context": "Ten years after Fire and Melo's Nobel Prize for discovery of gene silencing by double-stranded RNA, a remarkable progress was achieved in RNA interference (RNAi). Changes in the chemical structure of synthetic oligonucleotides make them more stable and specific, and new delivery strategies became progressively available. The attention of pharmaceutical industry rapidly turned to RNAi, as an opportunity to explore new drug targets. This review addresses nine small-interfering RNAs (siRNAs) and one unique microRNA (miRNA) inhibitor, which entered the phase 2-3 clinical trials. The siRNAs in focus are PF-04523655, TKM-080301, Atu027, SYL040012, SYL1001, siG12D-LODER (phase 2), QPI-1002, QPI-1007, and patisiran (phase 3). Regarding miRNAs, their content can be down- or up-regulated, by using miRNA inhibitors (AntimiRs) or miRNA mimics. Miravirsen is an AntimiR-122 for hepatitis C virus infection. The flexibility of RNAi technology is easily understood taking into account: (i) the different drug targets (i.e. p53, caspase 2, PKN3, \u03b22-adrenergic receptor, mutated KRAS, microRNAs); (ii) therapeutic conditions, including ophthalmic diseases, kidney injury, amyloidosis, pancreatic cancer, viral hepatitis; and (iii) routes of administration (ocular, intravenous, subcutaneous, intratumoral). Although some issues are still matters of concern (delivery, toxicity, cost, and biological barriers), RNAi definitively opens a wide avenue for drug development.", "qas": [{"question": "In November 2017,  in what phase  was  the clinical trial for the drug SYL040012?", "answers": ["Phase 3"], "qid": "d2fdd08c60094d70a63f61dde1ded606", "question_tokens": [["In", 0], ["November", 3], ["2017", 12], [",", 16], [" ", 18], ["in", 19], ["what", 22], ["phase", 27], [" ", 33], ["was", 34], [" ", 38], ["the", 39], ["clinical", 43], ["trial", 52], ["for", 58], ["the", 62], ["drug", 66], ["SYL040012", 71], ["?", 80]], "detected_answers": [{"text": "Phase 3", "token_spans": [[134, 135]], "char_spans": [[718, 724]]}]}], "context_tokens": [["Ten", 0], ["years", 4], ["after", 10], ["Fire", 16], ["and", 21], ["Melo", 25], ["'s", 29], ["Nobel", 32], ["Prize", 38], ["for", 44], ["discovery", 48], ["of", 58], ["gene", 61], ["silencing", 66], ["by", 76], ["double", 79], ["-", 85], ["stranded", 86], ["RNA", 95], [",", 98], ["a", 100], ["remarkable", 102], ["progress", 113], ["was", 122], ["achieved", 126], ["in", 135], ["RNA", 138], ["interference", 142], ["(", 155], ["RNAi", 156], [")", 160], [".", 161], ["Changes", 163], ["in", 171], ["the", 174], ["chemical", 178], ["structure", 187], ["of", 197], ["synthetic", 200], ["oligonucleotides", 210], ["make", 227], ["them", 232], ["more", 237], ["stable", 242], ["and", 249], ["specific", 253], [",", 261], ["and", 263], ["new", 267], ["delivery", 271], ["strategies", 280], ["became", 291], ["progressively", 298], ["available", 312], [".", 321], ["The", 323], ["attention", 327], ["of", 337], ["pharmaceutical", 340], ["industry", 355], ["rapidly", 364], ["turned", 372], ["to", 379], ["RNAi", 382], [",", 386], ["as", 388], ["an", 391], ["opportunity", 394], ["to", 406], ["explore", 409], ["new", 417], ["drug", 421], ["targets", 426], [".", 433], ["This", 435], ["review", 440], ["addresses", 447], ["nine", 457], ["small", 462], ["-", 467], ["interfering", 468], ["RNAs", 480], ["(", 485], ["siRNAs", 486], [")", 492], ["and", 494], ["one", 498], ["unique", 502], ["microRNA", 509], ["(", 518], ["miRNA", 519], [")", 524], ["inhibitor", 526], [",", 535], ["which", 537], ["entered", 543], ["the", 551], ["phase", 555], ["2", 561], ["-", 562], ["3", 563], ["clinical", 565], ["trials", 574], [".", 580], ["The", 582], ["siRNAs", 586], ["in", 593], ["focus", 596], ["are", 602], ["PF-04523655", 606], [",", 617], ["TKM-080301", 619], [",", 629], ["Atu027", 631], [",", 637], ["SYL040012", 639], [",", 648], ["SYL1001", 650], [",", 657], ["siG12D", 659], ["-", 665], ["LODER", 666], ["(", 672], ["phase", 673], ["2", 679], [")", 680], [",", 681], ["QPI-1002", 683], [",", 691], ["QPI-1007", 693], [",", 701], ["and", 703], ["patisiran", 707], ["(", 717], ["phase", 718], ["3", 724], [")", 725], [".", 726], ["Regarding", 728], ["miRNAs", 738], [",", 744], ["their", 746], ["content", 752], ["can", 760], ["be", 764], ["down-", 767], ["or", 773], ["up", 776], ["-", 778], ["regulated", 779], [",", 788], ["by", 790], ["using", 793], ["miRNA", 799], ["inhibitors", 805], ["(", 816], ["AntimiRs", 817], [")", 825], ["or", 827], ["miRNA", 830], ["mimics", 836], [".", 842], ["Miravirsen", 844], ["is", 855], ["an", 858], ["AntimiR-122", 861], ["for", 873], ["hepatitis", 877], ["C", 887], ["virus", 889], ["infection", 895], [".", 904], ["The", 906], ["flexibility", 910], ["of", 922], ["RNAi", 925], ["technology", 930], ["is", 941], ["easily", 944], ["understood", 951], ["taking", 962], ["into", 969], ["account", 974], [":", 981], ["(", 983], ["i", 984], [")", 985], ["the", 987], ["different", 991], ["drug", 1001], ["targets", 1006], ["(", 1014], ["i.e.", 1015], ["p53", 1020], [",", 1023], ["caspase", 1025], ["2", 1033], [",", 1034], ["PKN3", 1036], [",", 1040], ["\u03b22-adrenergic", 1042], ["receptor", 1056], [",", 1064], ["mutated", 1066], ["KRAS", 1074], [",", 1078], ["microRNAs", 1080], [")", 1089], [";", 1090], ["(", 1092], ["ii", 1093], [")", 1095], ["therapeutic", 1097], ["conditions", 1109], [",", 1119], ["including", 1121], ["ophthalmic", 1131], ["diseases", 1142], [",", 1150], ["kidney", 1152], ["injury", 1159], [",", 1165], ["amyloidosis", 1167], [",", 1178], ["pancreatic", 1180], ["cancer", 1191], [",", 1197], ["viral", 1199], ["hepatitis", 1205], [";", 1214], ["and", 1216], ["(", 1220], ["iii", 1221], [")", 1224], ["routes", 1226], ["of", 1233], ["administration", 1236], ["(", 1251], ["ocular", 1252], [",", 1258], ["intravenous", 1260], [",", 1271], ["subcutaneous", 1273], [",", 1285], ["intratumoral", 1287], [")", 1299], [".", 1300], ["Although", 1302], ["some", 1311], ["issues", 1316], ["are", 1323], ["still", 1327], ["matters", 1333], ["of", 1341], ["concern", 1344], ["(", 1352], ["delivery", 1353], [",", 1361], ["toxicity", 1363], [",", 1371], ["cost", 1373], [",", 1377], ["and", 1379], ["biological", 1383], ["barriers", 1394], [")", 1402], [",", 1403], ["RNAi", 1405], ["definitively", 1410], ["opens", 1423], ["a", 1429], ["wide", 1431], ["avenue", 1436], ["for", 1443], ["drug", 1447], ["development", 1452], [".", 1463]]}
{"context": "The Ca2+ overload by Ca2+ influx via Na+/Ca2+ exchanger (NCX) is a critical mechanism in myocardial ischemia/reperfusion injury. We investigated protective effects of a novel selective inhibitor of NCX, SEA0400, on cardiac function and energy metabolism during ischemia and reperfusion. Langendorff-perfused rat hearts were exposed to 35 minutes global ischemia and 40 minutes reperfusion. Using 31P nuclear magnetic resonance spectroscopy, cardiac phosphocreatine (PCr), ATP, and pHi were monitored. SEA0400 did not change the basic cardiac function, but improved the recovery of left ventricular developed pressure (LVDP) after reperfusion (27.6 +/- 4.9 mm Hg in control, 101.2 +/- 19.3 mm Hg in 0.1 microM, and 115.5 +/- 13.3 mm Hg in 1 microM SEA0400, means +/- SE, n = 6, P < 0.05). SEA0400 reduced left ventricular end-diastolic pressure and increased coronary flow after reperfusion. SEA0400 improved the recoveries of cardiac phosphocreatine and ATP after reperfusion, but did not affect pHi. There were significant linear correlations between left ventricular developed pressure and cardiac phosphocreatine (r = 0.79, P < 0.05), and left ventricular developed pressure and ATP (r = 0.80, P < 0.05). However, SEA0400 increased the incidence and duration of reperfusion ventricular arrhythmias. SEA0400 added only after reperfusion also improved both the contractile function and energy metabolism. It is concluded that the selective inhibition of NCX may be effective to preserve high-energy phosphates and to improve cardiac function after reperfusion, but may not be able to prevent fatal arrhythmias.", "qas": [{"question": "The small molecule SEA0400 is an inhibitor of which ion antiporter/exchanger?", "answers": ["Na(+)/Ca(2+) exchanger", "NCX"], "qid": "e732552a8ada436c980aa2d6f437c42b", "question_tokens": [["The", 0], ["small", 4], ["molecule", 10], ["SEA0400", 19], ["is", 27], ["an", 30], ["inhibitor", 33], ["of", 43], ["which", 46], ["ion", 52], ["antiporter", 56], ["/", 66], ["exchanger", 67], ["?", 76]], "detected_answers": [{"text": "NCX", "token_spans": [[36, 36], [13, 13], [266, 266]], "char_spans": [[198, 200], [57, 59], [1455, 1457]]}]}], "context_tokens": [["The", 0], ["Ca2", 4], ["+", 7], ["overload", 9], ["by", 18], ["Ca2", 21], ["+", 24], ["influx", 26], ["via", 33], ["Na+/Ca2", 37], ["+", 44], ["exchanger", 46], ["(", 56], ["NCX", 57], [")", 60], ["is", 62], ["a", 65], ["critical", 67], ["mechanism", 76], ["in", 86], ["myocardial", 89], ["ischemia", 100], ["/", 108], ["reperfusion", 109], ["injury", 121], [".", 127], ["We", 129], ["investigated", 132], ["protective", 145], ["effects", 156], ["of", 164], ["a", 167], ["novel", 169], ["selective", 175], ["inhibitor", 185], ["of", 195], ["NCX", 198], [",", 201], ["SEA0400", 203], [",", 210], ["on", 212], ["cardiac", 215], ["function", 223], ["and", 232], ["energy", 236], ["metabolism", 243], ["during", 254], ["ischemia", 261], ["and", 270], ["reperfusion", 274], [".", 285], ["Langendorff", 287], ["-", 298], ["perfused", 299], ["rat", 308], ["hearts", 312], ["were", 319], ["exposed", 324], ["to", 332], ["35", 335], ["minutes", 338], ["global", 346], ["ischemia", 353], ["and", 362], ["40", 366], ["minutes", 369], ["reperfusion", 377], [".", 388], ["Using", 390], ["31P", 396], ["nuclear", 400], ["magnetic", 408], ["resonance", 417], ["spectroscopy", 427], [",", 439], ["cardiac", 441], ["phosphocreatine", 449], ["(", 465], ["PCr", 466], [")", 469], [",", 470], ["ATP", 472], [",", 475], ["and", 477], ["pHi", 481], ["were", 485], ["monitored", 490], [".", 499], ["SEA0400", 501], ["did", 509], ["not", 513], ["change", 517], ["the", 524], ["basic", 528], ["cardiac", 534], ["function", 542], [",", 550], ["but", 552], ["improved", 556], ["the", 565], ["recovery", 569], ["of", 578], ["left", 581], ["ventricular", 586], ["developed", 598], ["pressure", 608], ["(", 617], ["LVDP", 618], [")", 622], ["after", 624], ["reperfusion", 630], ["(", 642], ["27.6", 643], ["+", 648], ["/-", 649], ["4.9", 652], ["mm", 656], ["Hg", 659], ["in", 662], ["control", 665], [",", 672], ["101.2", 674], ["+", 680], ["/-", 681], ["19.3", 684], ["mm", 689], ["Hg", 692], ["in", 695], ["0.1", 698], ["microM", 702], [",", 708], ["and", 710], ["115.5", 714], ["+", 720], ["/-", 721], ["13.3", 724], ["mm", 729], ["Hg", 732], ["in", 735], ["1", 738], ["microM", 740], ["SEA0400", 747], [",", 754], ["means", 756], ["+", 762], ["/-", 763], ["SE", 766], [",", 768], ["n", 770], ["=", 772], ["6", 774], [",", 775], ["P", 777], ["<", 779], ["0.05", 781], [")", 785], [".", 786], ["SEA0400", 788], ["reduced", 796], ["left", 804], ["ventricular", 809], ["end", 821], ["-", 824], ["diastolic", 825], ["pressure", 835], ["and", 844], ["increased", 848], ["coronary", 858], ["flow", 867], ["after", 872], ["reperfusion", 878], [".", 889], ["SEA0400", 891], ["improved", 899], ["the", 908], ["recoveries", 912], ["of", 923], ["cardiac", 926], ["phosphocreatine", 934], ["and", 950], ["ATP", 954], ["after", 958], ["reperfusion", 964], [",", 975], ["but", 977], ["did", 981], ["not", 985], ["affect", 989], ["pHi", 996], [".", 999], ["There", 1001], ["were", 1007], ["significant", 1012], ["linear", 1024], ["correlations", 1031], ["between", 1044], ["left", 1052], ["ventricular", 1057], ["developed", 1069], ["pressure", 1079], ["and", 1088], ["cardiac", 1092], ["phosphocreatine", 1100], ["(", 1116], ["r", 1117], ["=", 1119], ["0.79", 1121], [",", 1125], ["P", 1127], ["<", 1129], ["0.05", 1131], [")", 1135], [",", 1136], ["and", 1138], ["left", 1142], ["ventricular", 1147], ["developed", 1159], ["pressure", 1169], ["and", 1178], ["ATP", 1182], ["(", 1186], ["r", 1187], ["=", 1189], ["0.80", 1191], [",", 1195], ["P", 1197], ["<", 1199], ["0.05", 1201], [")", 1205], [".", 1206], ["However", 1208], [",", 1215], ["SEA0400", 1217], ["increased", 1225], ["the", 1235], ["incidence", 1239], ["and", 1249], ["duration", 1253], ["of", 1262], ["reperfusion", 1265], ["ventricular", 1277], ["arrhythmias", 1289], [".", 1300], ["SEA0400", 1302], ["added", 1310], ["only", 1316], ["after", 1321], ["reperfusion", 1327], ["also", 1339], ["improved", 1344], ["both", 1353], ["the", 1358], ["contractile", 1362], ["function", 1374], ["and", 1383], ["energy", 1387], ["metabolism", 1394], [".", 1404], ["It", 1406], ["is", 1409], ["concluded", 1412], ["that", 1422], ["the", 1427], ["selective", 1431], ["inhibition", 1441], ["of", 1452], ["NCX", 1455], ["may", 1459], ["be", 1463], ["effective", 1466], ["to", 1476], ["preserve", 1479], ["high", 1488], ["-", 1492], ["energy", 1493], ["phosphates", 1500], ["and", 1511], ["to", 1515], ["improve", 1518], ["cardiac", 1526], ["function", 1534], ["after", 1543], ["reperfusion", 1549], [",", 1560], ["but", 1562], ["may", 1566], ["not", 1570], ["be", 1574], ["able", 1577], ["to", 1582], ["prevent", 1585], ["fatal", 1593], ["arrhythmias", 1599], [".", 1610]]}
{"context": "SEA0400 is a selective inhibitor of the Na(+)/Ca(2+) exchanger having equal potencies to suppress both the forward and reverse mode operation of the Na(+)/Ca(2+) exchanger. Present experiments were designed to study the effect of partial blockade of Na(+)/Ca(2+) exchanger on Ca(2+) handling in isolated rat ventricular myocytes. Intracellular Ca(2+) transient and cell shortening were measured in ventricular myocytes loaded with Fura-2-AM fluorescent dye. Partial blockade of Na(+)/Ca(2+) exchanger was induced by superfusion of the cells with SEA0400 at a concentration of 0.3 microM. Amplitude of the intracellular Ca(2+) transient and cell shortening was significantly increased by SEA0400 in both field stimulated and voltage clamped myocytes, without significant elevation of diastolic Ca(2+) level and the decay time constant of the Ca(2+) transient. In patch clamped myocytes the SEA0400 induced increase in the Ca(2+) transient and cell shortening was accompanied by significant reduction of peak L-type Ca(2+) current. These effects can be explained by the autoregulative nature of cardiac Ca(2+) handling, as the reduced Ca(2+) efflux from the cell results in an increased Ca(2+) load to the sarcoplasmic reticulum leading to increased Ca(2+) release, which in turn may decrease the L-type Ca(2+) current by accelaration of Ca(2+) dependent inactivation of L-type Ca(2+) current. Our results suggest that complex changes in the Ca(2+) cycling can occur after selective pharmacological inhibition of the Na(+)/Ca(2+) exchanger.", "qas": [{"question": "The small molecule SEA0400 is an inhibitor of which ion antiporter/exchanger?", "answers": ["Na(+)/Ca(2+) exchanger", "NCX"], "qid": "4fe2e279a8224262a6918b198e8b0ed1", "question_tokens": [["The", 0], ["small", 4], ["molecule", 10], ["SEA0400", 19], ["is", 27], ["an", 30], ["inhibitor", 33], ["of", 43], ["which", 46], ["ion", 52], ["antiporter", 56], ["/", 66], ["exchanger", 67], ["?", 76]], "detected_answers": [{"text": "Na(+)/Ca(2+) exchanger", "token_spans": [[42, 45], [79, 82], [7, 10], [272, 275], [25, 28]], "char_spans": [[250, 271], [478, 499], [40, 61], [1515, 1536], [149, 170]]}]}], "context_tokens": [["SEA0400", 0], ["is", 8], ["a", 11], ["selective", 13], ["inhibitor", 23], ["of", 33], ["the", 36], ["Na(+)/Ca(2", 40], ["+", 50], [")", 51], ["exchanger", 53], ["having", 63], ["equal", 70], ["potencies", 76], ["to", 86], ["suppress", 89], ["both", 98], ["the", 103], ["forward", 107], ["and", 115], ["reverse", 119], ["mode", 127], ["operation", 132], ["of", 142], ["the", 145], ["Na(+)/Ca(2", 149], ["+", 159], [")", 160], ["exchanger", 162], [".", 171], ["Present", 173], ["experiments", 181], ["were", 193], ["designed", 198], ["to", 207], ["study", 210], ["the", 216], ["effect", 220], ["of", 227], ["partial", 230], ["blockade", 238], ["of", 247], ["Na(+)/Ca(2", 250], ["+", 260], [")", 261], ["exchanger", 263], ["on", 273], ["Ca(2", 276], ["+", 280], [")", 281], ["handling", 283], ["in", 292], ["isolated", 295], ["rat", 304], ["ventricular", 308], ["myocytes", 320], [".", 328], ["Intracellular", 330], ["Ca(2", 344], ["+", 348], [")", 349], ["transient", 351], ["and", 361], ["cell", 365], ["shortening", 370], ["were", 381], ["measured", 386], ["in", 395], ["ventricular", 398], ["myocytes", 410], ["loaded", 419], ["with", 426], ["Fura-2-AM", 431], ["fluorescent", 441], ["dye", 453], [".", 456], ["Partial", 458], ["blockade", 466], ["of", 475], ["Na(+)/Ca(2", 478], ["+", 488], [")", 489], ["exchanger", 491], ["was", 501], ["induced", 505], ["by", 513], ["superfusion", 516], ["of", 528], ["the", 531], ["cells", 535], ["with", 541], ["SEA0400", 546], ["at", 554], ["a", 557], ["concentration", 559], ["of", 573], ["0.3", 576], ["microM.", 580], ["Amplitude", 588], ["of", 598], ["the", 601], ["intracellular", 605], ["Ca(2", 619], ["+", 623], [")", 624], ["transient", 626], ["and", 636], ["cell", 640], ["shortening", 645], ["was", 656], ["significantly", 660], ["increased", 674], ["by", 684], ["SEA0400", 687], ["in", 695], ["both", 698], ["field", 703], ["stimulated", 709], ["and", 720], ["voltage", 724], ["clamped", 732], ["myocytes", 740], [",", 748], ["without", 750], ["significant", 758], ["elevation", 770], ["of", 780], ["diastolic", 783], ["Ca(2", 793], ["+", 797], [")", 798], ["level", 800], ["and", 806], ["the", 810], ["decay", 814], ["time", 820], ["constant", 825], ["of", 834], ["the", 837], ["Ca(2", 841], ["+", 845], [")", 846], ["transient", 848], [".", 857], ["In", 859], ["patch", 862], ["clamped", 868], ["myocytes", 876], ["the", 885], ["SEA0400", 889], ["induced", 897], ["increase", 905], ["in", 914], ["the", 917], ["Ca(2", 921], ["+", 925], [")", 926], ["transient", 928], ["and", 938], ["cell", 942], ["shortening", 947], ["was", 958], ["accompanied", 962], ["by", 974], ["significant", 977], ["reduction", 989], ["of", 999], ["peak", 1002], ["L", 1007], ["-", 1008], ["type", 1009], ["Ca(2", 1014], ["+", 1018], [")", 1019], ["current", 1021], [".", 1028], ["These", 1030], ["effects", 1036], ["can", 1044], ["be", 1048], ["explained", 1051], ["by", 1061], ["the", 1064], ["autoregulative", 1068], ["nature", 1083], ["of", 1090], ["cardiac", 1093], ["Ca(2", 1101], ["+", 1105], [")", 1106], ["handling", 1108], [",", 1116], ["as", 1118], ["the", 1121], ["reduced", 1125], ["Ca(2", 1133], ["+", 1137], [")", 1138], ["efflux", 1140], ["from", 1147], ["the", 1152], ["cell", 1156], ["results", 1161], ["in", 1169], ["an", 1172], ["increased", 1175], ["Ca(2", 1185], ["+", 1189], [")", 1190], ["load", 1192], ["to", 1197], ["the", 1200], ["sarcoplasmic", 1204], ["reticulum", 1217], ["leading", 1227], ["to", 1235], ["increased", 1238], ["Ca(2", 1248], ["+", 1252], [")", 1253], ["release", 1255], [",", 1262], ["which", 1264], ["in", 1270], ["turn", 1273], ["may", 1278], ["decrease", 1282], ["the", 1291], ["L", 1295], ["-", 1296], ["type", 1297], ["Ca(2", 1302], ["+", 1306], [")", 1307], ["current", 1309], ["by", 1317], ["accelaration", 1320], ["of", 1333], ["Ca(2", 1336], ["+", 1340], [")", 1341], ["dependent", 1343], ["inactivation", 1353], ["of", 1366], ["L", 1369], ["-", 1370], ["type", 1371], ["Ca(2", 1376], ["+", 1380], [")", 1381], ["current", 1383], [".", 1390], ["Our", 1392], ["results", 1396], ["suggest", 1404], ["that", 1412], ["complex", 1417], ["changes", 1425], ["in", 1433], ["the", 1436], ["Ca(2", 1440], ["+", 1444], [")", 1445], ["cycling", 1447], ["can", 1455], ["occur", 1459], ["after", 1465], ["selective", 1471], ["pharmacological", 1481], ["inhibition", 1497], ["of", 1508], ["the", 1511], ["Na(+)/Ca(2", 1515], ["+", 1525], [")", 1526], ["exchanger", 1528], [".", 1537]]}
{"context": "Centrioles are essential for the formation of cilia and flagella. They also form the core of the centrosome, which organizes microtubule arrays important for cell shape, polarity, motility and division. Here, we have used super-resolution 3D-structured illumination microscopy to analyse the spatial relationship of 18 centriole and pericentriolar matrix (PCM) components of human centrosomes at different cell cycle stages. During mitosis, PCM proteins formed extended networks with interspersed \u03b3-Tubulin. During interphase, most proteins were arranged at specific distances from the walls of centrioles, resulting in ring staining, often with discernible density masses. Through use of site-specific antibodies, we found the C-terminus of Cep152 to be closer to centrioles than the N-terminus, illustrating the power of 3D-SIM to study protein disposition. Appendage proteins showed rings with multiple density masses, and the number of these masses was strongly reduced during mitosis. At the proximal end of centrioles, Sas-6 formed a dot at the site of daughter centriole assembly, consistent with its role in cartwheel formation. Plk4 and STIL co-localized with Sas-6, but Cep135 was associated mostly with mother centrioles. Remarkably, Plk4 formed a dot on the surface of the mother centriole before Sas-6 staining became detectable, indicating that Plk4 constitutes an early marker for the site of nascent centriole formation. Our study provides novel insights into the architecture of human centrosomes and illustrates the power of super-resolution microscopy in revealing the relative localization of centriole and PCM proteins in unprecedented detail.", "qas": [{"question": "Where in the cell do we find the protein Cep135?", "answers": ["centrosome"], "qid": "9ac493dfeaa446d1b53b353bcedbf4eb", "question_tokens": [["Where", 0], ["in", 6], ["the", 9], ["cell", 13], ["do", 18], ["we", 21], ["find", 24], ["the", 29], ["protein", 33], ["Cep135", 41], ["?", 47]], "detected_answers": [{"text": "centrosome", "token_spans": [[18, 18]], "char_spans": [[97, 106]]}]}], "context_tokens": [["Centrioles", 0], ["are", 11], ["essential", 15], ["for", 25], ["the", 29], ["formation", 33], ["of", 43], ["cilia", 46], ["and", 52], ["flagella", 56], [".", 64], ["They", 66], ["also", 71], ["form", 76], ["the", 81], ["core", 85], ["of", 90], ["the", 93], ["centrosome", 97], [",", 107], ["which", 109], ["organizes", 115], ["microtubule", 125], ["arrays", 137], ["important", 144], ["for", 154], ["cell", 158], ["shape", 163], [",", 168], ["polarity", 170], [",", 178], ["motility", 180], ["and", 189], ["division", 193], [".", 201], ["Here", 203], [",", 207], ["we", 209], ["have", 212], ["used", 217], ["super", 222], ["-", 227], ["resolution", 228], ["3D", 239], ["-", 241], ["structured", 242], ["illumination", 253], ["microscopy", 266], ["to", 277], ["analyse", 280], ["the", 288], ["spatial", 292], ["relationship", 300], ["of", 313], ["18", 316], ["centriole", 319], ["and", 329], ["pericentriolar", 333], ["matrix", 348], ["(", 355], ["PCM", 356], [")", 359], ["components", 361], ["of", 372], ["human", 375], ["centrosomes", 381], ["at", 393], ["different", 396], ["cell", 406], ["cycle", 411], ["stages", 417], [".", 423], ["During", 425], ["mitosis", 432], [",", 439], ["PCM", 441], ["proteins", 445], ["formed", 454], ["extended", 461], ["networks", 470], ["with", 479], ["interspersed", 484], ["\u03b3", 497], ["-", 498], ["Tubulin", 499], [".", 506], ["During", 508], ["interphase", 515], [",", 525], ["most", 527], ["proteins", 532], ["were", 541], ["arranged", 546], ["at", 555], ["specific", 558], ["distances", 567], ["from", 577], ["the", 582], ["walls", 586], ["of", 592], ["centrioles", 595], [",", 605], ["resulting", 607], ["in", 617], ["ring", 620], ["staining", 625], [",", 633], ["often", 635], ["with", 641], ["discernible", 646], ["density", 658], ["masses", 666], [".", 672], ["Through", 674], ["use", 682], ["of", 686], ["site", 689], ["-", 693], ["specific", 694], ["antibodies", 703], [",", 713], ["we", 715], ["found", 718], ["the", 724], ["C", 728], ["-", 729], ["terminus", 730], ["of", 739], ["Cep152", 742], ["to", 749], ["be", 752], ["closer", 755], ["to", 762], ["centrioles", 765], ["than", 776], ["the", 781], ["N", 785], ["-", 786], ["terminus", 787], [",", 795], ["illustrating", 797], ["the", 810], ["power", 814], ["of", 820], ["3D", 823], ["-", 825], ["SIM", 826], ["to", 830], ["study", 833], ["protein", 839], ["disposition", 847], [".", 858], ["Appendage", 860], ["proteins", 870], ["showed", 879], ["rings", 886], ["with", 892], ["multiple", 897], ["density", 906], ["masses", 914], [",", 920], ["and", 922], ["the", 926], ["number", 930], ["of", 937], ["these", 940], ["masses", 946], ["was", 953], ["strongly", 957], ["reduced", 966], ["during", 974], ["mitosis", 981], [".", 988], ["At", 990], ["the", 993], ["proximal", 997], ["end", 1006], ["of", 1010], ["centrioles", 1013], [",", 1023], ["Sas-6", 1025], ["formed", 1031], ["a", 1038], ["dot", 1040], ["at", 1044], ["the", 1047], ["site", 1051], ["of", 1056], ["daughter", 1059], ["centriole", 1068], ["assembly", 1078], [",", 1086], ["consistent", 1088], ["with", 1099], ["its", 1104], ["role", 1108], ["in", 1113], ["cartwheel", 1116], ["formation", 1126], [".", 1135], ["Plk4", 1137], ["and", 1142], ["STIL", 1146], ["co", 1151], ["-", 1153], ["localized", 1154], ["with", 1164], ["Sas-6", 1169], [",", 1174], ["but", 1176], ["Cep135", 1180], ["was", 1187], ["associated", 1191], ["mostly", 1202], ["with", 1209], ["mother", 1214], ["centrioles", 1221], [".", 1231], ["Remarkably", 1233], [",", 1243], ["Plk4", 1245], ["formed", 1250], ["a", 1257], ["dot", 1259], ["on", 1263], ["the", 1266], ["surface", 1270], ["of", 1278], ["the", 1281], ["mother", 1285], ["centriole", 1292], ["before", 1302], ["Sas-6", 1309], ["staining", 1315], ["became", 1324], ["detectable", 1331], [",", 1341], ["indicating", 1343], ["that", 1354], ["Plk4", 1359], ["constitutes", 1364], ["an", 1376], ["early", 1379], ["marker", 1385], ["for", 1392], ["the", 1396], ["site", 1400], ["of", 1405], ["nascent", 1408], ["centriole", 1416], ["formation", 1426], [".", 1435], ["Our", 1437], ["study", 1441], ["provides", 1447], ["novel", 1456], ["insights", 1462], ["into", 1471], ["the", 1476], ["architecture", 1480], ["of", 1493], ["human", 1496], ["centrosomes", 1502], ["and", 1514], ["illustrates", 1518], ["the", 1530], ["power", 1534], ["of", 1540], ["super", 1543], ["-", 1548], ["resolution", 1549], ["microscopy", 1560], ["in", 1571], ["revealing", 1574], ["the", 1584], ["relative", 1588], ["localization", 1597], ["of", 1610], ["centriole", 1613], ["and", 1623], ["PCM", 1627], ["proteins", 1631], ["in", 1640], ["unprecedented", 1643], ["detail", 1657], [".", 1663]]}
{"context": "U.K ambulance services assess patients with suspected stroke using the Face Arm Speech Test (FAST). The Recognition Of Stroke In the Emergency Room (ROSIER) tool has been shown superior to the FAST in identifying strokes in emergency departments but has not previously been tested in the ambulance setting. We investigated whether ROSIER use by ambulance clinicians can improve stroke recognition. Ambulance clinicians used the ROSIER in place of the FAST to assess patients with suspected stroke. As the ROSIER includes all FAST elements, we calculated a FAST score from the ROSIER to enable comparisons between the two tools. Ambulance clinicians' provisional stroke diagnoses using the ROSIER and calculated FAST were compared with stroke consultants' diagnosis. We used stepwise logistic regression to compare the contribution of individual ROSIER and FAST items and patient demographics to the prediction of consultants' diagnoses. Sixty-four percent of strokes and 78% of nonstrokes identified by ambulance clinicians using the ROSIER were subsequently confirmed by a stroke consultant. There was no difference in the proportion of strokes correctly detected by the ROSIER or FAST with both displaying excellent levels of sensitivity. The ROSIER detected marginally more nonstroke cases than the FAST, but both demonstrated poor specificity. Facial weakness, arm weakness, seizure activity, age, and sex predicted consultants' diagnosis of stroke. The ROSIER was not better than the FAST for prehospital recognition of stroke. A revised version of the FAST incorporating assessment of seizure activity may improve stroke identification and decision making by ambulance clinicians.", "qas": [{"question": "ROSIER scale is used for which disorder?", "answers": ["stroke"], "qid": "14137672ed6a4876bd365f25ca43ab63", "question_tokens": [["ROSIER", 0], ["scale", 7], ["is", 13], ["used", 16], ["for", 21], ["which", 25], ["disorder", 31], ["?", 39]], "detected_answers": [{"text": "stroke", "token_spans": [[112, 112], [64, 64], [21, 21], [123, 123], [253, 253], [268, 268], [7, 7], [82, 82], [239, 239], [177, 177]], "char_spans": [[662, 667], [378, 383], [119, 124], [735, 740], [1525, 1530], [1620, 1625], [54, 59], [490, 495], [1446, 1451], [1074, 1079]]}]}], "context_tokens": [["U.K", 0], ["ambulance", 4], ["services", 14], ["assess", 23], ["patients", 30], ["with", 39], ["suspected", 44], ["stroke", 54], ["using", 61], ["the", 67], ["Face", 71], ["Arm", 76], ["Speech", 80], ["Test", 87], ["(", 92], ["FAST", 93], [")", 97], [".", 98], ["The", 100], ["Recognition", 104], ["Of", 116], ["Stroke", 119], ["In", 126], ["the", 129], ["Emergency", 133], ["Room", 143], ["(", 148], ["ROSIER", 149], [")", 155], ["tool", 157], ["has", 162], ["been", 166], ["shown", 171], ["superior", 177], ["to", 186], ["the", 189], ["FAST", 193], ["in", 198], ["identifying", 201], ["strokes", 213], ["in", 221], ["emergency", 224], ["departments", 234], ["but", 246], ["has", 250], ["not", 254], ["previously", 258], ["been", 269], ["tested", 274], ["in", 281], ["the", 284], ["ambulance", 288], ["setting", 298], [".", 305], ["We", 307], ["investigated", 310], ["whether", 323], ["ROSIER", 331], ["use", 338], ["by", 342], ["ambulance", 345], ["clinicians", 355], ["can", 366], ["improve", 370], ["stroke", 378], ["recognition", 385], [".", 396], ["Ambulance", 398], ["clinicians", 408], ["used", 419], ["the", 424], ["ROSIER", 428], ["in", 435], ["place", 438], ["of", 444], ["the", 447], ["FAST", 451], ["to", 456], ["assess", 459], ["patients", 466], ["with", 475], ["suspected", 480], ["stroke", 490], [".", 496], ["As", 498], ["the", 501], ["ROSIER", 505], ["includes", 512], ["all", 521], ["FAST", 525], ["elements", 530], [",", 538], ["we", 540], ["calculated", 543], ["a", 554], ["FAST", 556], ["score", 561], ["from", 567], ["the", 572], ["ROSIER", 576], ["to", 583], ["enable", 586], ["comparisons", 593], ["between", 605], ["the", 613], ["two", 617], ["tools", 621], [".", 626], ["Ambulance", 628], ["clinicians", 638], ["'", 648], ["provisional", 650], ["stroke", 662], ["diagnoses", 669], ["using", 679], ["the", 685], ["ROSIER", 689], ["and", 696], ["calculated", 700], ["FAST", 711], ["were", 716], ["compared", 721], ["with", 730], ["stroke", 735], ["consultants", 742], ["'", 753], ["diagnosis", 755], [".", 764], ["We", 766], ["used", 769], ["stepwise", 774], ["logistic", 783], ["regression", 792], ["to", 803], ["compare", 806], ["the", 814], ["contribution", 818], ["of", 831], ["individual", 834], ["ROSIER", 845], ["and", 852], ["FAST", 856], ["items", 861], ["and", 867], ["patient", 871], ["demographics", 879], ["to", 892], ["the", 895], ["prediction", 899], ["of", 910], ["consultants", 913], ["'", 924], ["diagnoses", 926], [".", 935], ["Sixty", 937], ["-", 942], ["four", 943], ["percent", 948], ["of", 956], ["strokes", 959], ["and", 967], ["78", 971], ["%", 973], ["of", 975], ["nonstrokes", 978], ["identified", 989], ["by", 1000], ["ambulance", 1003], ["clinicians", 1013], ["using", 1024], ["the", 1030], ["ROSIER", 1034], ["were", 1041], ["subsequently", 1046], ["confirmed", 1059], ["by", 1069], ["a", 1072], ["stroke", 1074], ["consultant", 1081], [".", 1091], ["There", 1093], ["was", 1099], ["no", 1103], ["difference", 1106], ["in", 1117], ["the", 1120], ["proportion", 1124], ["of", 1135], ["strokes", 1138], ["correctly", 1146], ["detected", 1156], ["by", 1165], ["the", 1168], ["ROSIER", 1172], ["or", 1179], ["FAST", 1182], ["with", 1187], ["both", 1192], ["displaying", 1197], ["excellent", 1208], ["levels", 1218], ["of", 1225], ["sensitivity", 1228], [".", 1239], ["The", 1241], ["ROSIER", 1245], ["detected", 1252], ["marginally", 1261], ["more", 1272], ["nonstroke", 1277], ["cases", 1287], ["than", 1293], ["the", 1298], ["FAST", 1302], [",", 1306], ["but", 1308], ["both", 1312], ["demonstrated", 1317], ["poor", 1330], ["specificity", 1335], [".", 1346], ["Facial", 1348], ["weakness", 1355], [",", 1363], ["arm", 1365], ["weakness", 1369], [",", 1377], ["seizure", 1379], ["activity", 1387], [",", 1395], ["age", 1397], [",", 1400], ["and", 1402], ["sex", 1406], ["predicted", 1410], ["consultants", 1420], ["'", 1431], ["diagnosis", 1433], ["of", 1443], ["stroke", 1446], [".", 1452], ["The", 1454], ["ROSIER", 1458], ["was", 1465], ["not", 1469], ["better", 1473], ["than", 1480], ["the", 1485], ["FAST", 1489], ["for", 1494], ["prehospital", 1498], ["recognition", 1510], ["of", 1522], ["stroke", 1525], [".", 1531], ["A", 1533], ["revised", 1535], ["version", 1543], ["of", 1551], ["the", 1554], ["FAST", 1558], ["incorporating", 1563], ["assessment", 1577], ["of", 1588], ["seizure", 1591], ["activity", 1599], ["may", 1608], ["improve", 1612], ["stroke", 1620], ["identification", 1627], ["and", 1642], ["decision", 1646], ["making", 1655], ["by", 1662], ["ambulance", 1665], ["clinicians", 1675], [".", 1685]]}
{"context": "Somatic mutations in exons encoding the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene are found in human lung adenocarcinomas and are associated with sensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib. Nearly 90% of the EGFR mutations are either short, in-frame deletions in exon 19 or point mutations that result in substitution of arginine for leucine at amino acid 858 (L858R). To study further the role of these mutations in the initiation and maintenance of lung cancer, we have developed transgenic mice that express an exon 19 deletion mutant (EGFR(DeltaL747-S752)) or the L858R mutant (EGFR(L858R)) in type II pneumocytes under the control of doxycycline. Expression of either EGFR mutant leads to the development of lung adenocarcinomas. Two weeks after induction with doxycycline, mice that express the EGFR(L858R) allele show diffuse lung cancer highly reminiscent of human bronchioloalveolar carcinoma and later develop interspersed multifocal adenocarcinomas. In contrast, mice expressing EGFR(DeltaL747-S752) develop multifocal tumors embedded in normal lung parenchyma with a longer latency. With mice carrying either EGFR allele, withdrawal of doxycycline (to reduce expression of the transgene) or treatment with erlotinib (to inhibit kinase activity) causes rapid tumor regression, as assessed by magnetic resonance imaging and histopathology, demonstrating that mutant EGFR is required for tumor maintenance. These models may be useful for developing improved therapies for patients with lung cancers bearing EGFR mutations.", "qas": [{"question": "Mutations in which gene determine response to both erlotinib and gefitinib?", "answers": ["epidermal growth factor receptor (EGFR) gene"], "qid": "c1fed25571dd435caf919c7770d931d8", "question_tokens": [["Mutations", 0], ["in", 10], ["which", 13], ["gene", 19], ["determine", 24], ["response", 34], ["to", 43], ["both", 46], ["erlotinib", 51], ["and", 61], ["gefitinib", 65], ["?", 74]], "detected_answers": [{"text": "epidermal growth factor receptor (EGFR) gene", "token_spans": [[11, 18]], "char_spans": [[70, 113]]}]}], "context_tokens": [["Somatic", 0], ["mutations", 8], ["in", 18], ["exons", 21], ["encoding", 27], ["the", 36], ["tyrosine", 40], ["kinase", 49], ["domain", 56], ["of", 63], ["the", 66], ["epidermal", 70], ["growth", 80], ["factor", 87], ["receptor", 94], ["(", 103], ["EGFR", 104], [")", 108], ["gene", 110], ["are", 115], ["found", 119], ["in", 125], ["human", 128], ["lung", 134], ["adenocarcinomas", 139], ["and", 155], ["are", 159], ["associated", 163], ["with", 174], ["sensitivity", 179], ["to", 191], ["the", 194], ["tyrosine", 198], ["kinase", 207], ["inhibitors", 214], ["gefitinib", 225], ["and", 235], ["erlotinib", 239], [".", 248], ["Nearly", 250], ["90", 257], ["%", 259], ["of", 261], ["the", 264], ["EGFR", 268], ["mutations", 273], ["are", 283], ["either", 287], ["short", 294], [",", 299], ["in", 301], ["-", 303], ["frame", 304], ["deletions", 310], ["in", 320], ["exon", 323], ["19", 328], ["or", 331], ["point", 334], ["mutations", 340], ["that", 350], ["result", 355], ["in", 362], ["substitution", 365], ["of", 378], ["arginine", 381], ["for", 390], ["leucine", 394], ["at", 402], ["amino", 405], ["acid", 411], ["858", 416], ["(", 420], ["L858R", 421], [")", 426], [".", 427], ["To", 429], ["study", 432], ["further", 438], ["the", 446], ["role", 450], ["of", 455], ["these", 458], ["mutations", 464], ["in", 474], ["the", 477], ["initiation", 481], ["and", 492], ["maintenance", 496], ["of", 508], ["lung", 511], ["cancer", 516], [",", 522], ["we", 524], ["have", 527], ["developed", 532], ["transgenic", 542], ["mice", 553], ["that", 558], ["express", 563], ["an", 571], ["exon", 574], ["19", 579], ["deletion", 582], ["mutant", 591], ["(", 598], ["EGFR(DeltaL747-S752", 599], [")", 618], [")", 619], ["or", 621], ["the", 624], ["L858R", 628], ["mutant", 634], ["(", 641], ["EGFR(L858R", 642], [")", 652], [")", 653], ["in", 655], ["type", 658], ["II", 663], ["pneumocytes", 666], ["under", 678], ["the", 684], ["control", 688], ["of", 696], ["doxycycline", 699], [".", 710], ["Expression", 712], ["of", 723], ["either", 726], ["EGFR", 733], ["mutant", 738], ["leads", 745], ["to", 751], ["the", 754], ["development", 758], ["of", 770], ["lung", 773], ["adenocarcinomas", 778], [".", 793], ["Two", 795], ["weeks", 799], ["after", 805], ["induction", 811], ["with", 821], ["doxycycline", 826], [",", 837], ["mice", 839], ["that", 844], ["express", 849], ["the", 857], ["EGFR(L858R", 861], [")", 871], ["allele", 873], ["show", 880], ["diffuse", 885], ["lung", 893], ["cancer", 898], ["highly", 905], ["reminiscent", 912], ["of", 924], ["human", 927], ["bronchioloalveolar", 933], ["carcinoma", 952], ["and", 962], ["later", 966], ["develop", 972], ["interspersed", 980], ["multifocal", 993], ["adenocarcinomas", 1004], [".", 1019], ["In", 1021], ["contrast", 1024], [",", 1032], ["mice", 1034], ["expressing", 1039], ["EGFR(DeltaL747-S752", 1050], [")", 1069], ["develop", 1071], ["multifocal", 1079], ["tumors", 1090], ["embedded", 1097], ["in", 1106], ["normal", 1109], ["lung", 1116], ["parenchyma", 1121], ["with", 1132], ["a", 1137], ["longer", 1139], ["latency", 1146], [".", 1153], ["With", 1155], ["mice", 1160], ["carrying", 1165], ["either", 1174], ["EGFR", 1181], ["allele", 1186], [",", 1192], ["withdrawal", 1194], ["of", 1205], ["doxycycline", 1208], ["(", 1220], ["to", 1221], ["reduce", 1224], ["expression", 1231], ["of", 1242], ["the", 1245], ["transgene", 1249], [")", 1258], ["or", 1260], ["treatment", 1263], ["with", 1273], ["erlotinib", 1278], ["(", 1288], ["to", 1289], ["inhibit", 1292], ["kinase", 1300], ["activity", 1307], [")", 1315], ["causes", 1317], ["rapid", 1324], ["tumor", 1330], ["regression", 1336], [",", 1346], ["as", 1348], ["assessed", 1351], ["by", 1360], ["magnetic", 1363], ["resonance", 1372], ["imaging", 1382], ["and", 1390], ["histopathology", 1394], [",", 1408], ["demonstrating", 1410], ["that", 1424], ["mutant", 1429], ["EGFR", 1436], ["is", 1441], ["required", 1444], ["for", 1453], ["tumor", 1457], ["maintenance", 1463], [".", 1474], ["These", 1476], ["models", 1482], ["may", 1489], ["be", 1493], ["useful", 1496], ["for", 1503], ["developing", 1507], ["improved", 1518], ["therapies", 1527], ["for", 1537], ["patients", 1541], ["with", 1550], ["lung", 1555], ["cancers", 1560], ["bearing", 1568], ["EGFR", 1576], ["mutations", 1581], [".", 1590]]}
{"context": "Rigel Pharmaceuticals Inc is developing fostamatinib, a prodrug of the spleen tyrosine kinase (Syk) inhibitor R-406, for the potential treatment of autoimmune diseases such as rheumatoid arthritis (RA), idiopathic thrombocytopenic purpura (ITP) and B-cell lymphomas. Syk is a key mediator of Fc and B-cell receptor signaling in inflammatory cells, such as B-cells, mast cells, macrophages and neutrophils. Preclinical studies of R-406 or fostamatinib demonstrated a significant reduction in major inflammatory mediators such as TNFalpha, IL-1, IL-6 and IL-18, leading to reduced inflammation and bone degradation in models of RA. In a phase II clinical trial, fostamatinib treatment effectively improved American College of Rheumatology response rates in patients with RA. Preclinical studies and phase II trials also suggested the potential of using fostamatinib for the treatment of ITP and B-cell lymphomas, by increasing platelet counts and inducing response rates, respectively. Fostamatinib is orally bioavailable and was well tolerated in phase I and II trials, with the most common side effect being gastrointestinal symptoms. At the time of publication, phase II trials for fostamatinib were ongoing in patients with RA, ITP and B-cell lymphomas. The Syk inhibitor appears to be a promising therapeutic for immunological diseases, but further data are required to establish the efficacy and long-term safety of the drug in humans.", "qas": [{"question": "Which enzyme is inhibited by a drug fostamatinib?", "answers": ["spleen tyrosine kinase"], "qid": "7a4fa67d3e7042d388d3a34034a61556", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["a", 29], ["drug", 31], ["fostamatinib", 36], ["?", 48]], "detected_answers": [{"text": "spleen tyrosine kinase", "token_spans": [[11, 13]], "char_spans": [[71, 92]]}]}], "context_tokens": [["Rigel", 0], ["Pharmaceuticals", 6], ["Inc", 22], ["is", 26], ["developing", 29], ["fostamatinib", 40], [",", 52], ["a", 54], ["prodrug", 56], ["of", 64], ["the", 67], ["spleen", 71], ["tyrosine", 78], ["kinase", 87], ["(", 94], ["Syk", 95], [")", 98], ["inhibitor", 100], ["R-406", 110], [",", 115], ["for", 117], ["the", 121], ["potential", 125], ["treatment", 135], ["of", 145], ["autoimmune", 148], ["diseases", 159], ["such", 168], ["as", 173], ["rheumatoid", 176], ["arthritis", 187], ["(", 197], ["RA", 198], [")", 200], [",", 201], ["idiopathic", 203], ["thrombocytopenic", 214], ["purpura", 231], ["(", 239], ["ITP", 240], [")", 243], ["and", 245], ["B", 249], ["-", 250], ["cell", 251], ["lymphomas", 256], [".", 265], ["Syk", 267], ["is", 271], ["a", 274], ["key", 276], ["mediator", 280], ["of", 289], ["Fc", 292], ["and", 295], ["B", 299], ["-", 300], ["cell", 301], ["receptor", 306], ["signaling", 315], ["in", 325], ["inflammatory", 328], ["cells", 341], [",", 346], ["such", 348], ["as", 353], ["B", 356], ["-", 357], ["cells", 358], [",", 363], ["mast", 365], ["cells", 370], [",", 375], ["macrophages", 377], ["and", 389], ["neutrophils", 393], [".", 404], ["Preclinical", 406], ["studies", 418], ["of", 426], ["R-406", 429], ["or", 435], ["fostamatinib", 438], ["demonstrated", 451], ["a", 464], ["significant", 466], ["reduction", 478], ["in", 488], ["major", 491], ["inflammatory", 497], ["mediators", 510], ["such", 520], ["as", 525], ["TNFalpha", 528], [",", 536], ["IL-1", 538], [",", 542], ["IL-6", 544], ["and", 549], ["IL-18", 553], [",", 558], ["leading", 560], ["to", 568], ["reduced", 571], ["inflammation", 579], ["and", 592], ["bone", 596], ["degradation", 601], ["in", 613], ["models", 616], ["of", 623], ["RA", 626], [".", 628], ["In", 630], ["a", 633], ["phase", 635], ["II", 641], ["clinical", 644], ["trial", 653], [",", 658], ["fostamatinib", 660], ["treatment", 673], ["effectively", 683], ["improved", 695], ["American", 704], ["College", 713], ["of", 721], ["Rheumatology", 724], ["response", 737], ["rates", 746], ["in", 752], ["patients", 755], ["with", 764], ["RA", 769], [".", 771], ["Preclinical", 773], ["studies", 785], ["and", 793], ["phase", 797], ["II", 803], ["trials", 806], ["also", 813], ["suggested", 818], ["the", 828], ["potential", 832], ["of", 842], ["using", 845], ["fostamatinib", 851], ["for", 864], ["the", 868], ["treatment", 872], ["of", 882], ["ITP", 885], ["and", 889], ["B", 893], ["-", 894], ["cell", 895], ["lymphomas", 900], [",", 909], ["by", 911], ["increasing", 914], ["platelet", 925], ["counts", 934], ["and", 941], ["inducing", 945], ["response", 954], ["rates", 963], [",", 968], ["respectively", 970], [".", 982], ["Fostamatinib", 984], ["is", 997], ["orally", 1000], ["bioavailable", 1007], ["and", 1020], ["was", 1024], ["well", 1028], ["tolerated", 1033], ["in", 1043], ["phase", 1046], ["I", 1052], ["and", 1054], ["II", 1058], ["trials", 1061], [",", 1067], ["with", 1069], ["the", 1074], ["most", 1078], ["common", 1083], ["side", 1090], ["effect", 1095], ["being", 1102], ["gastrointestinal", 1108], ["symptoms", 1125], [".", 1133], ["At", 1135], ["the", 1138], ["time", 1142], ["of", 1147], ["publication", 1150], [",", 1161], ["phase", 1163], ["II", 1169], ["trials", 1172], ["for", 1179], ["fostamatinib", 1183], ["were", 1196], ["ongoing", 1201], ["in", 1209], ["patients", 1212], ["with", 1221], ["RA", 1226], [",", 1228], ["ITP", 1230], ["and", 1234], ["B", 1238], ["-", 1239], ["cell", 1240], ["lymphomas", 1245], [".", 1254], ["The", 1256], ["Syk", 1260], ["inhibitor", 1264], ["appears", 1274], ["to", 1282], ["be", 1285], ["a", 1288], ["promising", 1290], ["therapeutic", 1300], ["for", 1312], ["immunological", 1316], ["diseases", 1330], [",", 1338], ["but", 1340], ["further", 1344], ["data", 1352], ["are", 1357], ["required", 1361], ["to", 1370], ["establish", 1373], ["the", 1383], ["efficacy", 1387], ["and", 1396], ["long", 1400], ["-", 1404], ["term", 1405], ["safety", 1410], ["of", 1417], ["the", 1420], ["drug", 1424], ["in", 1429], ["humans", 1432], [".", 1438]]}
{"context": "The spectrin heterodimer is formed by the antiparallel lateral association of an alpha and a beta subunit, each of which comprises largely a series of homologous triple-helical motifs. Initiation of dimer assembly involves strong binding between complementary motifs near the actin-binding end of the dimer. In this study, the mechanism of lateral spectrin association at this dimer nucleation site was investigated using the analytical ultracentrifuge to analyze heterodimers formed from recombinant peptides containing two or four homologous motifs from each subunit (alpha20-21/beta1-2; alpha18-21/beta1-4). Both the two-motif and four-motif dimer associations were weakened substantially with increasing salt concentration, indicating that electrostatic interactions are important for the dimer initiation process. Modeling of the electrostatic potential on the surface of the alpha20 and beta2 motifs showed that the side of the motifs comprising the A and B helices is the most favorable for association, with an area of positive electrostatic potential on the AB face of the beta2 motif opposite negative potential on the AB face of the alpha20 motif and vise versa. Protease protection analysis of the alpha20-21/beta1-2 dimer showed that multiple trypsin and proteinase K sites in the A helices of the beta2 and alpha21 motifs become buried upon dimer formation. Together, these data support a model where complementary long range electrostatic interactions on the AB faces of the triple-helical motifs in the dimer nucleation site initiate the correct pairing of motifs, i.e. alpha21-beta1 and alpha20-beta2. After initial docking of these complementary triple-helical motifs, this association is probably stabilized by subsequent formation of stronger hydrophobic interactions in a complex involving the A helices of both subunits and possibly most of the AB faces. The beta subunit A helix in particular appears to be buried in the dimer interface.", "qas": [{"question": "Alpha-spectrin and beta-spectrin subunits form parallel or antiparallel heterodimers?", "answers": ["antiparallel"], "qid": "341b721c73f64225b0bb8a8e9b4fdbef", "question_tokens": [["Alpha", 0], ["-", 5], ["spectrin", 6], ["and", 15], ["beta", 19], ["-", 23], ["spectrin", 24], ["subunits", 33], ["form", 42], ["parallel", 47], ["or", 56], ["antiparallel", 59], ["heterodimers", 72], ["?", 84]], "detected_answers": [{"text": "antiparallel", "token_spans": [[7, 7]], "char_spans": [[42, 53]]}]}], "context_tokens": [["The", 0], ["spectrin", 4], ["heterodimer", 13], ["is", 25], ["formed", 28], ["by", 35], ["the", 38], ["antiparallel", 42], ["lateral", 55], ["association", 63], ["of", 75], ["an", 78], ["alpha", 81], ["and", 87], ["a", 91], ["beta", 93], ["subunit", 98], [",", 105], ["each", 107], ["of", 112], ["which", 115], ["comprises", 121], ["largely", 131], ["a", 139], ["series", 141], ["of", 148], ["homologous", 151], ["triple", 162], ["-", 168], ["helical", 169], ["motifs", 177], [".", 183], ["Initiation", 185], ["of", 196], ["dimer", 199], ["assembly", 205], ["involves", 214], ["strong", 223], ["binding", 230], ["between", 238], ["complementary", 246], ["motifs", 260], ["near", 267], ["the", 272], ["actin", 276], ["-", 281], ["binding", 282], ["end", 290], ["of", 294], ["the", 297], ["dimer", 301], [".", 306], ["In", 308], ["this", 311], ["study", 316], [",", 321], ["the", 323], ["mechanism", 327], ["of", 337], ["lateral", 340], ["spectrin", 348], ["association", 357], ["at", 369], ["this", 372], ["dimer", 377], ["nucleation", 383], ["site", 394], ["was", 399], ["investigated", 403], ["using", 416], ["the", 422], ["analytical", 426], ["ultracentrifuge", 437], ["to", 453], ["analyze", 456], ["heterodimers", 464], ["formed", 477], ["from", 484], ["recombinant", 489], ["peptides", 501], ["containing", 510], ["two", 521], ["or", 525], ["four", 528], ["homologous", 533], ["motifs", 544], ["from", 551], ["each", 556], ["subunit", 561], ["(", 569], ["alpha20", 570], ["-", 577], ["21/beta1", 578], ["-", 586], ["2", 587], [";", 588], ["alpha18", 590], ["-", 597], ["21/beta1", 598], ["-", 606], ["4", 607], [")", 608], [".", 609], ["Both", 611], ["the", 616], ["two", 620], ["-", 623], ["motif", 624], ["and", 630], ["four", 634], ["-", 638], ["motif", 639], ["dimer", 645], ["associations", 651], ["were", 664], ["weakened", 669], ["substantially", 678], ["with", 692], ["increasing", 697], ["salt", 708], ["concentration", 713], [",", 726], ["indicating", 728], ["that", 739], ["electrostatic", 744], ["interactions", 758], ["are", 771], ["important", 775], ["for", 785], ["the", 789], ["dimer", 793], ["initiation", 799], ["process", 810], [".", 817], ["Modeling", 819], ["of", 828], ["the", 831], ["electrostatic", 835], ["potential", 849], ["on", 859], ["the", 862], ["surface", 866], ["of", 874], ["the", 877], ["alpha20", 881], ["and", 889], ["beta2", 893], ["motifs", 899], ["showed", 906], ["that", 913], ["the", 918], ["side", 922], ["of", 927], ["the", 930], ["motifs", 934], ["comprising", 941], ["the", 952], ["A", 956], ["and", 958], ["B", 962], ["helices", 964], ["is", 972], ["the", 975], ["most", 979], ["favorable", 984], ["for", 994], ["association", 998], [",", 1009], ["with", 1011], ["an", 1016], ["area", 1019], ["of", 1024], ["positive", 1027], ["electrostatic", 1036], ["potential", 1050], ["on", 1060], ["the", 1063], ["AB", 1067], ["face", 1070], ["of", 1075], ["the", 1078], ["beta2", 1082], ["motif", 1088], ["opposite", 1094], ["negative", 1103], ["potential", 1112], ["on", 1122], ["the", 1125], ["AB", 1129], ["face", 1132], ["of", 1137], ["the", 1140], ["alpha20", 1144], ["motif", 1152], ["and", 1158], ["vise", 1162], ["versa", 1167], [".", 1172], ["Protease", 1174], ["protection", 1183], ["analysis", 1194], ["of", 1203], ["the", 1206], ["alpha20", 1210], ["-", 1217], ["21/beta1", 1218], ["-", 1226], ["2", 1227], ["dimer", 1229], ["showed", 1235], ["that", 1242], ["multiple", 1247], ["trypsin", 1256], ["and", 1264], ["proteinase", 1268], ["K", 1279], ["sites", 1281], ["in", 1287], ["the", 1290], ["A", 1294], ["helices", 1296], ["of", 1304], ["the", 1307], ["beta2", 1311], ["and", 1317], ["alpha21", 1321], ["motifs", 1329], ["become", 1336], ["buried", 1343], ["upon", 1350], ["dimer", 1355], ["formation", 1361], [".", 1370], ["Together", 1372], [",", 1380], ["these", 1382], ["data", 1388], ["support", 1393], ["a", 1401], ["model", 1403], ["where", 1409], ["complementary", 1415], ["long", 1429], ["range", 1434], ["electrostatic", 1440], ["interactions", 1454], ["on", 1467], ["the", 1470], ["AB", 1474], ["faces", 1477], ["of", 1483], ["the", 1486], ["triple", 1490], ["-", 1496], ["helical", 1497], ["motifs", 1505], ["in", 1512], ["the", 1515], ["dimer", 1519], ["nucleation", 1525], ["site", 1536], ["initiate", 1541], ["the", 1550], ["correct", 1554], ["pairing", 1562], ["of", 1570], ["motifs", 1573], [",", 1579], ["i.e.", 1581], ["alpha21-beta1", 1586], ["and", 1600], ["alpha20-beta2", 1604], [".", 1617], ["After", 1619], ["initial", 1625], ["docking", 1633], ["of", 1641], ["these", 1644], ["complementary", 1650], ["triple", 1664], ["-", 1670], ["helical", 1671], ["motifs", 1679], [",", 1685], ["this", 1687], ["association", 1692], ["is", 1704], ["probably", 1707], ["stabilized", 1716], ["by", 1727], ["subsequent", 1730], ["formation", 1741], ["of", 1751], ["stronger", 1754], ["hydrophobic", 1763], ["interactions", 1775], ["in", 1788], ["a", 1791], ["complex", 1793], ["involving", 1801], ["the", 1811], ["A", 1815], ["helices", 1817], ["of", 1825], ["both", 1828], ["subunits", 1833], ["and", 1842], ["possibly", 1846], ["most", 1855], ["of", 1860], ["the", 1863], ["AB", 1867], ["faces", 1870], [".", 1875], ["The", 1877], ["beta", 1881], ["subunit", 1886], ["A", 1894], ["helix", 1896], ["in", 1902], ["particular", 1905], ["appears", 1916], ["to", 1924], ["be", 1927], ["buried", 1930], ["in", 1937], ["the", 1940], ["dimer", 1944], ["interface", 1950], [".", 1959]]}
{"context": "Neurofibromatosis type 1 (NF1) gene is a tumor suppressor gene, and the NF1 gene product, neurofibromin, can downregulate the N-ras gene. Because the N-ras gene is often mutated in acute myelogenous leukemia (AML), we wondered if the NF1 gene might be mutated in those AML samples not having N-ras mutations. We investigated the mutational status of the N-ras gene and the FLR exon of codons 1371-1423 of the open reading frame of the full-length NF1 cDNA, which has a strong homology with the mammalian ras GTPase-activating protein (GAP), especially for a stretch of three consecutive amino acids (F, L, R), by single-strand conformation polymorphism analysis and direct sequencing in samples from patients with AML. Of 48 AML patients, 10 (21%) had point (missense) mutations of the N-ras gene involving codons 12, 13 and 61. However, mutations in the FLR exon of the NF1 gene were not detected in any of the AML samples. We also examined the difference of clinical response to induction therapy between AML patients with and without N-ras mutation. A significantly lower rate of complete remission was noted in individuals with N-ras gene mutations. These results suggest that mutation of the NF1 gene, at least in the FLR exon, is very rare in AML and the NF1 gene probably is not a functional complement of the N-ras gene mutation. The presence of N-ras gene mutation may be associated with a lower clinical response to antileukemic therapy.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "fb9d60b81eed4b7e93174fdf341800eb", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[96, 96], [189, 189], [4, 4], [265, 265], [248, 248], [50, 50], [15, 15]], "char_spans": [[447, 449], [871, 873], [26, 28], [1261, 1263], [1197, 1199], [234, 236], [72, 74]]}]}], "context_tokens": [["Neurofibromatosis", 0], ["type", 18], ["1", 23], ["(", 25], ["NF1", 26], [")", 29], ["gene", 31], ["is", 36], ["a", 39], ["tumor", 41], ["suppressor", 47], ["gene", 58], [",", 62], ["and", 64], ["the", 68], ["NF1", 72], ["gene", 76], ["product", 81], [",", 88], ["neurofibromin", 90], [",", 103], ["can", 105], ["downregulate", 109], ["the", 122], ["N", 126], ["-", 127], ["ras", 128], ["gene", 132], [".", 136], ["Because", 138], ["the", 146], ["N", 150], ["-", 151], ["ras", 152], ["gene", 156], ["is", 161], ["often", 164], ["mutated", 170], ["in", 178], ["acute", 181], ["myelogenous", 187], ["leukemia", 199], ["(", 208], ["AML", 209], [")", 212], [",", 213], ["we", 215], ["wondered", 218], ["if", 227], ["the", 230], ["NF1", 234], ["gene", 238], ["might", 243], ["be", 249], ["mutated", 252], ["in", 260], ["those", 263], ["AML", 269], ["samples", 273], ["not", 281], ["having", 285], ["N", 292], ["-", 293], ["ras", 294], ["mutations", 298], [".", 307], ["We", 309], ["investigated", 312], ["the", 325], ["mutational", 329], ["status", 340], ["of", 347], ["the", 350], ["N", 354], ["-", 355], ["ras", 356], ["gene", 360], ["and", 365], ["the", 369], ["FLR", 373], ["exon", 377], ["of", 382], ["codons", 385], ["1371", 392], ["-", 396], ["1423", 397], ["of", 402], ["the", 405], ["open", 409], ["reading", 414], ["frame", 422], ["of", 428], ["the", 431], ["full", 435], ["-", 439], ["length", 440], ["NF1", 447], ["cDNA", 451], [",", 455], ["which", 457], ["has", 463], ["a", 467], ["strong", 469], ["homology", 476], ["with", 485], ["the", 490], ["mammalian", 494], ["ras", 504], ["GTPase", 508], ["-", 514], ["activating", 515], ["protein", 526], ["(", 534], ["GAP", 535], [")", 538], [",", 539], ["especially", 541], ["for", 552], ["a", 556], ["stretch", 558], ["of", 566], ["three", 569], ["consecutive", 575], ["amino", 587], ["acids", 593], ["(", 599], ["F", 600], [",", 601], ["L", 603], [",", 604], ["R", 606], [")", 607], [",", 608], ["by", 610], ["single", 613], ["-", 619], ["strand", 620], ["conformation", 627], ["polymorphism", 640], ["analysis", 653], ["and", 662], ["direct", 666], ["sequencing", 673], ["in", 684], ["samples", 687], ["from", 695], ["patients", 700], ["with", 709], ["AML", 714], [".", 717], ["Of", 719], ["48", 722], ["AML", 725], ["patients", 729], [",", 737], ["10", 739], ["(", 742], ["21", 743], ["%", 745], [")", 746], ["had", 748], ["point", 752], ["(", 758], ["missense", 759], [")", 767], ["mutations", 769], ["of", 779], ["the", 782], ["N", 786], ["-", 787], ["ras", 788], ["gene", 792], ["involving", 797], ["codons", 807], ["12", 814], [",", 816], ["13", 818], ["and", 821], ["61", 825], [".", 827], ["However", 829], [",", 836], ["mutations", 838], ["in", 848], ["the", 851], ["FLR", 855], ["exon", 859], ["of", 864], ["the", 867], ["NF1", 871], ["gene", 875], ["were", 880], ["not", 885], ["detected", 889], ["in", 898], ["any", 901], ["of", 905], ["the", 908], ["AML", 912], ["samples", 916], [".", 923], ["We", 925], ["also", 928], ["examined", 933], ["the", 942], ["difference", 946], ["of", 957], ["clinical", 960], ["response", 969], ["to", 978], ["induction", 981], ["therapy", 991], ["between", 999], ["AML", 1007], ["patients", 1011], ["with", 1020], ["and", 1025], ["without", 1029], ["N", 1037], ["-", 1038], ["ras", 1039], ["mutation", 1043], [".", 1051], ["A", 1053], ["significantly", 1055], ["lower", 1069], ["rate", 1075], ["of", 1080], ["complete", 1083], ["remission", 1092], ["was", 1102], ["noted", 1106], ["in", 1112], ["individuals", 1115], ["with", 1127], ["N", 1132], ["-", 1133], ["ras", 1134], ["gene", 1138], ["mutations", 1143], [".", 1152], ["These", 1154], ["results", 1160], ["suggest", 1168], ["that", 1176], ["mutation", 1181], ["of", 1190], ["the", 1193], ["NF1", 1197], ["gene", 1201], [",", 1205], ["at", 1207], ["least", 1210], ["in", 1216], ["the", 1219], ["FLR", 1223], ["exon", 1227], [",", 1231], ["is", 1233], ["very", 1236], ["rare", 1241], ["in", 1246], ["AML", 1249], ["and", 1253], ["the", 1257], ["NF1", 1261], ["gene", 1265], ["probably", 1270], ["is", 1279], ["not", 1282], ["a", 1286], ["functional", 1288], ["complement", 1299], ["of", 1310], ["the", 1313], ["N", 1317], ["-", 1318], ["ras", 1319], ["gene", 1323], ["mutation", 1328], [".", 1336], ["The", 1338], ["presence", 1342], ["of", 1351], ["N", 1354], ["-", 1355], ["ras", 1356], ["gene", 1360], ["mutation", 1365], ["may", 1374], ["be", 1378], ["associated", 1381], ["with", 1392], ["a", 1397], ["lower", 1399], ["clinical", 1405], ["response", 1414], ["to", 1423], ["antileukemic", 1426], ["therapy", 1439], [".", 1446]]}
{"context": "Increased nerve growth factor levels are associated with chronic pain conditions, including chronic low back pain (LBP). This study examined safety and analgesic efficacy of tanezumab, a humanized anti-nerve growth factor antibody, in adults with chronic LBP. Patients received intravenous tanezumab 200 \u03bcg/kg plus oral placebo (n=88), intravenous placebo plus oral naproxen 500 mg twice a day (n=88), or intravenous placebo plus oral placebo (n=41). Primary outcome was average LBP intensity (aLBPI) at Week 6. Secondary outcomes were proportion of patients with \u226530% or \u226550% reduction in aLBPI, Roland-Morris Disability Questionnaire and Brief Pain Inventory-short form scores, Patients' Global Assessment of LBP, Patients' Global Evaluation of study medication, and rescue medication use. Mean aLBPI change from baseline to Week 6 was greater with tanezumab vs naproxen (P=0.004) and placebo (P<0.001). Greater proportions of patients reported \u226530% and \u226550% reduction in aLBPI with tanezumab vs naproxen (P\u22640.013) and placebo (P<0.001), and greater improvements in Roland-Morris Disability Questionnaire (P<0.001) and other secondary outcomes except rescue medication use. Tanezumab was associated with adverse events (AEs) of abnormal peripheral sensation that were generally mild and resolved before study completion; however, there were no serious AEs. Nine patients (4 of whom were tanezumab-treated) discontinued due to AEs. In conclusion, tanezumab resulted in analgesic efficacy that was clinically and statistically superior to placebo and naproxen in patients with chronic LBP. Tanezumab clinical development is on regulatory hold due to AEs in osteoarthritis patients.", "qas": [{"question": "What is the target of tanezumab?", "answers": ["nerve growth factor", "NGF"], "qid": "b57cadd16f7a4c1795c6018b46b69e57", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["target", 12], ["of", 19], ["tanezumab", 22], ["?", 31]], "detected_answers": [{"text": "nerve growth factor", "token_spans": [[1, 3], [35, 37]], "char_spans": [[10, 28], [202, 220]]}]}], "context_tokens": [["Increased", 0], ["nerve", 10], ["growth", 16], ["factor", 23], ["levels", 30], ["are", 37], ["associated", 41], ["with", 52], ["chronic", 57], ["pain", 65], ["conditions", 70], [",", 80], ["including", 82], ["chronic", 92], ["low", 100], ["back", 104], ["pain", 109], ["(", 114], ["LBP", 115], [")", 118], [".", 119], ["This", 121], ["study", 126], ["examined", 132], ["safety", 141], ["and", 148], ["analgesic", 152], ["efficacy", 162], ["of", 171], ["tanezumab", 174], [",", 183], ["a", 185], ["humanized", 187], ["anti", 197], ["-", 201], ["nerve", 202], ["growth", 208], ["factor", 215], ["antibody", 222], [",", 230], ["in", 232], ["adults", 235], ["with", 242], ["chronic", 247], ["LBP", 255], [".", 258], ["Patients", 260], ["received", 269], ["intravenous", 278], ["tanezumab", 290], ["200", 300], ["\u03bcg", 304], ["/", 306], ["kg", 307], ["plus", 310], ["oral", 315], ["placebo", 320], ["(", 328], ["n=88", 329], [")", 333], [",", 334], ["intravenous", 336], ["placebo", 348], ["plus", 356], ["oral", 361], ["naproxen", 366], ["500", 375], ["mg", 379], ["twice", 382], ["a", 388], ["day", 390], ["(", 394], ["n=88", 395], [")", 399], [",", 400], ["or", 402], ["intravenous", 405], ["placebo", 417], ["plus", 425], ["oral", 430], ["placebo", 435], ["(", 443], ["n=41", 444], [")", 448], [".", 449], ["Primary", 451], ["outcome", 459], ["was", 467], ["average", 471], ["LBP", 479], ["intensity", 483], ["(", 493], ["aLBPI", 494], [")", 499], ["at", 501], ["Week", 504], ["6", 509], [".", 510], ["Secondary", 512], ["outcomes", 522], ["were", 531], ["proportion", 536], ["of", 547], ["patients", 550], ["with", 559], ["\u226530", 564], ["%", 567], ["or", 569], ["\u226550", 572], ["%", 575], ["reduction", 577], ["in", 587], ["aLBPI", 590], [",", 595], ["Roland", 597], ["-", 603], ["Morris", 604], ["Disability", 611], ["Questionnaire", 622], ["and", 636], ["Brief", 640], ["Pain", 646], ["Inventory", 651], ["-", 660], ["short", 661], ["form", 667], ["scores", 672], [",", 678], ["Patients", 680], ["'", 688], ["Global", 690], ["Assessment", 697], ["of", 708], ["LBP", 711], [",", 714], ["Patients", 716], ["'", 724], ["Global", 726], ["Evaluation", 733], ["of", 744], ["study", 747], ["medication", 753], [",", 763], ["and", 765], ["rescue", 769], ["medication", 776], ["use", 787], [".", 790], ["Mean", 792], ["aLBPI", 797], ["change", 803], ["from", 810], ["baseline", 815], ["to", 824], ["Week", 827], ["6", 832], ["was", 834], ["greater", 838], ["with", 846], ["tanezumab", 851], ["vs", 861], ["naproxen", 864], ["(", 873], ["P=0.004", 874], [")", 881], ["and", 883], ["placebo", 887], ["(", 895], ["P<0.001", 896], [")", 903], [".", 904], ["Greater", 906], ["proportions", 914], ["of", 926], ["patients", 929], ["reported", 938], ["\u226530", 947], ["%", 950], ["and", 952], ["\u226550", 956], ["%", 959], ["reduction", 961], ["in", 971], ["aLBPI", 974], ["with", 980], ["tanezumab", 985], ["vs", 995], ["naproxen", 998], ["(", 1007], ["P\u22640.013", 1008], [")", 1015], ["and", 1017], ["placebo", 1021], ["(", 1029], ["P<0.001", 1030], [")", 1037], [",", 1038], ["and", 1040], ["greater", 1044], ["improvements", 1052], ["in", 1065], ["Roland", 1068], ["-", 1074], ["Morris", 1075], ["Disability", 1082], ["Questionnaire", 1093], ["(", 1107], ["P<0.001", 1108], [")", 1115], ["and", 1117], ["other", 1121], ["secondary", 1127], ["outcomes", 1137], ["except", 1146], ["rescue", 1153], ["medication", 1160], ["use", 1171], [".", 1174], ["Tanezumab", 1176], ["was", 1186], ["associated", 1190], ["with", 1201], ["adverse", 1206], ["events", 1214], ["(", 1221], ["AEs", 1222], [")", 1225], ["of", 1227], ["abnormal", 1230], ["peripheral", 1239], ["sensation", 1250], ["that", 1260], ["were", 1265], ["generally", 1270], ["mild", 1280], ["and", 1285], ["resolved", 1289], ["before", 1298], ["study", 1305], ["completion", 1311], [";", 1321], ["however", 1323], [",", 1330], ["there", 1332], ["were", 1338], ["no", 1343], ["serious", 1346], ["AEs", 1354], [".", 1357], ["Nine", 1359], ["patients", 1364], ["(", 1373], ["4", 1374], ["of", 1376], ["whom", 1379], ["were", 1384], ["tanezumab", 1389], ["-", 1398], ["treated", 1399], [")", 1406], ["discontinued", 1408], ["due", 1421], ["to", 1425], ["AEs", 1428], [".", 1431], ["In", 1433], ["conclusion", 1436], [",", 1446], ["tanezumab", 1448], ["resulted", 1458], ["in", 1467], ["analgesic", 1470], ["efficacy", 1480], ["that", 1489], ["was", 1494], ["clinically", 1498], ["and", 1509], ["statistically", 1513], ["superior", 1527], ["to", 1536], ["placebo", 1539], ["and", 1547], ["naproxen", 1551], ["in", 1560], ["patients", 1563], ["with", 1572], ["chronic", 1577], ["LBP", 1585], [".", 1588], ["Tanezumab", 1590], ["clinical", 1600], ["development", 1609], ["is", 1621], ["on", 1624], ["regulatory", 1627], ["hold", 1638], ["due", 1643], ["to", 1647], ["AEs", 1650], ["in", 1654], ["osteoarthritis", 1657], ["patients", 1672], [".", 1680]]}
{"context": "Neuronal loss in specific brain regions and neurons with intracellular inclusions termed Lewy bodies are the pathologic hallmark in both Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Lewy bodies comprise of aggregated intracellular vesicles and proteins and \u03b1-synuclein is reported to be a major protein component. Using human brain tissue from control, PD and DLB and light and confocal immunohistochemistry with antibodies to superoxide dismutase 2 as a marker for mitochondria, \u03b1-synuclein for Lewy bodies and \u03b2III Tubulin for microtubules we have examined the relationship between Lewy bodies and mitochondrial loss. We have shown microtubule regression and mitochondrial and nuclear degradation in neurons with developing Lewy bodies. In PD, multiple Lewy bodies were often observed with \u03b1-synuclein interacting with DNA to cause marked nuclear degradation. In DLB, the mitochondria are drawn into the Lewy body and the mitochondrial integrity is lost. This work suggests that Lewy bodies are cytotoxic. In DLB, we suggest that microtubule regression and mitochondrial loss results in decreased cellular energy and axonal transport that leads to cell death. In PD, \u03b1-synuclein aggregations are associated with intact mitochondria but interacts with and causes nuclear degradation which may be the major cause of cell death.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "a26bb24d46114aeaa1d54858c6340119", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "\u03b1-synuclein", "token_spans": [[134, 136], [201, 203], [45, 47], [84, 86]], "char_spans": [[809, 819], [1186, 1196], [274, 284], [497, 507]]}]}], "context_tokens": [["Neuronal", 0], ["loss", 9], ["in", 14], ["specific", 17], ["brain", 26], ["regions", 32], ["and", 40], ["neurons", 44], ["with", 52], ["intracellular", 57], ["inclusions", 71], ["termed", 82], ["Lewy", 89], ["bodies", 94], ["are", 101], ["the", 105], ["pathologic", 109], ["hallmark", 120], ["in", 129], ["both", 132], ["Parkinson", 137], ["'s", 146], ["disease", 149], ["(", 157], ["PD", 158], [")", 160], ["and", 162], ["dementia", 166], ["with", 175], ["Lewy", 180], ["bodies", 185], ["(", 192], ["DLB", 193], [")", 196], [".", 197], ["Lewy", 199], ["bodies", 204], ["comprise", 211], ["of", 220], ["aggregated", 223], ["intracellular", 234], ["vesicles", 248], ["and", 257], ["proteins", 261], ["and", 270], ["\u03b1", 274], ["-", 275], ["synuclein", 276], ["is", 286], ["reported", 289], ["to", 298], ["be", 301], ["a", 304], ["major", 306], ["protein", 312], ["component", 320], [".", 329], ["Using", 331], ["human", 337], ["brain", 343], ["tissue", 349], ["from", 356], ["control", 361], [",", 368], ["PD", 370], ["and", 373], ["DLB", 377], ["and", 381], ["light", 385], ["and", 391], ["confocal", 395], ["immunohistochemistry", 404], ["with", 425], ["antibodies", 430], ["to", 441], ["superoxide", 444], ["dismutase", 455], ["2", 465], ["as", 467], ["a", 470], ["marker", 472], ["for", 479], ["mitochondria", 483], [",", 495], ["\u03b1", 497], ["-", 498], ["synuclein", 499], ["for", 509], ["Lewy", 513], ["bodies", 518], ["and", 525], ["\u03b2III", 529], ["Tubulin", 534], ["for", 542], ["microtubules", 546], ["we", 559], ["have", 562], ["examined", 567], ["the", 576], ["relationship", 580], ["between", 593], ["Lewy", 601], ["bodies", 606], ["and", 613], ["mitochondrial", 617], ["loss", 631], [".", 635], ["We", 637], ["have", 640], ["shown", 645], ["microtubule", 651], ["regression", 663], ["and", 674], ["mitochondrial", 678], ["and", 692], ["nuclear", 696], ["degradation", 704], ["in", 716], ["neurons", 719], ["with", 727], ["developing", 732], ["Lewy", 743], ["bodies", 748], [".", 754], ["In", 756], ["PD", 759], [",", 761], ["multiple", 763], ["Lewy", 772], ["bodies", 777], ["were", 784], ["often", 789], ["observed", 795], ["with", 804], ["\u03b1", 809], ["-", 810], ["synuclein", 811], ["interacting", 821], ["with", 833], ["DNA", 838], ["to", 842], ["cause", 845], ["marked", 851], ["nuclear", 858], ["degradation", 866], [".", 877], ["In", 879], ["DLB", 882], [",", 885], ["the", 887], ["mitochondria", 891], ["are", 904], ["drawn", 908], ["into", 914], ["the", 919], ["Lewy", 923], ["body", 928], ["and", 933], ["the", 937], ["mitochondrial", 941], ["integrity", 955], ["is", 965], ["lost", 968], [".", 972], ["This", 974], ["work", 979], ["suggests", 984], ["that", 993], ["Lewy", 998], ["bodies", 1003], ["are", 1010], ["cytotoxic", 1014], [".", 1023], ["In", 1025], ["DLB", 1028], [",", 1031], ["we", 1033], ["suggest", 1036], ["that", 1044], ["microtubule", 1049], ["regression", 1061], ["and", 1072], ["mitochondrial", 1076], ["loss", 1090], ["results", 1095], ["in", 1103], ["decreased", 1106], ["cellular", 1116], ["energy", 1125], ["and", 1132], ["axonal", 1136], ["transport", 1143], ["that", 1153], ["leads", 1158], ["to", 1164], ["cell", 1167], ["death", 1172], [".", 1177], ["In", 1179], ["PD", 1182], [",", 1184], ["\u03b1", 1186], ["-", 1187], ["synuclein", 1188], ["aggregations", 1198], ["are", 1211], ["associated", 1215], ["with", 1226], ["intact", 1231], ["mitochondria", 1238], ["but", 1251], ["interacts", 1255], ["with", 1265], ["and", 1270], ["causes", 1274], ["nuclear", 1281], ["degradation", 1289], ["which", 1301], ["may", 1307], ["be", 1311], ["the", 1314], ["major", 1318], ["cause", 1324], ["of", 1330], ["cell", 1333], ["death", 1338], [".", 1343]]}
{"context": "Schimke immuno-osseous dysplasia (OMIM 242900) is an uncommon autosomal-recessive multisystem disease caused by mutations in SMARCAL1 (swi/snf-related, matrix-associated, actin-dependent regulator of chromatin, subfamily a-like 1), a gene encoding a putative chromatin remodeling protein. Neurologic manifestations identified to date relate to enhanced atherosclerosis and cerebrovascular disease. Based on a clinical survey, we determined that half of Schimke immuno-osseous dysplasia patients have a small head circumference, and 15% have social, language, motor, or cognitive abnormalities. Postmortem examination of 2 Schimke immuno-osseous dysplasia patients showed low brain weights and subtle brain histologic abnormalities suggestive of perturbed neuron-glial migration such as heterotopia, irregular cortical thickness, incomplete gyral formation, and poor definition of cortical layers. We found that SMARCAL1 is highly expressed in the developing and adult mouse and human brain, including neural precursors and neuronal lineage cells. These observations suggest that SMARCAL1 deficiency may influence brain development and function in addition to its previously recognized effect on cerebral circulation.", "qas": [{"question": "Mutations in which gene cause Schimke immune-osseous dysplasia?", "answers": ["HARP", "SMARCAL1 (swi/snf-related, matrix-associated, actin-dependent regulator of chromatin, subfamily a-like 1", "SMARCAL1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A-Like 1)"], "qid": "86b60944892d4aba80de48bd155dcdcb", "question_tokens": [["Mutations", 0], ["in", 10], ["which", 13], ["gene", 19], ["cause", 24], ["Schimke", 30], ["immune", 38], ["-", 44], ["osseous", 45], ["dysplasia", 53], ["?", 62]], "detected_answers": [{"text": "SMARCAL1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A-Like 1)", "token_spans": [[21, 44]], "char_spans": [[125, 228]]}]}], "context_tokens": [["Schimke", 0], ["immuno", 8], ["-", 14], ["osseous", 15], ["dysplasia", 23], ["(", 33], ["OMIM", 34], ["242900", 39], [")", 45], ["is", 47], ["an", 50], ["uncommon", 53], ["autosomal", 62], ["-", 71], ["recessive", 72], ["multisystem", 82], ["disease", 94], ["caused", 102], ["by", 109], ["mutations", 112], ["in", 122], ["SMARCAL1", 125], ["(", 134], ["swi", 135], ["/", 138], ["snf", 139], ["-", 142], ["related", 143], [",", 150], ["matrix", 152], ["-", 158], ["associated", 159], [",", 169], ["actin", 171], ["-", 176], ["dependent", 177], ["regulator", 187], ["of", 197], ["chromatin", 200], [",", 209], ["subfamily", 211], ["a", 221], ["-", 222], ["like", 223], ["1", 228], [")", 229], [",", 230], ["a", 232], ["gene", 234], ["encoding", 239], ["a", 248], ["putative", 250], ["chromatin", 259], ["remodeling", 269], ["protein", 280], [".", 287], ["Neurologic", 289], ["manifestations", 300], ["identified", 315], ["to", 326], ["date", 329], ["relate", 334], ["to", 341], ["enhanced", 344], ["atherosclerosis", 353], ["and", 369], ["cerebrovascular", 373], ["disease", 389], [".", 396], ["Based", 398], ["on", 404], ["a", 407], ["clinical", 409], ["survey", 418], [",", 424], ["we", 426], ["determined", 429], ["that", 440], ["half", 445], ["of", 450], ["Schimke", 453], ["immuno", 461], ["-", 467], ["osseous", 468], ["dysplasia", 476], ["patients", 486], ["have", 495], ["a", 500], ["small", 502], ["head", 508], ["circumference", 513], [",", 526], ["and", 528], ["15", 532], ["%", 534], ["have", 536], ["social", 541], [",", 547], ["language", 549], [",", 557], ["motor", 559], [",", 564], ["or", 566], ["cognitive", 569], ["abnormalities", 579], [".", 592], ["Postmortem", 594], ["examination", 605], ["of", 617], ["2", 620], ["Schimke", 622], ["immuno", 630], ["-", 636], ["osseous", 637], ["dysplasia", 645], ["patients", 655], ["showed", 664], ["low", 671], ["brain", 675], ["weights", 681], ["and", 689], ["subtle", 693], ["brain", 700], ["histologic", 706], ["abnormalities", 717], ["suggestive", 731], ["of", 742], ["perturbed", 745], ["neuron", 755], ["-", 761], ["glial", 762], ["migration", 768], ["such", 778], ["as", 783], ["heterotopia", 786], [",", 797], ["irregular", 799], ["cortical", 809], ["thickness", 818], [",", 827], ["incomplete", 829], ["gyral", 840], ["formation", 846], [",", 855], ["and", 857], ["poor", 861], ["definition", 866], ["of", 877], ["cortical", 880], ["layers", 889], [".", 895], ["We", 897], ["found", 900], ["that", 906], ["SMARCAL1", 911], ["is", 920], ["highly", 923], ["expressed", 930], ["in", 940], ["the", 943], ["developing", 947], ["and", 958], ["adult", 962], ["mouse", 968], ["and", 974], ["human", 978], ["brain", 984], [",", 989], ["including", 991], ["neural", 1001], ["precursors", 1008], ["and", 1019], ["neuronal", 1023], ["lineage", 1032], ["cells", 1040], [".", 1045], ["These", 1047], ["observations", 1053], ["suggest", 1066], ["that", 1074], ["SMARCAL1", 1079], ["deficiency", 1088], ["may", 1099], ["influence", 1103], ["brain", 1113], ["development", 1119], ["and", 1131], ["function", 1135], ["in", 1144], ["addition", 1147], ["to", 1156], ["its", 1159], ["previously", 1163], ["recognized", 1174], ["effect", 1185], ["on", 1192], ["cerebral", 1195], ["circulation", 1204], [".", 1215]]}
{"context": "To review available studies of empagliflozin, a sodium glucose co-transporter-2 (SGLT2) inhibitor approved in 2014 by the European Commission and the United States Food and Drug Administration for the treatment of type 2 diabetes mellitus (T2DM). PubMed was searched using the search terms empagliflozin, BI 10773, and BI10773, for entries between January 1, 2000, and December 1, 2014. Reference lists from retrieved articles were searched manually for additional peer-reviewed publications. All publications reporting clinical trials of empagliflozin were eligible for inclusion. Empagliflozin is a new once-daily oral SGLT2 inhibitor with a mechanism of action that is independent of \u03b2-cell function and the insulin pathway. Data from a comprehensive phase III clinical trial program have demonstrated its efficacy as monotherapy, as add-on to other glucose-lowering agents, and in different patient populations. In these studies, empagliflozin resulted in improvements in blood glucose levels as well as reductions in body weight and blood pressure. Empagliflozin was well tolerated and was not associated with an increased risk of hypoglycemia versus placebo. The oral antidiabetes agent, empagliflozin, can be used as monotherapy or alongside other glucose-lowering treatments, including insulin, to treat T2DM.", "qas": [{"question": "Which protein does empagliflozin inhibit?", "answers": ["SGLT2"], "qid": "8e4362d962304849af0e9a9cf344f780", "question_tokens": [["Which", 0], ["protein", 6], ["does", 14], ["empagliflozin", 19], ["inhibit", 33], ["?", 40]], "detected_answers": [{"text": "SGLT2", "token_spans": [[108, 108], [14, 14]], "char_spans": [[621, 625], [81, 85]]}]}], "context_tokens": [["To", 0], ["review", 3], ["available", 10], ["studies", 20], ["of", 28], ["empagliflozin", 31], [",", 44], ["a", 46], ["sodium", 48], ["glucose", 55], ["co", 63], ["-", 65], ["transporter-2", 66], ["(", 80], ["SGLT2", 81], [")", 86], ["inhibitor", 88], ["approved", 98], ["in", 107], ["2014", 110], ["by", 115], ["the", 118], ["European", 122], ["Commission", 131], ["and", 142], ["the", 146], ["United", 150], ["States", 157], ["Food", 164], ["and", 169], ["Drug", 173], ["Administration", 178], ["for", 193], ["the", 197], ["treatment", 201], ["of", 211], ["type", 214], ["2", 219], ["diabetes", 221], ["mellitus", 230], ["(", 239], ["T2DM", 240], [")", 244], [".", 245], ["PubMed", 247], ["was", 254], ["searched", 258], ["using", 267], ["the", 273], ["search", 277], ["terms", 284], ["empagliflozin", 290], [",", 303], ["BI", 305], ["10773", 308], [",", 313], ["and", 315], ["BI10773", 319], [",", 326], ["for", 328], ["entries", 332], ["between", 340], ["January", 348], ["1", 356], [",", 357], ["2000", 359], [",", 363], ["and", 365], ["December", 369], ["1", 378], [",", 379], ["2014", 381], [".", 385], ["Reference", 387], ["lists", 397], ["from", 403], ["retrieved", 408], ["articles", 418], ["were", 427], ["searched", 432], ["manually", 441], ["for", 450], ["additional", 454], ["peer", 465], ["-", 469], ["reviewed", 470], ["publications", 479], [".", 491], ["All", 493], ["publications", 497], ["reporting", 510], ["clinical", 520], ["trials", 529], ["of", 536], ["empagliflozin", 539], ["were", 553], ["eligible", 558], ["for", 567], ["inclusion", 571], [".", 580], ["Empagliflozin", 582], ["is", 596], ["a", 599], ["new", 601], ["once", 605], ["-", 609], ["daily", 610], ["oral", 616], ["SGLT2", 621], ["inhibitor", 627], ["with", 637], ["a", 642], ["mechanism", 644], ["of", 654], ["action", 657], ["that", 664], ["is", 669], ["independent", 672], ["of", 684], ["\u03b2", 687], ["-", 688], ["cell", 689], ["function", 694], ["and", 703], ["the", 707], ["insulin", 711], ["pathway", 719], [".", 726], ["Data", 728], ["from", 733], ["a", 738], ["comprehensive", 740], ["phase", 754], ["III", 760], ["clinical", 764], ["trial", 773], ["program", 779], ["have", 787], ["demonstrated", 792], ["its", 805], ["efficacy", 809], ["as", 818], ["monotherapy", 821], [",", 832], ["as", 834], ["add", 837], ["-", 840], ["on", 841], ["to", 844], ["other", 847], ["glucose", 853], ["-", 860], ["lowering", 861], ["agents", 870], [",", 876], ["and", 878], ["in", 882], ["different", 885], ["patient", 895], ["populations", 903], [".", 914], ["In", 916], ["these", 919], ["studies", 925], [",", 932], ["empagliflozin", 934], ["resulted", 948], ["in", 957], ["improvements", 960], ["in", 973], ["blood", 976], ["glucose", 982], ["levels", 990], ["as", 997], ["well", 1000], ["as", 1005], ["reductions", 1008], ["in", 1019], ["body", 1022], ["weight", 1027], ["and", 1034], ["blood", 1038], ["pressure", 1044], [".", 1052], ["Empagliflozin", 1054], ["was", 1068], ["well", 1072], ["tolerated", 1077], ["and", 1087], ["was", 1091], ["not", 1095], ["associated", 1099], ["with", 1110], ["an", 1115], ["increased", 1118], ["risk", 1128], ["of", 1133], ["hypoglycemia", 1136], ["versus", 1149], ["placebo", 1156], [".", 1163], ["The", 1165], ["oral", 1169], ["antidiabetes", 1174], ["agent", 1187], [",", 1192], ["empagliflozin", 1194], [",", 1207], ["can", 1209], ["be", 1213], ["used", 1216], ["as", 1221], ["monotherapy", 1224], ["or", 1236], ["alongside", 1239], ["other", 1249], ["glucose", 1255], ["-", 1262], ["lowering", 1263], ["treatments", 1272], [",", 1282], ["including", 1284], ["insulin", 1294], [",", 1301], ["to", 1303], ["treat", 1306], ["T2DM", 1312], [".", 1316]]}
{"context": "Plasmids are ubiquitous mobile elements that serve as a pool of many host beneficial traits such as antibiotic resistance in bacterial communities. To understand the importance of plasmids in horizontal gene transfer, we need to gain insight into the 'evolutionary history' of these plasmids, i.e. the range of hosts in which they have evolved. Since extensive data support the proposal that foreign DNA acquires the host's nucleotide composition during long-term residence, comparison of nucleotide composition of plasmids and chromosomes could shed light on a plasmid's evolutionary history. The average absolute dinucleotide relative abundance difference, termed delta-distance, has been commonly used to measure differences in dinucleotide composition, or 'genomic signature', between bacterial chromosomes and plasmids. Here, we introduce the Mahalanobis distance, which takes into account the variance-covariance structure of the chromosome signatures. We demonstrate that the Mahalanobis distance is better than the delta-distance at measuring genomic signature differences between plasmids and chromosomes of potential hosts. We illustrate the usefulness of this metric for proposing candidate long-term hosts for plasmids, focusing on the virulence plasmids pXO1 from Bacillus anthracis, and pO157 from Escherichia coli O157:H7, as well as the broad host range multi-drug resistance plasmid pB10 from an unknown host.", "qas": [{"question": "Which is the most common measure of differences between dinucleotide relative abundance \"genomic signatures\"", "answers": ["delta-distance"], "qid": "082b7ea2976047d8b572fd00bfddec04", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["most", 13], ["common", 18], ["measure", 25], ["of", 33], ["differences", 36], ["between", 48], ["dinucleotide", 56], ["relative", 69], ["abundance", 78], ["\"", 88], ["genomic", 89], ["signatures", 97], ["\"", 107]], "detected_answers": [{"text": "delta-distance", "token_spans": [[108, 110], [167, 169]], "char_spans": [[666, 679], [1023, 1036]]}]}], "context_tokens": [["Plasmids", 0], ["are", 9], ["ubiquitous", 13], ["mobile", 24], ["elements", 31], ["that", 40], ["serve", 45], ["as", 51], ["a", 54], ["pool", 56], ["of", 61], ["many", 64], ["host", 69], ["beneficial", 74], ["traits", 85], ["such", 92], ["as", 97], ["antibiotic", 100], ["resistance", 111], ["in", 122], ["bacterial", 125], ["communities", 135], [".", 146], ["To", 148], ["understand", 151], ["the", 162], ["importance", 166], ["of", 177], ["plasmids", 180], ["in", 189], ["horizontal", 192], ["gene", 203], ["transfer", 208], [",", 216], ["we", 218], ["need", 221], ["to", 226], ["gain", 229], ["insight", 234], ["into", 242], ["the", 247], ["'", 251], ["evolutionary", 252], ["history", 265], ["'", 272], ["of", 274], ["these", 277], ["plasmids", 283], [",", 291], ["i.e.", 293], ["the", 298], ["range", 302], ["of", 308], ["hosts", 311], ["in", 317], ["which", 320], ["they", 326], ["have", 331], ["evolved", 336], [".", 343], ["Since", 345], ["extensive", 351], ["data", 361], ["support", 366], ["the", 374], ["proposal", 378], ["that", 387], ["foreign", 392], ["DNA", 400], ["acquires", 404], ["the", 413], ["host", 417], ["'s", 421], ["nucleotide", 424], ["composition", 435], ["during", 447], ["long", 454], ["-", 458], ["term", 459], ["residence", 464], [",", 473], ["comparison", 475], ["of", 486], ["nucleotide", 489], ["composition", 500], ["of", 512], ["plasmids", 515], ["and", 524], ["chromosomes", 528], ["could", 540], ["shed", 546], ["light", 551], ["on", 557], ["a", 560], ["plasmid", 562], ["'s", 569], ["evolutionary", 572], ["history", 585], [".", 592], ["The", 594], ["average", 598], ["absolute", 606], ["dinucleotide", 615], ["relative", 628], ["abundance", 637], ["difference", 647], [",", 657], ["termed", 659], ["delta", 666], ["-", 671], ["distance", 672], [",", 680], ["has", 682], ["been", 686], ["commonly", 691], ["used", 700], ["to", 705], ["measure", 708], ["differences", 716], ["in", 728], ["dinucleotide", 731], ["composition", 744], [",", 755], ["or", 757], ["'", 760], ["genomic", 761], ["signature", 769], ["'", 778], [",", 779], ["between", 781], ["bacterial", 789], ["chromosomes", 799], ["and", 811], ["plasmids", 815], [".", 823], ["Here", 825], [",", 829], ["we", 831], ["introduce", 834], ["the", 844], ["Mahalanobis", 848], ["distance", 860], [",", 868], ["which", 870], ["takes", 876], ["into", 882], ["account", 887], ["the", 895], ["variance", 899], ["-", 907], ["covariance", 908], ["structure", 919], ["of", 929], ["the", 932], ["chromosome", 936], ["signatures", 947], [".", 957], ["We", 959], ["demonstrate", 962], ["that", 974], ["the", 979], ["Mahalanobis", 983], ["distance", 995], ["is", 1004], ["better", 1007], ["than", 1014], ["the", 1019], ["delta", 1023], ["-", 1028], ["distance", 1029], ["at", 1038], ["measuring", 1041], ["genomic", 1051], ["signature", 1059], ["differences", 1069], ["between", 1081], ["plasmids", 1089], ["and", 1098], ["chromosomes", 1102], ["of", 1114], ["potential", 1117], ["hosts", 1127], [".", 1132], ["We", 1134], ["illustrate", 1137], ["the", 1148], ["usefulness", 1152], ["of", 1163], ["this", 1166], ["metric", 1171], ["for", 1178], ["proposing", 1182], ["candidate", 1192], ["long", 1202], ["-", 1206], ["term", 1207], ["hosts", 1212], ["for", 1218], ["plasmids", 1222], [",", 1230], ["focusing", 1232], ["on", 1241], ["the", 1244], ["virulence", 1248], ["plasmids", 1258], ["pXO1", 1267], ["from", 1272], ["Bacillus", 1277], ["anthracis", 1286], [",", 1295], ["and", 1297], ["pO157", 1301], ["from", 1307], ["Escherichia", 1312], ["coli", 1324], ["O157:H7", 1329], [",", 1336], ["as", 1338], ["well", 1341], ["as", 1346], ["the", 1349], ["broad", 1353], ["host", 1359], ["range", 1364], ["multi", 1370], ["-", 1375], ["drug", 1376], ["resistance", 1381], ["plasmid", 1392], ["pB10", 1400], ["from", 1405], ["an", 1410], ["unknown", 1413], ["host", 1421], [".", 1425]]}
{"context": "Chronic inflammation contributes to a wide variety of human disorders. In the stomach, longstanding gastritis often results in structural alterations in the gastric mucosa, including metaplastic changes and gastric cancers. Therefore, it is important to elucidate factors that are involved in gastric inflammation. Nardilysin (N-arginine dibasic convertase; Nrdc) is a metalloendopeptidase of the M16 family that promotes ectodomain shedding of the precursor forms of various growth factors and cytokines by enhancing the protease activities of a disintegrin and metalloproteinase (ADAM) proteins. Here, we have demonstrated that Nrdc crucially regulates gastric inflammation caused by Helicobacter felis infection or forced expression of prostaglandin E", "qas": [{"question": "Which is the enzymatic activity of nardilysin?", "answers": ["Nardilysin (N-arginine dibasic convertase; Nrdc) is a metalloendopeptidase of the M16 family that promotes ectodomain shedding of the precursor forms of various growth factors and cytokines by enhancing the protease activities of a disintegrin and metalloproteinase (ADAM) proteins."], "qid": "133771e8d5b9448681074f5d120771a8", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["enzymatic", 13], ["activity", 23], ["of", 32], ["nardilysin", 35], ["?", 45]], "detected_answers": [{"text": "Nardilysin (N-arginine dibasic convertase; Nrdc) is a metalloendopeptidase of the M16 family that promotes ectodomain shedding of the precursor forms of various growth factors and cytokines by enhancing the protease activities of a disintegrin and metalloproteinase (ADAM) proteins.", "token_spans": [[49, 93]], "char_spans": [[315, 595]]}]}], "context_tokens": [["Chronic", 0], ["inflammation", 8], ["contributes", 21], ["to", 33], ["a", 36], ["wide", 38], ["variety", 43], ["of", 51], ["human", 54], ["disorders", 60], [".", 69], ["In", 71], ["the", 74], ["stomach", 78], [",", 85], ["longstanding", 87], ["gastritis", 100], ["often", 110], ["results", 116], ["in", 124], ["structural", 127], ["alterations", 138], ["in", 150], ["the", 153], ["gastric", 157], ["mucosa", 165], [",", 171], ["including", 173], ["metaplastic", 183], ["changes", 195], ["and", 203], ["gastric", 207], ["cancers", 215], [".", 222], ["Therefore", 224], [",", 233], ["it", 235], ["is", 238], ["important", 241], ["to", 251], ["elucidate", 254], ["factors", 264], ["that", 272], ["are", 277], ["involved", 281], ["in", 290], ["gastric", 293], ["inflammation", 301], [".", 313], ["Nardilysin", 315], ["(", 326], ["N", 327], ["-", 328], ["arginine", 329], ["dibasic", 338], ["convertase", 346], [";", 356], ["Nrdc", 358], [")", 362], ["is", 364], ["a", 367], ["metalloendopeptidase", 369], ["of", 390], ["the", 393], ["M16", 397], ["family", 401], ["that", 408], ["promotes", 413], ["ectodomain", 422], ["shedding", 433], ["of", 442], ["the", 445], ["precursor", 449], ["forms", 459], ["of", 465], ["various", 468], ["growth", 476], ["factors", 483], ["and", 491], ["cytokines", 495], ["by", 505], ["enhancing", 508], ["the", 518], ["protease", 522], ["activities", 531], ["of", 542], ["a", 545], ["disintegrin", 547], ["and", 559], ["metalloproteinase", 563], ["(", 581], ["ADAM", 582], [")", 586], ["proteins", 588], [".", 596], ["Here", 598], [",", 602], ["we", 604], ["have", 607], ["demonstrated", 612], ["that", 625], ["Nrdc", 630], ["crucially", 635], ["regulates", 645], ["gastric", 655], ["inflammation", 663], ["caused", 676], ["by", 683], ["Helicobacter", 686], ["felis", 699], ["infection", 705], ["or", 715], ["forced", 718], ["expression", 725], ["of", 736], ["prostaglandin", 739], ["E", 753]]}
{"context": "Chronic myelogenous leukemia (CML) is a clonal hematopoietic disorder caused by the reciprocal translocation between chromosome 9 and 22. As a result of this translocation, a novel fusion gene, BCR-ABL, is created on Philadelphia (Ph) chromosome, and the constitutive activity of the BCR-ABL protein tyrosine kinase plays a critical role in the disease pathogenesis. Imatinib mesylate, a selective BCR-ABL tyrosine kinase inhibitor, was first given to a patient with CML in June 1998. Since then, it has continued to demonstrate remarkable efficacy in treating patients with CML. Based upon the results of early phase I and II studies, a phase III study (IRIS Study) that was randomized to first-line imatinib (400 mg/day) or to standard treatment with interferon+low-dose Ara-C, was conducted on 1,106 patients newly diagnosed (within 6 months) with chronic-phase CML. After median follow-up of 30 months, imatinib showed significantly superior tolerability, hematologic and cytogenetic responses (major cytogenetic response, 90%; complete cytogenetic response, 82%), and overall survival (95% without censoring allo-HSCT). Although imatinib is the first-line therapy and has changed the paradigm of CML treatment strategy, questions remain as to the meaning of cytogenetic and molecular response, curability, optimal dose, and relation with allo-HSCT.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "90bd5d6d1bbd4a51af5bf2328d5aebb7", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[73, 75], [53, 55], [34, 36]], "char_spans": [[398, 404], [284, 290], [194, 200]]}]}], "context_tokens": [["Chronic", 0], ["myelogenous", 8], ["leukemia", 20], ["(", 29], ["CML", 30], [")", 33], ["is", 35], ["a", 38], ["clonal", 40], ["hematopoietic", 47], ["disorder", 61], ["caused", 70], ["by", 77], ["the", 80], ["reciprocal", 84], ["translocation", 95], ["between", 109], ["chromosome", 117], ["9", 128], ["and", 130], ["22", 134], [".", 136], ["As", 138], ["a", 141], ["result", 143], ["of", 150], ["this", 153], ["translocation", 158], [",", 171], ["a", 173], ["novel", 175], ["fusion", 181], ["gene", 188], [",", 192], ["BCR", 194], ["-", 197], ["ABL", 198], [",", 201], ["is", 203], ["created", 206], ["on", 214], ["Philadelphia", 217], ["(", 230], ["Ph", 231], [")", 233], ["chromosome", 235], [",", 245], ["and", 247], ["the", 251], ["constitutive", 255], ["activity", 268], ["of", 277], ["the", 280], ["BCR", 284], ["-", 287], ["ABL", 288], ["protein", 292], ["tyrosine", 300], ["kinase", 309], ["plays", 316], ["a", 322], ["critical", 324], ["role", 333], ["in", 338], ["the", 341], ["disease", 345], ["pathogenesis", 353], [".", 365], ["Imatinib", 367], ["mesylate", 376], [",", 384], ["a", 386], ["selective", 388], ["BCR", 398], ["-", 401], ["ABL", 402], ["tyrosine", 406], ["kinase", 415], ["inhibitor", 422], [",", 431], ["was", 433], ["first", 437], ["given", 443], ["to", 449], ["a", 452], ["patient", 454], ["with", 462], ["CML", 467], ["in", 471], ["June", 474], ["1998", 479], [".", 483], ["Since", 485], ["then", 491], [",", 495], ["it", 497], ["has", 500], ["continued", 504], ["to", 514], ["demonstrate", 517], ["remarkable", 529], ["efficacy", 540], ["in", 549], ["treating", 552], ["patients", 561], ["with", 570], ["CML", 575], [".", 578], ["Based", 580], ["upon", 586], ["the", 591], ["results", 595], ["of", 603], ["early", 606], ["phase", 612], ["I", 618], ["and", 620], ["II", 624], ["studies", 627], [",", 634], ["a", 636], ["phase", 638], ["III", 644], ["study", 648], ["(", 654], ["IRIS", 655], ["Study", 660], [")", 665], ["that", 667], ["was", 672], ["randomized", 676], ["to", 687], ["first", 690], ["-", 695], ["line", 696], ["imatinib", 701], ["(", 710], ["400", 711], ["mg", 715], ["/", 717], ["day", 718], [")", 721], ["or", 723], ["to", 726], ["standard", 729], ["treatment", 738], ["with", 748], ["interferon+low", 753], ["-", 767], ["dose", 768], ["Ara", 773], ["-", 776], ["C", 777], [",", 778], ["was", 780], ["conducted", 784], ["on", 794], ["1,106", 797], ["patients", 803], ["newly", 812], ["diagnosed", 818], ["(", 828], ["within", 829], ["6", 836], ["months", 838], [")", 844], ["with", 846], ["chronic", 851], ["-", 858], ["phase", 859], ["CML", 865], [".", 868], ["After", 870], ["median", 876], ["follow", 883], ["-", 889], ["up", 890], ["of", 893], ["30", 896], ["months", 899], [",", 905], ["imatinib", 907], ["showed", 916], ["significantly", 923], ["superior", 937], ["tolerability", 946], [",", 958], ["hematologic", 960], ["and", 972], ["cytogenetic", 976], ["responses", 988], ["(", 998], ["major", 999], ["cytogenetic", 1005], ["response", 1017], [",", 1025], ["90", 1027], ["%", 1029], [";", 1030], ["complete", 1032], ["cytogenetic", 1041], ["response", 1053], [",", 1061], ["82", 1063], ["%", 1065], [")", 1066], [",", 1067], ["and", 1069], ["overall", 1073], ["survival", 1081], ["(", 1090], ["95", 1091], ["%", 1093], ["without", 1095], ["censoring", 1103], ["allo", 1113], ["-", 1117], ["HSCT", 1118], [")", 1122], [".", 1123], ["Although", 1125], ["imatinib", 1134], ["is", 1143], ["the", 1146], ["first", 1150], ["-", 1155], ["line", 1156], ["therapy", 1161], ["and", 1169], ["has", 1173], ["changed", 1177], ["the", 1185], ["paradigm", 1189], ["of", 1198], ["CML", 1201], ["treatment", 1205], ["strategy", 1215], [",", 1223], ["questions", 1225], ["remain", 1235], ["as", 1242], ["to", 1245], ["the", 1248], ["meaning", 1252], ["of", 1260], ["cytogenetic", 1263], ["and", 1275], ["molecular", 1279], ["response", 1289], [",", 1297], ["curability", 1299], [",", 1309], ["optimal", 1311], ["dose", 1319], [",", 1323], ["and", 1325], ["relation", 1329], ["with", 1338], ["allo", 1343], ["-", 1347], ["HSCT", 1348], [".", 1352]]}
{"context": "The Ehlers-Danlos syndrome is a heritable connective-tissue disorder caused by defects in fibrillar-collagen metabolism. Mutations in the type V collagen genes account for up to 50 percent of cases of classic Ehlers-Danlos syndrome, but many other cases are unexplained. We investigated whether the deficiency of the tenascins, extracellular-matrix proteins that are highly expressed in connective tissues, was associated with the Ehlers-Danlos syndrome. We screened serum samples from 151 patients with the classic, hypermobility, or vascular types of the Ehlers-Danlos syndrome; 75 patients with psoriasis; 93 patients with rheumatoid arthritis; and 21 healthy persons for the presence of tenascin-X and tenascin-C by enzyme-linked immunosorbent assay. We examined the expression of tenascins and type V collagen in skin by immunohistochemical methods and sequenced the tenascin-X gene. Tenascin-X was present in serum from all normal subjects, all patients with psoriasis, all patients with rheumatoid arthritis, and 146 of 151 patients with the Ehlers-Danlos syndrome. Tenascin-X was absent from the serum of the 5 remaining patients with Ehlers-Danlos syndrome, who were unrelated. Tenascin-X deficiency was confirmed in these patients by analysis of skin fibroblasts and by immunostaining of skin. The expression of tenascin-C and type V collagen was normal in these patients. All five of these patients had hypermobile joints, hyperelastic skin, and easy bruising, without atrophic scarring. Tenascin-X mutations were identified in all tenascin-X-deficient patients; one patient had a homozygous tenascin-X gene deletion, one was heterozygous for the deletion, and three others had homozygous truncating point mutations, confirming a causative role for tenascin-X and a recessive pattern of inheritance. Tenascin-X deficiency causes a clinically distinct, recessive form of the Ehlers-Danlos syndrome. This finding indicates that factors other than the collagens or collagen-processing enzymes can cause the syndrome and suggests a central role for tenascin-X in maintaining the integrity of collagenous matrix.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective-tissue", "connective tissue"], "qid": "84ecb54e06cc44c78c9482f8b29d119c", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[8, 10]], "char_spans": [[42, 58]]}]}], "context_tokens": [["The", 0], ["Ehlers", 4], ["-", 10], ["Danlos", 11], ["syndrome", 18], ["is", 27], ["a", 30], ["heritable", 32], ["connective", 42], ["-", 52], ["tissue", 53], ["disorder", 60], ["caused", 69], ["by", 76], ["defects", 79], ["in", 87], ["fibrillar", 90], ["-", 99], ["collagen", 100], ["metabolism", 109], [".", 119], ["Mutations", 121], ["in", 131], ["the", 134], ["type", 138], ["V", 143], ["collagen", 145], ["genes", 154], ["account", 160], ["for", 168], ["up", 172], ["to", 175], ["50", 178], ["percent", 181], ["of", 189], ["cases", 192], ["of", 198], ["classic", 201], ["Ehlers", 209], ["-", 215], ["Danlos", 216], ["syndrome", 223], [",", 231], ["but", 233], ["many", 237], ["other", 242], ["cases", 248], ["are", 254], ["unexplained", 258], [".", 269], ["We", 271], ["investigated", 274], ["whether", 287], ["the", 295], ["deficiency", 299], ["of", 310], ["the", 313], ["tenascins", 317], [",", 326], ["extracellular", 328], ["-", 341], ["matrix", 342], ["proteins", 349], ["that", 358], ["are", 363], ["highly", 367], ["expressed", 374], ["in", 384], ["connective", 387], ["tissues", 398], [",", 405], ["was", 407], ["associated", 411], ["with", 422], ["the", 427], ["Ehlers", 431], ["-", 437], ["Danlos", 438], ["syndrome", 445], [".", 453], ["We", 455], ["screened", 458], ["serum", 467], ["samples", 473], ["from", 481], ["151", 486], ["patients", 490], ["with", 499], ["the", 504], ["classic", 508], [",", 515], ["hypermobility", 517], [",", 530], ["or", 532], ["vascular", 535], ["types", 544], ["of", 550], ["the", 553], ["Ehlers", 557], ["-", 563], ["Danlos", 564], ["syndrome", 571], [";", 579], ["75", 581], ["patients", 584], ["with", 593], ["psoriasis", 598], [";", 607], ["93", 609], ["patients", 612], ["with", 621], ["rheumatoid", 626], ["arthritis", 637], [";", 646], ["and", 648], ["21", 652], ["healthy", 655], ["persons", 663], ["for", 671], ["the", 675], ["presence", 679], ["of", 688], ["tenascin", 691], ["-", 699], ["X", 700], ["and", 702], ["tenascin", 706], ["-", 714], ["C", 715], ["by", 717], ["enzyme", 720], ["-", 726], ["linked", 727], ["immunosorbent", 734], ["assay", 748], [".", 753], ["We", 755], ["examined", 758], ["the", 767], ["expression", 771], ["of", 782], ["tenascins", 785], ["and", 795], ["type", 799], ["V", 804], ["collagen", 806], ["in", 815], ["skin", 818], ["by", 823], ["immunohistochemical", 826], ["methods", 846], ["and", 854], ["sequenced", 858], ["the", 868], ["tenascin", 872], ["-", 880], ["X", 881], ["gene", 883], [".", 887], ["Tenascin", 889], ["-", 897], ["X", 898], ["was", 900], ["present", 904], ["in", 912], ["serum", 915], ["from", 921], ["all", 926], ["normal", 930], ["subjects", 937], [",", 945], ["all", 947], ["patients", 951], ["with", 960], ["psoriasis", 965], [",", 974], ["all", 976], ["patients", 980], ["with", 989], ["rheumatoid", 994], ["arthritis", 1005], [",", 1014], ["and", 1016], ["146", 1020], ["of", 1024], ["151", 1027], ["patients", 1031], ["with", 1040], ["the", 1045], ["Ehlers", 1049], ["-", 1055], ["Danlos", 1056], ["syndrome", 1063], [".", 1071], ["Tenascin", 1073], ["-", 1081], ["X", 1082], ["was", 1084], ["absent", 1088], ["from", 1095], ["the", 1100], ["serum", 1104], ["of", 1110], ["the", 1113], ["5", 1117], ["remaining", 1119], ["patients", 1129], ["with", 1138], ["Ehlers", 1143], ["-", 1149], ["Danlos", 1150], ["syndrome", 1157], [",", 1165], ["who", 1167], ["were", 1171], ["unrelated", 1176], [".", 1185], ["Tenascin", 1187], ["-", 1195], ["X", 1196], ["deficiency", 1198], ["was", 1209], ["confirmed", 1213], ["in", 1223], ["these", 1226], ["patients", 1232], ["by", 1241], ["analysis", 1244], ["of", 1253], ["skin", 1256], ["fibroblasts", 1261], ["and", 1273], ["by", 1277], ["immunostaining", 1280], ["of", 1295], ["skin", 1298], [".", 1302], ["The", 1304], ["expression", 1308], ["of", 1319], ["tenascin", 1322], ["-", 1330], ["C", 1331], ["and", 1333], ["type", 1337], ["V", 1342], ["collagen", 1344], ["was", 1353], ["normal", 1357], ["in", 1364], ["these", 1367], ["patients", 1373], [".", 1381], ["All", 1383], ["five", 1387], ["of", 1392], ["these", 1395], ["patients", 1401], ["had", 1410], ["hypermobile", 1414], ["joints", 1426], [",", 1432], ["hyperelastic", 1434], ["skin", 1447], [",", 1451], ["and", 1453], ["easy", 1457], ["bruising", 1462], [",", 1470], ["without", 1472], ["atrophic", 1480], ["scarring", 1489], [".", 1497], ["Tenascin", 1499], ["-", 1507], ["X", 1508], ["mutations", 1510], ["were", 1520], ["identified", 1525], ["in", 1536], ["all", 1539], ["tenascin", 1543], ["-", 1551], ["X", 1552], ["-", 1553], ["deficient", 1554], ["patients", 1564], [";", 1572], ["one", 1574], ["patient", 1578], ["had", 1586], ["a", 1590], ["homozygous", 1592], ["tenascin", 1603], ["-", 1611], ["X", 1612], ["gene", 1614], ["deletion", 1619], [",", 1627], ["one", 1629], ["was", 1633], ["heterozygous", 1637], ["for", 1650], ["the", 1654], ["deletion", 1658], [",", 1666], ["and", 1668], ["three", 1672], ["others", 1678], ["had", 1685], ["homozygous", 1689], ["truncating", 1700], ["point", 1711], ["mutations", 1717], [",", 1726], ["confirming", 1728], ["a", 1739], ["causative", 1741], ["role", 1751], ["for", 1756], ["tenascin", 1760], ["-", 1768], ["X", 1769], ["and", 1771], ["a", 1775], ["recessive", 1777], ["pattern", 1787], ["of", 1795], ["inheritance", 1798], [".", 1809], ["Tenascin", 1811], ["-", 1819], ["X", 1820], ["deficiency", 1822], ["causes", 1833], ["a", 1840], ["clinically", 1842], ["distinct", 1853], [",", 1861], ["recessive", 1863], ["form", 1873], ["of", 1878], ["the", 1881], ["Ehlers", 1885], ["-", 1891], ["Danlos", 1892], ["syndrome", 1899], [".", 1907], ["This", 1909], ["finding", 1914], ["indicates", 1922], ["that", 1932], ["factors", 1937], ["other", 1945], ["than", 1951], ["the", 1956], ["collagens", 1960], ["or", 1970], ["collagen", 1973], ["-", 1981], ["processing", 1982], ["enzymes", 1993], ["can", 2001], ["cause", 2005], ["the", 2011], ["syndrome", 2015], ["and", 2024], ["suggests", 2028], ["a", 2037], ["central", 2039], ["role", 2047], ["for", 2052], ["tenascin", 2056], ["-", 2064], ["X", 2065], ["in", 2067], ["maintaining", 2070], ["the", 2082], ["integrity", 2086], ["of", 2096], ["collagenous", 2099], ["matrix", 2111], [".", 2117]]}
{"context": "Parkinson's disease (PD) and related Lewy body diseases are characterized by deposition of \u03b1-synuclein aggregates in both the central nervous system and peripheral nervous system. Synucleinopathy lesions spread to larger brain areas as the disease progresses, and prion-like cell-to-cell transmission of aggregated \u03b1-synuclein is thought to be the underlying mechanism for this pathological spreading. LRRK2 is another protein linked to the pathogenesis of PD, and its presence in Lewy bodies has attracted much attention as to whether LRRK2 and \u03b1-synuclein interplay during the pathogenesis of PD. However, the relationship between these two crucial proteins still remains unclear. In this review article, we will discuss the current state of knowledge in terms of how these proteins cause the disease and provide the hypothetical mechanisms by which LRRK2 might modify the generation and progression of synucleinopathy.", "qas": [{"question": "Which disease of the central nervous system is characterized by the presence of Lewy bodies?", "answers": ["Parkinson's disease (PD)"], "qid": "ab5ce079faa34a7b97b77449fa304a3f", "question_tokens": [["Which", 0], ["disease", 6], ["of", 14], ["the", 17], ["central", 21], ["nervous", 29], ["system", 37], ["is", 44], ["characterized", 47], ["by", 61], ["the", 64], ["presence", 68], ["of", 77], ["Lewy", 80], ["bodies", 85], ["?", 91]], "detected_answers": [{"text": "Parkinson's disease (PD)", "token_spans": [[0, 4]], "char_spans": [[0, 22]]}]}], "context_tokens": [["Parkinson", 0], ["'s", 9], ["disease", 12], ["(", 20], ["PD", 21], [")", 23], ["and", 25], ["related", 29], ["Lewy", 37], ["body", 42], ["diseases", 47], ["are", 56], ["characterized", 60], ["by", 74], ["deposition", 77], ["of", 88], ["\u03b1", 91], ["-", 92], ["synuclein", 93], ["aggregates", 103], ["in", 114], ["both", 117], ["the", 122], ["central", 126], ["nervous", 134], ["system", 142], ["and", 149], ["peripheral", 153], ["nervous", 164], ["system", 172], [".", 178], ["Synucleinopathy", 180], ["lesions", 196], ["spread", 204], ["to", 211], ["larger", 214], ["brain", 221], ["areas", 227], ["as", 233], ["the", 236], ["disease", 240], ["progresses", 248], [",", 258], ["and", 260], ["prion", 264], ["-", 269], ["like", 270], ["cell", 275], ["-", 279], ["to", 280], ["-", 282], ["cell", 283], ["transmission", 288], ["of", 301], ["aggregated", 304], ["\u03b1", 315], ["-", 316], ["synuclein", 317], ["is", 327], ["thought", 330], ["to", 338], ["be", 341], ["the", 344], ["underlying", 348], ["mechanism", 359], ["for", 369], ["this", 373], ["pathological", 378], ["spreading", 391], [".", 400], ["LRRK2", 402], ["is", 408], ["another", 411], ["protein", 419], ["linked", 427], ["to", 434], ["the", 437], ["pathogenesis", 441], ["of", 454], ["PD", 457], [",", 459], ["and", 461], ["its", 465], ["presence", 469], ["in", 478], ["Lewy", 481], ["bodies", 486], ["has", 493], ["attracted", 497], ["much", 507], ["attention", 512], ["as", 522], ["to", 525], ["whether", 528], ["LRRK2", 536], ["and", 542], ["\u03b1", 546], ["-", 547], ["synuclein", 548], ["interplay", 558], ["during", 568], ["the", 575], ["pathogenesis", 579], ["of", 592], ["PD", 595], [".", 597], ["However", 599], [",", 606], ["the", 608], ["relationship", 612], ["between", 625], ["these", 633], ["two", 639], ["crucial", 643], ["proteins", 651], ["still", 660], ["remains", 666], ["unclear", 674], [".", 681], ["In", 683], ["this", 686], ["review", 691], ["article", 698], [",", 705], ["we", 707], ["will", 710], ["discuss", 715], ["the", 723], ["current", 727], ["state", 735], ["of", 741], ["knowledge", 744], ["in", 754], ["terms", 757], ["of", 763], ["how", 766], ["these", 770], ["proteins", 776], ["cause", 785], ["the", 791], ["disease", 795], ["and", 803], ["provide", 807], ["the", 815], ["hypothetical", 819], ["mechanisms", 832], ["by", 843], ["which", 846], ["LRRK2", 852], ["might", 858], ["modify", 864], ["the", 871], ["generation", 875], ["and", 886], ["progression", 890], ["of", 902], ["synucleinopathy", 905], [".", 920]]}
{"context": "One of the primary criticismes of vestibular schwannoma (VS) radiosurgery is that the risk of surgical morbidity is increased for patients whose tumor progresses after the procedures. We reviewed the French experience of operated patients after failed Gamma Knife radiosurgery. From July 1992 to January 2002, 25 out of the 1000 treated patients underwent another treatment procedure for a gamma knife failure. Excluding the NF2 patients, 21 patients have been operated and the present study shows the data collected for 20 of them. In order to analyze the difficulties observed during the surgery, a questionnaire was filled by the surgeons. The mean interval between radiosurgery and removal was 36 Months, from 10 to 83 Months. The mean increase in Volume was 559% (37 to 3036%, median 160%). Evolution of the Koos grading was found from 8 grade II, 10 grade III et 2 grade IV to 10 grade III and 10 grade IV. Patients have been operated for radiological tumor growth in 7 cases and for clinico-radiological evolution in 13 cases. In 9 cases, the surgeon considered that he had to face unusual difficulties mainly because of adhesion of the tumor to neurovascular structures. Tumor removal was total in 14 cases, near total in 4 cases and subtotal in 2 cases. One case of venous infarction was noticed at the second day following surgery responsible of hemiparesis and aphasia that gradually recovered. At last follow-up examination, facial nerve was normal (House and Brackmann grade I and II) in 10 cases while it was a grade III in 7 cases and grade IV and V in 3 cases. We recommend that the decision for surgical removal of growing vestibular schwannoma after Gamma Knife treatment should be done after a sufficiently long follow-up period. Our results show that the quality of removal and of facial nerve preservation might be impaired by radiosurgery in half of cases. However these results do not support a change in our policy of radiosurgical treatment of small to medium size vestibular schwannoma.", "qas": [{"question": "Which disease can be categorized using the Koos grading system?", "answers": ["vestibular schwannoma"], "qid": "82b7ad0ac3da45f8850154988038abc3", "question_tokens": [["Which", 0], ["disease", 6], ["can", 14], ["be", 18], ["categorized", 21], ["using", 33], ["the", 39], ["Koos", 43], ["grading", 48], ["system", 56], ["?", 62]], "detected_answers": [{"text": "vestibular schwannoma", "token_spans": [[312, 313], [6, 7], [372, 373]], "char_spans": [[1640, 1660], [34, 54], [1990, 2010]]}]}], "context_tokens": [["One", 0], ["of", 4], ["the", 7], ["primary", 11], ["criticismes", 19], ["of", 31], ["vestibular", 34], ["schwannoma", 45], ["(", 56], ["VS", 57], [")", 59], ["radiosurgery", 61], ["is", 74], ["that", 77], ["the", 82], ["risk", 86], ["of", 91], ["surgical", 94], ["morbidity", 103], ["is", 113], ["increased", 116], ["for", 126], ["patients", 130], ["whose", 139], ["tumor", 145], ["progresses", 151], ["after", 162], ["the", 168], ["procedures", 172], [".", 182], ["We", 184], ["reviewed", 187], ["the", 196], ["French", 200], ["experience", 207], ["of", 218], ["operated", 221], ["patients", 230], ["after", 239], ["failed", 245], ["Gamma", 252], ["Knife", 258], ["radiosurgery", 264], [".", 276], ["From", 278], ["July", 283], ["1992", 288], ["to", 293], ["January", 296], ["2002", 304], [",", 308], ["25", 310], ["out", 313], ["of", 317], ["the", 320], ["1000", 324], ["treated", 329], ["patients", 337], ["underwent", 346], ["another", 356], ["treatment", 364], ["procedure", 374], ["for", 384], ["a", 388], ["gamma", 390], ["knife", 396], ["failure", 402], [".", 409], ["Excluding", 411], ["the", 421], ["NF2", 425], ["patients", 429], [",", 437], ["21", 439], ["patients", 442], ["have", 451], ["been", 456], ["operated", 461], ["and", 470], ["the", 474], ["present", 478], ["study", 486], ["shows", 492], ["the", 498], ["data", 502], ["collected", 507], ["for", 517], ["20", 521], ["of", 524], ["them", 527], [".", 531], ["In", 533], ["order", 536], ["to", 542], ["analyze", 545], ["the", 553], ["difficulties", 557], ["observed", 570], ["during", 579], ["the", 586], ["surgery", 590], [",", 597], ["a", 599], ["questionnaire", 601], ["was", 615], ["filled", 619], ["by", 626], ["the", 629], ["surgeons", 633], [".", 641], ["The", 643], ["mean", 647], ["interval", 652], ["between", 661], ["radiosurgery", 669], ["and", 682], ["removal", 686], ["was", 694], ["36", 698], ["Months", 701], [",", 707], ["from", 709], ["10", 714], ["to", 717], ["83", 720], ["Months", 723], [".", 729], ["The", 731], ["mean", 735], ["increase", 740], ["in", 749], ["Volume", 752], ["was", 759], ["559", 763], ["%", 766], ["(", 768], ["37", 769], ["to", 772], ["3036", 775], ["%", 779], [",", 780], ["median", 782], ["160", 789], ["%", 792], [")", 793], [".", 794], ["Evolution", 796], ["of", 806], ["the", 809], ["Koos", 813], ["grading", 818], ["was", 826], ["found", 830], ["from", 836], ["8", 841], ["grade", 843], ["II", 849], [",", 851], ["10", 853], ["grade", 856], ["III", 862], ["et", 866], ["2", 869], ["grade", 871], ["IV", 877], ["to", 880], ["10", 883], ["grade", 886], ["III", 892], ["and", 896], ["10", 900], ["grade", 903], ["IV", 909], [".", 911], ["Patients", 913], ["have", 922], ["been", 927], ["operated", 932], ["for", 941], ["radiological", 945], ["tumor", 958], ["growth", 964], ["in", 971], ["7", 974], ["cases", 976], ["and", 982], ["for", 986], ["clinico", 990], ["-", 997], ["radiological", 998], ["evolution", 1011], ["in", 1021], ["13", 1024], ["cases", 1027], [".", 1032], ["In", 1034], ["9", 1037], ["cases", 1039], [",", 1044], ["the", 1046], ["surgeon", 1050], ["considered", 1058], ["that", 1069], ["he", 1074], ["had", 1077], ["to", 1081], ["face", 1084], ["unusual", 1089], ["difficulties", 1097], ["mainly", 1110], ["because", 1117], ["of", 1125], ["adhesion", 1128], ["of", 1137], ["the", 1140], ["tumor", 1144], ["to", 1150], ["neurovascular", 1153], ["structures", 1167], [".", 1177], ["Tumor", 1179], ["removal", 1185], ["was", 1193], ["total", 1197], ["in", 1203], ["14", 1206], ["cases", 1209], [",", 1214], ["near", 1216], ["total", 1221], ["in", 1227], ["4", 1230], ["cases", 1232], ["and", 1238], ["subtotal", 1242], ["in", 1251], ["2", 1254], ["cases", 1256], [".", 1261], ["One", 1263], ["case", 1267], ["of", 1272], ["venous", 1275], ["infarction", 1282], ["was", 1293], ["noticed", 1297], ["at", 1305], ["the", 1308], ["second", 1312], ["day", 1319], ["following", 1323], ["surgery", 1333], ["responsible", 1341], ["of", 1353], ["hemiparesis", 1356], ["and", 1368], ["aphasia", 1372], ["that", 1380], ["gradually", 1385], ["recovered", 1395], [".", 1404], ["At", 1406], ["last", 1409], ["follow", 1414], ["-", 1420], ["up", 1421], ["examination", 1424], [",", 1435], ["facial", 1437], ["nerve", 1444], ["was", 1450], ["normal", 1454], ["(", 1461], ["House", 1462], ["and", 1468], ["Brackmann", 1472], ["grade", 1482], ["I", 1488], ["and", 1490], ["II", 1494], [")", 1496], ["in", 1498], ["10", 1501], ["cases", 1504], ["while", 1510], ["it", 1516], ["was", 1519], ["a", 1523], ["grade", 1525], ["III", 1531], ["in", 1535], ["7", 1538], ["cases", 1540], ["and", 1546], ["grade", 1550], ["IV", 1556], ["and", 1559], ["V", 1563], ["in", 1565], ["3", 1568], ["cases", 1570], [".", 1575], ["We", 1577], ["recommend", 1580], ["that", 1590], ["the", 1595], ["decision", 1599], ["for", 1608], ["surgical", 1612], ["removal", 1621], ["of", 1629], ["growing", 1632], ["vestibular", 1640], ["schwannoma", 1651], ["after", 1662], ["Gamma", 1668], ["Knife", 1674], ["treatment", 1680], ["should", 1690], ["be", 1697], ["done", 1700], ["after", 1705], ["a", 1711], ["sufficiently", 1713], ["long", 1726], ["follow", 1731], ["-", 1737], ["up", 1738], ["period", 1741], [".", 1747], ["Our", 1749], ["results", 1753], ["show", 1761], ["that", 1766], ["the", 1771], ["quality", 1775], ["of", 1783], ["removal", 1786], ["and", 1794], ["of", 1798], ["facial", 1801], ["nerve", 1808], ["preservation", 1814], ["might", 1827], ["be", 1833], ["impaired", 1836], ["by", 1845], ["radiosurgery", 1848], ["in", 1861], ["half", 1864], ["of", 1869], ["cases", 1872], [".", 1877], ["However", 1879], ["these", 1887], ["results", 1893], ["do", 1901], ["not", 1904], ["support", 1908], ["a", 1916], ["change", 1918], ["in", 1925], ["our", 1928], ["policy", 1932], ["of", 1939], ["radiosurgical", 1942], ["treatment", 1956], ["of", 1966], ["small", 1969], ["to", 1975], ["medium", 1978], ["size", 1985], ["vestibular", 1990], ["schwannoma", 2001], [".", 2011]]}
{"context": "The aim of the present study was to investigate the antibiotic susceptibility patterns and molecular epidemiology of clinical methicillin-resistant Staphylococcus aureus (MRSA) isolates recovered in 24 hospitals in 20 cities in Croatia from October to December 2004. A total of 1815 consecutive S. aureus isolates were recovered, 248 of which were MRSA. The MRSA isolates were analysed using spa typing, multilocus sequence typing and SCCmec typing. Furthermore, the presence of Panton-Valentine leukocidin (PVL) genes was determined as a genetic marker for community-associated MRSA. The MRSA prevalence was 14%. Ninety-six per cent of the MRSA isolates were resistant to ciprofloxacin, 95% to clindamycin and azithromycin, 94% to gentamicin, and 93% to erythromycin. The majority of the MRSA isolates (78%) was associated with the ST111-MRSA-I clone. In addition, various other endemic MRSA clones were observed, such as the ST247-MRSA-I (4%), the ST45-MRSA-IV (2%), the ST5-MRSA-I (2%), the ST239-MRSA-III (2%), the ST5-MRSA-II (1%), the ST8-MRSA-IV (1%) and the ST5-MRSA-IV (<1%) clones. Furthermore, we observed one PVL-negative ST80-MRSA-IV isolate. Four PVL-positive MRSA isolates were found, associated with ST8-MRSA-IV, ST80-MRSA-IV and ST80-MRSA-I. The ST111-MRSA-I clone was predominant in Croatia. Future surveillance studies of MRSA are important to elucidate whether changes in the clonal distribution of MRSA will occur, and if the minor endemic MRSA clones observed in the present study will replace the ST111-MRSA-I clone on a large scale.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "d763f93b6e6f410da3bf3ba40aa856aa", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[114, 114], [101, 101], [253, 253], [285, 285], [60, 60], [164, 164], [57, 57], [297, 297], [24, 24], [306, 306], [98, 98], [143, 143]], "char_spans": [[641, 644], [589, 592], [1174, 1177], [1341, 1344], [358, 361], [888, 891], [348, 351], [1419, 1422], [171, 174], [1461, 1464], [579, 582], [789, 792]]}]}], "context_tokens": [["The", 0], ["aim", 4], ["of", 8], ["the", 11], ["present", 15], ["study", 23], ["was", 29], ["to", 33], ["investigate", 36], ["the", 48], ["antibiotic", 52], ["susceptibility", 63], ["patterns", 78], ["and", 87], ["molecular", 91], ["epidemiology", 101], ["of", 114], ["clinical", 117], ["methicillin", 126], ["-", 137], ["resistant", 138], ["Staphylococcus", 148], ["aureus", 163], ["(", 170], ["MRSA", 171], [")", 175], ["isolates", 177], ["recovered", 186], ["in", 196], ["24", 199], ["hospitals", 202], ["in", 212], ["20", 215], ["cities", 218], ["in", 225], ["Croatia", 228], ["from", 236], ["October", 241], ["to", 249], ["December", 252], ["2004", 261], [".", 265], ["A", 267], ["total", 269], ["of", 275], ["1815", 278], ["consecutive", 283], ["S.", 295], ["aureus", 298], ["isolates", 305], ["were", 314], ["recovered", 319], [",", 328], ["248", 330], ["of", 334], ["which", 337], ["were", 343], ["MRSA", 348], [".", 352], ["The", 354], ["MRSA", 358], ["isolates", 363], ["were", 372], ["analysed", 377], ["using", 386], ["spa", 392], ["typing", 396], [",", 402], ["multilocus", 404], ["sequence", 415], ["typing", 424], ["and", 431], ["SCCmec", 435], ["typing", 442], [".", 448], ["Furthermore", 450], [",", 461], ["the", 463], ["presence", 467], ["of", 476], ["Panton", 479], ["-", 485], ["Valentine", 486], ["leukocidin", 496], ["(", 507], ["PVL", 508], [")", 511], ["genes", 513], ["was", 519], ["determined", 523], ["as", 534], ["a", 537], ["genetic", 539], ["marker", 547], ["for", 554], ["community", 558], ["-", 567], ["associated", 568], ["MRSA", 579], [".", 583], ["The", 585], ["MRSA", 589], ["prevalence", 594], ["was", 605], ["14", 609], ["%", 611], [".", 612], ["Ninety", 614], ["-", 620], ["six", 621], ["per", 625], ["cent", 629], ["of", 634], ["the", 637], ["MRSA", 641], ["isolates", 646], ["were", 655], ["resistant", 660], ["to", 670], ["ciprofloxacin", 673], [",", 686], ["95", 688], ["%", 690], ["to", 692], ["clindamycin", 695], ["and", 707], ["azithromycin", 711], [",", 723], ["94", 725], ["%", 727], ["to", 729], ["gentamicin", 732], [",", 742], ["and", 744], ["93", 748], ["%", 750], ["to", 752], ["erythromycin", 755], [".", 767], ["The", 769], ["majority", 773], ["of", 782], ["the", 785], ["MRSA", 789], ["isolates", 794], ["(", 803], ["78", 804], ["%", 806], [")", 807], ["was", 809], ["associated", 813], ["with", 824], ["the", 829], ["ST111-MRSA", 833], ["-", 843], ["I", 844], ["clone", 846], [".", 851], ["In", 853], ["addition", 856], [",", 864], ["various", 866], ["other", 874], ["endemic", 880], ["MRSA", 888], ["clones", 893], ["were", 900], ["observed", 905], [",", 913], ["such", 915], ["as", 920], ["the", 923], ["ST247-MRSA", 927], ["-", 937], ["I", 938], ["(", 940], ["4", 941], ["%", 942], [")", 943], [",", 944], ["the", 946], ["ST45-MRSA", 950], ["-", 959], ["IV", 960], ["(", 963], ["2", 964], ["%", 965], [")", 966], [",", 967], ["the", 969], ["ST5-MRSA", 973], ["-", 981], ["I", 982], ["(", 984], ["2", 985], ["%", 986], [")", 987], [",", 988], ["the", 990], ["ST239-MRSA", 994], ["-", 1004], ["III", 1005], ["(", 1009], ["2", 1010], ["%", 1011], [")", 1012], [",", 1013], ["the", 1015], ["ST5-MRSA", 1019], ["-", 1027], ["II", 1028], ["(", 1031], ["1", 1032], ["%", 1033], [")", 1034], [",", 1035], ["the", 1037], ["ST8-MRSA", 1041], ["-", 1049], ["IV", 1050], ["(", 1053], ["1", 1054], ["%", 1055], [")", 1056], ["and", 1058], ["the", 1062], ["ST5-MRSA", 1066], ["-", 1074], ["IV", 1075], ["(", 1078], ["<", 1079], ["1", 1080], ["%", 1081], [")", 1082], ["clones", 1084], [".", 1090], ["Furthermore", 1092], [",", 1103], ["we", 1105], ["observed", 1108], ["one", 1117], ["PVL", 1121], ["-", 1124], ["negative", 1125], ["ST80-MRSA", 1134], ["-", 1143], ["IV", 1144], ["isolate", 1147], [".", 1154], ["Four", 1156], ["PVL", 1161], ["-", 1164], ["positive", 1165], ["MRSA", 1174], ["isolates", 1179], ["were", 1188], ["found", 1193], [",", 1198], ["associated", 1200], ["with", 1211], ["ST8-MRSA", 1216], ["-", 1224], ["IV", 1225], [",", 1227], ["ST80-MRSA", 1229], ["-", 1238], ["IV", 1239], ["and", 1242], ["ST80-MRSA", 1246], ["-", 1255], ["I.", 1256], ["The", 1259], ["ST111-MRSA", 1263], ["-", 1273], ["I", 1274], ["clone", 1276], ["was", 1282], ["predominant", 1286], ["in", 1298], ["Croatia", 1301], [".", 1308], ["Future", 1310], ["surveillance", 1317], ["studies", 1330], ["of", 1338], ["MRSA", 1341], ["are", 1346], ["important", 1350], ["to", 1360], ["elucidate", 1363], ["whether", 1373], ["changes", 1381], ["in", 1389], ["the", 1392], ["clonal", 1396], ["distribution", 1403], ["of", 1416], ["MRSA", 1419], ["will", 1424], ["occur", 1429], [",", 1434], ["and", 1436], ["if", 1440], ["the", 1443], ["minor", 1447], ["endemic", 1453], ["MRSA", 1461], ["clones", 1466], ["observed", 1473], ["in", 1482], ["the", 1485], ["present", 1489], ["study", 1497], ["will", 1503], ["replace", 1508], ["the", 1516], ["ST111-MRSA", 1520], ["-", 1530], ["I", 1531], ["clone", 1533], ["on", 1539], ["a", 1542], ["large", 1544], ["scale", 1550], [".", 1555]]}
{"context": "RNA editing is proposed as a modulator of transcriptomes, but its biological impact has not been fully elucidated. In particular, its importance for transposable elements is controversial. We found RNA editing on antisense read-through transcripts of KP elements, one of the deletion derivatives of P transposable elements in Drosophila melanogaster. Three kinds of RNA editing were detected at 20 sites around the terminal inverted repeats (TIR); 15 A-to-G, four U-to-C, and one C-to-U conversions. A-to-G conversions are suggested to be attributed to A-to-I RNA editing on KP element RNAs, because inosine (I) in RNA is recognized as G by reverse transcriptase. TIRs were deduced to form dsRNAs as a putative target of ADAR. This is the first report of RNA editing on mobile elements of Drosophila.", "qas": [{"question": "Which is the major RNA editing enzyme in Drosophila melanogaster?", "answers": ["ADAR", "adenosine deaminase, RNA-specific"], "qid": "ed3c30f4b2954727ac67c7b6e40750c9", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["major", 13], ["RNA", 19], ["editing", 23], ["enzyme", 31], ["in", 38], ["Drosophila", 41], ["melanogaster", 52], ["?", 64]], "detected_answers": [{"text": "ADAR", "token_spans": [[150, 150]], "char_spans": [[721, 724]]}]}], "context_tokens": [["RNA", 0], ["editing", 4], ["is", 12], ["proposed", 15], ["as", 24], ["a", 27], ["modulator", 29], ["of", 39], ["transcriptomes", 42], [",", 56], ["but", 58], ["its", 62], ["biological", 66], ["impact", 77], ["has", 84], ["not", 88], ["been", 92], ["fully", 97], ["elucidated", 103], [".", 113], ["In", 115], ["particular", 118], [",", 128], ["its", 130], ["importance", 134], ["for", 145], ["transposable", 149], ["elements", 162], ["is", 171], ["controversial", 174], [".", 187], ["We", 189], ["found", 192], ["RNA", 198], ["editing", 202], ["on", 210], ["antisense", 213], ["read", 223], ["-", 227], ["through", 228], ["transcripts", 236], ["of", 248], ["KP", 251], ["elements", 254], [",", 262], ["one", 264], ["of", 268], ["the", 271], ["deletion", 275], ["derivatives", 284], ["of", 296], ["P", 299], ["transposable", 301], ["elements", 314], ["in", 323], ["Drosophila", 326], ["melanogaster", 337], [".", 349], ["Three", 351], ["kinds", 357], ["of", 363], ["RNA", 366], ["editing", 370], ["were", 378], ["detected", 383], ["at", 392], ["20", 395], ["sites", 398], ["around", 404], ["the", 411], ["terminal", 415], ["inverted", 424], ["repeats", 433], ["(", 441], ["TIR", 442], [")", 445], [";", 446], ["15", 448], ["A", 451], ["-", 452], ["to", 453], ["-", 455], ["G", 456], [",", 457], ["four", 459], ["U", 464], ["-", 465], ["to", 466], ["-", 468], ["C", 469], [",", 470], ["and", 472], ["one", 476], ["C", 480], ["-", 481], ["to", 482], ["-", 484], ["U", 485], ["conversions", 487], [".", 498], ["A", 500], ["-", 501], ["to", 502], ["-", 504], ["G", 505], ["conversions", 507], ["are", 519], ["suggested", 523], ["to", 533], ["be", 536], ["attributed", 539], ["to", 550], ["A", 553], ["-", 554], ["to", 555], ["-", 557], ["I", 558], ["RNA", 560], ["editing", 564], ["on", 572], ["KP", 575], ["element", 578], ["RNAs", 586], [",", 590], ["because", 592], ["inosine", 600], ["(", 608], ["I", 609], [")", 610], ["in", 612], ["RNA", 615], ["is", 619], ["recognized", 622], ["as", 633], ["G", 636], ["by", 638], ["reverse", 641], ["transcriptase", 649], [".", 662], ["TIRs", 664], ["were", 669], ["deduced", 674], ["to", 682], ["form", 685], ["dsRNAs", 690], ["as", 697], ["a", 700], ["putative", 702], ["target", 711], ["of", 718], ["ADAR", 721], [".", 725], ["This", 727], ["is", 732], ["the", 735], ["first", 739], ["report", 745], ["of", 752], ["RNA", 755], ["editing", 759], ["on", 767], ["mobile", 770], ["elements", 777], ["of", 786], ["Drosophila", 789], [".", 799]]}
{"context": "Interleukin-1\u03b2 (IL-1\u03b2) is a key orchestrator in inflammatory and several immune responses. IL-1\u03b2 exerts its effects through interleukin-1 receptor type I (IL-1RI) and interleukin-1 receptor accessory protein (IL-1RAcP), which together form a heterotrimeric signaling-competent complex. Canakinumab and gevokizumab are highly specific IL-1\u03b2 monoclonal antibodies. Canakinumab is known to neutralize IL-1\u03b2 by competing for binding to IL-1R and therefore blocking signaling by the antigen:antibody complex. Gevokizumab is claimed to be a regulatory therapeutic antibody that modulates IL-1\u03b2 bioactivity by reducing the affinity for its IL-1RI:IL-1RAcP signaling complex. How IL-1\u03b2 signaling is affected by both canakinumab and gevokizumab was not yet experimentally determined. We have analyzed the crystal structures of canakinumab and gevokizumab antibody binding fragment (Fab) as well as of their binary complexes with IL-1\u03b2. Furthermore, we characterized the epitopes on IL-1\u03b2 employed by the antibodies by NMR epitope mapping studies. The direct comparison of NMR and X-ray data shows that the epitope defined by the crystal structure encompasses predominantly those residues whose NMR resonances are severely perturbed upon complex formation. The antigen:Fab co-structures confirm the previously identified key contact residues on IL-1\u03b2 and provide insight into the mechanisms leading to their distinct modulation of IL-1\u03b2 signaling. A significant steric overlap of the binding interfaces of IL-1R and canakinumab on IL-1\u03b2 causes competitive inhibition of the association of IL-1\u03b2 and its receptor. In contrast, gevokizumab occupies an allosteric site on IL-1\u03b2 and complex formation results in a minor reduction of binding affinity to IL-1RI. This suggests two different mechanisms of IL-1\u03b2 pathway attenuation.", "qas": [{"question": "Which molecule is targeted by the drug Gevokizumab?", "answers": ["IL-1\u03b2"], "qid": "2f0cee196ddb4065924495ca24e444df", "question_tokens": [["Which", 0], ["molecule", 6], ["is", 15], ["targeted", 18], ["by", 27], ["the", 30], ["drug", 34], ["Gevokizumab", 39], ["?", 50]], "detected_answers": [{"text": "IL-1\u03b2", "token_spans": [[144, 144], [61, 61], [90, 90], [52, 52], [212, 212], [105, 105], [153, 153], [249, 249], [263, 263], [284, 284], [225, 225], [2, 2], [15, 15], [241, 241]], "char_spans": [[920, 924], [398, 402], [582, 586], [334, 338], [1335, 1339], [672, 676], [973, 977], [1579, 1583], [1659, 1663], [1789, 1793], [1421, 1425], [16, 20], [91, 95], [1521, 1525]]}]}], "context_tokens": [["Interleukin-1\u03b2", 0], ["(", 15], ["IL-1\u03b2", 16], [")", 21], ["is", 23], ["a", 26], ["key", 28], ["orchestrator", 32], ["in", 45], ["inflammatory", 48], ["and", 61], ["several", 65], ["immune", 73], ["responses", 80], [".", 89], ["IL-1\u03b2", 91], ["exerts", 97], ["its", 104], ["effects", 108], ["through", 116], ["interleukin-1", 124], ["receptor", 138], ["type", 147], ["I", 152], ["(", 154], ["IL-1RI", 155], [")", 161], ["and", 163], ["interleukin-1", 167], ["receptor", 181], ["accessory", 190], ["protein", 200], ["(", 208], ["IL-1RAcP", 209], [")", 217], [",", 218], ["which", 220], ["together", 226], ["form", 235], ["a", 240], ["heterotrimeric", 242], ["signaling", 257], ["-", 266], ["competent", 267], ["complex", 277], [".", 284], ["Canakinumab", 286], ["and", 298], ["gevokizumab", 302], ["are", 314], ["highly", 318], ["specific", 325], ["IL-1\u03b2", 334], ["monoclonal", 340], ["antibodies", 351], [".", 361], ["Canakinumab", 363], ["is", 375], ["known", 378], ["to", 384], ["neutralize", 387], ["IL-1\u03b2", 398], ["by", 404], ["competing", 407], ["for", 417], ["binding", 421], ["to", 429], ["IL-1R", 432], ["and", 438], ["therefore", 442], ["blocking", 452], ["signaling", 461], ["by", 471], ["the", 474], ["antigen", 478], [":", 485], ["antibody", 486], ["complex", 495], [".", 502], ["Gevokizumab", 504], ["is", 516], ["claimed", 519], ["to", 527], ["be", 530], ["a", 533], ["regulatory", 535], ["therapeutic", 546], ["antibody", 558], ["that", 567], ["modulates", 572], ["IL-1\u03b2", 582], ["bioactivity", 588], ["by", 600], ["reducing", 603], ["the", 612], ["affinity", 616], ["for", 625], ["its", 629], ["IL-1RI", 633], [":", 639], ["IL-1RAcP", 640], ["signaling", 649], ["complex", 659], [".", 666], ["How", 668], ["IL-1\u03b2", 672], ["signaling", 678], ["is", 688], ["affected", 691], ["by", 700], ["both", 703], ["canakinumab", 708], ["and", 720], ["gevokizumab", 724], ["was", 736], ["not", 740], ["yet", 744], ["experimentally", 748], ["determined", 763], [".", 773], ["We", 775], ["have", 778], ["analyzed", 783], ["the", 792], ["crystal", 796], ["structures", 804], ["of", 815], ["canakinumab", 818], ["and", 830], ["gevokizumab", 834], ["antibody", 846], ["binding", 855], ["fragment", 863], ["(", 872], ["Fab", 873], [")", 876], ["as", 878], ["well", 881], ["as", 886], ["of", 889], ["their", 892], ["binary", 898], ["complexes", 905], ["with", 915], ["IL-1\u03b2", 920], [".", 925], ["Furthermore", 927], [",", 938], ["we", 940], ["characterized", 943], ["the", 957], ["epitopes", 961], ["on", 970], ["IL-1\u03b2", 973], ["employed", 979], ["by", 988], ["the", 991], ["antibodies", 995], ["by", 1006], ["NMR", 1009], ["epitope", 1013], ["mapping", 1021], ["studies", 1029], [".", 1036], ["The", 1038], ["direct", 1042], ["comparison", 1049], ["of", 1060], ["NMR", 1063], ["and", 1067], ["X", 1071], ["-", 1072], ["ray", 1073], ["data", 1077], ["shows", 1082], ["that", 1088], ["the", 1093], ["epitope", 1097], ["defined", 1105], ["by", 1113], ["the", 1116], ["crystal", 1120], ["structure", 1128], ["encompasses", 1138], ["predominantly", 1150], ["those", 1164], ["residues", 1170], ["whose", 1179], ["NMR", 1185], ["resonances", 1189], ["are", 1200], ["severely", 1204], ["perturbed", 1213], ["upon", 1223], ["complex", 1228], ["formation", 1236], [".", 1245], ["The", 1247], ["antigen", 1251], [":", 1258], ["Fab", 1259], ["co", 1263], ["-", 1265], ["structures", 1266], ["confirm", 1277], ["the", 1285], ["previously", 1289], ["identified", 1300], ["key", 1311], ["contact", 1315], ["residues", 1323], ["on", 1332], ["IL-1\u03b2", 1335], ["and", 1341], ["provide", 1345], ["insight", 1353], ["into", 1361], ["the", 1366], ["mechanisms", 1370], ["leading", 1381], ["to", 1389], ["their", 1392], ["distinct", 1398], ["modulation", 1407], ["of", 1418], ["IL-1\u03b2", 1421], ["signaling", 1427], [".", 1436], ["A", 1438], ["significant", 1440], ["steric", 1452], ["overlap", 1459], ["of", 1467], ["the", 1470], ["binding", 1474], ["interfaces", 1482], ["of", 1493], ["IL-1R", 1496], ["and", 1502], ["canakinumab", 1506], ["on", 1518], ["IL-1\u03b2", 1521], ["causes", 1527], ["competitive", 1534], ["inhibition", 1546], ["of", 1557], ["the", 1560], ["association", 1564], ["of", 1576], ["IL-1\u03b2", 1579], ["and", 1585], ["its", 1589], ["receptor", 1593], [".", 1601], ["In", 1603], ["contrast", 1606], [",", 1614], ["gevokizumab", 1616], ["occupies", 1628], ["an", 1637], ["allosteric", 1640], ["site", 1651], ["on", 1656], ["IL-1\u03b2", 1659], ["and", 1665], ["complex", 1669], ["formation", 1677], ["results", 1687], ["in", 1695], ["a", 1698], ["minor", 1700], ["reduction", 1706], ["of", 1716], ["binding", 1719], ["affinity", 1727], ["to", 1736], ["IL-1RI", 1739], [".", 1745], ["This", 1747], ["suggests", 1752], ["two", 1761], ["different", 1765], ["mechanisms", 1775], ["of", 1786], ["IL-1\u03b2", 1789], ["pathway", 1795], ["attenuation", 1803], [".", 1814]]}
{"context": "Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease, which causes progressive and eventually fatal loss of motor function. Here, we describe genetic and pathologic characterization of brain tissue banked from 19 ALS patients over nearly 20\u00a0years at the Department of Anatomy and the Centre for Brain Research, University of Auckland, New Zealand. We screened for mutations in SOD1, TARDBP, FUS, and C9ORF72 genes and for neuropathology caused by phosphorylated TDP-43, dipeptide repeats (DPRs), and ubiquilin. We identified 2 cases with C9ORF72 repeat expansions. Both harbored phosphorylated TDP-43 and DPR inclusions. We show that DPR inclusions can incorporate or occur independently of ubiquilin. We also identified 1 case with a UBQLN2 mutation, which showed phosphorylated TDP-43 and characteristic ubiquilin protein inclusions. This is the first study of ALS genetics in New Zealand, adding New Zealand to the growing list of countries in which C9ORF72 repeat expansion and UBQLN2 mutations are detected in ALS cases.", "qas": [{"question": "Which human disease is associated with mutated UBQLN2", "answers": ["ALS", "amyotrophic lateral sclerosis"], "qid": "56561ee2c5e6437da905d1d0cb1db046", "question_tokens": [["Which", 0], ["human", 6], ["disease", 12], ["is", 20], ["associated", 23], ["with", 34], ["mutated", 39], ["UBQLN2", 47]], "detected_answers": [{"text": "ALS", "token_spans": [[175, 175], [4, 4], [37, 37], [149, 149]], "char_spans": [[1041, 1043], [31, 33], [239, 241], [889, 891]]}, {"text": "amyotrophic lateral sclerosis", "token_spans": [[0, 2]], "char_spans": [[0, 28]]}]}], "context_tokens": [["Amyotrophic", 0], ["lateral", 12], ["sclerosis", 20], ["(", 30], ["ALS", 31], [")", 34], ["is", 36], ["a", 39], ["devastating", 41], ["neurodegenerative", 53], ["disease", 71], [",", 78], ["which", 80], ["causes", 86], ["progressive", 93], ["and", 105], ["eventually", 109], ["fatal", 120], ["loss", 126], ["of", 131], ["motor", 134], ["function", 140], [".", 148], ["Here", 150], [",", 154], ["we", 156], ["describe", 159], ["genetic", 168], ["and", 176], ["pathologic", 180], ["characterization", 191], ["of", 208], ["brain", 211], ["tissue", 217], ["banked", 224], ["from", 231], ["19", 236], ["ALS", 239], ["patients", 243], ["over", 252], ["nearly", 257], ["20", 264], ["years", 267], ["at", 273], ["the", 276], ["Department", 280], ["of", 291], ["Anatomy", 294], ["and", 302], ["the", 306], ["Centre", 310], ["for", 317], ["Brain", 321], ["Research", 327], [",", 335], ["University", 337], ["of", 348], ["Auckland", 351], [",", 359], ["New", 361], ["Zealand", 365], [".", 372], ["We", 374], ["screened", 377], ["for", 386], ["mutations", 390], ["in", 400], ["SOD1", 403], [",", 407], ["TARDBP", 409], [",", 415], ["FUS", 417], [",", 420], ["and", 422], ["C9ORF72", 426], ["genes", 434], ["and", 440], ["for", 444], ["neuropathology", 448], ["caused", 463], ["by", 470], ["phosphorylated", 473], ["TDP-43", 488], [",", 494], ["dipeptide", 496], ["repeats", 506], ["(", 514], ["DPRs", 515], [")", 519], [",", 520], ["and", 522], ["ubiquilin", 526], [".", 535], ["We", 537], ["identified", 540], ["2", 551], ["cases", 553], ["with", 559], ["C9ORF72", 564], ["repeat", 572], ["expansions", 579], [".", 589], ["Both", 591], ["harbored", 596], ["phosphorylated", 605], ["TDP-43", 620], ["and", 627], ["DPR", 631], ["inclusions", 635], [".", 645], ["We", 647], ["show", 650], ["that", 655], ["DPR", 660], ["inclusions", 664], ["can", 675], ["incorporate", 679], ["or", 691], ["occur", 694], ["independently", 700], ["of", 714], ["ubiquilin", 717], [".", 726], ["We", 728], ["also", 731], ["identified", 736], ["1", 747], ["case", 749], ["with", 754], ["a", 759], ["UBQLN2", 761], ["mutation", 768], [",", 776], ["which", 778], ["showed", 784], ["phosphorylated", 791], ["TDP-43", 806], ["and", 813], ["characteristic", 817], ["ubiquilin", 832], ["protein", 842], ["inclusions", 850], [".", 860], ["This", 862], ["is", 867], ["the", 870], ["first", 874], ["study", 880], ["of", 886], ["ALS", 889], ["genetics", 893], ["in", 902], ["New", 905], ["Zealand", 909], [",", 916], ["adding", 918], ["New", 925], ["Zealand", 929], ["to", 937], ["the", 940], ["growing", 944], ["list", 952], ["of", 957], ["countries", 960], ["in", 970], ["which", 973], ["C9ORF72", 979], ["repeat", 987], ["expansion", 994], ["and", 1004], ["UBQLN2", 1008], ["mutations", 1015], ["are", 1025], ["detected", 1029], ["in", 1038], ["ALS", 1041], ["cases", 1045], [".", 1050]]}
{"context": "Flumazenil is a benzodiazepine antagonist. It is widely used as an antidote in comatose patients suspected of having ingested a benzodiazepine overdose. Flumazenil is known to induce cardiac arythmias and seizures, in part because of drug interactions. We present a 75-year-old woman, who was brought to the Emergency Department with a drug overdose following a suicide attempt. She developed generalized seizures shortly after the administration of flumazenil.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "b31d0f65b3754a4091a4d59b39e2a6a4", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[24, 24], [0, 0], [74, 74]], "char_spans": [[153, 162], [0, 9], [450, 459]]}]}], "context_tokens": [["Flumazenil", 0], ["is", 11], ["a", 14], ["benzodiazepine", 16], ["antagonist", 31], [".", 41], ["It", 43], ["is", 46], ["widely", 49], ["used", 56], ["as", 61], ["an", 64], ["antidote", 67], ["in", 76], ["comatose", 79], ["patients", 88], ["suspected", 97], ["of", 107], ["having", 110], ["ingested", 117], ["a", 126], ["benzodiazepine", 128], ["overdose", 143], [".", 151], ["Flumazenil", 153], ["is", 164], ["known", 167], ["to", 173], ["induce", 176], ["cardiac", 183], ["arythmias", 191], ["and", 201], ["seizures", 205], [",", 213], ["in", 215], ["part", 218], ["because", 223], ["of", 231], ["drug", 234], ["interactions", 239], [".", 251], ["We", 253], ["present", 256], ["a", 264], ["75-year", 266], ["-", 273], ["old", 274], ["woman", 278], [",", 283], ["who", 285], ["was", 289], ["brought", 293], ["to", 301], ["the", 304], ["Emergency", 308], ["Department", 318], ["with", 329], ["a", 334], ["drug", 336], ["overdose", 341], ["following", 350], ["a", 360], ["suicide", 362], ["attempt", 370], [".", 377], ["She", 379], ["developed", 383], ["generalized", 393], ["seizures", 405], ["shortly", 414], ["after", 422], ["the", 428], ["administration", 432], ["of", 447], ["flumazenil", 450], [".", 460]]}
{"context": "In neurodegenerative diseases, it remains unclear why certain brain regions are selectively vulnerable to protein aggregation. In transgenic mice expressing human A53T \u03b1-synuclein, the brainstem and spinal cord develop the most prominent \u03b1-synuclein inclusions which correlate with age-dependent motor dysfunction. Herein we present the novel finding that this selective aggregation is in part dependent on the inability of chaperone-mediated autophagy (CMA) to effectively degrade \u03b1-synuclein in these brain regions. Lysosomal assays revealed that CMA activity was significantly decreased in aggregation-prone regions compared to the remainder of the brain. Previously, CMA activity has been shown to be proportional to levels of the CMA receptor Lamp-2a. Using antibodies, brain tissue from Lamp-2a null mice, enzymatic deglycosylation, and mass spectrometry, we identified Lamp2a as a novel 72kDa glycoprotein in the mouse brain. Examination of Lamp-2a levels revealed differences in expression across brain regions. The brainstem and the spinal cord had a more than three-fold greater levels of Lamp-2a as compared to regions less vulnerable to aggregation and exhibited a selective upregulation of Lamp-2a during development of \u03b1-synuclein inclusions. Despite this dynamic response of Lamp-2a, the levels of substrates bound to the brain lysosomes as well as the rates of substrate uptake and degradation were not proportional to the levels of Lamp-2a. These regional differences in CMA activity and Lamp-2a expression were found in both non-transgenic mice as well as A53T \u03b1-syn mice. Therefore, these are inherent variations and not a transgene-specific effect. However, differences in CMA activity may render select brain regions vulnerable to homeostatic dysfunction in the presence of stressors such as overexpression of human A53T \u03b1-syn. Collectively, the data provide a potential mechanism to explain the dichotomy of vulnerability or resistance that underlies brain regions during aggregate formation in neurodegenerative disease.", "qas": [{"question": "Which is the receptor for substrates of Chaperone Mediated Autophagy?", "answers": ["LAMP2A", "Lysosome-associated membrane protein 2 isoform A"], "qid": "fdc608c223704b0ca4a61d478dc8dbe2", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["receptor", 13], ["for", 22], ["substrates", 26], ["of", 37], ["Chaperone", 40], ["Mediated", 50], ["Autophagy", 59], ["?", 68]], "detected_answers": [{"text": "LAMP2A", "token_spans": [[146, 146]], "char_spans": [[876, 881]]}]}], "context_tokens": [["In", 0], ["neurodegenerative", 3], ["diseases", 21], [",", 29], ["it", 31], ["remains", 34], ["unclear", 42], ["why", 50], ["certain", 54], ["brain", 62], ["regions", 68], ["are", 76], ["selectively", 80], ["vulnerable", 92], ["to", 103], ["protein", 106], ["aggregation", 114], [".", 125], ["In", 127], ["transgenic", 130], ["mice", 141], ["expressing", 146], ["human", 157], ["A53", 163], ["T", 166], ["\u03b1", 168], ["-", 169], ["synuclein", 170], [",", 179], ["the", 181], ["brainstem", 185], ["and", 195], ["spinal", 199], ["cord", 206], ["develop", 211], ["the", 219], ["most", 223], ["prominent", 228], ["\u03b1", 238], ["-", 239], ["synuclein", 240], ["inclusions", 250], ["which", 261], ["correlate", 267], ["with", 277], ["age", 282], ["-", 285], ["dependent", 286], ["motor", 296], ["dysfunction", 302], [".", 313], ["Herein", 315], ["we", 322], ["present", 325], ["the", 333], ["novel", 337], ["finding", 343], ["that", 351], ["this", 356], ["selective", 361], ["aggregation", 371], ["is", 383], ["in", 386], ["part", 389], ["dependent", 394], ["on", 404], ["the", 407], ["inability", 411], ["of", 421], ["chaperone", 424], ["-", 433], ["mediated", 434], ["autophagy", 443], ["(", 453], ["CMA", 454], [")", 457], ["to", 459], ["effectively", 462], ["degrade", 474], ["\u03b1", 482], ["-", 483], ["synuclein", 484], ["in", 494], ["these", 497], ["brain", 503], ["regions", 509], [".", 516], ["Lysosomal", 518], ["assays", 528], ["revealed", 535], ["that", 544], ["CMA", 549], ["activity", 553], ["was", 562], ["significantly", 566], ["decreased", 580], ["in", 590], ["aggregation", 593], ["-", 604], ["prone", 605], ["regions", 611], ["compared", 619], ["to", 628], ["the", 631], ["remainder", 635], ["of", 645], ["the", 648], ["brain", 652], [".", 657], ["Previously", 659], [",", 669], ["CMA", 671], ["activity", 675], ["has", 684], ["been", 688], ["shown", 693], ["to", 699], ["be", 702], ["proportional", 705], ["to", 718], ["levels", 721], ["of", 728], ["the", 731], ["CMA", 735], ["receptor", 739], ["Lamp-2a", 748], [".", 755], ["Using", 757], ["antibodies", 763], [",", 773], ["brain", 775], ["tissue", 781], ["from", 788], ["Lamp-2a", 793], ["null", 801], ["mice", 806], [",", 810], ["enzymatic", 812], ["deglycosylation", 822], [",", 837], ["and", 839], ["mass", 843], ["spectrometry", 848], [",", 860], ["we", 862], ["identified", 865], ["Lamp2a", 876], ["as", 883], ["a", 886], ["novel", 888], ["72kDa", 894], ["glycoprotein", 900], ["in", 913], ["the", 916], ["mouse", 920], ["brain", 926], [".", 931], ["Examination", 933], ["of", 945], ["Lamp-2a", 948], ["levels", 956], ["revealed", 963], ["differences", 972], ["in", 984], ["expression", 987], ["across", 998], ["brain", 1005], ["regions", 1011], [".", 1018], ["The", 1020], ["brainstem", 1024], ["and", 1034], ["the", 1038], ["spinal", 1042], ["cord", 1049], ["had", 1054], ["a", 1058], ["more", 1060], ["than", 1065], ["three", 1070], ["-", 1075], ["fold", 1076], ["greater", 1081], ["levels", 1089], ["of", 1096], ["Lamp-2a", 1099], ["as", 1107], ["compared", 1110], ["to", 1119], ["regions", 1122], ["less", 1130], ["vulnerable", 1135], ["to", 1146], ["aggregation", 1149], ["and", 1161], ["exhibited", 1165], ["a", 1175], ["selective", 1177], ["upregulation", 1187], ["of", 1200], ["Lamp-2a", 1203], ["during", 1211], ["development", 1218], ["of", 1230], ["\u03b1", 1233], ["-", 1234], ["synuclein", 1235], ["inclusions", 1245], [".", 1255], ["Despite", 1257], ["this", 1265], ["dynamic", 1270], ["response", 1278], ["of", 1287], ["Lamp-2a", 1290], [",", 1297], ["the", 1299], ["levels", 1303], ["of", 1310], ["substrates", 1313], ["bound", 1324], ["to", 1330], ["the", 1333], ["brain", 1337], ["lysosomes", 1343], ["as", 1353], ["well", 1356], ["as", 1361], ["the", 1364], ["rates", 1368], ["of", 1374], ["substrate", 1377], ["uptake", 1387], ["and", 1394], ["degradation", 1398], ["were", 1410], ["not", 1415], ["proportional", 1419], ["to", 1432], ["the", 1435], ["levels", 1439], ["of", 1446], ["Lamp-2a", 1449], [".", 1456], ["These", 1458], ["regional", 1464], ["differences", 1473], ["in", 1485], ["CMA", 1488], ["activity", 1492], ["and", 1501], ["Lamp-2a", 1505], ["expression", 1513], ["were", 1524], ["found", 1529], ["in", 1535], ["both", 1538], ["non", 1543], ["-", 1546], ["transgenic", 1547], ["mice", 1558], ["as", 1563], ["well", 1566], ["as", 1571], ["A53", 1574], ["T", 1577], ["\u03b1", 1579], ["-", 1580], ["syn", 1581], ["mice", 1585], [".", 1589], ["Therefore", 1591], [",", 1600], ["these", 1602], ["are", 1608], ["inherent", 1612], ["variations", 1621], ["and", 1632], ["not", 1636], ["a", 1640], ["transgene", 1642], ["-", 1651], ["specific", 1652], ["effect", 1661], [".", 1667], ["However", 1669], [",", 1676], ["differences", 1678], ["in", 1690], ["CMA", 1693], ["activity", 1697], ["may", 1706], ["render", 1710], ["select", 1717], ["brain", 1724], ["regions", 1730], ["vulnerable", 1738], ["to", 1749], ["homeostatic", 1752], ["dysfunction", 1764], ["in", 1776], ["the", 1779], ["presence", 1783], ["of", 1792], ["stressors", 1795], ["such", 1805], ["as", 1810], ["overexpression", 1813], ["of", 1828], ["human", 1831], ["A53", 1837], ["T", 1840], ["\u03b1", 1842], ["-", 1843], ["syn", 1844], [".", 1847], ["Collectively", 1849], [",", 1861], ["the", 1863], ["data", 1867], ["provide", 1872], ["a", 1880], ["potential", 1882], ["mechanism", 1892], ["to", 1902], ["explain", 1905], ["the", 1913], ["dichotomy", 1917], ["of", 1927], ["vulnerability", 1930], ["or", 1944], ["resistance", 1947], ["that", 1958], ["underlies", 1963], ["brain", 1973], ["regions", 1979], ["during", 1987], ["aggregate", 1994], ["formation", 2004], ["in", 2014], ["neurodegenerative", 2017], ["disease", 2035], [".", 2042]]}
{"context": "Intravenous immunoglobulin (IVIG) has shown limited promise so far in human clinical studies on Alzheimer's disease (AD), yet overwhelmingly positive preclinical work in animals and human brain cultures support the notion that the therapy remains potentially efficacious. Here, we elaborate on IVIG neuropreservation by demonstrating that IVIG protects human primary neurons against oxidative stress in vitro and that IVIG preserves antioxidant defense mechanisms in vivo. Based on these results, we propose the following translational impact: If the dosage and treatment conditions are adequately optimized, then IVIG treatment could play a significant role in preventing and/or delaying the progression of neurodegenerative diseases, such as AD. We suggest that IVIG warrants further investigation to fully exploit its potential as an anti-oxidant, neuroprotective and synapto-protecting agent.", "qas": [{"question": "What is the administration route of IVIG in Alzheimer's disease patients?", "answers": ["Intravenous"], "qid": "b281754e18ae429e9ea7345319018381", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["administration", 12], ["route", 27], ["of", 33], ["IVIG", 36], ["in", 41], ["Alzheimer", 44], ["'s", 53], ["disease", 56], ["patients", 64], ["?", 72]], "detected_answers": [{"text": "Intravenous", "token_spans": [[0, 0]], "char_spans": [[0, 10]]}]}], "context_tokens": [["Intravenous", 0], ["immunoglobulin", 12], ["(", 27], ["IVIG", 28], [")", 32], ["has", 34], ["shown", 38], ["limited", 44], ["promise", 52], ["so", 60], ["far", 63], ["in", 67], ["human", 70], ["clinical", 76], ["studies", 85], ["on", 93], ["Alzheimer", 96], ["'s", 105], ["disease", 108], ["(", 116], ["AD", 117], [")", 119], [",", 120], ["yet", 122], ["overwhelmingly", 126], ["positive", 141], ["preclinical", 150], ["work", 162], ["in", 167], ["animals", 170], ["and", 178], ["human", 182], ["brain", 188], ["cultures", 194], ["support", 203], ["the", 211], ["notion", 215], ["that", 222], ["the", 227], ["therapy", 231], ["remains", 239], ["potentially", 247], ["efficacious", 259], [".", 270], ["Here", 272], [",", 276], ["we", 278], ["elaborate", 281], ["on", 291], ["IVIG", 294], ["neuropreservation", 299], ["by", 317], ["demonstrating", 320], ["that", 334], ["IVIG", 339], ["protects", 344], ["human", 353], ["primary", 359], ["neurons", 367], ["against", 375], ["oxidative", 383], ["stress", 393], ["in", 400], ["vitro", 403], ["and", 409], ["that", 413], ["IVIG", 418], ["preserves", 423], ["antioxidant", 433], ["defense", 445], ["mechanisms", 453], ["in", 464], ["vivo", 467], [".", 471], ["Based", 473], ["on", 479], ["these", 482], ["results", 488], [",", 495], ["we", 497], ["propose", 500], ["the", 508], ["following", 512], ["translational", 522], ["impact", 536], [":", 542], ["If", 544], ["the", 547], ["dosage", 551], ["and", 558], ["treatment", 562], ["conditions", 572], ["are", 583], ["adequately", 587], ["optimized", 598], [",", 607], ["then", 609], ["IVIG", 614], ["treatment", 619], ["could", 629], ["play", 635], ["a", 640], ["significant", 642], ["role", 654], ["in", 659], ["preventing", 662], ["and/or", 673], ["delaying", 680], ["the", 689], ["progression", 693], ["of", 705], ["neurodegenerative", 708], ["diseases", 726], [",", 734], ["such", 736], ["as", 741], ["AD", 744], [".", 746], ["We", 748], ["suggest", 751], ["that", 759], ["IVIG", 764], ["warrants", 769], ["further", 778], ["investigation", 786], ["to", 800], ["fully", 803], ["exploit", 809], ["its", 817], ["potential", 821], ["as", 831], ["an", 834], ["anti", 837], ["-", 841], ["oxidant", 842], [",", 849], ["neuroprotective", 851], ["and", 867], ["synapto", 871], ["-", 878], ["protecting", 879], ["agent", 890], [".", 895]]}
{"context": "Nonnucleoside reverse transcriptase inhibitors (NNRTIs) are widely used to treat HIV-1-infected individuals; indeed most first-line antiretroviral therapies typically include one NNRTI in combination with two nucleoside analogs. In 2008, the next-generation NNRTI etravirine was approved for the treatment of HIV-infected antiretroviral therapy-experienced individuals, including those with prior NNRTI exposure. NNRTIs are also increasingly being included in strategies to prevent HIV-1 infection. For example: (1) nevirapine is used to prevent mother-to-child transmission; (2) the ASPIRE (MTN 020) study will test whether a vaginal ring containing dapivirine can prevent HIV-1 infection in women; (3) a microbicide gel formulation containing the urea-PETT derivative MIV-150 is in a phase I study to evaluate safety, pharmacokinetics, pharmacodynamics and acceptability; and (4) a long acting rilpivirine formulation is under-development for pre-exposure prophylaxis. Given their widespread use, particularly in resource-limited settings, as well as their low genetic barriers to resistance, there are concerns about overlapping resistance between the different NNRTIs. Consequently, a better understanding of the resistance and cross-resistance profiles among the NNRTI class is important for predicting response to treatment, and surveillance of transmitted drug-resistance.", "qas": [{"question": "Which infection can be prevented with Dapivirine?", "answers": ["HIV"], "qid": "f8585ae680a84b258cfa4b315d1378ba", "question_tokens": [["Which", 0], ["infection", 6], ["can", 16], ["be", 20], ["prevented", 23], ["with", 33], ["Dapivirine", 38], ["?", 48]], "detected_answers": [{"text": "HIV", "token_spans": [[48, 48]], "char_spans": [[309, 311]]}]}], "context_tokens": [["Nonnucleoside", 0], ["reverse", 14], ["transcriptase", 22], ["inhibitors", 36], ["(", 47], ["NNRTIs", 48], [")", 54], ["are", 56], ["widely", 60], ["used", 67], ["to", 72], ["treat", 75], ["HIV-1-infected", 81], ["individuals", 96], [";", 107], ["indeed", 109], ["most", 116], ["first", 121], ["-", 126], ["line", 127], ["antiretroviral", 132], ["therapies", 147], ["typically", 157], ["include", 167], ["one", 175], ["NNRTI", 179], ["in", 185], ["combination", 188], ["with", 200], ["two", 205], ["nucleoside", 209], ["analogs", 220], [".", 227], ["In", 229], ["2008", 232], [",", 236], ["the", 238], ["next", 242], ["-", 246], ["generation", 247], ["NNRTI", 258], ["etravirine", 264], ["was", 275], ["approved", 279], ["for", 288], ["the", 292], ["treatment", 296], ["of", 306], ["HIV", 309], ["-", 312], ["infected", 313], ["antiretroviral", 322], ["therapy", 337], ["-", 344], ["experienced", 345], ["individuals", 357], [",", 368], ["including", 370], ["those", 380], ["with", 386], ["prior", 391], ["NNRTI", 397], ["exposure", 403], [".", 411], ["NNRTIs", 413], ["are", 420], ["also", 424], ["increasingly", 429], ["being", 442], ["included", 448], ["in", 457], ["strategies", 460], ["to", 471], ["prevent", 474], ["HIV-1", 482], ["infection", 488], [".", 497], ["For", 499], ["example", 503], [":", 510], ["(", 512], ["1", 513], [")", 514], ["nevirapine", 516], ["is", 527], ["used", 530], ["to", 535], ["prevent", 538], ["mother", 546], ["-", 552], ["to", 553], ["-", 555], ["child", 556], ["transmission", 562], [";", 574], ["(", 576], ["2", 577], [")", 578], ["the", 580], ["ASPIRE", 584], ["(", 591], ["MTN", 592], ["020", 596], [")", 599], ["study", 601], ["will", 607], ["test", 612], ["whether", 617], ["a", 625], ["vaginal", 627], ["ring", 635], ["containing", 640], ["dapivirine", 651], ["can", 662], ["prevent", 666], ["HIV-1", 674], ["infection", 680], ["in", 690], ["women", 693], [";", 698], ["(", 700], ["3", 701], [")", 702], ["a", 704], ["microbicide", 706], ["gel", 718], ["formulation", 722], ["containing", 734], ["the", 745], ["urea", 749], ["-", 753], ["PETT", 754], ["derivative", 759], ["MIV-150", 770], ["is", 778], ["in", 781], ["a", 784], ["phase", 786], ["I", 792], ["study", 794], ["to", 800], ["evaluate", 803], ["safety", 812], [",", 818], ["pharmacokinetics", 820], [",", 836], ["pharmacodynamics", 838], ["and", 855], ["acceptability", 859], [";", 872], ["and", 874], ["(", 878], ["4", 879], [")", 880], ["a", 882], ["long", 884], ["acting", 889], ["rilpivirine", 896], ["formulation", 908], ["is", 920], ["under", 923], ["-", 928], ["development", 929], ["for", 941], ["pre", 945], ["-", 948], ["exposure", 949], ["prophylaxis", 958], [".", 969], ["Given", 971], ["their", 977], ["widespread", 983], ["use", 994], [",", 997], ["particularly", 999], ["in", 1012], ["resource", 1015], ["-", 1023], ["limited", 1024], ["settings", 1032], [",", 1040], ["as", 1042], ["well", 1045], ["as", 1050], ["their", 1053], ["low", 1059], ["genetic", 1063], ["barriers", 1071], ["to", 1080], ["resistance", 1083], [",", 1093], ["there", 1095], ["are", 1101], ["concerns", 1105], ["about", 1114], ["overlapping", 1120], ["resistance", 1132], ["between", 1143], ["the", 1151], ["different", 1155], ["NNRTIs", 1165], [".", 1171], ["Consequently", 1173], [",", 1185], ["a", 1187], ["better", 1189], ["understanding", 1196], ["of", 1210], ["the", 1213], ["resistance", 1217], ["and", 1228], ["cross", 1232], ["-", 1237], ["resistance", 1238], ["profiles", 1249], ["among", 1258], ["the", 1264], ["NNRTI", 1268], ["class", 1274], ["is", 1280], ["important", 1283], ["for", 1293], ["predicting", 1297], ["response", 1308], ["to", 1317], ["treatment", 1320], [",", 1329], ["and", 1331], ["surveillance", 1335], ["of", 1348], ["transmitted", 1351], ["drug", 1363], ["-", 1367], ["resistance", 1368], [".", 1378]]}
{"context": "Chronic myelogenous leukemia (CML) is characterized by Philadelphia (Ph) chromosome with a chimeric gene BCR-ABL created by reciprocal t(9:22) (q34;q11) translocation. Variant Ph chromosome translocations involving chromosomes other than 9 and 22 are found in 5-10% of CML cases. We here report a CML patient who carries a four-way Ph chromosome translocation, t(9;22;15;19) (q34;q11;q15;q13). The patient was diagnosed in 1997 and initially treated with hydroxyurea. In 2002, treatment with imatinib, a selective BCR-ABL tyrosine kinase inhibitor (TKI), was started but Ph-positive chromosomes remained at the levels of 42-65%, indicating imatinib failure. In 2006, the point mutations of F359I and L387M were detected in BCR/ABL gene, which may be related to imatinib failure. Treatment with nilotinib, a TKI with high target specificity, was then started which resulted in durable major molecular response. Administration of nilotinib offered an effective treatment in a CML patient with variant Ph chromosome translocations and BCR-ABL point mutations after imatinib failure.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "fdeaba7b6cb142ef8d135fd8ca5d8c0a", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[193, 195], [141, 143], [18, 20], [96, 98]], "char_spans": [[1032, 1038], [723, 729], [105, 111], [514, 520]]}]}], "context_tokens": [["Chronic", 0], ["myelogenous", 8], ["leukemia", 20], ["(", 29], ["CML", 30], [")", 33], ["is", 35], ["characterized", 38], ["by", 52], ["Philadelphia", 55], ["(", 68], ["Ph", 69], [")", 71], ["chromosome", 73], ["with", 84], ["a", 89], ["chimeric", 91], ["gene", 100], ["BCR", 105], ["-", 108], ["ABL", 109], ["created", 113], ["by", 121], ["reciprocal", 124], ["t(9:22", 135], [")", 141], ["(", 143], ["q34;q11", 144], [")", 151], ["translocation", 153], [".", 166], ["Variant", 168], ["Ph", 176], ["chromosome", 179], ["translocations", 190], ["involving", 205], ["chromosomes", 215], ["other", 227], ["than", 233], ["9", 238], ["and", 240], ["22", 244], ["are", 247], ["found", 251], ["in", 257], ["5", 260], ["-", 261], ["10", 262], ["%", 264], ["of", 266], ["CML", 269], ["cases", 273], [".", 278], ["We", 280], ["here", 283], ["report", 288], ["a", 295], ["CML", 297], ["patient", 301], ["who", 309], ["carries", 313], ["a", 321], ["four", 323], ["-", 327], ["way", 328], ["Ph", 332], ["chromosome", 335], ["translocation", 346], [",", 359], ["t(9;22;15;19", 361], [")", 373], ["(", 375], ["q34;q11;q15;q13", 376], [")", 391], [".", 392], ["The", 394], ["patient", 398], ["was", 406], ["diagnosed", 410], ["in", 420], ["1997", 423], ["and", 428], ["initially", 432], ["treated", 442], ["with", 450], ["hydroxyurea", 455], [".", 466], ["In", 468], ["2002", 471], [",", 475], ["treatment", 477], ["with", 487], ["imatinib", 492], [",", 500], ["a", 502], ["selective", 504], ["BCR", 514], ["-", 517], ["ABL", 518], ["tyrosine", 522], ["kinase", 531], ["inhibitor", 538], ["(", 548], ["TKI", 549], [")", 552], [",", 553], ["was", 555], ["started", 559], ["but", 567], ["Ph", 571], ["-", 573], ["positive", 574], ["chromosomes", 583], ["remained", 595], ["at", 604], ["the", 607], ["levels", 611], ["of", 618], ["42", 621], ["-", 623], ["65", 624], ["%", 626], [",", 627], ["indicating", 629], ["imatinib", 640], ["failure", 649], [".", 656], ["In", 658], ["2006", 661], [",", 665], ["the", 667], ["point", 671], ["mutations", 677], ["of", 687], ["F359I", 690], ["and", 696], ["L387", 700], ["M", 704], ["were", 706], ["detected", 711], ["in", 720], ["BCR", 723], ["/", 726], ["ABL", 727], ["gene", 731], [",", 735], ["which", 737], ["may", 743], ["be", 747], ["related", 750], ["to", 758], ["imatinib", 761], ["failure", 770], [".", 777], ["Treatment", 779], ["with", 789], ["nilotinib", 794], [",", 803], ["a", 805], ["TKI", 807], ["with", 811], ["high", 816], ["target", 821], ["specificity", 828], [",", 839], ["was", 841], ["then", 845], ["started", 850], ["which", 858], ["resulted", 864], ["in", 873], ["durable", 876], ["major", 884], ["molecular", 890], ["response", 900], [".", 908], ["Administration", 910], ["of", 925], ["nilotinib", 928], ["offered", 938], ["an", 946], ["effective", 949], ["treatment", 959], ["in", 969], ["a", 972], ["CML", 974], ["patient", 978], ["with", 986], ["variant", 991], ["Ph", 999], ["chromosome", 1002], ["translocations", 1013], ["and", 1028], ["BCR", 1032], ["-", 1035], ["ABL", 1036], ["point", 1040], ["mutations", 1046], ["after", 1056], ["imatinib", 1062], ["failure", 1071], [".", 1078]]}
{"context": "Ehlers-Danlos syndromes (EDS) are a heterogeneous group of heritable connective tissue disorders. Gastrointestinal manifestations in EDS have been described but their frequency, nature and impact are poorly known. We aimed to assess digestive features in a national cohort of EDS patients. A questionnaire has been sent to 212 EDS patients through the French patient support group, all of which had been formally diagnosed according to the Villefranche criteria. The questionnaire included questions about digestive functional symptoms, the GIQLI (Gastrointestinal Quality of Life Index), KESS scoring system and the Rome III criteria. Overall, 135 patients (64% response rate) completed the questionnaire and 134 were analyzable (123 women; 91%). Mean age and Body Mass Index were respectively 35\u00b114.7 years and 24.3\u00b16.1 kg/m(2). The most common EDS subtype was hypermobility form (n=108; 80.6%). GIQLI and KESS median values were respectively 63.5 (27-117) and 19 [13.5-22]. Eighty four percent of patients had functional bowel disorders (FBD) according to the Rome III criteria. An irritable bowel syndrome according to the same criteria was observed in 64 patients (48%) and 48 patients (36%) reported functional constipation. A gastro-esophageal reflux disease (GERD) was reported in 90 patients (68.7%), significantly associated with a poorer GIQLI (60.5\u00b116.8 versus 75.9\u00b120.3; p<0.0001). GIQLI was also negatively impacted by the presence of an irritable bowel syndrome or functional constipation (p=0.007). There was a significant correlation between FBD and GERD. Natural frequency of gastrointestinal manifestations in EDS seems higher than previously assessed. FBD and GERD are very common in our study population, the largest ever published until now. Their impact is herein shown to be important. A systematic clinical assessment of digestive features should be recommended in EDS.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "922ae9318d264f8ea1e929e98b4bbe0b", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[13, 14]], "char_spans": [[69, 85]]}]}], "context_tokens": [["Ehlers", 0], ["-", 6], ["Danlos", 7], ["syndromes", 14], ["(", 24], ["EDS", 25], [")", 28], ["are", 30], ["a", 34], ["heterogeneous", 36], ["group", 50], ["of", 56], ["heritable", 59], ["connective", 69], ["tissue", 80], ["disorders", 87], [".", 96], ["Gastrointestinal", 98], ["manifestations", 115], ["in", 130], ["EDS", 133], ["have", 137], ["been", 142], ["described", 147], ["but", 157], ["their", 161], ["frequency", 167], [",", 176], ["nature", 178], ["and", 185], ["impact", 189], ["are", 196], ["poorly", 200], ["known", 207], [".", 212], ["We", 214], ["aimed", 217], ["to", 223], ["assess", 226], ["digestive", 233], ["features", 243], ["in", 252], ["a", 255], ["national", 257], ["cohort", 266], ["of", 273], ["EDS", 276], ["patients", 280], [".", 288], ["A", 290], ["questionnaire", 292], ["has", 306], ["been", 310], ["sent", 315], ["to", 320], ["212", 323], ["EDS", 327], ["patients", 331], ["through", 340], ["the", 348], ["French", 352], ["patient", 359], ["support", 367], ["group", 375], [",", 380], ["all", 382], ["of", 386], ["which", 389], ["had", 395], ["been", 399], ["formally", 404], ["diagnosed", 413], ["according", 423], ["to", 433], ["the", 436], ["Villefranche", 440], ["criteria", 453], [".", 461], ["The", 463], ["questionnaire", 467], ["included", 481], ["questions", 490], ["about", 500], ["digestive", 506], ["functional", 516], ["symptoms", 527], [",", 535], ["the", 537], ["GIQLI", 541], ["(", 547], ["Gastrointestinal", 548], ["Quality", 565], ["of", 573], ["Life", 576], ["Index", 581], [")", 586], [",", 587], ["KESS", 589], ["scoring", 594], ["system", 602], ["and", 609], ["the", 613], ["Rome", 617], ["III", 622], ["criteria", 626], [".", 634], ["Overall", 636], [",", 643], ["135", 645], ["patients", 649], ["(", 658], ["64", 659], ["%", 661], ["response", 663], ["rate", 672], [")", 676], ["completed", 678], ["the", 688], ["questionnaire", 692], ["and", 706], ["134", 710], ["were", 714], ["analyzable", 719], ["(", 730], ["123", 731], ["women", 735], [";", 740], ["91", 742], ["%", 744], [")", 745], [".", 746], ["Mean", 748], ["age", 753], ["and", 757], ["Body", 761], ["Mass", 766], ["Index", 771], ["were", 777], ["respectively", 782], ["35\u00b114.7", 795], ["years", 803], ["and", 809], ["24.3\u00b16.1", 813], ["kg", 822], ["/", 824], ["m(2", 825], [")", 828], [".", 829], ["The", 831], ["most", 835], ["common", 840], ["EDS", 847], ["subtype", 851], ["was", 859], ["hypermobility", 863], ["form", 877], ["(", 882], ["n=108", 883], [";", 888], ["80.6", 890], ["%", 894], [")", 895], [".", 896], ["GIQLI", 898], ["and", 904], ["KESS", 908], ["median", 913], ["values", 920], ["were", 927], ["respectively", 932], ["63.5", 945], ["(", 950], ["27", 951], ["-", 953], ["117", 954], [")", 957], ["and", 959], ["19", 963], ["[", 966], ["13.5", 967], ["-", 971], ["22].", 972], ["Eighty", 977], ["four", 984], ["percent", 989], ["of", 997], ["patients", 1000], ["had", 1009], ["functional", 1013], ["bowel", 1024], ["disorders", 1030], ["(", 1040], ["FBD", 1041], [")", 1044], ["according", 1046], ["to", 1056], ["the", 1059], ["Rome", 1063], ["III", 1068], ["criteria", 1072], [".", 1080], ["An", 1082], ["irritable", 1085], ["bowel", 1095], ["syndrome", 1101], ["according", 1110], ["to", 1120], ["the", 1123], ["same", 1127], ["criteria", 1132], ["was", 1141], ["observed", 1145], ["in", 1154], ["64", 1157], ["patients", 1160], ["(", 1169], ["48", 1170], ["%", 1172], [")", 1173], ["and", 1175], ["48", 1179], ["patients", 1182], ["(", 1191], ["36", 1192], ["%", 1194], [")", 1195], ["reported", 1197], ["functional", 1206], ["constipation", 1217], [".", 1229], ["A", 1231], ["gastro", 1233], ["-", 1239], ["esophageal", 1240], ["reflux", 1251], ["disease", 1258], ["(", 1266], ["GERD", 1267], [")", 1271], ["was", 1273], ["reported", 1277], ["in", 1286], ["90", 1289], ["patients", 1292], ["(", 1301], ["68.7", 1302], ["%", 1306], [")", 1307], [",", 1308], ["significantly", 1310], ["associated", 1324], ["with", 1335], ["a", 1340], ["poorer", 1342], ["GIQLI", 1349], ["(", 1355], ["60.5\u00b116.8", 1356], ["versus", 1366], ["75.9\u00b120.3", 1373], [";", 1382], ["p<0.0001", 1384], [")", 1392], [".", 1393], ["GIQLI", 1395], ["was", 1401], ["also", 1405], ["negatively", 1410], ["impacted", 1421], ["by", 1430], ["the", 1433], ["presence", 1437], ["of", 1446], ["an", 1449], ["irritable", 1452], ["bowel", 1462], ["syndrome", 1468], ["or", 1477], ["functional", 1480], ["constipation", 1491], ["(", 1504], ["p=0.007", 1505], [")", 1512], [".", 1513], ["There", 1515], ["was", 1521], ["a", 1525], ["significant", 1527], ["correlation", 1539], ["between", 1551], ["FBD", 1559], ["and", 1563], ["GERD", 1567], [".", 1571], ["Natural", 1573], ["frequency", 1581], ["of", 1591], ["gastrointestinal", 1594], ["manifestations", 1611], ["in", 1626], ["EDS", 1629], ["seems", 1633], ["higher", 1639], ["than", 1646], ["previously", 1651], ["assessed", 1662], [".", 1670], ["FBD", 1672], ["and", 1676], ["GERD", 1680], ["are", 1685], ["very", 1689], ["common", 1694], ["in", 1701], ["our", 1704], ["study", 1708], ["population", 1714], [",", 1724], ["the", 1726], ["largest", 1730], ["ever", 1738], ["published", 1743], ["until", 1753], ["now", 1759], [".", 1762], ["Their", 1764], ["impact", 1770], ["is", 1777], ["herein", 1780], ["shown", 1787], ["to", 1793], ["be", 1796], ["important", 1799], [".", 1808], ["A", 1810], ["systematic", 1812], ["clinical", 1823], ["assessment", 1832], ["of", 1843], ["digestive", 1846], ["features", 1856], ["should", 1865], ["be", 1872], ["recommended", 1875], ["in", 1887], ["EDS", 1890], [".", 1893]]}
{"context": "Myotonic dystrophy type 1 (DM1) is an autosomal dominant disorder, caused by an expansion of a CTG triplet repeat in the DMPK gene. The aims of the present study were to classify a cohort of children with DM1, to describe their neuropsychiatric problems and cognitive level, to estimate the size of the CTG expansion, and to correlate the molecular findings with the neuropsychiatric problems. Fifty-seven children and adolescents (26 females; 31 males) with DM1 (CTG repeats > 40) were included in the study. The following instruments were used: Autism Diagnostic Interview-Revised (ADI-R), 5-15, Griffiths Mental Development Scales, and the Wechsler Scales. Based on age at onset and presenting symptoms, the children were divided into four DM1 groups; severe congenital (n = 19), mild congenital (n = 18), childhood (n = 18), and classical DM1 (n = 2). Forty-nine percent had an autism spectrum disorder (ASD) and autistic disorder was the most common diagnosis present in 35% of the subjects. Eighty-six percent of the individuals with DM1 had mental retardation (MR), most of them moderate or severe MR. ASD was significantly correlated with the DM1 form; the more severe the form of DM1, the higher the frequency of ASD. The frequency of ASD increased with increasing CTG repeat expansions. ASD and/or other neuropsychiatric disorders such as attention deficit hyperactivity disorder, and Tourette's disorder were found in 54% of the total DM1 group. In conclusion, awareness of ASD comorbidity in DM1 is essential. Further studies are warranted to elucidate the molecular etiology causing neurodevelopmental symptoms such as ASD and MR in DM1.", "qas": [{"question": "How is myotonic dystrophy inherited?", "answers": ["autosomal dominant"], "qid": "d33ad3bcc29749269c3aa087a59610af", "question_tokens": [["How", 0], ["is", 4], ["myotonic", 7], ["dystrophy", 16], ["inherited", 26], ["?", 35]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[9, 10]], "char_spans": [[38, 55]]}]}], "context_tokens": [["Myotonic", 0], ["dystrophy", 9], ["type", 19], ["1", 24], ["(", 26], ["DM1", 27], [")", 30], ["is", 32], ["an", 35], ["autosomal", 38], ["dominant", 48], ["disorder", 57], [",", 65], ["caused", 67], ["by", 74], ["an", 77], ["expansion", 80], ["of", 90], ["a", 93], ["CTG", 95], ["triplet", 99], ["repeat", 107], ["in", 114], ["the", 117], ["DMPK", 121], ["gene", 126], [".", 130], ["The", 132], ["aims", 136], ["of", 141], ["the", 144], ["present", 148], ["study", 156], ["were", 162], ["to", 167], ["classify", 170], ["a", 179], ["cohort", 181], ["of", 188], ["children", 191], ["with", 200], ["DM1", 205], [",", 208], ["to", 210], ["describe", 213], ["their", 222], ["neuropsychiatric", 228], ["problems", 245], ["and", 254], ["cognitive", 258], ["level", 268], [",", 273], ["to", 275], ["estimate", 278], ["the", 287], ["size", 291], ["of", 296], ["the", 299], ["CTG", 303], ["expansion", 307], [",", 316], ["and", 318], ["to", 322], ["correlate", 325], ["the", 335], ["molecular", 339], ["findings", 349], ["with", 358], ["the", 363], ["neuropsychiatric", 367], ["problems", 384], [".", 392], ["Fifty", 394], ["-", 399], ["seven", 400], ["children", 406], ["and", 415], ["adolescents", 419], ["(", 431], ["26", 432], ["females", 435], [";", 442], ["31", 444], ["males", 447], [")", 452], ["with", 454], ["DM1", 459], ["(", 463], ["CTG", 464], ["repeats", 468], [">", 476], ["40", 478], [")", 480], ["were", 482], ["included", 487], ["in", 496], ["the", 499], ["study", 503], [".", 508], ["The", 510], ["following", 514], ["instruments", 524], ["were", 536], ["used", 541], [":", 545], ["Autism", 547], ["Diagnostic", 554], ["Interview", 565], ["-", 574], ["Revised", 575], ["(", 583], ["ADI", 584], ["-", 587], ["R", 588], [")", 589], [",", 590], ["5", 592], ["-", 593], ["15", 594], [",", 596], ["Griffiths", 598], ["Mental", 608], ["Development", 615], ["Scales", 627], [",", 633], ["and", 635], ["the", 639], ["Wechsler", 643], ["Scales", 652], [".", 658], ["Based", 660], ["on", 666], ["age", 669], ["at", 673], ["onset", 676], ["and", 682], ["presenting", 686], ["symptoms", 697], [",", 705], ["the", 707], ["children", 711], ["were", 720], ["divided", 725], ["into", 733], ["four", 738], ["DM1", 743], ["groups", 747], [";", 753], ["severe", 755], ["congenital", 762], ["(", 773], ["n", 774], ["=", 776], ["19", 778], [")", 780], [",", 781], ["mild", 783], ["congenital", 788], ["(", 799], ["n", 800], ["=", 802], ["18", 804], [")", 806], [",", 807], ["childhood", 809], ["(", 819], ["n", 820], ["=", 822], ["18", 824], [")", 826], [",", 827], ["and", 829], ["classical", 833], ["DM1", 843], ["(", 847], ["n", 848], ["=", 850], ["2", 852], [")", 853], [".", 854], ["Forty", 856], ["-", 861], ["nine", 862], ["percent", 867], ["had", 875], ["an", 879], ["autism", 882], ["spectrum", 889], ["disorder", 898], ["(", 907], ["ASD", 908], [")", 911], ["and", 913], ["autistic", 917], ["disorder", 926], ["was", 935], ["the", 939], ["most", 943], ["common", 948], ["diagnosis", 955], ["present", 965], ["in", 973], ["35", 976], ["%", 978], ["of", 980], ["the", 983], ["subjects", 987], [".", 995], ["Eighty", 997], ["-", 1003], ["six", 1004], ["percent", 1008], ["of", 1016], ["the", 1019], ["individuals", 1023], ["with", 1035], ["DM1", 1040], ["had", 1044], ["mental", 1048], ["retardation", 1055], ["(", 1067], ["MR", 1068], [")", 1070], [",", 1071], ["most", 1073], ["of", 1078], ["them", 1081], ["moderate", 1086], ["or", 1095], ["severe", 1098], ["MR", 1105], [".", 1107], ["ASD", 1109], ["was", 1113], ["significantly", 1117], ["correlated", 1131], ["with", 1142], ["the", 1147], ["DM1", 1151], ["form", 1155], [";", 1159], ["the", 1161], ["more", 1165], ["severe", 1170], ["the", 1177], ["form", 1181], ["of", 1186], ["DM1", 1189], [",", 1192], ["the", 1194], ["higher", 1198], ["the", 1205], ["frequency", 1209], ["of", 1219], ["ASD", 1222], [".", 1225], ["The", 1227], ["frequency", 1231], ["of", 1241], ["ASD", 1244], ["increased", 1248], ["with", 1258], ["increasing", 1263], ["CTG", 1274], ["repeat", 1278], ["expansions", 1285], [".", 1295], ["ASD", 1297], ["and/or", 1301], ["other", 1308], ["neuropsychiatric", 1314], ["disorders", 1331], ["such", 1341], ["as", 1346], ["attention", 1349], ["deficit", 1359], ["hyperactivity", 1367], ["disorder", 1381], [",", 1389], ["and", 1391], ["Tourette", 1395], ["'s", 1403], ["disorder", 1406], ["were", 1415], ["found", 1420], ["in", 1426], ["54", 1429], ["%", 1431], ["of", 1433], ["the", 1436], ["total", 1440], ["DM1", 1446], ["group", 1450], [".", 1455], ["In", 1457], ["conclusion", 1460], [",", 1470], ["awareness", 1472], ["of", 1482], ["ASD", 1485], ["comorbidity", 1489], ["in", 1501], ["DM1", 1504], ["is", 1508], ["essential", 1511], [".", 1520], ["Further", 1522], ["studies", 1530], ["are", 1538], ["warranted", 1542], ["to", 1552], ["elucidate", 1555], ["the", 1565], ["molecular", 1569], ["etiology", 1579], ["causing", 1588], ["neurodevelopmental", 1596], ["symptoms", 1615], ["such", 1624], ["as", 1629], ["ASD", 1632], ["and", 1636], ["MR", 1640], ["in", 1643], ["DM1", 1646], [".", 1649]]}
{"context": "Many neurodegenerative diseases are associated with the aggregation of misfolded proteins into amyloid oligomers or fibrils that are deposited as pathological lesions within areas of the brain. An attractive therapeutic strategy for preventing or ameliorating amyloid formation is to identify agents that inhibit the onset or propagation of protein aggregation. Here we demonstrate how solid-state nuclear magnetic resonance (ssNMR) may be used to identify key residues within amyloidogenic protein sequences that may be targeted to inhibit the aggregation of the host protein. For alpha-synuclein, the major protein component of Lewy bodies associated with Parkinson's disease, we have used a combination of ssNMR and biochemical data to identify the key region for self-aggregation of the protein as residues 77-82 (VAQKTV). We used our new structural information to design a peptide derived from residues 77 to 82 of alpha-synuclein with an N-methyl group at the C-terminal residue, which was able to disrupt the aggregation of alpha-synuclein. Thus, we have shown how structural data obtained from ssNMR can guide the design of modified peptides for use as amyloid inhibitors, as a primary step toward developing therapeutic compounds for prevention and/or treatment of amyloid diseases.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "ec3fbfeea1b541fd86801d3f230fe7ac", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[179, 181], [90, 92], [155, 157]], "char_spans": [[1031, 1045], [582, 596], [920, 934]]}]}], "context_tokens": [["Many", 0], ["neurodegenerative", 5], ["diseases", 23], ["are", 32], ["associated", 36], ["with", 47], ["the", 52], ["aggregation", 56], ["of", 68], ["misfolded", 71], ["proteins", 81], ["into", 90], ["amyloid", 95], ["oligomers", 103], ["or", 113], ["fibrils", 116], ["that", 124], ["are", 129], ["deposited", 133], ["as", 143], ["pathological", 146], ["lesions", 159], ["within", 167], ["areas", 174], ["of", 180], ["the", 183], ["brain", 187], [".", 192], ["An", 194], ["attractive", 197], ["therapeutic", 208], ["strategy", 220], ["for", 229], ["preventing", 233], ["or", 244], ["ameliorating", 247], ["amyloid", 260], ["formation", 268], ["is", 278], ["to", 281], ["identify", 284], ["agents", 293], ["that", 300], ["inhibit", 305], ["the", 313], ["onset", 317], ["or", 323], ["propagation", 326], ["of", 338], ["protein", 341], ["aggregation", 349], [".", 360], ["Here", 362], ["we", 367], ["demonstrate", 370], ["how", 382], ["solid", 386], ["-", 391], ["state", 392], ["nuclear", 398], ["magnetic", 406], ["resonance", 415], ["(", 425], ["ssNMR", 426], [")", 431], ["may", 433], ["be", 437], ["used", 440], ["to", 445], ["identify", 448], ["key", 457], ["residues", 461], ["within", 470], ["amyloidogenic", 477], ["protein", 491], ["sequences", 499], ["that", 509], ["may", 514], ["be", 518], ["targeted", 521], ["to", 530], ["inhibit", 533], ["the", 541], ["aggregation", 545], ["of", 557], ["the", 560], ["host", 564], ["protein", 569], [".", 576], ["For", 578], ["alpha", 582], ["-", 587], ["synuclein", 588], [",", 597], ["the", 599], ["major", 603], ["protein", 609], ["component", 617], ["of", 627], ["Lewy", 630], ["bodies", 635], ["associated", 642], ["with", 653], ["Parkinson", 658], ["'s", 667], ["disease", 670], [",", 677], ["we", 679], ["have", 682], ["used", 687], ["a", 692], ["combination", 694], ["of", 706], ["ssNMR", 709], ["and", 715], ["biochemical", 719], ["data", 731], ["to", 736], ["identify", 739], ["the", 748], ["key", 752], ["region", 756], ["for", 763], ["self", 767], ["-", 771], ["aggregation", 772], ["of", 784], ["the", 787], ["protein", 791], ["as", 799], ["residues", 802], ["77", 811], ["-", 813], ["82", 814], ["(", 817], ["VAQKTV", 818], [")", 824], [".", 825], ["We", 827], ["used", 830], ["our", 835], ["new", 839], ["structural", 843], ["information", 854], ["to", 866], ["design", 869], ["a", 876], ["peptide", 878], ["derived", 886], ["from", 894], ["residues", 899], ["77", 908], ["to", 911], ["82", 914], ["of", 917], ["alpha", 920], ["-", 925], ["synuclein", 926], ["with", 936], ["an", 941], ["N", 944], ["-", 945], ["methyl", 946], ["group", 953], ["at", 959], ["the", 962], ["C", 966], ["-", 967], ["terminal", 968], ["residue", 977], [",", 984], ["which", 986], ["was", 992], ["able", 996], ["to", 1001], ["disrupt", 1004], ["the", 1012], ["aggregation", 1016], ["of", 1028], ["alpha", 1031], ["-", 1036], ["synuclein", 1037], [".", 1046], ["Thus", 1048], [",", 1052], ["we", 1054], ["have", 1057], ["shown", 1062], ["how", 1068], ["structural", 1072], ["data", 1083], ["obtained", 1088], ["from", 1097], ["ssNMR", 1102], ["can", 1108], ["guide", 1112], ["the", 1118], ["design", 1122], ["of", 1129], ["modified", 1132], ["peptides", 1141], ["for", 1150], ["use", 1154], ["as", 1158], ["amyloid", 1161], ["inhibitors", 1169], [",", 1179], ["as", 1181], ["a", 1184], ["primary", 1186], ["step", 1194], ["toward", 1199], ["developing", 1206], ["therapeutic", 1217], ["compounds", 1229], ["for", 1239], ["prevention", 1243], ["and/or", 1254], ["treatment", 1261], ["of", 1271], ["amyloid", 1274], ["diseases", 1282], [".", 1290]]}
{"context": "Selenium (Se) is an essential trace element primarily found in selenoproteins as the 21st amino acid (selenocysteine, Sec, or U). Selenoproteins play an important role in growth and proliferation and are typically involved in cellular redox balance. Selenocysteine is encoded by an in-frame UGA codon specified by a stem-loop structure, the Sec insertion sequence element (SECIS), which, in eukaryotes, is located in the 3'-untranslated region (UTR). The availability of the Naegleria gruberi (ATCC 30224) genome sequence and the use of this organism as a model system for the pathogenic amoeba N. fowleri allowed us to investigate the Sec incorporation pathway in this primitive eukaryote. Using bioinformatics tools, we identified gene sequences encoding PSTK (O-phosphoseryl-tRNA(Sec) kinase), SepSecS (O-phosphoseryl-tRNA:selenocysteinyl-tRNA synthase), SelD/SPS2 (selenophosphate synthetase), EFSec (selenocysteine-specific elongation factor) and SBP (SECIS binding protein). These findings were confirmed by RT-PCR and by sequencing. A potential tRNA(Ser)Sec (SelC) gene and a putative selenoprotein with sequence similarity to a mitochondrial thioredoxin reductase (TR3) were also identified. Our results show that the selenocysteine incorporation machinery is indeed present in N. gruberi. Interestingly, the SelD/SPS2 gene is 2214 bp in length and contains two distinct domains. The N-terminal region shows sequence similarity to predicted methyltransferase proteins, and the C-terminal region is homologous to prokaryotic SelD/SPS2. Our results suggest the possibility of novel selenoproteins.", "qas": [{"question": "What is the name of the stem loop present in the 3' end of genes encoding for selenoproteins?", "answers": ["SECIS"], "qid": "0c52975c66384d66a1af964bd53fdfc5", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["stem", 24], ["loop", 29], ["present", 34], ["in", 42], ["the", 45], ["3", 49], ["'", 50], ["end", 52], ["of", 56], ["genes", 59], ["encoding", 65], ["for", 74], ["selenoproteins", 78], ["?", 92]], "detected_answers": [{"text": "SECIS", "token_spans": [[181, 181], [69, 69]], "char_spans": [[957, 961], [373, 377]]}]}], "context_tokens": [["Selenium", 0], ["(", 9], ["Se", 10], [")", 12], ["is", 14], ["an", 17], ["essential", 20], ["trace", 30], ["element", 36], ["primarily", 44], ["found", 54], ["in", 60], ["selenoproteins", 63], ["as", 78], ["the", 81], ["21st", 85], ["amino", 90], ["acid", 96], ["(", 101], ["selenocysteine", 102], [",", 116], ["Sec", 118], [",", 121], ["or", 123], ["U", 126], [")", 127], [".", 128], ["Selenoproteins", 130], ["play", 145], ["an", 150], ["important", 153], ["role", 163], ["in", 168], ["growth", 171], ["and", 178], ["proliferation", 182], ["and", 196], ["are", 200], ["typically", 204], ["involved", 214], ["in", 223], ["cellular", 226], ["redox", 235], ["balance", 241], [".", 248], ["Selenocysteine", 250], ["is", 265], ["encoded", 268], ["by", 276], ["an", 279], ["in", 282], ["-", 284], ["frame", 285], ["UGA", 291], ["codon", 295], ["specified", 301], ["by", 311], ["a", 314], ["stem", 316], ["-", 320], ["loop", 321], ["structure", 326], [",", 335], ["the", 337], ["Sec", 341], ["insertion", 345], ["sequence", 355], ["element", 364], ["(", 372], ["SECIS", 373], [")", 378], [",", 379], ["which", 381], [",", 386], ["in", 388], ["eukaryotes", 391], [",", 401], ["is", 403], ["located", 406], ["in", 414], ["the", 417], ["3'-untranslated", 421], ["region", 437], ["(", 444], ["UTR", 445], [")", 448], [".", 449], ["The", 451], ["availability", 455], ["of", 468], ["the", 471], ["Naegleria", 475], ["gruberi", 485], ["(", 493], ["ATCC", 494], ["30224", 499], [")", 504], ["genome", 506], ["sequence", 513], ["and", 522], ["the", 526], ["use", 530], ["of", 534], ["this", 537], ["organism", 542], ["as", 551], ["a", 554], ["model", 556], ["system", 562], ["for", 569], ["the", 573], ["pathogenic", 577], ["amoeba", 588], ["N.", 595], ["fowleri", 598], ["allowed", 606], ["us", 614], ["to", 617], ["investigate", 620], ["the", 632], ["Sec", 636], ["incorporation", 640], ["pathway", 654], ["in", 662], ["this", 665], ["primitive", 670], ["eukaryote", 680], [".", 689], ["Using", 691], ["bioinformatics", 697], ["tools", 712], [",", 717], ["we", 719], ["identified", 722], ["gene", 733], ["sequences", 738], ["encoding", 748], ["PSTK", 757], ["(", 762], ["O", 763], ["-", 764], ["phosphoseryl", 765], ["-", 777], ["tRNA(Sec", 778], [")", 786], ["kinase", 788], [")", 794], [",", 795], ["SepSecS", 797], ["(", 805], ["O", 806], ["-", 807], ["phosphoseryl", 808], ["-", 820], ["tRNA", 821], [":", 825], ["selenocysteinyl", 826], ["-", 841], ["tRNA", 842], ["synthase", 847], [")", 855], [",", 856], ["SelD", 858], ["/", 862], ["SPS2", 863], ["(", 868], ["selenophosphate", 869], ["synthetase", 885], [")", 895], [",", 896], ["EFSec", 898], ["(", 904], ["selenocysteine", 905], ["-", 919], ["specific", 920], ["elongation", 929], ["factor", 940], [")", 946], ["and", 948], ["SBP", 952], ["(", 956], ["SECIS", 957], ["binding", 963], ["protein", 971], [")", 978], [".", 979], ["These", 981], ["findings", 987], ["were", 996], ["confirmed", 1001], ["by", 1011], ["RT", 1014], ["-", 1016], ["PCR", 1017], ["and", 1021], ["by", 1025], ["sequencing", 1028], [".", 1038], ["A", 1040], ["potential", 1042], ["tRNA(Ser)Sec", 1052], ["(", 1065], ["SelC", 1066], [")", 1070], ["gene", 1072], ["and", 1077], ["a", 1081], ["putative", 1083], ["selenoprotein", 1092], ["with", 1106], ["sequence", 1111], ["similarity", 1120], ["to", 1131], ["a", 1134], ["mitochondrial", 1136], ["thioredoxin", 1150], ["reductase", 1162], ["(", 1172], ["TR3", 1173], [")", 1176], ["were", 1178], ["also", 1183], ["identified", 1188], [".", 1198], ["Our", 1200], ["results", 1204], ["show", 1212], ["that", 1217], ["the", 1222], ["selenocysteine", 1226], ["incorporation", 1241], ["machinery", 1255], ["is", 1265], ["indeed", 1268], ["present", 1275], ["in", 1283], ["N.", 1286], ["gruberi", 1289], [".", 1296], ["Interestingly", 1298], [",", 1311], ["the", 1313], ["SelD", 1317], ["/", 1321], ["SPS2", 1322], ["gene", 1327], ["is", 1332], ["2214", 1335], ["bp", 1340], ["in", 1343], ["length", 1346], ["and", 1353], ["contains", 1357], ["two", 1366], ["distinct", 1370], ["domains", 1379], [".", 1386], ["The", 1388], ["N", 1392], ["-", 1393], ["terminal", 1394], ["region", 1403], ["shows", 1410], ["sequence", 1416], ["similarity", 1425], ["to", 1436], ["predicted", 1439], ["methyltransferase", 1449], ["proteins", 1467], [",", 1475], ["and", 1477], ["the", 1481], ["C", 1485], ["-", 1486], ["terminal", 1487], ["region", 1496], ["is", 1503], ["homologous", 1506], ["to", 1517], ["prokaryotic", 1520], ["SelD", 1532], ["/", 1536], ["SPS2", 1537], [".", 1541], ["Our", 1543], ["results", 1547], ["suggest", 1555], ["the", 1563], ["possibility", 1567], ["of", 1579], ["novel", 1582], ["selenoproteins", 1588], [".", 1602]]}
{"context": "The management of de Quervain's disease (DD) is nonoperative in the first instance, but surgery should be considered if conservative measures fail. We present the long-term results of operative treatment of DD. From July 1988 to July 1998, 94 consecutive patients with DD were treated operatively by a single surgeon. There were 80 women and 14 men. Average age at the time of operation was 47.4 years (range 22-76). The right wrist was involved in 43 cases, the left in 51 cases. All operations were done under tourniquet control with local infiltration anaesthesia using a longitudinal incision and partial resection of the extensor ligament. There were six perioperative complications, including one superficial wound infection, one delayed wound healing, and four transient lesions of the radial nerve. A successful outcome was achieved in all cases with negative Finkelstein's test. Simple decompression of both tendons and partial resection of the extensor ligament with a maximum of 3 mm can be recommended in operative treatment of DD with excellent long-term results.", "qas": [{"question": "Which disease is diagnosed using the Finkelstein's test?", "answers": ["de Quervain's disease"], "qid": "94956aa6f46c40d6942aab9ac607436f", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["diagnosed", 17], ["using", 27], ["the", 33], ["Finkelstein", 37], ["'s", 48], ["test", 51], ["?", 55]], "detected_answers": [{"text": "de Quervain's disease", "token_spans": [[3, 6]], "char_spans": [[18, 38]]}]}], "context_tokens": [["The", 0], ["management", 4], ["of", 15], ["de", 18], ["Quervain", 21], ["'s", 29], ["disease", 32], ["(", 40], ["DD", 41], [")", 43], ["is", 45], ["nonoperative", 48], ["in", 61], ["the", 64], ["first", 68], ["instance", 74], [",", 82], ["but", 84], ["surgery", 88], ["should", 96], ["be", 103], ["considered", 106], ["if", 117], ["conservative", 120], ["measures", 133], ["fail", 142], [".", 146], ["We", 148], ["present", 151], ["the", 159], ["long", 163], ["-", 167], ["term", 168], ["results", 173], ["of", 181], ["operative", 184], ["treatment", 194], ["of", 204], ["DD", 207], [".", 209], ["From", 211], ["July", 216], ["1988", 221], ["to", 226], ["July", 229], ["1998", 234], [",", 238], ["94", 240], ["consecutive", 243], ["patients", 255], ["with", 264], ["DD", 269], ["were", 272], ["treated", 277], ["operatively", 285], ["by", 297], ["a", 300], ["single", 302], ["surgeon", 309], [".", 316], ["There", 318], ["were", 324], ["80", 329], ["women", 332], ["and", 338], ["14", 342], ["men", 345], [".", 348], ["Average", 350], ["age", 358], ["at", 362], ["the", 365], ["time", 369], ["of", 374], ["operation", 377], ["was", 387], ["47.4", 391], ["years", 396], ["(", 402], ["range", 403], ["22", 409], ["-", 411], ["76", 412], [")", 414], [".", 415], ["The", 417], ["right", 421], ["wrist", 427], ["was", 433], ["involved", 437], ["in", 446], ["43", 449], ["cases", 452], [",", 457], ["the", 459], ["left", 463], ["in", 468], ["51", 471], ["cases", 474], [".", 479], ["All", 481], ["operations", 485], ["were", 496], ["done", 501], ["under", 506], ["tourniquet", 512], ["control", 523], ["with", 531], ["local", 536], ["infiltration", 542], ["anaesthesia", 555], ["using", 567], ["a", 573], ["longitudinal", 575], ["incision", 588], ["and", 597], ["partial", 601], ["resection", 609], ["of", 619], ["the", 622], ["extensor", 626], ["ligament", 635], [".", 643], ["There", 645], ["were", 651], ["six", 656], ["perioperative", 660], ["complications", 674], [",", 687], ["including", 689], ["one", 699], ["superficial", 703], ["wound", 715], ["infection", 721], [",", 730], ["one", 732], ["delayed", 736], ["wound", 744], ["healing", 750], [",", 757], ["and", 759], ["four", 763], ["transient", 768], ["lesions", 778], ["of", 786], ["the", 789], ["radial", 793], ["nerve", 800], [".", 805], ["A", 807], ["successful", 809], ["outcome", 820], ["was", 828], ["achieved", 832], ["in", 841], ["all", 844], ["cases", 848], ["with", 854], ["negative", 859], ["Finkelstein", 868], ["'s", 879], ["test", 882], [".", 886], ["Simple", 888], ["decompression", 895], ["of", 909], ["both", 912], ["tendons", 917], ["and", 925], ["partial", 929], ["resection", 937], ["of", 947], ["the", 950], ["extensor", 954], ["ligament", 963], ["with", 972], ["a", 977], ["maximum", 979], ["of", 987], ["3", 990], ["mm", 992], ["can", 995], ["be", 999], ["recommended", 1002], ["in", 1014], ["operative", 1017], ["treatment", 1027], ["of", 1037], ["DD", 1040], ["with", 1043], ["excellent", 1048], ["long", 1058], ["-", 1062], ["term", 1063], ["results", 1068], [".", 1075]]}
{"context": "Transcription-coupled repair (TCR) is a subpathway of nucleotide excision repair (NER) that acts specifically on lesions in the transcribed strand of expressed genes. First reported in mammalian cells, TCR was then documented in Escherichia coli. In this organism, an RNA polymerase arrested at a lesion is displaced by the transcription repair coupling factor, Mfd. This protein recruits the NER lesion-recognition factor UvrA, and then dissociates from the DNA. UvrA binds UvrB, and the assembled UvrAB* complex initiates repair. In mutants lacking active Mfd, TCR is absent. A gene transcribed by the bacteriophage T7 RNA polymerase in E. coli also requires Mfd for TCR. The CSB protein (missing or defective in cells of patients with Cockayne syndrome, complementation group B) is essential for TCR in humans. CSB and its homologs in higher eukaryotes are likely functional equivalents of Mfd.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "a9840cebbd6f4308916ff40aa8133f59", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[24, 25]], "char_spans": [[128, 145]]}]}], "context_tokens": [["Transcription", 0], ["-", 13], ["coupled", 14], ["repair", 22], ["(", 29], ["TCR", 30], [")", 33], ["is", 35], ["a", 38], ["subpathway", 40], ["of", 51], ["nucleotide", 54], ["excision", 65], ["repair", 74], ["(", 81], ["NER", 82], [")", 85], ["that", 87], ["acts", 92], ["specifically", 97], ["on", 110], ["lesions", 113], ["in", 121], ["the", 124], ["transcribed", 128], ["strand", 140], ["of", 147], ["expressed", 150], ["genes", 160], [".", 165], ["First", 167], ["reported", 173], ["in", 182], ["mammalian", 185], ["cells", 195], [",", 200], ["TCR", 202], ["was", 206], ["then", 210], ["documented", 215], ["in", 226], ["Escherichia", 229], ["coli", 241], [".", 245], ["In", 247], ["this", 250], ["organism", 255], [",", 263], ["an", 265], ["RNA", 268], ["polymerase", 272], ["arrested", 283], ["at", 292], ["a", 295], ["lesion", 297], ["is", 304], ["displaced", 307], ["by", 317], ["the", 320], ["transcription", 324], ["repair", 338], ["coupling", 345], ["factor", 354], [",", 360], ["Mfd", 362], [".", 365], ["This", 367], ["protein", 372], ["recruits", 380], ["the", 389], ["NER", 393], ["lesion", 397], ["-", 403], ["recognition", 404], ["factor", 416], ["UvrA", 423], [",", 427], ["and", 429], ["then", 433], ["dissociates", 438], ["from", 450], ["the", 455], ["DNA", 459], [".", 462], ["UvrA", 464], ["binds", 469], ["UvrB", 475], [",", 479], ["and", 481], ["the", 485], ["assembled", 489], ["UvrAB", 499], ["*", 504], ["complex", 506], ["initiates", 514], ["repair", 524], [".", 530], ["In", 532], ["mutants", 535], ["lacking", 543], ["active", 551], ["Mfd", 558], [",", 561], ["TCR", 563], ["is", 567], ["absent", 570], [".", 576], ["A", 578], ["gene", 580], ["transcribed", 585], ["by", 597], ["the", 600], ["bacteriophage", 604], ["T7", 618], ["RNA", 621], ["polymerase", 625], ["in", 636], ["E.", 639], ["coli", 642], ["also", 647], ["requires", 652], ["Mfd", 661], ["for", 665], ["TCR", 669], [".", 672], ["The", 674], ["CSB", 678], ["protein", 682], ["(", 690], ["missing", 691], ["or", 699], ["defective", 702], ["in", 712], ["cells", 715], ["of", 721], ["patients", 724], ["with", 733], ["Cockayne", 738], ["syndrome", 747], [",", 755], ["complementation", 757], ["group", 773], ["B", 779], [")", 780], ["is", 782], ["essential", 785], ["for", 795], ["TCR", 799], ["in", 803], ["humans", 806], [".", 812], ["CSB", 814], ["and", 818], ["its", 822], ["homologs", 826], ["in", 835], ["higher", 838], ["eukaryotes", 845], ["are", 856], ["likely", 860], ["functional", 867], ["equivalents", 878], ["of", 890], ["Mfd", 893], [".", 896]]}
{"context": "The actions of benzodiazepines are due to the potentiation of the neural inhibition that is mediated by gamma-aminobutyric acid (GABA). Practically all effects of the benzodiazepines result from their actions on the ionotropic GABA(A) receptors in the central nervous system. Benzodiazepines do not activate GABA(A) receptors directly but they require GABA. The main effects of benzodiazepines are sedation, hypnosis, decreased anxiety, anterograde amnesia, centrally mediated muscle relaxation and anti-convulsant activity. In addition to their action on the central nervous system, benzodiazepines have a dose-dependent ventilatory depressant effect and they also cause a modest reduction in arterial blood pressure and an increase in heart rate as a result of a decrease of systemic vascular resistance. The four benzodiazepines, widely used in clinical anaesthesia, are the agonists midazolam, diazepam and lorazepam and the antagonist flumazenil. Midazolam, diazepam and flumazenil are metabolized by cytochrome P450 (CYP) enzymes and by glucuronide conjugation whereas lorazepam directly undergoes glucuronide conjugation. CYP3A4 is important in the biotransformation of both midazolam and diazepam. CYP2C19 is important in the biotransformation of diazepam. Liver and renal dysfunction have only a minor effect on the pharmacokinetics of lorazepam but they slow down the elimination of the other benzodiazepines used in clinical anaesthesia. The duration of action of all benzodiazepines is strongly dependent on the duration of their administration. Based on clinical studies and computer simulations, midazolam has the shortest recovery profile followed by lorazepam and diazepam. Being metabolized by CYP enzymes, midazolam and diazepam have many clinically significant interactions with inhibitors and inducers of CYP3A4 and 2C19. In addition to pharmacokinetic interactions, benzodiazepines have synergistic interactions with other hypnotics and opioids. Midazolam, diazepam and lorazepam are widely used for sedation and to some extent also for induction and maintenance of anaesthesia. Flumazenil is very useful in reversing benzodiazepine-induced sedation as well as to diagnose or treat benzodiazepine overdose.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "0652e34262bc426d97340af838f8da7e", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[161, 161], [155, 155], [330, 330]], "char_spans": [[976, 985], [940, 949], [2100, 2109]]}]}], "context_tokens": [["The", 0], ["actions", 4], ["of", 12], ["benzodiazepines", 15], ["are", 31], ["due", 35], ["to", 39], ["the", 42], ["potentiation", 46], ["of", 59], ["the", 62], ["neural", 66], ["inhibition", 73], ["that", 84], ["is", 89], ["mediated", 92], ["by", 101], ["gamma", 104], ["-", 109], ["aminobutyric", 110], ["acid", 123], ["(", 128], ["GABA", 129], [")", 133], [".", 134], ["Practically", 136], ["all", 148], ["effects", 152], ["of", 160], ["the", 163], ["benzodiazepines", 167], ["result", 183], ["from", 190], ["their", 195], ["actions", 201], ["on", 209], ["the", 212], ["ionotropic", 216], ["GABA(A", 227], [")", 233], ["receptors", 235], ["in", 245], ["the", 248], ["central", 252], ["nervous", 260], ["system", 268], [".", 274], ["Benzodiazepines", 276], ["do", 292], ["not", 295], ["activate", 299], ["GABA(A", 308], [")", 314], ["receptors", 316], ["directly", 326], ["but", 335], ["they", 339], ["require", 344], ["GABA", 352], [".", 356], ["The", 358], ["main", 362], ["effects", 367], ["of", 375], ["benzodiazepines", 378], ["are", 394], ["sedation", 398], [",", 406], ["hypnosis", 408], [",", 416], ["decreased", 418], ["anxiety", 428], [",", 435], ["anterograde", 437], ["amnesia", 449], [",", 456], ["centrally", 458], ["mediated", 468], ["muscle", 477], ["relaxation", 484], ["and", 495], ["anti", 499], ["-", 503], ["convulsant", 504], ["activity", 515], [".", 523], ["In", 525], ["addition", 528], ["to", 537], ["their", 540], ["action", 546], ["on", 553], ["the", 556], ["central", 560], ["nervous", 568], ["system", 576], [",", 582], ["benzodiazepines", 584], ["have", 600], ["a", 605], ["dose", 607], ["-", 611], ["dependent", 612], ["ventilatory", 622], ["depressant", 634], ["effect", 645], ["and", 652], ["they", 656], ["also", 661], ["cause", 666], ["a", 672], ["modest", 674], ["reduction", 681], ["in", 691], ["arterial", 694], ["blood", 703], ["pressure", 709], ["and", 718], ["an", 722], ["increase", 725], ["in", 734], ["heart", 737], ["rate", 743], ["as", 748], ["a", 751], ["result", 753], ["of", 760], ["a", 763], ["decrease", 765], ["of", 774], ["systemic", 777], ["vascular", 786], ["resistance", 795], [".", 805], ["The", 807], ["four", 811], ["benzodiazepines", 816], [",", 831], ["widely", 833], ["used", 840], ["in", 845], ["clinical", 848], ["anaesthesia", 857], [",", 868], ["are", 870], ["the", 874], ["agonists", 878], ["midazolam", 887], [",", 896], ["diazepam", 898], ["and", 907], ["lorazepam", 911], ["and", 921], ["the", 925], ["antagonist", 929], ["flumazenil", 940], [".", 950], ["Midazolam", 952], [",", 961], ["diazepam", 963], ["and", 972], ["flumazenil", 976], ["are", 987], ["metabolized", 991], ["by", 1003], ["cytochrome", 1006], ["P450", 1017], ["(", 1022], ["CYP", 1023], [")", 1026], ["enzymes", 1028], ["and", 1036], ["by", 1040], ["glucuronide", 1043], ["conjugation", 1055], ["whereas", 1067], ["lorazepam", 1075], ["directly", 1085], ["undergoes", 1094], ["glucuronide", 1104], ["conjugation", 1116], [".", 1127], ["CYP3A4", 1129], ["is", 1136], ["important", 1139], ["in", 1149], ["the", 1152], ["biotransformation", 1156], ["of", 1174], ["both", 1177], ["midazolam", 1182], ["and", 1192], ["diazepam", 1196], [".", 1204], ["CYP2C19", 1206], ["is", 1214], ["important", 1217], ["in", 1227], ["the", 1230], ["biotransformation", 1234], ["of", 1252], ["diazepam", 1255], [".", 1263], ["Liver", 1265], ["and", 1271], ["renal", 1275], ["dysfunction", 1281], ["have", 1293], ["only", 1298], ["a", 1303], ["minor", 1305], ["effect", 1311], ["on", 1318], ["the", 1321], ["pharmacokinetics", 1325], ["of", 1342], ["lorazepam", 1345], ["but", 1355], ["they", 1359], ["slow", 1364], ["down", 1369], ["the", 1374], ["elimination", 1378], ["of", 1390], ["the", 1393], ["other", 1397], ["benzodiazepines", 1403], ["used", 1419], ["in", 1424], ["clinical", 1427], ["anaesthesia", 1436], [".", 1447], ["The", 1449], ["duration", 1453], ["of", 1462], ["action", 1465], ["of", 1472], ["all", 1475], ["benzodiazepines", 1479], ["is", 1495], ["strongly", 1498], ["dependent", 1507], ["on", 1517], ["the", 1520], ["duration", 1524], ["of", 1533], ["their", 1536], ["administration", 1542], [".", 1556], ["Based", 1558], ["on", 1564], ["clinical", 1567], ["studies", 1576], ["and", 1584], ["computer", 1588], ["simulations", 1597], [",", 1608], ["midazolam", 1610], ["has", 1620], ["the", 1624], ["shortest", 1628], ["recovery", 1637], ["profile", 1646], ["followed", 1654], ["by", 1663], ["lorazepam", 1666], ["and", 1676], ["diazepam", 1680], [".", 1688], ["Being", 1690], ["metabolized", 1696], ["by", 1708], ["CYP", 1711], ["enzymes", 1715], [",", 1722], ["midazolam", 1724], ["and", 1734], ["diazepam", 1738], ["have", 1747], ["many", 1752], ["clinically", 1757], ["significant", 1768], ["interactions", 1780], ["with", 1793], ["inhibitors", 1798], ["and", 1809], ["inducers", 1813], ["of", 1822], ["CYP3A4", 1825], ["and", 1832], ["2C19", 1836], [".", 1840], ["In", 1842], ["addition", 1845], ["to", 1854], ["pharmacokinetic", 1857], ["interactions", 1873], [",", 1885], ["benzodiazepines", 1887], ["have", 1903], ["synergistic", 1908], ["interactions", 1920], ["with", 1933], ["other", 1938], ["hypnotics", 1944], ["and", 1954], ["opioids", 1958], [".", 1965], ["Midazolam", 1967], [",", 1976], ["diazepam", 1978], ["and", 1987], ["lorazepam", 1991], ["are", 2001], ["widely", 2005], ["used", 2012], ["for", 2017], ["sedation", 2021], ["and", 2030], ["to", 2034], ["some", 2037], ["extent", 2042], ["also", 2049], ["for", 2054], ["induction", 2058], ["and", 2068], ["maintenance", 2072], ["of", 2084], ["anaesthesia", 2087], [".", 2098], ["Flumazenil", 2100], ["is", 2111], ["very", 2114], ["useful", 2119], ["in", 2126], ["reversing", 2129], ["benzodiazepine", 2139], ["-", 2153], ["induced", 2154], ["sedation", 2162], ["as", 2171], ["well", 2174], ["as", 2179], ["to", 2182], ["diagnose", 2185], ["or", 2194], ["treat", 2197], ["benzodiazepine", 2203], ["overdose", 2218], [".", 2226]]}
{"context": "The cytogenetic characteristic of Chronic Myeloid Leukemia (CML) is the formation of the Philadelphia chromosome gene product, BCR-ABL. Given that BCR-ABL is the specific target of Gleevec in CML treatment, we investigated the regulation of the catalytic component of telomerase, hTERT, by BCR-ABL at multiple levels in K562 cells. Molecular techniques such as over expression, knockdown, real-time PCR, immunoprecipitation, western blotting, reporter assay, confocal microscopy, telomerase assays and microarray were used to suggest that hTERT expression and activity is modulated by BCR-ABL at multiple levels. Our results suggest that BCR-ABL plays an important role in regulating hTERT in K562 (BCR-ABL positive human leukemia) cells. When Gleevec inhibited the tyrosine kinase activity of BCR-ABL, phosphorylation of hTERT was downregulated, therefore suggesting a positive correlation between BCR-ABL and hTERT. Gleevec treatment inhibited hTERT at mRNA level and significantly reduced telomerase activity (TA) in K562 cells, but not in HL60 or Jurkat cells (BCR-ABL negative cells). We also demonstrated that the transcription factor STAT5a plays a critical role in hTERT gene regulation in K562 cells. Knockdown of STAT5a, but not STAT5b, resulted in a marked downregulation of hTERT mRNA level, TA and hTERT protein level in K562 cells. Furthermore, translocation of hTERT from nucleoli to nucleoplasm was observed in K562 cells induced by Gleevec. Our data reveal that BCR-ABL can regulate TA at multiple levels, including transcription, post-translational level, and proper localization. Thus, suppression of cell growth and induction of apoptosis by Gleevec treatment may be partially due to TA inhibition. Additionally, we have identified STAT5a as critical mediator of the hTERT gene expression in BCR-ABL positive CML cells, suggesting that targeting STAT5a may be a promising therapeutic strategy for BCR-ABL positive CML patients.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "0641e4745b234652b621a99faaec9192", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[145, 147], [161, 163], [20, 22], [270, 272], [53, 55], [26, 28], [104, 106], [328, 330], [346, 348], [194, 196], [128, 130], [115, 117]], "char_spans": [[794, 800], [899, 905], [127, 133], [1479, 1485], [290, 296], [147, 153], [585, 591], [1812, 1818], [1917, 1923], [1065, 1071], [699, 705], [638, 644]]}]}], "context_tokens": [["The", 0], ["cytogenetic", 4], ["characteristic", 16], ["of", 31], ["Chronic", 34], ["Myeloid", 42], ["Leukemia", 50], ["(", 59], ["CML", 60], [")", 63], ["is", 65], ["the", 68], ["formation", 72], ["of", 82], ["the", 85], ["Philadelphia", 89], ["chromosome", 102], ["gene", 113], ["product", 118], [",", 125], ["BCR", 127], ["-", 130], ["ABL", 131], [".", 134], ["Given", 136], ["that", 142], ["BCR", 147], ["-", 150], ["ABL", 151], ["is", 155], ["the", 158], ["specific", 162], ["target", 171], ["of", 178], ["Gleevec", 181], ["in", 189], ["CML", 192], ["treatment", 196], [",", 205], ["we", 207], ["investigated", 210], ["the", 223], ["regulation", 227], ["of", 238], ["the", 241], ["catalytic", 245], ["component", 255], ["of", 265], ["telomerase", 268], [",", 278], ["hTERT", 280], [",", 285], ["by", 287], ["BCR", 290], ["-", 293], ["ABL", 294], ["at", 298], ["multiple", 301], ["levels", 310], ["in", 317], ["K562", 320], ["cells", 325], [".", 330], ["Molecular", 332], ["techniques", 342], ["such", 353], ["as", 358], ["over", 361], ["expression", 366], [",", 376], ["knockdown", 378], [",", 387], ["real", 389], ["-", 393], ["time", 394], ["PCR", 399], [",", 402], ["immunoprecipitation", 404], [",", 423], ["western", 425], ["blotting", 433], [",", 441], ["reporter", 443], ["assay", 452], [",", 457], ["confocal", 459], ["microscopy", 468], [",", 478], ["telomerase", 480], ["assays", 491], ["and", 498], ["microarray", 502], ["were", 513], ["used", 518], ["to", 523], ["suggest", 526], ["that", 534], ["hTERT", 539], ["expression", 545], ["and", 556], ["activity", 560], ["is", 569], ["modulated", 572], ["by", 582], ["BCR", 585], ["-", 588], ["ABL", 589], ["at", 593], ["multiple", 596], ["levels", 605], [".", 611], ["Our", 613], ["results", 617], ["suggest", 625], ["that", 633], ["BCR", 638], ["-", 641], ["ABL", 642], ["plays", 646], ["an", 652], ["important", 655], ["role", 665], ["in", 670], ["regulating", 673], ["hTERT", 684], ["in", 690], ["K562", 693], ["(", 698], ["BCR", 699], ["-", 702], ["ABL", 703], ["positive", 707], ["human", 716], ["leukemia", 722], [")", 730], ["cells", 732], [".", 737], ["When", 739], ["Gleevec", 744], ["inhibited", 752], ["the", 762], ["tyrosine", 766], ["kinase", 775], ["activity", 782], ["of", 791], ["BCR", 794], ["-", 797], ["ABL", 798], [",", 801], ["phosphorylation", 803], ["of", 819], ["hTERT", 822], ["was", 828], ["downregulated", 832], [",", 845], ["therefore", 847], ["suggesting", 857], ["a", 868], ["positive", 870], ["correlation", 879], ["between", 891], ["BCR", 899], ["-", 902], ["ABL", 903], ["and", 907], ["hTERT", 911], [".", 916], ["Gleevec", 918], ["treatment", 926], ["inhibited", 936], ["hTERT", 946], ["at", 952], ["mRNA", 955], ["level", 960], ["and", 966], ["significantly", 970], ["reduced", 984], ["telomerase", 992], ["activity", 1003], ["(", 1012], ["TA", 1013], [")", 1015], ["in", 1017], ["K562", 1020], ["cells", 1025], [",", 1030], ["but", 1032], ["not", 1036], ["in", 1040], ["HL60", 1043], ["or", 1048], ["Jurkat", 1051], ["cells", 1058], ["(", 1064], ["BCR", 1065], ["-", 1068], ["ABL", 1069], ["negative", 1073], ["cells", 1082], [")", 1087], [".", 1088], ["We", 1090], ["also", 1093], ["demonstrated", 1098], ["that", 1111], ["the", 1116], ["transcription", 1120], ["factor", 1134], ["STAT5a", 1141], ["plays", 1148], ["a", 1154], ["critical", 1156], ["role", 1165], ["in", 1170], ["hTERT", 1173], ["gene", 1179], ["regulation", 1184], ["in", 1195], ["K562", 1198], ["cells", 1203], [".", 1208], ["Knockdown", 1210], ["of", 1220], ["STAT5a", 1223], [",", 1229], ["but", 1231], ["not", 1235], ["STAT5b", 1239], [",", 1245], ["resulted", 1247], ["in", 1256], ["a", 1259], ["marked", 1261], ["downregulation", 1268], ["of", 1283], ["hTERT", 1286], ["mRNA", 1292], ["level", 1297], [",", 1302], ["TA", 1304], ["and", 1307], ["hTERT", 1311], ["protein", 1317], ["level", 1325], ["in", 1331], ["K562", 1334], ["cells", 1339], [".", 1344], ["Furthermore", 1346], [",", 1357], ["translocation", 1359], ["of", 1373], ["hTERT", 1376], ["from", 1382], ["nucleoli", 1387], ["to", 1396], ["nucleoplasm", 1399], ["was", 1411], ["observed", 1415], ["in", 1424], ["K562", 1427], ["cells", 1432], ["induced", 1438], ["by", 1446], ["Gleevec", 1449], [".", 1456], ["Our", 1458], ["data", 1462], ["reveal", 1467], ["that", 1474], ["BCR", 1479], ["-", 1482], ["ABL", 1483], ["can", 1487], ["regulate", 1491], ["TA", 1500], ["at", 1503], ["multiple", 1506], ["levels", 1515], [",", 1521], ["including", 1523], ["transcription", 1533], [",", 1546], ["post", 1548], ["-", 1552], ["translational", 1553], ["level", 1567], [",", 1572], ["and", 1574], ["proper", 1578], ["localization", 1585], [".", 1597], ["Thus", 1599], [",", 1603], ["suppression", 1605], ["of", 1617], ["cell", 1620], ["growth", 1625], ["and", 1632], ["induction", 1636], ["of", 1646], ["apoptosis", 1649], ["by", 1659], ["Gleevec", 1662], ["treatment", 1670], ["may", 1680], ["be", 1684], ["partially", 1687], ["due", 1697], ["to", 1701], ["TA", 1704], ["inhibition", 1707], [".", 1717], ["Additionally", 1719], [",", 1731], ["we", 1733], ["have", 1736], ["identified", 1741], ["STAT5a", 1752], ["as", 1759], ["critical", 1762], ["mediator", 1771], ["of", 1780], ["the", 1783], ["hTERT", 1787], ["gene", 1793], ["expression", 1798], ["in", 1809], ["BCR", 1812], ["-", 1815], ["ABL", 1816], ["positive", 1820], ["CML", 1829], ["cells", 1833], [",", 1838], ["suggesting", 1840], ["that", 1851], ["targeting", 1856], ["STAT5a", 1866], ["may", 1873], ["be", 1877], ["a", 1880], ["promising", 1882], ["therapeutic", 1892], ["strategy", 1904], ["for", 1913], ["BCR", 1917], ["-", 1920], ["ABL", 1921], ["positive", 1925], ["CML", 1934], ["patients", 1938], [".", 1946]]}
{"context": "Neurological abnormalities associated with spiculated, \"acanthocytic\" red cells in blood have been described as neuroacanthocytosis. This is a heterogeneous group of conditions that can be clearly subdivided on the basis of recent genetic findings. The McLeod Syndrome, one of the core neuroacanthocytosis syndromes, is a rare X-linked disorder caused by mutations of the XK gene, an X-chromosomal gene of unknown function characterized by haemopoietic abnormalities and late-onset neurological and muscular defects. We report two Chilean brothers with the McLeod phenotype who showed important psychiatric features. The diagnosis may be elusive if the presence of acanthocytosis is not properly studied. We describe a method which allowed the diagnosis that unmasked acanthocytosis. Otherwise the condition could have remained undiagnosed as it had been for decades in this family. This syndrome must be considered when assessing a familial movement disorder, specially affecting males with relevant psychiatric features. A reliable test for acanthocytosis assessment is available.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "c79bc1f8f85548358708cf9eb729f140", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[62, 62]], "char_spans": [[372, 373]]}]}], "context_tokens": [["Neurological", 0], ["abnormalities", 13], ["associated", 27], ["with", 38], ["spiculated", 43], [",", 53], ["\"", 55], ["acanthocytic", 56], ["\"", 68], ["red", 70], ["cells", 74], ["in", 80], ["blood", 83], ["have", 89], ["been", 94], ["described", 99], ["as", 109], ["neuroacanthocytosis", 112], [".", 131], ["This", 133], ["is", 138], ["a", 141], ["heterogeneous", 143], ["group", 157], ["of", 163], ["conditions", 166], ["that", 177], ["can", 182], ["be", 186], ["clearly", 189], ["subdivided", 197], ["on", 208], ["the", 211], ["basis", 215], ["of", 221], ["recent", 224], ["genetic", 231], ["findings", 239], [".", 247], ["The", 249], ["McLeod", 253], ["Syndrome", 260], [",", 268], ["one", 270], ["of", 274], ["the", 277], ["core", 281], ["neuroacanthocytosis", 286], ["syndromes", 306], [",", 315], ["is", 317], ["a", 320], ["rare", 322], ["X", 327], ["-", 328], ["linked", 329], ["disorder", 336], ["caused", 345], ["by", 352], ["mutations", 355], ["of", 365], ["the", 368], ["XK", 372], ["gene", 375], [",", 379], ["an", 381], ["X", 384], ["-", 385], ["chromosomal", 386], ["gene", 398], ["of", 403], ["unknown", 406], ["function", 414], ["characterized", 423], ["by", 437], ["haemopoietic", 440], ["abnormalities", 453], ["and", 467], ["late", 471], ["-", 475], ["onset", 476], ["neurological", 482], ["and", 495], ["muscular", 499], ["defects", 508], [".", 515], ["We", 517], ["report", 520], ["two", 527], ["Chilean", 531], ["brothers", 539], ["with", 548], ["the", 553], ["McLeod", 557], ["phenotype", 564], ["who", 574], ["showed", 578], ["important", 585], ["psychiatric", 595], ["features", 607], [".", 615], ["The", 617], ["diagnosis", 621], ["may", 631], ["be", 635], ["elusive", 638], ["if", 646], ["the", 649], ["presence", 653], ["of", 662], ["acanthocytosis", 665], ["is", 680], ["not", 683], ["properly", 687], ["studied", 696], [".", 703], ["We", 705], ["describe", 708], ["a", 717], ["method", 719], ["which", 726], ["allowed", 732], ["the", 740], ["diagnosis", 744], ["that", 754], ["unmasked", 759], ["acanthocytosis", 768], [".", 782], ["Otherwise", 784], ["the", 794], ["condition", 798], ["could", 808], ["have", 814], ["remained", 819], ["undiagnosed", 828], ["as", 840], ["it", 843], ["had", 846], ["been", 850], ["for", 855], ["decades", 859], ["in", 867], ["this", 870], ["family", 875], [".", 881], ["This", 883], ["syndrome", 888], ["must", 897], ["be", 902], ["considered", 905], ["when", 916], ["assessing", 921], ["a", 931], ["familial", 933], ["movement", 942], ["disorder", 951], [",", 959], ["specially", 961], ["affecting", 971], ["males", 981], ["with", 987], ["relevant", 992], ["psychiatric", 1001], ["features", 1013], [".", 1021], ["A", 1023], ["reliable", 1025], ["test", 1034], ["for", 1039], ["acanthocytosis", 1043], ["assessment", 1058], ["is", 1069], ["available", 1072], [".", 1081]]}
{"context": "High circulating levels of group IIA secretory phospholipase A2 (sPLA2-IIA) activity and mass are independent cardiovascular risk factors. Therefore, inhibition of sPLA2-IIA may be a target for the treatment of atherosclerotic cardiovascular disease. The present study evaluated the effects of sPLA2-IIA inhibition with varespladib acid in a novel mouse model, human apolipoprotein B (apoB)/human cholesteryl ester transfer protein (CETP)/human sPLA2-IIA triple transgenic mice (TTT) fed a Western-type diet. sPLA2-IIA expression increased atherosclerotic lesion formation in TTT compared with human apoB/human CETP double transgenic mice (P<0.01). Varespladib acid effectively inhibited plasma sPLA2-IIA activity. Surprisingly, however, administration of varespladib acid to TTT had no impact on atherosclerosis, which could be attributed to a proatherogenic plasma lipoprotein profile that appears in response to sPLA2-IIA inhibition because of increased plasma CETP activity. In the TTT model, sPLA2-IIA decreased CETP activity by reducing the acceptor properties of sPLA2-IIA-modified very low-density lipoproteins specifically because of a significantly lower apoE content. Increasing very low-density lipoprotein-apoE content by means of adenovirus-mediated gene transfer in sPLA2-IIA transgenic mice restored the acceptor properties for CETP. These data show that in a humanized triple transgenic mouse model with hypercholesterolemia, sPLA2-IIA inhibition increases CETP activity via increasing the very low-density lipoprotein-apoE content, resulting in a proatherogenic lipoprotein profile.", "qas": [{"question": "Which enzyme is inhibited by Varespladib?", "answers": ["secretory phospholipase A2"], "qid": "9f57803776af4b0bbe0deae68fbd40b0", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["Varespladib", 29], ["?", 40]], "detected_answers": [{"text": "secretory phospholipase A2", "token_spans": [[6, 8]], "char_spans": [[37, 62]]}]}], "context_tokens": [["High", 0], ["circulating", 5], ["levels", 17], ["of", 24], ["group", 27], ["IIA", 33], ["secretory", 37], ["phospholipase", 47], ["A2", 61], ["(", 64], ["sPLA2-IIA", 65], [")", 74], ["activity", 76], ["and", 85], ["mass", 89], ["are", 94], ["independent", 98], ["cardiovascular", 110], ["risk", 125], ["factors", 130], [".", 137], ["Therefore", 139], [",", 148], ["inhibition", 150], ["of", 161], ["sPLA2-IIA", 164], ["may", 174], ["be", 178], ["a", 181], ["target", 183], ["for", 190], ["the", 194], ["treatment", 198], ["of", 208], ["atherosclerotic", 211], ["cardiovascular", 227], ["disease", 242], [".", 249], ["The", 251], ["present", 255], ["study", 263], ["evaluated", 269], ["the", 279], ["effects", 283], ["of", 291], ["sPLA2-IIA", 294], ["inhibition", 304], ["with", 315], ["varespladib", 320], ["acid", 332], ["in", 337], ["a", 340], ["novel", 342], ["mouse", 348], ["model", 354], [",", 359], ["human", 361], ["apolipoprotein", 367], ["B", 382], ["(", 384], ["apoB)/human", 385], ["cholesteryl", 397], ["ester", 409], ["transfer", 415], ["protein", 424], ["(", 432], ["CETP)/human", 433], ["sPLA2-IIA", 445], ["triple", 455], ["transgenic", 462], ["mice", 473], ["(", 478], ["TTT", 479], [")", 482], ["fed", 484], ["a", 488], ["Western", 490], ["-", 497], ["type", 498], ["diet", 503], [".", 507], ["sPLA2-IIA", 509], ["expression", 519], ["increased", 530], ["atherosclerotic", 540], ["lesion", 556], ["formation", 563], ["in", 573], ["TTT", 576], ["compared", 580], ["with", 589], ["human", 594], ["apoB", 600], ["/", 604], ["human", 605], ["CETP", 611], ["double", 616], ["transgenic", 623], ["mice", 634], ["(", 639], ["P<0.01", 640], [")", 646], [".", 647], ["Varespladib", 649], ["acid", 661], ["effectively", 666], ["inhibited", 678], ["plasma", 688], ["sPLA2-IIA", 695], ["activity", 705], [".", 713], ["Surprisingly", 715], [",", 727], ["however", 729], [",", 736], ["administration", 738], ["of", 753], ["varespladib", 756], ["acid", 768], ["to", 773], ["TTT", 776], ["had", 780], ["no", 784], ["impact", 787], ["on", 794], ["atherosclerosis", 797], [",", 812], ["which", 814], ["could", 820], ["be", 826], ["attributed", 829], ["to", 840], ["a", 843], ["proatherogenic", 845], ["plasma", 860], ["lipoprotein", 867], ["profile", 879], ["that", 887], ["appears", 892], ["in", 900], ["response", 903], ["to", 912], ["sPLA2-IIA", 915], ["inhibition", 925], ["because", 936], ["of", 944], ["increased", 947], ["plasma", 957], ["CETP", 964], ["activity", 969], [".", 977], ["In", 979], ["the", 982], ["TTT", 986], ["model", 990], [",", 995], ["sPLA2-IIA", 997], ["decreased", 1007], ["CETP", 1017], ["activity", 1022], ["by", 1031], ["reducing", 1034], ["the", 1043], ["acceptor", 1047], ["properties", 1056], ["of", 1067], ["sPLA2-IIA", 1070], ["-", 1079], ["modified", 1080], ["very", 1089], ["low", 1094], ["-", 1097], ["density", 1098], ["lipoproteins", 1106], ["specifically", 1119], ["because", 1132], ["of", 1140], ["a", 1143], ["significantly", 1145], ["lower", 1159], ["apoE", 1165], ["content", 1170], [".", 1177], ["Increasing", 1179], ["very", 1190], ["low", 1195], ["-", 1198], ["density", 1199], ["lipoprotein", 1207], ["-", 1218], ["apoE", 1219], ["content", 1224], ["by", 1232], ["means", 1235], ["of", 1241], ["adenovirus", 1244], ["-", 1254], ["mediated", 1255], ["gene", 1264], ["transfer", 1269], ["in", 1278], ["sPLA2-IIA", 1281], ["transgenic", 1291], ["mice", 1302], ["restored", 1307], ["the", 1316], ["acceptor", 1320], ["properties", 1329], ["for", 1340], ["CETP", 1344], [".", 1348], ["These", 1350], ["data", 1356], ["show", 1361], ["that", 1366], ["in", 1371], ["a", 1374], ["humanized", 1376], ["triple", 1386], ["transgenic", 1393], ["mouse", 1404], ["model", 1410], ["with", 1416], ["hypercholesterolemia", 1421], [",", 1441], ["sPLA2-IIA", 1443], ["inhibition", 1453], ["increases", 1464], ["CETP", 1474], ["activity", 1479], ["via", 1488], ["increasing", 1492], ["the", 1503], ["very", 1507], ["low", 1512], ["-", 1515], ["density", 1516], ["lipoprotein", 1524], ["-", 1535], ["apoE", 1536], ["content", 1541], [",", 1548], ["resulting", 1550], ["in", 1560], ["a", 1563], ["proatherogenic", 1565], ["lipoprotein", 1580], ["profile", 1592], [".", 1599]]}
{"context": "Neurofibromatosis type 1 (NF1) is a common disorder of dysregulated tissue growth secondary to mutations in the tumor suppressor gene NF1. Pulmonary arterial hypertension (PAH) in patients with NF1 is hypothesized to be secondary to an underlying vasculopathy. We describe the entity we term NF1-associated PAH (NF1-PAH) in four new patients and update the data on four previously published reports of patients with PAH and NF1. We performed genetic testing of the bone morphogenic protein receptor 2 (BMPR2) gene, which mutated in 70% of patients with familial PAH and approximately 25% of patients with idiopathic PAH. We report, for the first time, pathologic findings in the autopsy-obtained lung of one patient with NF1-PAH. Patients with NF1-PAH have a generally poor long-term prognosis. In four patients, we observed the mosaic pattern of lung attenuation on a CT scan of the chest, a radiographic finding that can be consistent with an underlying vasculopathy. No mutations or rearrangements in the BMPR2 gene were found. We observed complex plexiform lesions in the one available autopsy specimen. Similar lesions are a hallmark of plexogenic pulmonary arteriopathy and are associated with several severe types of PAH. (Plexiform lesions should not be confused with plexiform neurofibromas, which are distinctive tumors seen in NF1.) Our findings suggest that NF1 should be considered as being \"associated with PAH as outlined in the Revised Clinical Classification of Pulmonary Hypertension. Understanding the mechanism of PAH in NF1 may inform the pathogenesis of PAH, NF1-PAH itself, and other NF1-associated vasculopathies. The pulmonary vasculature should now be included among the arterial beds affected by NF1 vasculopathy.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "d0289ed00e594970840413f51ee34e30", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[243, 243], [299, 299], [22, 22], [236, 236], [4, 4], [73, 73], [270, 270], [33, 33]], "char_spans": [[1370, 1372], [1723, 1725], [134, 136], [1338, 1340], [26, 28], [424, 426], [1541, 1543], [194, 196]]}]}], "context_tokens": [["Neurofibromatosis", 0], ["type", 18], ["1", 23], ["(", 25], ["NF1", 26], [")", 29], ["is", 31], ["a", 34], ["common", 36], ["disorder", 43], ["of", 52], ["dysregulated", 55], ["tissue", 68], ["growth", 75], ["secondary", 82], ["to", 92], ["mutations", 95], ["in", 105], ["the", 108], ["tumor", 112], ["suppressor", 118], ["gene", 129], ["NF1", 134], [".", 137], ["Pulmonary", 139], ["arterial", 149], ["hypertension", 158], ["(", 171], ["PAH", 172], [")", 175], ["in", 177], ["patients", 180], ["with", 189], ["NF1", 194], ["is", 198], ["hypothesized", 201], ["to", 214], ["be", 217], ["secondary", 220], ["to", 230], ["an", 233], ["underlying", 236], ["vasculopathy", 247], [".", 259], ["We", 261], ["describe", 264], ["the", 273], ["entity", 277], ["we", 284], ["term", 287], ["NF1-associated", 292], ["PAH", 307], ["(", 311], ["NF1-PAH", 312], [")", 319], ["in", 321], ["four", 324], ["new", 329], ["patients", 333], ["and", 342], ["update", 346], ["the", 353], ["data", 357], ["on", 362], ["four", 365], ["previously", 370], ["published", 381], ["reports", 391], ["of", 399], ["patients", 402], ["with", 411], ["PAH", 416], ["and", 420], ["NF1", 424], [".", 427], ["We", 429], ["performed", 432], ["genetic", 442], ["testing", 450], ["of", 458], ["the", 461], ["bone", 465], ["morphogenic", 470], ["protein", 482], ["receptor", 490], ["2", 499], ["(", 501], ["BMPR2", 502], [")", 507], ["gene", 509], [",", 513], ["which", 515], ["mutated", 521], ["in", 529], ["70", 532], ["%", 534], ["of", 536], ["patients", 539], ["with", 548], ["familial", 553], ["PAH", 562], ["and", 566], ["approximately", 570], ["25", 584], ["%", 586], ["of", 588], ["patients", 591], ["with", 600], ["idiopathic", 605], ["PAH", 616], [".", 619], ["We", 621], ["report", 624], [",", 630], ["for", 632], ["the", 636], ["first", 640], ["time", 646], [",", 650], ["pathologic", 652], ["findings", 663], ["in", 672], ["the", 675], ["autopsy", 679], ["-", 686], ["obtained", 687], ["lung", 696], ["of", 701], ["one", 704], ["patient", 708], ["with", 716], ["NF1-PAH", 721], [".", 728], ["Patients", 730], ["with", 739], ["NF1-PAH", 744], ["have", 752], ["a", 757], ["generally", 759], ["poor", 769], ["long", 774], ["-", 778], ["term", 779], ["prognosis", 784], [".", 793], ["In", 795], ["four", 798], ["patients", 803], [",", 811], ["we", 813], ["observed", 816], ["the", 825], ["mosaic", 829], ["pattern", 836], ["of", 844], ["lung", 847], ["attenuation", 852], ["on", 864], ["a", 867], ["CT", 869], ["scan", 872], ["of", 877], ["the", 880], ["chest", 884], [",", 889], ["a", 891], ["radiographic", 893], ["finding", 906], ["that", 914], ["can", 919], ["be", 923], ["consistent", 926], ["with", 937], ["an", 942], ["underlying", 945], ["vasculopathy", 956], [".", 968], ["No", 970], ["mutations", 973], ["or", 983], ["rearrangements", 986], ["in", 1001], ["the", 1004], ["BMPR2", 1008], ["gene", 1014], ["were", 1019], ["found", 1024], [".", 1029], ["We", 1031], ["observed", 1034], ["complex", 1043], ["plexiform", 1051], ["lesions", 1061], ["in", 1069], ["the", 1072], ["one", 1076], ["available", 1080], ["autopsy", 1090], ["specimen", 1098], [".", 1106], ["Similar", 1108], ["lesions", 1116], ["are", 1124], ["a", 1128], ["hallmark", 1130], ["of", 1139], ["plexogenic", 1142], ["pulmonary", 1153], ["arteriopathy", 1163], ["and", 1176], ["are", 1180], ["associated", 1184], ["with", 1195], ["several", 1200], ["severe", 1208], ["types", 1215], ["of", 1221], ["PAH", 1224], [".", 1227], ["(", 1229], ["Plexiform", 1230], ["lesions", 1240], ["should", 1248], ["not", 1255], ["be", 1259], ["confused", 1262], ["with", 1271], ["plexiform", 1276], ["neurofibromas", 1286], [",", 1299], ["which", 1301], ["are", 1307], ["distinctive", 1311], ["tumors", 1323], ["seen", 1330], ["in", 1335], ["NF1", 1338], [".", 1341], [")", 1342], ["Our", 1344], ["findings", 1348], ["suggest", 1357], ["that", 1365], ["NF1", 1370], ["should", 1374], ["be", 1381], ["considered", 1384], ["as", 1395], ["being", 1398], ["\"", 1404], ["associated", 1405], ["with", 1416], ["PAH", 1421], ["as", 1425], ["outlined", 1428], ["in", 1437], ["the", 1440], ["Revised", 1444], ["Clinical", 1452], ["Classification", 1461], ["of", 1476], ["Pulmonary", 1479], ["Hypertension", 1489], [".", 1501], ["Understanding", 1503], ["the", 1517], ["mechanism", 1521], ["of", 1531], ["PAH", 1534], ["in", 1538], ["NF1", 1541], ["may", 1545], ["inform", 1549], ["the", 1556], ["pathogenesis", 1560], ["of", 1573], ["PAH", 1576], [",", 1579], ["NF1-PAH", 1581], ["itself", 1589], [",", 1595], ["and", 1597], ["other", 1601], ["NF1-associated", 1607], ["vasculopathies", 1622], [".", 1636], ["The", 1638], ["pulmonary", 1642], ["vasculature", 1652], ["should", 1664], ["now", 1671], ["be", 1675], ["included", 1678], ["among", 1687], ["the", 1693], ["arterial", 1697], ["beds", 1706], ["affected", 1711], ["by", 1720], ["NF1", 1723], ["vasculopathy", 1727], [".", 1739]]}
{"context": "Reperfusion injury to tissue following an ischemic event occurs as a consequence of an acute inflammatory response that can cause significant morbidity and mortality. Components of both the innate (complement, immunoglobulin, monocytes, and neutrophils) and adaptive (B and T lymphocytes) immune systems have been demonstrated to mediate tissue injury. Spleen tyrosine kinase (Syk) is responsible for membrane-mediated signaling in various cell types including B lymphocytes, macrophages, and T cells. We investigated the ability of a small drug Syk inhibitor, R788, to protect mice against mesenteric ischemia-reperfusion (I/R)-induced local (intestine) and remote lung injury. Mice were fed with chow containing a Syk inhibitor for 6 days before the performance of intestinal I/R, which resulted in silencing of the expression of the active phosphorylated Syk. Syk inhibition significantly suppressed both local and remote lung injury. The beneficial effect was associated with reduced IgM and complement 3 deposition in the tissues and significant reduction of polymorphonuclear cell infiltration. Our data place Syk upstream of events leading to the binding of natural antibodies to the ischemia-conditioned tissues and urge the consideration of the use of Syk inhibitors in the prevention or improvement of tissue injury of organs exposed to ischemia or hypoperfusion.", "qas": [{"question": "Which enzyme is inhibited by a drug fostamatinib?", "answers": ["spleen tyrosine kinase"], "qid": "c39a985f3db547f193720f8ea9d1d8ff", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["a", 29], ["drug", 31], ["fostamatinib", 36], ["?", 48]], "detected_answers": [{"text": "spleen tyrosine kinase", "token_spans": [[58, 60]], "char_spans": [[353, 374]]}]}], "context_tokens": [["Reperfusion", 0], ["injury", 12], ["to", 19], ["tissue", 22], ["following", 29], ["an", 39], ["ischemic", 42], ["event", 51], ["occurs", 57], ["as", 64], ["a", 67], ["consequence", 69], ["of", 81], ["an", 84], ["acute", 87], ["inflammatory", 93], ["response", 106], ["that", 115], ["can", 120], ["cause", 124], ["significant", 130], ["morbidity", 142], ["and", 152], ["mortality", 156], [".", 165], ["Components", 167], ["of", 178], ["both", 181], ["the", 186], ["innate", 190], ["(", 197], ["complement", 198], [",", 208], ["immunoglobulin", 210], [",", 224], ["monocytes", 226], [",", 235], ["and", 237], ["neutrophils", 241], [")", 252], ["and", 254], ["adaptive", 258], ["(", 267], ["B", 268], ["and", 270], ["T", 274], ["lymphocytes", 276], [")", 287], ["immune", 289], ["systems", 296], ["have", 304], ["been", 309], ["demonstrated", 314], ["to", 327], ["mediate", 330], ["tissue", 338], ["injury", 345], [".", 351], ["Spleen", 353], ["tyrosine", 360], ["kinase", 369], ["(", 376], ["Syk", 377], [")", 380], ["is", 382], ["responsible", 385], ["for", 397], ["membrane", 401], ["-", 409], ["mediated", 410], ["signaling", 419], ["in", 429], ["various", 432], ["cell", 440], ["types", 445], ["including", 451], ["B", 461], ["lymphocytes", 463], [",", 474], ["macrophages", 476], [",", 487], ["and", 489], ["T", 493], ["cells", 495], [".", 500], ["We", 502], ["investigated", 505], ["the", 518], ["ability", 522], ["of", 530], ["a", 533], ["small", 535], ["drug", 541], ["Syk", 546], ["inhibitor", 550], [",", 559], ["R788", 561], [",", 565], ["to", 567], ["protect", 570], ["mice", 578], ["against", 583], ["mesenteric", 591], ["ischemia", 602], ["-", 610], ["reperfusion", 611], ["(", 623], ["I", 624], ["/", 625], ["R)-induced", 626], ["local", 637], ["(", 643], ["intestine", 644], [")", 653], ["and", 655], ["remote", 659], ["lung", 666], ["injury", 671], [".", 677], ["Mice", 679], ["were", 684], ["fed", 689], ["with", 693], ["chow", 698], ["containing", 703], ["a", 714], ["Syk", 716], ["inhibitor", 720], ["for", 730], ["6", 734], ["days", 736], ["before", 741], ["the", 748], ["performance", 752], ["of", 764], ["intestinal", 767], ["I", 778], ["/", 779], ["R", 780], [",", 781], ["which", 783], ["resulted", 789], ["in", 798], ["silencing", 801], ["of", 811], ["the", 814], ["expression", 818], ["of", 829], ["the", 832], ["active", 836], ["phosphorylated", 843], ["Syk", 858], [".", 861], ["Syk", 863], ["inhibition", 867], ["significantly", 878], ["suppressed", 892], ["both", 903], ["local", 908], ["and", 914], ["remote", 918], ["lung", 925], ["injury", 930], [".", 936], ["The", 938], ["beneficial", 942], ["effect", 953], ["was", 960], ["associated", 964], ["with", 975], ["reduced", 980], ["IgM", 988], ["and", 992], ["complement", 996], ["3", 1007], ["deposition", 1009], ["in", 1020], ["the", 1023], ["tissues", 1027], ["and", 1035], ["significant", 1039], ["reduction", 1051], ["of", 1061], ["polymorphonuclear", 1064], ["cell", 1082], ["infiltration", 1087], [".", 1099], ["Our", 1101], ["data", 1105], ["place", 1110], ["Syk", 1116], ["upstream", 1120], ["of", 1129], ["events", 1132], ["leading", 1139], ["to", 1147], ["the", 1150], ["binding", 1154], ["of", 1162], ["natural", 1165], ["antibodies", 1173], ["to", 1184], ["the", 1187], ["ischemia", 1191], ["-", 1199], ["conditioned", 1200], ["tissues", 1212], ["and", 1220], ["urge", 1224], ["the", 1229], ["consideration", 1233], ["of", 1247], ["the", 1250], ["use", 1254], ["of", 1258], ["Syk", 1261], ["inhibitors", 1265], ["in", 1276], ["the", 1279], ["prevention", 1283], ["or", 1294], ["improvement", 1297], ["of", 1309], ["tissue", 1312], ["injury", 1319], ["of", 1326], ["organs", 1329], ["exposed", 1336], ["to", 1344], ["ischemia", 1347], ["or", 1356], ["hypoperfusion", 1359], [".", 1372]]}
{"context": "p73 is a p53 family transcription factor. Due to the presence in the 5' flanking region of two promoters, there are two N-terminal variants, TAp73, which retains a fully active transactivation domain (TA), and \u0394Np73, in which the N terminus is truncated. In addition, extensive 3' splicing gives rise to at least seven distinctive isoforms; TAp73-selective knockout highlights its role as a regulator of cell death, senescence and tumor suppressor. \u0394Np73-selective knockout, on the other hand, highlights anti-apoptotic function of \u0394Np73 and its involvement in DNA damage response. In this work, we investigated the expression pattern of murine p73 C-terminal isoforms. By using a RT-PCR approach, we were able to detect mRNAs of all the C-terminal isoforms described in humans. We characterized their in vivo expression profile in mouse organs and in different mouse developmental stages. Finally, we investigated p73 C-terminal expression profile following DNA damage, ex vivo after primary cultures treatment and in vivo after systemic administration of cytotoxic compounds. Overall, our study first elucidates spatio-temporal expression of mouse p73 isoforms and provides novel insights on their expression-switch under triggered conditions.", "qas": [{"question": "How many TAp73 isoforms have been identified in humans?", "answers": ["seven", "7"], "qid": "4d0d8f548cf94dc489db689b3aa53512", "question_tokens": [["How", 0], ["many", 4], ["TAp73", 9], ["isoforms", 15], ["have", 24], ["been", 29], ["identified", 34], ["in", 45], ["humans", 48], ["?", 54]], "detected_answers": [{"text": "seven", "token_spans": [[66, 66]], "char_spans": [[313, 317]]}]}], "context_tokens": [["p73", 0], ["is", 4], ["a", 7], ["p53", 9], ["family", 13], ["transcription", 20], ["factor", 34], [".", 40], ["Due", 42], ["to", 46], ["the", 49], ["presence", 53], ["in", 62], ["the", 65], ["5", 69], ["'", 70], ["flanking", 72], ["region", 81], ["of", 88], ["two", 91], ["promoters", 95], [",", 104], ["there", 106], ["are", 112], ["two", 116], ["N", 120], ["-", 121], ["terminal", 122], ["variants", 131], [",", 139], ["TAp73", 141], [",", 146], ["which", 148], ["retains", 154], ["a", 162], ["fully", 164], ["active", 170], ["transactivation", 177], ["domain", 193], ["(", 200], ["TA", 201], [")", 203], [",", 204], ["and", 206], ["\u0394Np73", 210], [",", 215], ["in", 217], ["which", 220], ["the", 226], ["N", 230], ["terminus", 232], ["is", 241], ["truncated", 244], [".", 253], ["In", 255], ["addition", 258], [",", 266], ["extensive", 268], ["3", 278], ["'", 279], ["splicing", 281], ["gives", 290], ["rise", 296], ["to", 301], ["at", 304], ["least", 307], ["seven", 313], ["distinctive", 319], ["isoforms", 331], [";", 339], ["TAp73-selective", 341], ["knockout", 357], ["highlights", 366], ["its", 377], ["role", 381], ["as", 386], ["a", 389], ["regulator", 391], ["of", 401], ["cell", 404], ["death", 409], [",", 414], ["senescence", 416], ["and", 427], ["tumor", 431], ["suppressor", 437], [".", 447], ["\u0394Np73-selective", 449], ["knockout", 465], [",", 473], ["on", 475], ["the", 478], ["other", 482], ["hand", 488], [",", 492], ["highlights", 494], ["anti", 505], ["-", 509], ["apoptotic", 510], ["function", 520], ["of", 529], ["\u0394Np73", 532], ["and", 538], ["its", 542], ["involvement", 546], ["in", 558], ["DNA", 561], ["damage", 565], ["response", 572], [".", 580], ["In", 582], ["this", 585], ["work", 590], [",", 594], ["we", 596], ["investigated", 599], ["the", 612], ["expression", 616], ["pattern", 627], ["of", 635], ["murine", 638], ["p73", 645], ["C", 649], ["-", 650], ["terminal", 651], ["isoforms", 660], [".", 668], ["By", 670], ["using", 673], ["a", 679], ["RT", 681], ["-", 683], ["PCR", 684], ["approach", 688], [",", 696], ["we", 698], ["were", 701], ["able", 706], ["to", 711], ["detect", 714], ["mRNAs", 721], ["of", 727], ["all", 730], ["the", 734], ["C", 738], ["-", 739], ["terminal", 740], ["isoforms", 749], ["described", 758], ["in", 768], ["humans", 771], [".", 777], ["We", 779], ["characterized", 782], ["their", 796], ["in", 802], ["vivo", 805], ["expression", 810], ["profile", 821], ["in", 829], ["mouse", 832], ["organs", 838], ["and", 845], ["in", 849], ["different", 852], ["mouse", 862], ["developmental", 868], ["stages", 882], [".", 888], ["Finally", 890], [",", 897], ["we", 899], ["investigated", 902], ["p73", 915], ["C", 919], ["-", 920], ["terminal", 921], ["expression", 930], ["profile", 941], ["following", 949], ["DNA", 959], ["damage", 963], [",", 969], ["ex", 971], ["vivo", 974], ["after", 979], ["primary", 985], ["cultures", 993], ["treatment", 1002], ["and", 1012], ["in", 1016], ["vivo", 1019], ["after", 1024], ["systemic", 1030], ["administration", 1039], ["of", 1054], ["cytotoxic", 1057], ["compounds", 1067], [".", 1076], ["Overall", 1078], [",", 1085], ["our", 1087], ["study", 1091], ["first", 1097], ["elucidates", 1103], ["spatio", 1114], ["-", 1120], ["temporal", 1121], ["expression", 1130], ["of", 1141], ["mouse", 1144], ["p73", 1150], ["isoforms", 1154], ["and", 1163], ["provides", 1167], ["novel", 1176], ["insights", 1182], ["on", 1191], ["their", 1194], ["expression", 1200], ["-", 1210], ["switch", 1211], ["under", 1218], ["triggered", 1224], ["conditions", 1234], [".", 1244]]}
{"context": "Histone variant H2A.Z-containing nucleosomes exist at most eukaryotic promoters and play important roles in gene transcription and genome stability. The multisubunit nucleosome-remodeling enzyme complex SWR1, conserved from yeast to mammals, catalyzes the ATP-dependent replacement of histone H2A in canonical nucleosomes with H2A.Z. How SWR1 catalyzes the replacement reaction is largely unknown. Here, we determined the crystal structure of the N-terminal region (599-627) of the catalytic subunit Swr1, termed Swr1-Z domain, in complex with the H2A.Z-H2B dimer at 1.78 \u00c5 resolution. The Swr1-Z domain forms a 310 helix and an irregular chain. A conserved LxxLF motif in the Swr1-Z 310 helix specifically recognizes the \u03b1C helix of H2A.Z. Our results show that the Swr1-Z domain can deliver the H2A.Z-H2B dimer to the DNA-(H3-H4)2 tetrasome to form the nucleosome by a histone chaperone mechanism.", "qas": [{"question": "Which protein mediates the replacement of H2A by H2A.Z in the yeast Saccharomyces cerevisiae?", "answers": ["SWR1"], "qid": "fd3253087bbd4003b295d765450a9097", "question_tokens": [["Which", 0], ["protein", 6], ["mediates", 14], ["the", 23], ["replacement", 27], ["of", 39], ["H2A", 42], ["by", 46], ["H2A.Z", 49], ["in", 55], ["the", 58], ["yeast", 62], ["Saccharomyces", 68], ["cerevisiae", 82], ["?", 92]], "detected_answers": [{"text": "SWR1", "token_spans": [[83, 83], [52, 52], [29, 29]], "char_spans": [[500, 503], [338, 341], [203, 206]]}]}], "context_tokens": [["Histone", 0], ["variant", 8], ["H2A.Z", 16], ["-", 21], ["containing", 22], ["nucleosomes", 33], ["exist", 45], ["at", 51], ["most", 54], ["eukaryotic", 59], ["promoters", 70], ["and", 80], ["play", 84], ["important", 89], ["roles", 99], ["in", 105], ["gene", 108], ["transcription", 113], ["and", 127], ["genome", 131], ["stability", 138], [".", 147], ["The", 149], ["multisubunit", 153], ["nucleosome", 166], ["-", 176], ["remodeling", 177], ["enzyme", 188], ["complex", 195], ["SWR1", 203], [",", 207], ["conserved", 209], ["from", 219], ["yeast", 224], ["to", 230], ["mammals", 233], [",", 240], ["catalyzes", 242], ["the", 252], ["ATP", 256], ["-", 259], ["dependent", 260], ["replacement", 270], ["of", 282], ["histone", 285], ["H2A", 293], ["in", 297], ["canonical", 300], ["nucleosomes", 310], ["with", 322], ["H2A.Z.", 327], ["How", 334], ["SWR1", 338], ["catalyzes", 343], ["the", 353], ["replacement", 357], ["reaction", 369], ["is", 378], ["largely", 381], ["unknown", 389], [".", 396], ["Here", 398], [",", 402], ["we", 404], ["determined", 407], ["the", 418], ["crystal", 422], ["structure", 430], ["of", 440], ["the", 443], ["N", 447], ["-", 448], ["terminal", 449], ["region", 458], ["(", 465], ["599", 466], ["-", 469], ["627", 470], [")", 473], ["of", 475], ["the", 478], ["catalytic", 482], ["subunit", 492], ["Swr1", 500], [",", 504], ["termed", 506], ["Swr1-Z", 513], ["domain", 520], [",", 526], ["in", 528], ["complex", 531], ["with", 539], ["the", 544], ["H2A.Z", 548], ["-", 553], ["H2B", 554], ["dimer", 558], ["at", 564], ["1.78", 567], ["\u00c5", 572], ["resolution", 574], [".", 584], ["The", 586], ["Swr1-Z", 590], ["domain", 597], ["forms", 604], ["a", 610], ["310", 612], ["helix", 616], ["and", 622], ["an", 626], ["irregular", 629], ["chain", 639], [".", 644], ["A", 646], ["conserved", 648], ["LxxLF", 658], ["motif", 664], ["in", 670], ["the", 673], ["Swr1-Z", 677], ["310", 684], ["helix", 688], ["specifically", 694], ["recognizes", 707], ["the", 718], ["\u03b1C", 722], ["helix", 725], ["of", 731], ["H2A.Z.", 734], ["Our", 741], ["results", 745], ["show", 753], ["that", 758], ["the", 763], ["Swr1-Z", 767], ["domain", 774], ["can", 781], ["deliver", 785], ["the", 793], ["H2A.Z", 797], ["-", 802], ["H2B", 803], ["dimer", 807], ["to", 813], ["the", 816], ["DNA-(H3-H4)2", 820], ["tetrasome", 833], ["to", 843], ["form", 846], ["the", 851], ["nucleosome", 855], ["by", 866], ["a", 869], ["histone", 871], ["chaperone", 879], ["mechanism", 889], [".", 898]]}
{"context": "The completeness of meningioma resection depends on the resection of dura mater invaded by the tumor. The pathological changes of the dura around the tumor can be interpreted by evaluating the dural tail sign (DTS) on MRI studies. The goal of this study was to clarify the pathological characteristics of the DTSs, propose a classification based on the histopathological and radiological correlation, and identify the invasive range of tumor cells in different types of DTS. The authors retrospectively reviewed 179 patients with convexity meningiomas who underwent Simpson Grade I resection. All patients underwent an enhanced MRI examination preoperatively. The convexity meningiomas were dichotomized into various subtypes in accordance with the 2007 WHO classification of tumors of the CNS, and the DTS was identified based on the Goldsher criteria. The range of resection of the involved dura was 3 cm from the base of the tumor, which corresponded with the length of DTS on MRI studies. Histopathological examination of dura at 0.5, 1.0, 1.5, 2.0, 2.5, and 3.0 cm from the base of the tumor was conducted, and the findings were correlated with the preoperative MRI appearance of the DTS. A total of 154 (86%) of 179 convexity meningiomas were classified into WHO Grade I subtype, including transitional (44 [28.6%] of 154), meningothelial (36 [23.4%] of 154), fibrous (23 [14.9%] of 154), psammomatous (22 [14.3%] of 154), secretory (10 [6.5%] of 154), and angiomatous (19 [12.3%] of 154). The other 25 (14%) were non-Grade I (WHO) tumors, including atypical (12 [48%] of 25), anaplastic (5 [20%] of 25), and papillary (8 [32%] of 25). The DTS was classified into 5 types: smooth (16 [8.9%] of 179), nodular (36 [20.1%] of 179), mixed (57 [31.8%] of 179), symmetrical multipolar (15 [8.4%] of 179), and asymmetrical multipolar (55 [30.7%] of 179). There was a significant difference in distribution of DTS type between Grade I and non-Grade I tumors (p = 0.004), whereas the difference was not significant among Grade I tumors (0.841) or among non-Grade I tumors (p = 0.818). All smooth-type DTSs were encountered in Grade I tumors, and the mixed DTS (52 [33.8%] of 154) was the most common type in these tumors. Nodular-type DTS was more commonly seen in non-Grade I tumors (12 [48%] of 25). Tumor invasion was found in 88.3% (158 of 179) of convexity meningiomas, of which the range of invasion in 82.3% (130 of 158) was within 2 cm and that in 94.9% (150 of 158) was within 2.5 cm. The incidence of invasion and the range invaded by tumor cells varied in different types of DTS, and differences were statistically significant (p < 0.001). Nodular-type DTS on MRI studies might be associated with non-Grade I tumors. The range of dural resection for convexity meningiomas should be 2.5 cm from the tumor base, and if this extent of resection is not feasible, the type of DTS should be considered. However, for skull base meningiomas, in which mostly Simpson Grade II resection is achieved, the use of this classification should be further validated. The classification of DTS enables the surgeon to predict preoperatively and then to achieve the optimal range of dural resection that might significantly reduce the recurrence rate of meningiomas.", "qas": [{"question": "Simpson grading is used to describe resection of which brain tumor?", "answers": ["meningioma"], "qid": "dfc371178f7740ec80686c0baf2ecc3a", "question_tokens": [["Simpson", 0], ["grading", 8], ["is", 16], ["used", 19], ["to", 24], ["describe", 27], ["resection", 36], ["of", 46], ["which", 49], ["brain", 55], ["tumor", 61], ["?", 66]], "detected_answers": [{"text": "meningioma", "token_spans": [[3, 3]], "char_spans": [[20, 29]]}]}], "context_tokens": [["The", 0], ["completeness", 4], ["of", 17], ["meningioma", 20], ["resection", 31], ["depends", 41], ["on", 49], ["the", 52], ["resection", 56], ["of", 66], ["dura", 69], ["mater", 74], ["invaded", 80], ["by", 88], ["the", 91], ["tumor", 95], [".", 100], ["The", 102], ["pathological", 106], ["changes", 119], ["of", 127], ["the", 130], ["dura", 134], ["around", 139], ["the", 146], ["tumor", 150], ["can", 156], ["be", 160], ["interpreted", 163], ["by", 175], ["evaluating", 178], ["the", 189], ["dural", 193], ["tail", 199], ["sign", 204], ["(", 209], ["DTS", 210], [")", 213], ["on", 215], ["MRI", 218], ["studies", 222], [".", 229], ["The", 231], ["goal", 235], ["of", 240], ["this", 243], ["study", 248], ["was", 254], ["to", 258], ["clarify", 261], ["the", 269], ["pathological", 273], ["characteristics", 286], ["of", 302], ["the", 305], ["DTSs", 309], [",", 313], ["propose", 315], ["a", 323], ["classification", 325], ["based", 340], ["on", 346], ["the", 349], ["histopathological", 353], ["and", 371], ["radiological", 375], ["correlation", 388], [",", 399], ["and", 401], ["identify", 405], ["the", 414], ["invasive", 418], ["range", 427], ["of", 433], ["tumor", 436], ["cells", 442], ["in", 448], ["different", 451], ["types", 461], ["of", 467], ["DTS", 470], [".", 473], ["The", 475], ["authors", 479], ["retrospectively", 487], ["reviewed", 503], ["179", 512], ["patients", 516], ["with", 525], ["convexity", 530], ["meningiomas", 540], ["who", 552], ["underwent", 556], ["Simpson", 566], ["Grade", 574], ["I", 580], ["resection", 582], [".", 591], ["All", 593], ["patients", 597], ["underwent", 606], ["an", 616], ["enhanced", 619], ["MRI", 628], ["examination", 632], ["preoperatively", 644], [".", 658], ["The", 660], ["convexity", 664], ["meningiomas", 674], ["were", 686], ["dichotomized", 691], ["into", 704], ["various", 709], ["subtypes", 717], ["in", 726], ["accordance", 729], ["with", 740], ["the", 745], ["2007", 749], ["WHO", 754], ["classification", 758], ["of", 773], ["tumors", 776], ["of", 783], ["the", 786], ["CNS", 790], [",", 793], ["and", 795], ["the", 799], ["DTS", 803], ["was", 807], ["identified", 811], ["based", 822], ["on", 828], ["the", 831], ["Goldsher", 835], ["criteria", 844], [".", 852], ["The", 854], ["range", 858], ["of", 864], ["resection", 867], ["of", 877], ["the", 880], ["involved", 884], ["dura", 893], ["was", 898], ["3", 902], ["cm", 904], ["from", 907], ["the", 912], ["base", 916], ["of", 921], ["the", 924], ["tumor", 928], [",", 933], ["which", 935], ["corresponded", 941], ["with", 954], ["the", 959], ["length", 963], ["of", 970], ["DTS", 973], ["on", 977], ["MRI", 980], ["studies", 984], [".", 991], ["Histopathological", 993], ["examination", 1011], ["of", 1023], ["dura", 1026], ["at", 1031], ["0.5", 1034], [",", 1037], ["1.0", 1039], [",", 1042], ["1.5", 1044], [",", 1047], ["2.0", 1049], [",", 1052], ["2.5", 1054], [",", 1057], ["and", 1059], ["3.0", 1063], ["cm", 1067], ["from", 1070], ["the", 1075], ["base", 1079], ["of", 1084], ["the", 1087], ["tumor", 1091], ["was", 1097], ["conducted", 1101], [",", 1110], ["and", 1112], ["the", 1116], ["findings", 1120], ["were", 1129], ["correlated", 1134], ["with", 1145], ["the", 1150], ["preoperative", 1154], ["MRI", 1167], ["appearance", 1171], ["of", 1182], ["the", 1185], ["DTS", 1189], [".", 1192], ["A", 1194], ["total", 1196], ["of", 1202], ["154", 1205], ["(", 1209], ["86", 1210], ["%", 1212], [")", 1213], ["of", 1215], ["179", 1218], ["convexity", 1222], ["meningiomas", 1232], ["were", 1244], ["classified", 1249], ["into", 1260], ["WHO", 1265], ["Grade", 1269], ["I", 1275], ["subtype", 1277], [",", 1284], ["including", 1286], ["transitional", 1296], ["(", 1309], ["44", 1310], ["[", 1313], ["28.6", 1314], ["%", 1318], ["]", 1319], ["of", 1321], ["154", 1324], [")", 1327], [",", 1328], ["meningothelial", 1330], ["(", 1345], ["36", 1346], ["[", 1349], ["23.4", 1350], ["%", 1354], ["]", 1355], ["of", 1357], ["154", 1360], [")", 1363], [",", 1364], ["fibrous", 1366], ["(", 1374], ["23", 1375], ["[", 1378], ["14.9", 1379], ["%", 1383], ["]", 1384], ["of", 1386], ["154", 1389], [")", 1392], [",", 1393], ["psammomatous", 1395], ["(", 1408], ["22", 1409], ["[", 1412], ["14.3", 1413], ["%", 1417], ["]", 1418], ["of", 1420], ["154", 1423], [")", 1426], [",", 1427], ["secretory", 1429], ["(", 1439], ["10", 1440], ["[", 1443], ["6.5", 1444], ["%", 1447], ["]", 1448], ["of", 1450], ["154", 1453], [")", 1456], [",", 1457], ["and", 1459], ["angiomatous", 1463], ["(", 1475], ["19", 1476], ["[", 1479], ["12.3", 1480], ["%", 1484], ["]", 1485], ["of", 1487], ["154", 1490], [")", 1493], [".", 1494], ["The", 1496], ["other", 1500], ["25", 1506], ["(", 1509], ["14", 1510], ["%", 1512], [")", 1513], ["were", 1515], ["non", 1520], ["-", 1523], ["Grade", 1524], ["I", 1530], ["(", 1532], ["WHO", 1533], [")", 1536], ["tumors", 1538], [",", 1544], ["including", 1546], ["atypical", 1556], ["(", 1565], ["12", 1566], ["[", 1569], ["48", 1570], ["%", 1572], ["]", 1573], ["of", 1575], ["25", 1578], [")", 1580], [",", 1581], ["anaplastic", 1583], ["(", 1594], ["5", 1595], ["[", 1597], ["20", 1598], ["%", 1600], ["]", 1601], ["of", 1603], ["25", 1606], [")", 1608], [",", 1609], ["and", 1611], ["papillary", 1615], ["(", 1625], ["8", 1626], ["[", 1628], ["32", 1629], ["%", 1631], ["]", 1632], ["of", 1634], ["25", 1637], [")", 1639], [".", 1640], ["The", 1642], ["DTS", 1646], ["was", 1650], ["classified", 1654], ["into", 1665], ["5", 1670], ["types", 1672], [":", 1677], ["smooth", 1679], ["(", 1686], ["16", 1687], ["[", 1690], ["8.9", 1691], ["%", 1694], ["]", 1695], ["of", 1697], ["179", 1700], [")", 1703], [",", 1704], ["nodular", 1706], ["(", 1714], ["36", 1715], ["[", 1718], ["20.1", 1719], ["%", 1723], ["]", 1724], ["of", 1726], ["179", 1729], [")", 1732], [",", 1733], ["mixed", 1735], ["(", 1741], ["57", 1742], ["[", 1745], ["31.8", 1746], ["%", 1750], ["]", 1751], ["of", 1753], ["179", 1756], [")", 1759], [",", 1760], ["symmetrical", 1762], ["multipolar", 1774], ["(", 1785], ["15", 1786], ["[", 1789], ["8.4", 1790], ["%", 1793], ["]", 1794], ["of", 1796], ["179", 1799], [")", 1802], [",", 1803], ["and", 1805], ["asymmetrical", 1809], ["multipolar", 1822], ["(", 1833], ["55", 1834], ["[", 1837], ["30.7", 1838], ["%", 1842], ["]", 1843], ["of", 1845], ["179", 1848], [")", 1851], [".", 1852], ["There", 1854], ["was", 1860], ["a", 1864], ["significant", 1866], ["difference", 1878], ["in", 1889], ["distribution", 1892], ["of", 1905], ["DTS", 1908], ["type", 1912], ["between", 1917], ["Grade", 1925], ["I", 1931], ["and", 1933], ["non", 1937], ["-", 1940], ["Grade", 1941], ["I", 1947], ["tumors", 1949], ["(", 1956], ["p", 1957], ["=", 1959], ["0.004", 1961], [")", 1966], [",", 1967], ["whereas", 1969], ["the", 1977], ["difference", 1981], ["was", 1992], ["not", 1996], ["significant", 2000], ["among", 2012], ["Grade", 2018], ["I", 2024], ["tumors", 2026], ["(", 2033], ["0.841", 2034], [")", 2039], ["or", 2041], ["among", 2044], ["non", 2050], ["-", 2053], ["Grade", 2054], ["I", 2060], ["tumors", 2062], ["(", 2069], ["p", 2070], ["=", 2072], ["0.818", 2074], [")", 2079], [".", 2080], ["All", 2082], ["smooth", 2086], ["-", 2092], ["type", 2093], ["DTSs", 2098], ["were", 2103], ["encountered", 2108], ["in", 2120], ["Grade", 2123], ["I", 2129], ["tumors", 2131], [",", 2137], ["and", 2139], ["the", 2143], ["mixed", 2147], ["DTS", 2153], ["(", 2157], ["52", 2158], ["[", 2161], ["33.8", 2162], ["%", 2166], ["]", 2167], ["of", 2169], ["154", 2172], [")", 2175], ["was", 2177], ["the", 2181], ["most", 2185], ["common", 2190], ["type", 2197], ["in", 2202], ["these", 2205], ["tumors", 2211], [".", 2217], ["Nodular", 2219], ["-", 2226], ["type", 2227], ["DTS", 2232], ["was", 2236], ["more", 2240], ["commonly", 2245], ["seen", 2254], ["in", 2259], ["non", 2262], ["-", 2265], ["Grade", 2266], ["I", 2272], ["tumors", 2274], ["(", 2281], ["12", 2282], ["[", 2285], ["48", 2286], ["%", 2288], ["]", 2289], ["of", 2291], ["25", 2294], [")", 2296], [".", 2297], ["Tumor", 2299], ["invasion", 2305], ["was", 2314], ["found", 2318], ["in", 2324], ["88.3", 2327], ["%", 2331], ["(", 2333], ["158", 2334], ["of", 2338], ["179", 2341], [")", 2344], ["of", 2346], ["convexity", 2349], ["meningiomas", 2359], [",", 2370], ["of", 2372], ["which", 2375], ["the", 2381], ["range", 2385], ["of", 2391], ["invasion", 2394], ["in", 2403], ["82.3", 2406], ["%", 2410], ["(", 2412], ["130", 2413], ["of", 2417], ["158", 2420], [")", 2423], ["was", 2425], ["within", 2429], ["2", 2436], ["cm", 2438], ["and", 2441], ["that", 2445], ["in", 2450], ["94.9", 2453], ["%", 2457], ["(", 2459], ["150", 2460], ["of", 2464], ["158", 2467], [")", 2470], ["was", 2472], ["within", 2476], ["2.5", 2483], ["cm", 2487], [".", 2489], ["The", 2491], ["incidence", 2495], ["of", 2505], ["invasion", 2508], ["and", 2517], ["the", 2521], ["range", 2525], ["invaded", 2531], ["by", 2539], ["tumor", 2542], ["cells", 2548], ["varied", 2554], ["in", 2561], ["different", 2564], ["types", 2574], ["of", 2580], ["DTS", 2583], [",", 2586], ["and", 2588], ["differences", 2592], ["were", 2604], ["statistically", 2609], ["significant", 2623], ["(", 2635], ["p", 2636], ["<", 2638], ["0.001", 2640], [")", 2645], [".", 2646], ["Nodular", 2648], ["-", 2655], ["type", 2656], ["DTS", 2661], ["on", 2665], ["MRI", 2668], ["studies", 2672], ["might", 2680], ["be", 2686], ["associated", 2689], ["with", 2700], ["non", 2705], ["-", 2708], ["Grade", 2709], ["I", 2715], ["tumors", 2717], [".", 2723], ["The", 2725], ["range", 2729], ["of", 2735], ["dural", 2738], ["resection", 2744], ["for", 2754], ["convexity", 2758], ["meningiomas", 2768], ["should", 2780], ["be", 2787], ["2.5", 2790], ["cm", 2794], ["from", 2797], ["the", 2802], ["tumor", 2806], ["base", 2812], [",", 2816], ["and", 2818], ["if", 2822], ["this", 2825], ["extent", 2830], ["of", 2837], ["resection", 2840], ["is", 2850], ["not", 2853], ["feasible", 2857], [",", 2865], ["the", 2867], ["type", 2871], ["of", 2876], ["DTS", 2879], ["should", 2883], ["be", 2890], ["considered", 2893], [".", 2903], ["However", 2905], [",", 2912], ["for", 2914], ["skull", 2918], ["base", 2924], ["meningiomas", 2929], [",", 2940], ["in", 2942], ["which", 2945], ["mostly", 2951], ["Simpson", 2958], ["Grade", 2966], ["II", 2972], ["resection", 2975], ["is", 2985], ["achieved", 2988], [",", 2996], ["the", 2998], ["use", 3002], ["of", 3006], ["this", 3009], ["classification", 3014], ["should", 3029], ["be", 3036], ["further", 3039], ["validated", 3047], [".", 3056], ["The", 3058], ["classification", 3062], ["of", 3077], ["DTS", 3080], ["enables", 3084], ["the", 3092], ["surgeon", 3096], ["to", 3104], ["predict", 3107], ["preoperatively", 3115], ["and", 3130], ["then", 3134], ["to", 3139], ["achieve", 3142], ["the", 3150], ["optimal", 3154], ["range", 3162], ["of", 3168], ["dural", 3171], ["resection", 3177], ["that", 3187], ["might", 3192], ["significantly", 3198], ["reduce", 3212], ["the", 3219], ["recurrence", 3223], ["rate", 3234], ["of", 3239], ["meningiomas", 3242], [".", 3253]]}
{"context": "A family with the Romano-Ward syndrome is presented. This family showed typical features of this syndrome with QT prolongation, torsades de pointes ventricular tachycardia, sudden death and an autosomal dominant inheritance pattern. The index case presented with an exacerbation of torsades de pointes ventricular tachycardia from diuretic induced hypokalaemia, and responded to diuretic withdrawal and beta blocker therapy.", "qas": [{"question": "What is the mode of inheritance of Romano Ward long QT syndrome?", "answers": ["autosomal dominant"], "qid": "f3e0556321574bc9984f02992df32320", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Romano", 35], ["Ward", 42], ["long", 47], ["QT", 52], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[33, 34]], "char_spans": [[193, 210]]}]}], "context_tokens": [["A", 0], ["family", 2], ["with", 9], ["the", 14], ["Romano", 18], ["-", 24], ["Ward", 25], ["syndrome", 30], ["is", 39], ["presented", 42], [".", 51], ["This", 53], ["family", 58], ["showed", 65], ["typical", 72], ["features", 80], ["of", 89], ["this", 92], ["syndrome", 97], ["with", 106], ["QT", 111], ["prolongation", 114], [",", 126], ["torsades", 128], ["de", 137], ["pointes", 140], ["ventricular", 148], ["tachycardia", 160], [",", 171], ["sudden", 173], ["death", 180], ["and", 186], ["an", 190], ["autosomal", 193], ["dominant", 203], ["inheritance", 212], ["pattern", 224], [".", 231], ["The", 233], ["index", 237], ["case", 243], ["presented", 248], ["with", 258], ["an", 263], ["exacerbation", 266], ["of", 279], ["torsades", 282], ["de", 291], ["pointes", 294], ["ventricular", 302], ["tachycardia", 314], ["from", 326], ["diuretic", 331], ["induced", 340], ["hypokalaemia", 348], [",", 360], ["and", 362], ["responded", 366], ["to", 376], ["diuretic", 379], ["withdrawal", 388], ["and", 399], ["beta", 403], ["blocker", 408], ["therapy", 416], [".", 423]]}
{"context": "Nerve growth factor (NGF) is indispensable during normal embryonic development and critical for the amplification of pain signals in adults. Intervention in NGF signaling holds promise for the alleviation of pain resulting from human diseases such as osteoarthritis, cancer and chronic lower back disorders. We developed a fast, high-fidelity method to convert a hybridoma-derived NGF-targeted mouse antibody into a clinical candidate. This method, termed Library Scanning Mutagenesis (LSM), resulted in the ultra-high affinity antibody tanezumab, a first-in-class anti-hyperalgesic specific for an NGF epitope. Functional and structural comparisons between tanezumab and the mouse 911 precursor antibody using neurotrophin-specific cell survival assays and X-ray crystal structures of both Fab-antigen complexes illustrated high fidelity retention of the NGF epitope. These results suggest the potential for wide applicability of the LSM method for optimization of well-characterized antibodies during humanization.", "qas": [{"question": "What is the target of tanezumab?", "answers": ["nerve growth factor", "NGF"], "qid": "702ca078e3664e4f8f2e876395b0f7d4", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["target", 12], ["of", 19], ["tanezumab", 22], ["?", 31]], "detected_answers": [{"text": "nerve growth factor", "token_spans": [[0, 2]], "char_spans": [[0, 18]]}, {"text": "NGF", "token_spans": [[64, 64], [107, 107], [147, 147], [4, 4], [25, 25]], "char_spans": [[381, 383], [599, 601], [856, 858], [21, 23], [157, 159]]}]}], "context_tokens": [["Nerve", 0], ["growth", 6], ["factor", 13], ["(", 20], ["NGF", 21], [")", 24], ["is", 26], ["indispensable", 29], ["during", 43], ["normal", 50], ["embryonic", 57], ["development", 67], ["and", 79], ["critical", 83], ["for", 92], ["the", 96], ["amplification", 100], ["of", 114], ["pain", 117], ["signals", 122], ["in", 130], ["adults", 133], [".", 139], ["Intervention", 141], ["in", 154], ["NGF", 157], ["signaling", 161], ["holds", 171], ["promise", 177], ["for", 185], ["the", 189], ["alleviation", 193], ["of", 205], ["pain", 208], ["resulting", 213], ["from", 223], ["human", 228], ["diseases", 234], ["such", 243], ["as", 248], ["osteoarthritis", 251], [",", 265], ["cancer", 267], ["and", 274], ["chronic", 278], ["lower", 286], ["back", 292], ["disorders", 297], [".", 306], ["We", 308], ["developed", 311], ["a", 321], ["fast", 323], [",", 327], ["high", 329], ["-", 333], ["fidelity", 334], ["method", 343], ["to", 350], ["convert", 353], ["a", 361], ["hybridoma", 363], ["-", 372], ["derived", 373], ["NGF", 381], ["-", 384], ["targeted", 385], ["mouse", 394], ["antibody", 400], ["into", 409], ["a", 414], ["clinical", 416], ["candidate", 425], [".", 434], ["This", 436], ["method", 441], [",", 447], ["termed", 449], ["Library", 456], ["Scanning", 464], ["Mutagenesis", 473], ["(", 485], ["LSM", 486], [")", 489], [",", 490], ["resulted", 492], ["in", 501], ["the", 504], ["ultra", 508], ["-", 513], ["high", 514], ["affinity", 519], ["antibody", 528], ["tanezumab", 537], [",", 546], ["a", 548], ["first", 550], ["-", 555], ["in", 556], ["-", 558], ["class", 559], ["anti", 565], ["-", 569], ["hyperalgesic", 570], ["specific", 583], ["for", 592], ["an", 596], ["NGF", 599], ["epitope", 603], [".", 610], ["Functional", 612], ["and", 623], ["structural", 627], ["comparisons", 638], ["between", 650], ["tanezumab", 658], ["and", 668], ["the", 672], ["mouse", 676], ["911", 682], ["precursor", 686], ["antibody", 696], ["using", 705], ["neurotrophin", 711], ["-", 723], ["specific", 724], ["cell", 733], ["survival", 738], ["assays", 747], ["and", 754], ["X", 758], ["-", 759], ["ray", 760], ["crystal", 764], ["structures", 772], ["of", 783], ["both", 786], ["Fab", 791], ["-", 794], ["antigen", 795], ["complexes", 803], ["illustrated", 813], ["high", 825], ["fidelity", 830], ["retention", 839], ["of", 849], ["the", 852], ["NGF", 856], ["epitope", 860], [".", 867], ["These", 869], ["results", 875], ["suggest", 883], ["the", 891], ["potential", 895], ["for", 905], ["wide", 909], ["applicability", 914], ["of", 928], ["the", 931], ["LSM", 935], ["method", 939], ["for", 946], ["optimization", 950], ["of", 963], ["well", 966], ["-", 970], ["characterized", 971], ["antibodies", 985], ["during", 996], ["humanization", 1003], [".", 1015]]}
{"context": "To evaluate short- and mid-term level of imbalance after vestibular schwannoma (VS) microsurgery by the transpetrosal approach, to search for factors predictive of vestibular compensation, and to determine which patient categories need a postoperative vestibular rehabilitation program. Prospective cohort study at a tertiary referral center. Between 2010 and 2011, patients aged 18 to 75 operated on for VS by transpetrosal approaches were included. VS was characterized by its size (Koos classification) and the presence or not of a cystic component. Hearing was classified according to the Gardner Robertson grading. The preoperative workup included an audiogram, computerized video nystagmography (VNG) with caloric testing, gaze study, rotatory tests, click-evoked cervical vestibular evoked myogenic potential measurements (cVEMPs), and subjective visual vertical test. Patients were asked to complete a Dizziness Handicap Inventory (DHI). Postoperatively, patients were reevaluated on D7 (clinical status), D90 (VNG and DHI), and D180 (DHI). Timing and duration of vestibular rehabilitation were also recorded. Forty-eight patients were included. Preoperatively, 77% experienced mild instability problems with a mean DHI score of 14.1 (range 4-32). Postoperatively, 71% reported stable or even improved perceived stability. Mean DHI scores were 28.1 on D90 and 19.8 on D180. Serviceable hearing, cystic transformation, normal cVEMPs, diplopia, and vestibular syndrome on D7 were found to be predictive of worse equilibrium outcome than when absent. A preoperative caloric deficit greater than 75% seemed to be a good prognostic factor. Vestibular rehabilitation was conducted in 56% of patients. Starting it early (<1 mo) seemed to be beneficial for final equilibrium outcome. VS microsurgery provides good stability results. Some preoperative parameters may be predictive of worse or improved balance recovery, as is clinical status on D7.", "qas": [{"question": "Which disease can be categorized using the Koos grading system?", "answers": ["vestibular schwannoma"], "qid": "44cd890f1a1b4d6a9b055e363d1c3221", "question_tokens": [["Which", 0], ["disease", 6], ["can", 14], ["be", 18], ["categorized", 21], ["using", 33], ["the", 39], ["Koos", 43], ["grading", 48], ["system", 56], ["?", 62]], "detected_answers": [{"text": "vestibular schwannoma", "token_spans": [[11, 12]], "char_spans": [[57, 77]]}]}], "context_tokens": [["To", 0], ["evaluate", 3], ["short-", 12], ["and", 19], ["mid", 23], ["-", 26], ["term", 27], ["level", 32], ["of", 38], ["imbalance", 41], ["after", 51], ["vestibular", 57], ["schwannoma", 68], ["(", 79], ["VS", 80], [")", 82], ["microsurgery", 84], ["by", 97], ["the", 100], ["transpetrosal", 104], ["approach", 118], [",", 126], ["to", 128], ["search", 131], ["for", 138], ["factors", 142], ["predictive", 150], ["of", 161], ["vestibular", 164], ["compensation", 175], [",", 187], ["and", 189], ["to", 193], ["determine", 196], ["which", 206], ["patient", 212], ["categories", 220], ["need", 231], ["a", 236], ["postoperative", 238], ["vestibular", 252], ["rehabilitation", 263], ["program", 278], [".", 285], ["Prospective", 287], ["cohort", 299], ["study", 306], ["at", 312], ["a", 315], ["tertiary", 317], ["referral", 326], ["center", 335], [".", 341], ["Between", 343], ["2010", 351], ["and", 356], ["2011", 360], [",", 364], ["patients", 366], ["aged", 375], ["18", 380], ["to", 383], ["75", 386], ["operated", 389], ["on", 398], ["for", 401], ["VS", 405], ["by", 408], ["transpetrosal", 411], ["approaches", 425], ["were", 436], ["included", 441], [".", 449], ["VS", 451], ["was", 454], ["characterized", 458], ["by", 472], ["its", 475], ["size", 479], ["(", 484], ["Koos", 485], ["classification", 490], [")", 504], ["and", 506], ["the", 510], ["presence", 514], ["or", 523], ["not", 526], ["of", 530], ["a", 533], ["cystic", 535], ["component", 542], [".", 551], ["Hearing", 553], ["was", 561], ["classified", 565], ["according", 576], ["to", 586], ["the", 589], ["Gardner", 593], ["Robertson", 601], ["grading", 611], [".", 618], ["The", 620], ["preoperative", 624], ["workup", 637], ["included", 644], ["an", 653], ["audiogram", 656], [",", 665], ["computerized", 667], ["video", 680], ["nystagmography", 686], ["(", 701], ["VNG", 702], [")", 705], ["with", 707], ["caloric", 712], ["testing", 720], [",", 727], ["gaze", 729], ["study", 734], [",", 739], ["rotatory", 741], ["tests", 750], [",", 755], ["click", 757], ["-", 762], ["evoked", 763], ["cervical", 770], ["vestibular", 779], ["evoked", 790], ["myogenic", 797], ["potential", 806], ["measurements", 816], ["(", 829], ["cVEMPs", 830], [")", 836], [",", 837], ["and", 839], ["subjective", 843], ["visual", 854], ["vertical", 861], ["test", 870], [".", 874], ["Patients", 876], ["were", 885], ["asked", 890], ["to", 896], ["complete", 899], ["a", 908], ["Dizziness", 910], ["Handicap", 920], ["Inventory", 929], ["(", 939], ["DHI", 940], [")", 943], [".", 944], ["Postoperatively", 946], [",", 961], ["patients", 963], ["were", 972], ["reevaluated", 977], ["on", 989], ["D7", 992], ["(", 995], ["clinical", 996], ["status", 1005], [")", 1011], [",", 1012], ["D90", 1014], ["(", 1018], ["VNG", 1019], ["and", 1023], ["DHI", 1027], [")", 1030], [",", 1031], ["and", 1033], ["D180", 1037], ["(", 1042], ["DHI", 1043], [")", 1046], [".", 1047], ["Timing", 1049], ["and", 1056], ["duration", 1060], ["of", 1069], ["vestibular", 1072], ["rehabilitation", 1083], ["were", 1098], ["also", 1103], ["recorded", 1108], [".", 1116], ["Forty", 1118], ["-", 1123], ["eight", 1124], ["patients", 1130], ["were", 1139], ["included", 1144], [".", 1152], ["Preoperatively", 1154], [",", 1168], ["77", 1170], ["%", 1172], ["experienced", 1174], ["mild", 1186], ["instability", 1191], ["problems", 1203], ["with", 1212], ["a", 1217], ["mean", 1219], ["DHI", 1224], ["score", 1228], ["of", 1234], ["14.1", 1237], ["(", 1242], ["range", 1243], ["4", 1249], ["-", 1250], ["32", 1251], [")", 1253], [".", 1254], ["Postoperatively", 1256], [",", 1271], ["71", 1273], ["%", 1275], ["reported", 1277], ["stable", 1286], ["or", 1293], ["even", 1296], ["improved", 1301], ["perceived", 1310], ["stability", 1320], [".", 1329], ["Mean", 1331], ["DHI", 1336], ["scores", 1340], ["were", 1347], ["28.1", 1352], ["on", 1357], ["D90", 1360], ["and", 1364], ["19.8", 1368], ["on", 1373], ["D180", 1376], [".", 1380], ["Serviceable", 1382], ["hearing", 1394], [",", 1401], ["cystic", 1403], ["transformation", 1410], [",", 1424], ["normal", 1426], ["cVEMPs", 1433], [",", 1439], ["diplopia", 1441], [",", 1449], ["and", 1451], ["vestibular", 1455], ["syndrome", 1466], ["on", 1475], ["D7", 1478], ["were", 1481], ["found", 1486], ["to", 1492], ["be", 1495], ["predictive", 1498], ["of", 1509], ["worse", 1512], ["equilibrium", 1518], ["outcome", 1530], ["than", 1538], ["when", 1543], ["absent", 1548], [".", 1554], ["A", 1556], ["preoperative", 1558], ["caloric", 1571], ["deficit", 1579], ["greater", 1587], ["than", 1595], ["75", 1600], ["%", 1602], ["seemed", 1604], ["to", 1611], ["be", 1614], ["a", 1617], ["good", 1619], ["prognostic", 1624], ["factor", 1635], [".", 1641], ["Vestibular", 1643], ["rehabilitation", 1654], ["was", 1669], ["conducted", 1673], ["in", 1683], ["56", 1686], ["%", 1688], ["of", 1690], ["patients", 1693], [".", 1701], ["Starting", 1703], ["it", 1712], ["early", 1715], ["(", 1721], ["<", 1722], ["1", 1723], ["mo", 1725], [")", 1727], ["seemed", 1729], ["to", 1736], ["be", 1739], ["beneficial", 1742], ["for", 1753], ["final", 1757], ["equilibrium", 1763], ["outcome", 1775], [".", 1782], ["VS", 1784], ["microsurgery", 1787], ["provides", 1800], ["good", 1809], ["stability", 1814], ["results", 1824], [".", 1831], ["Some", 1833], ["preoperative", 1838], ["parameters", 1851], ["may", 1862], ["be", 1866], ["predictive", 1869], ["of", 1880], ["worse", 1883], ["or", 1889], ["improved", 1892], ["balance", 1901], ["recovery", 1909], [",", 1917], ["as", 1919], ["is", 1922], ["clinical", 1925], ["status", 1934], ["on", 1941], ["D7", 1944], [".", 1946]]}
{"context": "Turner syndrome (TS) is the most common genetic problem affecting women and occurs when an X chromosome is completely deleted, portions of an X chromosome are deleted, or chromosomal mosaicism occurs. Girls with TS may also have occult Y chromosome sequences. Whereas some girls with TS are identified in infancy or early childhood, many girls with TS are not detected until after 10 yr of age, resulting in delayed evaluation and treatment. To prevent the delayed recognition and treatment of TS, a quantitative method of genotyping that can be performed as part of newborn screening is needed. To screen for sex chromosome abnormalities, we assembled a panel of informative single nucleotide polymorphism (SNP) markers that span the X chromosome from the dbSNP database. Pyrosequencing assays suitable for quantitative assessment of signal strength from single nucleotides were designed and used to genotype 46,XX; 46,XY; 45,X; and TS mosaics, examining zygosity and signal strength for individual alleles. Pyrosequencing assays were also designed for the detection of Y chromosome material. With just four informative SNP markers for the X chromosome, all TS girls with 45,X, partial X chromosome deletions, or mosaicism were identified with 100% sensitivity. In mosaic individuals, Y chromosomal material was detected with 100% sensitivity. These results suggest that inexpensive high-throughput screening is possible for TS and other sex chromosome disorders using quantitative genotyping approaches.", "qas": [{"question": "What chromosome is affected in Turner's syndrome?", "answers": ["X"], "qid": "4d9adbc83c164890a231325d350c9a93", "question_tokens": [["What", 0], ["chromosome", 5], ["is", 16], ["affected", 19], ["in", 28], ["Turner", 31], ["'s", 37], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "X", "token_spans": [[131, 131], [26, 26], [196, 196], [206, 206], [17, 17]], "char_spans": [[735, 735], [142, 142], [1141, 1141], [1187, 1187], [91, 91]]}]}], "context_tokens": [["Turner", 0], ["syndrome", 7], ["(", 16], ["TS", 17], [")", 19], ["is", 21], ["the", 24], ["most", 28], ["common", 33], ["genetic", 40], ["problem", 48], ["affecting", 56], ["women", 66], ["and", 72], ["occurs", 76], ["when", 83], ["an", 88], ["X", 91], ["chromosome", 93], ["is", 104], ["completely", 107], ["deleted", 118], [",", 125], ["portions", 127], ["of", 136], ["an", 139], ["X", 142], ["chromosome", 144], ["are", 155], ["deleted", 159], [",", 166], ["or", 168], ["chromosomal", 171], ["mosaicism", 183], ["occurs", 193], [".", 199], ["Girls", 201], ["with", 207], ["TS", 212], ["may", 215], ["also", 219], ["have", 224], ["occult", 229], ["Y", 236], ["chromosome", 238], ["sequences", 249], [".", 258], ["Whereas", 260], ["some", 268], ["girls", 273], ["with", 279], ["TS", 284], ["are", 287], ["identified", 291], ["in", 302], ["infancy", 305], ["or", 313], ["early", 316], ["childhood", 322], [",", 331], ["many", 333], ["girls", 338], ["with", 344], ["TS", 349], ["are", 352], ["not", 356], ["detected", 360], ["until", 369], ["after", 375], ["10", 381], ["yr", 384], ["of", 387], ["age", 390], [",", 393], ["resulting", 395], ["in", 405], ["delayed", 408], ["evaluation", 416], ["and", 427], ["treatment", 431], [".", 440], ["To", 442], ["prevent", 445], ["the", 453], ["delayed", 457], ["recognition", 465], ["and", 477], ["treatment", 481], ["of", 491], ["TS", 494], [",", 496], ["a", 498], ["quantitative", 500], ["method", 513], ["of", 520], ["genotyping", 523], ["that", 534], ["can", 539], ["be", 543], ["performed", 546], ["as", 556], ["part", 559], ["of", 564], ["newborn", 567], ["screening", 575], ["is", 585], ["needed", 588], [".", 594], ["To", 596], ["screen", 599], ["for", 606], ["sex", 610], ["chromosome", 614], ["abnormalities", 625], [",", 638], ["we", 640], ["assembled", 643], ["a", 653], ["panel", 655], ["of", 661], ["informative", 664], ["single", 676], ["nucleotide", 683], ["polymorphism", 694], ["(", 707], ["SNP", 708], [")", 711], ["markers", 713], ["that", 721], ["span", 726], ["the", 731], ["X", 735], ["chromosome", 737], ["from", 748], ["the", 753], ["dbSNP", 757], ["database", 763], [".", 771], ["Pyrosequencing", 773], ["assays", 788], ["suitable", 795], ["for", 804], ["quantitative", 808], ["assessment", 821], ["of", 832], ["signal", 835], ["strength", 842], ["from", 851], ["single", 856], ["nucleotides", 863], ["were", 875], ["designed", 880], ["and", 889], ["used", 893], ["to", 898], ["genotype", 901], ["46,XX", 910], [";", 915], ["46,XY", 917], [";", 922], ["45,X", 924], [";", 928], ["and", 930], ["TS", 934], ["mosaics", 937], [",", 944], ["examining", 946], ["zygosity", 956], ["and", 965], ["signal", 969], ["strength", 976], ["for", 985], ["individual", 989], ["alleles", 1000], [".", 1007], ["Pyrosequencing", 1009], ["assays", 1024], ["were", 1031], ["also", 1036], ["designed", 1041], ["for", 1050], ["the", 1054], ["detection", 1058], ["of", 1068], ["Y", 1071], ["chromosome", 1073], ["material", 1084], [".", 1092], ["With", 1094], ["just", 1099], ["four", 1104], ["informative", 1109], ["SNP", 1121], ["markers", 1125], ["for", 1133], ["the", 1137], ["X", 1141], ["chromosome", 1143], [",", 1153], ["all", 1155], ["TS", 1159], ["girls", 1162], ["with", 1168], ["45,X", 1173], [",", 1177], ["partial", 1179], ["X", 1187], ["chromosome", 1189], ["deletions", 1200], [",", 1209], ["or", 1211], ["mosaicism", 1214], ["were", 1224], ["identified", 1229], ["with", 1240], ["100", 1245], ["%", 1248], ["sensitivity", 1250], [".", 1261], ["In", 1263], ["mosaic", 1266], ["individuals", 1273], [",", 1284], ["Y", 1286], ["chromosomal", 1288], ["material", 1300], ["was", 1309], ["detected", 1313], ["with", 1322], ["100", 1327], ["%", 1330], ["sensitivity", 1332], [".", 1343], ["These", 1345], ["results", 1351], ["suggest", 1359], ["that", 1367], ["inexpensive", 1372], ["high", 1384], ["-", 1388], ["throughput", 1389], ["screening", 1400], ["is", 1410], ["possible", 1413], ["for", 1422], ["TS", 1426], ["and", 1429], ["other", 1433], ["sex", 1439], ["chromosome", 1443], ["disorders", 1454], ["using", 1464], ["quantitative", 1470], ["genotyping", 1483], ["approaches", 1494], [".", 1504]]}
{"context": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA) represents a quite poorly understood and inadequately defined phenotype of methicillin resistance. BORSA strains show low, borderline resistance to penicillinase-resistant penicillins (PRPs), with oxacillin MICs typically equal to 1-8\u2009\u00b5g\u2009ml", "qas": [{"question": "What is BORSA?", "answers": ["Borderline oxacillin-resistant Staphylococcus aureus"], "qid": "6bf60ce1cd73408f93464f39ccdb6be4", "question_tokens": [["What", 0], ["is", 5], ["BORSA", 8], ["?", 13]], "detected_answers": [{"text": "Borderline oxacillin-resistant Staphylococcus aureus", "token_spans": [[0, 5]], "char_spans": [[0, 51]]}]}], "context_tokens": [["Borderline", 0], ["oxacillin", 11], ["-", 20], ["resistant", 21], ["Staphylococcus", 31], ["aureus", 46], ["(", 53], ["BORSA", 54], [")", 59], ["represents", 61], ["a", 72], ["quite", 74], ["poorly", 80], ["understood", 87], ["and", 98], ["inadequately", 102], ["defined", 115], ["phenotype", 123], ["of", 133], ["methicillin", 136], ["resistance", 148], [".", 158], ["BORSA", 160], ["strains", 166], ["show", 174], ["low", 179], [",", 182], ["borderline", 184], ["resistance", 195], ["to", 206], ["penicillinase", 209], ["-", 222], ["resistant", 223], ["penicillins", 233], ["(", 245], ["PRPs", 246], [")", 250], [",", 251], ["with", 253], ["oxacillin", 258], ["MICs", 268], ["typically", 273], ["equal", 283], ["to", 289], ["1", 292], ["-", 293], ["8", 294], ["\u00b5g", 296], ["ml", 299]]}
{"context": "Here, we report the biochemical and genetic basis of the Vel blood group antigen, which has been a vexing mystery for decades, especially as anti-Vel regularly causes severe haemolytic transfusion reactions. The protein carrying the Vel blood group antigen was biochemically purified from red blood cell membranes. Mass spectrometry-based de novo peptide sequencing identified this protein to be small integral membrane protein 1 (SMIM1), a previously uncharacterized single-pass membrane protein. Expression of SMIM1 cDNA in Vel- cultured cells generated anti-Vel cell surface reactivity, confirming that SMIM1 encoded the Vel blood group antigen. A cohort of 70 Vel- individuals was found to be uniformly homozygous for a 17 nucleotide deletion in the coding sequence of SMIM1. The genetic homogeneity of the Vel- blood type, likely having a common origin, facilitated the development of two highly specific DNA-based tests for rapid Vel genotyping, which can be easily integrated into blood group genotyping platforms. These results answer a 60-year-old riddle and provide tools of immediate assistance to all clinicians involved in the care of Vel- patients.", "qas": [{"question": "Which gene-defect causes the Vel-blood type?", "answers": ["a 17 nucleotide deletion"], "qid": "1a0f88859ac041309e802081a92d69d7", "question_tokens": [["Which", 0], ["gene", 6], ["-", 10], ["defect", 11], ["causes", 18], ["the", 25], ["Vel", 29], ["-", 32], ["blood", 33], ["type", 39], ["?", 43]], "detected_answers": [{"text": "a 17 nucleotide deletion", "token_spans": [[125, 127]], "char_spans": [[724, 745]]}]}], "context_tokens": [["Here", 0], [",", 4], ["we", 6], ["report", 9], ["the", 16], ["biochemical", 20], ["and", 32], ["genetic", 36], ["basis", 44], ["of", 50], ["the", 53], ["Vel", 57], ["blood", 61], ["group", 67], ["antigen", 73], [",", 80], ["which", 82], ["has", 88], ["been", 92], ["a", 97], ["vexing", 99], ["mystery", 106], ["for", 114], ["decades", 118], [",", 125], ["especially", 127], ["as", 138], ["anti", 141], ["-", 145], ["Vel", 146], ["regularly", 150], ["causes", 160], ["severe", 167], ["haemolytic", 174], ["transfusion", 185], ["reactions", 197], [".", 206], ["The", 208], ["protein", 212], ["carrying", 220], ["the", 229], ["Vel", 233], ["blood", 237], ["group", 243], ["antigen", 249], ["was", 257], ["biochemically", 261], ["purified", 275], ["from", 284], ["red", 289], ["blood", 293], ["cell", 299], ["membranes", 304], [".", 313], ["Mass", 315], ["spectrometry", 320], ["-", 332], ["based", 333], ["de", 339], ["novo", 342], ["peptide", 347], ["sequencing", 355], ["identified", 366], ["this", 377], ["protein", 382], ["to", 390], ["be", 393], ["small", 396], ["integral", 402], ["membrane", 411], ["protein", 420], ["1", 428], ["(", 430], ["SMIM1", 431], [")", 436], [",", 437], ["a", 439], ["previously", 441], ["uncharacterized", 452], ["single", 468], ["-", 474], ["pass", 475], ["membrane", 480], ["protein", 489], [".", 496], ["Expression", 498], ["of", 509], ["SMIM1", 512], ["cDNA", 518], ["in", 523], ["Vel-", 526], ["cultured", 531], ["cells", 540], ["generated", 546], ["anti", 556], ["-", 560], ["Vel", 561], ["cell", 565], ["surface", 570], ["reactivity", 578], [",", 588], ["confirming", 590], ["that", 601], ["SMIM1", 606], ["encoded", 612], ["the", 620], ["Vel", 624], ["blood", 628], ["group", 634], ["antigen", 640], [".", 647], ["A", 649], ["cohort", 651], ["of", 658], ["70", 661], ["Vel-", 664], ["individuals", 669], ["was", 681], ["found", 685], ["to", 691], ["be", 694], ["uniformly", 697], ["homozygous", 707], ["for", 718], ["a", 722], ["17", 724], ["nucleotide", 727], ["deletion", 738], ["in", 747], ["the", 750], ["coding", 754], ["sequence", 761], ["of", 770], ["SMIM1", 773], [".", 778], ["The", 780], ["genetic", 784], ["homogeneity", 792], ["of", 804], ["the", 807], ["Vel-", 811], ["blood", 816], ["type", 822], [",", 826], ["likely", 828], ["having", 835], ["a", 842], ["common", 844], ["origin", 851], [",", 857], ["facilitated", 859], ["the", 871], ["development", 875], ["of", 887], ["two", 890], ["highly", 894], ["specific", 901], ["DNA", 910], ["-", 913], ["based", 914], ["tests", 920], ["for", 926], ["rapid", 930], ["Vel", 936], ["genotyping", 940], [",", 950], ["which", 952], ["can", 958], ["be", 962], ["easily", 965], ["integrated", 972], ["into", 983], ["blood", 988], ["group", 994], ["genotyping", 1000], ["platforms", 1011], [".", 1020], ["These", 1022], ["results", 1028], ["answer", 1036], ["a", 1043], ["60-year", 1045], ["-", 1052], ["old", 1053], ["riddle", 1057], ["and", 1064], ["provide", 1068], ["tools", 1076], ["of", 1082], ["immediate", 1085], ["assistance", 1095], ["to", 1106], ["all", 1109], ["clinicians", 1113], ["involved", 1124], ["in", 1133], ["the", 1136], ["care", 1140], ["of", 1145], ["Vel-", 1148], ["patients", 1153], [".", 1161]]}
{"context": "The dynamin-related protein Opa1 is localized to the mitochondrial intermembrane space, where it facilitates fusion between mitochondria. Apoptosis causes Opa1 release into the cytosol and causes mitochondria to fragment. Loss of mitochondrial membrane potential also causes mitochondrial fragmentation but not Opa1 release into the cytosol. Both conditions induce the proteolytic cleavage of Opa1, suggesting that mitochondrial fragmentation is triggered by Opa1 inactivation. The opposite effect was observed with knockdown of the mitochondrial intermembrane space protease Yme1. Knockdown of Yme1 prevents the constitutive cleavage of a subset of Opa1 splice variants but does not affect carbonyl cyanide m-chlorophenyl hydrazone or apoptosis-induced cleavage. Knockdown of Yme1 also increases mitochondrial connectivity, but this effect is independent of Opa1 because it also occurs in Opa1 knockdown cells. We conclude that Yme1 constitutively regulates a subset of Opa1 isoforms and an unknown mitochondrial morphology protein, whereas the loss of membrane potential induces the further proteolysis of Opa1.", "qas": [{"question": "Which is the cellular localization of the protein Opa1?", "answers": ["mitochondrial intermembrane space"], "qid": "06ee6c4a1f9d4cd19afcd49b8dd40d16", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["cellular", 13], ["localization", 22], ["of", 35], ["the", 38], ["protein", 42], ["Opa1", 50], ["?", 54]], "detected_answers": [{"text": "mitochondrial intermembrane space", "token_spans": [[10, 12], [79, 81]], "char_spans": [[53, 85], [533, 565]]}]}], "context_tokens": [["The", 0], ["dynamin", 4], ["-", 11], ["related", 12], ["protein", 20], ["Opa1", 28], ["is", 33], ["localized", 36], ["to", 46], ["the", 49], ["mitochondrial", 53], ["intermembrane", 67], ["space", 81], [",", 86], ["where", 88], ["it", 94], ["facilitates", 97], ["fusion", 109], ["between", 116], ["mitochondria", 124], [".", 136], ["Apoptosis", 138], ["causes", 148], ["Opa1", 155], ["release", 160], ["into", 168], ["the", 173], ["cytosol", 177], ["and", 185], ["causes", 189], ["mitochondria", 196], ["to", 209], ["fragment", 212], [".", 220], ["Loss", 222], ["of", 227], ["mitochondrial", 230], ["membrane", 244], ["potential", 253], ["also", 263], ["causes", 268], ["mitochondrial", 275], ["fragmentation", 289], ["but", 303], ["not", 307], ["Opa1", 311], ["release", 316], ["into", 324], ["the", 329], ["cytosol", 333], [".", 340], ["Both", 342], ["conditions", 347], ["induce", 358], ["the", 365], ["proteolytic", 369], ["cleavage", 381], ["of", 390], ["Opa1", 393], [",", 397], ["suggesting", 399], ["that", 410], ["mitochondrial", 415], ["fragmentation", 429], ["is", 443], ["triggered", 446], ["by", 456], ["Opa1", 459], ["inactivation", 464], [".", 476], ["The", 478], ["opposite", 482], ["effect", 491], ["was", 498], ["observed", 502], ["with", 511], ["knockdown", 516], ["of", 526], ["the", 529], ["mitochondrial", 533], ["intermembrane", 547], ["space", 561], ["protease", 567], ["Yme1", 576], [".", 580], ["Knockdown", 582], ["of", 592], ["Yme1", 595], ["prevents", 600], ["the", 609], ["constitutive", 613], ["cleavage", 626], ["of", 635], ["a", 638], ["subset", 640], ["of", 647], ["Opa1", 650], ["splice", 655], ["variants", 662], ["but", 671], ["does", 675], ["not", 680], ["affect", 684], ["carbonyl", 691], ["cyanide", 700], ["m", 708], ["-", 709], ["chlorophenyl", 710], ["hydrazone", 723], ["or", 733], ["apoptosis", 736], ["-", 745], ["induced", 746], ["cleavage", 754], [".", 762], ["Knockdown", 764], ["of", 774], ["Yme1", 777], ["also", 782], ["increases", 787], ["mitochondrial", 797], ["connectivity", 811], [",", 823], ["but", 825], ["this", 829], ["effect", 834], ["is", 841], ["independent", 844], ["of", 856], ["Opa1", 859], ["because", 864], ["it", 872], ["also", 875], ["occurs", 880], ["in", 887], ["Opa1", 890], ["knockdown", 895], ["cells", 905], [".", 910], ["We", 912], ["conclude", 915], ["that", 924], ["Yme1", 929], ["constitutively", 934], ["regulates", 949], ["a", 959], ["subset", 961], ["of", 968], ["Opa1", 971], ["isoforms", 976], ["and", 985], ["an", 989], ["unknown", 992], ["mitochondrial", 1000], ["morphology", 1014], ["protein", 1025], [",", 1032], ["whereas", 1034], ["the", 1042], ["loss", 1046], ["of", 1051], ["membrane", 1054], ["potential", 1063], ["induces", 1073], ["the", 1081], ["further", 1085], ["proteolysis", 1093], ["of", 1105], ["Opa1", 1108], [".", 1112]]}
{"context": "To define the relationship between body indices of healthy adults and cross-sectional areas of the carpal tunnel and median nerve and to obtain the nerve/tunnel index, which represents a new standard for diagnosing carpal tunnel syndrome using sonography. Body indices (height, weight, and body mass index) were analyzed in 60 healthy adults, and electromyography and sonography were also performed. The cross-sectional areas of the proximal and distal median nerve and carpal tunnel were obtained by sonography. The proximal and distal nerve/tunnel indices were obtained by calculating the ratio between the proximal and distal cross-sectional areas of the median nerve to those of the carpal tunnel and multiplying the value by 100. Although the proximal cross-sectional areas of the median nerve and body indices showed statistically significant relationships with weak positive correlations, the proximal and distal areas of the carpal tunnel showed relatively stronger correlations with body indices. Between sexes, there were significant differences in the proximal median nerve cross-sectional area (mean \u00b1 SD: male, 10.48 \u00b1 3.21 mm(2); female, 8.81 \u00b1 3.21 mm(2); P < .05) and proximal carpal tunnel area (male, 182.50 \u00b1 21.15 mm(2); female, 151.23 \u00b1 21.14 mm(2); P < .05). There was no difference in the proximal nerve/tunnel index (male, 5.80% \u00b1 1.72%; female, 5.91% \u00b1 1.63%). There was a statistically significant difference in the distal carpal tunnel cross-sectional area (male, 138.90 \u00b1 20.95 mm(2); female, 121.50 \u00b1 18.99 mm(2); P < .05) between sexes, but the distal median area (male, 9.99 \u00b1 3.42 mm(2); female, 8.46 \u00b1 1.84 mm(2)) and distal nerve/tunnel index (male, 7.15% \u00b1 2.00%; female, 7.01% \u00b1 1.38%) showed no significant differences. The proximal index was significantly higher than the distal index (proximal, 5.85% \u00b1 1.66%; distal, 7.08% \u00b1 1.71%). The nerve/tunnel index is unaffected by body indices or sex and thus may be a useful and objective standard for diagnosing carpal tunnel syndrome.", "qas": [{"question": "What nerve is involved in carpal tunnel syndrome?", "answers": ["median"], "qid": "75f0878c248e4bbab73420d14772e958", "question_tokens": [["What", 0], ["nerve", 5], ["is", 11], ["involved", 14], ["in", 23], ["carpal", 26], ["tunnel", 33], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "median", "token_spans": [[181, 181], [310, 310], [116, 116], [140, 140], [20, 20], [81, 81]], "char_spans": [[1072, 1077], [1582, 1587], [658, 663], [786, 791], [117, 122], [453, 458]]}]}], "context_tokens": [["To", 0], ["define", 3], ["the", 10], ["relationship", 14], ["between", 27], ["body", 35], ["indices", 40], ["of", 48], ["healthy", 51], ["adults", 59], ["and", 66], ["cross", 70], ["-", 75], ["sectional", 76], ["areas", 86], ["of", 92], ["the", 95], ["carpal", 99], ["tunnel", 106], ["and", 113], ["median", 117], ["nerve", 124], ["and", 130], ["to", 134], ["obtain", 137], ["the", 144], ["nerve", 148], ["/", 153], ["tunnel", 154], ["index", 161], [",", 166], ["which", 168], ["represents", 174], ["a", 185], ["new", 187], ["standard", 191], ["for", 200], ["diagnosing", 204], ["carpal", 215], ["tunnel", 222], ["syndrome", 229], ["using", 238], ["sonography", 244], [".", 254], ["Body", 256], ["indices", 261], ["(", 269], ["height", 270], [",", 276], ["weight", 278], [",", 284], ["and", 286], ["body", 290], ["mass", 295], ["index", 300], [")", 305], ["were", 307], ["analyzed", 312], ["in", 321], ["60", 324], ["healthy", 327], ["adults", 335], [",", 341], ["and", 343], ["electromyography", 347], ["and", 364], ["sonography", 368], ["were", 379], ["also", 384], ["performed", 389], [".", 398], ["The", 400], ["cross", 404], ["-", 409], ["sectional", 410], ["areas", 420], ["of", 426], ["the", 429], ["proximal", 433], ["and", 442], ["distal", 446], ["median", 453], ["nerve", 460], ["and", 466], ["carpal", 470], ["tunnel", 477], ["were", 484], ["obtained", 489], ["by", 498], ["sonography", 501], [".", 511], ["The", 513], ["proximal", 517], ["and", 526], ["distal", 530], ["nerve", 537], ["/", 542], ["tunnel", 543], ["indices", 550], ["were", 558], ["obtained", 563], ["by", 572], ["calculating", 575], ["the", 587], ["ratio", 591], ["between", 597], ["the", 605], ["proximal", 609], ["and", 618], ["distal", 622], ["cross", 629], ["-", 634], ["sectional", 635], ["areas", 645], ["of", 651], ["the", 654], ["median", 658], ["nerve", 665], ["to", 671], ["those", 674], ["of", 680], ["the", 683], ["carpal", 687], ["tunnel", 694], ["and", 701], ["multiplying", 705], ["the", 717], ["value", 721], ["by", 727], ["100", 730], [".", 733], ["Although", 735], ["the", 744], ["proximal", 748], ["cross", 757], ["-", 762], ["sectional", 763], ["areas", 773], ["of", 779], ["the", 782], ["median", 786], ["nerve", 793], ["and", 799], ["body", 803], ["indices", 808], ["showed", 816], ["statistically", 823], ["significant", 837], ["relationships", 849], ["with", 863], ["weak", 868], ["positive", 873], ["correlations", 882], [",", 894], ["the", 896], ["proximal", 900], ["and", 909], ["distal", 913], ["areas", 920], ["of", 926], ["the", 929], ["carpal", 933], ["tunnel", 940], ["showed", 947], ["relatively", 954], ["stronger", 965], ["correlations", 974], ["with", 987], ["body", 992], ["indices", 997], [".", 1004], ["Between", 1006], ["sexes", 1014], [",", 1019], ["there", 1021], ["were", 1027], ["significant", 1032], ["differences", 1044], ["in", 1056], ["the", 1059], ["proximal", 1063], ["median", 1072], ["nerve", 1079], ["cross", 1085], ["-", 1090], ["sectional", 1091], ["area", 1101], ["(", 1106], ["mean", 1107], ["\u00b1", 1112], ["SD", 1114], [":", 1116], ["male", 1118], [",", 1122], ["10.48", 1124], ["\u00b1", 1130], ["3.21", 1132], ["mm(2", 1137], [")", 1141], [";", 1142], ["female", 1144], [",", 1150], ["8.81", 1152], ["\u00b1", 1157], ["3.21", 1159], ["mm(2", 1164], [")", 1168], [";", 1169], ["P", 1171], ["<", 1173], [".05", 1175], [")", 1178], ["and", 1180], ["proximal", 1184], ["carpal", 1193], ["tunnel", 1200], ["area", 1207], ["(", 1212], ["male", 1213], [",", 1217], ["182.50", 1219], ["\u00b1", 1226], ["21.15", 1228], ["mm(2", 1234], [")", 1238], [";", 1239], ["female", 1241], [",", 1247], ["151.23", 1249], ["\u00b1", 1256], ["21.14", 1258], ["mm(2", 1264], [")", 1268], [";", 1269], ["P", 1271], ["<", 1273], [".05", 1275], [")", 1278], [".", 1279], ["There", 1281], ["was", 1287], ["no", 1291], ["difference", 1294], ["in", 1305], ["the", 1308], ["proximal", 1312], ["nerve", 1321], ["/", 1326], ["tunnel", 1327], ["index", 1334], ["(", 1340], ["male", 1341], [",", 1345], ["5.80", 1347], ["%", 1351], ["\u00b1", 1353], ["1.72", 1355], ["%", 1359], [";", 1360], ["female", 1362], [",", 1368], ["5.91", 1370], ["%", 1374], ["\u00b1", 1376], ["1.63", 1378], ["%", 1382], [")", 1383], [".", 1384], ["There", 1386], ["was", 1392], ["a", 1396], ["statistically", 1398], ["significant", 1412], ["difference", 1424], ["in", 1435], ["the", 1438], ["distal", 1442], ["carpal", 1449], ["tunnel", 1456], ["cross", 1463], ["-", 1468], ["sectional", 1469], ["area", 1479], ["(", 1484], ["male", 1485], [",", 1489], ["138.90", 1491], ["\u00b1", 1498], ["20.95", 1500], ["mm(2", 1506], [")", 1510], [";", 1511], ["female", 1513], [",", 1519], ["121.50", 1521], ["\u00b1", 1528], ["18.99", 1530], ["mm(2", 1536], [")", 1540], [";", 1541], ["P", 1543], ["<", 1545], [".05", 1547], [")", 1550], ["between", 1552], ["sexes", 1560], [",", 1565], ["but", 1567], ["the", 1571], ["distal", 1575], ["median", 1582], ["area", 1589], ["(", 1594], ["male", 1595], [",", 1599], ["9.99", 1601], ["\u00b1", 1606], ["3.42", 1608], ["mm(2", 1613], [")", 1617], [";", 1618], ["female", 1620], [",", 1626], ["8.46", 1628], ["\u00b1", 1633], ["1.84", 1635], ["mm(2", 1640], [")", 1644], [")", 1645], ["and", 1647], ["distal", 1651], ["nerve", 1658], ["/", 1663], ["tunnel", 1664], ["index", 1671], ["(", 1677], ["male", 1678], [",", 1682], ["7.15", 1684], ["%", 1688], ["\u00b1", 1690], ["2.00", 1692], ["%", 1696], [";", 1697], ["female", 1699], [",", 1705], ["7.01", 1707], ["%", 1711], ["\u00b1", 1713], ["1.38", 1715], ["%", 1719], [")", 1720], ["showed", 1722], ["no", 1729], ["significant", 1732], ["differences", 1744], [".", 1755], ["The", 1757], ["proximal", 1761], ["index", 1770], ["was", 1776], ["significantly", 1780], ["higher", 1794], ["than", 1801], ["the", 1806], ["distal", 1810], ["index", 1817], ["(", 1823], ["proximal", 1824], [",", 1832], ["5.85", 1834], ["%", 1838], ["\u00b1", 1840], ["1.66", 1842], ["%", 1846], [";", 1847], ["distal", 1849], [",", 1855], ["7.08", 1857], ["%", 1861], ["\u00b1", 1863], ["1.71", 1865], ["%", 1869], [")", 1870], [".", 1871], ["The", 1873], ["nerve", 1877], ["/", 1882], ["tunnel", 1883], ["index", 1890], ["is", 1896], ["unaffected", 1899], ["by", 1910], ["body", 1913], ["indices", 1918], ["or", 1926], ["sex", 1929], ["and", 1933], ["thus", 1937], ["may", 1942], ["be", 1946], ["a", 1949], ["useful", 1951], ["and", 1958], ["objective", 1962], ["standard", 1972], ["for", 1981], ["diagnosing", 1985], ["carpal", 1996], ["tunnel", 2003], ["syndrome", 2010], [".", 2018]]}
{"context": "Psychiatric disorders have a great impact on morbidity and mortality. Genotype-phenotype resources for psychiatric diseases are key to enable the translation of research findings to a better care of patients. PsyGeNET is a knowledge resource on psychiatric diseases and their genes, developed by text mining and curated by domain experts. We present psygenet2r, an R package that contains a variety of functions for leveraging PsyGeNET database and facilitating its analysis and interpretation. The package offers different types of queries to the database along with variety of analysis and visualization tools, including the study of the anatomical structures in which the genes are expressed and gaining insight of gene's molecular function. Psygenet2r is especially suited for network medicine analysis of psychiatric disorders. The package is implemented in R and is available under MIT license from Bioconductor (http://bioconductor.org/packages/release/bioc/html/psygenet2r.html). juanr.gonzalez@isglobal.org or laura.furlong@upf.edu. Supplementary data are available at Bioinformatics online.", "qas": [{"question": "Which R/Bioconductor package has been developed for the analysis of psychiatric disease genes?", "answers": ["Psygenet2r"], "qid": "4d4e76e2c6944123bd9d9709e0e9d250", "question_tokens": [["Which", 0], ["R", 6], ["/", 7], ["Bioconductor", 8], ["package", 21], ["has", 29], ["been", 33], ["developed", 38], ["for", 48], ["the", 52], ["analysis", 56], ["of", 65], ["psychiatric", 68], ["disease", 80], ["genes", 88], ["?", 93]], "detected_answers": [{"text": "Psygenet2r", "token_spans": [[121, 121], [58, 58]], "char_spans": [[745, 754], [350, 359]]}]}], "context_tokens": [["Psychiatric", 0], ["disorders", 12], ["have", 22], ["a", 27], ["great", 29], ["impact", 35], ["on", 42], ["morbidity", 45], ["and", 55], ["mortality", 59], [".", 68], ["Genotype", 70], ["-", 78], ["phenotype", 79], ["resources", 89], ["for", 99], ["psychiatric", 103], ["diseases", 115], ["are", 124], ["key", 128], ["to", 132], ["enable", 135], ["the", 142], ["translation", 146], ["of", 158], ["research", 161], ["findings", 170], ["to", 179], ["a", 182], ["better", 184], ["care", 191], ["of", 196], ["patients", 199], [".", 207], ["PsyGeNET", 209], ["is", 218], ["a", 221], ["knowledge", 223], ["resource", 233], ["on", 242], ["psychiatric", 245], ["diseases", 257], ["and", 266], ["their", 270], ["genes", 276], [",", 281], ["developed", 283], ["by", 293], ["text", 296], ["mining", 301], ["and", 308], ["curated", 312], ["by", 320], ["domain", 323], ["experts", 330], [".", 337], ["We", 339], ["present", 342], ["psygenet2r", 350], [",", 360], ["an", 362], ["R", 365], ["package", 367], ["that", 375], ["contains", 380], ["a", 389], ["variety", 391], ["of", 399], ["functions", 402], ["for", 412], ["leveraging", 416], ["PsyGeNET", 427], ["database", 436], ["and", 445], ["facilitating", 449], ["its", 462], ["analysis", 466], ["and", 475], ["interpretation", 479], [".", 493], ["The", 495], ["package", 499], ["offers", 507], ["different", 514], ["types", 524], ["of", 530], ["queries", 533], ["to", 541], ["the", 544], ["database", 548], ["along", 557], ["with", 563], ["variety", 568], ["of", 576], ["analysis", 579], ["and", 588], ["visualization", 592], ["tools", 606], [",", 611], ["including", 613], ["the", 623], ["study", 627], ["of", 633], ["the", 636], ["anatomical", 640], ["structures", 651], ["in", 662], ["which", 665], ["the", 671], ["genes", 675], ["are", 681], ["expressed", 685], ["and", 695], ["gaining", 699], ["insight", 707], ["of", 715], ["gene", 718], ["'s", 722], ["molecular", 725], ["function", 735], [".", 743], ["Psygenet2r", 745], ["is", 756], ["especially", 759], ["suited", 770], ["for", 777], ["network", 781], ["medicine", 789], ["analysis", 798], ["of", 807], ["psychiatric", 810], ["disorders", 822], [".", 831], ["The", 833], ["package", 837], ["is", 845], ["implemented", 848], ["in", 860], ["R", 863], ["and", 865], ["is", 869], ["available", 872], ["under", 882], ["MIT", 888], ["license", 892], ["from", 900], ["Bioconductor", 905], ["(", 918], ["http://bioconductor.org/packages/release/bioc/html/psygenet2r.html", 919], [")", 985], [".", 986], ["juanr.gonzalez@isglobal.org", 988], ["or", 1016], ["laura.furlong@upf.edu", 1019], [".", 1040], ["Supplementary", 1042], ["data", 1056], ["are", 1061], ["available", 1065], ["at", 1075], ["Bioinformatics", 1078], ["online", 1093], [".", 1099]]}
{"context": "Histone variant H2A.Z-containing nucleosomes are incorporated at most eukaryotic promoters. This incorporation is mediated by the conserved SWR1 complex, which replaces histone H2A in canonical nucleosomes with H2A.Z in an ATP-dependent manner. Here, we show that promoter-proximal nucleosomes are highly heterogeneous for H2A.Z in Saccharomyces cerevisiae, with substantial representation of nucleosomes containing one, two, or zero H2A.Z molecules. SWR1-catalyzed H2A.Z replacement in vitro occurs in a stepwise and unidirectional fashion, one H2A.Z-H2B dimer at a time, producing heterotypic nucleosomes as intermediates and homotypic H2A.Z nucleosomes as end products. The ATPase activity of SWR1 is specifically stimulated by H2A-containing nucleosomes without ensuing histone H2A eviction. Remarkably, further addition of free H2A.Z-H2B dimer leads to hyperstimulation of ATPase activity, eviction of nucleosomal H2A-H2B, and deposition of H2A.Z-H2B. These results suggest that the combination of H2A-containing nucleosome and free H2A.Z-H2B dimer acting as both effector and substrate for SWR1 governs the specificity and outcome of the replacement reaction.", "qas": [{"question": "Which protein mediates the replacement of H2A by H2A.Z in the yeast Saccharomyces cerevisiae?", "answers": ["SWR1"], "qid": "9473f38b4dee41f9afdbbe99bea8b018", "question_tokens": [["Which", 0], ["protein", 6], ["mediates", 14], ["the", 23], ["replacement", 27], ["of", 39], ["H2A", 42], ["by", 46], ["H2A.Z", 49], ["in", 55], ["the", 58], ["yeast", 62], ["Saccharomyces", 68], ["cerevisiae", 82], ["?", 92]], "detected_answers": [{"text": "SWR1", "token_spans": [[20, 20], [180, 180], [111, 111]], "char_spans": [[140, 143], [1096, 1099], [696, 699]]}]}], "context_tokens": [["Histone", 0], ["variant", 8], ["H2A.Z", 16], ["-", 21], ["containing", 22], ["nucleosomes", 33], ["are", 45], ["incorporated", 49], ["at", 62], ["most", 65], ["eukaryotic", 70], ["promoters", 81], [".", 90], ["This", 92], ["incorporation", 97], ["is", 111], ["mediated", 114], ["by", 123], ["the", 126], ["conserved", 130], ["SWR1", 140], ["complex", 145], [",", 152], ["which", 154], ["replaces", 160], ["histone", 169], ["H2A", 177], ["in", 181], ["canonical", 184], ["nucleosomes", 194], ["with", 206], ["H2A.Z", 211], ["in", 217], ["an", 220], ["ATP", 223], ["-", 226], ["dependent", 227], ["manner", 237], [".", 243], ["Here", 245], [",", 249], ["we", 251], ["show", 254], ["that", 259], ["promoter", 264], ["-", 272], ["proximal", 273], ["nucleosomes", 282], ["are", 294], ["highly", 298], ["heterogeneous", 305], ["for", 319], ["H2A.Z", 323], ["in", 329], ["Saccharomyces", 332], ["cerevisiae", 346], [",", 356], ["with", 358], ["substantial", 363], ["representation", 375], ["of", 390], ["nucleosomes", 393], ["containing", 405], ["one", 416], [",", 419], ["two", 421], [",", 424], ["or", 426], ["zero", 429], ["H2A.Z", 434], ["molecules", 440], [".", 449], ["SWR1-catalyzed", 451], ["H2A.Z", 466], ["replacement", 472], ["in", 484], ["vitro", 487], ["occurs", 493], ["in", 500], ["a", 503], ["stepwise", 505], ["and", 514], ["unidirectional", 518], ["fashion", 533], [",", 540], ["one", 542], ["H2A.Z", 546], ["-", 551], ["H2B", 552], ["dimer", 556], ["at", 562], ["a", 565], ["time", 567], [",", 571], ["producing", 573], ["heterotypic", 583], ["nucleosomes", 595], ["as", 607], ["intermediates", 610], ["and", 624], ["homotypic", 628], ["H2A.Z", 638], ["nucleosomes", 644], ["as", 656], ["end", 659], ["products", 663], [".", 671], ["The", 673], ["ATPase", 677], ["activity", 684], ["of", 693], ["SWR1", 696], ["is", 701], ["specifically", 704], ["stimulated", 717], ["by", 728], ["H2A", 731], ["-", 734], ["containing", 735], ["nucleosomes", 746], ["without", 758], ["ensuing", 766], ["histone", 774], ["H2A", 782], ["eviction", 786], [".", 794], ["Remarkably", 796], [",", 806], ["further", 808], ["addition", 816], ["of", 825], ["free", 828], ["H2A.Z", 833], ["-", 838], ["H2B", 839], ["dimer", 843], ["leads", 849], ["to", 855], ["hyperstimulation", 858], ["of", 875], ["ATPase", 878], ["activity", 885], [",", 893], ["eviction", 895], ["of", 904], ["nucleosomal", 907], ["H2A", 919], ["-", 922], ["H2B", 923], [",", 926], ["and", 928], ["deposition", 932], ["of", 943], ["H2A.Z", 946], ["-", 951], ["H2B.", 952], ["These", 957], ["results", 963], ["suggest", 971], ["that", 979], ["the", 984], ["combination", 988], ["of", 1000], ["H2A", 1003], ["-", 1006], ["containing", 1007], ["nucleosome", 1018], ["and", 1029], ["free", 1033], ["H2A.Z", 1038], ["-", 1043], ["H2B", 1044], ["dimer", 1048], ["acting", 1054], ["as", 1061], ["both", 1064], ["effector", 1069], ["and", 1078], ["substrate", 1082], ["for", 1092], ["SWR1", 1096], ["governs", 1101], ["the", 1109], ["specificity", 1113], ["and", 1125], ["outcome", 1129], ["of", 1137], ["the", 1140], ["replacement", 1144], ["reaction", 1156], [".", 1164]]}
{"context": "The purpose of this study was to describe the technique and usefulness of ultrasound-guided intrasheath injection of triamcinolone in the treatment of de Quervain's disease (dQD). Our study was retrospective in design. Seventy-one wrists of 62 patients who were treated with an ultrasound-guided triamcinolone injection for dQD were included. A literature search was performed to compare our results. In the literature we found supportive evidence that accurate injection of triamcinolone in the first dorsal compartment of the wrist is important for a good outcome. In this retrospective study we found that treatment with ultrasound-guided injections of triamcinolone is both safe and effective. After two injections, 91% of the patients had good long-term results, which is a higher cure rate than found in most other studies. Furthermore, we found that Finkelstein's test can give a false positive result. Therefore, ultrasound should not only be considered to improve the treatment outcome, but can also be useful as a diagnostic tool in the management of de Quervain's disease.", "qas": [{"question": "Which disease is diagnosed using the Finkelstein's test?", "answers": ["de Quervain's disease"], "qid": "28c063ee9b8f48c0a4043216a47ce037", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["diagnosed", 17], ["using", 27], ["the", 33], ["Finkelstein", 37], ["'s", 48], ["test", 51], ["?", 55]], "detected_answers": [{"text": "de Quervain's disease", "token_spans": [[190, 193], [24, 27]], "char_spans": [[1061, 1081], [151, 171]]}]}], "context_tokens": [["The", 0], ["purpose", 4], ["of", 12], ["this", 15], ["study", 20], ["was", 26], ["to", 30], ["describe", 33], ["the", 42], ["technique", 46], ["and", 56], ["usefulness", 60], ["of", 71], ["ultrasound", 74], ["-", 84], ["guided", 85], ["intrasheath", 92], ["injection", 104], ["of", 114], ["triamcinolone", 117], ["in", 131], ["the", 134], ["treatment", 138], ["of", 148], ["de", 151], ["Quervain", 154], ["'s", 162], ["disease", 165], ["(", 173], ["dQD", 174], [")", 177], [".", 178], ["Our", 180], ["study", 184], ["was", 190], ["retrospective", 194], ["in", 208], ["design", 211], [".", 217], ["Seventy", 219], ["-", 226], ["one", 227], ["wrists", 231], ["of", 238], ["62", 241], ["patients", 244], ["who", 253], ["were", 257], ["treated", 262], ["with", 270], ["an", 275], ["ultrasound", 278], ["-", 288], ["guided", 289], ["triamcinolone", 296], ["injection", 310], ["for", 320], ["dQD", 324], ["were", 328], ["included", 333], [".", 341], ["A", 343], ["literature", 345], ["search", 356], ["was", 363], ["performed", 367], ["to", 377], ["compare", 380], ["our", 388], ["results", 392], [".", 399], ["In", 401], ["the", 404], ["literature", 408], ["we", 419], ["found", 422], ["supportive", 428], ["evidence", 439], ["that", 448], ["accurate", 453], ["injection", 462], ["of", 472], ["triamcinolone", 475], ["in", 489], ["the", 492], ["first", 496], ["dorsal", 502], ["compartment", 509], ["of", 521], ["the", 524], ["wrist", 528], ["is", 534], ["important", 537], ["for", 547], ["a", 551], ["good", 553], ["outcome", 558], [".", 565], ["In", 567], ["this", 570], ["retrospective", 575], ["study", 589], ["we", 595], ["found", 598], ["that", 604], ["treatment", 609], ["with", 619], ["ultrasound", 624], ["-", 634], ["guided", 635], ["injections", 642], ["of", 653], ["triamcinolone", 656], ["is", 670], ["both", 673], ["safe", 678], ["and", 683], ["effective", 687], [".", 696], ["After", 698], ["two", 704], ["injections", 708], [",", 718], ["91", 720], ["%", 722], ["of", 724], ["the", 727], ["patients", 731], ["had", 740], ["good", 744], ["long", 749], ["-", 753], ["term", 754], ["results", 759], [",", 766], ["which", 768], ["is", 774], ["a", 777], ["higher", 779], ["cure", 786], ["rate", 791], ["than", 796], ["found", 801], ["in", 807], ["most", 810], ["other", 815], ["studies", 821], [".", 828], ["Furthermore", 830], [",", 841], ["we", 843], ["found", 846], ["that", 852], ["Finkelstein", 857], ["'s", 868], ["test", 871], ["can", 876], ["give", 880], ["a", 885], ["false", 887], ["positive", 893], ["result", 902], [".", 908], ["Therefore", 910], [",", 919], ["ultrasound", 921], ["should", 932], ["not", 939], ["only", 943], ["be", 948], ["considered", 951], ["to", 962], ["improve", 965], ["the", 973], ["treatment", 977], ["outcome", 987], [",", 994], ["but", 996], ["can", 1000], ["also", 1004], ["be", 1009], ["useful", 1012], ["as", 1019], ["a", 1022], ["diagnostic", 1024], ["tool", 1035], ["in", 1040], ["the", 1043], ["management", 1047], ["of", 1058], ["de", 1061], ["Quervain", 1064], ["'s", 1072], ["disease", 1075], [".", 1082]]}
{"context": "In cancer research, background models for mutation rates have been extensively calibrated in coding regions, leading to the identification of many driver genes, recurrently mutated more than expected. Noncoding regions are also associated with disease; however, background models for them have not been investigated in as much detail. This is partially due to limited noncoding functional annotation. Also, great mutation heterogeneity and potential correlations between neighboring sites give rise to substantial overdispersion in mutation count, resulting in problematic background rate estimation. Here, we address these issues with a new computational framework called LARVA. It integrates variants with a comprehensive set of noncoding functional elements, modeling the mutation counts of the elements with a \u03b2-binomial distribution to handle overdispersion. LARVA, moreover, uses regional genomic features such as replication timing to better estimate local mutation rates and mutational hotspots. We demonstrate LARVA's effectiveness on 760 whole-genome tumor sequences, showing that it identifies well-known noncoding drivers, such as mutations in the TERT promoter. Furthermore, LARVA highlights several novel highly mutated regulatory sites that could potentially be noncoding drivers. We make LARVA available as a software tool and release our highly mutated annotations as an online resource (larva.gersteinlab.org).", "qas": [{"question": "Which tool is used for the identification of recurrent variants in noncoding regions?", "answers": ["LARVA"], "qid": "b64f61ec5c4c4a3383e26a39db26cd14", "question_tokens": [["Which", 0], ["tool", 6], ["is", 11], ["used", 14], ["for", 19], ["the", 23], ["identification", 27], ["of", 42], ["recurrent", 45], ["variants", 55], ["in", 64], ["noncoding", 67], ["regions", 77], ["?", 84]], "detected_answers": [{"text": "LARVA", "token_spans": [[135, 135], [104, 104], [159, 159], [190, 190], [207, 207]], "char_spans": [[864, 868], [673, 677], [1019, 1023], [1188, 1192], [1304, 1308]]}]}], "context_tokens": [["In", 0], ["cancer", 3], ["research", 10], [",", 18], ["background", 20], ["models", 31], ["for", 38], ["mutation", 42], ["rates", 51], ["have", 57], ["been", 62], ["extensively", 67], ["calibrated", 79], ["in", 90], ["coding", 93], ["regions", 100], [",", 107], ["leading", 109], ["to", 117], ["the", 120], ["identification", 124], ["of", 139], ["many", 142], ["driver", 147], ["genes", 154], [",", 159], ["recurrently", 161], ["mutated", 173], ["more", 181], ["than", 186], ["expected", 191], [".", 199], ["Noncoding", 201], ["regions", 211], ["are", 219], ["also", 223], ["associated", 228], ["with", 239], ["disease", 244], [";", 251], ["however", 253], [",", 260], ["background", 262], ["models", 273], ["for", 280], ["them", 284], ["have", 289], ["not", 294], ["been", 298], ["investigated", 303], ["in", 316], ["as", 319], ["much", 322], ["detail", 327], [".", 333], ["This", 335], ["is", 340], ["partially", 343], ["due", 353], ["to", 357], ["limited", 360], ["noncoding", 368], ["functional", 378], ["annotation", 389], [".", 399], ["Also", 401], [",", 405], ["great", 407], ["mutation", 413], ["heterogeneity", 422], ["and", 436], ["potential", 440], ["correlations", 450], ["between", 463], ["neighboring", 471], ["sites", 483], ["give", 489], ["rise", 494], ["to", 499], ["substantial", 502], ["overdispersion", 514], ["in", 529], ["mutation", 532], ["count", 541], [",", 546], ["resulting", 548], ["in", 558], ["problematic", 561], ["background", 573], ["rate", 584], ["estimation", 589], [".", 599], ["Here", 601], [",", 605], ["we", 607], ["address", 610], ["these", 618], ["issues", 624], ["with", 631], ["a", 636], ["new", 638], ["computational", 642], ["framework", 656], ["called", 666], ["LARVA", 673], [".", 678], ["It", 680], ["integrates", 683], ["variants", 694], ["with", 703], ["a", 708], ["comprehensive", 710], ["set", 724], ["of", 728], ["noncoding", 731], ["functional", 741], ["elements", 752], [",", 760], ["modeling", 762], ["the", 771], ["mutation", 775], ["counts", 784], ["of", 791], ["the", 794], ["elements", 798], ["with", 807], ["a", 812], ["\u03b2", 814], ["-", 815], ["binomial", 816], ["distribution", 825], ["to", 838], ["handle", 841], ["overdispersion", 848], [".", 862], ["LARVA", 864], [",", 869], ["moreover", 871], [",", 879], ["uses", 881], ["regional", 886], ["genomic", 895], ["features", 903], ["such", 912], ["as", 917], ["replication", 920], ["timing", 932], ["to", 939], ["better", 942], ["estimate", 949], ["local", 958], ["mutation", 964], ["rates", 973], ["and", 979], ["mutational", 983], ["hotspots", 994], [".", 1002], ["We", 1004], ["demonstrate", 1007], ["LARVA", 1019], ["'s", 1024], ["effectiveness", 1027], ["on", 1041], ["760", 1044], ["whole", 1048], ["-", 1053], ["genome", 1054], ["tumor", 1061], ["sequences", 1067], [",", 1076], ["showing", 1078], ["that", 1086], ["it", 1091], ["identifies", 1094], ["well", 1105], ["-", 1109], ["known", 1110], ["noncoding", 1116], ["drivers", 1126], [",", 1133], ["such", 1135], ["as", 1140], ["mutations", 1143], ["in", 1153], ["the", 1156], ["TERT", 1160], ["promoter", 1165], [".", 1173], ["Furthermore", 1175], [",", 1186], ["LARVA", 1188], ["highlights", 1194], ["several", 1205], ["novel", 1213], ["highly", 1219], ["mutated", 1226], ["regulatory", 1234], ["sites", 1245], ["that", 1251], ["could", 1256], ["potentially", 1262], ["be", 1274], ["noncoding", 1277], ["drivers", 1287], [".", 1294], ["We", 1296], ["make", 1299], ["LARVA", 1304], ["available", 1310], ["as", 1320], ["a", 1323], ["software", 1325], ["tool", 1334], ["and", 1339], ["release", 1343], ["our", 1351], ["highly", 1355], ["mutated", 1362], ["annotations", 1370], ["as", 1382], ["an", 1385], ["online", 1388], ["resource", 1395], ["(", 1404], ["larva.gersteinlab.org", 1405], [")", 1426], [".", 1427]]}
{"context": "Eighty-eight Staphylococcus aureus clinical isolates meeting criteria for borderline oxacillin resistance (intermediate susceptibility or resistance to oxacillin but susceptibility to amoxicillin/clavulanic acid upon disk diffusion testing) were studied to determine optimal test techniques and conditions for differentiating borderline oxacillin-resistant Staphylococcus aureus (BORSA) from methicillin-resistant Staphylococcus aureus (MRSA). Further testing revealed three distinct resistance patterns: 61 strains (69%) consistently met BORSA criteria and had average beta-lactamase levels five- to six-fold higher than oxacillin-susceptible controls; 11 strains (13%) were markedly heteroresistant MRSA with delayed appearance of resistant colonies leading to spurious susceptibility to amoxicillin/clavulanic acid; 16 strains (18%) appeared to be oxacillin-susceptible on repetitive testing. Under conditions used to elicit intrinsic methicillin resistance in Staphylococcus aureus, a large percentage of BORSA appeared resistant to amoxicillin/clavulanic acid. This clearly shows that BORSA may be misidentified as MRSA while heteroresistant MRSA may appear to be BORSA. It is concluded that amoxicillin/clavulanic acid zone sizes should be measured after a full 24 hours of incubation, that susceptibility testing of Staphylococcus aureus under certain environmental conditions should be interpreted with caution, and that MIC testing is the most reliable technique for differentiating these two resistance patterns in Staphylococcus aureus.", "qas": [{"question": "What is BORSA?", "answers": ["Borderline oxacillin-resistant Staphylococcus aureus"], "qid": "3d2f68914f0e4658990df1920e00cd94", "question_tokens": [["What", 0], ["is", 5], ["BORSA", 8], ["?", 13]], "detected_answers": [{"text": "Borderline oxacillin-resistant Staphylococcus aureus", "token_spans": [[43, 48]], "char_spans": [[326, 377]]}]}], "context_tokens": [["Eighty", 0], ["-", 6], ["eight", 7], ["Staphylococcus", 13], ["aureus", 28], ["clinical", 35], ["isolates", 44], ["meeting", 53], ["criteria", 61], ["for", 70], ["borderline", 74], ["oxacillin", 85], ["resistance", 95], ["(", 106], ["intermediate", 107], ["susceptibility", 120], ["or", 135], ["resistance", 138], ["to", 149], ["oxacillin", 152], ["but", 162], ["susceptibility", 166], ["to", 181], ["amoxicillin", 184], ["/", 195], ["clavulanic", 196], ["acid", 207], ["upon", 212], ["disk", 217], ["diffusion", 222], ["testing", 232], [")", 239], ["were", 241], ["studied", 246], ["to", 254], ["determine", 257], ["optimal", 267], ["test", 275], ["techniques", 280], ["and", 291], ["conditions", 295], ["for", 306], ["differentiating", 310], ["borderline", 326], ["oxacillin", 337], ["-", 346], ["resistant", 347], ["Staphylococcus", 357], ["aureus", 372], ["(", 379], ["BORSA", 380], [")", 385], ["from", 387], ["methicillin", 392], ["-", 403], ["resistant", 404], ["Staphylococcus", 414], ["aureus", 429], ["(", 436], ["MRSA", 437], [")", 441], [".", 442], ["Further", 444], ["testing", 452], ["revealed", 460], ["three", 469], ["distinct", 475], ["resistance", 484], ["patterns", 495], [":", 503], ["61", 505], ["strains", 508], ["(", 516], ["69", 517], ["%", 519], [")", 520], ["consistently", 522], ["met", 535], ["BORSA", 539], ["criteria", 545], ["and", 554], ["had", 558], ["average", 562], ["beta", 570], ["-", 574], ["lactamase", 575], ["levels", 585], ["five-", 592], ["to", 598], ["six", 601], ["-", 604], ["fold", 605], ["higher", 610], ["than", 617], ["oxacillin", 622], ["-", 631], ["susceptible", 632], ["controls", 644], [";", 652], ["11", 654], ["strains", 657], ["(", 665], ["13", 666], ["%", 668], [")", 669], ["were", 671], ["markedly", 676], ["heteroresistant", 685], ["MRSA", 701], ["with", 706], ["delayed", 711], ["appearance", 719], ["of", 730], ["resistant", 733], ["colonies", 743], ["leading", 752], ["to", 760], ["spurious", 763], ["susceptibility", 772], ["to", 787], ["amoxicillin", 790], ["/", 801], ["clavulanic", 802], ["acid", 813], [";", 817], ["16", 819], ["strains", 822], ["(", 830], ["18", 831], ["%", 833], [")", 834], ["appeared", 836], ["to", 845], ["be", 848], ["oxacillin", 851], ["-", 860], ["susceptible", 861], ["on", 873], ["repetitive", 876], ["testing", 887], [".", 894], ["Under", 896], ["conditions", 902], ["used", 913], ["to", 918], ["elicit", 921], ["intrinsic", 928], ["methicillin", 938], ["resistance", 950], ["in", 961], ["Staphylococcus", 964], ["aureus", 979], [",", 985], ["a", 987], ["large", 989], ["percentage", 995], ["of", 1006], ["BORSA", 1009], ["appeared", 1015], ["resistant", 1024], ["to", 1034], ["amoxicillin", 1037], ["/", 1048], ["clavulanic", 1049], ["acid", 1060], [".", 1064], ["This", 1066], ["clearly", 1071], ["shows", 1079], ["that", 1085], ["BORSA", 1090], ["may", 1096], ["be", 1100], ["misidentified", 1103], ["as", 1117], ["MRSA", 1120], ["while", 1125], ["heteroresistant", 1131], ["MRSA", 1147], ["may", 1152], ["appear", 1156], ["to", 1163], ["be", 1166], ["BORSA", 1169], [".", 1174], ["It", 1176], ["is", 1179], ["concluded", 1182], ["that", 1192], ["amoxicillin", 1197], ["/", 1208], ["clavulanic", 1209], ["acid", 1220], ["zone", 1225], ["sizes", 1230], ["should", 1236], ["be", 1243], ["measured", 1246], ["after", 1255], ["a", 1261], ["full", 1263], ["24", 1268], ["hours", 1271], ["of", 1277], ["incubation", 1280], [",", 1290], ["that", 1292], ["susceptibility", 1297], ["testing", 1312], ["of", 1320], ["Staphylococcus", 1323], ["aureus", 1338], ["under", 1345], ["certain", 1351], ["environmental", 1359], ["conditions", 1373], ["should", 1384], ["be", 1391], ["interpreted", 1394], ["with", 1406], ["caution", 1411], [",", 1418], ["and", 1420], ["that", 1424], ["MIC", 1429], ["testing", 1433], ["is", 1441], ["the", 1444], ["most", 1448], ["reliable", 1453], ["technique", 1462], ["for", 1472], ["differentiating", 1476], ["these", 1492], ["two", 1498], ["resistance", 1502], ["patterns", 1513], ["in", 1522], ["Staphylococcus", 1525], ["aureus", 1540], [".", 1546]]}
{"context": "Vascular Ehlers-Danlos Syndrome (VEDS), previously called Ehlers-Danlos syndrome type-IV, is a heterogeneous group of heritable connective tissue disorders characterized by thin, translucent skin, easy bruising, arterial, intestinal, and/or uterine fragility. There is large vessel involvement that leads to arterial rupture often preceded by aneurysm, arteriovenous fistulae, or dissection. Noninvasive imaging studies such as CT angiography and MR angiography are preferred as diagnostic studies for this condition. We are reporting a 4 years old girl who was presented with right sided unilateral convulsions and hypertension. CT angiogram showed stenosis with post-stenotic dilatation of coeliac and superior mesenteric arteries. There were extensive calcified plaques with atherosclerotic changes in the segment of right common iliac artery with aneurysmal dilatation of celiac, superior mesenteric and common iliac artery. Radiological findings were consistent with vascular Ehlers-Danlos syndrome. She was successfully managed with anti-hypertensive and anticonvulsants.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "c4aa033a18f745d98c38639082418fe4", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[25, 26]], "char_spans": [[128, 144]]}]}], "context_tokens": [["Vascular", 0], ["Ehlers", 9], ["-", 15], ["Danlos", 16], ["Syndrome", 23], ["(", 32], ["VEDS", 33], [")", 37], [",", 38], ["previously", 40], ["called", 51], ["Ehlers", 58], ["-", 64], ["Danlos", 65], ["syndrome", 72], ["type", 81], ["-", 85], ["IV", 86], [",", 88], ["is", 90], ["a", 93], ["heterogeneous", 95], ["group", 109], ["of", 115], ["heritable", 118], ["connective", 128], ["tissue", 139], ["disorders", 146], ["characterized", 156], ["by", 170], ["thin", 173], [",", 177], ["translucent", 179], ["skin", 191], [",", 195], ["easy", 197], ["bruising", 202], [",", 210], ["arterial", 212], [",", 220], ["intestinal", 222], [",", 232], ["and/or", 234], ["uterine", 241], ["fragility", 249], [".", 258], ["There", 260], ["is", 266], ["large", 269], ["vessel", 275], ["involvement", 282], ["that", 294], ["leads", 299], ["to", 305], ["arterial", 308], ["rupture", 317], ["often", 325], ["preceded", 331], ["by", 340], ["aneurysm", 343], [",", 351], ["arteriovenous", 353], ["fistulae", 367], [",", 375], ["or", 377], ["dissection", 380], [".", 390], ["Noninvasive", 392], ["imaging", 404], ["studies", 412], ["such", 420], ["as", 425], ["CT", 428], ["angiography", 431], ["and", 443], ["MR", 447], ["angiography", 450], ["are", 462], ["preferred", 466], ["as", 476], ["diagnostic", 479], ["studies", 490], ["for", 498], ["this", 502], ["condition", 507], [".", 516], ["We", 518], ["are", 521], ["reporting", 525], ["a", 535], ["4", 537], ["years", 539], ["old", 545], ["girl", 549], ["who", 554], ["was", 558], ["presented", 562], ["with", 572], ["right", 577], ["sided", 583], ["unilateral", 589], ["convulsions", 600], ["and", 612], ["hypertension", 616], [".", 628], ["CT", 630], ["angiogram", 633], ["showed", 643], ["stenosis", 650], ["with", 659], ["post", 664], ["-", 668], ["stenotic", 669], ["dilatation", 678], ["of", 689], ["coeliac", 692], ["and", 700], ["superior", 704], ["mesenteric", 713], ["arteries", 724], [".", 732], ["There", 734], ["were", 740], ["extensive", 745], ["calcified", 755], ["plaques", 765], ["with", 773], ["atherosclerotic", 778], ["changes", 794], ["in", 802], ["the", 805], ["segment", 809], ["of", 817], ["right", 820], ["common", 826], ["iliac", 833], ["artery", 839], ["with", 846], ["aneurysmal", 851], ["dilatation", 862], ["of", 873], ["celiac", 876], [",", 882], ["superior", 884], ["mesenteric", 893], ["and", 904], ["common", 908], ["iliac", 915], ["artery", 921], [".", 927], ["Radiological", 929], ["findings", 942], ["were", 951], ["consistent", 956], ["with", 967], ["vascular", 972], ["Ehlers", 981], ["-", 987], ["Danlos", 988], ["syndrome", 995], [".", 1003], ["She", 1005], ["was", 1009], ["successfully", 1013], ["managed", 1026], ["with", 1034], ["anti", 1039], ["-", 1043], ["hypertensive", 1044], ["and", 1057], ["anticonvulsants", 1061], [".", 1076]]}
{"context": "Defects in DNA mismatch repair have been shown to lead to increased genomic instability and mutability. We recently found that human cells defective in the DNA mismatch repair gene, hMSH2, were deficient in the transcription-coupled repair (TCR) of both oxidative DNA damage, including thymine glycols, and UV-induced DNA damage. However, in a hMLH1 mutant, only a reduction in the TCR of UV damage was observed. In this study, we examined whether TCR of thymine glycols in Saccharomyces cerecisiae also requires the genes involved in DNA mismatch repair. We found that yeast cells containing mutations in MSH2 were deficient in the removal of thymine glycols from the transcribed strand of the RPB2 gene, while cells with mutations in either MLH1 or PMS1 alone showed near normal levels of TCR of thymine glycols. Interestingly, double mutants in the MLH1 and PMS1 genes were deficient in TCR of thymine glycols. Taken together, these results suggest that these two MutL homologues can act independently of each other, but that they have overlapping roles in TCR. Overall levels of thymine glycol removal were not reduced in the mismatch repair mutants. In contrast to the results with thymine glycols, no defects in TCR of pyrimidine dimers were found in cells with mutations in MSH2, MLH1, PMS1, and MLH1/PMS1.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "e3dbeab284f84daeb820a11a28cd701d", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[123, 124]], "char_spans": [[669, 686]]}]}], "context_tokens": [["Defects", 0], ["in", 8], ["DNA", 11], ["mismatch", 15], ["repair", 24], ["have", 31], ["been", 36], ["shown", 41], ["to", 47], ["lead", 50], ["to", 55], ["increased", 58], ["genomic", 68], ["instability", 76], ["and", 88], ["mutability", 92], [".", 102], ["We", 104], ["recently", 107], ["found", 116], ["that", 122], ["human", 127], ["cells", 133], ["defective", 139], ["in", 149], ["the", 152], ["DNA", 156], ["mismatch", 160], ["repair", 169], ["gene", 176], [",", 180], ["hMSH2", 182], [",", 187], ["were", 189], ["deficient", 194], ["in", 204], ["the", 207], ["transcription", 211], ["-", 224], ["coupled", 225], ["repair", 233], ["(", 240], ["TCR", 241], [")", 244], ["of", 246], ["both", 249], ["oxidative", 254], ["DNA", 264], ["damage", 268], [",", 274], ["including", 276], ["thymine", 286], ["glycols", 294], [",", 301], ["and", 303], ["UV", 307], ["-", 309], ["induced", 310], ["DNA", 318], ["damage", 322], [".", 328], ["However", 330], [",", 337], ["in", 339], ["a", 342], ["hMLH1", 344], ["mutant", 350], [",", 356], ["only", 358], ["a", 363], ["reduction", 365], ["in", 375], ["the", 378], ["TCR", 382], ["of", 386], ["UV", 389], ["damage", 392], ["was", 399], ["observed", 403], [".", 411], ["In", 413], ["this", 416], ["study", 421], [",", 426], ["we", 428], ["examined", 431], ["whether", 440], ["TCR", 448], ["of", 452], ["thymine", 455], ["glycols", 463], ["in", 471], ["Saccharomyces", 474], ["cerecisiae", 488], ["also", 499], ["requires", 504], ["the", 513], ["genes", 517], ["involved", 523], ["in", 532], ["DNA", 535], ["mismatch", 539], ["repair", 548], [".", 554], ["We", 556], ["found", 559], ["that", 565], ["yeast", 570], ["cells", 576], ["containing", 582], ["mutations", 593], ["in", 603], ["MSH2", 606], ["were", 611], ["deficient", 616], ["in", 626], ["the", 629], ["removal", 633], ["of", 641], ["thymine", 644], ["glycols", 652], ["from", 660], ["the", 665], ["transcribed", 669], ["strand", 681], ["of", 688], ["the", 691], ["RPB2", 695], ["gene", 700], [",", 704], ["while", 706], ["cells", 712], ["with", 718], ["mutations", 723], ["in", 733], ["either", 736], ["MLH1", 743], ["or", 748], ["PMS1", 751], ["alone", 756], ["showed", 762], ["near", 769], ["normal", 774], ["levels", 781], ["of", 788], ["TCR", 791], ["of", 795], ["thymine", 798], ["glycols", 806], [".", 813], ["Interestingly", 815], [",", 828], ["double", 830], ["mutants", 837], ["in", 845], ["the", 848], ["MLH1", 852], ["and", 857], ["PMS1", 861], ["genes", 866], ["were", 872], ["deficient", 877], ["in", 887], ["TCR", 890], ["of", 894], ["thymine", 897], ["glycols", 905], [".", 912], ["Taken", 914], ["together", 920], [",", 928], ["these", 930], ["results", 936], ["suggest", 944], ["that", 952], ["these", 957], ["two", 963], ["MutL", 967], ["homologues", 972], ["can", 983], ["act", 987], ["independently", 991], ["of", 1005], ["each", 1008], ["other", 1013], [",", 1018], ["but", 1020], ["that", 1024], ["they", 1029], ["have", 1034], ["overlapping", 1039], ["roles", 1051], ["in", 1057], ["TCR", 1060], [".", 1063], ["Overall", 1065], ["levels", 1073], ["of", 1080], ["thymine", 1083], ["glycol", 1091], ["removal", 1098], ["were", 1106], ["not", 1111], ["reduced", 1115], ["in", 1123], ["the", 1126], ["mismatch", 1130], ["repair", 1139], ["mutants", 1146], [".", 1153], ["In", 1155], ["contrast", 1158], ["to", 1167], ["the", 1170], ["results", 1174], ["with", 1182], ["thymine", 1187], ["glycols", 1195], [",", 1202], ["no", 1204], ["defects", 1207], ["in", 1215], ["TCR", 1218], ["of", 1222], ["pyrimidine", 1225], ["dimers", 1236], ["were", 1243], ["found", 1248], ["in", 1254], ["cells", 1257], ["with", 1263], ["mutations", 1268], ["in", 1278], ["MSH2", 1281], [",", 1285], ["MLH1", 1287], [",", 1291], ["PMS1", 1293], [",", 1297], ["and", 1299], ["MLH1/PMS1", 1303], [".", 1312]]}
{"context": "The development of novel oral anticoagulants (NOACs) has revolutionized oral anticoagulation. Rapid incorporation of NOACs into general practice has heightened the demand for directed reversal agents. Idarucizumab is a targeted reversal agent that is approved for the urgent reversal of the anticoagulant effects of dabigatran. While it is a welcome addition to reversal strategies of dabigatran, a number of clinical questions exist regarding its place in therapy. We describe controversies regarding the use of idarucizumab therapy in patients with dabigatran-associated bleeding. Although existing clinical studies show a rapid reversal of coagulation assays, these studies did not describe a corresponding improvement in mortality or rapid cessation of hemorrhage. It is questionable how heavily clinicians can rely upon the use of the surrogate endpoints in clinical studies, such as ecarin clotting time and dilute thrombin time. Another issue is whether patients exhibiting re-elevation of coagulation assays would benefit from an additional dose of idarucizumab, because this has not been studied. It is currently unclear if blood products must be given in addition to idarucizumab can be used as monotherapy. The initial data suggest a definite role for idarucizumab in treatment of bleeding associated with dabigatran. As more clinical practice experience is gained with the agent and the remaining data on its use are released, clinicians can better guide the clinical use of idarucizumab. At present, there is currently not enough evidence for idarucizumab to be used as monotherapy.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "dc40f38b59fd40f9bfc5fdd3040d8e0c", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[60, 60], [48, 48], [211, 211], [86, 86]], "char_spans": [[385, 394], [316, 325], [1317, 1326], [551, 560]]}]}], "context_tokens": [["The", 0], ["development", 4], ["of", 16], ["novel", 19], ["oral", 25], ["anticoagulants", 30], ["(", 45], ["NOACs", 46], [")", 51], ["has", 53], ["revolutionized", 57], ["oral", 72], ["anticoagulation", 77], [".", 92], ["Rapid", 94], ["incorporation", 100], ["of", 114], ["NOACs", 117], ["into", 123], ["general", 128], ["practice", 136], ["has", 145], ["heightened", 149], ["the", 160], ["demand", 164], ["for", 171], ["directed", 175], ["reversal", 184], ["agents", 193], [".", 199], ["Idarucizumab", 201], ["is", 214], ["a", 217], ["targeted", 219], ["reversal", 228], ["agent", 237], ["that", 243], ["is", 248], ["approved", 251], ["for", 260], ["the", 264], ["urgent", 268], ["reversal", 275], ["of", 284], ["the", 287], ["anticoagulant", 291], ["effects", 305], ["of", 313], ["dabigatran", 316], [".", 326], ["While", 328], ["it", 334], ["is", 337], ["a", 340], ["welcome", 342], ["addition", 350], ["to", 359], ["reversal", 362], ["strategies", 371], ["of", 382], ["dabigatran", 385], [",", 395], ["a", 397], ["number", 399], ["of", 406], ["clinical", 409], ["questions", 418], ["exist", 428], ["regarding", 434], ["its", 444], ["place", 448], ["in", 454], ["therapy", 457], [".", 464], ["We", 466], ["describe", 469], ["controversies", 478], ["regarding", 492], ["the", 502], ["use", 506], ["of", 510], ["idarucizumab", 513], ["therapy", 526], ["in", 534], ["patients", 537], ["with", 546], ["dabigatran", 551], ["-", 561], ["associated", 562], ["bleeding", 573], [".", 581], ["Although", 583], ["existing", 592], ["clinical", 601], ["studies", 610], ["show", 618], ["a", 623], ["rapid", 625], ["reversal", 631], ["of", 640], ["coagulation", 643], ["assays", 655], [",", 661], ["these", 663], ["studies", 669], ["did", 677], ["not", 681], ["describe", 685], ["a", 694], ["corresponding", 696], ["improvement", 710], ["in", 722], ["mortality", 725], ["or", 735], ["rapid", 738], ["cessation", 744], ["of", 754], ["hemorrhage", 757], [".", 767], ["It", 769], ["is", 772], ["questionable", 775], ["how", 788], ["heavily", 792], ["clinicians", 800], ["can", 811], ["rely", 815], ["upon", 820], ["the", 825], ["use", 829], ["of", 833], ["the", 836], ["surrogate", 840], ["endpoints", 850], ["in", 860], ["clinical", 863], ["studies", 872], [",", 879], ["such", 881], ["as", 886], ["ecarin", 889], ["clotting", 896], ["time", 905], ["and", 910], ["dilute", 914], ["thrombin", 921], ["time", 930], [".", 934], ["Another", 936], ["issue", 944], ["is", 950], ["whether", 953], ["patients", 961], ["exhibiting", 970], ["re", 981], ["-", 983], ["elevation", 984], ["of", 994], ["coagulation", 997], ["assays", 1009], ["would", 1016], ["benefit", 1022], ["from", 1030], ["an", 1035], ["additional", 1038], ["dose", 1049], ["of", 1054], ["idarucizumab", 1057], [",", 1069], ["because", 1071], ["this", 1079], ["has", 1084], ["not", 1088], ["been", 1092], ["studied", 1097], [".", 1104], ["It", 1106], ["is", 1109], ["currently", 1112], ["unclear", 1122], ["if", 1130], ["blood", 1133], ["products", 1139], ["must", 1148], ["be", 1153], ["given", 1156], ["in", 1162], ["addition", 1165], ["to", 1174], ["idarucizumab", 1177], ["can", 1190], ["be", 1194], ["used", 1197], ["as", 1202], ["monotherapy", 1205], [".", 1216], ["The", 1218], ["initial", 1222], ["data", 1230], ["suggest", 1235], ["a", 1243], ["definite", 1245], ["role", 1254], ["for", 1259], ["idarucizumab", 1263], ["in", 1276], ["treatment", 1279], ["of", 1289], ["bleeding", 1292], ["associated", 1301], ["with", 1312], ["dabigatran", 1317], [".", 1327], ["As", 1329], ["more", 1332], ["clinical", 1337], ["practice", 1346], ["experience", 1355], ["is", 1366], ["gained", 1369], ["with", 1376], ["the", 1381], ["agent", 1385], ["and", 1391], ["the", 1395], ["remaining", 1399], ["data", 1409], ["on", 1414], ["its", 1417], ["use", 1421], ["are", 1425], ["released", 1429], [",", 1437], ["clinicians", 1439], ["can", 1450], ["better", 1454], ["guide", 1461], ["the", 1467], ["clinical", 1471], ["use", 1480], ["of", 1484], ["idarucizumab", 1487], [".", 1499], ["At", 1501], ["present", 1504], [",", 1511], ["there", 1513], ["is", 1519], ["currently", 1522], ["not", 1532], ["enough", 1536], ["evidence", 1543], ["for", 1552], ["idarucizumab", 1556], ["to", 1569], ["be", 1572], ["used", 1575], ["as", 1580], ["monotherapy", 1583], [".", 1594]]}
{"context": "Neurofibromatosis type 1 (NF1) is characterized primarily by tumor formation in the nervous system, but patients report other neurological complications including pain and itch. Individuals with NF1 harbor 1 mutated NF1 allele causing heterozygous expression in all of their cells. In mice, Nf1 heterozygosity leads to hyperexcitability of sensory neurons and hyperproliferation of mast cells, both of which could lead to increased hypersensitivity and scratching in response to noxious and pruritic stimuli. To determine whether Nf1 heterozygosity may increase pain and itch behaviors independent of secondary effects of tumor formation, we used mice with a targeted, heterozygous Nf1 gene deletion (Nf1\u00b1) that lack tumors. Nf1\u00b1 mice exhibited normal baseline responses to thermal and mechanical stimuli. Moreover, similar to wild-type littermates, Nf1\u00b1 mice developed inflammation-induced heat\u00a0and mechanical hypersensitivity, capsaicin-induced nocifensive behavior, histamine-dependent or -independent scratching, and chronic constriction injury-induced cold allodynia. However, Nf1\u00b1\u00a0mice exhibited an attenuated first phase of formalin-induced spontaneous behavior and expedited resolution of formalin-induced heat hypersensitivity. These results are not consistent with the hypothesis that Nf1 heterozygosity alone is sufficient to increase pain and itch sensation in mice, and they suggest that additional mechanisms may underlie reports of increased pain and itch in NF1 patients. This study assessed whether Nf1 heterozygosity in mice increased hypersensitivity and scratching following noxious and pruritic stimuli. Using Nf1\u00b1 mice lacking tumors, this study finds no increases in pain or itch behavior, suggesting that there is no predisposition for either clinical symptom solely due to Nf1 heterozygosity.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "40227f76b00344a78411177630545e7b", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[48, 48], [83, 83], [107, 107], [30, 30], [205, 205], [234, 234], [285, 285], [4, 4], [34, 34], [241, 241]], "char_spans": [[291, 293], [530, 532], [682, 684], [195, 197], [1295, 1297], [1474, 1476], [1798, 1800], [26, 28], [216, 218], [1516, 1518]]}]}], "context_tokens": [["Neurofibromatosis", 0], ["type", 18], ["1", 23], ["(", 25], ["NF1", 26], [")", 29], ["is", 31], ["characterized", 34], ["primarily", 48], ["by", 58], ["tumor", 61], ["formation", 67], ["in", 77], ["the", 80], ["nervous", 84], ["system", 92], [",", 98], ["but", 100], ["patients", 104], ["report", 113], ["other", 120], ["neurological", 126], ["complications", 139], ["including", 153], ["pain", 163], ["and", 168], ["itch", 172], [".", 176], ["Individuals", 178], ["with", 190], ["NF1", 195], ["harbor", 199], ["1", 206], ["mutated", 208], ["NF1", 216], ["allele", 220], ["causing", 227], ["heterozygous", 235], ["expression", 248], ["in", 259], ["all", 262], ["of", 266], ["their", 269], ["cells", 275], [".", 280], ["In", 282], ["mice", 285], [",", 289], ["Nf1", 291], ["heterozygosity", 295], ["leads", 310], ["to", 316], ["hyperexcitability", 319], ["of", 337], ["sensory", 340], ["neurons", 348], ["and", 356], ["hyperproliferation", 360], ["of", 379], ["mast", 382], ["cells", 387], [",", 392], ["both", 394], ["of", 399], ["which", 402], ["could", 408], ["lead", 414], ["to", 419], ["increased", 422], ["hypersensitivity", 432], ["and", 449], ["scratching", 453], ["in", 464], ["response", 467], ["to", 476], ["noxious", 479], ["and", 487], ["pruritic", 491], ["stimuli", 500], [".", 507], ["To", 509], ["determine", 512], ["whether", 522], ["Nf1", 530], ["heterozygosity", 534], ["may", 549], ["increase", 553], ["pain", 562], ["and", 567], ["itch", 571], ["behaviors", 576], ["independent", 586], ["of", 598], ["secondary", 601], ["effects", 611], ["of", 619], ["tumor", 622], ["formation", 628], [",", 637], ["we", 639], ["used", 642], ["mice", 647], ["with", 652], ["a", 657], ["targeted", 659], [",", 667], ["heterozygous", 669], ["Nf1", 682], ["gene", 686], ["deletion", 691], ["(", 700], ["Nf1\u00b1", 701], [")", 705], ["that", 707], ["lack", 712], ["tumors", 717], [".", 723], ["Nf1\u00b1", 725], ["mice", 730], ["exhibited", 735], ["normal", 745], ["baseline", 752], ["responses", 761], ["to", 771], ["thermal", 774], ["and", 782], ["mechanical", 786], ["stimuli", 797], [".", 804], ["Moreover", 806], [",", 814], ["similar", 816], ["to", 824], ["wild", 827], ["-", 831], ["type", 832], ["littermates", 837], [",", 848], ["Nf1\u00b1", 850], ["mice", 855], ["developed", 860], ["inflammation", 870], ["-", 882], ["induced", 883], ["heat", 891], ["and", 896], ["mechanical", 900], ["hypersensitivity", 911], [",", 927], ["capsaicin", 929], ["-", 938], ["induced", 939], ["nocifensive", 947], ["behavior", 959], [",", 967], ["histamine", 969], ["-", 978], ["dependent", 979], ["or", 989], ["-independent", 992], ["scratching", 1005], [",", 1015], ["and", 1017], ["chronic", 1021], ["constriction", 1029], ["injury", 1042], ["-", 1048], ["induced", 1049], ["cold", 1057], ["allodynia", 1062], [".", 1071], ["However", 1073], [",", 1080], ["Nf1\u00b1", 1082], ["mice", 1087], ["exhibited", 1092], ["an", 1102], ["attenuated", 1105], ["first", 1116], ["phase", 1122], ["of", 1128], ["formalin", 1131], ["-", 1139], ["induced", 1140], ["spontaneous", 1148], ["behavior", 1160], ["and", 1169], ["expedited", 1173], ["resolution", 1183], ["of", 1194], ["formalin", 1197], ["-", 1205], ["induced", 1206], ["heat", 1214], ["hypersensitivity", 1219], [".", 1235], ["These", 1237], ["results", 1243], ["are", 1251], ["not", 1255], ["consistent", 1259], ["with", 1270], ["the", 1275], ["hypothesis", 1279], ["that", 1290], ["Nf1", 1295], ["heterozygosity", 1299], ["alone", 1314], ["is", 1320], ["sufficient", 1323], ["to", 1334], ["increase", 1337], ["pain", 1346], ["and", 1351], ["itch", 1355], ["sensation", 1360], ["in", 1370], ["mice", 1373], [",", 1377], ["and", 1379], ["they", 1383], ["suggest", 1388], ["that", 1396], ["additional", 1401], ["mechanisms", 1412], ["may", 1423], ["underlie", 1427], ["reports", 1436], ["of", 1444], ["increased", 1447], ["pain", 1457], ["and", 1462], ["itch", 1466], ["in", 1471], ["NF1", 1474], ["patients", 1478], [".", 1486], ["This", 1488], ["study", 1493], ["assessed", 1499], ["whether", 1508], ["Nf1", 1516], ["heterozygosity", 1520], ["in", 1535], ["mice", 1538], ["increased", 1543], ["hypersensitivity", 1553], ["and", 1570], ["scratching", 1574], ["following", 1585], ["noxious", 1595], ["and", 1603], ["pruritic", 1607], ["stimuli", 1616], [".", 1623], ["Using", 1625], ["Nf1\u00b1", 1631], ["mice", 1636], ["lacking", 1641], ["tumors", 1649], [",", 1655], ["this", 1657], ["study", 1662], ["finds", 1668], ["no", 1674], ["increases", 1677], ["in", 1687], ["pain", 1690], ["or", 1695], ["itch", 1698], ["behavior", 1703], [",", 1711], ["suggesting", 1713], ["that", 1724], ["there", 1729], ["is", 1735], ["no", 1738], ["predisposition", 1741], ["for", 1756], ["either", 1760], ["clinical", 1767], ["symptom", 1776], ["solely", 1784], ["due", 1791], ["to", 1795], ["Nf1", 1798], ["heterozygosity", 1802], [".", 1816]]}
{"context": "Loss-of-function mutations in the gene ced-8 lead to the late appearance of cell corpses during embryonic development in C. elegans. ced-8 functions downstream of or in parallel to-the regulatory cell death gene ced-9 and may function as a cell death effector downstream of the caspase encoded by the programmed cell death killer gene ced-3. In ced-8 mutants, embryonic programmed cell death probably initiates normally but proceeds slowly. ced-8 encodes a transmembrane protein that appears to be localized to the plasma membrane. The CED-8 protein is similar to human XK, a putative membrane transport protein implicated in McLeod Syndrome, a form of hereditary neuroacanthocytosis.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "0574b68d8a1845829336d0bb8c46aef6", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[99, 99]], "char_spans": [[570, 571]]}]}], "context_tokens": [["Loss", 0], ["-", 4], ["of", 5], ["-", 7], ["function", 8], ["mutations", 17], ["in", 27], ["the", 30], ["gene", 34], ["ced-8", 39], ["lead", 45], ["to", 50], ["the", 53], ["late", 57], ["appearance", 62], ["of", 73], ["cell", 76], ["corpses", 81], ["during", 89], ["embryonic", 96], ["development", 106], ["in", 118], ["C.", 121], ["elegans", 124], [".", 131], ["ced-8", 133], ["functions", 139], ["downstream", 149], ["of", 160], ["or", 163], ["in", 166], ["parallel", 169], ["to", 178], ["-", 180], ["the", 181], ["regulatory", 185], ["cell", 196], ["death", 201], ["gene", 207], ["ced-9", 212], ["and", 218], ["may", 222], ["function", 226], ["as", 235], ["a", 238], ["cell", 240], ["death", 245], ["effector", 251], ["downstream", 260], ["of", 271], ["the", 274], ["caspase", 278], ["encoded", 286], ["by", 294], ["the", 297], ["programmed", 301], ["cell", 312], ["death", 317], ["killer", 323], ["gene", 330], ["ced-3", 335], [".", 340], ["In", 342], ["ced-8", 345], ["mutants", 351], [",", 358], ["embryonic", 360], ["programmed", 370], ["cell", 381], ["death", 386], ["probably", 392], ["initiates", 401], ["normally", 411], ["but", 420], ["proceeds", 424], ["slowly", 433], [".", 439], ["ced-8", 441], ["encodes", 447], ["a", 455], ["transmembrane", 457], ["protein", 471], ["that", 479], ["appears", 484], ["to", 492], ["be", 495], ["localized", 498], ["to", 508], ["the", 511], ["plasma", 515], ["membrane", 522], [".", 530], ["The", 532], ["CED-8", 536], ["protein", 542], ["is", 550], ["similar", 553], ["to", 561], ["human", 564], ["XK", 570], [",", 572], ["a", 574], ["putative", 576], ["membrane", 585], ["transport", 594], ["protein", 604], ["implicated", 612], ["in", 623], ["McLeod", 626], ["Syndrome", 633], [",", 641], ["a", 643], ["form", 645], ["of", 650], ["hereditary", 653], ["neuroacanthocytosis", 664], [".", 683]]}
{"context": "Chediak-Higashi syndrome (CHS) is an inherited immunodeficiency disease characterized by giant lysosomes and impaired leukocyte degranulation. CHS results from mutations in the lysosomal trafficking regulator (LYST) gene, which encodes a 425-kD cytoplasmic protein of unknown function. The goal of this study was to identify proteins that interact with LYST as a first step in understanding how LYST modulates lysosomal exocytosis. Fourteen cDNA fragments, covering the entire coding domain of LYST, were used as baits to screen five human cDNA libraries by a yeast two-hybrid method, modified to allow screening in the activation and the binding domain, three selectable markers, and more stringent confirmation procedures. Five of the interactions were confirmed by an in vitro binding assay. Twenty-one proteins that interact with LYST were identified in yeast two-hybrid screens. Four interactions, confirmed directly, were with proteins important in vesicular transport and signal transduction (the SNARE-complex protein HRS, 14-3-3, and casein kinase II). On the basis of protein interactions, LYST appears to function as an adapter protein that may juxtapose proteins that mediate intracellular membrane fusion reactions. The pathologic manifestations observed in CHS patients and in mice with the homologous mutation beige suggest that understanding the role of LYST may be relevant to the treatment of not only CHS but also of diseases such as asthma, urticaria, and lupus, as well as to the molecular dissection of the CHS-associated cancer predisposition.", "qas": [{"question": "Which syndrome is associated with mutations in the LYST gene?", "answers": ["Chediak-Higashi syndrome"], "qid": "6a6c0c5ae87d4079ad03b0e1d5ecdd40", "question_tokens": [["Which", 0], ["syndrome", 6], ["is", 15], ["associated", 18], ["with", 29], ["mutations", 34], ["in", 44], ["the", 47], ["LYST", 51], ["gene", 56], ["?", 60]], "detected_answers": [{"text": "Chediak-Higashi syndrome", "token_spans": [[0, 3]], "char_spans": [[0, 23]]}]}], "context_tokens": [["Chediak", 0], ["-", 7], ["Higashi", 8], ["syndrome", 16], ["(", 25], ["CHS", 26], [")", 29], ["is", 31], ["an", 34], ["inherited", 37], ["immunodeficiency", 47], ["disease", 64], ["characterized", 72], ["by", 86], ["giant", 89], ["lysosomes", 95], ["and", 105], ["impaired", 109], ["leukocyte", 118], ["degranulation", 128], [".", 141], ["CHS", 143], ["results", 147], ["from", 155], ["mutations", 160], ["in", 170], ["the", 173], ["lysosomal", 177], ["trafficking", 187], ["regulator", 199], ["(", 209], ["LYST", 210], [")", 214], ["gene", 216], [",", 220], ["which", 222], ["encodes", 228], ["a", 236], ["425-kD", 238], ["cytoplasmic", 245], ["protein", 257], ["of", 265], ["unknown", 268], ["function", 276], [".", 284], ["The", 286], ["goal", 290], ["of", 295], ["this", 298], ["study", 303], ["was", 309], ["to", 313], ["identify", 316], ["proteins", 325], ["that", 334], ["interact", 339], ["with", 348], ["LYST", 353], ["as", 358], ["a", 361], ["first", 363], ["step", 369], ["in", 374], ["understanding", 377], ["how", 391], ["LYST", 395], ["modulates", 400], ["lysosomal", 410], ["exocytosis", 420], [".", 430], ["Fourteen", 432], ["cDNA", 441], ["fragments", 446], [",", 455], ["covering", 457], ["the", 466], ["entire", 470], ["coding", 477], ["domain", 484], ["of", 491], ["LYST", 494], [",", 498], ["were", 500], ["used", 505], ["as", 510], ["baits", 513], ["to", 519], ["screen", 522], ["five", 529], ["human", 534], ["cDNA", 540], ["libraries", 545], ["by", 555], ["a", 558], ["yeast", 560], ["two", 566], ["-", 569], ["hybrid", 570], ["method", 577], [",", 583], ["modified", 585], ["to", 594], ["allow", 597], ["screening", 603], ["in", 613], ["the", 616], ["activation", 620], ["and", 631], ["the", 635], ["binding", 639], ["domain", 647], [",", 653], ["three", 655], ["selectable", 661], ["markers", 672], [",", 679], ["and", 681], ["more", 685], ["stringent", 690], ["confirmation", 700], ["procedures", 713], [".", 723], ["Five", 725], ["of", 730], ["the", 733], ["interactions", 737], ["were", 750], ["confirmed", 755], ["by", 765], ["an", 768], ["in", 771], ["vitro", 774], ["binding", 780], ["assay", 788], [".", 793], ["Twenty", 795], ["-", 801], ["one", 802], ["proteins", 806], ["that", 815], ["interact", 820], ["with", 829], ["LYST", 834], ["were", 839], ["identified", 844], ["in", 855], ["yeast", 858], ["two", 864], ["-", 867], ["hybrid", 868], ["screens", 875], [".", 882], ["Four", 884], ["interactions", 889], [",", 901], ["confirmed", 903], ["directly", 913], [",", 921], ["were", 923], ["with", 928], ["proteins", 933], ["important", 942], ["in", 952], ["vesicular", 955], ["transport", 965], ["and", 975], ["signal", 979], ["transduction", 986], ["(", 999], ["the", 1000], ["SNARE", 1004], ["-", 1009], ["complex", 1010], ["protein", 1018], ["HRS", 1026], [",", 1029], ["14", 1031], ["-", 1033], ["3", 1034], ["-", 1035], ["3", 1036], [",", 1037], ["and", 1039], ["casein", 1043], ["kinase", 1050], ["II", 1057], [")", 1059], [".", 1060], ["On", 1062], ["the", 1065], ["basis", 1069], ["of", 1075], ["protein", 1078], ["interactions", 1086], [",", 1098], ["LYST", 1100], ["appears", 1105], ["to", 1113], ["function", 1116], ["as", 1125], ["an", 1128], ["adapter", 1131], ["protein", 1139], ["that", 1147], ["may", 1152], ["juxtapose", 1156], ["proteins", 1166], ["that", 1175], ["mediate", 1180], ["intracellular", 1188], ["membrane", 1202], ["fusion", 1211], ["reactions", 1218], [".", 1227], ["The", 1229], ["pathologic", 1233], ["manifestations", 1244], ["observed", 1259], ["in", 1268], ["CHS", 1271], ["patients", 1275], ["and", 1284], ["in", 1288], ["mice", 1291], ["with", 1296], ["the", 1301], ["homologous", 1305], ["mutation", 1316], ["beige", 1325], ["suggest", 1331], ["that", 1339], ["understanding", 1344], ["the", 1358], ["role", 1362], ["of", 1367], ["LYST", 1370], ["may", 1375], ["be", 1379], ["relevant", 1382], ["to", 1391], ["the", 1394], ["treatment", 1398], ["of", 1408], ["not", 1411], ["only", 1415], ["CHS", 1420], ["but", 1424], ["also", 1428], ["of", 1433], ["diseases", 1436], ["such", 1445], ["as", 1450], ["asthma", 1453], [",", 1459], ["urticaria", 1461], [",", 1470], ["and", 1472], ["lupus", 1476], [",", 1481], ["as", 1483], ["well", 1486], ["as", 1491], ["to", 1494], ["the", 1497], ["molecular", 1501], ["dissection", 1511], ["of", 1522], ["the", 1525], ["CHS", 1529], ["-", 1532], ["associated", 1533], ["cancer", 1544], ["predisposition", 1551], [".", 1565]]}
{"context": "Protective protein/cathepsin A (PPCA) has a serine carboxypeptidase activity of unknown physiological function. We now demonstrate that this protease activity triggers the degradation of the lysosome-associated membrane protein type 2a (lamp2a), a receptor for chaperone-mediated autophagy (CMA). Degradation of lamp2a is important because its level in the lysosomal membrane is a rate-limiting step of CMA. Cells defective in PPCA show reduced rates of lamp2a degradation, higher levels of lamp2a and higher rates of CMA. Restoration of PPCA protease activity increases rates of lamp2a degradation, reduces levels of lysosomal lamp2a and reduces rates of CMA. PPCA associates with lamp2a on the lysosomal membrane and cleaves lamp2a near the boundary between the luminal and transmembrane domains. In addition to the well-studied role of PPCA in targeting and protecting two lysosomal glycosidases, we have defined a role for the proteolytic activity of this multifunctional protein.", "qas": [{"question": "Which is the receptor for substrates of Chaperone Mediated Autophagy?", "answers": ["LAMP2A", "Lysosome-associated membrane protein 2 isoform A"], "qid": "a636a925df634cada0c2d6964688e93a", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["receptor", 13], ["for", 22], ["substrates", 26], ["of", 37], ["Chaperone", 40], ["Mediated", 50], ["Autophagy", 59], ["?", 68]], "detected_answers": [{"text": "LAMP2A", "token_spans": [[109, 109], [54, 54], [102, 102], [38, 38], [87, 87], [119, 119], [126, 126], [81, 81]], "char_spans": [[628, 633], [312, 317], [580, 585], [237, 242], [491, 496], [682, 687], [727, 732], [454, 459]]}]}], "context_tokens": [["Protective", 0], ["protein", 11], ["/", 18], ["cathepsin", 19], ["A", 29], ["(", 31], ["PPCA", 32], [")", 36], ["has", 38], ["a", 42], ["serine", 44], ["carboxypeptidase", 51], ["activity", 68], ["of", 77], ["unknown", 80], ["physiological", 88], ["function", 102], [".", 110], ["We", 112], ["now", 115], ["demonstrate", 119], ["that", 131], ["this", 136], ["protease", 141], ["activity", 150], ["triggers", 159], ["the", 168], ["degradation", 172], ["of", 184], ["the", 187], ["lysosome", 191], ["-", 199], ["associated", 200], ["membrane", 211], ["protein", 220], ["type", 228], ["2a", 233], ["(", 236], ["lamp2a", 237], [")", 243], [",", 244], ["a", 246], ["receptor", 248], ["for", 257], ["chaperone", 261], ["-", 270], ["mediated", 271], ["autophagy", 280], ["(", 290], ["CMA", 291], [")", 294], [".", 295], ["Degradation", 297], ["of", 309], ["lamp2a", 312], ["is", 319], ["important", 322], ["because", 332], ["its", 340], ["level", 344], ["in", 350], ["the", 353], ["lysosomal", 357], ["membrane", 367], ["is", 376], ["a", 379], ["rate", 381], ["-", 385], ["limiting", 386], ["step", 395], ["of", 400], ["CMA", 403], [".", 406], ["Cells", 408], ["defective", 414], ["in", 424], ["PPCA", 427], ["show", 432], ["reduced", 437], ["rates", 445], ["of", 451], ["lamp2a", 454], ["degradation", 461], [",", 472], ["higher", 474], ["levels", 481], ["of", 488], ["lamp2a", 491], ["and", 498], ["higher", 502], ["rates", 509], ["of", 515], ["CMA", 518], [".", 521], ["Restoration", 523], ["of", 535], ["PPCA", 538], ["protease", 543], ["activity", 552], ["increases", 561], ["rates", 571], ["of", 577], ["lamp2a", 580], ["degradation", 587], [",", 598], ["reduces", 600], ["levels", 608], ["of", 615], ["lysosomal", 618], ["lamp2a", 628], ["and", 635], ["reduces", 639], ["rates", 647], ["of", 653], ["CMA", 656], [".", 659], ["PPCA", 661], ["associates", 666], ["with", 677], ["lamp2a", 682], ["on", 689], ["the", 692], ["lysosomal", 696], ["membrane", 706], ["and", 715], ["cleaves", 719], ["lamp2a", 727], ["near", 734], ["the", 739], ["boundary", 743], ["between", 752], ["the", 760], ["luminal", 764], ["and", 772], ["transmembrane", 776], ["domains", 790], [".", 797], ["In", 799], ["addition", 802], ["to", 811], ["the", 814], ["well", 818], ["-", 822], ["studied", 823], ["role", 831], ["of", 836], ["PPCA", 839], ["in", 844], ["targeting", 847], ["and", 857], ["protecting", 861], ["two", 872], ["lysosomal", 876], ["glycosidases", 886], [",", 898], ["we", 900], ["have", 903], ["defined", 908], ["a", 916], ["role", 918], ["for", 923], ["the", 927], ["proteolytic", 931], ["activity", 943], ["of", 952], ["this", 955], ["multifunctional", 960], ["protein", 976], [".", 983]]}
{"context": "This study examined the accuracy of the 17-item Dutch version of the Davidson Trauma Scale (DTS) and the four-item SPAN (Startle, Physiological Arousal, Anger and Numbness) to detect survivors at risk for posttraumatic stress disorder (PTSD) within the first 2 weeks after the trauma. 203 civilian survivors of recent trauma with relatively mild symptoms completed the DTS a mean of 8.7 days after experiencing trauma. SPAN scores were computed from the DTS. At a mean of 64.6 days posttrauma, 160 respondents were assessed for diagnosis of PTSD with the Structured Interview for PTSD. Receiver operating characteristic curves showed that the DTS showed good overall screening accuracy (84%). At a cut-off value of 64, the DTS demonstrated a sensitivity of 0.86, a specificity of 0.70, a positive predictive value (PPV) of 0.12, and a negative predictive value (NPV) of 0.98. Overall accuracy of the SPAN was good (89%). At a cut-off of 10 the SPAN showed a sensitivity of 0.86, a specificity of 0.86, a PPV of 0.22, and a NPV of 0.98. The low PPVs were possibly due to the low of prevalence of PTSD in our sample (4.4%). This study shows that both the DTS and the SPAN are comparably accurate in screening early trauma survivors at risk for developing PTSD. The very brief four-item SPAN may be preferred over the longer 17-item DTS especially in settings in which time and resources are limited. Future studies should aim to cross-validate these results in random samples.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "f39ba0ef13d74fbbbee6b6a7495a7da1", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "PTSD", "token_spans": [[224, 224], [106, 106], [44, 44], [100, 100], [255, 255]], "char_spans": [[1095, 1098], [580, 583], [236, 239], [541, 544], [1253, 1256]]}]}], "context_tokens": [["This", 0], ["study", 5], ["examined", 11], ["the", 20], ["accuracy", 24], ["of", 33], ["the", 36], ["17-item", 40], ["Dutch", 48], ["version", 54], ["of", 62], ["the", 65], ["Davidson", 69], ["Trauma", 78], ["Scale", 85], ["(", 91], ["DTS", 92], [")", 95], ["and", 97], ["the", 101], ["four", 105], ["-", 109], ["item", 110], ["SPAN", 115], ["(", 120], ["Startle", 121], [",", 128], ["Physiological", 130], ["Arousal", 144], [",", 151], ["Anger", 153], ["and", 159], ["Numbness", 163], [")", 171], ["to", 173], ["detect", 176], ["survivors", 183], ["at", 193], ["risk", 196], ["for", 201], ["posttraumatic", 205], ["stress", 219], ["disorder", 226], ["(", 235], ["PTSD", 236], [")", 240], ["within", 242], ["the", 249], ["first", 253], ["2", 259], ["weeks", 261], ["after", 267], ["the", 273], ["trauma", 277], [".", 283], ["203", 285], ["civilian", 289], ["survivors", 298], ["of", 308], ["recent", 311], ["trauma", 318], ["with", 325], ["relatively", 330], ["mild", 341], ["symptoms", 346], ["completed", 355], ["the", 365], ["DTS", 369], ["a", 373], ["mean", 375], ["of", 380], ["8.7", 383], ["days", 387], ["after", 392], ["experiencing", 398], ["trauma", 411], [".", 417], ["SPAN", 419], ["scores", 424], ["were", 431], ["computed", 436], ["from", 445], ["the", 450], ["DTS", 454], [".", 457], ["At", 459], ["a", 462], ["mean", 464], ["of", 469], ["64.6", 472], ["days", 477], ["posttrauma", 482], [",", 492], ["160", 494], ["respondents", 498], ["were", 510], ["assessed", 515], ["for", 524], ["diagnosis", 528], ["of", 538], ["PTSD", 541], ["with", 546], ["the", 551], ["Structured", 555], ["Interview", 566], ["for", 576], ["PTSD", 580], [".", 584], ["Receiver", 586], ["operating", 595], ["characteristic", 605], ["curves", 620], ["showed", 627], ["that", 634], ["the", 639], ["DTS", 643], ["showed", 647], ["good", 654], ["overall", 659], ["screening", 667], ["accuracy", 677], ["(", 686], ["84", 687], ["%", 689], [")", 690], [".", 691], ["At", 693], ["a", 696], ["cut", 698], ["-", 701], ["off", 702], ["value", 706], ["of", 712], ["64", 715], [",", 717], ["the", 719], ["DTS", 723], ["demonstrated", 727], ["a", 740], ["sensitivity", 742], ["of", 754], ["0.86", 757], [",", 761], ["a", 763], ["specificity", 765], ["of", 777], ["0.70", 780], [",", 784], ["a", 786], ["positive", 788], ["predictive", 797], ["value", 808], ["(", 814], ["PPV", 815], [")", 818], ["of", 820], ["0.12", 823], [",", 827], ["and", 829], ["a", 833], ["negative", 835], ["predictive", 844], ["value", 855], ["(", 861], ["NPV", 862], [")", 865], ["of", 867], ["0.98", 870], [".", 874], ["Overall", 876], ["accuracy", 884], ["of", 893], ["the", 896], ["SPAN", 900], ["was", 905], ["good", 909], ["(", 914], ["89", 915], ["%", 917], [")", 918], [".", 919], ["At", 921], ["a", 924], ["cut", 926], ["-", 929], ["off", 930], ["of", 934], ["10", 937], ["the", 940], ["SPAN", 944], ["showed", 949], ["a", 956], ["sensitivity", 958], ["of", 970], ["0.86", 973], [",", 977], ["a", 979], ["specificity", 981], ["of", 993], ["0.86", 996], [",", 1000], ["a", 1002], ["PPV", 1004], ["of", 1008], ["0.22", 1011], [",", 1015], ["and", 1017], ["a", 1021], ["NPV", 1023], ["of", 1027], ["0.98", 1030], [".", 1034], ["The", 1036], ["low", 1040], ["PPVs", 1044], ["were", 1049], ["possibly", 1054], ["due", 1063], ["to", 1067], ["the", 1070], ["low", 1074], ["of", 1078], ["prevalence", 1081], ["of", 1092], ["PTSD", 1095], ["in", 1100], ["our", 1103], ["sample", 1107], ["(", 1114], ["4.4", 1115], ["%", 1118], [")", 1119], [".", 1120], ["This", 1122], ["study", 1127], ["shows", 1133], ["that", 1139], ["both", 1144], ["the", 1149], ["DTS", 1153], ["and", 1157], ["the", 1161], ["SPAN", 1165], ["are", 1170], ["comparably", 1174], ["accurate", 1185], ["in", 1194], ["screening", 1197], ["early", 1207], ["trauma", 1213], ["survivors", 1220], ["at", 1230], ["risk", 1233], ["for", 1238], ["developing", 1242], ["PTSD", 1253], [".", 1257], ["The", 1259], ["very", 1263], ["brief", 1268], ["four", 1274], ["-", 1278], ["item", 1279], ["SPAN", 1284], ["may", 1289], ["be", 1293], ["preferred", 1296], ["over", 1306], ["the", 1311], ["longer", 1315], ["17-item", 1322], ["DTS", 1330], ["especially", 1334], ["in", 1345], ["settings", 1348], ["in", 1357], ["which", 1360], ["time", 1366], ["and", 1371], ["resources", 1375], ["are", 1385], ["limited", 1389], [".", 1396], ["Future", 1398], ["studies", 1405], ["should", 1413], ["aim", 1420], ["to", 1424], ["cross", 1427], ["-", 1432], ["validate", 1433], ["these", 1442], ["results", 1448], ["in", 1456], ["random", 1459], ["samples", 1466], [".", 1473]]}
{"context": "Untreated sleep disorders may contribute to secondary causes of uncontrolled hypertension, cardiovascular disease (CVD), and stroke. Restless legs syndrome, or Willis-Ekbom Disease (RLS/WED), is a common sensorimotor disorder with a circadian rhythmicity defined by an uncontrollable urge to move the legs that worsens during periods of inactivity or at rest in the evening, often resulting in sleep disruptions. Sleep disorders such as insomnia and obstructive sleep apnea (OSA) are established risk factors for increased risk of hypertension and vascular diseases. This literature review outlines the lessons learned from studies demonstrating insomnia and OSA as risk factors for hypertension and vascular diseases to support the epidemiologic and physiologic evidence suggesting a similar increase in hypertension and vascular disease risk due to RLS. Understanding the relationships between RLS and hypertension, CVD, and stroke has important implications for reducing the risks associated with these diseases.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "3117044f9a5c499699d0b54e0b238a5a", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[21, 23]], "char_spans": [[133, 154]]}]}], "context_tokens": [["Untreated", 0], ["sleep", 10], ["disorders", 16], ["may", 26], ["contribute", 30], ["to", 41], ["secondary", 44], ["causes", 54], ["of", 61], ["uncontrolled", 64], ["hypertension", 77], [",", 89], ["cardiovascular", 91], ["disease", 106], ["(", 114], ["CVD", 115], [")", 118], [",", 119], ["and", 121], ["stroke", 125], [".", 131], ["Restless", 133], ["legs", 142], ["syndrome", 147], [",", 155], ["or", 157], ["Willis", 160], ["-", 166], ["Ekbom", 167], ["Disease", 173], ["(", 181], ["RLS", 182], ["/", 185], ["WED", 186], [")", 189], [",", 190], ["is", 192], ["a", 195], ["common", 197], ["sensorimotor", 204], ["disorder", 217], ["with", 226], ["a", 231], ["circadian", 233], ["rhythmicity", 243], ["defined", 255], ["by", 263], ["an", 266], ["uncontrollable", 269], ["urge", 284], ["to", 289], ["move", 292], ["the", 297], ["legs", 301], ["that", 306], ["worsens", 311], ["during", 319], ["periods", 326], ["of", 334], ["inactivity", 337], ["or", 348], ["at", 351], ["rest", 354], ["in", 359], ["the", 362], ["evening", 366], [",", 373], ["often", 375], ["resulting", 381], ["in", 391], ["sleep", 394], ["disruptions", 400], [".", 411], ["Sleep", 413], ["disorders", 419], ["such", 429], ["as", 434], ["insomnia", 437], ["and", 446], ["obstructive", 450], ["sleep", 462], ["apnea", 468], ["(", 474], ["OSA", 475], [")", 478], ["are", 480], ["established", 484], ["risk", 496], ["factors", 501], ["for", 509], ["increased", 513], ["risk", 523], ["of", 528], ["hypertension", 531], ["and", 544], ["vascular", 548], ["diseases", 557], [".", 565], ["This", 567], ["literature", 572], ["review", 583], ["outlines", 590], ["the", 599], ["lessons", 603], ["learned", 611], ["from", 619], ["studies", 624], ["demonstrating", 632], ["insomnia", 646], ["and", 655], ["OSA", 659], ["as", 663], ["risk", 666], ["factors", 671], ["for", 679], ["hypertension", 683], ["and", 696], ["vascular", 700], ["diseases", 709], ["to", 718], ["support", 721], ["the", 729], ["epidemiologic", 733], ["and", 747], ["physiologic", 751], ["evidence", 763], ["suggesting", 772], ["a", 783], ["similar", 785], ["increase", 793], ["in", 802], ["hypertension", 805], ["and", 818], ["vascular", 822], ["disease", 831], ["risk", 839], ["due", 844], ["to", 848], ["RLS", 851], [".", 854], ["Understanding", 856], ["the", 870], ["relationships", 874], ["between", 888], ["RLS", 896], ["and", 900], ["hypertension", 904], [",", 916], ["CVD", 918], [",", 921], ["and", 923], ["stroke", 927], ["has", 934], ["important", 938], ["implications", 948], ["for", 961], ["reducing", 965], ["the", 974], ["risks", 978], ["associated", 984], ["with", 995], ["these", 1000], ["diseases", 1006], [".", 1014]]}
{"context": "OBJECTIVE Estimating the risk of a complicated course of Clostridium difficile infection (CDI) might help doctors guide treatment. We aimed to validate 3 published prediction models: Hensgens (2014), Na (2015), and Welfare (2011). METHODS The validation cohort comprised 148 patients diagnosed with CDI between May 2013 and March 2014. During this period, 70 endemic cases of CDI occurred as well as 78 cases of CDI related to an outbreak of C. difficile ribotype 027. Model calibration and discrimination were assessed for the 3 prediction rules. RESULTS A complicated course (ie, death, colectomy, or ICU admission due to CDI) was observed in 31 patients (21%), and 23 patients (16%) died within 30 days of CDI diagnosis. The performance of all 3 prediction models was poor when applied to the total validation cohort with an estimated area under the curve (AUC) of 0.68 for the Hensgens model, 0.54 for the Na model, and 0.61 for the Welfare model. For those patients diagnosed with CDI due to non-outbreak strains, the prediction model developed by Hensgens performed the best, with an AUC of 0.78. CONCLUSION All 3 prediction models performed poorly when using our total cohort, which included CDI cases from an outbreak as well as endemic cases. The prediction model of Hensgens performed relatively well for patients diagnosed with CDI due to non-outbreak strains, and this model may be useful in endemic settings. Infect Control Hosp Epidemiol 2017;38:897-905.", "qas": [{"question": "Which main ribotype of Clostridium difficile is responsible of the recent outbreak?", "answers": ["Ribotype 027"], "qid": "25f9511121624df9b2da1467fc1efe81", "question_tokens": [["Which", 0], ["main", 6], ["ribotype", 11], ["of", 20], ["Clostridium", 23], ["difficile", 35], ["is", 45], ["responsible", 48], ["of", 60], ["the", 63], ["recent", 67], ["outbreak", 74], ["?", 82]], "detected_answers": [{"text": "Ribotype 027", "token_spans": [[87, 88]], "char_spans": [[455, 466]]}]}], "context_tokens": [["OBJECTIVE", 0], ["Estimating", 10], ["the", 21], ["risk", 25], ["of", 30], ["a", 33], ["complicated", 35], ["course", 47], ["of", 54], ["Clostridium", 57], ["difficile", 69], ["infection", 79], ["(", 89], ["CDI", 90], [")", 93], ["might", 95], ["help", 101], ["doctors", 106], ["guide", 114], ["treatment", 120], [".", 129], ["We", 131], ["aimed", 134], ["to", 140], ["validate", 143], ["3", 152], ["published", 154], ["prediction", 164], ["models", 175], [":", 181], ["Hensgens", 183], ["(", 192], ["2014", 193], [")", 197], [",", 198], ["Na", 200], ["(", 203], ["2015", 204], [")", 208], [",", 209], ["and", 211], ["Welfare", 215], ["(", 223], ["2011", 224], [")", 228], [".", 229], ["METHODS", 231], ["The", 239], ["validation", 243], ["cohort", 254], ["comprised", 261], ["148", 271], ["patients", 275], ["diagnosed", 284], ["with", 294], ["CDI", 299], ["between", 303], ["May", 311], ["2013", 315], ["and", 320], ["March", 324], ["2014", 330], [".", 334], ["During", 336], ["this", 343], ["period", 348], [",", 354], ["70", 356], ["endemic", 359], ["cases", 367], ["of", 373], ["CDI", 376], ["occurred", 380], ["as", 389], ["well", 392], ["as", 397], ["78", 400], ["cases", 403], ["of", 409], ["CDI", 412], ["related", 416], ["to", 424], ["an", 427], ["outbreak", 430], ["of", 439], ["C.", 442], ["difficile", 445], ["ribotype", 455], ["027", 464], [".", 467], ["Model", 469], ["calibration", 475], ["and", 487], ["discrimination", 491], ["were", 506], ["assessed", 511], ["for", 520], ["the", 524], ["3", 528], ["prediction", 530], ["rules", 541], [".", 546], ["RESULTS", 548], ["A", 556], ["complicated", 558], ["course", 570], ["(", 577], ["ie", 578], [",", 580], ["death", 582], [",", 587], ["colectomy", 589], [",", 598], ["or", 600], ["ICU", 603], ["admission", 607], ["due", 617], ["to", 621], ["CDI", 624], [")", 627], ["was", 629], ["observed", 633], ["in", 642], ["31", 645], ["patients", 648], ["(", 657], ["21", 658], ["%", 660], [")", 661], [",", 662], ["and", 664], ["23", 668], ["patients", 671], ["(", 680], ["16", 681], ["%", 683], [")", 684], ["died", 686], ["within", 691], ["30", 698], ["days", 701], ["of", 706], ["CDI", 709], ["diagnosis", 713], [".", 722], ["The", 724], ["performance", 728], ["of", 740], ["all", 743], ["3", 747], ["prediction", 749], ["models", 760], ["was", 767], ["poor", 771], ["when", 776], ["applied", 781], ["to", 789], ["the", 792], ["total", 796], ["validation", 802], ["cohort", 813], ["with", 820], ["an", 825], ["estimated", 828], ["area", 838], ["under", 843], ["the", 849], ["curve", 853], ["(", 859], ["AUC", 860], [")", 863], ["of", 865], ["0.68", 868], ["for", 873], ["the", 877], ["Hensgens", 881], ["model", 890], [",", 895], ["0.54", 897], ["for", 902], ["the", 906], ["Na", 910], ["model", 913], [",", 918], ["and", 920], ["0.61", 924], ["for", 929], ["the", 933], ["Welfare", 937], ["model", 945], [".", 950], ["For", 952], ["those", 956], ["patients", 962], ["diagnosed", 971], ["with", 981], ["CDI", 986], ["due", 990], ["to", 994], ["non", 997], ["-", 1000], ["outbreak", 1001], ["strains", 1010], [",", 1017], ["the", 1019], ["prediction", 1023], ["model", 1034], ["developed", 1040], ["by", 1050], ["Hensgens", 1053], ["performed", 1062], ["the", 1072], ["best", 1076], [",", 1080], ["with", 1082], ["an", 1087], ["AUC", 1090], ["of", 1094], ["0.78", 1097], [".", 1101], ["CONCLUSION", 1103], ["All", 1114], ["3", 1118], ["prediction", 1120], ["models", 1131], ["performed", 1138], ["poorly", 1148], ["when", 1155], ["using", 1160], ["our", 1166], ["total", 1170], ["cohort", 1176], [",", 1182], ["which", 1184], ["included", 1190], ["CDI", 1199], ["cases", 1203], ["from", 1209], ["an", 1214], ["outbreak", 1217], ["as", 1226], ["well", 1229], ["as", 1234], ["endemic", 1237], ["cases", 1245], [".", 1250], ["The", 1252], ["prediction", 1256], ["model", 1267], ["of", 1273], ["Hensgens", 1276], ["performed", 1285], ["relatively", 1295], ["well", 1306], ["for", 1311], ["patients", 1315], ["diagnosed", 1324], ["with", 1334], ["CDI", 1339], ["due", 1343], ["to", 1347], ["non", 1350], ["-", 1353], ["outbreak", 1354], ["strains", 1363], [",", 1370], ["and", 1372], ["this", 1376], ["model", 1381], ["may", 1387], ["be", 1391], ["useful", 1394], ["in", 1401], ["endemic", 1404], ["settings", 1412], [".", 1420], ["Infect", 1422], ["Control", 1429], ["Hosp", 1437], ["Epidemiol", 1442], ["2017;38:897", 1452], ["-", 1463], ["905", 1464], [".", 1467]]}
{"context": "Methicillin-resistant Staphylococcus aureus (MRSA) is an emerging threat to public health, especially in correctional settings. Outbreaks have been seen in jails and prisons in Mississippi, California, Texas, and Georgia in recent years. Also, many correctional settings have seen an increase in MRSA infection greater than in the general population. This article examines the lessons that have been learned about MRSA in correctional settings and ponders what is yet to be learned about this disease in these populations.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "9b31d25da19c48398b26285c6f9b1754", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[52, 52], [71, 71], [6, 6]], "char_spans": [[296, 299], [414, 417], [45, 48]]}]}], "context_tokens": [["Methicillin", 0], ["-", 11], ["resistant", 12], ["Staphylococcus", 22], ["aureus", 37], ["(", 44], ["MRSA", 45], [")", 49], ["is", 51], ["an", 54], ["emerging", 57], ["threat", 66], ["to", 73], ["public", 76], ["health", 83], [",", 89], ["especially", 91], ["in", 102], ["correctional", 105], ["settings", 118], [".", 126], ["Outbreaks", 128], ["have", 138], ["been", 143], ["seen", 148], ["in", 153], ["jails", 156], ["and", 162], ["prisons", 166], ["in", 174], ["Mississippi", 177], [",", 188], ["California", 190], [",", 200], ["Texas", 202], [",", 207], ["and", 209], ["Georgia", 213], ["in", 221], ["recent", 224], ["years", 231], [".", 236], ["Also", 238], [",", 242], ["many", 244], ["correctional", 249], ["settings", 262], ["have", 271], ["seen", 276], ["an", 281], ["increase", 284], ["in", 293], ["MRSA", 296], ["infection", 301], ["greater", 311], ["than", 319], ["in", 324], ["the", 327], ["general", 331], ["population", 339], [".", 349], ["This", 351], ["article", 356], ["examines", 364], ["the", 373], ["lessons", 377], ["that", 385], ["have", 390], ["been", 395], ["learned", 400], ["about", 408], ["MRSA", 414], ["in", 419], ["correctional", 422], ["settings", 435], ["and", 444], ["ponders", 448], ["what", 456], ["is", 461], ["yet", 464], ["to", 468], ["be", 471], ["learned", 474], ["about", 482], ["this", 488], ["disease", 493], ["in", 501], ["these", 504], ["populations", 510], [".", 521]]}
{"context": "Spleen tyrosine kinase (Syk) is a cytoplasmic tyrosine kinase involved in signalling in many of the cells that drive immune inflammation. The development of small molecules that inhibit Syk kinase may change the way we treat disorders such as rheumatoid arthritis (RA), as well as a range of other inflammatory diseases. Fostamatinib (R-788) is an orally bioavailable small molecule. It is the prodrug of R406, which is a potent Syk inhibitor. Fostamatinib was developed because it has more favourable physiochemical properties. It is rapidly converted to R406 by intestinal enterocytes. It has been evaluated in experimental models of RA, such as collagen-induced arthritis. In these models, fostamatinib suppressed clinical arthritis, bone erosions, pannus formation and synovitis. A phase II programme with fostamatinib has largely been completed. Three key trials have been published, lasting 12-26 weeks and each enrolling 189-457 patients (875 in total). All these trials involved placebo therapy and patients continued to receive methotrexate in addition to active treatment with fostamatinib. The first dose-ranging trial evaluated three treatment doses in RA patients who had not fully responded to methotrexate therapy. The second trial compared two treatment doses in patients who had not responded to methotrexate therapy. The third trial compared a single treatment dose with placebo in patients who had not responded to biological therapy. The primary outcome measure was the number of patients achieving American College of Rheumatology (ACR) 20% (ACR20) responses. Placebo ACR20 response rates in all three trials were similar (35-38%). All three trials involved one treatment arm receiving fostamatinib 100 mg twice daily; ACR20 responses with this active treatment ranged from 38% to 67%. A meta-analysis of ACR responses in these trials, using responses to the highest dose in each trial for comparisons with placebo therapy in a random effects model, showed a borderline benefit with ACR20 responses. There were more significant differences with ACR50 and ACR70 responses. The reason that this meta-analysis was not more strongly positive is that the third trial, which evaluated patients who had failed to respond to biological treatments, gave negative results. Individual ACR response components, such as changes in swollen joint counts, showed significant differences in the first two trials, but there were no definite treatment benefits in the third trial. Overall, the differences were significant in a meta-analysis of all three trials. The most important adverse reactions were diarrhoea, neutropenia and raised ALT levels, which all showed significant excesses with active treatment compared with placebo. Too few patients have been studied for a definitive safety profile to be known. Overall, the results of the phase II trials were sufficiently encouraging for a phase III programme to be initiated. It will be some years before their definitive results are available.", "qas": [{"question": "Which enzyme is inhibited by a drug fostamatinib?", "answers": ["spleen tyrosine kinase"], "qid": "cdffae7e17c6461b9d318dade835ff28", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["a", 29], ["drug", 31], ["fostamatinib", 36], ["?", 48]], "detected_answers": [{"text": "spleen tyrosine kinase", "token_spans": [[0, 2]], "char_spans": [[0, 21]]}]}], "context_tokens": [["Spleen", 0], ["tyrosine", 7], ["kinase", 16], ["(", 23], ["Syk", 24], [")", 27], ["is", 29], ["a", 32], ["cytoplasmic", 34], ["tyrosine", 46], ["kinase", 55], ["involved", 62], ["in", 71], ["signalling", 74], ["in", 85], ["many", 88], ["of", 93], ["the", 96], ["cells", 100], ["that", 106], ["drive", 111], ["immune", 117], ["inflammation", 124], [".", 136], ["The", 138], ["development", 142], ["of", 154], ["small", 157], ["molecules", 163], ["that", 173], ["inhibit", 178], ["Syk", 186], ["kinase", 190], ["may", 197], ["change", 201], ["the", 208], ["way", 212], ["we", 216], ["treat", 219], ["disorders", 225], ["such", 235], ["as", 240], ["rheumatoid", 243], ["arthritis", 254], ["(", 264], ["RA", 265], [")", 267], [",", 268], ["as", 270], ["well", 273], ["as", 278], ["a", 281], ["range", 283], ["of", 289], ["other", 292], ["inflammatory", 298], ["diseases", 311], [".", 319], ["Fostamatinib", 321], ["(", 334], ["R-788", 335], [")", 340], ["is", 342], ["an", 345], ["orally", 348], ["bioavailable", 355], ["small", 368], ["molecule", 374], [".", 382], ["It", 384], ["is", 387], ["the", 390], ["prodrug", 394], ["of", 402], ["R406", 405], [",", 409], ["which", 411], ["is", 417], ["a", 420], ["potent", 422], ["Syk", 429], ["inhibitor", 433], [".", 442], ["Fostamatinib", 444], ["was", 457], ["developed", 461], ["because", 471], ["it", 479], ["has", 482], ["more", 486], ["favourable", 491], ["physiochemical", 502], ["properties", 517], [".", 527], ["It", 529], ["is", 532], ["rapidly", 535], ["converted", 543], ["to", 553], ["R406", 556], ["by", 561], ["intestinal", 564], ["enterocytes", 575], [".", 586], ["It", 588], ["has", 591], ["been", 595], ["evaluated", 600], ["in", 610], ["experimental", 613], ["models", 626], ["of", 633], ["RA", 636], [",", 638], ["such", 640], ["as", 645], ["collagen", 648], ["-", 656], ["induced", 657], ["arthritis", 665], [".", 674], ["In", 676], ["these", 679], ["models", 685], [",", 691], ["fostamatinib", 693], ["suppressed", 706], ["clinical", 717], ["arthritis", 726], [",", 735], ["bone", 737], ["erosions", 742], [",", 750], ["pannus", 752], ["formation", 759], ["and", 769], ["synovitis", 773], [".", 782], ["A", 784], ["phase", 786], ["II", 792], ["programme", 795], ["with", 805], ["fostamatinib", 810], ["has", 823], ["largely", 827], ["been", 835], ["completed", 840], [".", 849], ["Three", 851], ["key", 857], ["trials", 861], ["have", 868], ["been", 873], ["published", 878], [",", 887], ["lasting", 889], ["12", 897], ["-", 899], ["26", 900], ["weeks", 903], ["and", 909], ["each", 913], ["enrolling", 918], ["189", 928], ["-", 931], ["457", 932], ["patients", 936], ["(", 945], ["875", 946], ["in", 950], ["total", 953], [")", 958], [".", 959], ["All", 961], ["these", 965], ["trials", 971], ["involved", 978], ["placebo", 987], ["therapy", 995], ["and", 1003], ["patients", 1007], ["continued", 1016], ["to", 1026], ["receive", 1029], ["methotrexate", 1037], ["in", 1050], ["addition", 1053], ["to", 1062], ["active", 1065], ["treatment", 1072], ["with", 1082], ["fostamatinib", 1087], [".", 1099], ["The", 1101], ["first", 1105], ["dose", 1111], ["-", 1115], ["ranging", 1116], ["trial", 1124], ["evaluated", 1130], ["three", 1140], ["treatment", 1146], ["doses", 1156], ["in", 1162], ["RA", 1165], ["patients", 1168], ["who", 1177], ["had", 1181], ["not", 1185], ["fully", 1189], ["responded", 1195], ["to", 1205], ["methotrexate", 1208], ["therapy", 1221], [".", 1228], ["The", 1230], ["second", 1234], ["trial", 1241], ["compared", 1247], ["two", 1256], ["treatment", 1260], ["doses", 1270], ["in", 1276], ["patients", 1279], ["who", 1288], ["had", 1292], ["not", 1296], ["responded", 1300], ["to", 1310], ["methotrexate", 1313], ["therapy", 1326], [".", 1333], ["The", 1335], ["third", 1339], ["trial", 1345], ["compared", 1351], ["a", 1360], ["single", 1362], ["treatment", 1369], ["dose", 1379], ["with", 1384], ["placebo", 1389], ["in", 1397], ["patients", 1400], ["who", 1409], ["had", 1413], ["not", 1417], ["responded", 1421], ["to", 1431], ["biological", 1434], ["therapy", 1445], [".", 1452], ["The", 1454], ["primary", 1458], ["outcome", 1466], ["measure", 1474], ["was", 1482], ["the", 1486], ["number", 1490], ["of", 1497], ["patients", 1500], ["achieving", 1509], ["American", 1519], ["College", 1528], ["of", 1536], ["Rheumatology", 1539], ["(", 1552], ["ACR", 1553], [")", 1556], ["20", 1558], ["%", 1560], ["(", 1562], ["ACR20", 1563], [")", 1568], ["responses", 1570], [".", 1579], ["Placebo", 1581], ["ACR20", 1589], ["response", 1595], ["rates", 1604], ["in", 1610], ["all", 1613], ["three", 1617], ["trials", 1623], ["were", 1630], ["similar", 1635], ["(", 1643], ["35", 1644], ["-", 1646], ["38", 1647], ["%", 1649], [")", 1650], [".", 1651], ["All", 1653], ["three", 1657], ["trials", 1663], ["involved", 1670], ["one", 1679], ["treatment", 1683], ["arm", 1693], ["receiving", 1697], ["fostamatinib", 1707], ["100", 1720], ["mg", 1724], ["twice", 1727], ["daily", 1733], [";", 1738], ["ACR20", 1740], ["responses", 1746], ["with", 1756], ["this", 1761], ["active", 1766], ["treatment", 1773], ["ranged", 1783], ["from", 1790], ["38", 1795], ["%", 1797], ["to", 1799], ["67", 1802], ["%", 1804], [".", 1805], ["A", 1807], ["meta", 1809], ["-", 1813], ["analysis", 1814], ["of", 1823], ["ACR", 1826], ["responses", 1830], ["in", 1840], ["these", 1843], ["trials", 1849], [",", 1855], ["using", 1857], ["responses", 1863], ["to", 1873], ["the", 1876], ["highest", 1880], ["dose", 1888], ["in", 1893], ["each", 1896], ["trial", 1901], ["for", 1907], ["comparisons", 1911], ["with", 1923], ["placebo", 1928], ["therapy", 1936], ["in", 1944], ["a", 1947], ["random", 1949], ["effects", 1956], ["model", 1964], [",", 1969], ["showed", 1971], ["a", 1978], ["borderline", 1980], ["benefit", 1991], ["with", 1999], ["ACR20", 2004], ["responses", 2010], [".", 2019], ["There", 2021], ["were", 2027], ["more", 2032], ["significant", 2037], ["differences", 2049], ["with", 2061], ["ACR50", 2066], ["and", 2072], ["ACR70", 2076], ["responses", 2082], [".", 2091], ["The", 2093], ["reason", 2097], ["that", 2104], ["this", 2109], ["meta", 2114], ["-", 2118], ["analysis", 2119], ["was", 2128], ["not", 2132], ["more", 2136], ["strongly", 2141], ["positive", 2150], ["is", 2159], ["that", 2162], ["the", 2167], ["third", 2171], ["trial", 2177], [",", 2182], ["which", 2184], ["evaluated", 2190], ["patients", 2200], ["who", 2209], ["had", 2213], ["failed", 2217], ["to", 2224], ["respond", 2227], ["to", 2235], ["biological", 2238], ["treatments", 2249], [",", 2259], ["gave", 2261], ["negative", 2266], ["results", 2275], [".", 2282], ["Individual", 2284], ["ACR", 2295], ["response", 2299], ["components", 2308], [",", 2318], ["such", 2320], ["as", 2325], ["changes", 2328], ["in", 2336], ["swollen", 2339], ["joint", 2347], ["counts", 2353], [",", 2359], ["showed", 2361], ["significant", 2368], ["differences", 2380], ["in", 2392], ["the", 2395], ["first", 2399], ["two", 2405], ["trials", 2409], [",", 2415], ["but", 2417], ["there", 2421], ["were", 2427], ["no", 2432], ["definite", 2435], ["treatment", 2444], ["benefits", 2454], ["in", 2463], ["the", 2466], ["third", 2470], ["trial", 2476], [".", 2481], ["Overall", 2483], [",", 2490], ["the", 2492], ["differences", 2496], ["were", 2508], ["significant", 2513], ["in", 2525], ["a", 2528], ["meta", 2530], ["-", 2534], ["analysis", 2535], ["of", 2544], ["all", 2547], ["three", 2551], ["trials", 2557], [".", 2563], ["The", 2565], ["most", 2569], ["important", 2574], ["adverse", 2584], ["reactions", 2592], ["were", 2602], ["diarrhoea", 2607], [",", 2616], ["neutropenia", 2618], ["and", 2630], ["raised", 2634], ["ALT", 2641], ["levels", 2645], [",", 2651], ["which", 2653], ["all", 2659], ["showed", 2663], ["significant", 2670], ["excesses", 2682], ["with", 2691], ["active", 2696], ["treatment", 2703], ["compared", 2713], ["with", 2722], ["placebo", 2727], [".", 2734], ["Too", 2736], ["few", 2740], ["patients", 2744], ["have", 2753], ["been", 2758], ["studied", 2763], ["for", 2771], ["a", 2775], ["definitive", 2777], ["safety", 2788], ["profile", 2795], ["to", 2803], ["be", 2806], ["known", 2809], [".", 2814], ["Overall", 2816], [",", 2823], ["the", 2825], ["results", 2829], ["of", 2837], ["the", 2840], ["phase", 2844], ["II", 2850], ["trials", 2853], ["were", 2860], ["sufficiently", 2865], ["encouraging", 2878], ["for", 2890], ["a", 2894], ["phase", 2896], ["III", 2902], ["programme", 2906], ["to", 2916], ["be", 2919], ["initiated", 2922], [".", 2931], ["It", 2933], ["will", 2936], ["be", 2941], ["some", 2944], ["years", 2949], ["before", 2955], ["their", 2962], ["definitive", 2968], ["results", 2979], ["are", 2987], ["available", 2991], [".", 3000]]}
{"context": "Iron deficiency is the most common nutritional disorder affecting at least one third of world's population. Though anemia is common manifestation of iron deficiency, other effects of iron deficiency on various tissues, organs and systems are usually under recognized. Impaired brain development and cognitive, behavioural and psychomotor impairment are most worrisome manifestations of iron deficiency. Studies have demonstrated that some of these changes occurring during period of brain growth spurt (<2 years age) may be irreversible. Association of iron deficiency with febrile seizures, pica, breath holding spells, restless leg syndrome and thrombosis is increasingly being recognized. Impaired cell-mediated immunity and bactericidal function are generally noted in iron-deficient persons; however, the findings are inconsistent. Despite proven reversible functional immunological defects in vitro studies, a clinically important relationship between states of iron deficiency and susceptibility to infections remains controversial. Studies from malaria endemic regions have reported increased incidence of malaria in association with iron supplementation. These and some other aspects of iron deficiency are reviewed in this article.", "qas": [{"question": "Which deficiency is the cause of restless leg syndrome?", "answers": ["iron"], "qid": "012f50f15b46427a95f71bd22cb9066f", "question_tokens": [["Which", 0], ["deficiency", 6], ["is", 17], ["the", 20], ["cause", 24], ["of", 30], ["restless", 33], ["leg", 42], ["syndrome", 46], ["?", 54]], "detected_answers": [{"text": "iron", "token_spans": [[0, 0], [59, 59], [123, 123], [89, 89], [24, 24], [152, 152], [184, 184], [30, 30], [175, 175]], "char_spans": [[0, 3], [386, 389], [773, 776], [553, 556], [149, 152], [968, 971], [1196, 1199], [183, 186], [1142, 1145]]}]}], "context_tokens": [["Iron", 0], ["deficiency", 5], ["is", 16], ["the", 19], ["most", 23], ["common", 28], ["nutritional", 35], ["disorder", 47], ["affecting", 56], ["at", 66], ["least", 69], ["one", 75], ["third", 79], ["of", 85], ["world", 88], ["'s", 93], ["population", 96], [".", 106], ["Though", 108], ["anemia", 115], ["is", 122], ["common", 125], ["manifestation", 132], ["of", 146], ["iron", 149], ["deficiency", 154], [",", 164], ["other", 166], ["effects", 172], ["of", 180], ["iron", 183], ["deficiency", 188], ["on", 199], ["various", 202], ["tissues", 210], [",", 217], ["organs", 219], ["and", 226], ["systems", 230], ["are", 238], ["usually", 242], ["under", 250], ["recognized", 256], [".", 266], ["Impaired", 268], ["brain", 277], ["development", 283], ["and", 295], ["cognitive", 299], [",", 308], ["behavioural", 310], ["and", 322], ["psychomotor", 326], ["impairment", 338], ["are", 349], ["most", 353], ["worrisome", 358], ["manifestations", 368], ["of", 383], ["iron", 386], ["deficiency", 391], [".", 401], ["Studies", 403], ["have", 411], ["demonstrated", 416], ["that", 429], ["some", 434], ["of", 439], ["these", 442], ["changes", 448], ["occurring", 456], ["during", 466], ["period", 473], ["of", 480], ["brain", 483], ["growth", 489], ["spurt", 496], ["(", 502], ["<", 503], ["2", 504], ["years", 506], ["age", 512], [")", 515], ["may", 517], ["be", 521], ["irreversible", 524], [".", 536], ["Association", 538], ["of", 550], ["iron", 553], ["deficiency", 558], ["with", 569], ["febrile", 574], ["seizures", 582], [",", 590], ["pica", 592], [",", 596], ["breath", 598], ["holding", 605], ["spells", 613], [",", 619], ["restless", 621], ["leg", 630], ["syndrome", 634], ["and", 643], ["thrombosis", 647], ["is", 658], ["increasingly", 661], ["being", 674], ["recognized", 680], [".", 690], ["Impaired", 692], ["cell", 701], ["-", 705], ["mediated", 706], ["immunity", 715], ["and", 724], ["bactericidal", 728], ["function", 741], ["are", 750], ["generally", 754], ["noted", 764], ["in", 770], ["iron", 773], ["-", 777], ["deficient", 778], ["persons", 788], [";", 795], ["however", 797], [",", 804], ["the", 806], ["findings", 810], ["are", 819], ["inconsistent", 823], [".", 835], ["Despite", 837], ["proven", 845], ["reversible", 852], ["functional", 863], ["immunological", 874], ["defects", 888], ["in", 896], ["vitro", 899], ["studies", 905], [",", 912], ["a", 914], ["clinically", 916], ["important", 927], ["relationship", 937], ["between", 950], ["states", 958], ["of", 965], ["iron", 968], ["deficiency", 973], ["and", 984], ["susceptibility", 988], ["to", 1003], ["infections", 1006], ["remains", 1017], ["controversial", 1025], [".", 1038], ["Studies", 1040], ["from", 1048], ["malaria", 1053], ["endemic", 1061], ["regions", 1069], ["have", 1077], ["reported", 1082], ["increased", 1091], ["incidence", 1101], ["of", 1111], ["malaria", 1114], ["in", 1122], ["association", 1125], ["with", 1137], ["iron", 1142], ["supplementation", 1147], [".", 1162], ["These", 1164], ["and", 1170], ["some", 1174], ["other", 1179], ["aspects", 1185], ["of", 1193], ["iron", 1196], ["deficiency", 1201], ["are", 1212], ["reviewed", 1216], ["in", 1225], ["this", 1228], ["article", 1233], [".", 1240]]}
{"context": "Fostamatinib (R788) is a prodrug rapidly converted to its active metabolite on oral administration. This (known as R406) is a potent inhibitor of spleen tyrosine kinase, required for the expression of a number of proinflammatory cytokines. Fostamatinib has shown significantly superior efficacy (when compared with placebo) in the control of patients with rheumatoid arthritis not responding to methotrexate in Phase II clinical trials. Treatment emergent adverse events with a higher frequency than in those on placebo included diarrhea, hypertension, urinary tract infections, neutropenia and elevated transaminases. The studied doses have shown a linear pharmacokinetic pattern and the administration of methotrexate does not affect it. Fostamatinib may have a role in the therapy of patients with rheumatoid arthritis with poor response to conventional therapy. If these results are confirmed once Phase III studies are completed, it may find a place in the evolving treatment algorithm for rheumatoid arthritis.", "qas": [{"question": "Which enzyme is inhibited by a drug fostamatinib?", "answers": ["spleen tyrosine kinase"], "qid": "7c88f7862dc74ae8bded750a958b2e65", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["a", 29], ["drug", 31], ["fostamatinib", 36], ["?", 48]], "detected_answers": [{"text": "spleen tyrosine kinase", "token_spans": [[28, 30]], "char_spans": [[146, 167]]}]}], "context_tokens": [["Fostamatinib", 0], ["(", 13], ["R788", 14], [")", 18], ["is", 20], ["a", 23], ["prodrug", 25], ["rapidly", 33], ["converted", 41], ["to", 51], ["its", 54], ["active", 58], ["metabolite", 65], ["on", 76], ["oral", 79], ["administration", 84], [".", 98], ["This", 100], ["(", 105], ["known", 106], ["as", 112], ["R406", 115], [")", 119], ["is", 121], ["a", 124], ["potent", 126], ["inhibitor", 133], ["of", 143], ["spleen", 146], ["tyrosine", 153], ["kinase", 162], [",", 168], ["required", 170], ["for", 179], ["the", 183], ["expression", 187], ["of", 198], ["a", 201], ["number", 203], ["of", 210], ["proinflammatory", 213], ["cytokines", 229], [".", 238], ["Fostamatinib", 240], ["has", 253], ["shown", 257], ["significantly", 263], ["superior", 277], ["efficacy", 286], ["(", 295], ["when", 296], ["compared", 301], ["with", 310], ["placebo", 315], [")", 322], ["in", 324], ["the", 327], ["control", 331], ["of", 339], ["patients", 342], ["with", 351], ["rheumatoid", 356], ["arthritis", 367], ["not", 377], ["responding", 381], ["to", 392], ["methotrexate", 395], ["in", 408], ["Phase", 411], ["II", 417], ["clinical", 420], ["trials", 429], [".", 435], ["Treatment", 437], ["emergent", 447], ["adverse", 456], ["events", 464], ["with", 471], ["a", 476], ["higher", 478], ["frequency", 485], ["than", 495], ["in", 500], ["those", 503], ["on", 509], ["placebo", 512], ["included", 520], ["diarrhea", 529], [",", 537], ["hypertension", 539], [",", 551], ["urinary", 553], ["tract", 561], ["infections", 567], [",", 577], ["neutropenia", 579], ["and", 591], ["elevated", 595], ["transaminases", 604], [".", 617], ["The", 619], ["studied", 623], ["doses", 631], ["have", 637], ["shown", 642], ["a", 648], ["linear", 650], ["pharmacokinetic", 657], ["pattern", 673], ["and", 681], ["the", 685], ["administration", 689], ["of", 704], ["methotrexate", 707], ["does", 720], ["not", 725], ["affect", 729], ["it", 736], [".", 738], ["Fostamatinib", 740], ["may", 753], ["have", 757], ["a", 762], ["role", 764], ["in", 769], ["the", 772], ["therapy", 776], ["of", 784], ["patients", 787], ["with", 796], ["rheumatoid", 801], ["arthritis", 812], ["with", 822], ["poor", 827], ["response", 832], ["to", 841], ["conventional", 844], ["therapy", 857], [".", 864], ["If", 866], ["these", 869], ["results", 875], ["are", 883], ["confirmed", 887], ["once", 897], ["Phase", 902], ["III", 908], ["studies", 912], ["are", 920], ["completed", 924], [",", 933], ["it", 935], ["may", 938], ["find", 942], ["a", 947], ["place", 949], ["in", 955], ["the", 958], ["evolving", 962], ["treatment", 971], ["algorithm", 981], ["for", 991], ["rheumatoid", 995], ["arthritis", 1006], [".", 1015]]}
{"context": "The calcium-sensing receptor (CaSR) is a G-protein-coupled receptor that plays an essential role in maintaining calcium homeostasis. In the present study, we analyzed the CaSR gene in a Korean family with familial hypocalciuric hypercalcemia (FHH). Genetic studies were performed by direct sequence analysis of the CaSR gene in genomic DNA obtained from peripheral leukocytes. A novel heterozygous G to T substitution at nucleotide position 1711 in exon 6, resulting in the G571W mutation, was identified in the CaSR gene in a 26-year-old female with asymptomatic hypercalcemia, a low calcium/creatinine clearance ratio, and normal intact parathyroid hormone. To study CaSR expression, the mutation was introduced by site-directed mutagenesis into a wild-type (WT) CaSR-expressing pCR3.1 vector, and COS-7 cells were transfected with either the WT or mutant CaSR-containing vector. Transfected cells loaded with Fura-2/AM, a fluorescent indicator of Ca", "qas": [{"question": "What is the function of calcium-sensing receptor (CaSR)?", "answers": ["The calcium-sensing receptor (CaSR) is a G-protein-coupled receptor that plays an essential role in maintaining calcium homeostasis."], "qid": "1f0adb77304f4c188ae40ccb27db4e56", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["function", 12], ["of", 21], ["calcium", 24], ["-", 31], ["sensing", 32], ["receptor", 40], ["(", 49], ["CaSR", 50], [")", 54], ["?", 55]], "detected_answers": [{"text": "The calcium-sensing receptor (CaSR) is a G-protein-coupled receptor that plays an essential role in maintaining calcium homeostasis.", "token_spans": [[1, 24]], "char_spans": [[4, 130]]}]}], "context_tokens": [["The", 0], ["calcium", 4], ["-", 11], ["sensing", 12], ["receptor", 20], ["(", 29], ["CaSR", 30], [")", 34], ["is", 36], ["a", 39], ["G", 41], ["-", 42], ["protein", 43], ["-", 50], ["coupled", 51], ["receptor", 59], ["that", 68], ["plays", 73], ["an", 79], ["essential", 82], ["role", 92], ["in", 97], ["maintaining", 100], ["calcium", 112], ["homeostasis", 120], [".", 131], ["In", 133], ["the", 136], ["present", 140], ["study", 148], [",", 153], ["we", 155], ["analyzed", 158], ["the", 167], ["CaSR", 171], ["gene", 176], ["in", 181], ["a", 184], ["Korean", 186], ["family", 193], ["with", 200], ["familial", 205], ["hypocalciuric", 214], ["hypercalcemia", 228], ["(", 242], ["FHH", 243], [")", 246], [".", 247], ["Genetic", 249], ["studies", 257], ["were", 265], ["performed", 270], ["by", 280], ["direct", 283], ["sequence", 290], ["analysis", 299], ["of", 308], ["the", 311], ["CaSR", 315], ["gene", 320], ["in", 325], ["genomic", 328], ["DNA", 336], ["obtained", 340], ["from", 349], ["peripheral", 354], ["leukocytes", 365], [".", 375], ["A", 377], ["novel", 379], ["heterozygous", 385], ["G", 398], ["to", 400], ["T", 403], ["substitution", 405], ["at", 418], ["nucleotide", 421], ["position", 432], ["1711", 441], ["in", 446], ["exon", 449], ["6", 454], [",", 455], ["resulting", 457], ["in", 467], ["the", 470], ["G571W", 474], ["mutation", 480], [",", 488], ["was", 490], ["identified", 494], ["in", 505], ["the", 508], ["CaSR", 512], ["gene", 517], ["in", 522], ["a", 525], ["26-year", 527], ["-", 534], ["old", 535], ["female", 539], ["with", 546], ["asymptomatic", 551], ["hypercalcemia", 564], [",", 577], ["a", 579], ["low", 581], ["calcium", 585], ["/", 592], ["creatinine", 593], ["clearance", 604], ["ratio", 614], [",", 619], ["and", 621], ["normal", 625], ["intact", 632], ["parathyroid", 639], ["hormone", 651], [".", 658], ["To", 660], ["study", 663], ["CaSR", 669], ["expression", 674], [",", 684], ["the", 686], ["mutation", 690], ["was", 699], ["introduced", 703], ["by", 714], ["site", 717], ["-", 721], ["directed", 722], ["mutagenesis", 731], ["into", 743], ["a", 748], ["wild", 750], ["-", 754], ["type", 755], ["(", 760], ["WT", 761], [")", 763], ["CaSR", 765], ["-", 769], ["expressing", 770], ["pCR3.1", 781], ["vector", 788], [",", 794], ["and", 796], ["COS-7", 800], ["cells", 806], ["were", 812], ["transfected", 817], ["with", 829], ["either", 834], ["the", 841], ["WT", 845], ["or", 848], ["mutant", 851], ["CaSR", 858], ["-", 862], ["containing", 863], ["vector", 874], [".", 880], ["Transfected", 882], ["cells", 894], ["loaded", 900], ["with", 907], ["Fura-2/AM", 912], [",", 921], ["a", 923], ["fluorescent", 925], ["indicator", 937], ["of", 947], ["Ca", 950]]}
{"context": "The blockage of transcription elongation by RNA polymerase II (pol II) at a DNA damage site on the transcribed strand triggers a transcription-coupled DNA repair (TCR), which rapidly removes DNA damage on the transcribed strand of the expressed gene and allows the resumption of transcription. To analyze the effect of UV-induced DNA damage on transcription elongation, an in vitro transcription elongation system using pol II and oligo(dC)-tailed templates containing a cyclobutane pyrimidine dimer (CPD) or 6-4 photoproduct (6-4PP) at a specific site was employed. The results showed that pol II incorporated nucleotides opposite the CPD and 6-4PP and then stalled. Pol II formed a stable ternary complex consisting of pol II, the DNA damage template, and the nascent transcript. Furthermore, atomic force microscopy imaging revealed that pol II stalled at the damaged region. These findings may provide the basis for analysis of the initiation step of TCR.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "6b2c71580a6f442ab8605c69fe2e4b66", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[20, 21], [40, 41]], "char_spans": [[99, 116], [209, 226]]}]}], "context_tokens": [["The", 0], ["blockage", 4], ["of", 13], ["transcription", 16], ["elongation", 30], ["by", 41], ["RNA", 44], ["polymerase", 48], ["II", 59], ["(", 62], ["pol", 63], ["II", 67], [")", 69], ["at", 71], ["a", 74], ["DNA", 76], ["damage", 80], ["site", 87], ["on", 92], ["the", 95], ["transcribed", 99], ["strand", 111], ["triggers", 118], ["a", 127], ["transcription", 129], ["-", 142], ["coupled", 143], ["DNA", 151], ["repair", 155], ["(", 162], ["TCR", 163], [")", 166], [",", 167], ["which", 169], ["rapidly", 175], ["removes", 183], ["DNA", 191], ["damage", 195], ["on", 202], ["the", 205], ["transcribed", 209], ["strand", 221], ["of", 228], ["the", 231], ["expressed", 235], ["gene", 245], ["and", 250], ["allows", 254], ["the", 261], ["resumption", 265], ["of", 276], ["transcription", 279], [".", 292], ["To", 294], ["analyze", 297], ["the", 305], ["effect", 309], ["of", 316], ["UV", 319], ["-", 321], ["induced", 322], ["DNA", 330], ["damage", 334], ["on", 341], ["transcription", 344], ["elongation", 358], [",", 368], ["an", 370], ["in", 373], ["vitro", 376], ["transcription", 382], ["elongation", 396], ["system", 407], ["using", 414], ["pol", 420], ["II", 424], ["and", 427], ["oligo(dC)-tailed", 431], ["templates", 448], ["containing", 458], ["a", 469], ["cyclobutane", 471], ["pyrimidine", 483], ["dimer", 494], ["(", 500], ["CPD", 501], [")", 504], ["or", 506], ["6", 509], ["-", 510], ["4", 511], ["photoproduct", 513], ["(", 526], ["6", 527], ["-", 528], ["4PP", 529], [")", 532], ["at", 534], ["a", 537], ["specific", 539], ["site", 548], ["was", 553], ["employed", 557], [".", 565], ["The", 567], ["results", 571], ["showed", 579], ["that", 586], ["pol", 591], ["II", 595], ["incorporated", 598], ["nucleotides", 611], ["opposite", 623], ["the", 632], ["CPD", 636], ["and", 640], ["6", 644], ["-", 645], ["4PP", 646], ["and", 650], ["then", 654], ["stalled", 659], [".", 666], ["Pol", 668], ["II", 672], ["formed", 675], ["a", 682], ["stable", 684], ["ternary", 691], ["complex", 699], ["consisting", 707], ["of", 718], ["pol", 721], ["II", 725], [",", 727], ["the", 729], ["DNA", 733], ["damage", 737], ["template", 744], [",", 752], ["and", 754], ["the", 758], ["nascent", 762], ["transcript", 770], [".", 780], ["Furthermore", 782], [",", 793], ["atomic", 795], ["force", 802], ["microscopy", 808], ["imaging", 819], ["revealed", 827], ["that", 836], ["pol", 841], ["II", 845], ["stalled", 848], ["at", 856], ["the", 859], ["damaged", 863], ["region", 871], [".", 877], ["These", 879], ["findings", 885], ["may", 894], ["provide", 898], ["the", 906], ["basis", 910], ["for", 916], ["analysis", 920], ["of", 929], ["the", 932], ["initiation", 936], ["step", 947], ["of", 952], ["TCR", 955], [".", 958]]}
{"context": "X monosomic mice (39,XO) have a remarkably mild phenotype when compared to women with Turner syndrome (45,XO). The generally accepted hypothesis to explain this discrepancy is that the number of genes on the mouse X chromosome which escape X inactivation, and thus are expressed at higher levels in females, is very small. However this hypothesis has never been tested and only a small number of genes have been assayed for their X-inactivation status in the mouse. We performed a global expression analysis in four somatic tissues (brain, liver, kidney and muscle) of adult 40,XX and 39,XO mice using the Illumina Mouse WG-6 v1_1 Expression BeadChip and an extensive validation by quantitative real time PCR, in order to identify which genes are expressed from both X chromosomes. We identified several genes on the X chromosome which are overexpressed in XX females, including those previously reported as escaping X inactivation, as well as new candidates. However, the results obtained by microarray and qPCR were not fully concordant, illustrating the difficulty in ascertaining modest fold changes, such as those expected for genes escaping X inactivation. Remarkably, considerable variation was observed between tissues, suggesting that inactivation patterns may be tissue-dependent. Our analysis also exposed several autosomal genes involved in mitochondrial metabolism and in protein translation which are differentially expressed between XX and XO mice, revealing secondary transcriptional changes to the alteration in X chromosome dosage. Our results support the prediction that the mouse inactive X chromosome is largely silent, while providing a list of the genes potentially escaping X inactivation in rodents. Although the lower expression of X-linked genes in XO mice may not be relevant in the particular tissues/systems which are affected in human X chromosome monosomy, genes deregulated in XO mice are good candidates for further study in an involvement in Turner Syndrome phenotype.", "qas": [{"question": "What chromosome is affected in Turner's syndrome?", "answers": ["X"], "qid": "f60eb4dfa5774b8c8a56567d0989deff", "question_tokens": [["What", 0], ["chromosome", 5], ["is", 16], ["affected", 19], ["in", 28], ["Turner", 31], ["'s", 37], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "X", "token_spans": [[0, 0], [43, 43], [149, 149], [203, 203], [286, 286], [140, 140], [164, 164], [39, 39], [296, 296], [318, 318], [258, 258], [79, 79], [271, 271]], "char_spans": [[0, 0], [240, 240], [817, 817], [1147, 1147], [1698, 1698], [767, 767], [917, 917], [214, 214], [1758, 1758], [1866, 1866], [1529, 1529], [430, 430], [1609, 1609]]}]}], "context_tokens": [["X", 0], ["monosomic", 2], ["mice", 12], ["(", 17], ["39,XO", 18], [")", 23], ["have", 25], ["a", 30], ["remarkably", 32], ["mild", 43], ["phenotype", 48], ["when", 58], ["compared", 63], ["to", 72], ["women", 75], ["with", 81], ["Turner", 86], ["syndrome", 93], ["(", 102], ["45,XO", 103], [")", 108], [".", 109], ["The", 111], ["generally", 115], ["accepted", 125], ["hypothesis", 134], ["to", 145], ["explain", 148], ["this", 156], ["discrepancy", 161], ["is", 173], ["that", 176], ["the", 181], ["number", 185], ["of", 192], ["genes", 195], ["on", 201], ["the", 204], ["mouse", 208], ["X", 214], ["chromosome", 216], ["which", 227], ["escape", 233], ["X", 240], ["inactivation", 242], [",", 254], ["and", 256], ["thus", 260], ["are", 265], ["expressed", 269], ["at", 279], ["higher", 282], ["levels", 289], ["in", 296], ["females", 299], [",", 306], ["is", 308], ["very", 311], ["small", 316], [".", 321], ["However", 323], ["this", 331], ["hypothesis", 336], ["has", 347], ["never", 351], ["been", 357], ["tested", 362], ["and", 369], ["only", 373], ["a", 378], ["small", 380], ["number", 386], ["of", 393], ["genes", 396], ["have", 402], ["been", 407], ["assayed", 412], ["for", 420], ["their", 424], ["X", 430], ["-", 431], ["inactivation", 432], ["status", 445], ["in", 452], ["the", 455], ["mouse", 459], [".", 464], ["We", 466], ["performed", 469], ["a", 479], ["global", 481], ["expression", 488], ["analysis", 499], ["in", 508], ["four", 511], ["somatic", 516], ["tissues", 524], ["(", 532], ["brain", 533], [",", 538], ["liver", 540], [",", 545], ["kidney", 547], ["and", 554], ["muscle", 558], [")", 564], ["of", 566], ["adult", 569], ["40,XX", 575], ["and", 581], ["39,XO", 585], ["mice", 591], ["using", 596], ["the", 602], ["Illumina", 606], ["Mouse", 615], ["WG-6", 621], ["v1_1", 626], ["Expression", 631], ["BeadChip", 642], ["and", 651], ["an", 655], ["extensive", 658], ["validation", 668], ["by", 679], ["quantitative", 682], ["real", 695], ["time", 700], ["PCR", 705], [",", 708], ["in", 710], ["order", 713], ["to", 719], ["identify", 722], ["which", 731], ["genes", 737], ["are", 743], ["expressed", 747], ["from", 757], ["both", 762], ["X", 767], ["chromosomes", 769], [".", 780], ["We", 782], ["identified", 785], ["several", 796], ["genes", 804], ["on", 810], ["the", 813], ["X", 817], ["chromosome", 819], ["which", 830], ["are", 836], ["overexpressed", 840], ["in", 854], ["XX", 857], ["females", 860], [",", 867], ["including", 869], ["those", 879], ["previously", 885], ["reported", 896], ["as", 905], ["escaping", 908], ["X", 917], ["inactivation", 919], [",", 931], ["as", 933], ["well", 936], ["as", 941], ["new", 944], ["candidates", 948], [".", 958], ["However", 960], [",", 967], ["the", 969], ["results", 973], ["obtained", 981], ["by", 990], ["microarray", 993], ["and", 1004], ["qPCR", 1008], ["were", 1013], ["not", 1018], ["fully", 1022], ["concordant", 1028], [",", 1038], ["illustrating", 1040], ["the", 1053], ["difficulty", 1057], ["in", 1068], ["ascertaining", 1071], ["modest", 1084], ["fold", 1091], ["changes", 1096], [",", 1103], ["such", 1105], ["as", 1110], ["those", 1113], ["expected", 1119], ["for", 1128], ["genes", 1132], ["escaping", 1138], ["X", 1147], ["inactivation", 1149], [".", 1161], ["Remarkably", 1163], [",", 1173], ["considerable", 1175], ["variation", 1188], ["was", 1198], ["observed", 1202], ["between", 1211], ["tissues", 1219], [",", 1226], ["suggesting", 1228], ["that", 1239], ["inactivation", 1244], ["patterns", 1257], ["may", 1266], ["be", 1270], ["tissue", 1273], ["-", 1279], ["dependent", 1280], [".", 1289], ["Our", 1291], ["analysis", 1295], ["also", 1304], ["exposed", 1309], ["several", 1317], ["autosomal", 1325], ["genes", 1335], ["involved", 1341], ["in", 1350], ["mitochondrial", 1353], ["metabolism", 1367], ["and", 1378], ["in", 1382], ["protein", 1385], ["translation", 1393], ["which", 1405], ["are", 1411], ["differentially", 1415], ["expressed", 1430], ["between", 1440], ["XX", 1448], ["and", 1451], ["XO", 1455], ["mice", 1458], [",", 1462], ["revealing", 1464], ["secondary", 1474], ["transcriptional", 1484], ["changes", 1500], ["to", 1508], ["the", 1511], ["alteration", 1515], ["in", 1526], ["X", 1529], ["chromosome", 1531], ["dosage", 1542], [".", 1548], ["Our", 1550], ["results", 1554], ["support", 1562], ["the", 1570], ["prediction", 1574], ["that", 1585], ["the", 1590], ["mouse", 1594], ["inactive", 1600], ["X", 1609], ["chromosome", 1611], ["is", 1622], ["largely", 1625], ["silent", 1633], [",", 1639], ["while", 1641], ["providing", 1647], ["a", 1657], ["list", 1659], ["of", 1664], ["the", 1667], ["genes", 1671], ["potentially", 1677], ["escaping", 1689], ["X", 1698], ["inactivation", 1700], ["in", 1713], ["rodents", 1716], [".", 1723], ["Although", 1725], ["the", 1734], ["lower", 1738], ["expression", 1744], ["of", 1755], ["X", 1758], ["-", 1759], ["linked", 1760], ["genes", 1767], ["in", 1773], ["XO", 1776], ["mice", 1779], ["may", 1784], ["not", 1788], ["be", 1792], ["relevant", 1795], ["in", 1804], ["the", 1807], ["particular", 1811], ["tissues", 1822], ["/", 1829], ["systems", 1830], ["which", 1838], ["are", 1844], ["affected", 1848], ["in", 1857], ["human", 1860], ["X", 1866], ["chromosome", 1868], ["monosomy", 1879], [",", 1887], ["genes", 1889], ["deregulated", 1895], ["in", 1907], ["XO", 1910], ["mice", 1913], ["are", 1918], ["good", 1922], ["candidates", 1927], ["for", 1938], ["further", 1942], ["study", 1950], ["in", 1956], ["an", 1959], ["involvement", 1962], ["in", 1974], ["Turner", 1977], ["Syndrome", 1984], ["phenotype", 1993], [".", 2002]]}
{"context": "Hepcidin, a 25-amino-acid peptide secreted by the liver, distributed in the plasma and excreted in urine, is a key central regulator of body iron homeostasis. This hormone decreases export of cellular iron by binding to ferroportin, an iron exporter present at the basolateral surface of enterocytes and macrophages (the sites of dietary iron absorption and iron recycling, respectively), inducing its internalization and degradation. Hepcidin contains eight cysteine residues that form four disulfide bridges, which stabilize a hairpin-shaped structure with two beta sheets. We noticed in the sequence of hepcidin a Cys*-X-Cys* motif which can act as a metal binding site able to trap iron and/or copper. We have tested this hypothesis using a pseudopeptidic synthetic bis-disulfide analogue and we have shown that direct metalation of such ligand leads to the formation of a copper(III) complex with the typical N(2)S(2)\u00a0donor set. This compound crystallizes in the orthorhombic system, space group Imma. The Cu(III) configuration is square planar, built up from two carboximado-N and two thiolato-S donors. This complex is converted back to the bis-disulfide, with release of the copper salt, upon oxidation with iodine.", "qas": [{"question": "How many disulfide bridges has the protein hepcidin got?", "answers": ["Hepcidin contains eight cysteine residues that form four disulfide bridges"], "qid": "1f9ba193c3004e76bc6c7b235f7af430", "question_tokens": [["How", 0], ["many", 4], ["disulfide", 9], ["bridges", 19], ["has", 27], ["the", 31], ["protein", 35], ["hepcidin", 43], ["got", 52], ["?", 55]], "detected_answers": [{"text": "Hepcidin contains eight cysteine residues that form four disulfide bridges", "token_spans": [[75, 84]], "char_spans": [[435, 508]]}]}], "context_tokens": [["Hepcidin", 0], [",", 8], ["a", 10], ["25-amino", 12], ["-", 20], ["acid", 21], ["peptide", 26], ["secreted", 34], ["by", 43], ["the", 46], ["liver", 50], [",", 55], ["distributed", 57], ["in", 69], ["the", 72], ["plasma", 76], ["and", 83], ["excreted", 87], ["in", 96], ["urine", 99], [",", 104], ["is", 106], ["a", 109], ["key", 111], ["central", 115], ["regulator", 123], ["of", 133], ["body", 136], ["iron", 141], ["homeostasis", 146], [".", 157], ["This", 159], ["hormone", 164], ["decreases", 172], ["export", 182], ["of", 189], ["cellular", 192], ["iron", 201], ["by", 206], ["binding", 209], ["to", 217], ["ferroportin", 220], [",", 231], ["an", 233], ["iron", 236], ["exporter", 241], ["present", 250], ["at", 258], ["the", 261], ["basolateral", 265], ["surface", 277], ["of", 285], ["enterocytes", 288], ["and", 300], ["macrophages", 304], ["(", 316], ["the", 317], ["sites", 321], ["of", 327], ["dietary", 330], ["iron", 338], ["absorption", 343], ["and", 354], ["iron", 358], ["recycling", 363], [",", 372], ["respectively", 374], [")", 386], [",", 387], ["inducing", 389], ["its", 398], ["internalization", 402], ["and", 418], ["degradation", 422], [".", 433], ["Hepcidin", 435], ["contains", 444], ["eight", 453], ["cysteine", 459], ["residues", 468], ["that", 477], ["form", 482], ["four", 487], ["disulfide", 492], ["bridges", 502], [",", 509], ["which", 511], ["stabilize", 517], ["a", 527], ["hairpin", 529], ["-", 536], ["shaped", 537], ["structure", 544], ["with", 554], ["two", 559], ["beta", 563], ["sheets", 568], [".", 574], ["We", 576], ["noticed", 579], ["in", 587], ["the", 590], ["sequence", 594], ["of", 603], ["hepcidin", 606], ["a", 615], ["Cys*-X", 617], ["-", 623], ["Cys", 624], ["*", 627], ["motif", 629], ["which", 635], ["can", 641], ["act", 645], ["as", 649], ["a", 652], ["metal", 654], ["binding", 660], ["site", 668], ["able", 673], ["to", 678], ["trap", 681], ["iron", 686], ["and/or", 691], ["copper", 698], [".", 704], ["We", 706], ["have", 709], ["tested", 714], ["this", 721], ["hypothesis", 726], ["using", 737], ["a", 743], ["pseudopeptidic", 745], ["synthetic", 760], ["bis", 770], ["-", 773], ["disulfide", 774], ["analogue", 784], ["and", 793], ["we", 797], ["have", 800], ["shown", 805], ["that", 811], ["direct", 816], ["metalation", 823], ["of", 834], ["such", 837], ["ligand", 842], ["leads", 849], ["to", 855], ["the", 858], ["formation", 862], ["of", 872], ["a", 875], ["copper(III", 877], [")", 887], ["complex", 889], ["with", 897], ["the", 902], ["typical", 906], ["N(2)S(2", 914], [")", 921], ["donor", 923], ["set", 929], [".", 932], ["This", 934], ["compound", 939], ["crystallizes", 948], ["in", 961], ["the", 964], ["orthorhombic", 968], ["system", 981], [",", 987], ["space", 989], ["group", 995], ["Imma", 1001], [".", 1005], ["The", 1007], ["Cu(III", 1011], [")", 1017], ["configuration", 1019], ["is", 1033], ["square", 1036], ["planar", 1043], [",", 1049], ["built", 1051], ["up", 1057], ["from", 1060], ["two", 1065], ["carboximado", 1069], ["-", 1080], ["N", 1081], ["and", 1083], ["two", 1087], ["thiolato", 1091], ["-", 1099], ["S", 1100], ["donors", 1102], [".", 1108], ["This", 1110], ["complex", 1115], ["is", 1123], ["converted", 1126], ["back", 1136], ["to", 1141], ["the", 1144], ["bis", 1148], ["-", 1151], ["disulfide", 1152], [",", 1161], ["with", 1163], ["release", 1168], ["of", 1176], ["the", 1179], ["copper", 1183], ["salt", 1190], [",", 1194], ["upon", 1196], ["oxidation", 1201], ["with", 1211], ["iodine", 1216], [".", 1222]]}
{"context": "The susceptibility to arbekacin (ABK) of methicillin-resistant Staphylococcus aureus (MRSA) was investigated to find out how it related to aac(6')/aph(2\") gene. In 49 isolates of MRSA for which MIC of ABK ranged from 0.125 to 64 micrograms/ml, the MICs of ABK for 38 strains carrying aac(6')/aph(2\") gene were widely distributed from 0.25 to 64, whereas those for 11 strains without that gene were all < or = 0.5 microgram/ml. Residual rate of ABK activity was higher than that of gentamicin after the reaction with each crude enzyme preparation extracted from 3 isolates of MRSA, carrying aac(6')/aph(2\") and aad(4',4\") genes. Furthermore, 97 strains of MRSA isolated at Kanagawa prefecture in Japan in 1999 were all sensitive to ABK, although 28 strains of them carried aac(6')/aph(2\") gene. These results showed that ABK resistance was not necessarily related to carrying aac(6')/aph(2\") gene in clinical isolates of MRSA.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "c28f41488c09478c988e4e82f733d188", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[14, 14], [128, 128], [34, 34], [174, 174], [111, 111]], "char_spans": [[86, 89], [655, 658], [179, 182], [920, 923], [575, 578]]}]}], "context_tokens": [["The", 0], ["susceptibility", 4], ["to", 19], ["arbekacin", 22], ["(", 32], ["ABK", 33], [")", 36], ["of", 38], ["methicillin", 41], ["-", 52], ["resistant", 53], ["Staphylococcus", 63], ["aureus", 78], ["(", 85], ["MRSA", 86], [")", 90], ["was", 92], ["investigated", 96], ["to", 109], ["find", 112], ["out", 117], ["how", 121], ["it", 125], ["related", 128], ["to", 136], ["aac(6')/aph(2", 139], ["\"", 152], [")", 153], ["gene", 155], [".", 159], ["In", 161], ["49", 164], ["isolates", 167], ["of", 176], ["MRSA", 179], ["for", 184], ["which", 188], ["MIC", 194], ["of", 198], ["ABK", 201], ["ranged", 205], ["from", 212], ["0.125", 217], ["to", 223], ["64", 226], ["micrograms", 229], ["/", 239], ["ml", 240], [",", 242], ["the", 244], ["MICs", 248], ["of", 253], ["ABK", 256], ["for", 260], ["38", 264], ["strains", 267], ["carrying", 275], ["aac(6')/aph(2", 284], ["\"", 297], [")", 298], ["gene", 300], ["were", 305], ["widely", 310], ["distributed", 317], ["from", 329], ["0.25", 334], ["to", 339], ["64", 342], [",", 344], ["whereas", 346], ["those", 354], ["for", 360], ["11", 364], ["strains", 367], ["without", 375], ["that", 383], ["gene", 388], ["were", 393], ["all", 398], ["<", 402], ["or", 404], ["=", 407], ["0.5", 409], ["microgram", 413], ["/", 422], ["ml", 423], [".", 425], ["Residual", 427], ["rate", 436], ["of", 441], ["ABK", 444], ["activity", 448], ["was", 457], ["higher", 461], ["than", 468], ["that", 473], ["of", 478], ["gentamicin", 481], ["after", 492], ["the", 498], ["reaction", 502], ["with", 511], ["each", 516], ["crude", 521], ["enzyme", 527], ["preparation", 534], ["extracted", 546], ["from", 556], ["3", 561], ["isolates", 563], ["of", 572], ["MRSA", 575], [",", 579], ["carrying", 581], ["aac(6')/aph(2", 590], ["\"", 603], [")", 604], ["and", 606], ["aad(4',4", 610], ["\"", 618], [")", 619], ["genes", 621], [".", 626], ["Furthermore", 628], [",", 639], ["97", 641], ["strains", 644], ["of", 652], ["MRSA", 655], ["isolated", 660], ["at", 669], ["Kanagawa", 672], ["prefecture", 681], ["in", 692], ["Japan", 695], ["in", 701], ["1999", 704], ["were", 709], ["all", 714], ["sensitive", 718], ["to", 728], ["ABK", 731], [",", 734], ["although", 736], ["28", 745], ["strains", 748], ["of", 756], ["them", 759], ["carried", 764], ["aac(6')/aph(2", 772], ["\"", 785], [")", 786], ["gene", 788], [".", 792], ["These", 794], ["results", 800], ["showed", 808], ["that", 815], ["ABK", 820], ["resistance", 824], ["was", 835], ["not", 839], ["necessarily", 843], ["related", 855], ["to", 863], ["carrying", 866], ["aac(6')/aph(2", 875], ["\"", 888], [")", 889], ["gene", 891], ["in", 896], ["clinical", 899], ["isolates", 908], ["of", 917], ["MRSA", 920], [".", 924]]}
{"context": "It is unanimously accepted that there is an unmet need for pain medications that are both effective and safe. Unfortunately, no really novel analgesics have been approved over the past three decades. In view of both experimental and clinical evidence of a major role for nerve growth factor (NGF) in the generation and maintenance of a wide range of pain states, drug discovery efforts focusing on the development of anti-NGF agents have aroused particular interest. Several humanized anti-NGF monoclonal antibodies (mAbs) have entered clinical trials as potential analgesics. In this respect, tanezumab is at an advanced stage of clinical development while fulranumab, fasinumab and ABT-110, previously known as PG110, are in early phases of clinical development. This Current Opinion article aims at describing the rationale for targeting NGF for pain, reviewing the analgesic efficacy and safety of anti-NGF agents based on data from fully published studies, conference abstracts, and the US Food and Drug Administration (FDA) website, and discussing the possible future of these agents in managing chronic pain. Anti-NGF mAbs produced significant pain relief and functional improvement in patients with osteoarthritis of the knee and/or hip. Conversely, studies in non-specific lower back pain generated mixed results; overall, this condition appeared to be less responsive to anti-NGF agents than osteoarthritis. Finally, there was no conclusive evidence of the effectiveness of anti-NGF mAbs in some types of chronic visceral or neuropathic pain. Furthermore, these studies raised safety concerns about anti-NGF mAbs. As a class, these drugs may cause or worsen peripheral neuropathies. But the most problematic issue-which prompted the FDA to place studies of these compounds on clinical hold in 2010-was rapid joint destruction leading to joint replacement surgery. The aetiologies of these side effects have been much debated and their pathophysiology is poorly understood. After an Arthritis Advisory Committee meeting held in March 2012, pharmaceutical companies negotiated with the FDA on the conditions for restarting clinical studies. Although the FDA lifted its clinical hold, there remain many unresolved issues about the long-term efficacy and safety of anti-NGF mAbs. While acknowledging that the future of these drugs is unforeseeable, it appears that they may not be the safe and effective painkillers that have been awaited for decades.", "qas": [{"question": "What is the target of tanezumab?", "answers": ["nerve growth factor", "NGF"], "qid": "9345b19e2b08406092884e3a093f3bd3", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["target", 12], ["of", 19], ["tanezumab", 22], ["?", 31]], "detected_answers": [{"text": "nerve growth factor", "token_spans": [[48, 50]], "char_spans": [[271, 289]]}, {"text": "NGF", "token_spans": [[77, 77], [262, 262], [52, 52], [244, 244], [199, 199], [284, 284], [396, 396], [88, 88], [146, 146], [159, 159]], "char_spans": [[422, 424], [1489, 1491], [292, 294], [1386, 1388], [1121, 1123], [1614, 1616], [2276, 2278], [490, 492], [841, 843], [907, 909]]}]}], "context_tokens": [["It", 0], ["is", 3], ["unanimously", 6], ["accepted", 18], ["that", 27], ["there", 32], ["is", 38], ["an", 41], ["unmet", 44], ["need", 50], ["for", 55], ["pain", 59], ["medications", 64], ["that", 76], ["are", 81], ["both", 85], ["effective", 90], ["and", 100], ["safe", 104], [".", 108], ["Unfortunately", 110], [",", 123], ["no", 125], ["really", 128], ["novel", 135], ["analgesics", 141], ["have", 152], ["been", 157], ["approved", 162], ["over", 171], ["the", 176], ["past", 180], ["three", 185], ["decades", 191], [".", 198], ["In", 200], ["view", 203], ["of", 208], ["both", 211], ["experimental", 216], ["and", 229], ["clinical", 233], ["evidence", 242], ["of", 251], ["a", 254], ["major", 256], ["role", 262], ["for", 267], ["nerve", 271], ["growth", 277], ["factor", 284], ["(", 291], ["NGF", 292], [")", 295], ["in", 297], ["the", 300], ["generation", 304], ["and", 315], ["maintenance", 319], ["of", 331], ["a", 334], ["wide", 336], ["range", 341], ["of", 347], ["pain", 350], ["states", 355], [",", 361], ["drug", 363], ["discovery", 368], ["efforts", 378], ["focusing", 386], ["on", 395], ["the", 398], ["development", 402], ["of", 414], ["anti", 417], ["-", 421], ["NGF", 422], ["agents", 426], ["have", 433], ["aroused", 438], ["particular", 446], ["interest", 457], [".", 465], ["Several", 467], ["humanized", 475], ["anti", 485], ["-", 489], ["NGF", 490], ["monoclonal", 494], ["antibodies", 505], ["(", 516], ["mAbs", 517], [")", 521], ["have", 523], ["entered", 528], ["clinical", 536], ["trials", 545], ["as", 552], ["potential", 555], ["analgesics", 565], [".", 575], ["In", 577], ["this", 580], ["respect", 585], [",", 592], ["tanezumab", 594], ["is", 604], ["at", 607], ["an", 610], ["advanced", 613], ["stage", 622], ["of", 628], ["clinical", 631], ["development", 640], ["while", 652], ["fulranumab", 658], [",", 668], ["fasinumab", 670], ["and", 680], ["ABT-110", 684], [",", 691], ["previously", 693], ["known", 704], ["as", 710], ["PG110", 713], [",", 718], ["are", 720], ["in", 724], ["early", 727], ["phases", 733], ["of", 740], ["clinical", 743], ["development", 752], [".", 763], ["This", 765], ["Current", 770], ["Opinion", 778], ["article", 786], ["aims", 794], ["at", 799], ["describing", 802], ["the", 813], ["rationale", 817], ["for", 827], ["targeting", 831], ["NGF", 841], ["for", 845], ["pain", 849], [",", 853], ["reviewing", 855], ["the", 865], ["analgesic", 869], ["efficacy", 879], ["and", 888], ["safety", 892], ["of", 899], ["anti", 902], ["-", 906], ["NGF", 907], ["agents", 911], ["based", 918], ["on", 924], ["data", 927], ["from", 932], ["fully", 937], ["published", 943], ["studies", 953], [",", 960], ["conference", 962], ["abstracts", 973], [",", 982], ["and", 984], ["the", 988], ["US", 992], ["Food", 995], ["and", 1000], ["Drug", 1004], ["Administration", 1009], ["(", 1024], ["FDA", 1025], [")", 1028], ["website", 1030], [",", 1037], ["and", 1039], ["discussing", 1043], ["the", 1054], ["possible", 1058], ["future", 1067], ["of", 1074], ["these", 1077], ["agents", 1083], ["in", 1090], ["managing", 1093], ["chronic", 1102], ["pain", 1110], [".", 1114], ["Anti", 1116], ["-", 1120], ["NGF", 1121], ["mAbs", 1125], ["produced", 1130], ["significant", 1139], ["pain", 1151], ["relief", 1156], ["and", 1163], ["functional", 1167], ["improvement", 1178], ["in", 1190], ["patients", 1193], ["with", 1202], ["osteoarthritis", 1207], ["of", 1222], ["the", 1225], ["knee", 1229], ["and/or", 1234], ["hip", 1241], [".", 1244], ["Conversely", 1246], [",", 1256], ["studies", 1258], ["in", 1266], ["non", 1269], ["-", 1272], ["specific", 1273], ["lower", 1282], ["back", 1288], ["pain", 1293], ["generated", 1298], ["mixed", 1308], ["results", 1314], [";", 1321], ["overall", 1323], [",", 1330], ["this", 1332], ["condition", 1337], ["appeared", 1347], ["to", 1356], ["be", 1359], ["less", 1362], ["responsive", 1367], ["to", 1378], ["anti", 1381], ["-", 1385], ["NGF", 1386], ["agents", 1390], ["than", 1397], ["osteoarthritis", 1402], [".", 1416], ["Finally", 1418], [",", 1425], ["there", 1427], ["was", 1433], ["no", 1437], ["conclusive", 1440], ["evidence", 1451], ["of", 1460], ["the", 1463], ["effectiveness", 1467], ["of", 1481], ["anti", 1484], ["-", 1488], ["NGF", 1489], ["mAbs", 1493], ["in", 1498], ["some", 1501], ["types", 1506], ["of", 1512], ["chronic", 1515], ["visceral", 1523], ["or", 1532], ["neuropathic", 1535], ["pain", 1547], [".", 1551], ["Furthermore", 1553], [",", 1564], ["these", 1566], ["studies", 1572], ["raised", 1580], ["safety", 1587], ["concerns", 1594], ["about", 1603], ["anti", 1609], ["-", 1613], ["NGF", 1614], ["mAbs", 1618], [".", 1622], ["As", 1624], ["a", 1627], ["class", 1629], [",", 1634], ["these", 1636], ["drugs", 1642], ["may", 1648], ["cause", 1652], ["or", 1658], ["worsen", 1661], ["peripheral", 1668], ["neuropathies", 1679], [".", 1691], ["But", 1693], ["the", 1697], ["most", 1701], ["problematic", 1706], ["issue", 1718], ["-", 1723], ["which", 1724], ["prompted", 1730], ["the", 1739], ["FDA", 1743], ["to", 1747], ["place", 1750], ["studies", 1756], ["of", 1764], ["these", 1767], ["compounds", 1773], ["on", 1783], ["clinical", 1786], ["hold", 1795], ["in", 1800], ["2010-was", 1803], ["rapid", 1812], ["joint", 1818], ["destruction", 1824], ["leading", 1836], ["to", 1844], ["joint", 1847], ["replacement", 1853], ["surgery", 1865], [".", 1872], ["The", 1874], ["aetiologies", 1878], ["of", 1890], ["these", 1893], ["side", 1899], ["effects", 1904], ["have", 1912], ["been", 1917], ["much", 1922], ["debated", 1927], ["and", 1935], ["their", 1939], ["pathophysiology", 1945], ["is", 1961], ["poorly", 1964], ["understood", 1971], [".", 1981], ["After", 1983], ["an", 1989], ["Arthritis", 1992], ["Advisory", 2002], ["Committee", 2011], ["meeting", 2021], ["held", 2029], ["in", 2034], ["March", 2037], ["2012", 2043], [",", 2047], ["pharmaceutical", 2049], ["companies", 2064], ["negotiated", 2074], ["with", 2085], ["the", 2090], ["FDA", 2094], ["on", 2098], ["the", 2101], ["conditions", 2105], ["for", 2116], ["restarting", 2120], ["clinical", 2131], ["studies", 2140], [".", 2147], ["Although", 2149], ["the", 2158], ["FDA", 2162], ["lifted", 2166], ["its", 2173], ["clinical", 2177], ["hold", 2186], [",", 2190], ["there", 2192], ["remain", 2198], ["many", 2205], ["unresolved", 2210], ["issues", 2221], ["about", 2228], ["the", 2234], ["long", 2238], ["-", 2242], ["term", 2243], ["efficacy", 2248], ["and", 2257], ["safety", 2261], ["of", 2268], ["anti", 2271], ["-", 2275], ["NGF", 2276], ["mAbs", 2280], [".", 2284], ["While", 2286], ["acknowledging", 2292], ["that", 2306], ["the", 2311], ["future", 2315], ["of", 2322], ["these", 2325], ["drugs", 2331], ["is", 2337], ["unforeseeable", 2340], [",", 2353], ["it", 2355], ["appears", 2358], ["that", 2366], ["they", 2371], ["may", 2376], ["not", 2380], ["be", 2384], ["the", 2387], ["safe", 2391], ["and", 2396], ["effective", 2400], ["painkillers", 2410], ["that", 2422], ["have", 2427], ["been", 2432], ["awaited", 2437], ["for", 2445], ["decades", 2449], [".", 2456]]}
{"context": "Apical membrane antigen 1 (AMA1) is an asexual blood-stage protein expressed in the invasive merozoite form of Plasmodia species, which are the causative agent of malaria. We have complemented the function of Plasmodium falciparum AMA1 (PfAMA1) with a divergent AMA1 transgene from Plasmodium chabaudi (PcAMA1). It was not possible to disrupt the PfAMA1 gene using 'knock-out' plasmids, although we demonstrate that the PfAMA1 gene can be targeted by homologous recombination. These experiments suggest that PfAMA1 is critical, perhaps essential, for blood-stage growth. Importantly, we showed that PcAMA1 expression in P. falciparum provides trans-species complementation to at least 35% of the function of endogenous PfAMA1 in human red cells. Furthermore, expression of this transgene in P. falciparum leads to more efficient invasion of murine erythrocytes. These results indicate an important role for AMA1 in the invasion of red blood cells (RBCs) across divergent Plasmodium species.", "qas": [{"question": "Which is the causative agent of malaria?", "answers": ["Plasmodium species", "Plasmodium spp."], "qid": "e3479299b8474eb5a5963d6564d7faa9", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["causative", 13], ["agent", 23], ["of", 29], ["malaria", 32], ["?", 39]], "detected_answers": [{"text": "Plasmodium species", "token_spans": [[173, 174]], "char_spans": [[971, 988]]}]}], "context_tokens": [["Apical", 0], ["membrane", 7], ["antigen", 16], ["1", 24], ["(", 26], ["AMA1", 27], [")", 31], ["is", 33], ["an", 36], ["asexual", 39], ["blood", 47], ["-", 52], ["stage", 53], ["protein", 59], ["expressed", 67], ["in", 77], ["the", 80], ["invasive", 84], ["merozoite", 93], ["form", 103], ["of", 108], ["Plasmodia", 111], ["species", 121], [",", 128], ["which", 130], ["are", 136], ["the", 140], ["causative", 144], ["agent", 154], ["of", 160], ["malaria", 163], [".", 170], ["We", 172], ["have", 175], ["complemented", 180], ["the", 193], ["function", 197], ["of", 206], ["Plasmodium", 209], ["falciparum", 220], ["AMA1", 231], ["(", 236], ["PfAMA1", 237], [")", 243], ["with", 245], ["a", 250], ["divergent", 252], ["AMA1", 262], ["transgene", 267], ["from", 277], ["Plasmodium", 282], ["chabaudi", 293], ["(", 302], ["PcAMA1", 303], [")", 309], [".", 310], ["It", 312], ["was", 315], ["not", 319], ["possible", 323], ["to", 332], ["disrupt", 335], ["the", 343], ["PfAMA1", 347], ["gene", 354], ["using", 359], ["'", 365], ["knock", 366], ["-", 371], ["out", 372], ["'", 375], ["plasmids", 377], [",", 385], ["although", 387], ["we", 396], ["demonstrate", 399], ["that", 411], ["the", 416], ["PfAMA1", 420], ["gene", 427], ["can", 432], ["be", 436], ["targeted", 439], ["by", 448], ["homologous", 451], ["recombination", 462], [".", 475], ["These", 477], ["experiments", 483], ["suggest", 495], ["that", 503], ["PfAMA1", 508], ["is", 515], ["critical", 518], [",", 526], ["perhaps", 528], ["essential", 536], [",", 545], ["for", 547], ["blood", 551], ["-", 556], ["stage", 557], ["growth", 563], [".", 569], ["Importantly", 571], [",", 582], ["we", 584], ["showed", 587], ["that", 594], ["PcAMA1", 599], ["expression", 606], ["in", 617], ["P.", 620], ["falciparum", 623], ["provides", 634], ["trans", 643], ["-", 648], ["species", 649], ["complementation", 657], ["to", 673], ["at", 676], ["least", 679], ["35", 685], ["%", 687], ["of", 689], ["the", 692], ["function", 696], ["of", 705], ["endogenous", 708], ["PfAMA1", 719], ["in", 726], ["human", 729], ["red", 735], ["cells", 739], [".", 744], ["Furthermore", 746], [",", 757], ["expression", 759], ["of", 770], ["this", 773], ["transgene", 778], ["in", 788], ["P.", 791], ["falciparum", 794], ["leads", 805], ["to", 811], ["more", 814], ["efficient", 819], ["invasion", 829], ["of", 838], ["murine", 841], ["erythrocytes", 848], [".", 860], ["These", 862], ["results", 868], ["indicate", 876], ["an", 885], ["important", 888], ["role", 898], ["for", 903], ["AMA1", 907], ["in", 912], ["the", 915], ["invasion", 919], ["of", 928], ["red", 931], ["blood", 935], ["cells", 941], ["(", 947], ["RBCs", 948], [")", 952], ["across", 954], ["divergent", 961], ["Plasmodium", 971], ["species", 982], [".", 989]]}
{"context": "A blinded, retrospective study was performed to determine the value of supine abdominal radiographs in diagnosing pneumoperitoneum. Supine films from 44 cases of pneumoperitoneum were randomly interspersed among supine films from 87 control subjects without free air, and the films were reviewed for the presence or absence of various signs of pneumoperitoneum, including Rigler's sign (gas on both sides of the bowel wall), the falciform ligament sign (gas outlining the falciform ligament), the football sign (gas outlining the peritoneal cavity), the inverted-V sign (gas outlining the medial umbilical folds), and the right-upper-quadrant gas sign (localized gas in the right upper quadrant). One or more of these signs were present in 26 cases (59%) of pneumoperitoneum, including the right-upper-quadrant gas sign in 18 cases (41%), Rigler's sign in 14 cases (32%), and the falciform ligament and football signs in one case each (2%). Unfortunately, there were frequent errors in the interpretation of the right-upper-quadrant gas sign and Rigler's sign, with a total of 11 false-positive cases (13%). Further analysis of the true-positive right-upper-quadrant gas signs showed that these gas collections were always triangular or linear with an inferolateral to superomedial orientation and, if triangular, a concave superolateral border. In the true-positive Rigler's signs, the bowel wall thickness ranged from 1 to 8 mm, whereas the false positives all had a bowel wall thickness of 1 mm or less. Proper interpretation of the various signs of pneumoperitoneum on supine films should lead to more accurate diagnosis of this condition.", "qas": [{"question": "Falciform ligament sign is characteristic to which disease?", "answers": ["pneumoperitoneum"], "qid": "9305f4338a854725ab83e9b81c3c35b4", "question_tokens": [["Falciform", 0], ["ligament", 10], ["sign", 19], ["is", 24], ["characteristic", 27], ["to", 42], ["which", 45], ["disease", 51], ["?", 58]], "detected_answers": [{"text": "pneumoperitoneum", "token_spans": [[309, 309], [54, 54], [25, 25], [17, 17], [143, 143]], "char_spans": [[1553, 1568], [344, 359], [162, 177], [114, 129], [758, 773]]}]}], "context_tokens": [["A", 0], ["blinded", 2], [",", 9], ["retrospective", 11], ["study", 25], ["was", 31], ["performed", 35], ["to", 45], ["determine", 48], ["the", 58], ["value", 62], ["of", 68], ["supine", 71], ["abdominal", 78], ["radiographs", 88], ["in", 100], ["diagnosing", 103], ["pneumoperitoneum", 114], [".", 130], ["Supine", 132], ["films", 139], ["from", 145], ["44", 150], ["cases", 153], ["of", 159], ["pneumoperitoneum", 162], ["were", 179], ["randomly", 184], ["interspersed", 193], ["among", 206], ["supine", 212], ["films", 219], ["from", 225], ["87", 230], ["control", 233], ["subjects", 241], ["without", 250], ["free", 258], ["air", 263], [",", 266], ["and", 268], ["the", 272], ["films", 276], ["were", 282], ["reviewed", 287], ["for", 296], ["the", 300], ["presence", 304], ["or", 313], ["absence", 316], ["of", 324], ["various", 327], ["signs", 335], ["of", 341], ["pneumoperitoneum", 344], [",", 360], ["including", 362], ["Rigler", 372], ["'s", 378], ["sign", 381], ["(", 386], ["gas", 387], ["on", 391], ["both", 394], ["sides", 399], ["of", 405], ["the", 408], ["bowel", 412], ["wall", 418], [")", 422], [",", 423], ["the", 425], ["falciform", 429], ["ligament", 439], ["sign", 448], ["(", 453], ["gas", 454], ["outlining", 458], ["the", 468], ["falciform", 472], ["ligament", 482], [")", 490], [",", 491], ["the", 493], ["football", 497], ["sign", 506], ["(", 511], ["gas", 512], ["outlining", 516], ["the", 526], ["peritoneal", 530], ["cavity", 541], [")", 547], [",", 548], ["the", 550], ["inverted", 554], ["-", 562], ["V", 563], ["sign", 565], ["(", 570], ["gas", 571], ["outlining", 575], ["the", 585], ["medial", 589], ["umbilical", 596], ["folds", 606], [")", 611], [",", 612], ["and", 614], ["the", 618], ["right", 622], ["-", 627], ["upper", 628], ["-", 633], ["quadrant", 634], ["gas", 643], ["sign", 647], ["(", 652], ["localized", 653], ["gas", 663], ["in", 667], ["the", 670], ["right", 674], ["upper", 680], ["quadrant", 686], [")", 694], [".", 695], ["One", 697], ["or", 701], ["more", 704], ["of", 709], ["these", 712], ["signs", 718], ["were", 724], ["present", 729], ["in", 737], ["26", 740], ["cases", 743], ["(", 749], ["59", 750], ["%", 752], [")", 753], ["of", 755], ["pneumoperitoneum", 758], [",", 774], ["including", 776], ["the", 786], ["right", 790], ["-", 795], ["upper", 796], ["-", 801], ["quadrant", 802], ["gas", 811], ["sign", 815], ["in", 820], ["18", 823], ["cases", 826], ["(", 832], ["41", 833], ["%", 835], [")", 836], [",", 837], ["Rigler", 839], ["'s", 845], ["sign", 848], ["in", 853], ["14", 856], ["cases", 859], ["(", 865], ["32", 866], ["%", 868], [")", 869], [",", 870], ["and", 872], ["the", 876], ["falciform", 880], ["ligament", 890], ["and", 899], ["football", 903], ["signs", 912], ["in", 918], ["one", 921], ["case", 925], ["each", 930], ["(", 935], ["2", 936], ["%", 937], [")", 938], [".", 939], ["Unfortunately", 941], [",", 954], ["there", 956], ["were", 962], ["frequent", 967], ["errors", 976], ["in", 983], ["the", 986], ["interpretation", 990], ["of", 1005], ["the", 1008], ["right", 1012], ["-", 1017], ["upper", 1018], ["-", 1023], ["quadrant", 1024], ["gas", 1033], ["sign", 1037], ["and", 1042], ["Rigler", 1046], ["'s", 1052], ["sign", 1055], [",", 1059], ["with", 1061], ["a", 1066], ["total", 1068], ["of", 1074], ["11", 1077], ["false", 1080], ["-", 1085], ["positive", 1086], ["cases", 1095], ["(", 1101], ["13", 1102], ["%", 1104], [")", 1105], [".", 1106], ["Further", 1108], ["analysis", 1116], ["of", 1125], ["the", 1128], ["true", 1132], ["-", 1136], ["positive", 1137], ["right", 1146], ["-", 1151], ["upper", 1152], ["-", 1157], ["quadrant", 1158], ["gas", 1167], ["signs", 1171], ["showed", 1177], ["that", 1184], ["these", 1189], ["gas", 1195], ["collections", 1199], ["were", 1211], ["always", 1216], ["triangular", 1223], ["or", 1234], ["linear", 1237], ["with", 1244], ["an", 1249], ["inferolateral", 1252], ["to", 1266], ["superomedial", 1269], ["orientation", 1282], ["and", 1294], [",", 1297], ["if", 1299], ["triangular", 1302], [",", 1312], ["a", 1314], ["concave", 1316], ["superolateral", 1324], ["border", 1338], [".", 1344], ["In", 1346], ["the", 1349], ["true", 1353], ["-", 1357], ["positive", 1358], ["Rigler", 1367], ["'s", 1373], ["signs", 1376], [",", 1381], ["the", 1383], ["bowel", 1387], ["wall", 1393], ["thickness", 1398], ["ranged", 1408], ["from", 1415], ["1", 1420], ["to", 1422], ["8", 1425], ["mm", 1427], [",", 1429], ["whereas", 1431], ["the", 1439], ["false", 1443], ["positives", 1449], ["all", 1459], ["had", 1463], ["a", 1467], ["bowel", 1469], ["wall", 1475], ["thickness", 1480], ["of", 1490], ["1", 1493], ["mm", 1495], ["or", 1498], ["less", 1501], [".", 1505], ["Proper", 1507], ["interpretation", 1514], ["of", 1529], ["the", 1532], ["various", 1536], ["signs", 1544], ["of", 1550], ["pneumoperitoneum", 1553], ["on", 1570], ["supine", 1573], ["films", 1580], ["should", 1586], ["lead", 1593], ["to", 1598], ["more", 1601], ["accurate", 1606], ["diagnosis", 1615], ["of", 1625], ["this", 1628], ["condition", 1633], [".", 1642]]}
{"context": "There has been much debate about the appropriate statistical methodology for the evaluation of malaria field studies and the challenges in interpreting data arising from these trials. The present paper describes, for a pivotal phase III efficacy of the RTS, S/AS01 malaria vaccine, the methods of the statistical analysis and the rationale for their selection. The methods used to estimate efficacy of the primary course of vaccination, and of a booster dose, in preventing clinical episodes of uncomplicated and severe malaria, and to determine the duration of protection, are described. The interpretation of various measures of efficacy in terms of the potential public health impact of the vaccine is discussed. The methodology selected to analyse the clinical trial must be scientifically sound, acceptable to regulatory authorities and meaningful to those responsible for malaria control and public health policy.", "qas": [{"question": "RTS S AS01 vaccine was developed to prevent which disease?", "answers": ["malaria"], "qid": "565e79886a2d468ab49544a0c8e4d2c9", "question_tokens": [["RTS", 0], ["S", 4], ["AS01", 6], ["vaccine", 11], ["was", 19], ["developed", 23], ["to", 33], ["prevent", 36], ["which", 44], ["disease", 50], ["?", 57]], "detected_answers": [{"text": "malaria", "token_spans": [[146, 146], [89, 89], [46, 46], [14, 14]], "char_spans": [[878, 884], [520, 526], [265, 271], [95, 101]]}]}], "context_tokens": [["There", 0], ["has", 6], ["been", 10], ["much", 15], ["debate", 20], ["about", 27], ["the", 33], ["appropriate", 37], ["statistical", 49], ["methodology", 61], ["for", 73], ["the", 77], ["evaluation", 81], ["of", 92], ["malaria", 95], ["field", 103], ["studies", 109], ["and", 117], ["the", 121], ["challenges", 125], ["in", 136], ["interpreting", 139], ["data", 152], ["arising", 157], ["from", 165], ["these", 170], ["trials", 176], [".", 182], ["The", 184], ["present", 188], ["paper", 196], ["describes", 202], [",", 211], ["for", 213], ["a", 217], ["pivotal", 219], ["phase", 227], ["III", 233], ["efficacy", 237], ["of", 246], ["the", 249], ["RTS", 253], [",", 256], ["S", 258], ["/", 259], ["AS01", 260], ["malaria", 265], ["vaccine", 273], [",", 280], ["the", 282], ["methods", 286], ["of", 294], ["the", 297], ["statistical", 301], ["analysis", 313], ["and", 322], ["the", 326], ["rationale", 330], ["for", 340], ["their", 344], ["selection", 350], [".", 359], ["The", 361], ["methods", 365], ["used", 373], ["to", 378], ["estimate", 381], ["efficacy", 390], ["of", 399], ["the", 402], ["primary", 406], ["course", 414], ["of", 421], ["vaccination", 424], [",", 435], ["and", 437], ["of", 441], ["a", 444], ["booster", 446], ["dose", 454], [",", 458], ["in", 460], ["preventing", 463], ["clinical", 474], ["episodes", 483], ["of", 492], ["uncomplicated", 495], ["and", 509], ["severe", 513], ["malaria", 520], [",", 527], ["and", 529], ["to", 533], ["determine", 536], ["the", 546], ["duration", 550], ["of", 559], ["protection", 562], [",", 572], ["are", 574], ["described", 578], [".", 587], ["The", 589], ["interpretation", 593], ["of", 608], ["various", 611], ["measures", 619], ["of", 628], ["efficacy", 631], ["in", 640], ["terms", 643], ["of", 649], ["the", 652], ["potential", 656], ["public", 666], ["health", 673], ["impact", 680], ["of", 687], ["the", 690], ["vaccine", 694], ["is", 702], ["discussed", 705], [".", 714], ["The", 716], ["methodology", 720], ["selected", 732], ["to", 741], ["analyse", 744], ["the", 752], ["clinical", 756], ["trial", 765], ["must", 771], ["be", 776], ["scientifically", 779], ["sound", 794], [",", 799], ["acceptable", 801], ["to", 812], ["regulatory", 815], ["authorities", 826], ["and", 838], ["meaningful", 842], ["to", 853], ["those", 856], ["responsible", 862], ["for", 874], ["malaria", 878], ["control", 886], ["and", 894], ["public", 898], ["health", 905], ["policy", 912], [".", 918]]}
{"context": "The reactive oxygen-generating NADPH oxidases (Noxes) function in a variety of biological roles, and can be broadly classified into those that are regulated by subunit interactions and those that are regulated by calcium. The prototypical subunit-regulated Nox, Nox2, is the membrane-associated catalytic subunit of the phagocyte NADPH-oxidase. Nox2 forms a heterodimer with the integral membrane protein, p22phox, and this heterodimer binds to the regulatory subunits p47phox, p67phox, p40phox and the small GTPase Rac, triggering superoxide generation. Nox-organizer protein 1 (NOXO1) and Nox-activator 1 (NOXA1), respective homologs of p47phox and p67phox, together with p22phox and Rac, activate Nox1, a non-phagocytic homolog of Nox2. NOXO1 and p22phox also regulate Nox3, whereas Nox4 requires only p22phox. In this study, we have assembled and analyzed amino acid sequences of Nox regulatory subunit orthologs from vertebrates, a urochordate, an echinoderm, a mollusc, a cnidarian, a choanoflagellate, fungi and a slime mold amoeba to investigate the evolutionary history of these subunits. Ancestral p47phox, p67phox, and p22phox genes are broadly seen in the metazoa, except for the ecdysozoans. The choanoflagellate Monosiga brevicollis, the unicellular organism that is the closest relatives of multicellular animals, encodes early prototypes of p22phox, p47phox as well as the earliest known Nox2-like ancestor of the Nox1-3 subfamily. p67phox- and p47phox-like genes are seen in the sea urchin Strongylocentrotus purpuratus and the limpet Lottia gigantea that also possess Nox2-like co-orthologs of vertebrate Nox1-3. Duplication of primordial p47phox and p67phox genes occurred in vertebrates, with the duplicated branches evolving into NOXO1 and NOXA1. Analysis of characteristic domains of regulatory subunits suggests a novel view of the evolution of Nox: in fish, p40phox participated in regulating both Nox1 and Nox2, but after the appearance of mammals, Nox1 (but not Nox2) became independent of p40phox. In the fish Oryzias latipes, a NOXO1 ortholog retains an autoinhibitory region that is characteristic of mammalian p47phox, and this was subsequently lost from NOXO1 in later vertebrates. Detailed amino acid sequence comparisons identified both putative key residues conserved in characteristic domains and previously unidentified conserved regions. Also, candidate organizer/activator proteins in fungi and amoeba are identified and hypothetical activation models are suggested. This is the first report to provide the comprehensive view of the molecular evolution of regulatory subunits for Nox enzymes. This approach provides clues for understanding the evolution of biochemical and physiological functions for regulatory-subunit-dependent Nox enzymes.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "c9411266b7014dedb3a042e1c5632fa7", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NOX1", "token_spans": [[128, 128], [288, 288], [349, 349], [338, 338], [255, 255]], "char_spans": [[700, 703], [1623, 1626], [1974, 1977], [1922, 1925], [1430, 1433]]}]}], "context_tokens": [["The", 0], ["reactive", 4], ["oxygen", 13], ["-", 19], ["generating", 20], ["NADPH", 31], ["oxidases", 37], ["(", 46], ["Noxes", 47], [")", 52], ["function", 54], ["in", 63], ["a", 66], ["variety", 68], ["of", 76], ["biological", 79], ["roles", 90], [",", 95], ["and", 97], ["can", 101], ["be", 105], ["broadly", 108], ["classified", 116], ["into", 127], ["those", 132], ["that", 138], ["are", 143], ["regulated", 147], ["by", 157], ["subunit", 160], ["interactions", 168], ["and", 181], ["those", 185], ["that", 191], ["are", 196], ["regulated", 200], ["by", 210], ["calcium", 213], [".", 220], ["The", 222], ["prototypical", 226], ["subunit", 239], ["-", 246], ["regulated", 247], ["Nox", 257], [",", 260], ["Nox2", 262], [",", 266], ["is", 268], ["the", 271], ["membrane", 275], ["-", 283], ["associated", 284], ["catalytic", 295], ["subunit", 305], ["of", 313], ["the", 316], ["phagocyte", 320], ["NADPH", 330], ["-", 335], ["oxidase", 336], [".", 343], ["Nox2", 345], ["forms", 350], ["a", 356], ["heterodimer", 358], ["with", 370], ["the", 375], ["integral", 379], ["membrane", 388], ["protein", 397], [",", 404], ["p22phox", 406], [",", 413], ["and", 415], ["this", 419], ["heterodimer", 424], ["binds", 436], ["to", 442], ["the", 445], ["regulatory", 449], ["subunits", 460], ["p47phox", 469], [",", 476], ["p67phox", 478], [",", 485], ["p40phox", 487], ["and", 495], ["the", 499], ["small", 503], ["GTPase", 509], ["Rac", 516], [",", 519], ["triggering", 521], ["superoxide", 532], ["generation", 543], [".", 553], ["Nox", 555], ["-", 558], ["organizer", 559], ["protein", 569], ["1", 577], ["(", 579], ["NOXO1", 580], [")", 585], ["and", 587], ["Nox", 591], ["-", 594], ["activator", 595], ["1", 605], ["(", 607], ["NOXA1", 608], [")", 613], [",", 614], ["respective", 616], ["homologs", 627], ["of", 636], ["p47phox", 639], ["and", 647], ["p67phox", 651], [",", 658], ["together", 660], ["with", 669], ["p22phox", 674], ["and", 682], ["Rac", 686], [",", 689], ["activate", 691], ["Nox1", 700], [",", 704], ["a", 706], ["non", 708], ["-", 711], ["phagocytic", 712], ["homolog", 723], ["of", 731], ["Nox2", 734], [".", 738], ["NOXO1", 740], ["and", 746], ["p22phox", 750], ["also", 758], ["regulate", 763], ["Nox3", 772], [",", 776], ["whereas", 778], ["Nox4", 786], ["requires", 791], ["only", 800], ["p22phox", 805], [".", 812], ["In", 814], ["this", 817], ["study", 822], [",", 827], ["we", 829], ["have", 832], ["assembled", 837], ["and", 847], ["analyzed", 851], ["amino", 860], ["acid", 866], ["sequences", 871], ["of", 881], ["Nox", 884], ["regulatory", 888], ["subunit", 899], ["orthologs", 907], ["from", 917], ["vertebrates", 922], [",", 933], ["a", 935], ["urochordate", 937], [",", 948], ["an", 950], ["echinoderm", 953], [",", 963], ["a", 965], ["mollusc", 967], [",", 974], ["a", 976], ["cnidarian", 978], [",", 987], ["a", 989], ["choanoflagellate", 991], [",", 1007], ["fungi", 1009], ["and", 1015], ["a", 1019], ["slime", 1021], ["mold", 1027], ["amoeba", 1032], ["to", 1039], ["investigate", 1042], ["the", 1054], ["evolutionary", 1058], ["history", 1071], ["of", 1079], ["these", 1082], ["subunits", 1088], [".", 1096], ["Ancestral", 1098], ["p47phox", 1108], [",", 1115], ["p67phox", 1117], [",", 1124], ["and", 1126], ["p22phox", 1130], ["genes", 1138], ["are", 1144], ["broadly", 1148], ["seen", 1156], ["in", 1161], ["the", 1164], ["metazoa", 1168], [",", 1175], ["except", 1177], ["for", 1184], ["the", 1188], ["ecdysozoans", 1192], [".", 1203], ["The", 1205], ["choanoflagellate", 1209], ["Monosiga", 1226], ["brevicollis", 1235], [",", 1246], ["the", 1248], ["unicellular", 1252], ["organism", 1264], ["that", 1273], ["is", 1278], ["the", 1281], ["closest", 1285], ["relatives", 1293], ["of", 1303], ["multicellular", 1306], ["animals", 1320], [",", 1327], ["encodes", 1329], ["early", 1337], ["prototypes", 1343], ["of", 1354], ["p22phox", 1357], [",", 1364], ["p47phox", 1366], ["as", 1374], ["well", 1377], ["as", 1382], ["the", 1385], ["earliest", 1389], ["known", 1398], ["Nox2-like", 1404], ["ancestor", 1414], ["of", 1423], ["the", 1426], ["Nox1", 1430], ["-", 1434], ["3", 1435], ["subfamily", 1437], [".", 1446], ["p67phox-", 1448], ["and", 1457], ["p47phox", 1461], ["-", 1468], ["like", 1469], ["genes", 1474], ["are", 1480], ["seen", 1484], ["in", 1489], ["the", 1492], ["sea", 1496], ["urchin", 1500], ["Strongylocentrotus", 1507], ["purpuratus", 1526], ["and", 1537], ["the", 1541], ["limpet", 1545], ["Lottia", 1552], ["gigantea", 1559], ["that", 1568], ["also", 1573], ["possess", 1578], ["Nox2-like", 1586], ["co", 1596], ["-", 1598], ["orthologs", 1599], ["of", 1609], ["vertebrate", 1612], ["Nox1", 1623], ["-", 1627], ["3", 1628], [".", 1629], ["Duplication", 1631], ["of", 1643], ["primordial", 1646], ["p47phox", 1657], ["and", 1665], ["p67phox", 1669], ["genes", 1677], ["occurred", 1683], ["in", 1692], ["vertebrates", 1695], [",", 1706], ["with", 1708], ["the", 1713], ["duplicated", 1717], ["branches", 1728], ["evolving", 1737], ["into", 1746], ["NOXO1", 1751], ["and", 1757], ["NOXA1", 1761], [".", 1766], ["Analysis", 1768], ["of", 1777], ["characteristic", 1780], ["domains", 1795], ["of", 1803], ["regulatory", 1806], ["subunits", 1817], ["suggests", 1826], ["a", 1835], ["novel", 1837], ["view", 1843], ["of", 1848], ["the", 1851], ["evolution", 1855], ["of", 1865], ["Nox", 1868], [":", 1871], ["in", 1873], ["fish", 1876], [",", 1880], ["p40phox", 1882], ["participated", 1890], ["in", 1903], ["regulating", 1906], ["both", 1917], ["Nox1", 1922], ["and", 1927], ["Nox2", 1931], [",", 1935], ["but", 1937], ["after", 1941], ["the", 1947], ["appearance", 1951], ["of", 1962], ["mammals", 1965], [",", 1972], ["Nox1", 1974], ["(", 1979], ["but", 1980], ["not", 1984], ["Nox2", 1988], [")", 1992], ["became", 1994], ["independent", 2001], ["of", 2013], ["p40phox", 2016], [".", 2023], ["In", 2025], ["the", 2028], ["fish", 2032], ["Oryzias", 2037], ["latipes", 2045], [",", 2052], ["a", 2054], ["NOXO1", 2056], ["ortholog", 2062], ["retains", 2071], ["an", 2079], ["autoinhibitory", 2082], ["region", 2097], ["that", 2104], ["is", 2109], ["characteristic", 2112], ["of", 2127], ["mammalian", 2130], ["p47phox", 2140], [",", 2147], ["and", 2149], ["this", 2153], ["was", 2158], ["subsequently", 2162], ["lost", 2175], ["from", 2180], ["NOXO1", 2185], ["in", 2191], ["later", 2194], ["vertebrates", 2200], [".", 2211], ["Detailed", 2213], ["amino", 2222], ["acid", 2228], ["sequence", 2233], ["comparisons", 2242], ["identified", 2254], ["both", 2265], ["putative", 2270], ["key", 2279], ["residues", 2283], ["conserved", 2292], ["in", 2302], ["characteristic", 2305], ["domains", 2320], ["and", 2328], ["previously", 2332], ["unidentified", 2343], ["conserved", 2356], ["regions", 2366], [".", 2373], ["Also", 2375], [",", 2379], ["candidate", 2381], ["organizer", 2391], ["/", 2400], ["activator", 2401], ["proteins", 2411], ["in", 2420], ["fungi", 2423], ["and", 2429], ["amoeba", 2433], ["are", 2440], ["identified", 2444], ["and", 2455], ["hypothetical", 2459], ["activation", 2472], ["models", 2483], ["are", 2490], ["suggested", 2494], [".", 2503], ["This", 2505], ["is", 2510], ["the", 2513], ["first", 2517], ["report", 2523], ["to", 2530], ["provide", 2533], ["the", 2541], ["comprehensive", 2545], ["view", 2559], ["of", 2564], ["the", 2567], ["molecular", 2571], ["evolution", 2581], ["of", 2591], ["regulatory", 2594], ["subunits", 2605], ["for", 2614], ["Nox", 2618], ["enzymes", 2622], [".", 2629], ["This", 2631], ["approach", 2636], ["provides", 2645], ["clues", 2654], ["for", 2660], ["understanding", 2664], ["the", 2678], ["evolution", 2682], ["of", 2692], ["biochemical", 2695], ["and", 2707], ["physiological", 2711], ["functions", 2725], ["for", 2735], ["regulatory", 2739], ["-", 2749], ["subunit", 2750], ["-", 2757], ["dependent", 2758], ["Nox", 2768], ["enzymes", 2772], [".", 2779]]}
{"context": "Spectrin, the major component of the erythroid membrane skeleton, is a long, asymmetrical rodlike protein that interacts with several other proteins to form a two-dimensional membrane skeleton. Progress in several laboratories over the past few years including substantial partial peptide and nucleotide sequence determination has greatly enhanced our knowledge of the structural properties of this large molecule (heterodimer = 465,000 daltons). The alpha and beta subunits are homologous with approximately 30% identity. They are aligned in an antiparallel side-to-side orientation with the amino- and carboxy-termini near opposite physical ends of the molecule. The predominant structural feature elucidated from sequencing this large molecule is the nearly universal occurrence in both subunits of a single type of repetitive structure. The periodicity of this homologous structure is exactly 106 amino acid residues. As many as 36 homologous, but nonidentical, repeats exist and comprise more than 90% of the mass of the heterodimer. Each of these repetitive units is folded into a triple-stranded structure that is highly helical. Peptide maps, antibody crossreactivity, peptide sequence analysis, and more recently nucleic acid sequences have defined several major properties of the erythroid molecule and related proteins in other tissues. Tissue-specific spectrins have the same 106-residue repetitive structure and show sequence homology to erythroid spectrin.", "qas": [{"question": "Alpha-spectrin and beta-spectrin subunits form parallel or antiparallel heterodimers?", "answers": ["antiparallel"], "qid": "98eb6a6cc03a4c00a5f1dbda3e4cead5", "question_tokens": [["Alpha", 0], ["-", 5], ["spectrin", 6], ["and", 15], ["beta", 19], ["-", 23], ["spectrin", 24], ["subunits", 33], ["form", 42], ["parallel", 47], ["or", 56], ["antiparallel", 59], ["heterodimers", 72], ["?", 84]], "detected_answers": [{"text": "antiparallel", "token_spans": [[88, 88]], "char_spans": [[546, 557]]}]}], "context_tokens": [["Spectrin", 0], [",", 8], ["the", 10], ["major", 14], ["component", 20], ["of", 30], ["the", 33], ["erythroid", 37], ["membrane", 47], ["skeleton", 56], [",", 64], ["is", 66], ["a", 69], ["long", 71], [",", 75], ["asymmetrical", 77], ["rodlike", 90], ["protein", 98], ["that", 106], ["interacts", 111], ["with", 121], ["several", 126], ["other", 134], ["proteins", 140], ["to", 149], ["form", 152], ["a", 157], ["two", 159], ["-", 162], ["dimensional", 163], ["membrane", 175], ["skeleton", 184], [".", 192], ["Progress", 194], ["in", 203], ["several", 206], ["laboratories", 214], ["over", 227], ["the", 232], ["past", 236], ["few", 241], ["years", 245], ["including", 251], ["substantial", 261], ["partial", 273], ["peptide", 281], ["and", 289], ["nucleotide", 293], ["sequence", 304], ["determination", 313], ["has", 327], ["greatly", 331], ["enhanced", 339], ["our", 348], ["knowledge", 352], ["of", 362], ["the", 365], ["structural", 369], ["properties", 380], ["of", 391], ["this", 394], ["large", 399], ["molecule", 405], ["(", 414], ["heterodimer", 415], ["=", 427], ["465,000", 429], ["daltons", 437], [")", 444], [".", 445], ["The", 447], ["alpha", 451], ["and", 457], ["beta", 461], ["subunits", 466], ["are", 475], ["homologous", 479], ["with", 490], ["approximately", 495], ["30", 509], ["%", 511], ["identity", 513], [".", 521], ["They", 523], ["are", 528], ["aligned", 532], ["in", 540], ["an", 543], ["antiparallel", 546], ["side", 559], ["-", 563], ["to", 564], ["-", 566], ["side", 567], ["orientation", 572], ["with", 584], ["the", 589], ["amino-", 593], ["and", 600], ["carboxy", 604], ["-", 611], ["termini", 612], ["near", 620], ["opposite", 625], ["physical", 634], ["ends", 643], ["of", 648], ["the", 651], ["molecule", 655], [".", 663], ["The", 665], ["predominant", 669], ["structural", 681], ["feature", 692], ["elucidated", 700], ["from", 711], ["sequencing", 716], ["this", 727], ["large", 732], ["molecule", 738], ["is", 747], ["the", 750], ["nearly", 754], ["universal", 761], ["occurrence", 771], ["in", 782], ["both", 785], ["subunits", 790], ["of", 799], ["a", 802], ["single", 804], ["type", 811], ["of", 816], ["repetitive", 819], ["structure", 830], [".", 839], ["The", 841], ["periodicity", 845], ["of", 857], ["this", 860], ["homologous", 865], ["structure", 876], ["is", 886], ["exactly", 889], ["106", 897], ["amino", 901], ["acid", 907], ["residues", 912], [".", 920], ["As", 922], ["many", 925], ["as", 930], ["36", 933], ["homologous", 936], [",", 946], ["but", 948], ["nonidentical", 952], [",", 964], ["repeats", 966], ["exist", 974], ["and", 980], ["comprise", 984], ["more", 993], ["than", 998], ["90", 1003], ["%", 1005], ["of", 1007], ["the", 1010], ["mass", 1014], ["of", 1019], ["the", 1022], ["heterodimer", 1026], [".", 1037], ["Each", 1039], ["of", 1044], ["these", 1047], ["repetitive", 1053], ["units", 1064], ["is", 1070], ["folded", 1073], ["into", 1080], ["a", 1085], ["triple", 1087], ["-", 1093], ["stranded", 1094], ["structure", 1103], ["that", 1113], ["is", 1118], ["highly", 1121], ["helical", 1128], [".", 1135], ["Peptide", 1137], ["maps", 1145], [",", 1149], ["antibody", 1151], ["crossreactivity", 1160], [",", 1175], ["peptide", 1177], ["sequence", 1185], ["analysis", 1194], [",", 1202], ["and", 1204], ["more", 1208], ["recently", 1213], ["nucleic", 1222], ["acid", 1230], ["sequences", 1235], ["have", 1245], ["defined", 1250], ["several", 1258], ["major", 1266], ["properties", 1272], ["of", 1283], ["the", 1286], ["erythroid", 1290], ["molecule", 1300], ["and", 1309], ["related", 1313], ["proteins", 1321], ["in", 1330], ["other", 1333], ["tissues", 1339], [".", 1346], ["Tissue", 1348], ["-", 1354], ["specific", 1355], ["spectrins", 1364], ["have", 1374], ["the", 1379], ["same", 1383], ["106-residue", 1388], ["repetitive", 1400], ["structure", 1411], ["and", 1421], ["show", 1425], ["sequence", 1430], ["homology", 1439], ["to", 1448], ["erythroid", 1451], ["spectrin", 1461], [".", 1469]]}
{"context": "Chronic myeloid leukaemia (CML) is a genetically associated malignancy of haematopoietic stem cells, characterized by a t(9;22) translocation that forms the Philadelphia chromosome and creates a novel fusion gene, BCR-ABL. Treatment with molecular-targeted therapy is usually initiated with imatinib, an inhibitor of BCR-ABL tyrosine kinase. Imatinib resistance is, however, observed in some CML patients, especially in those with advanced disease. Through computerized literature searches, a systematic analysis was conducted to examine the efficacy and benefits of dasatinib therapy for imatinib resistant or intolerant CML patients in the chronic phase (CP), accelerated phase (AP) and fatal blast crisis phase (BC). In terms of major haematological and cytogenetic responses, this meta-analysis showed no significant differences in dasatinib treatment between myeloid BC-CML and lymphoid BC-CML patients with imatinib resistance or intolerance. Dasatinib therapy was, however, significantly more effective in improving major haematological and cytogenetic responses for CP-CML patients than for AP-CML patients with imatinib resistance or intolerance.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "4039d749db1e402c81b273c51d21f59b", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[53, 55], [34, 36]], "char_spans": [[317, 323], [214, 220]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukaemia", 16], ["(", 26], ["CML", 27], [")", 30], ["is", 32], ["a", 35], ["genetically", 37], ["associated", 49], ["malignancy", 60], ["of", 71], ["haematopoietic", 74], ["stem", 89], ["cells", 94], [",", 99], ["characterized", 101], ["by", 115], ["a", 118], ["t(9;22", 120], [")", 126], ["translocation", 128], ["that", 142], ["forms", 147], ["the", 153], ["Philadelphia", 157], ["chromosome", 170], ["and", 181], ["creates", 185], ["a", 193], ["novel", 195], ["fusion", 201], ["gene", 208], [",", 212], ["BCR", 214], ["-", 217], ["ABL", 218], [".", 221], ["Treatment", 223], ["with", 233], ["molecular", 238], ["-", 247], ["targeted", 248], ["therapy", 257], ["is", 265], ["usually", 268], ["initiated", 276], ["with", 286], ["imatinib", 291], [",", 299], ["an", 301], ["inhibitor", 304], ["of", 314], ["BCR", 317], ["-", 320], ["ABL", 321], ["tyrosine", 325], ["kinase", 334], [".", 340], ["Imatinib", 342], ["resistance", 351], ["is", 362], [",", 364], ["however", 366], [",", 373], ["observed", 375], ["in", 384], ["some", 387], ["CML", 392], ["patients", 396], [",", 404], ["especially", 406], ["in", 417], ["those", 420], ["with", 426], ["advanced", 431], ["disease", 440], [".", 447], ["Through", 449], ["computerized", 457], ["literature", 470], ["searches", 481], [",", 489], ["a", 491], ["systematic", 493], ["analysis", 504], ["was", 513], ["conducted", 517], ["to", 527], ["examine", 530], ["the", 538], ["efficacy", 542], ["and", 551], ["benefits", 555], ["of", 564], ["dasatinib", 567], ["therapy", 577], ["for", 585], ["imatinib", 589], ["resistant", 598], ["or", 608], ["intolerant", 611], ["CML", 622], ["patients", 626], ["in", 635], ["the", 638], ["chronic", 642], ["phase", 650], ["(", 656], ["CP", 657], [")", 659], [",", 660], ["accelerated", 662], ["phase", 674], ["(", 680], ["AP", 681], [")", 683], ["and", 685], ["fatal", 689], ["blast", 695], ["crisis", 701], ["phase", 708], ["(", 714], ["BC", 715], [")", 717], [".", 718], ["In", 720], ["terms", 723], ["of", 729], ["major", 732], ["haematological", 738], ["and", 753], ["cytogenetic", 757], ["responses", 769], [",", 778], ["this", 780], ["meta", 785], ["-", 789], ["analysis", 790], ["showed", 799], ["no", 806], ["significant", 809], ["differences", 821], ["in", 833], ["dasatinib", 836], ["treatment", 846], ["between", 856], ["myeloid", 864], ["BC", 872], ["-", 874], ["CML", 875], ["and", 879], ["lymphoid", 883], ["BC", 892], ["-", 894], ["CML", 895], ["patients", 899], ["with", 908], ["imatinib", 913], ["resistance", 922], ["or", 933], ["intolerance", 936], [".", 947], ["Dasatinib", 949], ["therapy", 959], ["was", 967], [",", 970], ["however", 972], [",", 979], ["significantly", 981], ["more", 995], ["effective", 1000], ["in", 1010], ["improving", 1013], ["major", 1023], ["haematological", 1029], ["and", 1044], ["cytogenetic", 1048], ["responses", 1060], ["for", 1070], ["CP", 1074], ["-", 1076], ["CML", 1077], ["patients", 1081], ["than", 1090], ["for", 1095], ["AP", 1099], ["-", 1101], ["CML", 1102], ["patients", 1106], ["with", 1115], ["imatinib", 1120], ["resistance", 1129], ["or", 1140], ["intolerance", 1143], [".", 1154]]}
{"context": "Histone H3 lysine 4 (K4) methylation is a prevalent mark associated with transcription activation and is mainly catalyzed by the MLL/SET1 family histone methyltransferases. A common feature of the mammalian MLL/SET1 complexes is the presence of three core components (RbBP5, Ash2L and WDR5) and a catalytic subunit containing a SET domain. Unlike most other histone lysine methyltransferases, all four proteins are required for efficient H3 K4 methylation. Despite extensive efforts, mechanisms for how three core components regulate MLL/SET1 methyltransferase activity remain elusive. Here we show that a heterodimer of Ash2L and RbBP5 has intrinsic histone methyltransferase activity. This activity requires the highly conserved SPRY domain of Ash2L and a short peptide of RbBP5. We demonstrate that both Ash2L and the MLL1 SET domain are capable of binding to S-adenosyl-L- [methyl-(3)H] methionine in the MLL1 core complex. Mutations in the MLL1 SET domain that fail to support overall H3 K4 methylation also compromise SAM binding by Ash2L. Taken together, our results show that the Ash2L/RbBP5 heterodimer plays a critical role in the overall catalysis of MLL1 mediated H3 K4 methylation. The results we describe here provide mechanistic insights for unique regulation of the MLL1 methyltransferase activity. It suggests that both Ash2L/RbBP5 and the MLL1 SET domain make direct contacts with the substrates and contribute to the formation of a joint catalytic center. Given the shared core configuration among all MLL/SET1 family HMTs, it will be interesting to test whether the mechanism we describe here can be generalized to other MLL/SET1 family members in the future.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "e1caec128d5f4cb4a20159f0430b80d1", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[140, 141], [59, 60], [166, 167], [236, 237]], "char_spans": [[826, 835], [328, 337], [950, 959], [1362, 1371]]}]}], "context_tokens": [["Histone", 0], ["H3", 8], ["lysine", 11], ["4", 18], ["(", 20], ["K4", 21], [")", 23], ["methylation", 25], ["is", 37], ["a", 40], ["prevalent", 42], ["mark", 52], ["associated", 57], ["with", 68], ["transcription", 73], ["activation", 87], ["and", 98], ["is", 102], ["mainly", 105], ["catalyzed", 112], ["by", 122], ["the", 125], ["MLL", 129], ["/", 132], ["SET1", 133], ["family", 138], ["histone", 145], ["methyltransferases", 153], [".", 171], ["A", 173], ["common", 175], ["feature", 182], ["of", 190], ["the", 193], ["mammalian", 197], ["MLL", 207], ["/", 210], ["SET1", 211], ["complexes", 216], ["is", 226], ["the", 229], ["presence", 233], ["of", 242], ["three", 245], ["core", 251], ["components", 256], ["(", 267], ["RbBP5", 268], [",", 273], ["Ash2L", 275], ["and", 281], ["WDR5", 285], [")", 289], ["and", 291], ["a", 295], ["catalytic", 297], ["subunit", 307], ["containing", 315], ["a", 326], ["SET", 328], ["domain", 332], [".", 338], ["Unlike", 340], ["most", 347], ["other", 352], ["histone", 358], ["lysine", 366], ["methyltransferases", 373], [",", 391], ["all", 393], ["four", 397], ["proteins", 402], ["are", 411], ["required", 415], ["for", 424], ["efficient", 428], ["H3", 438], ["K4", 441], ["methylation", 444], [".", 455], ["Despite", 457], ["extensive", 465], ["efforts", 475], [",", 482], ["mechanisms", 484], ["for", 495], ["how", 499], ["three", 503], ["core", 509], ["components", 514], ["regulate", 525], ["MLL", 534], ["/", 537], ["SET1", 538], ["methyltransferase", 543], ["activity", 561], ["remain", 570], ["elusive", 577], [".", 584], ["Here", 586], ["we", 591], ["show", 594], ["that", 599], ["a", 604], ["heterodimer", 606], ["of", 618], ["Ash2L", 621], ["and", 627], ["RbBP5", 631], ["has", 637], ["intrinsic", 641], ["histone", 651], ["methyltransferase", 659], ["activity", 677], [".", 685], ["This", 687], ["activity", 692], ["requires", 701], ["the", 710], ["highly", 714], ["conserved", 721], ["SPRY", 731], ["domain", 736], ["of", 743], ["Ash2L", 746], ["and", 752], ["a", 756], ["short", 758], ["peptide", 764], ["of", 772], ["RbBP5", 775], [".", 780], ["We", 782], ["demonstrate", 785], ["that", 797], ["both", 802], ["Ash2L", 807], ["and", 813], ["the", 817], ["MLL1", 821], ["SET", 826], ["domain", 830], ["are", 837], ["capable", 841], ["of", 849], ["binding", 852], ["to", 860], ["S", 863], ["-", 864], ["adenosyl", 865], ["-", 873], ["L-", 874], ["[", 877], ["methyl-(3)H", 878], ["]", 889], ["methionine", 891], ["in", 902], ["the", 905], ["MLL1", 909], ["core", 914], ["complex", 919], [".", 926], ["Mutations", 928], ["in", 938], ["the", 941], ["MLL1", 945], ["SET", 950], ["domain", 954], ["that", 961], ["fail", 966], ["to", 971], ["support", 974], ["overall", 982], ["H3", 990], ["K4", 993], ["methylation", 996], ["also", 1008], ["compromise", 1013], ["SAM", 1024], ["binding", 1028], ["by", 1036], ["Ash2L.", 1039], ["Taken", 1046], ["together", 1052], [",", 1060], ["our", 1062], ["results", 1066], ["show", 1074], ["that", 1079], ["the", 1084], ["Ash2L", 1088], ["/", 1093], ["RbBP5", 1094], ["heterodimer", 1100], ["plays", 1112], ["a", 1118], ["critical", 1120], ["role", 1129], ["in", 1134], ["the", 1137], ["overall", 1141], ["catalysis", 1149], ["of", 1159], ["MLL1", 1162], ["mediated", 1167], ["H3", 1176], ["K4", 1179], ["methylation", 1182], [".", 1193], ["The", 1195], ["results", 1199], ["we", 1207], ["describe", 1210], ["here", 1219], ["provide", 1224], ["mechanistic", 1232], ["insights", 1244], ["for", 1253], ["unique", 1257], ["regulation", 1264], ["of", 1275], ["the", 1278], ["MLL1", 1282], ["methyltransferase", 1287], ["activity", 1305], [".", 1313], ["It", 1315], ["suggests", 1318], ["that", 1327], ["both", 1332], ["Ash2L", 1337], ["/", 1342], ["RbBP5", 1343], ["and", 1349], ["the", 1353], ["MLL1", 1357], ["SET", 1362], ["domain", 1366], ["make", 1373], ["direct", 1378], ["contacts", 1385], ["with", 1394], ["the", 1399], ["substrates", 1403], ["and", 1414], ["contribute", 1418], ["to", 1429], ["the", 1432], ["formation", 1436], ["of", 1446], ["a", 1449], ["joint", 1451], ["catalytic", 1457], ["center", 1467], [".", 1473], ["Given", 1475], ["the", 1481], ["shared", 1485], ["core", 1492], ["configuration", 1497], ["among", 1511], ["all", 1517], ["MLL", 1521], ["/", 1524], ["SET1", 1525], ["family", 1530], ["HMTs", 1537], [",", 1541], ["it", 1543], ["will", 1546], ["be", 1551], ["interesting", 1554], ["to", 1566], ["test", 1569], ["whether", 1574], ["the", 1582], ["mechanism", 1586], ["we", 1596], ["describe", 1599], ["here", 1608], ["can", 1613], ["be", 1617], ["generalized", 1620], ["to", 1632], ["other", 1635], ["MLL", 1641], ["/", 1644], ["SET1", 1645], ["family", 1650], ["members", 1657], ["in", 1665], ["the", 1668], ["future", 1672], [".", 1678]]}
{"context": "Neural stem/progenitor cells (NSCs) reside in the subventricular zone (SVZ) and subgranular zone of the hippocampal dentate gyrus in adult mammals. The ubiquitin ligase HRD1 is associated with degradation of amyloid precursor protein and believed to be specifically expressed in neurons and not in astrocytes. We investigated expression of HRD1 using immunohistochemistry and found colocalization of HRD1 with the NSC marker protein nestin and glial fibrillary acidic protein in the NSCs of the SVZ (the SVZ astrocytes) but not in the hippocampus. In the hippocampal dentate gyrus, HRD1 is localized in the nucleus of nestin-positive cells.", "qas": [{"question": "Which intermediate filament (IF) protein can be used as a non-specific marker of the neuronal precursor cells of the subventricular zone?", "answers": ["Nestin"], "qid": "2955684affa14660b9c3b54689b9b2d2", "question_tokens": [["Which", 0], ["intermediate", 6], ["filament", 19], ["(", 28], ["IF", 29], [")", 31], ["protein", 33], ["can", 41], ["be", 45], ["used", 48], ["as", 53], ["a", 56], ["non", 58], ["-", 61], ["specific", 62], ["marker", 71], ["of", 78], ["the", 81], ["neuronal", 85], ["precursor", 94], ["cells", 104], ["of", 110], ["the", 113], ["subventricular", 117], ["zone", 132], ["?", 136]], "detected_answers": [{"text": "Nestin", "token_spans": [[106, 106], [70, 70]], "char_spans": [[618, 623], [433, 438]]}]}], "context_tokens": [["Neural", 0], ["stem", 7], ["/", 11], ["progenitor", 12], ["cells", 23], ["(", 29], ["NSCs", 30], [")", 34], ["reside", 36], ["in", 43], ["the", 46], ["subventricular", 50], ["zone", 65], ["(", 70], ["SVZ", 71], [")", 74], ["and", 76], ["subgranular", 80], ["zone", 92], ["of", 97], ["the", 100], ["hippocampal", 104], ["dentate", 116], ["gyrus", 124], ["in", 130], ["adult", 133], ["mammals", 139], [".", 146], ["The", 148], ["ubiquitin", 152], ["ligase", 162], ["HRD1", 169], ["is", 174], ["associated", 177], ["with", 188], ["degradation", 193], ["of", 205], ["amyloid", 208], ["precursor", 216], ["protein", 226], ["and", 234], ["believed", 238], ["to", 247], ["be", 250], ["specifically", 253], ["expressed", 266], ["in", 276], ["neurons", 279], ["and", 287], ["not", 291], ["in", 295], ["astrocytes", 298], [".", 308], ["We", 310], ["investigated", 313], ["expression", 326], ["of", 337], ["HRD1", 340], ["using", 345], ["immunohistochemistry", 351], ["and", 372], ["found", 376], ["colocalization", 382], ["of", 397], ["HRD1", 400], ["with", 405], ["the", 410], ["NSC", 414], ["marker", 418], ["protein", 425], ["nestin", 433], ["and", 440], ["glial", 444], ["fibrillary", 450], ["acidic", 461], ["protein", 468], ["in", 476], ["the", 479], ["NSCs", 483], ["of", 488], ["the", 491], ["SVZ", 495], ["(", 499], ["the", 500], ["SVZ", 504], ["astrocytes", 508], [")", 518], ["but", 520], ["not", 524], ["in", 528], ["the", 531], ["hippocampus", 535], [".", 546], ["In", 548], ["the", 551], ["hippocampal", 555], ["dentate", 567], ["gyrus", 575], [",", 580], ["HRD1", 582], ["is", 587], ["localized", 590], ["in", 600], ["the", 603], ["nucleus", 607], ["of", 615], ["nestin", 618], ["-", 624], ["positive", 625], ["cells", 634], [".", 639]]}
{"context": "A 75-year-old woman presented with altered mental status, septic picture, and influenza-like symptoms. Initial investigations revealed atypical lymphocytosis, thrombocytopenia, elevated liver enzymes, and a positive monospot test result. Further investigation showed the Epstein-Barr virus viral capsid antibody IgM/IgG and Epstein-Barr virus DNA by polymerase chain reaction to be negative; however, interestingly her cytomegalovirus (CMV) IgM and IgG were positive, suggesting that her mononucleosis-like syndrome was due to acute CMV infection. Herein, we report the first case of a heterophile-positive mononucleosis syndrome caused by acute CMV infection in an elderly immunocompetent woman. This case conveys that monospot test can yield false-positive result in the setting of acute CMV infection.", "qas": [{"question": "Which virus can be diagnosed with the monospot test?", "answers": ["Epstein-Barr virus"], "qid": "0460fc84d839453e88d73ec2691da940", "question_tokens": [["Which", 0], ["virus", 6], ["can", 12], ["be", 16], ["diagnosed", 19], ["with", 29], ["the", 34], ["monospot", 38], ["test", 47], ["?", 51]], "detected_answers": [{"text": "Epstein-Barr virus", "token_spans": [[54, 57], [43, 46]], "char_spans": [[324, 341], [271, 288]]}]}], "context_tokens": [["A", 0], ["75-year", 2], ["-", 9], ["old", 10], ["woman", 14], ["presented", 20], ["with", 30], ["altered", 35], ["mental", 43], ["status", 50], [",", 56], ["septic", 58], ["picture", 65], [",", 72], ["and", 74], ["influenza", 78], ["-", 87], ["like", 88], ["symptoms", 93], [".", 101], ["Initial", 103], ["investigations", 111], ["revealed", 126], ["atypical", 135], ["lymphocytosis", 144], [",", 157], ["thrombocytopenia", 159], [",", 175], ["elevated", 177], ["liver", 186], ["enzymes", 192], [",", 199], ["and", 201], ["a", 205], ["positive", 207], ["monospot", 216], ["test", 225], ["result", 230], [".", 236], ["Further", 238], ["investigation", 246], ["showed", 260], ["the", 267], ["Epstein", 271], ["-", 278], ["Barr", 279], ["virus", 284], ["viral", 290], ["capsid", 296], ["antibody", 303], ["IgM", 312], ["/", 315], ["IgG", 316], ["and", 320], ["Epstein", 324], ["-", 331], ["Barr", 332], ["virus", 337], ["DNA", 343], ["by", 347], ["polymerase", 350], ["chain", 361], ["reaction", 367], ["to", 376], ["be", 379], ["negative", 382], [";", 390], ["however", 392], [",", 399], ["interestingly", 401], ["her", 415], ["cytomegalovirus", 419], ["(", 435], ["CMV", 436], [")", 439], ["IgM", 441], ["and", 445], ["IgG", 449], ["were", 453], ["positive", 458], [",", 466], ["suggesting", 468], ["that", 479], ["her", 484], ["mononucleosis", 488], ["-", 501], ["like", 502], ["syndrome", 507], ["was", 516], ["due", 520], ["to", 524], ["acute", 527], ["CMV", 533], ["infection", 537], [".", 546], ["Herein", 548], [",", 554], ["we", 556], ["report", 559], ["the", 566], ["first", 570], ["case", 576], ["of", 581], ["a", 584], ["heterophile", 586], ["-", 597], ["positive", 598], ["mononucleosis", 607], ["syndrome", 621], ["caused", 630], ["by", 637], ["acute", 640], ["CMV", 646], ["infection", 650], ["in", 660], ["an", 663], ["elderly", 666], ["immunocompetent", 674], ["woman", 690], [".", 695], ["This", 697], ["case", 702], ["conveys", 707], ["that", 715], ["monospot", 720], ["test", 729], ["can", 734], ["yield", 738], ["false", 744], ["-", 749], ["positive", 750], ["result", 759], ["in", 766], ["the", 769], ["setting", 773], ["of", 781], ["acute", 784], ["CMV", 790], ["infection", 794], [".", 803]]}
{"context": "It has been previously shown that disruption of RAD26 in yeast strain W303-1B results in a strain that is deficient in transcription-coupled repair (TCR), the preferential repair of the transcribed strand of an expressed gene over the non-transcribed strand and the rest of the genome. RAD26 encodes a protein that is homologous to Cockayne syndrome group B protein (CSB) and is a member of the SWI2/SNF2 family of DNA-dependent ATPases involved in chromatin remodeling. Like the rad26 mutant, cells from Cockayne syndrome patients are defective in TCR. We examined the role of Rad26 in TCR by disrupting RAD26 in two repair-proficient laboratory strains and, remarkably, observed no effect upon TCR. Our results indicate that disruption of RAD26 alone is insufficient to impair TCR. Thus, W303-1B must already possess a mutation that, together with disruption of RAD26, causes a deficiency in TCR. We suggest that other genes are mutated in Cockayne syndrome cells that contribute to the deficiency in TCR. Surprisingly, deletion of RAD26 results in expression of genes that are repressed by flanking transposon delta elements, an Spt(-) phenotype. The delta elements appear to perturb local chromatin structure. Expression of genes flanked by delta elements in rad26Delta mutants is consistent with a role for Rad26 in chromatin remodeling.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "d013353ea4e742219ed6b636f0489445", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[36, 37], [46, 47]], "char_spans": [[186, 203], [239, 256]]}]}], "context_tokens": [["It", 0], ["has", 3], ["been", 7], ["previously", 12], ["shown", 23], ["that", 29], ["disruption", 34], ["of", 45], ["RAD26", 48], ["in", 54], ["yeast", 57], ["strain", 63], ["W303", 70], ["-", 74], ["1B", 75], ["results", 78], ["in", 86], ["a", 89], ["strain", 91], ["that", 98], ["is", 103], ["deficient", 106], ["in", 116], ["transcription", 119], ["-", 132], ["coupled", 133], ["repair", 141], ["(", 148], ["TCR", 149], [")", 152], [",", 153], ["the", 155], ["preferential", 159], ["repair", 172], ["of", 179], ["the", 182], ["transcribed", 186], ["strand", 198], ["of", 205], ["an", 208], ["expressed", 211], ["gene", 221], ["over", 226], ["the", 231], ["non", 235], ["-", 238], ["transcribed", 239], ["strand", 251], ["and", 258], ["the", 262], ["rest", 266], ["of", 271], ["the", 274], ["genome", 278], [".", 284], ["RAD26", 286], ["encodes", 292], ["a", 300], ["protein", 302], ["that", 310], ["is", 315], ["homologous", 318], ["to", 329], ["Cockayne", 332], ["syndrome", 341], ["group", 350], ["B", 356], ["protein", 358], ["(", 366], ["CSB", 367], [")", 370], ["and", 372], ["is", 376], ["a", 379], ["member", 381], ["of", 388], ["the", 391], ["SWI2/SNF2", 395], ["family", 405], ["of", 412], ["DNA", 415], ["-", 418], ["dependent", 419], ["ATPases", 429], ["involved", 437], ["in", 446], ["chromatin", 449], ["remodeling", 459], [".", 469], ["Like", 471], ["the", 476], ["rad26", 480], ["mutant", 486], [",", 492], ["cells", 494], ["from", 500], ["Cockayne", 505], ["syndrome", 514], ["patients", 523], ["are", 532], ["defective", 536], ["in", 546], ["TCR", 549], [".", 552], ["We", 554], ["examined", 557], ["the", 566], ["role", 570], ["of", 575], ["Rad26", 578], ["in", 584], ["TCR", 587], ["by", 591], ["disrupting", 594], ["RAD26", 605], ["in", 611], ["two", 614], ["repair", 618], ["-", 624], ["proficient", 625], ["laboratory", 636], ["strains", 647], ["and", 655], [",", 658], ["remarkably", 660], [",", 670], ["observed", 672], ["no", 681], ["effect", 684], ["upon", 691], ["TCR", 696], [".", 699], ["Our", 701], ["results", 705], ["indicate", 713], ["that", 722], ["disruption", 727], ["of", 738], ["RAD26", 741], ["alone", 747], ["is", 753], ["insufficient", 756], ["to", 769], ["impair", 772], ["TCR", 779], [".", 782], ["Thus", 784], [",", 788], ["W303", 790], ["-", 794], ["1B", 795], ["must", 798], ["already", 803], ["possess", 811], ["a", 819], ["mutation", 821], ["that", 830], [",", 834], ["together", 836], ["with", 845], ["disruption", 850], ["of", 861], ["RAD26", 864], [",", 869], ["causes", 871], ["a", 878], ["deficiency", 880], ["in", 891], ["TCR", 894], [".", 897], ["We", 899], ["suggest", 902], ["that", 910], ["other", 915], ["genes", 921], ["are", 927], ["mutated", 931], ["in", 939], ["Cockayne", 942], ["syndrome", 951], ["cells", 960], ["that", 966], ["contribute", 971], ["to", 982], ["the", 985], ["deficiency", 989], ["in", 1000], ["TCR", 1003], [".", 1006], ["Surprisingly", 1008], [",", 1020], ["deletion", 1022], ["of", 1031], ["RAD26", 1034], ["results", 1040], ["in", 1048], ["expression", 1051], ["of", 1062], ["genes", 1065], ["that", 1071], ["are", 1076], ["repressed", 1080], ["by", 1090], ["flanking", 1093], ["transposon", 1102], ["delta", 1113], ["elements", 1119], [",", 1127], ["an", 1129], ["Spt(-", 1132], [")", 1137], ["phenotype", 1139], [".", 1148], ["The", 1150], ["delta", 1154], ["elements", 1160], ["appear", 1169], ["to", 1176], ["perturb", 1179], ["local", 1187], ["chromatin", 1193], ["structure", 1203], [".", 1212], ["Expression", 1214], ["of", 1225], ["genes", 1228], ["flanked", 1234], ["by", 1242], ["delta", 1245], ["elements", 1251], ["in", 1260], ["rad26Delta", 1263], ["mutants", 1274], ["is", 1282], ["consistent", 1285], ["with", 1296], ["a", 1301], ["role", 1303], ["for", 1308], ["Rad26", 1312], ["in", 1318], ["chromatin", 1321], ["remodeling", 1331], [".", 1341]]}
{"context": "Tanezumab, an antibody to nerve growth factor, was administered to pregnant cynomolgus monkeys at 0, 0.5, 4, and 30\u2009mg/kg weekly, beginning gestation day (GD) 20 through parturition (\u223cGD165). Maternal tanezumab administration appeared to increase stillbirths and infant mortality, but no consistent pattern of gross and/or microscopic change was detected to explain the mortality. Offspring exposed in utero were evaluated at 12 months of age using light microscopy (all tissues), stereology (basal forebrain cholinergic and dorsal root ganglia neurons), and morphometry (sural nerve). Light microscopy revealed decreased number of neurons in sympathetic ganglia (superior mesenteric, cervicothoracic, and ganglia in the thoracic sympathetic trunk). Stereologic assessment indicated an overall decrease in dorsal root ganglion (thoracic) volume and number of neurons in animals exposed to tanezumab 4\u2009mg/kg (n\u2009=\u20099) and 30\u2009mg/kg (n\u2009=\u20091). At all tanezumab doses, the sural nerve was small due to decreases in myelinated and unmyelinated axons. Existing axons/myelin sheaths appeared normal when viewed with light and transmission electron microscopy. There was no indication of tanezumab-related, active neuron/nerve fiber degeneration/necrosis in any tissue, indicating decreased sensory/sympathetic neurons and axonal changes were due to hypoplasia or atrophy. These changes in the sensory and sympathetic portions of the peripheral nervous system suggest some degree of developmental neurotoxicity, although what effect, if any, the changes had on normal function and survival was not apparent. Overall, these changes were consistent with published data from rodent studies.", "qas": [{"question": "What is the target of tanezumab?", "answers": ["nerve growth factor", "NGF"], "qid": "341ad31d93c34ba196d196dbeca4aa12", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["target", 12], ["of", 19], ["tanezumab", 22], ["?", 31]], "detected_answers": [{"text": "nerve growth factor", "token_spans": [[5, 7]], "char_spans": [[26, 44]]}]}], "context_tokens": [["Tanezumab", 0], [",", 9], ["an", 11], ["antibody", 14], ["to", 23], ["nerve", 26], ["growth", 32], ["factor", 39], [",", 45], ["was", 47], ["administered", 51], ["to", 64], ["pregnant", 67], ["cynomolgus", 76], ["monkeys", 87], ["at", 95], ["0", 98], [",", 99], ["0.5", 101], [",", 104], ["4", 106], [",", 107], ["and", 109], ["30", 113], ["mg", 116], ["/", 118], ["kg", 119], ["weekly", 122], [",", 128], ["beginning", 130], ["gestation", 140], ["day", 150], ["(", 154], ["GD", 155], [")", 157], ["20", 159], ["through", 162], ["parturition", 170], ["(", 182], ["\u223cGD165", 183], [")", 189], [".", 190], ["Maternal", 192], ["tanezumab", 201], ["administration", 211], ["appeared", 226], ["to", 235], ["increase", 238], ["stillbirths", 247], ["and", 259], ["infant", 263], ["mortality", 270], [",", 279], ["but", 281], ["no", 285], ["consistent", 288], ["pattern", 299], ["of", 307], ["gross", 310], ["and/or", 316], ["microscopic", 323], ["change", 335], ["was", 342], ["detected", 346], ["to", 355], ["explain", 358], ["the", 366], ["mortality", 370], [".", 379], ["Offspring", 381], ["exposed", 391], ["in", 399], ["utero", 402], ["were", 408], ["evaluated", 413], ["at", 423], ["12", 426], ["months", 429], ["of", 436], ["age", 439], ["using", 443], ["light", 449], ["microscopy", 455], ["(", 466], ["all", 467], ["tissues", 471], [")", 478], [",", 479], ["stereology", 481], ["(", 492], ["basal", 493], ["forebrain", 499], ["cholinergic", 509], ["and", 521], ["dorsal", 525], ["root", 532], ["ganglia", 537], ["neurons", 545], [")", 552], [",", 553], ["and", 555], ["morphometry", 559], ["(", 571], ["sural", 572], ["nerve", 578], [")", 583], [".", 584], ["Light", 586], ["microscopy", 592], ["revealed", 603], ["decreased", 612], ["number", 622], ["of", 629], ["neurons", 632], ["in", 640], ["sympathetic", 643], ["ganglia", 655], ["(", 663], ["superior", 664], ["mesenteric", 673], [",", 683], ["cervicothoracic", 685], [",", 700], ["and", 702], ["ganglia", 706], ["in", 714], ["the", 717], ["thoracic", 721], ["sympathetic", 730], ["trunk", 742], [")", 747], [".", 748], ["Stereologic", 750], ["assessment", 762], ["indicated", 773], ["an", 783], ["overall", 786], ["decrease", 794], ["in", 803], ["dorsal", 806], ["root", 813], ["ganglion", 818], ["(", 827], ["thoracic", 828], [")", 836], ["volume", 838], ["and", 845], ["number", 849], ["of", 856], ["neurons", 859], ["in", 867], ["animals", 870], ["exposed", 878], ["to", 886], ["tanezumab", 889], ["4", 899], ["mg", 901], ["/", 903], ["kg", 904], ["(", 907], ["n", 908], ["=", 910], ["9", 912], [")", 913], ["and", 915], ["30", 919], ["mg", 922], ["/", 924], ["kg", 925], ["(", 928], ["n", 929], ["=", 931], ["1", 933], [")", 934], [".", 935], ["At", 937], ["all", 940], ["tanezumab", 944], ["doses", 954], [",", 959], ["the", 961], ["sural", 965], ["nerve", 971], ["was", 977], ["small", 981], ["due", 987], ["to", 991], ["decreases", 994], ["in", 1004], ["myelinated", 1007], ["and", 1018], ["unmyelinated", 1022], ["axons", 1035], [".", 1040], ["Existing", 1042], ["axons", 1051], ["/", 1056], ["myelin", 1057], ["sheaths", 1064], ["appeared", 1072], ["normal", 1081], ["when", 1088], ["viewed", 1093], ["with", 1100], ["light", 1105], ["and", 1111], ["transmission", 1115], ["electron", 1128], ["microscopy", 1137], [".", 1147], ["There", 1149], ["was", 1155], ["no", 1159], ["indication", 1162], ["of", 1173], ["tanezumab", 1176], ["-", 1185], ["related", 1186], [",", 1193], ["active", 1195], ["neuron", 1202], ["/", 1208], ["nerve", 1209], ["fiber", 1215], ["degeneration", 1221], ["/", 1233], ["necrosis", 1234], ["in", 1243], ["any", 1246], ["tissue", 1250], [",", 1256], ["indicating", 1258], ["decreased", 1269], ["sensory", 1279], ["/", 1286], ["sympathetic", 1287], ["neurons", 1299], ["and", 1307], ["axonal", 1311], ["changes", 1318], ["were", 1326], ["due", 1331], ["to", 1335], ["hypoplasia", 1338], ["or", 1349], ["atrophy", 1352], [".", 1359], ["These", 1361], ["changes", 1367], ["in", 1375], ["the", 1378], ["sensory", 1382], ["and", 1390], ["sympathetic", 1394], ["portions", 1406], ["of", 1415], ["the", 1418], ["peripheral", 1422], ["nervous", 1433], ["system", 1441], ["suggest", 1448], ["some", 1456], ["degree", 1461], ["of", 1468], ["developmental", 1471], ["neurotoxicity", 1485], [",", 1498], ["although", 1500], ["what", 1509], ["effect", 1514], [",", 1520], ["if", 1522], ["any", 1525], [",", 1528], ["the", 1530], ["changes", 1534], ["had", 1542], ["on", 1546], ["normal", 1549], ["function", 1556], ["and", 1565], ["survival", 1569], ["was", 1578], ["not", 1582], ["apparent", 1586], [".", 1594], ["Overall", 1596], [",", 1603], ["these", 1605], ["changes", 1611], ["were", 1619], ["consistent", 1624], ["with", 1635], ["published", 1640], ["data", 1650], ["from", 1655], ["rodent", 1660], ["studies", 1667], [".", 1674]]}
{"context": "Finkelstein's test is the classic diagnostic test for de Quervain's disease. Finkelstein hypothesized that the entry of the muscle bellies of the extensor pollicis brevis (EPB) and abductor pollicis longus (APL) tendons into the first extensor compartment was responsible for the findings observed in his now eponymous test. We agree with Finkelstein's hypothesis and further hypothesize that this position would induce measurable bulk (muscle mass within the retinaculum) and tethering (stretching of synovial tissue) effects within the compartment. To test this latter hypothesis we measured the excursion and gliding resistance of the EPB and APL tendons within the first compartment. Fifteen fresh-frozen cadavers were used. Gliding resistance and excursion were measured in 4 different wrist positions, including the wrist position of Finkelstein's test (30 degrees ulnar deviation). The bulk and tethering effect was calculated based on the mean gliding resistance over the tendon proximal/distal excursion cycle and the gliding resistance at the terminal distal excursion. The EPB tendon excursion was significantly more distal in 30 degrees ulnar deviation than in 60 degrees extension. Additionally the bulk and tethering resistance was significantly greater in 30 degrees ulnar deviation compared with 60 degrees extension. For the APL tendon there was no significant difference in either the tendon excursion or the bulk and tethering resistance between 30 degrees ulnar deviation and 60 degrees extension. We showed that in the position of Finkelstein's test the EPB tendon is significantly more distal and has significantly greater bulk and tethering effect compared with the other EPB positions. This is not the case for the APL tendon in the position of Finkelstein's test. These results suggest that an abnormal Finkelstein's test reflects differences of the EPB more than it does the APL.", "qas": [{"question": "Which disease is diagnosed using the Finkelstein's test?", "answers": ["de Quervain's disease"], "qid": "0f8cd91547cb45a1a13bab044219379b", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["diagnosed", 17], ["using", 27], ["the", 33], ["Finkelstein", 37], ["'s", 48], ["test", 51], ["?", 55]], "detected_answers": [{"text": "de Quervain's disease", "token_spans": [[9, 12]], "char_spans": [[54, 74]]}]}], "context_tokens": [["Finkelstein", 0], ["'s", 11], ["test", 14], ["is", 19], ["the", 22], ["classic", 26], ["diagnostic", 34], ["test", 45], ["for", 50], ["de", 54], ["Quervain", 57], ["'s", 65], ["disease", 68], [".", 75], ["Finkelstein", 77], ["hypothesized", 89], ["that", 102], ["the", 107], ["entry", 111], ["of", 117], ["the", 120], ["muscle", 124], ["bellies", 131], ["of", 139], ["the", 142], ["extensor", 146], ["pollicis", 155], ["brevis", 164], ["(", 171], ["EPB", 172], [")", 175], ["and", 177], ["abductor", 181], ["pollicis", 190], ["longus", 199], ["(", 206], ["APL", 207], [")", 210], ["tendons", 212], ["into", 220], ["the", 225], ["first", 229], ["extensor", 235], ["compartment", 244], ["was", 256], ["responsible", 260], ["for", 272], ["the", 276], ["findings", 280], ["observed", 289], ["in", 298], ["his", 301], ["now", 305], ["eponymous", 309], ["test", 319], [".", 323], ["We", 325], ["agree", 328], ["with", 334], ["Finkelstein", 339], ["'s", 350], ["hypothesis", 353], ["and", 364], ["further", 368], ["hypothesize", 376], ["that", 388], ["this", 393], ["position", 398], ["would", 407], ["induce", 413], ["measurable", 420], ["bulk", 431], ["(", 436], ["muscle", 437], ["mass", 444], ["within", 449], ["the", 456], ["retinaculum", 460], [")", 471], ["and", 473], ["tethering", 477], ["(", 487], ["stretching", 488], ["of", 499], ["synovial", 502], ["tissue", 511], [")", 517], ["effects", 519], ["within", 527], ["the", 534], ["compartment", 538], [".", 549], ["To", 551], ["test", 554], ["this", 559], ["latter", 564], ["hypothesis", 571], ["we", 582], ["measured", 585], ["the", 594], ["excursion", 598], ["and", 608], ["gliding", 612], ["resistance", 620], ["of", 631], ["the", 634], ["EPB", 638], ["and", 642], ["APL", 646], ["tendons", 650], ["within", 658], ["the", 665], ["first", 669], ["compartment", 675], [".", 686], ["Fifteen", 688], ["fresh", 696], ["-", 701], ["frozen", 702], ["cadavers", 709], ["were", 718], ["used", 723], [".", 727], ["Gliding", 729], ["resistance", 737], ["and", 748], ["excursion", 752], ["were", 762], ["measured", 767], ["in", 776], ["4", 779], ["different", 781], ["wrist", 791], ["positions", 797], [",", 806], ["including", 808], ["the", 818], ["wrist", 822], ["position", 828], ["of", 837], ["Finkelstein", 840], ["'s", 851], ["test", 854], ["(", 859], ["30", 860], ["degrees", 863], ["ulnar", 871], ["deviation", 877], [")", 886], [".", 887], ["The", 889], ["bulk", 893], ["and", 898], ["tethering", 902], ["effect", 912], ["was", 919], ["calculated", 923], ["based", 934], ["on", 940], ["the", 943], ["mean", 947], ["gliding", 952], ["resistance", 960], ["over", 971], ["the", 976], ["tendon", 980], ["proximal", 987], ["/", 995], ["distal", 996], ["excursion", 1003], ["cycle", 1013], ["and", 1019], ["the", 1023], ["gliding", 1027], ["resistance", 1035], ["at", 1046], ["the", 1049], ["terminal", 1053], ["distal", 1062], ["excursion", 1069], [".", 1078], ["The", 1080], ["EPB", 1084], ["tendon", 1088], ["excursion", 1095], ["was", 1105], ["significantly", 1109], ["more", 1123], ["distal", 1128], ["in", 1135], ["30", 1138], ["degrees", 1141], ["ulnar", 1149], ["deviation", 1155], ["than", 1165], ["in", 1170], ["60", 1173], ["degrees", 1176], ["extension", 1184], [".", 1193], ["Additionally", 1195], ["the", 1208], ["bulk", 1212], ["and", 1217], ["tethering", 1221], ["resistance", 1231], ["was", 1242], ["significantly", 1246], ["greater", 1260], ["in", 1268], ["30", 1271], ["degrees", 1274], ["ulnar", 1282], ["deviation", 1288], ["compared", 1298], ["with", 1307], ["60", 1312], ["degrees", 1315], ["extension", 1323], [".", 1332], ["For", 1334], ["the", 1338], ["APL", 1342], ["tendon", 1346], ["there", 1353], ["was", 1359], ["no", 1363], ["significant", 1366], ["difference", 1378], ["in", 1389], ["either", 1392], ["the", 1399], ["tendon", 1403], ["excursion", 1410], ["or", 1420], ["the", 1423], ["bulk", 1427], ["and", 1432], ["tethering", 1436], ["resistance", 1446], ["between", 1457], ["30", 1465], ["degrees", 1468], ["ulnar", 1476], ["deviation", 1482], ["and", 1492], ["60", 1496], ["degrees", 1499], ["extension", 1507], [".", 1516], ["We", 1518], ["showed", 1521], ["that", 1528], ["in", 1533], ["the", 1536], ["position", 1540], ["of", 1549], ["Finkelstein", 1552], ["'s", 1563], ["test", 1566], ["the", 1571], ["EPB", 1575], ["tendon", 1579], ["is", 1586], ["significantly", 1589], ["more", 1603], ["distal", 1608], ["and", 1615], ["has", 1619], ["significantly", 1623], ["greater", 1637], ["bulk", 1645], ["and", 1650], ["tethering", 1654], ["effect", 1664], ["compared", 1671], ["with", 1680], ["the", 1685], ["other", 1689], ["EPB", 1695], ["positions", 1699], [".", 1708], ["This", 1710], ["is", 1715], ["not", 1718], ["the", 1722], ["case", 1726], ["for", 1731], ["the", 1735], ["APL", 1739], ["tendon", 1743], ["in", 1750], ["the", 1753], ["position", 1757], ["of", 1766], ["Finkelstein", 1769], ["'s", 1780], ["test", 1783], [".", 1787], ["These", 1789], ["results", 1795], ["suggest", 1803], ["that", 1811], ["an", 1816], ["abnormal", 1819], ["Finkelstein", 1828], ["'s", 1839], ["test", 1842], ["reflects", 1847], ["differences", 1856], ["of", 1868], ["the", 1871], ["EPB", 1875], ["more", 1879], ["than", 1884], ["it", 1889], ["does", 1892], ["the", 1897], ["APL", 1901], [".", 1904]]}
{"context": "Detection of latent tuberculosis infection is an important step in the control of tuberculosis. The tuberculin skin test is the only proven method for identifying tuberculosis infection in patients who do not have tuberculosis disease. The prevalence of tuberculosis infection among hospitalized patients in a pneumological department of an inner-city hospital was evaluated, using the intradermal tuberculin skin test (Mantoux technique). Interpretation of the Mantoux test was based on the size of induration in millimeters and the individual risk profile of the patients, according to the guidelines of the American Thoracic Society and the Centers for Disease Control, revised in 1989. Of 697 tested patients, 252 showed test results consistent with tuberculosis infection (36.2%). 55 of these 697 patients had active tuberculosis disease or a prior history of tuberculosis (7.9%). A positive tuberculin skin test was found in 197 of 642 patients (30.7%) with a diagnosis different from tuberculosis (COPD, pneumonia, cancer and others). In our study, the sensitivity of the tuberculin skin test for active tuberculosis infection was 95%. The present study revealed a high prevalence of tuberculosis infection among hospitalized patients in a pneumological department. Further studies are needed to assess the usefulness of routine tuberculin skin testing in hospitalized populations.", "qas": [{"question": "The Mantoux test detects what latent infection/disease?", "answers": ["tuberculosis"], "qid": "a2d8fa1d4aec4b51af662fbe80cc7535", "question_tokens": [["The", 0], ["Mantoux", 4], ["test", 12], ["detects", 17], ["what", 25], ["latent", 30], ["infection", 37], ["/", 46], ["disease", 47], ["?", 54]], "detected_answers": [{"text": "tuberculosis", "token_spans": [[144, 144], [3, 3], [13, 13], [26, 26], [123, 123], [171, 171], [195, 195], [137, 137], [40, 40], [34, 34], [209, 209]], "char_spans": [[865, 876], [20, 31], [82, 93], [163, 174], [754, 765], [991, 1002], [1111, 1122], [822, 833], [254, 265], [214, 225], [1191, 1202]]}]}], "context_tokens": [["Detection", 0], ["of", 10], ["latent", 13], ["tuberculosis", 20], ["infection", 33], ["is", 43], ["an", 46], ["important", 49], ["step", 59], ["in", 64], ["the", 67], ["control", 71], ["of", 79], ["tuberculosis", 82], [".", 94], ["The", 96], ["tuberculin", 100], ["skin", 111], ["test", 116], ["is", 121], ["the", 124], ["only", 128], ["proven", 133], ["method", 140], ["for", 147], ["identifying", 151], ["tuberculosis", 163], ["infection", 176], ["in", 186], ["patients", 189], ["who", 198], ["do", 202], ["not", 205], ["have", 209], ["tuberculosis", 214], ["disease", 227], [".", 234], ["The", 236], ["prevalence", 240], ["of", 251], ["tuberculosis", 254], ["infection", 267], ["among", 277], ["hospitalized", 283], ["patients", 296], ["in", 305], ["a", 308], ["pneumological", 310], ["department", 324], ["of", 335], ["an", 338], ["inner", 341], ["-", 346], ["city", 347], ["hospital", 352], ["was", 361], ["evaluated", 365], [",", 374], ["using", 376], ["the", 382], ["intradermal", 386], ["tuberculin", 398], ["skin", 409], ["test", 414], ["(", 419], ["Mantoux", 420], ["technique", 428], [")", 437], [".", 438], ["Interpretation", 440], ["of", 455], ["the", 458], ["Mantoux", 462], ["test", 470], ["was", 475], ["based", 479], ["on", 485], ["the", 488], ["size", 492], ["of", 497], ["induration", 500], ["in", 511], ["millimeters", 514], ["and", 526], ["the", 530], ["individual", 534], ["risk", 545], ["profile", 550], ["of", 558], ["the", 561], ["patients", 565], [",", 573], ["according", 575], ["to", 585], ["the", 588], ["guidelines", 592], ["of", 603], ["the", 606], ["American", 610], ["Thoracic", 619], ["Society", 628], ["and", 636], ["the", 640], ["Centers", 644], ["for", 652], ["Disease", 656], ["Control", 664], [",", 671], ["revised", 673], ["in", 681], ["1989", 684], [".", 688], ["Of", 690], ["697", 693], ["tested", 697], ["patients", 704], [",", 712], ["252", 714], ["showed", 718], ["test", 725], ["results", 730], ["consistent", 738], ["with", 749], ["tuberculosis", 754], ["infection", 767], ["(", 777], ["36.2", 778], ["%", 782], [")", 783], [".", 784], ["55", 786], ["of", 789], ["these", 792], ["697", 798], ["patients", 802], ["had", 811], ["active", 815], ["tuberculosis", 822], ["disease", 835], ["or", 843], ["a", 846], ["prior", 848], ["history", 854], ["of", 862], ["tuberculosis", 865], ["(", 878], ["7.9", 879], ["%", 882], [")", 883], [".", 884], ["A", 886], ["positive", 888], ["tuberculin", 897], ["skin", 908], ["test", 913], ["was", 918], ["found", 922], ["in", 928], ["197", 931], ["of", 935], ["642", 938], ["patients", 942], ["(", 951], ["30.7", 952], ["%", 956], [")", 957], ["with", 959], ["a", 964], ["diagnosis", 966], ["different", 976], ["from", 986], ["tuberculosis", 991], ["(", 1004], ["COPD", 1005], [",", 1009], ["pneumonia", 1011], [",", 1020], ["cancer", 1022], ["and", 1029], ["others", 1033], [")", 1039], [".", 1040], ["In", 1042], ["our", 1045], ["study", 1049], [",", 1054], ["the", 1056], ["sensitivity", 1060], ["of", 1072], ["the", 1075], ["tuberculin", 1079], ["skin", 1090], ["test", 1095], ["for", 1100], ["active", 1104], ["tuberculosis", 1111], ["infection", 1124], ["was", 1134], ["95", 1138], ["%", 1140], [".", 1141], ["The", 1143], ["present", 1147], ["study", 1155], ["revealed", 1161], ["a", 1170], ["high", 1172], ["prevalence", 1177], ["of", 1188], ["tuberculosis", 1191], ["infection", 1204], ["among", 1214], ["hospitalized", 1220], ["patients", 1233], ["in", 1242], ["a", 1245], ["pneumological", 1247], ["department", 1261], [".", 1271], ["Further", 1273], ["studies", 1281], ["are", 1289], ["needed", 1293], ["to", 1300], ["assess", 1303], ["the", 1310], ["usefulness", 1314], ["of", 1325], ["routine", 1328], ["tuberculin", 1336], ["skin", 1347], ["testing", 1352], ["in", 1360], ["hospitalized", 1363], ["populations", 1376], [".", 1387]]}
{"context": "Selexipag is a first-in-class orally available selective non-prostanoid IP receptor agonist. This review was based on a PubMed search and focuses on the potential role of selexipag in the treatment of pulmonary arterial hypertension (PAH). Selexipag is rapidly hydrolyzed to an active metabolite, ACT-333679. Both selexipag and its metabolite are highly selective for the IP receptor compared with other prostanoid receptors. This selectivity for the IP receptor offers the potential for improved tolerability with selexipag, as side effects (e.g., nausea and vomiting) that might result from activation of the other prostanoid receptors may be minimized. In addition, the selexipag metabolite has a half-life of 7.9 h, thus permitting oral dosing twice daily. Selexipag showed effects on pharmacodynamic end points obtained with right heart catheterization in a Phase II trial in patients with PAH, and is being evaluated in the ongoing Phase III trial (GRIPHON trial, Clinicaltrials.gov NCT01106014). The signal of a beneficial effect of selexipag on disease progression may become more robust for long term under prolonged exposure. Pending the GRIPHON trial results, selexipag could provide a convenient first-line prostacyclin treatment option for patients with PAH.", "qas": [{"question": "Selexipag is used for which disease?", "answers": ["pulmonary arterial hypertension"], "qid": "d69c9463ec08444a919447d7f33855f7", "question_tokens": [["Selexipag", 0], ["is", 10], ["used", 13], ["for", 18], ["which", 22], ["disease", 28], ["?", 35]], "detected_answers": [{"text": "pulmonary arterial hypertension", "token_spans": [[38, 40]], "char_spans": [[201, 231]]}]}], "context_tokens": [["Selexipag", 0], ["is", 10], ["a", 13], ["first", 15], ["-", 20], ["in", 21], ["-", 23], ["class", 24], ["orally", 30], ["available", 37], ["selective", 47], ["non", 57], ["-", 60], ["prostanoid", 61], ["IP", 72], ["receptor", 75], ["agonist", 84], [".", 91], ["This", 93], ["review", 98], ["was", 105], ["based", 109], ["on", 115], ["a", 118], ["PubMed", 120], ["search", 127], ["and", 134], ["focuses", 138], ["on", 146], ["the", 149], ["potential", 153], ["role", 163], ["of", 168], ["selexipag", 171], ["in", 181], ["the", 184], ["treatment", 188], ["of", 198], ["pulmonary", 201], ["arterial", 211], ["hypertension", 220], ["(", 233], ["PAH", 234], [")", 237], [".", 238], ["Selexipag", 240], ["is", 250], ["rapidly", 253], ["hydrolyzed", 261], ["to", 272], ["an", 275], ["active", 278], ["metabolite", 285], [",", 295], ["ACT-333679", 297], [".", 307], ["Both", 309], ["selexipag", 314], ["and", 324], ["its", 328], ["metabolite", 332], ["are", 343], ["highly", 347], ["selective", 354], ["for", 364], ["the", 368], ["IP", 372], ["receptor", 375], ["compared", 384], ["with", 393], ["other", 398], ["prostanoid", 404], ["receptors", 415], [".", 424], ["This", 426], ["selectivity", 431], ["for", 443], ["the", 447], ["IP", 451], ["receptor", 454], ["offers", 463], ["the", 470], ["potential", 474], ["for", 484], ["improved", 488], ["tolerability", 497], ["with", 510], ["selexipag", 515], [",", 524], ["as", 526], ["side", 529], ["effects", 534], ["(", 542], ["e.g.", 543], [",", 547], ["nausea", 549], ["and", 556], ["vomiting", 560], [")", 568], ["that", 570], ["might", 575], ["result", 581], ["from", 588], ["activation", 593], ["of", 604], ["the", 607], ["other", 611], ["prostanoid", 617], ["receptors", 628], ["may", 638], ["be", 642], ["minimized", 645], [".", 654], ["In", 656], ["addition", 659], [",", 667], ["the", 669], ["selexipag", 673], ["metabolite", 683], ["has", 694], ["a", 698], ["half", 700], ["-", 704], ["life", 705], ["of", 710], ["7.9", 713], ["h", 717], [",", 718], ["thus", 720], ["permitting", 725], ["oral", 736], ["dosing", 741], ["twice", 748], ["daily", 754], [".", 759], ["Selexipag", 761], ["showed", 771], ["effects", 778], ["on", 786], ["pharmacodynamic", 789], ["end", 805], ["points", 809], ["obtained", 816], ["with", 825], ["right", 830], ["heart", 836], ["catheterization", 842], ["in", 858], ["a", 861], ["Phase", 863], ["II", 869], ["trial", 872], ["in", 878], ["patients", 881], ["with", 890], ["PAH", 895], [",", 898], ["and", 900], ["is", 904], ["being", 907], ["evaluated", 913], ["in", 923], ["the", 926], ["ongoing", 930], ["Phase", 938], ["III", 944], ["trial", 948], ["(", 954], ["GRIPHON", 955], ["trial", 963], [",", 968], ["Clinicaltrials.gov", 970], ["NCT01106014", 989], [")", 1000], [".", 1001], ["The", 1003], ["signal", 1007], ["of", 1014], ["a", 1017], ["beneficial", 1019], ["effect", 1030], ["of", 1037], ["selexipag", 1040], ["on", 1050], ["disease", 1053], ["progression", 1061], ["may", 1073], ["become", 1077], ["more", 1084], ["robust", 1089], ["for", 1096], ["long", 1100], ["term", 1105], ["under", 1110], ["prolonged", 1116], ["exposure", 1126], [".", 1134], ["Pending", 1136], ["the", 1144], ["GRIPHON", 1148], ["trial", 1156], ["results", 1162], [",", 1169], ["selexipag", 1171], ["could", 1181], ["provide", 1187], ["a", 1195], ["convenient", 1197], ["first", 1208], ["-", 1213], ["line", 1214], ["prostacyclin", 1219], ["treatment", 1232], ["option", 1242], ["for", 1249], ["patients", 1253], ["with", 1262], ["PAH", 1267], [".", 1270]]}
{"context": "To investigate the clinical feature of Parkinson's disease (PD) with restless leg syndrome (RLS) and the pathogenesis of RLS. We conducted a cross-sectional and control study. The case group concluded 31 PD with RLS patients, meanwhile 39 PD patients were selected as the control group. Clinical history, clinical manifestations, complications and laboratory examinations were compared respectively between the two groups. All the RLS symptoms did not appear in RLS patients until the PD symptoms came out. Significant differences were found in complications such as swallow disturbance, constipation and illusion, when we compared the two PD groups (P < 0.05). Compared with the PD or healthy group, the level of serum ferritin and the H-reflex latency of tibial nerve were significantly decreased in PD with RLS group (P < 0.05). Secondary RLS is a complication of PD. Deficiency of iron and decreased inhibition function of spinal cord may lead to the occurrence of RLS in PD patients. When their motor symptoms are serious and complications are more common, PD patients are more possible to have RLS symptoms.", "qas": [{"question": "Which deficiency is the cause of restless leg syndrome?", "answers": ["iron"], "qid": "174f261677d84e0880d30296aca0dc8a", "question_tokens": [["Which", 0], ["deficiency", 6], ["is", 17], ["the", 20], ["cause", 24], ["of", 30], ["restless", 33], ["leg", 42], ["syndrome", 46], ["?", 54]], "detected_answers": [{"text": "iron", "token_spans": [[165, 165]], "char_spans": [[885, 888]]}]}], "context_tokens": [["To", 0], ["investigate", 3], ["the", 15], ["clinical", 19], ["feature", 28], ["of", 36], ["Parkinson", 39], ["'s", 48], ["disease", 51], ["(", 59], ["PD", 60], [")", 62], ["with", 64], ["restless", 69], ["leg", 78], ["syndrome", 82], ["(", 91], ["RLS", 92], [")", 95], ["and", 97], ["the", 101], ["pathogenesis", 105], ["of", 118], ["RLS", 121], [".", 124], ["We", 126], ["conducted", 129], ["a", 139], ["cross", 141], ["-", 146], ["sectional", 147], ["and", 157], ["control", 161], ["study", 169], [".", 174], ["The", 176], ["case", 180], ["group", 185], ["concluded", 191], ["31", 201], ["PD", 204], ["with", 207], ["RLS", 212], ["patients", 216], [",", 224], ["meanwhile", 226], ["39", 236], ["PD", 239], ["patients", 242], ["were", 251], ["selected", 256], ["as", 265], ["the", 268], ["control", 272], ["group", 280], [".", 285], ["Clinical", 287], ["history", 296], [",", 303], ["clinical", 305], ["manifestations", 314], [",", 328], ["complications", 330], ["and", 344], ["laboratory", 348], ["examinations", 359], ["were", 372], ["compared", 377], ["respectively", 386], ["between", 399], ["the", 407], ["two", 411], ["groups", 415], [".", 421], ["All", 423], ["the", 427], ["RLS", 431], ["symptoms", 435], ["did", 444], ["not", 448], ["appear", 452], ["in", 459], ["RLS", 462], ["patients", 466], ["until", 475], ["the", 481], ["PD", 485], ["symptoms", 488], ["came", 497], ["out", 502], [".", 505], ["Significant", 507], ["differences", 519], ["were", 531], ["found", 536], ["in", 542], ["complications", 545], ["such", 559], ["as", 564], ["swallow", 567], ["disturbance", 575], [",", 586], ["constipation", 588], ["and", 601], ["illusion", 605], [",", 613], ["when", 615], ["we", 620], ["compared", 623], ["the", 632], ["two", 636], ["PD", 640], ["groups", 643], ["(", 650], ["P", 651], ["<", 653], ["0.05", 655], [")", 659], [".", 660], ["Compared", 662], ["with", 671], ["the", 676], ["PD", 680], ["or", 683], ["healthy", 686], ["group", 694], [",", 699], ["the", 701], ["level", 705], ["of", 711], ["serum", 714], ["ferritin", 720], ["and", 729], ["the", 733], ["H", 737], ["-", 738], ["reflex", 739], ["latency", 746], ["of", 754], ["tibial", 757], ["nerve", 764], ["were", 770], ["significantly", 775], ["decreased", 789], ["in", 799], ["PD", 802], ["with", 805], ["RLS", 810], ["group", 814], ["(", 820], ["P", 821], ["<", 823], ["0.05", 825], [")", 829], [".", 830], ["Secondary", 832], ["RLS", 842], ["is", 846], ["a", 849], ["complication", 851], ["of", 864], ["PD", 867], [".", 869], ["Deficiency", 871], ["of", 882], ["iron", 885], ["and", 890], ["decreased", 894], ["inhibition", 904], ["function", 915], ["of", 924], ["spinal", 927], ["cord", 934], ["may", 939], ["lead", 943], ["to", 948], ["the", 951], ["occurrence", 955], ["of", 966], ["RLS", 969], ["in", 973], ["PD", 976], ["patients", 979], [".", 987], ["When", 989], ["their", 994], ["motor", 1000], ["symptoms", 1006], ["are", 1015], ["serious", 1019], ["and", 1027], ["complications", 1031], ["are", 1045], ["more", 1049], ["common", 1054], [",", 1060], ["PD", 1062], ["patients", 1065], ["are", 1074], ["more", 1078], ["possible", 1083], ["to", 1092], ["have", 1095], ["RLS", 1100], ["symptoms", 1104], [".", 1112]]}
{"context": "Human selenoprotein P (HSelP) is unique protein that contains 10 selenocysteines encoded by 10 inframe UGA, which typically function as stop codon. The function of HSelP remains unclear, in part due to the inability to express it by gene recombinant technique. This study is to investigate expression and purification of recombinant HSelP in prokaryotic expression system, and its activity to induce apoptosis in vitro. The shorter HSelP isoform was cloned. After the selenocysteine (SeCys) at 40th position from N terminus of the HSelP shorter isoform was mutated into cysteine by PCR, it was expressed in E. coli. The expressed product was purified with DEAE column and identified by Western blot. Subsequently, its function on induction of mitochondrial apoptotic activity was studied. The mutant HSelP shorter isoform expressed in prokaryotic system was purified by DEAE column to 90% homogeneity. The purified product, HSelP280m, induced the opening of mitochondrial permeability transition pore (PTP) and decreased the transmembrane potential in a dose-dependent manner. These events could be abolished by PTP specific inhibitors. HSelP280m can induce the opening of mitochondrial PTP, which provides a basis for investigating the structure and function of recombinant HSelP.", "qas": [{"question": "Which is the human selenoprotein that contains several Se-Cys residues?", "answers": ["Selenoprotein P"], "qid": "c67a56187ba94d478fbc8c8608cabb52", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["human", 13], ["selenoprotein", 19], ["that", 33], ["contains", 38], ["several", 47], ["Se", 55], ["-", 57], ["Cys", 58], ["residues", 62], ["?", 70]], "detected_answers": [{"text": "Selenoprotein P", "token_spans": [[1, 2]], "char_spans": [[6, 20]]}]}], "context_tokens": [["Human", 0], ["selenoprotein", 6], ["P", 20], ["(", 22], ["HSelP", 23], [")", 28], ["is", 30], ["unique", 33], ["protein", 40], ["that", 48], ["contains", 53], ["10", 62], ["selenocysteines", 65], ["encoded", 81], ["by", 89], ["10", 92], ["inframe", 95], ["UGA", 103], [",", 106], ["which", 108], ["typically", 114], ["function", 124], ["as", 133], ["stop", 136], ["codon", 141], [".", 146], ["The", 148], ["function", 152], ["of", 161], ["HSelP", 164], ["remains", 170], ["unclear", 178], [",", 185], ["in", 187], ["part", 190], ["due", 195], ["to", 199], ["the", 202], ["inability", 206], ["to", 216], ["express", 219], ["it", 227], ["by", 230], ["gene", 233], ["recombinant", 238], ["technique", 250], [".", 259], ["This", 261], ["study", 266], ["is", 272], ["to", 275], ["investigate", 278], ["expression", 290], ["and", 301], ["purification", 305], ["of", 318], ["recombinant", 321], ["HSelP", 333], ["in", 339], ["prokaryotic", 342], ["expression", 354], ["system", 365], [",", 371], ["and", 373], ["its", 377], ["activity", 381], ["to", 390], ["induce", 393], ["apoptosis", 400], ["in", 410], ["vitro", 413], [".", 418], ["The", 420], ["shorter", 424], ["HSelP", 432], ["isoform", 438], ["was", 446], ["cloned", 450], [".", 456], ["After", 458], ["the", 464], ["selenocysteine", 468], ["(", 483], ["SeCys", 484], [")", 489], ["at", 491], ["40th", 494], ["position", 499], ["from", 508], ["N", 513], ["terminus", 515], ["of", 524], ["the", 527], ["HSelP", 531], ["shorter", 537], ["isoform", 545], ["was", 553], ["mutated", 557], ["into", 565], ["cysteine", 570], ["by", 579], ["PCR", 582], [",", 585], ["it", 587], ["was", 590], ["expressed", 594], ["in", 604], ["E.", 607], ["coli", 610], [".", 614], ["The", 616], ["expressed", 620], ["product", 630], ["was", 638], ["purified", 642], ["with", 651], ["DEAE", 656], ["column", 661], ["and", 668], ["identified", 672], ["by", 683], ["Western", 686], ["blot", 694], [".", 698], ["Subsequently", 700], [",", 712], ["its", 714], ["function", 718], ["on", 727], ["induction", 730], ["of", 740], ["mitochondrial", 743], ["apoptotic", 757], ["activity", 767], ["was", 776], ["studied", 780], [".", 787], ["The", 789], ["mutant", 793], ["HSelP", 800], ["shorter", 806], ["isoform", 814], ["expressed", 822], ["in", 832], ["prokaryotic", 835], ["system", 847], ["was", 854], ["purified", 858], ["by", 867], ["DEAE", 870], ["column", 875], ["to", 882], ["90", 885], ["%", 887], ["homogeneity", 889], [".", 900], ["The", 902], ["purified", 906], ["product", 915], [",", 922], ["HSelP280", 924], ["m", 932], [",", 933], ["induced", 935], ["the", 943], ["opening", 947], ["of", 955], ["mitochondrial", 958], ["permeability", 972], ["transition", 985], ["pore", 996], ["(", 1001], ["PTP", 1002], [")", 1005], ["and", 1007], ["decreased", 1011], ["the", 1021], ["transmembrane", 1025], ["potential", 1039], ["in", 1049], ["a", 1052], ["dose", 1054], ["-", 1058], ["dependent", 1059], ["manner", 1069], [".", 1075], ["These", 1077], ["events", 1083], ["could", 1090], ["be", 1096], ["abolished", 1099], ["by", 1109], ["PTP", 1112], ["specific", 1116], ["inhibitors", 1125], [".", 1135], ["HSelP280", 1137], ["m", 1145], ["can", 1147], ["induce", 1151], ["the", 1158], ["opening", 1162], ["of", 1170], ["mitochondrial", 1173], ["PTP", 1187], [",", 1190], ["which", 1192], ["provides", 1198], ["a", 1207], ["basis", 1209], ["for", 1215], ["investigating", 1219], ["the", 1233], ["structure", 1237], ["and", 1247], ["function", 1251], ["of", 1260], ["recombinant", 1263], ["HSelP.", 1275]]}
{"context": "Bacillus anthracis plasmid pXO1 carries the structural genes for the three anthrax toxin proteins, cya (edema factor), lef (lethal factor), and pag (protective antigen). Expression of the toxin genes by B. anthracis is enhanced during growth under elevated levels of CO2. This CO2 effect is observed only in the presence of another pXO1 gene, atxA, which encodes a transactivator of anthrax toxin synthesis. Here we show that transcription of atxA does not appear to differ in cells grown in 5% CO2 compared with cells grown in air. Using a new efficient method for gene replacement in B. anthracis, we constructed an atxA-null mutant in which the atxA-coding sequence on pXO1 is replaced with an omega km-2 cassette. Transcription of all three toxin genes is decreased in the absence of atxA. The pag gene possesses two apparent transcription start sites, P1 and P2; only transcripts with 5' ends mapping to P1 are decreased in the atxA-null mutant. Deletion analysis of the pag promoter region indicates that the 111 bp region upstream of the P1 site is sufficient for atxA-mediated activation of this transcript. The cya and lef genes each have one apparent start site for transcription. Transcripts with 5' ends mapping to these sites are not detected in the atxA-null mutant. The atxA-null mutant is avirulent in mice. Moreover, the antibody response to all three toxin proteins is decreased significantly in atxA-null mutant-infected mice. These data suggest that the atxA gene product also regulates toxin gene expression during infection.", "qas": [{"question": "Which metabolite activates AtxA?", "answers": ["CO2", "bicarbonate"], "qid": "e37eef543acc42c0902146dfb8efe1c7", "question_tokens": [["Which", 0], ["metabolite", 6], ["activates", 17], ["AtxA", 27], ["?", 31]], "detected_answers": [{"text": "CO2", "token_spans": [[95, 95], [53, 53], [50, 50]], "char_spans": [[495, 497], [277, 279], [267, 269]]}]}], "context_tokens": [["Bacillus", 0], ["anthracis", 9], ["plasmid", 19], ["pXO1", 27], ["carries", 32], ["the", 40], ["structural", 44], ["genes", 55], ["for", 61], ["the", 65], ["three", 69], ["anthrax", 75], ["toxin", 83], ["proteins", 89], [",", 97], ["cya", 99], ["(", 103], ["edema", 104], ["factor", 110], [")", 116], [",", 117], ["lef", 119], ["(", 123], ["lethal", 124], ["factor", 131], [")", 137], [",", 138], ["and", 140], ["pag", 144], ["(", 148], ["protective", 149], ["antigen", 160], [")", 167], [".", 168], ["Expression", 170], ["of", 181], ["the", 184], ["toxin", 188], ["genes", 194], ["by", 200], ["B.", 203], ["anthracis", 206], ["is", 216], ["enhanced", 219], ["during", 228], ["growth", 235], ["under", 242], ["elevated", 248], ["levels", 257], ["of", 264], ["CO2", 267], [".", 270], ["This", 272], ["CO2", 277], ["effect", 281], ["is", 288], ["observed", 291], ["only", 300], ["in", 305], ["the", 308], ["presence", 312], ["of", 321], ["another", 324], ["pXO1", 332], ["gene", 337], [",", 341], ["atxA", 343], [",", 347], ["which", 349], ["encodes", 355], ["a", 363], ["transactivator", 365], ["of", 380], ["anthrax", 383], ["toxin", 391], ["synthesis", 397], [".", 406], ["Here", 408], ["we", 413], ["show", 416], ["that", 421], ["transcription", 426], ["of", 440], ["atxA", 443], ["does", 448], ["not", 453], ["appear", 457], ["to", 464], ["differ", 467], ["in", 474], ["cells", 477], ["grown", 483], ["in", 489], ["5", 492], ["%", 493], ["CO2", 495], ["compared", 499], ["with", 508], ["cells", 513], ["grown", 519], ["in", 525], ["air", 528], [".", 531], ["Using", 533], ["a", 539], ["new", 541], ["efficient", 545], ["method", 555], ["for", 562], ["gene", 566], ["replacement", 571], ["in", 583], ["B.", 586], ["anthracis", 589], [",", 598], ["we", 600], ["constructed", 603], ["an", 615], ["atxA", 618], ["-", 622], ["null", 623], ["mutant", 628], ["in", 635], ["which", 638], ["the", 644], ["atxA", 648], ["-", 652], ["coding", 653], ["sequence", 660], ["on", 669], ["pXO1", 672], ["is", 677], ["replaced", 680], ["with", 689], ["an", 694], ["omega", 697], ["km-2", 703], ["cassette", 708], [".", 716], ["Transcription", 718], ["of", 732], ["all", 735], ["three", 739], ["toxin", 745], ["genes", 751], ["is", 757], ["decreased", 760], ["in", 770], ["the", 773], ["absence", 777], ["of", 785], ["atxA.", 788], ["The", 794], ["pag", 798], ["gene", 802], ["possesses", 807], ["two", 817], ["apparent", 821], ["transcription", 830], ["start", 844], ["sites", 850], [",", 855], ["P1", 857], ["and", 860], ["P2", 864], [";", 866], ["only", 868], ["transcripts", 873], ["with", 885], ["5", 890], ["'", 891], ["ends", 893], ["mapping", 898], ["to", 906], ["P1", 909], ["are", 912], ["decreased", 916], ["in", 926], ["the", 929], ["atxA", 933], ["-", 937], ["null", 938], ["mutant", 943], [".", 949], ["Deletion", 951], ["analysis", 960], ["of", 969], ["the", 972], ["pag", 976], ["promoter", 980], ["region", 989], ["indicates", 996], ["that", 1006], ["the", 1011], ["111", 1015], ["bp", 1019], ["region", 1022], ["upstream", 1029], ["of", 1038], ["the", 1041], ["P1", 1045], ["site", 1048], ["is", 1053], ["sufficient", 1056], ["for", 1067], ["atxA", 1071], ["-", 1075], ["mediated", 1076], ["activation", 1085], ["of", 1096], ["this", 1099], ["transcript", 1104], [".", 1114], ["The", 1116], ["cya", 1120], ["and", 1124], ["lef", 1128], ["genes", 1132], ["each", 1138], ["have", 1143], ["one", 1148], ["apparent", 1152], ["start", 1161], ["site", 1167], ["for", 1172], ["transcription", 1176], [".", 1189], ["Transcripts", 1191], ["with", 1203], ["5", 1208], ["'", 1209], ["ends", 1211], ["mapping", 1216], ["to", 1224], ["these", 1227], ["sites", 1233], ["are", 1239], ["not", 1243], ["detected", 1247], ["in", 1256], ["the", 1259], ["atxA", 1263], ["-", 1267], ["null", 1268], ["mutant", 1273], [".", 1279], ["The", 1281], ["atxA", 1285], ["-", 1289], ["null", 1290], ["mutant", 1295], ["is", 1302], ["avirulent", 1305], ["in", 1315], ["mice", 1318], [".", 1322], ["Moreover", 1324], [",", 1332], ["the", 1334], ["antibody", 1338], ["response", 1347], ["to", 1356], ["all", 1359], ["three", 1363], ["toxin", 1369], ["proteins", 1375], ["is", 1384], ["decreased", 1387], ["significantly", 1397], ["in", 1411], ["atxA", 1414], ["-", 1418], ["null", 1419], ["mutant", 1424], ["-", 1430], ["infected", 1431], ["mice", 1440], [".", 1444], ["These", 1446], ["data", 1452], ["suggest", 1457], ["that", 1465], ["the", 1470], ["atxA", 1474], ["gene", 1479], ["product", 1484], ["also", 1492], ["regulates", 1497], ["toxin", 1507], ["gene", 1513], ["expression", 1518], ["during", 1529], ["infection", 1536], [".", 1545]]}
{"context": "Romano-Ward syndrome is a subtype of prolonged QT syndrome with autosomal dominant inheritance. Stress-induced syncope and sudden death are secondary to ventricular tachydysrhythmias. A case report of Romano-Ward syndrome complicating pregnancy is presented. Successful therapy with propranolol for life-threatening dysrhythmias was achieved. An excellent neonatal outcome occurred.", "qas": [{"question": "What is the mode of inheritance of Romano Ward long QT syndrome?", "answers": ["autosomal dominant"], "qid": "34757c8e5ca444a192856060543f7791", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Romano", 35], ["Ward", 42], ["long", 47], ["QT", 52], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[12, 13]], "char_spans": [[64, 81]]}]}], "context_tokens": [["Romano", 0], ["-", 6], ["Ward", 7], ["syndrome", 12], ["is", 21], ["a", 24], ["subtype", 26], ["of", 34], ["prolonged", 37], ["QT", 47], ["syndrome", 50], ["with", 59], ["autosomal", 64], ["dominant", 74], ["inheritance", 83], [".", 94], ["Stress", 96], ["-", 102], ["induced", 103], ["syncope", 111], ["and", 119], ["sudden", 123], ["death", 130], ["are", 136], ["secondary", 140], ["to", 150], ["ventricular", 153], ["tachydysrhythmias", 165], [".", 182], ["A", 184], ["case", 186], ["report", 191], ["of", 198], ["Romano", 201], ["-", 207], ["Ward", 208], ["syndrome", 213], ["complicating", 222], ["pregnancy", 235], ["is", 245], ["presented", 248], [".", 257], ["Successful", 259], ["therapy", 270], ["with", 278], ["propranolol", 283], ["for", 295], ["life", 299], ["-", 303], ["threatening", 304], ["dysrhythmias", 316], ["was", 329], ["achieved", 333], [".", 341], ["An", 343], ["excellent", 346], ["neonatal", 356], ["outcome", 365], ["occurred", 373], [".", 381]]}
{"context": "In 2005, a distinct clone of methicillin resistant Staphylococcus aureus (MRSA CC398) was found in pigs and people in contact with pigs. The structure of the pig production chain in high technology pig husbandry enables pathogens to spread during animal trading, with an increasing prevalence in herds further down the chain. The objective of this study was to quantify the effect of the MRSA status of the supplying herd on the MRSA status of the receiving herd in order to gain more insight into the role of animal trading as a transmission route for MRSA CC398. Nasal samples (60-80 pigs per herd) were collected from 38 herds; in 20 herds, environmental samples were collected as well. Ten MRSA-positive herds (based on the results of nasal swabs of 10 individual pigs per herd) from a prior study were included in the data analysis. Herds were classified as MRSA positive if at least one sample tested positive. The 48 herds were part of 14 complete (40 herds) and 4 incomplete (8 herds) pig production chains. Fifty-six percent of the herds were classified as MRSA positive. MRSA-positive herds were observed at the start (breeding herds), middle (farrowing herds) and the end (finishing herds) of the pig production chain. All of the herds in 8 chains tested MRSA positive;, all of the herds in 5 chains tested MRSA negative and in the remaining 5 chains, MRSA-positive and MRSA-negative herds were detected. Seven spa types were found, which were all previously confirmed to belong to CC398. All of the isolates were susceptible to mupirocin, linezolid, rifampicin, fusidic acid and cotrimoxazole. Resistance against tetracycline, erythromycin and clindamycin was found in 100, 74 and 76% of the isolates, respectively. Seventy-nine percent of herds with a MRSA-positive supplier of pigs were MRSA positive, whereas 23% of herds with a MRSA-negative supplier were MRSA positive (OR=10.8; 95% CI: 1.5-110.1; P=0.011). The presence of entirely MRSA-positive and MRSA-negative chains and the strong association between the MRSA status of herds and their suppliers illustrates a large risk associated with purchasing pigs from MRSA-positive herds; a top-down strategy for future control programs is, therefore, a basic requirement. However, 23% of herds with a MRSA-negative supplier were MRSA positive and furthermore, 46% of the herds at the top of the pig production chain without a supplier tested MRSA positive. This underlined the need for the identification of additional risk factors for MRSA.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "f4ea9fa4a4b04d9bb9a697ce1418abdb", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[208, 208], [272, 272], [403, 403], [77, 77], [211, 211], [454, 454], [491, 491], [12, 12], [276, 276], [263, 263], [364, 364], [69, 69], [131, 131], [251, 251], [389, 389], [369, 369], [449, 449], [165, 165], [347, 347], [419, 419], [100, 100], [476, 476], [393, 393], [354, 354]], "char_spans": [[1066, 1069], [1363, 1366], [2028, 2031], [429, 432], [1081, 1084], [2293, 2296], [2500, 2503], [74, 77], [1381, 1384], [1318, 1321], [1844, 1847], [388, 391], [694, 697], [1266, 1269], [1950, 1953], [1872, 1875], [2265, 2268], [863, 866], [1765, 1768], [2131, 2134], [553, 556], [2406, 2409], [1968, 1971], [1801, 1804]]}]}], "context_tokens": [["In", 0], ["2005", 3], [",", 7], ["a", 9], ["distinct", 11], ["clone", 20], ["of", 26], ["methicillin", 29], ["resistant", 41], ["Staphylococcus", 51], ["aureus", 66], ["(", 73], ["MRSA", 74], ["CC398", 79], [")", 84], ["was", 86], ["found", 90], ["in", 96], ["pigs", 99], ["and", 104], ["people", 108], ["in", 115], ["contact", 118], ["with", 126], ["pigs", 131], [".", 135], ["The", 137], ["structure", 141], ["of", 151], ["the", 154], ["pig", 158], ["production", 162], ["chain", 173], ["in", 179], ["high", 182], ["technology", 187], ["pig", 198], ["husbandry", 202], ["enables", 212], ["pathogens", 220], ["to", 230], ["spread", 233], ["during", 240], ["animal", 247], ["trading", 254], [",", 261], ["with", 263], ["an", 268], ["increasing", 271], ["prevalence", 282], ["in", 293], ["herds", 296], ["further", 302], ["down", 310], ["the", 315], ["chain", 319], [".", 324], ["The", 326], ["objective", 330], ["of", 340], ["this", 343], ["study", 348], ["was", 354], ["to", 358], ["quantify", 361], ["the", 370], ["effect", 374], ["of", 381], ["the", 384], ["MRSA", 388], ["status", 393], ["of", 400], ["the", 403], ["supplying", 407], ["herd", 417], ["on", 422], ["the", 425], ["MRSA", 429], ["status", 434], ["of", 441], ["the", 444], ["receiving", 448], ["herd", 458], ["in", 463], ["order", 466], ["to", 472], ["gain", 475], ["more", 480], ["insight", 485], ["into", 493], ["the", 498], ["role", 502], ["of", 507], ["animal", 510], ["trading", 517], ["as", 525], ["a", 528], ["transmission", 530], ["route", 543], ["for", 549], ["MRSA", 553], ["CC398", 558], [".", 563], ["Nasal", 565], ["samples", 571], ["(", 579], ["60", 580], ["-", 582], ["80", 583], ["pigs", 586], ["per", 591], ["herd", 595], [")", 599], ["were", 601], ["collected", 606], ["from", 616], ["38", 621], ["herds", 624], [";", 629], ["in", 631], ["20", 634], ["herds", 637], [",", 642], ["environmental", 644], ["samples", 658], ["were", 666], ["collected", 671], ["as", 681], ["well", 684], [".", 688], ["Ten", 690], ["MRSA", 694], ["-", 698], ["positive", 699], ["herds", 708], ["(", 714], ["based", 715], ["on", 721], ["the", 724], ["results", 728], ["of", 736], ["nasal", 739], ["swabs", 745], ["of", 751], ["10", 754], ["individual", 757], ["pigs", 768], ["per", 773], ["herd", 777], [")", 781], ["from", 783], ["a", 788], ["prior", 790], ["study", 796], ["were", 802], ["included", 807], ["in", 816], ["the", 819], ["data", 823], ["analysis", 828], [".", 836], ["Herds", 838], ["were", 844], ["classified", 849], ["as", 860], ["MRSA", 863], ["positive", 868], ["if", 877], ["at", 880], ["least", 883], ["one", 889], ["sample", 893], ["tested", 900], ["positive", 907], [".", 915], ["The", 917], ["48", 921], ["herds", 924], ["were", 930], ["part", 935], ["of", 940], ["14", 943], ["complete", 946], ["(", 955], ["40", 956], ["herds", 959], [")", 964], ["and", 966], ["4", 970], ["incomplete", 972], ["(", 983], ["8", 984], ["herds", 986], [")", 991], ["pig", 993], ["production", 997], ["chains", 1008], [".", 1014], ["Fifty", 1016], ["-", 1021], ["six", 1022], ["percent", 1026], ["of", 1034], ["the", 1037], ["herds", 1041], ["were", 1047], ["classified", 1052], ["as", 1063], ["MRSA", 1066], ["positive", 1071], [".", 1079], ["MRSA", 1081], ["-", 1085], ["positive", 1086], ["herds", 1095], ["were", 1101], ["observed", 1106], ["at", 1115], ["the", 1118], ["start", 1122], ["(", 1128], ["breeding", 1129], ["herds", 1138], [")", 1143], [",", 1144], ["middle", 1146], ["(", 1153], ["farrowing", 1154], ["herds", 1164], [")", 1169], ["and", 1171], ["the", 1175], ["end", 1179], ["(", 1183], ["finishing", 1184], ["herds", 1194], [")", 1199], ["of", 1201], ["the", 1204], ["pig", 1208], ["production", 1212], ["chain", 1223], [".", 1228], ["All", 1230], ["of", 1234], ["the", 1237], ["herds", 1241], ["in", 1247], ["8", 1250], ["chains", 1252], ["tested", 1259], ["MRSA", 1266], ["positive", 1271], [";", 1279], [",", 1280], ["all", 1282], ["of", 1286], ["the", 1289], ["herds", 1293], ["in", 1299], ["5", 1302], ["chains", 1304], ["tested", 1311], ["MRSA", 1318], ["negative", 1323], ["and", 1332], ["in", 1336], ["the", 1339], ["remaining", 1343], ["5", 1353], ["chains", 1355], [",", 1361], ["MRSA", 1363], ["-", 1367], ["positive", 1368], ["and", 1377], ["MRSA", 1381], ["-", 1385], ["negative", 1386], ["herds", 1395], ["were", 1401], ["detected", 1406], [".", 1414], ["Seven", 1416], ["spa", 1422], ["types", 1426], ["were", 1432], ["found", 1437], [",", 1442], ["which", 1444], ["were", 1450], ["all", 1455], ["previously", 1459], ["confirmed", 1470], ["to", 1480], ["belong", 1483], ["to", 1490], ["CC398", 1493], [".", 1498], ["All", 1500], ["of", 1504], ["the", 1507], ["isolates", 1511], ["were", 1520], ["susceptible", 1525], ["to", 1537], ["mupirocin", 1540], [",", 1549], ["linezolid", 1551], [",", 1560], ["rifampicin", 1562], [",", 1572], ["fusidic", 1574], ["acid", 1582], ["and", 1587], ["cotrimoxazole", 1591], [".", 1604], ["Resistance", 1606], ["against", 1617], ["tetracycline", 1625], [",", 1637], ["erythromycin", 1639], ["and", 1652], ["clindamycin", 1656], ["was", 1668], ["found", 1672], ["in", 1678], ["100", 1681], [",", 1684], ["74", 1686], ["and", 1689], ["76", 1693], ["%", 1695], ["of", 1697], ["the", 1700], ["isolates", 1704], [",", 1712], ["respectively", 1714], [".", 1726], ["Seventy", 1728], ["-", 1735], ["nine", 1736], ["percent", 1741], ["of", 1749], ["herds", 1752], ["with", 1758], ["a", 1763], ["MRSA", 1765], ["-", 1769], ["positive", 1770], ["supplier", 1779], ["of", 1788], ["pigs", 1791], ["were", 1796], ["MRSA", 1801], ["positive", 1806], [",", 1814], ["whereas", 1816], ["23", 1824], ["%", 1826], ["of", 1828], ["herds", 1831], ["with", 1837], ["a", 1842], ["MRSA", 1844], ["-", 1848], ["negative", 1849], ["supplier", 1858], ["were", 1867], ["MRSA", 1872], ["positive", 1877], ["(", 1886], ["OR=10.8", 1887], [";", 1894], ["95", 1896], ["%", 1898], ["CI", 1900], [":", 1902], ["1.5", 1904], ["-", 1907], ["110.1", 1908], [";", 1913], ["P=0.011", 1915], [")", 1922], [".", 1923], ["The", 1925], ["presence", 1929], ["of", 1938], ["entirely", 1941], ["MRSA", 1950], ["-", 1954], ["positive", 1955], ["and", 1964], ["MRSA", 1968], ["-", 1972], ["negative", 1973], ["chains", 1982], ["and", 1989], ["the", 1993], ["strong", 1997], ["association", 2004], ["between", 2016], ["the", 2024], ["MRSA", 2028], ["status", 2033], ["of", 2040], ["herds", 2043], ["and", 2049], ["their", 2053], ["suppliers", 2059], ["illustrates", 2069], ["a", 2081], ["large", 2083], ["risk", 2089], ["associated", 2094], ["with", 2105], ["purchasing", 2110], ["pigs", 2121], ["from", 2126], ["MRSA", 2131], ["-", 2135], ["positive", 2136], ["herds", 2145], [";", 2150], ["a", 2152], ["top", 2154], ["-", 2157], ["down", 2158], ["strategy", 2163], ["for", 2172], ["future", 2176], ["control", 2183], ["programs", 2191], ["is", 2200], [",", 2202], ["therefore", 2204], [",", 2213], ["a", 2215], ["basic", 2217], ["requirement", 2223], [".", 2234], ["However", 2236], [",", 2243], ["23", 2245], ["%", 2247], ["of", 2249], ["herds", 2252], ["with", 2258], ["a", 2263], ["MRSA", 2265], ["-", 2269], ["negative", 2270], ["supplier", 2279], ["were", 2288], ["MRSA", 2293], ["positive", 2298], ["and", 2307], ["furthermore", 2311], [",", 2322], ["46", 2324], ["%", 2326], ["of", 2328], ["the", 2331], ["herds", 2335], ["at", 2341], ["the", 2344], ["top", 2348], ["of", 2352], ["the", 2355], ["pig", 2359], ["production", 2363], ["chain", 2374], ["without", 2380], ["a", 2388], ["supplier", 2390], ["tested", 2399], ["MRSA", 2406], ["positive", 2411], [".", 2419], ["This", 2421], ["underlined", 2426], ["the", 2437], ["need", 2441], ["for", 2446], ["the", 2450], ["identification", 2454], ["of", 2469], ["additional", 2472], ["risk", 2483], ["factors", 2488], ["for", 2496], ["MRSA", 2500], [".", 2504]]}
{"context": "The large size of spectrin, the flexible protein promoting reversible deformation of red cells, has been an obstacle to elucidating the molecular mechanism of its function. By studying cloned fragments of the repeating unit domain, we have found a correspondence between positions of selected spectrin repeats in a tetramer with their stabilities of folding. Six fragments consisting of two spectrin repeats were selected for study primarily on the basis of the predicted secondary structures of their linker regions. Fragments with a putatively helical linker were more stable to urea- and heat-induced unfolding than those with a putatively nonhelical linker. Two of the less stably folded fragments, human erythroid alpha-spectrin repeats 13 and 14 (HEalpha13,14) and human erythroid beta-spectrin repeats 8 and 9 (HEbeta8,9), are located opposite each other on antiparallel spectrin dimers. At least partial unfolding of these repeats under physiological conditions indicates that they may serve as a hinge. Also less stably folded, the fragment of human erythroid alpha-spectrin repeats 4 and 5 (HEalpha4,5) lies opposite the site of interaction between the partial repeats at the C- and N-terminal ends of beta- and alpha-spectrin, respectively, on the opposing dimer. More stably folded fragments, human erythroid alpha-spectrin repeats 1 and 2 (HEalpha1,2) and human erythroid alpha-spectrin repeats 2 and 3 (HEalpha2,3), lie nearly opposite each other on antiparallel spectrin dimers of a tetramer. These clusterings along the spectrin tetramer of repeats with similar stabilities of folding may have relevance for spectrin function, particularly for its well known flexibility.", "qas": [{"question": "Alpha-spectrin and beta-spectrin subunits form parallel or antiparallel heterodimers?", "answers": ["antiparallel"], "qid": "47e09473d3cd4d209e14ce17285a816e", "question_tokens": [["Alpha", 0], ["-", 5], ["spectrin", 6], ["and", 15], ["beta", 19], ["-", 23], ["spectrin", 24], ["subunits", 33], ["form", 42], ["parallel", 47], ["or", 56], ["antiparallel", 59], ["heterodimers", 72], ["?", 84]], "detected_answers": [{"text": "antiparallel", "token_spans": [[148, 148], [260, 260]], "char_spans": [[865, 876], [1464, 1475]]}]}], "context_tokens": [["The", 0], ["large", 4], ["size", 10], ["of", 15], ["spectrin", 18], [",", 26], ["the", 28], ["flexible", 32], ["protein", 41], ["promoting", 49], ["reversible", 59], ["deformation", 70], ["of", 82], ["red", 85], ["cells", 89], [",", 94], ["has", 96], ["been", 100], ["an", 105], ["obstacle", 108], ["to", 117], ["elucidating", 120], ["the", 132], ["molecular", 136], ["mechanism", 146], ["of", 156], ["its", 159], ["function", 163], [".", 171], ["By", 173], ["studying", 176], ["cloned", 185], ["fragments", 192], ["of", 202], ["the", 205], ["repeating", 209], ["unit", 219], ["domain", 224], [",", 230], ["we", 232], ["have", 235], ["found", 240], ["a", 246], ["correspondence", 248], ["between", 263], ["positions", 271], ["of", 281], ["selected", 284], ["spectrin", 293], ["repeats", 302], ["in", 310], ["a", 313], ["tetramer", 315], ["with", 324], ["their", 329], ["stabilities", 335], ["of", 347], ["folding", 350], [".", 357], ["Six", 359], ["fragments", 363], ["consisting", 373], ["of", 384], ["two", 387], ["spectrin", 391], ["repeats", 400], ["were", 408], ["selected", 413], ["for", 422], ["study", 426], ["primarily", 432], ["on", 442], ["the", 445], ["basis", 449], ["of", 455], ["the", 458], ["predicted", 462], ["secondary", 472], ["structures", 482], ["of", 493], ["their", 496], ["linker", 502], ["regions", 509], [".", 516], ["Fragments", 518], ["with", 528], ["a", 533], ["putatively", 535], ["helical", 546], ["linker", 554], ["were", 561], ["more", 566], ["stable", 571], ["to", 578], ["urea-", 581], ["and", 587], ["heat", 591], ["-", 595], ["induced", 596], ["unfolding", 604], ["than", 614], ["those", 619], ["with", 625], ["a", 630], ["putatively", 632], ["nonhelical", 643], ["linker", 654], [".", 660], ["Two", 662], ["of", 666], ["the", 669], ["less", 673], ["stably", 678], ["folded", 685], ["fragments", 692], [",", 701], ["human", 703], ["erythroid", 709], ["alpha", 719], ["-", 724], ["spectrin", 725], ["repeats", 734], ["13", 742], ["and", 745], ["14", 749], ["(", 752], ["HEalpha13,14", 753], [")", 765], ["and", 767], ["human", 771], ["erythroid", 777], ["beta", 787], ["-", 791], ["spectrin", 792], ["repeats", 801], ["8", 809], ["and", 811], ["9", 815], ["(", 817], ["HEbeta8,9", 818], [")", 827], [",", 828], ["are", 830], ["located", 834], ["opposite", 842], ["each", 851], ["other", 856], ["on", 862], ["antiparallel", 865], ["spectrin", 878], ["dimers", 887], [".", 893], ["At", 895], ["least", 898], ["partial", 904], ["unfolding", 912], ["of", 922], ["these", 925], ["repeats", 931], ["under", 939], ["physiological", 945], ["conditions", 959], ["indicates", 970], ["that", 980], ["they", 985], ["may", 990], ["serve", 994], ["as", 1000], ["a", 1003], ["hinge", 1005], [".", 1010], ["Also", 1012], ["less", 1017], ["stably", 1022], ["folded", 1029], [",", 1035], ["the", 1037], ["fragment", 1041], ["of", 1050], ["human", 1053], ["erythroid", 1059], ["alpha", 1069], ["-", 1074], ["spectrin", 1075], ["repeats", 1084], ["4", 1092], ["and", 1094], ["5", 1098], ["(", 1100], ["HEalpha4,5", 1101], [")", 1111], ["lies", 1113], ["opposite", 1118], ["the", 1127], ["site", 1131], ["of", 1136], ["interaction", 1139], ["between", 1151], ["the", 1159], ["partial", 1163], ["repeats", 1171], ["at", 1179], ["the", 1182], ["C-", 1186], ["and", 1189], ["N", 1193], ["-", 1194], ["terminal", 1195], ["ends", 1204], ["of", 1209], ["beta-", 1212], ["and", 1218], ["alpha", 1222], ["-", 1227], ["spectrin", 1228], [",", 1236], ["respectively", 1238], [",", 1250], ["on", 1252], ["the", 1255], ["opposing", 1259], ["dimer", 1268], [".", 1273], ["More", 1275], ["stably", 1280], ["folded", 1287], ["fragments", 1294], [",", 1303], ["human", 1305], ["erythroid", 1311], ["alpha", 1321], ["-", 1326], ["spectrin", 1327], ["repeats", 1336], ["1", 1344], ["and", 1346], ["2", 1350], ["(", 1352], ["HEalpha1,2", 1353], [")", 1363], ["and", 1365], ["human", 1369], ["erythroid", 1375], ["alpha", 1385], ["-", 1390], ["spectrin", 1391], ["repeats", 1400], ["2", 1408], ["and", 1410], ["3", 1414], ["(", 1416], ["HEalpha2,3", 1417], [")", 1427], [",", 1428], ["lie", 1430], ["nearly", 1434], ["opposite", 1441], ["each", 1450], ["other", 1455], ["on", 1461], ["antiparallel", 1464], ["spectrin", 1477], ["dimers", 1486], ["of", 1493], ["a", 1496], ["tetramer", 1498], [".", 1506], ["These", 1508], ["clusterings", 1514], ["along", 1526], ["the", 1532], ["spectrin", 1536], ["tetramer", 1545], ["of", 1554], ["repeats", 1557], ["with", 1565], ["similar", 1570], ["stabilities", 1578], ["of", 1590], ["folding", 1593], ["may", 1601], ["have", 1605], ["relevance", 1610], ["for", 1620], ["spectrin", 1624], ["function", 1633], [",", 1641], ["particularly", 1643], ["for", 1656], ["its", 1660], ["well", 1664], ["known", 1669], ["flexibility", 1675], [".", 1686]]}
{"context": "The relevance of the Simpson grading system as a predictor of meningioma progression or recurrence in modern neurosurgical practice has recently been called into question. The aim of our study was to compare the risk of progression/recurrence of tumours that had been treated with different Simpson grade resections in a contemporary population of benign (WHO grade I) meningioma patients. One hundred eighty-three patients with histologically confirmed WHO grade I meningioma were retrospectively analysed. All patients underwent first-time craniotomy as their initial therapy between 2004 and 2012. Univariate analysis was performed using log-rank testing and Kaplan-Meier analysis for progression/recurrence-free survival. Multivariate analysis was performed using Cox proportional hazards regression modelling. The three-year progression/recurrence-free survival rates for patients receiving Simpson grade 1, 2 or 4 resections were 95 %, 87 % and 67 %, respectively. Simpson grade 4 resections progressed/recurred at a significantly greater rate than Simpson grade 1 resections (hazard ratio [HR]\u2009=\u20093.26, P\u2009=\u20090.04), whereas Simpson grade 2 resections did not progress/recur at a significantly greater rate than Simpson grade 1 resections (HR\u2009=\u20091.78, P\u2009=\u20090.29). Subtotal resections progressed/recurred at a significantly greater rate than gross-total resections (HR\u2009=\u20092.47, P\u2009=\u20090.03). Tumours that undergo subtotal resection are at a significantly greater risk of progression/recurrence than tumours that undergo gross-total resection. Gross-total resection should therefore be the aim of surgery. However, given modern access to follow-up imaging and stereotactic radiosurgery, these results should not be used to justify overly 'heroic' tumour resection.", "qas": [{"question": "Simpson grading is used to describe resection of which brain tumor?", "answers": ["meningioma"], "qid": "44e178e35d844cdd95994960d939d4dd", "question_tokens": [["Simpson", 0], ["grading", 8], ["is", 16], ["used", 19], ["to", 24], ["describe", 27], ["resection", 36], ["of", 46], ["which", 49], ["brain", 55], ["tumor", 61], ["?", 66]], "detected_answers": [{"text": "meningioma", "token_spans": [[11, 11], [77, 77], [62, 62]], "char_spans": [[62, 71], [466, 475], [369, 378]]}]}], "context_tokens": [["The", 0], ["relevance", 4], ["of", 14], ["the", 17], ["Simpson", 21], ["grading", 29], ["system", 37], ["as", 44], ["a", 47], ["predictor", 49], ["of", 59], ["meningioma", 62], ["progression", 73], ["or", 85], ["recurrence", 88], ["in", 99], ["modern", 102], ["neurosurgical", 109], ["practice", 123], ["has", 132], ["recently", 136], ["been", 145], ["called", 150], ["into", 157], ["question", 162], [".", 170], ["The", 172], ["aim", 176], ["of", 180], ["our", 183], ["study", 187], ["was", 193], ["to", 197], ["compare", 200], ["the", 208], ["risk", 212], ["of", 217], ["progression", 220], ["/", 231], ["recurrence", 232], ["of", 243], ["tumours", 246], ["that", 254], ["had", 259], ["been", 263], ["treated", 268], ["with", 276], ["different", 281], ["Simpson", 291], ["grade", 299], ["resections", 305], ["in", 316], ["a", 319], ["contemporary", 321], ["population", 334], ["of", 345], ["benign", 348], ["(", 355], ["WHO", 356], ["grade", 360], ["I", 366], [")", 367], ["meningioma", 369], ["patients", 380], [".", 388], ["One", 390], ["hundred", 394], ["eighty", 402], ["-", 408], ["three", 409], ["patients", 415], ["with", 424], ["histologically", 429], ["confirmed", 444], ["WHO", 454], ["grade", 458], ["I", 464], ["meningioma", 466], ["were", 477], ["retrospectively", 482], ["analysed", 498], [".", 506], ["All", 508], ["patients", 512], ["underwent", 521], ["first", 531], ["-", 536], ["time", 537], ["craniotomy", 542], ["as", 553], ["their", 556], ["initial", 562], ["therapy", 570], ["between", 578], ["2004", 586], ["and", 591], ["2012", 595], [".", 599], ["Univariate", 601], ["analysis", 612], ["was", 621], ["performed", 625], ["using", 635], ["log", 641], ["-", 644], ["rank", 645], ["testing", 650], ["and", 658], ["Kaplan", 662], ["-", 668], ["Meier", 669], ["analysis", 675], ["for", 684], ["progression", 688], ["/", 699], ["recurrence", 700], ["-", 710], ["free", 711], ["survival", 716], [".", 724], ["Multivariate", 726], ["analysis", 739], ["was", 748], ["performed", 752], ["using", 762], ["Cox", 768], ["proportional", 772], ["hazards", 785], ["regression", 793], ["modelling", 804], [".", 813], ["The", 815], ["three", 819], ["-", 824], ["year", 825], ["progression", 830], ["/", 841], ["recurrence", 842], ["-", 852], ["free", 853], ["survival", 858], ["rates", 867], ["for", 873], ["patients", 877], ["receiving", 886], ["Simpson", 896], ["grade", 904], ["1", 910], [",", 911], ["2", 913], ["or", 915], ["4", 918], ["resections", 920], ["were", 931], ["95", 936], ["%", 939], [",", 940], ["87", 942], ["%", 945], ["and", 947], ["67", 951], ["%", 954], [",", 955], ["respectively", 957], [".", 969], ["Simpson", 971], ["grade", 979], ["4", 985], ["resections", 987], ["progressed", 998], ["/", 1008], ["recurred", 1009], ["at", 1018], ["a", 1021], ["significantly", 1023], ["greater", 1037], ["rate", 1045], ["than", 1050], ["Simpson", 1055], ["grade", 1063], ["1", 1069], ["resections", 1071], ["(", 1082], ["hazard", 1083], ["ratio", 1090], ["[", 1096], ["HR", 1097], ["]", 1099], ["=", 1101], ["3.26", 1103], [",", 1107], ["P", 1109], ["=", 1111], ["0.04", 1113], [")", 1117], [",", 1118], ["whereas", 1120], ["Simpson", 1128], ["grade", 1136], ["2", 1142], ["resections", 1144], ["did", 1155], ["not", 1159], ["progress", 1163], ["/", 1171], ["recur", 1172], ["at", 1178], ["a", 1181], ["significantly", 1183], ["greater", 1197], ["rate", 1205], ["than", 1210], ["Simpson", 1215], ["grade", 1223], ["1", 1229], ["resections", 1231], ["(", 1242], ["HR", 1243], ["=", 1246], ["1.78", 1248], [",", 1252], ["P", 1254], ["=", 1256], ["0.29", 1258], [")", 1262], [".", 1263], ["Subtotal", 1265], ["resections", 1274], ["progressed", 1285], ["/", 1295], ["recurred", 1296], ["at", 1305], ["a", 1308], ["significantly", 1310], ["greater", 1324], ["rate", 1332], ["than", 1337], ["gross", 1342], ["-", 1347], ["total", 1348], ["resections", 1354], ["(", 1365], ["HR", 1366], ["=", 1369], ["2.47", 1371], [",", 1375], ["P", 1377], ["=", 1379], ["0.03", 1381], [")", 1385], [".", 1386], ["Tumours", 1388], ["that", 1396], ["undergo", 1401], ["subtotal", 1409], ["resection", 1418], ["are", 1428], ["at", 1432], ["a", 1435], ["significantly", 1437], ["greater", 1451], ["risk", 1459], ["of", 1464], ["progression", 1467], ["/", 1478], ["recurrence", 1479], ["than", 1490], ["tumours", 1495], ["that", 1503], ["undergo", 1508], ["gross", 1516], ["-", 1521], ["total", 1522], ["resection", 1528], [".", 1537], ["Gross", 1539], ["-", 1544], ["total", 1545], ["resection", 1551], ["should", 1561], ["therefore", 1568], ["be", 1578], ["the", 1581], ["aim", 1585], ["of", 1589], ["surgery", 1592], [".", 1599], ["However", 1601], [",", 1608], ["given", 1610], ["modern", 1616], ["access", 1623], ["to", 1630], ["follow", 1633], ["-", 1639], ["up", 1640], ["imaging", 1643], ["and", 1651], ["stereotactic", 1655], ["radiosurgery", 1668], [",", 1680], ["these", 1682], ["results", 1688], ["should", 1696], ["not", 1703], ["be", 1707], ["used", 1710], ["to", 1715], ["justify", 1718], ["overly", 1726], ["'", 1733], ["heroic", 1734], ["'", 1740], ["tumour", 1742], ["resection", 1749], [".", 1758]]}
{"context": "Aging research in vertebrates is hampered by the lack of short-lived models. Annual fishes of the genus Nothobranchius live in East African seasonal ponds. Their life expectancy in the wild is limited by the duration of the wet season and their lifespan in captivity is also short. Nothobranchius are popular aquarium fishes and many different species are kept as captive strains, providing rich material for comparative studies. The present paper aims at reviving the interest in these fishes by reporting that: (1) Nothobranchius can be cultured, and their eggs stored dry at room temperature for months or years, offering inexpensive methods of embryo storage; (2) Nothobranchius show accelerated growth and expression of aging biomarkers at the level of histology and behaviour; (3) the species Nothobranchius furzeri has a maximum lifespan of only 3 months and offers the possibility to perform investigations thus far unthinkable in a vertebrate, such as drug screening with life-long pharmacological treatments and experimental evolution; (4) when the lifespan of different species is compared, a general correlation is found between wet season duration in their natural habitat and longevity in captivity; and (5) vertebrate aging-related genes, such as p66Shc and MTP, can be easily isolated in Nothobranchius by homology cloning. These fishes can become excellent models for aging studies. They can be employed to test the effects of experimental manipulation on aging at a pace comparable with that of Drosophila and to probe the effects of natural selection on the evolution of aging-related genes.", "qas": [{"question": "What can Nothobranchius furzeri be used as a model system for?", "answers": ["aging research"], "qid": "ea59c7ee76424a47bdecc74c9987666f", "question_tokens": [["What", 0], ["can", 5], ["Nothobranchius", 9], ["furzeri", 24], ["be", 32], ["used", 35], ["as", 40], ["a", 43], ["model", 45], ["system", 51], ["for", 58], ["?", 61]], "detected_answers": [{"text": "aging research", "token_spans": [[0, 1]], "char_spans": [[0, 13]]}]}], "context_tokens": [["Aging", 0], ["research", 6], ["in", 15], ["vertebrates", 18], ["is", 30], ["hampered", 33], ["by", 42], ["the", 45], ["lack", 49], ["of", 54], ["short", 57], ["-", 62], ["lived", 63], ["models", 69], [".", 75], ["Annual", 77], ["fishes", 84], ["of", 91], ["the", 94], ["genus", 98], ["Nothobranchius", 104], ["live", 119], ["in", 124], ["East", 127], ["African", 132], ["seasonal", 140], ["ponds", 149], [".", 154], ["Their", 156], ["life", 162], ["expectancy", 167], ["in", 178], ["the", 181], ["wild", 185], ["is", 190], ["limited", 193], ["by", 201], ["the", 204], ["duration", 208], ["of", 217], ["the", 220], ["wet", 224], ["season", 228], ["and", 235], ["their", 239], ["lifespan", 245], ["in", 254], ["captivity", 257], ["is", 267], ["also", 270], ["short", 275], [".", 280], ["Nothobranchius", 282], ["are", 297], ["popular", 301], ["aquarium", 309], ["fishes", 318], ["and", 325], ["many", 329], ["different", 334], ["species", 344], ["are", 352], ["kept", 356], ["as", 361], ["captive", 364], ["strains", 372], [",", 379], ["providing", 381], ["rich", 391], ["material", 396], ["for", 405], ["comparative", 409], ["studies", 421], [".", 428], ["The", 430], ["present", 434], ["paper", 442], ["aims", 448], ["at", 453], ["reviving", 456], ["the", 465], ["interest", 469], ["in", 478], ["these", 481], ["fishes", 487], ["by", 494], ["reporting", 497], ["that", 507], [":", 511], ["(", 513], ["1", 514], [")", 515], ["Nothobranchius", 517], ["can", 532], ["be", 536], ["cultured", 539], [",", 547], ["and", 549], ["their", 553], ["eggs", 559], ["stored", 564], ["dry", 571], ["at", 575], ["room", 578], ["temperature", 583], ["for", 595], ["months", 599], ["or", 606], ["years", 609], [",", 614], ["offering", 616], ["inexpensive", 625], ["methods", 637], ["of", 645], ["embryo", 648], ["storage", 655], [";", 662], ["(", 664], ["2", 665], [")", 666], ["Nothobranchius", 668], ["show", 683], ["accelerated", 688], ["growth", 700], ["and", 707], ["expression", 711], ["of", 722], ["aging", 725], ["biomarkers", 731], ["at", 742], ["the", 745], ["level", 749], ["of", 755], ["histology", 758], ["and", 768], ["behaviour", 772], [";", 781], ["(", 783], ["3", 784], [")", 785], ["the", 787], ["species", 791], ["Nothobranchius", 799], ["furzeri", 814], ["has", 822], ["a", 826], ["maximum", 828], ["lifespan", 836], ["of", 845], ["only", 848], ["3", 853], ["months", 855], ["and", 862], ["offers", 866], ["the", 873], ["possibility", 877], ["to", 889], ["perform", 892], ["investigations", 900], ["thus", 915], ["far", 920], ["unthinkable", 924], ["in", 936], ["a", 939], ["vertebrate", 941], [",", 951], ["such", 953], ["as", 958], ["drug", 961], ["screening", 966], ["with", 976], ["life", 981], ["-", 985], ["long", 986], ["pharmacological", 991], ["treatments", 1007], ["and", 1018], ["experimental", 1022], ["evolution", 1035], [";", 1044], ["(", 1046], ["4", 1047], [")", 1048], ["when", 1050], ["the", 1055], ["lifespan", 1059], ["of", 1068], ["different", 1071], ["species", 1081], ["is", 1089], ["compared", 1092], [",", 1100], ["a", 1102], ["general", 1104], ["correlation", 1112], ["is", 1124], ["found", 1127], ["between", 1133], ["wet", 1141], ["season", 1145], ["duration", 1152], ["in", 1161], ["their", 1164], ["natural", 1170], ["habitat", 1178], ["and", 1186], ["longevity", 1190], ["in", 1200], ["captivity", 1203], [";", 1212], ["and", 1214], ["(", 1218], ["5", 1219], [")", 1220], ["vertebrate", 1222], ["aging", 1233], ["-", 1238], ["related", 1239], ["genes", 1247], [",", 1252], ["such", 1254], ["as", 1259], ["p66Shc", 1262], ["and", 1269], ["MTP", 1273], [",", 1276], ["can", 1278], ["be", 1282], ["easily", 1285], ["isolated", 1292], ["in", 1301], ["Nothobranchius", 1304], ["by", 1319], ["homology", 1322], ["cloning", 1331], [".", 1338], ["These", 1340], ["fishes", 1346], ["can", 1353], ["become", 1357], ["excellent", 1364], ["models", 1374], ["for", 1381], ["aging", 1385], ["studies", 1391], [".", 1398], ["They", 1400], ["can", 1405], ["be", 1409], ["employed", 1412], ["to", 1421], ["test", 1424], ["the", 1429], ["effects", 1433], ["of", 1441], ["experimental", 1444], ["manipulation", 1457], ["on", 1470], ["aging", 1473], ["at", 1479], ["a", 1482], ["pace", 1484], ["comparable", 1489], ["with", 1500], ["that", 1505], ["of", 1510], ["Drosophila", 1513], ["and", 1524], ["to", 1528], ["probe", 1531], ["the", 1537], ["effects", 1541], ["of", 1549], ["natural", 1552], ["selection", 1560], ["on", 1570], ["the", 1573], ["evolution", 1577], ["of", 1587], ["aging", 1590], ["-", 1595], ["related", 1596], ["genes", 1604], [".", 1609]]}
{"context": "Transcription of the major Bacillus anthracis virulence genes is triggered by CO2, a signal mimicking the host environment. A 182-kb plasmid, pXO1, carries the anthrax toxin genes and the genes responsible for their regulation of transcription, namely atxA and, pagR, the second gene of the pag operon. AtxA has major effects on the physiology of B. anthracis. It coordinates the transcription activation of the toxin genes with that of the capsule biosynthetic enzyme operon, located on the second virulence plasmid, pXO2. In rich medium, B. anthracis synthesises alternatively two S-layer proteins (Sap and EA1). An exponential phase \"Sap-layer\" is subsequently replaced by a stationary phase \"EA1-layer\". S-layer gene transcription is controlled by alternative sigma factors and by Sap acting as a transcriptional repressor of eag. Furthermore, in vitro in presence of CO2 and in vivo, AtxA is part of the sap and eag regulatory network. Only eag is significantly expressed in these conditions and this is due to AtxA activating eag and repressing sap transcription. PagR, and not AtxA itself, is the direct effector of this regulation by binding to sap and eag promoter regions. Therefore, PagR mediates the effect of AtxA on eag and sap and is the most downstream element of a signalling cascade initiated by AtxA. Taken together, these results indicate that the B. anthracis transcriptional regulator AtxA is controlling the synthesis of the three toxin components and of the surface elements (capsule and S-layer). Thus, AtxA is a master regulator that coordinates the response to host signals by orchestrating positive and negative controls over genes located on all genetic elements.", "qas": [{"question": "Which metabolite activates AtxA?", "answers": ["CO2", "bicarbonate"], "qid": "877eabc12fb54287bc30ec4db7f37e8a", "question_tokens": [["Which", 0], ["metabolite", 6], ["activates", 17], ["AtxA", 27], ["?", 31]], "detected_answers": [{"text": "CO2", "token_spans": [[160, 160], [11, 11]], "char_spans": [[872, 874], [78, 80]]}]}], "context_tokens": [["Transcription", 0], ["of", 14], ["the", 17], ["major", 21], ["Bacillus", 27], ["anthracis", 36], ["virulence", 46], ["genes", 56], ["is", 62], ["triggered", 65], ["by", 75], ["CO2", 78], [",", 81], ["a", 83], ["signal", 85], ["mimicking", 92], ["the", 102], ["host", 106], ["environment", 111], [".", 122], ["A", 124], ["182-kb", 126], ["plasmid", 133], [",", 140], ["pXO1", 142], [",", 146], ["carries", 148], ["the", 156], ["anthrax", 160], ["toxin", 168], ["genes", 174], ["and", 180], ["the", 184], ["genes", 188], ["responsible", 194], ["for", 206], ["their", 210], ["regulation", 216], ["of", 227], ["transcription", 230], [",", 243], ["namely", 245], ["atxA", 252], ["and", 257], [",", 260], ["pagR", 262], [",", 266], ["the", 268], ["second", 272], ["gene", 279], ["of", 284], ["the", 287], ["pag", 291], ["operon", 295], [".", 301], ["AtxA", 303], ["has", 308], ["major", 312], ["effects", 318], ["on", 326], ["the", 329], ["physiology", 333], ["of", 344], ["B.", 347], ["anthracis", 350], [".", 359], ["It", 361], ["coordinates", 364], ["the", 376], ["transcription", 380], ["activation", 394], ["of", 405], ["the", 408], ["toxin", 412], ["genes", 418], ["with", 424], ["that", 429], ["of", 434], ["the", 437], ["capsule", 441], ["biosynthetic", 449], ["enzyme", 462], ["operon", 469], [",", 475], ["located", 477], ["on", 485], ["the", 488], ["second", 492], ["virulence", 499], ["plasmid", 509], [",", 516], ["pXO2", 518], [".", 522], ["In", 524], ["rich", 527], ["medium", 532], [",", 538], ["B.", 540], ["anthracis", 543], ["synthesises", 553], ["alternatively", 565], ["two", 579], ["S", 583], ["-", 584], ["layer", 585], ["proteins", 591], ["(", 600], ["Sap", 601], ["and", 605], ["EA1", 609], [")", 612], [".", 613], ["An", 615], ["exponential", 618], ["phase", 630], ["\"", 636], ["Sap", 637], ["-", 640], ["layer", 641], ["\"", 646], ["is", 648], ["subsequently", 651], ["replaced", 664], ["by", 673], ["a", 676], ["stationary", 678], ["phase", 689], ["\"", 695], ["EA1-layer", 696], ["\"", 705], [".", 706], ["S", 708], ["-", 709], ["layer", 710], ["gene", 716], ["transcription", 721], ["is", 735], ["controlled", 738], ["by", 749], ["alternative", 752], ["sigma", 764], ["factors", 770], ["and", 778], ["by", 782], ["Sap", 785], ["acting", 789], ["as", 796], ["a", 799], ["transcriptional", 801], ["repressor", 817], ["of", 827], ["eag", 830], [".", 833], ["Furthermore", 835], [",", 846], ["in", 848], ["vitro", 851], ["in", 857], ["presence", 860], ["of", 869], ["CO2", 872], ["and", 876], ["in", 880], ["vivo", 883], [",", 887], ["AtxA", 889], ["is", 894], ["part", 897], ["of", 902], ["the", 905], ["sap", 909], ["and", 913], ["eag", 917], ["regulatory", 921], ["network", 932], [".", 939], ["Only", 941], ["eag", 946], ["is", 950], ["significantly", 953], ["expressed", 967], ["in", 977], ["these", 980], ["conditions", 986], ["and", 997], ["this", 1001], ["is", 1006], ["due", 1009], ["to", 1013], ["AtxA", 1016], ["activating", 1021], ["eag", 1032], ["and", 1036], ["repressing", 1040], ["sap", 1051], ["transcription", 1055], [".", 1068], ["PagR", 1070], [",", 1074], ["and", 1076], ["not", 1080], ["AtxA", 1084], ["itself", 1089], [",", 1095], ["is", 1097], ["the", 1100], ["direct", 1104], ["effector", 1111], ["of", 1120], ["this", 1123], ["regulation", 1128], ["by", 1139], ["binding", 1142], ["to", 1150], ["sap", 1153], ["and", 1157], ["eag", 1161], ["promoter", 1165], ["regions", 1174], [".", 1181], ["Therefore", 1183], [",", 1192], ["PagR", 1194], ["mediates", 1199], ["the", 1208], ["effect", 1212], ["of", 1219], ["AtxA", 1222], ["on", 1227], ["eag", 1230], ["and", 1234], ["sap", 1238], ["and", 1242], ["is", 1246], ["the", 1249], ["most", 1253], ["downstream", 1258], ["element", 1269], ["of", 1277], ["a", 1280], ["signalling", 1282], ["cascade", 1293], ["initiated", 1301], ["by", 1311], ["AtxA.", 1314], ["Taken", 1320], ["together", 1326], [",", 1334], ["these", 1336], ["results", 1342], ["indicate", 1350], ["that", 1359], ["the", 1364], ["B.", 1368], ["anthracis", 1371], ["transcriptional", 1381], ["regulator", 1397], ["AtxA", 1407], ["is", 1412], ["controlling", 1415], ["the", 1427], ["synthesis", 1431], ["of", 1441], ["the", 1444], ["three", 1448], ["toxin", 1454], ["components", 1460], ["and", 1471], ["of", 1475], ["the", 1478], ["surface", 1482], ["elements", 1490], ["(", 1499], ["capsule", 1500], ["and", 1508], ["S", 1512], ["-", 1513], ["layer", 1514], [")", 1519], [".", 1520], ["Thus", 1522], [",", 1526], ["AtxA", 1528], ["is", 1533], ["a", 1536], ["master", 1538], ["regulator", 1545], ["that", 1555], ["coordinates", 1560], ["the", 1572], ["response", 1576], ["to", 1585], ["host", 1588], ["signals", 1593], ["by", 1601], ["orchestrating", 1604], ["positive", 1618], ["and", 1627], ["negative", 1631], ["controls", 1640], ["over", 1649], ["genes", 1654], ["located", 1660], ["on", 1668], ["all", 1671], ["genetic", 1675], ["elements", 1683], [".", 1691]]}
{"context": "Vanoxerine has been in clinical trials for Parkinsonism, depression and cocaine addiction but lacked efficacy. Although a potent blocker of hERG, it produced no serious adverse events. We attributed the unexpected result to offsetting Multiple Ion Channel Effects (MICE). Vanoxerine's effects were strongly frequency-dependent and we repositioned it for treatment of atrial fibrillation and flutter. Vanoxerine terminated AF/AFL in an animal model and a dose-ranging clinical trial. Reversion to normal rhythm was associated with QT prolongation yet absent proarrhythmia markers for Torsade de Pointes (TdP). To understand the QT/TdP discordance, we used quantitative profiling and compared vanoxerine with dofetilide, a selective hERG-blocking torsadogen used for intractable AF, verapamil, a non-torsadogenic MICE comparator and bepridil, a torsadogenic MICE comparator. At clinically relevant concentrations, verapamil blocked hCav1.2 and hERG, as did vanoxerine and bepridil both of which also blocked hNav1.5. In acute experiments and simulations, dofetilide produced early after depolarizations (EADs) and arrhythmias, whereas verapamil, vanoxerine and bepridil produced no proarrhythmia markers. Of the MICE drugs only bepridil inhibited hERG trafficking following overnight exposure. The results are consistent with the emphasis on MICE of the CiPA assay. Additionally we propose that trafficking inhibition of hERG be added to CiPA.", "qas": [{"question": "What alternate indication has Vanoxerine been repositioned for?", "answers": ["atrial fibrillation and flutter"], "qid": "1a4946e6636c4ab3a37f421bb4397409", "question_tokens": [["What", 0], ["alternate", 5], ["indication", 15], ["has", 26], ["Vanoxerine", 30], ["been", 41], ["repositioned", 46], ["for", 59], ["?", 62]], "detected_answers": [{"text": "atrial fibrillation and flutter", "token_spans": [[61, 64]], "char_spans": [[367, 397]]}]}], "context_tokens": [["Vanoxerine", 0], ["has", 11], ["been", 15], ["in", 20], ["clinical", 23], ["trials", 32], ["for", 39], ["Parkinsonism", 43], [",", 55], ["depression", 57], ["and", 68], ["cocaine", 72], ["addiction", 80], ["but", 90], ["lacked", 94], ["efficacy", 101], [".", 109], ["Although", 111], ["a", 120], ["potent", 122], ["blocker", 129], ["of", 137], ["hERG", 140], [",", 144], ["it", 146], ["produced", 149], ["no", 158], ["serious", 161], ["adverse", 169], ["events", 177], [".", 183], ["We", 185], ["attributed", 188], ["the", 199], ["unexpected", 203], ["result", 214], ["to", 221], ["offsetting", 224], ["Multiple", 235], ["Ion", 244], ["Channel", 248], ["Effects", 256], ["(", 264], ["MICE", 265], [")", 269], [".", 270], ["Vanoxerine", 272], ["'s", 282], ["effects", 285], ["were", 293], ["strongly", 298], ["frequency", 307], ["-", 316], ["dependent", 317], ["and", 327], ["we", 331], ["repositioned", 334], ["it", 347], ["for", 350], ["treatment", 354], ["of", 364], ["atrial", 367], ["fibrillation", 374], ["and", 387], ["flutter", 391], [".", 398], ["Vanoxerine", 400], ["terminated", 411], ["AF", 422], ["/", 424], ["AFL", 425], ["in", 429], ["an", 432], ["animal", 435], ["model", 442], ["and", 448], ["a", 452], ["dose", 454], ["-", 458], ["ranging", 459], ["clinical", 467], ["trial", 476], [".", 481], ["Reversion", 483], ["to", 493], ["normal", 496], ["rhythm", 503], ["was", 510], ["associated", 514], ["with", 525], ["QT", 530], ["prolongation", 533], ["yet", 546], ["absent", 550], ["proarrhythmia", 557], ["markers", 571], ["for", 579], ["Torsade", 583], ["de", 591], ["Pointes", 594], ["(", 602], ["TdP", 603], [")", 606], [".", 607], ["To", 609], ["understand", 612], ["the", 623], ["QT", 627], ["/", 629], ["TdP", 630], ["discordance", 634], [",", 645], ["we", 647], ["used", 650], ["quantitative", 655], ["profiling", 668], ["and", 678], ["compared", 682], ["vanoxerine", 691], ["with", 702], ["dofetilide", 707], [",", 717], ["a", 719], ["selective", 721], ["hERG", 731], ["-", 735], ["blocking", 736], ["torsadogen", 745], ["used", 756], ["for", 761], ["intractable", 765], ["AF", 777], [",", 779], ["verapamil", 781], [",", 790], ["a", 792], ["non", 794], ["-", 797], ["torsadogenic", 798], ["MICE", 811], ["comparator", 816], ["and", 827], ["bepridil", 831], [",", 839], ["a", 841], ["torsadogenic", 843], ["MICE", 856], ["comparator", 861], [".", 871], ["At", 873], ["clinically", 876], ["relevant", 887], ["concentrations", 896], [",", 910], ["verapamil", 912], ["blocked", 922], ["hCav1.2", 930], ["and", 938], ["hERG", 942], [",", 946], ["as", 948], ["did", 951], ["vanoxerine", 955], ["and", 966], ["bepridil", 970], ["both", 979], ["of", 984], ["which", 987], ["also", 993], ["blocked", 998], ["hNav1.5", 1006], [".", 1013], ["In", 1015], ["acute", 1018], ["experiments", 1024], ["and", 1036], ["simulations", 1040], [",", 1051], ["dofetilide", 1053], ["produced", 1064], ["early", 1073], ["after", 1079], ["depolarizations", 1085], ["(", 1101], ["EADs", 1102], [")", 1106], ["and", 1108], ["arrhythmias", 1112], [",", 1123], ["whereas", 1125], ["verapamil", 1133], [",", 1142], ["vanoxerine", 1144], ["and", 1155], ["bepridil", 1159], ["produced", 1168], ["no", 1177], ["proarrhythmia", 1180], ["markers", 1194], [".", 1201], ["Of", 1203], ["the", 1206], ["MICE", 1210], ["drugs", 1215], ["only", 1221], ["bepridil", 1226], ["inhibited", 1235], ["hERG", 1245], ["trafficking", 1250], ["following", 1262], ["overnight", 1272], ["exposure", 1282], [".", 1290], ["The", 1292], ["results", 1296], ["are", 1304], ["consistent", 1308], ["with", 1319], ["the", 1324], ["emphasis", 1328], ["on", 1337], ["MICE", 1340], ["of", 1345], ["the", 1348], ["CiPA", 1352], ["assay", 1357], [".", 1362], ["Additionally", 1364], ["we", 1377], ["propose", 1380], ["that", 1388], ["trafficking", 1393], ["inhibition", 1405], ["of", 1416], ["hERG", 1419], ["be", 1424], ["added", 1427], ["to", 1433], ["CiPA", 1436], [".", 1440]]}
{"context": "Prostate cancer is the most common cancer in men in Europe and the United             States, and the third leading cause of death from cancer in Europe. Survival of             prostate cancer cells is dependent on the activation of androgen receptors (AR),             that are overexpressed in this tumor. Furthermore, ~90% of prostate cancer patients             that respond to first-line androgen deprivation therapy (ADT) undergo rapid progression.             This condition is defined as castration-resistant prostate cancer (CRPC). Docetaxel-based             regimens significantly improve overall survival (OS) in patients with CRPC and             represent the only treatment strategy approved by the Food and Drug Administration             (FDA). Recently, abiraterone (second hormonal therapy) and cabazitaxel (new taxane)             have been shown to improve survival in patients with CRPC who progressed following             docetaxel-based chemotherapy. Vaccine therapy has also been demonstrated to improve             OS in patients with asymptomatic or minimally symptomatic metastatic CRPC. Additional             therapeutic targets have been analyzed in prostate cancer, including apoptosis,             angiogenic receptors, vitamin D and Src pathways. Several phase II studies are             ongoing. The high frequency of prostate cancer-related metastatic bone disease             has led to consider this pathway as a therapeutic target. To this end, several             bone-targeted agents have been investigated, most notably zoledronic acid, which             is highly effective at stabilizing the bone and preventing skeletal complications.             More recently, a nuclear factor-\u03b2 ligand (RANKL) inhibitor, denosumab, has been             developed for the treatment of bone metastases.", "qas": [{"question": "To the ligand of which receptors does Denosumab (Prolia) bind?", "answers": ["RANKL"], "qid": "db3d5700fb404c9d9b22de58652e441b", "question_tokens": [["To", 0], ["the", 3], ["ligand", 7], ["of", 14], ["which", 17], ["receptors", 23], ["does", 33], ["Denosumab", 38], ["(", 48], ["Prolia", 49], [")", 55], ["bind", 57], ["?", 61]], "detected_answers": [{"text": "RANKL", "token_spans": [[265, 265]], "char_spans": [[1736, 1740]]}]}], "context_tokens": [["Prostate", 0], ["cancer", 9], ["is", 16], ["the", 19], ["most", 23], ["common", 28], ["cancer", 35], ["in", 42], ["men", 45], ["in", 49], ["Europe", 52], ["and", 59], ["the", 63], ["United", 67], ["States", 86], [",", 92], ["and", 94], ["the", 98], ["third", 102], ["leading", 108], ["cause", 116], ["of", 122], ["death", 125], ["from", 131], ["cancer", 136], ["in", 143], ["Europe", 146], [".", 152], ["Survival", 154], ["of", 163], ["prostate", 178], ["cancer", 187], ["cells", 194], ["is", 200], ["dependent", 203], ["on", 213], ["the", 216], ["activation", 220], ["of", 231], ["androgen", 234], ["receptors", 243], ["(", 253], ["AR", 254], [")", 256], [",", 257], ["that", 271], ["are", 276], ["overexpressed", 280], ["in", 294], ["this", 297], ["tumor", 302], [".", 307], ["Furthermore", 309], [",", 320], ["~90", 322], ["%", 325], ["of", 327], ["prostate", 330], ["cancer", 339], ["patients", 346], ["that", 367], ["respond", 372], ["to", 380], ["first", 383], ["-", 388], ["line", 389], ["androgen", 394], ["deprivation", 403], ["therapy", 415], ["(", 423], ["ADT", 424], [")", 427], ["undergo", 429], ["rapid", 437], ["progression", 443], [".", 454], ["This", 468], ["condition", 473], ["is", 483], ["defined", 486], ["as", 494], ["castration", 497], ["-", 507], ["resistant", 508], ["prostate", 518], ["cancer", 527], ["(", 534], ["CRPC", 535], [")", 539], [".", 540], ["Docetaxel", 542], ["-", 551], ["based", 552], ["regimens", 570], ["significantly", 579], ["improve", 593], ["overall", 601], ["survival", 609], ["(", 618], ["OS", 619], [")", 621], ["in", 623], ["patients", 626], ["with", 635], ["CRPC", 640], ["and", 645], ["represent", 661], ["the", 671], ["only", 675], ["treatment", 680], ["strategy", 690], ["approved", 699], ["by", 708], ["the", 711], ["Food", 715], ["and", 720], ["Drug", 724], ["Administration", 729], ["(", 756], ["FDA", 757], [")", 760], [".", 761], ["Recently", 763], [",", 771], ["abiraterone", 773], ["(", 785], ["second", 786], ["hormonal", 793], ["therapy", 802], [")", 809], ["and", 811], ["cabazitaxel", 815], ["(", 827], ["new", 828], ["taxane", 832], [")", 838], ["have", 852], ["been", 857], ["shown", 862], ["to", 868], ["improve", 871], ["survival", 879], ["in", 888], ["patients", 891], ["with", 900], ["CRPC", 905], ["who", 910], ["progressed", 914], ["following", 925], ["docetaxel", 947], ["-", 956], ["based", 957], ["chemotherapy", 963], [".", 975], ["Vaccine", 977], ["therapy", 985], ["has", 993], ["also", 997], ["been", 1002], ["demonstrated", 1007], ["to", 1020], ["improve", 1023], ["OS", 1043], ["in", 1046], ["patients", 1049], ["with", 1058], ["asymptomatic", 1063], ["or", 1076], ["minimally", 1079], ["symptomatic", 1089], ["metastatic", 1101], ["CRPC", 1112], [".", 1116], ["Additional", 1118], ["therapeutic", 1141], ["targets", 1153], ["have", 1161], ["been", 1166], ["analyzed", 1171], ["in", 1180], ["prostate", 1183], ["cancer", 1192], [",", 1198], ["including", 1200], ["apoptosis", 1210], [",", 1219], ["angiogenic", 1233], ["receptors", 1244], [",", 1253], ["vitamin", 1255], ["D", 1263], ["and", 1265], ["Src", 1269], ["pathways", 1273], [".", 1281], ["Several", 1283], ["phase", 1291], ["II", 1297], ["studies", 1300], ["are", 1308], ["ongoing", 1324], [".", 1331], ["The", 1333], ["high", 1337], ["frequency", 1342], ["of", 1352], ["prostate", 1355], ["cancer", 1364], ["-", 1370], ["related", 1371], ["metastatic", 1379], ["bone", 1390], ["disease", 1395], ["has", 1415], ["led", 1419], ["to", 1423], ["consider", 1426], ["this", 1435], ["pathway", 1440], ["as", 1448], ["a", 1451], ["therapeutic", 1453], ["target", 1465], [".", 1471], ["To", 1473], ["this", 1476], ["end", 1481], [",", 1484], ["several", 1486], ["bone", 1506], ["-", 1510], ["targeted", 1511], ["agents", 1520], ["have", 1527], ["been", 1532], ["investigated", 1537], [",", 1549], ["most", 1551], ["notably", 1556], ["zoledronic", 1564], ["acid", 1575], [",", 1579], ["which", 1581], ["is", 1599], ["highly", 1602], ["effective", 1609], ["at", 1619], ["stabilizing", 1622], ["the", 1634], ["bone", 1638], ["and", 1643], ["preventing", 1647], ["skeletal", 1658], ["complications", 1667], [".", 1680], ["More", 1694], ["recently", 1699], [",", 1707], ["a", 1709], ["nuclear", 1711], ["factor", 1719], ["-", 1725], ["\u03b2", 1726], ["ligand", 1728], ["(", 1735], ["RANKL", 1736], [")", 1741], ["inhibitor", 1743], [",", 1752], ["denosumab", 1754], [",", 1763], ["has", 1765], ["been", 1769], ["developed", 1786], ["for", 1796], ["the", 1800], ["treatment", 1804], ["of", 1814], ["bone", 1817], ["metastases", 1822], [".", 1832]]}
{"context": "Mowat-Wilson syndrome (MWS) is a relatively newly described multiple congenital anomaly/mental retardation syndrome. Haploinsufficiency of a gene termed ZFHX1B (also known as SIP1) on chromosome 2 is responsible for this condition, and clinical genetic testing for MWS recently became available. The majority of reports in the literature originate from Northern Europe and Australia. Here we report our clinical experience with 12 patients diagnosed with MWS within a 2-year period of time in the United States, with particular emphasis on clinical characteristics and management strategies. Individuals with this condition have characteristic facial features, including microcephaly, hypertelorism, medially flared and broad eyebrows, prominent columella, pointed chin, and uplifted earlobes, which typically prompt the clinician to consider the diagnosis. Medical issues in our cohort of patients included seizures (75%) with no predeliction for any particular seizure type; agenesis of the corpus callosum (60% of our patients studied); congenital heart defects (75%), particularly involving the pulmonary arteries and/or valves; hypospadias (55% of males); severely impaired or absent speech (100% of individuals over 1 year of age) with relatively spared receptive language; and Hirschsprung disease (50%) or chronic constipation (25%). The incidence of MWS is unknown, but based on the number of patients identified in a short period of time within the US, it is likely greatly under recognized. MWS should be considered in any individual with severely impaired or absent speech, especially in the presence of seizures and anomalies involving the pulmonary arteries (particularly pulmonary artery sling) or pulmonary valves.", "qas": [{"question": "Which gene is responsible for the development of the Mowat-Wilson syndrome?", "answers": ["ZFHX1B", "ZEB2", "SIP-1"], "qid": "ba508f5b8dfb4fbc83ecf9831706b686", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["the", 49], ["Mowat", 53], ["-", 58], ["Wilson", 59], ["syndrome", 66], ["?", 74]], "detected_answers": [{"text": "ZFHX1B", "token_spans": [[25, 25]], "char_spans": [[153, 158]]}]}], "context_tokens": [["Mowat", 0], ["-", 5], ["Wilson", 6], ["syndrome", 13], ["(", 22], ["MWS", 23], [")", 26], ["is", 28], ["a", 31], ["relatively", 33], ["newly", 44], ["described", 50], ["multiple", 60], ["congenital", 69], ["anomaly", 80], ["/", 87], ["mental", 88], ["retardation", 95], ["syndrome", 107], [".", 115], ["Haploinsufficiency", 117], ["of", 136], ["a", 139], ["gene", 141], ["termed", 146], ["ZFHX1B", 153], ["(", 160], ["also", 161], ["known", 166], ["as", 172], ["SIP1", 175], [")", 179], ["on", 181], ["chromosome", 184], ["2", 195], ["is", 197], ["responsible", 200], ["for", 212], ["this", 216], ["condition", 221], [",", 230], ["and", 232], ["clinical", 236], ["genetic", 245], ["testing", 253], ["for", 261], ["MWS", 265], ["recently", 269], ["became", 278], ["available", 285], [".", 294], ["The", 296], ["majority", 300], ["of", 309], ["reports", 312], ["in", 320], ["the", 323], ["literature", 327], ["originate", 338], ["from", 348], ["Northern", 353], ["Europe", 362], ["and", 369], ["Australia", 373], [".", 382], ["Here", 384], ["we", 389], ["report", 392], ["our", 399], ["clinical", 403], ["experience", 412], ["with", 423], ["12", 428], ["patients", 431], ["diagnosed", 440], ["with", 450], ["MWS", 455], ["within", 459], ["a", 466], ["2-year", 468], ["period", 475], ["of", 482], ["time", 485], ["in", 490], ["the", 493], ["United", 497], ["States", 504], [",", 510], ["with", 512], ["particular", 517], ["emphasis", 528], ["on", 537], ["clinical", 540], ["characteristics", 549], ["and", 565], ["management", 569], ["strategies", 580], [".", 590], ["Individuals", 592], ["with", 604], ["this", 609], ["condition", 614], ["have", 624], ["characteristic", 629], ["facial", 644], ["features", 651], [",", 659], ["including", 661], ["microcephaly", 671], [",", 683], ["hypertelorism", 685], [",", 698], ["medially", 700], ["flared", 709], ["and", 716], ["broad", 720], ["eyebrows", 726], [",", 734], ["prominent", 736], ["columella", 746], [",", 755], ["pointed", 757], ["chin", 765], [",", 769], ["and", 771], ["uplifted", 775], ["earlobes", 784], [",", 792], ["which", 794], ["typically", 800], ["prompt", 810], ["the", 817], ["clinician", 821], ["to", 831], ["consider", 834], ["the", 843], ["diagnosis", 847], [".", 856], ["Medical", 858], ["issues", 866], ["in", 873], ["our", 876], ["cohort", 880], ["of", 887], ["patients", 890], ["included", 899], ["seizures", 908], ["(", 917], ["75", 918], ["%", 920], [")", 921], ["with", 923], ["no", 928], ["predeliction", 931], ["for", 944], ["any", 948], ["particular", 952], ["seizure", 963], ["type", 971], [";", 975], ["agenesis", 977], ["of", 986], ["the", 989], ["corpus", 993], ["callosum", 1000], ["(", 1009], ["60", 1010], ["%", 1012], ["of", 1014], ["our", 1017], ["patients", 1021], ["studied", 1030], [")", 1037], [";", 1038], ["congenital", 1040], ["heart", 1051], ["defects", 1057], ["(", 1065], ["75", 1066], ["%", 1068], [")", 1069], [",", 1070], ["particularly", 1072], ["involving", 1085], ["the", 1095], ["pulmonary", 1099], ["arteries", 1109], ["and/or", 1118], ["valves", 1125], [";", 1131], ["hypospadias", 1133], ["(", 1145], ["55", 1146], ["%", 1148], ["of", 1150], ["males", 1153], [")", 1158], [";", 1159], ["severely", 1161], ["impaired", 1170], ["or", 1179], ["absent", 1182], ["speech", 1189], ["(", 1196], ["100", 1197], ["%", 1200], ["of", 1202], ["individuals", 1205], ["over", 1217], ["1", 1222], ["year", 1224], ["of", 1229], ["age", 1232], [")", 1235], ["with", 1237], ["relatively", 1242], ["spared", 1253], ["receptive", 1260], ["language", 1270], [";", 1278], ["and", 1280], ["Hirschsprung", 1284], ["disease", 1297], ["(", 1305], ["50", 1306], ["%", 1308], [")", 1309], ["or", 1311], ["chronic", 1314], ["constipation", 1322], ["(", 1335], ["25", 1336], ["%", 1338], [")", 1339], [".", 1340], ["The", 1342], ["incidence", 1346], ["of", 1356], ["MWS", 1359], ["is", 1363], ["unknown", 1366], [",", 1373], ["but", 1375], ["based", 1379], ["on", 1385], ["the", 1388], ["number", 1392], ["of", 1399], ["patients", 1402], ["identified", 1411], ["in", 1422], ["a", 1425], ["short", 1427], ["period", 1433], ["of", 1440], ["time", 1443], ["within", 1448], ["the", 1455], ["US", 1459], [",", 1461], ["it", 1463], ["is", 1466], ["likely", 1469], ["greatly", 1476], ["under", 1484], ["recognized", 1490], [".", 1500], ["MWS", 1502], ["should", 1506], ["be", 1513], ["considered", 1516], ["in", 1527], ["any", 1530], ["individual", 1534], ["with", 1545], ["severely", 1550], ["impaired", 1559], ["or", 1568], ["absent", 1571], ["speech", 1578], [",", 1584], ["especially", 1586], ["in", 1597], ["the", 1600], ["presence", 1604], ["of", 1613], ["seizures", 1616], ["and", 1625], ["anomalies", 1629], ["involving", 1639], ["the", 1649], ["pulmonary", 1653], ["arteries", 1663], ["(", 1672], ["particularly", 1673], ["pulmonary", 1686], ["artery", 1696], ["sling", 1703], [")", 1708], ["or", 1710], ["pulmonary", 1713], ["valves", 1723], [".", 1729]]}
{"context": "Long QT and short QT syndromes (LQTS and SQTS) are cardiac repolarization abnormalities that are characterized by length perturbations of the QT interval as measured on electrocardiogram (ECG). Prolonged QT interval and a propensity for ventricular tachycardia of the torsades de pointes (TdP) type are characteristic of LQTS, while SQTS is characterized by shortened QT interval with tall peaked T-waves and a propensity for atrial fibrillation. Both syndromes represent a high risk for syncope and sudden death. LQTS exists as a congenital genetic disease (cLQTS) with more than 700 mutations described in 12 genes (LQT1-12), but can also be acquired (aLQTS). The genetic forms of LQTS include Romano-Ward syndrome (RWS), which is characterized by isolated LQTS and an autosomal dominant pattern of inheritance, and syndromes with LQTS in association with other conditions. The latter includes Jervell and Lange-Nielsen syndrome (JLNS), Andersen syndrome (AS), and Timothy syndrome (TS). The genetics are further complicated by the occurrence of double and triple heterozygotes in LQTS and a considerable number of nonpathogenic rare polymorphisms in the involved genes. SQTS is a very rare condition, caused by mutations in five genes (SQTS1-5). The present mutation update is a comprehensive description of all known LQTS- and SQTS-associated mutations.", "qas": [{"question": "What is the mode of inheritance of Romano Ward long QT syndrome?", "answers": ["autosomal dominant"], "qid": "857f5bd2ba3140ffa45bbf468805dfa3", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Romano", 35], ["Ward", 42], ["long", 47], ["QT", 52], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[145, 146]], "char_spans": [[771, 788]]}]}], "context_tokens": [["Long", 0], ["QT", 5], ["and", 8], ["short", 12], ["QT", 18], ["syndromes", 21], ["(", 31], ["LQTS", 32], ["and", 37], ["SQTS", 41], [")", 45], ["are", 47], ["cardiac", 51], ["repolarization", 59], ["abnormalities", 74], ["that", 88], ["are", 93], ["characterized", 97], ["by", 111], ["length", 114], ["perturbations", 121], ["of", 135], ["the", 138], ["QT", 142], ["interval", 145], ["as", 154], ["measured", 157], ["on", 166], ["electrocardiogram", 169], ["(", 187], ["ECG", 188], [")", 191], [".", 192], ["Prolonged", 194], ["QT", 204], ["interval", 207], ["and", 216], ["a", 220], ["propensity", 222], ["for", 233], ["ventricular", 237], ["tachycardia", 249], ["of", 261], ["the", 264], ["torsades", 268], ["de", 277], ["pointes", 280], ["(", 288], ["TdP", 289], [")", 292], ["type", 294], ["are", 299], ["characteristic", 303], ["of", 318], ["LQTS", 321], [",", 325], ["while", 327], ["SQTS", 333], ["is", 338], ["characterized", 341], ["by", 355], ["shortened", 358], ["QT", 368], ["interval", 371], ["with", 380], ["tall", 385], ["peaked", 390], ["T", 397], ["-", 398], ["waves", 399], ["and", 405], ["a", 409], ["propensity", 411], ["for", 422], ["atrial", 426], ["fibrillation", 433], [".", 445], ["Both", 447], ["syndromes", 452], ["represent", 462], ["a", 472], ["high", 474], ["risk", 479], ["for", 484], ["syncope", 488], ["and", 496], ["sudden", 500], ["death", 507], [".", 512], ["LQTS", 514], ["exists", 519], ["as", 526], ["a", 529], ["congenital", 531], ["genetic", 542], ["disease", 550], ["(", 558], ["cLQTS", 559], [")", 564], ["with", 566], ["more", 571], ["than", 576], ["700", 581], ["mutations", 585], ["described", 595], ["in", 605], ["12", 608], ["genes", 611], ["(", 617], ["LQT1", 618], ["-", 622], ["12", 623], [")", 625], [",", 626], ["but", 628], ["can", 632], ["also", 636], ["be", 641], ["acquired", 644], ["(", 653], ["aLQTS", 654], [")", 659], [".", 660], ["The", 662], ["genetic", 666], ["forms", 674], ["of", 680], ["LQTS", 683], ["include", 688], ["Romano", 696], ["-", 702], ["Ward", 703], ["syndrome", 708], ["(", 717], ["RWS", 718], [")", 721], [",", 722], ["which", 724], ["is", 730], ["characterized", 733], ["by", 747], ["isolated", 750], ["LQTS", 759], ["and", 764], ["an", 768], ["autosomal", 771], ["dominant", 781], ["pattern", 790], ["of", 798], ["inheritance", 801], [",", 812], ["and", 814], ["syndromes", 818], ["with", 828], ["LQTS", 833], ["in", 838], ["association", 841], ["with", 853], ["other", 858], ["conditions", 864], [".", 874], ["The", 876], ["latter", 880], ["includes", 887], ["Jervell", 896], ["and", 904], ["Lange", 908], ["-", 913], ["Nielsen", 914], ["syndrome", 922], ["(", 931], ["JLNS", 932], [")", 936], [",", 937], ["Andersen", 939], ["syndrome", 948], ["(", 957], ["AS", 958], [")", 960], [",", 961], ["and", 963], ["Timothy", 967], ["syndrome", 975], ["(", 984], ["TS", 985], [")", 987], [".", 988], ["The", 990], ["genetics", 994], ["are", 1003], ["further", 1007], ["complicated", 1015], ["by", 1027], ["the", 1030], ["occurrence", 1034], ["of", 1045], ["double", 1048], ["and", 1055], ["triple", 1059], ["heterozygotes", 1066], ["in", 1080], ["LQTS", 1083], ["and", 1088], ["a", 1092], ["considerable", 1094], ["number", 1107], ["of", 1114], ["nonpathogenic", 1117], ["rare", 1131], ["polymorphisms", 1136], ["in", 1150], ["the", 1153], ["involved", 1157], ["genes", 1166], [".", 1171], ["SQTS", 1173], ["is", 1178], ["a", 1181], ["very", 1183], ["rare", 1188], ["condition", 1193], [",", 1202], ["caused", 1204], ["by", 1211], ["mutations", 1214], ["in", 1224], ["five", 1227], ["genes", 1232], ["(", 1238], ["SQTS1", 1239], ["-", 1244], ["5", 1245], [")", 1246], [".", 1247], ["The", 1249], ["present", 1253], ["mutation", 1261], ["update", 1270], ["is", 1277], ["a", 1280], ["comprehensive", 1282], ["description", 1296], ["of", 1308], ["all", 1311], ["known", 1315], ["LQTS-", 1321], ["and", 1327], ["SQTS", 1331], ["-", 1335], ["associated", 1336], ["mutations", 1347], [".", 1356]]}
{"context": "Turner syndrome is a genetic disorder caused by the complete or partial absence of an X chromosome in affected women. Individuals with TS show characteristic difficulties with executive functions, visual-spatial and mathematical cognition, with relatively intact verbal skills, and congruent abnormalities in structural development of the posterior parietal cortex (PPC). The functionally heterogeneous PPC has recently been investigated using connectivity-based clustering methods, which sub-divide a given region into clusters of voxels showing similar structural or functional connectivity to other brain regions. In the present study, we extended this method to compare connectivity-based clustering between groups and investigate whether functional networks differentially recruit the PPC in TS. To this end, we parcellated the PPC into sub-regions based on temporal correlations with other regions of the brain. fMRI data were collected from 15 girls with TS and 14 typically developing (TD) girls, aged 7-14, while they performed a visual-spatial task. Temporal correlations between voxels in the PPC and a set of seed regions were calculated, and the PPC divided into clusters of voxels showing similar connectivity. It was found that in general the PPC parcellates similarly in TS and TD girls, but that regions in bilateral inferior parietal lobules, and posterior right superior parietal lobule, were reliably recruited by different networks in TS relative to TD participants. These regions showed weaker correlation in TS with a set of regions involved in visual processing. These results suggest that abnormal development of visuospatial functional networks in TS may relate to the well documented cognitive difficulties in this disorder.", "qas": [{"question": "What chromosome is affected in Turner's syndrome?", "answers": ["X"], "qid": "9aae75f96acc4b5ba4f5bc32a39f1e8f", "question_tokens": [["What", 0], ["chromosome", 5], ["is", 16], ["affected", 19], ["in", 28], ["Turner", 31], ["'s", 37], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "X", "token_spans": [[15, 15]], "char_spans": [[86, 86]]}]}], "context_tokens": [["Turner", 0], ["syndrome", 7], ["is", 16], ["a", 19], ["genetic", 21], ["disorder", 29], ["caused", 38], ["by", 45], ["the", 48], ["complete", 52], ["or", 61], ["partial", 64], ["absence", 72], ["of", 80], ["an", 83], ["X", 86], ["chromosome", 88], ["in", 99], ["affected", 102], ["women", 111], [".", 116], ["Individuals", 118], ["with", 130], ["TS", 135], ["show", 138], ["characteristic", 143], ["difficulties", 158], ["with", 171], ["executive", 176], ["functions", 186], [",", 195], ["visual", 197], ["-", 203], ["spatial", 204], ["and", 212], ["mathematical", 216], ["cognition", 229], [",", 238], ["with", 240], ["relatively", 245], ["intact", 256], ["verbal", 263], ["skills", 270], [",", 276], ["and", 278], ["congruent", 282], ["abnormalities", 292], ["in", 306], ["structural", 309], ["development", 320], ["of", 332], ["the", 335], ["posterior", 339], ["parietal", 349], ["cortex", 358], ["(", 365], ["PPC", 366], [")", 369], [".", 370], ["The", 372], ["functionally", 376], ["heterogeneous", 389], ["PPC", 403], ["has", 407], ["recently", 411], ["been", 420], ["investigated", 425], ["using", 438], ["connectivity", 444], ["-", 456], ["based", 457], ["clustering", 463], ["methods", 474], [",", 481], ["which", 483], ["sub", 489], ["-", 492], ["divide", 493], ["a", 500], ["given", 502], ["region", 508], ["into", 515], ["clusters", 520], ["of", 529], ["voxels", 532], ["showing", 539], ["similar", 547], ["structural", 555], ["or", 566], ["functional", 569], ["connectivity", 580], ["to", 593], ["other", 596], ["brain", 602], ["regions", 608], [".", 615], ["In", 617], ["the", 620], ["present", 624], ["study", 632], [",", 637], ["we", 639], ["extended", 642], ["this", 651], ["method", 656], ["to", 663], ["compare", 666], ["connectivity", 674], ["-", 686], ["based", 687], ["clustering", 693], ["between", 704], ["groups", 712], ["and", 719], ["investigate", 723], ["whether", 735], ["functional", 743], ["networks", 754], ["differentially", 763], ["recruit", 778], ["the", 786], ["PPC", 790], ["in", 794], ["TS", 797], [".", 799], ["To", 801], ["this", 804], ["end", 809], [",", 812], ["we", 814], ["parcellated", 817], ["the", 829], ["PPC", 833], ["into", 837], ["sub", 842], ["-", 845], ["regions", 846], ["based", 854], ["on", 860], ["temporal", 863], ["correlations", 872], ["with", 885], ["other", 890], ["regions", 896], ["of", 904], ["the", 907], ["brain", 911], [".", 916], ["fMRI", 918], ["data", 923], ["were", 928], ["collected", 933], ["from", 943], ["15", 948], ["girls", 951], ["with", 957], ["TS", 962], ["and", 965], ["14", 969], ["typically", 972], ["developing", 982], ["(", 993], ["TD", 994], [")", 996], ["girls", 998], [",", 1003], ["aged", 1005], ["7", 1010], ["-", 1011], ["14", 1012], [",", 1014], ["while", 1016], ["they", 1022], ["performed", 1027], ["a", 1037], ["visual", 1039], ["-", 1045], ["spatial", 1046], ["task", 1054], [".", 1058], ["Temporal", 1060], ["correlations", 1069], ["between", 1082], ["voxels", 1090], ["in", 1097], ["the", 1100], ["PPC", 1104], ["and", 1108], ["a", 1112], ["set", 1114], ["of", 1118], ["seed", 1121], ["regions", 1126], ["were", 1134], ["calculated", 1139], [",", 1149], ["and", 1151], ["the", 1155], ["PPC", 1159], ["divided", 1163], ["into", 1171], ["clusters", 1176], ["of", 1185], ["voxels", 1188], ["showing", 1195], ["similar", 1203], ["connectivity", 1211], [".", 1223], ["It", 1225], ["was", 1228], ["found", 1232], ["that", 1238], ["in", 1243], ["general", 1246], ["the", 1254], ["PPC", 1258], ["parcellates", 1262], ["similarly", 1274], ["in", 1284], ["TS", 1287], ["and", 1290], ["TD", 1294], ["girls", 1297], [",", 1302], ["but", 1304], ["that", 1308], ["regions", 1313], ["in", 1321], ["bilateral", 1324], ["inferior", 1334], ["parietal", 1343], ["lobules", 1352], [",", 1359], ["and", 1361], ["posterior", 1365], ["right", 1375], ["superior", 1381], ["parietal", 1390], ["lobule", 1399], [",", 1405], ["were", 1407], ["reliably", 1412], ["recruited", 1421], ["by", 1431], ["different", 1434], ["networks", 1444], ["in", 1453], ["TS", 1456], ["relative", 1459], ["to", 1468], ["TD", 1471], ["participants", 1474], [".", 1486], ["These", 1488], ["regions", 1494], ["showed", 1502], ["weaker", 1509], ["correlation", 1516], ["in", 1528], ["TS", 1531], ["with", 1534], ["a", 1539], ["set", 1541], ["of", 1545], ["regions", 1548], ["involved", 1556], ["in", 1565], ["visual", 1568], ["processing", 1575], [".", 1585], ["These", 1587], ["results", 1593], ["suggest", 1601], ["that", 1609], ["abnormal", 1614], ["development", 1623], ["of", 1635], ["visuospatial", 1638], ["functional", 1651], ["networks", 1662], ["in", 1671], ["TS", 1674], ["may", 1677], ["relate", 1681], ["to", 1688], ["the", 1691], ["well", 1695], ["documented", 1700], ["cognitive", 1711], ["difficulties", 1721], ["in", 1734], ["this", 1737], ["disorder", 1742], [".", 1750]]}
{"context": "Reactive oxygen species (ROS) production by NADPH oxidase 1 (NOX1), which is mainly expressed in colon epithelial cells, requires the membrane-bound component p22(PHOX) and the cytosolic partners NOX organizer 1 (NOXO1), NOX activator 1 (NOXA1), and Rac1. Contrary to that of its phagocyte counterpart NOX2, the molecular basis of NOX1 regulation is not clear. Because NOXO1 lacks the phosphorylated region found in its homolog p47(PHOX), the current view is that NOX1 activation occurs without NOXO1 phosphorylation. Here, however, we demonstrate that phorbol myristate acetate (PMA) stimulates NOXO1 phosphorylation in a transfected human embryonic kidney (HEK) 293 epithelial cell model via protein kinase C and identify Ser-154 as the major phosphorylated site. Endogenous NOXO1 from T84 colon epithelial cells was also phosphorylated, suggesting that NOXO1 phosphorylation is physiologically relevant. In transfected HEK-293 cells, PMA-induced phosphorylation on Ser-154 enhanced NOXO1 binding to NOXA1 (+97%) and to the p22(PHOX) C-terminal region (+384%), increased NOXO1 colocalization with p22(PHOX), and allowed optimal ROS production by NOX1 as demonstrated by the use of S154A and S154D mutants compared with that by wild-type NOXO1 (P<0.05). Pulldown experiments revealed that phos-phorylation on Ser-154 was sufficient to markedly enhance NOXO1 binding to NOXA1, which in turn acts as a molecular switch, allowing optimal interaction of NOXO1 with p22(PHOX). This study unexpectedly revealed that full assembly and activation of NOX1 is a tightly regulated process in which NOXO1 phosphorylation on Ser-154 is the initial trigger.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "ce8e78ef06ed459386b6f776879b5c3c", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NADPH oxidase 1", "token_spans": [[8, 10]], "char_spans": [[44, 58]]}, {"text": "NOX1", "token_spans": [[275, 275], [205, 205], [90, 90], [12, 12], [66, 66]], "char_spans": [[1543, 1546], [1148, 1151], [464, 467], [61, 64], [331, 334]]}]}], "context_tokens": [["Reactive", 0], ["oxygen", 9], ["species", 16], ["(", 24], ["ROS", 25], [")", 28], ["production", 30], ["by", 41], ["NADPH", 44], ["oxidase", 50], ["1", 58], ["(", 60], ["NOX1", 61], [")", 65], [",", 66], ["which", 68], ["is", 74], ["mainly", 77], ["expressed", 84], ["in", 94], ["colon", 97], ["epithelial", 103], ["cells", 114], [",", 119], ["requires", 121], ["the", 130], ["membrane", 134], ["-", 142], ["bound", 143], ["component", 149], ["p22(PHOX", 159], [")", 167], ["and", 169], ["the", 173], ["cytosolic", 177], ["partners", 187], ["NOX", 196], ["organizer", 200], ["1", 210], ["(", 212], ["NOXO1", 213], [")", 218], [",", 219], ["NOX", 221], ["activator", 225], ["1", 235], ["(", 237], ["NOXA1", 238], [")", 243], [",", 244], ["and", 246], ["Rac1", 250], [".", 254], ["Contrary", 256], ["to", 265], ["that", 268], ["of", 273], ["its", 276], ["phagocyte", 280], ["counterpart", 290], ["NOX2", 302], [",", 306], ["the", 308], ["molecular", 312], ["basis", 322], ["of", 328], ["NOX1", 331], ["regulation", 336], ["is", 347], ["not", 350], ["clear", 354], [".", 359], ["Because", 361], ["NOXO1", 369], ["lacks", 375], ["the", 381], ["phosphorylated", 385], ["region", 400], ["found", 407], ["in", 413], ["its", 416], ["homolog", 420], ["p47(PHOX", 428], [")", 436], [",", 437], ["the", 439], ["current", 443], ["view", 451], ["is", 456], ["that", 459], ["NOX1", 464], ["activation", 469], ["occurs", 480], ["without", 487], ["NOXO1", 495], ["phosphorylation", 501], [".", 516], ["Here", 518], [",", 522], ["however", 524], [",", 531], ["we", 533], ["demonstrate", 536], ["that", 548], ["phorbol", 553], ["myristate", 561], ["acetate", 571], ["(", 579], ["PMA", 580], [")", 583], ["stimulates", 585], ["NOXO1", 596], ["phosphorylation", 602], ["in", 618], ["a", 621], ["transfected", 623], ["human", 635], ["embryonic", 641], ["kidney", 651], ["(", 658], ["HEK", 659], [")", 662], ["293", 664], ["epithelial", 668], ["cell", 679], ["model", 684], ["via", 690], ["protein", 694], ["kinase", 702], ["C", 709], ["and", 711], ["identify", 715], ["Ser-154", 724], ["as", 732], ["the", 735], ["major", 739], ["phosphorylated", 745], ["site", 760], [".", 764], ["Endogenous", 766], ["NOXO1", 777], ["from", 783], ["T84", 788], ["colon", 792], ["epithelial", 798], ["cells", 809], ["was", 815], ["also", 819], ["phosphorylated", 824], [",", 838], ["suggesting", 840], ["that", 851], ["NOXO1", 856], ["phosphorylation", 862], ["is", 878], ["physiologically", 881], ["relevant", 897], [".", 905], ["In", 907], ["transfected", 910], ["HEK-293", 922], ["cells", 930], [",", 935], ["PMA", 937], ["-", 940], ["induced", 941], ["phosphorylation", 949], ["on", 965], ["Ser-154", 968], ["enhanced", 976], ["NOXO1", 985], ["binding", 991], ["to", 999], ["NOXA1", 1002], ["(", 1008], ["+97", 1009], ["%", 1012], [")", 1013], ["and", 1015], ["to", 1019], ["the", 1022], ["p22(PHOX", 1026], [")", 1034], ["C", 1036], ["-", 1037], ["terminal", 1038], ["region", 1047], ["(", 1054], ["+384", 1055], ["%", 1059], [")", 1060], [",", 1061], ["increased", 1063], ["NOXO1", 1073], ["colocalization", 1079], ["with", 1094], ["p22(PHOX", 1099], [")", 1107], [",", 1108], ["and", 1110], ["allowed", 1114], ["optimal", 1122], ["ROS", 1130], ["production", 1134], ["by", 1145], ["NOX1", 1148], ["as", 1153], ["demonstrated", 1156], ["by", 1169], ["the", 1172], ["use", 1176], ["of", 1180], ["S154A", 1183], ["and", 1189], ["S154D", 1193], ["mutants", 1199], ["compared", 1207], ["with", 1216], ["that", 1221], ["by", 1226], ["wild", 1229], ["-", 1233], ["type", 1234], ["NOXO1", 1239], ["(", 1245], ["P<0.05", 1246], [")", 1252], [".", 1253], ["Pulldown", 1255], ["experiments", 1264], ["revealed", 1276], ["that", 1285], ["phos", 1290], ["-", 1294], ["phorylation", 1295], ["on", 1307], ["Ser-154", 1310], ["was", 1318], ["sufficient", 1322], ["to", 1333], ["markedly", 1336], ["enhance", 1345], ["NOXO1", 1353], ["binding", 1359], ["to", 1367], ["NOXA1", 1370], [",", 1375], ["which", 1377], ["in", 1383], ["turn", 1386], ["acts", 1391], ["as", 1396], ["a", 1399], ["molecular", 1401], ["switch", 1411], [",", 1417], ["allowing", 1419], ["optimal", 1428], ["interaction", 1436], ["of", 1448], ["NOXO1", 1451], ["with", 1457], ["p22(PHOX", 1462], [")", 1470], [".", 1471], ["This", 1473], ["study", 1478], ["unexpectedly", 1484], ["revealed", 1497], ["that", 1506], ["full", 1511], ["assembly", 1516], ["and", 1525], ["activation", 1529], ["of", 1540], ["NOX1", 1543], ["is", 1548], ["a", 1551], ["tightly", 1553], ["regulated", 1561], ["process", 1571], ["in", 1579], ["which", 1582], ["NOXO1", 1588], ["phosphorylation", 1594], ["on", 1610], ["Ser-154", 1613], ["is", 1621], ["the", 1624], ["initial", 1628], ["trigger", 1636], [".", 1643]]}
{"context": "Dapivirine, formerly known as TMC 120, is a poorly-water soluble anti-HIV drug, currently being developed as a vaginal microbicide. The clinical use of this drug has been limited due to its poor solubility. The aim of this study was to design solid dispersion systems of Dapivirine to improve its solubility. Solid dispersions were prepared by solvent and fusion methods. Dapivirine release from the solid dispersion system was determined by conducting in-vitro dissolution studies. The physicochemical characteristics of the drug and its formulation were studied using Differential Scanning Calorimetry (DSC), powder X-ray Diffraction (XRD), Fourier-transform Infrared Spectroscopy (FTIR) and Scanning Electron Microscopy (SEM). A significant improvement in drug dissolution rate was observed with the solid dispersion systems. XRD, SEM and DSC results indicated the transformation of pure Dapivirine which exists in crystalline form into an amorphous form in selected solid dispersion formulations. FTIR and HPLC analysis confirmed the absence of drug-excipient interactions. Solid dispersion systems can be used to improve the dissolution rate of Dapivirine. This improvement could be attributed to the reduction or absence of drug crystallinity, existence of drug particles in an amorphous form and improved wettability of the drug.", "qas": [{"question": "Which infection can be prevented with Dapivirine?", "answers": ["HIV"], "qid": "ac9d766d13164566b8388415dae6d5db", "question_tokens": [["Which", 0], ["infection", 6], ["can", 16], ["be", 20], ["prevented", 23], ["with", 33], ["Dapivirine", 38], ["?", 48]], "detected_answers": [{"text": "HIV", "token_spans": [[16, 16]], "char_spans": [[70, 72]]}]}], "context_tokens": [["Dapivirine", 0], [",", 10], ["formerly", 12], ["known", 21], ["as", 27], ["TMC", 30], ["120", 34], [",", 37], ["is", 39], ["a", 42], ["poorly", 44], ["-", 50], ["water", 51], ["soluble", 57], ["anti", 65], ["-", 69], ["HIV", 70], ["drug", 74], [",", 78], ["currently", 80], ["being", 90], ["developed", 96], ["as", 106], ["a", 109], ["vaginal", 111], ["microbicide", 119], [".", 130], ["The", 132], ["clinical", 136], ["use", 145], ["of", 149], ["this", 152], ["drug", 157], ["has", 162], ["been", 166], ["limited", 171], ["due", 179], ["to", 183], ["its", 186], ["poor", 190], ["solubility", 195], [".", 205], ["The", 207], ["aim", 211], ["of", 215], ["this", 218], ["study", 223], ["was", 229], ["to", 233], ["design", 236], ["solid", 243], ["dispersion", 249], ["systems", 260], ["of", 268], ["Dapivirine", 271], ["to", 282], ["improve", 285], ["its", 293], ["solubility", 297], [".", 307], ["Solid", 309], ["dispersions", 315], ["were", 327], ["prepared", 332], ["by", 341], ["solvent", 344], ["and", 352], ["fusion", 356], ["methods", 363], [".", 370], ["Dapivirine", 372], ["release", 383], ["from", 391], ["the", 396], ["solid", 400], ["dispersion", 406], ["system", 417], ["was", 424], ["determined", 428], ["by", 439], ["conducting", 442], ["in", 453], ["-", 455], ["vitro", 456], ["dissolution", 462], ["studies", 474], [".", 481], ["The", 483], ["physicochemical", 487], ["characteristics", 503], ["of", 519], ["the", 522], ["drug", 526], ["and", 531], ["its", 535], ["formulation", 539], ["were", 551], ["studied", 556], ["using", 564], ["Differential", 570], ["Scanning", 583], ["Calorimetry", 592], ["(", 604], ["DSC", 605], [")", 608], [",", 609], ["powder", 611], ["X", 618], ["-", 619], ["ray", 620], ["Diffraction", 624], ["(", 636], ["XRD", 637], [")", 640], [",", 641], ["Fourier", 643], ["-", 650], ["transform", 651], ["Infrared", 661], ["Spectroscopy", 670], ["(", 683], ["FTIR", 684], [")", 688], ["and", 690], ["Scanning", 694], ["Electron", 703], ["Microscopy", 712], ["(", 723], ["SEM", 724], [")", 727], [".", 728], ["A", 730], ["significant", 732], ["improvement", 744], ["in", 756], ["drug", 759], ["dissolution", 764], ["rate", 776], ["was", 781], ["observed", 785], ["with", 794], ["the", 799], ["solid", 803], ["dispersion", 809], ["systems", 820], [".", 827], ["XRD", 829], [",", 832], ["SEM", 834], ["and", 838], ["DSC", 842], ["results", 846], ["indicated", 854], ["the", 864], ["transformation", 868], ["of", 883], ["pure", 886], ["Dapivirine", 891], ["which", 902], ["exists", 908], ["in", 915], ["crystalline", 918], ["form", 930], ["into", 935], ["an", 940], ["amorphous", 943], ["form", 953], ["in", 958], ["selected", 961], ["solid", 970], ["dispersion", 976], ["formulations", 987], [".", 999], ["FTIR", 1001], ["and", 1006], ["HPLC", 1010], ["analysis", 1015], ["confirmed", 1024], ["the", 1034], ["absence", 1038], ["of", 1046], ["drug", 1049], ["-", 1053], ["excipient", 1054], ["interactions", 1064], [".", 1076], ["Solid", 1078], ["dispersion", 1084], ["systems", 1095], ["can", 1103], ["be", 1107], ["used", 1110], ["to", 1115], ["improve", 1118], ["the", 1126], ["dissolution", 1130], ["rate", 1142], ["of", 1147], ["Dapivirine", 1150], [".", 1160], ["This", 1162], ["improvement", 1167], ["could", 1179], ["be", 1185], ["attributed", 1188], ["to", 1199], ["the", 1202], ["reduction", 1206], ["or", 1216], ["absence", 1219], ["of", 1227], ["drug", 1230], ["crystallinity", 1235], [",", 1248], ["existence", 1250], ["of", 1260], ["drug", 1263], ["particles", 1268], ["in", 1278], ["an", 1281], ["amorphous", 1284], ["form", 1294], ["and", 1299], ["improved", 1303], ["wettability", 1312], ["of", 1324], ["the", 1327], ["drug", 1331], [".", 1335]]}
{"context": "Since reports that precursor cells in the adult subventricular zone (SVZ) contribute to regenerative neuro- and gliogenesis in CA1, we wondered whether a similar route of migration might also exist under physiological conditions. Permanent labeling of SVZ precursor cells with a lentiviral vector for green fluorescent protein did not reveal any migration from the SVZ into CA1 in the intact murine brain. However, in a nestin-GFP reporter mouse we found proliferating cells within the corpus callosum/alveus region expressing nestin and glial fibrillary acidic protein similar to precursor cells in the neighboring neurogenic region of the adult dentate gyrus. Within 3 weeks of BrdU administration, BrdU-positive nestin-GFP-expressing protoplasmic astrocytes emerged in CA1. Similar to precursor cells isolated from the dentate gyrus and the SVZ, nestin-GFP-expressing cells from corpus callosum/alveus were self-renewing and multipotent in vitro, whereas cells isolated from CA1 were not. Nestin-GFP-expressing cells in CA1 differentiated into postmitotic astrocytes characterized by S100beta expression. No new neurons were found in CA1. The number of nestin-GFP-expressing astrocytes in CA1 was increased by environmental enrichment. We conclude that astrogenesis in CA1 is influenced by environmental conditions. However, SVZ precursor cells do not contribute to physiological cellular plasticity in CA1.", "qas": [{"question": "Which intermediate filament (IF) protein can be used as a non-specific marker of the neuronal precursor cells of the subventricular zone?", "answers": ["Nestin"], "qid": "030fff89fcaf4f7a8d31056a6f48f949", "question_tokens": [["Which", 0], ["intermediate", 6], ["filament", 19], ["(", 28], ["IF", 29], [")", 31], ["protein", 33], ["can", 41], ["be", 45], ["used", 48], ["as", 53], ["a", 56], ["non", 58], ["-", 61], ["specific", 62], ["marker", 71], ["of", 78], ["the", 81], ["neuronal", 85], ["precursor", 94], ["cells", 104], ["of", 110], ["the", 113], ["subventricular", 117], ["zone", 132], ["?", 136]], "detected_answers": [{"text": "Nestin", "token_spans": [[171, 171], [119, 119], [71, 71], [199, 199], [88, 88], [143, 143]], "char_spans": [[992, 997], [715, 720], [420, 425], [1156, 1161], [527, 532], [849, 854]]}]}], "context_tokens": [["Since", 0], ["reports", 6], ["that", 14], ["precursor", 19], ["cells", 29], ["in", 35], ["the", 38], ["adult", 42], ["subventricular", 48], ["zone", 63], ["(", 68], ["SVZ", 69], [")", 72], ["contribute", 74], ["to", 85], ["regenerative", 88], ["neuro-", 101], ["and", 108], ["gliogenesis", 112], ["in", 124], ["CA1", 127], [",", 130], ["we", 132], ["wondered", 135], ["whether", 144], ["a", 152], ["similar", 154], ["route", 162], ["of", 168], ["migration", 171], ["might", 181], ["also", 187], ["exist", 192], ["under", 198], ["physiological", 204], ["conditions", 218], [".", 228], ["Permanent", 230], ["labeling", 240], ["of", 249], ["SVZ", 252], ["precursor", 256], ["cells", 266], ["with", 272], ["a", 277], ["lentiviral", 279], ["vector", 290], ["for", 297], ["green", 301], ["fluorescent", 307], ["protein", 319], ["did", 327], ["not", 331], ["reveal", 335], ["any", 342], ["migration", 346], ["from", 356], ["the", 361], ["SVZ", 365], ["into", 369], ["CA1", 374], ["in", 378], ["the", 381], ["intact", 385], ["murine", 392], ["brain", 399], [".", 404], ["However", 406], [",", 413], ["in", 415], ["a", 418], ["nestin", 420], ["-", 426], ["GFP", 427], ["reporter", 431], ["mouse", 440], ["we", 446], ["found", 449], ["proliferating", 455], ["cells", 469], ["within", 475], ["the", 482], ["corpus", 486], ["callosum", 493], ["/", 501], ["alveus", 502], ["region", 509], ["expressing", 516], ["nestin", 527], ["and", 534], ["glial", 538], ["fibrillary", 544], ["acidic", 555], ["protein", 562], ["similar", 570], ["to", 578], ["precursor", 581], ["cells", 591], ["in", 597], ["the", 600], ["neighboring", 604], ["neurogenic", 616], ["region", 627], ["of", 634], ["the", 637], ["adult", 641], ["dentate", 647], ["gyrus", 655], [".", 660], ["Within", 662], ["3", 669], ["weeks", 671], ["of", 677], ["BrdU", 680], ["administration", 685], [",", 699], ["BrdU", 701], ["-", 705], ["positive", 706], ["nestin", 715], ["-", 721], ["GFP", 722], ["-", 725], ["expressing", 726], ["protoplasmic", 737], ["astrocytes", 750], ["emerged", 761], ["in", 769], ["CA1", 772], [".", 775], ["Similar", 777], ["to", 785], ["precursor", 788], ["cells", 798], ["isolated", 804], ["from", 813], ["the", 818], ["dentate", 822], ["gyrus", 830], ["and", 836], ["the", 840], ["SVZ", 844], [",", 847], ["nestin", 849], ["-", 855], ["GFP", 856], ["-", 859], ["expressing", 860], ["cells", 871], ["from", 877], ["corpus", 882], ["callosum", 889], ["/", 897], ["alveus", 898], ["were", 905], ["self", 910], ["-", 914], ["renewing", 915], ["and", 924], ["multipotent", 928], ["in", 940], ["vitro", 943], [",", 948], ["whereas", 950], ["cells", 958], ["isolated", 964], ["from", 973], ["CA1", 978], ["were", 982], ["not", 987], [".", 990], ["Nestin", 992], ["-", 998], ["GFP", 999], ["-", 1002], ["expressing", 1003], ["cells", 1014], ["in", 1020], ["CA1", 1023], ["differentiated", 1027], ["into", 1042], ["postmitotic", 1047], ["astrocytes", 1059], ["characterized", 1070], ["by", 1084], ["S100beta", 1087], ["expression", 1096], [".", 1106], ["No", 1108], ["new", 1111], ["neurons", 1115], ["were", 1123], ["found", 1128], ["in", 1134], ["CA1", 1137], [".", 1140], ["The", 1142], ["number", 1146], ["of", 1153], ["nestin", 1156], ["-", 1162], ["GFP", 1163], ["-", 1166], ["expressing", 1167], ["astrocytes", 1178], ["in", 1189], ["CA1", 1192], ["was", 1196], ["increased", 1200], ["by", 1210], ["environmental", 1213], ["enrichment", 1227], [".", 1237], ["We", 1239], ["conclude", 1242], ["that", 1251], ["astrogenesis", 1256], ["in", 1269], ["CA1", 1272], ["is", 1276], ["influenced", 1279], ["by", 1290], ["environmental", 1293], ["conditions", 1307], [".", 1317], ["However", 1319], [",", 1326], ["SVZ", 1328], ["precursor", 1332], ["cells", 1342], ["do", 1348], ["not", 1351], ["contribute", 1355], ["to", 1366], ["physiological", 1369], ["cellular", 1383], ["plasticity", 1392], ["in", 1403], ["CA1", 1406], [".", 1409]]}
{"context": "To assess the efficacy and safety of R788 (fostamatinib disodium), an inhibitor of spleen tyrosine kinase (Syk), in patients with active rheumatoid arthritis (RA) that did not respond to biologic therapies. A total of 219 patients with active RA in whom treatment with biologic agents had failed were enrolled in a 3-month multicenter, randomized, double-blind, placebo-controlled trial of R788. The primary end point was the percentage of patients who met the American College of Rheumatology 20% improvement criteria (achieved an ACR20 response) at month 3. Secondary end points included changes in inflammation and damage, as assessed by magnetic resonance imaging (MRI), and changes in the Disease Activity Score. The ACR20 response in the R788 100 mg twice daily group was 38%, versus 37% in the placebo group, at month 3. No significant differences were achieved in the ACR20, ACR50, or ACR70 response levels at 3 months. There were differences between the groups from baseline to month 3 in the secondary end points C-reactive protein (CRP) level and synovitis score on MRI. There were baseline differences in steroid use, prior biologic use, and synovitis score on MRI between the R788 group and the placebo group that may have affected the outcomes. A high placebo response rate was seen in this trial, and exploratory analysis suggested that this may in part have been driven by patients who entered the trial with an elevated erythrocyte sedimentation rate but normal CRP level. Our findings indicate that there were no differences in the primary end point between the R788 and placebo groups. Differences were observed between the R788 and placebo groups in secondary end points, particularly in those patients who entered the study with an elevated CRP level.", "qas": [{"question": "Which enzyme is inhibited by a drug fostamatinib?", "answers": ["spleen tyrosine kinase"], "qid": "da2a8dc6772a49fb956f810030d12b53", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["a", 29], ["drug", 31], ["fostamatinib", 36], ["?", 48]], "detected_answers": [{"text": "spleen tyrosine kinase", "token_spans": [[16, 18]], "char_spans": [[83, 104]]}]}], "context_tokens": [["To", 0], ["assess", 3], ["the", 10], ["efficacy", 14], ["and", 23], ["safety", 27], ["of", 34], ["R788", 37], ["(", 42], ["fostamatinib", 43], ["disodium", 56], [")", 64], [",", 65], ["an", 67], ["inhibitor", 70], ["of", 80], ["spleen", 83], ["tyrosine", 90], ["kinase", 99], ["(", 106], ["Syk", 107], [")", 110], [",", 111], ["in", 113], ["patients", 116], ["with", 125], ["active", 130], ["rheumatoid", 137], ["arthritis", 148], ["(", 158], ["RA", 159], [")", 161], ["that", 163], ["did", 168], ["not", 172], ["respond", 176], ["to", 184], ["biologic", 187], ["therapies", 196], [".", 205], ["A", 207], ["total", 209], ["of", 215], ["219", 218], ["patients", 222], ["with", 231], ["active", 236], ["RA", 243], ["in", 246], ["whom", 249], ["treatment", 254], ["with", 264], ["biologic", 269], ["agents", 278], ["had", 285], ["failed", 289], ["were", 296], ["enrolled", 301], ["in", 310], ["a", 313], ["3-month", 315], ["multicenter", 323], [",", 334], ["randomized", 336], [",", 346], ["double", 348], ["-", 354], ["blind", 355], [",", 360], ["placebo", 362], ["-", 369], ["controlled", 370], ["trial", 381], ["of", 387], ["R788", 390], [".", 394], ["The", 396], ["primary", 400], ["end", 408], ["point", 412], ["was", 418], ["the", 422], ["percentage", 426], ["of", 437], ["patients", 440], ["who", 449], ["met", 453], ["the", 457], ["American", 461], ["College", 470], ["of", 478], ["Rheumatology", 481], ["20", 494], ["%", 496], ["improvement", 498], ["criteria", 510], ["(", 519], ["achieved", 520], ["an", 529], ["ACR20", 532], ["response", 538], [")", 546], ["at", 548], ["month", 551], ["3", 557], [".", 558], ["Secondary", 560], ["end", 570], ["points", 574], ["included", 581], ["changes", 590], ["in", 598], ["inflammation", 601], ["and", 614], ["damage", 618], [",", 624], ["as", 626], ["assessed", 629], ["by", 638], ["magnetic", 641], ["resonance", 650], ["imaging", 660], ["(", 668], ["MRI", 669], [")", 672], [",", 673], ["and", 675], ["changes", 679], ["in", 687], ["the", 690], ["Disease", 694], ["Activity", 702], ["Score", 711], [".", 716], ["The", 718], ["ACR20", 722], ["response", 728], ["in", 737], ["the", 740], ["R788", 744], ["100", 749], ["mg", 753], ["twice", 756], ["daily", 762], ["group", 768], ["was", 774], ["38", 778], ["%", 780], [",", 781], ["versus", 783], ["37", 790], ["%", 792], ["in", 794], ["the", 797], ["placebo", 801], ["group", 809], [",", 814], ["at", 816], ["month", 819], ["3", 825], [".", 826], ["No", 828], ["significant", 831], ["differences", 843], ["were", 855], ["achieved", 860], ["in", 869], ["the", 872], ["ACR20", 876], [",", 881], ["ACR50", 883], [",", 888], ["or", 890], ["ACR70", 893], ["response", 899], ["levels", 908], ["at", 915], ["3", 918], ["months", 920], [".", 926], ["There", 928], ["were", 934], ["differences", 939], ["between", 951], ["the", 959], ["groups", 963], ["from", 970], ["baseline", 975], ["to", 984], ["month", 987], ["3", 993], ["in", 995], ["the", 998], ["secondary", 1002], ["end", 1012], ["points", 1016], ["C", 1023], ["-", 1024], ["reactive", 1025], ["protein", 1034], ["(", 1042], ["CRP", 1043], [")", 1046], ["level", 1048], ["and", 1054], ["synovitis", 1058], ["score", 1068], ["on", 1074], ["MRI", 1077], [".", 1080], ["There", 1082], ["were", 1088], ["baseline", 1093], ["differences", 1102], ["in", 1114], ["steroid", 1117], ["use", 1125], [",", 1128], ["prior", 1130], ["biologic", 1136], ["use", 1145], [",", 1148], ["and", 1150], ["synovitis", 1154], ["score", 1164], ["on", 1170], ["MRI", 1173], ["between", 1177], ["the", 1185], ["R788", 1189], ["group", 1194], ["and", 1200], ["the", 1204], ["placebo", 1208], ["group", 1216], ["that", 1222], ["may", 1227], ["have", 1231], ["affected", 1236], ["the", 1245], ["outcomes", 1249], [".", 1257], ["A", 1259], ["high", 1261], ["placebo", 1266], ["response", 1274], ["rate", 1283], ["was", 1288], ["seen", 1292], ["in", 1297], ["this", 1300], ["trial", 1305], [",", 1310], ["and", 1312], ["exploratory", 1316], ["analysis", 1328], ["suggested", 1337], ["that", 1347], ["this", 1352], ["may", 1357], ["in", 1361], ["part", 1364], ["have", 1369], ["been", 1374], ["driven", 1379], ["by", 1386], ["patients", 1389], ["who", 1398], ["entered", 1402], ["the", 1410], ["trial", 1414], ["with", 1420], ["an", 1425], ["elevated", 1428], ["erythrocyte", 1437], ["sedimentation", 1449], ["rate", 1463], ["but", 1468], ["normal", 1472], ["CRP", 1479], ["level", 1483], [".", 1488], ["Our", 1490], ["findings", 1494], ["indicate", 1503], ["that", 1512], ["there", 1517], ["were", 1523], ["no", 1528], ["differences", 1531], ["in", 1543], ["the", 1546], ["primary", 1550], ["end", 1558], ["point", 1562], ["between", 1568], ["the", 1576], ["R788", 1580], ["and", 1585], ["placebo", 1589], ["groups", 1597], [".", 1603], ["Differences", 1605], ["were", 1617], ["observed", 1622], ["between", 1631], ["the", 1639], ["R788", 1643], ["and", 1648], ["placebo", 1652], ["groups", 1660], ["in", 1667], ["secondary", 1670], ["end", 1680], ["points", 1684], [",", 1690], ["particularly", 1692], ["in", 1705], ["those", 1708], ["patients", 1714], ["who", 1723], ["entered", 1727], ["the", 1735], ["study", 1739], ["with", 1745], ["an", 1750], ["elevated", 1753], ["CRP", 1762], ["level", 1766], [".", 1771]]}
{"context": "The limited availability of effective drugs causes difficulties in the management of multidrug-resistant tuberculosis (MDR-TB) and novel therapeutic agents are needed. Delamanid , a new nitro-hydro-imidazooxazole derivative, inhibits mycolic acid synthesis. This review covers the efficacy and safety of delamanid for MDR-TB. This paper reviews the pharmacological profile of delamanid and the results of clinical trials evaluating its efficacy for treating MDR-TB in combination with other anti-TB drugs. The drug's safety and tolerability profiles are also considered. Delamanid showed potent activity against drug-susceptible and -resistant Mycobacterium tuberculosis in both in vitro and in vivo studies. In clinical trials, the drug showed significant early bactericidal activity in pulmonary TB patients, and increased culture conversion after 2 months of treatment in combination with an optimized background regimen in MDR-TB patients. In addition, decreased mortality was observed in MDR-TB patients who received > 6 months of delamanid treatment. The drug was generally tolerable, but QT prolongation should be monitored carefully using electrocardiograms and potassium levels. Therefore, delamanid could be used as part of an appropriate combination regimen for pulmonary MDR-TB in adult patients when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability.", "qas": [{"question": "Which disease can be treated with Delamanid?", "answers": ["tuberculosis"], "qid": "ffa61ee66681406ea24f30171ebbc713", "question_tokens": [["Which", 0], ["disease", 6], ["can", 14], ["be", 18], ["treated", 21], ["with", 29], ["Delamanid", 34], ["?", 43]], "detected_answers": [{"text": "tuberculosis", "token_spans": [[111, 111], [15, 15]], "char_spans": [[658, 669], [105, 116]]}]}], "context_tokens": [["The", 0], ["limited", 4], ["availability", 12], ["of", 25], ["effective", 28], ["drugs", 38], ["causes", 44], ["difficulties", 51], ["in", 64], ["the", 67], ["management", 71], ["of", 82], ["multidrug", 85], ["-", 94], ["resistant", 95], ["tuberculosis", 105], ["(", 118], ["MDR", 119], ["-", 122], ["TB", 123], [")", 125], ["and", 127], ["novel", 131], ["therapeutic", 137], ["agents", 149], ["are", 156], ["needed", 160], [".", 166], ["Delamanid", 168], [",", 178], ["a", 180], ["new", 182], ["nitro", 186], ["-", 191], ["hydro", 192], ["-", 197], ["imidazooxazole", 198], ["derivative", 213], [",", 223], ["inhibits", 225], ["mycolic", 234], ["acid", 242], ["synthesis", 247], [".", 256], ["This", 258], ["review", 263], ["covers", 270], ["the", 277], ["efficacy", 281], ["and", 290], ["safety", 294], ["of", 301], ["delamanid", 304], ["for", 314], ["MDR", 318], ["-", 321], ["TB", 322], [".", 324], ["This", 326], ["paper", 331], ["reviews", 337], ["the", 345], ["pharmacological", 349], ["profile", 365], ["of", 373], ["delamanid", 376], ["and", 386], ["the", 390], ["results", 394], ["of", 402], ["clinical", 405], ["trials", 414], ["evaluating", 421], ["its", 432], ["efficacy", 436], ["for", 445], ["treating", 449], ["MDR", 458], ["-", 461], ["TB", 462], ["in", 465], ["combination", 468], ["with", 480], ["other", 485], ["anti", 491], ["-", 495], ["TB", 496], ["drugs", 499], [".", 504], ["The", 506], ["drug", 510], ["'s", 514], ["safety", 517], ["and", 524], ["tolerability", 528], ["profiles", 541], ["are", 550], ["also", 554], ["considered", 559], [".", 569], ["Delamanid", 571], ["showed", 581], ["potent", 588], ["activity", 595], ["against", 604], ["drug", 612], ["-", 616], ["susceptible", 617], ["and", 629], ["-resistant", 633], ["Mycobacterium", 644], ["tuberculosis", 658], ["in", 671], ["both", 674], ["in", 679], ["vitro", 682], ["and", 688], ["in", 692], ["vivo", 695], ["studies", 700], [".", 707], ["In", 709], ["clinical", 712], ["trials", 721], [",", 727], ["the", 729], ["drug", 733], ["showed", 738], ["significant", 745], ["early", 757], ["bactericidal", 763], ["activity", 776], ["in", 785], ["pulmonary", 788], ["TB", 798], ["patients", 801], [",", 809], ["and", 811], ["increased", 815], ["culture", 825], ["conversion", 833], ["after", 844], ["2", 850], ["months", 852], ["of", 859], ["treatment", 862], ["in", 872], ["combination", 875], ["with", 887], ["an", 892], ["optimized", 895], ["background", 905], ["regimen", 916], ["in", 924], ["MDR", 927], ["-", 930], ["TB", 931], ["patients", 934], [".", 942], ["In", 944], ["addition", 947], [",", 955], ["decreased", 957], ["mortality", 967], ["was", 977], ["observed", 981], ["in", 990], ["MDR", 993], ["-", 996], ["TB", 997], ["patients", 1000], ["who", 1009], ["received", 1013], [">", 1022], ["6", 1024], ["months", 1026], ["of", 1033], ["delamanid", 1036], ["treatment", 1046], [".", 1055], ["The", 1057], ["drug", 1061], ["was", 1066], ["generally", 1070], ["tolerable", 1080], [",", 1089], ["but", 1091], ["QT", 1095], ["prolongation", 1098], ["should", 1111], ["be", 1118], ["monitored", 1121], ["carefully", 1131], ["using", 1141], ["electrocardiograms", 1147], ["and", 1166], ["potassium", 1170], ["levels", 1180], [".", 1186], ["Therefore", 1188], [",", 1197], ["delamanid", 1199], ["could", 1209], ["be", 1215], ["used", 1218], ["as", 1223], ["part", 1226], ["of", 1231], ["an", 1234], ["appropriate", 1237], ["combination", 1249], ["regimen", 1261], ["for", 1269], ["pulmonary", 1273], ["MDR", 1283], ["-", 1286], ["TB", 1287], ["in", 1290], ["adult", 1293], ["patients", 1299], ["when", 1308], ["an", 1313], ["effective", 1316], ["treatment", 1326], ["regimen", 1336], ["can", 1344], ["not", 1347], ["otherwise", 1351], ["be", 1361], ["composed", 1364], ["for", 1373], ["reasons", 1377], ["of", 1385], ["resistance", 1388], ["or", 1399], ["tolerability", 1402], [".", 1414]]}
{"context": "In melanoma, transition to the vertical growth phase is the critical step in conversion to a deadly malignant disease. Here, we offer the first evidence that an antioxidant enzyme has a key role in this transition. We found that the antioxidant enzyme peroxiredoxin-2 (Prx2) inversely correlated with the metastatic capacity of human melanoma cells. Silencing Prx2 expression stimulated proliferation and migration, whereas ectopic expression of Prx2 produced the opposite effect. Mechanistic investigations indicated that Prx2 negatively regulated Src/ERK activation status, which in turn fortified adherens junctions function by increasing E-cadherin expression and phospho-Y654-dependent retention of \u03b2-catenin in the plasma membrane. In murine melanoma cells, Prx2 silencing enhanced lung metastasis in vivo. Interestingly, the natural compound gliotoxin, which is known to exert a Prx-like activity, inhibited proliferation and migration as well as lung metastasis of Prx2-deficient melanoma cells. Overall, our findings reveal that Prx2 is a key regulator of invasion and metastasis in melanoma, and also suggest a pharmacologic strategy to effectively decrease deadly malignant forms of this disease.", "qas": [{"question": "What type of enzyme is peroxiredoxin 2 (PRDX2)?", "answers": ["antioxidant"], "qid": "4725ab4959074b2b82db8e9b8383de5d", "question_tokens": [["What", 0], ["type", 5], ["of", 10], ["enzyme", 13], ["is", 20], ["peroxiredoxin", 23], ["2", 37], ["(", 39], ["PRDX2", 40], [")", 45], ["?", 46]], "detected_answers": [{"text": "antioxidant", "token_spans": [[44, 44], [30, 30]], "char_spans": [[233, 243], [161, 171]]}]}], "context_tokens": [["In", 0], ["melanoma", 3], [",", 11], ["transition", 13], ["to", 24], ["the", 27], ["vertical", 31], ["growth", 40], ["phase", 47], ["is", 53], ["the", 56], ["critical", 60], ["step", 69], ["in", 74], ["conversion", 77], ["to", 88], ["a", 91], ["deadly", 93], ["malignant", 100], ["disease", 110], [".", 117], ["Here", 119], [",", 123], ["we", 125], ["offer", 128], ["the", 134], ["first", 138], ["evidence", 144], ["that", 153], ["an", 158], ["antioxidant", 161], ["enzyme", 173], ["has", 180], ["a", 184], ["key", 186], ["role", 190], ["in", 195], ["this", 198], ["transition", 203], [".", 213], ["We", 215], ["found", 218], ["that", 224], ["the", 229], ["antioxidant", 233], ["enzyme", 245], ["peroxiredoxin-2", 252], ["(", 268], ["Prx2", 269], [")", 273], ["inversely", 275], ["correlated", 285], ["with", 296], ["the", 301], ["metastatic", 305], ["capacity", 316], ["of", 325], ["human", 328], ["melanoma", 334], ["cells", 343], [".", 348], ["Silencing", 350], ["Prx2", 360], ["expression", 365], ["stimulated", 376], ["proliferation", 387], ["and", 401], ["migration", 405], [",", 414], ["whereas", 416], ["ectopic", 424], ["expression", 432], ["of", 443], ["Prx2", 446], ["produced", 451], ["the", 460], ["opposite", 464], ["effect", 473], [".", 479], ["Mechanistic", 481], ["investigations", 493], ["indicated", 508], ["that", 518], ["Prx2", 523], ["negatively", 528], ["regulated", 539], ["Src", 549], ["/", 552], ["ERK", 553], ["activation", 557], ["status", 568], [",", 574], ["which", 576], ["in", 582], ["turn", 585], ["fortified", 590], ["adherens", 600], ["junctions", 609], ["function", 619], ["by", 628], ["increasing", 631], ["E", 642], ["-", 643], ["cadherin", 644], ["expression", 653], ["and", 664], ["phospho", 668], ["-", 675], ["Y654-dependent", 676], ["retention", 691], ["of", 701], ["\u03b2", 704], ["-", 705], ["catenin", 706], ["in", 714], ["the", 717], ["plasma", 721], ["membrane", 728], [".", 736], ["In", 738], ["murine", 741], ["melanoma", 748], ["cells", 757], [",", 762], ["Prx2", 764], ["silencing", 769], ["enhanced", 779], ["lung", 788], ["metastasis", 793], ["in", 804], ["vivo", 807], [".", 811], ["Interestingly", 813], [",", 826], ["the", 828], ["natural", 832], ["compound", 840], ["gliotoxin", 849], [",", 858], ["which", 860], ["is", 866], ["known", 869], ["to", 875], ["exert", 878], ["a", 884], ["Prx", 886], ["-", 889], ["like", 890], ["activity", 895], [",", 903], ["inhibited", 905], ["proliferation", 915], ["and", 929], ["migration", 933], ["as", 943], ["well", 946], ["as", 951], ["lung", 954], ["metastasis", 959], ["of", 970], ["Prx2-deficient", 973], ["melanoma", 988], ["cells", 997], [".", 1002], ["Overall", 1004], [",", 1011], ["our", 1013], ["findings", 1017], ["reveal", 1026], ["that", 1033], ["Prx2", 1038], ["is", 1043], ["a", 1046], ["key", 1048], ["regulator", 1052], ["of", 1062], ["invasion", 1065], ["and", 1074], ["metastasis", 1078], ["in", 1089], ["melanoma", 1092], [",", 1100], ["and", 1102], ["also", 1106], ["suggest", 1111], ["a", 1119], ["pharmacologic", 1121], ["strategy", 1135], ["to", 1144], ["effectively", 1147], ["decrease", 1159], ["deadly", 1168], ["malignant", 1175], ["forms", 1185], ["of", 1191], ["this", 1194], ["disease", 1199], [".", 1206]]}
{"context": "Imatinib mesylate, a selective Bcr-Abl tyrosine kinase inhibitor, has proved to be most effective therapy of Philadelphia chromosome-positive chronic myelogenous leukemia. Imatinib induces complete haematological and cytogenetic response in high percentage of patients. The aim of this study was to identify potential prognostic factors before beginning treatment with imatinib associated with complete cytogenetic response. We analyzed 20 patients with newly diagnosed Philadelphia positive chronic myelogenous leukemia treated at our institution from June 2006 until May 2009. These patients were treated with imatinib mesylate in oral dose of 400 to 800 mg daily. Complete blood counts were performed every month, while serum chemistry evaluations and bone marrow evaluations including morphology and cytogenetics were performed every 6 months. Of the 20 patients analyzed in this study, 19 (95%) achieved complete haematologic response within three months. In all patients cytogenetic analyses were done and all have achieved absolute cytogenetic response. The best cytogenetic response rate at any time during study treatment among 20 patients was: complete cytogenetic response in 15, partial cytogenetic response in three and minor cytogenetic response in two patients. Among 11 observed base-line patients' characteristics five were independent predictors of a high rate of complete cytogenetic response; the absence of blasts and basophils in peripheral blood, the presence of less than 5 percent of bone marrow blasts, white blood cell count less than 10 x 10(9)/L and the absence of splenomegaly (p < 0.01). Our results showed that some pre-treatment characteristics of patients might be the cause of differences in treatment outcome. On the basis of this analysis, we identified several pre-treatment patients' characteristics to be independent prognostic factors for achievement of complete cytogenetic response.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "6a2e5c9b921c417c892010de2379c6d7", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[5, 7]], "char_spans": [[31, 37]]}]}], "context_tokens": [["Imatinib", 0], ["mesylate", 9], [",", 17], ["a", 19], ["selective", 21], ["Bcr", 31], ["-", 34], ["Abl", 35], ["tyrosine", 39], ["kinase", 48], ["inhibitor", 55], [",", 64], ["has", 66], ["proved", 70], ["to", 77], ["be", 80], ["most", 83], ["effective", 88], ["therapy", 98], ["of", 106], ["Philadelphia", 109], ["chromosome", 122], ["-", 132], ["positive", 133], ["chronic", 142], ["myelogenous", 150], ["leukemia", 162], [".", 170], ["Imatinib", 172], ["induces", 181], ["complete", 189], ["haematological", 198], ["and", 213], ["cytogenetic", 217], ["response", 229], ["in", 238], ["high", 241], ["percentage", 246], ["of", 257], ["patients", 260], [".", 268], ["The", 270], ["aim", 274], ["of", 278], ["this", 281], ["study", 286], ["was", 292], ["to", 296], ["identify", 299], ["potential", 308], ["prognostic", 318], ["factors", 329], ["before", 337], ["beginning", 344], ["treatment", 354], ["with", 364], ["imatinib", 369], ["associated", 378], ["with", 389], ["complete", 394], ["cytogenetic", 403], ["response", 415], [".", 423], ["We", 425], ["analyzed", 428], ["20", 437], ["patients", 440], ["with", 449], ["newly", 454], ["diagnosed", 460], ["Philadelphia", 470], ["positive", 483], ["chronic", 492], ["myelogenous", 500], ["leukemia", 512], ["treated", 521], ["at", 529], ["our", 532], ["institution", 536], ["from", 548], ["June", 553], ["2006", 558], ["until", 563], ["May", 569], ["2009", 573], [".", 577], ["These", 579], ["patients", 585], ["were", 594], ["treated", 599], ["with", 607], ["imatinib", 612], ["mesylate", 621], ["in", 630], ["oral", 633], ["dose", 638], ["of", 643], ["400", 646], ["to", 650], ["800", 653], ["mg", 657], ["daily", 660], [".", 665], ["Complete", 667], ["blood", 676], ["counts", 682], ["were", 689], ["performed", 694], ["every", 704], ["month", 710], [",", 715], ["while", 717], ["serum", 723], ["chemistry", 729], ["evaluations", 739], ["and", 751], ["bone", 755], ["marrow", 760], ["evaluations", 767], ["including", 779], ["morphology", 789], ["and", 800], ["cytogenetics", 804], ["were", 817], ["performed", 822], ["every", 832], ["6", 838], ["months", 840], [".", 846], ["Of", 848], ["the", 851], ["20", 855], ["patients", 858], ["analyzed", 867], ["in", 876], ["this", 879], ["study", 884], [",", 889], ["19", 891], ["(", 894], ["95", 895], ["%", 897], [")", 898], ["achieved", 900], ["complete", 909], ["haematologic", 918], ["response", 931], ["within", 940], ["three", 947], ["months", 953], [".", 959], ["In", 961], ["all", 964], ["patients", 968], ["cytogenetic", 977], ["analyses", 989], ["were", 998], ["done", 1003], ["and", 1008], ["all", 1012], ["have", 1016], ["achieved", 1021], ["absolute", 1030], ["cytogenetic", 1039], ["response", 1051], [".", 1059], ["The", 1061], ["best", 1065], ["cytogenetic", 1070], ["response", 1082], ["rate", 1091], ["at", 1096], ["any", 1099], ["time", 1103], ["during", 1108], ["study", 1115], ["treatment", 1121], ["among", 1131], ["20", 1137], ["patients", 1140], ["was", 1149], [":", 1152], ["complete", 1154], ["cytogenetic", 1163], ["response", 1175], ["in", 1184], ["15", 1187], [",", 1189], ["partial", 1191], ["cytogenetic", 1199], ["response", 1211], ["in", 1220], ["three", 1223], ["and", 1229], ["minor", 1233], ["cytogenetic", 1239], ["response", 1251], ["in", 1260], ["two", 1263], ["patients", 1267], [".", 1275], ["Among", 1277], ["11", 1283], ["observed", 1286], ["base", 1295], ["-", 1299], ["line", 1300], ["patients", 1305], ["'", 1313], ["characteristics", 1315], ["five", 1331], ["were", 1336], ["independent", 1341], ["predictors", 1353], ["of", 1364], ["a", 1367], ["high", 1369], ["rate", 1374], ["of", 1379], ["complete", 1382], ["cytogenetic", 1391], ["response", 1403], [";", 1411], ["the", 1413], ["absence", 1417], ["of", 1425], ["blasts", 1428], ["and", 1435], ["basophils", 1439], ["in", 1449], ["peripheral", 1452], ["blood", 1463], [",", 1468], ["the", 1470], ["presence", 1474], ["of", 1483], ["less", 1486], ["than", 1491], ["5", 1496], ["percent", 1498], ["of", 1506], ["bone", 1509], ["marrow", 1514], ["blasts", 1521], [",", 1527], ["white", 1529], ["blood", 1535], ["cell", 1541], ["count", 1546], ["less", 1552], ["than", 1557], ["10", 1562], ["x", 1565], ["10(9)/L", 1567], ["and", 1575], ["the", 1579], ["absence", 1583], ["of", 1591], ["splenomegaly", 1594], ["(", 1607], ["p", 1608], ["<", 1610], ["0.01", 1612], [")", 1616], [".", 1617], ["Our", 1619], ["results", 1623], ["showed", 1631], ["that", 1638], ["some", 1643], ["pre", 1648], ["-", 1651], ["treatment", 1652], ["characteristics", 1662], ["of", 1678], ["patients", 1681], ["might", 1690], ["be", 1696], ["the", 1699], ["cause", 1703], ["of", 1709], ["differences", 1712], ["in", 1724], ["treatment", 1727], ["outcome", 1737], [".", 1744], ["On", 1746], ["the", 1749], ["basis", 1753], ["of", 1759], ["this", 1762], ["analysis", 1767], [",", 1775], ["we", 1777], ["identified", 1780], ["several", 1791], ["pre", 1799], ["-", 1802], ["treatment", 1803], ["patients", 1813], ["'", 1821], ["characteristics", 1823], ["to", 1839], ["be", 1842], ["independent", 1845], ["prognostic", 1857], ["factors", 1868], ["for", 1876], ["achievement", 1880], ["of", 1892], ["complete", 1895], ["cytogenetic", 1904], ["response", 1916], [".", 1924]]}
{"context": "Although methicillin (meticillin)-resistant Staphylococcus aureus (MRSA) strains with reduced susceptibility to vancomycin (RVS-MRSA; including vancomycin-intermediate S. aureus [VISA] and heterogeneous VISA [hVISA]) have been linked with vancomycin treatment failure, it is unclear whether they are more pathogenic than vancomycin-susceptible MRSA (VS-MRSA). We prospectively assessed patients with clinical MRSA isolates during a 10-month period to determine clinical status (infection versus colonization) and therapeutic outcome before correlating these findings with the results of detailed in vitro assessment of vancomycin susceptibility, including population analysis profile (PAP) testing. hVISA and VISA were defined by standard PAP criteria (area-under-the-curve ratio compared to that of the reference hVISA strain Mu3 [>or=0.9]) and routine CLSI criteria (vancomycin MIC, 4 to 8 microg/ml), respectively. Among the 117 patients assessed, 58 had RVS-MRSA isolates (56 hVISA and 2 VISA) and 59 had VS-MRSA isolates; the patient demographics and comorbidities were similar. RVS-MRSA was associated with a lower rate of infection than VS-MRSA (29/58 versus 46/59; P = 0.003), including a lower rate of bacteremia (3/58 versus 20/59, respectively; P < 0.001). The cure rates in RVS-MRSA and VS-MRSA groups were not statistically different (16/26 versus 31/42; P = 0.43), but the post hoc assessment of treatment regimes and study size made detailed conclusions difficult. The results of the macro method Etest correlated well with the PAP results (sensitivity, 98.3%, and specificity, 91.5%), but broth microdilution and our preliminary RVS-MRSA detection method correlated poorly. All isolates were susceptible to linezolid and daptomycin. These data suggest that detailed prospective laboratory identification of RVS-MRSA isolates may be of limited value and that, instead, such in vitro investigation should be reserved for isolates from patients who are failing appropriate anti-MRSA therapy.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "ceea58daf75a47a2a1f4006fe10ba779", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[69, 69], [211, 211], [186, 186], [246, 246], [250, 250], [342, 342], [60, 60], [172, 172], [7, 7], [199, 199], [316, 316], [371, 371], [56, 56], [18, 18]], "char_spans": [[409, 412], [1147, 1150], [1012, 1015], [1290, 1293], [1302, 1305], [1827, 1830], [353, 356], [962, 965], [67, 70], [1088, 1091], [1649, 1652], [1991, 1994], [344, 347], [128, 131]]}]}], "context_tokens": [["Although", 0], ["methicillin", 9], ["(", 21], ["meticillin)-resistant", 22], ["Staphylococcus", 44], ["aureus", 59], ["(", 66], ["MRSA", 67], [")", 71], ["strains", 73], ["with", 81], ["reduced", 86], ["susceptibility", 94], ["to", 109], ["vancomycin", 112], ["(", 123], ["RVS", 124], ["-", 127], ["MRSA", 128], [";", 132], ["including", 134], ["vancomycin", 144], ["-", 154], ["intermediate", 155], ["S.", 168], ["aureus", 171], ["[", 178], ["VISA", 179], ["]", 183], ["and", 185], ["heterogeneous", 189], ["VISA", 203], ["[", 208], ["hVISA", 209], ["]", 214], [")", 215], ["have", 217], ["been", 222], ["linked", 227], ["with", 234], ["vancomycin", 239], ["treatment", 250], ["failure", 260], [",", 267], ["it", 269], ["is", 272], ["unclear", 275], ["whether", 283], ["they", 291], ["are", 296], ["more", 300], ["pathogenic", 305], ["than", 316], ["vancomycin", 321], ["-", 331], ["susceptible", 332], ["MRSA", 344], ["(", 349], ["VS", 350], ["-", 352], ["MRSA", 353], [")", 357], [".", 358], ["We", 360], ["prospectively", 363], ["assessed", 377], ["patients", 386], ["with", 395], ["clinical", 400], ["MRSA", 409], ["isolates", 414], ["during", 423], ["a", 430], ["10-month", 432], ["period", 441], ["to", 448], ["determine", 451], ["clinical", 461], ["status", 470], ["(", 477], ["infection", 478], ["versus", 488], ["colonization", 495], [")", 507], ["and", 509], ["therapeutic", 513], ["outcome", 525], ["before", 533], ["correlating", 540], ["these", 552], ["findings", 558], ["with", 567], ["the", 572], ["results", 576], ["of", 584], ["detailed", 587], ["in", 596], ["vitro", 599], ["assessment", 605], ["of", 616], ["vancomycin", 619], ["susceptibility", 630], [",", 644], ["including", 646], ["population", 656], ["analysis", 667], ["profile", 676], ["(", 684], ["PAP", 685], [")", 688], ["testing", 690], [".", 697], ["hVISA", 699], ["and", 705], ["VISA", 709], ["were", 714], ["defined", 719], ["by", 727], ["standard", 730], ["PAP", 739], ["criteria", 743], ["(", 752], ["area", 753], ["-", 757], ["under", 758], ["-", 763], ["the", 764], ["-", 767], ["curve", 768], ["ratio", 774], ["compared", 780], ["to", 789], ["that", 792], ["of", 797], ["the", 800], ["reference", 804], ["hVISA", 814], ["strain", 820], ["Mu3", 827], ["[", 831], [">", 832], ["or=0.9", 833], ["]", 839], [")", 840], ["and", 842], ["routine", 846], ["CLSI", 854], ["criteria", 859], ["(", 868], ["vancomycin", 869], ["MIC", 880], [",", 883], ["4", 885], ["to", 887], ["8", 890], ["microg", 892], ["/", 898], ["ml", 899], [")", 901], [",", 902], ["respectively", 904], [".", 916], ["Among", 918], ["the", 924], ["117", 928], ["patients", 932], ["assessed", 941], [",", 949], ["58", 951], ["had", 954], ["RVS", 958], ["-", 961], ["MRSA", 962], ["isolates", 967], ["(", 976], ["56", 977], ["hVISA", 980], ["and", 986], ["2", 990], ["VISA", 992], [")", 996], ["and", 998], ["59", 1002], ["had", 1005], ["VS", 1009], ["-", 1011], ["MRSA", 1012], ["isolates", 1017], [";", 1025], ["the", 1027], ["patient", 1031], ["demographics", 1039], ["and", 1052], ["comorbidities", 1056], ["were", 1070], ["similar", 1075], [".", 1082], ["RVS", 1084], ["-", 1087], ["MRSA", 1088], ["was", 1093], ["associated", 1097], ["with", 1108], ["a", 1113], ["lower", 1115], ["rate", 1121], ["of", 1126], ["infection", 1129], ["than", 1139], ["VS", 1144], ["-", 1146], ["MRSA", 1147], ["(", 1152], ["29/58", 1153], ["versus", 1159], ["46/59", 1166], [";", 1171], ["P", 1173], ["=", 1175], ["0.003", 1177], [")", 1182], [",", 1183], ["including", 1185], ["a", 1195], ["lower", 1197], ["rate", 1203], ["of", 1208], ["bacteremia", 1211], ["(", 1222], ["3/58", 1223], ["versus", 1228], ["20/59", 1235], [",", 1240], ["respectively", 1242], [";", 1254], ["P", 1256], ["<", 1258], ["0.001", 1260], [")", 1265], [".", 1266], ["The", 1268], ["cure", 1272], ["rates", 1277], ["in", 1283], ["RVS", 1286], ["-", 1289], ["MRSA", 1290], ["and", 1295], ["VS", 1299], ["-", 1301], ["MRSA", 1302], ["groups", 1307], ["were", 1314], ["not", 1319], ["statistically", 1323], ["different", 1337], ["(", 1347], ["16/26", 1348], ["versus", 1354], ["31/42", 1361], [";", 1366], ["P", 1368], ["=", 1370], ["0.43", 1372], [")", 1376], [",", 1377], ["but", 1379], ["the", 1383], ["post", 1387], ["hoc", 1392], ["assessment", 1396], ["of", 1407], ["treatment", 1410], ["regimes", 1420], ["and", 1428], ["study", 1432], ["size", 1438], ["made", 1443], ["detailed", 1448], ["conclusions", 1457], ["difficult", 1469], [".", 1478], ["The", 1480], ["results", 1484], ["of", 1492], ["the", 1495], ["macro", 1499], ["method", 1505], ["Etest", 1512], ["correlated", 1518], ["well", 1529], ["with", 1534], ["the", 1539], ["PAP", 1543], ["results", 1547], ["(", 1555], ["sensitivity", 1556], [",", 1567], ["98.3", 1569], ["%", 1573], [",", 1574], ["and", 1576], ["specificity", 1580], [",", 1591], ["91.5", 1593], ["%", 1597], [")", 1598], [",", 1599], ["but", 1601], ["broth", 1605], ["microdilution", 1611], ["and", 1625], ["our", 1629], ["preliminary", 1633], ["RVS", 1645], ["-", 1648], ["MRSA", 1649], ["detection", 1654], ["method", 1664], ["correlated", 1671], ["poorly", 1682], [".", 1688], ["All", 1690], ["isolates", 1694], ["were", 1703], ["susceptible", 1708], ["to", 1720], ["linezolid", 1723], ["and", 1733], ["daptomycin", 1737], [".", 1747], ["These", 1749], ["data", 1755], ["suggest", 1760], ["that", 1768], ["detailed", 1773], ["prospective", 1782], ["laboratory", 1794], ["identification", 1805], ["of", 1820], ["RVS", 1823], ["-", 1826], ["MRSA", 1827], ["isolates", 1832], ["may", 1841], ["be", 1845], ["of", 1848], ["limited", 1851], ["value", 1859], ["and", 1865], ["that", 1869], [",", 1873], ["instead", 1875], [",", 1882], ["such", 1884], ["in", 1889], ["vitro", 1892], ["investigation", 1898], ["should", 1912], ["be", 1919], ["reserved", 1922], ["for", 1931], ["isolates", 1935], ["from", 1944], ["patients", 1949], ["who", 1958], ["are", 1962], ["failing", 1966], ["appropriate", 1974], ["anti", 1986], ["-", 1990], ["MRSA", 1991], ["therapy", 1996], [".", 2003]]}
{"context": "Survivors of acute respiratory failure commonly experience long-term psychological sequelae and impaired quality of life. For researchers interested in general mental health, using multiple condition-specific instruments may be unnecessary and inefficient when using the Medical Outcomes Study Short Form (SF)-36, a recommended outcome measure, may suffice. However, relationships between the SF-36 scores and commonly used measures of psychological symptoms in acute survivors of respiratory failure are unknown. Our objective is to examine the relationship of the SF-36 mental health domain (MH) and mental health component summary (MCS) scores with symptoms of depression, anxiety, and post-traumatic stress disorder (PTSD) evaluated using validated psychological instruments. We conducted a cross-sectional analysis of 1,229 participants at 6- and 12-month follow-up assessment using data from five studies from the United States, the United Kingdom, and Australia. Symptoms were assessed using the Hospital Anxiety and Depression Scale (HADS), Depression Anxiety Stress Scales, the Davidson Trauma Scale, Impact of Event Scale (IES), and IES-Revised (IES-R). At 6-month assessment there were moderate to strong correlations of the SF-36 MH scores with HADS depression and anxiety symptoms (r\u2009=\u2009-0.74 and -0.79) and with IES-R PTSD symptoms (r\u2009=\u2009-0.60) in the pooled analyses. Using the normalized population mean of 50 on the SF-36 MH domain score as a cut-off, positive predictive values were 16 and 55% for substantial depression; 20 and 68% for substantial anxiety (Depression Anxiety Stress Scales and HADS, respectively); and 40, 44, and 67% for substantial PTSD symptoms (IES-R, IES, and Davidson Trauma Scale, respectively). Negative predictive values were high. The area under the receiver operating characteristics curve of the SF-36 MH score was high for depression, anxiety, and PTSD symptoms (0.88, 0.91, and 0.84, respectively). All results were consistent for the MCS, across the individual studies, and for the 12-month assessment. For researchers interested in general mental health status, the SF-36 MH or MCS offers a strong measure of psychological symptoms prevalent among survivors of acute respiratory failure. For researchers interested in specific conditions, validated psychological instruments should be considered.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "76adb600c4da481db13a307c2a13062f", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "post-traumatic stress disorder", "token_spans": [[112, 116]], "char_spans": [[689, 718]]}, {"text": "PTSD", "token_spans": [[350, 350], [306, 306], [235, 235], [118, 118]], "char_spans": [[1895, 1898], [1668, 1671], [1331, 1334], [721, 724]]}]}], "context_tokens": [["Survivors", 0], ["of", 10], ["acute", 13], ["respiratory", 19], ["failure", 31], ["commonly", 39], ["experience", 48], ["long", 59], ["-", 63], ["term", 64], ["psychological", 69], ["sequelae", 83], ["and", 92], ["impaired", 96], ["quality", 105], ["of", 113], ["life", 116], [".", 120], ["For", 122], ["researchers", 126], ["interested", 138], ["in", 149], ["general", 152], ["mental", 160], ["health", 167], [",", 173], ["using", 175], ["multiple", 181], ["condition", 190], ["-", 199], ["specific", 200], ["instruments", 209], ["may", 221], ["be", 225], ["unnecessary", 228], ["and", 240], ["inefficient", 244], ["when", 256], ["using", 261], ["the", 267], ["Medical", 271], ["Outcomes", 279], ["Study", 288], ["Short", 294], ["Form", 300], ["(", 305], ["SF)-36", 306], [",", 312], ["a", 314], ["recommended", 316], ["outcome", 328], ["measure", 336], [",", 343], ["may", 345], ["suffice", 349], [".", 356], ["However", 358], [",", 365], ["relationships", 367], ["between", 381], ["the", 389], ["SF-36", 393], ["scores", 399], ["and", 406], ["commonly", 410], ["used", 419], ["measures", 424], ["of", 433], ["psychological", 436], ["symptoms", 450], ["in", 459], ["acute", 462], ["survivors", 468], ["of", 478], ["respiratory", 481], ["failure", 493], ["are", 501], ["unknown", 505], [".", 512], ["Our", 514], ["objective", 518], ["is", 528], ["to", 531], ["examine", 534], ["the", 542], ["relationship", 546], ["of", 559], ["the", 562], ["SF-36", 566], ["mental", 572], ["health", 579], ["domain", 586], ["(", 593], ["MH", 594], [")", 596], ["and", 598], ["mental", 602], ["health", 609], ["component", 616], ["summary", 626], ["(", 634], ["MCS", 635], [")", 638], ["scores", 640], ["with", 647], ["symptoms", 652], ["of", 661], ["depression", 664], [",", 674], ["anxiety", 676], [",", 683], ["and", 685], ["post", 689], ["-", 693], ["traumatic", 694], ["stress", 704], ["disorder", 711], ["(", 720], ["PTSD", 721], [")", 725], ["evaluated", 727], ["using", 737], ["validated", 743], ["psychological", 753], ["instruments", 767], [".", 778], ["We", 780], ["conducted", 783], ["a", 793], ["cross", 795], ["-", 800], ["sectional", 801], ["analysis", 811], ["of", 820], ["1,229", 823], ["participants", 829], ["at", 842], ["6-", 845], ["and", 848], ["12-month", 852], ["follow", 861], ["-", 867], ["up", 868], ["assessment", 871], ["using", 882], ["data", 888], ["from", 893], ["five", 898], ["studies", 903], ["from", 911], ["the", 916], ["United", 920], ["States", 927], [",", 933], ["the", 935], ["United", 939], ["Kingdom", 946], [",", 953], ["and", 955], ["Australia", 959], [".", 968], ["Symptoms", 970], ["were", 979], ["assessed", 984], ["using", 993], ["the", 999], ["Hospital", 1003], ["Anxiety", 1012], ["and", 1020], ["Depression", 1024], ["Scale", 1035], ["(", 1041], ["HADS", 1042], [")", 1046], [",", 1047], ["Depression", 1049], ["Anxiety", 1060], ["Stress", 1068], ["Scales", 1075], [",", 1081], ["the", 1083], ["Davidson", 1087], ["Trauma", 1096], ["Scale", 1103], [",", 1108], ["Impact", 1110], ["of", 1117], ["Event", 1120], ["Scale", 1126], ["(", 1132], ["IES", 1133], [")", 1136], [",", 1137], ["and", 1139], ["IES", 1143], ["-", 1146], ["Revised", 1147], ["(", 1155], ["IES", 1156], ["-", 1159], ["R", 1160], [")", 1161], [".", 1162], ["At", 1164], ["6-month", 1167], ["assessment", 1175], ["there", 1186], ["were", 1192], ["moderate", 1197], ["to", 1206], ["strong", 1209], ["correlations", 1216], ["of", 1229], ["the", 1232], ["SF-36", 1236], ["MH", 1242], ["scores", 1245], ["with", 1252], ["HADS", 1257], ["depression", 1262], ["and", 1273], ["anxiety", 1277], ["symptoms", 1285], ["(", 1294], ["r", 1295], ["=", 1297], ["-0.74", 1299], ["and", 1305], ["-0.79", 1309], [")", 1314], ["and", 1316], ["with", 1320], ["IES", 1325], ["-", 1328], ["R", 1329], ["PTSD", 1331], ["symptoms", 1336], ["(", 1345], ["r", 1346], ["=", 1348], ["-0.60", 1350], [")", 1355], ["in", 1357], ["the", 1360], ["pooled", 1364], ["analyses", 1371], [".", 1379], ["Using", 1381], ["the", 1387], ["normalized", 1391], ["population", 1402], ["mean", 1413], ["of", 1418], ["50", 1421], ["on", 1424], ["the", 1427], ["SF-36", 1431], ["MH", 1437], ["domain", 1440], ["score", 1447], ["as", 1453], ["a", 1456], ["cut", 1458], ["-", 1461], ["off", 1462], [",", 1465], ["positive", 1467], ["predictive", 1476], ["values", 1487], ["were", 1494], ["16", 1499], ["and", 1502], ["55", 1506], ["%", 1508], ["for", 1510], ["substantial", 1514], ["depression", 1526], [";", 1536], ["20", 1538], ["and", 1541], ["68", 1545], ["%", 1547], ["for", 1549], ["substantial", 1553], ["anxiety", 1565], ["(", 1573], ["Depression", 1574], ["Anxiety", 1585], ["Stress", 1593], ["Scales", 1600], ["and", 1607], ["HADS", 1611], [",", 1615], ["respectively", 1617], [")", 1629], [";", 1630], ["and", 1632], ["40", 1636], [",", 1638], ["44", 1640], [",", 1642], ["and", 1644], ["67", 1648], ["%", 1650], ["for", 1652], ["substantial", 1656], ["PTSD", 1668], ["symptoms", 1673], ["(", 1682], ["IES", 1683], ["-", 1686], ["R", 1687], [",", 1688], ["IES", 1690], [",", 1693], ["and", 1695], ["Davidson", 1699], ["Trauma", 1708], ["Scale", 1715], [",", 1720], ["respectively", 1722], [")", 1734], [".", 1735], ["Negative", 1737], ["predictive", 1746], ["values", 1757], ["were", 1764], ["high", 1769], [".", 1773], ["The", 1775], ["area", 1779], ["under", 1784], ["the", 1790], ["receiver", 1794], ["operating", 1803], ["characteristics", 1813], ["curve", 1829], ["of", 1835], ["the", 1838], ["SF-36", 1842], ["MH", 1848], ["score", 1851], ["was", 1857], ["high", 1861], ["for", 1866], ["depression", 1870], [",", 1880], ["anxiety", 1882], [",", 1889], ["and", 1891], ["PTSD", 1895], ["symptoms", 1900], ["(", 1909], ["0.88", 1910], [",", 1914], ["0.91", 1916], [",", 1920], ["and", 1922], ["0.84", 1926], [",", 1930], ["respectively", 1932], [")", 1944], [".", 1945], ["All", 1947], ["results", 1951], ["were", 1959], ["consistent", 1964], ["for", 1975], ["the", 1979], ["MCS", 1983], [",", 1986], ["across", 1988], ["the", 1995], ["individual", 1999], ["studies", 2010], [",", 2017], ["and", 2019], ["for", 2023], ["the", 2027], ["12-month", 2031], ["assessment", 2040], [".", 2050], ["For", 2052], ["researchers", 2056], ["interested", 2068], ["in", 2079], ["general", 2082], ["mental", 2090], ["health", 2097], ["status", 2104], [",", 2110], ["the", 2112], ["SF-36", 2116], ["MH", 2122], ["or", 2125], ["MCS", 2128], ["offers", 2132], ["a", 2139], ["strong", 2141], ["measure", 2148], ["of", 2156], ["psychological", 2159], ["symptoms", 2173], ["prevalent", 2182], ["among", 2192], ["survivors", 2198], ["of", 2208], ["acute", 2211], ["respiratory", 2217], ["failure", 2229], [".", 2236], ["For", 2238], ["researchers", 2242], ["interested", 2254], ["in", 2265], ["specific", 2268], ["conditions", 2277], [",", 2287], ["validated", 2289], ["psychological", 2299], ["instruments", 2313], ["should", 2325], ["be", 2332], ["considered", 2335], [".", 2345]]}
{"context": "Kx is lacking in the RBCs of patients with the McLeod syndrome. This condition is sometimes associated with chronic granulomatous disease (CGD). If given allogeneic RBCs, CGD patients with the McLeod phenotype may produce anti-Kx and anti-Km, and only phenotypically matched McLeod blood would be compatible. McLeod phenotype persons without CGD have made anti-Km but not anti-Kx (2 examples), and thus both McLeod and K(O) blood would be compatible. RBCs from a transfused patient with the McLeod phenotype but not with CGD (non-CGD McLeod) were typed for the Kell blood group antigens, and the plasma was analyzed for the presence of antibody by agglutination. The molecular basis was determined by analyzing for XK protein on RBC membranes by Western immunoblotting, by sequencing the XK gene, and by RFLP. The RBCs did not react with anti-Kx + anti-Km and showed weakening of Kell system antigens. The patient's plasma reacted moderately (2+) with RBCs of common Kell type and strongly (4+) with K(O) RBCs and RBCs of common Kell type treated with dithiothreitol, and did not react with McLeod RBCs. XK protein was absent from the RBC membranes. The XK gene had a point mutation in the donor splice site of intron 1 (G>C). This is the first report describing the molecular alteration in a non-CGD McLeod patient who has made anti-Kx. The immune response of people with the McLeod phenotype can vary, and K(O) blood may not always be compatible.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "ae5bb34ab378486298ab61b3973ece7b", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[232, 232], [150, 150], [222, 222], [138, 138]], "char_spans": [[1154, 1155], [788, 789], [1104, 1105], [715, 716]]}]}], "context_tokens": [["Kx", 0], ["is", 3], ["lacking", 6], ["in", 14], ["the", 17], ["RBCs", 21], ["of", 26], ["patients", 29], ["with", 38], ["the", 43], ["McLeod", 47], ["syndrome", 54], [".", 62], ["This", 64], ["condition", 69], ["is", 79], ["sometimes", 82], ["associated", 92], ["with", 103], ["chronic", 108], ["granulomatous", 116], ["disease", 130], ["(", 138], ["CGD", 139], [")", 142], [".", 143], ["If", 145], ["given", 148], ["allogeneic", 154], ["RBCs", 165], [",", 169], ["CGD", 171], ["patients", 175], ["with", 184], ["the", 189], ["McLeod", 193], ["phenotype", 200], ["may", 210], ["produce", 214], ["anti", 222], ["-", 226], ["Kx", 227], ["and", 230], ["anti", 234], ["-", 238], ["Km", 239], [",", 241], ["and", 243], ["only", 247], ["phenotypically", 252], ["matched", 267], ["McLeod", 275], ["blood", 282], ["would", 288], ["be", 294], ["compatible", 297], [".", 307], ["McLeod", 309], ["phenotype", 316], ["persons", 326], ["without", 334], ["CGD", 342], ["have", 346], ["made", 351], ["anti", 356], ["-", 360], ["Km", 361], ["but", 364], ["not", 368], ["anti", 372], ["-", 376], ["Kx", 377], ["(", 380], ["2", 381], ["examples", 383], [")", 391], [",", 392], ["and", 394], ["thus", 398], ["both", 403], ["McLeod", 408], ["and", 415], ["K(O", 419], [")", 422], ["blood", 424], ["would", 430], ["be", 436], ["compatible", 439], [".", 449], ["RBCs", 451], ["from", 456], ["a", 461], ["transfused", 463], ["patient", 474], ["with", 482], ["the", 487], ["McLeod", 491], ["phenotype", 498], ["but", 508], ["not", 512], ["with", 516], ["CGD", 521], ["(", 525], ["non", 526], ["-", 529], ["CGD", 530], ["McLeod", 534], [")", 540], ["were", 542], ["typed", 547], ["for", 553], ["the", 557], ["Kell", 561], ["blood", 566], ["group", 572], ["antigens", 578], [",", 586], ["and", 588], ["the", 592], ["plasma", 596], ["was", 603], ["analyzed", 607], ["for", 616], ["the", 620], ["presence", 624], ["of", 633], ["antibody", 636], ["by", 645], ["agglutination", 648], [".", 661], ["The", 663], ["molecular", 667], ["basis", 677], ["was", 683], ["determined", 687], ["by", 698], ["analyzing", 701], ["for", 711], ["XK", 715], ["protein", 718], ["on", 726], ["RBC", 729], ["membranes", 733], ["by", 743], ["Western", 746], ["immunoblotting", 754], [",", 768], ["by", 770], ["sequencing", 773], ["the", 784], ["XK", 788], ["gene", 791], [",", 795], ["and", 797], ["by", 801], ["RFLP", 804], [".", 808], ["The", 810], ["RBCs", 814], ["did", 819], ["not", 823], ["react", 827], ["with", 833], ["anti", 838], ["-", 842], ["Kx", 843], ["+", 846], ["anti", 848], ["-", 852], ["Km", 853], ["and", 856], ["showed", 860], ["weakening", 867], ["of", 877], ["Kell", 880], ["system", 885], ["antigens", 892], [".", 900], ["The", 902], ["patient", 906], ["'s", 913], ["plasma", 916], ["reacted", 923], ["moderately", 931], ["(", 942], ["2", 943], ["+", 944], [")", 945], ["with", 947], ["RBCs", 952], ["of", 957], ["common", 960], ["Kell", 967], ["type", 972], ["and", 977], ["strongly", 981], ["(", 990], ["4", 991], ["+", 992], [")", 993], ["with", 995], ["K(O", 1000], [")", 1003], ["RBCs", 1005], ["and", 1010], ["RBCs", 1014], ["of", 1019], ["common", 1022], ["Kell", 1029], ["type", 1034], ["treated", 1039], ["with", 1047], ["dithiothreitol", 1052], [",", 1066], ["and", 1068], ["did", 1072], ["not", 1076], ["react", 1080], ["with", 1086], ["McLeod", 1091], ["RBCs", 1098], [".", 1102], ["XK", 1104], ["protein", 1107], ["was", 1115], ["absent", 1119], ["from", 1126], ["the", 1131], ["RBC", 1135], ["membranes", 1139], [".", 1148], ["The", 1150], ["XK", 1154], ["gene", 1157], ["had", 1162], ["a", 1166], ["point", 1168], ["mutation", 1174], ["in", 1183], ["the", 1186], ["donor", 1190], ["splice", 1196], ["site", 1203], ["of", 1208], ["intron", 1211], ["1", 1218], ["(", 1220], ["G", 1221], [">", 1222], ["C", 1223], [")", 1224], [".", 1225], ["This", 1227], ["is", 1232], ["the", 1235], ["first", 1239], ["report", 1245], ["describing", 1252], ["the", 1263], ["molecular", 1267], ["alteration", 1277], ["in", 1288], ["a", 1291], ["non", 1293], ["-", 1296], ["CGD", 1297], ["McLeod", 1301], ["patient", 1308], ["who", 1316], ["has", 1320], ["made", 1324], ["anti", 1329], ["-", 1333], ["Kx", 1334], [".", 1336], ["The", 1338], ["immune", 1342], ["response", 1349], ["of", 1358], ["people", 1361], ["with", 1368], ["the", 1373], ["McLeod", 1377], ["phenotype", 1384], ["can", 1394], ["vary", 1398], [",", 1402], ["and", 1404], ["K(O", 1408], [")", 1411], ["blood", 1413], ["may", 1419], ["not", 1423], ["always", 1427], ["be", 1434], ["compatible", 1437], [".", 1447]]}
{"context": "Previous X-ray crystal structures have shown that linkers of five amino acid residues connecting pairs of chicken brain alpha-spectrin and human erythroid beta-spectrin repeats can undergo bending without losing their alpha-helical structure. To test whether bending at one linker can influence bending at an adjacent linker, the structures of two and three repeat fragments of chicken brain alpha-spectrin have been determined by X-ray crystallography. The structure of the three-repeat fragment clearly shows that bending at one linker can occur independently of bending at an adjacent linker. This observation increases the possible trajectories of modeled chains of spectrin repeats. Furthermore, the three-repeat molecule crystallized as an antiparallel dimer with a significantly smaller buried interfacial area than that of alpha-actinin, a spectrin-related molecule, but large enough and of a type indicating biological specificity. Comparison of the structures of the spectrin and alpha-actinin dimers supports weak association of the former, which could not be detected by analytical ultracentrifugation, versus strong association of the latter, which has been observed by others. To correlate features of the structure with solution properties and to test a previous model of stable spectrin and dystrophin repeats, the number of inter-helical interactions in each repeat of several spectrin structures were counted and compared to their thermal stabilities. Inter-helical interactions, but not all interactions, increased in parallel with measured thermal stabilities of each repeat and in agreement with the thermal stabilities of two and three repeats and also partial repeats of spectrin.", "qas": [{"question": "Alpha-spectrin and beta-spectrin subunits form parallel or antiparallel heterodimers?", "answers": ["antiparallel"], "qid": "159e2ef1d3ca4a3b889fd3fd5ef2acb9", "question_tokens": [["Alpha", 0], ["-", 5], ["spectrin", 6], ["and", 15], ["beta", 19], ["-", 23], ["spectrin", 24], ["subunits", 33], ["form", 42], ["parallel", 47], ["or", 56], ["antiparallel", 59], ["heterodimers", 72], ["?", 84]], "detected_answers": [{"text": "antiparallel", "token_spans": [[127, 127]], "char_spans": [[746, 757]]}]}], "context_tokens": [["Previous", 0], ["X", 9], ["-", 10], ["ray", 11], ["crystal", 15], ["structures", 23], ["have", 34], ["shown", 39], ["that", 45], ["linkers", 50], ["of", 58], ["five", 61], ["amino", 66], ["acid", 72], ["residues", 77], ["connecting", 86], ["pairs", 97], ["of", 103], ["chicken", 106], ["brain", 114], ["alpha", 120], ["-", 125], ["spectrin", 126], ["and", 135], ["human", 139], ["erythroid", 145], ["beta", 155], ["-", 159], ["spectrin", 160], ["repeats", 169], ["can", 177], ["undergo", 181], ["bending", 189], ["without", 197], ["losing", 205], ["their", 212], ["alpha", 218], ["-", 223], ["helical", 224], ["structure", 232], [".", 241], ["To", 243], ["test", 246], ["whether", 251], ["bending", 259], ["at", 267], ["one", 270], ["linker", 274], ["can", 281], ["influence", 285], ["bending", 295], ["at", 303], ["an", 306], ["adjacent", 309], ["linker", 318], [",", 324], ["the", 326], ["structures", 330], ["of", 341], ["two", 344], ["and", 348], ["three", 352], ["repeat", 358], ["fragments", 365], ["of", 375], ["chicken", 378], ["brain", 386], ["alpha", 392], ["-", 397], ["spectrin", 398], ["have", 407], ["been", 412], ["determined", 417], ["by", 428], ["X", 431], ["-", 432], ["ray", 433], ["crystallography", 437], [".", 452], ["The", 454], ["structure", 458], ["of", 468], ["the", 471], ["three", 475], ["-", 480], ["repeat", 481], ["fragment", 488], ["clearly", 497], ["shows", 505], ["that", 511], ["bending", 516], ["at", 524], ["one", 527], ["linker", 531], ["can", 538], ["occur", 542], ["independently", 548], ["of", 562], ["bending", 565], ["at", 573], ["an", 576], ["adjacent", 579], ["linker", 588], [".", 594], ["This", 596], ["observation", 601], ["increases", 613], ["the", 623], ["possible", 627], ["trajectories", 636], ["of", 649], ["modeled", 652], ["chains", 660], ["of", 667], ["spectrin", 670], ["repeats", 679], [".", 686], ["Furthermore", 688], [",", 699], ["the", 701], ["three", 705], ["-", 710], ["repeat", 711], ["molecule", 718], ["crystallized", 727], ["as", 740], ["an", 743], ["antiparallel", 746], ["dimer", 759], ["with", 765], ["a", 770], ["significantly", 772], ["smaller", 786], ["buried", 794], ["interfacial", 801], ["area", 813], ["than", 818], ["that", 823], ["of", 828], ["alpha", 831], ["-", 836], ["actinin", 837], [",", 844], ["a", 846], ["spectrin", 848], ["-", 856], ["related", 857], ["molecule", 865], [",", 873], ["but", 875], ["large", 879], ["enough", 885], ["and", 892], ["of", 896], ["a", 899], ["type", 901], ["indicating", 906], ["biological", 917], ["specificity", 928], [".", 939], ["Comparison", 941], ["of", 952], ["the", 955], ["structures", 959], ["of", 970], ["the", 973], ["spectrin", 977], ["and", 986], ["alpha", 990], ["-", 995], ["actinin", 996], ["dimers", 1004], ["supports", 1011], ["weak", 1020], ["association", 1025], ["of", 1037], ["the", 1040], ["former", 1044], [",", 1050], ["which", 1052], ["could", 1058], ["not", 1064], ["be", 1068], ["detected", 1071], ["by", 1080], ["analytical", 1083], ["ultracentrifugation", 1094], [",", 1113], ["versus", 1115], ["strong", 1122], ["association", 1129], ["of", 1141], ["the", 1144], ["latter", 1148], [",", 1154], ["which", 1156], ["has", 1162], ["been", 1166], ["observed", 1171], ["by", 1180], ["others", 1183], [".", 1189], ["To", 1191], ["correlate", 1194], ["features", 1204], ["of", 1213], ["the", 1216], ["structure", 1220], ["with", 1230], ["solution", 1235], ["properties", 1244], ["and", 1255], ["to", 1259], ["test", 1262], ["a", 1267], ["previous", 1269], ["model", 1278], ["of", 1284], ["stable", 1287], ["spectrin", 1294], ["and", 1303], ["dystrophin", 1307], ["repeats", 1318], [",", 1325], ["the", 1327], ["number", 1331], ["of", 1338], ["inter", 1341], ["-", 1346], ["helical", 1347], ["interactions", 1355], ["in", 1368], ["each", 1371], ["repeat", 1376], ["of", 1383], ["several", 1386], ["spectrin", 1394], ["structures", 1403], ["were", 1414], ["counted", 1419], ["and", 1427], ["compared", 1431], ["to", 1440], ["their", 1443], ["thermal", 1449], ["stabilities", 1457], [".", 1468], ["Inter", 1470], ["-", 1475], ["helical", 1476], ["interactions", 1484], [",", 1496], ["but", 1498], ["not", 1502], ["all", 1506], ["interactions", 1510], [",", 1522], ["increased", 1524], ["in", 1534], ["parallel", 1537], ["with", 1546], ["measured", 1551], ["thermal", 1560], ["stabilities", 1568], ["of", 1580], ["each", 1583], ["repeat", 1588], ["and", 1595], ["in", 1599], ["agreement", 1602], ["with", 1612], ["the", 1617], ["thermal", 1621], ["stabilities", 1629], ["of", 1641], ["two", 1644], ["and", 1648], ["three", 1652], ["repeats", 1658], ["and", 1666], ["also", 1670], ["partial", 1675], ["repeats", 1683], ["of", 1691], ["spectrin", 1694], [".", 1702]]}
{"context": "Chronic myeloid leukemia (CML) is a clonal hematopoietic stem cell disorder characterized by Philadelphia chromosome and resultant production of the constitutively activated BCR-ABL tyrosine kinase. Imatinib (STI571), selective inhibitor of the ABL-tyrosine kinase, inhibits the activity of BCR-ABL tyrosine kinase. A phase I and II study of STI571 showed remarkable cytogenetic effect in patients with interferon-refractory CML, offering new hope for therapy for CML. It will, however, require long-term follow-up data from phase II and III clinical studies to validate the effect of STI571 on survival. As therapy for CML improves, monitoring minimal residual disease will be important.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "0bb3119e6d6d48ffa24785cf272e280e", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[48, 50], [24, 26]], "char_spans": [[291, 297], [174, 180]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukemia", 16], ["(", 25], ["CML", 26], [")", 29], ["is", 31], ["a", 34], ["clonal", 36], ["hematopoietic", 43], ["stem", 57], ["cell", 62], ["disorder", 67], ["characterized", 76], ["by", 90], ["Philadelphia", 93], ["chromosome", 106], ["and", 117], ["resultant", 121], ["production", 131], ["of", 142], ["the", 145], ["constitutively", 149], ["activated", 164], ["BCR", 174], ["-", 177], ["ABL", 178], ["tyrosine", 182], ["kinase", 191], [".", 197], ["Imatinib", 199], ["(", 208], ["STI571", 209], [")", 215], [",", 216], ["selective", 218], ["inhibitor", 228], ["of", 238], ["the", 241], ["ABL", 245], ["-", 248], ["tyrosine", 249], ["kinase", 258], [",", 264], ["inhibits", 266], ["the", 275], ["activity", 279], ["of", 288], ["BCR", 291], ["-", 294], ["ABL", 295], ["tyrosine", 299], ["kinase", 308], [".", 314], ["A", 316], ["phase", 318], ["I", 324], ["and", 326], ["II", 330], ["study", 333], ["of", 339], ["STI571", 342], ["showed", 349], ["remarkable", 356], ["cytogenetic", 367], ["effect", 379], ["in", 386], ["patients", 389], ["with", 398], ["interferon", 403], ["-", 413], ["refractory", 414], ["CML", 425], [",", 428], ["offering", 430], ["new", 439], ["hope", 443], ["for", 448], ["therapy", 452], ["for", 460], ["CML", 464], [".", 467], ["It", 469], ["will", 472], [",", 476], ["however", 478], [",", 485], ["require", 487], ["long", 495], ["-", 499], ["term", 500], ["follow", 505], ["-", 511], ["up", 512], ["data", 515], ["from", 520], ["phase", 525], ["II", 531], ["and", 534], ["III", 538], ["clinical", 542], ["studies", 551], ["to", 559], ["validate", 562], ["the", 571], ["effect", 575], ["of", 582], ["STI571", 585], ["on", 592], ["survival", 595], [".", 603], ["As", 605], ["therapy", 608], ["for", 616], ["CML", 620], ["improves", 624], [",", 632], ["monitoring", 634], ["minimal", 645], ["residual", 653], ["disease", 662], ["will", 670], ["be", 675], ["important", 678], [".", 687]]}
{"context": "Marfanoid phenotype with craniosynostosis (Shprintzen-Goldberg syndrome) is a rare disorder previously described in only 5 patients. We report on the sixth known patient with this condition. The findings which distinguish our patient from others reported previously are that she was ascertained prenatally as having a cloverleaf skull; this is the first female patient described with this condition. Postnatally, she presented with arachnodactyly, camptodactyly, and clover-leaf skull. Imaging studies of the brain documented microcephaly with malformed brain, hydrocephaly, and hypoplasia of the corpus callosum. She also had choanal atresia and stenosis, a clinical finding previously reported only once, in this disorder.", "qas": [{"question": "Which disease is included as an additional feature in the Goldberg-Shprintzen syndrome?", "answers": ["Craniosynostosis"], "qid": "78c142601b5048dd9ab83e39d4e8e15f", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["included", 17], ["as", 26], ["an", 29], ["additional", 32], ["feature", 43], ["in", 51], ["the", 54], ["Goldberg", 58], ["-", 66], ["Shprintzen", 67], ["syndrome", 78], ["?", 86]], "detected_answers": [{"text": "Craniosynostosis", "token_spans": [[3, 3]], "char_spans": [[25, 40]]}]}], "context_tokens": [["Marfanoid", 0], ["phenotype", 10], ["with", 20], ["craniosynostosis", 25], ["(", 42], ["Shprintzen", 43], ["-", 53], ["Goldberg", 54], ["syndrome", 63], [")", 71], ["is", 73], ["a", 76], ["rare", 78], ["disorder", 83], ["previously", 92], ["described", 103], ["in", 113], ["only", 116], ["5", 121], ["patients", 123], [".", 131], ["We", 133], ["report", 136], ["on", 143], ["the", 146], ["sixth", 150], ["known", 156], ["patient", 162], ["with", 170], ["this", 175], ["condition", 180], [".", 189], ["The", 191], ["findings", 195], ["which", 204], ["distinguish", 210], ["our", 222], ["patient", 226], ["from", 234], ["others", 239], ["reported", 246], ["previously", 255], ["are", 266], ["that", 270], ["she", 275], ["was", 279], ["ascertained", 283], ["prenatally", 295], ["as", 306], ["having", 309], ["a", 316], ["cloverleaf", 318], ["skull", 329], [";", 334], ["this", 336], ["is", 341], ["the", 344], ["first", 348], ["female", 354], ["patient", 361], ["described", 369], ["with", 379], ["this", 384], ["condition", 389], [".", 398], ["Postnatally", 400], [",", 411], ["she", 413], ["presented", 417], ["with", 427], ["arachnodactyly", 432], [",", 446], ["camptodactyly", 448], [",", 461], ["and", 463], ["clover", 467], ["-", 473], ["leaf", 474], ["skull", 479], [".", 484], ["Imaging", 486], ["studies", 494], ["of", 502], ["the", 505], ["brain", 509], ["documented", 515], ["microcephaly", 526], ["with", 539], ["malformed", 544], ["brain", 554], [",", 559], ["hydrocephaly", 561], [",", 573], ["and", 575], ["hypoplasia", 579], ["of", 590], ["the", 593], ["corpus", 597], ["callosum", 604], [".", 612], ["She", 614], ["also", 618], ["had", 623], ["choanal", 627], ["atresia", 635], ["and", 643], ["stenosis", 647], [",", 655], ["a", 657], ["clinical", 659], ["finding", 668], ["previously", 676], ["reported", 687], ["only", 696], ["once", 701], [",", 705], ["in", 707], ["this", 710], ["disorder", 715], [".", 723]]}
{"context": "The BCR/ABL gene fusion, the hallmark of chronic myelogenous leukemia (CML) is generated in 2-10% of patients by a variant Ph translocation involving 9q34, 22q11.2, and one or more additional genomic regions. The objective of this study was the characterization by conventional and molecular cytogenetics of complex variant Ph translocations present at diagnosis. FISH studies were performed in 7 cases using the LSI BCR/ABL ES probe allowing the detection of the fusion BCR/ABL gene on the Ph chromosome in all of them and 9q34 deletions in 2 cases. Three cryptic complex rearrangements were detected by FISH studies. The third and the fourth chromosome regions involved in the 8 complex variant translocations were: 1q21, 1p36, 5q31, 11q13, 12q13, 12p13, and 20q12. In conclusion, FISH studies have been useful in the detection of the BCR/ABL rearrangements and 9q34 deletions, and to identify complex rearrangements that differ from the ones previously established by conventional cytogenetics.", "qas": [{"question": "Which gene fusion is the result of the \"philadelphia translocation\" or the \"philadelphia chromosome\" mutation?", "answers": ["The BCR/ABL gene fusion", "ABL/BCR fusion"], "qid": "85a18e64fb2d47b0afeee4832c599891", "question_tokens": [["Which", 0], ["gene", 6], ["fusion", 11], ["is", 18], ["the", 21], ["result", 25], ["of", 32], ["the", 35], ["\"", 39], ["philadelphia", 40], ["translocation", 53], ["\"", 66], ["or", 68], ["the", 71], ["\"", 75], ["philadelphia", 76], ["chromosome", 89], ["\"", 99], ["mutation", 101], ["?", 109]], "detected_answers": [{"text": "The BCR/ABL gene fusion", "token_spans": [[1, 5]], "char_spans": [[4, 22]]}]}], "context_tokens": [["The", 0], ["BCR", 4], ["/", 7], ["ABL", 8], ["gene", 12], ["fusion", 17], [",", 23], ["the", 25], ["hallmark", 29], ["of", 38], ["chronic", 41], ["myelogenous", 49], ["leukemia", 61], ["(", 70], ["CML", 71], [")", 74], ["is", 76], ["generated", 79], ["in", 89], ["2", 92], ["-", 93], ["10", 94], ["%", 96], ["of", 98], ["patients", 101], ["by", 110], ["a", 113], ["variant", 115], ["Ph", 123], ["translocation", 126], ["involving", 140], ["9q34", 150], [",", 154], ["22q11.2", 156], [",", 163], ["and", 165], ["one", 169], ["or", 173], ["more", 176], ["additional", 181], ["genomic", 192], ["regions", 200], [".", 207], ["The", 209], ["objective", 213], ["of", 223], ["this", 226], ["study", 231], ["was", 237], ["the", 241], ["characterization", 245], ["by", 262], ["conventional", 265], ["and", 278], ["molecular", 282], ["cytogenetics", 292], ["of", 305], ["complex", 308], ["variant", 316], ["Ph", 324], ["translocations", 327], ["present", 342], ["at", 350], ["diagnosis", 353], [".", 362], ["FISH", 364], ["studies", 369], ["were", 377], ["performed", 382], ["in", 392], ["7", 395], ["cases", 397], ["using", 403], ["the", 409], ["LSI", 413], ["BCR", 417], ["/", 420], ["ABL", 421], ["ES", 425], ["probe", 428], ["allowing", 434], ["the", 443], ["detection", 447], ["of", 457], ["the", 460], ["fusion", 464], ["BCR", 471], ["/", 474], ["ABL", 475], ["gene", 479], ["on", 484], ["the", 487], ["Ph", 491], ["chromosome", 494], ["in", 505], ["all", 508], ["of", 512], ["them", 515], ["and", 520], ["9q34", 524], ["deletions", 529], ["in", 539], ["2", 542], ["cases", 544], [".", 549], ["Three", 551], ["cryptic", 557], ["complex", 565], ["rearrangements", 573], ["were", 588], ["detected", 593], ["by", 602], ["FISH", 605], ["studies", 610], [".", 617], ["The", 619], ["third", 623], ["and", 629], ["the", 633], ["fourth", 637], ["chromosome", 644], ["regions", 655], ["involved", 663], ["in", 672], ["the", 675], ["8", 679], ["complex", 681], ["variant", 689], ["translocations", 697], ["were", 712], [":", 716], ["1q21", 718], [",", 722], ["1p36", 724], [",", 728], ["5q31", 730], [",", 734], ["11q13", 736], [",", 741], ["12q13", 743], [",", 748], ["12p13", 750], [",", 755], ["and", 757], ["20q12", 761], [".", 766], ["In", 768], ["conclusion", 771], [",", 781], ["FISH", 783], ["studies", 788], ["have", 796], ["been", 801], ["useful", 806], ["in", 813], ["the", 816], ["detection", 820], ["of", 830], ["the", 833], ["BCR", 837], ["/", 840], ["ABL", 841], ["rearrangements", 845], ["and", 860], ["9q34", 864], ["deletions", 869], [",", 878], ["and", 880], ["to", 884], ["identify", 887], ["complex", 896], ["rearrangements", 904], ["that", 919], ["differ", 924], ["from", 931], ["the", 936], ["ones", 940], ["previously", 945], ["established", 956], ["by", 968], ["conventional", 971], ["cytogenetics", 984], [".", 996]]}
{"context": "Cystic fibrosis (CF) is the most common inherited disorder in Caucasian populations, with over 1400 mutations identified in the Cystic Fibrosis Transmembrane conductance Regulator (CFTR) gene. Mutations in the CFTR gene may be also causative for CBAVD (Congenital Bilateral Absence of the Vas Deferens). The type and distribution of mutations varies widely between different countries and/or ethnic groups, and is relatively unknown in Iran. We therefore performed a comprehensive analysis of the CFTR gene in Iranian CF patients. 69 Iranian CF patients, and 1 CBAVD patient, were analysed for mutations in the complete coding region, and its exon/intron junctions, of their CFTR genes, using different methods, such as ARMS (amplification refractory mutation system)-PCR, SSCP (single stranded conformation polymorphism) analysis, restriction enzyme digestion analysis, direct sequencing, and MLPA (Multiplex Ligation-mediated Probe Amplification). CFTR mutation analysis revealed the identification of 37 mutations in 69 Iranian CF patients. Overall, 81.9% (113/138) CFTR genes derived from Iranian CF patients could be characterized for a disease-causing mutation. The CBAVD patient was found to be homozygous for the p.W1145R mutation. The most common mutations were p.F508del (DeltaF508) (18.1%), c.2183_2184delAAinsG (2183AA>G) (6.5%), p.S466X (5.8%), p.N1303K (4.3%), c.2789+5G>A (4.3%), p.G542X (3.6%), c.3120+1G>A (3.6%), p.R334W (2.9%) and c.3130delA (2.9%). These 9 types of mutant CFTR genes totaled for 52% of all CFTR genes derived from the 69 Iranian CF patients. Eight mutations, c.406-8T>C, p.A566D, c.2576delA, c.2752-1_2756delGGTGGCinsTTG, p.T1036I, p.W1145R, c.3850-24G>A, c.1342-?_1524+?del, were found for the first time in this study. We identified 37 CFTR mutations in 69 well characterized Iranian CF patients, obtaining a CFTR mutation detection rate of 81.9%, the highest detection rate obtained in the Iranian population so far. These findings will assist in genetic counseling, prenatal diagnosis and future screening of CF in Iran.", "qas": [{"question": "Which is the most common CFTR mutation in Caucasians?", "answers": ["deltaF508"], "qid": "721f570c564a469791dc784b8d46492b", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["most", 13], ["common", 18], ["CFTR", 25], ["mutation", 30], ["in", 39], ["Caucasians", 42], ["?", 52]], "detected_answers": [{"text": "deltaF508", "token_spans": [[226, 226]], "char_spans": [[1282, 1290]]}]}], "context_tokens": [["Cystic", 0], ["fibrosis", 7], ["(", 16], ["CF", 17], [")", 19], ["is", 21], ["the", 24], ["most", 28], ["common", 33], ["inherited", 40], ["disorder", 50], ["in", 59], ["Caucasian", 62], ["populations", 72], [",", 83], ["with", 85], ["over", 90], ["1400", 95], ["mutations", 100], ["identified", 110], ["in", 121], ["the", 124], ["Cystic", 128], ["Fibrosis", 135], ["Transmembrane", 144], ["conductance", 158], ["Regulator", 170], ["(", 180], ["CFTR", 181], [")", 185], ["gene", 187], [".", 191], ["Mutations", 193], ["in", 203], ["the", 206], ["CFTR", 210], ["gene", 215], ["may", 220], ["be", 224], ["also", 227], ["causative", 232], ["for", 242], ["CBAVD", 246], ["(", 252], ["Congenital", 253], ["Bilateral", 264], ["Absence", 274], ["of", 282], ["the", 285], ["Vas", 289], ["Deferens", 293], [")", 301], [".", 302], ["The", 304], ["type", 308], ["and", 313], ["distribution", 317], ["of", 330], ["mutations", 333], ["varies", 343], ["widely", 350], ["between", 357], ["different", 365], ["countries", 375], ["and/or", 385], ["ethnic", 392], ["groups", 399], [",", 405], ["and", 407], ["is", 411], ["relatively", 414], ["unknown", 425], ["in", 433], ["Iran", 436], [".", 440], ["We", 442], ["therefore", 445], ["performed", 455], ["a", 465], ["comprehensive", 467], ["analysis", 481], ["of", 490], ["the", 493], ["CFTR", 497], ["gene", 502], ["in", 507], ["Iranian", 510], ["CF", 518], ["patients", 521], [".", 529], ["69", 531], ["Iranian", 534], ["CF", 542], ["patients", 545], [",", 553], ["and", 555], ["1", 559], ["CBAVD", 561], ["patient", 567], [",", 574], ["were", 576], ["analysed", 581], ["for", 590], ["mutations", 594], ["in", 604], ["the", 607], ["complete", 611], ["coding", 620], ["region", 627], [",", 633], ["and", 635], ["its", 639], ["exon", 643], ["/", 647], ["intron", 648], ["junctions", 655], [",", 664], ["of", 666], ["their", 669], ["CFTR", 675], ["genes", 680], [",", 685], ["using", 687], ["different", 693], ["methods", 703], [",", 710], ["such", 712], ["as", 717], ["ARMS", 720], ["(", 725], ["amplification", 726], ["refractory", 740], ["mutation", 751], ["system)-PCR", 760], [",", 771], ["SSCP", 773], ["(", 778], ["single", 779], ["stranded", 786], ["conformation", 795], ["polymorphism", 808], [")", 820], ["analysis", 822], [",", 830], ["restriction", 832], ["enzyme", 844], ["digestion", 851], ["analysis", 861], [",", 869], ["direct", 871], ["sequencing", 878], [",", 888], ["and", 890], ["MLPA", 894], ["(", 899], ["Multiplex", 900], ["Ligation", 910], ["-", 918], ["mediated", 919], ["Probe", 928], ["Amplification", 934], [")", 947], [".", 948], ["CFTR", 950], ["mutation", 955], ["analysis", 964], ["revealed", 973], ["the", 982], ["identification", 986], ["of", 1001], ["37", 1004], ["mutations", 1007], ["in", 1017], ["69", 1020], ["Iranian", 1023], ["CF", 1031], ["patients", 1034], [".", 1042], ["Overall", 1044], [",", 1051], ["81.9", 1053], ["%", 1057], ["(", 1059], ["113/138", 1060], [")", 1067], ["CFTR", 1069], ["genes", 1074], ["derived", 1080], ["from", 1088], ["Iranian", 1093], ["CF", 1101], ["patients", 1104], ["could", 1113], ["be", 1119], ["characterized", 1122], ["for", 1136], ["a", 1140], ["disease", 1142], ["-", 1149], ["causing", 1150], ["mutation", 1158], [".", 1166], ["The", 1168], ["CBAVD", 1172], ["patient", 1178], ["was", 1186], ["found", 1190], ["to", 1196], ["be", 1199], ["homozygous", 1202], ["for", 1213], ["the", 1217], ["p", 1221], [".", 1222], ["W1145R", 1223], ["mutation", 1230], [".", 1238], ["The", 1240], ["most", 1244], ["common", 1249], ["mutations", 1256], ["were", 1266], ["p", 1271], [".", 1272], ["F508del", 1273], ["(", 1281], ["DeltaF508", 1282], [")", 1291], ["(", 1293], ["18.1", 1294], ["%", 1298], [")", 1299], [",", 1300], ["c.2183_2184delAAinsG", 1302], ["(", 1323], ["2183AA", 1324], [">", 1330], ["G", 1331], [")", 1332], ["(", 1334], ["6.5", 1335], ["%", 1338], [")", 1339], [",", 1340], ["p", 1342], [".", 1343], ["S466X", 1344], ["(", 1350], ["5.8", 1351], ["%", 1354], [")", 1355], [",", 1356], ["p", 1358], [".", 1359], ["N1303", 1360], ["K", 1365], ["(", 1367], ["4.3", 1368], ["%", 1371], [")", 1372], [",", 1373], ["c.2789", 1375], ["+", 1381], ["5G", 1382], [">", 1384], ["A", 1385], ["(", 1387], ["4.3", 1388], ["%", 1391], [")", 1392], [",", 1393], ["p", 1395], [".", 1396], ["G542X", 1397], ["(", 1403], ["3.6", 1404], ["%", 1407], [")", 1408], [",", 1409], ["c.3120", 1411], ["+", 1417], ["1G", 1418], [">", 1420], ["A", 1421], ["(", 1423], ["3.6", 1424], ["%", 1427], [")", 1428], [",", 1429], ["p", 1431], [".", 1432], ["R334W", 1433], ["(", 1439], ["2.9", 1440], ["%", 1443], [")", 1444], ["and", 1446], ["c.3130delA", 1450], ["(", 1461], ["2.9", 1462], ["%", 1465], [")", 1466], [".", 1467], ["These", 1469], ["9", 1475], ["types", 1477], ["of", 1483], ["mutant", 1486], ["CFTR", 1493], ["genes", 1498], ["totaled", 1504], ["for", 1512], ["52", 1516], ["%", 1518], ["of", 1520], ["all", 1523], ["CFTR", 1527], ["genes", 1532], ["derived", 1538], ["from", 1546], ["the", 1551], ["69", 1555], ["Iranian", 1558], ["CF", 1566], ["patients", 1569], [".", 1577], ["Eight", 1579], ["mutations", 1585], [",", 1594], ["c.406", 1596], ["-", 1601], ["8T", 1602], [">", 1604], ["C", 1605], [",", 1606], ["p", 1608], [".", 1609], ["A566D", 1610], [",", 1615], ["c.2576delA", 1617], [",", 1627], ["c.2752", 1629], ["-", 1635], ["1_2756delGGTGGCinsTTG", 1636], [",", 1657], ["p", 1659], [".", 1660], ["T1036I", 1661], [",", 1667], ["p", 1669], [".", 1670], ["W1145R", 1671], [",", 1677], ["c.3850", 1679], ["-", 1685], ["24G", 1686], [">", 1689], ["A", 1690], [",", 1691], ["c.1342-?_1524+?del", 1693], [",", 1711], ["were", 1713], ["found", 1718], ["for", 1724], ["the", 1728], ["first", 1732], ["time", 1738], ["in", 1743], ["this", 1746], ["study", 1751], [".", 1756], ["We", 1758], ["identified", 1761], ["37", 1772], ["CFTR", 1775], ["mutations", 1780], ["in", 1790], ["69", 1793], ["well", 1796], ["characterized", 1801], ["Iranian", 1815], ["CF", 1823], ["patients", 1826], [",", 1834], ["obtaining", 1836], ["a", 1846], ["CFTR", 1848], ["mutation", 1853], ["detection", 1862], ["rate", 1872], ["of", 1877], ["81.9", 1880], ["%", 1884], [",", 1885], ["the", 1887], ["highest", 1891], ["detection", 1899], ["rate", 1909], ["obtained", 1914], ["in", 1923], ["the", 1926], ["Iranian", 1930], ["population", 1938], ["so", 1949], ["far", 1952], [".", 1955], ["These", 1957], ["findings", 1963], ["will", 1972], ["assist", 1977], ["in", 1984], ["genetic", 1987], ["counseling", 1995], [",", 2005], ["prenatal", 2007], ["diagnosis", 2016], ["and", 2026], ["future", 2030], ["screening", 2037], ["of", 2047], ["CF", 2050], ["in", 2053], ["Iran", 2056], [".", 2060]]}
{"context": "One of the major histopathological hallmarks of Alzheimer's disease (AD) is cerebral deposits of extracellular \u03b2-amyloid peptides. Preclinical studies have pointed to glucagon-like peptide 1 (GLP-1) receptors as a potential novel target in the treatment of AD. GLP-1 receptor agonists, including exendin-4 and liraglutide, have been shown to promote plaque-lowering and mnemonic effects of in a number of experimental models of AD. Transgenic mouse models carrying genetic mutations of amyloid protein precursor (APP) and presenilin-1 (PS1) are commonly used to assess the pharmacodynamics of potential amyloidosis-lowering and pro-cognitive compounds. In this study, effects of long-term liraglutide treatment were therefore determined in two double APP/PS1 transgenic mouse models of Alzheimer's disease carrying different clinical APP/PS1 mutations, i.e. the 'London' (hAPPLon/PS1A246E) and 'Swedish' mutation variant (hAPPSwe/PS1\u0394E9) of APP, with co-expression of distinct PS1 variants. Liraglutide was administered in 5 month-old hAPPLon/PS1A246E mice for 3 months (100 or 500 ng/kg/day, s.c.), or 7 month-old hAPPSwe/PS1\u0394E9 mice for 5 months (500 ng/kg/day, s.c.). In both models, regional plaque load was quantified throughout the brain using stereological methods. Vehicle-dosed hAPPSwe/PS1\u0394E9 mice exhibited considerably higher cerebral plaque load than hAPPLon/PS1A246E control mice. Compared to vehicle-dosed transgenic controls, liraglutide treatment had no effect on the plaque levels in hAPPLon/PS1A246E and hAPPSwe/PS1\u0394E9 mice. In conclusion, long-term liraglutide treatment exhibited no effect on cerebral plaque load in two transgenic mouse models of low- and high-grade amyloidosis, which suggests differential sensitivity to long-term liraglutide treatment in various transgenic mouse models mimicking distinct pathological hallmarks of AD.", "qas": [{"question": "Which disease the London mutation involved in?", "answers": ["Alzheimer's Disease", "AD"], "qid": "9e28aa040a2f43c3ab63eeba84b5f4de", "question_tokens": [["Which", 0], ["disease", 6], ["the", 14], ["London", 18], ["mutation", 25], ["involved", 34], ["in", 43], ["?", 45]], "detected_answers": [{"text": "Alzheimer's Disease", "token_spans": [[138, 140], [7, 9]], "char_spans": [[786, 804], [48, 66]]}, {"text": "AD", "token_spans": [[76, 76], [11, 11], [346, 346], [46, 46]], "char_spans": [[428, 429], [69, 70], [1856, 1857], [257, 258]]}]}], "context_tokens": [["One", 0], ["of", 4], ["the", 7], ["major", 11], ["histopathological", 17], ["hallmarks", 35], ["of", 45], ["Alzheimer", 48], ["'s", 57], ["disease", 60], ["(", 68], ["AD", 69], [")", 71], ["is", 73], ["cerebral", 76], ["deposits", 85], ["of", 94], ["extracellular", 97], ["\u03b2", 111], ["-", 112], ["amyloid", 113], ["peptides", 121], [".", 129], ["Preclinical", 131], ["studies", 143], ["have", 151], ["pointed", 156], ["to", 164], ["glucagon", 167], ["-", 175], ["like", 176], ["peptide", 181], ["1", 189], ["(", 191], ["GLP-1", 192], [")", 197], ["receptors", 199], ["as", 209], ["a", 212], ["potential", 214], ["novel", 224], ["target", 230], ["in", 237], ["the", 240], ["treatment", 244], ["of", 254], ["AD", 257], [".", 259], ["GLP-1", 261], ["receptor", 267], ["agonists", 276], [",", 284], ["including", 286], ["exendin-4", 296], ["and", 306], ["liraglutide", 310], [",", 321], ["have", 323], ["been", 328], ["shown", 333], ["to", 339], ["promote", 342], ["plaque", 350], ["-", 356], ["lowering", 357], ["and", 366], ["mnemonic", 370], ["effects", 379], ["of", 387], ["in", 390], ["a", 393], ["number", 395], ["of", 402], ["experimental", 405], ["models", 418], ["of", 425], ["AD", 428], [".", 430], ["Transgenic", 432], ["mouse", 443], ["models", 449], ["carrying", 456], ["genetic", 465], ["mutations", 473], ["of", 483], ["amyloid", 486], ["protein", 494], ["precursor", 502], ["(", 512], ["APP", 513], [")", 516], ["and", 518], ["presenilin-1", 522], ["(", 535], ["PS1", 536], [")", 539], ["are", 541], ["commonly", 545], ["used", 554], ["to", 559], ["assess", 562], ["the", 569], ["pharmacodynamics", 573], ["of", 590], ["potential", 593], ["amyloidosis", 603], ["-", 614], ["lowering", 615], ["and", 624], ["pro", 628], ["-", 631], ["cognitive", 632], ["compounds", 642], [".", 651], ["In", 653], ["this", 656], ["study", 661], [",", 666], ["effects", 668], ["of", 676], ["long", 679], ["-", 683], ["term", 684], ["liraglutide", 689], ["treatment", 701], ["were", 711], ["therefore", 716], ["determined", 726], ["in", 737], ["two", 740], ["double", 744], ["APP", 751], ["/", 754], ["PS1", 755], ["transgenic", 759], ["mouse", 770], ["models", 776], ["of", 783], ["Alzheimer", 786], ["'s", 795], ["disease", 798], ["carrying", 806], ["different", 815], ["clinical", 825], ["APP", 834], ["/", 837], ["PS1", 838], ["mutations", 842], [",", 851], ["i.e.", 853], ["the", 858], ["'", 862], ["London", 863], ["'", 869], ["(", 871], ["hAPPLon", 872], ["/", 879], ["PS1A246E", 880], [")", 888], ["and", 890], ["'", 894], ["Swedish", 895], ["'", 902], ["mutation", 904], ["variant", 913], ["(", 921], ["hAPPSwe", 922], ["/", 929], ["PS1\u0394E9", 930], [")", 936], ["of", 938], ["APP", 941], [",", 944], ["with", 946], ["co", 951], ["-", 953], ["expression", 954], ["of", 965], ["distinct", 968], ["PS1", 977], ["variants", 981], [".", 989], ["Liraglutide", 991], ["was", 1003], ["administered", 1007], ["in", 1020], ["5", 1023], ["month", 1025], ["-", 1030], ["old", 1031], ["hAPPLon", 1035], ["/", 1042], ["PS1A246E", 1043], ["mice", 1052], ["for", 1057], ["3", 1061], ["months", 1063], ["(", 1070], ["100", 1071], ["or", 1075], ["500", 1078], ["ng", 1082], ["/", 1084], ["kg", 1085], ["/", 1087], ["day", 1088], [",", 1091], ["s.c", 1093], [".", 1096], [")", 1097], [",", 1098], ["or", 1100], ["7", 1103], ["month", 1105], ["-", 1110], ["old", 1111], ["hAPPSwe", 1115], ["/", 1122], ["PS1\u0394E9", 1123], ["mice", 1130], ["for", 1135], ["5", 1139], ["months", 1141], ["(", 1148], ["500", 1149], ["ng", 1153], ["/", 1155], ["kg", 1156], ["/", 1158], ["day", 1159], [",", 1162], ["s.c", 1164], [".", 1167], [")", 1168], [".", 1169], ["In", 1171], ["both", 1174], ["models", 1179], [",", 1185], ["regional", 1187], ["plaque", 1196], ["load", 1203], ["was", 1208], ["quantified", 1212], ["throughout", 1223], ["the", 1234], ["brain", 1238], ["using", 1244], ["stereological", 1250], ["methods", 1264], [".", 1271], ["Vehicle", 1273], ["-", 1280], ["dosed", 1281], ["hAPPSwe", 1287], ["/", 1294], ["PS1\u0394E9", 1295], ["mice", 1302], ["exhibited", 1307], ["considerably", 1317], ["higher", 1330], ["cerebral", 1337], ["plaque", 1346], ["load", 1353], ["than", 1358], ["hAPPLon", 1363], ["/", 1370], ["PS1A246E", 1371], ["control", 1380], ["mice", 1388], [".", 1392], ["Compared", 1394], ["to", 1403], ["vehicle", 1406], ["-", 1413], ["dosed", 1414], ["transgenic", 1420], ["controls", 1431], [",", 1439], ["liraglutide", 1441], ["treatment", 1453], ["had", 1463], ["no", 1467], ["effect", 1470], ["on", 1477], ["the", 1480], ["plaque", 1484], ["levels", 1491], ["in", 1498], ["hAPPLon", 1501], ["/", 1508], ["PS1A246E", 1509], ["and", 1518], ["hAPPSwe", 1522], ["/", 1529], ["PS1\u0394E9", 1530], ["mice", 1537], [".", 1541], ["In", 1543], ["conclusion", 1546], [",", 1556], ["long", 1558], ["-", 1562], ["term", 1563], ["liraglutide", 1568], ["treatment", 1580], ["exhibited", 1590], ["no", 1600], ["effect", 1603], ["on", 1610], ["cerebral", 1613], ["plaque", 1622], ["load", 1629], ["in", 1634], ["two", 1637], ["transgenic", 1641], ["mouse", 1652], ["models", 1658], ["of", 1665], ["low-", 1668], ["and", 1673], ["high", 1677], ["-", 1681], ["grade", 1682], ["amyloidosis", 1688], [",", 1699], ["which", 1701], ["suggests", 1707], ["differential", 1716], ["sensitivity", 1729], ["to", 1741], ["long", 1744], ["-", 1748], ["term", 1749], ["liraglutide", 1754], ["treatment", 1766], ["in", 1776], ["various", 1779], ["transgenic", 1787], ["mouse", 1798], ["models", 1804], ["mimicking", 1811], ["distinct", 1821], ["pathological", 1830], ["hallmarks", 1843], ["of", 1853], ["AD", 1856], [".", 1858]]}
{"context": "Malaria remains one of the few diseases those continue to scourge human civilization despite the significant advances in disease control strategies over the last century. Malaria is responsible for more than 500 million cases and 1-3 million deaths annually. Approximately 85% of these deaths are among children, mostly in Africa, primarily due to P. falciparum. Whole cell vaccines, irradiated sporozoites and genetically attenuated sporozoites have demonstrated long lasting, sterile protection against plasmodium infection in animal and experimental clinical studies. Atypical membrane protein 1 and merozoite surface protein 1 are the two most extensively studied asexual blood stage vaccine candidates. The most promising candidate vaccine under development is RTS, S combined with AS01 adjuvant. Initial results from phase III trials of this candidate vaccine show 50% reduction of malaria in 5-17 mo aged children during the 12 mo after vaccination. WHO anticipates that the RTS,S/AS01 vaccine will be recommended for the 6-14 week age group for co-administration together with other vaccines as part of routine immunization programs in malaria endemic countries. Malaria vaccine could play an important role in elimination and eventual eradication of malaria.", "qas": [{"question": "RTS S AS01 vaccine was developed to prevent which disease?", "answers": ["malaria"], "qid": "34237e2593fe47159c2577f4c10f4577", "question_tokens": [["RTS", 0], ["S", 4], ["AS01", 6], ["vaccine", 11], ["was", 19], ["developed", 23], ["to", 33], ["prevent", 36], ["which", 44], ["disease", 50], ["?", 57]], "detected_answers": [{"text": "malaria", "token_spans": [[0, 0], [197, 197], [26, 26], [210, 210], [142, 142], [193, 193]], "char_spans": [[0, 6], [1171, 1177], [171, 177], [1259, 1265], [888, 894], [1144, 1150]]}]}], "context_tokens": [["Malaria", 0], ["remains", 8], ["one", 16], ["of", 20], ["the", 23], ["few", 27], ["diseases", 31], ["those", 40], ["continue", 46], ["to", 55], ["scourge", 58], ["human", 66], ["civilization", 72], ["despite", 85], ["the", 93], ["significant", 97], ["advances", 109], ["in", 118], ["disease", 121], ["control", 129], ["strategies", 137], ["over", 148], ["the", 153], ["last", 157], ["century", 162], [".", 169], ["Malaria", 171], ["is", 179], ["responsible", 182], ["for", 194], ["more", 198], ["than", 203], ["500", 208], ["million", 212], ["cases", 220], ["and", 226], ["1", 230], ["-", 231], ["3", 232], ["million", 234], ["deaths", 242], ["annually", 249], [".", 257], ["Approximately", 259], ["85", 273], ["%", 275], ["of", 277], ["these", 280], ["deaths", 286], ["are", 293], ["among", 297], ["children", 303], [",", 311], ["mostly", 313], ["in", 320], ["Africa", 323], [",", 329], ["primarily", 331], ["due", 341], ["to", 345], ["P.", 348], ["falciparum", 351], [".", 361], ["Whole", 363], ["cell", 369], ["vaccines", 374], [",", 382], ["irradiated", 384], ["sporozoites", 395], ["and", 407], ["genetically", 411], ["attenuated", 423], ["sporozoites", 434], ["have", 446], ["demonstrated", 451], ["long", 464], ["lasting", 469], [",", 476], ["sterile", 478], ["protection", 486], ["against", 497], ["plasmodium", 505], ["infection", 516], ["in", 526], ["animal", 529], ["and", 536], ["experimental", 540], ["clinical", 553], ["studies", 562], [".", 569], ["Atypical", 571], ["membrane", 580], ["protein", 589], ["1", 597], ["and", 599], ["merozoite", 603], ["surface", 613], ["protein", 621], ["1", 629], ["are", 631], ["the", 635], ["two", 639], ["most", 643], ["extensively", 648], ["studied", 660], ["asexual", 668], ["blood", 676], ["stage", 682], ["vaccine", 688], ["candidates", 696], [".", 706], ["The", 708], ["most", 712], ["promising", 717], ["candidate", 727], ["vaccine", 737], ["under", 745], ["development", 751], ["is", 763], ["RTS", 766], [",", 769], ["S", 771], ["combined", 773], ["with", 782], ["AS01", 787], ["adjuvant", 792], [".", 800], ["Initial", 802], ["results", 810], ["from", 818], ["phase", 823], ["III", 829], ["trials", 833], ["of", 840], ["this", 843], ["candidate", 848], ["vaccine", 858], ["show", 866], ["50", 871], ["%", 873], ["reduction", 875], ["of", 885], ["malaria", 888], ["in", 896], ["5", 899], ["-", 900], ["17", 901], ["mo", 904], ["aged", 907], ["children", 912], ["during", 921], ["the", 928], ["12", 932], ["mo", 935], ["after", 938], ["vaccination", 944], [".", 955], ["WHO", 957], ["anticipates", 961], ["that", 973], ["the", 978], ["RTS", 982], [",", 985], ["S", 986], ["/", 987], ["AS01", 988], ["vaccine", 993], ["will", 1001], ["be", 1006], ["recommended", 1009], ["for", 1021], ["the", 1025], ["6", 1029], ["-", 1030], ["14", 1031], ["week", 1034], ["age", 1039], ["group", 1043], ["for", 1049], ["co", 1053], ["-", 1055], ["administration", 1056], ["together", 1071], ["with", 1080], ["other", 1085], ["vaccines", 1091], ["as", 1100], ["part", 1103], ["of", 1108], ["routine", 1111], ["immunization", 1119], ["programs", 1132], ["in", 1141], ["malaria", 1144], ["endemic", 1152], ["countries", 1160], [".", 1169], ["Malaria", 1171], ["vaccine", 1179], ["could", 1187], ["play", 1193], ["an", 1198], ["important", 1201], ["role", 1211], ["in", 1216], ["elimination", 1219], ["and", 1231], ["eventual", 1235], ["eradication", 1244], ["of", 1256], ["malaria", 1259], [".", 1266]]}
{"context": "Angelman syndrome (AS) is caused by a lack of expression of the maternally inherited UBE3A gene in the brain. However, about 10% of individuals with a clinical diagnosis of AS do not have an identifiable molecular defect. It is likely that most of those individuals have an AS-like syndrome that is clinically and molecularly distinct from AS. These AS-like syndromes can be broadly classified into chromosomal microdeletion and microduplication syndromes, and single-gene disorders. The microdeletion/microduplication syndromes are now easily identified by chromosomal microarray analysis and include Phelan\u2013McDermid syndrome (chromosome 22q13.3 deletion), MBD5 haploinsufficiency syndrome (chromosome 2q23.1 deletion), and KANSL1 haploinsufficiency syndrome (chromosome 17q21.31 deletion). The single-gene disorders include Pitt\u2013Hopkins syndrome (TCF4), Christianson syndrome (SLC9A6), Mowat\u2013Wilson syndrome (ZEB2), Kleefstra syndrome (EHMT1), and Rett (MECP2) syndrome. They also include disorders due to mutations in HERC2, adenylosuccinase lyase (ADSL), CDKL5, FOXG1, MECP2 (duplications), MEF2C, and ATRX. Although many of these single-gene disorders can be caused by chromosomal microdeletions resulting in haploinsufficiency of the critical gene, the individual disorders are often caused by intragenic mutations that cannot be detected by chromosomal microarray analysis. We provide an overview of the clinical features of these syndromes, comparing and contrasting them with AS, in the hope that it will help guide clinicians in the diagnostic work-up of individuals with AS-like syndromes.", "qas": [{"question": "Mutation of which gene is implicated in the Christianson syndrome?", "answers": ["SLC9A6"], "qid": "ddf1ff17a2ea4e5088dd93222e4a7289", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["implicated", 26], ["in", 37], ["the", 40], ["Christianson", 44], ["syndrome", 57], ["?", 65]], "detected_answers": [{"text": "SLC9A6", "token_spans": [[149, 149]], "char_spans": [[879, 884]]}]}], "context_tokens": [["Angelman", 0], ["syndrome", 9], ["(", 18], ["AS", 19], [")", 21], ["is", 23], ["caused", 26], ["by", 33], ["a", 36], ["lack", 38], ["of", 43], ["expression", 46], ["of", 57], ["the", 60], ["maternally", 64], ["inherited", 75], ["UBE3A", 85], ["gene", 91], ["in", 96], ["the", 99], ["brain", 103], [".", 108], ["However", 110], [",", 117], ["about", 119], ["10", 125], ["%", 127], ["of", 129], ["individuals", 132], ["with", 144], ["a", 149], ["clinical", 151], ["diagnosis", 160], ["of", 170], ["AS", 173], ["do", 176], ["not", 179], ["have", 183], ["an", 188], ["identifiable", 191], ["molecular", 204], ["defect", 214], [".", 220], ["It", 222], ["is", 225], ["likely", 228], ["that", 235], ["most", 240], ["of", 245], ["those", 248], ["individuals", 254], ["have", 266], ["an", 271], ["AS", 274], ["-", 276], ["like", 277], ["syndrome", 282], ["that", 291], ["is", 296], ["clinically", 299], ["and", 310], ["molecularly", 314], ["distinct", 326], ["from", 335], ["AS", 340], [".", 342], ["These", 344], ["AS", 350], ["-", 352], ["like", 353], ["syndromes", 358], ["can", 368], ["be", 372], ["broadly", 375], ["classified", 383], ["into", 394], ["chromosomal", 399], ["microdeletion", 411], ["and", 425], ["microduplication", 429], ["syndromes", 446], [",", 455], ["and", 457], ["single", 461], ["-", 467], ["gene", 468], ["disorders", 473], [".", 482], ["The", 484], ["microdeletion", 488], ["/", 501], ["microduplication", 502], ["syndromes", 519], ["are", 529], ["now", 533], ["easily", 537], ["identified", 544], ["by", 555], ["chromosomal", 558], ["microarray", 570], ["analysis", 581], ["and", 590], ["include", 594], ["Phelan", 602], ["\u2013", 608], ["McDermid", 609], ["syndrome", 618], ["(", 627], ["chromosome", 628], ["22q13.3", 639], ["deletion", 647], [")", 655], [",", 656], ["MBD5", 658], ["haploinsufficiency", 663], ["syndrome", 682], ["(", 691], ["chromosome", 692], ["2q23.1", 703], ["deletion", 710], [")", 718], [",", 719], ["and", 721], ["KANSL1", 725], ["haploinsufficiency", 732], ["syndrome", 751], ["(", 760], ["chromosome", 761], ["17q21.31", 772], ["deletion", 781], [")", 789], [".", 790], ["The", 792], ["single", 796], ["-", 802], ["gene", 803], ["disorders", 808], ["include", 818], ["Pitt", 826], ["\u2013", 830], ["Hopkins", 831], ["syndrome", 839], ["(", 848], ["TCF4", 849], [")", 853], [",", 854], ["Christianson", 856], ["syndrome", 869], ["(", 878], ["SLC9A6", 879], [")", 885], [",", 886], ["Mowat", 888], ["\u2013", 893], ["Wilson", 894], ["syndrome", 901], ["(", 910], ["ZEB2", 911], [")", 915], [",", 916], ["Kleefstra", 918], ["syndrome", 928], ["(", 937], ["EHMT1", 938], [")", 943], [",", 944], ["and", 946], ["Rett", 950], ["(", 955], ["MECP2", 956], [")", 961], ["syndrome", 963], [".", 971], ["They", 973], ["also", 978], ["include", 983], ["disorders", 991], ["due", 1001], ["to", 1005], ["mutations", 1008], ["in", 1018], ["HERC2", 1021], [",", 1026], ["adenylosuccinase", 1028], ["lyase", 1045], ["(", 1051], ["ADSL", 1052], [")", 1056], [",", 1057], ["CDKL5", 1059], [",", 1064], ["FOXG1", 1066], [",", 1071], ["MECP2", 1073], ["(", 1079], ["duplications", 1080], [")", 1092], [",", 1093], ["MEF2C", 1095], [",", 1100], ["and", 1102], ["ATRX", 1106], [".", 1110], ["Although", 1112], ["many", 1121], ["of", 1126], ["these", 1129], ["single", 1135], ["-", 1141], ["gene", 1142], ["disorders", 1147], ["can", 1157], ["be", 1161], ["caused", 1164], ["by", 1171], ["chromosomal", 1174], ["microdeletions", 1186], ["resulting", 1201], ["in", 1211], ["haploinsufficiency", 1214], ["of", 1233], ["the", 1236], ["critical", 1240], ["gene", 1249], [",", 1253], ["the", 1255], ["individual", 1259], ["disorders", 1270], ["are", 1280], ["often", 1284], ["caused", 1290], ["by", 1297], ["intragenic", 1300], ["mutations", 1311], ["that", 1321], ["can", 1326], ["not", 1329], ["be", 1333], ["detected", 1336], ["by", 1345], ["chromosomal", 1348], ["microarray", 1360], ["analysis", 1371], [".", 1379], ["We", 1381], ["provide", 1384], ["an", 1392], ["overview", 1395], ["of", 1404], ["the", 1407], ["clinical", 1411], ["features", 1420], ["of", 1429], ["these", 1432], ["syndromes", 1438], [",", 1447], ["comparing", 1449], ["and", 1459], ["contrasting", 1463], ["them", 1475], ["with", 1480], ["AS", 1485], [",", 1487], ["in", 1489], ["the", 1492], ["hope", 1496], ["that", 1501], ["it", 1506], ["will", 1509], ["help", 1514], ["guide", 1519], ["clinicians", 1525], ["in", 1536], ["the", 1539], ["diagnostic", 1543], ["work", 1554], ["-", 1558], ["up", 1559], ["of", 1562], ["individuals", 1565], ["with", 1577], ["AS", 1582], ["-", 1584], ["like", 1585], ["syndromes", 1590], [".", 1599]]}
{"context": "(S)-(-)-3-(3-(methylsulfonyl)phenyl)-1-propylpiperidine ((-)-OSU6162) is a phenylpiperidine derivative which exhibits low affinity to the dopamine D2 receptor in vitro. However, in vivo, positron emission tomography scanning studies show that the compound displaces the selective dopamine D2 receptor antagonist, raclopride. We have evaluated, in this study, the effect of (-)-OSU6162, on L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesias in a primate model of Parkinson's disease. Five 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated cynomolgus monkeys with a stable parkinsonian syndrome and reproducible dyskinesias to L-DOPA were used in this study. The monkeys were housed in observation cages equipped with an electronic motility monitoring system. They were injected subcutaneously (s.c.) with L-DOPA methyl ester (125 mg per animal) plus benserazide (50 mg per animal; L-DOPA/benserazide) alone or in combination with (-)-OSU6162 (1.0, 3.0, 6.0 or 10 mg/kg, s.c.). Subcutaneous injection of sterile saline was used as control. L-DOPA/benserazide increased locomotion and improved parkinsonism but also induced dyskinesias. Co-administration of (-)-OSU6162 with L-DOPA/benserazide produced a significant reduction in L-DOPA-induced dyskinesias. This improvement in L-DOPA-induced dyskinesias occurred mainly at the onset of the L-DOPA/benserazide effect as reflected by an increase in the duration of the \"ON\" state without dyskinesias up to 3.4 fold after (-)-OSU6162 co-administration as compared to L-DOPA/benserazide alone. The anti-dyskinetic effect of (-)-OSU6162 was maintained during 14 days and no tolerance to this effect was observed. Our data suggests that (-)-OSU6162 could be of significant clinical value to reduce L-DOPA-induced dyskinesias in fluctuating advanced Parkinson's disease patients.", "qas": [{"question": "Which drug is benserazide usually co-administered with?", "answers": ["L-Dopa"], "qid": "fd218c6955b9465b8d895d3154d58ebb", "question_tokens": [["Which", 0], ["drug", 6], ["is", 11], ["benserazide", 14], ["usually", 26], ["co", 34], ["-", 36], ["administered", 37], ["with", 50], ["?", 54]], "detected_answers": [{"text": "L-Dopa", "token_spans": [[91, 93], [204, 206], [182, 184], [124, 126], [214, 216], [237, 239], [272, 274], [224, 226], [315, 317], [143, 145]], "char_spans": [[642, 647], [1189, 1194], [1055, 1060], [821, 826], [1244, 1249], [1355, 1360], [1529, 1534], [1292, 1297], [1757, 1762], [897, 902]]}]}], "context_tokens": [["(", 0], ["S)-(-)-3-(3-(methylsulfonyl)phenyl)-1-propylpiperidine", 1], ["(", 56], ["(", 57], ["-)-OSU6162", 58], [")", 68], ["is", 70], ["a", 73], ["phenylpiperidine", 75], ["derivative", 92], ["which", 103], ["exhibits", 109], ["low", 118], ["affinity", 122], ["to", 131], ["the", 134], ["dopamine", 138], ["D2", 147], ["receptor", 150], ["in", 159], ["vitro", 162], [".", 167], ["However", 169], [",", 176], ["in", 178], ["vivo", 181], [",", 185], ["positron", 187], ["emission", 196], ["tomography", 205], ["scanning", 216], ["studies", 225], ["show", 233], ["that", 238], ["the", 243], ["compound", 247], ["displaces", 256], ["the", 266], ["selective", 270], ["dopamine", 280], ["D2", 289], ["receptor", 292], ["antagonist", 301], [",", 311], ["raclopride", 313], [".", 323], ["We", 325], ["have", 328], ["evaluated", 333], [",", 342], ["in", 344], ["this", 347], ["study", 352], [",", 357], ["the", 359], ["effect", 363], ["of", 370], ["(", 373], ["-)-OSU6162", 374], [",", 384], ["on", 386], ["L-3,4-dihydroxyphenylalanine", 389], ["(", 418], ["L", 419], ["-", 420], ["DOPA)-induced", 421], ["dyskinesias", 435], ["in", 447], ["a", 450], ["primate", 452], ["model", 460], ["of", 466], ["Parkinson", 469], ["'s", 478], ["disease", 481], [".", 488], ["Five", 490], ["1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine", 495], ["(", 540], ["MPTP)-treated", 541], ["cynomolgus", 555], ["monkeys", 566], ["with", 574], ["a", 579], ["stable", 581], ["parkinsonian", 588], ["syndrome", 601], ["and", 610], ["reproducible", 614], ["dyskinesias", 627], ["to", 639], ["L", 642], ["-", 643], ["DOPA", 644], ["were", 649], ["used", 654], ["in", 659], ["this", 662], ["study", 667], [".", 672], ["The", 674], ["monkeys", 678], ["were", 686], ["housed", 691], ["in", 698], ["observation", 701], ["cages", 713], ["equipped", 719], ["with", 728], ["an", 733], ["electronic", 736], ["motility", 747], ["monitoring", 756], ["system", 767], [".", 773], ["They", 775], ["were", 780], ["injected", 785], ["subcutaneously", 794], ["(", 809], ["s.c", 810], [".", 813], [")", 814], ["with", 816], ["L", 821], ["-", 822], ["DOPA", 823], ["methyl", 828], ["ester", 835], ["(", 841], ["125", 842], ["mg", 846], ["per", 849], ["animal", 853], [")", 859], ["plus", 861], ["benserazide", 866], ["(", 878], ["50", 879], ["mg", 882], ["per", 885], ["animal", 889], [";", 895], ["L", 897], ["-", 898], ["DOPA", 899], ["/", 903], ["benserazide", 904], [")", 915], ["alone", 917], ["or", 923], ["in", 926], ["combination", 929], ["with", 941], ["(", 946], ["-)-OSU6162", 947], ["(", 958], ["1.0", 959], [",", 962], ["3.0", 964], [",", 967], ["6.0", 969], ["or", 973], ["10", 976], ["mg", 979], ["/", 981], ["kg", 982], [",", 984], ["s.c", 986], [".", 989], [")", 990], [".", 991], ["Subcutaneous", 993], ["injection", 1006], ["of", 1016], ["sterile", 1019], ["saline", 1027], ["was", 1034], ["used", 1038], ["as", 1043], ["control", 1046], [".", 1053], ["L", 1055], ["-", 1056], ["DOPA", 1057], ["/", 1061], ["benserazide", 1062], ["increased", 1074], ["locomotion", 1084], ["and", 1095], ["improved", 1099], ["parkinsonism", 1108], ["but", 1121], ["also", 1125], ["induced", 1130], ["dyskinesias", 1138], [".", 1149], ["Co", 1151], ["-", 1153], ["administration", 1154], ["of", 1169], ["(", 1172], ["-)-OSU6162", 1173], ["with", 1184], ["L", 1189], ["-", 1190], ["DOPA", 1191], ["/", 1195], ["benserazide", 1196], ["produced", 1208], ["a", 1217], ["significant", 1219], ["reduction", 1231], ["in", 1241], ["L", 1244], ["-", 1245], ["DOPA", 1246], ["-", 1250], ["induced", 1251], ["dyskinesias", 1259], [".", 1270], ["This", 1272], ["improvement", 1277], ["in", 1289], ["L", 1292], ["-", 1293], ["DOPA", 1294], ["-", 1298], ["induced", 1299], ["dyskinesias", 1307], ["occurred", 1319], ["mainly", 1328], ["at", 1335], ["the", 1338], ["onset", 1342], ["of", 1348], ["the", 1351], ["L", 1355], ["-", 1356], ["DOPA", 1357], ["/", 1361], ["benserazide", 1362], ["effect", 1374], ["as", 1381], ["reflected", 1384], ["by", 1394], ["an", 1397], ["increase", 1400], ["in", 1409], ["the", 1412], ["duration", 1416], ["of", 1425], ["the", 1428], ["\"", 1432], ["ON", 1433], ["\"", 1435], ["state", 1437], ["without", 1443], ["dyskinesias", 1451], ["up", 1463], ["to", 1466], ["3.4", 1469], ["fold", 1473], ["after", 1478], ["(", 1484], ["-)-OSU6162", 1485], ["co", 1496], ["-", 1498], ["administration", 1499], ["as", 1514], ["compared", 1517], ["to", 1526], ["L", 1529], ["-", 1530], ["DOPA", 1531], ["/", 1535], ["benserazide", 1536], ["alone", 1548], [".", 1553], ["The", 1555], ["anti", 1559], ["-", 1563], ["dyskinetic", 1564], ["effect", 1575], ["of", 1582], ["(", 1585], ["-)-OSU6162", 1586], ["was", 1597], ["maintained", 1601], ["during", 1612], ["14", 1619], ["days", 1622], ["and", 1627], ["no", 1631], ["tolerance", 1634], ["to", 1644], ["this", 1647], ["effect", 1652], ["was", 1659], ["observed", 1663], [".", 1671], ["Our", 1673], ["data", 1677], ["suggests", 1682], ["that", 1691], ["(", 1696], ["-)-OSU6162", 1697], ["could", 1708], ["be", 1714], ["of", 1717], ["significant", 1720], ["clinical", 1732], ["value", 1741], ["to", 1747], ["reduce", 1750], ["L", 1757], ["-", 1758], ["DOPA", 1759], ["-", 1763], ["induced", 1764], ["dyskinesias", 1772], ["in", 1784], ["fluctuating", 1787], ["advanced", 1799], ["Parkinson", 1808], ["'s", 1817], ["disease", 1820], ["patients", 1828], [".", 1836]]}
{"context": "The apolipoprotein E (ApoE) \u03b54 allele is the strongest risk factor of sporadic Alzheimer's disease (AD), however, the fluid concentrations of ApoE and its different isoforms (ApoE2, ApoE3 and ApoE4) in AD patients and among APOE genotypes (APOE \u03b52, \u03b53, \u03b54) remain controversial. Using a novel mass spectrometry-based method, we quantified total ApoE and specific ApoE isoform concentrations and potential associations with age, cognitive status, cholesterol levels and established AD biomarkers in cerebrospinal fluid (CSF) from AD patients versus non-AD individuals with different APOE genotypes. We also investigated plasma total ApoE and ApoE isoform composition in a subset of these individuals. In total n = 43 AD and n = 43 non-AD subjects were included. We found that CSF and plasma total ApoE levels did not correlate with age or cognitive status and did not differ between AD and non-AD subjects deeming ApoE as an unfit diagnostic marker for AD. Also, whereas CSF ApoE levels did not vary between APOE genotypes APOE \u03b54 carriers exhibited significantly decreased plasma ApoE levels attributed to a specific decrease in the ApoE4 isoform concentrations. CSF total ApoE concentrations were positively associated with CSF, total tau, tau phosphorylated at Thr181 and A\u03b21-42 of which the latter association was weaker and only present in APOE \u03b54 carriers indicating a differential involvement of ApoE in tau versus A\u03b2-linked neuropathological processes. Future studies need to elucidate whether the observed plasma ApoE4 deficiency is a life-long condition in APOE \u025b4 carriers and whether this decrease in plasma ApoE predisposes APOE \u025b4 carriers to AD.", "qas": [{"question": "Which ApoE isoform is associated with atherosclerosis and Alzheimer's disease?", "answers": ["ApoE4 isoform", "Apolipoprotein E4 isoform"], "qid": "19f812e350824082b6b21522a0ba9fa9", "question_tokens": [["Which", 0], ["ApoE", 6], ["isoform", 11], ["is", 19], ["associated", 22], ["with", 33], ["atherosclerosis", 38], ["and", 54], ["Alzheimer", 58], ["'s", 67], ["disease", 70], ["?", 77]], "detected_answers": [{"text": "ApoE4 isoform", "token_spans": [[210, 211]], "char_spans": [[1133, 1145]]}]}], "context_tokens": [["The", 0], ["apolipoprotein", 4], ["E", 19], ["(", 21], ["ApoE", 22], [")", 26], ["\u03b54", 28], ["allele", 31], ["is", 38], ["the", 41], ["strongest", 45], ["risk", 55], ["factor", 60], ["of", 67], ["sporadic", 70], ["Alzheimer", 79], ["'s", 88], ["disease", 91], ["(", 99], ["AD", 100], [")", 102], [",", 103], ["however", 105], [",", 112], ["the", 114], ["fluid", 118], ["concentrations", 124], ["of", 139], ["ApoE", 142], ["and", 147], ["its", 151], ["different", 155], ["isoforms", 165], ["(", 174], ["ApoE2", 175], [",", 180], ["ApoE3", 182], ["and", 188], ["ApoE4", 192], [")", 197], ["in", 199], ["AD", 202], ["patients", 205], ["and", 214], ["among", 218], ["APOE", 224], ["genotypes", 229], ["(", 239], ["APOE", 240], ["\u03b52", 245], [",", 247], ["\u03b53", 249], [",", 251], ["\u03b54", 253], [")", 255], ["remain", 257], ["controversial", 264], [".", 277], ["Using", 279], ["a", 285], ["novel", 287], ["mass", 293], ["spectrometry", 298], ["-", 310], ["based", 311], ["method", 317], [",", 323], ["we", 325], ["quantified", 328], ["total", 339], ["ApoE", 345], ["and", 350], ["specific", 354], ["ApoE", 363], ["isoform", 368], ["concentrations", 376], ["and", 391], ["potential", 395], ["associations", 405], ["with", 418], ["age", 423], [",", 426], ["cognitive", 428], ["status", 438], [",", 444], ["cholesterol", 446], ["levels", 458], ["and", 465], ["established", 469], ["AD", 481], ["biomarkers", 484], ["in", 495], ["cerebrospinal", 498], ["fluid", 512], ["(", 518], ["CSF", 519], [")", 522], ["from", 524], ["AD", 529], ["patients", 532], ["versus", 541], ["non", 548], ["-", 551], ["AD", 552], ["individuals", 555], ["with", 567], ["different", 572], ["APOE", 582], ["genotypes", 587], [".", 596], ["We", 598], ["also", 601], ["investigated", 606], ["plasma", 619], ["total", 626], ["ApoE", 632], ["and", 637], ["ApoE", 641], ["isoform", 646], ["composition", 654], ["in", 666], ["a", 669], ["subset", 671], ["of", 678], ["these", 681], ["individuals", 687], [".", 698], ["In", 700], ["total", 703], ["n", 709], ["=", 711], ["43", 713], ["AD", 716], ["and", 719], ["n", 723], ["=", 725], ["43", 727], ["non", 730], ["-", 733], ["AD", 734], ["subjects", 737], ["were", 746], ["included", 751], [".", 759], ["We", 761], ["found", 764], ["that", 770], ["CSF", 775], ["and", 779], ["plasma", 783], ["total", 790], ["ApoE", 796], ["levels", 801], ["did", 808], ["not", 812], ["correlate", 816], ["with", 826], ["age", 831], ["or", 835], ["cognitive", 838], ["status", 848], ["and", 855], ["did", 859], ["not", 863], ["differ", 867], ["between", 874], ["AD", 882], ["and", 885], ["non", 889], ["-", 892], ["AD", 893], ["subjects", 896], ["deeming", 905], ["ApoE", 913], ["as", 918], ["an", 921], ["unfit", 924], ["diagnostic", 930], ["marker", 941], ["for", 948], ["AD", 952], [".", 954], ["Also", 956], [",", 960], ["whereas", 962], ["CSF", 970], ["ApoE", 974], ["levels", 979], ["did", 986], ["not", 990], ["vary", 994], ["between", 999], ["APOE", 1007], ["genotypes", 1012], ["APOE", 1022], ["\u03b54", 1027], ["carriers", 1030], ["exhibited", 1039], ["significantly", 1049], ["decreased", 1063], ["plasma", 1073], ["ApoE", 1080], ["levels", 1085], ["attributed", 1092], ["to", 1103], ["a", 1106], ["specific", 1108], ["decrease", 1117], ["in", 1126], ["the", 1129], ["ApoE4", 1133], ["isoform", 1139], ["concentrations", 1147], [".", 1161], ["CSF", 1163], ["total", 1167], ["ApoE", 1173], ["concentrations", 1178], ["were", 1193], ["positively", 1198], ["associated", 1209], ["with", 1220], ["CSF", 1225], [",", 1228], ["total", 1230], ["tau", 1236], [",", 1239], ["tau", 1241], ["phosphorylated", 1245], ["at", 1260], ["Thr181", 1263], ["and", 1270], ["A\u03b21", 1274], ["-", 1277], ["42", 1278], ["of", 1281], ["which", 1284], ["the", 1290], ["latter", 1294], ["association", 1301], ["was", 1313], ["weaker", 1317], ["and", 1324], ["only", 1328], ["present", 1333], ["in", 1341], ["APOE", 1344], ["\u03b54", 1349], ["carriers", 1352], ["indicating", 1361], ["a", 1372], ["differential", 1374], ["involvement", 1387], ["of", 1399], ["ApoE", 1402], ["in", 1407], ["tau", 1410], ["versus", 1414], ["A\u03b2", 1421], ["-", 1423], ["linked", 1424], ["neuropathological", 1431], ["processes", 1449], [".", 1458], ["Future", 1460], ["studies", 1467], ["need", 1475], ["to", 1480], ["elucidate", 1483], ["whether", 1493], ["the", 1501], ["observed", 1505], ["plasma", 1514], ["ApoE4", 1521], ["deficiency", 1527], ["is", 1538], ["a", 1541], ["life", 1543], ["-", 1547], ["long", 1548], ["condition", 1553], ["in", 1563], ["APOE", 1566], ["\u025b4", 1571], ["carriers", 1574], ["and", 1583], ["whether", 1587], ["this", 1595], ["decrease", 1600], ["in", 1609], ["plasma", 1612], ["ApoE", 1619], ["predisposes", 1624], ["APOE", 1636], ["\u025b4", 1641], ["carriers", 1644], ["to", 1653], ["AD", 1656], [".", 1658]]}
{"context": "mDia proteins are members of the formin family of actin nucleating proteins that polymerize linear actin filaments. Such filaments form the core of thin, tubular, membrane-bound cell surface protrusions known as filopodia, which are a major feature of mammalian cell morphology. Filopodia are dynamic structures that help cells sense environmental cues, and play a role in cell migration, axon guidance, angiogenesis and other processes. RhoGTPases bind to and control the activity of mDia proteins, and several other binding partners of the three mDia1 isoforms-mDia1, mDia2 and mDia3-have been documented. Two independent pathways controlling mammalian filopodium formation have emerged, with one driven by the RhoGTPase Cdc42, and the other by Rif. While mDia2 has been the main formin implicated in forming filopodia, mDia1 has recently surfaced as the key formin utilized by both the Cdc42 and Rif pathways to drive filopodial protrusion.", "qas": [{"question": "What family do mDia proteins belong in?", "answers": ["mDia proteins are members of the formin family"], "qid": "df45d243d5b846c9b8dd26f62bbe479e", "question_tokens": [["What", 0], ["family", 5], ["do", 12], ["mDia", 15], ["proteins", 20], ["belong", 29], ["in", 36], ["?", 38]], "detected_answers": [{"text": "mDia proteins are members of the formin family", "token_spans": [[0, 7]], "char_spans": [[0, 45]]}]}], "context_tokens": [["mDia", 0], ["proteins", 5], ["are", 14], ["members", 18], ["of", 26], ["the", 29], ["formin", 33], ["family", 40], ["of", 47], ["actin", 50], ["nucleating", 56], ["proteins", 67], ["that", 76], ["polymerize", 81], ["linear", 92], ["actin", 99], ["filaments", 105], [".", 114], ["Such", 116], ["filaments", 121], ["form", 131], ["the", 136], ["core", 140], ["of", 145], ["thin", 148], [",", 152], ["tubular", 154], [",", 161], ["membrane", 163], ["-", 171], ["bound", 172], ["cell", 178], ["surface", 183], ["protrusions", 191], ["known", 203], ["as", 209], ["filopodia", 212], [",", 221], ["which", 223], ["are", 229], ["a", 233], ["major", 235], ["feature", 241], ["of", 249], ["mammalian", 252], ["cell", 262], ["morphology", 267], [".", 277], ["Filopodia", 279], ["are", 289], ["dynamic", 293], ["structures", 301], ["that", 312], ["help", 317], ["cells", 322], ["sense", 328], ["environmental", 334], ["cues", 348], [",", 352], ["and", 354], ["play", 358], ["a", 363], ["role", 365], ["in", 370], ["cell", 373], ["migration", 378], [",", 387], ["axon", 389], ["guidance", 394], [",", 402], ["angiogenesis", 404], ["and", 417], ["other", 421], ["processes", 427], [".", 436], ["RhoGTPases", 438], ["bind", 449], ["to", 454], ["and", 457], ["control", 461], ["the", 469], ["activity", 473], ["of", 482], ["mDia", 485], ["proteins", 490], [",", 498], ["and", 500], ["several", 504], ["other", 512], ["binding", 518], ["partners", 526], ["of", 535], ["the", 538], ["three", 542], ["mDia1", 548], ["isoforms", 554], ["-", 562], ["mDia1", 563], [",", 568], ["mDia2", 570], ["and", 576], ["mDia3-have", 580], ["been", 591], ["documented", 596], [".", 606], ["Two", 608], ["independent", 612], ["pathways", 624], ["controlling", 633], ["mammalian", 645], ["filopodium", 655], ["formation", 666], ["have", 676], ["emerged", 681], [",", 688], ["with", 690], ["one", 695], ["driven", 699], ["by", 706], ["the", 709], ["RhoGTPase", 713], ["Cdc42", 723], [",", 728], ["and", 730], ["the", 734], ["other", 738], ["by", 744], ["Rif", 747], [".", 750], ["While", 752], ["mDia2", 758], ["has", 764], ["been", 768], ["the", 773], ["main", 777], ["formin", 782], ["implicated", 789], ["in", 800], ["forming", 803], ["filopodia", 811], [",", 820], ["mDia1", 822], ["has", 828], ["recently", 832], ["surfaced", 841], ["as", 850], ["the", 853], ["key", 857], ["formin", 861], ["utilized", 868], ["by", 877], ["both", 880], ["the", 885], ["Cdc42", 889], ["and", 895], ["Rif", 899], ["pathways", 903], ["to", 912], ["drive", 915], ["filopodial", 921], ["protrusion", 932], [".", 942]]}
{"context": "Abnormal accumulation of Abeta and tau in senile plaques (SP) and neurofibrillary tangles (NFTs) is a key event in Alzheimer's disease (AD). Here, we show that T668-phosphorylated cytoplasmic domain of APP (pT668-ACD) accumulates Abeta and tau in AD and its transgenic models. Anti-pT668 immunostaining of AD brain sections with hydrated autoclave enhancement identified SP neurites and NFTs in which pT668-ACD colocalizes with tau. We produced and examined transgenic (Tg) mice that overexpress human APP695, harboring the double Swedish/London mutation, and develop age-dependently Abeta plaques in the brain. All Abeta plaques contain co-accumulations of pT668-ACD, but co-accumulation of tau appears in only a fraction of Abeta plaques in older animals. We also examined the established tau Tg mice that overexpress the smallest human brain tau isoform and develop neuronal accumulations of tau in older animals. Examination of the old tau Tg mice showed that neuronal cells affected by tau accumulation induce co-accumulation of pT668-ACD. We speculate that in AD brains, extracellular Abeta deposition is accompanied by intracellular accumulation of pT668-ACD, followed by tau accumulation in the SP with dystrophic neurites and that neuronal cells affected by tau accumulation induce co-accumulation of pT668-ACD in NFTs. Thus, pT668-ACD is likely to mediate pathological interaction between Abeta and tau.", "qas": [{"question": "Which disease the London mutation involved in?", "answers": ["Alzheimer's Disease", "AD"], "qid": "359b351dab714a9eb679ec9eef3d8227", "question_tokens": [["Which", 0], ["disease", 6], ["the", 14], ["London", 18], ["mutation", 25], ["involved", 34], ["in", 43], ["?", 45]], "detected_answers": [{"text": "Alzheimer's Disease", "token_spans": [[23, 25]], "char_spans": [[115, 133]]}, {"text": "AD", "token_spans": [[191, 191], [59, 59], [48, 48], [27, 27]], "char_spans": [[1066, 1067], [306, 307], [247, 248], [136, 137]]}]}], "context_tokens": [["Abnormal", 0], ["accumulation", 9], ["of", 22], ["Abeta", 25], ["and", 31], ["tau", 35], ["in", 39], ["senile", 42], ["plaques", 49], ["(", 57], ["SP", 58], [")", 60], ["and", 62], ["neurofibrillary", 66], ["tangles", 82], ["(", 90], ["NFTs", 91], [")", 95], ["is", 97], ["a", 100], ["key", 102], ["event", 106], ["in", 112], ["Alzheimer", 115], ["'s", 124], ["disease", 127], ["(", 135], ["AD", 136], [")", 138], [".", 139], ["Here", 141], [",", 145], ["we", 147], ["show", 150], ["that", 155], ["T668-phosphorylated", 160], ["cytoplasmic", 180], ["domain", 192], ["of", 199], ["APP", 202], ["(", 206], ["pT668-ACD", 207], [")", 216], ["accumulates", 218], ["Abeta", 230], ["and", 236], ["tau", 240], ["in", 244], ["AD", 247], ["and", 250], ["its", 254], ["transgenic", 258], ["models", 269], [".", 275], ["Anti", 277], ["-", 281], ["pT668", 282], ["immunostaining", 288], ["of", 303], ["AD", 306], ["brain", 309], ["sections", 315], ["with", 324], ["hydrated", 329], ["autoclave", 338], ["enhancement", 348], ["identified", 360], ["SP", 371], ["neurites", 374], ["and", 383], ["NFTs", 387], ["in", 392], ["which", 395], ["pT668-ACD", 401], ["colocalizes", 411], ["with", 423], ["tau", 428], [".", 431], ["We", 433], ["produced", 436], ["and", 445], ["examined", 449], ["transgenic", 458], ["(", 469], ["Tg", 470], [")", 472], ["mice", 474], ["that", 479], ["overexpress", 484], ["human", 496], ["APP695", 502], [",", 508], ["harboring", 510], ["the", 520], ["double", 524], ["Swedish", 531], ["/", 538], ["London", 539], ["mutation", 546], [",", 554], ["and", 556], ["develop", 560], ["age", 568], ["-", 571], ["dependently", 572], ["Abeta", 584], ["plaques", 590], ["in", 598], ["the", 601], ["brain", 605], [".", 610], ["All", 612], ["Abeta", 616], ["plaques", 622], ["contain", 630], ["co", 638], ["-", 640], ["accumulations", 641], ["of", 655], ["pT668-ACD", 658], [",", 667], ["but", 669], ["co", 673], ["-", 675], ["accumulation", 676], ["of", 689], ["tau", 692], ["appears", 696], ["in", 704], ["only", 707], ["a", 712], ["fraction", 714], ["of", 723], ["Abeta", 726], ["plaques", 732], ["in", 740], ["older", 743], ["animals", 749], [".", 756], ["We", 758], ["also", 761], ["examined", 766], ["the", 775], ["established", 779], ["tau", 791], ["Tg", 795], ["mice", 798], ["that", 803], ["overexpress", 808], ["the", 820], ["smallest", 824], ["human", 833], ["brain", 839], ["tau", 845], ["isoform", 849], ["and", 857], ["develop", 861], ["neuronal", 869], ["accumulations", 878], ["of", 892], ["tau", 895], ["in", 899], ["older", 902], ["animals", 908], [".", 915], ["Examination", 917], ["of", 929], ["the", 932], ["old", 936], ["tau", 940], ["Tg", 944], ["mice", 947], ["showed", 952], ["that", 959], ["neuronal", 964], ["cells", 973], ["affected", 979], ["by", 988], ["tau", 991], ["accumulation", 995], ["induce", 1008], ["co", 1015], ["-", 1017], ["accumulation", 1018], ["of", 1031], ["pT668-ACD", 1034], [".", 1043], ["We", 1045], ["speculate", 1048], ["that", 1058], ["in", 1063], ["AD", 1066], ["brains", 1069], [",", 1075], ["extracellular", 1077], ["Abeta", 1091], ["deposition", 1097], ["is", 1108], ["accompanied", 1111], ["by", 1123], ["intracellular", 1126], ["accumulation", 1140], ["of", 1153], ["pT668-ACD", 1156], [",", 1165], ["followed", 1167], ["by", 1176], ["tau", 1179], ["accumulation", 1183], ["in", 1196], ["the", 1199], ["SP", 1203], ["with", 1206], ["dystrophic", 1211], ["neurites", 1222], ["and", 1231], ["that", 1235], ["neuronal", 1240], ["cells", 1249], ["affected", 1255], ["by", 1264], ["tau", 1267], ["accumulation", 1271], ["induce", 1284], ["co", 1291], ["-", 1293], ["accumulation", 1294], ["of", 1307], ["pT668-ACD", 1310], ["in", 1320], ["NFTs", 1323], [".", 1327], ["Thus", 1329], [",", 1333], ["pT668-ACD", 1335], ["is", 1345], ["likely", 1348], ["to", 1355], ["mediate", 1358], ["pathological", 1366], ["interaction", 1379], ["between", 1391], ["Abeta", 1399], ["and", 1405], ["tau", 1409], [".", 1412]]}
{"context": "Past studies have documented a crosstalk between H2B ubiquitylation (H2Bub) and H3K4 methylation, but little (if any) direct evidence exists explaining the mechanism underlying H2Bub-dependent H3K4 methylation on chromatin templates. Here, we took advantage of an in vitro histone methyltransferase assay employing a reconstituted yeast Set1 complex (ySet1C) and a recombinant chromatin template containing fully ubiquitylated H2B to gain valuable insights. Combined with genetic analyses, we demonstrate that the n-SET domain within Set1, but not Swd2, is essential for H2Bub-dependent H3K4 methylation. Spp1, a homolog of human CFP1, is conditionally involved in this crosstalk. Our findings extend to the human Set1 complex, underscoring the conserved nature of this disease-relevant crosstalk pathway. As not all members of the H3K4 methyltransferase family contain n-SET domains, our studies draw attention to the n-SET domain as a predictor of an H2B ubiquitylation-sensing mechanism that leads to downstream H3K4 methylation.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "0e9ad5ae9db7422d92338cea8e52e210", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[84, 85], [161, 162]], "char_spans": [[516, 525], [921, 930]]}]}], "context_tokens": [["Past", 0], ["studies", 5], ["have", 13], ["documented", 18], ["a", 29], ["crosstalk", 31], ["between", 41], ["H2B", 49], ["ubiquitylation", 53], ["(", 68], ["H2Bub", 69], [")", 74], ["and", 76], ["H3K4", 80], ["methylation", 85], [",", 96], ["but", 98], ["little", 102], ["(", 109], ["if", 110], ["any", 113], [")", 116], ["direct", 118], ["evidence", 125], ["exists", 134], ["explaining", 141], ["the", 152], ["mechanism", 156], ["underlying", 166], ["H2Bub", 177], ["-", 182], ["dependent", 183], ["H3K4", 193], ["methylation", 198], ["on", 210], ["chromatin", 213], ["templates", 223], [".", 232], ["Here", 234], [",", 238], ["we", 240], ["took", 243], ["advantage", 248], ["of", 258], ["an", 261], ["in", 264], ["vitro", 267], ["histone", 273], ["methyltransferase", 281], ["assay", 299], ["employing", 305], ["a", 315], ["reconstituted", 317], ["yeast", 331], ["Set1", 337], ["complex", 342], ["(", 350], ["ySet1C", 351], [")", 357], ["and", 359], ["a", 363], ["recombinant", 365], ["chromatin", 377], ["template", 387], ["containing", 396], ["fully", 407], ["ubiquitylated", 413], ["H2B", 427], ["to", 431], ["gain", 434], ["valuable", 439], ["insights", 448], [".", 456], ["Combined", 458], ["with", 467], ["genetic", 472], ["analyses", 480], [",", 488], ["we", 490], ["demonstrate", 493], ["that", 505], ["the", 510], ["n", 514], ["-", 515], ["SET", 516], ["domain", 520], ["within", 527], ["Set1", 534], [",", 538], ["but", 540], ["not", 544], ["Swd2", 548], [",", 552], ["is", 554], ["essential", 557], ["for", 567], ["H2Bub", 571], ["-", 576], ["dependent", 577], ["H3K4", 587], ["methylation", 592], [".", 603], ["Spp1", 605], [",", 609], ["a", 611], ["homolog", 613], ["of", 621], ["human", 624], ["CFP1", 630], [",", 634], ["is", 636], ["conditionally", 639], ["involved", 653], ["in", 662], ["this", 665], ["crosstalk", 670], [".", 679], ["Our", 681], ["findings", 685], ["extend", 694], ["to", 701], ["the", 704], ["human", 708], ["Set1", 714], ["complex", 719], [",", 726], ["underscoring", 728], ["the", 741], ["conserved", 745], ["nature", 755], ["of", 762], ["this", 765], ["disease", 770], ["-", 777], ["relevant", 778], ["crosstalk", 787], ["pathway", 797], [".", 804], ["As", 806], ["not", 809], ["all", 813], ["members", 817], ["of", 825], ["the", 828], ["H3K4", 832], ["methyltransferase", 837], ["family", 855], ["contain", 862], ["n", 870], ["-", 871], ["SET", 872], ["domains", 876], [",", 883], ["our", 885], ["studies", 889], ["draw", 897], ["attention", 902], ["to", 912], ["the", 915], ["n", 919], ["-", 920], ["SET", 921], ["domain", 925], ["as", 932], ["a", 935], ["predictor", 937], ["of", 947], ["an", 950], ["H2B", 953], ["ubiquitylation", 957], ["-", 971], ["sensing", 972], ["mechanism", 980], ["that", 990], ["leads", 995], ["to", 1001], ["downstream", 1004], ["H3K4", 1015], ["methylation", 1020], [".", 1031]]}
{"context": "Tuberculosis (Tb) continues to be a dreadful infection worldwide with nearly 1.5 million deaths in 2013. Furthermore multi/extensively drug-resistant Tb (MDR/XDR-Tb) worsens the condition. Recently approved anti-Tb drugs (bedaquiline and delamanid) have the potential to induce arrhythmia and are recommended in patients with MDR-Tb when other alternatives fail. The goal of elimination of Tb by 2050 will not be achieved without an effective new vaccine. The recent advancement in the development of Tb vaccines is the keen focus of this review. To date, Bacille Calmette Guerin (BCG) is the only licensed Tb vaccine in use, however its efficacy in pulmonary Tb is variable in adolescents and adults. There are nearly 15 vaccine candidates in various phases of clinical trials, includes five protein or adjuvant vaccines, four viral-vectored vaccines, three mycobacterial whole cell or extract vaccines, and one each of the recombinant live and the attenuated Mycobacterium tuberculosis (Mtb) vaccine.", "qas": [{"question": "Which disease can be treated with Delamanid?", "answers": ["tuberculosis"], "qid": "70def1204d7c4c8eacdf2cc36356ec55", "question_tokens": [["Which", 0], ["disease", 6], ["can", 14], ["be", 18], ["treated", 21], ["with", 29], ["Delamanid", 34], ["?", 43]], "detected_answers": [{"text": "tuberculosis", "token_spans": [[0, 0], [180, 180]], "char_spans": [[0, 11], [975, 986]]}]}], "context_tokens": [["Tuberculosis", 0], ["(", 13], ["Tb", 14], [")", 16], ["continues", 18], ["to", 28], ["be", 31], ["a", 34], ["dreadful", 36], ["infection", 45], ["worldwide", 55], ["with", 65], ["nearly", 70], ["1.5", 77], ["million", 81], ["deaths", 89], ["in", 96], ["2013", 99], [".", 103], ["Furthermore", 105], ["multi", 117], ["/", 122], ["extensively", 123], ["drug", 135], ["-", 139], ["resistant", 140], ["Tb", 150], ["(", 153], ["MDR", 154], ["/", 157], ["XDR", 158], ["-", 161], ["Tb", 162], [")", 164], ["worsens", 166], ["the", 174], ["condition", 178], [".", 187], ["Recently", 189], ["approved", 198], ["anti", 207], ["-", 211], ["Tb", 212], ["drugs", 215], ["(", 221], ["bedaquiline", 222], ["and", 234], ["delamanid", 238], [")", 247], ["have", 249], ["the", 254], ["potential", 258], ["to", 268], ["induce", 271], ["arrhythmia", 278], ["and", 289], ["are", 293], ["recommended", 297], ["in", 309], ["patients", 312], ["with", 321], ["MDR", 326], ["-", 329], ["Tb", 330], ["when", 333], ["other", 338], ["alternatives", 344], ["fail", 357], [".", 361], ["The", 363], ["goal", 367], ["of", 372], ["elimination", 375], ["of", 387], ["Tb", 390], ["by", 393], ["2050", 396], ["will", 401], ["not", 406], ["be", 410], ["achieved", 413], ["without", 422], ["an", 430], ["effective", 433], ["new", 443], ["vaccine", 447], [".", 454], ["The", 456], ["recent", 460], ["advancement", 467], ["in", 479], ["the", 482], ["development", 486], ["of", 498], ["Tb", 501], ["vaccines", 504], ["is", 513], ["the", 516], ["keen", 520], ["focus", 525], ["of", 531], ["this", 534], ["review", 539], [".", 545], ["To", 547], ["date", 550], [",", 554], ["Bacille", 556], ["Calmette", 564], ["Guerin", 573], ["(", 580], ["BCG", 581], [")", 584], ["is", 586], ["the", 589], ["only", 593], ["licensed", 598], ["Tb", 607], ["vaccine", 610], ["in", 618], ["use", 621], [",", 624], ["however", 626], ["its", 634], ["efficacy", 638], ["in", 647], ["pulmonary", 650], ["Tb", 660], ["is", 663], ["variable", 666], ["in", 675], ["adolescents", 678], ["and", 690], ["adults", 694], [".", 700], ["There", 702], ["are", 708], ["nearly", 712], ["15", 719], ["vaccine", 722], ["candidates", 730], ["in", 741], ["various", 744], ["phases", 752], ["of", 759], ["clinical", 762], ["trials", 771], [",", 777], ["includes", 779], ["five", 788], ["protein", 793], ["or", 801], ["adjuvant", 804], ["vaccines", 813], [",", 821], ["four", 823], ["viral", 828], ["-", 833], ["vectored", 834], ["vaccines", 843], [",", 851], ["three", 853], ["mycobacterial", 859], ["whole", 873], ["cell", 879], ["or", 884], ["extract", 887], ["vaccines", 895], [",", 903], ["and", 905], ["one", 909], ["each", 913], ["of", 918], ["the", 921], ["recombinant", 925], ["live", 937], ["and", 942], ["the", 946], ["attenuated", 950], ["Mycobacterium", 961], ["tuberculosis", 975], ["(", 988], ["Mtb", 989], [")", 992], ["vaccine", 994], [".", 1001]]}
{"context": "Clozapine reduces L-3,4-dihydroxyphenylalanine (L-Dopa)-induced dyskinesias in parkinsonian patients. To test if the antidyskinetic effect of clozapine is related to antagonism at the dopamine D(4) receptor, we investigated the effect of 8-methyl-6-(4-methyl-1-piperazinyl)-11H-pyrido[2,3-b][1, 4]benzodiazepine (JL-18), a structural analog of clozapine which is more selective for this receptor. Four 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine (MPTP)-treated cynomolgus monkeys with a stable parkinsonian syndrome and reproducible dyskinesias to L-Dopa were used in this study. They were injected subcutaneously (s.c.) with L-Dopa methyl ester (125 mg per animal) plus benserazide (50 mg per animal; L-Dopa/benserazide) alone or in combination with JL-18 (at the doses of 0.1, 0.3, or 0.9 mg/kg, s.c.). Subcutaneous injection of sterile saline was used as control. L-Dopa/benserazide increased locomotion and improved parkinsonism but also induced dyskinesias. Co-administration of JL-18, at low doses (0.1, 0.3 mg/kg) with L-Dopa/benserazide, produced a dose-dependent reduction in L-Dopa-induced dyskinesias without a parallel return to parkinsonism. The present results suggest that novel selective dopamine D(4) receptor antagonists may represent a useful tool to reduce L-Dopa-induced dyskinesias.", "qas": [{"question": "Which drug is benserazide usually co-administered with?", "answers": ["L-Dopa"], "qid": "7084fb7065f745f3870b1046a517cc3a", "question_tokens": [["Which", 0], ["drug", 6], ["is", 11], ["benserazide", 14], ["usually", 26], ["co", 34], ["-", 36], ["administered", 37], ["with", 50], ["?", 54]], "detected_answers": [{"text": "L-Dopa", "token_spans": [[231, 233], [199, 201], [93, 95], [186, 188], [153, 155], [112, 114], [75, 77]], "char_spans": [[1279, 1284], [1087, 1092], [628, 633], [1028, 1033], [869, 874], [704, 709], [550, 555]]}]}], "context_tokens": [["Clozapine", 0], ["reduces", 10], ["L-3,4-dihydroxyphenylalanine", 18], ["(", 47], ["L", 48], ["-", 49], ["Dopa)-induced", 50], ["dyskinesias", 64], ["in", 76], ["parkinsonian", 79], ["patients", 92], [".", 100], ["To", 102], ["test", 105], ["if", 110], ["the", 113], ["antidyskinetic", 117], ["effect", 132], ["of", 139], ["clozapine", 142], ["is", 152], ["related", 155], ["to", 163], ["antagonism", 166], ["at", 177], ["the", 180], ["dopamine", 184], ["D(4", 193], [")", 196], ["receptor", 198], [",", 206], ["we", 208], ["investigated", 211], ["the", 224], ["effect", 228], ["of", 235], ["8-methyl-6-(4-methyl-1-piperazinyl)-11H", 238], ["-", 277], ["pyrido[2,3-b][1", 278], [",", 293], ["4]benzodiazepine", 295], ["(", 312], ["JL-18", 313], [")", 318], [",", 319], ["a", 321], ["structural", 323], ["analog", 334], ["of", 341], ["clozapine", 344], ["which", 354], ["is", 360], ["more", 363], ["selective", 368], ["for", 378], ["this", 382], ["receptor", 387], [".", 395], ["Four", 397], ["1-methyl-4-phenyl-1,2,3", 402], [",", 425], ["6-tetrahydropyridine", 427], ["(", 448], ["MPTP)-treated", 449], ["cynomolgus", 463], ["monkeys", 474], ["with", 482], ["a", 487], ["stable", 489], ["parkinsonian", 496], ["syndrome", 509], ["and", 518], ["reproducible", 522], ["dyskinesias", 535], ["to", 547], ["L", 550], ["-", 551], ["Dopa", 552], ["were", 557], ["used", 562], ["in", 567], ["this", 570], ["study", 575], [".", 580], ["They", 582], ["were", 587], ["injected", 592], ["subcutaneously", 601], ["(", 616], ["s.c", 617], [".", 620], [")", 621], ["with", 623], ["L", 628], ["-", 629], ["Dopa", 630], ["methyl", 635], ["ester", 642], ["(", 648], ["125", 649], ["mg", 653], ["per", 656], ["animal", 660], [")", 666], ["plus", 668], ["benserazide", 673], ["(", 685], ["50", 686], ["mg", 689], ["per", 692], ["animal", 696], [";", 702], ["L", 704], ["-", 705], ["Dopa", 706], ["/", 710], ["benserazide", 711], [")", 722], ["alone", 724], ["or", 730], ["in", 733], ["combination", 736], ["with", 748], ["JL-18", 753], ["(", 759], ["at", 760], ["the", 763], ["doses", 767], ["of", 773], ["0.1", 776], [",", 779], ["0.3", 781], [",", 784], ["or", 786], ["0.9", 789], ["mg", 793], ["/", 795], ["kg", 796], [",", 798], ["s.c", 800], [".", 803], [")", 804], [".", 805], ["Subcutaneous", 807], ["injection", 820], ["of", 830], ["sterile", 833], ["saline", 841], ["was", 848], ["used", 852], ["as", 857], ["control", 860], [".", 867], ["L", 869], ["-", 870], ["Dopa", 871], ["/", 875], ["benserazide", 876], ["increased", 888], ["locomotion", 898], ["and", 909], ["improved", 913], ["parkinsonism", 922], ["but", 935], ["also", 939], ["induced", 944], ["dyskinesias", 952], [".", 963], ["Co", 965], ["-", 967], ["administration", 968], ["of", 983], ["JL-18", 986], [",", 991], ["at", 993], ["low", 996], ["doses", 1000], ["(", 1006], ["0.1", 1007], [",", 1010], ["0.3", 1012], ["mg", 1016], ["/", 1018], ["kg", 1019], [")", 1021], ["with", 1023], ["L", 1028], ["-", 1029], ["Dopa", 1030], ["/", 1034], ["benserazide", 1035], [",", 1046], ["produced", 1048], ["a", 1057], ["dose", 1059], ["-", 1063], ["dependent", 1064], ["reduction", 1074], ["in", 1084], ["L", 1087], ["-", 1088], ["Dopa", 1089], ["-", 1093], ["induced", 1094], ["dyskinesias", 1102], ["without", 1114], ["a", 1122], ["parallel", 1124], ["return", 1133], ["to", 1140], ["parkinsonism", 1143], [".", 1155], ["The", 1157], ["present", 1161], ["results", 1169], ["suggest", 1177], ["that", 1185], ["novel", 1190], ["selective", 1196], ["dopamine", 1206], ["D(4", 1215], [")", 1218], ["receptor", 1220], ["antagonists", 1229], ["may", 1241], ["represent", 1245], ["a", 1255], ["useful", 1257], ["tool", 1264], ["to", 1269], ["reduce", 1272], ["L", 1279], ["-", 1280], ["Dopa", 1281], ["-", 1285], ["induced", 1286], ["dyskinesias", 1294], [".", 1305]]}
{"context": "Neurofibromatosis type 1 (NF1) is the most frequent neurocutaneous disorder with autosomal dominant inheritance. Phenotype variability is high ranging from merely several caf\u00e9-au-lait spots to malignant peripheral nerve sheath tumors or severe disfigurement through plexiform neurofibromas. Identification of genetic factors that modify the NF1 phenotype would contribute to the understanding of NF1 pathophysiology and improve patient counselling. As even monozygotic (MZ) twins with NF1 may differ phenotypically, we wondered whether these variations might be inherited in a non-Mendelian fashion. Mitochondrial DNA (mtDNA) is inherited extrachromosomally through the cytoplasm of the oocyte and often harbours heteroplasmic sequence variations. At the time of blastomere separation, these variants may be skewedly distributed and effect phenotypic differences. Because of their co-localization with the tumor suppressor protein neurofibromin, which is mutated in NF1, mitochondria were particular attractive candidates for investigation. MtDNA was extracted from nucleated blood cells of four pairs of discordant MZ twins with NF1 and from cutaneous neurofibromas of one twin pair. We sequenced the entire mitochondrial genome and determined the state of heteroplasmy by investigating a microsatellite region of the mitochondrial D-loop (D310-tract). The clinical diagnosis was confirmed in all patients by detection of pathogenic mutations in the NF1 gene. Monozygosity was verified by genotyping. However, we did not detect evidence for mtDNA sequence differences or for different degrees of heteroplasmy between individuals of the same twin pair. The phenotypic discordance of MZ twins with NF1 cannot be explained by skewed distribution of mtDNA mutations or polymorphisms.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "1c8a233817e24aaf970974c3d66dfce4", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[59, 59], [51, 51], [150, 150], [74, 74], [227, 227], [4, 4], [268, 268], [175, 175]], "char_spans": [[396, 398], [341, 343], [966, 968], [485, 487], [1451, 1453], [26, 28], [1697, 1699], [1130, 1132]]}]}], "context_tokens": [["Neurofibromatosis", 0], ["type", 18], ["1", 23], ["(", 25], ["NF1", 26], [")", 29], ["is", 31], ["the", 34], ["most", 38], ["frequent", 43], ["neurocutaneous", 52], ["disorder", 67], ["with", 76], ["autosomal", 81], ["dominant", 91], ["inheritance", 100], [".", 111], ["Phenotype", 113], ["variability", 123], ["is", 135], ["high", 138], ["ranging", 143], ["from", 151], ["merely", 156], ["several", 163], ["caf\u00e9", 171], ["-", 175], ["au", 176], ["-", 178], ["lait", 179], ["spots", 184], ["to", 190], ["malignant", 193], ["peripheral", 203], ["nerve", 214], ["sheath", 220], ["tumors", 227], ["or", 234], ["severe", 237], ["disfigurement", 244], ["through", 258], ["plexiform", 266], ["neurofibromas", 276], [".", 289], ["Identification", 291], ["of", 306], ["genetic", 309], ["factors", 317], ["that", 325], ["modify", 330], ["the", 337], ["NF1", 341], ["phenotype", 345], ["would", 355], ["contribute", 361], ["to", 372], ["the", 375], ["understanding", 379], ["of", 393], ["NF1", 396], ["pathophysiology", 400], ["and", 416], ["improve", 420], ["patient", 428], ["counselling", 436], [".", 447], ["As", 449], ["even", 452], ["monozygotic", 457], ["(", 469], ["MZ", 470], [")", 472], ["twins", 474], ["with", 480], ["NF1", 485], ["may", 489], ["differ", 493], ["phenotypically", 500], [",", 514], ["we", 516], ["wondered", 519], ["whether", 528], ["these", 536], ["variations", 542], ["might", 553], ["be", 559], ["inherited", 562], ["in", 572], ["a", 575], ["non", 577], ["-", 580], ["Mendelian", 581], ["fashion", 591], [".", 598], ["Mitochondrial", 600], ["DNA", 614], ["(", 618], ["mtDNA", 619], [")", 624], ["is", 626], ["inherited", 629], ["extrachromosomally", 639], ["through", 658], ["the", 666], ["cytoplasm", 670], ["of", 680], ["the", 683], ["oocyte", 687], ["and", 694], ["often", 698], ["harbours", 704], ["heteroplasmic", 713], ["sequence", 727], ["variations", 736], [".", 746], ["At", 748], ["the", 751], ["time", 755], ["of", 760], ["blastomere", 763], ["separation", 774], [",", 784], ["these", 786], ["variants", 792], ["may", 801], ["be", 805], ["skewedly", 808], ["distributed", 817], ["and", 829], ["effect", 833], ["phenotypic", 840], ["differences", 851], [".", 862], ["Because", 864], ["of", 872], ["their", 875], ["co", 881], ["-", 883], ["localization", 884], ["with", 897], ["the", 902], ["tumor", 906], ["suppressor", 912], ["protein", 923], ["neurofibromin", 931], [",", 944], ["which", 946], ["is", 952], ["mutated", 955], ["in", 963], ["NF1", 966], [",", 969], ["mitochondria", 971], ["were", 984], ["particular", 989], ["attractive", 1000], ["candidates", 1011], ["for", 1022], ["investigation", 1026], [".", 1039], ["MtDNA", 1041], ["was", 1047], ["extracted", 1051], ["from", 1061], ["nucleated", 1066], ["blood", 1076], ["cells", 1082], ["of", 1088], ["four", 1091], ["pairs", 1096], ["of", 1102], ["discordant", 1105], ["MZ", 1116], ["twins", 1119], ["with", 1125], ["NF1", 1130], ["and", 1134], ["from", 1138], ["cutaneous", 1143], ["neurofibromas", 1153], ["of", 1167], ["one", 1170], ["twin", 1174], ["pair", 1179], [".", 1183], ["We", 1185], ["sequenced", 1188], ["the", 1198], ["entire", 1202], ["mitochondrial", 1209], ["genome", 1223], ["and", 1230], ["determined", 1234], ["the", 1245], ["state", 1249], ["of", 1255], ["heteroplasmy", 1258], ["by", 1271], ["investigating", 1274], ["a", 1288], ["microsatellite", 1290], ["region", 1305], ["of", 1312], ["the", 1315], ["mitochondrial", 1319], ["D", 1333], ["-", 1334], ["loop", 1335], ["(", 1340], ["D310-tract", 1341], [")", 1351], [".", 1352], ["The", 1354], ["clinical", 1358], ["diagnosis", 1367], ["was", 1377], ["confirmed", 1381], ["in", 1391], ["all", 1394], ["patients", 1398], ["by", 1407], ["detection", 1410], ["of", 1420], ["pathogenic", 1423], ["mutations", 1434], ["in", 1444], ["the", 1447], ["NF1", 1451], ["gene", 1455], [".", 1459], ["Monozygosity", 1461], ["was", 1474], ["verified", 1478], ["by", 1487], ["genotyping", 1490], [".", 1500], ["However", 1502], [",", 1509], ["we", 1511], ["did", 1514], ["not", 1518], ["detect", 1522], ["evidence", 1529], ["for", 1538], ["mtDNA", 1542], ["sequence", 1548], ["differences", 1557], ["or", 1569], ["for", 1572], ["different", 1576], ["degrees", 1586], ["of", 1594], ["heteroplasmy", 1597], ["between", 1610], ["individuals", 1618], ["of", 1630], ["the", 1633], ["same", 1637], ["twin", 1642], ["pair", 1647], [".", 1651], ["The", 1653], ["phenotypic", 1657], ["discordance", 1668], ["of", 1680], ["MZ", 1683], ["twins", 1686], ["with", 1692], ["NF1", 1697], ["can", 1701], ["not", 1704], ["be", 1708], ["explained", 1711], ["by", 1721], ["skewed", 1724], ["distribution", 1731], ["of", 1744], ["mtDNA", 1747], ["mutations", 1753], ["or", 1763], ["polymorphisms", 1766], [".", 1779]]}
{"context": "Restless legs syndrome/Willis Ekbom disease (RLS/WED) has been recognized as a significant medical disorder since the 17th century. It was studied mostly in the last 50 years in relation to increasing interest in sleep medicine and health-related quality of life. This led to recognition that the disease is not well characterized as restless feelings in the legs. These symptoms are reported in many situations, but the subjective experience of RLS/WED patients differs from that experienced by others. Thus a new name has been introduced that avoids problems of symptom definition of a disease by naming it after those who first characterized it, i.e. 'Willis Ekbom disease'. This article emphasizes the importance of RLS/WED for psychiatry. The disease carries significant increased risk for depression and anxiety disorders. Treatment requires consideration of these co-morbid disorders. RLS/WED can exacerbate or even engender psychiatric disease, so treatment of psychiatric disease should also include consideration of RLS/WED. The need for attention to RLS/WED is particularly significant for depression. Most anti-depressants exacerbate or can even engender RLS/WED. Thus this article seeks to introduce RLS/WED in relation to psychiatric practice. It presents the RLS/WED disease, its overlap with psychiatry and the current treatment options.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "289d6353e4064a62a58db9f9192b3eff", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[0, 2]], "char_spans": [[0, 21]]}]}], "context_tokens": [["Restless", 0], ["legs", 9], ["syndrome", 14], ["/", 22], ["Willis", 23], ["Ekbom", 30], ["disease", 36], ["(", 44], ["RLS", 45], ["/", 48], ["WED", 49], [")", 52], ["has", 54], ["been", 58], ["recognized", 63], ["as", 74], ["a", 77], ["significant", 79], ["medical", 91], ["disorder", 99], ["since", 108], ["the", 114], ["17th", 118], ["century", 123], [".", 130], ["It", 132], ["was", 135], ["studied", 139], ["mostly", 147], ["in", 154], ["the", 157], ["last", 161], ["50", 166], ["years", 169], ["in", 175], ["relation", 178], ["to", 187], ["increasing", 190], ["interest", 201], ["in", 210], ["sleep", 213], ["medicine", 219], ["and", 228], ["health", 232], ["-", 238], ["related", 239], ["quality", 247], ["of", 255], ["life", 258], [".", 262], ["This", 264], ["led", 269], ["to", 273], ["recognition", 276], ["that", 288], ["the", 293], ["disease", 297], ["is", 305], ["not", 308], ["well", 312], ["characterized", 317], ["as", 331], ["restless", 334], ["feelings", 343], ["in", 352], ["the", 355], ["legs", 359], [".", 363], ["These", 365], ["symptoms", 371], ["are", 380], ["reported", 384], ["in", 393], ["many", 396], ["situations", 401], [",", 411], ["but", 413], ["the", 417], ["subjective", 421], ["experience", 432], ["of", 443], ["RLS", 446], ["/", 449], ["WED", 450], ["patients", 454], ["differs", 463], ["from", 471], ["that", 476], ["experienced", 481], ["by", 493], ["others", 496], [".", 502], ["Thus", 504], ["a", 509], ["new", 511], ["name", 515], ["has", 520], ["been", 524], ["introduced", 529], ["that", 540], ["avoids", 545], ["problems", 552], ["of", 561], ["symptom", 564], ["definition", 572], ["of", 583], ["a", 586], ["disease", 588], ["by", 596], ["naming", 599], ["it", 606], ["after", 609], ["those", 615], ["who", 621], ["first", 625], ["characterized", 631], ["it", 645], [",", 647], ["i.e.", 649], ["'", 654], ["Willis", 655], ["Ekbom", 662], ["disease", 668], ["'", 675], [".", 676], ["This", 678], ["article", 683], ["emphasizes", 691], ["the", 702], ["importance", 706], ["of", 717], ["RLS", 720], ["/", 723], ["WED", 724], ["for", 728], ["psychiatry", 732], [".", 742], ["The", 744], ["disease", 748], ["carries", 756], ["significant", 764], ["increased", 776], ["risk", 786], ["for", 791], ["depression", 795], ["and", 806], ["anxiety", 810], ["disorders", 818], [".", 827], ["Treatment", 829], ["requires", 839], ["consideration", 848], ["of", 862], ["these", 865], ["co", 871], ["-", 873], ["morbid", 874], ["disorders", 881], [".", 890], ["RLS", 892], ["/", 895], ["WED", 896], ["can", 900], ["exacerbate", 904], ["or", 915], ["even", 918], ["engender", 923], ["psychiatric", 932], ["disease", 944], [",", 951], ["so", 953], ["treatment", 956], ["of", 966], ["psychiatric", 969], ["disease", 981], ["should", 989], ["also", 996], ["include", 1001], ["consideration", 1009], ["of", 1023], ["RLS", 1026], ["/", 1029], ["WED", 1030], [".", 1033], ["The", 1035], ["need", 1039], ["for", 1044], ["attention", 1048], ["to", 1058], ["RLS", 1061], ["/", 1064], ["WED", 1065], ["is", 1069], ["particularly", 1072], ["significant", 1085], ["for", 1097], ["depression", 1101], [".", 1111], ["Most", 1113], ["anti", 1118], ["-", 1122], ["depressants", 1123], ["exacerbate", 1135], ["or", 1146], ["can", 1149], ["even", 1153], ["engender", 1158], ["RLS", 1167], ["/", 1170], ["WED", 1171], [".", 1174], ["Thus", 1176], ["this", 1181], ["article", 1186], ["seeks", 1194], ["to", 1200], ["introduce", 1203], ["RLS", 1213], ["/", 1216], ["WED", 1217], ["in", 1221], ["relation", 1224], ["to", 1233], ["psychiatric", 1236], ["practice", 1248], [".", 1256], ["It", 1258], ["presents", 1261], ["the", 1270], ["RLS", 1274], ["/", 1277], ["WED", 1278], ["disease", 1282], [",", 1289], ["its", 1291], ["overlap", 1295], ["with", 1303], ["psychiatry", 1308], ["and", 1319], ["the", 1323], ["current", 1327], ["treatment", 1335], ["options", 1345], [".", 1352]]}
{"context": "The natural phytoalexin resveratrol, found in grapes and red wine, recently rose to public fame for its positive effects on longevity in yeasts, worms and flies. Resveratrol anti-cancer and anti-inflammatory in vitro action on mammalian cell cultures also suggest a possible positive effect on human health and life-expectancy. To study the effects of resveratrol on vertebrate aging is obviously a particularly relevant question. We have studied resveratrol effects in a very short-lived vertebrate: the annual fish Nothobranchius furzeri. Resveratrol treatment prolonged lifespan and delayed the onset of age-related dysfunctions in this fish. This result identifies resveratrol as the first molecule which consistently retards aging in organisms as diverse as yeast, worm, fly and fish, but it also reveals the potential of this short-lived fish as an animal model for pharmacological research. Moreover, being related to stickleback (Gasterosteus aculeatus) the \"pufferfishes\" Takifugu and Tetraodon, and even more closely related to medaka (Oryzias latipes), it can greatly beneficiate from the recent development of genomic resources for these fish models and in the future become a complete model system for the aging research community.", "qas": [{"question": "What can Nothobranchius furzeri be used as a model system for?", "answers": ["aging research"], "qid": "28273676388a4bd8b10c28cc78703649", "question_tokens": [["What", 0], ["can", 5], ["Nothobranchius", 9], ["furzeri", 24], ["be", 32], ["used", 35], ["as", 40], ["a", 43], ["model", 45], ["system", 51], ["for", 58], ["?", 61]], "detected_answers": [{"text": "aging research", "token_spans": [[212, 213]], "char_spans": [[1219, 1232]]}]}], "context_tokens": [["The", 0], ["natural", 4], ["phytoalexin", 12], ["resveratrol", 24], [",", 35], ["found", 37], ["in", 43], ["grapes", 46], ["and", 53], ["red", 57], ["wine", 61], [",", 65], ["recently", 67], ["rose", 76], ["to", 81], ["public", 84], ["fame", 91], ["for", 96], ["its", 100], ["positive", 104], ["effects", 113], ["on", 121], ["longevity", 124], ["in", 134], ["yeasts", 137], [",", 143], ["worms", 145], ["and", 151], ["flies", 155], [".", 160], ["Resveratrol", 162], ["anti", 174], ["-", 178], ["cancer", 179], ["and", 186], ["anti", 190], ["-", 194], ["inflammatory", 195], ["in", 208], ["vitro", 211], ["action", 217], ["on", 224], ["mammalian", 227], ["cell", 237], ["cultures", 242], ["also", 251], ["suggest", 256], ["a", 264], ["possible", 266], ["positive", 275], ["effect", 284], ["on", 291], ["human", 294], ["health", 300], ["and", 307], ["life", 311], ["-", 315], ["expectancy", 316], [".", 326], ["To", 328], ["study", 331], ["the", 337], ["effects", 341], ["of", 349], ["resveratrol", 352], ["on", 364], ["vertebrate", 367], ["aging", 378], ["is", 384], ["obviously", 387], ["a", 397], ["particularly", 399], ["relevant", 412], ["question", 421], [".", 429], ["We", 431], ["have", 434], ["studied", 439], ["resveratrol", 447], ["effects", 459], ["in", 467], ["a", 470], ["very", 472], ["short", 477], ["-", 482], ["lived", 483], ["vertebrate", 489], [":", 499], ["the", 501], ["annual", 505], ["fish", 512], ["Nothobranchius", 517], ["furzeri", 532], [".", 539], ["Resveratrol", 541], ["treatment", 553], ["prolonged", 563], ["lifespan", 573], ["and", 582], ["delayed", 586], ["the", 594], ["onset", 598], ["of", 604], ["age", 607], ["-", 610], ["related", 611], ["dysfunctions", 619], ["in", 632], ["this", 635], ["fish", 640], [".", 644], ["This", 646], ["result", 651], ["identifies", 658], ["resveratrol", 669], ["as", 681], ["the", 684], ["first", 688], ["molecule", 694], ["which", 703], ["consistently", 709], ["retards", 722], ["aging", 730], ["in", 736], ["organisms", 739], ["as", 749], ["diverse", 752], ["as", 760], ["yeast", 763], [",", 768], ["worm", 770], [",", 774], ["fly", 776], ["and", 780], ["fish", 784], [",", 788], ["but", 790], ["it", 794], ["also", 797], ["reveals", 802], ["the", 810], ["potential", 814], ["of", 824], ["this", 827], ["short", 832], ["-", 837], ["lived", 838], ["fish", 844], ["as", 849], ["an", 852], ["animal", 855], ["model", 862], ["for", 868], ["pharmacological", 872], ["research", 888], [".", 896], ["Moreover", 898], [",", 906], ["being", 908], ["related", 914], ["to", 922], ["stickleback", 925], ["(", 937], ["Gasterosteus", 938], ["aculeatus", 951], [")", 960], ["the", 962], ["\"", 966], ["pufferfishes", 967], ["\"", 979], ["Takifugu", 981], ["and", 990], ["Tetraodon", 994], [",", 1003], ["and", 1005], ["even", 1009], ["more", 1014], ["closely", 1019], ["related", 1027], ["to", 1035], ["medaka", 1038], ["(", 1045], ["Oryzias", 1046], ["latipes", 1054], [")", 1061], [",", 1062], ["it", 1064], ["can", 1067], ["greatly", 1071], ["beneficiate", 1079], ["from", 1091], ["the", 1096], ["recent", 1100], ["development", 1107], ["of", 1119], ["genomic", 1122], ["resources", 1130], ["for", 1140], ["these", 1144], ["fish", 1150], ["models", 1155], ["and", 1162], ["in", 1166], ["the", 1169], ["future", 1173], ["become", 1180], ["a", 1187], ["complete", 1189], ["model", 1198], ["system", 1204], ["for", 1211], ["the", 1215], ["aging", 1219], ["research", 1225], ["community", 1234], [".", 1243]]}
{"context": "Insulin is the cornerstone of type 1 diabetes mellitus (T1DM) therapy. However, it cannot achieve a delay in the onset or evolution of this condition, while cardiovascular morbidity remains an unquestionable threat. In this review, the authors discuss gevokizumab (XOMA 052), a recombinant monoclonal antibody that can neutralize human IL-1\u03b2 by binding to it. This is relevant, because this IL has been associated with \u03b2-cell toxicity in both diabetes types. Moreover, gevokizumab presents two major advantages: it spares IL-1\u03b1 and it exhibits favorable pharmacokinetic properties. Gevokizumab has already proven its safety and efficacy in improving glycemic control, \u03b2 cell function and inflammation markers in clinical trials in diabetic patients. Despite the very promising characteristics of gevokizumab, important questions remain to be answered. One important question is what to expect from a combination of this agent with insulin and if there is a subset of patients that might respond more favorably to treatment. We also need to know at what stage in the natural history of T1DM could gevokizumab be most efficacious, as well as its potential effects on cardiovascular outcomes.", "qas": [{"question": "Which molecule is targeted by the drug Gevokizumab?", "answers": ["IL-1\u03b2"], "qid": "c44c66126f324ce3acbc22cbc8a73352", "question_tokens": [["Which", 0], ["molecule", 6], ["is", 15], ["targeted", 18], ["by", 27], ["the", 30], ["drug", 34], ["Gevokizumab", 39], ["?", 50]], "detected_answers": [{"text": "IL-1\u03b2", "token_spans": [[60, 60]], "char_spans": [[336, 340]]}]}], "context_tokens": [["Insulin", 0], ["is", 8], ["the", 11], ["cornerstone", 15], ["of", 27], ["type", 30], ["1", 35], ["diabetes", 37], ["mellitus", 46], ["(", 55], ["T1DM", 56], [")", 60], ["therapy", 62], [".", 69], ["However", 71], [",", 78], ["it", 80], ["can", 83], ["not", 86], ["achieve", 90], ["a", 98], ["delay", 100], ["in", 106], ["the", 109], ["onset", 113], ["or", 119], ["evolution", 122], ["of", 132], ["this", 135], ["condition", 140], [",", 149], ["while", 151], ["cardiovascular", 157], ["morbidity", 172], ["remains", 182], ["an", 190], ["unquestionable", 193], ["threat", 208], [".", 214], ["In", 216], ["this", 219], ["review", 224], [",", 230], ["the", 232], ["authors", 236], ["discuss", 244], ["gevokizumab", 252], ["(", 264], ["XOMA", 265], ["052", 270], [")", 273], [",", 274], ["a", 276], ["recombinant", 278], ["monoclonal", 290], ["antibody", 301], ["that", 310], ["can", 315], ["neutralize", 319], ["human", 330], ["IL-1\u03b2", 336], ["by", 342], ["binding", 345], ["to", 353], ["it", 356], [".", 358], ["This", 360], ["is", 365], ["relevant", 368], [",", 376], ["because", 378], ["this", 386], ["IL", 391], ["has", 394], ["been", 398], ["associated", 403], ["with", 414], ["\u03b2", 419], ["-", 420], ["cell", 421], ["toxicity", 426], ["in", 435], ["both", 438], ["diabetes", 443], ["types", 452], [".", 457], ["Moreover", 459], [",", 467], ["gevokizumab", 469], ["presents", 481], ["two", 490], ["major", 494], ["advantages", 500], [":", 510], ["it", 512], ["spares", 515], ["IL-1\u03b1", 522], ["and", 528], ["it", 532], ["exhibits", 535], ["favorable", 544], ["pharmacokinetic", 554], ["properties", 570], [".", 580], ["Gevokizumab", 582], ["has", 594], ["already", 598], ["proven", 606], ["its", 613], ["safety", 617], ["and", 624], ["efficacy", 628], ["in", 637], ["improving", 640], ["glycemic", 650], ["control", 659], [",", 666], ["\u03b2", 668], ["cell", 670], ["function", 675], ["and", 684], ["inflammation", 688], ["markers", 701], ["in", 709], ["clinical", 712], ["trials", 721], ["in", 728], ["diabetic", 731], ["patients", 740], [".", 748], ["Despite", 750], ["the", 758], ["very", 762], ["promising", 767], ["characteristics", 777], ["of", 793], ["gevokizumab", 796], [",", 807], ["important", 809], ["questions", 819], ["remain", 829], ["to", 836], ["be", 839], ["answered", 842], [".", 850], ["One", 852], ["important", 856], ["question", 866], ["is", 875], ["what", 878], ["to", 883], ["expect", 886], ["from", 893], ["a", 898], ["combination", 900], ["of", 912], ["this", 915], ["agent", 920], ["with", 926], ["insulin", 931], ["and", 939], ["if", 943], ["there", 946], ["is", 952], ["a", 955], ["subset", 957], ["of", 964], ["patients", 967], ["that", 976], ["might", 981], ["respond", 987], ["more", 995], ["favorably", 1000], ["to", 1010], ["treatment", 1013], [".", 1022], ["We", 1024], ["also", 1027], ["need", 1032], ["to", 1037], ["know", 1040], ["at", 1045], ["what", 1048], ["stage", 1053], ["in", 1059], ["the", 1062], ["natural", 1066], ["history", 1074], ["of", 1082], ["T1DM", 1085], ["could", 1090], ["gevokizumab", 1096], ["be", 1108], ["most", 1111], ["efficacious", 1116], [",", 1127], ["as", 1129], ["well", 1132], ["as", 1137], ["its", 1140], ["potential", 1144], ["effects", 1154], ["on", 1162], ["cardiovascular", 1165], ["outcomes", 1180], [".", 1188]]}
{"context": "Selenium, an essential trace element, is incorporated into selenoproteins as selenocysteine (Sec), the 21st amino acid. In order to synthesize selenoproteins, a translational reprogramming event must occur since Sec is encoded by the UGA stop codon. In mammals, the recoding of UGA as Sec depends on the selenocysteine insertion sequence (SECIS) element, a stem-loop structure in the 3' untranslated region of the transcript. The SECIS acts as a platform for RNA-binding proteins, which mediate or regulate the recoding mechanism. Using UV crosslinking, we identified a 110 kDa protein, which binds with high affinity to SECIS elements from a subset of selenoprotein mRNAs. The crosslinking activity was purified by RNA affinity chromatography and identified as nucleolin by mass spectrometry analysis. In vitro binding assays showed that purified nucleolin discriminates among SECIS elements in the absence of other factors. Based on siRNA experiments, nucleolin is required for the optimal expression of certain selenoproteins. There was a good correlation between the affinity of nucleolin for a SECIS and its effect on selenoprotein expression. As selenoprotein transcript levels and localization did not change in siRNA-treated cells, our results suggest that nucleolin selectively enhances the expression of a subset of selenoproteins at the translational level.", "qas": [{"question": "What is the name of the stem loop present in the 3' end of genes encoding for selenoproteins?", "answers": ["SECIS"], "qid": "0a4156b343cd4fec9fc3e8a4b0331052", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["stem", 24], ["loop", 29], ["present", 34], ["in", 42], ["the", 45], ["3", 49], ["'", 50], ["end", 52], ["of", 56], ["genes", 59], ["encoding", 65], ["for", 74], ["selenoproteins", 78], ["?", 92]], "detected_answers": [{"text": "SECIS", "token_spans": [[80, 80], [116, 116], [60, 60], [153, 153], [190, 190]], "char_spans": [[430, 434], [621, 625], [339, 343], [878, 882], [1099, 1103]]}]}], "context_tokens": [["Selenium", 0], [",", 8], ["an", 10], ["essential", 13], ["trace", 23], ["element", 29], [",", 36], ["is", 38], ["incorporated", 41], ["into", 54], ["selenoproteins", 59], ["as", 74], ["selenocysteine", 77], ["(", 92], ["Sec", 93], [")", 96], [",", 97], ["the", 99], ["21st", 103], ["amino", 108], ["acid", 114], [".", 118], ["In", 120], ["order", 123], ["to", 129], ["synthesize", 132], ["selenoproteins", 143], [",", 157], ["a", 159], ["translational", 161], ["reprogramming", 175], ["event", 189], ["must", 195], ["occur", 200], ["since", 206], ["Sec", 212], ["is", 216], ["encoded", 219], ["by", 227], ["the", 230], ["UGA", 234], ["stop", 238], ["codon", 243], [".", 248], ["In", 250], ["mammals", 253], [",", 260], ["the", 262], ["recoding", 266], ["of", 275], ["UGA", 278], ["as", 282], ["Sec", 285], ["depends", 289], ["on", 297], ["the", 300], ["selenocysteine", 304], ["insertion", 319], ["sequence", 329], ["(", 338], ["SECIS", 339], [")", 344], ["element", 346], [",", 353], ["a", 355], ["stem", 357], ["-", 361], ["loop", 362], ["structure", 367], ["in", 377], ["the", 380], ["3", 384], ["'", 385], ["untranslated", 387], ["region", 400], ["of", 407], ["the", 410], ["transcript", 414], [".", 424], ["The", 426], ["SECIS", 430], ["acts", 436], ["as", 441], ["a", 444], ["platform", 446], ["for", 455], ["RNA", 459], ["-", 462], ["binding", 463], ["proteins", 471], [",", 479], ["which", 481], ["mediate", 487], ["or", 495], ["regulate", 498], ["the", 507], ["recoding", 511], ["mechanism", 520], [".", 529], ["Using", 531], ["UV", 537], ["crosslinking", 540], [",", 552], ["we", 554], ["identified", 557], ["a", 568], ["110", 570], ["kDa", 574], ["protein", 578], [",", 585], ["which", 587], ["binds", 593], ["with", 599], ["high", 604], ["affinity", 609], ["to", 618], ["SECIS", 621], ["elements", 627], ["from", 636], ["a", 641], ["subset", 643], ["of", 650], ["selenoprotein", 653], ["mRNAs", 667], [".", 672], ["The", 674], ["crosslinking", 678], ["activity", 691], ["was", 700], ["purified", 704], ["by", 713], ["RNA", 716], ["affinity", 720], ["chromatography", 729], ["and", 744], ["identified", 748], ["as", 759], ["nucleolin", 762], ["by", 772], ["mass", 775], ["spectrometry", 780], ["analysis", 793], [".", 801], ["In", 803], ["vitro", 806], ["binding", 812], ["assays", 820], ["showed", 827], ["that", 834], ["purified", 839], ["nucleolin", 848], ["discriminates", 858], ["among", 872], ["SECIS", 878], ["elements", 884], ["in", 893], ["the", 896], ["absence", 900], ["of", 908], ["other", 911], ["factors", 917], [".", 924], ["Based", 926], ["on", 932], ["siRNA", 935], ["experiments", 941], [",", 952], ["nucleolin", 954], ["is", 964], ["required", 967], ["for", 976], ["the", 980], ["optimal", 984], ["expression", 992], ["of", 1003], ["certain", 1006], ["selenoproteins", 1014], [".", 1028], ["There", 1030], ["was", 1036], ["a", 1040], ["good", 1042], ["correlation", 1047], ["between", 1059], ["the", 1067], ["affinity", 1071], ["of", 1080], ["nucleolin", 1083], ["for", 1093], ["a", 1097], ["SECIS", 1099], ["and", 1105], ["its", 1109], ["effect", 1113], ["on", 1120], ["selenoprotein", 1123], ["expression", 1137], [".", 1147], ["As", 1149], ["selenoprotein", 1152], ["transcript", 1166], ["levels", 1177], ["and", 1184], ["localization", 1188], ["did", 1201], ["not", 1205], ["change", 1209], ["in", 1216], ["siRNA", 1219], ["-", 1224], ["treated", 1225], ["cells", 1233], [",", 1238], ["our", 1240], ["results", 1244], ["suggest", 1252], ["that", 1260], ["nucleolin", 1265], ["selectively", 1275], ["enhances", 1287], ["the", 1296], ["expression", 1300], ["of", 1311], ["a", 1314], ["subset", 1316], ["of", 1323], ["selenoproteins", 1326], ["at", 1341], ["the", 1344], ["translational", 1348], ["level", 1362], [".", 1367]]}
{"context": "Community-associated methicillin-resistant Staphylococcus aureus-(CA-MRSA) strains have emerged in Argentina. We investigated the clinical and molecular evolution of community-onset MRSA infections (CO-MRSA) in children of C\u00f3rdoba, Argentina, 2005-2008. Additionally, data from 2007 were compared with the epidemiology of these infections in other regions of the country. Two datasets were used: i) lab-based prospective surveillance of CA-MRSA isolates from 3 C\u00f3rdoba pediatric hospitals-(CBAH1-H3) in 2007-2008 (compared to previously published data of 2005) and ii) a sampling of CO-MRSA from a study involving both, healthcare-associated community-onset-(HACO) infections in children with risk-factors for healthcare-associated infections-(HRFs), and CA-MRSA infections in patients without HRFs detected in multiple centers of Argentina in 2007. Molecular typing was performed on the CA-MRSA-(n: 99) isolates from the CBAH1-H3-dataset and on the HACO-MRSA-(n: 51) and CA-MRSA-(n: 213) isolates from other regions. Between 2005-2008, the annual proportion of CA-MRSA/CA-S. aureus in C\u00f3rdoba hospitals increased from 25% to 49%, P<0.01. Total CA-MRSA infections increased 3.6 fold-(5.1 to 18.6 cases/100,000 annual-visits, P<0.0001), associated with an important increase of invasive CA-MRSA infections-(8.5 fold). In all regions analyzed, a single genotype prevailed in both CA-MRSA (82%) and HACO-MRSA(57%), which showed pulsed-field-gel electrophoresis-(PFGE)-type-\"I\", sequence-type-5-(ST5), SCCmec-type-IVa, spa-t311, and was positive for PVL. The second clone, pulsotype-N/ST30/CC30/SCCmecIVc/t019/PVL(+), accounted for 11.5% of total CA-MRSA infections. Importantly, the first 4 isolates of Argentina belonging to South American-USA300 clone-(USA300/ST8/CC8/SCCmecIVc/t008/PVL(+)/ACME(-)) were detected. We also demonstrated that a HA-MRSA clone-(pulsotype-C/ST100/CC5) caused 2% and 10% of CA-MRSA and HACO-MRSA infections respectively and was associated with a SCCmec type closely related to SCCmecIV(2B&5). The dissemination of epidemic MRSA clone, ST5-IV-PVL(+) was the main cause of increasing staphylococcal community-onset infections in Argentinean children (2003-2008), conversely to other countries. The predominance of this clone, which has capacity to express the h-VISA phenotype, in healthcare-associated community-onset cases suggests that it has infiltrated into hospital-settings.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "e471eaad8b7f456298a4d3d189d07e9f", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[226, 226], [384, 384], [141, 141], [250, 250], [28, 28], [204, 204], [9, 9], [268, 268], [332, 332], [364, 364], [380, 380], [404, 404], [110, 110], [33, 33], [81, 81]], "char_spans": [[1148, 1151], [1917, 1920], [758, 761], [1289, 1292], [182, 185], [1065, 1068], [69, 72], [1381, 1384], [1646, 1649], [1844, 1847], [1903, 1906], [2049, 2052], [586, 589], [202, 205], [440, 443]]}]}], "context_tokens": [["Community", 0], ["-", 9], ["associated", 10], ["methicillin", 21], ["-", 32], ["resistant", 33], ["Staphylococcus", 43], ["aureus-(CA", 58], ["-", 68], ["MRSA", 69], [")", 73], ["strains", 75], ["have", 83], ["emerged", 88], ["in", 96], ["Argentina", 99], [".", 108], ["We", 110], ["investigated", 113], ["the", 126], ["clinical", 130], ["and", 139], ["molecular", 143], ["evolution", 153], ["of", 163], ["community", 166], ["-", 175], ["onset", 176], ["MRSA", 182], ["infections", 187], ["(", 198], ["CO", 199], ["-", 201], ["MRSA", 202], [")", 206], ["in", 208], ["children", 211], ["of", 220], ["C\u00f3rdoba", 223], [",", 230], ["Argentina", 232], [",", 241], ["2005", 243], ["-", 247], ["2008", 248], [".", 252], ["Additionally", 254], [",", 266], ["data", 268], ["from", 273], ["2007", 278], ["were", 283], ["compared", 288], ["with", 297], ["the", 302], ["epidemiology", 306], ["of", 319], ["these", 322], ["infections", 328], ["in", 339], ["other", 342], ["regions", 348], ["of", 356], ["the", 359], ["country", 363], [".", 370], ["Two", 372], ["datasets", 376], ["were", 385], ["used", 390], [":", 394], ["i", 396], [")", 397], ["lab", 399], ["-", 402], ["based", 403], ["prospective", 409], ["surveillance", 421], ["of", 434], ["CA", 437], ["-", 439], ["MRSA", 440], ["isolates", 445], ["from", 454], ["3", 459], ["C\u00f3rdoba", 461], ["pediatric", 469], ["hospitals-(CBAH1-H3", 479], [")", 498], ["in", 500], ["2007", 503], ["-", 507], ["2008", 508], ["(", 513], ["compared", 514], ["to", 523], ["previously", 526], ["published", 537], ["data", 547], ["of", 552], ["2005", 555], [")", 559], ["and", 561], ["ii", 565], [")", 567], ["a", 569], ["sampling", 571], ["of", 580], ["CO", 583], ["-", 585], ["MRSA", 586], ["from", 591], ["a", 596], ["study", 598], ["involving", 604], ["both", 614], [",", 618], ["healthcare", 620], ["-", 630], ["associated", 631], ["community", 642], ["-", 651], ["onset-(HACO", 652], [")", 663], ["infections", 665], ["in", 676], ["children", 679], ["with", 688], ["risk", 693], ["-", 697], ["factors", 698], ["for", 706], ["healthcare", 710], ["-", 720], ["associated", 721], ["infections-(HRFs", 732], [")", 748], [",", 749], ["and", 751], ["CA", 755], ["-", 757], ["MRSA", 758], ["infections", 763], ["in", 774], ["patients", 777], ["without", 786], ["HRFs", 794], ["detected", 799], ["in", 808], ["multiple", 811], ["centers", 820], ["of", 828], ["Argentina", 831], ["in", 841], ["2007", 844], [".", 848], ["Molecular", 850], ["typing", 860], ["was", 867], ["performed", 871], ["on", 881], ["the", 884], ["CA", 888], ["-", 890], ["MRSA-(n", 891], [":", 898], ["99", 900], [")", 902], ["isolates", 904], ["from", 913], ["the", 918], ["CBAH1-H3-dataset", 922], ["and", 939], ["on", 943], ["the", 946], ["HACO", 950], ["-", 954], ["MRSA-(n", 955], [":", 962], ["51", 964], [")", 966], ["and", 968], ["CA", 972], ["-", 974], ["MRSA-(n", 975], [":", 982], ["213", 984], [")", 987], ["isolates", 989], ["from", 998], ["other", 1003], ["regions", 1009], [".", 1016], ["Between", 1018], ["2005", 1026], ["-", 1030], ["2008", 1031], [",", 1035], ["the", 1037], ["annual", 1041], ["proportion", 1048], ["of", 1059], ["CA", 1062], ["-", 1064], ["MRSA", 1065], ["/", 1069], ["CA", 1070], ["-", 1072], ["S.", 1073], ["aureus", 1076], ["in", 1083], ["C\u00f3rdoba", 1086], ["hospitals", 1094], ["increased", 1104], ["from", 1114], ["25", 1119], ["%", 1121], ["to", 1123], ["49", 1126], ["%", 1128], [",", 1129], ["P<0.01", 1131], [".", 1137], ["Total", 1139], ["CA", 1145], ["-", 1147], ["MRSA", 1148], ["infections", 1153], ["increased", 1164], ["3.6", 1174], ["fold-(5.1", 1178], ["to", 1188], ["18.6", 1191], ["cases/100,000", 1196], ["annual", 1210], ["-", 1216], ["visits", 1217], [",", 1223], ["P<0.0001", 1225], [")", 1233], [",", 1234], ["associated", 1236], ["with", 1247], ["an", 1252], ["important", 1255], ["increase", 1265], ["of", 1274], ["invasive", 1277], ["CA", 1286], ["-", 1288], ["MRSA", 1289], ["infections-(8.5", 1294], ["fold", 1310], [")", 1314], [".", 1315], ["In", 1317], ["all", 1320], ["regions", 1324], ["analyzed", 1332], [",", 1340], ["a", 1342], ["single", 1344], ["genotype", 1351], ["prevailed", 1360], ["in", 1370], ["both", 1373], ["CA", 1378], ["-", 1380], ["MRSA", 1381], ["(", 1386], ["82", 1387], ["%", 1389], [")", 1390], ["and", 1392], ["HACO", 1396], ["-", 1400], ["MRSA(57", 1401], ["%", 1408], [")", 1409], [",", 1410], ["which", 1412], ["showed", 1418], ["pulsed", 1425], ["-", 1431], ["field", 1432], ["-", 1437], ["gel", 1438], ["electrophoresis-(PFGE)-type-\"I", 1442], ["\"", 1472], [",", 1473], ["sequence", 1475], ["-", 1483], ["type-5-(ST5", 1484], [")", 1495], [",", 1496], ["SCCmec", 1498], ["-", 1504], ["type", 1505], ["-", 1509], ["IVa", 1510], [",", 1513], ["spa", 1515], ["-", 1518], ["t311", 1519], [",", 1523], ["and", 1525], ["was", 1529], ["positive", 1533], ["for", 1542], ["PVL", 1546], [".", 1549], ["The", 1551], ["second", 1555], ["clone", 1562], [",", 1567], ["pulsotype", 1569], ["-", 1578], ["N", 1579], ["/", 1580], ["ST30/CC30/SCCmecIVc", 1581], ["/", 1600], ["t019/PVL(+", 1601], [")", 1611], [",", 1612], ["accounted", 1614], ["for", 1624], ["11.5", 1628], ["%", 1632], ["of", 1634], ["total", 1637], ["CA", 1643], ["-", 1645], ["MRSA", 1646], ["infections", 1651], [".", 1661], ["Importantly", 1663], [",", 1674], ["the", 1676], ["first", 1680], ["4", 1686], ["isolates", 1688], ["of", 1697], ["Argentina", 1700], ["belonging", 1710], ["to", 1720], ["South", 1723], ["American", 1729], ["-", 1737], ["USA300", 1738], ["clone-(USA300/ST8/CC8/SCCmecIVc", 1745], ["/", 1776], ["t008/PVL(+)/ACME(-", 1777], [")", 1795], [")", 1796], ["were", 1798], ["detected", 1803], [".", 1811], ["We", 1813], ["also", 1816], ["demonstrated", 1821], ["that", 1834], ["a", 1839], ["HA", 1841], ["-", 1843], ["MRSA", 1844], ["clone-(pulsotype", 1849], ["-", 1865], ["C", 1866], ["/", 1867], ["ST100/CC5", 1868], [")", 1877], ["caused", 1879], ["2", 1886], ["%", 1887], ["and", 1889], ["10", 1893], ["%", 1895], ["of", 1897], ["CA", 1900], ["-", 1902], ["MRSA", 1903], ["and", 1908], ["HACO", 1912], ["-", 1916], ["MRSA", 1917], ["infections", 1922], ["respectively", 1933], ["and", 1946], ["was", 1950], ["associated", 1954], ["with", 1965], ["a", 1970], ["SCCmec", 1972], ["type", 1979], ["closely", 1984], ["related", 1992], ["to", 2000], ["SCCmecIV(2B&5", 2003], [")", 2016], [".", 2017], ["The", 2019], ["dissemination", 2023], ["of", 2037], ["epidemic", 2040], ["MRSA", 2049], ["clone", 2054], [",", 2059], ["ST5-IV", 2061], ["-", 2067], ["PVL(+", 2068], [")", 2073], ["was", 2075], ["the", 2079], ["main", 2083], ["cause", 2088], ["of", 2094], ["increasing", 2097], ["staphylococcal", 2108], ["community", 2123], ["-", 2132], ["onset", 2133], ["infections", 2139], ["in", 2150], ["Argentinean", 2153], ["children", 2165], ["(", 2174], ["2003", 2175], ["-", 2179], ["2008", 2180], [")", 2184], [",", 2185], ["conversely", 2187], ["to", 2198], ["other", 2201], ["countries", 2207], [".", 2216], ["The", 2218], ["predominance", 2222], ["of", 2235], ["this", 2238], ["clone", 2243], [",", 2248], ["which", 2250], ["has", 2256], ["capacity", 2260], ["to", 2269], ["express", 2272], ["the", 2280], ["h", 2284], ["-", 2285], ["VISA", 2286], ["phenotype", 2291], [",", 2300], ["in", 2302], ["healthcare", 2305], ["-", 2315], ["associated", 2316], ["community", 2327], ["-", 2336], ["onset", 2337], ["cases", 2343], ["suggests", 2349], ["that", 2358], ["it", 2363], ["has", 2366], ["infiltrated", 2370], ["into", 2382], ["hospital", 2387], ["-", 2395], ["settings", 2396], [".", 2404]]}
{"context": "A 50-year-old man presented with worsening, virtually lifelong, chorea and progressive behavioural disturbance, involving disinhibition and hoarding, over 10 years. Clinical assessment revealed chorea, dysarthria, areflexia, an inappropriately jovial, impulsive manner and neuropsychological evidence of frontosubcortical dysfunction. Investigation results included an elevated creatine kinase, caudate atrophy and hypoperfusion, acanthocytes in the peripheral blood and the McLeod phenotype. DNA studies demonstrated a single-base deletion at position 172 in exon 1 of the XK gene, giving rise to a premature stop codon at position 129 in exon 2.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "c44de3a52803425c8e515bdb5fb039ac", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[88, 88]], "char_spans": [[574, 575]]}]}], "context_tokens": [["A", 0], ["50-year", 2], ["-", 9], ["old", 10], ["man", 14], ["presented", 18], ["with", 28], ["worsening", 33], [",", 42], ["virtually", 44], ["lifelong", 54], [",", 62], ["chorea", 64], ["and", 71], ["progressive", 75], ["behavioural", 87], ["disturbance", 99], [",", 110], ["involving", 112], ["disinhibition", 122], ["and", 136], ["hoarding", 140], [",", 148], ["over", 150], ["10", 155], ["years", 158], [".", 163], ["Clinical", 165], ["assessment", 174], ["revealed", 185], ["chorea", 194], [",", 200], ["dysarthria", 202], [",", 212], ["areflexia", 214], [",", 223], ["an", 225], ["inappropriately", 228], ["jovial", 244], [",", 250], ["impulsive", 252], ["manner", 262], ["and", 269], ["neuropsychological", 273], ["evidence", 292], ["of", 301], ["frontosubcortical", 304], ["dysfunction", 322], [".", 333], ["Investigation", 335], ["results", 349], ["included", 357], ["an", 366], ["elevated", 369], ["creatine", 378], ["kinase", 387], [",", 393], ["caudate", 395], ["atrophy", 403], ["and", 411], ["hypoperfusion", 415], [",", 428], ["acanthocytes", 430], ["in", 443], ["the", 446], ["peripheral", 450], ["blood", 461], ["and", 467], ["the", 471], ["McLeod", 475], ["phenotype", 482], [".", 491], ["DNA", 493], ["studies", 497], ["demonstrated", 505], ["a", 518], ["single", 520], ["-", 526], ["base", 527], ["deletion", 532], ["at", 541], ["position", 544], ["172", 553], ["in", 557], ["exon", 560], ["1", 565], ["of", 567], ["the", 570], ["XK", 574], ["gene", 577], [",", 581], ["giving", 583], ["rise", 590], ["to", 595], ["a", 598], ["premature", 600], ["stop", 610], ["codon", 615], ["at", 621], ["position", 624], ["129", 633], ["in", 637], ["exon", 640], ["2", 645], [".", 646]]}
{"context": "Since the discovery of non-coding, small, highly structured, satellite RNAs (satRNAs) and viroids as subviral pathogens of plants , have been of great interest to molecular biologists as possible living fossils of pre-cellular evolution in an RNA world. Despite extensive studies performed in the last four decades, there is still mystery surrounding the origin and evolutionary relationship between these subviral pathogens. Recent technical advances revealed some commonly shared replication features between these two subviral pathogens. In this review, we discuss our current perception of replication and evolutionary origin of these petite RNA pathogens.", "qas": [{"question": "Which are the smallest known subviral pathogens of plants?", "answers": ["Viroids"], "qid": "0133a9c3b1f74db79d96f61d59105870", "question_tokens": [["Which", 0], ["are", 6], ["the", 10], ["smallest", 14], ["known", 23], ["subviral", 29], ["pathogens", 38], ["of", 48], ["plants", 51], ["?", 57]], "detected_answers": [{"text": "Viroids", "token_spans": [[19, 19]], "char_spans": [[90, 96]]}]}], "context_tokens": [["Since", 0], ["the", 6], ["discovery", 10], ["of", 20], ["non", 23], ["-", 26], ["coding", 27], [",", 33], ["small", 35], [",", 40], ["highly", 42], ["structured", 49], [",", 59], ["satellite", 61], ["RNAs", 71], ["(", 76], ["satRNAs", 77], [")", 84], ["and", 86], ["viroids", 90], ["as", 98], ["subviral", 101], ["pathogens", 110], ["of", 120], ["plants", 123], [",", 130], ["have", 132], ["been", 137], ["of", 142], ["great", 145], ["interest", 151], ["to", 160], ["molecular", 163], ["biologists", 173], ["as", 184], ["possible", 187], ["living", 196], ["fossils", 203], ["of", 211], ["pre", 214], ["-", 217], ["cellular", 218], ["evolution", 227], ["in", 237], ["an", 240], ["RNA", 243], ["world", 247], [".", 252], ["Despite", 254], ["extensive", 262], ["studies", 272], ["performed", 280], ["in", 290], ["the", 293], ["last", 297], ["four", 302], ["decades", 307], [",", 314], ["there", 316], ["is", 322], ["still", 325], ["mystery", 331], ["surrounding", 339], ["the", 351], ["origin", 355], ["and", 362], ["evolutionary", 366], ["relationship", 379], ["between", 392], ["these", 400], ["subviral", 406], ["pathogens", 415], [".", 424], ["Recent", 426], ["technical", 433], ["advances", 443], ["revealed", 452], ["some", 461], ["commonly", 466], ["shared", 475], ["replication", 482], ["features", 494], ["between", 503], ["these", 511], ["two", 517], ["subviral", 521], ["pathogens", 530], [".", 539], ["In", 541], ["this", 544], ["review", 549], [",", 555], ["we", 557], ["discuss", 560], ["our", 568], ["current", 572], ["perception", 580], ["of", 591], ["replication", 594], ["and", 606], ["evolutionary", 610], ["origin", 623], ["of", 630], ["these", 633], ["petite", 639], ["RNA", 646], ["pathogens", 650], [".", 659]]}
{"context": "Transcription factors belonging to the nuclear factor of activated T cells (NFAT) family regulate the expression of cytokine genes and other inducible genes during the immune response. The functions of NFAT proteins are directly controlled by the calcium- and calmodulin-dependent phosphatase calcineurin. Here we show that the binding of calcineurin to NFAT is substantially increased when calcineurin is activated with calmodulin and calcium. FK506.FKBP12 drug-immunophilin complexes inhibited the interaction of NFAT with activated calcineurin much more effectively than they inhibited the interaction with inactive calcineurin, suggesting that part of the interaction with activated calcineurin involved the enzyme active site. We have previously shown that NFAT is targeted to inactive calcineurin at a region distinct from the calcineurin active site (Aramburu, J., Garcia-Cozar, F. J., Raghavan, A., Okamura, H., Rao, A., and Hogan, P. G. (1998) Mol. Cell 1, 627-637); this region is also involved in NFAT binding to activated calcineurin, since binding is inhibited by an NFAT peptide spanning the calcineurin docking site on NFAT. The interacting surfaces are located on the catalytic domain of the calcineurin A chain and on an 86-amino acid fragment of the NFAT regulatory domain. NFAT binding to the calcineurin catalytic domain was inhibited by the calcineurin autoinhibitory domain and the RII substrate peptide, which bind in the calcineurin active site, as well as by the NFAT docking site peptide, which binds to a region of calcineurin distinct from the active site. We propose that, in resting cells, NFAT is targeted to a region of the calcineurin catalytic domain that does not overlap the calcineurin active site. Upon cell activation, displacement of the autoinhibitory domain by calmodulin binding allows NFAT to bind additionally to the calcineurin active site, thus positioning NFAT for immediate dephosphorylation at functional phosphoserine residues.", "qas": [{"question": "Which calcium/calmodulin dependent protein phosphatase is involved in the activation of the family of NFAT transcription factors (Nuclear Factors of Activated T cells)?", "answers": ["Calcineurin", "CaN", "phosphatase 2b"], "qid": "95cd880240a7419293999192f422b60e", "question_tokens": [["Which", 0], ["calcium", 6], ["/", 13], ["calmodulin", 14], ["dependent", 25], ["protein", 35], ["phosphatase", 43], ["is", 55], ["involved", 58], ["in", 67], ["the", 70], ["activation", 74], ["of", 85], ["the", 88], ["family", 92], ["of", 99], ["NFAT", 102], ["transcription", 107], ["factors", 121], ["(", 129], ["Nuclear", 130], ["Factors", 138], ["of", 146], ["Activated", 149], ["T", 159], ["cells", 161], [")", 166], ["?", 167]], "detected_answers": [{"text": "Calcineurin", "token_spans": [[194, 194], [293, 293], [93, 93], [211, 211], [82, 82], [46, 46], [182, 182], [230, 230], [237, 237], [250, 250], [55, 55], [103, 103], [324, 324], [270, 270], [120, 120], [62, 62], [301, 301], [127, 127]], "char_spans": [[1106, 1116], [1656, 1666], [619, 629], [1208, 1218], [535, 545], [293, 303], [1034, 1044], [1312, 1322], [1362, 1372], [1445, 1455], [339, 349], [687, 697], [1862, 1872], [1542, 1552], [791, 801], [391, 401], [1711, 1721], [833, 843]]}]}], "context_tokens": [["Transcription", 0], ["factors", 14], ["belonging", 22], ["to", 32], ["the", 35], ["nuclear", 39], ["factor", 47], ["of", 54], ["activated", 57], ["T", 67], ["cells", 69], ["(", 75], ["NFAT", 76], [")", 80], ["family", 82], ["regulate", 89], ["the", 98], ["expression", 102], ["of", 113], ["cytokine", 116], ["genes", 125], ["and", 131], ["other", 135], ["inducible", 141], ["genes", 151], ["during", 157], ["the", 164], ["immune", 168], ["response", 175], [".", 183], ["The", 185], ["functions", 189], ["of", 199], ["NFAT", 202], ["proteins", 207], ["are", 216], ["directly", 220], ["controlled", 229], ["by", 240], ["the", 243], ["calcium-", 247], ["and", 256], ["calmodulin", 260], ["-", 270], ["dependent", 271], ["phosphatase", 281], ["calcineurin", 293], [".", 304], ["Here", 306], ["we", 311], ["show", 314], ["that", 319], ["the", 324], ["binding", 328], ["of", 336], ["calcineurin", 339], ["to", 351], ["NFAT", 354], ["is", 359], ["substantially", 362], ["increased", 376], ["when", 386], ["calcineurin", 391], ["is", 403], ["activated", 406], ["with", 416], ["calmodulin", 421], ["and", 432], ["calcium", 436], [".", 443], ["FK506.FKBP12", 445], ["drug", 458], ["-", 462], ["immunophilin", 463], ["complexes", 476], ["inhibited", 486], ["the", 496], ["interaction", 500], ["of", 512], ["NFAT", 515], ["with", 520], ["activated", 525], ["calcineurin", 535], ["much", 547], ["more", 552], ["effectively", 557], ["than", 569], ["they", 574], ["inhibited", 579], ["the", 589], ["interaction", 593], ["with", 605], ["inactive", 610], ["calcineurin", 619], [",", 630], ["suggesting", 632], ["that", 643], ["part", 648], ["of", 653], ["the", 656], ["interaction", 660], ["with", 672], ["activated", 677], ["calcineurin", 687], ["involved", 699], ["the", 708], ["enzyme", 712], ["active", 719], ["site", 726], [".", 730], ["We", 732], ["have", 735], ["previously", 740], ["shown", 751], ["that", 757], ["NFAT", 762], ["is", 767], ["targeted", 770], ["to", 779], ["inactive", 782], ["calcineurin", 791], ["at", 803], ["a", 806], ["region", 808], ["distinct", 815], ["from", 824], ["the", 829], ["calcineurin", 833], ["active", 845], ["site", 852], ["(", 857], ["Aramburu", 858], [",", 866], ["J.", 868], [",", 870], ["Garcia", 872], ["-", 878], ["Cozar", 879], [",", 884], ["F.", 886], ["J.", 889], [",", 891], ["Raghavan", 893], [",", 901], ["A.", 903], [",", 905], ["Okamura", 907], [",", 914], ["H.", 916], [",", 918], ["Rao", 920], [",", 923], ["A.", 925], [",", 927], ["and", 929], ["Hogan", 933], [",", 938], ["P.", 940], ["G.", 943], ["(", 946], ["1998", 947], [")", 951], ["Mol", 953], [".", 956], ["Cell", 958], ["1", 963], [",", 964], ["627", 966], ["-", 969], ["637", 970], [")", 973], [";", 974], ["this", 976], ["region", 981], ["is", 988], ["also", 991], ["involved", 996], ["in", 1005], ["NFAT", 1008], ["binding", 1013], ["to", 1021], ["activated", 1024], ["calcineurin", 1034], [",", 1045], ["since", 1047], ["binding", 1053], ["is", 1061], ["inhibited", 1064], ["by", 1074], ["an", 1077], ["NFAT", 1080], ["peptide", 1085], ["spanning", 1093], ["the", 1102], ["calcineurin", 1106], ["docking", 1118], ["site", 1126], ["on", 1131], ["NFAT", 1134], [".", 1138], ["The", 1140], ["interacting", 1144], ["surfaces", 1156], ["are", 1165], ["located", 1169], ["on", 1177], ["the", 1180], ["catalytic", 1184], ["domain", 1194], ["of", 1201], ["the", 1204], ["calcineurin", 1208], ["A", 1220], ["chain", 1222], ["and", 1228], ["on", 1232], ["an", 1235], ["86-amino", 1238], ["acid", 1247], ["fragment", 1252], ["of", 1261], ["the", 1264], ["NFAT", 1268], ["regulatory", 1273], ["domain", 1284], [".", 1290], ["NFAT", 1292], ["binding", 1297], ["to", 1305], ["the", 1308], ["calcineurin", 1312], ["catalytic", 1324], ["domain", 1334], ["was", 1341], ["inhibited", 1345], ["by", 1355], ["the", 1358], ["calcineurin", 1362], ["autoinhibitory", 1374], ["domain", 1389], ["and", 1396], ["the", 1400], ["RII", 1404], ["substrate", 1408], ["peptide", 1418], [",", 1425], ["which", 1427], ["bind", 1433], ["in", 1438], ["the", 1441], ["calcineurin", 1445], ["active", 1457], ["site", 1464], [",", 1468], ["as", 1470], ["well", 1473], ["as", 1478], ["by", 1481], ["the", 1484], ["NFAT", 1488], ["docking", 1493], ["site", 1501], ["peptide", 1506], [",", 1513], ["which", 1515], ["binds", 1521], ["to", 1527], ["a", 1530], ["region", 1532], ["of", 1539], ["calcineurin", 1542], ["distinct", 1554], ["from", 1563], ["the", 1568], ["active", 1572], ["site", 1579], [".", 1583], ["We", 1585], ["propose", 1588], ["that", 1596], [",", 1600], ["in", 1602], ["resting", 1605], ["cells", 1613], [",", 1618], ["NFAT", 1620], ["is", 1625], ["targeted", 1628], ["to", 1637], ["a", 1640], ["region", 1642], ["of", 1649], ["the", 1652], ["calcineurin", 1656], ["catalytic", 1668], ["domain", 1678], ["that", 1685], ["does", 1690], ["not", 1695], ["overlap", 1699], ["the", 1707], ["calcineurin", 1711], ["active", 1723], ["site", 1730], [".", 1734], ["Upon", 1736], ["cell", 1741], ["activation", 1746], [",", 1756], ["displacement", 1758], ["of", 1771], ["the", 1774], ["autoinhibitory", 1778], ["domain", 1793], ["by", 1800], ["calmodulin", 1803], ["binding", 1814], ["allows", 1822], ["NFAT", 1829], ["to", 1834], ["bind", 1837], ["additionally", 1842], ["to", 1855], ["the", 1858], ["calcineurin", 1862], ["active", 1874], ["site", 1881], [",", 1885], ["thus", 1887], ["positioning", 1892], ["NFAT", 1904], ["for", 1909], ["immediate", 1913], ["dephosphorylation", 1923], ["at", 1941], ["functional", 1944], ["phosphoserine", 1955], ["residues", 1969], [".", 1977]]}
{"context": "Aggregation of \u03b1-synuclein (\u03b1Syn), the primary protein component in Lewy body inclusions of patients with Parkinson's disease, arises when the normally soluble intrinsically disordered protein converts to amyloid fibrils. In this work, we provide a mechanistic view of the role of N-terminal acetylation on fibrillation by first establishing a quantitative relationship between monomer secondary structural propensity and fibril assembly kinetics, and secondly by demonstrating in the N-terminal acetylated form of the early onset A53T mutation, that N-terminal transient helices formed and/or inhibited by N-terminal acetylation modulate the fibril assembly rates. Using NMR chemical shifts and fluorescence experiments, we report that secondary structural propensity in residues 5-8, 14-31, and 50-57 are highly correlated to fibril growth rate. A four-way comparison of secondary structure propensity and fibril growth rates of N-terminally acetylated A53T and WT \u03b1Syn with non-acetylated A53T and WT \u03b1Syn present novel mechanistic insight into the role of N-terminal acetylation in amyloid fibril formation. We show that N-terminal acetylation inhibits the formation of the \"fibrillation promoting\" transient helix at residues 14-31 resulting from the A53T mutation in the non-acetylated variant and supports the formation of the \"fibrillation inhibiting\" transient helix in residues 1-12 thereby resulting in slower fibrillation rates relative to the previously studied non-acetylated A53T variant. Our results highlight the critical interplay of the region-specific transient secondary structure of the N-terminal region with fibrillation, and the inhibitory role of the N-terminal acetyl group in fibril formation.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "98e46197609848b39e1fb5db6b9f7fa8", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "\u03b1-synuclein", "token_spans": [[2, 4]], "char_spans": [[15, 25]]}, {"text": "\u03b1Syn", "token_spans": [[169, 169], [178, 178], [6, 6]], "char_spans": [[967, 970], [1004, 1007], [28, 31]]}]}], "context_tokens": [["Aggregation", 0], ["of", 12], ["\u03b1", 15], ["-", 16], ["synuclein", 17], ["(", 27], ["\u03b1Syn", 28], [")", 32], [",", 33], ["the", 35], ["primary", 39], ["protein", 47], ["component", 55], ["in", 65], ["Lewy", 68], ["body", 73], ["inclusions", 78], ["of", 89], ["patients", 92], ["with", 101], ["Parkinson", 106], ["'s", 115], ["disease", 118], [",", 125], ["arises", 127], ["when", 134], ["the", 139], ["normally", 143], ["soluble", 152], ["intrinsically", 160], ["disordered", 174], ["protein", 185], ["converts", 193], ["to", 202], ["amyloid", 205], ["fibrils", 213], [".", 220], ["In", 222], ["this", 225], ["work", 230], [",", 234], ["we", 236], ["provide", 239], ["a", 247], ["mechanistic", 249], ["view", 261], ["of", 266], ["the", 269], ["role", 273], ["of", 278], ["N", 281], ["-", 282], ["terminal", 283], ["acetylation", 292], ["on", 304], ["fibrillation", 307], ["by", 320], ["first", 323], ["establishing", 329], ["a", 342], ["quantitative", 344], ["relationship", 357], ["between", 370], ["monomer", 378], ["secondary", 386], ["structural", 396], ["propensity", 407], ["and", 418], ["fibril", 422], ["assembly", 429], ["kinetics", 438], [",", 446], ["and", 448], ["secondly", 452], ["by", 461], ["demonstrating", 464], ["in", 478], ["the", 481], ["N", 485], ["-", 486], ["terminal", 487], ["acetylated", 496], ["form", 507], ["of", 512], ["the", 515], ["early", 519], ["onset", 525], ["A53", 531], ["T", 534], ["mutation", 536], [",", 544], ["that", 546], ["N", 551], ["-", 552], ["terminal", 553], ["transient", 562], ["helices", 572], ["formed", 580], ["and/or", 587], ["inhibited", 594], ["by", 604], ["N", 607], ["-", 608], ["terminal", 609], ["acetylation", 618], ["modulate", 630], ["the", 639], ["fibril", 643], ["assembly", 650], ["rates", 659], [".", 664], ["Using", 666], ["NMR", 672], ["chemical", 676], ["shifts", 685], ["and", 692], ["fluorescence", 696], ["experiments", 709], [",", 720], ["we", 722], ["report", 725], ["that", 732], ["secondary", 737], ["structural", 747], ["propensity", 758], ["in", 769], ["residues", 772], ["5", 781], ["-", 782], ["8", 783], [",", 784], ["14", 786], ["-", 788], ["31", 789], [",", 791], ["and", 793], ["50", 797], ["-", 799], ["57", 800], ["are", 803], ["highly", 807], ["correlated", 814], ["to", 825], ["fibril", 828], ["growth", 835], ["rate", 842], [".", 846], ["A", 848], ["four", 850], ["-", 854], ["way", 855], ["comparison", 859], ["of", 870], ["secondary", 873], ["structure", 883], ["propensity", 893], ["and", 904], ["fibril", 908], ["growth", 915], ["rates", 922], ["of", 928], ["N", 931], ["-", 932], ["terminally", 933], ["acetylated", 944], ["A53", 955], ["T", 958], ["and", 960], ["WT", 964], ["\u03b1Syn", 967], ["with", 972], ["non", 977], ["-", 980], ["acetylated", 981], ["A53", 992], ["T", 995], ["and", 997], ["WT", 1001], ["\u03b1Syn", 1004], ["present", 1009], ["novel", 1017], ["mechanistic", 1023], ["insight", 1035], ["into", 1043], ["the", 1048], ["role", 1052], ["of", 1057], ["N", 1060], ["-", 1061], ["terminal", 1062], ["acetylation", 1071], ["in", 1083], ["amyloid", 1086], ["fibril", 1094], ["formation", 1101], [".", 1110], ["We", 1112], ["show", 1115], ["that", 1120], ["N", 1125], ["-", 1126], ["terminal", 1127], ["acetylation", 1136], ["inhibits", 1148], ["the", 1157], ["formation", 1161], ["of", 1171], ["the", 1174], ["\"", 1178], ["fibrillation", 1179], ["promoting", 1192], ["\"", 1201], ["transient", 1203], ["helix", 1213], ["at", 1219], ["residues", 1222], ["14", 1231], ["-", 1233], ["31", 1234], ["resulting", 1237], ["from", 1247], ["the", 1252], ["A53", 1256], ["T", 1259], ["mutation", 1261], ["in", 1270], ["the", 1273], ["non", 1277], ["-", 1280], ["acetylated", 1281], ["variant", 1292], ["and", 1300], ["supports", 1304], ["the", 1313], ["formation", 1317], ["of", 1327], ["the", 1330], ["\"", 1334], ["fibrillation", 1335], ["inhibiting", 1348], ["\"", 1358], ["transient", 1360], ["helix", 1370], ["in", 1376], ["residues", 1379], ["1", 1388], ["-", 1389], ["12", 1390], ["thereby", 1393], ["resulting", 1401], ["in", 1411], ["slower", 1414], ["fibrillation", 1421], ["rates", 1434], ["relative", 1440], ["to", 1449], ["the", 1452], ["previously", 1456], ["studied", 1467], ["non", 1475], ["-", 1478], ["acetylated", 1479], ["A53", 1490], ["T", 1493], ["variant", 1495], [".", 1502], ["Our", 1504], ["results", 1508], ["highlight", 1516], ["the", 1526], ["critical", 1530], ["interplay", 1539], ["of", 1549], ["the", 1552], ["region", 1556], ["-", 1562], ["specific", 1563], ["transient", 1572], ["secondary", 1582], ["structure", 1592], ["of", 1602], ["the", 1605], ["N", 1609], ["-", 1610], ["terminal", 1611], ["region", 1620], ["with", 1627], ["fibrillation", 1632], [",", 1644], ["and", 1646], ["the", 1650], ["inhibitory", 1654], ["role", 1665], ["of", 1670], ["the", 1673], ["N", 1677], ["-", 1678], ["terminal", 1679], ["acetyl", 1688], ["group", 1695], ["in", 1701], ["fibril", 1704], ["formation", 1711], [".", 1720]]}
{"context": "Nucleotide excision repair (NER), which is arguably the most versatile DNA repair system, is strongly attenuated in human cells of the monocytic lineage when they differentiate into macrophages. Within active genes, however, both DNA strands continue to be proficiently repaired. The proficient repair of the nontranscribed strand cannot be explained by the dedicated subpathway of transcription-coupled repair (TCR), which is targeted to the transcribed strand in expressed genes. We now report that the previously termed differentiation-associated repair (DAR) depends upon transcription, but not simply upon RNA polymerase II (RNAPII) encountering a lesion: proficient repair of both DNA strands can occur in a part of a gene that the polymerase never reaches, and even if the translocation of RNAPII is blocked with transcription inhibitors. This suggests that DAR may be a subset of global NER, restricted to the subnuclear compartments or chromatin domains within which transcription occurs. Downregulation of selected NER genes with small interfering RNA has confirmed that DAR relies upon the same genes as global genome repair, rather than upon TCR-specific genes. Our findings support the general view that the genomic domains within which transcription is active are more accessible than the bulk of the genome to the recognition and repair of lesions through the global pathway and that TCR is superimposed upon that pathway of NER.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "84dfe31ea9704f369ff876aaf7937ab8", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[77, 78]], "char_spans": [[443, 460]]}]}], "context_tokens": [["Nucleotide", 0], ["excision", 11], ["repair", 20], ["(", 27], ["NER", 28], [")", 31], [",", 32], ["which", 34], ["is", 40], ["arguably", 43], ["the", 52], ["most", 56], ["versatile", 61], ["DNA", 71], ["repair", 75], ["system", 82], [",", 88], ["is", 90], ["strongly", 93], ["attenuated", 102], ["in", 113], ["human", 116], ["cells", 122], ["of", 128], ["the", 131], ["monocytic", 135], ["lineage", 145], ["when", 153], ["they", 158], ["differentiate", 163], ["into", 177], ["macrophages", 182], [".", 193], ["Within", 195], ["active", 202], ["genes", 209], [",", 214], ["however", 216], [",", 223], ["both", 225], ["DNA", 230], ["strands", 234], ["continue", 242], ["to", 251], ["be", 254], ["proficiently", 257], ["repaired", 270], [".", 278], ["The", 280], ["proficient", 284], ["repair", 295], ["of", 302], ["the", 305], ["nontranscribed", 309], ["strand", 324], ["can", 331], ["not", 334], ["be", 338], ["explained", 341], ["by", 351], ["the", 354], ["dedicated", 358], ["subpathway", 368], ["of", 379], ["transcription", 382], ["-", 395], ["coupled", 396], ["repair", 404], ["(", 411], ["TCR", 412], [")", 415], [",", 416], ["which", 418], ["is", 424], ["targeted", 427], ["to", 436], ["the", 439], ["transcribed", 443], ["strand", 455], ["in", 462], ["expressed", 465], ["genes", 475], [".", 480], ["We", 482], ["now", 485], ["report", 489], ["that", 496], ["the", 501], ["previously", 505], ["termed", 516], ["differentiation", 523], ["-", 538], ["associated", 539], ["repair", 550], ["(", 557], ["DAR", 558], [")", 561], ["depends", 563], ["upon", 571], ["transcription", 576], [",", 589], ["but", 591], ["not", 595], ["simply", 599], ["upon", 606], ["RNA", 611], ["polymerase", 615], ["II", 626], ["(", 629], ["RNAPII", 630], [")", 636], ["encountering", 638], ["a", 651], ["lesion", 653], [":", 659], ["proficient", 661], ["repair", 672], ["of", 679], ["both", 682], ["DNA", 687], ["strands", 691], ["can", 699], ["occur", 703], ["in", 709], ["a", 712], ["part", 714], ["of", 719], ["a", 722], ["gene", 724], ["that", 729], ["the", 734], ["polymerase", 738], ["never", 749], ["reaches", 755], [",", 762], ["and", 764], ["even", 768], ["if", 773], ["the", 776], ["translocation", 780], ["of", 794], ["RNAPII", 797], ["is", 804], ["blocked", 807], ["with", 815], ["transcription", 820], ["inhibitors", 834], [".", 844], ["This", 846], ["suggests", 851], ["that", 860], ["DAR", 865], ["may", 869], ["be", 873], ["a", 876], ["subset", 878], ["of", 885], ["global", 888], ["NER", 895], [",", 898], ["restricted", 900], ["to", 911], ["the", 914], ["subnuclear", 918], ["compartments", 929], ["or", 942], ["chromatin", 945], ["domains", 955], ["within", 963], ["which", 970], ["transcription", 976], ["occurs", 990], [".", 996], ["Downregulation", 998], ["of", 1013], ["selected", 1016], ["NER", 1025], ["genes", 1029], ["with", 1035], ["small", 1040], ["interfering", 1046], ["RNA", 1058], ["has", 1062], ["confirmed", 1066], ["that", 1076], ["DAR", 1081], ["relies", 1085], ["upon", 1092], ["the", 1097], ["same", 1101], ["genes", 1106], ["as", 1112], ["global", 1115], ["genome", 1122], ["repair", 1129], [",", 1135], ["rather", 1137], ["than", 1144], ["upon", 1149], ["TCR", 1154], ["-", 1157], ["specific", 1158], ["genes", 1167], [".", 1172], ["Our", 1174], ["findings", 1178], ["support", 1187], ["the", 1195], ["general", 1199], ["view", 1207], ["that", 1212], ["the", 1217], ["genomic", 1221], ["domains", 1229], ["within", 1237], ["which", 1244], ["transcription", 1250], ["is", 1264], ["active", 1267], ["are", 1274], ["more", 1278], ["accessible", 1283], ["than", 1294], ["the", 1299], ["bulk", 1303], ["of", 1308], ["the", 1311], ["genome", 1315], ["to", 1322], ["the", 1325], ["recognition", 1329], ["and", 1341], ["repair", 1345], ["of", 1352], ["lesions", 1355], ["through", 1363], ["the", 1371], ["global", 1375], ["pathway", 1382], ["and", 1390], ["that", 1394], ["TCR", 1399], ["is", 1403], ["superimposed", 1406], ["upon", 1419], ["that", 1424], ["pathway", 1429], ["of", 1437], ["NER", 1440], [".", 1443]]}
{"context": "Desmosomes are cell-cell adhesion structures that integrate cytoskeletal networks. In addition to binding intermediate filaments, the desmosomal protein desmoplakin (DP) regulates microtubule reorganization in the epidermis. In this paper, we identify a specific subset of centrosomal proteins that are recruited to the cell cortex by DP upon epidermal differentiation. These include Lis1 and Ndel1, which are centrosomal proteins that regulate microtubule organization and anchoring in other cell types. This recruitment was mediated by a region of DP specific to a single isoform, DPI. Furthermore, we demonstrate that the epidermal-specific loss of Lis1 results in dramatic defects in microtubule reorganization. Lis1 ablation also causes desmosomal defects, characterized by decreased levels of desmosomal components, decreased attachment of keratin filaments, and increased turnover of desmosomal proteins at the cell cortex. This contributes to loss of epidermal barrier activity, resulting in completely penetrant perinatal lethality. This work reveals essential desmosome-associated components that control cortical microtubule organization and unexpected roles for centrosomal proteins in epidermal function.", "qas": [{"question": "What are the structures formed when keratin molecules come together?", "answers": ["Intermediate filaments"], "qid": "d4ee2e1fb7364cd6bb5931d72186c5bb", "question_tokens": [["What", 0], ["are", 5], ["the", 9], ["structures", 13], ["formed", 24], ["when", 31], ["keratin", 36], ["molecules", 44], ["come", 54], ["together", 59], ["?", 67]], "detected_answers": [{"text": "Intermediate filaments", "token_spans": [[16, 17]], "char_spans": [[106, 127]]}]}], "context_tokens": [["Desmosomes", 0], ["are", 11], ["cell", 15], ["-", 19], ["cell", 20], ["adhesion", 25], ["structures", 34], ["that", 45], ["integrate", 50], ["cytoskeletal", 60], ["networks", 73], [".", 81], ["In", 83], ["addition", 86], ["to", 95], ["binding", 98], ["intermediate", 106], ["filaments", 119], [",", 128], ["the", 130], ["desmosomal", 134], ["protein", 145], ["desmoplakin", 153], ["(", 165], ["DP", 166], [")", 168], ["regulates", 170], ["microtubule", 180], ["reorganization", 192], ["in", 207], ["the", 210], ["epidermis", 214], [".", 223], ["In", 225], ["this", 228], ["paper", 233], [",", 238], ["we", 240], ["identify", 243], ["a", 252], ["specific", 254], ["subset", 263], ["of", 270], ["centrosomal", 273], ["proteins", 285], ["that", 294], ["are", 299], ["recruited", 303], ["to", 313], ["the", 316], ["cell", 320], ["cortex", 325], ["by", 332], ["DP", 335], ["upon", 338], ["epidermal", 343], ["differentiation", 353], [".", 368], ["These", 370], ["include", 376], ["Lis1", 384], ["and", 389], ["Ndel1", 393], [",", 398], ["which", 400], ["are", 406], ["centrosomal", 410], ["proteins", 422], ["that", 431], ["regulate", 436], ["microtubule", 445], ["organization", 457], ["and", 470], ["anchoring", 474], ["in", 484], ["other", 487], ["cell", 493], ["types", 498], [".", 503], ["This", 505], ["recruitment", 510], ["was", 522], ["mediated", 526], ["by", 535], ["a", 538], ["region", 540], ["of", 547], ["DP", 550], ["specific", 553], ["to", 562], ["a", 565], ["single", 567], ["isoform", 574], [",", 581], ["DPI", 583], [".", 586], ["Furthermore", 588], [",", 599], ["we", 601], ["demonstrate", 604], ["that", 616], ["the", 621], ["epidermal", 625], ["-", 634], ["specific", 635], ["loss", 644], ["of", 649], ["Lis1", 652], ["results", 657], ["in", 665], ["dramatic", 668], ["defects", 677], ["in", 685], ["microtubule", 688], ["reorganization", 700], [".", 714], ["Lis1", 716], ["ablation", 721], ["also", 730], ["causes", 735], ["desmosomal", 742], ["defects", 753], [",", 760], ["characterized", 762], ["by", 776], ["decreased", 779], ["levels", 789], ["of", 796], ["desmosomal", 799], ["components", 810], [",", 820], ["decreased", 822], ["attachment", 832], ["of", 843], ["keratin", 846], ["filaments", 854], [",", 863], ["and", 865], ["increased", 869], ["turnover", 879], ["of", 888], ["desmosomal", 891], ["proteins", 902], ["at", 911], ["the", 914], ["cell", 918], ["cortex", 923], [".", 929], ["This", 931], ["contributes", 936], ["to", 948], ["loss", 951], ["of", 956], ["epidermal", 959], ["barrier", 969], ["activity", 977], [",", 985], ["resulting", 987], ["in", 997], ["completely", 1000], ["penetrant", 1011], ["perinatal", 1021], ["lethality", 1031], [".", 1040], ["This", 1042], ["work", 1047], ["reveals", 1052], ["essential", 1060], ["desmosome", 1070], ["-", 1079], ["associated", 1080], ["components", 1091], ["that", 1102], ["control", 1107], ["cortical", 1115], ["microtubule", 1124], ["organization", 1136], ["and", 1149], ["unexpected", 1153], ["roles", 1164], ["for", 1170], ["centrosomal", 1174], ["proteins", 1186], ["in", 1195], ["epidermal", 1198], ["function", 1208], [".", 1216]]}
{"context": "Although first described as early as 1898 and long considered a vestigial organelle of little functional importance, the primary cilium has become one of the hottest research topics in modern cell biology and physiology. Primary cilia are nonmotile sensory organelles present in a single copy on the surface of most growth-arrested or differentiated mammalian cells, and defects in their assembly or function are tightly coupled to many developmental defects, diseases and disorders. In normal tissues, the primary cilium coordinates a series of signal transduction pathways, including Hedgehog, Wnt, PDGFRalpha and integrin signaling. In the kidney, the primary cilium may function as a mechano-, chemo- and osmosensing unit that probes the extracellular environment and transmits signals to the cell via, e.g., polycystins, which depend on ciliary localization for appropriate function. Indeed, hypomorphic mutations in the mouse ift88 (previously called Tg737) gene, which encodes a ciliogenic intraflagellar transport protein, result in malformation of primary cilia, and in the collecting ducts of kidney tubules this is accompanied by development of autosomal recessive polycystic kidney disease (PKD). While PKD was one of the first diseases to be linked to dysfunctional primary cilia, defects in this organelle have subsequently been associated with many other phenotypes, including cancer, obesity, diabetes as well as a number of developmental defects. Collectively, these disorders of the cilium are now referred to as the ciliopathies. In this review, we provide a brief overview of the structure and function of primary cilia and some of their roles in coordinating signal transduction pathways in mammalian development, health and disease.", "qas": [{"question": "Which is the most common disease attributed to malfunction or absence of primary cilia?", "answers": ["Polycystic kidney disease (PKD)"], "qid": "f11dbef10d7344129874377bdcfdef01", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["most", 13], ["common", 18], ["disease", 25], ["attributed", 33], ["to", 44], ["malfunction", 47], ["or", 59], ["absence", 62], ["of", 70], ["primary", 73], ["cilia", 81], ["?", 86]], "detected_answers": [{"text": "Polycystic kidney disease (PKD)", "token_spans": [[193, 197]], "char_spans": [[1176, 1205]]}]}], "context_tokens": [["Although", 0], ["first", 9], ["described", 15], ["as", 25], ["early", 28], ["as", 34], ["1898", 37], ["and", 42], ["long", 46], ["considered", 51], ["a", 62], ["vestigial", 64], ["organelle", 74], ["of", 84], ["little", 87], ["functional", 94], ["importance", 105], [",", 115], ["the", 117], ["primary", 121], ["cilium", 129], ["has", 136], ["become", 140], ["one", 147], ["of", 151], ["the", 154], ["hottest", 158], ["research", 166], ["topics", 175], ["in", 182], ["modern", 185], ["cell", 192], ["biology", 197], ["and", 205], ["physiology", 209], [".", 219], ["Primary", 221], ["cilia", 229], ["are", 235], ["nonmotile", 239], ["sensory", 249], ["organelles", 257], ["present", 268], ["in", 276], ["a", 279], ["single", 281], ["copy", 288], ["on", 293], ["the", 296], ["surface", 300], ["of", 308], ["most", 311], ["growth", 316], ["-", 322], ["arrested", 323], ["or", 332], ["differentiated", 335], ["mammalian", 350], ["cells", 360], [",", 365], ["and", 367], ["defects", 371], ["in", 379], ["their", 382], ["assembly", 388], ["or", 397], ["function", 400], ["are", 409], ["tightly", 413], ["coupled", 421], ["to", 429], ["many", 432], ["developmental", 437], ["defects", 451], [",", 458], ["diseases", 460], ["and", 469], ["disorders", 473], [".", 482], ["In", 484], ["normal", 487], ["tissues", 494], [",", 501], ["the", 503], ["primary", 507], ["cilium", 515], ["coordinates", 522], ["a", 534], ["series", 536], ["of", 543], ["signal", 546], ["transduction", 553], ["pathways", 566], [",", 574], ["including", 576], ["Hedgehog", 586], [",", 594], ["Wnt", 596], [",", 599], ["PDGFRalpha", 601], ["and", 612], ["integrin", 616], ["signaling", 625], [".", 634], ["In", 636], ["the", 639], ["kidney", 643], [",", 649], ["the", 651], ["primary", 655], ["cilium", 663], ["may", 670], ["function", 674], ["as", 683], ["a", 686], ["mechano-", 688], [",", 696], ["chemo-", 698], ["and", 705], ["osmosensing", 709], ["unit", 721], ["that", 726], ["probes", 731], ["the", 738], ["extracellular", 742], ["environment", 756], ["and", 768], ["transmits", 772], ["signals", 782], ["to", 790], ["the", 793], ["cell", 797], ["via", 802], [",", 805], ["e.g.", 807], [",", 811], ["polycystins", 813], [",", 824], ["which", 826], ["depend", 832], ["on", 839], ["ciliary", 842], ["localization", 850], ["for", 863], ["appropriate", 867], ["function", 879], [".", 887], ["Indeed", 889], [",", 895], ["hypomorphic", 897], ["mutations", 909], ["in", 919], ["the", 922], ["mouse", 926], ["ift88", 932], ["(", 938], ["previously", 939], ["called", 950], ["Tg737", 957], [")", 962], ["gene", 964], [",", 968], ["which", 970], ["encodes", 976], ["a", 984], ["ciliogenic", 986], ["intraflagellar", 997], ["transport", 1012], ["protein", 1022], [",", 1029], ["result", 1031], ["in", 1038], ["malformation", 1041], ["of", 1054], ["primary", 1057], ["cilia", 1065], [",", 1070], ["and", 1072], ["in", 1076], ["the", 1079], ["collecting", 1083], ["ducts", 1094], ["of", 1100], ["kidney", 1103], ["tubules", 1110], ["this", 1118], ["is", 1123], ["accompanied", 1126], ["by", 1138], ["development", 1141], ["of", 1153], ["autosomal", 1156], ["recessive", 1166], ["polycystic", 1176], ["kidney", 1187], ["disease", 1194], ["(", 1202], ["PKD", 1203], [")", 1206], [".", 1207], ["While", 1209], ["PKD", 1215], ["was", 1219], ["one", 1223], ["of", 1227], ["the", 1230], ["first", 1234], ["diseases", 1240], ["to", 1249], ["be", 1252], ["linked", 1255], ["to", 1262], ["dysfunctional", 1265], ["primary", 1279], ["cilia", 1287], [",", 1292], ["defects", 1294], ["in", 1302], ["this", 1305], ["organelle", 1310], ["have", 1320], ["subsequently", 1325], ["been", 1338], ["associated", 1343], ["with", 1354], ["many", 1359], ["other", 1364], ["phenotypes", 1370], [",", 1380], ["including", 1382], ["cancer", 1392], [",", 1398], ["obesity", 1400], [",", 1407], ["diabetes", 1409], ["as", 1418], ["well", 1421], ["as", 1426], ["a", 1429], ["number", 1431], ["of", 1438], ["developmental", 1441], ["defects", 1455], [".", 1462], ["Collectively", 1464], [",", 1476], ["these", 1478], ["disorders", 1484], ["of", 1494], ["the", 1497], ["cilium", 1501], ["are", 1508], ["now", 1512], ["referred", 1516], ["to", 1525], ["as", 1528], ["the", 1531], ["ciliopathies", 1535], [".", 1547], ["In", 1549], ["this", 1552], ["review", 1557], [",", 1563], ["we", 1565], ["provide", 1568], ["a", 1576], ["brief", 1578], ["overview", 1584], ["of", 1593], ["the", 1596], ["structure", 1600], ["and", 1610], ["function", 1614], ["of", 1623], ["primary", 1626], ["cilia", 1634], ["and", 1640], ["some", 1644], ["of", 1649], ["their", 1652], ["roles", 1658], ["in", 1664], ["coordinating", 1667], ["signal", 1680], ["transduction", 1687], ["pathways", 1700], ["in", 1709], ["mammalian", 1712], ["development", 1722], [",", 1733], ["health", 1735], ["and", 1742], ["disease", 1746], [".", 1753]]}
{"context": "Ubiquilin proteins facilitate delivery of ubiquitinated proteins to the proteasome for degradation. Interest in the proteins has been heightened by the discovery that gene mutations in UBQLN2 cause dominant inheritance of amyotrophic lateral sclerosis (ALS). However, the mechanisms by which the mutations cause ALS are not known. Here we report on the underlying defect of ubiquilin-2 proteins containing ALS-linked mutations in affecting proteasome-mediated degradation. We found that overexpression of ubiquilin-2 proteins containing any one of five different ALS mutations slow degradation of Myc, a prototypic proteasome substrate. Examination of coprecipitating proteins indicated that the mutant proteins are generally capable of binding polyubiquitinated proteins, but defective in binding the proteasome. GST-pulldown studies revealed that many of the mutants bind weaker to the S5a subunit of the proteasome, compared with wild type (WT) ubiquilin-2 protein. The results suggest the mutant proteins are unable to deliver their captured cargo to the proteasome for degradation, which presumably leads to toxicity. Quantification of cell death is consistent with this idea. Measurement of protein turnover further indicated the mutant proteins have longer half-lives than WT ubiquilin-2. Our studies provide novel insight into the mechanism by which ALS-linked mutations in UBQLN2 interfere with protein degradation.", "qas": [{"question": "Which human disease is associated with mutated UBQLN2", "answers": ["ALS", "amyotrophic lateral sclerosis"], "qid": "512ddca4bf4d4b0b858b5f2fc87b8f28", "question_tokens": [["Which", 0], ["human", 6], ["disease", 12], ["is", 20], ["associated", 23], ["with", 34], ["mutated", 39], ["UBQLN2", 47]], "detected_answers": [{"text": "ALS", "token_spans": [[48, 48], [64, 64], [36, 36], [217, 217], [88, 88]], "char_spans": [[312, 314], [406, 408], [253, 255], [1358, 1360], [563, 565]]}, {"text": "amyotrophic lateral sclerosis", "token_spans": [[32, 34]], "char_spans": [[222, 250]]}]}], "context_tokens": [["Ubiquilin", 0], ["proteins", 10], ["facilitate", 19], ["delivery", 30], ["of", 39], ["ubiquitinated", 42], ["proteins", 56], ["to", 65], ["the", 68], ["proteasome", 72], ["for", 83], ["degradation", 87], [".", 98], ["Interest", 100], ["in", 109], ["the", 112], ["proteins", 116], ["has", 125], ["been", 129], ["heightened", 134], ["by", 145], ["the", 148], ["discovery", 152], ["that", 162], ["gene", 167], ["mutations", 172], ["in", 182], ["UBQLN2", 185], ["cause", 192], ["dominant", 198], ["inheritance", 207], ["of", 219], ["amyotrophic", 222], ["lateral", 234], ["sclerosis", 242], ["(", 252], ["ALS", 253], [")", 256], [".", 257], ["However", 259], [",", 266], ["the", 268], ["mechanisms", 272], ["by", 283], ["which", 286], ["the", 292], ["mutations", 296], ["cause", 306], ["ALS", 312], ["are", 316], ["not", 320], ["known", 324], [".", 329], ["Here", 331], ["we", 336], ["report", 339], ["on", 346], ["the", 349], ["underlying", 353], ["defect", 364], ["of", 371], ["ubiquilin-2", 374], ["proteins", 386], ["containing", 395], ["ALS", 406], ["-", 409], ["linked", 410], ["mutations", 417], ["in", 427], ["affecting", 430], ["proteasome", 440], ["-", 450], ["mediated", 451], ["degradation", 460], [".", 471], ["We", 473], ["found", 476], ["that", 482], ["overexpression", 487], ["of", 502], ["ubiquilin-2", 505], ["proteins", 517], ["containing", 526], ["any", 537], ["one", 541], ["of", 545], ["five", 548], ["different", 553], ["ALS", 563], ["mutations", 567], ["slow", 577], ["degradation", 582], ["of", 594], ["Myc", 597], [",", 600], ["a", 602], ["prototypic", 604], ["proteasome", 615], ["substrate", 626], [".", 635], ["Examination", 637], ["of", 649], ["coprecipitating", 652], ["proteins", 668], ["indicated", 677], ["that", 687], ["the", 692], ["mutant", 696], ["proteins", 703], ["are", 712], ["generally", 716], ["capable", 726], ["of", 734], ["binding", 737], ["polyubiquitinated", 745], ["proteins", 763], [",", 771], ["but", 773], ["defective", 777], ["in", 787], ["binding", 790], ["the", 798], ["proteasome", 802], [".", 812], ["GST", 814], ["-", 817], ["pulldown", 818], ["studies", 827], ["revealed", 835], ["that", 844], ["many", 849], ["of", 854], ["the", 857], ["mutants", 861], ["bind", 869], ["weaker", 874], ["to", 881], ["the", 884], ["S5a", 888], ["subunit", 892], ["of", 900], ["the", 903], ["proteasome", 907], [",", 917], ["compared", 919], ["with", 928], ["wild", 933], ["type", 938], ["(", 943], ["WT", 944], [")", 946], ["ubiquilin-2", 948], ["protein", 960], [".", 967], ["The", 969], ["results", 973], ["suggest", 981], ["the", 989], ["mutant", 993], ["proteins", 1000], ["are", 1009], ["unable", 1013], ["to", 1020], ["deliver", 1023], ["their", 1031], ["captured", 1037], ["cargo", 1046], ["to", 1052], ["the", 1055], ["proteasome", 1059], ["for", 1070], ["degradation", 1074], [",", 1085], ["which", 1087], ["presumably", 1093], ["leads", 1104], ["to", 1110], ["toxicity", 1113], [".", 1121], ["Quantification", 1123], ["of", 1138], ["cell", 1141], ["death", 1146], ["is", 1152], ["consistent", 1155], ["with", 1166], ["this", 1171], ["idea", 1176], [".", 1180], ["Measurement", 1182], ["of", 1194], ["protein", 1197], ["turnover", 1205], ["further", 1214], ["indicated", 1222], ["the", 1232], ["mutant", 1236], ["proteins", 1243], ["have", 1252], ["longer", 1257], ["half", 1264], ["-", 1268], ["lives", 1269], ["than", 1275], ["WT", 1280], ["ubiquilin-2", 1283], [".", 1294], ["Our", 1296], ["studies", 1300], ["provide", 1308], ["novel", 1316], ["insight", 1322], ["into", 1330], ["the", 1335], ["mechanism", 1339], ["by", 1349], ["which", 1352], ["ALS", 1358], ["-", 1361], ["linked", 1362], ["mutations", 1369], ["in", 1379], ["UBQLN2", 1382], ["interfere", 1389], ["with", 1399], ["protein", 1404], ["degradation", 1412], [".", 1423]]}
{"context": "Calcineurin, a Ca(2+)/calmodulin-stimulated protein phosphatase, plays a key role in T-cell activation by regulating the activity of NFAT (nuclear factor of activated T cells), a family of transcription factors required for the synthesis of several cytokine genes. Calcineurin is the target of the immunosuppressive drugs cyclosporin A and FK506 complexed with their cytoplasmic receptors cyclophilin and FKBP12, respectively. In this study we report that calcineurin is also the target of a recently identified Ca(2+)-binding protein, CHP (for calcineurin homologous protein), which shares a high degree of homology with the regulatory B subunit of calcineurin and with calmodulin. In Jurkat and HeLa cells, overexpression of CHP specifically impaired the nuclear translocation and transcriptional activity of NFAT but had no effect on AP-1 transcriptional activity and only a small (<25%) inhibitory effect on the transcriptional activity of NFkappaB. Further study indicated that CHP inhibits calcineurin activity. In cells overexpressing CHP, the phosphatase activity of immunoprecipitated calcineurin was inhibited by approximately 50%; and in a reconstituted assay, the activity of purified calcineurin was inhibited up to 97% by the addition of purified recombinant CHP in a dose-dependent manner. Moreover, prolonged activation of Jurkat cells was associated with a decreased abundance of CHP, suggesting a possible regulatory mechanism allowing activation of calcineurin. CHP, therefore, is a previously unrecognized endogenous inhibitor of calcineurin activity.", "qas": [{"question": "Which calcium/calmodulin dependent protein phosphatase is involved in the activation of the family of NFAT transcription factors (Nuclear Factors of Activated T cells)?", "answers": ["Calcineurin", "CaN", "phosphatase 2b"], "qid": "e689ed17e25f4a969ae75153c594f23b", "question_tokens": [["Which", 0], ["calcium", 6], ["/", 13], ["calmodulin", 14], ["dependent", 25], ["protein", 35], ["phosphatase", 43], ["is", 55], ["involved", 58], ["in", 67], ["the", 70], ["activation", 74], ["of", 85], ["the", 88], ["family", 92], ["of", 99], ["NFAT", 102], ["transcription", 107], ["factors", 121], ["(", 129], ["Nuclear", 130], ["Factors", 138], ["of", 146], ["Activated", 149], ["T", 159], ["cells", 161], [")", 166], ["?", 167]], "detected_answers": [{"text": "Calcineurin", "token_spans": [[0, 0], [240, 240], [91, 91], [109, 109], [177, 177], [195, 195], [253, 253], [76, 76], [164, 164], [47, 47]], "char_spans": [[0, 10], [1468, 1478], [545, 555], [650, 660], [1094, 1104], [1197, 1207], [1550, 1560], [456, 466], [996, 1006], [265, 275]]}]}], "context_tokens": [["Calcineurin", 0], [",", 11], ["a", 13], ["Ca(2+)/calmodulin", 15], ["-", 32], ["stimulated", 33], ["protein", 44], ["phosphatase", 52], [",", 63], ["plays", 65], ["a", 71], ["key", 73], ["role", 77], ["in", 82], ["T", 85], ["-", 86], ["cell", 87], ["activation", 92], ["by", 103], ["regulating", 106], ["the", 117], ["activity", 121], ["of", 130], ["NFAT", 133], ["(", 138], ["nuclear", 139], ["factor", 147], ["of", 154], ["activated", 157], ["T", 167], ["cells", 169], [")", 174], [",", 175], ["a", 177], ["family", 179], ["of", 186], ["transcription", 189], ["factors", 203], ["required", 211], ["for", 220], ["the", 224], ["synthesis", 228], ["of", 238], ["several", 241], ["cytokine", 249], ["genes", 258], [".", 263], ["Calcineurin", 265], ["is", 277], ["the", 280], ["target", 284], ["of", 291], ["the", 294], ["immunosuppressive", 298], ["drugs", 316], ["cyclosporin", 322], ["A", 334], ["and", 336], ["FK506", 340], ["complexed", 346], ["with", 356], ["their", 361], ["cytoplasmic", 367], ["receptors", 379], ["cyclophilin", 389], ["and", 401], ["FKBP12", 405], [",", 411], ["respectively", 413], [".", 425], ["In", 427], ["this", 430], ["study", 435], ["we", 441], ["report", 444], ["that", 451], ["calcineurin", 456], ["is", 468], ["also", 471], ["the", 476], ["target", 480], ["of", 487], ["a", 490], ["recently", 492], ["identified", 501], ["Ca(2+)-binding", 512], ["protein", 527], [",", 534], ["CHP", 536], ["(", 540], ["for", 541], ["calcineurin", 545], ["homologous", 557], ["protein", 568], [")", 575], [",", 576], ["which", 578], ["shares", 584], ["a", 591], ["high", 593], ["degree", 598], ["of", 605], ["homology", 608], ["with", 617], ["the", 622], ["regulatory", 626], ["B", 637], ["subunit", 639], ["of", 647], ["calcineurin", 650], ["and", 662], ["with", 666], ["calmodulin", 671], [".", 681], ["In", 683], ["Jurkat", 686], ["and", 693], ["HeLa", 697], ["cells", 702], [",", 707], ["overexpression", 709], ["of", 724], ["CHP", 727], ["specifically", 731], ["impaired", 744], ["the", 753], ["nuclear", 757], ["translocation", 765], ["and", 779], ["transcriptional", 783], ["activity", 799], ["of", 808], ["NFAT", 811], ["but", 816], ["had", 820], ["no", 824], ["effect", 827], ["on", 834], ["AP-1", 837], ["transcriptional", 842], ["activity", 858], ["and", 867], ["only", 871], ["a", 876], ["small", 878], ["(", 884], ["<", 885], ["25", 886], ["%", 888], [")", 889], ["inhibitory", 891], ["effect", 902], ["on", 909], ["the", 912], ["transcriptional", 916], ["activity", 932], ["of", 941], ["NFkappaB.", 944], ["Further", 954], ["study", 962], ["indicated", 968], ["that", 978], ["CHP", 983], ["inhibits", 987], ["calcineurin", 996], ["activity", 1008], [".", 1016], ["In", 1018], ["cells", 1021], ["overexpressing", 1027], ["CHP", 1042], [",", 1045], ["the", 1047], ["phosphatase", 1051], ["activity", 1063], ["of", 1072], ["immunoprecipitated", 1075], ["calcineurin", 1094], ["was", 1106], ["inhibited", 1110], ["by", 1120], ["approximately", 1123], ["50", 1137], ["%", 1139], [";", 1140], ["and", 1142], ["in", 1146], ["a", 1149], ["reconstituted", 1151], ["assay", 1165], [",", 1170], ["the", 1172], ["activity", 1176], ["of", 1185], ["purified", 1188], ["calcineurin", 1197], ["was", 1209], ["inhibited", 1213], ["up", 1223], ["to", 1226], ["97", 1229], ["%", 1231], ["by", 1233], ["the", 1236], ["addition", 1240], ["of", 1249], ["purified", 1252], ["recombinant", 1261], ["CHP", 1273], ["in", 1277], ["a", 1280], ["dose", 1282], ["-", 1286], ["dependent", 1287], ["manner", 1297], [".", 1303], ["Moreover", 1305], [",", 1313], ["prolonged", 1315], ["activation", 1325], ["of", 1336], ["Jurkat", 1339], ["cells", 1346], ["was", 1352], ["associated", 1356], ["with", 1367], ["a", 1372], ["decreased", 1374], ["abundance", 1384], ["of", 1394], ["CHP", 1397], [",", 1400], ["suggesting", 1402], ["a", 1413], ["possible", 1415], ["regulatory", 1424], ["mechanism", 1435], ["allowing", 1445], ["activation", 1454], ["of", 1465], ["calcineurin", 1468], [".", 1479], ["CHP", 1481], [",", 1484], ["therefore", 1486], [",", 1495], ["is", 1497], ["a", 1500], ["previously", 1502], ["unrecognized", 1513], ["endogenous", 1526], ["inhibitor", 1537], ["of", 1547], ["calcineurin", 1550], ["activity", 1562], [".", 1570]]}
{"context": "To study the mechanism of centrosome duplication in cycling cells, we established a novel system of multiple centrosome formation in two types of cells: CHO cells treated with RO3306, a Cyclin-dependent kinase 1 (Cdk1) inhibitor and DT40 cells, in which Cdks were knocked out by chemical genetics. Cdk1-inactivated cells initiated DNA replication and centrosome duplication at the onset of S phase. They became arrested at the end of G2, but the centrosome cycle continued to produce supernumerary centrioles/centrosomes without DNA endoreplication in those cells. Centrosomes were amplified in a highly synchronous and reproducible manner: all of them were located next to the nucleus and spread widely apart from each other with several \u03bcm in distance. Double knockout of Cdk1 and Cdk2 caused cell cycle arrest at G1/S and centrosomes were no longer duplicated. However, cells continued to grow and increased their volume over 10-fold during 48 hr of culture. Centrosome components, including \u03b3-tubulin and Cep135, were synthesized and accumulated during the arrest, allowing rapid centrosome multiplication upon recovery from the cell cycle arrest or expression of exogenous Plk4 in G1/S cells. Thus centrosome amplification results from the discoordination of the centrosome cycle from the progression of other cell cycle events, which is controlled by different levels of Cdk activities.", "qas": [{"question": "Where in the cell do we find the protein Cep135?", "answers": ["centrosome"], "qid": "0c06ab7dd90c4dad83de126afa2b4101", "question_tokens": [["Where", 0], ["in", 6], ["the", 9], ["cell", 13], ["do", 18], ["we", 21], ["find", 24], ["the", 29], ["protein", 33], ["Cep135", 41], ["?", 47]], "detected_answers": [{"text": "centrosome", "token_spans": [[5, 5], [82, 82], [188, 188], [215, 215], [18, 18], [168, 168], [62, 62], [207, 207]], "char_spans": [[26, 35], [446, 455], [1084, 1093], [1268, 1277], [109, 118], [962, 971], [351, 360], [1203, 1212]]}]}], "context_tokens": [["To", 0], ["study", 3], ["the", 9], ["mechanism", 13], ["of", 23], ["centrosome", 26], ["duplication", 37], ["in", 49], ["cycling", 52], ["cells", 60], [",", 65], ["we", 67], ["established", 70], ["a", 82], ["novel", 84], ["system", 90], ["of", 97], ["multiple", 100], ["centrosome", 109], ["formation", 120], ["in", 130], ["two", 133], ["types", 137], ["of", 143], ["cells", 146], [":", 151], ["CHO", 153], ["cells", 157], ["treated", 163], ["with", 171], ["RO3306", 176], [",", 182], ["a", 184], ["Cyclin", 186], ["-", 192], ["dependent", 193], ["kinase", 203], ["1", 210], ["(", 212], ["Cdk1", 213], [")", 217], ["inhibitor", 219], ["and", 229], ["DT40", 233], ["cells", 238], [",", 243], ["in", 245], ["which", 248], ["Cdks", 254], ["were", 259], ["knocked", 264], ["out", 272], ["by", 276], ["chemical", 279], ["genetics", 288], [".", 296], ["Cdk1-inactivated", 298], ["cells", 315], ["initiated", 321], ["DNA", 331], ["replication", 335], ["and", 347], ["centrosome", 351], ["duplication", 362], ["at", 374], ["the", 377], ["onset", 381], ["of", 387], ["S", 390], ["phase", 392], [".", 397], ["They", 399], ["became", 404], ["arrested", 411], ["at", 420], ["the", 423], ["end", 427], ["of", 431], ["G2", 434], [",", 436], ["but", 438], ["the", 442], ["centrosome", 446], ["cycle", 457], ["continued", 463], ["to", 473], ["produce", 476], ["supernumerary", 484], ["centrioles", 498], ["/", 508], ["centrosomes", 509], ["without", 521], ["DNA", 529], ["endoreplication", 533], ["in", 549], ["those", 552], ["cells", 558], [".", 563], ["Centrosomes", 565], ["were", 577], ["amplified", 582], ["in", 592], ["a", 595], ["highly", 597], ["synchronous", 604], ["and", 616], ["reproducible", 620], ["manner", 633], [":", 639], ["all", 641], ["of", 645], ["them", 648], ["were", 653], ["located", 658], ["next", 666], ["to", 671], ["the", 674], ["nucleus", 678], ["and", 686], ["spread", 690], ["widely", 697], ["apart", 704], ["from", 710], ["each", 715], ["other", 720], ["with", 726], ["several", 731], ["\u03bcm", 739], ["in", 742], ["distance", 745], [".", 753], ["Double", 755], ["knockout", 762], ["of", 771], ["Cdk1", 774], ["and", 779], ["Cdk2", 783], ["caused", 788], ["cell", 795], ["cycle", 800], ["arrest", 806], ["at", 813], ["G1/S", 816], ["and", 821], ["centrosomes", 825], ["were", 837], ["no", 842], ["longer", 845], ["duplicated", 852], [".", 862], ["However", 864], [",", 871], ["cells", 873], ["continued", 879], ["to", 889], ["grow", 892], ["and", 897], ["increased", 901], ["their", 911], ["volume", 917], ["over", 924], ["10-fold", 929], ["during", 937], ["48", 944], ["hr", 947], ["of", 950], ["culture", 953], [".", 960], ["Centrosome", 962], ["components", 973], [",", 983], ["including", 985], ["\u03b3", 995], ["-", 996], ["tubulin", 997], ["and", 1005], ["Cep135", 1009], [",", 1015], ["were", 1017], ["synthesized", 1022], ["and", 1034], ["accumulated", 1038], ["during", 1050], ["the", 1057], ["arrest", 1061], [",", 1067], ["allowing", 1069], ["rapid", 1078], ["centrosome", 1084], ["multiplication", 1095], ["upon", 1110], ["recovery", 1115], ["from", 1124], ["the", 1129], ["cell", 1133], ["cycle", 1138], ["arrest", 1144], ["or", 1151], ["expression", 1154], ["of", 1165], ["exogenous", 1168], ["Plk4", 1178], ["in", 1183], ["G1/S", 1186], ["cells", 1191], [".", 1196], ["Thus", 1198], ["centrosome", 1203], ["amplification", 1214], ["results", 1228], ["from", 1236], ["the", 1241], ["discoordination", 1245], ["of", 1261], ["the", 1264], ["centrosome", 1268], ["cycle", 1279], ["from", 1285], ["the", 1290], ["progression", 1294], ["of", 1306], ["other", 1309], ["cell", 1315], ["cycle", 1320], ["events", 1326], [",", 1332], ["which", 1334], ["is", 1340], ["controlled", 1343], ["by", 1354], ["different", 1357], ["levels", 1367], ["of", 1374], ["Cdk", 1377], ["activities", 1381], [".", 1391]]}
{"context": "Many different cellular pathways have evolved to protect the genome from the deleterious effects of DNA damage that result from exposure to chemical and physical agents. Among these is a process called transcription-coupled repair (TCR) that catalyzes the removal of DNA lesions from the transcribed strand of expressed genes, often resulting in a preferential bias of damage clearance from this strand relative to its non-transcribed counterpart. Lesions subject to this type of repair include cyclobutane pyrimidine dimers that are normally repaired by nucleotide excision repair (NER) and thymine glycols (TGs) that are removed primarily by base excision repair (BER). While the mechanism underlying TCR is not completely clear, it is known that its facilitation requires proteins used by other repair pathways like NER. It is also believed that the signal for TCR is the stalled RNA polymerase that results when DNA damage prevents its translocation during transcription elongation. While there is a clear role for some NER proteins in TCR, the involvement of BER proteins is less clear. To explore this further, we studied the removal of 7-methylguanine (7MeG) and 3-methyladenine (3MeA) from the dihydrofolate reductase (dhfr) gene of murine cell lines that vary in their repair phenotypes. 7MeG and 3MeA constitute the two principal N-methylpurines formed in DNA following exposure to methylating agents. In mammalian cells, alkyladenine DNA alkyladenine glycosylase (Aag) is the major enzyme required for the repair of these lesions via BER, and their removal from the total genome is quite rapid. There is no observable TCR of these lesions in specific genes in DNA repair proficient cells; however, it is possible that the rapid repair of these adducts by BER masks any TCR. The repair of 3MeA and 7MeG was examined in cells lacking Aag, NER, or both Aag and NER to determine if rapid overall repair masks TCR. The results show that both 3MeA and 7MeG are removed without strand bias from the dhfr gene of BER deficient (Aag deficient) and NER deficient murine cell lines. Furthermore, repair of 3MeA in this region is highly dependent on Aag, but repair of 7MeG is equally efficient in the repair proficient, BER deficient, and NER deficient cell lines. Strikingly, in the absence of both BER and NER, neither 7MeG nor 3MeA is repaired. These results demonstrate that NER, but not TCR, contributes to the repair of 7MeG, and to a lesser extent 3MeA.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "1cde295a27944b1b94e1e91a3f0c2a84", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[49, 50]], "char_spans": [[288, 305]]}]}], "context_tokens": [["Many", 0], ["different", 5], ["cellular", 15], ["pathways", 24], ["have", 33], ["evolved", 38], ["to", 46], ["protect", 49], ["the", 57], ["genome", 61], ["from", 68], ["the", 73], ["deleterious", 77], ["effects", 89], ["of", 97], ["DNA", 100], ["damage", 104], ["that", 111], ["result", 116], ["from", 123], ["exposure", 128], ["to", 137], ["chemical", 140], ["and", 149], ["physical", 153], ["agents", 162], [".", 168], ["Among", 170], ["these", 176], ["is", 182], ["a", 185], ["process", 187], ["called", 195], ["transcription", 202], ["-", 215], ["coupled", 216], ["repair", 224], ["(", 231], ["TCR", 232], [")", 235], ["that", 237], ["catalyzes", 242], ["the", 252], ["removal", 256], ["of", 264], ["DNA", 267], ["lesions", 271], ["from", 279], ["the", 284], ["transcribed", 288], ["strand", 300], ["of", 307], ["expressed", 310], ["genes", 320], [",", 325], ["often", 327], ["resulting", 333], ["in", 343], ["a", 346], ["preferential", 348], ["bias", 361], ["of", 366], ["damage", 369], ["clearance", 376], ["from", 386], ["this", 391], ["strand", 396], ["relative", 403], ["to", 412], ["its", 415], ["non", 419], ["-", 422], ["transcribed", 423], ["counterpart", 435], [".", 446], ["Lesions", 448], ["subject", 456], ["to", 464], ["this", 467], ["type", 472], ["of", 477], ["repair", 480], ["include", 487], ["cyclobutane", 495], ["pyrimidine", 507], ["dimers", 518], ["that", 525], ["are", 530], ["normally", 534], ["repaired", 543], ["by", 552], ["nucleotide", 555], ["excision", 566], ["repair", 575], ["(", 582], ["NER", 583], [")", 586], ["and", 588], ["thymine", 592], ["glycols", 600], ["(", 608], ["TGs", 609], [")", 612], ["that", 614], ["are", 619], ["removed", 623], ["primarily", 631], ["by", 641], ["base", 644], ["excision", 649], ["repair", 658], ["(", 665], ["BER", 666], [")", 669], [".", 670], ["While", 672], ["the", 678], ["mechanism", 682], ["underlying", 692], ["TCR", 703], ["is", 707], ["not", 710], ["completely", 714], ["clear", 725], [",", 730], ["it", 732], ["is", 735], ["known", 738], ["that", 744], ["its", 749], ["facilitation", 753], ["requires", 766], ["proteins", 775], ["used", 784], ["by", 789], ["other", 792], ["repair", 798], ["pathways", 805], ["like", 814], ["NER", 819], [".", 822], ["It", 824], ["is", 827], ["also", 830], ["believed", 835], ["that", 844], ["the", 849], ["signal", 853], ["for", 860], ["TCR", 864], ["is", 868], ["the", 871], ["stalled", 875], ["RNA", 883], ["polymerase", 887], ["that", 898], ["results", 903], ["when", 911], ["DNA", 916], ["damage", 920], ["prevents", 927], ["its", 936], ["translocation", 940], ["during", 954], ["transcription", 961], ["elongation", 975], [".", 985], ["While", 987], ["there", 993], ["is", 999], ["a", 1002], ["clear", 1004], ["role", 1010], ["for", 1015], ["some", 1019], ["NER", 1024], ["proteins", 1028], ["in", 1037], ["TCR", 1040], [",", 1043], ["the", 1045], ["involvement", 1049], ["of", 1061], ["BER", 1064], ["proteins", 1068], ["is", 1077], ["less", 1080], ["clear", 1085], [".", 1090], ["To", 1092], ["explore", 1095], ["this", 1103], ["further", 1108], [",", 1115], ["we", 1117], ["studied", 1120], ["the", 1128], ["removal", 1132], ["of", 1140], ["7-methylguanine", 1143], ["(", 1159], ["7MeG", 1160], [")", 1164], ["and", 1166], ["3-methyladenine", 1170], ["(", 1186], ["3MeA", 1187], [")", 1191], ["from", 1193], ["the", 1198], ["dihydrofolate", 1202], ["reductase", 1216], ["(", 1226], ["dhfr", 1227], [")", 1231], ["gene", 1233], ["of", 1238], ["murine", 1241], ["cell", 1248], ["lines", 1253], ["that", 1259], ["vary", 1264], ["in", 1269], ["their", 1272], ["repair", 1278], ["phenotypes", 1285], [".", 1295], ["7MeG", 1297], ["and", 1302], ["3MeA", 1306], ["constitute", 1311], ["the", 1322], ["two", 1326], ["principal", 1330], ["N", 1340], ["-", 1341], ["methylpurines", 1342], ["formed", 1356], ["in", 1363], ["DNA", 1366], ["following", 1370], ["exposure", 1380], ["to", 1389], ["methylating", 1392], ["agents", 1404], [".", 1410], ["In", 1412], ["mammalian", 1415], ["cells", 1425], [",", 1430], ["alkyladenine", 1432], ["DNA", 1445], ["alkyladenine", 1449], ["glycosylase", 1462], ["(", 1474], ["Aag", 1475], [")", 1478], ["is", 1480], ["the", 1483], ["major", 1487], ["enzyme", 1493], ["required", 1500], ["for", 1509], ["the", 1513], ["repair", 1517], ["of", 1524], ["these", 1527], ["lesions", 1533], ["via", 1541], ["BER", 1545], [",", 1548], ["and", 1550], ["their", 1554], ["removal", 1560], ["from", 1568], ["the", 1573], ["total", 1577], ["genome", 1583], ["is", 1590], ["quite", 1593], ["rapid", 1599], [".", 1604], ["There", 1606], ["is", 1612], ["no", 1615], ["observable", 1618], ["TCR", 1629], ["of", 1633], ["these", 1636], ["lesions", 1642], ["in", 1650], ["specific", 1653], ["genes", 1662], ["in", 1668], ["DNA", 1671], ["repair", 1675], ["proficient", 1682], ["cells", 1693], [";", 1698], ["however", 1700], [",", 1707], ["it", 1709], ["is", 1712], ["possible", 1715], ["that", 1724], ["the", 1729], ["rapid", 1733], ["repair", 1739], ["of", 1746], ["these", 1749], ["adducts", 1755], ["by", 1763], ["BER", 1766], ["masks", 1770], ["any", 1776], ["TCR", 1780], [".", 1783], ["The", 1785], ["repair", 1789], ["of", 1796], ["3MeA", 1799], ["and", 1804], ["7MeG", 1808], ["was", 1813], ["examined", 1817], ["in", 1826], ["cells", 1829], ["lacking", 1835], ["Aag", 1843], [",", 1846], ["NER", 1848], [",", 1851], ["or", 1853], ["both", 1856], ["Aag", 1861], ["and", 1865], ["NER", 1869], ["to", 1873], ["determine", 1876], ["if", 1886], ["rapid", 1889], ["overall", 1895], ["repair", 1903], ["masks", 1910], ["TCR", 1916], [".", 1919], ["The", 1921], ["results", 1925], ["show", 1933], ["that", 1938], ["both", 1943], ["3MeA", 1948], ["and", 1953], ["7MeG", 1957], ["are", 1962], ["removed", 1966], ["without", 1974], ["strand", 1982], ["bias", 1989], ["from", 1994], ["the", 1999], ["dhfr", 2003], ["gene", 2008], ["of", 2013], ["BER", 2016], ["deficient", 2020], ["(", 2030], ["Aag", 2031], ["deficient", 2035], [")", 2044], ["and", 2046], ["NER", 2050], ["deficient", 2054], ["murine", 2064], ["cell", 2071], ["lines", 2076], [".", 2081], ["Furthermore", 2083], [",", 2094], ["repair", 2096], ["of", 2103], ["3MeA", 2106], ["in", 2111], ["this", 2114], ["region", 2119], ["is", 2126], ["highly", 2129], ["dependent", 2136], ["on", 2146], ["Aag", 2149], [",", 2152], ["but", 2154], ["repair", 2158], ["of", 2165], ["7MeG", 2168], ["is", 2173], ["equally", 2176], ["efficient", 2184], ["in", 2194], ["the", 2197], ["repair", 2201], ["proficient", 2208], [",", 2218], ["BER", 2220], ["deficient", 2224], [",", 2233], ["and", 2235], ["NER", 2239], ["deficient", 2243], ["cell", 2253], ["lines", 2258], [".", 2263], ["Strikingly", 2265], [",", 2275], ["in", 2277], ["the", 2280], ["absence", 2284], ["of", 2292], ["both", 2295], ["BER", 2300], ["and", 2304], ["NER", 2308], [",", 2311], ["neither", 2313], ["7MeG", 2321], ["nor", 2326], ["3MeA", 2330], ["is", 2335], ["repaired", 2338], [".", 2346], ["These", 2348], ["results", 2354], ["demonstrate", 2362], ["that", 2374], ["NER", 2379], [",", 2382], ["but", 2384], ["not", 2388], ["TCR", 2392], [",", 2395], ["contributes", 2397], ["to", 2409], ["the", 2412], ["repair", 2416], ["of", 2423], ["7MeG", 2426], [",", 2430], ["and", 2432], ["to", 2436], ["a", 2439], ["lesser", 2441], ["extent", 2448], ["3MeA.", 2455]]}
{"context": "ADARs are RNA editing enzymes that target double stranded RNA and convert adenosine to inosine, which is read by translation machinery as if it were guanosine. Aside from their role in generating protein diversity in the central nervous system, ADARs have been implicated in the hypermutation of some RNA viruses, although why this hypermutation occurs is not well understood. Here we describe the hypermutation of adenosines to guanosines in the genome of the sigma virus--a negative sense RNA virus that infects Drosophila melanogaster. The clustering of these mutations and the context in which they occur indicates that they have been caused by ADARs. However, ADAR-editing of viral RNA is either rare or edited viral RNA are rapidly degraded, as we only detected evidence for editing in two of the 104 viral isolates we studied. This is the first evidence for ADARs targeting viruses outside of mammals, and it raises the possibility that ADARs could play a role in the antiviral defences of insects.", "qas": [{"question": "Which is the major RNA editing enzyme in Drosophila melanogaster?", "answers": ["ADAR", "adenosine deaminase, RNA-specific"], "qid": "67f5860ba0e248caa2b54394c294ce80", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["major", 13], ["RNA", 19], ["editing", 23], ["enzyme", 31], ["in", 38], ["Drosophila", 41], ["melanogaster", 52], ["?", 64]], "detected_answers": [{"text": "ADAR", "token_spans": [[114, 114]], "char_spans": [[665, 668]]}]}], "context_tokens": [["ADARs", 0], ["are", 6], ["RNA", 10], ["editing", 14], ["enzymes", 22], ["that", 30], ["target", 35], ["double", 42], ["stranded", 49], ["RNA", 58], ["and", 62], ["convert", 66], ["adenosine", 74], ["to", 84], ["inosine", 87], [",", 94], ["which", 96], ["is", 102], ["read", 105], ["by", 110], ["translation", 113], ["machinery", 125], ["as", 135], ["if", 138], ["it", 141], ["were", 144], ["guanosine", 149], [".", 158], ["Aside", 160], ["from", 166], ["their", 171], ["role", 177], ["in", 182], ["generating", 185], ["protein", 196], ["diversity", 204], ["in", 214], ["the", 217], ["central", 221], ["nervous", 229], ["system", 237], [",", 243], ["ADARs", 245], ["have", 251], ["been", 256], ["implicated", 261], ["in", 272], ["the", 275], ["hypermutation", 279], ["of", 293], ["some", 296], ["RNA", 301], ["viruses", 305], [",", 312], ["although", 314], ["why", 323], ["this", 327], ["hypermutation", 332], ["occurs", 346], ["is", 353], ["not", 356], ["well", 360], ["understood", 365], [".", 375], ["Here", 377], ["we", 382], ["describe", 385], ["the", 394], ["hypermutation", 398], ["of", 412], ["adenosines", 415], ["to", 426], ["guanosines", 429], ["in", 440], ["the", 443], ["genome", 447], ["of", 454], ["the", 457], ["sigma", 461], ["virus", 467], ["--", 472], ["a", 474], ["negative", 476], ["sense", 485], ["RNA", 491], ["virus", 495], ["that", 501], ["infects", 506], ["Drosophila", 514], ["melanogaster", 525], [".", 537], ["The", 539], ["clustering", 543], ["of", 554], ["these", 557], ["mutations", 563], ["and", 573], ["the", 577], ["context", 581], ["in", 589], ["which", 592], ["they", 598], ["occur", 603], ["indicates", 609], ["that", 619], ["they", 624], ["have", 629], ["been", 634], ["caused", 639], ["by", 646], ["ADARs", 649], [".", 654], ["However", 656], [",", 663], ["ADAR", 665], ["-", 669], ["editing", 670], ["of", 678], ["viral", 681], ["RNA", 687], ["is", 691], ["either", 694], ["rare", 701], ["or", 706], ["edited", 709], ["viral", 716], ["RNA", 722], ["are", 726], ["rapidly", 730], ["degraded", 738], [",", 746], ["as", 748], ["we", 751], ["only", 754], ["detected", 759], ["evidence", 768], ["for", 777], ["editing", 781], ["in", 789], ["two", 792], ["of", 796], ["the", 799], ["104", 803], ["viral", 807], ["isolates", 813], ["we", 822], ["studied", 825], [".", 832], ["This", 834], ["is", 839], ["the", 842], ["first", 846], ["evidence", 852], ["for", 861], ["ADARs", 865], ["targeting", 871], ["viruses", 881], ["outside", 889], ["of", 897], ["mammals", 900], [",", 907], ["and", 909], ["it", 913], ["raises", 916], ["the", 923], ["possibility", 927], ["that", 939], ["ADARs", 944], ["could", 950], ["play", 956], ["a", 961], ["role", 963], ["in", 968], ["the", 971], ["antiviral", 975], ["defences", 985], ["of", 994], ["insects", 997], [".", 1004]]}
{"context": "Neurofibromatosis type 1 (NF1) is a common genetic disease caused by haploinsufficiency of the NF1 tumor-suppressor gene. Different pathogenetic mechanisms have been identified, with the majority (95%) causing intragenic lesions. Single or multiexon NF1 copy number changes occur in about 2% of patients, but little is known about the molecular mechanisms behind these intragenic deletions. We report here on the molecular characterization of a novel NF1 multiexonic deletion. The application of a multidisciplinary approach including multiplex ligation-dependent probe amplification, allelic segregation analysis, and fluorescent in situ hybridization allowed us to map the breakpoints in IVS27b and IVS48. Furthermore, the breakpoint junction was characterized by sequencing. Using bioinformatic analysis, we identified some recombinogenic motifs in close proximity to the centromeric and telomeric breakpoints and predicted the presence of a mutated messenger ribonucleic acid, which was deleted between exons 28 and 48 and encodes a neurofibromin that lacks some domains essential for its function. Through reverse transcriptase-polymerase chain reaction, the expression of the mutated allele was verified, showing the junction between exons 27b and 49 and, as expected, was not subjected to nonsense-mediated decay. Multiexonic deletions represent 2% of NF1 mutations, and until now, the breakpoint has been identified in only a few cases. The fine characterization of multiexonic deletions broadens the mutational repertoire of the NF1 gene, allowing for the identification of different pathogenetic mechanisms causing NF1.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "354f714bfea84f6b8e02e7acba3f7d67", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[16, 16], [221, 221], [43, 43], [251, 251], [4, 4], [263, 263], [78, 78]], "char_spans": [[95, 97], [1359, 1361], [250, 252], [1538, 1540], [26, 28], [1625, 1627], [451, 453]]}]}], "context_tokens": [["Neurofibromatosis", 0], ["type", 18], ["1", 23], ["(", 25], ["NF1", 26], [")", 29], ["is", 31], ["a", 34], ["common", 36], ["genetic", 43], ["disease", 51], ["caused", 59], ["by", 66], ["haploinsufficiency", 69], ["of", 88], ["the", 91], ["NF1", 95], ["tumor", 99], ["-", 104], ["suppressor", 105], ["gene", 116], [".", 120], ["Different", 122], ["pathogenetic", 132], ["mechanisms", 145], ["have", 156], ["been", 161], ["identified", 166], [",", 176], ["with", 178], ["the", 183], ["majority", 187], ["(", 196], ["95", 197], ["%", 199], [")", 200], ["causing", 202], ["intragenic", 210], ["lesions", 221], [".", 228], ["Single", 230], ["or", 237], ["multiexon", 240], ["NF1", 250], ["copy", 254], ["number", 259], ["changes", 266], ["occur", 274], ["in", 280], ["about", 283], ["2", 289], ["%", 290], ["of", 292], ["patients", 295], [",", 303], ["but", 305], ["little", 309], ["is", 316], ["known", 319], ["about", 325], ["the", 331], ["molecular", 335], ["mechanisms", 345], ["behind", 356], ["these", 363], ["intragenic", 369], ["deletions", 380], [".", 389], ["We", 391], ["report", 394], ["here", 401], ["on", 406], ["the", 409], ["molecular", 413], ["characterization", 423], ["of", 440], ["a", 443], ["novel", 445], ["NF1", 451], ["multiexonic", 455], ["deletion", 467], [".", 475], ["The", 477], ["application", 481], ["of", 493], ["a", 496], ["multidisciplinary", 498], ["approach", 516], ["including", 525], ["multiplex", 535], ["ligation", 545], ["-", 553], ["dependent", 554], ["probe", 564], ["amplification", 570], [",", 583], ["allelic", 585], ["segregation", 593], ["analysis", 605], [",", 613], ["and", 615], ["fluorescent", 619], ["in", 631], ["situ", 634], ["hybridization", 639], ["allowed", 653], ["us", 661], ["to", 664], ["map", 667], ["the", 671], ["breakpoints", 675], ["in", 687], ["IVS27b", 690], ["and", 697], ["IVS48", 701], [".", 706], ["Furthermore", 708], [",", 719], ["the", 721], ["breakpoint", 725], ["junction", 736], ["was", 745], ["characterized", 749], ["by", 763], ["sequencing", 766], [".", 776], ["Using", 778], ["bioinformatic", 784], ["analysis", 798], [",", 806], ["we", 808], ["identified", 811], ["some", 822], ["recombinogenic", 827], ["motifs", 842], ["in", 849], ["close", 852], ["proximity", 858], ["to", 868], ["the", 871], ["centromeric", 875], ["and", 887], ["telomeric", 891], ["breakpoints", 901], ["and", 913], ["predicted", 917], ["the", 927], ["presence", 931], ["of", 940], ["a", 943], ["mutated", 945], ["messenger", 953], ["ribonucleic", 963], ["acid", 975], [",", 979], ["which", 981], ["was", 987], ["deleted", 991], ["between", 999], ["exons", 1007], ["28", 1013], ["and", 1016], ["48", 1020], ["and", 1023], ["encodes", 1027], ["a", 1035], ["neurofibromin", 1037], ["that", 1051], ["lacks", 1056], ["some", 1062], ["domains", 1067], ["essential", 1075], ["for", 1085], ["its", 1089], ["function", 1093], [".", 1101], ["Through", 1103], ["reverse", 1111], ["transcriptase", 1119], ["-", 1132], ["polymerase", 1133], ["chain", 1144], ["reaction", 1150], [",", 1158], ["the", 1160], ["expression", 1164], ["of", 1175], ["the", 1178], ["mutated", 1182], ["allele", 1190], ["was", 1197], ["verified", 1201], [",", 1209], ["showing", 1211], ["the", 1219], ["junction", 1223], ["between", 1232], ["exons", 1240], ["27b", 1246], ["and", 1250], ["49", 1254], ["and", 1257], [",", 1260], ["as", 1262], ["expected", 1265], [",", 1273], ["was", 1275], ["not", 1279], ["subjected", 1283], ["to", 1293], ["nonsense", 1296], ["-", 1304], ["mediated", 1305], ["decay", 1314], [".", 1319], ["Multiexonic", 1321], ["deletions", 1333], ["represent", 1343], ["2", 1353], ["%", 1354], ["of", 1356], ["NF1", 1359], ["mutations", 1363], [",", 1372], ["and", 1374], ["until", 1378], ["now", 1384], [",", 1387], ["the", 1389], ["breakpoint", 1393], ["has", 1404], ["been", 1408], ["identified", 1413], ["in", 1424], ["only", 1427], ["a", 1432], ["few", 1434], ["cases", 1438], [".", 1443], ["The", 1445], ["fine", 1449], ["characterization", 1454], ["of", 1471], ["multiexonic", 1474], ["deletions", 1486], ["broadens", 1496], ["the", 1505], ["mutational", 1509], ["repertoire", 1520], ["of", 1531], ["the", 1534], ["NF1", 1538], ["gene", 1542], [",", 1546], ["allowing", 1548], ["for", 1557], ["the", 1561], ["identification", 1565], ["of", 1580], ["different", 1583], ["pathogenetic", 1593], ["mechanisms", 1606], ["causing", 1617], ["NF1", 1625], [".", 1628]]}
{"context": "Idarucizumab, a monoclonal antibody fragment that binds dabigatran with high affinity, is in development as a specific antidote for dabigatran. In this first-in-human, single-rising-dose study, we investigated the pharmacokinetics, safety and tolerability of idarucizumab. Healthy male volunteers aged 18-45 years received between 20 mg and 8 g idarucizumab as a 1-hour intravenous infusion in 10 sequential dose groups, or 1, 2 or 4 g idarucizumab as a 5-minute infusion. Subjects within each dose group were randomised 3:1 to idarucizumab or placebo. A total of 110 randomised subjects received study drug (27 placebo, 83 idarucizumab). Peak and total exposure to idarucizumab increased proportionally with dose. Maximum plasma concentrations were achieved near the end of infusion, followed by a rapid decline, with an initial idarucizumab half-life of ~45 minutes. For the 5-minute infusions, this resulted in a reduction of plasma concentrations to less than 5\u2009% of peak within 4 hours. Idarucizumab (in the absence of dabigatran) had no effect on coagulation parameters or endogenous thrombin potential. Overall adverse event (AE) frequency was similar for idarucizumab and placebo, and no relationship with idarucizumab dose was observed. Drug-related AEs (primary endpoint) were rare (occurring in 2 placebo and 3 idarucizumab subjects) and were mostly of mild intensity; none of them resulted in study discontinuation. In conclusion, the pharmacokinetic profile of idarucizumab meets the requirement for rapid peak exposure and rapid elimination, with no effect on pharmacodynamic parameters. Idarucizumab was safe and well tolerated in healthy males.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "3f65fd0a084c4760bb532f7a2c44c223", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[188, 188], [8, 8], [21, 21]], "char_spans": [[1024, 1033], [56, 65], [132, 141]]}]}], "context_tokens": [["Idarucizumab", 0], [",", 12], ["a", 14], ["monoclonal", 16], ["antibody", 27], ["fragment", 36], ["that", 45], ["binds", 50], ["dabigatran", 56], ["with", 67], ["high", 72], ["affinity", 77], [",", 85], ["is", 87], ["in", 90], ["development", 93], ["as", 105], ["a", 108], ["specific", 110], ["antidote", 119], ["for", 128], ["dabigatran", 132], [".", 142], ["In", 144], ["this", 147], ["first", 152], ["-", 157], ["in", 158], ["-", 160], ["human", 161], [",", 166], ["single", 168], ["-", 174], ["rising", 175], ["-", 181], ["dose", 182], ["study", 187], [",", 192], ["we", 194], ["investigated", 197], ["the", 210], ["pharmacokinetics", 214], [",", 230], ["safety", 232], ["and", 239], ["tolerability", 243], ["of", 256], ["idarucizumab", 259], [".", 271], ["Healthy", 273], ["male", 281], ["volunteers", 286], ["aged", 297], ["18", 302], ["-", 304], ["45", 305], ["years", 308], ["received", 314], ["between", 323], ["20", 331], ["mg", 334], ["and", 337], ["8", 341], ["g", 343], ["idarucizumab", 345], ["as", 358], ["a", 361], ["1-hour", 363], ["intravenous", 370], ["infusion", 382], ["in", 391], ["10", 394], ["sequential", 397], ["dose", 408], ["groups", 413], [",", 419], ["or", 421], ["1", 424], [",", 425], ["2", 427], ["or", 429], ["4", 432], ["g", 434], ["idarucizumab", 436], ["as", 449], ["a", 452], ["5-minute", 454], ["infusion", 463], [".", 471], ["Subjects", 473], ["within", 482], ["each", 489], ["dose", 494], ["group", 499], ["were", 505], ["randomised", 510], ["3:1", 521], ["to", 525], ["idarucizumab", 528], ["or", 541], ["placebo", 544], [".", 551], ["A", 553], ["total", 555], ["of", 561], ["110", 564], ["randomised", 568], ["subjects", 579], ["received", 588], ["study", 597], ["drug", 603], ["(", 608], ["27", 609], ["placebo", 612], [",", 619], ["83", 621], ["idarucizumab", 624], [")", 636], [".", 637], ["Peak", 639], ["and", 644], ["total", 648], ["exposure", 654], ["to", 663], ["idarucizumab", 666], ["increased", 679], ["proportionally", 689], ["with", 704], ["dose", 709], [".", 713], ["Maximum", 715], ["plasma", 723], ["concentrations", 730], ["were", 745], ["achieved", 750], ["near", 759], ["the", 764], ["end", 768], ["of", 772], ["infusion", 775], [",", 783], ["followed", 785], ["by", 794], ["a", 797], ["rapid", 799], ["decline", 805], [",", 812], ["with", 814], ["an", 819], ["initial", 822], ["idarucizumab", 830], ["half", 843], ["-", 847], ["life", 848], ["of", 853], ["~45", 856], ["minutes", 860], [".", 867], ["For", 869], ["the", 873], ["5-minute", 877], ["infusions", 886], [",", 895], ["this", 897], ["resulted", 902], ["in", 911], ["a", 914], ["reduction", 916], ["of", 926], ["plasma", 929], ["concentrations", 936], ["to", 951], ["less", 954], ["than", 959], ["5", 964], ["%", 966], ["of", 968], ["peak", 971], ["within", 976], ["4", 983], ["hours", 985], [".", 990], ["Idarucizumab", 992], ["(", 1005], ["in", 1006], ["the", 1009], ["absence", 1013], ["of", 1021], ["dabigatran", 1024], [")", 1034], ["had", 1036], ["no", 1040], ["effect", 1043], ["on", 1050], ["coagulation", 1053], ["parameters", 1065], ["or", 1076], ["endogenous", 1079], ["thrombin", 1090], ["potential", 1099], [".", 1108], ["Overall", 1110], ["adverse", 1118], ["event", 1126], ["(", 1132], ["AE", 1133], [")", 1135], ["frequency", 1137], ["was", 1147], ["similar", 1151], ["for", 1159], ["idarucizumab", 1163], ["and", 1176], ["placebo", 1180], [",", 1187], ["and", 1189], ["no", 1193], ["relationship", 1196], ["with", 1209], ["idarucizumab", 1214], ["dose", 1227], ["was", 1232], ["observed", 1236], [".", 1244], ["Drug", 1246], ["-", 1250], ["related", 1251], ["AEs", 1259], ["(", 1263], ["primary", 1264], ["endpoint", 1272], [")", 1280], ["were", 1282], ["rare", 1287], ["(", 1292], ["occurring", 1293], ["in", 1303], ["2", 1306], ["placebo", 1308], ["and", 1316], ["3", 1320], ["idarucizumab", 1322], ["subjects", 1335], [")", 1343], ["and", 1345], ["were", 1349], ["mostly", 1354], ["of", 1361], ["mild", 1364], ["intensity", 1369], [";", 1378], ["none", 1380], ["of", 1385], ["them", 1388], ["resulted", 1393], ["in", 1402], ["study", 1405], ["discontinuation", 1411], [".", 1426], ["In", 1428], ["conclusion", 1431], [",", 1441], ["the", 1443], ["pharmacokinetic", 1447], ["profile", 1463], ["of", 1471], ["idarucizumab", 1474], ["meets", 1487], ["the", 1493], ["requirement", 1497], ["for", 1509], ["rapid", 1513], ["peak", 1519], ["exposure", 1524], ["and", 1533], ["rapid", 1537], ["elimination", 1543], [",", 1554], ["with", 1556], ["no", 1561], ["effect", 1564], ["on", 1571], ["pharmacodynamic", 1574], ["parameters", 1590], [".", 1600], ["Idarucizumab", 1602], ["was", 1615], ["safe", 1619], ["and", 1624], ["well", 1628], ["tolerated", 1633], ["in", 1643], ["healthy", 1646], ["males", 1654], [".", 1659]]}
{"context": "Treslin/TICRR (TopBP1-interacting, replication stimulating protein/TopBP1-interacting, checkpoint, and replication regulator), the human ortholog of the yeast Sld3 protein, is an essential DNA replication factor that is regulated by cyclin-dependent kinases and the DNA damage checkpoint. We identified MDM two binding protein (MTBP) as a factor that interacts with Treslin/TICRR throughout the cell cycle. We show that MTBP depletion by means of small interfering RNA inhibits DNA replication by preventing assembly of the CMG (Cdc45-MCM-GINS) holohelicase during origin firing. Although MTBP has been implicated in the function of the p53 tumor suppressor, we found MTBP is required for DNA replication irrespective of a cell's p53 status. We propose that MTBP acts with Treslin/TICRR to integrate signals from cell cycle and DNA damage response pathways to control the initiation of DNA replication in human cells.", "qas": [{"question": "Which factor interacts with Treslin/TICRR throughout the cell cycle of human cells?", "answers": ["MDM two binding protein (MTBP)"], "qid": "470f42e7c572482a84dd8e9d4a279059", "question_tokens": [["Which", 0], ["factor", 6], ["interacts", 13], ["with", 23], ["Treslin", 28], ["/", 35], ["TICRR", 36], ["throughout", 42], ["the", 53], ["cell", 57], ["cycle", 62], ["of", 68], ["human", 71], ["cells", 77], ["?", 82]], "detected_answers": [{"text": "MDM two binding protein (MTBP)", "token_spans": [[50, 55]], "char_spans": [[303, 331]]}]}], "context_tokens": [["Treslin", 0], ["/", 7], ["TICRR", 8], ["(", 14], ["TopBP1-interacting", 15], [",", 33], ["replication", 35], ["stimulating", 47], ["protein", 59], ["/", 66], ["TopBP1-interacting", 67], [",", 85], ["checkpoint", 87], [",", 97], ["and", 99], ["replication", 103], ["regulator", 115], [")", 124], [",", 125], ["the", 127], ["human", 131], ["ortholog", 137], ["of", 146], ["the", 149], ["yeast", 153], ["Sld3", 159], ["protein", 164], [",", 171], ["is", 173], ["an", 176], ["essential", 179], ["DNA", 189], ["replication", 193], ["factor", 205], ["that", 212], ["is", 217], ["regulated", 220], ["by", 230], ["cyclin", 233], ["-", 239], ["dependent", 240], ["kinases", 250], ["and", 258], ["the", 262], ["DNA", 266], ["damage", 270], ["checkpoint", 277], [".", 287], ["We", 289], ["identified", 292], ["MDM", 303], ["two", 307], ["binding", 311], ["protein", 319], ["(", 327], ["MTBP", 328], [")", 332], ["as", 334], ["a", 337], ["factor", 339], ["that", 346], ["interacts", 351], ["with", 361], ["Treslin", 366], ["/", 373], ["TICRR", 374], ["throughout", 380], ["the", 391], ["cell", 395], ["cycle", 400], [".", 405], ["We", 407], ["show", 410], ["that", 415], ["MTBP", 420], ["depletion", 425], ["by", 435], ["means", 438], ["of", 444], ["small", 447], ["interfering", 453], ["RNA", 465], ["inhibits", 469], ["DNA", 478], ["replication", 482], ["by", 494], ["preventing", 497], ["assembly", 508], ["of", 517], ["the", 520], ["CMG", 524], ["(", 528], ["Cdc45-MCM", 529], ["-", 538], ["GINS", 539], [")", 543], ["holohelicase", 545], ["during", 558], ["origin", 565], ["firing", 572], [".", 578], ["Although", 580], ["MTBP", 589], ["has", 594], ["been", 598], ["implicated", 603], ["in", 614], ["the", 617], ["function", 621], ["of", 630], ["the", 633], ["p53", 637], ["tumor", 641], ["suppressor", 647], [",", 657], ["we", 659], ["found", 662], ["MTBP", 668], ["is", 673], ["required", 676], ["for", 685], ["DNA", 689], ["replication", 693], ["irrespective", 705], ["of", 718], ["a", 721], ["cell", 723], ["'s", 727], ["p53", 730], ["status", 734], [".", 740], ["We", 742], ["propose", 745], ["that", 753], ["MTBP", 758], ["acts", 763], ["with", 768], ["Treslin", 773], ["/", 780], ["TICRR", 781], ["to", 787], ["integrate", 790], ["signals", 800], ["from", 808], ["cell", 813], ["cycle", 818], ["and", 824], ["DNA", 828], ["damage", 832], ["response", 839], ["pathways", 848], ["to", 857], ["control", 860], ["the", 868], ["initiation", 872], ["of", 883], ["DNA", 886], ["replication", 890], ["in", 902], ["human", 905], ["cells", 911], [".", 916]]}
{"context": "Transactivation response DNA-binding protein 43 (TDP-43) proteinopathies are classified based upon the extent of modified TDP-43 and include a growing number of neurodegenerative diseases such as amyotrophic lateral sclerosis, frontotemporal lobar degeneration with ubiquitin-immunoreactive, tau-negative inclusions and frontotemporal lobar degeneration with motor neuron disease. The purpose of the study was to examine whether proteolytic modifications of TDP-43 are a relevant finding in Parkinson's disease (PD) and dementia with Lewy bodies (DLB). A novel site-directed caspase cleavage antibody, termed TDP caspase cleavage product antibody (TDPccp), was utilized based upon a known caspase 3 cleavage consensus site within TDP-43 at position 219. Application of this antibody to postmortem brain sections from PD and DLB patients revealed the presence of caspase-cleaved TDP-43 in Lewy bodies and Hirano bodies in all cases examined. Colocalization of TDPccp with an antibody to alpha-synuclein (alpha-Syn), which served as a general marker for Lewy bodies, was evident within the substantia nigra in both alpha-synucleinopathies. Interestingly, the TDPccp antibody detected a greater number of Lewy bodies in PD and DLB compared to the alpha-Syn antibody. In addition, a semiquantitative analysis in both diseases confirmed this finding by indicating that the percentage of caspase-cleaved TDP-43 single-labeled Lewy bodies was approximately twice that of alpha-Syn labeling (in DLB 13.4 vs. 5.5%, while in PD 34.6 vs. 17.6%). Collectively, these data have identified caspase-cleaved TDP-43 as a primary component of Lewy and Hirano bodies in PD and DLB, and suggest that the TDPccp antibody is an effective marker for the detection of Lewy bodies in these neurodegenerative diseases.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "4a93e831ea4b4c5fb6f059f0b2cca5be", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[163, 165]], "char_spans": [[986, 1000]]}]}], "context_tokens": [["Transactivation", 0], ["response", 16], ["DNA", 25], ["-", 28], ["binding", 29], ["protein", 37], ["43", 45], ["(", 48], ["TDP-43", 49], [")", 55], ["proteinopathies", 57], ["are", 73], ["classified", 77], ["based", 88], ["upon", 94], ["the", 99], ["extent", 103], ["of", 110], ["modified", 113], ["TDP-43", 122], ["and", 129], ["include", 133], ["a", 141], ["growing", 143], ["number", 151], ["of", 158], ["neurodegenerative", 161], ["diseases", 179], ["such", 188], ["as", 193], ["amyotrophic", 196], ["lateral", 208], ["sclerosis", 216], [",", 225], ["frontotemporal", 227], ["lobar", 242], ["degeneration", 248], ["with", 261], ["ubiquitin", 266], ["-", 275], ["immunoreactive", 276], [",", 290], ["tau", 292], ["-", 295], ["negative", 296], ["inclusions", 305], ["and", 316], ["frontotemporal", 320], ["lobar", 335], ["degeneration", 341], ["with", 354], ["motor", 359], ["neuron", 365], ["disease", 372], [".", 379], ["The", 381], ["purpose", 385], ["of", 393], ["the", 396], ["study", 400], ["was", 406], ["to", 410], ["examine", 413], ["whether", 421], ["proteolytic", 429], ["modifications", 441], ["of", 455], ["TDP-43", 458], ["are", 465], ["a", 469], ["relevant", 471], ["finding", 480], ["in", 488], ["Parkinson", 491], ["'s", 500], ["disease", 503], ["(", 511], ["PD", 512], [")", 514], ["and", 516], ["dementia", 520], ["with", 529], ["Lewy", 534], ["bodies", 539], ["(", 546], ["DLB", 547], [")", 550], [".", 551], ["A", 553], ["novel", 555], ["site", 561], ["-", 565], ["directed", 566], ["caspase", 575], ["cleavage", 583], ["antibody", 592], [",", 600], ["termed", 602], ["TDP", 609], ["caspase", 613], ["cleavage", 621], ["product", 630], ["antibody", 638], ["(", 647], ["TDPccp", 648], [")", 654], [",", 655], ["was", 657], ["utilized", 661], ["based", 670], ["upon", 676], ["a", 681], ["known", 683], ["caspase", 689], ["3", 697], ["cleavage", 699], ["consensus", 708], ["site", 718], ["within", 723], ["TDP-43", 730], ["at", 737], ["position", 740], ["219", 749], [".", 752], ["Application", 754], ["of", 766], ["this", 769], ["antibody", 774], ["to", 783], ["postmortem", 786], ["brain", 797], ["sections", 803], ["from", 812], ["PD", 817], ["and", 820], ["DLB", 824], ["patients", 828], ["revealed", 837], ["the", 846], ["presence", 850], ["of", 859], ["caspase", 862], ["-", 869], ["cleaved", 870], ["TDP-43", 878], ["in", 885], ["Lewy", 888], ["bodies", 893], ["and", 900], ["Hirano", 904], ["bodies", 911], ["in", 918], ["all", 921], ["cases", 925], ["examined", 931], [".", 939], ["Colocalization", 941], ["of", 956], ["TDPccp", 959], ["with", 966], ["an", 971], ["antibody", 974], ["to", 983], ["alpha", 986], ["-", 991], ["synuclein", 992], ["(", 1002], ["alpha", 1003], ["-", 1008], ["Syn", 1009], [")", 1012], [",", 1013], ["which", 1015], ["served", 1021], ["as", 1028], ["a", 1031], ["general", 1033], ["marker", 1041], ["for", 1048], ["Lewy", 1052], ["bodies", 1057], [",", 1063], ["was", 1065], ["evident", 1069], ["within", 1077], ["the", 1084], ["substantia", 1088], ["nigra", 1099], ["in", 1105], ["both", 1108], ["alpha", 1113], ["-", 1118], ["synucleinopathies", 1119], [".", 1136], ["Interestingly", 1138], [",", 1151], ["the", 1153], ["TDPccp", 1157], ["antibody", 1164], ["detected", 1173], ["a", 1182], ["greater", 1184], ["number", 1192], ["of", 1199], ["Lewy", 1202], ["bodies", 1207], ["in", 1214], ["PD", 1217], ["and", 1220], ["DLB", 1224], ["compared", 1228], ["to", 1237], ["the", 1240], ["alpha", 1244], ["-", 1249], ["Syn", 1250], ["antibody", 1254], [".", 1262], ["In", 1264], ["addition", 1267], [",", 1275], ["a", 1277], ["semiquantitative", 1279], ["analysis", 1296], ["in", 1305], ["both", 1308], ["diseases", 1313], ["confirmed", 1322], ["this", 1332], ["finding", 1337], ["by", 1345], ["indicating", 1348], ["that", 1359], ["the", 1364], ["percentage", 1368], ["of", 1379], ["caspase", 1382], ["-", 1389], ["cleaved", 1390], ["TDP-43", 1398], ["single", 1405], ["-", 1411], ["labeled", 1412], ["Lewy", 1420], ["bodies", 1425], ["was", 1432], ["approximately", 1436], ["twice", 1450], ["that", 1456], ["of", 1461], ["alpha", 1464], ["-", 1469], ["Syn", 1470], ["labeling", 1474], ["(", 1483], ["in", 1484], ["DLB", 1487], ["13.4", 1491], ["vs.", 1496], ["5.5", 1500], ["%", 1503], [",", 1504], ["while", 1506], ["in", 1512], ["PD", 1515], ["34.6", 1518], ["vs.", 1523], ["17.6", 1527], ["%", 1531], [")", 1532], [".", 1533], ["Collectively", 1535], [",", 1547], ["these", 1549], ["data", 1555], ["have", 1560], ["identified", 1565], ["caspase", 1576], ["-", 1583], ["cleaved", 1584], ["TDP-43", 1592], ["as", 1599], ["a", 1602], ["primary", 1604], ["component", 1612], ["of", 1622], ["Lewy", 1625], ["and", 1630], ["Hirano", 1634], ["bodies", 1641], ["in", 1648], ["PD", 1651], ["and", 1654], ["DLB", 1658], [",", 1661], ["and", 1663], ["suggest", 1667], ["that", 1675], ["the", 1680], ["TDPccp", 1684], ["antibody", 1691], ["is", 1700], ["an", 1703], ["effective", 1706], ["marker", 1716], ["for", 1723], ["the", 1727], ["detection", 1731], ["of", 1741], ["Lewy", 1744], ["bodies", 1749], ["in", 1756], ["these", 1759], ["neurodegenerative", 1765], ["diseases", 1783], [".", 1791]]}
{"context": "Mowat-Wilson syndrome (MWS) is a severe intellectual disability (ID)-distinctive facial gestalt-multiple congenital anomaly syndrome, commonly associating microcephaly, epilepsy, corpus callosum agenesis, conotruncal heart defects, urogenital malformations and Hirschsprung disease (HSCR). MWS is caused by de novo heterozygous mutations in the ZEB2 gene. The majority of mutations lead to haplo-insufficiency through premature stop codons or large gene deletions. Only three missense mutations have been reported so far; none of which resides in a known functional domain of ZEB2. In this study, we report and analyze the functional consequences of three novel missense mutations, p.Tyr1055Cys, p.Ser1071Pro and p.His1045Arg, identified in the highly conserved C-zinc-finger (C-ZF) domain of ZEB2. Patients' phenotype included the facial gestalt of MWS and moderate ID, but no microcephaly, heart defects or HSCR. In vitro studies showed that all the three mutations prevented binding and repression of the E-cadherin promoter, a characterized ZEB2 target gene. Taking advantage of the zebrafish morphant technology, we performed rescue experiments using wild-type (WT) and mutant human ZEB2 mRNAs. Variable, mutation-dependent, embryo rescue, correlating with the severity of patients' phenotype, was observed. Our data provide evidence that these missense mutations cause a partial loss of function of ZEB2, suggesting that its role is not restricted to repression of E-cadherin. Functional domains other than C-ZF may play a role in early embryonic development. Finally, these findings broaden the clinical spectrum of ZEB2 mutations, indicating that MWS ought to be considered in patients with lesser degrees of ID and a suggestive facial gestalt, even in the absence of congenital malformation.", "qas": [{"question": "Which gene is responsible for the development of the Mowat-Wilson syndrome?", "answers": ["ZFHX1B", "ZEB2", "SIP-1"], "qid": "66de6d84167b4ec996cf97c56aab9b0c", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["the", 49], ["Mowat", 53], ["-", 58], ["Wilson", 59], ["syndrome", 66], ["?", 74]], "detected_answers": [{"text": "ZEB2", "token_spans": [[96, 96], [144, 144], [55, 55], [216, 216], [296, 296], [190, 190], [255, 255]], "char_spans": [[576, 579], [793, 796], [345, 348], [1188, 1191], [1623, 1626], [1045, 1048], [1405, 1408]]}]}], "context_tokens": [["Mowat", 0], ["-", 5], ["Wilson", 6], ["syndrome", 13], ["(", 22], ["MWS", 23], [")", 26], ["is", 28], ["a", 31], ["severe", 33], ["intellectual", 40], ["disability", 53], ["(", 64], ["ID)-distinctive", 65], ["facial", 81], ["gestalt", 88], ["-", 95], ["multiple", 96], ["congenital", 105], ["anomaly", 116], ["syndrome", 124], [",", 132], ["commonly", 134], ["associating", 143], ["microcephaly", 155], [",", 167], ["epilepsy", 169], [",", 177], ["corpus", 179], ["callosum", 186], ["agenesis", 195], [",", 203], ["conotruncal", 205], ["heart", 217], ["defects", 223], [",", 230], ["urogenital", 232], ["malformations", 243], ["and", 257], ["Hirschsprung", 261], ["disease", 274], ["(", 282], ["HSCR", 283], [")", 287], [".", 288], ["MWS", 290], ["is", 294], ["caused", 297], ["by", 304], ["de", 307], ["novo", 310], ["heterozygous", 315], ["mutations", 328], ["in", 338], ["the", 341], ["ZEB2", 345], ["gene", 350], [".", 354], ["The", 356], ["majority", 360], ["of", 369], ["mutations", 372], ["lead", 382], ["to", 387], ["haplo", 390], ["-", 395], ["insufficiency", 396], ["through", 410], ["premature", 418], ["stop", 428], ["codons", 433], ["or", 440], ["large", 443], ["gene", 449], ["deletions", 454], [".", 463], ["Only", 465], ["three", 470], ["missense", 476], ["mutations", 485], ["have", 495], ["been", 500], ["reported", 505], ["so", 514], ["far", 517], [";", 520], ["none", 522], ["of", 527], ["which", 530], ["resides", 536], ["in", 544], ["a", 547], ["known", 549], ["functional", 555], ["domain", 566], ["of", 573], ["ZEB2", 576], [".", 580], ["In", 582], ["this", 585], ["study", 590], [",", 595], ["we", 597], ["report", 600], ["and", 607], ["analyze", 611], ["the", 619], ["functional", 623], ["consequences", 634], ["of", 647], ["three", 650], ["novel", 656], ["missense", 662], ["mutations", 671], [",", 680], ["p", 682], [".", 683], ["Tyr1055Cys", 684], [",", 694], ["p", 696], [".", 697], ["Ser1071Pro", 698], ["and", 709], ["p", 713], [".", 714], ["His1045Arg", 715], [",", 725], ["identified", 727], ["in", 738], ["the", 741], ["highly", 745], ["conserved", 752], ["C", 762], ["-", 763], ["zinc", 764], ["-", 768], ["finger", 769], ["(", 776], ["C", 777], ["-", 778], ["ZF", 779], [")", 781], ["domain", 783], ["of", 790], ["ZEB2", 793], [".", 797], ["Patients", 799], ["'", 807], ["phenotype", 809], ["included", 819], ["the", 828], ["facial", 832], ["gestalt", 839], ["of", 847], ["MWS", 850], ["and", 854], ["moderate", 858], ["ID", 867], [",", 869], ["but", 871], ["no", 875], ["microcephaly", 878], [",", 890], ["heart", 892], ["defects", 898], ["or", 906], ["HSCR", 909], [".", 913], ["In", 915], ["vitro", 918], ["studies", 924], ["showed", 932], ["that", 939], ["all", 944], ["the", 948], ["three", 952], ["mutations", 958], ["prevented", 968], ["binding", 978], ["and", 986], ["repression", 990], ["of", 1001], ["the", 1004], ["E", 1008], ["-", 1009], ["cadherin", 1010], ["promoter", 1019], [",", 1027], ["a", 1029], ["characterized", 1031], ["ZEB2", 1045], ["target", 1050], ["gene", 1057], [".", 1061], ["Taking", 1063], ["advantage", 1070], ["of", 1080], ["the", 1083], ["zebrafish", 1087], ["morphant", 1097], ["technology", 1106], [",", 1116], ["we", 1118], ["performed", 1121], ["rescue", 1131], ["experiments", 1138], ["using", 1150], ["wild", 1156], ["-", 1160], ["type", 1161], ["(", 1166], ["WT", 1167], [")", 1169], ["and", 1171], ["mutant", 1175], ["human", 1182], ["ZEB2", 1188], ["mRNAs", 1193], [".", 1198], ["Variable", 1200], [",", 1208], ["mutation", 1210], ["-", 1218], ["dependent", 1219], [",", 1228], ["embryo", 1230], ["rescue", 1237], [",", 1243], ["correlating", 1245], ["with", 1257], ["the", 1262], ["severity", 1266], ["of", 1275], ["patients", 1278], ["'", 1286], ["phenotype", 1288], [",", 1297], ["was", 1299], ["observed", 1303], [".", 1311], ["Our", 1313], ["data", 1317], ["provide", 1322], ["evidence", 1330], ["that", 1339], ["these", 1344], ["missense", 1350], ["mutations", 1359], ["cause", 1369], ["a", 1375], ["partial", 1377], ["loss", 1385], ["of", 1390], ["function", 1393], ["of", 1402], ["ZEB2", 1405], [",", 1409], ["suggesting", 1411], ["that", 1422], ["its", 1427], ["role", 1431], ["is", 1436], ["not", 1439], ["restricted", 1443], ["to", 1454], ["repression", 1457], ["of", 1468], ["E", 1471], ["-", 1472], ["cadherin", 1473], [".", 1481], ["Functional", 1483], ["domains", 1494], ["other", 1502], ["than", 1508], ["C", 1513], ["-", 1514], ["ZF", 1515], ["may", 1518], ["play", 1522], ["a", 1527], ["role", 1529], ["in", 1534], ["early", 1537], ["embryonic", 1543], ["development", 1553], [".", 1564], ["Finally", 1566], [",", 1573], ["these", 1575], ["findings", 1581], ["broaden", 1590], ["the", 1598], ["clinical", 1602], ["spectrum", 1611], ["of", 1620], ["ZEB2", 1623], ["mutations", 1628], [",", 1637], ["indicating", 1639], ["that", 1650], ["MWS", 1655], ["ought", 1659], ["to", 1665], ["be", 1668], ["considered", 1671], ["in", 1682], ["patients", 1685], ["with", 1694], ["lesser", 1699], ["degrees", 1706], ["of", 1714], ["ID", 1717], ["and", 1720], ["a", 1724], ["suggestive", 1726], ["facial", 1737], ["gestalt", 1744], [",", 1751], ["even", 1753], ["in", 1758], ["the", 1761], ["absence", 1765], ["of", 1773], ["congenital", 1776], ["malformation", 1787], [".", 1799]]}
{"context": "Since the publication of the first European Federation of Neurological Societies (EFNS) guidelines in 2005 on the management of restless legs syndrome (RLS; also known as Willis-Ekbom disease), there have been major therapeutic advances in the field. Furthermore, the management of RLS is now a part of routine neurological practice in Europe. New drugs have also become available, and further randomized controlled trials have been undertaken. These guidelines were undertaken by the EFNS in collaboration with the European Neurological Society and the European Sleep Research Society. To provide an evidence-based update of new treatments published since 2005 for the management of RLS. First, we determined what the objectives of management of primary and secondary RLS should be. We developed the search strategy and conducted a review of the scientific literature up to 31 December 2011 (print and electronic publications) for the drug classes and interventions employed in RLS treatment. Previous guidelines were consulted. All trials were analysed according to class of evidence, and recommendations made according to the 2004 EFNS criteria for rating. Level A recommendations can be made for rotigotine, ropinirole, pramipexole, gabapentin enacarbil, gabapentin and pregabalin, which are all considered effective for the short-term treatment for RLS. However, for the long-term treatment for RLS, rotigotine is considered effective, gabapentin enacarbil is probably effective, and ropinirole, pramipexole and gabapentin are considered possibly effective. Cabergoline has according to our criteria a level A recommendation, but the taskforce cannot recommend this drug because of its serious adverse events.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "de513d59252e439c8c943b250eba9f14", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[21, 23]], "char_spans": [[128, 149]]}]}], "context_tokens": [["Since", 0], ["the", 6], ["publication", 10], ["of", 22], ["the", 25], ["first", 29], ["European", 35], ["Federation", 44], ["of", 55], ["Neurological", 58], ["Societies", 71], ["(", 81], ["EFNS", 82], [")", 86], ["guidelines", 88], ["in", 99], ["2005", 102], ["on", 107], ["the", 110], ["management", 114], ["of", 125], ["restless", 128], ["legs", 137], ["syndrome", 142], ["(", 151], ["RLS", 152], [";", 155], ["also", 157], ["known", 162], ["as", 168], ["Willis", 171], ["-", 177], ["Ekbom", 178], ["disease", 184], [")", 191], [",", 192], ["there", 194], ["have", 200], ["been", 205], ["major", 210], ["therapeutic", 216], ["advances", 228], ["in", 237], ["the", 240], ["field", 244], [".", 249], ["Furthermore", 251], [",", 262], ["the", 264], ["management", 268], ["of", 279], ["RLS", 282], ["is", 286], ["now", 289], ["a", 293], ["part", 295], ["of", 300], ["routine", 303], ["neurological", 311], ["practice", 324], ["in", 333], ["Europe", 336], [".", 342], ["New", 344], ["drugs", 348], ["have", 354], ["also", 359], ["become", 364], ["available", 371], [",", 380], ["and", 382], ["further", 386], ["randomized", 394], ["controlled", 405], ["trials", 416], ["have", 423], ["been", 428], ["undertaken", 433], [".", 443], ["These", 445], ["guidelines", 451], ["were", 462], ["undertaken", 467], ["by", 478], ["the", 481], ["EFNS", 485], ["in", 490], ["collaboration", 493], ["with", 507], ["the", 512], ["European", 516], ["Neurological", 525], ["Society", 538], ["and", 546], ["the", 550], ["European", 554], ["Sleep", 563], ["Research", 569], ["Society", 578], [".", 585], ["To", 587], ["provide", 590], ["an", 598], ["evidence", 601], ["-", 609], ["based", 610], ["update", 616], ["of", 623], ["new", 626], ["treatments", 630], ["published", 641], ["since", 651], ["2005", 657], ["for", 662], ["the", 666], ["management", 670], ["of", 681], ["RLS", 684], [".", 687], ["First", 689], [",", 694], ["we", 696], ["determined", 699], ["what", 710], ["the", 715], ["objectives", 719], ["of", 730], ["management", 733], ["of", 744], ["primary", 747], ["and", 755], ["secondary", 759], ["RLS", 769], ["should", 773], ["be", 780], [".", 782], ["We", 784], ["developed", 787], ["the", 797], ["search", 801], ["strategy", 808], ["and", 817], ["conducted", 821], ["a", 831], ["review", 833], ["of", 840], ["the", 843], ["scientific", 847], ["literature", 858], ["up", 869], ["to", 872], ["31", 875], ["December", 878], ["2011", 887], ["(", 892], ["print", 893], ["and", 899], ["electronic", 903], ["publications", 914], [")", 926], ["for", 928], ["the", 932], ["drug", 936], ["classes", 941], ["and", 949], ["interventions", 953], ["employed", 967], ["in", 976], ["RLS", 979], ["treatment", 983], [".", 992], ["Previous", 994], ["guidelines", 1003], ["were", 1014], ["consulted", 1019], [".", 1028], ["All", 1030], ["trials", 1034], ["were", 1041], ["analysed", 1046], ["according", 1055], ["to", 1065], ["class", 1068], ["of", 1074], ["evidence", 1077], [",", 1085], ["and", 1087], ["recommendations", 1091], ["made", 1107], ["according", 1112], ["to", 1122], ["the", 1125], ["2004", 1129], ["EFNS", 1134], ["criteria", 1139], ["for", 1148], ["rating", 1152], [".", 1158], ["Level", 1160], ["A", 1166], ["recommendations", 1168], ["can", 1184], ["be", 1188], ["made", 1191], ["for", 1196], ["rotigotine", 1200], [",", 1210], ["ropinirole", 1212], [",", 1222], ["pramipexole", 1224], [",", 1235], ["gabapentin", 1237], ["enacarbil", 1248], [",", 1257], ["gabapentin", 1259], ["and", 1270], ["pregabalin", 1274], [",", 1284], ["which", 1286], ["are", 1292], ["all", 1296], ["considered", 1300], ["effective", 1311], ["for", 1321], ["the", 1325], ["short", 1329], ["-", 1334], ["term", 1335], ["treatment", 1340], ["for", 1350], ["RLS", 1354], [".", 1357], ["However", 1359], [",", 1366], ["for", 1368], ["the", 1372], ["long", 1376], ["-", 1380], ["term", 1381], ["treatment", 1386], ["for", 1396], ["RLS", 1400], [",", 1403], ["rotigotine", 1405], ["is", 1416], ["considered", 1419], ["effective", 1430], [",", 1439], ["gabapentin", 1441], ["enacarbil", 1452], ["is", 1462], ["probably", 1465], ["effective", 1474], [",", 1483], ["and", 1485], ["ropinirole", 1489], [",", 1499], ["pramipexole", 1501], ["and", 1513], ["gabapentin", 1517], ["are", 1528], ["considered", 1532], ["possibly", 1543], ["effective", 1552], [".", 1561], ["Cabergoline", 1563], ["has", 1575], ["according", 1579], ["to", 1589], ["our", 1592], ["criteria", 1596], ["a", 1605], ["level", 1607], ["A", 1613], ["recommendation", 1615], [",", 1629], ["but", 1631], ["the", 1635], ["taskforce", 1639], ["can", 1649], ["not", 1652], ["recommend", 1656], ["this", 1666], ["drug", 1671], ["because", 1676], ["of", 1684], ["its", 1687], ["serious", 1691], ["adverse", 1699], ["events", 1707], [".", 1713]]}
{"context": "Mutations and deletions of the NSD1 gene, located on chromosome 5q35, are responsible for over 90% of cases of Sotos syndrome. Fluorescent in situ hybridization analysis (FISH), MLPA or multiplex quantitative PCR allow detection of total/partial NSD1 deletions and direct sequencing allows detection of NSD1 mutations. We describe two boys with Sotos syndrome in whom PCR amplification and direct sequencing of the NSD1 gene identified two novel mutations not previously described: c.4736dupG in exon 12 and c.3938_3939insT in exon 7. In addition to the cardinal and major features of the syndrome (abnormal facial appearance, overgrowth, cardiac anomalies, renal anomalies, hypotonia, neonatal jaundice, seizures and brain MRI abnormalities) in both patients, one boy also had cryptorchidism and vertebral anomalies, features considered not common. Despite the wide range of possible combinations of phenotypic features, molecular analysis can correctly identify Sotos syndrome.", "qas": [{"question": "Which gene is responsible for the development of Sotos syndrome?", "answers": ["NSD1 gene"], "qid": "da2112b55fe74ffe80afbc48f42143f7", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["Sotos", 49], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "NSD1 gene", "token_spans": [[5, 6], [72, 73]], "char_spans": [[31, 39], [415, 423]]}]}], "context_tokens": [["Mutations", 0], ["and", 10], ["deletions", 14], ["of", 24], ["the", 27], ["NSD1", 31], ["gene", 36], [",", 40], ["located", 42], ["on", 50], ["chromosome", 53], ["5q35", 64], [",", 68], ["are", 70], ["responsible", 74], ["for", 86], ["over", 90], ["90", 95], ["%", 97], ["of", 99], ["cases", 102], ["of", 108], ["Sotos", 111], ["syndrome", 117], [".", 125], ["Fluorescent", 127], ["in", 139], ["situ", 142], ["hybridization", 147], ["analysis", 161], ["(", 170], ["FISH", 171], [")", 175], [",", 176], ["MLPA", 178], ["or", 183], ["multiplex", 186], ["quantitative", 196], ["PCR", 209], ["allow", 213], ["detection", 219], ["of", 229], ["total", 232], ["/", 237], ["partial", 238], ["NSD1", 246], ["deletions", 251], ["and", 261], ["direct", 265], ["sequencing", 272], ["allows", 283], ["detection", 290], ["of", 300], ["NSD1", 303], ["mutations", 308], [".", 317], ["We", 319], ["describe", 322], ["two", 331], ["boys", 335], ["with", 340], ["Sotos", 345], ["syndrome", 351], ["in", 360], ["whom", 363], ["PCR", 368], ["amplification", 372], ["and", 386], ["direct", 390], ["sequencing", 397], ["of", 408], ["the", 411], ["NSD1", 415], ["gene", 420], ["identified", 425], ["two", 436], ["novel", 440], ["mutations", 446], ["not", 456], ["previously", 460], ["described", 471], [":", 480], ["c.4736dupG", 482], ["in", 493], ["exon", 496], ["12", 501], ["and", 504], ["c.3938_3939insT", 508], ["in", 524], ["exon", 527], ["7", 532], [".", 533], ["In", 535], ["addition", 538], ["to", 547], ["the", 550], ["cardinal", 554], ["and", 563], ["major", 567], ["features", 573], ["of", 582], ["the", 585], ["syndrome", 589], ["(", 598], ["abnormal", 599], ["facial", 608], ["appearance", 615], [",", 625], ["overgrowth", 627], [",", 637], ["cardiac", 639], ["anomalies", 647], [",", 656], ["renal", 658], ["anomalies", 664], [",", 673], ["hypotonia", 675], [",", 684], ["neonatal", 686], ["jaundice", 695], [",", 703], ["seizures", 705], ["and", 714], ["brain", 718], ["MRI", 724], ["abnormalities", 728], [")", 741], ["in", 743], ["both", 746], ["patients", 751], [",", 759], ["one", 761], ["boy", 765], ["also", 769], ["had", 774], ["cryptorchidism", 778], ["and", 793], ["vertebral", 797], ["anomalies", 807], [",", 816], ["features", 818], ["considered", 827], ["not", 838], ["common", 842], [".", 848], ["Despite", 850], ["the", 858], ["wide", 862], ["range", 867], ["of", 873], ["possible", 876], ["combinations", 885], ["of", 898], ["phenotypic", 901], ["features", 912], [",", 920], ["molecular", 922], ["analysis", 932], ["can", 941], ["correctly", 945], ["identify", 955], ["Sotos", 964], ["syndrome", 970], [".", 978]]}
{"context": "Chronic myeloid leukaemia (CML) is characterized cytogenetically by a t(9;22)(q34;ql1) reciprocal translocation which gives origin to a hybrid BCR-ABL gene, encoding a p2lO(BCR-ABL) fusion protein with elevated tyrosine kinase activity and transforming abilities. The t(9;22) was suggested to be associated with genomic imprinting of centromeric regions of chromosomes 9 and 22, but the genes directly affected by the translocation, ABL and BCR, were shown not to be imprinted. For most diagnostic and research purposes the BCR-ABL gene can be efficiently identified by reverse-transcription and polymerase chain reaction (RT/PCR) amplification of its fusion transcripts, which can be quantified by competitive PCR and similar assays for assessment of residual disease in the follow-up of therapy. In the great majority of CML patients the BCR-ABL transcripts exhibit a b2a2 and/or a b3a2 junction; in rare cases, the only detectable BCR-ABL transcripts have unusual junctions, such as b2a3, b3a3, e1a2 or e6a2. There is a recent suggestion that the BCR-ABL gene may not be always 'functional', since extremely low levels of BCR-ABL transcripts can be found in leucocytes from normal individuals and, conversely, it appears that no BCR-ABL transcription can be detected in a proportion of Ph-positive haematopoietic progenitors from some CML patients. The role, if any, of the reciprocal ABL-BCR hybrid gene in CML is unknown. Although its mRNA message is in frame, no ABL-BCR fusion protein has yet been identified in CML patients. The blast crisis of CML has been variably associated with abnormalities of proto-oncogenes, such as RAS and MYC, or of tumour suppressor genes, in particular RB, p53 and p16, or with the generation of chimeric transcription factors, as in the AML1-EVI1 gene fusion. It is likely, therefore, that multiple and alternative molecular defects, as opposed to a single universal mechanism, underlie the acute transformation of the disease.", "qas": [{"question": "Which gene fusion is the result of the \"philadelphia translocation\" or the \"philadelphia chromosome\" mutation?", "answers": ["The BCR/ABL gene fusion", "ABL/BCR fusion"], "qid": "bab3517808284dd78fb78dee6116e087", "question_tokens": [["Which", 0], ["gene", 6], ["fusion", 11], ["is", 18], ["the", 21], ["result", 25], ["of", 32], ["the", 35], ["\"", 39], ["philadelphia", 40], ["translocation", 53], ["\"", 66], ["or", 68], ["the", 71], ["\"", 75], ["philadelphia", 76], ["chromosome", 89], ["\"", 99], ["mutation", 101], ["?", 109]], "detected_answers": [{"text": "ABL/BCR fusion", "token_spans": [[278, 281]], "char_spans": [[1469, 1482]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukaemia", 16], ["(", 26], ["CML", 27], [")", 30], ["is", 32], ["characterized", 35], ["cytogenetically", 49], ["by", 65], ["a", 68], ["t(9;22)(q34;ql1", 70], [")", 85], ["reciprocal", 87], ["translocation", 98], ["which", 112], ["gives", 118], ["origin", 124], ["to", 131], ["a", 134], ["hybrid", 136], ["BCR", 143], ["-", 146], ["ABL", 147], ["gene", 151], [",", 155], ["encoding", 157], ["a", 166], ["p2lO(BCR", 168], ["-", 176], ["ABL", 177], [")", 180], ["fusion", 182], ["protein", 189], ["with", 197], ["elevated", 202], ["tyrosine", 211], ["kinase", 220], ["activity", 227], ["and", 236], ["transforming", 240], ["abilities", 253], [".", 262], ["The", 264], ["t(9;22", 268], [")", 274], ["was", 276], ["suggested", 280], ["to", 290], ["be", 293], ["associated", 296], ["with", 307], ["genomic", 312], ["imprinting", 320], ["of", 331], ["centromeric", 334], ["regions", 346], ["of", 354], ["chromosomes", 357], ["9", 369], ["and", 371], ["22", 375], [",", 377], ["but", 379], ["the", 383], ["genes", 387], ["directly", 393], ["affected", 402], ["by", 411], ["the", 414], ["translocation", 418], [",", 431], ["ABL", 433], ["and", 437], ["BCR", 441], [",", 444], ["were", 446], ["shown", 451], ["not", 457], ["to", 461], ["be", 464], ["imprinted", 467], [".", 476], ["For", 478], ["most", 482], ["diagnostic", 487], ["and", 498], ["research", 502], ["purposes", 511], ["the", 520], ["BCR", 524], ["-", 527], ["ABL", 528], ["gene", 532], ["can", 537], ["be", 541], ["efficiently", 544], ["identified", 556], ["by", 567], ["reverse", 570], ["-", 577], ["transcription", 578], ["and", 592], ["polymerase", 596], ["chain", 607], ["reaction", 613], ["(", 622], ["RT", 623], ["/", 625], ["PCR", 626], [")", 629], ["amplification", 631], ["of", 645], ["its", 648], ["fusion", 652], ["transcripts", 659], [",", 670], ["which", 672], ["can", 678], ["be", 682], ["quantified", 685], ["by", 696], ["competitive", 699], ["PCR", 711], ["and", 715], ["similar", 719], ["assays", 727], ["for", 734], ["assessment", 738], ["of", 749], ["residual", 752], ["disease", 761], ["in", 769], ["the", 772], ["follow", 776], ["-", 782], ["up", 783], ["of", 786], ["therapy", 789], [".", 796], ["In", 798], ["the", 801], ["great", 805], ["majority", 811], ["of", 820], ["CML", 823], ["patients", 827], ["the", 836], ["BCR", 840], ["-", 843], ["ABL", 844], ["transcripts", 848], ["exhibit", 860], ["a", 868], ["b2a2", 870], ["and/or", 875], ["a", 882], ["b3a2", 884], ["junction", 889], [";", 897], ["in", 899], ["rare", 902], ["cases", 907], [",", 912], ["the", 914], ["only", 918], ["detectable", 923], ["BCR", 934], ["-", 937], ["ABL", 938], ["transcripts", 942], ["have", 954], ["unusual", 959], ["junctions", 967], [",", 976], ["such", 978], ["as", 983], ["b2a3", 986], [",", 990], ["b3a3", 992], [",", 996], ["e1a2", 998], ["or", 1003], ["e6a2", 1006], [".", 1010], ["There", 1012], ["is", 1018], ["a", 1021], ["recent", 1023], ["suggestion", 1030], ["that", 1041], ["the", 1046], ["BCR", 1050], ["-", 1053], ["ABL", 1054], ["gene", 1058], ["may", 1063], ["not", 1067], ["be", 1071], ["always", 1074], ["'", 1081], ["functional", 1082], ["'", 1092], [",", 1093], ["since", 1095], ["extremely", 1101], ["low", 1111], ["levels", 1115], ["of", 1122], ["BCR", 1125], ["-", 1128], ["ABL", 1129], ["transcripts", 1133], ["can", 1145], ["be", 1149], ["found", 1152], ["in", 1158], ["leucocytes", 1161], ["from", 1172], ["normal", 1177], ["individuals", 1184], ["and", 1196], [",", 1199], ["conversely", 1201], [",", 1211], ["it", 1213], ["appears", 1216], ["that", 1224], ["no", 1229], ["BCR", 1232], ["-", 1235], ["ABL", 1236], ["transcription", 1240], ["can", 1254], ["be", 1258], ["detected", 1261], ["in", 1270], ["a", 1273], ["proportion", 1275], ["of", 1286], ["Ph", 1289], ["-", 1291], ["positive", 1292], ["haematopoietic", 1301], ["progenitors", 1316], ["from", 1328], ["some", 1333], ["CML", 1338], ["patients", 1342], [".", 1350], ["The", 1352], ["role", 1356], [",", 1360], ["if", 1362], ["any", 1365], [",", 1368], ["of", 1370], ["the", 1373], ["reciprocal", 1377], ["ABL", 1388], ["-", 1391], ["BCR", 1392], ["hybrid", 1396], ["gene", 1403], ["in", 1408], ["CML", 1411], ["is", 1415], ["unknown", 1418], [".", 1425], ["Although", 1427], ["its", 1436], ["mRNA", 1440], ["message", 1445], ["is", 1453], ["in", 1456], ["frame", 1459], [",", 1464], ["no", 1466], ["ABL", 1469], ["-", 1472], ["BCR", 1473], ["fusion", 1477], ["protein", 1484], ["has", 1492], ["yet", 1496], ["been", 1500], ["identified", 1505], ["in", 1516], ["CML", 1519], ["patients", 1523], [".", 1531], ["The", 1533], ["blast", 1537], ["crisis", 1543], ["of", 1550], ["CML", 1553], ["has", 1557], ["been", 1561], ["variably", 1566], ["associated", 1575], ["with", 1586], ["abnormalities", 1591], ["of", 1605], ["proto", 1608], ["-", 1613], ["oncogenes", 1614], [",", 1623], ["such", 1625], ["as", 1630], ["RAS", 1633], ["and", 1637], ["MYC", 1641], [",", 1644], ["or", 1646], ["of", 1649], ["tumour", 1652], ["suppressor", 1659], ["genes", 1670], [",", 1675], ["in", 1677], ["particular", 1680], ["RB", 1691], [",", 1693], ["p53", 1695], ["and", 1699], ["p16", 1703], [",", 1706], ["or", 1708], ["with", 1711], ["the", 1716], ["generation", 1720], ["of", 1731], ["chimeric", 1734], ["transcription", 1743], ["factors", 1757], [",", 1764], ["as", 1766], ["in", 1769], ["the", 1772], ["AML1-EVI1", 1776], ["gene", 1786], ["fusion", 1791], [".", 1797], ["It", 1799], ["is", 1802], ["likely", 1805], [",", 1811], ["therefore", 1813], [",", 1822], ["that", 1824], ["multiple", 1829], ["and", 1838], ["alternative", 1842], ["molecular", 1854], ["defects", 1864], [",", 1871], ["as", 1873], ["opposed", 1876], ["to", 1884], ["a", 1887], ["single", 1889], ["universal", 1896], ["mechanism", 1906], [",", 1915], ["underlie", 1917], ["the", 1926], ["acute", 1930], ["transformation", 1936], ["of", 1951], ["the", 1954], ["disease", 1958], [".", 1965]]}
{"context": "CLIP-Seq protocols such as PAR-CLIP, HITS-CLIP or iCLIP allow a genome-wide analysis of protein-RNA interactions. For the processing of the resulting short read data, various tools are utilized. Some of these tools were specifically developed for CLIP-Seq data, whereas others were designed for the analysis of RNA-Seq data. To this date, however, it has not been assessed which of the available tools are most appropriate for the analysis of CLIP-Seq data. This is because an experimental gold standard dataset on which methods can be accessed and compared, is still not available. To address this lack of a gold-standard dataset, we here present Cseq-Simulator, a simulator for PAR-CLIP, HITS-CLIP and iCLIP-data. This simulator can be applied to generate realistic datasets that can serve as surrogates for experimental gold standard dataset. In this work, we also show how Cseq-Simulator can be used to perform a comparison of steps of typical CLIP-Seq analysis pipelines, such as the read alignment or the peak calling. These comparisons show which tools are useful in different settings and also allow identifying pitfalls in the data analysis.", "qas": [{"question": "Which data simulator is available for CLIP-SEQ experiments?", "answers": ["Cseq-Simulator"], "qid": "eb43bbf0c4bb484dba710614100c1204", "question_tokens": [["Which", 0], ["data", 6], ["simulator", 11], ["is", 21], ["available", 24], ["for", 34], ["CLIP", 38], ["-", 42], ["SEQ", 43], ["experiments", 47], ["?", 58]], "detected_answers": [{"text": "Cseq-Simulator", "token_spans": [[132, 134], [179, 181]], "char_spans": [[648, 661], [877, 890]]}]}], "context_tokens": [["CLIP", 0], ["-", 4], ["Seq", 5], ["protocols", 9], ["such", 19], ["as", 24], ["PAR", 27], ["-", 30], ["CLIP", 31], [",", 35], ["HITS", 37], ["-", 41], ["CLIP", 42], ["or", 47], ["iCLIP", 50], ["allow", 56], ["a", 62], ["genome", 64], ["-", 70], ["wide", 71], ["analysis", 76], ["of", 85], ["protein", 88], ["-", 95], ["RNA", 96], ["interactions", 100], [".", 112], ["For", 114], ["the", 118], ["processing", 122], ["of", 133], ["the", 136], ["resulting", 140], ["short", 150], ["read", 156], ["data", 161], [",", 165], ["various", 167], ["tools", 175], ["are", 181], ["utilized", 185], [".", 193], ["Some", 195], ["of", 200], ["these", 203], ["tools", 209], ["were", 215], ["specifically", 220], ["developed", 233], ["for", 243], ["CLIP", 247], ["-", 251], ["Seq", 252], ["data", 256], [",", 260], ["whereas", 262], ["others", 270], ["were", 277], ["designed", 282], ["for", 291], ["the", 295], ["analysis", 299], ["of", 308], ["RNA", 311], ["-", 314], ["Seq", 315], ["data", 319], [".", 323], ["To", 325], ["this", 328], ["date", 333], [",", 337], ["however", 339], [",", 346], ["it", 348], ["has", 351], ["not", 355], ["been", 359], ["assessed", 364], ["which", 373], ["of", 379], ["the", 382], ["available", 386], ["tools", 396], ["are", 402], ["most", 406], ["appropriate", 411], ["for", 423], ["the", 427], ["analysis", 431], ["of", 440], ["CLIP", 443], ["-", 447], ["Seq", 448], ["data", 452], [".", 456], ["This", 458], ["is", 463], ["because", 466], ["an", 474], ["experimental", 477], ["gold", 490], ["standard", 495], ["dataset", 504], ["on", 512], ["which", 515], ["methods", 521], ["can", 529], ["be", 533], ["accessed", 536], ["and", 545], ["compared", 549], [",", 557], ["is", 559], ["still", 562], ["not", 568], ["available", 572], [".", 581], ["To", 583], ["address", 586], ["this", 594], ["lack", 599], ["of", 604], ["a", 607], ["gold", 609], ["-", 613], ["standard", 614], ["dataset", 623], [",", 630], ["we", 632], ["here", 635], ["present", 640], ["Cseq", 648], ["-", 652], ["Simulator", 653], [",", 662], ["a", 664], ["simulator", 666], ["for", 676], ["PAR", 680], ["-", 683], ["CLIP", 684], [",", 688], ["HITS", 690], ["-", 694], ["CLIP", 695], ["and", 700], ["iCLIP", 704], ["-", 709], ["data", 710], [".", 714], ["This", 716], ["simulator", 721], ["can", 731], ["be", 735], ["applied", 738], ["to", 746], ["generate", 749], ["realistic", 758], ["datasets", 768], ["that", 777], ["can", 782], ["serve", 786], ["as", 792], ["surrogates", 795], ["for", 806], ["experimental", 810], ["gold", 823], ["standard", 828], ["dataset", 837], [".", 844], ["In", 846], ["this", 849], ["work", 854], [",", 858], ["we", 860], ["also", 863], ["show", 868], ["how", 873], ["Cseq", 877], ["-", 881], ["Simulator", 882], ["can", 892], ["be", 896], ["used", 899], ["to", 904], ["perform", 907], ["a", 915], ["comparison", 917], ["of", 928], ["steps", 931], ["of", 937], ["typical", 940], ["CLIP", 948], ["-", 952], ["Seq", 953], ["analysis", 957], ["pipelines", 966], [",", 975], ["such", 977], ["as", 982], ["the", 985], ["read", 989], ["alignment", 994], ["or", 1004], ["the", 1007], ["peak", 1011], ["calling", 1016], [".", 1023], ["These", 1025], ["comparisons", 1031], ["show", 1043], ["which", 1048], ["tools", 1054], ["are", 1060], ["useful", 1064], ["in", 1071], ["different", 1074], ["settings", 1084], ["and", 1093], ["also", 1097], ["allow", 1102], ["identifying", 1108], ["pitfalls", 1120], ["in", 1129], ["the", 1132], ["data", 1136], ["analysis", 1141], [".", 1149]]}
{"context": "Flumazenil, a specific benzodiazepine antagonist, is useful in reversing the sedation and respiratory depression that often occur when benzodiazepines are administered to patients undergoing anesthesia or when patients have taken an intentional benzodiazepine overdose. Judicious use of flumazenil may provide useful diagnostic information and may obviate the need for mechanical ventilation and other invasive supportive measures. Although some controversy exists regarding the possible precipitation of seizure activity in the setting of mixed tricyclic antidepressant-benzodiazepine overdose, worldwide experience with flumazenil has validated its safety and efficacy.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "b4b16d825b304cf98373a45e742826da", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[0, 0], [85, 85], [40, 40]], "char_spans": [[0, 9], [622, 631], [287, 296]]}]}], "context_tokens": [["Flumazenil", 0], [",", 10], ["a", 12], ["specific", 14], ["benzodiazepine", 23], ["antagonist", 38], [",", 48], ["is", 50], ["useful", 53], ["in", 60], ["reversing", 63], ["the", 73], ["sedation", 77], ["and", 86], ["respiratory", 90], ["depression", 102], ["that", 113], ["often", 118], ["occur", 124], ["when", 130], ["benzodiazepines", 135], ["are", 151], ["administered", 155], ["to", 168], ["patients", 171], ["undergoing", 180], ["anesthesia", 191], ["or", 202], ["when", 205], ["patients", 210], ["have", 219], ["taken", 224], ["an", 230], ["intentional", 233], ["benzodiazepine", 245], ["overdose", 260], [".", 268], ["Judicious", 270], ["use", 280], ["of", 284], ["flumazenil", 287], ["may", 298], ["provide", 302], ["useful", 310], ["diagnostic", 317], ["information", 328], ["and", 340], ["may", 344], ["obviate", 348], ["the", 356], ["need", 360], ["for", 365], ["mechanical", 369], ["ventilation", 380], ["and", 392], ["other", 396], ["invasive", 402], ["supportive", 411], ["measures", 422], [".", 430], ["Although", 432], ["some", 441], ["controversy", 446], ["exists", 458], ["regarding", 465], ["the", 475], ["possible", 479], ["precipitation", 488], ["of", 502], ["seizure", 505], ["activity", 513], ["in", 522], ["the", 525], ["setting", 529], ["of", 537], ["mixed", 540], ["tricyclic", 546], ["antidepressant", 556], ["-", 570], ["benzodiazepine", 571], ["overdose", 586], [",", 594], ["worldwide", 596], ["experience", 606], ["with", 617], ["flumazenil", 622], ["has", 633], ["validated", 637], ["its", 647], ["safety", 651], ["and", 658], ["efficacy", 662], [".", 670]]}
{"context": "DUX4, a homeobox-containing gene present in a tandem array, is implicated in facioscapulohumeral muscular dystrophy (FSHD), a dominant autosomal disease. New findings about DUX4 have raised as many fundamental questions about the molecular pathology of this unique disease as they have answered. This review discusses recent studies addressing the question of whether there is extensive FSHD-related transcription dysregulation in adult-derived myoblasts and myotubes, the precursors for muscle repair. Two models for the role of DUX4 in FSHD are presented. One involves transient pathogenic expression of DUX4 in many cells in the muscle lineage before the myoblast stage resulting in a persistent, disease-related transcription profile ('Majority Rules'), which might be enhanced by subsequent oscillatory expression of DUX4. The other model emphasizes the toxic effects of inappropriate expression of DUX4 in only an extremely small percentage of FSHD myoblasts or myotube nuclei ('Minority Rules'). The currently favored Minority Rules model is not supported by recent studies of transcription dysregulation in FSHD myoblasts and myotubes. It also presents other difficulties, for example, explaining the expression of full-length DUX4 transcripts in FSHD fibroblasts. The Majority Rules model is the simpler explanation of findings about FSHD-associated gene expression and the DUX4-encoded homeodomain-type protein.", "qas": [{"question": "Which disease is associated with the ectopic expression of the protein encoded by the gene DUX4?", "answers": ["Facioscapulohumeral dystrophy", "FSHD"], "qid": "6a92b3312fe9468e9d709a8e59c9fadc", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["associated", 17], ["with", 28], ["the", 33], ["ectopic", 37], ["expression", 45], ["of", 56], ["the", 59], ["protein", 63], ["encoded", 71], ["by", 79], ["the", 82], ["gene", 86], ["DUX4", 91], ["?", 95]], "detected_answers": [{"text": "FSHD", "token_spans": [[64, 64], [160, 160], [91, 91], [188, 188], [20, 20], [212, 212], [226, 226]], "char_spans": [[387, 390], [950, 953], [538, 541], [1115, 1118], [117, 120], [1255, 1258], [1343, 1346]]}]}], "context_tokens": [["DUX4", 0], [",", 4], ["a", 6], ["homeobox", 8], ["-", 16], ["containing", 17], ["gene", 28], ["present", 33], ["in", 41], ["a", 44], ["tandem", 46], ["array", 53], [",", 58], ["is", 60], ["implicated", 63], ["in", 74], ["facioscapulohumeral", 77], ["muscular", 97], ["dystrophy", 106], ["(", 116], ["FSHD", 117], [")", 121], [",", 122], ["a", 124], ["dominant", 126], ["autosomal", 135], ["disease", 145], [".", 152], ["New", 154], ["findings", 158], ["about", 167], ["DUX4", 173], ["have", 178], ["raised", 183], ["as", 190], ["many", 193], ["fundamental", 198], ["questions", 210], ["about", 220], ["the", 226], ["molecular", 230], ["pathology", 240], ["of", 250], ["this", 253], ["unique", 258], ["disease", 265], ["as", 273], ["they", 276], ["have", 281], ["answered", 286], [".", 294], ["This", 296], ["review", 301], ["discusses", 308], ["recent", 318], ["studies", 325], ["addressing", 333], ["the", 344], ["question", 348], ["of", 357], ["whether", 360], ["there", 368], ["is", 374], ["extensive", 377], ["FSHD", 387], ["-", 391], ["related", 392], ["transcription", 400], ["dysregulation", 414], ["in", 428], ["adult", 431], ["-", 436], ["derived", 437], ["myoblasts", 445], ["and", 455], ["myotubes", 459], [",", 467], ["the", 469], ["precursors", 473], ["for", 484], ["muscle", 488], ["repair", 495], [".", 501], ["Two", 503], ["models", 507], ["for", 514], ["the", 518], ["role", 522], ["of", 527], ["DUX4", 530], ["in", 535], ["FSHD", 538], ["are", 543], ["presented", 547], [".", 556], ["One", 558], ["involves", 562], ["transient", 571], ["pathogenic", 581], ["expression", 592], ["of", 603], ["DUX4", 606], ["in", 611], ["many", 614], ["cells", 619], ["in", 625], ["the", 628], ["muscle", 632], ["lineage", 639], ["before", 647], ["the", 654], ["myoblast", 658], ["stage", 667], ["resulting", 673], ["in", 683], ["a", 686], ["persistent", 688], [",", 698], ["disease", 700], ["-", 707], ["related", 708], ["transcription", 716], ["profile", 730], ["(", 738], ["'", 739], ["Majority", 740], ["Rules", 749], ["'", 754], [")", 755], [",", 756], ["which", 758], ["might", 764], ["be", 770], ["enhanced", 773], ["by", 782], ["subsequent", 785], ["oscillatory", 796], ["expression", 808], ["of", 819], ["DUX4", 822], [".", 826], ["The", 828], ["other", 832], ["model", 838], ["emphasizes", 844], ["the", 855], ["toxic", 859], ["effects", 865], ["of", 873], ["inappropriate", 876], ["expression", 890], ["of", 901], ["DUX4", 904], ["in", 909], ["only", 912], ["an", 917], ["extremely", 920], ["small", 930], ["percentage", 936], ["of", 947], ["FSHD", 950], ["myoblasts", 955], ["or", 965], ["myotube", 968], ["nuclei", 976], ["(", 983], ["'", 984], ["Minority", 985], ["Rules", 994], ["'", 999], [")", 1000], [".", 1001], ["The", 1003], ["currently", 1007], ["favored", 1017], ["Minority", 1025], ["Rules", 1034], ["model", 1040], ["is", 1046], ["not", 1049], ["supported", 1053], ["by", 1063], ["recent", 1066], ["studies", 1073], ["of", 1081], ["transcription", 1084], ["dysregulation", 1098], ["in", 1112], ["FSHD", 1115], ["myoblasts", 1120], ["and", 1130], ["myotubes", 1134], [".", 1142], ["It", 1144], ["also", 1147], ["presents", 1152], ["other", 1161], ["difficulties", 1167], [",", 1179], ["for", 1181], ["example", 1185], [",", 1192], ["explaining", 1194], ["the", 1205], ["expression", 1209], ["of", 1220], ["full", 1223], ["-", 1227], ["length", 1228], ["DUX4", 1235], ["transcripts", 1240], ["in", 1252], ["FSHD", 1255], ["fibroblasts", 1260], [".", 1271], ["The", 1273], ["Majority", 1277], ["Rules", 1286], ["model", 1292], ["is", 1298], ["the", 1301], ["simpler", 1305], ["explanation", 1313], ["of", 1325], ["findings", 1328], ["about", 1337], ["FSHD", 1343], ["-", 1347], ["associated", 1348], ["gene", 1359], ["expression", 1364], ["and", 1375], ["the", 1379], ["DUX4-encoded", 1383], ["homeodomain", 1396], ["-", 1407], ["type", 1408], ["protein", 1413], [".", 1420]]}
{"context": "To evaluate the role of idarucizumab, a humanized monoclonal antibody fragment, as a specific reversal agent for the anticoagulant activity of dabigatran and to review the pharmacology, pharmacokinetic properties, efficacy, and safety of this agent. A literature search was conducted consisting of a PubMed database using the MeSH term idarucizumab and the key word dabigatran antidote. Studies evaluating the pharmacology, pharmacokinetics, safety, and efficacy of idarucizumab for the reversal of the anticoagulant activity of dabigatran were included. Idarucizumab represents a novel treatment option as it is the only humanized, monoclonal antibody fragment that specifically binds to dabigatran. Studies evaluating reversal of dabigatran-induced anticoagulation have demonstrated immediate, complete, and sustained effects with idarucizumab. Idarucizumab did not overcorrect thrombin generation. Additionally, evaluations have shown that dabigatran can be safely reinitiated 24 hours after the administration of idarucizumab. The United States Food and Drug Administration granted priority review for the biologic license application and accelerated approval for idarucizumab. Idarucizumab represents an encouraging development in the reversal of dabigatran. Its novel mechanism of action, pharmacokinetics, tolerability, and lack of thrombotic events contribute positively to its use in patients who experience bleeding or for those who require emergent surgery or procedures.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "ef28a6cc8b5d472b98e489b35d514e0b", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[186, 186], [108, 108], [60, 60], [84, 84], [23, 23], [114, 114], [143, 143]], "char_spans": [[1252, 1261], [689, 698], [366, 375], [529, 538], [143, 152], [732, 741], [943, 952]]}]}], "context_tokens": [["To", 0], ["evaluate", 3], ["the", 12], ["role", 16], ["of", 21], ["idarucizumab", 24], [",", 36], ["a", 38], ["humanized", 40], ["monoclonal", 50], ["antibody", 61], ["fragment", 70], [",", 78], ["as", 80], ["a", 83], ["specific", 85], ["reversal", 94], ["agent", 103], ["for", 109], ["the", 113], ["anticoagulant", 117], ["activity", 131], ["of", 140], ["dabigatran", 143], ["and", 154], ["to", 158], ["review", 161], ["the", 168], ["pharmacology", 172], [",", 184], ["pharmacokinetic", 186], ["properties", 202], [",", 212], ["efficacy", 214], [",", 222], ["and", 224], ["safety", 228], ["of", 235], ["this", 238], ["agent", 243], [".", 248], ["A", 250], ["literature", 252], ["search", 263], ["was", 270], ["conducted", 274], ["consisting", 284], ["of", 295], ["a", 298], ["PubMed", 300], ["database", 307], ["using", 316], ["the", 322], ["MeSH", 326], ["term", 331], ["idarucizumab", 336], ["and", 349], ["the", 353], ["key", 357], ["word", 361], ["dabigatran", 366], ["antidote", 377], [".", 385], ["Studies", 387], ["evaluating", 395], ["the", 406], ["pharmacology", 410], [",", 422], ["pharmacokinetics", 424], [",", 440], ["safety", 442], [",", 448], ["and", 450], ["efficacy", 454], ["of", 463], ["idarucizumab", 466], ["for", 479], ["the", 483], ["reversal", 487], ["of", 496], ["the", 499], ["anticoagulant", 503], ["activity", 517], ["of", 526], ["dabigatran", 529], ["were", 540], ["included", 545], [".", 553], ["Idarucizumab", 555], ["represents", 568], ["a", 579], ["novel", 581], ["treatment", 587], ["option", 597], ["as", 604], ["it", 607], ["is", 610], ["the", 613], ["only", 617], ["humanized", 622], [",", 631], ["monoclonal", 633], ["antibody", 644], ["fragment", 653], ["that", 662], ["specifically", 667], ["binds", 680], ["to", 686], ["dabigatran", 689], [".", 699], ["Studies", 701], ["evaluating", 709], ["reversal", 720], ["of", 729], ["dabigatran", 732], ["-", 742], ["induced", 743], ["anticoagulation", 751], ["have", 767], ["demonstrated", 772], ["immediate", 785], [",", 794], ["complete", 796], [",", 804], ["and", 806], ["sustained", 810], ["effects", 820], ["with", 828], ["idarucizumab", 833], [".", 845], ["Idarucizumab", 847], ["did", 860], ["not", 864], ["overcorrect", 868], ["thrombin", 880], ["generation", 889], [".", 899], ["Additionally", 901], [",", 913], ["evaluations", 915], ["have", 927], ["shown", 932], ["that", 938], ["dabigatran", 943], ["can", 954], ["be", 958], ["safely", 961], ["reinitiated", 968], ["24", 980], ["hours", 983], ["after", 989], ["the", 995], ["administration", 999], ["of", 1014], ["idarucizumab", 1017], [".", 1029], ["The", 1031], ["United", 1035], ["States", 1042], ["Food", 1049], ["and", 1054], ["Drug", 1058], ["Administration", 1063], ["granted", 1078], ["priority", 1086], ["review", 1095], ["for", 1102], ["the", 1106], ["biologic", 1110], ["license", 1119], ["application", 1127], ["and", 1139], ["accelerated", 1143], ["approval", 1155], ["for", 1164], ["idarucizumab", 1168], [".", 1180], ["Idarucizumab", 1182], ["represents", 1195], ["an", 1206], ["encouraging", 1209], ["development", 1221], ["in", 1233], ["the", 1236], ["reversal", 1240], ["of", 1249], ["dabigatran", 1252], [".", 1262], ["Its", 1264], ["novel", 1268], ["mechanism", 1274], ["of", 1284], ["action", 1287], [",", 1293], ["pharmacokinetics", 1295], [",", 1311], ["tolerability", 1313], [",", 1325], ["and", 1327], ["lack", 1331], ["of", 1336], ["thrombotic", 1339], ["events", 1350], ["contribute", 1357], ["positively", 1368], ["to", 1379], ["its", 1382], ["use", 1386], ["in", 1390], ["patients", 1393], ["who", 1402], ["experience", 1406], ["bleeding", 1417], ["or", 1426], ["for", 1429], ["those", 1433], ["who", 1439], ["require", 1443], ["emergent", 1451], ["surgery", 1460], ["or", 1468], ["procedures", 1471], [".", 1481]]}
{"context": "Postoperative methicillin-resistant Staphylococcus aureus (MRSA) infections are occasionally fatal. We hypothesized that nasal MRSA screening might predict the risk of postoperative MRSA infections. The aim of the current study was to elucidate the relationship between the positivity of nasal MRSA screening and postoperative MRSA infections. Six hundred and fourteen surgical patients who were admitted to the intensive care unit and underwent nasal MRSA screening between April 2006 and March 2011 were divided into MRSA-positive and -negative groups. The incidence of postoperative MRSA infections in the MRSA-positive and MRSA-negative groups were compared, and various risk factors for MRSA infections were evaluated. The incidence of postoperative MRSA infections, such as pneumonia and enteritis, in the MRSA-positive group was significantly higher than that in the MRSA-negative group (41.9 vs. 3.1 %). The significant independent risk factors for postoperative MRSA infections were a positive MRSA screening, an operation lasting more than 300 min and an emergency operation. A positive MRSA screening was the most statistically significant risk factor for postoperative MRSA pneumonia and enteritis, but was not a risk factor for MRSA surgical site infections. Nasal MRSA screening can help to identify patients who have an increased risk of developing postoperative MRSA infections, and would enable physicians to take a prompt action if these complications occur.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "a9817a6931814cc1929eed39d878021d", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[80, 80], [160, 160], [45, 45], [205, 205], [211, 211], [7, 7], [111, 111], [120, 120], [69, 69], [131, 131], [142, 142], [226, 226], [193, 193], [49, 49], [26, 26], [91, 91], [99, 99], [165, 165], [182, 182], [18, 18], [95, 95]], "char_spans": [[519, 522], [971, 974], [294, 297], [1241, 1244], [1278, 1281], [59, 62], [692, 695], [755, 758], [452, 455], [812, 815], [874, 877], [1378, 1381], [1181, 1184], [327, 330], [182, 185], [586, 589], [627, 630], [1003, 1006], [1097, 1100], [127, 130], [609, 612]]}]}], "context_tokens": [["Postoperative", 0], ["methicillin", 14], ["-", 25], ["resistant", 26], ["Staphylococcus", 36], ["aureus", 51], ["(", 58], ["MRSA", 59], [")", 63], ["infections", 65], ["are", 76], ["occasionally", 80], ["fatal", 93], [".", 98], ["We", 100], ["hypothesized", 103], ["that", 116], ["nasal", 121], ["MRSA", 127], ["screening", 132], ["might", 142], ["predict", 148], ["the", 156], ["risk", 160], ["of", 165], ["postoperative", 168], ["MRSA", 182], ["infections", 187], [".", 197], ["The", 199], ["aim", 203], ["of", 207], ["the", 210], ["current", 214], ["study", 222], ["was", 228], ["to", 232], ["elucidate", 235], ["the", 245], ["relationship", 249], ["between", 262], ["the", 270], ["positivity", 274], ["of", 285], ["nasal", 288], ["MRSA", 294], ["screening", 299], ["and", 309], ["postoperative", 313], ["MRSA", 327], ["infections", 332], [".", 342], ["Six", 344], ["hundred", 348], ["and", 356], ["fourteen", 360], ["surgical", 369], ["patients", 378], ["who", 387], ["were", 391], ["admitted", 396], ["to", 405], ["the", 408], ["intensive", 412], ["care", 422], ["unit", 427], ["and", 432], ["underwent", 436], ["nasal", 446], ["MRSA", 452], ["screening", 457], ["between", 467], ["April", 475], ["2006", 481], ["and", 486], ["March", 490], ["2011", 496], ["were", 501], ["divided", 506], ["into", 514], ["MRSA", 519], ["-", 523], ["positive", 524], ["and", 533], ["-negative", 537], ["groups", 547], [".", 553], ["The", 555], ["incidence", 559], ["of", 569], ["postoperative", 572], ["MRSA", 586], ["infections", 591], ["in", 602], ["the", 605], ["MRSA", 609], ["-", 613], ["positive", 614], ["and", 623], ["MRSA", 627], ["-", 631], ["negative", 632], ["groups", 641], ["were", 648], ["compared", 653], [",", 661], ["and", 663], ["various", 667], ["risk", 675], ["factors", 680], ["for", 688], ["MRSA", 692], ["infections", 697], ["were", 708], ["evaluated", 713], [".", 722], ["The", 724], ["incidence", 728], ["of", 738], ["postoperative", 741], ["MRSA", 755], ["infections", 760], [",", 770], ["such", 772], ["as", 777], ["pneumonia", 780], ["and", 790], ["enteritis", 794], [",", 803], ["in", 805], ["the", 808], ["MRSA", 812], ["-", 816], ["positive", 817], ["group", 826], ["was", 832], ["significantly", 836], ["higher", 850], ["than", 857], ["that", 862], ["in", 867], ["the", 870], ["MRSA", 874], ["-", 878], ["negative", 879], ["group", 888], ["(", 894], ["41.9", 895], ["vs.", 900], ["3.1", 904], ["%", 908], [")", 909], [".", 910], ["The", 912], ["significant", 916], ["independent", 928], ["risk", 940], ["factors", 945], ["for", 953], ["postoperative", 957], ["MRSA", 971], ["infections", 976], ["were", 987], ["a", 992], ["positive", 994], ["MRSA", 1003], ["screening", 1008], [",", 1017], ["an", 1019], ["operation", 1022], ["lasting", 1032], ["more", 1040], ["than", 1045], ["300", 1050], ["min", 1054], ["and", 1058], ["an", 1062], ["emergency", 1065], ["operation", 1075], [".", 1084], ["A", 1086], ["positive", 1088], ["MRSA", 1097], ["screening", 1102], ["was", 1112], ["the", 1116], ["most", 1120], ["statistically", 1125], ["significant", 1139], ["risk", 1151], ["factor", 1156], ["for", 1163], ["postoperative", 1167], ["MRSA", 1181], ["pneumonia", 1186], ["and", 1196], ["enteritis", 1200], [",", 1209], ["but", 1211], ["was", 1215], ["not", 1219], ["a", 1223], ["risk", 1225], ["factor", 1230], ["for", 1237], ["MRSA", 1241], ["surgical", 1246], ["site", 1255], ["infections", 1260], [".", 1270], ["Nasal", 1272], ["MRSA", 1278], ["screening", 1283], ["can", 1293], ["help", 1297], ["to", 1302], ["identify", 1305], ["patients", 1314], ["who", 1323], ["have", 1327], ["an", 1332], ["increased", 1335], ["risk", 1345], ["of", 1350], ["developing", 1353], ["postoperative", 1364], ["MRSA", 1378], ["infections", 1383], [",", 1393], ["and", 1395], ["would", 1399], ["enable", 1405], ["physicians", 1412], ["to", 1423], ["take", 1426], ["a", 1431], ["prompt", 1433], ["action", 1440], ["if", 1447], ["these", 1450], ["complications", 1456], ["occur", 1470], [".", 1475]]}
{"context": "Double homeobox 4 (DUX4) is a candidate disease gene for facioscapulohumeral dystrophy (FSHD), one of the most common muscular dystrophies characterized by progressive skeletal muscle degeneration. Despite great strides in understanding precise genetics of FSHD, the molecular pathophysiology of the disease remains unclear. One of the major limitations has been the availability of appropriate molecular tools to study DUX4 protein. In the present study, we report the development of five new monoclonal antibodies targeted against the N- and C-termini of human DUX4, and characterize their reactivity using Western blot and immunofluorescence staining. Additionally, we show that expression of the canonical full coding DUX4 induces cell death in human primary muscle cells, whereas the expression of a shorter splice form of DUX4 results in no such toxicity. Immunostaining with these new antibodies reveals a differential effect of two DUX4 isoforms on human muscle cells. These antibodies will provide an excellent tool for investigating the role of DUX4 in FSHD pathogenesis.", "qas": [{"question": "Which disease is associated with the ectopic expression of the protein encoded by the gene DUX4?", "answers": ["Facioscapulohumeral dystrophy", "FSHD"], "qid": "7247ffe169f140339020744b6f54923c", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["associated", 17], ["with", 28], ["the", 33], ["ectopic", 37], ["expression", 45], ["of", 56], ["the", 59], ["protein", 63], ["encoded", 71], ["by", 79], ["the", 82], ["gene", 86], ["DUX4", 91], ["?", 95]], "detected_answers": [{"text": "Facioscapulohumeral dystrophy", "token_spans": [[12, 13]], "char_spans": [[57, 85]]}, {"text": "FSHD", "token_spans": [[175, 175], [40, 40], [15, 15]], "char_spans": [[1063, 1066], [257, 260], [88, 91]]}]}], "context_tokens": [["Double", 0], ["homeobox", 7], ["4", 16], ["(", 18], ["DUX4", 19], [")", 23], ["is", 25], ["a", 28], ["candidate", 30], ["disease", 40], ["gene", 48], ["for", 53], ["facioscapulohumeral", 57], ["dystrophy", 77], ["(", 87], ["FSHD", 88], [")", 92], [",", 93], ["one", 95], ["of", 99], ["the", 102], ["most", 106], ["common", 111], ["muscular", 118], ["dystrophies", 127], ["characterized", 139], ["by", 153], ["progressive", 156], ["skeletal", 168], ["muscle", 177], ["degeneration", 184], [".", 196], ["Despite", 198], ["great", 206], ["strides", 212], ["in", 220], ["understanding", 223], ["precise", 237], ["genetics", 245], ["of", 254], ["FSHD", 257], [",", 261], ["the", 263], ["molecular", 267], ["pathophysiology", 277], ["of", 293], ["the", 296], ["disease", 300], ["remains", 308], ["unclear", 316], [".", 323], ["One", 325], ["of", 329], ["the", 332], ["major", 336], ["limitations", 342], ["has", 354], ["been", 358], ["the", 363], ["availability", 367], ["of", 380], ["appropriate", 383], ["molecular", 395], ["tools", 405], ["to", 411], ["study", 414], ["DUX4", 420], ["protein", 425], [".", 432], ["In", 434], ["the", 437], ["present", 441], ["study", 449], [",", 454], ["we", 456], ["report", 459], ["the", 466], ["development", 470], ["of", 482], ["five", 485], ["new", 490], ["monoclonal", 494], ["antibodies", 505], ["targeted", 516], ["against", 525], ["the", 533], ["N-", 537], ["and", 540], ["C", 544], ["-", 545], ["termini", 546], ["of", 554], ["human", 557], ["DUX4", 563], [",", 567], ["and", 569], ["characterize", 573], ["their", 586], ["reactivity", 592], ["using", 603], ["Western", 609], ["blot", 617], ["and", 622], ["immunofluorescence", 626], ["staining", 645], [".", 653], ["Additionally", 655], [",", 667], ["we", 669], ["show", 672], ["that", 677], ["expression", 682], ["of", 693], ["the", 696], ["canonical", 700], ["full", 710], ["coding", 715], ["DUX4", 722], ["induces", 727], ["cell", 735], ["death", 740], ["in", 746], ["human", 749], ["primary", 755], ["muscle", 763], ["cells", 770], [",", 775], ["whereas", 777], ["the", 785], ["expression", 789], ["of", 800], ["a", 803], ["shorter", 805], ["splice", 813], ["form", 820], ["of", 825], ["DUX4", 828], ["results", 833], ["in", 841], ["no", 844], ["such", 847], ["toxicity", 852], [".", 860], ["Immunostaining", 862], ["with", 877], ["these", 882], ["new", 888], ["antibodies", 892], ["reveals", 903], ["a", 911], ["differential", 913], ["effect", 926], ["of", 933], ["two", 936], ["DUX4", 940], ["isoforms", 945], ["on", 954], ["human", 957], ["muscle", 963], ["cells", 970], [".", 975], ["These", 977], ["antibodies", 983], ["will", 994], ["provide", 999], ["an", 1007], ["excellent", 1010], ["tool", 1020], ["for", 1025], ["investigating", 1029], ["the", 1043], ["role", 1047], ["of", 1052], ["DUX4", 1055], ["in", 1060], ["FSHD", 1063], ["pathogenesis", 1068], [".", 1080]]}
{"context": "The subventricular zone of the rodent brain retains the capacity of generating new neurons in adulthood. The newly formed neuroblasts migrate rostrally toward the olfactory bulb, where they differentiate as granular and periglomerular interneurons. The reported presence of differentiated neurons expressing the neuronal isoform of nitric oxide synthase (NOS) in the periphery of the neurogenic region and the organization of their varicose axons as a network in which the precursors are immersed raised the hypothesis that endogenous nitric oxide (NO) may participate in the control of neurogenesis in the subventricular zone. Systemic administration of the NOS inhibitors N(omega)-nitro-L-arginine methyl ester or 7-nitroindazole to adult mice produced a dose- and time-dependent increase in the number of mitotic cells in the subventricular zone, rostral migratory stream, and olfactory bulb, but not in the dentate gyrus of the hippocampus, without affecting apoptosis. In the subventricular zone, this effect was exerted selectively on a precursor subpopulation expressing nestin but not neuronal or glial cell-specific proteins. In addition, in the olfactory bulb, analysis of maturation markers in the newly generated neurons indicated that chronic NOS inhibition caused a delay in neuronal differentiation. Postmitotic cell survival and migration were not affected when NO production was impaired. Our results suggest that NO, produced by nitrergic neurons in the adult mouse subventricular zone and olfactory bulb, exerts a negative control on the size of the undifferentiated precursor pool and promotes neuronal differentiation.", "qas": [{"question": "Which intermediate filament (IF) protein can be used as a non-specific marker of the neuronal precursor cells of the subventricular zone?", "answers": ["Nestin"], "qid": "ab3ff6a5a146419f8fd61b433587067c", "question_tokens": [["Which", 0], ["intermediate", 6], ["filament", 19], ["(", 28], ["IF", 29], [")", 31], ["protein", 33], ["can", 41], ["be", 45], ["used", 48], ["as", 53], ["a", 56], ["non", 58], ["-", 61], ["specific", 62], ["marker", 71], ["of", 78], ["the", 81], ["neuronal", 85], ["precursor", 94], ["cells", 104], ["of", 110], ["the", 113], ["subventricular", 117], ["zone", 132], ["?", 136]], "detected_answers": [{"text": "Nestin", "token_spans": [[173, 173]], "char_spans": [[1078, 1083]]}]}], "context_tokens": [["The", 0], ["subventricular", 4], ["zone", 19], ["of", 24], ["the", 27], ["rodent", 31], ["brain", 38], ["retains", 44], ["the", 52], ["capacity", 56], ["of", 65], ["generating", 68], ["new", 79], ["neurons", 83], ["in", 91], ["adulthood", 94], [".", 103], ["The", 105], ["newly", 109], ["formed", 115], ["neuroblasts", 122], ["migrate", 134], ["rostrally", 142], ["toward", 152], ["the", 159], ["olfactory", 163], ["bulb", 173], [",", 177], ["where", 179], ["they", 185], ["differentiate", 190], ["as", 204], ["granular", 207], ["and", 216], ["periglomerular", 220], ["interneurons", 235], [".", 247], ["The", 249], ["reported", 253], ["presence", 262], ["of", 271], ["differentiated", 274], ["neurons", 289], ["expressing", 297], ["the", 308], ["neuronal", 312], ["isoform", 321], ["of", 329], ["nitric", 332], ["oxide", 339], ["synthase", 345], ["(", 354], ["NOS", 355], [")", 358], ["in", 360], ["the", 363], ["periphery", 367], ["of", 377], ["the", 380], ["neurogenic", 384], ["region", 395], ["and", 402], ["the", 406], ["organization", 410], ["of", 423], ["their", 426], ["varicose", 432], ["axons", 441], ["as", 447], ["a", 450], ["network", 452], ["in", 460], ["which", 463], ["the", 469], ["precursors", 473], ["are", 484], ["immersed", 488], ["raised", 497], ["the", 504], ["hypothesis", 508], ["that", 519], ["endogenous", 524], ["nitric", 535], ["oxide", 542], ["(", 548], ["NO", 549], [")", 551], ["may", 553], ["participate", 557], ["in", 569], ["the", 572], ["control", 576], ["of", 584], ["neurogenesis", 587], ["in", 600], ["the", 603], ["subventricular", 607], ["zone", 622], [".", 626], ["Systemic", 628], ["administration", 637], ["of", 652], ["the", 655], ["NOS", 659], ["inhibitors", 663], ["N(omega)-nitro", 674], ["-", 688], ["L", 689], ["-", 690], ["arginine", 691], ["methyl", 700], ["ester", 707], ["or", 713], ["7-nitroindazole", 716], ["to", 732], ["adult", 735], ["mice", 741], ["produced", 746], ["a", 755], ["dose-", 757], ["and", 763], ["time", 767], ["-", 771], ["dependent", 772], ["increase", 782], ["in", 791], ["the", 794], ["number", 798], ["of", 805], ["mitotic", 808], ["cells", 816], ["in", 822], ["the", 825], ["subventricular", 829], ["zone", 844], [",", 848], ["rostral", 850], ["migratory", 858], ["stream", 868], [",", 874], ["and", 876], ["olfactory", 880], ["bulb", 890], [",", 894], ["but", 896], ["not", 900], ["in", 904], ["the", 907], ["dentate", 911], ["gyrus", 919], ["of", 925], ["the", 928], ["hippocampus", 932], [",", 943], ["without", 945], ["affecting", 953], ["apoptosis", 963], [".", 972], ["In", 974], ["the", 977], ["subventricular", 981], ["zone", 996], [",", 1000], ["this", 1002], ["effect", 1007], ["was", 1014], ["exerted", 1018], ["selectively", 1026], ["on", 1038], ["a", 1041], ["precursor", 1043], ["subpopulation", 1053], ["expressing", 1067], ["nestin", 1078], ["but", 1085], ["not", 1089], ["neuronal", 1093], ["or", 1102], ["glial", 1105], ["cell", 1111], ["-", 1115], ["specific", 1116], ["proteins", 1125], [".", 1133], ["In", 1135], ["addition", 1138], [",", 1146], ["in", 1148], ["the", 1151], ["olfactory", 1155], ["bulb", 1165], [",", 1169], ["analysis", 1171], ["of", 1180], ["maturation", 1183], ["markers", 1194], ["in", 1202], ["the", 1205], ["newly", 1209], ["generated", 1215], ["neurons", 1225], ["indicated", 1233], ["that", 1243], ["chronic", 1248], ["NOS", 1256], ["inhibition", 1260], ["caused", 1271], ["a", 1278], ["delay", 1280], ["in", 1286], ["neuronal", 1289], ["differentiation", 1298], [".", 1313], ["Postmitotic", 1315], ["cell", 1327], ["survival", 1332], ["and", 1341], ["migration", 1345], ["were", 1355], ["not", 1360], ["affected", 1364], ["when", 1373], ["NO", 1378], ["production", 1381], ["was", 1392], ["impaired", 1396], [".", 1404], ["Our", 1406], ["results", 1410], ["suggest", 1418], ["that", 1426], ["NO", 1431], [",", 1433], ["produced", 1435], ["by", 1444], ["nitrergic", 1447], ["neurons", 1457], ["in", 1465], ["the", 1468], ["adult", 1472], ["mouse", 1478], ["subventricular", 1484], ["zone", 1499], ["and", 1504], ["olfactory", 1508], ["bulb", 1518], [",", 1522], ["exerts", 1524], ["a", 1531], ["negative", 1533], ["control", 1542], ["on", 1550], ["the", 1553], ["size", 1557], ["of", 1562], ["the", 1565], ["undifferentiated", 1569], ["precursor", 1586], ["pool", 1596], ["and", 1601], ["promotes", 1605], ["neuronal", 1614], ["differentiation", 1623], [".", 1638]]}
{"context": "In breast cancer the development of metastasis is a major turning point in the treatment and outcome of the disease. Throughout tumour development, and especially in the development of metastasis, epithelial mesenchymal transition takes place. During this transformation into a mesenchymal phenotype, the tumour cells undergo a series of structural changes. The loss of structural integrity and adoption of mesenchymal filaments enables cells to detach from the epithelial cell layer and metastasise. Keratins form the intermediate filaments of the cytoskeleton and provide scaffold structures within cells. During cancer progression the intermediate filaments are reorganised, and dramatic changes are seen in their protein components. Keratins K8, K18, K19 and vimentin are intermediate filament proteins with altered expression profiles during tumour development. We have used in vivo and in vitro models to analyse changes in intermediate filament proteins. Antibody-based methods were used to study K8 levels and proteomic analysis to profile the protein content of metastatic breast cancer cell variants. K8 expression declines as human breast tumours progress into an invasive phenotype. Analysis of IF proteins indicated altered expression profiles of K8, K18, K19 and vimentin, with K8, K18, K19 expressed in high levels in the T47D and MCF-7 cell lines, whereas the highly metastatic cell lines expressed lower levels of K8 and K18 and no detectable K19. Vimentin showed reverse expression profile with T47D and MCF-7 cells having no detectable vimentin expression whereas the highly metastatic MDA-MB-231 and MDA-MB-436 showed high levels. Analysis of acetylation status using specific antibodies suggested acetylation occurred within the central coiled domain in the MCF-7 and T47D cells. Inhibition of tumour growth by tissue factor (TF) shRNA resulted in a dramatic re-elevation of expression of K8 in xenographs of the highly metastatic MDA-MB-436 line. Intermediate filament expression alters during epithelial mesenchymal transition. Identified post translational modifications may play a role in alterations seen in the organisation, solubility and stability of these filaments. Epithelial mesenchymal transition can be reversed and an epithelial phenotype re-established.", "qas": [{"question": "What are the structures formed when keratin molecules come together?", "answers": ["Intermediate filaments"], "qid": "0b44e46a198e44a3a793781a09543148", "question_tokens": [["What", 0], ["are", 5], ["the", 9], ["structures", 13], ["formed", 24], ["when", 31], ["keratin", 36], ["molecules", 44], ["come", 54], ["together", 59], ["?", 67]], "detected_answers": [{"text": "Intermediate filaments", "token_spans": [[82, 83], [98, 99]], "char_spans": [[519, 540], [638, 659]]}]}], "context_tokens": [["In", 0], ["breast", 3], ["cancer", 10], ["the", 17], ["development", 21], ["of", 33], ["metastasis", 36], ["is", 47], ["a", 50], ["major", 52], ["turning", 58], ["point", 66], ["in", 72], ["the", 75], ["treatment", 79], ["and", 89], ["outcome", 93], ["of", 101], ["the", 104], ["disease", 108], [".", 115], ["Throughout", 117], ["tumour", 128], ["development", 135], [",", 146], ["and", 148], ["especially", 152], ["in", 163], ["the", 166], ["development", 170], ["of", 182], ["metastasis", 185], [",", 195], ["epithelial", 197], ["mesenchymal", 208], ["transition", 220], ["takes", 231], ["place", 237], [".", 242], ["During", 244], ["this", 251], ["transformation", 256], ["into", 271], ["a", 276], ["mesenchymal", 278], ["phenotype", 290], [",", 299], ["the", 301], ["tumour", 305], ["cells", 312], ["undergo", 318], ["a", 326], ["series", 328], ["of", 335], ["structural", 338], ["changes", 349], [".", 356], ["The", 358], ["loss", 362], ["of", 367], ["structural", 370], ["integrity", 381], ["and", 391], ["adoption", 395], ["of", 404], ["mesenchymal", 407], ["filaments", 419], ["enables", 429], ["cells", 437], ["to", 443], ["detach", 446], ["from", 453], ["the", 458], ["epithelial", 462], ["cell", 473], ["layer", 478], ["and", 484], ["metastasise", 488], [".", 499], ["Keratins", 501], ["form", 510], ["the", 515], ["intermediate", 519], ["filaments", 532], ["of", 542], ["the", 545], ["cytoskeleton", 549], ["and", 562], ["provide", 566], ["scaffold", 574], ["structures", 583], ["within", 594], ["cells", 601], [".", 606], ["During", 608], ["cancer", 615], ["progression", 622], ["the", 634], ["intermediate", 638], ["filaments", 651], ["are", 661], ["reorganised", 665], [",", 676], ["and", 678], ["dramatic", 682], ["changes", 691], ["are", 699], ["seen", 703], ["in", 708], ["their", 711], ["protein", 717], ["components", 725], [".", 735], ["Keratins", 737], ["K8", 746], [",", 748], ["K18", 750], [",", 753], ["K19", 755], ["and", 759], ["vimentin", 763], ["are", 772], ["intermediate", 776], ["filament", 789], ["proteins", 798], ["with", 807], ["altered", 812], ["expression", 820], ["profiles", 831], ["during", 840], ["tumour", 847], ["development", 854], [".", 865], ["We", 867], ["have", 870], ["used", 875], ["in", 880], ["vivo", 883], ["and", 888], ["in", 892], ["vitro", 895], ["models", 901], ["to", 908], ["analyse", 911], ["changes", 919], ["in", 927], ["intermediate", 930], ["filament", 943], ["proteins", 952], [".", 960], ["Antibody", 962], ["-", 970], ["based", 971], ["methods", 977], ["were", 985], ["used", 990], ["to", 995], ["study", 998], ["K8", 1004], ["levels", 1007], ["and", 1014], ["proteomic", 1018], ["analysis", 1028], ["to", 1037], ["profile", 1040], ["the", 1048], ["protein", 1052], ["content", 1060], ["of", 1068], ["metastatic", 1071], ["breast", 1082], ["cancer", 1089], ["cell", 1096], ["variants", 1101], [".", 1109], ["K8", 1111], ["expression", 1114], ["declines", 1125], ["as", 1134], ["human", 1137], ["breast", 1143], ["tumours", 1150], ["progress", 1158], ["into", 1167], ["an", 1172], ["invasive", 1175], ["phenotype", 1184], [".", 1193], ["Analysis", 1195], ["of", 1204], ["IF", 1207], ["proteins", 1210], ["indicated", 1219], ["altered", 1229], ["expression", 1237], ["profiles", 1248], ["of", 1257], ["K8", 1260], [",", 1262], ["K18", 1264], [",", 1267], ["K19", 1269], ["and", 1273], ["vimentin", 1277], [",", 1285], ["with", 1287], ["K8", 1292], [",", 1294], ["K18", 1296], [",", 1299], ["K19", 1301], ["expressed", 1305], ["in", 1315], ["high", 1318], ["levels", 1323], ["in", 1330], ["the", 1333], ["T47D", 1337], ["and", 1342], ["MCF-7", 1346], ["cell", 1352], ["lines", 1357], [",", 1362], ["whereas", 1364], ["the", 1372], ["highly", 1376], ["metastatic", 1383], ["cell", 1394], ["lines", 1399], ["expressed", 1405], ["lower", 1415], ["levels", 1421], ["of", 1428], ["K8", 1431], ["and", 1434], ["K18", 1438], ["and", 1442], ["no", 1446], ["detectable", 1449], ["K19", 1460], [".", 1463], ["Vimentin", 1465], ["showed", 1474], ["reverse", 1481], ["expression", 1489], ["profile", 1500], ["with", 1508], ["T47D", 1513], ["and", 1518], ["MCF-7", 1522], ["cells", 1528], ["having", 1534], ["no", 1541], ["detectable", 1544], ["vimentin", 1555], ["expression", 1564], ["whereas", 1575], ["the", 1583], ["highly", 1587], ["metastatic", 1594], ["MDA", 1605], ["-", 1608], ["MB-231", 1609], ["and", 1616], ["MDA", 1620], ["-", 1623], ["MB-436", 1624], ["showed", 1631], ["high", 1638], ["levels", 1643], [".", 1649], ["Analysis", 1651], ["of", 1660], ["acetylation", 1663], ["status", 1675], ["using", 1682], ["specific", 1688], ["antibodies", 1697], ["suggested", 1708], ["acetylation", 1718], ["occurred", 1730], ["within", 1739], ["the", 1746], ["central", 1750], ["coiled", 1758], ["domain", 1765], ["in", 1772], ["the", 1775], ["MCF-7", 1779], ["and", 1785], ["T47D", 1789], ["cells", 1794], [".", 1799], ["Inhibition", 1801], ["of", 1812], ["tumour", 1815], ["growth", 1822], ["by", 1829], ["tissue", 1832], ["factor", 1839], ["(", 1846], ["TF", 1847], [")", 1849], ["shRNA", 1851], ["resulted", 1857], ["in", 1866], ["a", 1869], ["dramatic", 1871], ["re", 1880], ["-", 1882], ["elevation", 1883], ["of", 1893], ["expression", 1896], ["of", 1907], ["K8", 1910], ["in", 1913], ["xenographs", 1916], ["of", 1927], ["the", 1930], ["highly", 1934], ["metastatic", 1941], ["MDA", 1952], ["-", 1955], ["MB-436", 1956], ["line", 1963], [".", 1967], ["Intermediate", 1969], ["filament", 1982], ["expression", 1991], ["alters", 2002], ["during", 2009], ["epithelial", 2016], ["mesenchymal", 2027], ["transition", 2039], [".", 2049], ["Identified", 2051], ["post", 2062], ["translational", 2067], ["modifications", 2081], ["may", 2095], ["play", 2099], ["a", 2104], ["role", 2106], ["in", 2111], ["alterations", 2114], ["seen", 2126], ["in", 2131], ["the", 2134], ["organisation", 2138], [",", 2150], ["solubility", 2152], ["and", 2163], ["stability", 2167], ["of", 2177], ["these", 2180], ["filaments", 2186], [".", 2195], ["Epithelial", 2197], ["mesenchymal", 2208], ["transition", 2220], ["can", 2231], ["be", 2235], ["reversed", 2238], ["and", 2247], ["an", 2251], ["epithelial", 2254], ["phenotype", 2265], ["re", 2275], ["-", 2277], ["established", 2278], [".", 2289]]}
{"context": "The complex expression patterns observed for many genes are often regulated by distal transcription enhancers. Changes in the nucleotide sequences of enhancers may therefore lead to changes in gene expression, representing a central mechanism by which organisms evolve. With the development of the experimental technique of chromatin immunoprecipitation (ChIP), in which discrete regions of the genome bound by specific proteins can be identified, it is now possible to identify transcription factor binding events (putative cis-regulatory elements) in entire genomes. Comparing protein-DNA binding maps allows us, for the first time, to attempt to identify regulatory differences and infer global patterns of change in gene expression across species. Here, we review studies that used genome-wide ChIP to study the evolution of enhancers. The trend is one of high divergence of cis-regulatory elements between species, possibly compensated by extensive creation and loss of regulatory elements and rewiring of their target genes. We speculate on the meaning of the differences observed and discuss that although ChIP experiments identify the biochemical event of protein-DNA interaction, it cannot determine whether the event results in a biological function, and therefore more studies are required to establish the effect of divergence of binding events on species-specific gene expression.", "qas": [{"question": "Are human enhancers or promoters evolving faster?", "answers": ["enhancers"], "qid": "2127733422e64157bc1703f3baf19fbd", "question_tokens": [["Are", 0], ["human", 4], ["enhancers", 10], ["or", 20], ["promoters", 23], ["evolving", 33], ["faster", 42], ["?", 48]], "detected_answers": [{"text": "enhancers", "token_spans": [[22, 22], [139, 139], [14, 14]], "char_spans": [[150, 158], [829, 837], [100, 108]]}]}], "context_tokens": [["The", 0], ["complex", 4], ["expression", 12], ["patterns", 23], ["observed", 32], ["for", 41], ["many", 45], ["genes", 50], ["are", 56], ["often", 60], ["regulated", 66], ["by", 76], ["distal", 79], ["transcription", 86], ["enhancers", 100], [".", 109], ["Changes", 111], ["in", 119], ["the", 122], ["nucleotide", 126], ["sequences", 137], ["of", 147], ["enhancers", 150], ["may", 160], ["therefore", 164], ["lead", 174], ["to", 179], ["changes", 182], ["in", 190], ["gene", 193], ["expression", 198], [",", 208], ["representing", 210], ["a", 223], ["central", 225], ["mechanism", 233], ["by", 243], ["which", 246], ["organisms", 252], ["evolve", 262], [".", 268], ["With", 270], ["the", 275], ["development", 279], ["of", 291], ["the", 294], ["experimental", 298], ["technique", 311], ["of", 321], ["chromatin", 324], ["immunoprecipitation", 334], ["(", 354], ["ChIP", 355], [")", 359], [",", 360], ["in", 362], ["which", 365], ["discrete", 371], ["regions", 380], ["of", 388], ["the", 391], ["genome", 395], ["bound", 402], ["by", 408], ["specific", 411], ["proteins", 420], ["can", 429], ["be", 433], ["identified", 436], [",", 446], ["it", 448], ["is", 451], ["now", 454], ["possible", 458], ["to", 467], ["identify", 470], ["transcription", 479], ["factor", 493], ["binding", 500], ["events", 508], ["(", 515], ["putative", 516], ["cis", 525], ["-", 528], ["regulatory", 529], ["elements", 540], [")", 548], ["in", 550], ["entire", 553], ["genomes", 560], [".", 567], ["Comparing", 569], ["protein", 579], ["-", 586], ["DNA", 587], ["binding", 591], ["maps", 599], ["allows", 604], ["us", 611], [",", 613], ["for", 615], ["the", 619], ["first", 623], ["time", 629], [",", 633], ["to", 635], ["attempt", 638], ["to", 646], ["identify", 649], ["regulatory", 658], ["differences", 669], ["and", 681], ["infer", 685], ["global", 691], ["patterns", 698], ["of", 707], ["change", 710], ["in", 717], ["gene", 720], ["expression", 725], ["across", 736], ["species", 743], [".", 750], ["Here", 752], [",", 756], ["we", 758], ["review", 761], ["studies", 768], ["that", 776], ["used", 781], ["genome", 786], ["-", 792], ["wide", 793], ["ChIP", 798], ["to", 803], ["study", 806], ["the", 812], ["evolution", 816], ["of", 826], ["enhancers", 829], [".", 838], ["The", 840], ["trend", 844], ["is", 850], ["one", 853], ["of", 857], ["high", 860], ["divergence", 865], ["of", 876], ["cis", 879], ["-", 882], ["regulatory", 883], ["elements", 894], ["between", 903], ["species", 911], [",", 918], ["possibly", 920], ["compensated", 929], ["by", 941], ["extensive", 944], ["creation", 954], ["and", 963], ["loss", 967], ["of", 972], ["regulatory", 975], ["elements", 986], ["and", 995], ["rewiring", 999], ["of", 1008], ["their", 1011], ["target", 1017], ["genes", 1024], [".", 1029], ["We", 1031], ["speculate", 1034], ["on", 1044], ["the", 1047], ["meaning", 1051], ["of", 1059], ["the", 1062], ["differences", 1066], ["observed", 1078], ["and", 1087], ["discuss", 1091], ["that", 1099], ["although", 1104], ["ChIP", 1113], ["experiments", 1118], ["identify", 1130], ["the", 1139], ["biochemical", 1143], ["event", 1155], ["of", 1161], ["protein", 1164], ["-", 1171], ["DNA", 1172], ["interaction", 1176], [",", 1187], ["it", 1189], ["can", 1192], ["not", 1195], ["determine", 1199], ["whether", 1209], ["the", 1217], ["event", 1221], ["results", 1227], ["in", 1235], ["a", 1238], ["biological", 1240], ["function", 1251], [",", 1259], ["and", 1261], ["therefore", 1265], ["more", 1275], ["studies", 1280], ["are", 1288], ["required", 1292], ["to", 1301], ["establish", 1304], ["the", 1314], ["effect", 1318], ["of", 1325], ["divergence", 1328], ["of", 1339], ["binding", 1342], ["events", 1350], ["on", 1357], ["species", 1360], ["-", 1367], ["specific", 1368], ["gene", 1377], ["expression", 1382], [".", 1392]]}
{"context": "The transcriptional networks that regulate embryonic stem (ES) cell pluripotency and lineage specification are the subject of considerable attention. To date such studies have focused almost exclusively on protein-coding transcripts. However, recent transcriptome analyses show that the mammalian genome contains thousands of long noncoding RNAs (ncRNAs), many of which appear to be expressed in a developmentally regulated manner. The functions of these remain untested. To identify ncRNAs involved in ES cell biology, we used a custom-designed microarray to examine the expression profiles of mouse ES cells differentiating as embryoid bodies (EBs) over a 16-d time course. We identified 945 ncRNAs expressed during EB differentiation, of which 174 were differentially expressed, many correlating with pluripotency or specific differentiation events. Candidate ncRNAs were identified for further characterization by an integrated examination of expression profiles, genomic context, chromatin state, and promoter analysis. Many ncRNAs showed coordinated expression with genomically associated developmental genes, such as Dlx1, Dlx4, Gata6, and Ecsit. We examined two novel developmentally regulated ncRNAs, Evx1as and Hoxb5/6as, which are derived from homeotic loci and share similar expression patterns and localization in mouse embryos with their associated protein-coding genes. Using chromatin immunoprecipitation, we provide evidence that both ncRNAs are associated with trimethylated H3K4 histones and histone methyltransferase MLL1, suggesting a role in epigenetic regulation of homeotic loci during ES cell differentiation. Taken together, our data indicate that long ncRNAs are likely to be important in processes directing pluripotency and alternative differentiation programs, in some cases through engagement of the epigenetic machinery.", "qas": [{"question": "Which is the histone residue methylated by MLL1?", "answers": ["H3K4"], "qid": "7f852a929e6a4b24adcfac462afb1477", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["histone", 13], ["residue", 21], ["methylated", 29], ["by", 40], ["MLL1", 43], ["?", 47]], "detected_answers": [{"text": "H3K4", "token_spans": [[236, 236]], "char_spans": [[1493, 1496]]}]}], "context_tokens": [["The", 0], ["transcriptional", 4], ["networks", 20], ["that", 29], ["regulate", 34], ["embryonic", 43], ["stem", 53], ["(", 58], ["ES", 59], [")", 61], ["cell", 63], ["pluripotency", 68], ["and", 81], ["lineage", 85], ["specification", 93], ["are", 107], ["the", 111], ["subject", 115], ["of", 123], ["considerable", 126], ["attention", 139], [".", 148], ["To", 150], ["date", 153], ["such", 158], ["studies", 163], ["have", 171], ["focused", 176], ["almost", 184], ["exclusively", 191], ["on", 203], ["protein", 206], ["-", 213], ["coding", 214], ["transcripts", 221], [".", 232], ["However", 234], [",", 241], ["recent", 243], ["transcriptome", 250], ["analyses", 264], ["show", 273], ["that", 278], ["the", 283], ["mammalian", 287], ["genome", 297], ["contains", 304], ["thousands", 313], ["of", 323], ["long", 326], ["noncoding", 331], ["RNAs", 341], ["(", 346], ["ncRNAs", 347], [")", 353], [",", 354], ["many", 356], ["of", 361], ["which", 364], ["appear", 370], ["to", 377], ["be", 380], ["expressed", 383], ["in", 393], ["a", 396], ["developmentally", 398], ["regulated", 414], ["manner", 424], [".", 430], ["The", 432], ["functions", 436], ["of", 446], ["these", 449], ["remain", 455], ["untested", 462], [".", 470], ["To", 472], ["identify", 475], ["ncRNAs", 484], ["involved", 491], ["in", 500], ["ES", 503], ["cell", 506], ["biology", 511], [",", 518], ["we", 520], ["used", 523], ["a", 528], ["custom", 530], ["-", 536], ["designed", 537], ["microarray", 546], ["to", 557], ["examine", 560], ["the", 568], ["expression", 572], ["profiles", 583], ["of", 592], ["mouse", 595], ["ES", 601], ["cells", 604], ["differentiating", 610], ["as", 626], ["embryoid", 629], ["bodies", 638], ["(", 645], ["EBs", 646], [")", 649], ["over", 651], ["a", 656], ["16-d", 658], ["time", 663], ["course", 668], [".", 674], ["We", 676], ["identified", 679], ["945", 690], ["ncRNAs", 694], ["expressed", 701], ["during", 711], ["EB", 718], ["differentiation", 721], [",", 736], ["of", 738], ["which", 741], ["174", 747], ["were", 751], ["differentially", 756], ["expressed", 771], [",", 780], ["many", 782], ["correlating", 787], ["with", 799], ["pluripotency", 804], ["or", 817], ["specific", 820], ["differentiation", 829], ["events", 845], [".", 851], ["Candidate", 853], ["ncRNAs", 863], ["were", 870], ["identified", 875], ["for", 886], ["further", 890], ["characterization", 898], ["by", 915], ["an", 918], ["integrated", 921], ["examination", 932], ["of", 944], ["expression", 947], ["profiles", 958], [",", 966], ["genomic", 968], ["context", 976], [",", 983], ["chromatin", 985], ["state", 995], [",", 1000], ["and", 1002], ["promoter", 1006], ["analysis", 1015], [".", 1023], ["Many", 1025], ["ncRNAs", 1030], ["showed", 1037], ["coordinated", 1044], ["expression", 1056], ["with", 1067], ["genomically", 1072], ["associated", 1084], ["developmental", 1095], ["genes", 1109], [",", 1114], ["such", 1116], ["as", 1121], ["Dlx1", 1124], [",", 1128], ["Dlx4", 1130], [",", 1134], ["Gata6", 1136], [",", 1141], ["and", 1143], ["Ecsit", 1147], [".", 1152], ["We", 1154], ["examined", 1157], ["two", 1166], ["novel", 1170], ["developmentally", 1176], ["regulated", 1192], ["ncRNAs", 1202], [",", 1208], ["Evx1as", 1210], ["and", 1217], ["Hoxb5/6as", 1221], [",", 1230], ["which", 1232], ["are", 1238], ["derived", 1242], ["from", 1250], ["homeotic", 1255], ["loci", 1264], ["and", 1269], ["share", 1273], ["similar", 1279], ["expression", 1287], ["patterns", 1298], ["and", 1307], ["localization", 1311], ["in", 1324], ["mouse", 1327], ["embryos", 1333], ["with", 1341], ["their", 1346], ["associated", 1352], ["protein", 1363], ["-", 1370], ["coding", 1371], ["genes", 1378], [".", 1383], ["Using", 1385], ["chromatin", 1391], ["immunoprecipitation", 1401], [",", 1420], ["we", 1422], ["provide", 1425], ["evidence", 1433], ["that", 1442], ["both", 1447], ["ncRNAs", 1452], ["are", 1459], ["associated", 1463], ["with", 1474], ["trimethylated", 1479], ["H3K4", 1493], ["histones", 1498], ["and", 1507], ["histone", 1511], ["methyltransferase", 1519], ["MLL1", 1537], [",", 1541], ["suggesting", 1543], ["a", 1554], ["role", 1556], ["in", 1561], ["epigenetic", 1564], ["regulation", 1575], ["of", 1586], ["homeotic", 1589], ["loci", 1598], ["during", 1603], ["ES", 1610], ["cell", 1613], ["differentiation", 1618], [".", 1633], ["Taken", 1635], ["together", 1641], [",", 1649], ["our", 1651], ["data", 1655], ["indicate", 1660], ["that", 1669], ["long", 1674], ["ncRNAs", 1679], ["are", 1686], ["likely", 1690], ["to", 1697], ["be", 1700], ["important", 1703], ["in", 1713], ["processes", 1716], ["directing", 1726], ["pluripotency", 1736], ["and", 1749], ["alternative", 1753], ["differentiation", 1765], ["programs", 1781], [",", 1789], ["in", 1791], ["some", 1794], ["cases", 1799], ["through", 1805], ["engagement", 1813], ["of", 1824], ["the", 1827], ["epigenetic", 1831], ["machinery", 1842], [".", 1851]]}
{"context": "The Swc4p protein, encoded by an essential gene, is shared by two chromatin-remodeling complexes in Saccharomyces cerevisiae cells: NuA4 (nucleosome acetyltransferase of H4) and SWR1. The SWR1 complex catalyzes ATP-dependent exchange of the nucleosomal histone H2A for H2AZ (Htz1p). The activity of NuA4 is responsible mainly for the acetylation of the H4 histone but also for the acetylation of H2A and H2AZ. In this work we investigated the role of the Swc4p protein. Using random mutagenesis we isolated a collection of swc4 mutants and showed that the essential function of Swc4p resides in its N-terminal part, within the first 269 amino acids of the 476-amino acid-long protein. We also demonstrated that Swc4p is able to accommodate numerous mutations without losing its functionality under standard growth conditions. However, when swc4 mutants were exposed to methyl methanesulfonate (MMS), hydroxyurea or benomyl, severe growth deficiencies appeared, pointing to an involvement of Swc4p in many chromatin-based processes. The mutants' phenotypes did not result from an impairment of histone acetylation, as in the mutant which bears the shortest isolated variant of truncated Swc4p, the level of overall H4 acetylation was unchanged.", "qas": [{"question": "Which protein mediates the replacement of H2A by H2A.Z in the yeast Saccharomyces cerevisiae?", "answers": ["SWR1"], "qid": "464136c1262c4537a73e251dcc6d6f54", "question_tokens": [["Which", 0], ["protein", 6], ["mediates", 14], ["the", 23], ["replacement", 27], ["of", 39], ["H2A", 42], ["by", 46], ["H2A.Z", 49], ["in", 55], ["the", 58], ["yeast", 62], ["Saccharomyces", 68], ["cerevisiae", 82], ["?", 92]], "detected_answers": [{"text": "SWR1", "token_spans": [[31, 31], [34, 34]], "char_spans": [[178, 181], [188, 191]]}]}], "context_tokens": [["The", 0], ["Swc4p", 4], ["protein", 10], [",", 17], ["encoded", 19], ["by", 27], ["an", 30], ["essential", 33], ["gene", 43], [",", 47], ["is", 49], ["shared", 52], ["by", 59], ["two", 62], ["chromatin", 66], ["-", 75], ["remodeling", 76], ["complexes", 87], ["in", 97], ["Saccharomyces", 100], ["cerevisiae", 114], ["cells", 125], [":", 130], ["NuA4", 132], ["(", 137], ["nucleosome", 138], ["acetyltransferase", 149], ["of", 167], ["H4", 170], [")", 172], ["and", 174], ["SWR1", 178], [".", 182], ["The", 184], ["SWR1", 188], ["complex", 193], ["catalyzes", 201], ["ATP", 211], ["-", 214], ["dependent", 215], ["exchange", 225], ["of", 234], ["the", 237], ["nucleosomal", 241], ["histone", 253], ["H2A", 261], ["for", 265], ["H2AZ", 269], ["(", 274], ["Htz1p", 275], [")", 280], [".", 281], ["The", 283], ["activity", 287], ["of", 296], ["NuA4", 299], ["is", 304], ["responsible", 307], ["mainly", 319], ["for", 326], ["the", 330], ["acetylation", 334], ["of", 346], ["the", 349], ["H4", 353], ["histone", 356], ["but", 364], ["also", 368], ["for", 373], ["the", 377], ["acetylation", 381], ["of", 393], ["H2A", 396], ["and", 400], ["H2AZ", 404], [".", 408], ["In", 410], ["this", 413], ["work", 418], ["we", 423], ["investigated", 426], ["the", 439], ["role", 443], ["of", 448], ["the", 451], ["Swc4p", 455], ["protein", 461], [".", 468], ["Using", 470], ["random", 476], ["mutagenesis", 483], ["we", 495], ["isolated", 498], ["a", 507], ["collection", 509], ["of", 520], ["swc4", 523], ["mutants", 528], ["and", 536], ["showed", 540], ["that", 547], ["the", 552], ["essential", 556], ["function", 566], ["of", 575], ["Swc4p", 578], ["resides", 584], ["in", 592], ["its", 595], ["N", 599], ["-", 600], ["terminal", 601], ["part", 610], [",", 614], ["within", 616], ["the", 623], ["first", 627], ["269", 633], ["amino", 637], ["acids", 643], ["of", 649], ["the", 652], ["476-amino", 656], ["acid", 666], ["-", 670], ["long", 671], ["protein", 676], [".", 683], ["We", 685], ["also", 688], ["demonstrated", 693], ["that", 706], ["Swc4p", 711], ["is", 717], ["able", 720], ["to", 725], ["accommodate", 728], ["numerous", 740], ["mutations", 749], ["without", 759], ["losing", 767], ["its", 774], ["functionality", 778], ["under", 792], ["standard", 798], ["growth", 807], ["conditions", 814], [".", 824], ["However", 826], [",", 833], ["when", 835], ["swc4", 840], ["mutants", 845], ["were", 853], ["exposed", 858], ["to", 866], ["methyl", 869], ["methanesulfonate", 876], ["(", 893], ["MMS", 894], [")", 897], [",", 898], ["hydroxyurea", 900], ["or", 912], ["benomyl", 915], [",", 922], ["severe", 924], ["growth", 931], ["deficiencies", 938], ["appeared", 951], [",", 959], ["pointing", 961], ["to", 970], ["an", 973], ["involvement", 976], ["of", 988], ["Swc4p", 991], ["in", 997], ["many", 1000], ["chromatin", 1005], ["-", 1014], ["based", 1015], ["processes", 1021], [".", 1030], ["The", 1032], ["mutants", 1036], ["'", 1043], ["phenotypes", 1045], ["did", 1056], ["not", 1060], ["result", 1064], ["from", 1071], ["an", 1076], ["impairment", 1079], ["of", 1090], ["histone", 1093], ["acetylation", 1101], [",", 1112], ["as", 1114], ["in", 1117], ["the", 1120], ["mutant", 1124], ["which", 1131], ["bears", 1137], ["the", 1143], ["shortest", 1147], ["isolated", 1156], ["variant", 1165], ["of", 1173], ["truncated", 1176], ["Swc4p", 1186], [",", 1191], ["the", 1193], ["level", 1197], ["of", 1203], ["overall", 1206], ["H4", 1214], ["acetylation", 1217], ["was", 1229], ["unchanged", 1233], [".", 1242]]}
{"context": "In Russia, an intradermal Diaskintest\u00ae drug has been designed, which is a recombinant tuberculosis allergen based on M. tuberculosis-- specific proteins: ESAT-6 and CFP-10 produced by a genetically modified Escherichia coli culture. Diaskintest\u00ae test and Mantoux test with 2TE PPD-L were concurrently carried out in 300 children and adolescents with tuberculosis and followed up in risk groups at a tuberculosis dispensary to determine the sensitivity of the new skin test in active tuberculosis infection. Diaskintest\u00ae showed a high sensitivity not only in active tuberculosis, but also in occult, the so-called latent, tuberculosis infection. This is suggested by the following evidence. The high percentage (83.8%) of positive responses to Diaskintest\u00ae is noted in children and adolescents with tuberculosis, receiving an intensive course of chemotherapy. Negative tests were observed only in minor forms at the resolution stage. In the children who had completed treatment, positive tests were seen in 78.3%, moreover in those with prior tuberculosis of intrathoracic lymph nodes; negative tests were observed not earlier than 18 months after start of treatment. The highest sensitivity of Diaskintest\u00ae was shown in children with early primary tuberculosis infection and through family contact with bacteria-excreting subjects (91.7%). These children may be judged with the highest assurance to have latent tuberculosis infection, the population of which is in an active state at the moment of the study. The children with early primary tuberculosis infection, but in no family contact with bacteria-excreting individuals, showed a lower percentage of positive responses to Diaskintest\u00ae both before (37.5%) and after (10%) treatment, which suggests that there must be a lower bacterial burden in the child. A high percentage of positive responses to Diaskintest\u00ae (76.2%) were found in subjects with hyperergic reactions to tuberculin. These were in only 16.7% in the group of patients receiving preventive therapy. In children and adolescents with a persistent positive Mantoux test (for more than 3 years), the response to Diaskintest\u00ae was negative in most cases since in early infection when mycobacteria propagated, the reaction to the drug was positive, but as 3 years pass the probability of the infection transition to the persistence stage is high--at that time the response to Diaskintest\u00ae becomes negative. Diaskintest\u00ae induces no delayed hypersensitivity associated with BCG vaccination, suggesting its high specificity. There were no positive reactions in patients with nonspecific lung diseases.", "qas": [{"question": "The Mantoux test detects what latent infection/disease?", "answers": ["tuberculosis"], "qid": "bceaab52532745f2b18e2703008352a9", "question_tokens": [["The", 0], ["Mantoux", 4], ["test", 12], ["detects", 17], ["what", 25], ["latent", 30], ["infection", 37], ["/", 46], ["disease", 47], ["?", 54]], "detected_answers": [{"text": "tuberculosis", "token_spans": [[16, 16], [80, 80], [67, 67], [21, 21], [58, 58], [93, 93], [106, 106], [213, 213], [180, 180], [137, 137], [265, 265], [241, 241]], "char_spans": [[86, 97], [483, 494], [399, 410], [120, 133], [350, 361], [565, 576], [621, 632], [1248, 1259], [1042, 1053], [798, 809], [1541, 1552], [1411, 1422]]}]}], "context_tokens": [["In", 0], ["Russia", 3], [",", 9], ["an", 11], ["intradermal", 14], ["Diaskintest", 26], ["\u00ae", 37], ["drug", 39], ["has", 44], ["been", 48], ["designed", 53], [",", 61], ["which", 63], ["is", 69], ["a", 72], ["recombinant", 74], ["tuberculosis", 86], ["allergen", 99], ["based", 108], ["on", 114], ["M.", 117], ["tuberculosis--", 120], ["specific", 135], ["proteins", 144], [":", 152], ["ESAT-6", 154], ["and", 161], ["CFP-10", 165], ["produced", 172], ["by", 181], ["a", 184], ["genetically", 186], ["modified", 198], ["Escherichia", 207], ["coli", 219], ["culture", 224], [".", 231], ["Diaskintest", 233], ["\u00ae", 244], ["test", 246], ["and", 251], ["Mantoux", 255], ["test", 263], ["with", 268], ["2TE", 273], ["PPD", 277], ["-", 280], ["L", 281], ["were", 283], ["concurrently", 288], ["carried", 301], ["out", 309], ["in", 313], ["300", 316], ["children", 320], ["and", 329], ["adolescents", 333], ["with", 345], ["tuberculosis", 350], ["and", 363], ["followed", 367], ["up", 376], ["in", 379], ["risk", 382], ["groups", 387], ["at", 394], ["a", 397], ["tuberculosis", 399], ["dispensary", 412], ["to", 423], ["determine", 426], ["the", 436], ["sensitivity", 440], ["of", 452], ["the", 455], ["new", 459], ["skin", 463], ["test", 468], ["in", 473], ["active", 476], ["tuberculosis", 483], ["infection", 496], [".", 505], ["Diaskintest", 507], ["\u00ae", 518], ["showed", 520], ["a", 527], ["high", 529], ["sensitivity", 534], ["not", 546], ["only", 550], ["in", 555], ["active", 558], ["tuberculosis", 565], [",", 577], ["but", 579], ["also", 583], ["in", 588], ["occult", 591], [",", 597], ["the", 599], ["so", 603], ["-", 605], ["called", 606], ["latent", 613], [",", 619], ["tuberculosis", 621], ["infection", 634], [".", 643], ["This", 645], ["is", 650], ["suggested", 653], ["by", 663], ["the", 666], ["following", 670], ["evidence", 680], [".", 688], ["The", 690], ["high", 694], ["percentage", 699], ["(", 710], ["83.8", 711], ["%", 715], [")", 716], ["of", 718], ["positive", 721], ["responses", 730], ["to", 740], ["Diaskintest", 743], ["\u00ae", 754], ["is", 756], ["noted", 759], ["in", 765], ["children", 768], ["and", 777], ["adolescents", 781], ["with", 793], ["tuberculosis", 798], [",", 810], ["receiving", 812], ["an", 822], ["intensive", 825], ["course", 835], ["of", 842], ["chemotherapy", 845], [".", 857], ["Negative", 859], ["tests", 868], ["were", 874], ["observed", 879], ["only", 888], ["in", 893], ["minor", 896], ["forms", 902], ["at", 908], ["the", 911], ["resolution", 915], ["stage", 926], [".", 931], ["In", 933], ["the", 936], ["children", 940], ["who", 949], ["had", 953], ["completed", 957], ["treatment", 967], [",", 976], ["positive", 978], ["tests", 987], ["were", 993], ["seen", 998], ["in", 1003], ["78.3", 1006], ["%", 1010], [",", 1011], ["moreover", 1013], ["in", 1022], ["those", 1025], ["with", 1031], ["prior", 1036], ["tuberculosis", 1042], ["of", 1055], ["intrathoracic", 1058], ["lymph", 1072], ["nodes", 1078], [";", 1083], ["negative", 1085], ["tests", 1094], ["were", 1100], ["observed", 1105], ["not", 1114], ["earlier", 1118], ["than", 1126], ["18", 1131], ["months", 1134], ["after", 1141], ["start", 1147], ["of", 1153], ["treatment", 1156], [".", 1165], ["The", 1167], ["highest", 1171], ["sensitivity", 1179], ["of", 1191], ["Diaskintest", 1194], ["\u00ae", 1205], ["was", 1207], ["shown", 1211], ["in", 1217], ["children", 1220], ["with", 1229], ["early", 1234], ["primary", 1240], ["tuberculosis", 1248], ["infection", 1261], ["and", 1271], ["through", 1275], ["family", 1283], ["contact", 1290], ["with", 1298], ["bacteria", 1303], ["-", 1311], ["excreting", 1312], ["subjects", 1322], ["(", 1331], ["91.7", 1332], ["%", 1336], [")", 1337], [".", 1338], ["These", 1340], ["children", 1346], ["may", 1355], ["be", 1359], ["judged", 1362], ["with", 1369], ["the", 1374], ["highest", 1378], ["assurance", 1386], ["to", 1396], ["have", 1399], ["latent", 1404], ["tuberculosis", 1411], ["infection", 1424], [",", 1433], ["the", 1435], ["population", 1439], ["of", 1450], ["which", 1453], ["is", 1459], ["in", 1462], ["an", 1465], ["active", 1468], ["state", 1475], ["at", 1481], ["the", 1484], ["moment", 1488], ["of", 1495], ["the", 1498], ["study", 1502], [".", 1507], ["The", 1509], ["children", 1513], ["with", 1522], ["early", 1527], ["primary", 1533], ["tuberculosis", 1541], ["infection", 1554], [",", 1563], ["but", 1565], ["in", 1569], ["no", 1572], ["family", 1575], ["contact", 1582], ["with", 1590], ["bacteria", 1595], ["-", 1603], ["excreting", 1604], ["individuals", 1614], [",", 1625], ["showed", 1627], ["a", 1634], ["lower", 1636], ["percentage", 1642], ["of", 1653], ["positive", 1656], ["responses", 1665], ["to", 1675], ["Diaskintest", 1678], ["\u00ae", 1689], ["both", 1691], ["before", 1696], ["(", 1703], ["37.5", 1704], ["%", 1708], [")", 1709], ["and", 1711], ["after", 1715], ["(", 1721], ["10", 1722], ["%", 1724], [")", 1725], ["treatment", 1727], [",", 1736], ["which", 1738], ["suggests", 1744], ["that", 1753], ["there", 1758], ["must", 1764], ["be", 1769], ["a", 1772], ["lower", 1774], ["bacterial", 1780], ["burden", 1790], ["in", 1797], ["the", 1800], ["child", 1804], [".", 1809], ["A", 1811], ["high", 1813], ["percentage", 1818], ["of", 1829], ["positive", 1832], ["responses", 1841], ["to", 1851], ["Diaskintest", 1854], ["\u00ae", 1865], ["(", 1867], ["76.2", 1868], ["%", 1872], [")", 1873], ["were", 1875], ["found", 1880], ["in", 1886], ["subjects", 1889], ["with", 1898], ["hyperergic", 1903], ["reactions", 1914], ["to", 1924], ["tuberculin", 1927], [".", 1937], ["These", 1939], ["were", 1945], ["in", 1950], ["only", 1953], ["16.7", 1958], ["%", 1962], ["in", 1964], ["the", 1967], ["group", 1971], ["of", 1977], ["patients", 1980], ["receiving", 1989], ["preventive", 1999], ["therapy", 2010], [".", 2017], ["In", 2019], ["children", 2022], ["and", 2031], ["adolescents", 2035], ["with", 2047], ["a", 2052], ["persistent", 2054], ["positive", 2065], ["Mantoux", 2074], ["test", 2082], ["(", 2087], ["for", 2088], ["more", 2092], ["than", 2097], ["3", 2102], ["years", 2104], [")", 2109], [",", 2110], ["the", 2112], ["response", 2116], ["to", 2125], ["Diaskintest", 2128], ["\u00ae", 2139], ["was", 2141], ["negative", 2145], ["in", 2154], ["most", 2157], ["cases", 2162], ["since", 2168], ["in", 2174], ["early", 2177], ["infection", 2183], ["when", 2193], ["mycobacteria", 2198], ["propagated", 2211], [",", 2221], ["the", 2223], ["reaction", 2227], ["to", 2236], ["the", 2239], ["drug", 2243], ["was", 2248], ["positive", 2252], [",", 2260], ["but", 2262], ["as", 2266], ["3", 2269], ["years", 2271], ["pass", 2277], ["the", 2282], ["probability", 2286], ["of", 2298], ["the", 2301], ["infection", 2305], ["transition", 2315], ["to", 2326], ["the", 2329], ["persistence", 2333], ["stage", 2345], ["is", 2351], ["high", 2354], ["--", 2358], ["at", 2360], ["that", 2363], ["time", 2368], ["the", 2373], ["response", 2377], ["to", 2386], ["Diaskintest", 2389], ["\u00ae", 2400], ["becomes", 2402], ["negative", 2410], [".", 2418], ["Diaskintest", 2420], ["\u00ae", 2431], ["induces", 2433], ["no", 2441], ["delayed", 2444], ["hypersensitivity", 2452], ["associated", 2469], ["with", 2480], ["BCG", 2485], ["vaccination", 2489], [",", 2500], ["suggesting", 2502], ["its", 2513], ["high", 2517], ["specificity", 2522], [".", 2533], ["There", 2535], ["were", 2541], ["no", 2546], ["positive", 2549], ["reactions", 2558], ["in", 2568], ["patients", 2571], ["with", 2580], ["nonspecific", 2585], ["lung", 2597], ["diseases", 2602], [".", 2610]]}
{"context": "The methylation of lysine residues of histones plays a pivotal role in the regulation of chromatin structure and gene expression. Here, we report two crystal structures of SET7/9, a histone methyltransferase (HMTase) that transfers methyl groups to Lys4 of histone H3, in complex with S-adenosyl-L-methionine (AdoMet) determined at 1.7 and 2.3 A resolution. The structures reveal an active site consisting of: (i) a binding pocket between the SET domain and a c-SET helix where an AdoMet molecule in an unusual conformation binds; (ii) a narrow substrate-specific channel that only unmethylated lysine residues can access; and (iii) a catalytic tyrosine residue. The methyl group of AdoMet is directed to the narrow channel where a substrate lysine enters from the opposite side. We demonstrate that SET7/9 can transfer two but not three methyl groups to unmodified Lys4 of H3 without substrate dissociation. The unusual features of the SET domain-containing HMTase discriminate between the un- and methylated lysine substrate, and the methylation sites for the histone H3 tail.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "56ed50d7657b481ea0e2512c19bb0438", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[85, 86], [176, 177]], "char_spans": [[443, 452], [937, 946]]}]}], "context_tokens": [["The", 0], ["methylation", 4], ["of", 16], ["lysine", 19], ["residues", 26], ["of", 35], ["histones", 38], ["plays", 47], ["a", 53], ["pivotal", 55], ["role", 63], ["in", 68], ["the", 71], ["regulation", 75], ["of", 86], ["chromatin", 89], ["structure", 99], ["and", 109], ["gene", 113], ["expression", 118], [".", 128], ["Here", 130], [",", 134], ["we", 136], ["report", 139], ["two", 146], ["crystal", 150], ["structures", 158], ["of", 169], ["SET7/9", 172], [",", 178], ["a", 180], ["histone", 182], ["methyltransferase", 190], ["(", 208], ["HMTase", 209], [")", 215], ["that", 217], ["transfers", 222], ["methyl", 232], ["groups", 239], ["to", 246], ["Lys4", 249], ["of", 254], ["histone", 257], ["H3", 265], [",", 267], ["in", 269], ["complex", 272], ["with", 280], ["S", 285], ["-", 286], ["adenosyl", 287], ["-", 295], ["L", 296], ["-", 297], ["methionine", 298], ["(", 309], ["AdoMet", 310], [")", 316], ["determined", 318], ["at", 329], ["1.7", 332], ["and", 336], ["2.3", 340], ["A", 344], ["resolution", 346], [".", 356], ["The", 358], ["structures", 362], ["reveal", 373], ["an", 380], ["active", 383], ["site", 390], ["consisting", 395], ["of", 406], [":", 408], ["(", 410], ["i", 411], [")", 412], ["a", 414], ["binding", 416], ["pocket", 424], ["between", 431], ["the", 439], ["SET", 443], ["domain", 447], ["and", 454], ["a", 458], ["c", 460], ["-", 461], ["SET", 462], ["helix", 466], ["where", 472], ["an", 478], ["AdoMet", 481], ["molecule", 488], ["in", 497], ["an", 500], ["unusual", 503], ["conformation", 511], ["binds", 524], [";", 529], ["(", 531], ["ii", 532], [")", 534], ["a", 536], ["narrow", 538], ["substrate", 545], ["-", 554], ["specific", 555], ["channel", 564], ["that", 572], ["only", 577], ["unmethylated", 582], ["lysine", 595], ["residues", 602], ["can", 611], ["access", 615], [";", 621], ["and", 623], ["(", 627], ["iii", 628], [")", 631], ["a", 633], ["catalytic", 635], ["tyrosine", 645], ["residue", 654], [".", 661], ["The", 663], ["methyl", 667], ["group", 674], ["of", 680], ["AdoMet", 683], ["is", 690], ["directed", 693], ["to", 702], ["the", 705], ["narrow", 709], ["channel", 716], ["where", 724], ["a", 730], ["substrate", 732], ["lysine", 742], ["enters", 749], ["from", 756], ["the", 761], ["opposite", 765], ["side", 774], [".", 778], ["We", 780], ["demonstrate", 783], ["that", 795], ["SET7/9", 800], ["can", 807], ["transfer", 811], ["two", 820], ["but", 824], ["not", 828], ["three", 832], ["methyl", 838], ["groups", 845], ["to", 852], ["unmodified", 855], ["Lys4", 866], ["of", 871], ["H3", 874], ["without", 877], ["substrate", 885], ["dissociation", 895], [".", 907], ["The", 909], ["unusual", 913], ["features", 921], ["of", 930], ["the", 933], ["SET", 937], ["domain", 941], ["-", 947], ["containing", 948], ["HMTase", 959], ["discriminate", 966], ["between", 979], ["the", 987], ["un-", 991], ["and", 995], ["methylated", 999], ["lysine", 1010], ["substrate", 1017], [",", 1026], ["and", 1028], ["the", 1032], ["methylation", 1036], ["sites", 1048], ["for", 1054], ["the", 1058], ["histone", 1062], ["H3", 1070], ["tail", 1073], [".", 1077]]}
{"context": "Approximately 2-4% of genetic material in human populations outside Africa is derived from Neanderthals who interbred with anatomically modern humans. Recent studies have shown that this Neanderthal DNA is depleted around functional genomic regions; this has been suggested to be a consequence of harmful epistatic interactions between human and Neanderthal alleles. However, using published estimates of Neanderthal inbreeding and the distribution of mutational fitness effects, we infer that Neanderthals had at least 40% lower fitness than humans on average; this increased load predicts the reduction in Neanderthal introgression around genes without the need to invoke epistasis. We also predict a residual Neanderthal mutational load in non-Africans, leading to a fitness reduction of at least 0.5%. This effect of Neanderthal admixture has been left out of previous debate on mutation load differences between Africans and non-Africans. We also show that if many deleterious mutations are recessive, the Neanderthal admixture fraction could increase over time due to the protective effect of Neanderthal haplotypes against deleterious alleles that arose recently in the human population. This might partially explain why so many organisms retain gene flow from other species and appear to derive adaptive benefits from introgression.", "qas": [{"question": "What percentage of Homo sapiens DNA is of Neanderthal origin?", "answers": ["2-4%"], "qid": "483a3885738d4b65a527e3fd3445ef78", "question_tokens": [["What", 0], ["percentage", 5], ["of", 16], ["Homo", 19], ["sapiens", 24], ["DNA", 32], ["is", 36], ["of", 39], ["Neanderthal", 42], ["origin", 54], ["?", 60]], "detected_answers": [{"text": "2-4%", "token_spans": [[1, 3]], "char_spans": [[14, 16]]}]}], "context_tokens": [["Approximately", 0], ["2", 14], ["-", 15], ["4", 16], ["%", 17], ["of", 19], ["genetic", 22], ["material", 30], ["in", 39], ["human", 42], ["populations", 48], ["outside", 60], ["Africa", 68], ["is", 75], ["derived", 78], ["from", 86], ["Neanderthals", 91], ["who", 104], ["interbred", 108], ["with", 118], ["anatomically", 123], ["modern", 136], ["humans", 143], [".", 149], ["Recent", 151], ["studies", 158], ["have", 166], ["shown", 171], ["that", 177], ["this", 182], ["Neanderthal", 187], ["DNA", 199], ["is", 203], ["depleted", 206], ["around", 215], ["functional", 222], ["genomic", 233], ["regions", 241], [";", 248], ["this", 250], ["has", 255], ["been", 259], ["suggested", 264], ["to", 274], ["be", 277], ["a", 280], ["consequence", 282], ["of", 294], ["harmful", 297], ["epistatic", 305], ["interactions", 315], ["between", 328], ["human", 336], ["and", 342], ["Neanderthal", 346], ["alleles", 358], [".", 365], ["However", 367], [",", 374], ["using", 376], ["published", 382], ["estimates", 392], ["of", 402], ["Neanderthal", 405], ["inbreeding", 417], ["and", 428], ["the", 432], ["distribution", 436], ["of", 449], ["mutational", 452], ["fitness", 463], ["effects", 471], [",", 478], ["we", 480], ["infer", 483], ["that", 489], ["Neanderthals", 494], ["had", 507], ["at", 511], ["least", 514], ["40", 520], ["%", 522], ["lower", 524], ["fitness", 530], ["than", 538], ["humans", 543], ["on", 550], ["average", 553], [";", 560], ["this", 562], ["increased", 567], ["load", 577], ["predicts", 582], ["the", 591], ["reduction", 595], ["in", 605], ["Neanderthal", 608], ["introgression", 620], ["around", 634], ["genes", 641], ["without", 647], ["the", 655], ["need", 659], ["to", 664], ["invoke", 667], ["epistasis", 674], [".", 683], ["We", 685], ["also", 688], ["predict", 693], ["a", 701], ["residual", 703], ["Neanderthal", 712], ["mutational", 724], ["load", 735], ["in", 740], ["non", 743], ["-", 746], ["Africans", 747], [",", 755], ["leading", 757], ["to", 765], ["a", 768], ["fitness", 770], ["reduction", 778], ["of", 788], ["at", 791], ["least", 794], ["0.5", 800], ["%", 803], [".", 804], ["This", 806], ["effect", 811], ["of", 818], ["Neanderthal", 821], ["admixture", 833], ["has", 843], ["been", 847], ["left", 852], ["out", 857], ["of", 861], ["previous", 864], ["debate", 873], ["on", 880], ["mutation", 883], ["load", 892], ["differences", 897], ["between", 909], ["Africans", 917], ["and", 926], ["non", 930], ["-", 933], ["Africans", 934], [".", 942], ["We", 944], ["also", 947], ["show", 952], ["that", 957], ["if", 962], ["many", 965], ["deleterious", 970], ["mutations", 982], ["are", 992], ["recessive", 996], [",", 1005], ["the", 1007], ["Neanderthal", 1011], ["admixture", 1023], ["fraction", 1033], ["could", 1042], ["increase", 1048], ["over", 1057], ["time", 1062], ["due", 1067], ["to", 1071], ["the", 1074], ["protective", 1078], ["effect", 1089], ["of", 1096], ["Neanderthal", 1099], ["haplotypes", 1111], ["against", 1122], ["deleterious", 1130], ["alleles", 1142], ["that", 1150], ["arose", 1155], ["recently", 1161], ["in", 1170], ["the", 1173], ["human", 1177], ["population", 1183], [".", 1193], ["This", 1195], ["might", 1200], ["partially", 1206], ["explain", 1216], ["why", 1224], ["so", 1228], ["many", 1231], ["organisms", 1236], ["retain", 1246], ["gene", 1253], ["flow", 1258], ["from", 1263], ["other", 1268], ["species", 1274], ["and", 1282], ["appear", 1286], ["to", 1293], ["derive", 1296], ["adaptive", 1303], ["benefits", 1312], ["from", 1321], ["introgression", 1326], [".", 1339]]}
{"context": "Chronic myeloid leukemia cells contain a BCR-ABL oncoprotein with an enhanced tyrosine kinase activity, which is considered to be the principal 'cause' of the leukemia. Though the precise mechanisms underlying the leukemogenesis remains enigmatic, the use of imatinib to inhibit the dysregulated kinase activity has proved remarkably successful in clinical practice. Imatinib was the first small molecule developed to inhibit BCR-ABL tyrosine kinase activity and its success introduced the current era of molecularly targeted therapies for a number of other malignancies. In patients with chronic myeloid leukaemia who develop resistance to imatinib, the Bcr-Abl signaling pathway is often re-established. This has led to the emergence of a number of alternative treatment strategies designed to target the leukemic cell which are resistant to imatinib.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "34f1609a5e28421ea7ca56e3a8591062", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[104, 106], [6, 8], [67, 69]], "char_spans": [[655, 661], [41, 47], [426, 432]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukemia", 16], ["cells", 25], ["contain", 31], ["a", 39], ["BCR", 41], ["-", 44], ["ABL", 45], ["oncoprotein", 49], ["with", 61], ["an", 66], ["enhanced", 69], ["tyrosine", 78], ["kinase", 87], ["activity", 94], [",", 102], ["which", 104], ["is", 110], ["considered", 113], ["to", 124], ["be", 127], ["the", 130], ["principal", 134], ["'cause", 144], ["'", 150], ["of", 152], ["the", 155], ["leukemia", 159], [".", 167], ["Though", 169], ["the", 176], ["precise", 180], ["mechanisms", 188], ["underlying", 199], ["the", 210], ["leukemogenesis", 214], ["remains", 229], ["enigmatic", 237], [",", 246], ["the", 248], ["use", 252], ["of", 256], ["imatinib", 259], ["to", 268], ["inhibit", 271], ["the", 279], ["dysregulated", 283], ["kinase", 296], ["activity", 303], ["has", 312], ["proved", 316], ["remarkably", 323], ["successful", 334], ["in", 345], ["clinical", 348], ["practice", 357], [".", 365], ["Imatinib", 367], ["was", 376], ["the", 380], ["first", 384], ["small", 390], ["molecule", 396], ["developed", 405], ["to", 415], ["inhibit", 418], ["BCR", 426], ["-", 429], ["ABL", 430], ["tyrosine", 434], ["kinase", 443], ["activity", 450], ["and", 459], ["its", 463], ["success", 467], ["introduced", 475], ["the", 486], ["current", 490], ["era", 498], ["of", 502], ["molecularly", 505], ["targeted", 517], ["therapies", 526], ["for", 536], ["a", 540], ["number", 542], ["of", 549], ["other", 552], ["malignancies", 558], [".", 570], ["In", 572], ["patients", 575], ["with", 584], ["chronic", 589], ["myeloid", 597], ["leukaemia", 605], ["who", 615], ["develop", 619], ["resistance", 627], ["to", 638], ["imatinib", 641], [",", 649], ["the", 651], ["Bcr", 655], ["-", 658], ["Abl", 659], ["signaling", 663], ["pathway", 673], ["is", 681], ["often", 684], ["re", 690], ["-", 692], ["established", 693], [".", 704], ["This", 706], ["has", 711], ["led", 715], ["to", 719], ["the", 722], ["emergence", 726], ["of", 736], ["a", 739], ["number", 741], ["of", 748], ["alternative", 751], ["treatment", 763], ["strategies", 773], ["designed", 784], ["to", 793], ["target", 796], ["the", 803], ["leukemic", 807], ["cell", 816], ["which", 821], ["are", 827], ["resistant", 831], ["to", 841], ["imatinib", 844], [".", 852]]}
{"context": "Spleen tyrosine kinase (SYK) has come into focus as a potential therapeutic target in chronic inflammatory diseases, such as rheumatoid arthritis and asthma, as well as in B-cell lymphomas. SYK has also been involved in the signaling of immunoreceptors, cytokine receptors, and integrins. We therefore hypothesized that inhibition of SYK attenuates the inflammatory process underlying atherosclerosis and reduces plaque development. Low-density lipoprotein receptor-deficient mice consuming a high-cholesterol diet supplemented with 2 doses of the orally available SYK inhibitor fostamatinib for 16 weeks showed a dose-dependent reduction in atherosclerotic lesion size by up to 59\u00b16% compared with the respective controls. Lesions of fostamatinib-treated animals contained fewer macrophages but more smooth muscle cells and collagen-characteristics associated with more stable plaques in humans. Mechanistically, fostamatinib attenuated adhesion and migration of inflammatory cells and limited macrophage survival. Furthermore, fostamatinib normalized high-cholesterol diet -induced monocytosis and inflammatory gene expression. We present the novel finding that the SYK inhibitor fostamatinib attenuates atherogenesis in mice. Our data identify SYK inhibition as a potentially fruitful antiinflammatory therapeutic strategy in atherosclerosis.", "qas": [{"question": "Which enzyme is inhibited by a drug fostamatinib?", "answers": ["spleen tyrosine kinase"], "qid": "89a7ef2839a844569cd9d4d936eba6c3", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["a", 29], ["drug", 31], ["fostamatinib", 36], ["?", 48]], "detected_answers": [{"text": "spleen tyrosine kinase", "token_spans": [[0, 2]], "char_spans": [[0, 21]]}]}], "context_tokens": [["Spleen", 0], ["tyrosine", 7], ["kinase", 16], ["(", 23], ["SYK", 24], [")", 27], ["has", 29], ["come", 33], ["into", 38], ["focus", 43], ["as", 49], ["a", 52], ["potential", 54], ["therapeutic", 64], ["target", 76], ["in", 83], ["chronic", 86], ["inflammatory", 94], ["diseases", 107], [",", 115], ["such", 117], ["as", 122], ["rheumatoid", 125], ["arthritis", 136], ["and", 146], ["asthma", 150], [",", 156], ["as", 158], ["well", 161], ["as", 166], ["in", 169], ["B", 172], ["-", 173], ["cell", 174], ["lymphomas", 179], [".", 188], ["SYK", 190], ["has", 194], ["also", 198], ["been", 203], ["involved", 208], ["in", 217], ["the", 220], ["signaling", 224], ["of", 234], ["immunoreceptors", 237], [",", 252], ["cytokine", 254], ["receptors", 263], [",", 272], ["and", 274], ["integrins", 278], [".", 287], ["We", 289], ["therefore", 292], ["hypothesized", 302], ["that", 315], ["inhibition", 320], ["of", 331], ["SYK", 334], ["attenuates", 338], ["the", 349], ["inflammatory", 353], ["process", 366], ["underlying", 374], ["atherosclerosis", 385], ["and", 401], ["reduces", 405], ["plaque", 413], ["development", 420], [".", 431], ["Low", 433], ["-", 436], ["density", 437], ["lipoprotein", 445], ["receptor", 457], ["-", 465], ["deficient", 466], ["mice", 476], ["consuming", 481], ["a", 491], ["high", 493], ["-", 497], ["cholesterol", 498], ["diet", 510], ["supplemented", 515], ["with", 528], ["2", 533], ["doses", 535], ["of", 541], ["the", 544], ["orally", 548], ["available", 555], ["SYK", 565], ["inhibitor", 569], ["fostamatinib", 579], ["for", 592], ["16", 596], ["weeks", 599], ["showed", 605], ["a", 612], ["dose", 614], ["-", 618], ["dependent", 619], ["reduction", 629], ["in", 639], ["atherosclerotic", 642], ["lesion", 658], ["size", 665], ["by", 670], ["up", 673], ["to", 676], ["59\u00b16", 679], ["%", 683], ["compared", 685], ["with", 694], ["the", 699], ["respective", 703], ["controls", 714], [".", 722], ["Lesions", 724], ["of", 732], ["fostamatinib", 735], ["-", 747], ["treated", 748], ["animals", 756], ["contained", 764], ["fewer", 774], ["macrophages", 780], ["but", 792], ["more", 796], ["smooth", 801], ["muscle", 808], ["cells", 815], ["and", 821], ["collagen", 825], ["-", 833], ["characteristics", 834], ["associated", 850], ["with", 861], ["more", 866], ["stable", 871], ["plaques", 878], ["in", 886], ["humans", 889], [".", 895], ["Mechanistically", 897], [",", 912], ["fostamatinib", 914], ["attenuated", 927], ["adhesion", 938], ["and", 947], ["migration", 951], ["of", 961], ["inflammatory", 964], ["cells", 977], ["and", 983], ["limited", 987], ["macrophage", 995], ["survival", 1006], [".", 1014], ["Furthermore", 1016], [",", 1027], ["fostamatinib", 1029], ["normalized", 1042], ["high", 1053], ["-", 1057], ["cholesterol", 1058], ["diet", 1070], ["-induced", 1075], ["monocytosis", 1084], ["and", 1096], ["inflammatory", 1100], ["gene", 1113], ["expression", 1118], [".", 1128], ["We", 1130], ["present", 1133], ["the", 1141], ["novel", 1145], ["finding", 1151], ["that", 1159], ["the", 1164], ["SYK", 1168], ["inhibitor", 1172], ["fostamatinib", 1182], ["attenuates", 1195], ["atherogenesis", 1206], ["in", 1220], ["mice", 1223], [".", 1227], ["Our", 1229], ["data", 1233], ["identify", 1238], ["SYK", 1247], ["inhibition", 1251], ["as", 1262], ["a", 1265], ["potentially", 1267], ["fruitful", 1279], ["antiinflammatory", 1288], ["therapeutic", 1305], ["strategy", 1317], ["in", 1326], ["atherosclerosis", 1329], [".", 1344]]}
{"context": "Interleukin-17A is considered to be central to the pathogenesis of psoriasis. We evaluated secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe plaque psoriasis. In two phase 3, double-blind, 52-week trials, ERASURE (Efficacy of Response and Safety of Two Fixed Secukinumab Regimens in Psoriasis) and FIXTURE (Full Year Investigative Examination of Secukinumab vs. Etanercept Using Two Dosing Regimens to Determine Efficacy in Psoriasis), we randomly assigned 738 patients (in the ERASURE study) and 1306 patients (in the FIXTURE study) to subcutaneous secukinumab at a dose of 300 mg or 150 mg (administered once weekly for 5 weeks, then every 4 weeks), placebo, or (in the FIXTURE study only) etanercept at a dose of 50 mg (administered twice weekly for 12 weeks, then once weekly). The objective of each study was to show the superiority of secukinumab over placebo at week 12 with respect to the proportion of patients who had a reduction of 75% or more from baseline in the psoriasis area-and-severity index score (PASI 75) and a score of 0 (clear) or 1 (almost clear) on a 5-point modified investigator's global assessment (coprimary end points). The proportion of patients who met the criterion for PASI 75 at week 12 was higher with each secukinumab dose than with placebo or etanercept: in the ERASURE study, the rates were 81.6% with 300 mg of secukinumab, 71.6% with 150 mg of secukinumab, and 4.5% with placebo; in the FIXTURE study, the rates were 77.1% with 300 mg of secukinumab, 67.0% with 150 mg of secukinumab, 44.0% with etanercept, and 4.9% with placebo (P<0.001 for each secukinumab dose vs. comparators). The proportion of patients with a response of 0 or 1 on the modified investigator's global assessment at week 12 was higher with each secukinumab dose than with placebo or etanercept: in the ERASURE study, the rates were 65.3% with 300 mg of secukinumab, 51.2% with 150 mg of secukinumab, and 2.4% with placebo; in the FIXTURE study, the rates were 62.5% with 300 mg of secukinumab, 51.1% with 150 mg of secukinumab, 27.2% with etanercept, and 2.8% with placebo (P<0.001 for each secukinumab dose vs. comparators). The rates of infection were higher with secukinumab than with placebo in both studies and were similar to those with etanercept. Secukinumab was effective for psoriasis in two randomized trials, validating interleukin-17A as a therapeutic target. (Funded by Novartis Pharmaceuticals; ERASURE and FIXTURE ClinicalTrials.gov numbers, NCT01365455 and NCT01358578, respectively.).", "qas": [{"question": "Which molecule is targeted by a monoclonal antibody Secukinumab?", "answers": ["interleukin-17A"], "qid": "d6448dc3be2e45b2be46a0805cc13200", "question_tokens": [["Which", 0], ["molecule", 6], ["is", 15], ["targeted", 18], ["by", 27], ["a", 30], ["monoclonal", 32], ["antibody", 43], ["Secukinumab", 52], ["?", 63]], "detected_answers": [{"text": "interleukin-17A", "token_spans": [[0, 0], [21, 21], [478, 478]], "char_spans": [[0, 14], [123, 137], [2400, 2414]]}]}], "context_tokens": [["Interleukin-17A", 0], ["is", 16], ["considered", 19], ["to", 30], ["be", 33], ["central", 36], ["to", 44], ["the", 47], ["pathogenesis", 51], ["of", 64], ["psoriasis", 67], [".", 76], ["We", 78], ["evaluated", 81], ["secukinumab", 91], [",", 102], ["a", 104], ["fully", 106], ["human", 112], ["anti", 118], ["-", 122], ["interleukin-17A", 123], ["monoclonal", 139], ["antibody", 150], [",", 158], ["in", 160], ["patients", 163], ["with", 172], ["moderate", 177], ["-", 185], ["to", 186], ["-", 188], ["severe", 189], ["plaque", 196], ["psoriasis", 203], [".", 212], ["In", 214], ["two", 217], ["phase", 221], ["3", 227], [",", 228], ["double", 230], ["-", 236], ["blind", 237], [",", 242], ["52-week", 244], ["trials", 252], [",", 258], ["ERASURE", 260], ["(", 268], ["Efficacy", 269], ["of", 278], ["Response", 281], ["and", 290], ["Safety", 294], ["of", 301], ["Two", 304], ["Fixed", 308], ["Secukinumab", 314], ["Regimens", 326], ["in", 335], ["Psoriasis", 338], [")", 347], ["and", 349], ["FIXTURE", 353], ["(", 361], ["Full", 362], ["Year", 367], ["Investigative", 372], ["Examination", 386], ["of", 398], ["Secukinumab", 401], ["vs.", 413], ["Etanercept", 417], ["Using", 428], ["Two", 434], ["Dosing", 438], ["Regimens", 445], ["to", 454], ["Determine", 457], ["Efficacy", 467], ["in", 476], ["Psoriasis", 479], [")", 488], [",", 489], ["we", 491], ["randomly", 494], ["assigned", 503], ["738", 512], ["patients", 516], ["(", 525], ["in", 526], ["the", 529], ["ERASURE", 533], ["study", 541], [")", 546], ["and", 548], ["1306", 552], ["patients", 557], ["(", 566], ["in", 567], ["the", 570], ["FIXTURE", 574], ["study", 582], [")", 587], ["to", 589], ["subcutaneous", 592], ["secukinumab", 605], ["at", 617], ["a", 620], ["dose", 622], ["of", 627], ["300", 630], ["mg", 634], ["or", 637], ["150", 640], ["mg", 644], ["(", 647], ["administered", 648], ["once", 661], ["weekly", 666], ["for", 673], ["5", 677], ["weeks", 679], [",", 684], ["then", 686], ["every", 691], ["4", 697], ["weeks", 699], [")", 704], [",", 705], ["placebo", 707], [",", 714], ["or", 716], ["(", 719], ["in", 720], ["the", 723], ["FIXTURE", 727], ["study", 735], ["only", 741], [")", 745], ["etanercept", 747], ["at", 758], ["a", 761], ["dose", 763], ["of", 768], ["50", 771], ["mg", 774], ["(", 777], ["administered", 778], ["twice", 791], ["weekly", 797], ["for", 804], ["12", 808], ["weeks", 811], [",", 816], ["then", 818], ["once", 823], ["weekly", 828], [")", 834], [".", 835], ["The", 837], ["objective", 841], ["of", 851], ["each", 854], ["study", 859], ["was", 865], ["to", 869], ["show", 872], ["the", 877], ["superiority", 881], ["of", 893], ["secukinumab", 896], ["over", 908], ["placebo", 913], ["at", 921], ["week", 924], ["12", 929], ["with", 932], ["respect", 937], ["to", 945], ["the", 948], ["proportion", 952], ["of", 963], ["patients", 966], ["who", 975], ["had", 979], ["a", 983], ["reduction", 985], ["of", 995], ["75", 998], ["%", 1000], ["or", 1002], ["more", 1005], ["from", 1010], ["baseline", 1015], ["in", 1024], ["the", 1027], ["psoriasis", 1031], ["area", 1041], ["-", 1045], ["and", 1046], ["-", 1049], ["severity", 1050], ["index", 1059], ["score", 1065], ["(", 1071], ["PASI", 1072], ["75", 1077], [")", 1079], ["and", 1081], ["a", 1085], ["score", 1087], ["of", 1093], ["0", 1096], ["(", 1098], ["clear", 1099], [")", 1104], ["or", 1106], ["1", 1109], ["(", 1111], ["almost", 1112], ["clear", 1119], [")", 1124], ["on", 1126], ["a", 1129], ["5-point", 1131], ["modified", 1139], ["investigator", 1148], ["'s", 1160], ["global", 1163], ["assessment", 1170], ["(", 1181], ["coprimary", 1182], ["end", 1192], ["points", 1196], [")", 1202], [".", 1203], ["The", 1205], ["proportion", 1209], ["of", 1220], ["patients", 1223], ["who", 1232], ["met", 1236], ["the", 1240], ["criterion", 1244], ["for", 1254], ["PASI", 1258], ["75", 1263], ["at", 1266], ["week", 1269], ["12", 1274], ["was", 1277], ["higher", 1281], ["with", 1288], ["each", 1293], ["secukinumab", 1298], ["dose", 1310], ["than", 1315], ["with", 1320], ["placebo", 1325], ["or", 1333], ["etanercept", 1336], [":", 1346], ["in", 1348], ["the", 1351], ["ERASURE", 1355], ["study", 1363], [",", 1368], ["the", 1370], ["rates", 1374], ["were", 1380], ["81.6", 1385], ["%", 1389], ["with", 1391], ["300", 1396], ["mg", 1400], ["of", 1403], ["secukinumab", 1406], [",", 1417], ["71.6", 1419], ["%", 1423], ["with", 1425], ["150", 1430], ["mg", 1434], ["of", 1437], ["secukinumab", 1440], [",", 1451], ["and", 1453], ["4.5", 1457], ["%", 1460], ["with", 1462], ["placebo", 1467], [";", 1474], ["in", 1476], ["the", 1479], ["FIXTURE", 1483], ["study", 1491], [",", 1496], ["the", 1498], ["rates", 1502], ["were", 1508], ["77.1", 1513], ["%", 1517], ["with", 1519], ["300", 1524], ["mg", 1528], ["of", 1531], ["secukinumab", 1534], [",", 1545], ["67.0", 1547], ["%", 1551], ["with", 1553], ["150", 1558], ["mg", 1562], ["of", 1565], ["secukinumab", 1568], [",", 1579], ["44.0", 1581], ["%", 1585], ["with", 1587], ["etanercept", 1592], [",", 1602], ["and", 1604], ["4.9", 1608], ["%", 1611], ["with", 1613], ["placebo", 1618], ["(", 1626], ["P<0.001", 1627], ["for", 1635], ["each", 1639], ["secukinumab", 1644], ["dose", 1656], ["vs.", 1661], ["comparators", 1665], [")", 1676], [".", 1677], ["The", 1679], ["proportion", 1683], ["of", 1694], ["patients", 1697], ["with", 1706], ["a", 1711], ["response", 1713], ["of", 1722], ["0", 1725], ["or", 1727], ["1", 1730], ["on", 1732], ["the", 1735], ["modified", 1739], ["investigator", 1748], ["'s", 1760], ["global", 1763], ["assessment", 1770], ["at", 1781], ["week", 1784], ["12", 1789], ["was", 1792], ["higher", 1796], ["with", 1803], ["each", 1808], ["secukinumab", 1813], ["dose", 1825], ["than", 1830], ["with", 1835], ["placebo", 1840], ["or", 1848], ["etanercept", 1851], [":", 1861], ["in", 1863], ["the", 1866], ["ERASURE", 1870], ["study", 1878], [",", 1883], ["the", 1885], ["rates", 1889], ["were", 1895], ["65.3", 1900], ["%", 1904], ["with", 1906], ["300", 1911], ["mg", 1915], ["of", 1918], ["secukinumab", 1921], [",", 1932], ["51.2", 1934], ["%", 1938], ["with", 1940], ["150", 1945], ["mg", 1949], ["of", 1952], ["secukinumab", 1955], [",", 1966], ["and", 1968], ["2.4", 1972], ["%", 1975], ["with", 1977], ["placebo", 1982], [";", 1989], ["in", 1991], ["the", 1994], ["FIXTURE", 1998], ["study", 2006], [",", 2011], ["the", 2013], ["rates", 2017], ["were", 2023], ["62.5", 2028], ["%", 2032], ["with", 2034], ["300", 2039], ["mg", 2043], ["of", 2046], ["secukinumab", 2049], [",", 2060], ["51.1", 2062], ["%", 2066], ["with", 2068], ["150", 2073], ["mg", 2077], ["of", 2080], ["secukinumab", 2083], [",", 2094], ["27.2", 2096], ["%", 2100], ["with", 2102], ["etanercept", 2107], [",", 2117], ["and", 2119], ["2.8", 2123], ["%", 2126], ["with", 2128], ["placebo", 2133], ["(", 2141], ["P<0.001", 2142], ["for", 2150], ["each", 2154], ["secukinumab", 2159], ["dose", 2171], ["vs.", 2176], ["comparators", 2180], [")", 2191], [".", 2192], ["The", 2194], ["rates", 2198], ["of", 2204], ["infection", 2207], ["were", 2217], ["higher", 2222], ["with", 2229], ["secukinumab", 2234], ["than", 2246], ["with", 2251], ["placebo", 2256], ["in", 2264], ["both", 2267], ["studies", 2272], ["and", 2280], ["were", 2284], ["similar", 2289], ["to", 2297], ["those", 2300], ["with", 2306], ["etanercept", 2311], [".", 2321], ["Secukinumab", 2323], ["was", 2335], ["effective", 2339], ["for", 2349], ["psoriasis", 2353], ["in", 2363], ["two", 2366], ["randomized", 2370], ["trials", 2381], [",", 2387], ["validating", 2389], ["interleukin-17A", 2400], ["as", 2416], ["a", 2419], ["therapeutic", 2421], ["target", 2433], [".", 2439], ["(", 2441], ["Funded", 2442], ["by", 2449], ["Novartis", 2452], ["Pharmaceuticals", 2461], [";", 2476], ["ERASURE", 2478], ["and", 2486], ["FIXTURE", 2490], ["ClinicalTrials.gov", 2498], ["numbers", 2517], [",", 2524], ["NCT01365455", 2526], ["and", 2538], ["NCT01358578", 2542], [",", 2553], ["respectively", 2555], [".", 2567], [")", 2568], [".", 2569]]}
{"context": "Carpal tunnel syndrome is a complex of symptoms as a result of compression of the median nerve in the carpal tunnel. As nerve entrapment induces impairment of somatic fibres followed by clinical symptoms and signs of the syndrome, one can assume that sympathetic fibres are involved too. Results of studies focused on this problem show presence of sympathetic symptoms in about half of patients, including Raynaud phenomenon, blanching of hands, painful swelling of fingers, dry or excessive sweating of palms. Activity of sympathetic system can be investigated by means of sympathetic skin response and vasomotor response. Eight papers presenting the results of sympathetic skin response from median nerve in carpal tunnel syndrome were analysed. Results of 4 studies showed decreased sympathetic activity, in 2 findings were equivocal and 2 studies failed to reveal any abnormalities. The following variables were considered in the interpretation of sympathetic skin response curve: amplitude, latency and area under the chart, each of them having limited diagnostic value due to inter-and intrasubject variation of these parameters. Vasomotor response was investigated in 2 studies by means of Doppler ultrasound flow examination in digital arteries. Results of both studies showed decreased vasomotor response in carpal tunnel syndrome. The review of current knowledge on sympathetic impairment in carpal tunnel syndrome fails to provide a definitive determination of its range and clinical consequences. It confirms, however, that routine examination of sympathetic disturbances is unnecessary due to their minor clinical significance.", "qas": [{"question": "What nerve is involved in carpal tunnel syndrome?", "answers": ["median"], "qid": "3da4e2bccf984afb8212d78a6eab3d6f", "question_tokens": [["What", 0], ["nerve", 5], ["is", 11], ["involved", 14], ["in", 23], ["carpal", 26], ["tunnel", 33], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "median", "token_spans": [[15, 15], [115, 115]], "char_spans": [[82, 87], [694, 699]]}]}], "context_tokens": [["Carpal", 0], ["tunnel", 7], ["syndrome", 14], ["is", 23], ["a", 26], ["complex", 28], ["of", 36], ["symptoms", 39], ["as", 48], ["a", 51], ["result", 53], ["of", 60], ["compression", 63], ["of", 75], ["the", 78], ["median", 82], ["nerve", 89], ["in", 95], ["the", 98], ["carpal", 102], ["tunnel", 109], [".", 115], ["As", 117], ["nerve", 120], ["entrapment", 126], ["induces", 137], ["impairment", 145], ["of", 156], ["somatic", 159], ["fibres", 167], ["followed", 174], ["by", 183], ["clinical", 186], ["symptoms", 195], ["and", 204], ["signs", 208], ["of", 214], ["the", 217], ["syndrome", 221], [",", 229], ["one", 231], ["can", 235], ["assume", 239], ["that", 246], ["sympathetic", 251], ["fibres", 263], ["are", 270], ["involved", 274], ["too", 283], [".", 286], ["Results", 288], ["of", 296], ["studies", 299], ["focused", 307], ["on", 315], ["this", 318], ["problem", 323], ["show", 331], ["presence", 336], ["of", 345], ["sympathetic", 348], ["symptoms", 360], ["in", 369], ["about", 372], ["half", 378], ["of", 383], ["patients", 386], [",", 394], ["including", 396], ["Raynaud", 406], ["phenomenon", 414], [",", 424], ["blanching", 426], ["of", 436], ["hands", 439], [",", 444], ["painful", 446], ["swelling", 454], ["of", 463], ["fingers", 466], [",", 473], ["dry", 475], ["or", 479], ["excessive", 482], ["sweating", 492], ["of", 501], ["palms", 504], [".", 509], ["Activity", 511], ["of", 520], ["sympathetic", 523], ["system", 535], ["can", 542], ["be", 546], ["investigated", 549], ["by", 562], ["means", 565], ["of", 571], ["sympathetic", 574], ["skin", 586], ["response", 591], ["and", 600], ["vasomotor", 604], ["response", 614], [".", 622], ["Eight", 624], ["papers", 630], ["presenting", 637], ["the", 648], ["results", 652], ["of", 660], ["sympathetic", 663], ["skin", 675], ["response", 680], ["from", 689], ["median", 694], ["nerve", 701], ["in", 707], ["carpal", 710], ["tunnel", 717], ["syndrome", 724], ["were", 733], ["analysed", 738], [".", 746], ["Results", 748], ["of", 756], ["4", 759], ["studies", 761], ["showed", 769], ["decreased", 776], ["sympathetic", 786], ["activity", 798], [",", 806], ["in", 808], ["2", 811], ["findings", 813], ["were", 822], ["equivocal", 827], ["and", 837], ["2", 841], ["studies", 843], ["failed", 851], ["to", 858], ["reveal", 861], ["any", 868], ["abnormalities", 872], [".", 885], ["The", 887], ["following", 891], ["variables", 901], ["were", 911], ["considered", 916], ["in", 927], ["the", 930], ["interpretation", 934], ["of", 949], ["sympathetic", 952], ["skin", 964], ["response", 969], ["curve", 978], [":", 983], ["amplitude", 985], [",", 994], ["latency", 996], ["and", 1004], ["area", 1008], ["under", 1013], ["the", 1019], ["chart", 1023], [",", 1028], ["each", 1030], ["of", 1035], ["them", 1038], ["having", 1043], ["limited", 1050], ["diagnostic", 1058], ["value", 1069], ["due", 1075], ["to", 1079], ["inter", 1082], ["-", 1087], ["and", 1088], ["intrasubject", 1092], ["variation", 1105], ["of", 1115], ["these", 1118], ["parameters", 1124], [".", 1134], ["Vasomotor", 1136], ["response", 1146], ["was", 1155], ["investigated", 1159], ["in", 1172], ["2", 1175], ["studies", 1177], ["by", 1185], ["means", 1188], ["of", 1194], ["Doppler", 1197], ["ultrasound", 1205], ["flow", 1216], ["examination", 1221], ["in", 1233], ["digital", 1236], ["arteries", 1244], [".", 1252], ["Results", 1254], ["of", 1262], ["both", 1265], ["studies", 1270], ["showed", 1278], ["decreased", 1285], ["vasomotor", 1295], ["response", 1305], ["in", 1314], ["carpal", 1317], ["tunnel", 1324], ["syndrome", 1331], [".", 1339], ["The", 1341], ["review", 1345], ["of", 1352], ["current", 1355], ["knowledge", 1363], ["on", 1373], ["sympathetic", 1376], ["impairment", 1388], ["in", 1399], ["carpal", 1402], ["tunnel", 1409], ["syndrome", 1416], ["fails", 1425], ["to", 1431], ["provide", 1434], ["a", 1442], ["definitive", 1444], ["determination", 1455], ["of", 1469], ["its", 1472], ["range", 1476], ["and", 1482], ["clinical", 1486], ["consequences", 1495], [".", 1507], ["It", 1509], ["confirms", 1512], [",", 1520], ["however", 1522], [",", 1529], ["that", 1531], ["routine", 1536], ["examination", 1544], ["of", 1556], ["sympathetic", 1559], ["disturbances", 1571], ["is", 1584], ["unnecessary", 1587], ["due", 1599], ["to", 1603], ["their", 1606], ["minor", 1612], ["clinical", 1618], ["significance", 1627], [".", 1639]]}
{"context": "The mixed-lineage leukemia protein MLL1 is a transcriptional regulator with an essential role in early development and hematopoiesis. The biological function of MLL1 is mediated by the histone H3K4 methyltransferase activity of the carboxyl-terminal SET domain. We have determined the crystal structure of the MLL1 SET domain in complex with cofactor product AdoHcy and a histone H3 peptide. This structure indicates that, in order to form a well-ordered active site, a highly variable but essential component of the SET domain must be repositioned. To test this idea, we compared the effect of the addition of MLL complex members on methyltransferase activity and show that both RbBP5 and Ash2L but not Wdr5 stimulate activity. Additionally, we have determined the effect of posttranslational modifications on histone H3 residues downstream and upstream from the target lysine and provide a structural explanation for why H3T3 phosphorylation and H3K9 acetylation regulate activity.", "qas": [{"question": "Which is the histone residue methylated by MLL1?", "answers": ["H3K4"], "qid": "76dece4105a44e9e9041be62fc48fbed", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["histone", 13], ["residue", 21], ["methylated", 29], ["by", 40], ["MLL1", 43], ["?", 47]], "detected_answers": [{"text": "H3K4", "token_spans": [[31, 31]], "char_spans": [[193, 196]]}]}], "context_tokens": [["The", 0], ["mixed", 4], ["-", 9], ["lineage", 10], ["leukemia", 18], ["protein", 27], ["MLL1", 35], ["is", 40], ["a", 43], ["transcriptional", 45], ["regulator", 61], ["with", 71], ["an", 76], ["essential", 79], ["role", 89], ["in", 94], ["early", 97], ["development", 103], ["and", 115], ["hematopoiesis", 119], [".", 132], ["The", 134], ["biological", 138], ["function", 149], ["of", 158], ["MLL1", 161], ["is", 166], ["mediated", 169], ["by", 178], ["the", 181], ["histone", 185], ["H3K4", 193], ["methyltransferase", 198], ["activity", 216], ["of", 225], ["the", 228], ["carboxyl", 232], ["-", 240], ["terminal", 241], ["SET", 250], ["domain", 254], [".", 260], ["We", 262], ["have", 265], ["determined", 270], ["the", 281], ["crystal", 285], ["structure", 293], ["of", 303], ["the", 306], ["MLL1", 310], ["SET", 315], ["domain", 319], ["in", 326], ["complex", 329], ["with", 337], ["cofactor", 342], ["product", 351], ["AdoHcy", 359], ["and", 366], ["a", 370], ["histone", 372], ["H3", 380], ["peptide", 383], [".", 390], ["This", 392], ["structure", 397], ["indicates", 407], ["that", 417], [",", 421], ["in", 423], ["order", 426], ["to", 432], ["form", 435], ["a", 440], ["well", 442], ["-", 446], ["ordered", 447], ["active", 455], ["site", 462], [",", 466], ["a", 468], ["highly", 470], ["variable", 477], ["but", 486], ["essential", 490], ["component", 500], ["of", 510], ["the", 513], ["SET", 517], ["domain", 521], ["must", 528], ["be", 533], ["repositioned", 536], [".", 548], ["To", 550], ["test", 553], ["this", 558], ["idea", 563], [",", 567], ["we", 569], ["compared", 572], ["the", 581], ["effect", 585], ["of", 592], ["the", 595], ["addition", 599], ["of", 608], ["MLL", 611], ["complex", 615], ["members", 623], ["on", 631], ["methyltransferase", 634], ["activity", 652], ["and", 661], ["show", 665], ["that", 670], ["both", 675], ["RbBP5", 680], ["and", 686], ["Ash2L", 690], ["but", 696], ["not", 700], ["Wdr5", 704], ["stimulate", 709], ["activity", 719], [".", 727], ["Additionally", 729], [",", 741], ["we", 743], ["have", 746], ["determined", 751], ["the", 762], ["effect", 766], ["of", 773], ["posttranslational", 776], ["modifications", 794], ["on", 808], ["histone", 811], ["H3", 819], ["residues", 822], ["downstream", 831], ["and", 842], ["upstream", 846], ["from", 855], ["the", 860], ["target", 864], ["lysine", 871], ["and", 878], ["provide", 882], ["a", 890], ["structural", 892], ["explanation", 903], ["for", 915], ["why", 919], ["H3T3", 923], ["phosphorylation", 928], ["and", 944], ["H3K9", 948], ["acetylation", 953], ["regulate", 965], ["activity", 974], [".", 982]]}
{"context": "The ubiquitin-proteasome pathway is involved in intracellular protein turnover, and its function is crucial to cellular homeostasis. First synthesized as probes of proteolytic processes, proteasome inhibitors began to be thought of as potential drug candidates when they were found to induce programmed cell death preferentially in transformed cells. They made their first leap into the clinic to be tested as therapeutic agents 10 years ago, and since then, great strides have been made in defining their mechanisms of action, their clinical efficacy and toxicity, and some of their limitations in the form of resistance pathways. Validation of the ubiquitin-proteasome pathway as a target for cancer therapy has come in the form of approvals of the first such inhibitor, bortezomib, for relapsed/refractory multiple myeloma and mantle cell lymphoma, for which this agent has become a standard of care. Lessons learned from this first-in-class agent are now being applied to the development of a new generation of proteasome inhibitors that hold the promise of efficacy in bortezomib-resistant disease and possibly in a broader spectrum of diseases. This saga provides a salient example of the promise of translational medicine and a paradigm by which other agents may be successfully brought from the bench to the bedside.", "qas": [{"question": "Which is the target of bortezomib used in cancer therapy?", "answers": ["The ubiquitin/proteasome pathway"], "qid": "19279b71c3f24df98e4583f3b5b1ad1e", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["target", 13], ["of", 20], ["bortezomib", 23], ["used", 34], ["in", 39], ["cancer", 42], ["therapy", 49], ["?", 56]], "detected_answers": [{"text": "The ubiquitin/proteasome pathway", "token_spans": [[109, 112], [1, 4]], "char_spans": [[650, 677], [4, 31]]}]}], "context_tokens": [["The", 0], ["ubiquitin", 4], ["-", 13], ["proteasome", 14], ["pathway", 25], ["is", 33], ["involved", 36], ["in", 45], ["intracellular", 48], ["protein", 62], ["turnover", 70], [",", 78], ["and", 80], ["its", 84], ["function", 88], ["is", 97], ["crucial", 100], ["to", 108], ["cellular", 111], ["homeostasis", 120], [".", 131], ["First", 133], ["synthesized", 139], ["as", 151], ["probes", 154], ["of", 161], ["proteolytic", 164], ["processes", 176], [",", 185], ["proteasome", 187], ["inhibitors", 198], ["began", 209], ["to", 215], ["be", 218], ["thought", 221], ["of", 229], ["as", 232], ["potential", 235], ["drug", 245], ["candidates", 250], ["when", 261], ["they", 266], ["were", 271], ["found", 276], ["to", 282], ["induce", 285], ["programmed", 292], ["cell", 303], ["death", 308], ["preferentially", 314], ["in", 329], ["transformed", 332], ["cells", 344], [".", 349], ["They", 351], ["made", 356], ["their", 361], ["first", 367], ["leap", 373], ["into", 378], ["the", 383], ["clinic", 387], ["to", 394], ["be", 397], ["tested", 400], ["as", 407], ["therapeutic", 410], ["agents", 422], ["10", 429], ["years", 432], ["ago", 438], [",", 441], ["and", 443], ["since", 447], ["then", 453], [",", 457], ["great", 459], ["strides", 465], ["have", 473], ["been", 478], ["made", 483], ["in", 488], ["defining", 491], ["their", 500], ["mechanisms", 506], ["of", 517], ["action", 520], [",", 526], ["their", 528], ["clinical", 534], ["efficacy", 543], ["and", 552], ["toxicity", 556], [",", 564], ["and", 566], ["some", 570], ["of", 575], ["their", 578], ["limitations", 584], ["in", 596], ["the", 599], ["form", 603], ["of", 608], ["resistance", 611], ["pathways", 622], [".", 630], ["Validation", 632], ["of", 643], ["the", 646], ["ubiquitin", 650], ["-", 659], ["proteasome", 660], ["pathway", 671], ["as", 679], ["a", 682], ["target", 684], ["for", 691], ["cancer", 695], ["therapy", 702], ["has", 710], ["come", 714], ["in", 719], ["the", 722], ["form", 726], ["of", 731], ["approvals", 734], ["of", 744], ["the", 747], ["first", 751], ["such", 757], ["inhibitor", 762], [",", 771], ["bortezomib", 773], [",", 783], ["for", 785], ["relapsed", 789], ["/", 797], ["refractory", 798], ["multiple", 809], ["myeloma", 818], ["and", 826], ["mantle", 830], ["cell", 837], ["lymphoma", 842], [",", 850], ["for", 852], ["which", 856], ["this", 862], ["agent", 867], ["has", 873], ["become", 877], ["a", 884], ["standard", 886], ["of", 895], ["care", 898], [".", 902], ["Lessons", 904], ["learned", 912], ["from", 920], ["this", 925], ["first", 930], ["-", 935], ["in", 936], ["-", 938], ["class", 939], ["agent", 945], ["are", 951], ["now", 955], ["being", 959], ["applied", 965], ["to", 973], ["the", 976], ["development", 980], ["of", 992], ["a", 995], ["new", 997], ["generation", 1001], ["of", 1012], ["proteasome", 1015], ["inhibitors", 1026], ["that", 1037], ["hold", 1042], ["the", 1047], ["promise", 1051], ["of", 1059], ["efficacy", 1062], ["in", 1071], ["bortezomib", 1074], ["-", 1084], ["resistant", 1085], ["disease", 1095], ["and", 1103], ["possibly", 1107], ["in", 1116], ["a", 1119], ["broader", 1121], ["spectrum", 1129], ["of", 1138], ["diseases", 1141], [".", 1149], ["This", 1151], ["saga", 1156], ["provides", 1161], ["a", 1170], ["salient", 1172], ["example", 1180], ["of", 1188], ["the", 1191], ["promise", 1195], ["of", 1203], ["translational", 1206], ["medicine", 1220], ["and", 1229], ["a", 1233], ["paradigm", 1235], ["by", 1244], ["which", 1247], ["other", 1253], ["agents", 1259], ["may", 1266], ["be", 1270], ["successfully", 1273], ["brought", 1286], ["from", 1294], ["the", 1299], ["bench", 1303], ["to", 1309], ["the", 1312], ["bedside", 1316], [".", 1323]]}
{"context": "The antennal lobe (primary olfactory center of insects) is completely reorganized during metamorphosis. This reorganization is accompanied by changing patterns of calcium signaling in neurons and glial cells. In the present study, we investigated the developmental distribution of a major calcium-dependent protein, viz., calcium/calmodulin-dependent protein kinase II (CaM kinase II), in the antennal lobe of the sphinx moth Manduca sexta by using a monoclonal antibody. During synaptogenesis (developmental stages 6-10), we found a redistribution of CaM kinase II immunoreactivity, from a homogeneous distribution in the immature neuropil to an accumulation in the neuropil of the glomeruli. CaM kinase II immunoreactivity was less intense in olfactory receptor axons of the antennal nerve and antennal lobe glial cells. Western blot analysis revealed a growing content of CaM kinase II in antennal lobe tissue throughout metamorphosis. Injection of the CaM kinase inhibitor KN-93 into pupae resulted in a reduced number of antennal lobe glial cells migrating into the neuropil to form borders around glomeruli. The results suggest that CaM kinase II is involved in glial cell migration.", "qas": [{"question": "Which kinase is inhibited by the small molecule KN-93?", "answers": ["CAMK2", "calcium/calmodulin-dependent protein kinase II", "The calcium/calmodulin-dependent protein kinase-II", "CaM kinase II"], "qid": "f06d0fa0fbbc473f94d4d0b3591a5676", "question_tokens": [["Which", 0], ["kinase", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["the", 29], ["small", 33], ["molecule", 39], ["KN-93", 48], ["?", 53]], "detected_answers": [{"text": "The calcium/calmodulin-dependent protein kinase-II", "token_spans": [[53, 60]], "char_spans": [[322, 367]]}, {"text": "CaM kinase II", "token_spans": [[193, 195], [150, 152], [62, 64], [121, 123], [98, 100]], "char_spans": [[1139, 1151], [875, 887], [370, 382], [694, 706], [552, 564]]}]}], "context_tokens": [["The", 0], ["antennal", 4], ["lobe", 13], ["(", 18], ["primary", 19], ["olfactory", 27], ["center", 37], ["of", 44], ["insects", 47], [")", 54], ["is", 56], ["completely", 59], ["reorganized", 70], ["during", 82], ["metamorphosis", 89], [".", 102], ["This", 104], ["reorganization", 109], ["is", 124], ["accompanied", 127], ["by", 139], ["changing", 142], ["patterns", 151], ["of", 160], ["calcium", 163], ["signaling", 171], ["in", 181], ["neurons", 184], ["and", 192], ["glial", 196], ["cells", 202], [".", 207], ["In", 209], ["the", 212], ["present", 216], ["study", 224], [",", 229], ["we", 231], ["investigated", 234], ["the", 247], ["developmental", 251], ["distribution", 265], ["of", 278], ["a", 281], ["major", 283], ["calcium", 289], ["-", 296], ["dependent", 297], ["protein", 307], [",", 314], ["viz", 316], [".", 319], [",", 320], ["calcium", 322], ["/", 329], ["calmodulin", 330], ["-", 340], ["dependent", 341], ["protein", 351], ["kinase", 359], ["II", 366], ["(", 369], ["CaM", 370], ["kinase", 374], ["II", 381], [")", 383], [",", 384], ["in", 386], ["the", 389], ["antennal", 393], ["lobe", 402], ["of", 407], ["the", 410], ["sphinx", 414], ["moth", 421], ["Manduca", 426], ["sexta", 434], ["by", 440], ["using", 443], ["a", 449], ["monoclonal", 451], ["antibody", 462], [".", 470], ["During", 472], ["synaptogenesis", 479], ["(", 494], ["developmental", 495], ["stages", 509], ["6", 516], ["-", 517], ["10", 518], [")", 520], [",", 521], ["we", 523], ["found", 526], ["a", 532], ["redistribution", 534], ["of", 549], ["CaM", 552], ["kinase", 556], ["II", 563], ["immunoreactivity", 566], [",", 582], ["from", 584], ["a", 589], ["homogeneous", 591], ["distribution", 603], ["in", 616], ["the", 619], ["immature", 623], ["neuropil", 632], ["to", 641], ["an", 644], ["accumulation", 647], ["in", 660], ["the", 663], ["neuropil", 667], ["of", 676], ["the", 679], ["glomeruli", 683], [".", 692], ["CaM", 694], ["kinase", 698], ["II", 705], ["immunoreactivity", 708], ["was", 725], ["less", 729], ["intense", 734], ["in", 742], ["olfactory", 745], ["receptor", 755], ["axons", 764], ["of", 770], ["the", 773], ["antennal", 777], ["nerve", 786], ["and", 792], ["antennal", 796], ["lobe", 805], ["glial", 810], ["cells", 816], [".", 821], ["Western", 823], ["blot", 831], ["analysis", 836], ["revealed", 845], ["a", 854], ["growing", 856], ["content", 864], ["of", 872], ["CaM", 875], ["kinase", 879], ["II", 886], ["in", 889], ["antennal", 892], ["lobe", 901], ["tissue", 906], ["throughout", 913], ["metamorphosis", 924], [".", 937], ["Injection", 939], ["of", 949], ["the", 952], ["CaM", 956], ["kinase", 960], ["inhibitor", 967], ["KN-93", 977], ["into", 983], ["pupae", 988], ["resulted", 994], ["in", 1003], ["a", 1006], ["reduced", 1008], ["number", 1016], ["of", 1023], ["antennal", 1026], ["lobe", 1035], ["glial", 1040], ["cells", 1046], ["migrating", 1052], ["into", 1062], ["the", 1067], ["neuropil", 1071], ["to", 1080], ["form", 1083], ["borders", 1088], ["around", 1096], ["glomeruli", 1103], [".", 1112], ["The", 1114], ["results", 1118], ["suggest", 1126], ["that", 1134], ["CaM", 1139], ["kinase", 1143], ["II", 1150], ["is", 1153], ["involved", 1156], ["in", 1165], ["glial", 1168], ["cell", 1174], ["migration", 1179], [".", 1188]]}
{"context": "Empagliflozin is a selective sodium glucose cotransporter 2 (SGLT2) inhibitor that inhibits renal glucose reabsorption and is being investigated for the treatment of type 2 diabetes mellitus (T2DM). In this open-label study, the effect of renal impairment on the pharmacokinetics, pharmacodynamics and safety of a 50\u2009mg dose of empagliflozin was investigated in 40 subjects, grouped according to estimated glomerular filtration rate (eGFR). Maximum empagliflozin plasma concentrations were similar in subjects with normal renal function and renal impairment. Area under the empagliflozin concentration-time curve (AUC0 -\u221e ) values increased by approximately 18, 20, 66 and 48% in subjects with mild, moderate, severe renal impairment and renal failure/end stage renal disease (ESRD), respectively, in comparison to healthy subjects. This was attributed to decreased renal clearance (CLR ). Urinary glucose excretion (UGE) decreased with increasing renal impairment and correlated with decreased eGFR and CLR . Empagliflozin was well tolerated, with no increase in adverse events associated with renal impairment. Renal insufficiency resulted in decreased CLR of empagliflozin, moderately increased systemic exposure and decreased UGE. A single 50\u2009mg dose of empagliflozin was well tolerated in subjects with normal renal function and any degree of renal impairment. The pharmacokinetic results of this study indicate that no dose adjustment of empagliflozin is required in patients with renal impairment.", "qas": [{"question": "Which protein does empagliflozin inhibit?", "answers": ["SGLT2"], "qid": "d298832c62de4e73ad3b013ea2443d51", "question_tokens": [["Which", 0], ["protein", 6], ["does", 14], ["empagliflozin", 19], ["inhibit", 33], ["?", 40]], "detected_answers": [{"text": "SGLT2", "token_spans": [[9, 9]], "char_spans": [[61, 65]]}]}], "context_tokens": [["Empagliflozin", 0], ["is", 14], ["a", 17], ["selective", 19], ["sodium", 29], ["glucose", 36], ["cotransporter", 44], ["2", 58], ["(", 60], ["SGLT2", 61], [")", 66], ["inhibitor", 68], ["that", 78], ["inhibits", 83], ["renal", 92], ["glucose", 98], ["reabsorption", 106], ["and", 119], ["is", 123], ["being", 126], ["investigated", 132], ["for", 145], ["the", 149], ["treatment", 153], ["of", 163], ["type", 166], ["2", 171], ["diabetes", 173], ["mellitus", 182], ["(", 191], ["T2DM", 192], [")", 196], [".", 197], ["In", 199], ["this", 202], ["open", 207], ["-", 211], ["label", 212], ["study", 218], [",", 223], ["the", 225], ["effect", 229], ["of", 236], ["renal", 239], ["impairment", 245], ["on", 256], ["the", 259], ["pharmacokinetics", 263], [",", 279], ["pharmacodynamics", 281], ["and", 298], ["safety", 302], ["of", 309], ["a", 312], ["50", 314], ["mg", 317], ["dose", 320], ["of", 325], ["empagliflozin", 328], ["was", 342], ["investigated", 346], ["in", 359], ["40", 362], ["subjects", 365], [",", 373], ["grouped", 375], ["according", 383], ["to", 393], ["estimated", 396], ["glomerular", 406], ["filtration", 417], ["rate", 428], ["(", 433], ["eGFR", 434], [")", 438], [".", 439], ["Maximum", 441], ["empagliflozin", 449], ["plasma", 463], ["concentrations", 470], ["were", 485], ["similar", 490], ["in", 498], ["subjects", 501], ["with", 510], ["normal", 515], ["renal", 522], ["function", 528], ["and", 537], ["renal", 541], ["impairment", 547], [".", 557], ["Area", 559], ["under", 564], ["the", 570], ["empagliflozin", 574], ["concentration", 588], ["-", 601], ["time", 602], ["curve", 607], ["(", 613], ["AUC0", 614], ["-\u221e", 619], [")", 622], ["values", 624], ["increased", 631], ["by", 641], ["approximately", 644], ["18", 658], [",", 660], ["20", 662], [",", 664], ["66", 666], ["and", 669], ["48", 673], ["%", 675], ["in", 677], ["subjects", 680], ["with", 689], ["mild", 694], [",", 698], ["moderate", 700], [",", 708], ["severe", 710], ["renal", 717], ["impairment", 723], ["and", 734], ["renal", 738], ["failure", 744], ["/", 751], ["end", 752], ["stage", 756], ["renal", 762], ["disease", 768], ["(", 776], ["ESRD", 777], [")", 781], [",", 782], ["respectively", 784], [",", 796], ["in", 798], ["comparison", 801], ["to", 812], ["healthy", 815], ["subjects", 823], [".", 831], ["This", 833], ["was", 838], ["attributed", 842], ["to", 853], ["decreased", 856], ["renal", 866], ["clearance", 872], ["(", 882], ["CLR", 883], [")", 887], [".", 888], ["Urinary", 890], ["glucose", 898], ["excretion", 906], ["(", 916], ["UGE", 917], [")", 920], ["decreased", 922], ["with", 932], ["increasing", 937], ["renal", 948], ["impairment", 954], ["and", 965], ["correlated", 969], ["with", 980], ["decreased", 985], ["eGFR", 995], ["and", 1000], ["CLR", 1004], [".", 1008], ["Empagliflozin", 1010], ["was", 1024], ["well", 1028], ["tolerated", 1033], [",", 1042], ["with", 1044], ["no", 1049], ["increase", 1052], ["in", 1061], ["adverse", 1064], ["events", 1072], ["associated", 1079], ["with", 1090], ["renal", 1095], ["impairment", 1101], [".", 1111], ["Renal", 1113], ["insufficiency", 1119], ["resulted", 1133], ["in", 1142], ["decreased", 1145], ["CLR", 1155], ["of", 1159], ["empagliflozin", 1162], [",", 1175], ["moderately", 1177], ["increased", 1188], ["systemic", 1198], ["exposure", 1207], ["and", 1216], ["decreased", 1220], ["UGE", 1230], [".", 1233], ["A", 1235], ["single", 1237], ["50", 1244], ["mg", 1247], ["dose", 1250], ["of", 1255], ["empagliflozin", 1258], ["was", 1272], ["well", 1276], ["tolerated", 1281], ["in", 1291], ["subjects", 1294], ["with", 1303], ["normal", 1308], ["renal", 1315], ["function", 1321], ["and", 1330], ["any", 1334], ["degree", 1338], ["of", 1345], ["renal", 1348], ["impairment", 1354], [".", 1364], ["The", 1366], ["pharmacokinetic", 1370], ["results", 1386], ["of", 1394], ["this", 1397], ["study", 1402], ["indicate", 1408], ["that", 1417], ["no", 1422], ["dose", 1425], ["adjustment", 1430], ["of", 1441], ["empagliflozin", 1444], ["is", 1458], ["required", 1461], ["in", 1470], ["patients", 1473], ["with", 1482], ["renal", 1487], ["impairment", 1493], [".", 1503]]}
{"context": "Accumulation and deposition of \u03b2-amyloid peptides (A\u03b2) in the brain is a central event in the pathogenesis of Alzheimer's disease (AD). Besides the parenchymal pathology, A\u03b2 is known to undergo active transport across the blood-brain barrier and cerebral amyloid angiopathy (CAA) is a prominent feature in the majority of AD. Although impaired cerebral blood flow (CBF) has been implicated in faulty A\u03b2 transport and clearance, and cerebral hypoperfusion can exist in the pre-clinical phase of Alzheimer's disease (AD), it is still unclear whether it is one of the causal factors for AD pathogenesis, or an early consequence of a multi-factor condition that would lead to AD at late stage. To study the potential interaction between faulty CBF and amyloid accumulation in clinical-relevant situation, we generated a new amyloid precursor protein (APP) knock-in allele that expresses humanized A\u03b2 and a Dutch mutation in addition to Swedish/London mutations and compared this line with an equivalent knock-in line but in the absence of the Dutch mutation, both crossed onto the PS1M146V knock-in background. Introduction of the Dutch mutation results in robust CAA and parenchymal A\u03b2 pathology, age-dependent reduction of spatial learning and memory deficits, and CBF reduction as detected by fMRI. Direct manipulation of CBF by transverse aortic constriction surgery on the left common carotid artery caused differential changes in CBF in the anterior and middle region of the cortex, where it is reduced on the left side and increased on the right side. However these perturbations in CBF resulted in the same effect: both significantly exacerbate CAA and amyloid pathology. Our study reveals a direct and positive link between vascular and parenchymal A\u03b2; both can be modulated by CBF. The new APP knock-in mouse model recapitulates many symptoms of AD including progressive vascular and parenchymal A\u03b2 pathology and behavioral deficits in the absence of APP overexpression.", "qas": [{"question": "Which disease the London mutation involved in?", "answers": ["Alzheimer's Disease", "AD"], "qid": "fd787f32d19848dbb65fe34c00222562", "question_tokens": [["Which", 0], ["disease", 6], ["the", 14], ["London", 18], ["mutation", 25], ["involved", 34], ["in", 43], ["?", 45]], "detected_answers": [{"text": "Alzheimer's Disease", "token_spans": [[22, 24], [94, 96]], "char_spans": [[110, 128], [494, 512]]}, {"text": "AD", "token_spans": [[131, 131], [98, 98], [26, 26], [342, 342], [62, 62], [114, 114]], "char_spans": [[672, 673], [515, 516], [131, 132], [1852, 1853], [322, 323], [584, 585]]}]}], "context_tokens": [["Accumulation", 0], ["and", 13], ["deposition", 17], ["of", 28], ["\u03b2", 31], ["-", 32], ["amyloid", 33], ["peptides", 41], ["(", 50], ["A\u03b2", 51], [")", 53], ["in", 55], ["the", 58], ["brain", 62], ["is", 68], ["a", 71], ["central", 73], ["event", 81], ["in", 87], ["the", 90], ["pathogenesis", 94], ["of", 107], ["Alzheimer", 110], ["'s", 119], ["disease", 122], ["(", 130], ["AD", 131], [")", 133], [".", 134], ["Besides", 136], ["the", 144], ["parenchymal", 148], ["pathology", 160], [",", 169], ["A\u03b2", 171], ["is", 174], ["known", 177], ["to", 183], ["undergo", 186], ["active", 194], ["transport", 201], ["across", 211], ["the", 218], ["blood", 222], ["-", 227], ["brain", 228], ["barrier", 234], ["and", 242], ["cerebral", 246], ["amyloid", 255], ["angiopathy", 263], ["(", 274], ["CAA", 275], [")", 278], ["is", 280], ["a", 283], ["prominent", 285], ["feature", 295], ["in", 303], ["the", 306], ["majority", 310], ["of", 319], ["AD", 322], [".", 324], ["Although", 326], ["impaired", 335], ["cerebral", 344], ["blood", 353], ["flow", 359], ["(", 364], ["CBF", 365], [")", 368], ["has", 370], ["been", 374], ["implicated", 379], ["in", 390], ["faulty", 393], ["A\u03b2", 400], ["transport", 403], ["and", 413], ["clearance", 417], [",", 426], ["and", 428], ["cerebral", 432], ["hypoperfusion", 441], ["can", 455], ["exist", 459], ["in", 465], ["the", 468], ["pre", 472], ["-", 475], ["clinical", 476], ["phase", 485], ["of", 491], ["Alzheimer", 494], ["'s", 503], ["disease", 506], ["(", 514], ["AD", 515], [")", 517], [",", 518], ["it", 520], ["is", 523], ["still", 526], ["unclear", 532], ["whether", 540], ["it", 548], ["is", 551], ["one", 554], ["of", 558], ["the", 561], ["causal", 565], ["factors", 572], ["for", 580], ["AD", 584], ["pathogenesis", 587], [",", 599], ["or", 601], ["an", 604], ["early", 607], ["consequence", 613], ["of", 625], ["a", 628], ["multi", 630], ["-", 635], ["factor", 636], ["condition", 643], ["that", 653], ["would", 658], ["lead", 664], ["to", 669], ["AD", 672], ["at", 675], ["late", 678], ["stage", 683], [".", 688], ["To", 690], ["study", 693], ["the", 699], ["potential", 703], ["interaction", 713], ["between", 725], ["faulty", 733], ["CBF", 740], ["and", 744], ["amyloid", 748], ["accumulation", 756], ["in", 769], ["clinical", 772], ["-", 780], ["relevant", 781], ["situation", 790], [",", 799], ["we", 801], ["generated", 804], ["a", 814], ["new", 816], ["amyloid", 820], ["precursor", 828], ["protein", 838], ["(", 846], ["APP", 847], [")", 850], ["knock", 852], ["-", 857], ["in", 858], ["allele", 861], ["that", 868], ["expresses", 873], ["humanized", 883], ["A\u03b2", 893], ["and", 896], ["a", 900], ["Dutch", 902], ["mutation", 908], ["in", 917], ["addition", 920], ["to", 929], ["Swedish", 932], ["/", 939], ["London", 940], ["mutations", 947], ["and", 957], ["compared", 961], ["this", 970], ["line", 975], ["with", 980], ["an", 985], ["equivalent", 988], ["knock", 999], ["-", 1004], ["in", 1005], ["line", 1008], ["but", 1013], ["in", 1017], ["the", 1020], ["absence", 1024], ["of", 1032], ["the", 1035], ["Dutch", 1039], ["mutation", 1045], [",", 1053], ["both", 1055], ["crossed", 1060], ["onto", 1068], ["the", 1073], ["PS1M146V", 1077], ["knock", 1086], ["-", 1091], ["in", 1092], ["background", 1095], [".", 1105], ["Introduction", 1107], ["of", 1120], ["the", 1123], ["Dutch", 1127], ["mutation", 1133], ["results", 1142], ["in", 1150], ["robust", 1153], ["CAA", 1160], ["and", 1164], ["parenchymal", 1168], ["A\u03b2", 1180], ["pathology", 1183], [",", 1192], ["age", 1194], ["-", 1197], ["dependent", 1198], ["reduction", 1208], ["of", 1218], ["spatial", 1221], ["learning", 1229], ["and", 1238], ["memory", 1242], ["deficits", 1249], [",", 1257], ["and", 1259], ["CBF", 1263], ["reduction", 1267], ["as", 1277], ["detected", 1280], ["by", 1289], ["fMRI", 1292], [".", 1296], ["Direct", 1298], ["manipulation", 1305], ["of", 1318], ["CBF", 1321], ["by", 1325], ["transverse", 1328], ["aortic", 1339], ["constriction", 1346], ["surgery", 1359], ["on", 1367], ["the", 1370], ["left", 1374], ["common", 1379], ["carotid", 1386], ["artery", 1394], ["caused", 1401], ["differential", 1408], ["changes", 1421], ["in", 1429], ["CBF", 1432], ["in", 1436], ["the", 1439], ["anterior", 1443], ["and", 1452], ["middle", 1456], ["region", 1463], ["of", 1470], ["the", 1473], ["cortex", 1477], [",", 1483], ["where", 1485], ["it", 1491], ["is", 1494], ["reduced", 1497], ["on", 1505], ["the", 1508], ["left", 1512], ["side", 1517], ["and", 1522], ["increased", 1526], ["on", 1536], ["the", 1539], ["right", 1543], ["side", 1549], [".", 1553], ["However", 1555], ["these", 1563], ["perturbations", 1569], ["in", 1583], ["CBF", 1586], ["resulted", 1590], ["in", 1599], ["the", 1602], ["same", 1606], ["effect", 1611], [":", 1617], ["both", 1619], ["significantly", 1624], ["exacerbate", 1638], ["CAA", 1649], ["and", 1653], ["amyloid", 1657], ["pathology", 1665], [".", 1674], ["Our", 1676], ["study", 1680], ["reveals", 1686], ["a", 1694], ["direct", 1696], ["and", 1703], ["positive", 1707], ["link", 1716], ["between", 1721], ["vascular", 1729], ["and", 1738], ["parenchymal", 1742], ["A\u03b2", 1754], [";", 1756], ["both", 1758], ["can", 1763], ["be", 1767], ["modulated", 1770], ["by", 1780], ["CBF", 1783], [".", 1786], ["The", 1788], ["new", 1792], ["APP", 1796], ["knock", 1800], ["-", 1805], ["in", 1806], ["mouse", 1809], ["model", 1815], ["recapitulates", 1821], ["many", 1835], ["symptoms", 1840], ["of", 1849], ["AD", 1852], ["including", 1855], ["progressive", 1865], ["vascular", 1877], ["and", 1886], ["parenchymal", 1890], ["A\u03b2", 1902], ["pathology", 1905], ["and", 1915], ["behavioral", 1919], ["deficits", 1930], ["in", 1939], ["the", 1942], ["absence", 1946], ["of", 1954], ["APP", 1957], ["overexpression", 1961], [".", 1975]]}
{"context": "S100A4 is a small calcium-binding protein that is commonly overexpressed in a range of different tumor types, and it is widely accepted that S100A4 has an important role in the process of cancer metastasis. In vitro binding assays has shown that S100A4 interacts with the tumor suppressor protein p53, indicating that S100A4 may have additional roles in tumor development. In the present study, we show that endogenous S100A4 and p53 interact in complex samples, and that the interaction increases after inhibition of MDM2-dependent p53 degradation using Nutlin-3A. Further, using proximity ligation assay, we show that the interaction takes place in the cell nucleus. S100A4 knockdown experiments in two p53 wild-type cell lines, A549 and HeLa, resulted in stabilization of p53 protein, indicating that S100A4 is promoting p53 degradation. Finally, we demonstrate that S100A4 knockdown leads to p53-dependent cell cycle arrest and increased cisplatin-induced apoptosis. Thus, our data add a new layer to the oncogenic properties of S100A4 through its inhibition of p53-dependent processes.", "qas": [{"question": "Where in the cell does the proteins S100A4 and p53 interact ?", "answers": ["nucleus"], "qid": "b2838cb187da4004873628ecd5e3851c", "question_tokens": [["Where", 0], ["in", 6], ["the", 9], ["cell", 13], ["does", 18], ["the", 23], ["proteins", 27], ["S100A4", 36], ["and", 43], ["p53", 47], ["interact", 51], ["?", 60]], "detected_answers": [{"text": "nucleus", "token_spans": [[112, 112]], "char_spans": [[660, 666]]}]}], "context_tokens": [["S100A4", 0], ["is", 7], ["a", 10], ["small", 12], ["calcium", 18], ["-", 25], ["binding", 26], ["protein", 34], ["that", 42], ["is", 47], ["commonly", 50], ["overexpressed", 59], ["in", 73], ["a", 76], ["range", 78], ["of", 84], ["different", 87], ["tumor", 97], ["types", 103], [",", 108], ["and", 110], ["it", 114], ["is", 117], ["widely", 120], ["accepted", 127], ["that", 136], ["S100A4", 141], ["has", 148], ["an", 152], ["important", 155], ["role", 165], ["in", 170], ["the", 173], ["process", 177], ["of", 185], ["cancer", 188], ["metastasis", 195], [".", 205], ["In", 207], ["vitro", 210], ["binding", 216], ["assays", 224], ["has", 231], ["shown", 235], ["that", 241], ["S100A4", 246], ["interacts", 253], ["with", 263], ["the", 268], ["tumor", 272], ["suppressor", 278], ["protein", 289], ["p53", 297], [",", 300], ["indicating", 302], ["that", 313], ["S100A4", 318], ["may", 325], ["have", 329], ["additional", 334], ["roles", 345], ["in", 351], ["tumor", 354], ["development", 360], [".", 371], ["In", 373], ["the", 376], ["present", 380], ["study", 388], [",", 393], ["we", 395], ["show", 398], ["that", 403], ["endogenous", 408], ["S100A4", 419], ["and", 426], ["p53", 430], ["interact", 434], ["in", 443], ["complex", 446], ["samples", 454], [",", 461], ["and", 463], ["that", 467], ["the", 472], ["interaction", 476], ["increases", 488], ["after", 498], ["inhibition", 504], ["of", 515], ["MDM2-dependent", 518], ["p53", 533], ["degradation", 537], ["using", 549], ["Nutlin-3A.", 555], ["Further", 566], [",", 573], ["using", 575], ["proximity", 581], ["ligation", 591], ["assay", 600], [",", 605], ["we", 607], ["show", 610], ["that", 615], ["the", 620], ["interaction", 624], ["takes", 636], ["place", 642], ["in", 648], ["the", 651], ["cell", 655], ["nucleus", 660], [".", 667], ["S100A4", 669], ["knockdown", 676], ["experiments", 686], ["in", 698], ["two", 701], ["p53", 705], ["wild", 709], ["-", 713], ["type", 714], ["cell", 719], ["lines", 724], [",", 729], ["A549", 731], ["and", 736], ["HeLa", 740], [",", 744], ["resulted", 746], ["in", 755], ["stabilization", 758], ["of", 772], ["p53", 775], ["protein", 779], [",", 786], ["indicating", 788], ["that", 799], ["S100A4", 804], ["is", 811], ["promoting", 814], ["p53", 824], ["degradation", 828], [".", 839], ["Finally", 841], [",", 848], ["we", 850], ["demonstrate", 853], ["that", 865], ["S100A4", 870], ["knockdown", 877], ["leads", 887], ["to", 893], ["p53-dependent", 896], ["cell", 910], ["cycle", 915], ["arrest", 921], ["and", 928], ["increased", 932], ["cisplatin", 942], ["-", 951], ["induced", 952], ["apoptosis", 960], [".", 969], ["Thus", 971], [",", 975], ["our", 977], ["data", 981], ["add", 986], ["a", 990], ["new", 992], ["layer", 996], ["to", 1002], ["the", 1005], ["oncogenic", 1009], ["properties", 1019], ["of", 1030], ["S100A4", 1033], ["through", 1040], ["its", 1048], ["inhibition", 1052], ["of", 1063], ["p53-dependent", 1066], ["processes", 1080], [".", 1089]]}
{"context": "Restless legs syndrome (RLS), also known as Willis-Ekbom disease (WED), is a common movement disorder characterised by an uncontrollable urge to move because of uncomfortable, sometimes painful sensations in the legs with a diurnal variation and a release with movement. The pathophysiology is only partially known and a genetic component together with dopaminergic and brain iron dysregulation plays an important role. Secondary causes for RLS need to be excluded. Treatment depends on the severity and frequency of RLS symptoms, comprises non-pharmacological (eg lifestyle changes) and pharmacological interventions (eg dopaminergic medication, alpha-2-delta calcium channel ligands, opioids) and relieves symptoms only. Augmentation is the main complication of long-term dopaminergic treatment of RLS. This article will provide a clinically useful overview of RLS with provision of diagnostic criteria, differential diagnoses, possible investigations and different treatment strategies with their associated complications.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "ee27b6a18fa848d0a07f50eae299fa52", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[0, 2]], "char_spans": [[0, 21]]}]}], "context_tokens": [["Restless", 0], ["legs", 9], ["syndrome", 14], ["(", 23], ["RLS", 24], [")", 27], [",", 28], ["also", 30], ["known", 35], ["as", 41], ["Willis", 44], ["-", 50], ["Ekbom", 51], ["disease", 57], ["(", 65], ["WED", 66], [")", 69], [",", 70], ["is", 72], ["a", 75], ["common", 77], ["movement", 84], ["disorder", 93], ["characterised", 102], ["by", 116], ["an", 119], ["uncontrollable", 122], ["urge", 137], ["to", 142], ["move", 145], ["because", 150], ["of", 158], ["uncomfortable", 161], [",", 174], ["sometimes", 176], ["painful", 186], ["sensations", 194], ["in", 205], ["the", 208], ["legs", 212], ["with", 217], ["a", 222], ["diurnal", 224], ["variation", 232], ["and", 242], ["a", 246], ["release", 248], ["with", 256], ["movement", 261], [".", 269], ["The", 271], ["pathophysiology", 275], ["is", 291], ["only", 294], ["partially", 299], ["known", 309], ["and", 315], ["a", 319], ["genetic", 321], ["component", 329], ["together", 339], ["with", 348], ["dopaminergic", 353], ["and", 366], ["brain", 370], ["iron", 376], ["dysregulation", 381], ["plays", 395], ["an", 401], ["important", 404], ["role", 414], [".", 418], ["Secondary", 420], ["causes", 430], ["for", 437], ["RLS", 441], ["need", 445], ["to", 450], ["be", 453], ["excluded", 456], [".", 464], ["Treatment", 466], ["depends", 476], ["on", 484], ["the", 487], ["severity", 491], ["and", 500], ["frequency", 504], ["of", 514], ["RLS", 517], ["symptoms", 521], [",", 529], ["comprises", 531], ["non", 541], ["-", 544], ["pharmacological", 545], ["(", 561], ["eg", 562], ["lifestyle", 565], ["changes", 575], [")", 582], ["and", 584], ["pharmacological", 588], ["interventions", 604], ["(", 618], ["eg", 619], ["dopaminergic", 622], ["medication", 635], [",", 645], ["alpha-2-delta", 647], ["calcium", 661], ["channel", 669], ["ligands", 677], [",", 684], ["opioids", 686], [")", 693], ["and", 695], ["relieves", 699], ["symptoms", 708], ["only", 717], [".", 721], ["Augmentation", 723], ["is", 736], ["the", 739], ["main", 743], ["complication", 748], ["of", 761], ["long", 764], ["-", 768], ["term", 769], ["dopaminergic", 774], ["treatment", 787], ["of", 797], ["RLS", 800], [".", 803], ["This", 805], ["article", 810], ["will", 818], ["provide", 823], ["a", 831], ["clinically", 833], ["useful", 844], ["overview", 851], ["of", 860], ["RLS", 863], ["with", 867], ["provision", 872], ["of", 882], ["diagnostic", 885], ["criteria", 896], [",", 904], ["differential", 906], ["diagnoses", 919], [",", 928], ["possible", 930], ["investigations", 939], ["and", 954], ["different", 958], ["treatment", 968], ["strategies", 978], ["with", 989], ["their", 994], ["associated", 1000], ["complications", 1011], [".", 1024]]}
{"context": "Parkinson's disease and dementia with Lewy bodies are very frequent neurological disorders of the elderly. Mutations in the alpha-synuclein (alphaSYN) gene cause Parkinson's disease, often associated with dementia. Neuropathologically these diseases are characterized by the presence of Lewy bodies and Lewy neurites, intraneuronal inclusions mostly composed of alphaSYN protein fibrils. Moreover, alphaSYN is phosphorylated at S129 (phospho-serine-129 [PSer129]) in neuropathological lesions. Using our (Thy1)-[A30P]alphaSYN transgenic mouse model that develops age-dependent impairment in fear conditioning behavior, we investigated PSer129 immunostaining in the brain. We found distinct staining patterns using new, sensitive monoclonal antibodies. Somal and nuclear PSer129 immunoreactivity increased with age in hippocampal and cortical areas as well as the lateral/basolateral amygdalar nuclei and was present also in young, pre-symptomatic mice, but not wild-type controls. The tendency of PSer129 immunostaining to accumulate in the nucleus was confirmed in cell culture. (Thy1)-[A30P]alphaSYN transgenic mice further developed age-dependent, specific neuritic/terminal alphaSYN pathology in the medial parts of the central amygdalar nucleus and one of its projection areas, the lateral hypothalamus. Interestingly, this type of PSer129 neuropathology was thioflavine S negative, unlike the Lewy-like neuropathology present in the brain stem of (Thy1)-[A30P]alphaSYN mice. Thus, alphaSYN becomes phosphorylated in distinct parts of the brain in this alpha-synucleinopathy mouse model, showing age-dependent increases of nuclear PSer129 in cortical brain areas and the formation of neuritic/terminal PSer129 neuropathology with variable amyloid quality within the fear conditioning circuitry and the brain stem.", "qas": [{"question": "Against which protein is the antibody used for immonostaining of Lewy bodies raised?", "answers": ["alpha-Synuclein"], "qid": "3005311091144dfdb1464aeae598c703", "question_tokens": [["Against", 0], ["which", 8], ["protein", 14], ["is", 22], ["the", 25], ["antibody", 29], ["used", 38], ["for", 43], ["immonostaining", 47], ["of", 62], ["Lewy", 65], ["bodies", 70], ["raised", 77], ["?", 83]], "detected_answers": [{"text": "alpha-Synuclein", "token_spans": [[20, 22]], "char_spans": [[124, 138]]}]}], "context_tokens": [["Parkinson", 0], ["'s", 9], ["disease", 12], ["and", 20], ["dementia", 24], ["with", 33], ["Lewy", 38], ["bodies", 43], ["are", 50], ["very", 54], ["frequent", 59], ["neurological", 68], ["disorders", 81], ["of", 91], ["the", 94], ["elderly", 98], [".", 105], ["Mutations", 107], ["in", 117], ["the", 120], ["alpha", 124], ["-", 129], ["synuclein", 130], ["(", 140], ["alphaSYN", 141], [")", 149], ["gene", 151], ["cause", 156], ["Parkinson", 162], ["'s", 171], ["disease", 174], [",", 181], ["often", 183], ["associated", 189], ["with", 200], ["dementia", 205], [".", 213], ["Neuropathologically", 215], ["these", 235], ["diseases", 241], ["are", 250], ["characterized", 254], ["by", 268], ["the", 271], ["presence", 275], ["of", 284], ["Lewy", 287], ["bodies", 292], ["and", 299], ["Lewy", 303], ["neurites", 308], [",", 316], ["intraneuronal", 318], ["inclusions", 332], ["mostly", 343], ["composed", 350], ["of", 359], ["alphaSYN", 362], ["protein", 371], ["fibrils", 379], [".", 386], ["Moreover", 388], [",", 396], ["alphaSYN", 398], ["is", 407], ["phosphorylated", 410], ["at", 425], ["S129", 428], ["(", 433], ["phospho", 434], ["-", 441], ["serine-129", 442], ["[", 453], ["PSer129", 454], ["]", 461], [")", 462], ["in", 464], ["neuropathological", 467], ["lesions", 485], [".", 492], ["Using", 494], ["our", 500], ["(", 504], ["Thy1)-[A30P]alphaSYN", 505], ["transgenic", 526], ["mouse", 537], ["model", 543], ["that", 549], ["develops", 554], ["age", 563], ["-", 566], ["dependent", 567], ["impairment", 577], ["in", 588], ["fear", 591], ["conditioning", 596], ["behavior", 609], [",", 617], ["we", 619], ["investigated", 622], ["PSer129", 635], ["immunostaining", 643], ["in", 658], ["the", 661], ["brain", 665], [".", 670], ["We", 672], ["found", 675], ["distinct", 681], ["staining", 690], ["patterns", 699], ["using", 708], ["new", 714], [",", 717], ["sensitive", 719], ["monoclonal", 729], ["antibodies", 740], [".", 750], ["Somal", 752], ["and", 758], ["nuclear", 762], ["PSer129", 770], ["immunoreactivity", 778], ["increased", 795], ["with", 805], ["age", 810], ["in", 814], ["hippocampal", 817], ["and", 829], ["cortical", 833], ["areas", 842], ["as", 848], ["well", 851], ["as", 856], ["the", 859], ["lateral", 863], ["/", 870], ["basolateral", 871], ["amygdalar", 883], ["nuclei", 893], ["and", 900], ["was", 904], ["present", 908], ["also", 916], ["in", 921], ["young", 924], [",", 929], ["pre", 931], ["-", 934], ["symptomatic", 935], ["mice", 947], [",", 951], ["but", 953], ["not", 957], ["wild", 961], ["-", 965], ["type", 966], ["controls", 971], [".", 979], ["The", 981], ["tendency", 985], ["of", 994], ["PSer129", 997], ["immunostaining", 1005], ["to", 1020], ["accumulate", 1023], ["in", 1034], ["the", 1037], ["nucleus", 1041], ["was", 1049], ["confirmed", 1053], ["in", 1063], ["cell", 1066], ["culture", 1071], [".", 1078], ["(", 1080], ["Thy1)-[A30P]alphaSYN", 1081], ["transgenic", 1102], ["mice", 1113], ["further", 1118], ["developed", 1126], ["age", 1136], ["-", 1139], ["dependent", 1140], [",", 1149], ["specific", 1151], ["neuritic", 1160], ["/", 1168], ["terminal", 1169], ["alphaSYN", 1178], ["pathology", 1187], ["in", 1197], ["the", 1200], ["medial", 1204], ["parts", 1211], ["of", 1217], ["the", 1220], ["central", 1224], ["amygdalar", 1232], ["nucleus", 1242], ["and", 1250], ["one", 1254], ["of", 1258], ["its", 1261], ["projection", 1265], ["areas", 1276], [",", 1281], ["the", 1283], ["lateral", 1287], ["hypothalamus", 1295], [".", 1307], ["Interestingly", 1309], [",", 1322], ["this", 1324], ["type", 1329], ["of", 1334], ["PSer129", 1337], ["neuropathology", 1345], ["was", 1360], ["thioflavine", 1364], ["S", 1376], ["negative", 1378], [",", 1386], ["unlike", 1388], ["the", 1395], ["Lewy", 1399], ["-", 1403], ["like", 1404], ["neuropathology", 1409], ["present", 1424], ["in", 1432], ["the", 1435], ["brain", 1439], ["stem", 1445], ["of", 1450], ["(", 1453], ["Thy1)-[A30P]alphaSYN", 1454], ["mice", 1475], [".", 1479], ["Thus", 1481], [",", 1485], ["alphaSYN", 1487], ["becomes", 1496], ["phosphorylated", 1504], ["in", 1519], ["distinct", 1522], ["parts", 1531], ["of", 1537], ["the", 1540], ["brain", 1544], ["in", 1550], ["this", 1553], ["alpha", 1558], ["-", 1563], ["synucleinopathy", 1564], ["mouse", 1580], ["model", 1586], [",", 1591], ["showing", 1593], ["age", 1601], ["-", 1604], ["dependent", 1605], ["increases", 1615], ["of", 1625], ["nuclear", 1628], ["PSer129", 1636], ["in", 1644], ["cortical", 1647], ["brain", 1656], ["areas", 1662], ["and", 1668], ["the", 1672], ["formation", 1676], ["of", 1686], ["neuritic", 1689], ["/", 1697], ["terminal", 1698], ["PSer129", 1707], ["neuropathology", 1715], ["with", 1730], ["variable", 1735], ["amyloid", 1744], ["quality", 1752], ["within", 1760], ["the", 1767], ["fear", 1771], ["conditioning", 1776], ["circuitry", 1789], ["and", 1799], ["the", 1803], ["brain", 1807], ["stem", 1813], [".", 1817]]}
{"context": "Diamond-Blackfan anemia (DBA) is a congenital bone marrow failure syndrome characterized by a specific deficiency in erythroid progenitors. Forty percent of the patients are blood transfusion-dependent. Recent reports show that the ribosomal protein S19 (RPS19) gene is mutated in 25% of all patients with DBA. We constructed oncoretroviral vectors containing the RPS19 gene to develop gene therapy for RPS19-deficient DBA. These vectors were used to introduce the RPS19 gene into CD34(+) bone marrow (BM) cells from 4 patients with DBA with RPS19 gene mutations. Overexpression of the RPS19 transgene increased the number of erythroid colonies by almost 3-fold. High expression levels of the RPS19 transgene improved erythroid colony-forming ability substantially whereas low expression levels had no effect. Overexpression of RPS19 had no detrimental effect on granulocyte-macrophage colony formation. Therefore, these findings suggest that gene therapy for RPS19-deficient patients with DBA using viral vectors that express the RPS19 gene is feasible.", "qas": [{"question": "In which syndrome is the RPS19 gene most frequently mutated?", "answers": ["Diamond-Blackfan Anemia", "DBA"], "qid": "0bede4582a9e40d4bb498c8ee7d6c64e", "question_tokens": [["In", 0], ["which", 3], ["syndrome", 9], ["is", 18], ["the", 21], ["RPS19", 25], ["gene", 31], ["most", 36], ["frequently", 41], ["mutated", 52], ["?", 59]], "detected_answers": [{"text": "Diamond-Blackfan Anemia", "token_spans": [[0, 3]], "char_spans": [[0, 22]]}, {"text": "DBA", "token_spans": [[5, 5], [164, 164], [55, 55], [71, 71], [95, 95]], "char_spans": [[25, 27], [990, 992], [306, 308], [419, 421], [533, 535]]}]}], "context_tokens": [["Diamond", 0], ["-", 7], ["Blackfan", 8], ["anemia", 17], ["(", 24], ["DBA", 25], [")", 28], ["is", 30], ["a", 33], ["congenital", 35], ["bone", 46], ["marrow", 51], ["failure", 58], ["syndrome", 66], ["characterized", 75], ["by", 89], ["a", 92], ["specific", 94], ["deficiency", 103], ["in", 114], ["erythroid", 117], ["progenitors", 127], [".", 138], ["Forty", 140], ["percent", 146], ["of", 154], ["the", 157], ["patients", 161], ["are", 170], ["blood", 174], ["transfusion", 180], ["-", 191], ["dependent", 192], [".", 201], ["Recent", 203], ["reports", 210], ["show", 218], ["that", 223], ["the", 228], ["ribosomal", 232], ["protein", 242], ["S19", 250], ["(", 254], ["RPS19", 255], [")", 260], ["gene", 262], ["is", 267], ["mutated", 270], ["in", 278], ["25", 281], ["%", 283], ["of", 285], ["all", 288], ["patients", 292], ["with", 301], ["DBA", 306], [".", 309], ["We", 311], ["constructed", 314], ["oncoretroviral", 326], ["vectors", 341], ["containing", 349], ["the", 360], ["RPS19", 364], ["gene", 370], ["to", 375], ["develop", 378], ["gene", 386], ["therapy", 391], ["for", 399], ["RPS19-deficient", 403], ["DBA", 419], [".", 422], ["These", 424], ["vectors", 430], ["were", 438], ["used", 443], ["to", 448], ["introduce", 451], ["the", 461], ["RPS19", 465], ["gene", 471], ["into", 476], ["CD34(+", 481], [")", 487], ["bone", 489], ["marrow", 494], ["(", 501], ["BM", 502], [")", 504], ["cells", 506], ["from", 512], ["4", 517], ["patients", 519], ["with", 528], ["DBA", 533], ["with", 537], ["RPS19", 542], ["gene", 548], ["mutations", 553], [".", 562], ["Overexpression", 564], ["of", 579], ["the", 582], ["RPS19", 586], ["transgene", 592], ["increased", 602], ["the", 612], ["number", 616], ["of", 623], ["erythroid", 626], ["colonies", 636], ["by", 645], ["almost", 648], ["3-fold", 655], [".", 661], ["High", 663], ["expression", 668], ["levels", 679], ["of", 686], ["the", 689], ["RPS19", 693], ["transgene", 699], ["improved", 709], ["erythroid", 718], ["colony", 728], ["-", 734], ["forming", 735], ["ability", 743], ["substantially", 751], ["whereas", 765], ["low", 773], ["expression", 777], ["levels", 788], ["had", 795], ["no", 799], ["effect", 802], [".", 808], ["Overexpression", 810], ["of", 825], ["RPS19", 828], ["had", 834], ["no", 838], ["detrimental", 841], ["effect", 853], ["on", 860], ["granulocyte", 863], ["-", 874], ["macrophage", 875], ["colony", 886], ["formation", 893], [".", 902], ["Therefore", 904], [",", 913], ["these", 915], ["findings", 921], ["suggest", 930], ["that", 938], ["gene", 943], ["therapy", 948], ["for", 956], ["RPS19-deficient", 960], ["patients", 976], ["with", 985], ["DBA", 990], ["using", 994], ["viral", 1000], ["vectors", 1006], ["that", 1014], ["express", 1019], ["the", 1027], ["RPS19", 1031], ["gene", 1037], ["is", 1042], ["feasible", 1045], [".", 1053]]}
{"context": "Osteoprotegerin (OPG) and receptor activator of nuclear factor-kappaB ligand (RANKL) are dominant regulators of bone resorption. Many hormones, cytokines and growth factors mediate bone resorption by altering the ratio of RANKL to OPG. RANKL and OPG expression is also altered in numerous bone diseases, and these changes can reflect disease etiology or compensatory responses to disease. RANKL stimulates osteoclast formation, function and survival, and each of these effects is inhibited by OPG. OPG suppresses bone resorption and increases the density, area and strength of both cancellous and cortical bone. Denosumab (AMG 162), a fully human monoclonal antibody to RANKL, shares the pharmacologic attributes of OPG but has a significantly longer half-life that allows less frequent administration.", "qas": [{"question": "To the ligand of which receptors does Denosumab (Prolia) bind?", "answers": ["RANKL"], "qid": "bd9c8ec49b8446ba9d107c61a8280a06", "question_tokens": [["To", 0], ["the", 3], ["ligand", 7], ["of", 14], ["which", 17], ["receptors", 23], ["does", 33], ["Denosumab", 38], ["(", 48], ["Prolia", 49], [")", 55], ["bind", 57], ["?", 61]], "detected_answers": [{"text": "RANKL", "token_spans": [[117, 117], [67, 67], [42, 42], [38, 38], [14, 14]], "char_spans": [[670, 674], [389, 393], [236, 240], [222, 226], [78, 82]]}]}], "context_tokens": [["Osteoprotegerin", 0], ["(", 16], ["OPG", 17], [")", 20], ["and", 22], ["receptor", 26], ["activator", 35], ["of", 45], ["nuclear", 48], ["factor", 56], ["-", 62], ["kappaB", 63], ["ligand", 70], ["(", 77], ["RANKL", 78], [")", 83], ["are", 85], ["dominant", 89], ["regulators", 98], ["of", 109], ["bone", 112], ["resorption", 117], [".", 127], ["Many", 129], ["hormones", 134], [",", 142], ["cytokines", 144], ["and", 154], ["growth", 158], ["factors", 165], ["mediate", 173], ["bone", 181], ["resorption", 186], ["by", 197], ["altering", 200], ["the", 209], ["ratio", 213], ["of", 219], ["RANKL", 222], ["to", 228], ["OPG", 231], [".", 234], ["RANKL", 236], ["and", 242], ["OPG", 246], ["expression", 250], ["is", 261], ["also", 264], ["altered", 269], ["in", 277], ["numerous", 280], ["bone", 289], ["diseases", 294], [",", 302], ["and", 304], ["these", 308], ["changes", 314], ["can", 322], ["reflect", 326], ["disease", 334], ["etiology", 342], ["or", 351], ["compensatory", 354], ["responses", 367], ["to", 377], ["disease", 380], [".", 387], ["RANKL", 389], ["stimulates", 395], ["osteoclast", 406], ["formation", 417], [",", 426], ["function", 428], ["and", 437], ["survival", 441], [",", 449], ["and", 451], ["each", 455], ["of", 460], ["these", 463], ["effects", 469], ["is", 477], ["inhibited", 480], ["by", 490], ["OPG", 493], [".", 496], ["OPG", 498], ["suppresses", 502], ["bone", 513], ["resorption", 518], ["and", 529], ["increases", 533], ["the", 543], ["density", 547], [",", 554], ["area", 556], ["and", 561], ["strength", 565], ["of", 574], ["both", 577], ["cancellous", 582], ["and", 593], ["cortical", 597], ["bone", 606], [".", 610], ["Denosumab", 612], ["(", 622], ["AMG", 623], ["162", 627], [")", 630], [",", 631], ["a", 633], ["fully", 635], ["human", 641], ["monoclonal", 647], ["antibody", 658], ["to", 667], ["RANKL", 670], [",", 675], ["shares", 677], ["the", 684], ["pharmacologic", 688], ["attributes", 702], ["of", 713], ["OPG", 716], ["but", 720], ["has", 724], ["a", 728], ["significantly", 730], ["longer", 744], ["half", 751], ["-", 755], ["life", 756], ["that", 761], ["allows", 766], ["less", 773], ["frequent", 778], ["administration", 787], [".", 801]]}
